TW202313972A - New nrg1 fusions, fusion junctions and methods for detecting them - Google Patents

Abstract

The disclosure relates to the field of neuregulin-1 (NRG1) fusions, methods for detecting such, identifying or diagnosing patients with such fusions and methods of treatment of a cancer, a tumor or an aberrant cell comprising an NRG1 fusion. Also, it relates to the field of therapeutic (human) compounds for the treatment of subjects with an ErbB-2/ErbB-3 positive cancer that comprise a NRG1 fusion.

Description

New NRG1 fusions, fusion junctions and methods of detecting them

The present disclosure pertains to the field of neuregulin 1 (NRG1) fusions, methods of detecting such fusions, methods of identifying or diagnosing patients with such fusions, and treating cancers, tumors or disorders comprising NRG1 fusions cell method. Furthermore, the disclosure is in the field of therapeutic (human) antibodies for use in the treatment of individuals with ErbB-2/ErbB-3 positive cancers comprising NRG1 fusions.

Proteolytic processing of the extracellular domain of the transmembrane NRG1 isoform releases soluble factors. HRG1-β1 is one of the proteins encoded by the NRG1 gene. NRG1 contains an Ig domain and an EGF-like domain that is necessary for direct binding to the receptor tyrosine kinases ErbB-3 and ErbB-4. The NRG1 gene and its isoforms are known by many different aliases, such as: Neuregulin 1; Pro-NRG1; HRGA; SMDF; HGL; GGF; NDF; , does not encode a protein); Heregulin, α (45kD, ERBB2 P185-activator); Acetylcholine Receptor-Inducing Activity (Acetylcholine Receptor-Inducing Activity); Pro-Neuregulin-1 (Pro-Neuregulin-1), for Membrane-bound isoforms; sensory and motor neuron-derived factors; Neu Differentiation Factor; glial growth factor 2; NRG1-IT2; MSTP131; MST131; ARIA; GGF2; HRG1; and HRG. The external Ids of the NRG1 gene are HGNC: 7997; Entrez Gene: 3084; Ensembl: ENSG00000157168; OMIM: 142445 and UniProtKB: Q02297.

Isomorphic systems of NRG1 are produced by alternative splicing and include transmembrane, external membrane-bound, shed, secreted, or intracellular forms (Exp Cell Res 284: 14–30 in Falls, 2003; Hayes et al. Gullick, J. Mammary Gland Biol Neoplasia 13: 205-214, 2008). These bind to ErbB-3 or ErbB-4, which is understood to facilitate heterodimer formation with ErbB-2 (HER2). Although the NRG1-encoded protein is generally considered a mitogen, it is also a potent promoter of apoptosis: in particular, expression of NRG1 in cells can cause apoptosis in such expressing cells (see Weinstein et al. oncogene 17: 2107 –2113, 1998).

Given the variety of tumor types with NRG1 fusions, there is a need for faster and more robust diagnostic methods based on novel fusion partners and new breakpoints between NRG1 and fusion partners, and the need to identify previously unknown NRGs Fusion method.

The present disclosure generally provides fusions involving NRG1 and novel fusion partners, as well as polypeptide fusions encoded thereby. The present disclosure provides a fusion involving NRG1 and VAPB, NRG1 and PVALB, NRG1 and DAAM1, NRG1 and ASPH, NRG1 and ZFAT, or NRG1 and DSCAML1 as novel fusion partners, generally referred to herein as VAPB- NRG1, PVALB-NRG1, DAAM1-NRG1, ASPH-NRG1, ZFAT-NRG1 and DSCAML1-NRG1. More particularly, this aspect of this disclosure relates to: a polynucleotide comprising a VAPB nucleic acid sequence or a portion of a VAPB nucleic acid sequence fused to a portion of an NRG1 nucleic acid sequence or a portion of an NRG1 nucleic acid sequence, or A polynucleotide comprising a PVALB nucleic acid sequence or a portion of a PVALB nucleic acid sequence fused to a portion of an NRG1 nucleic acid sequence or a portion of an NRG1 nucleic acid sequence, or A polynucleotide comprising a DAAM1 nucleic acid sequence or a portion of a DAAM1 nucleic acid sequence fused to a portion of an NRG1 nucleic acid sequence or a portion of an NRG1 nucleic acid sequence, or a polynucleotide comprising an ASPH nucleic acid sequence or a portion of an ASPH nucleic acid sequence fused to a portion of an NRG1 nucleic acid sequence or a portion of an NRG1 nucleic acid sequence, or A polynucleotide comprising a ZFAT nucleic acid sequence or a part of a ZFAT nucleic acid sequence fused to a part of an NRG1 nucleic acid sequence or a part of an NRG1 nucleic acid sequence, or A polynucleotide comprising a DSCAML1 nucleic acid sequence or a part of a DSCAML1 nucleic acid sequence fused to a part of an NRG1 nucleic acid sequence or a part of an NRG1 nucleic acid sequence.

Preferably, the VAPB nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 17-23 or consists of it, or comprises an allele variation of any one of the SEQ ID NOs: 17-23 body (part of) or consists of. Preferably, the NRG1 nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 125-138 or consists of, or comprises an allele of any one of the sequences SEQ ID NO: 125-138 or consisting of (part of) a variant.

Alternatively or in addition, the present disclosure provides an allele variant comprising exon 1 or exon 1 of VAPB and its allele with exon 2 or exon 2 of NRG1 A polynucleotide in which a portion of a variant is fused. Preferably, VAPB exon 1 comprises or consists of SEQ ID NO: 17, and its allele variant is preferably a variant of SEQ ID NO: 17. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

Preferably, the PVALB nucleic acid sequence comprises (a part of) any of the sequences SEQ ID NO: 439-444 or consists of, or comprises an allele variation of any of SEQ ID NO: 439-444 body (part of) or consists of. Preferably, the NRG1 nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 125-138 or consists of, or comprises an allele of any one of the sequences SEQ ID NO: 125-138 or consisting of (part of) a variant.

Alternatively or in addition, the present disclosure provides an allele variant comprising exon 4 or exon 4 of PVALB and its allele with exon 6 or exon 6 of NRG1 A polynucleotide in which a portion of a variant is fused. Preferably, exon 4 of PVALB comprises or consists of SEQ ID NO: 422, and its allele variant is preferably a variant of SEQ ID NO: 422. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

Preferably, the DAAM1 nucleic acid sequence comprises (a part of) any of the sequences SEQ ID NO: 606-631 or consists of, or comprises an allele variation of any of SEQ ID NO: 606-631 body (part of) or consists of. Preferably, the NRG1 nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 125-138 or consists of, or comprises an allele of any one of the sequences SEQ ID NO: 125-138 or consisting of (part of) a variant.

Alternatively or in addition, the present disclosure provides an allele variant comprising a portion of DAAM1 exon 1 or exon 1 allele variant with NRG1 exon 1 or exon 1 allele A polynucleotide in which a portion of a variant is fused. Preferably, exon 1 of DAAM1 comprises or consists of SEQ ID NO: 606, and its allele variant is preferably a variant of SEQ ID NO: 606. Exon 1 of NRG1 comprises or consists of SEQ ID NO: 125, and its allele variant is preferably a variant of SEQ ID NO: 125.

Preferably, the ASPH nucleic acid sequence comprises (a part of) any of the sequences SEQ ID NO: 637-662 or consists of, or comprises an allele variation of any of SEQ ID NO: 637-662 body (part of) or consists of. Preferably, the NRG1 nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 125-138 or consists of, or comprises an allele of any one of the sequences SEQ ID NO: 125-138 or consisting of (part of) a variant.

Alternatively or in addition, the present disclosure provides an allele variant comprising exon 22 or exon 22 of ASPH and its allele with exon 2 or exon 2 of NRG1 A polynucleotide in which a portion of a variant is fused. Preferably, ASPH exon 22 comprises or consists of SEQ ID NO: 658, and the allele variant thereof is preferably a variant of SEQ ID NO: 658. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

Preferably, the ZFAT nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 830-846 or consists of, or comprises an allele variation of any one of the SEQ ID NOs: 830-846 body (part of) or consists of. Preferably, the NRG1 nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 125-138 or consists of, or comprises an allele of any one of the sequences SEQ ID NO: 125-138 or consisting of (part of) a variant.

Alternatively or in addition, the present disclosure provides an allele variant comprising exon 12 or exon 12 of ZFAT and its allele with exon 6 or exon 6 of NRG1 A polynucleotide in which a portion of a variant is fused. Preferably, ZFAT exon 12 comprises or consists of SEQ ID NO: 841, and its allele variant is preferably a variant of SEQ ID NO: 841. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

Preferably, the DSCAML1 nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 870-903 or consists of, or comprises an allele variation of any one of SEQ ID NO: 870-903 body (part of) or consists of. Preferably, the NRG1 nucleic acid sequence comprises (a part of) any one of the sequences SEQ ID NO: 125-138 or consists of, or comprises an allele of any one of the sequences SEQ ID NO: 125-138 or consisting of (part of) a variant.

Alternatively or in addition, the present disclosure provides an allele variant comprising exon 3 or exon 3 of DSCAML1 and its allele with exon 2 or exon 2 of NRG1 A polynucleotide in which a portion of a variant is fused. Preferably, exon 3 of DSCAML1 comprises or consists of SEQ ID NO: 872, and the allele variant thereof is preferably a variant of SEQ ID NO: 872. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

Additionally, the present disclosure provides fusions involving NRG1 having previously undisclosed fusion junctions, as well as polypeptide fusions encoded thereby. In particular, the present disclosure additionally provides fusions involving NRG1 and CADM1, generally referred to herein as CADM1-NRG1. The present disclosure also provides fusions involving NRG1 and CD44, generally referred to herein as CD44-NRG1. The present disclosure also provides fusions involving NRG1 and SLC3A2, generally referred to herein as SLC3A2-NRG1. The present disclosure also provides fusions involving NRG1 and VTCN1, generally referred to herein as VTCN1-NRG1. The present disclosure also provides fusions involving NRG1 and CDH1, generally referred to herein as CDH1-NRG1. The present disclosure also provides fusions involving NRG1 and CXADR, generally referred to herein as CXADR-NRG1. The present disclosure also provides fusions involving NRG1 and GTF2E2, generally referred to herein as GTF2E2-NRG1. The present disclosure also provides fusions involving NRG1 and CSMD1, generally referred to herein as CSMD1-NRG1. The present disclosure also provides fusions involving NRG1 and PTN, generally referred to herein as PTN-NRG1. The present disclosure also provides fusions involving NRG1 and ST14, generally referred to herein as ST14-NRG1. The present disclosure also provides fusions involving NRG1 and THBS1, generally referred to herein as THBS1-NRG1. The present disclosure also provides fusions involving NRG1 and AGRN, generally referred to herein as AGRN-NRG1. The present disclosure also provides fusions involving NRG1 and APP, generally referred to herein as APP-NRG1. The present disclosure also provides fusions involving NRG1 and WRN, generally referred to herein as WRN-NRG1. The present disclosure also provides fusions involving NRG1 and NRG1, generally referred to herein as NRG1-NRG1. The present disclosure also provides fusions involving NRG1 and NOTCH2, generally referred to herein as NOTCH2-NRG1. The present disclosure also provides fusions involving NRG1 and CD74, generally referred to herein as CD74-NRG1. The present disclosure also provides fusions involving NRG1 and SDC4, generally referred to herein as SDC4-NRG1. The present disclosure also provides fusions involving NRG1 and SLC4A4, generally referred to herein as SLC4A4-NRG1.

The present disclosure provides the following novel fusion junctions. In particular, the present disclosure provides a multikaryon comprising exon 7 or a portion of an allogenic variant of exon 7 of CADM1 fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 7 of CADM1 comprises or consists of SEQ ID NO: 39, and its allele variant is preferably a variant of SEQ ID NO: 39. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the disclosure provides a multinuclear CD44 comprising exon 5 or a portion of an allogenic variant of exon 5 fused to exon 2 or a portion of an allogenic variant of NRG1 glycosides. Preferably, exon 5 of CD44 comprises or consists of SEQ ID NO: 65, and the allele variant thereof is preferably a variant of SEQ ID NO: 65. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the disclosure provides a multinuclear CD44 comprising exon 5 or a portion of an allogenic variant of exon 5 fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 5 of CD44 comprises or consists of SEQ ID NO: 65, and the allele variant thereof is preferably a variant of SEQ ID NO: 65. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides an allele variant comprising exon 1 of transcript 6 of SLC3A2 or a part of an allele variant of exon 1 of transcript 6 and paired with exon 5 or exon 2 of NRG1 A polynucleotide in which a portion of a gene variant is fused. Preferably, the exon of SLC3A2 comprises or consists of SEQ ID NO: 103, and the allele variant thereof is preferably a variant of SEQ ID NO: 103. Exon 5 of NRG1 comprises or consists of SEQ ID NO: 129, and the allele variant thereof is preferably a variant of SEQ ID NO: 129.

In particular, the present disclosure provides a multikaryon comprising exon 2 or part of an allogenic variant of exon 2 of VTCN1 fused to exon 2 or part of an allogenic variant of exon 2 of NRG1 glycosides. Preferably, VTCN1 exon 2 comprises or consists of SEQ ID NO: 169, and its allele variant is preferably a variant of SEQ ID NO: 169. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the present disclosure provides a multikaryon comprising exon 11 or part of an allogenic variant of exon 11 of CDH1 fused to exon 2 or part of an allogenic variant of exon 2 of NRG1 glycosides. Preferably, exon 11 of CDH1 comprises or consists of SEQ ID NO: 198, and the allele variant thereof is preferably a variant of SEQ ID NO: 198. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the present disclosure provides a multinuclear CXADR comprising exon 1 or part of an allogenic variant of exon 1 fused to exon 2 or part of an allogenic variant of exon 2 of NRG1 glycosides. Preferably, CXADR exon 1 comprises or consists of SEQ ID NO: 219, and its allele variant is preferably a variant of SEQ ID NO: 219. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the present disclosure provides a multikaryon comprising exon 2 or part of an allogenic variant of exon 2 of GTF2E2 fused to exon 2 or part of an allogenic variant of exon 2 of NRG1 glycosides. Preferably, exon 2 of GTF2E2 comprises or consists of SEQ ID NO: 236, and the allele variant thereof is preferably a variant of SEQ ID NO: 236. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the present disclosure provides a multikaryon comprising exon 23 or a portion of an allogenic variant of exon 23 of CSMD1 fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 23 of CSMD1 comprises or consists of SEQ ID NO: 279, and its allele variant is preferably a variant of SEQ ID NO: 279. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a multikaryon comprising exon 4 or part of an allogenic variant of exon 4 of PTN fused to exon 2 or part of an allogenic variant of exon 2 of NRG1 glycosides. Preferably, PTN exon 4 comprises or consists of SEQ ID NO: 318, and its allele variant is preferably a variant of SEQ ID NO: 318. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the present disclosure provides a multikaryon comprising exon 11 or a portion of an allogenic variant of exon 11 of ST14 fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 11 of ST14 comprises or consists of SEQ ID NO: 342, and the allele variant thereof is preferably a variant of SEQ ID NO: 342. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a multikaryon comprising exon 9 or part of an allogenic variant of exon 9 of THBS1 fused to exon 6 or part of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 9 of THBS1 comprises or consists of SEQ ID NO: 386, and the allele variant thereof is preferably a variant of SEQ ID NO: 386. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a multikaryon comprising exon 12 or a portion of an allogenic variant of exon 12 of AGRN fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 12 of AGRN comprises or consists of SEQ ID NO: 416, and the allele variant thereof is preferably a variant of SEQ ID NO: 416. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a multinuclear polynucleotide comprising exon 4 or a portion of an allogenic variant of exon 4 of PVALB fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 4 of PVALB comprises or consists of SEQ ID NO: 442, and the allele variant thereof is preferably a variant of SEQ ID NO: 442. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a part of an allele variant comprising exon 2 of transcript 3 or exon 2 of transcript 3 of SLC3A2 and its pairing with exon 6 or exon 6 of NRG1 A polynucleotide in which a portion of a gene variant is fused. Preferably, the exon of SLC3A2 comprises or consists of SEQ ID NO: 457, and its allele variant is preferably a variant of SEQ ID NO: 457. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a multikaryon comprising exon 14 or a portion of an allogenic variant of exon 14 of APP fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, APP exon 14 comprises or consists of SEQ ID NO: 501, and its allele variant is preferably a variant of SEQ ID NO: 501. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a multinuclear WRN comprising exon 33 or a portion of an allogenic variant of exon 33 fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, WRN exon 33 comprises or consists of SEQ ID NO: 562, and its allele variant is preferably a variant of SEQ ID NO: 562. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a multikaryon comprising exon 6 or a portion of an allogenic variant of exon 6 of NOTCH2 fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 6 of NOTCH2 comprises or consists of SEQ ID NO: 700, and the allele variant thereof is preferably a variant of SEQ ID NO: 700. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

In particular, the present disclosure provides a multinuclear CD74 comprising exon 2 or part of an allogenic variant of exon 2 fused to exon 2 or part of an allogenic variant of exon 2 of NRG1 glycosides. Preferably, exon 2 of CD74 comprises or consists of SEQ ID NO: 720, and the allele variant thereof is preferably a variant of SEQ ID NO: 720. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the present disclosure provides a multikaryon comprising exon 2 or part of an allogenic variant of exon 2 of SDC4 fused to exon 2 or part of an allogenic variant of exon 2 of NRG1 glycosides. Preferably, exon 2 of SDC4 comprises or consists of SEQ ID NO: 746, and the allele variant thereof is preferably a variant of SEQ ID NO: 746. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the present disclosure provides a multikaryon comprising exon 4 or a portion of an allogenic variant of exon 4 of SDC4 fused to exon 2 or a portion of an allogenic variant of exon 2 of NRG1 glycosides. Preferably, exon 4 of SDC4 comprises or consists of SEQ ID NO: 748, and the allele variant thereof is preferably a variant of SEQ ID NO: 748. NRG1 exon 2 comprises or consists of SEQ ID NO: 126, and its allele variant is preferably a variant of SEQ ID NO: 126.

In particular, the present disclosure provides a multinuclear polynucleotide comprising exon 14 or a portion of an allogenic variant of exon 14 of SLC4A4 fused to exon 6 or a portion of an allogenic variant of exon 6 of NRG1 glycosides. Preferably, exon 14 of SLC4A4 comprises or consists of SEQ ID NO: 780, and the allele variant thereof is preferably a variant of SEQ ID NO: 780. Exon 6 of NRG1 comprises or consists of SEQ ID NO: 130, and its allele variant is preferably a variant of SEQ ID NO: 130.

The NRG1 fusions provided herein have all been observed in samples derived from patients, particularly patients diagnosed with cancer.

The disclosed identification of these NRG1 fusions and gene rearrangements may provide new methods for determining whether NRG1 polynucleotide fusions or polypeptides are present in or derived from biological samples, methods for determining the activity of NRG1 polypeptide fusions , a method for diagnosing a cancer, tumor or abnormal cell expressing an NRG1 polypeptide fusion, a method for determining the activity of an NRG1 polypeptide fusion, a method for treating a cancer, tumor or abnormal cell expressing an NRG1 polypeptide fusion , and/or a method of inhibiting the course of a neoplasia characterized by NRG1 polynucleotide fusions or polypeptides. The present disclosure therefore also provides these or more aspects and are described in detail below.

The disclosure also provides a polypeptide fusion encoded by any polynucleotide fusion selected from the group consisting of: VAPB-NRG1, CADM1-NRG1 CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4- NRG1, SLC4A4-NRG1, ZFAT-NRG1 and DSCAML1-NRG1. When any polypeptide fusion of the present disclosure is expressed by the abnormal cells mentioned herein, it preferably also comprises the EGF-like domain of NRG1. When any one of the polynucleotide fusions of the present disclosure is contained in the abnormal cells mentioned herein, it preferably comprises an NRG1 exon encoding an EGF-like domain, such as NRG1 exon 6, 7 or 8 , preferably comprising exons 6 and 7 of the NRG1 polynucleotide sequence.

A vector comprising the polynucleotide fusion of the present disclosure, a host cell comprising the polynucleotide and/or the vector are also provided. Also provided is a method of producing a polypeptide of the present disclosure, comprising maintaining the recombinant host cell under conditions suitable for expression of the polynucleotide, thereby expressing the polynucleotide fusion and producing a polypeptide fusion, followed by isolation or purification The peptide. Also provided is a method of producing a recombinant host cell, comprising introducing the vector into the host cell.

Also provided are a nucleic acid probe, primer or primer pair for detecting a polynucleotide fusion of the present disclosure and an assay comprising a nucleic acid probe, primer or primer pair for detecting the presence of a polynucleotide fusion of the present disclosure Assay. Such nucleic acid probes, primers or primer pairs of the present disclosure preferably have a length of 10-40 nucleotides.

Also provided are a first antibody or a pair of first and second antibodies for detecting a polypeptide encoded by a polynucleotide fusion of the present disclosure, and a pair of antibodies comprising the first antibody or the pair of first and second antibodies With detection assays for detecting the presence of polypeptides encoded by polynucleotide fusions of the present disclosure. Preferably, the first antibody binds to a polypeptide fusion selected from: VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4-NRG1, SLC4A4- NRG1, ZFAT-NRG1 and DSCAML1-NRG1, and the first and second antibody pair groups are respectively associated with VAPB and NRG1, or CADM1 and NRG1, or CD44 and NRG1, or SLC3A2 and NRG1, or VTCN1 and NRG1, or CDH1 and NRG1 , or CXADR and NRG1, or GTF2E2 and NRG1, or CSMD1 and NRG1, or PTN and NRG1, or ST14 and NRG1, or THBS1 and NRG1, or AGRN and NRG1, or PVALB and NRG1, APP and NRG1, or WRN and NRG1, Or ASPH and NRG1, or NOTCH2 and NRG1, or CD74 and NRG1, or SDC4 and NRG1, or SLC4A4 and NRG1, or ZFAT and NRG1, or DSCAML1 and NRG1 combined.

The present disclosure includes methods of identifying or detecting NRG1 fusions in a human subject, and further encompasses methods of diagnosis, treatment selection, and drug therapy, and combinations thereof, to ameliorate NRG1 fusion-associated diseases, including solid tumors. Among other things, the present disclosure provides a straightforward means or assay to quickly assess whether an individual has or is predisposed to cancer, tumor, or abnormal cells. Such NRG1 fusion information can be advantageously used as a biomarker in a diagnostic tool.

Accordingly, there is also provided a method of identifying in a sample any polynucleotide fusion as referred to herein, or a polypeptide encoded thereby, which method comprises testing a sample obtained from an individual to detect in the sample Whether the fusion exists.

Also provided is a method of detecting the presence in a sample of any polynucleotide fusion as referred to herein, or a polypeptide encoded thereby, said method comprising testing a sample obtained from an individual to detect in the sample Whether the fusion exists.

Also provided is a method of determining whether an abnormal cell from an individual, such as a cancer cell or a tumor cell, comprises any of the polynucleotide fusions mentioned herein, or a polypeptide encoded thereby, comprising testing the Whether the cells of the individual or the polynucleotide or polypeptide content of the cells are present in the sample with the fusion.

Also provided is a method of identifying an individual carrying a polynucleotide fusion referred to herein, or a polypeptide encoded thereby, said method comprising testing a sample obtained from an individual to detect the presence of the fusion in the sample . Preferably the test is followed by the step of associating the fusion detected in the sample with the individual carrying the fusion.

The testing of samples referred to herein is preferably part of an in vitro analysis or such method, or an ex vivo analysis or such method.

Preferably, the individual is a mammalian or human individual and the polynucleotide or polypeptide is a mammalian or human polynucleotide or polypeptide.

Preferably, any of the polynucleotide fusions mentioned herein and/or the polypeptides encoded thereby mentioned herein are isolated and/or purified or substantially isolated or substantially purified.

This disclosure relates to individuals suffering from or suspected of having cancer, especially solid cancer or tumors. In particular, such cancer is adenocarcinoma, more especially mucinous adenocarcinoma, pancreatic cancer, more especially pancreatic adenocarcinoma, or renal cell carcinoma, cholangiocarcinoma, brain cancer, glioblastoma, cholangiocarcinoma, glial Tumor, pancreatic duct adenocarcinoma, sarcoma, bladder cancer, colorectal cancer, rectal cancer, colorectal cancer, gallbladder cancer, head and neck cancer, prostate cancer, uterine cancer, breast cancer, ovarian cancer, liver cancer, endometrial cancer, lung cancer, especially non- Small cell lung cancer, or invasive mucinous adenocarcinoma. The cancer can be a primary cancer or a metastatic cancer.

The present disclosure also provides a method of treating an individual suffering from ErbB-2 and/or ErbB-3 positive abnormal cells (such as cancer or tumor), said abnormal cells comprising the polynucleotide fusions mentioned herein, and/ Or such cells express a polypeptide fusion encoded thereby, the method comprising administering to the individual a therapeutic amount of an ErbB-2 and/or ErbB-3 targeting agent. Preferably, the polynucleotide or polypeptide fusions mentioned herein are detected prior to administration of said targeting agent.

The present disclosure also provides a method of inhibiting the disease course of an individual suffering from ErbB-2 and ErbB-3 positive abnormal cells comprising and/or expressing the polynucleotide fusions mentioned herein. A polypeptide fusion, the method comprising administering to the individual a therapeutic amount of an ErbB-2 and/or ErbB-3 targeting agent. Preferably, the polynucleotide or polypeptide fusions mentioned herein are detected prior to administration of said targeting agent.

The disclosure also provides an ErbB-2 and/or ErbB-3 targeting agent for use in the treatment of an individual with an ErbB-2 and ErbB-3 positive cancer or tumor, including the cancers or tumors mentioned herein and a polynucleotide fusion thereof, and/or a polypeptide fusion encoded thereby, wherein the treatment comprises administering to the individual a therapeutic amount of an ErbB-2 and/or ErbB-3 targeting agent. Preferably, the polynucleotide or polypeptide fusions mentioned herein are detected prior to administration of said targeting agent.

The disclosure also provides a method of diagnosing an individual with abnormal cells comprising a polypeptide encoded by a polynucleotide fusion mentioned herein, the method comprising testing a sample obtained from the individual to detect whether This fusion exists.

The present disclosure also provides a treatment method or use of an ErbB-2 and/or ErbB-3 targeting agent, wherein an individual is screened for the presence of the NGR1 fusion mentioned herein, and then administered ErbB-2 and/or ErbB- 3 targeting agents.

The present disclosure also includes in vivo models, such as xenograft or transgenic animal models of transplanted abnormal cells expressing in their genes or comprising the polynucleotide fusions mentioned herein, and/or expressing the genes encoded by them. and treatment of such models using ERB2 and/or Erb3 targeting agents or other targeting agents. Preferably, the animal model is a non-human animal model.

The present disclosure provides fusions involving NRG1 and novel fusion partners, as well as polypeptide fusions encoded thereby. In addition, the present disclosure provides fusions involving NRG1 with previously undisclosed fusion junctions, as well as polypeptide fusions encoded thereby.

In general, the present disclosure provides fusions involving NRG1 and a fusion partner selected from the group consisting of VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB , APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1. Said fusions are referred to herein as VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14 -NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, DAAM1-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4-NRG1, SLC4A4-NRG1, ZFAT-NRG1 or DSCAML1-NRG1. The presence of any of the NRG1 fusions of the present disclosure, whether polynucleotides or polypeptides translated therefrom, indicates the presence of abnormal cells such as cancer or tumors. NRG1

The NRG1 gene encodes various isoforms of NRG1. Various isoforms and their predicted functions are described in Adelaide et al. Genes Chromosomes Cancer, Aug; 37(4):333-45 (2003). The GGF and GGF2 isoforms contain kringle-like sequences plus Ig and EGF-like domains; and the SMDF isoforms share only the EGF-like domain with the other isoforms. The receptors for the NRG1 isoforms are the ErbB family of tyrosine kinase transmembrane receptors. This family is also known as the human epidermal growth factor (EGF) receptor family (HER). There are four members of this family: ErbB (erythroblastoma)-1, ErbB-2, ErbB-3, and ErbB-4. The receptor (reviewed in Yarden and Pines, Nat Rev Cancer. 2012 Jul 12;12(8):553-63) is widely expressed on epithelial cells. Upregulation of HER receptors or their ligands, such as heregulin (HRG) or epidermal growth factor (EGF), is a common event in human cancers (Wilson, Fridlyand et al., Nature. 2012 Jul 26; 487(7408): 505–509). Overexpression of ErbB-1 and ErbB-2 occurs particularly in epithelial tumors and is associated with tumor invasion, metastasis, chemotherapy resistance, and poor prognosis (Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R. et al. (2007) Erbb receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest., 117, 2051- 2058). In the normal breast, ErbB-3 has been shown to be important in the growth and differentiation of the luminal epithelium. For example, loss/inhibition of ErbB-3 leads to basal-selective expansion on luminal epithelium (Balko, Miller et al., 2012 PNAS January 3, 2012 109 (1) 221-226). Ligand binding to the extracellular domain of a tyrosine kinase receptor induces receptor dimerization between the same (homodimerization) and different (heterodimerization) receptors Between isoforms. Dimerization can activate intracellular tyrosine kinase domains, allowing these domains to autophosphorylate and subsequently activate many downstream pro-proliferative signaling pathways, including mitogen-activated protein kinase (MAPK ) and the pathway mediated by the pro-survival pathway Akt (reviewed in Yarden and Pines, 2012). ErbB-3 can be activated by engagement of its ligands. These ligands include but are not limited to neuregulin (NRG) and Neuromodulatory factor (HRG), and NRG1 fusions.

Various NRG1 fusion gene lines are described in Dhanasekaran et al. Nature Communications 5:5893, 2014, and Jonna et al., Clin Cancer Res August 15 2019, 25 (16) 4966-4972.

The term "NRG1" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. The NRG1 gene and its isoforms are known by many different aliases, such as: Neuregulin 1; Pro-NRG1; HRGA; SMDF; HGL; GGF; NDF; , does not encode a protein); Heregulin, α (45kD, ERBB2 P185-activator); Acetylcholine Receptor-Inducing Activity (Acetylcholine Receptor-Inducing Activity); Pro-Neuregulin-1 (Pro-Neuregulin-1), for Membrane-bound isoforms; sensory and motor neuron-derived factors; Neu Differentiation Factor; glial growth factor 2; NRG1-IT2; MSTP131; MST131; ARIA; GGF2; HRG1; and HRG. The external Ids of the NRG1 gene are HGNC: 7997; Entrez Gene: 3084; Ensembl: ENSG00000157168; OMIM: 142445 and UniProtKB: Q02297. For the avoidance of doubt, a sequence with NRG1 refers to any polynucleotide sequence, including coding sequence or any exon, but also any A polypeptide sequence, or any portion thereof. Preferably, the entire polynucleotide sequence of NRG1 disclosed herein is transcribed according to SEQ ID NO: 138, and the transcribed polypeptide sequence of NRG1 is transcribed according to SEQ ID NO: 152.

Preferably, the polynucleotide fusion part encoding NRG1 protein sequence or NRG1 exon further comprises or encodes the EGF-like domain of NRG1. The NRG1 gene in the fusion (eg the 3' end of the NRG1 gene) preferably comprises the coding sequence of exon 6, 7 or 8. This domain is encoded by the portion located 3' of the NRG1 gene (eg, exons 6-8) and is necessary for binding to ErbB-3. The NRG1 fusion gene preferably comprises a nucleic acid sequence encoding the EGF-like domain of NRG1. The NRG1 fusions of the present disclosure preferably retain the in-frame coding region of the EGF-like domain at the 3' end of the fusion molecule. The EGF-like domain is generally a sequence of about thirty to forty amino acid residues long, and its prototype is found in the sequence of epidermal growth factor (EGF) [PMID: 2288911, PMID: 6334307, PMID: 1522591, PMID: 6607417, PMID: 3282918, PMID: 11498013]. It is known to exist in a roughly conserved form among many other, mainly animal, proteins. A common feature of EGF-like domains is that they are found in the extracellular domain of membrane-bound proteins or proteins known to be secreted (exception: prostaglandin G/H synthase). EGF-like domains generally include six cysteine residues, which (in EGF) have been shown to involve disulfide bonds. The main structure is a double-stranded beta flap followed by a short double-stranded flap looped to the C-terminus. The subdomains between conserved cysteines vary in length. The exemplary EGF-like domain of the present disclosure is preferably composed of exons 6-8 of NCBI reference sequence NM_001159999.3, more preferably exons 6 and 7, but the present disclosure is not related to any aspect of NRG1 Functional EGF-like domain. The EGF-like domain of NRG1 therefore preferably comprises, or is at least 85% identical to, or at least 90%, 92%, 94%, 95%, 96% or Even allele variants with at least 98% identity.

Any NRG1 fusion polynucleotide disclosed herein preferably at least comprises VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, The 5' part of ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1 was used as a fusion partner to fuse with the 3' part of the NRG1 nucleic acid sequence. The translated polypeptide fusion comprises the free C-terminus of the NRG1 fusion polypeptide and the free N-terminus of the fusion partner. To reflect this alignment at the molecular fusion level, either fusion partner of NRG1 is mentioned first, followed by NRG1 as its fusion partner. VAPB

VAPB or vesicle-associated membrane protein-associated protein B/C are known by many different names, such as VAMP-associated protein B and C; VAMP (vesicle-associated membrane protein)-associated protein B and C; VAP-B; VAPB; ALS8; VAMP-related 33 KDa protein; VAMP-related protein B/C; VAMP-B/VAMP-C; VAP-B/VAP-C; VAMP-B and VAP-C. The external Ids of the VAPB gene are HGNC: 12649; Entrez Gene: 9217; Ensembl: ENSG00000124164; OMIM: 605704; and UniProtKB: 095292. The term "VAPB" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, a VAPB sequence refers to any polynucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI Reference Sequence NM_004738.4 or any allogenic variant thereof sequence, or any part thereof. CADM1

CADM1 or cell adhesion molecule 1 is known by many different names such as lung cancer tumor suppressor 1; TSLC1; TSLC-1; spermatogenic immunoglobulin superfamily; SgIgSF; SgIGSF; immunoglobulin superfamily member 4; IGSF4; IgSF4 ; IGSF4A; Synaptic cell adhesion molecule; SynCAM1; SYNCAM1; SynCAM; SYNCAM; Nectin-like protein 2; NECL2; NECL-2; Nectin-like 2; Necl-2; RA175; ST17; BL2; Variant 1; member of the immunoglobulin superfamily 4D variant 2; member of the immunoglobulin superfamily 4; TSLC1/Nectin-like 2/IGSF4; truncated CADM1 protein 1 and STSLC-1. The external Ids of CADM1 are HGNC: 5951; Entrez Gene: 23705; Ensembl: ENSG00000182985; OMIM: 605686; and UniProtKB: Q9BY67. The term "CADM1" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, carrying a CADM1 sequence means carrying any polynucleotide sequence, including coding sequence or any exon, but also including any polypeptide, derived from such as NCBI Reference Sequence NM_001301045.1 or any allogenic variant thereof sequence, or any part thereof. CD44

CD44 is known by many different names such as CD44 molecule (Indian blood group); hematopoietic E- and L-selectin ligand; GP90 lymphocyte homing/adhesion receptor; chondroitin sulfate proteoglycan; extracellular matrix Receptor III; Chondroitin Sulfate Proteoglycan; Phagocyte Glycoprotein 1; Hyaluronic Acid Receptor; Hermes Antigen; CD44 Antigen; ECMR-III; HUTCH-I; Epican; MDU2; MDU3; MIC4; LHR; CD44 antigen (homing function and Indian blood group system); homing function and Indian blood group system; cell surface glycoprotein CD44; Indian blood group antigen; phagocyte glycoprotein I; soluble CD44; CDW44; CSPG8; HCELL; CDw44; PGP -1; MC56; Pgpl; and In. The external Ids of the CD44 gene are HGNC: 1681; Entrez Gene: 960; Ensembl: ENSG00000026508; OMIM: 107269; and UniProtKB: P16070. The term "CD44" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, carrying NRG1 sequence refers to carrying any polynucleotide sequence, including coding sequence or any exon, but also including any polypeptide, derived from such as CD44 reference sequence NM_000610. sequence, or any part thereof. SLC3A2

SLC3A2 or solute carrier family 3 member 2 is known by many different names, such as lymphocyte activation antigen 4F2 large subunit; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 ; antigen recognized by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43; solute carrier family 3 (amino acid transporter heavy chain), member 2; 4F2 cell surface antigen heavy chain; CD98 heavy chain; 4F2HC; MDU1 Antigen defined by monoclonal antibody 4F2, heavy chain; Antigen defined by monoclonal antibody 4F2; 4F2 heavy chain antigen; 4F2 heavy chain; CD98 antigen; CD98HC; 4T2HC; NACAE; CD98 and 4F2. The external Ids of SLC3A2 are HGNC: 11026; Entrez Gene: 6520; Ensembl: ENSG00000168003; OMIM: 158070; and UniProtKB: P08195. The term "SLC3A2" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, a sequence with SLC3A2 transcript 6 refers to any polynucleotide sequence, including coding sequence or any exon, from such as NCBI reference sequence NM_001013251.3 or any of its allele variants, but also Include any polypeptide sequence, or any portion thereof. And with SLC3A2 transcript 3 sequence refers to any polynucleotide sequence from such as NCBI reference sequence NM_001013251.3 or any of its allele variants, including coding sequence or any exon, but also includes any polypeptide sequence, or any part thereof. VTCN1

VTCN1 is known by many different names, such as V-Set domain containing inhibitor of T cell activation 1; B7-H4; B7H4; immune co-stimulatory protein B7-H4; B7 superfamily member 1; B7 family member, H4; B7 homologue 4; B7h.5; B7S1; T cell co-stimulatory molecule B7x; protein B7S1; The external Ids of VTCN1 are HGNC: 28873; NCBI Entrez Gene: 79679; Ensembl: ENSG00000134258; OMIM®: 608162 and UniProtKB/Swiss-Prot: Q7Z7D3. The term "VTCN1" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, carrying a VTCN1 sequence means carrying any nucleotide sequence, including coding sequence or any exon, but also including any polypeptide, derived from such as NCBI reference sequence NM_024626. sequence, or any part thereof. CDH1

CDH1 or Cadherin 1 is known by many different names such as Uvomorulin; Cadherin 1, type 1, E-cadherin (epithelial); Epithelial-cadherin; E-cadherin Protein; Cadherin-1; CAM 120/80; CD324; CDHE; UVO; CAM 120/80; CD324 antigen; E-cadherin; Arc-1; BCDS1; ECAD; and LCAM. The external Ids of CDH1 are HGNC: 1748; NCBI Entrez Gene: 999; Ensembl: ENSG00000039068; OMIM®: 192090 and UniProtKB/Swiss-Prot: P12830. The term "CDH1" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, carrying a CDH1 sequence means carrying any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI reference sequence NM_001317185.2 or any allogenic variant sequence, or any part thereof. CXADR

CXADR, or coxsackievirus and adenovirus receptor, is a type I membrane receptor for group B coxsackieviruses and subgroup C adenoviruses. Several transcript variants encoding different isoforms of this gene have been found. Diseases associated with CXADR include myocarditis and keratoconjunctivitis. Associated pathways include adhesion and allograft rejection. It is a component of the apical junctional complex of epithelial cells, functions as a homophilic cell adhesion molecule, and is critical for the integrity of cellular tight junctions. It is also involved in the migration of leukocytes across epithelial cells through adhesive interactions with the transmembrane protein JAML of the leukocyte membrane plasma membrane. Interactions between these two receptors also mediate the activation of γ-δ T cells, an epithelial-resident T cell subpopulation, and are involved in tissue homeostasis and repair. Upon CXADR binding in epithelial cells, JAML mediates downstream cell signaling events in γ-δ T cells through PI3 kinase and MAP kinase. This stimulates the proliferation and production of cytokines and growth factors by T cells which in turn stimulate epithelial cell tissue repair. External Ids of CXADR include HGNC: 2559 NCBI; Entrez Gene: 1525; Ensembl: ENSG00000154639; OMIM®: 602621; UniProtKB/Swiss-Prot: P78310. The term "CXADR" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, a sequence with CXADR means any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI Reference Sequence NM_001207063.2 or any of its allele variants sequence, or any part thereof. GTF2E2

GTF2E2 or shared transcription factor IIE (TFIIE) is part of the RNA polymerase II transcription initiation complex that takes up TFIIH and is absolutely essential for RNA polymerase II to clear the promoter. TFIIE is a heterodimer (and sometimes a heterotetramer) containing α and β subunits. The protein encoded by this gene expresses the beta subunit of TFIIE. Diseases associated with GTF2E2 include sulfodysplasia6, non-photosensitive sulfodysplasia. The related pathways are the apoptotic pathway in synovial fibroblasts and the CCR5 pathway in macrophages. External Ids of GTF2E2 include HGNC: 4651; NCBI Entrez Gene: 2961; Ensembl: ENSG00000197265; OMIM®: 189964; UniProtKB/Swiss-Prot: P29084. The term "GTF2E2" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having a GTF2E2 sequence means having any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI Reference Sequence NM_002095.6 or any of its allele variants sequence, or any part thereof. CSMD1

CSMD1 (or CUB and Sushi Multiple Domain 1) is a protein associated with disorders including autism and schizophrenia. External Ids of CSMD1 include HGNC: 14026; NCBI Entrez Gene: 64478; Ensembl: ENSG00000183117; OMIM®: 608397; UniProtKB/Swiss-Prot: Q96PZ7. The term "CSMD1" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, a sequence with CSMD1 means any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI reference sequence NM_033225.6 or any of its allele variants sequence, or any part thereof. PTN

Pleiotrophin (PTN) protein is a secreted heparin-binding growth factor. This protein plays an important role in cell growth and survival, cell migration, angiogenesis, and tumorigenesis. PTN (Pleiotrophin) is a protein-coding gene. Diseases associated with PTN include Peyronie's Disease and nasal olfactory neuroblastoma. The related pathways include GPCR pathway and apoptosis pathway in synovial membrane fibroblasts. External Ids of PTN include HGNC: 9630; NCBI Entrez Gene: 5764; Ensembl: ENSG00000105894; OMIM®: 162095; UniProtKB/Swiss-Prot: P21246. The term "PTN" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having a PTN sequence means having any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI Reference Sequence NM_001321386.2 or any allogenic variant thereof sequence, or any part thereof. ST14

ST14 or ST14 transmembrane serine protease Matriptase is an epithelial cell-derived membrane host protein serine protease. This protease forms a complex with the Kunitz-type serine protease inhibitor HAI-1 and was found to be activated by sphingosine 1-phosphate. This protease has been shown to cleave and activate hepatocyte growth factor/separator, as well as urokinase plasminogen activator, suggesting a function of this protease as an epithelial membrane activator of other proteases and potential growth factors. Diseases associated with ST14 include different types of ichthyosis. Related pathways include developmental biology and adhesion. External Ids of ST14 include HGNC: 11344; NCBI Entrez Gene: 6768; Ensembl: ENSG00000149418; OMIM®: 606797; UniProtKB/Swiss-Prot: Q9Y5Y6. The term "ST14" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, a sequence with ST14 means any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI reference sequence NM_021978.4 or any of its allele variants sequence, or any part thereof. THBS1

THBS1 or Thrombospondin 1 is a disulfide-linked homotrimeric protein subunit. This protein is an adhesion glycoprotein and mediates cell-cell and cell-matrix interactions. This protein can bind to fibrinogen, fibronectin, laminin, collagen type V, and integrin α-V/β-1. This protein has been shown to play an important role in platelet aggregation, angiogenesis, and tumorigenesis. Diseases associated with THBS1 include thrombotic thrombocytopenic purpura and Peters-Plus syndrome. The related pathways are proteoglycan and extracellular matrix degradation in cancer. Gene Ontology (GO) markers associated with this gene include calcium binding and heparin binding. External Ids of THBS1 include HGNC: 11785; NCBI Entrez Gene: 7057; Ensembl: ENSG00000137801; OMIM®: 188060; UniProtKB/Swiss-Prot: P07996. The term "THBS1" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, carrying a THBS1 sequence means carrying any nucleotide sequence, including coding sequence or any exon, but also including any polypeptide, derived from such as NCBI reference sequence NM_003246.4 or any allele variant sequence, or any part thereof. AGRN

AGRN, or Agrin, is one of several proteins important in the development of the neuromuscular junction. The encoded protein contains several laminin G, Kazal-type serine protein inhibitors, and epidermal growth factor domains. Other post-translational modifications occur in the addition of glycosaminoglycans and disulfide bonds. Mutations in this gene have been found in a family of genes associated with congenital myasthenic syndromes affecting the limb-girdle muscles. Disorders associated with AGRN include myasthenic syndrome, congenital, 8, and presynaptic congenital myasthenic syndrome. Related pathways are Agrin interactions at the neuromuscular junction, the blood-brain barrier, and translocation of immune cells. External Ids of AGRN include HGNC: 329; NCBI Entrez Gene: 375790; Ensembl: ENSG00000188157; OMIM®: 103320; UniProtKB/Swiss-Prot: O00468. The term "AGRN" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having an AGRN sequence means having any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI Reference Sequence NM_001305275.2 or any of its allele variants sequence, or any part thereof. PVALB

PVALB or Parvalbumin is a high-affinity calcium ion-binding protein, which is similar to calmodulin and optic C in structure and function. The encoded protein is thought to be involved in muscle relaxation. Disorders associated with PVALB include fish allergy and fetal alcohol syndrome. Gene ontology markers associated with this gene include calcium ion binding and protein heterodimerization activity. External Ids for PVALB include HGNC: 9704; NCBI Entrez Gene: 5816; Ensembl: ENSG00000100362; OMIM®: 168890; UniProtKB/Swiss-Prot: P20472. The term "PVALB" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having a PVALB sequence means having any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI Reference Sequence NM_002854.3 or any of its allele variants sequence, or any part thereof. app

APP is known by many different names such as amyloid beta precursor protein, alpha-SAPP, AD1, Alzheimer's disease amyloid A4 protein homologue, amyloid beta (A4) precursor protein, Alzheimer's disease Silent disease amyloid, cerebrovascular amyloid peptide, amyloid β precursor protein, amyloid precursor protein, peptidase-linked protein (Nexin)-II, protease-linked protein-II, PN-II, PreA4, ABPP, APPI, CVAP, β-amyloid precursor protein, testicular tissue protein Li 2, β-amyloid peptide (1-40), β-amyloid peptide (1-42), amyloid β-A4 protein, β-amyloid peptide, Alzheimer's disease, CTFγ, ABETA, AAA, PN2 and A4. The external IDs of the APP gene are HGNC: 620; Entrez Gene: 351; Ensembl: ENSG00000142192; OMIM®: 104760 and UniProtKB/Swiss-Prot: P05067. The external Ids of the APP gene are HGNC: 620; Entrez Gene: 351; Ensembl: ENSG00000142192; OMIM®: 104760 and UniProtKB/Swiss-Prot: P05067. The term "APP" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having an APP sequence means having any nucleotide sequence, including coding sequence or any exon, but also including any polypeptide, derived from such as NCBI Reference Sequence NM_001136130.3 or any allogenic variant thereof sequence, or any part thereof. WRN

WRN or Werner Syndrome ATP-dependent helicase is known by many different names such as WRN RecQ-like helicase; RECQL2; RECQ3; Werner syndrome RecQ-like helicase; DNA helicase , RecQ-like type 3; RecQ protein-like 2; exonuclease WRN; Werner syndrome, RecQ helicase-like; Werner syndrome; EC 3.6.4.12; RECQL3; and RecQ3. The external IDs of the WRN gene are HGNC: 12791; NCBI Entrez Gene: 7486; Ensembl: ENSG00000165392; OMIM®: 604611; and UniProtKB/Swiss-Prot: Q14191. The term "WRN" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having a WRN sequence means having any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI Reference Sequence NM_000553.6 or any allele variant sequence, or any part thereof. DAAM1

DAAM1 or Morphogenesis Disorder-Associated Activator 1 is known by many different names such as KIAA0666; and Morphogenesis Disorder-Associated Activator 1 . The external Ids of the DAAM1 gene are HGNC: 18142; NCBI Entrez Gene: 23002; Ensembl: ENSG00000100592; OMIM®: 606626; and UniProtKB/Swiss-Prot: Q9Y4D1. The term "DAAM1" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having a DAAM1 sequence means having any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI reference sequence NM_001270520.2 or any allogenic variant sequence, or any part thereof. ASPH

ASPH or Aspartate β-Hydroxylase is known by many different names such as BAH, CASQ2BP1, JCTN, HAAH, Aspartate/Asparagine-based β-Hydroxylase, Peptide-Aspartate β-Dioxygenase, ASP β-Hydroxylase, Junctate, Junctin, Humbug, Cardiac Junctin, EC 1.14.11.16, AβHJJ, FDLAB, and AAH. The external Ids of the ASPH gene are HGNC: 757; Entrez Gene: 444; Ensembl: ENSG00000198363; OMIM®: 600582 and UniProtKB/Swiss-Prot: Q12797. The term "ASPH" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, bearing an ASPH sequence means bearing any nucleotide sequence, including coding sequence or any exon, but also including any polypeptide sequence, or any part thereof. NOTCH2

NOTCH2 or Notch receptor 2 is known by many different names such as Notch 2; Neurogenic site Notch homolog 2; HN2; Notch (Drosophila) homolog 2; Notch homolog 2 (Drosophila) ; Notch homolog 2; HJCYS; and AGS2. The external Ids of the NOTCH2 gene are HGNC: 7882; NCBI Entrez Gene: 4853; Ensembl: ENSG00000134250; OMIM®: 600275; and UniProtKB/Swiss-Prot: Q04721. The term "NOTCH2" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, a NOTCH2 sequence refers to any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as the NCBI reference sequence NM_024408.4 or any of its allele variants sequence, or any part thereof. CD74

CD74 is known by many different names such as CD74 molecule; DHLAG; CD74 molecule, major histocompatibility complex, class II invariant chain; HLA class II histocompatibility antigen gamma chain; MHC class II associated invariant chain Peptide; HLA-DR antigen-associated invariant chain; gamma chain of class II antigen; Ia-associated invariant chain; MHC HLA-DR gamma chain; HLA-DR-γ; CLIP; Ia antigen-associated invariant chain; CD74 antigen; Ia -γ; HLADG; P33; II; The term "CD74" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, carrying a CD74 sequence means carrying any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI reference sequence NM_001025159.3 or any allogenic variant sequence, or any part thereof. SDC4

SDC4 or Syndecan 4 is known by many different names such as Amphiglycan; SYND4; Amphiglycan, Ryudocan; Syndecan protein Glycan 4; Ryudocan core protein; Syndecan-4; Ryudocan; and Ryudocan amphiphilic proteoglycan. The external Ids of the SDC4 gene are HGNC: 10661; NCBI Entrez Gene: 6385; Ensembl: ENSG00000124145; OMIM®: 600017; and UniProtKB/Swiss-Prot: P31431. The term "SDC4" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having a SDC4 sequence means having any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI reference sequence NM_002999.4 or any of its allele variants sequence, or any part thereof. SLC4A4

SLC4A4 or solute carrier family 4 member 4 is known by many different names such as NBC1; HNBC1; HhNMC; NBC2; PNBC; solute carrier family 4 (sodium bicarbonate cotransporter), member 4; protein 1; Na(+)/HCO3(-) cotransporter; SLC4A5; KNBC1; sodium bicarbonate cotransporter 1 (sodium bicarbonate cotransporter, kidney; sodium bicarbonate cotransporter, pancreas); solute carrier Family 4, sodium bicarbonate cotransporter, member 4, brain type; solute carrier family 4, sodium bicarbonate cotransporter, member 4; solute carrier family 4, sodium bicarbonate cotransporter, member 5; sodium bicarbonate cotransporter Transporter; NBCel-A; NBCE1; KNBC; and NBC. The external Ids of the SLC4A4 gene are HGNC: 11030; NCBI Entrez Gene: 8671; Ensembl: ENSG00000080493; OMIM®: 603345; and UniProtKB/Swiss-Prot: Q9Y6R1. The term "SLC4A4" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, having a SLC4A4 sequence means having any nucleotide sequence, including coding sequence or any exon, but also any polypeptide, derived from such as NCBI Reference Sequence NM_001098484.3 or any of its allele variants sequence, or any part thereof. ZFAT

ZFAT or Zing Finger And AT-Hook Domain Containing is known by many different names, such as zinc finger protein 406; KIAA1485; ZNF406; ZFAT1; zinc finger protein ZFAT; Zinc finger genes in prevalent thyroid disease; zinc finger genes in the AITD susceptibility region; and AITD3. The external Ids of ZFAT genes are HGNC: 19899; NCBI Entrez Gene: 57623; Ensembl: ENSG00000066827; OMIM®: 610931; and UniProtKB/Swiss-Prot: Q9P243. The term "ZFAT" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, carrying a ZFAT sequence means carrying any nucleotide sequence, including coding sequence or any exon, but also including any polypeptide, derived from such as NCBI reference sequence NM_020863. sequence, or any part thereof. DSCAML1

DSCAML1 or DS-like cell adhesion molecule 1 is known by many different names such as KIAA1132; Down's syndrome-like cell adhesion molecule protein 1; Down's syndrome-like cell adhesion molecule 2; DSCAM2; Down's syndrome-like cell adhesion molecule 1; Syndrome Cell Adhesion Molecule 1; and DSCAM-like 1. The external Ids of the DSCAML1 gene are HGNC: 14656; NCBI Entrez Gene: 57453; Ensembl: ENSG00000177103; OMIM®: 611782; and UniProtKB/Swiss-Prot: Q8TD84. The term "DSCAML1" as used herein is not meant to be limited to any form such as protein, RNA, mRNA, cDNA or DNA sequence, but includes all such forms unless the context clearly indicates which form. For the avoidance of doubt, carrying a DSCAML1 sequence means carrying any nucleotide sequence, including coding sequence or any exon, but also including any polypeptide, derived from such as NCBI reference sequence NM_020693.4 or any allogenic variant sequence, or any part thereof. NRG1 polynucleotide fusion

In light of the present disclosure, previously unknown gene rearrangements that result in the expression of NRG1 fusion products that result in the fusion of NRG1 to a fusion partner are provided. In particular, polynucleotide fusions comprising NRG1 are provided, including VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1 , PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, DAAM1-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4-NRG1, SLC4A4 - NRG1, ZFAT-NRG1 or DSCAML1-NRG1. In particular, such fusions are present or have been identified in human patients diagnosed with cancer and are mentioned in more detail in the next section.

In certain embodiments, the NRG1 fusion may comprise an additional downstream fusion partner 3' to the sequence encoding the EGF-like domain. VAPB-NRG1 polynucleotide fusion

According to the present disclosure, there is also provided a polynucleotide comprising a fusion of a VAPB nucleic acid sequence (or a part of the VAPB nucleic acid sequence) and an NRG1 nucleic acid sequence (or a part of the NRG1 nucleic acid sequence). Allele variants of VAPB and NRG1 nucleic acid sequences are also included in the fusion.

Preferably, the VAPB nucleic acid sequence (or part thereof) comprises, or consists of, any one of SEQ ID NOs: 17-23 or an allele variant of any one of SEQ ID NOs: 17-23 , and the NRG1 nucleic acid sequence (or part thereof) comprises any one of SEQ ID NOs: 125-138 or an allele variant of any one of SEQ ID NOs: 125-138, or consists of it. More preferably, the VAPB nucleic acid sequence comprises a part of SEQ ID NO: 23 or an allele variant of SEQ ID NO: 23, or consists of it, and the NRG1 nucleic acid sequence comprises SEQ ID NO: 138 or SEQ ID NO: 138 is part of, or consists of, the allele variant. SEQ ID NO: 17-22 correspond to individual exons 1-6, respectively, of VAPB according to NM_004738.4. SEQ ID NO: 23 corresponds to exons 1-5 of VAPB according to NM_004738.4. SEQ ID NO: 125-137 correspond to individual exons 1-13 of NRG1 according to NM_001159999, respectively. SEQ ID NO: 138 corresponds to exons 1-13 of NRG1 according to NM_001159999.

In a preferred embodiment, the VAPB nucleic acid sequence part comprises 2 to About 10, about 20, about 30, or up to about 40 or even all of the continuous nucleic acid, and the NRG1 nucleic acid sequence part comprises from any one of SEQ ID NO: 125-138 (or SEQ ID NO: 125-138 Allele variants of any) from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids.

Preferably, the VAPB nucleic acid sequence or part thereof is located 5' to the NRG1 nucleic acid sequence or part thereof.

Preferably, the polynucleotide comprising VAPB nucleic acid sequence (or a part of said sequence) fused with NRG1 nucleic acid sequence (or a part of said sequence) of VAPB comprises or encodes the EGF-like domain of NRG1. Abnormal cell lines containing the VAPB-NRG1 polynucleotide fusion or expressing the polypeptide fusion contain or encode the EGF-like domain of NRG1. For detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between VAPB and NRG1 is in-frame and occurs at a position such that the resulting fusion product, nucleic acid or protein contains the EGF-like domain of NRG1 That's it. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the allele variant of the VAPB nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 17-23, preferably at least 90% identity, and 92%, 94% identity with it , 96% or better at least 98% sequence identity; and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, 92%, 94%, 96% or better at least 98% sequence identity thereto.

In a preferred embodiment, the polynucleotide comprising the fusion of VAPB nucleic acid and NRG1 nucleic acid comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 3 Contiguous nucleic acids, and preferably include the nucleic acids at positions 43 and 44. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least Nucleic acids at positions 53 and 54 are included.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 3, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 3 and preferably Polynucleotides that include nucleic acids at positions 43 and 44. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 43 and 44.

Preferably, the polynucleotide portion of the NRG1 nucleic acid sequence (or an allele variant thereof) encodes an EGF-like domain of NRG1, preferably an EGF-like domain according to SEQ ID NO: 163.

In an alternative aspect, there is provided a polynucleotide comprising a portion of VAPB exon 1 or an allogenic variant thereof fused to a portion of NRG1 exon 2 or an allogenic variant thereof. Preferably, VAPB exon 1 is the exon of SEQ ID NO: 17. Preferably, exon 2 of NRG1 is the exon of SEQ ID NO: 126. Said part of VAPB exon 1 preferably comprises or consists of SEQ ID NO: 1 or its allele variant. The portion of exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 2 or an allele variant thereof. When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further includes any sequence 3' to exon 2 of NRG1, but in order to be able to use polynucleotide-based detection Assays to detect fusion junctions, the presence of at least SEQ ID NO: 17 and 126 may be sufficient. Any sequence from 3' of NRG1 exon 2 comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or is derived from it composition.

Preferably, the allele variant of exon 1 of VAPB has at least 85% identity to SEQ ID NO: 17, preferably at least 90% identity, 92%, 94%, 96% or More preferably at least 98% sequence identity, and the allele variant of exon 2 of NRG1 is at least 85% identical to SEQ ID NO: 126, preferably at least 90% identical to its 92 %, 94%, 96% or better at least 98% sequence identity.

In a preferred embodiment, the part of exon 1 of VAPB comprises or consists of SEQ ID NO: 1, and its allele variant has at least 85% identity with SEQ ID NO: 1, preferably At least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity. The portion of exon 2 of NRG1 in the fusion comprises or consists of SEQ ID NO: 2, and its allele variant is at least 85% identical to SEQ ID NO: 2, preferably at least 90% identical % identity, 92%, 94%, 96% or better at least 98% sequence identity with it. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between VAPB and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion. More preferably, the part of VAPB exon 1 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 1, and At least the nucleic acid at position 43 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 43 nucleic acid. More preferably, the part of exon 1 of VAPB comprises or is according to SEQ ID NO: 1 or an allele variant thereof.

Alternatively, the portion of VAPB exon 1 comprises or consists of SEQ ID NO: 17 (or an allele variant of SEQ ID NO: 17), including at least the nucleic acid at position 399. Preferably, the portion of VAPB exon 1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 17 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 399. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 399 nucleic acid. In this alternative, the part of VAPB exon 1 preferably comprises or is according to SEQ ID NO: 17 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with VAPB comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In an alternative preferred embodiment, the polynucleotide comprising a portion of VAPB exon 1 fused to a portion of NRG1 exon 2 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 43 and 44. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 43 and 44 nucleic acids. SEQ ID NO: 3 includes a junction between VAPB and NRG1, in particular the junction is between a nucleic acid derived from position 43 of VAPB and a nucleic acid derived from position 44 of NRG1. Preferably, the polynucleotide comprising a part of exon 1 of VAPB fused with a part of exon 2 of NRG1 has the polynucleotide sequence of SEQ ID NO: 3 or an allele variant thereof.

Preferably, any of the VAPB-NRG1 polynucleotide fusions provided herein is an in-frame fusion of VAPB and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 1 or a part of exon 1 of VAPB and exon 2 or a part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 3 or an allele variant thereof.

Preferably, the part of VAPB exon 1 (or its allegenic variant) is located 5' to NRG1 exon 2 (or its allegene variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of VAPB and the C-terminus of NRG1. In addition, the VAPB-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from VAPB and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The VAPB-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, including lung or adenocarcinoma, especially lung adenocarcinoma or non-small cell lung cancer. CADM1-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 7 of CADM1 fused to a portion of exon 6 of NRG1. CADM1 exon 7 is preferably the exon of SEQ ID NO: 39 or an allogenic variant of SEQ ID NO: 39, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

Preferably, the allele variant of CADM1 exon 7 is at least 85% identical to SEQ ID NO: 39, preferably at least 90% identical, 92%, 94%, 96% or better identical thereto At least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity with SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94% , 96% or better at least 98% sequence identity.

Preferably, the part of exon 7 of CADM1 comprises or is according to SEQ ID NO: 5, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 5 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with CADM1 is preferably or comprises a sequence such as SEQ ID NO: 6, and its allele variant has at least 85% identity with SEQ ID NO: 6, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between CADM1 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion. More preferably, the part of exon 7 of CADM1 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 5, and At least the nucleic acid at position 43 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 53 nucleic acid. More preferably, the part of exon 7 of CADM1 comprises or is according to SEQ ID NO: 5 or an allele variant thereof.

Alternatively, the portion of CADM1 exon 7 comprises or consists of SEQ ID NO: 39 (or an allele variant of SEQ ID NO: 39), including at least the nucleic acid at position 173. Preferably, the portion of CADM1 exon 7 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 39 or its allele variant or is composed of It consists of, and at least includes, the nucleic acid at position 173. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 173 nucleic acid. In this alternative, the portion of CADM1 exon 7 preferably comprises or is according to SEQ ID NO: 39 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with CADM1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In an alternative preferred embodiment, the polynucleotide comprising a part of exon 7 of CADM1 fused to a part of exon 6 of NRG1 is comprised of sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 53 and 54. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 53 and 54 nucleic acids. SEQ ID NO: 7 includes the junction between CADM1 and NRG1, in particular the junction is between the nucleic acid derived from position 53 of CADM1 and the nucleic acid derived from position 54 of NRG1. Preferably, the polynucleotide comprising a part of exon 7 of CADM1 fused with a part of exon 6 of NRG1 has the polynucleotide sequence of SEQ ID NO: 7 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 7, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 7 and preferably A polynucleotide that includes the nucleic acids at positions 53 and 54. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 53 and 54.

Preferably, any of the CADM1-NRG1 polynucleotide fusions provided herein is an in-frame fusion of CADM1 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 7 or a part of exon 7 of CADM1 and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 7 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 7, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

Preferably, the polynucleotide comprising a part of CADM1 exon 7 (or its allele variant) fused to a part of NRG1 exon 6 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving CADM1 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between CADM1 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of exon 7 of CADM1 (or its allele variant) is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of CADM1 and the C-terminus of NRG1. In addition, the CADM1-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from CADM1 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The CADM1-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, including lung or adenocarcinoma, especially lung adenocarcinoma.

When present in abnormal cells of a patient or individual, the CADM1-NRG1 polynucleotide fusion preferably further comprises any sequence 5' to exon 7 of CADM1 and 3' to exon 6 of NRG1 However, in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 39 and 130 may be sufficient. Any sequence from 5' of CADM1 exon 7 comprising, or consisting of, one or all of SEQ ID NO: 33-38 (or any allele variant of SEQ ID NO: 33-38) , and any sequence from 3' of NRG1 exon 6 comprises any or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is composed of it. CD44-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 5 of CD44 fused to a portion of exon 2 of NRG1. CD44 exon 5 is preferably the exon of SEQ ID NO: 65 or an allogenic variant of SEQ ID NO: 65, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

Preferably, the allele variant of CD44 exon 5 is at least 85% identical to SEQ ID NO: 65, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 5 of CD44 comprises or is according to SEQ ID NO: 9, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 9 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with CD44 is preferably or comprises a sequence such as SEQ ID NO: 10, and its allele variant has at least 85% identity with SEQ ID NO: 10, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of exon 5 of CD44 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 9, and At least the nucleic acid at position 52 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 52 nucleic acid. More preferably, the portion of exon 5 of CD44 comprises or is according to SEQ ID NO: 9 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between CD44 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1 sexual fusion.

Alternatively, the portion of exon 5 of CD44 comprises or consists of SEQ ID NO: 65 (or an allele variant of SEQ ID NO: 65), including at least the nucleic acid at position 231. Preferably, the portion of CD44 exon 5 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 65 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 231. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 231 nucleic acid. In this alternative, the portion of CD44 exon 5 preferably comprises or is according to SEQ ID NO: 231 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with CD44 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In an alternative preferred embodiment, the polynucleotide comprising a part of exon 5 of CD44 fused to a part of exon 2 of NRG1 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 52 and 53. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 52 and 53 nucleic acids. SEQ ID NO: 11 includes a junction between CD44 and NRG1, in particular the junction is between a nucleic acid derived from position 52 of CD44 and a nucleic acid derived from position 53 of NRG1. Preferably, the polynucleotide comprising a part of exon 5 of CD44 fused with a part of exon 2 of NRG1 has the polynucleotide sequence of SEQ ID NO: 15 or its allele variant.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 11, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 11 and preferably A polynucleotide that includes the nucleic acids at positions 52 and 53. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 52 and 53.

Preferably, any of the CD44-NRG1 polynucleotide fusions provided herein are in-frame fusions of CD44 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 5 (or a part of exon 5) of CD44 and exon 2 of NRG1 (or a part of exon 2 of NRG1). The in-frame fusion is preferably a fusion of SEQ ID NO: 11 or its allogeneic variant, and the allogeneic variant has at least 85% identity to SEQ ID NO: 11, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

Preferably, the polynucleotide comprising a part of exon 5 of CD44 (or its allele variant) fused to a part of NRG1 exon 2 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving CD44 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between CD44 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the portion of exon 5 (or its allele variant) of CD44 is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of CD44 and the C-terminus of NRG1. In addition, the CD44-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from CD44 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The CD44-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, including pancreatic cancer or pancreatic adenocarcinoma, especially pancreatic ductal adenocarcinoma (or PDAC).

When present in abnormal cells of a patient or individual, the CD44-NRG1 polynucleotide fusion preferably further comprises any sequence 5' to exon 5 of CD44 and 3' to exon 2 of NRG1 However, in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 65 and 126 may be sufficient. Any sequence from 5' of exon 5 of CD44 comprising or consisting of one or all of SEQ ID NO: 61-64 (or any allele variant of SEQ ID NO: 61-64) , and any sequence from 3' of NRG1 exon 6 comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or is derived from its composition.

Furthermore, a polynucleotide fusion comprising a portion of exon 5 of CD44 fused to a portion of exon 6 of NRG1 is provided. The CD44 exon 5 is preferably the exon of SEQ ID NO: 65 or the allele variant of SEQ ID NO: 65, and the NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: Exon of the allele variant of 130.

Preferably, the allele variant of CD44 exon 5 has at least 85% identity to SEQ ID NO: 65, preferably at least 90% identity, 92%, 94%, 96% or More preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 is at least 85% identical to SEQ ID NO: 130, preferably at least 90% identical to 92% identical to SEQ ID NO: 130 , 94%, 96% or better at least 98% sequence identity.

Preferably, the part of exon 5 of CD44 comprises or is according to SEQ ID NO: 759, and its allele variant has at least 85% identity with SEQ ID NO: 9, preferably at least 90% 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. The part of exon 6 of NRG1 in the fusion with CD44 is preferably or comprises a sequence such as SEQ ID NO: 760, and its allele variant has at least 85% identity with SEQ ID NO: 760, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of exon 5 of CD44 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 759, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the part of exon 5 of CD44 comprises or is according to SEQ ID NO: 759 or its allele variant. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between CD44 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1 sexual fusion.

Alternatively, the portion of exon 5 of CD44 comprises or consists of SEQ ID NO: 65 (or an allele variant of SEQ ID NO: 65), at least including the nucleic acid at position 231. Preferably, the portion of exon 5 of CD44 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 65 or its allele variant or consists of and includes at least the nucleic acid at position 231. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 231 nucleic acid. In this alternative, the portion of CD44 exon 5 preferably comprises or is according to SEQ ID NO: 65 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with CD44 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any of the CD44-NRG1 polynucleotide fusions provided herein are in-frame fusions of CD44 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 5 or a part of exon 5 of CD44 and exon 6 of NRG1 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 761 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 761, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a part of exon 5 of CD44 fused with a part of exon 6 of NRG1 comprises from 2 to about 10 of SEQ ID NO: 761, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 761 includes a junction between CD44 and NRG1, in particular the junction is between the nucleic acid derived from position 75 of CD44 and the nucleic acid derived from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 5 of CD44 fused with a part of exon 6 of NRG1 has the polynucleotide sequence of SEQ ID NO: 761 or its allele variant.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 761, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 761 and preferably A polynucleotide that includes the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 75 and 76.

Preferably, the polynucleotide comprising a part of CD44 exon 5 (or its allogeneic variant) fused to a part of NRG1 exon 6 (or its allogeneic variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving said CD44 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between CD44 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the portion of exon 5 (or its allele variant) of CD44 is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of CD44 and the C-terminus of NRG1. In addition, the CD44-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from CD44 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The CD44-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially pancreatic cancer.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of exon 5 of CD44 and any sequence at the 3' of exon 6 of NRG1. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 65 and 130 may be sufficient. Any sequence from 5' of exon 5 of CD44 comprising, or consisting of, one or all of SEQ ID NO: 61-64 (or any allele variant of SEQ ID NO: 61-64) , and any sequence from 3' of NRG1 exon 6 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is derived from its composition. SLC3A2-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 1 of SLC3A2 transcript fused to a portion of exon 5 of NRG1. The SLC3A2 exon 1 is preferably the exon of SEQ ID NO: 103 or the allele variant of SEQ ID NO: 103, and the NRG1 exon 5 is preferably SEQ ID NO: 129 or SEQ ID NO: Exon of the allele variant of 129.

Preferably, the allele variant of exon 1 of SLC3A2 has at least 85% identity to SEQ ID NO: 103, preferably at least 90% identity, 92%, 94%, 96% or More preferably at least 98% sequence identity, and the allele variant of NRG1 exon 5 has at least 85% identity with SEQ ID NO: 129, preferably at least 90% identity, and 92% with SEQ ID NO: 129 , 94%, 96% or better at least 98% sequence identity.

Preferably, the part of exon 1 of SLC3A2 comprises or is according to SEQ ID NO: 13, and its allele variant has at least 85% identity with SEQ ID NO: 13, preferably at least 90% 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. The part of exon 5 of NRG1 in the fusion with SLC3A2 is preferably or comprises a sequence such as SEQ ID NO: 14, and its allele variant has at least 85% identity with SEQ ID NO: 14, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 1 of the SLC3A2 comprises or consists of continuous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 13 , and at least including the nucleic acid at position 53. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 53 nucleic acid. More preferably, the part of exon 1 of SLC3A2 comprises or is according to SEQ ID NO: 13 or its allele variant. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between SLC3A2 and NRG1 and determining whether such fusions are oncogenic in frame containing the EGF-like domain of NRG1 sexual fusion.

Alternatively, the portion of exon 1 of SLC3A2 comprises or consists of SEQ ID NO: 103 (or an allele variant of SEQ ID NO: 103), at least including the nucleic acid at position 552. Preferably, the portion of exon 1 of SLC3A2 comprises 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 103 or its allele variants or consists of and includes at least the nucleic acid at position 552. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 552 nucleic acid. In this alternative, the portion of exon 1 of SLC3A2 preferably comprises or is according to SEQ ID NO: 103 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 5 in the fusion with said SLC3A2 comprises from 2 to about 10, about 20, about 30, or up to about 40 of SEQ ID NO: 157 or an allele variant thereof or even all of the contiguous nucleic acids or consist thereof, and at least including the nucleic acid at position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any SLC3A2-NRG1 polynucleotide fusion provided herein is an in-frame fusion of SLC3A2 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 1 or a part of exon 1 of transcript 6 of SLC3A2 and exon 5 or a part of exon 5 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 15 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 15, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a part of exon 1 of SLC3A2 fused with a part of exon 5 of NRG1 is a polynucleotide comprising from 2 to about 10 of SEQ ID NO: 15, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 53 and 54. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 53 and 54 nucleic acids. SEQ ID NO: 15 includes the junction between SLC3A2 and NRG1, in particular the junction is between the nucleic acid derived from position 53 of SLC3A2 and the nucleic acid derived from position 54 of NRG1. Preferably, the polynucleotide comprising a part of exon 1 of SLC3A2 fused with a part of exon 5 of NRG1 has a polynucleotide sequence of SEQ ID NO: 15 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 15, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 15 and preferably A polynucleotide that includes the nucleic acids at positions 53 and 54. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 53 and 54.

Preferably, the polynucleotide comprising a part of exon 1 of SLC3A2 transcript 6 (or its allele variant) fused with a part of NRG1 exon 5 (or its allele variant) is a A portion of a longer polynucleotide further comprising or encoding the EGF-like domain of NRG1. Abnormal cell lines containing polynucleotide fusions involving said SLC3A2 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between said SLC3A2 and NRG1 is in-frame and occurs when the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 Such a location will suffice. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of exon 1 of the SLC3A2 transcript 6 (or its allele variant) is located at the 5' position of NRG1 exon 5 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of SLC3A2 and the C-terminus of NRG1. In addition, the SLC3A2-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from SLC3A2 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The SLC3A2-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, including lung or adenocarcinoma, especially lung adenocarcinoma.

When present in abnormal cells of a patient or individual, the SCL3A2-NRG1 polynucleotide fusion preferably further includes any sequence at the 3' of exon 5 of NRG1, but in order to be able to use the polynucleotide as For basic detection assays to detect fusion junctions, the presence of at least SEQ ID NO: 103 and 129 may be sufficient. Any sequence from 3' of NRG1 exon 5 comprises one or all of SEQ ID NO: 130-137 (or any allele variant of SEQ ID NO: 130-137), or is derived from it composition.

Furthermore, a polynucleotide fusion comprising a part of exon 2 of SLC3A2 transcript 3 fused to a part of exon 6 of NRG1 is provided. The SLC3A2 exon 2 is preferably the exon of SEQ ID NO: 457 or the allele variant of SEQ ID NO: 457, and the NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: Exon of the allele variant of 130.

Preferably, the allele variant of exon 2 of SLC3A2 has at least 85% identity to SEQ ID NO: 457, preferably at least 90% identity, 92%, 94%, 96% or More preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 is at least 85% identical to SEQ ID NO: 130, preferably at least 90% identical to 92% identical to SEQ ID NO: 130 , 94%, 96% or better at least 98% sequence identity.

Preferably, the part of exon 2 of SLC3A2 comprises or is according to SEQ ID NO: 452, and its allele variant has at least 85% identity with SEQ ID NO: 452, preferably at least 90% 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. The part of exon 6 of NRG1 in the fusion with SLC3A2 is preferably or comprises a sequence such as SEQ ID NO: 453, and its allele variant has at least 85% identity with SEQ ID NO: 453, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 2 of SLC3A2 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 452, and At least the nucleic acid at position 93 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 93 nucleic acid. More preferably, the part of exon 2 of SLC3A2 comprises or is according to SEQ ID NO: 452 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between SLC3A2 and NRG1 and determining whether such fusions are oncogenic in frame containing the EGF-like domain of NRG1 sexual fusion.

Alternatively, the portion of exon 2 of SLC3A2 comprises or consists of SEQ ID NO: 457 (or an allele variant of SEQ ID NO: 457), including at least the nucleic acid at position 93. Preferably, the portion of exon 2 of SLC3A2 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 457 or its allele variant or consists of and includes at least the nucleic acid at position 93. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 457 nucleic acid. In this alternative, the portion of exon 2 of SLC3A2 preferably comprises or is according to SEQ ID NO: 457 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with SLC3A2 transcript 3 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids are or consist of them, at least including the nucleic acid at position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any SLC3A2-NRG1 polynucleotide fusion provided herein is an in-frame fusion of SLC3A2 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 2 or a part of exon 2 of transcript 3 of SLC3A2 and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 454 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 454, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising the fusion of a part of exon 2 of SLC3A2 and a part of exon 6 of NRG1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 93 and 94. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 93 And 94 nucleic acids. SEQ ID NO: 454 includes the junction between said SLC3A2 and NRG1, in particular the junction is between the nucleic acid derived from position 93 of SLC3A2 and the nucleic acid derived from position 94 of NRG1. Preferably, the polynucleotide comprising a part of exon 2 of SLC3A2 fused with a part of exon 6 of NRG1 has a polynucleotide sequence of SEQ ID NO: 454 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 454, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 454 and preferably A polynucleotide that includes the nucleic acids at positions 93 and 94. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 93 and 94.

Preferably, the polynucleotide comprising a part of exon 2 of SLC3A2 transcript 3 (or its allele variant) fused with a part of NRG1 exon 6 (or its allele variant) is a A portion of a longer polynucleotide further comprising or encoding the EGF-like domain of NRG1. Abnormal cell lines containing polynucleotide fusions involving said SLC3A2 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between said SLC3A2 and NRG1 is in-frame and occurs when the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 Such a location will suffice. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of exon 2 (or its allele variant) of the SLC3A2 transcript 3 is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of SLC3A2 and the C-terminus of NRG1. In addition, the SLC3A2-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from SLC3A2 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The CADM1-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, including lung or adenocarcinoma, especially lung adenocarcinoma.

When present in abnormal cells of a patient or individual, the SCL3A2-NRG1 polynucleotide fusion preferably further includes any sequence at the 3' of exon 6 of NRG1, but in order to be able to use the polynucleotide as For basic detection assays to detect fusion junctions, the presence of at least SEQ ID NO: 457 and 130 may be sufficient. Any sequence from 3' of NRG1 exon 6 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is derived from it composition. VTCN1-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 2 of VTCN1 fused to a portion of exon 2 of NRG1. VTCN1 exon 2 is preferably the exon of SEQ ID NO: 169 or an allogenic variant of SEQ ID NO: 169, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

Preferably, the allele variant of VTCN1 exon 2 is at least 85% identical to SEQ ID NO: 169, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of VTCN1 exon 2 comprises or is according to SEQ ID NO: 164, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 164 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with VTCN1 is preferably or comprises a sequence such as SEQ ID NO: 165, and its allele variant has at least 85% identity with SEQ ID NO: 165, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 2 of VTCN1 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 164, and At least the nucleic acid at position 65 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 65 nucleic acid. More preferably, the part of exon 2 of VTCN1 comprises or is according to SEQ ID NO: 164 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between VTCN1 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Preferably, any VTCN1-NRG1 polynucleotide fusion provided herein is an in-frame fusion of VTCN1 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 2 or a part of exon 2 of VTCN1 and exon 2 or a part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 166 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 166, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a part of VTCN1 exon 2 fused to a part of NRG1 exon 2 comprises from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 65 and 66. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 65 and 66 nucleic acids. SEQ ID NO: 166 includes the junction between VTCN1 and NRG1, in particular the junction is between the nucleic acid at position 65 from VTCN1 and the nucleic acid at position 66 from NRG1. Preferably, the polynucleotide comprising a part of exon 2 of VTCN1 fused with a part of exon 2 of NRG1 has a polynucleotide sequence of SEQ ID NO: 166 or an allele variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with VTCN1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 166, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 166 and preferably A polynucleotide that includes the nucleic acids at positions 65 and 66. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 65 and 66.

Preferably, the polynucleotide comprising a part of VTCN1 exon 2 (or its allogeneic variant) fused to a part of NRG1 exon 2 (or its allogeneic variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving VTCN1 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between VTCN1 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of VTCN1 exon 2 (or its allele variant) is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of VTCN1 and the C-terminus of NRG1. In addition, the VTCN1-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from VTCN1 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The VTCN1-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinomas.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of VTCN1 exon 2 and any sequence at the 3' of NRG1 exon 2 sequences, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 169 and 126 may be sufficient. Any sequence from 5' of VTCN1 exon 2 comprising or consisting of SEQ ID NO: 168 (or any allele variant of SEQ ID NO: 168), and from 3 of NRG1 exon 2 Any sequence at ' comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or consists of it. CDH1-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 11 of CDH1 fused to a portion of exon 2 of NRG1. CDH1 exon 11 is preferably the exon of SEQ ID NO: 198 or an allogenic variant of SEQ ID NO: 198, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of CDH1 exon 11 and any sequence at the 3' of NRG1 exon 2. sequences, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 198 and 126 may be sufficient. Any sequence from the 5' of exon 11 of CDH1 comprises or consists of one or all of SEQ ID NO: 188-197 (or any allele variant of SEQ ID NO: 188-197) , and any sequence from 3' of NRG1 exon 2 comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or is formed by its composition.

Preferably, the allele variant of CDH1 exon 11 is at least 85% identical to SEQ ID NO: 198, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 11 of CDH1 comprises or is according to SEQ ID NO: 184, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 184 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with CDH1 is preferably or comprises a sequence such as SEQ ID NO: 185, and its allele variant has at least 85% identity with SEQ ID NO: 185, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 11 of CDH1 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 184, and At least the nucleic acid at position 119 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 119 nucleic acid. More preferably, the portion of exon 11 of CDH1 comprises or is according to SEQ ID NO: 184 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between CDH1 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of CDH1 exon 11 comprises or consists of SEQ ID NO: 198 (or an allele variant of SEQ ID NO: 198), including at least the nucleic acid at position 146. Preferably, the portion of CDH1 exon 11 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 198 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 146. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 146 nucleic acid. In this alternative, the portion of exon 11 of CDH1 preferably comprises or is according to SEQ ID NO: 198 or an allegenic variant thereof.

Preferably, any CDH1-NRG1 polynucleotide fusion provided herein is an in-frame fusion of CDH1 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 11 or a part of exon 2 of CDH1 and exon 2 or a part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 186 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 186, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a part of exon 11 of CDH1 fused to a part of exon 2 of NRG1 is a polynucleotide comprising from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 119 and 120. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 119 and 120 nucleic acids. SEQ ID NO: 186 includes the junction between CDH1 and NRG1, in particular the junction is between the nucleic acid from position 119 of CDH1 and the nucleic acid from position 120 of NRG1. Preferably, the polynucleotide comprising a part of exon 11 of CDH1 fused with a part of exon 2 of NRG1 has the polynucleotide sequence of SEQ ID NO: 186 or its allele variant.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 186, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 186 and preferably A polynucleotide that includes the nucleic acids at positions 119 and 120. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 119 and 120.

Preferably, the polynucleotide comprising a part of exon 11 of CDH1 (or its allele variant) fused to a part of NRG1 exon 2 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving CDH1 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between CDH1 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of exon 11 of CDH1 (or its allele variant) is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of CDH1 and the C-terminus of NRG1. In addition, the CDH1-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from CDH1 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The CDH1-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, including lung or adenocarcinoma, especially lung adenocarcinoma. CXADR-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 1 of CXADR fused to a portion of exon 2 of NRG1. CXADR exon 1 is preferably the exon of the allele variant of SEQ ID NO: 2199 or SEQ ID NO: 219, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of CXADR exon 1 and any sequence at the 3' of NRG1 exon 2. sequences, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 219 and 126 may be sufficient. Any sequence at the 3' of NRG1 exon 2 comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or consists of it .

Preferably, the CXADR exon 1 allele variant is at least 85% identical to SEQ ID NO: 219, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 1 of CXADR comprises or is according to SEQ ID NO: 215, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 215 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with CXADR is preferably or comprises a sequence such as SEQ ID NO: 216, and its allele variant has at least 85% identity with SEQ ID NO: 216, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 1 of CXADR comprises or consists of contiguous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 215, and At least the nucleic acid at position 43 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 43 nucleic acid. More preferably, the part of exon 1 of CXADR comprises or is according to SEQ ID NO: 215 or an allegenic variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between CXADR and NRG1 and determining whether such fusions are oncogenic in frame containing the EGF-like domain of NRG1 sexual fusion.

Alternatively, the portion of CXADR exon 1 comprises or consists of SEQ ID NO: 219 (or an allele variant of SEQ ID NO: 219), including at least the nucleic acid at position 130. Preferably, the portion of CXADR exon 1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 219 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 130. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 130 nucleic acid. In this alternative, the part of CXADR exon 1 preferably comprises or is according to SEQ ID NO: 219 or an allegenic variant thereof.

Preferably, any of the CXADR-NRG1 polynucleotide fusions provided herein are in-frame fusions of CXADR and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 1 or part of exon 2 of CXADR and exon 2 or part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 217 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 217, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of CXADR exon 1 fused to a portion of NRG1 exon 2 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 43 and 44. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 43 and 44 nucleic acids. SEQ ID NO: 217 includes a junction between CXADR and NRG1, in particular the junction is between a nucleic acid derived from position 43 of CXADR and a nucleic acid derived from position 44 of NRG1. Preferably, the polynucleotide comprising a part of exon 1 of CXADR fused with a part of exon 2 of NRG1 has the polynucleotide sequence of SEQ ID NO: 217 or an allele variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with CXADR comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 217, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 217 and preferably Polynucleotides that include nucleic acids at positions 43 and 44. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 43 and 44.

Preferably, the polynucleotide comprising a part of CXADR exon 1 (or its allele variant) fused to a part of NRG1 exon 2 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving CXADR or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between CXADR and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of CXADR exon 1 (or its allele variant) is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of CXADR and the C-terminus of NRG1. In addition, the CXADR-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from CXADR and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The CXADR-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially colorectal cancer. GTF2E2-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 2 of GTF2E2 fused to a portion of exon 2 of NRG1. GTF2E2 exon 2 is preferably the exon of SEQ ID NO: 236 or an allogenic variant of SEQ ID NO: 236, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of GTF2E2 exon 2 and any sequence at the 3' of NRG1 exon 2 sequences, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 236 and 126 may be sufficient. Any sequence from 5' of exon 2 of GTF2E2 comprising or consisting of SEQ ID NO: 235 (or any allele variant of SEQ ID NO: 235), and from 3 of exon 2 of NRG1 Any sequence at ' comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or consists of it.

Preferably, the allele variant of GTF2E2 exon 2 is at least 85% identical to SEQ ID NO: 236, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the portion of exon 2 of GTF2E2 comprises or is according to SEQ ID NO: 231, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 231 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with GTF2E2 is preferably or comprises a sequence such as SEQ ID NO: 232, and its allele variant has at least 85% identity with SEQ ID NO: 232, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 2 of GTF2E2 comprises or consists of contiguous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 231, and At least the nucleic acid at position 141 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 141 nucleic acid. More preferably, the portion of exon 2 of GTF2E2 comprises or is according to SEQ ID NO: 231 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between GTF2E2 and NRG1 and determining whether such fusions are oncogenic in frame containing the EGF-like domain of NRG1 sexual fusion.

Alternatively, the portion of GTF2E2 exon 2 comprises or consists of SEQ ID NO: 236 (or an allele variant of SEQ ID NO: 236), including at least the nucleic acid at position 170. Preferably, the portion of GTF2E2 exon 2 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 236 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 170. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 170 nucleic acid. In this alternative, the portion of exon 2 of GTF2E2 preferably comprises or is according to SEQ ID NO: 236 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with GTF2E2 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any of the GTF2E2-NRG1 polynucleotide fusions provided herein is an in-frame fusion of GTF2E2 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 2 or part of exon 2 of GTF2E2 and exon 2 or part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 233 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 233, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of exon 2 of GTF2E2 fused to a portion of exon 2 of NRG1 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 141 and 142. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 141 and 142 nucleic acids. SEQ ID NO: 233 includes a junction between GTF2E2 and NRG1, in particular the junction is between the nucleic acid from position 141 of GTF2E2 and the nucleic acid from position 142 of NRG1. Preferably, the polynucleotide comprising a part of exon 2 of GTF2E2 fused with a part of exon 2 of NRG1 has a polynucleotide sequence of SEQ ID NO: 233 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 233, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 233 and preferably A polynucleotide that includes the nucleic acids at positions 141 and 142. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 141 and 142.

Preferably, the polynucleotide comprising a part of exon 2 of GTF2E2 (or its allele variant) fused with a part of NRG1 exon 2 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving GTF2E2 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between GTF2E2 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of GTF2E2 exon 2 (or its allele variant) is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of GTF2E2 and the C-terminus of NRG1. In addition, the GTF2E2-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from GTF2E2 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The GTF2E2-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, more particularly (metastatic) breast cancer NOS. CSMD1-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 23 of CSMD1 fused to a portion of exon 6 of NRG1. CSMD1 exon 23 is preferably the exon of SEQ ID NO: 279 or an allogenic variant of SEQ ID NO: 279, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of CSMD1 exon 23 and any sequence at the 3' of NRG1 exon 6. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 279 and 130 may be sufficient. Any sequence from 5' of CSMD1 exon 23 comprising any or all of SEQ ID NO: 257-278 (or any allele variant of SEQ ID NO: 257-278), or derived from its composition, and any sequence from 3' of exon 6 of NRG1 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is composed of it.

Preferably, the allele variant of CSMD1 exon 23 is at least 85% identical to SEQ ID NO: 279, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 23 of CSMD1 comprises or is according to SEQ ID NO: 253, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 253 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with CSMD1 is preferably or comprises a sequence such as SEQ ID NO: 254, and its allele variant has at least 85% identity with SEQ ID NO: 254, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 23 of CSMD1 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 253, and At least the nucleic acid at position 88 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 88 nucleic acid. More preferably, the portion of exon 23 of CSMD1 comprises or is according to SEQ ID NO: 253 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between CSMD1 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of CSMD1 exon 23 comprises or consists of SEQ ID NO: 279 (or an allele variant of SEQ ID NO: 279), including at least the nucleic acid at position 157. Preferably, the portion of CSMD1 exon 23 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 279 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 157. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 157 nucleic acid. In this alternative, the portion of exon 23 of CSMD1 preferably comprises or is according to SEQ ID NO: 279 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with CSMD1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any CSMD1-NRG1 polynucleotide fusion provided herein is an in-frame fusion of CSMD1 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 23 or a part of exon 6 of CSMD1 and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 255 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 255, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of CSMD1 exon 23 fused to a portion of NRG1 exon 6 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 88 and 89. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 88 and 89 nucleic acids. SEQ ID NO: 255 includes the junction between CSMD1 and NRG1, in particular the junction is between the nucleic acid from position 88 of CSMD1 and the nucleic acid from position 89 of NRG1. Preferably, the polynucleotide comprising a part of exon 23 of CSMD1 fused with a part of exon 6 of NRG1 has a polynucleotide sequence of SEQ ID NO: 255 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 255, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 255 and preferably Polynucleotides that include nucleic acids at positions 88 and 89. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 88 and 89.

Preferably, the polynucleotide comprising a part of CSMD1 exon 23 (or its allogeneic variant) fused to a part of NRG1 exon 6 (or its allogeneic variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving CSMD1 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between CSMD1 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of exon 23 of CSMD1 (or its allele variant) is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of CSMD1 and the C-terminus of NRG1. In addition, the CSMD1-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from CSMD1 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The CSMD1-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinoma, and more particularly pancreatic ductal adenocarcinoma. PTN-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 4 of PTN fused to a portion of exon 2 of NRG1. PTN exon 4 is preferably the exon of SEQ ID NO: 318 or an allogenic variant of SEQ ID NO: 318, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of PTN exon 4 and any sequence at the 3' of NRG1 exon 2. sequences, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 318 and 126 may be sufficient. Any sequence from 5' of PTN exon 4 comprising any or all of SEQ ID NO: 315-317 (or any allele variant of SEQ ID NO: 315-317), or derived from its composition, and any sequence from 3' of NRG1 exon 2 comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or is composed of it.

Preferably, the allele variant of PTN exon 4 is at least 85% identical to SEQ ID NO: 318, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 4 of PTN comprises or is according to SEQ ID NO: 311, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 311 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with PTN is preferably or comprises a sequence such as SEQ ID NO: 312, and its allele variant has at least 85% identity with SEQ ID NO: 312, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 4 of PTN comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 311, and At least the nucleic acid at position 102 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 102 nucleic acid. More preferably, the portion of exon 4 of PTN comprises or is according to SEQ ID NO: 311 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between PTN and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1 sexual fusion.

Alternatively, the portion of PTN exon 4 comprises or consists of SEQ ID NO: 318 (or an allele variant of SEQ ID NO: 318), including at least the nucleic acid at position 162. Preferably, the portion of PTN exon 4 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 318 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 162. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 162 nucleic acid. In this alternative, the portion of PTN exon 4 preferably comprises or is according to SEQ ID NO: 318 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with PTN comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any of the PTN-NRG1 polynucleotide fusions provided herein is an in-frame fusion of PTN and NRG1. More preferably, the fusion is an in-frame fusion comprising a part of exon 4 or exon 2 of PTN and a part of exon 2 or exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 313 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 313, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of PTN exon 4 fused to a portion of NRG1 exon 2 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 102 and 103. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 102 and 103 nucleic acids. SEQ ID NO: 313 includes a junction between PTN and NRG1, in particular the junction is between the nucleic acid from position 102 of PTN and the nucleic acid from position 103 of NRG1. Preferably, the polynucleotide comprising a part of PTN exon 4 fused with a part of NRG1 exon 2 is a polynucleotide sequence of SEQ ID NO: 313 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 313, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 313 and preferably A polynucleotide that includes the nucleic acids at positions 102 and 103. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 102 and 103.

Preferably, the polynucleotide comprising a part of PTN exon 4 (or its allele variant) fused to a part of NRG1 exon 2 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving PTN or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between PTN and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of PTN exon 4 (or its allele variant) is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of PTN and the C-terminus of NRG1. In addition, the PTN-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from PTN and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The PTN-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinoma, and more particularly pancreatic ductal adenocarcinoma. ST14-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 11 of ST14 fused to a portion of exon 6 of NRG1. ST14 exon 11 is preferably the exon of SEQ ID NO: 342 or an allogenic variant of SEQ ID NO: 342, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of ST14 exon 11 and any sequence at the 3' of NRG1 exon 6. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 324 and 130 may be sufficient. Any sequence from the 5' of ST14 exon 11 comprising any or all of SEQ ID NO: 332-341 (or any allele variant of SEQ ID NO: 332-341), or derived from its composition, and any sequence from 3' of exon 6 of NRG1 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is composed of it.

Preferably, the ST14 exon 11 allele variant is at least 85% identical to SEQ ID NO: 342, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 11 of ST14 comprises or is according to SEQ ID NO: 328, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 328 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with ST14 is preferably or comprises a sequence such as SEQ ID NO: 329, and its allele variant has at least 85% identity with SEQ ID NO: 329, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of exon 11 of ST14 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 328, and At least the nucleic acid at position 95 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 95 nucleic acid. More preferably, the portion of exon 11 of ST14 comprises or is according to SEQ ID NO: 328 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between ST14 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1 sexual fusion.

Alternatively, the portion of ST14 exon 11 comprises or consists of SEQ ID NO: 342 (or an allele variant of SEQ ID NO: 342), including at least the nucleic acid at position 131. Preferably, the portion of ST14 exon 11 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 342 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 131. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 131 nucleic acid. In this alternative, the portion of ST14 exon 11 preferably comprises or is according to SEQ ID NO: 342 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with ST14 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any of the ST14-NRG1 polynucleotide fusions provided herein is an in-frame fusion of ST14 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 11 or a part of exon 6 of ST14 and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 330 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 330, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of ST14 exon 11 fused to a portion of NRG1 exon 6 comprises from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 95 and 96. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 95 And 96 nucleic acids. SEQ ID NO: 330 includes the junction between ST14 and NRG1, in particular the junction is between the nucleic acid derived from position 95 of ST14 and the nucleic acid derived from position 96 of NRG1. Preferably, the polynucleotide comprising a part of ST14 exon 11 fused with a part of NRG1 exon 6 has the polynucleotide sequence of SEQ ID NO: 330 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 330, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 330 and preferably Polynucleotides that include nucleic acids at positions 95 and 96. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 95 and 96.

Preferably, the polynucleotide comprising a part of ST14 exon 11 (or its allogeneic variant) fused to a part of NRG1 exon 6 (or its allogeneic variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving ST14 or expressing the polypeptide fusion contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between ST14 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the portion of ST14 exon 11 (or its allele variant) is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of ST14 and the C-terminus of NRG1. In addition, the ST14-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from ST14 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The ST14-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinomas, more particularly pancreatic ductal adenocarcinomas. THBS1-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 9 of THBS1 fused to a portion of exon 6 of NRG1. THBS1 exon 9 is preferably the exon of SEQ ID NO: 386 or an allogenic variant of SEQ ID NO: 386, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of THBS1 exon 9 and any sequence at the 3' of NRG1 exon 6. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 386 and 130 may be sufficient. Any sequence from 5' of THBS1 exon 9 comprising any or all of SEQ ID NO: 378-385 (or any allele variant of SEQ ID NO: 378-385), or derived from its composition, and any sequence from 3' of exon 6 of NRG1 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is composed of it.

Preferably, the allele variant of THBS1 exon 9 is at least 85% identical to SEQ ID NO: 386, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 9 of THBS1 comprises or is according to SEQ ID NO: 374, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 374 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with THBS1 is preferably or comprises a sequence such as SEQ ID NO: 375, and its allele variant has at least 85% identity with SEQ ID NO: 375, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of exon 9 of THBS1 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 374, and At least the nucleic acid at position 56 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 56 nucleic acid. More preferably, the portion of exon 9 of THBS1 comprises or is according to SEQ ID NO: 374 or an allegenic variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between THBS1 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of THBS1 exon 9 comprises or consists of SEQ ID NO: 386 (or an allele variant of SEQ ID NO: 386), including at least the nucleic acid at position 177. Preferably, the portion of THBS1 exon 9 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 386 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 177. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 177 nucleic acid. In this alternative, the portion of THBS1 exon 9 preferably comprises or is according to SEQ ID NO: 386 or an allegenic variant thereof. Preferably, the portion of exon 6 of NRG1 in the fusion with THBS1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any THBS1-NRG1 polynucleotide fusion provided herein is an in-frame fusion of THBS1 and NRG1. More preferably, the fusion is an in-frame fusion comprising a part of exon 9 or exon 6 of THBS1 and a part of exon 6 or exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 376 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 376, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a part of exon 9 of THBS1 fused to a part of exon 6 of NRG1 is comprised of 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 56 and 57. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 56 and 57 nucleic acids. SEQ ID NO: 376 includes the junction between THBS1 and NRG1, in particular the junction is between the nucleic acid derived from position 56 of THBS1 and the nucleic acid derived from position 57 of NRG1. Preferably, the polynucleotide comprising a part of exon 9 of THBS1 fused with a part of exon 6 of NRG1 has a polynucleotide sequence of SEQ ID NO: 376 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 376, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 376 and preferably A polynucleotide that includes the nucleic acids at positions 56 and 57. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 56 and 57.

Preferably, the polynucleotide comprising a part of THBS1 exon 9 (or its allele variant) fused to a part of NRG1 exon 6 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving THBS1 or expressing the polypeptide fusion contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between THBS1 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the portion of exon 9 of THBS1 (or its allele variant) is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of THBS1 and the C-terminus of NRG1. In addition, the THBS1-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from THBS1 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The THBS1-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinoma, and more particularly pancreatic ductal adenocarcinoma. AGRN-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 12 of AGRN fused to a portion of exon 6 of NRG1. AGRN exon 12 is preferably the exon of SEQ ID NO: 416 or an allogenic variant of SEQ ID NO: 416, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of AGRN exon 12 and any sequence at the 3' of NRG1 exon 6. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 416 and 130 may be sufficient. Any sequence from 5' of AGRN exon 12 comprising any or all of SEQ ID NO: 405-415 (or any allele variant of SEQ ID NO: 405-415), or derived from its composition, and any sequence from 3' of exon 6 of NRG1 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is composed of it.

Preferably, the allele variant of AGRN exon 12 is at least 85% identical to SEQ ID NO: 416, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 12 of AGRN comprises or is according to SEQ ID NO: 401, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 401 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with AGRN is preferably or comprises a sequence such as SEQ ID NO: 402, and its allele variant has at least 85% identity with SEQ ID NO: 402, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 12 of AGRN comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 401, and At least the nucleic acid at position 106 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 106 nucleic acid. More preferably, the portion of exon 12 of AGRN comprises or is according to SEQ ID NO: 401 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between AGRN and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of AGRN exon 12 comprises or consists of SEQ ID NO: 416 (or an allele variant of SEQ ID NO: 416), including at least the nucleic acid at position 106. Preferably, the portion of AGRN exon 12 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 416 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 106. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 106 nucleic acid. In this alternative, the portion of AGRN exon 12 preferably comprises or is according to SEQ ID NO: 416 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with AGRN comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any AGRN-NRG1 polynucleotide fusion provided herein is an in-frame fusion of AGRN and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 12 or a part of exon 12 of AGRN and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 403 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 403, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of AGRN exon 12 fused to a portion of NRG1 exon 6 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 106 and 107. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 106 and 107 nucleic acids. SEQ ID NO: 403 includes a junction between AGRN and NRG1, in particular the junction is between the nucleic acid from position 106 of AGRN and the nucleic acid from position 107 of NRG1. Preferably, the polynucleotide comprising a part of exon 12 of AGRN fused with a part of exon 6 of NRG1 has a polynucleotide sequence of SEQ ID NO: 403 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 403, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 403 and preferably A polynucleotide that includes the nucleic acids at positions 106 and 107. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 106 and 107.

Preferably, the polynucleotide comprising a part of AGRN exon 12 (or its allogeneic variant) fused to a part of NRG1 exon 6 (or its allogeneic variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving AGRN or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between AGRN and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of AGRN exon 12 (or its allogeneic variant) is located at the 5' position of NRG1 exon 6 (or its allogeneic variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of AGRN and the C-terminus of NRG1. In addition, the AGRN-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from AGRN and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The AGRN-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinoma, and more particularly pancreatic ductal adenocarcinoma. PVALB-NRG1 polynucleotide fusion

According to the present disclosure, there is also provided a polynucleotide comprising the fusion of the PVALB nucleic acid sequence (or a part of the PVALB nucleic acid sequence) and the NRG1 nucleic acid sequence (or a part of the NRG1 nucleic acid sequence). Allele variants of PVALB and NRG1 nucleic acid sequences are also included in the fusion.

Preferably, the PVALB nucleic acid sequence (or part thereof) comprises any one of SEQ ID NO: 439-444 or an allele variant of any one of SEQ ID NO: 439-444, or consists of it , and the NRG1 nucleic acid sequence (or part thereof) comprises any one of SEQ ID NOs: 125-138 or an allele variant of any one of SEQ ID NOs: 125-138, or consists of it. More preferably, the PVALB nucleic acid sequence comprises a part of SEQ ID NO: 444 or an allele variant of SEQ ID NO: 444, or consists of it, and the NRG1 nucleic acid sequence comprises SEQ ID NO: 138 or SEQ ID NO: 138 is part of, or consists of, the allele variant. SEQ ID NO: 439-443 correspond to individual exons 1-5 of PVALB according to NM_002854.3, respectively. SEQ ID NO: 444 corresponds to exons 1-5 of PVALB according to NM_002854.3. SEQ ID NO: 125-137 correspond to individual exons 1-13 of NRG1 according to NM_001159999, respectively. SEQ ID NO: 138 corresponds to exons 1-13 of NRG1 according to NM_001159999.

In a preferred embodiment, the PVALB nucleic acid sequence part comprises 2 to About 10, about 20, about 30, or up to about 40 or even all of the continuous nucleic acid, and the NRG1 nucleic acid sequence part comprises from any one of SEQ ID NO: 125-138 (or SEQ ID NO: 125-138 Allele variants of any) from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids.

Also provided is a polynucleotide fusion comprising a portion of exon 4 of PVALB fused to a portion of exon 6 of NRG1. PVALB exon 4 is preferably the exon of SEQ ID NO: 442 or an allogenic variant of SEQ ID NO: 442, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of PVALB exon 4 and any sequence at the 3' of NRG1 exon 6. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 422 and 130 may be sufficient. Any sequence from 5' of PVALB exon 4 comprising any or all of SEQ ID NO: 439-441 (or any allele variant of SEQ ID NO: 439-441), or derived from its composition, and any sequence from 3' of exon 6 of NRG1 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is composed of it.

Preferably, the allele variant of PVALB exon 4 is at least 85% identical to SEQ ID NO: 442, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the portion of exon 4 of PVALB comprises or is according to SEQ ID NO: 435, and its allele variant is at least 85% identical to SEQ ID NO: 435, preferably at least 90% identical 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with PVALB is preferably or comprises a sequence such as SEQ ID NO: 436, and its allele variant has at least 85% identity with SEQ ID NO: 436, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 4 of PVALB comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 435, and At least the nucleic acid at position 102 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 102 nucleic acid. More preferably, the portion of exon 4 of PVALB comprises or is according to SEQ ID NO: 435 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between PVALB and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1 sexual fusion.

Alternatively, the portion of PVALB exon 4 comprises or consists of SEQ ID NO: 442 (or an allele variant of SEQ ID NO: 442), including at least the nucleic acid at position 110. Preferably, the portion of PVALB exon 4 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 442 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 110. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 110 nucleic acid. In this alternative, the portion of PVALB exon 4 preferably comprises or is according to SEQ ID NO: 442 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with PVALB comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any of the PVALB-NRG1 polynucleotide fusions provided herein is an in-frame fusion of PVALB and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 4 or a part of exon 4 of PVALB and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 437 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 437, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of PVALB exon 4 fused to a portion of NRG1 exon 6 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 102 and 103. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 102 and 103 nucleic acids. SEQ ID NO: 437 includes a junction between PVALB and NRG1, in particular the junction is between the nucleic acid at position 102 from PVALB and the nucleic acid at position 103 from NRG1. Preferably, the polynucleotide comprising a part of exon 4 of PVALB fused with a part of exon 6 of NRG1 has a polynucleotide sequence of SEQ ID NO: 437 or an allele variant thereof.

Preferably, the polynucleotide comprising a part of exon 4 of PVALB (or its allele variant) fused to a part of NRG1 exon 6 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving PVALB or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between PVALB and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of PVALB exon 4 (or its allegenic variant) is located 5' to NRG1 exon 6 (or its allegene variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of PVALB and the C-terminus of NRG1. In addition, the PVALB-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from PVALB and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The PVALB-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinoma, and more particularly pancreatic ductal adenocarcinoma. APP-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of APP exon 14 fused to a portion of NRG1 exon 6. APP exon 14 is preferably the exon of SEQ ID NO: 501 or an allogenic variant of SEQ ID NO: 501, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of APP exon 14 and any sequence at the 3' of NRG1 exon 6. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 501 and 130 may be sufficient. Any sequence from the 5' of APP exon 14 comprising any or all of SEQ ID NO: 488-500 (or any allele variant of SEQ ID NO: 488-500), or derived from its composition, and any sequence from 3' of exon 6 of NRG1 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is composed of it.

Preferably, the APP exon 14 allele variant is at least 85% identical to SEQ ID NO: 501, preferably at least 90% identical, 92%, 94%, 96% or more identical to SEQ ID NO: 501 Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 14 of APP comprises or is according to SEQ ID NO: 484, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 484 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with APP is preferably or comprises a sequence such as SEQ ID NO: 485, and its allele variant has at least 85% identity with SEQ ID NO: 485, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 14 of APP comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 484, and At least the nucleic acid at position 54 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 54 nucleic acid. More preferably, the portion of APP exon 14 comprises or is according to SEQ ID NO: 484 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between APP and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of APP exon 14 comprises or consists of SEQ ID NO: 501 (or an allele variant of SEQ ID NO: 501), including at least the nucleic acid at position 54. Preferably, the portion of APP exon 14 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 501 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 54. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 54 nucleic acid. In this alternative, the portion of APP exon 14 preferably comprises or is according to SEQ ID NO: 501 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with APP comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any APP-NRG1 polynucleotide fusion provided herein is an in-frame fusion of APP and NRG1. More preferably, the fusion is an in-frame fusion comprising APP exon 14 or a part of exon 14 and NRG1 exon 6 or a part of exon 6. The in-frame fusion is preferably a fusion of SEQ ID NO: 486 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 486, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of APP exon 14 fused to a portion of NRG1 exon 6 comprises from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 54 and 55. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 54 And 55 nucleic acids. SEQ ID NO: 486 includes a junction between APP and NRG1, in particular the junction is between the nucleic acid at position 54 from APP and the nucleic acid at position 54 from NRG1. Preferably, the polynucleotide comprising a part of APP exon 14 fused with a part of NRG1 exon 6 has the polynucleotide sequence of SEQ ID NO: 486 or its allele variant.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 486, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 486 and preferably A polynucleotide that includes the nucleic acids at positions 54 and 55. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 54 and 55.

Preferably, the polynucleotide comprising a part of APP exon 14 (or its allele variant) fused to a part of NRG1 exon 6 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving APP or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between APP and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the APP exon 14 (or its allogeneic variant) part is located at the 5' of NRG1 exon 6 (or its allogeneic variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of APP and the C-terminus of NRG1. In addition, the APP-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from APP and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The APP-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinoma, and more particularly pancreatic ductal adenocarcinoma. WRN-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of WRN exon 33 fused to a portion of NRG1 exon 6. WRN exon 33 is preferably the exon of SEQ ID NO: 562 or an allogenic variant of SEQ ID NO: 562, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of WRN exon 33 and any sequence at the 3' of NRG1 exon 6. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 562 and 130 may be sufficient. Any sequence from 5' of WRN exon 33 comprising any or all of SEQ ID NO: 530-561 (or any allele variant of SEQ ID NO: 530-561), or derived from its composition, and any sequence from 3' of exon 6 of NRG1 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is composed of it.

Preferably, the allele variant of WRN exon 33 is at least 85% identical to SEQ ID NO: 562, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of WRN exon 33 comprises or is according to SEQ ID NO: 526, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 526 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with WRN is preferably or comprises a sequence such as SEQ ID NO: 527, and its allele variant has at least 85% identity with SEQ ID NO: 527, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 33 of WRN comprises or consists of contiguous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 526, and At least the nucleic acid at position 96 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 96 nucleic acid. More preferably, the portion of WRN exon 33 comprises or is according to SEQ ID NO: 526 or an allegenic variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between WRN and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of WRN exon 33 comprises or consists of SEQ ID NO: 562 (or an allele variant of SEQ ID NO: 562), including at least the nucleic acid at position 163. Preferably, the portion of WRN exon 33 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 562 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 163. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 163 nucleic acid. In this alternative, the part of WRN exon 33 preferably comprises or is according to SEQ ID NO: 562 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with WRN comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any WRN-NRG1 polynucleotide fusion provided herein is an in-frame fusion of WRN and NRG1. More preferably, the fusion is an in-frame fusion comprising WRN exon 33 or a part of exon 33 and NRG1 exon 6 or a part of exon 6. The in-frame fusion is preferably a fusion of SEQ ID NO: 528 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 528, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of WRN exon 33 fused to a portion of NRG1 exon 6 comprises from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 96 and 97. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 96 And 97 nucleic acids. SEQ ID NO: 528 includes a junction between WRN and NRG1, in particular the junction is between a nucleic acid derived from position 96 of WRN and a nucleic acid derived from position 97 of NRG1. Preferably, the polynucleotide comprising a part of WRN exon 33 fused with a part of NRG1 exon 6 has the polynucleotide sequence of SEQ ID NO: 528 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 528, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 528 and preferably A polynucleotide that includes the nucleic acids at positions 96 and 97. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 96 and 97.

Preferably, the polynucleotide comprising a part of WRN exon 33 (or its allele variant) fused to a part of NRG1 exon 6 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving WRN or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between WRN and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of WRN exon 33 (or its allele variant) is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of WRN and the C-terminus of NRG1. In addition, the WRN-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from WRN and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The WRN-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially breast cancer. DAAM1-NRG1 polynucleotide fusion

According to the present disclosure, there is also provided a polynucleotide comprising a fusion of DAAM1 nucleic acid sequence (or a part of DAAM1 nucleic acid sequence) and NRG1 nucleic acid sequence (or a part of NRG1 nucleic acid sequence). Allele variants of DAAM1 and NRG1 nucleic acid sequences are also included in the fusion.

Preferably, the DAAM1 nucleic acid sequence (or part thereof) comprises, or consists of, any one of SEQ ID NOs: 606-631 or an allele variant of any one of SEQ ID NOs: 606-631 , and the NRG1 nucleic acid sequence (or part thereof) comprises any one of SEQ ID NOs: 125-138 or an allele variant of any one of SEQ ID NOs: 125-138, or consists of it. More preferably, the DAAM1 nucleic acid sequence comprises SEQ ID NO: 631 or a part of the allele variant of SEQ ID NO: 631, or consists of it, and the NRG1 nucleic acid sequence comprises SEQ ID NO: 138 or SEQ ID NO: 138 is part of, or consists of, the allele variant. SEQ ID NO: 606-630 correspond to individual exons 1-25 of DAAM1 according to NM_001270520.2, respectively. SEQ ID NO: 631 corresponds to exons 1-25 of DAAM1 according to NM_001270520.2. SEQ ID NO: 125-137 correspond to individual exons 1-13 of NRG1 according to NM_001159999.3, respectively. SEQ ID NO: 138 corresponds to exons 1-13 of NRG1 according to NM_001159999.3.

In a preferred embodiment, the DAAM1 nucleic acid sequence part comprises 2 to About 10, about 20, about 30, or up to about 40 or even all of the continuous nucleic acid, and the NRG1 nucleic acid sequence part comprises from any one of SEQ ID NO: 125-138 (or SEQ ID NO: 125-138 Allele variants of any) from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids.

Preferably, the allele variant of the DAAM1 nucleic acid sequence is at least 85% identical to any one of SEQ ID NO: 606-631, preferably at least 90% identical, and 92%, 94% identical to any one of SEQ ID NO: 606-631 , 96% or better at least 98% sequence identity; and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, 92%, 94%, 96% or better at least 98% sequence identity thereto.

Preferably, the DAAM1 nucleic acid sequence or part thereof is located 5' to the NRG1 nucleic acid sequence or part thereof.

Preferably, the polynucleotide comprising DAAM1 nucleic acid sequence (or a part of said sequence) fused with NRG1 nucleic acid sequence (or a part of said sequence) of DAAM1 comprises or encodes the EGF-like domain of NRG1. Abnormal cell lines containing the DAAM1-NRG1 polynucleotide fusion contain or encode the EGF-like domain of NRG1. For detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between DAAM1 and NRG1 is in-frame and occurs at a position such that the resulting fusion nucleic acid encodes the EGF-like domain of NRG1. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Also provided is a polynucleotide fusion comprising a portion of exon 1 of DAAM1 fused to a portion of exon 1 of NRG1. DAAM1 exon 1 is preferably the exon of SEQ ID NO: 606 or an allogenic variant of SEQ ID NO: 606, and NRG1 exon 1 is preferably SEQ ID NO: 125 or SEQ ID NO: Exons of 125 allele variants.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of DAAM1 exon 1 and any sequence at the 3' of NRG1 exon 1 sequences, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 606 and 125 may be sufficient. Any sequence from 5' of DAAM1 exon 1 comprising or consisting of SEQ ID NO: 606 (or any allele variant of SEQ ID NO: 606), and from 3 of NRG1 exon 1 Any sequence at ' comprises one or all of SEQ ID NO: 126-137 (or any allele variant of SEQ ID NO: 126-137), or consists of it.

Preferably, the allele variant of DAAM1 exon 1 is at least 85% identical to SEQ ID NO: 606, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 1 has at least 85% identity to SEQ ID NO: 125, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 1 of DAAM1 comprises or is according to SEQ ID NO: 603, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 603 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 1 of NRG1 in the fusion with DAAM1 is preferably or comprises a sequence such as SEQ ID NO: 604, and its allele variant has at least 85% identity with SEQ ID NO: 604, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 1 of DAAM1 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 603, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the part of exon 1 of DAAM1 comprises or is according to SEQ ID NO: 603 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between DAAM1 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of DAAM1 exon 1 comprises or consists of SEQ ID NO: 606 (or an allele variant of SEQ ID NO: 606), including at least the nucleic acid at position 102. Preferably, the portion of DAAM1 exon 1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 606 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 102. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 102 nucleic acid. In this alternative, the portion of DAAM1 exon 1 preferably comprises or is according to SEQ ID NO: 606 or an allegenic variant thereof. Preferably, the portion of exon 1 of NRG1 in the fusion with DAAM1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In an alternative preferred embodiment, the polynucleotide comprising a portion of DAAM1 exon 1 fused to a portion of NRG1 exon 1 comprises from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 605 includes a junction between DAAM1 and NRG1, in particular the junction is between the nucleic acid derived from position 75 of DAAM1 and the nucleic acid derived from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 1 of DAAM1 fused with a part of exon 1 of NRG1 has a polynucleotide sequence of SEQ ID NO: 605 or an allele variant thereof.

Preferably, any of the DAAM1-NRG1 polynucleotide fusions provided herein is a fusion of a portion of the untranslated region of DAAM1 with a portion of the untranslated region of NRG1. More preferably, the fusion is a fusion comprising DAAM1 exon 1 (or a part of exon 1) and NRG1 exon 1 (or a part of NRG1 exon 1). The fusion is preferably a fusion of SEQ ID NO: 605 or an allele variant thereof, and is at least 85% identical to SEQ ID NO: 605, preferably at least 90%, 92%, 94% identical thereto , 96% or even 98% agreement.

Preferably, the part of DAAM1 exon 1 (or its allegenic variant) is located 5' to NRG1 exon 1 (or its allegene variant). The NRG1 protein thus becomes downstream of the DAAM1 promoter and is expected to be transcriptionally controlled by said promoter. The resulting fusion thus results in expression of the NRG1 protein that is not a protein fusion, and thus contains an EGF-like domain. With it came the ability to drive the proliferation and survival of a small group of human cancers, especially breast cancer. ASPH-NRG1 polynucleotide fusion

According to the disclosure, there is also provided a polynucleotide comprising an ASPH nucleic acid sequence (or a part of the ASPH nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of the NRG1 nucleic acid sequence). Allele variants of ASPH and NRG1 nucleic acid sequences are also included in the fusion.

Preferably, the ASPH nucleic acid sequence (or part thereof) comprises, or consists of, any one of SEQ ID NOs: 637-662 or an allele variant of any one of SEQ ID NOs: 637-662 , and the NRG1 nucleic acid sequence (or part thereof) comprises any one of SEQ ID NOs: 125-138 or an allele variant of any one of SEQ ID NOs: 125-138, or consists of it. More preferably, the ASPH nucleic acid sequence comprises SEQ ID NO: 662 or a part of the allele variant of SEQ ID NO: 662, or consists of it, and the NRG1 nucleic acid sequence comprises SEQ ID NO: 138 or SEQ ID NO: 138 is part of, or consists of, the allele variant. SEQ ID NO: 637-661 correspond to individual exons 1-25 of ASPH according to NM_001164750.2, respectively. SEQ ID NO: 662 corresponds to exons 1-25 of ASPH according to NM_001164750.2. SEQ ID NO: 125-137 correspond to individual exons 1-13 of NRG1 according to NM_001159999.3, respectively. SEQ ID NO: 138 corresponds to exons 1-13 of NRG1 according to NM_001159999.3.

In a preferred embodiment, the ASPH nucleic acid sequence part comprises 2 to About 10, about 20, about 30, or up to about 40 or even all of the continuous nucleic acid, and the NRG1 nucleic acid sequence part comprises from any one of SEQ ID NO: 125-138 (or SEQ ID NO: 125-138 Allele variants of any) from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids.

Preferably, the allele variant of the ASPH nucleic acid sequence is at least 85% identical to any one of SEQ ID NO: 637-662, preferably at least 90% identical, and 92%, 94% identical to any one of SEQ ID NO: 637-662 , 96% or better at least 98% sequence identity; and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, 92%, 94%, 96% or better at least 98% sequence identity thereto.

Preferably, the ASPH nucleic acid sequence or part thereof is located 5' to the NRG1 nucleic acid sequence or part thereof.

Preferably, the polynucleotide comprising ASPH nucleic acid sequence (or a part of said sequence) fused to NRG1 nucleic acid sequence (or a part of said sequence) comprises or encodes the EGF-like domain of NRG1. Abnormal cell lines containing the ASPH-NRG1 polynucleotide fusion or expressing the polypeptide fusion contain or encode the EGF-like domain of NRG1. For the purposes of detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between ASPH and NRG1 is in-frame and occurs at a position such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1. Can. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Also provided is a polynucleotide fusion comprising a portion of ASPH exon 22 fused to a portion of NRG1 exon 2. ASPH exon 22 is preferably the exon of SEQ ID NO: 658 or an allogenic variant of SEQ ID NO: 658, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence 5' to ASPH exon 22 and any sequence 3' to NRG1 exon 2. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 658 and 126 may be sufficient. Any sequence from the 5' of ASPH exon 22 comprises one or all of SEQ ID NO: 637-657 (or any allele variant of SEQ ID NO: 637-657), while the sequence from NRG1 exon Any sequence at the 3' of sub2 comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or consists of it.

Preferably, the allele variant of ASPH exon 22 is at least 85% identical to SEQ ID NO: 658, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the portion of exon 22 of ASPH comprises or is according to SEQ ID NO: 633, and the allele variant thereof is at least 85% identical, preferably at least 90% identical to SEQ ID NO: 633 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with ASPH is preferably or comprises a sequence such as SEQ ID NO: 634, and its allele variant has at least 85% identity with SEQ ID NO: 634, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of ASPH exon 22 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 633, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the portion of exon 22 of ASPH comprises or is according to SEQ ID NO: 633 or an allegenic variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between ASPH and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of ASPH exon 22 comprises or consists of SEQ ID NO: 658 (or an allele variant of SEQ ID NO: 658), including at least the nucleic acid at position 136. Preferably, the portion of ASPH exon 22 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 658 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 136. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 136 nucleic acid. In this alternative, the portion of ASPH exon 22 preferably comprises or is according to SEQ ID NO: 658 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with ASPH comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In an alternative preferred embodiment, the polynucleotide comprising a portion of ASPH exon 22 fused to a portion of NRG1 exon 2 comprises from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 635 includes a junction between ASPH and NRG1, in particular the junction is between a nucleic acid derived from position 75 of ASPH and a nucleic acid derived from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 22 of ASPH fused with a part of exon 2 of NRG1 has a polynucleotide sequence of SEQ ID NO: 635 or an allele variant thereof.

Preferably, any ASPH-NRG1 polynucleotide fusion provided herein is an in-frame fusion of ASPH and NRG1. More preferably, the fusion is an in-frame fusion comprising ASPH exon 22 or a part of exon 22 and NRG1 exon 2 or a part of exon 2. The in-frame fusion is preferably a fusion of SEQ ID NO: 635 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 635, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

Preferably, the portion of ASPH exon 2 (or its allegenic variant) is located 5' to NRG1 exon 2 (or its allelic variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of ASPH and the C-terminus of NRG1. In addition, the ASPH-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from ASPH and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The ASPH-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinomas, more particularly colorectal adenocarcinomas. NOTCH2-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 6 of NOTCH2 fused to a portion of exon 6 of NRG1. Exon 6 of NOTCH2 is preferably the exon of SEQ ID NO: 700 or an allogenic variant of SEQ ID NO: 700, and exon 1 of NRG1 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of NOTCH2 exon 6 and any sequence at the 3' of NRG1 exon 6 sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 700 and 130 may be sufficient. Any sequence from the 5' of NOTCH2 exon 6 comprising or consisting of one or all of SEQ ID NO: 695-699 (or any allele variant of SEQ ID NO: 695-699) , and any sequence from 3' of NRG1 exon 6 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is derived from its composition.

Preferably, the allele variant of NOTCH2 exon 6 is at least 85% identical to SEQ ID NO: 700, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the portion of exon 6 of NOTCH2 comprises or is according to SEQ ID NO: 691, and the allele variant thereof is at least 85% identical, preferably at least 90% identical to SEQ ID NO: 691 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with NOTCH2 is preferably or comprises a sequence such as SEQ ID NO: 692, and its allele variant has at least 85% identity with SEQ ID NO: 692, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of exon 6 of NOTCH2 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 691, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the portion of exon 6 of NOTCH2 comprises or is according to SEQ ID NO: 691 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between NOTCH2 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of NOTCH2 exon 6 comprises or consists of SEQ ID NO: 700 (or an allele variant of SEQ ID NO: 700), including at least the nucleic acid at position 234. Preferably, the portion of NOTCH2 exon 6 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 700 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 234. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 234 nucleic acid. In this alternative, the portion of NOTCH2 exon 6 preferably comprises or is according to SEQ ID NO: 700 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with NOTCH2 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any NOTCH2-NRG1 polynucleotide fusion provided herein is an in-frame fusion of NOTCH2 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 6 or a part of exon 6 of NOTCH2 and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 693 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 693, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of NOTCH2 exon 6 fused to a portion of NRG1 exon 6 comprises from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 693 includes the junction between NOTCH2 and NRG1, in particular the junction is between the nucleic acid from position 75 of NOTCH2 and the nucleic acid from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 6 of NOTCH2 fused with a part of exon 6 of NRG1 has a polynucleotide sequence of SEQ ID NO: 693 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 693, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 693 and preferably A polynucleotide that includes the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 75 and 76.

Preferably, the polynucleotide comprising a part of NOTCH2 exon 6 (or its allogeneic variant) fused to a part of NRG1 exon 6 (or its allogeneic variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving NOTCH2 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For the purposes of rapid detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between NOTCH2 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the portion of NOTCH2 exon 6 (or its allele variant) is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of NOTCH2 and the C-terminus of NRG1. In addition, the NOTCH2-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from NOTCH2 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The NOTCH2-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinoma, and more particularly pancreatic ductal adenocarcinoma. CD74-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 2 of CD74 fused to a portion of exon 2 of NRG1. CD74 exon 2 is preferably the exon of SEQ ID NO: 720 or an allogenic variant of SEQ ID NO: 720, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of exon 2 of CD74 and any sequence at the 3' of exon 2 of NRG1 sequences, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 720 and 126 may be sufficient. Any sequence from 5' of exon 2 of CD74 comprising or consisting of SEQ ID NO: 719 (or any allele variant of SEQ ID NO: 719), and from 3 of NRG1 exon 2 Any sequence at ' comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or consists of it.

Preferably, the allele variant of CD74 exon 2 is at least 85% identical to SEQ ID NO: 720, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 2 of CD74 comprises or is according to SEQ ID NO: 715, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 715 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with CD74 is preferably or comprises a sequence such as SEQ ID NO: 716, and its allele variant has at least 85% identity with SEQ ID NO: 716, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of exon 2 of CD74 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 715, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the portion of exon 2 of CD74 comprises or is according to SEQ ID NO: 715 or an allegenic variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between CD74 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1 sexual fusion.

Alternatively, the portion of CD74 exon 2 comprises or consists of SEQ ID NO: 720 (or an allele variant of SEQ ID NO: 720), including at least the nucleic acid at position 173. Preferably, the portion of CD74 exon 2 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 720 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 173. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 173 nucleic acid. In this alternative, the portion of CD74 exon 2 preferably comprises or is according to SEQ ID NO: 720 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with CD74 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any CD74-NRG1 polynucleotide fusion provided herein is an in-frame fusion of CD74 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 2 or part of exon 2 of CD74 and exon 2 or part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 717 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 717, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of exon 2 of CD74 fused to a portion of exon 2 of NRG1 comprises sequences from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 53 and 54. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 717 includes a junction between CD74 and NRG1, in particular the junction is between the nucleic acid derived from position 75 of CD74 and the nucleic acid derived from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 2 of CD74 fused with a part of exon 2 of NRG1 has a polynucleotide sequence of SEQ ID NO: 717 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 717, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 717 and preferably A polynucleotide that includes the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 75 and 76.

Preferably, the polynucleotide comprising a part of exon 2 of CD74 (or its allele variant) fused to a part of NRG1 exon 2 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving CD74 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between CD74 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the portion of exon 2 of CD74 (or its allele variant) is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of CD74 and the C-terminus of NRG1. In addition, the CD74-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from CD74 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The CD74-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially lung cancer. SDC4-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 2 of SDC4 fused to a portion of exon 2 of NRG1. The SDC4 exon 2 is preferably the exon of SEQ ID NO: 746 or the allele variant of SEQ ID NO: 746, and the NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: Exon of the allele variant of 126.

Preferably, the allele variant of SDC4 exon 2 has at least 85% identity to SEQ ID NO: 746, preferably at least 90% identity, 92%, 94%, 96% or More preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 2 of SDC4 comprises or is according to SEQ ID NO: 741, and its allele variant has at least 85% identity with SEQ ID NO: 741, preferably at least 90% 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. The part of exon 2 of NRG1 in the fusion with SDC4 is preferably or comprises a sequence such as SEQ ID NO: 742, and its allele variant has at least 85% identity with SEQ ID NO: 742, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of exon 2 of SDC4 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 741, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the part of exon 2 of SDC4 comprises or is according to SEQ ID NO: 741 or its allele variant. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between SDC4 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, said portion of SDC4 exon 2 comprises or consists of SEQ ID NO: 746 (or an allele variant of SEQ ID NO: 746), at least including the nucleic acid at position 139. Preferably, the portion of the SDC4 exon 2 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 746 or its allele variant or consists of and includes at least the nucleic acid at position 139. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 139 nucleic acid. In this alternative, the part of SDC4 exon 2 preferably comprises or is according to SEQ ID NO: 746 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with SDC4 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any of the SDC4-NRG1 polynucleotide fusions provided herein is an in-frame fusion of SDC4 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 2 or part of exon 2 of SDC4 and exon 2 or part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 743 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 743, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a part of exon 2 of SDC4 fused with a part of exon 2 of NRG1 comprises from 2 to about 10 of SEQ ID NO: 743, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 743 includes the junction between SDC4 and NRG1, in particular the junction is between the nucleic acid from position 75 of SDC4 and the nucleic acid from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 2 of SDC4 fused with a part of exon 2 of NRG1 has a polynucleotide sequence of SEQ ID NO: 743 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 743, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 743 and preferably A polynucleotide that includes the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 75 and 76.

Preferably, the polynucleotide comprising a part of SDC4 exon 2 (or its allele variant) fused to a part of NRG1 exon 2 (or its allele variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Abnormal cell lines containing polynucleotide fusions involving said SDC4 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between SDC4 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of exon 2 of SDC4 (or its allele variant) is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of SDC4 and the C-terminus of NRG1. In addition, the SDC4-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from SDC4 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The SDC4-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially lung cancer.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of exon 2 of SDC4 and any sequence at the 3' of exon 2 of NRG1 sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 746 and 126 may be sufficient. Any sequence from 5' of exon 2 of SDC4 comprising or consisting of SEQ ID NO: 745 (or any allele variant of SEQ ID NO: 745), and from 3 of exon 2 of NRG1 Any sequence at ' comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or consists of it.

Furthermore, a polynucleotide fusion comprising a portion of exon 4 of SDC4 fused to a portion of exon 2 of NRG1 is provided. The SDC4 exon 4 is preferably the exon of SEQ ID NO: 748 or the allele variant of SEQ ID NO: 748, and the NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: Exon of the allele variant of 126.

Preferably, the allele variant of exon 4 of SDC4 has at least 85% identity to SEQ ID NO: 748, preferably at least 90% identity, 92%, 94%, 96% or More preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 is at least 85% identical to SEQ ID NO: 126, preferably at least 90% identical to 92% identical to SEQ ID NO: 126 , 94%, 96% or better at least 98% sequence identity.

Preferably, the part of exon 4 of SDC4 comprises or is according to SEQ ID NO: 822, and its allele variant has at least 85% identity with SEQ ID NO: 822, preferably at least 90% 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. The part of exon 2 of NRG1 in the fusion with SDC4 is preferably or comprises a sequence such as SEQ ID NO: 823, and its allele variant has at least 85% identity with SEQ ID NO: 823, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the portion of exon 4 of SDC4 comprises or consists of contiguous nucleic acids from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 822, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the part of exon 4 of SDC4 comprises or is according to SEQ ID NO: 822 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between SDC4 and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1. sexual fusion.

Alternatively, the portion of exon 4 of SDC4 comprises or consists of SEQ ID NO: 748 (or an allele variant of SEQ ID NO: 748), at least including the nucleic acid at position 199. Preferably, the portion of the SDC4 exon 4 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 748 or its allele variant or consists of and includes at least the nucleic acid at position 199. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 199 nucleic acid. In this alternative, the portion of exon 4 of SDC4 preferably comprises or is according to SEQ ID NO: 748 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with SDC4 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any of the SDC4-NRG1 polynucleotide fusions provided herein is an in-frame fusion of SDC4 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 4 or a part of exon 4 of SDC4 and exon 2 or a part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 824 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 824, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a part of exon 4 of SDC4 fused with a part of exon 2 of NRG1 comprises from 2 to about 10 of SEQ ID NO: 824, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 824 includes the junction between SDC4 and NRG1, in particular the junction is between the nucleic acid from position 75 of SDC4 and the nucleic acid from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 4 of SDC4 fused with a part of exon 2 of NRG1 has a polynucleotide sequence of SEQ ID NO: 824 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 824, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 824 and preferably A polynucleotide that includes the nucleic acids at positions 53 and 54. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 75 and 76.

Preferably, the polynucleotide comprising a part of SDC4 exon 4 (or its allogeneic variant) fused to a part of NRG1 exon 2 (or its allogeneic variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Abnormal cell lines containing polynucleotide fusions involving said SDC4 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between SDC4 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of exon 4 of SDC4 (or its allele variant) is located at the 5' position of NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of SDC4 and the C-terminus of NRG1. In addition, the SDC4-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from SDC4 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The SDC4-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, including lung cancer, especially non-small cell lung cancer.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of exon 4 of SDC4 and any sequence at the 3' of exon 2 of NRG1. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 748 and 126 may be sufficient. Any sequence from the 5' of exon 4 of SDC4 comprising or consisting of one or all of SEQ ID NO: 745-747 (or any allele variant of SEQ ID NO: 745-747) , and any sequence from 3' of NRG1 exon 2 comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or is derived from its composition. SLC4A4-NRG1 polynucleotide fusion

Also provided is a polynucleotide fusion comprising a portion of exon 14 of SLC4A4 fused to a portion of exon 6 of NRG1. SLC4A4 exon 14 is preferably the exon of SEQ ID NO: 780 or an allele variant of SEQ ID NO: 780, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of exon 14 of SLC4A4 and any sequence at the 3' of exon 6 of NRG1. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 780 and 130 may be sufficient. Any sequence from the 5' of exon 14 of SLC4A4 comprising or consisting of one or all of SEQ ID NO: 767-779 (or any allele variant of SEQ ID NO: 767-779) , and any sequence from 3' of NRG1 exon 6 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is derived from its composition.

Preferably, the allele variant of exon 14 of SLC4A4 is at least 85% identical to SEQ ID NO: 780, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 14 of SLC4A4 comprises or is according to SEQ ID NO: 763, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 763 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with SLC4A4 is preferably or comprises a sequence such as SEQ ID NO: 764, and its allele variant has at least 85% identity with SEQ ID NO: 764, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 14 of SLC4A4 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 763, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the portion of exon 14 of SLC4A4 comprises or is according to SEQ ID NO: 763 or an allele variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between SLC4A4 and NRG1 and determining whether such fusions are oncogenic in frame containing the EGF-like domain of NRG1 sexual fusion.

Alternatively, the portion of exon 14 of SLC4A4 comprises or consists of SEQ ID NO: 780 (or an allele variant of SEQ ID NO: 780), including at least the nucleic acid at position 272. Preferably, the portion of SLC4A4 exon 14 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acid from SEQ ID NO: 780 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 272. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 272 nucleic acid. In this alternative, the portion of exon 14 of SLC4A4 preferably comprises or is according to SEQ ID NO: 780 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with SLC4A4 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

Preferably, any of the SLC4A4-NRG1 polynucleotide fusions provided herein is an in-frame fusion of SLC4A4 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 14 or a part of exon 14 of SLC4A4 and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 765 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 765, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

In an alternative preferred embodiment, the polynucleotide comprising a portion of exon 14 of SLC4A4 fused to a portion of exon 6 of NRG1 comprises a sequence from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 765 includes the junction between SLC4A4 and NRG1, in particular the junction is between the nucleic acid from position 75 of SLC4A4 and the nucleic acid from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 14 of SLC4A4 fused with a part of exon 6 of NRG1 has a polynucleotide sequence of SEQ ID NO: 765 or an allele variant thereof.

In a preferred embodiment, there is provided a polynucleotide according to SEQ ID NO: 765, or a contiguous nucleic acid comprising about 20, about 30, about 40 or all of SEQ ID NO: 765 and preferably A polynucleotide that includes the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and preferably at least including the nucleic acids at positions 75 and 76.

Preferably, the polynucleotide comprising a part of SLC4A4 exon 14 (or its allogeneic variant) fused to a part of NRG1 exon 6 (or its allogeneic variant) is a polynucleotide further comprising or Part of a longer polynucleotide encoding the EGF-like domain of NRG1. Aberrant cell lines containing polynucleotide fusions involving SLC4A4 or expressing such polypeptide fusions contain or encode the EGF-like domain of NRG1. For rapid detection, diagnostic or identification purposes, it is only necessary to demonstrate that the fusion junction between SLC4A4 and NRG1 is in-frame and occurs at one such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1 The location is fine. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Preferably, the part of exon 14 of SLC4A4 (or its allogeneic variant) is located at the 5' of NRG1 exon 6 (or its allogeneic variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of SLC4A4 and the C-terminus of NRG1. In addition, the SLC4A4-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is the polypeptide sequence from SLC4A4 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The SLC4A4-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially pancreatic cancer. ZFAT-NRG1 polynucleotide fusion

According to the present disclosure, there is also provided a polynucleotide comprising a fusion of a ZFAT nucleic acid sequence (or a part of the ZFAT nucleic acid sequence) and an NRG1 nucleic acid sequence (or a part of the NRG1 nucleic acid sequence). Allele variants of ZFAT and NRG1 nucleic acid sequences are also included in the fusion.

Preferably, the ZFAT nucleic acid sequence (or part thereof) comprises any one of SEQ ID NOs: 830-846 or an allele variant of any one of SEQ ID NOs: 830-846, or consists of it , and the NRG1 nucleic acid sequence (or part thereof) comprises any one of SEQ ID NOs: 125-138 or an allele variant of any one of SEQ ID NOs: 125-138, or consists of it. More preferably, the ZFAT nucleic acid sequence comprises SEQ ID NO: 846 or a part of the allele variant of SEQ ID NO: 846, or consists of it, and the NRG1 nucleic acid sequence comprises SEQ ID NO: 138 or SEQ ID NO: 138 is part of, or consists of, the allele variant. SEQ ID NO: 830-845 correspond to individual exons 1-16 of the ZFAT according to NM_020863.4, respectively. SEQ ID NO: 846 corresponds to exons 1-16 of the ZFAT according to NM_020863.4. SEQ ID NO: 125-137 correspond to individual exons 1-13 of NRG1 according to NM_001159999.3, respectively. SEQ ID NO: 138 corresponds to exons 1-13 of NRG1 according to NM_001159999.3.

In a preferred embodiment, the ZFAT nucleic acid sequence part comprises 2 to About 10, about 20, about 30, or up to about 40 or even all of the continuous nucleic acid, and the NRG1 nucleic acid sequence part comprises from any one of SEQ ID NO: 125-138 (or SEQ ID NO: 125-138 Allele variants of any) from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids.

Preferably, the allele variant of the ZFAT nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 830-846, preferably at least 90% identity, and its 92%, 94% identity , 96% or better at least 98% sequence identity; and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, 92%, 94%, 96% or better at least 98% sequence identity thereto.

Preferably, the ZFAT nucleic acid sequence or part thereof is located 5' to the NRG1 nucleic acid sequence or part thereof.

Preferably, the polynucleotide comprising a ZFAT nucleic acid sequence (or a part of said sequence) fused to an NRG1 nucleic acid sequence (or a part of said sequence) comprises or encodes the EGF-like domain of NRG1.

Abnormal cell lines containing the ZFAT-NRG1 polynucleotide fusion or expressing the polypeptide fusion contain or encode the EGF-like domain of NRG1. For the purposes of detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between ZFAT and NRG1 is in-frame and occurs at a position such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1. Can. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Also provided is a polynucleotide fusion comprising a portion of exon 12 of ZFAT fused to a portion of exon 6 of NRG1. ZFAT exon 12 is preferably the exon of SEQ ID NO: 841 or an allogenic variant of SEQ ID NO: 841, and NRG1 exon 6 is preferably SEQ ID NO: 130 or SEQ ID NO: 130 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of ZFAT exon 12 and any sequence at the 3' of NRG1 exon 6. sequence, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 841 and 130 may be sufficient. Any sequence from the 5' of ZFAT exon 12 comprises one or all of SEQ ID NO: 830-840 (or any allele variant of SEQ ID NO: 830-840), or consists of it , and any sequence from 3' of NRG1 exon 6 comprises one or all of SEQ ID NO: 131-137 (or any allele variant of SEQ ID NO: 131-137), or is derived from its composition.

Preferably, the allele variant of ZFAT exon 12 is at least 85% identical to SEQ ID NO: 841, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 6 has at least 85% identity to SEQ ID NO: 130, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of ZFAT exon 12 comprises or is according to SEQ ID NO: 826, and its allele variant has at least 85% identity with SEQ ID NO: 826, preferably at least 90% identity 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 6 of NRG1 in the fusion with ZFAT is preferably or comprises a sequence such as SEQ ID NO: 827, and its allele variant has at least 85% identity with SEQ ID NO: 827, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of ZFAT exon 12 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 826, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the part of ZFAT exon 12 comprises or is according to SEQ ID NO: 826 or its allegenic variant. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between ZFAT and NRG1 and determining whether such fusions are oncogenic containing in-frame EGF-like domains of NRG1 sexual fusion.

Alternatively, the portion of ZFAT exon 12 comprises or consists of SEQ ID NO: 841 (or an allele variant of SEQ ID NO: 841), including at least the nucleic acid at position 139. Preferably, the portion of ZFAT exon 12 comprises 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 841 or its allele variants or is composed of It consists of, and at least includes, the nucleic acid at position 139. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 139 nucleic acid. In this alternative, the portion of ZFAT exon 12 preferably comprises or is according to SEQ ID NO: 841 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 6 in the fusion with ZFAT comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In an alternative preferred embodiment, the polynucleotide comprising a portion of ZFAT exon 12 fused to a portion of NRG1 exon 2 comprises from 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 828 includes a junction between ZFAT and NRG1, in particular the junction is between a nucleic acid derived from position 75 of ZFAT and a nucleic acid derived from position 76 of NRG1. Preferably, the polynucleotide comprising a part of ZFAT exon 12 fused with a part of NRG1 exon 6 has a polynucleotide sequence of SEQ ID NO: 828 or an allele variant thereof.

Preferably, any ZFAT-NRG1 polynucleotide fusion provided herein is an in-frame fusion of ZFAT and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 12 or a part of exon 12 of ZFAT and exon 6 or a part of exon 6 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 828 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 828, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

Preferably, the part of ZFAT exon 12 (or its allele variant) is located at the 5' position of NRG1 exon 6 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of ZFAT and the C-terminus of NRG1. In addition, the ZFAT-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from ZFAT and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The ZFAT-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially non-small cell lung cancer. DSCAML1-NRG1 polynucleotide fusion

According to the present disclosure, there is also provided a polynucleotide comprising a fusion of DSCAML1 nucleic acid sequence (or a part of DSCAML1 nucleic acid sequence) and NRG1 nucleic acid sequence (or a part of NRG1 nucleic acid sequence). Allele variants of DSCAML1 and NRG1 nucleic acid sequences are also included in the fusion.

Preferably, the DSCAML1 nucleic acid sequence (or part thereof) comprises, or consists of, any one of SEQ ID NOs: 870-903 or an allele variant of any one of SEQ ID NOs: 870-903 , and the NRG1 nucleic acid sequence (or part thereof) comprises any one of SEQ ID NOs: 125-138 or an allele variant of any one of SEQ ID NOs: 125-138, or consists of it. More preferably, the DSCAML1 nucleic acid sequence comprises a part of SEQ ID NO: 903 or an allele variant of SEQ ID NO: 903, or consists of it, and the NRG1 nucleic acid sequence comprises SEQ ID NO: 138 or SEQ ID NO: 138 is part of, or consists of, the allele variant. SEQ ID NO: 870-902 correspond to individual exons 1-33 of DSCAML1 according to NM_020693.4, respectively. SEQ ID NO: 903 corresponds to exons 1-33 of DSCAML1 according to NM_020693.4. SEQ ID NO: 125-137 correspond to individual exons 1-13 of NRG1 according to NM_001159999.3, respectively. SEQ ID NO: 138 corresponds to exons 1-13 of NRG1 according to NM_001159999.3.

In a preferred embodiment, the DSCAML1 nucleic acid sequence part comprises 2 to About 10, about 20, about 30, or up to about 40 or even all of the continuous nucleic acid, and the NRG1 nucleic acid sequence part comprises from any one of SEQ ID NO: 125-138 (or SEQ ID NO: 125-138 Allele variants of any) from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids.

Preferably, the allele variant of the DSCAML1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 870-903, preferably at least 90% identity, and 92%, 94% identity with it , 96% or better at least 98% sequence identity; and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, 92%, 94%, 96% or better at least 98% sequence identity thereto.

Preferably, the DSCAML1 nucleic acid sequence or part thereof is located 5' to the NRG1 nucleic acid sequence or part thereof.

Preferably, the polynucleotide comprising DSCAML1 nucleic acid sequence (or a part of said sequence) fused with NRG1 nucleic acid sequence (or a part of said sequence) of DSCAML1 comprises or encodes the EGF-like domain of NRG1.

Abnormal cell lines containing the DSCAML1-NRG1 polynucleotide fusion or expressing the polypeptide fusion contain or encode the EGF-like domain of NRG1. For the purposes of detection, diagnosis or identification, it is only necessary to demonstrate that the fusion junction between DSCAML1 and NRG1 is in-frame and occurs at a position such that the resulting fusion product, nucleic acid or protein comprises the EGF-like domain of NRG1. Can. The EGF-like domain is preferably an EGF-like domain according to SEQ ID NO: 163 or an allele variant thereof and has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 163 , with 92%, 94%, 96% or better at least 98% sequence identity therewith.

Also provided is a polynucleotide fusion comprising a portion of exon 3 of DSCAML1 fused to a portion of exon 2 of NRG1. DSCAML1 exon 3 is preferably the exon of SEQ ID NO: 872 or an allogenic variant of SEQ ID NO: 872, and NRG1 exon 2 is preferably SEQ ID NO: 126 or SEQ ID NO: 126 exons of the allele variant.

When present in abnormal cells of a patient or individual, the polynucleotide fusion preferably further comprises any sequence at the 5' of DSCAML1 exon 3 and any sequence at the 3' of NRG1 exon 2 sequences, but in order to be able to detect fusion junctions using polynucleotide-based detection assays, the presence of at least SEQ ID NO: 872 and 126 may be sufficient. Any sequence from 5' of exon 3 of DSCAML1 comprising or consisting of one or all of SEQ ID NO: 870-871 (or any allele variant of SEQ ID NO: 870-871) , and any sequence from 3' of NRG1 exon 2 comprises one or all of SEQ ID NO: 127-137 (or any allele variant of SEQ ID NO: 127-137), or is formed by its composition.

Preferably, the allele variant of exon 3 of DSCAML1 is at least 85% identical to SEQ ID NO: 872, preferably at least 90% identical, 92%, 94%, 96% or more identical thereto Preferably at least 98% sequence identity, and the allele variant of NRG1 exon 2 has at least 85% identity to SEQ ID NO: 126, preferably at least 90% identity, and its 92%, 94%, 96% or better still at least 98% sequence identity.

Preferably, the part of exon 3 of DSCAML1 comprises or is according to SEQ ID NO: 866, and its allele variant has at least 85% identity, preferably at least 90% identity with SEQ ID NO: 866 92%, 94%, 96% or better at least 98% sequence identity therewith. The part of exon 2 of NRG1 in the fusion with DSCAML1 is preferably or comprises a sequence such as SEQ ID NO: 867, and its allele variant has at least 85% identity with SEQ ID NO: 867, Preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. More preferably, the part of exon 3 of DSCAML1 comprises or consists of continuous nucleic acid from 2 to about 10, about 20, about 30, or up to about 40 or even all of SEQ ID NO: 866, and At least the nucleic acid at position 75 is included. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 nucleic acid. More preferably, the part of exon 3 of DSCAML1 comprises or is according to SEQ ID NO: 866 or an allegenic variant thereof. Such short polynucleotide sequences are particularly useful for detecting the presence of larger polynucleotide fusions between DSCAML1 and NRG1 and determining whether such fusions are in-frame oncogenic agents containing the EGF-like domain of NRG1. sexual fusion.

Alternatively, the portion of exon 3 of DSCAML1 comprises or consists of SEQ ID NO: 872 (or an allele variant of SEQ ID NO: 872), including at least the nucleic acid at position 147. Preferably, the portion of exon 3 of DSCAML1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or even all of the contiguous nucleic acids from SEQ ID NO: 872 or an allele variant thereof or is composed of It consists of, and at least includes, the nucleic acid at position 147. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 147 nucleic acid. In this alternative, the portion of exon 3 of DSCAML1 preferably comprises or is according to SEQ ID NO: 872 or an allegenic variant thereof. Preferably, the portion of NRG1 exon 2 in the fusion with DSCAML1 comprises from 2 to about 10, about 20, about 30, or up to about 40 or Even the entire continuous nucleic acid or consists of it, and at least includes the nucleic acid in position 1. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, including at least position 1 nucleic acid.

In an alternative preferred embodiment, the polynucleotide comprising a portion of exon 3 of DSCAML1 fused to a portion of exon 2 of NRG1 is comprised of 2 to about 10, about 20, About 30, or up to about 40 or even all of the contiguous nucleic acids, and including the nucleic acids at positions 75 and 76. The number of consecutive nucleic acids can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or all of the nucleic acids, and at least including position 75 and 76 nucleic acids. SEQ ID NO: 868 includes the junction between DSCAML1 and NRG1, in particular the junction is between the nucleic acid from position 75 of DSCAML1 and the nucleic acid from position 76 of NRG1. Preferably, the polynucleotide comprising a part of exon 3 of DSCAML1 fused with a part of exon 2 of NRG1 has a polynucleotide sequence of SEQ ID NO: 868 or an allele variant thereof.

Preferably, any DSCAML1-NRG1 polynucleotide fusion provided herein is an in-frame fusion of DSCAML1 and NRG1. More preferably, the fusion is an in-frame fusion comprising exon 3 or a part of exon 3 of DSCAML1 and exon 2 or a part of exon 2 of NRG1. The in-frame fusion is preferably a fusion of SEQ ID NO: 868 or an allele variant thereof, and the allele variant has at least 85% identity to SEQ ID NO: 868, preferably at least 90%, 92%, 94%, 96% or even 98% agreement.

Preferably, the part of exon 3 of DSCAML1 (or its allele variant) is located 5' to NRG1 exon 2 (or its allele variant). This nucleic acid-level alignment results in a fusion polypeptide product containing the N-terminus of DSCAML1 and the C-terminus of NRG1. In addition, the DSCAML1-NRG1 polynucleotide fusions provided herein result in a protein fusion in which the portion from the N-terminus to the fusion junction is a polypeptide sequence from DSCAML1 and the portion from the junction to the C-terminus is NRG1 polypeptide sequence, wherein the NRG1 portion also provides its EGF-like domain. The DSCAML1-NRG1 fusion protein thus retains the EGF-like domain of NRG1 and the ability to drive proliferation and survival of a small group of human cancers, especially adenocarcinoma, and more particularly pancreatic ductal adenocarcinoma.

Each polynucleotide fusion containing NRG1 mentioned herein includes VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, DAAM1-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4- NRG1, SLC4A4-NRG1, ZFAT-NRG1 or DSCAML1-NRG1, are preferably isolated. Any of the methods of the invention preferably comprises isolating one or more polynucleotide-containing fractions from the sample. The one or more polynucleotide-containing components are typically isolated from any cells or cellular material in the sample. NRG1 polypeptide fusion

According to the present disclosure, there are now provided polypeptide fusions comprising NRG1, including VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1- NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4-NRG1, SLC4A4-NRG1, ZFAT-NRG1 and DSCAML1-NRG1. In particular, such fusions are present or have been identified in human patients diagnosed with cancer and are mentioned in more detail in the next section. VAPB-NRG1 polypeptide fusion

According to the disclosure, there is also provided a polypeptide fusion encoded by a polynucleotide comprising a VAPB nucleic acid sequence (or a part of the VAPB nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of the NRG1 nucleic acid sequence). The VAPB nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 24-30 (or an allele variant of any one of these SEQ ID NOs) or derived from its constituent sequences. The NRG1 nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 139-152 (or an allele variant of any one of these SEQ ID NOs) or derived from its constituent sequences.

The VAPB allele variant of any one of SEQ ID NO: 24-30 preferably has at least 85% sequence identity with these sequences, more preferably 90%, 92%, 94%, 96% therewith Or even better at least 98% sequence identity. The NRG1 allele variant of any one of SEQ ID NOs: 139-152 preferably has at least 85% sequence identity to these sequences, more preferably 90%, 92%, 94%, 96% thereto Or even better at least 98% sequence identity.

Preferably, the VAPB nucleic acid sequence part of the fusion is a polypeptide part of encoding VAPB, and this polypeptide part comprises any one (or any one of SEQ ID NOs: 24-30) from SEQ ID NO: 24-30. or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of Preferably, the NRG1 nucleic acid sequence part of the fusion is a polypeptide part of encoding NRG1, and this polypeptide part comprises any one (or any one of SEQ ID NOs: 139-152) from SEQ ID NO: 139-152 or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of

Preferably, any VAPB-NRG1 polypeptide fusion of the present disclosure includes the polypeptide sequence of any one of SEQ ID NO: 24-30, and this polypeptide sequence has one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutation to add, delete or replace any amino acid of the polypeptide of SEQ ID NO: 24-30. Preferably, the polypeptide fusion comprises the polypeptide sequence of any one of SEQ ID NO: 24-30, and this polypeptide sequence has 1, 2, 3, 4 or 5 point mutations added, deleted or substituted for SEQ ID NO : Any amino acid of the polypeptide of 24-30. More preferably, the polynucleotide fusion comprises the polypeptide sequence of any one of SEQ ID NO: 24-30, and this polypeptide sequence has 1, 2 or 3 point mutations to add, delete or replace SEQ ID NO: 24 Any amino acid of the polypeptide of -30.

In a preferred embodiment, there is also provided a polynucleoside comprising a part of VAPB exon 1 (or its allele variant) and a part of NRG1 exon 2 (or its allele variant) Acid-encoded polypeptide fusion. The polypeptide encoded by exon 1 of VAPB preferably comprises or consists of SEQ ID NO: 24 or the allele variant of SEQ ID NO: 24. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises any or all of SEQ ID NO: 141-151, or any allele variant of SEQ ID NO: 141-151. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be according to SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 1 part of VAPB comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 24 or the allele variant of SEQ ID NO: 24 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 24, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any VAPB-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 4 or its allele variant. SEQ ID NO: 4 contains a fusion junction between VAPB and NRG1 between the amino acid at position 14 (with amino acids at positions 1-13 of the stalk of VAPB) and between position 16 between the amino acids (which tie together with the amino acids at positions 17-31 of the handle of NRG1). At position 15, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with VAPB. Preferably, the VAPB-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 4 or its allele variant, at least including positions 14, 15 and 16 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 4, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 4 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 14, 15 and 16. The polypeptide sequence has at least 85% identity to SEQ ID NO: 4, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any VAPB-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 4, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 4. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 4 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 4. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 4 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 4 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and VAPB are aligned so that the portion spanning the N-terminus to the fusion junction is a polypeptide sequence from VAPB, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the VAPB-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. CADM1-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of CADM1 exon 7 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 7 of CADM1 preferably comprises or consists of SEQ ID NO: 51 or the allele variant of SEQ ID NO: 51. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any or all of SEQ ID NO: 45-50, or any allele variant of any of SEQ ID NO: 45-50, and is more Preferably further comprising any one of SEQ ID NO: 145-151, or any allogeneic variant of any one of SEQ ID NO: 145-151. SEQ ID NOs: 45-50 correspond to individual polypeptide sequences encoded by exons 1-7 of CADM1, respectively. SEQ ID NOs: 145-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by exon 7 of CADM1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 51 or the allele variant of SEQ ID NO: 51 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 51, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CADM1-NRG1 polypeptide fusion of the present disclosure comprises a polypeptide sequence such as SEQ ID NO: 8 or an allele variant thereof. SEQ ID NO: 8 contains a fusion junction between CADM1 and NRG1 between the amino acid at position 17 (with the amino acids at positions 1-16 of the stalk of CADM1) and between position 19 between the amino acids (which tie together with the amino acids at positions 20-28 of the handle of NRG1). At position 18, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 and CADM1. Preferably, the CADM1-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 8 or its allele variant, including at least positions 17, 18 and 19 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 8, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 8 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 17, 18 and 19. The polypeptide sequence has at least 85% identity to SEQ ID NO: 8, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CADM1-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 8, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 8. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 8 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 8. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 8 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 8 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and CADM1 are aligned such that the portion spanning the N-terminus to the fusion junction is a polypeptide sequence from CADM1, and the portion spanning the fusion junction to the C-terminus Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the CADM1-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. CD44-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of CD44 exon 5 (or its allogeneic variant) and a portion of NRG1 exon 2 (or its allogeneic variant). The polypeptide encoded by exon 5 of CD44 preferably comprises or consists of SEQ ID NO: 84 or an allele variant of SEQ ID NO: 84. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises any or all of SEQ ID NO: 80-83, or any allele variant of any of SEQ ID NO: 80-83, and more Preferably further comprising any one of SEQ ID NO: 141-151, or any allogeneic variant of any one of SEQ ID NO: 141-151. SEQ ID NOs: 80-83 correspond to individual polypeptide sequences encoded by exons 1-4 of CD44, respectively. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 5 part of CD44 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive allele variants from SEQ ID NO: 84 or SEQ ID NO: 84 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 84, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CD44-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 12 or its allele variant. SEQ ID NO: 12 contains a fusion junction between CD44 and NRG1 between the amino acid at position 17 (with the amino acids at positions 1-16 of the stalk of CD44) and between position 19 Amino acids (which tie together with the amino acids at positions 20-36 of the handle of NRG1). At position 18, a threonine (T, Thr) residue was present due to an unexpected in-frame fusion of NRG1 with CD44. Preferably, the CD44-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 12 or its allele variant, including at least positions 17, 18 and 19 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 12, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 12 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 17, 18 and 19. The polypeptide sequence has at least 85% identity to SEQ ID NO: 12, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CD44-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 12, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 12. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 12 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 12. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 12 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 12 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and CD44 are aligned such that the portion spanning the N-terminus to the fusion junction is a polypeptide sequence from CD44, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the CD44-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein.

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of CD44 exon 5 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 5 of CD44 preferably comprises or consists of SEQ ID NO: 84 or an allele variant of SEQ ID NO: 84. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 80-83, or any allele variant of SEQ ID NO: 80-83, and preferably further comprises SEQ ID NO : 145-151 or any allele variant of SEQ ID NO: 145-151. SEQ ID NOs: 80-83 correspond to individual polypeptide sequences encoded by exons 1-4 of CD44, respectively. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by the exon 5 part of CD44 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive allele variants from SEQ ID NO: 84 or SEQ ID NO: 84 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 84, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CD44-NRG1 polypeptide fusion of the present disclosure comprises a polypeptide sequence such as SEQ ID NO: 762 or an allele variant thereof. SEQ ID NO: 762 contains a fusion junction between CD44- and NRG1 with the amino acid at position 24 (together with the amino acids at positions 1-23 of the stalk of CD44-) and position Between the amino acids of 26 (which are together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, a threonine (T, Thr) residue is present due to an unexpected in-frame fusion of NRG1 to CD44-. Preferably, the CD44--NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 762 or its allele variant, including at least position 24 , 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 762, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 762 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 762, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CD44-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 762, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 762. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 762 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 762 : Any amino acid of the polypeptide of 762. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 762 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 762 of any amino acid.

Preferably, the polypeptide fusions provided herein between CD44 and NRG1 are aligned so that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from CD44, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the CD44-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. SLC3A2-NRG1 polypeptide fusion

Also provided is a polynucleotide encoded by a portion of exon 1 (or its allele variant) of transcript 6 of SLC3A2 and a portion of NRG1 exon 5 (or its allele variant) Polypeptide Fusions. The polypeptide encoded by exon 1 of SLC3A2 preferably comprises or consists of SEQ ID NO: 113 or the allele variant of SEQ ID NO: 113. The polypeptide encoded by exon 5 of NRG1 preferably comprises or consists of SEQ ID NO: 143 or an allele variant of SEQ ID NO: 143. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 144-151, or any allele variant of any one of SEQ ID NO: 144-151. SEQ ID NOs: 144-151 correspond to individual polypeptide sequences encoded by exons 6-13 of NRG1, respectively. The exon 5 part of NRG1 may also be composed of SEQ ID NO: 158 or an allele variant of SEQ ID NO: 158, the sequence of which corresponds to the polypeptide sequence encoded by all exons 6-13 and includes a sequence consisting of The extra serine residue encoded by the most 3' in-frame triplet of exon 5.

Preferably, the polypeptide encoded by exon 1 part of exon 6 of the transcript of SLC3A2 comprises 8, 9, 10, 11, 12, 13 from SEQ ID NO: 113 or the allele variant of SEQ ID NO: 113 or 14 consecutive amino acids, or consists of them. The allele variant has at least 85% identity to SEQ ID NO: 113, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. In a preferred embodiment, the NRG1 exon 5 part in the SLC3A2-NRG1 fusion comprises at least the amino acid at position 16 of SEQ ID NO: 143, or the corresponding allele variant of SEQ ID NO: 143 amino acids. The allele variant has at least 85% identity to SEQ ID NO: 143, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any transcript 6 of the SLC3A2-NRG1 polypeptide fusion disclosed herein includes a polypeptide sequence such as SEQ ID NO: 16 or its allele variant. SEQ ID NO: 16 contains a fusion junction between SLC3A2 and NRG1 between the amino acid at position 17 (with the amino acids at positions 1-16 of the stalk of SLC3A2) and between position 19 Amino acids (which tie together with the amino acids at positions 20-29 of the handle of NRG1). At position 18, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 to the SLC3A2 transcript. Preferably, the SLC3A2-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 16 or its allele variant, including at least positions 17 and 18 and 19 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 16, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 16 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 17, 18 and 19. The polypeptide sequence has at least 85% identity to SEQ ID NO: 16, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any transcript 6 of the SLC3A2-NRG1 polypeptide fusion disclosed herein includes one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) points A mutated polypeptide sequence of SEQ ID NO: 16, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 16. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 16 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 16. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 16 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 16 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and transcript 6 of SLC3A2 are aligned such that the portion spanning the N-terminus to the fusion junction is a polypeptide sequence from SLC3A2, and the portion spanning the fusion junction The part to the C-terminus is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the SLC3A2-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein.

Also provided is a polynucleotide encoded by a portion of exon 2 (or its allele variant) of transcript 3 of SLC3A2 and a portion of NRG1 exon 6 (or its allele variant) Polypeptide Fusions. The polypeptide encoded by exon 2 of SLC3A2 preferably comprises or consists of SEQ ID NO: 470 or the allele variant of SEQ ID NO: 470. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 469 or 145-151, or any allele variant of SEQ ID NO: 469 or 145-151. SEQ ID NOs: 145-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by the exon 2 part of transcript 3 of the SLC3A2 comprises 8, 9, 10, 11, 12, 13 from SEQ ID NO: 470 or the allele variant of SEQ ID NO: 470 or 14 consecutive amino acids, or consists of them. The allele variant has at least 85% identity to SEQ ID NO: 470, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. In a preferred embodiment, the portion of exon 6 of NRG1 in the SLC3A2-NRG1 fusion comprises or is the sequence according to SEQ ID NO: 144 or the allele variant of SEQ ID NO: 144. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any transcript 3 of the SLC3A2-NRG1 polypeptide fusion disclosed herein includes a polypeptide sequence such as SEQ ID NO: 455 or its allele variant. SEQ ID NO: 455 contains a fusion junction between SLC3A2 and NRG1 between the amino acid at position 30 (together with the amino acids at positions 1-29 of the stalk of SLC3A2) and between position 32 between the amino acids (which tie together with the amino acids at positions 33-39 of the handle of NRG1). At position 31, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 to the SLC3A2 transcript. Preferably, the SLC3A2-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 455 or its allele variants, including at least positions 30 and 31 and 32 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 455, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 455 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 30, 31 and 32. The polypeptide sequence has at least 85% identity to SEQ ID NO: 455, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any transcript 3 of the SLC3A2-NRG1 polypeptide fusion disclosed herein includes one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) points A mutated polypeptide sequence of SEQ ID NO: 455, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 455. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 455 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 455. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 455 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 455 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and transcript 6 of SLC3A2 are aligned such that the portion spanning the N-terminus to the fusion junction is a polypeptide sequence from SLC3A2 and spanning the fusion junction The part to the C-terminus is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the SLC3A2-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. VTCN1-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of VTCN1 exon 2 (or its allogeneic variant) and a portion of NRG1 exon 2 (or its allogeneic variant). The polypeptide encoded by exon 2 of VTCN1 preferably comprises or consists of SEQ ID NO: 176 or the allele variant of SEQ ID NO: 176. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises SEQ ID NO: 175 or an allele variant of SEQ ID NO: 175, and preferably further comprises any one of SEQ ID NO: 141-151, or SEQ ID NO: 141-151, or SEQ ID NO: 175 Any allele variant of any of ID NOs: 141-151. SEQ ID NO: 175 corresponds to the polypeptide sequence encoded by exon 1 of VTCN1. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 2 part of VTCN1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 176 or the allele variant of SEQ ID NO: 176 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 176, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any VTCN1-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 167 or an allele variant thereof. SEQ ID NO: 167 contains a fusion junction between VTCN1 and NRG1 between the amino acid at position 21 (with the amino acids at positions 1-20 of the stalk of VTCN1 ) and between position 23 between the amino acids (which tie together with the amino acids at positions 24-30 of the handle of NRG1). At position 22, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 and VTCN1. Preferably, the VTCN1-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 167 or its allele variant, including at least positions 21, 22 and 23 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 167, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 167 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 21, 22 and 23. The polypeptide sequence has at least 85% identity to SEQ ID NO: 167, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any VTCN1-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 167, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 167. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 167 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 167. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 167 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 167 of any amino acid.

Preferably, the polypeptide fusions provided herein between VTCN1 and NRG1 are aligned so that the part spanning the N-terminus to the fusion junction is the polypeptide sequence from VTCN1, and the part spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the VTCN1-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. CDH1-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of CDH1 exon 11 (or its allogeneic variant) and a portion of NRG1 exon 2 (or its allogeneic variant). The polypeptide encoded by exon 11 of CDH1 preferably comprises or consists of SEQ ID NO: 206 or the allele variant of SEQ ID NO: 206. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises SEQ ID NO: 205 or an allele variant of SEQ ID NO: 205, and preferably further comprises any one of SEQ ID NO: 141-151, or SEQ ID NO: 141-151, or SEQ ID NO: Any allele variant of any of ID NOs: 141-151. SEQ ID NO: 205 corresponds to the polypeptide sequence encoded by exon 10 of CDH1. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 11 part of CDH1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive allele variants from SEQ ID NO: 206 or SEQ ID NO: 206 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 206, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CDH1-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 187 or its allele variant. SEQ ID NO: 187 contains a fusion junction between CDH1 and NRG1 between the amino acid at position 39 (together with the amino acids at positions 1-38 of the handle of CDH1) and between position 41 between the amino acids (which tie together with the amino acids at positions 42-49 of the handle of NRG1). At position 40, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 and CDH1. Preferably, the CDH1-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 187 or its allele variant, including at least positions 39, 40 and 41 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 187, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 187 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 39, 40 and 41. The polypeptide sequence has at least 85% identity to SEQ ID NO: 187, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CDH1-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 187, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 187. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 187 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 187. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 187 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 187 of any amino acid.

Preferably, the polypeptide fusions provided herein between CDH1 and NRG1 are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from CDH1, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the CDH1-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. CXADR-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of CXADR exon 1 (or its allelic variant) and a portion of NRG1 exon 2 (or its allelic variant). The polypeptide encoded by exon 1 of CXADR preferably comprises or consists of SEQ ID NO: 225 or an allele variant of SEQ ID NO: 225. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises SEQ ID NO: 141-151, or any allele variant of SEQ ID NO: 141-151. SEQ ID NO: 225 corresponds to the polypeptide sequence encoded by exon 1 of CXADR. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the CXADR exon 1 part comprises 8, 9, 10, 11, 12, 13 or 14 contiguous Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 225, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CXADR-NRG1 polypeptide fusion of the present disclosure comprises a polypeptide sequence such as SEQ ID NO: 218 or an allele variant thereof. SEQ ID NO: 218 contains a fusion junction between CXADR and NRG1 between the amino acid at position 14 (together with the amino acids at positions 1-13 of the stalk of CXADR) and position 16 Amino acids (which tie together with the amino acids at positions 17-33 of the handle of NRG1). At position 15, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 to CXADR. Preferably, the CXADR-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 218 or its allele variant, including at least positions 14, 14, 15 and 16 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 218, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 218 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 14, 15 and 16. The polypeptide sequence has at least 85% identity to SEQ ID NO: 218, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CXADR-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 218, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 218. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 218 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 218. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 218 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 218 of any amino acid.

Preferably, the polypeptide fusions provided herein between CXADR and NRG1 are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from CXADR, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the CXADR-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. GTF2E2-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of GTF2E2 exon 2 (or its allelic variant) and a portion of NRG1 exon 2 (or its allelic variant). The polypeptide encoded by exon 2 of GTF2E2 preferably comprises or consists of SEQ ID NO: 244 or an allele variant of SEQ ID NO: 244. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises SEQ ID NO: 141-151, or any allele variant of SEQ ID NO: 141-151. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 2 part of GTF2E2 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 244 or an allele variant of SEQ ID NO: 244 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 244, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any GTF2E2-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 234 or an allele variant thereof. SEQ ID NO: 234 contains a fusion junction between GTF2E2 and NRG1 between the amino acid at position 46 (together with the amino acids at positions 1-45 of the handle of GTF2E2) and between position 48 Amino acids (which tie together with the amino acids at positions 49-88 of the handle of NRG1). At position 47, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion between NRG1 and GTF2E2. Preferably, the GTF2E2-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 234 or its allele variant, including at least positions 46, 47 and 48 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 234, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 234 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 46, 47 and 48. The polypeptide sequence has at least 85% identity to SEQ ID NO: 234, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any GTF2E2-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 234, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 234. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 234 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 234 : Any amino acid of the polypeptide of 234. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 234 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 234 of any amino acid.

Preferably, the polypeptide fusions provided herein between GTF2E2 and NRG1 are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from GTF2E2, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the GTF2E2-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. CSMD1-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of CSMD1 exon 23 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 23 of CSMD1 preferably comprises or consists of SEQ ID NO: 305 or an allele variant of SEQ ID NO: 305. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 283-304, or any allele variant of SEQ ID NO: 283-304, and preferably further comprises SEQ ID NO: 145-151, or any allele variant of SEQ ID NO: 145-151. SEQ ID NO: 283-304 correspond to individual polypeptide sequences encoded by exons 1-22 of CSMD1, respectively. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by exon 23 of CSMD1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 305 or the allele variant of SEQ ID NO: 305 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 305, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CSMD1-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 256 or an allele variant thereof. SEQ ID NO: 256 contains a fusion junction between CSMD1 and NRG1 between the amino acid at position 29 (with the amino acids at positions 1-28 of the stalk of CSMD1) and between position 31 between the amino acids (which tie together with the amino acids at positions 32-50 of the handle of NRG1). At position 30, a threonine (T, Thr) residue was present due to an unexpected in-frame fusion of NRG1 and CSMD1. Preferably, the CSMD1-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 256 or its allele variant, including at least positions 29, 30 and 31 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 256, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 256 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 29, 30 and 31. The polypeptide sequence has at least 85% identity to SEQ ID NO: 256, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CSMD1-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 256, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 256. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 218 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 256. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 256 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 256 of any amino acid.

Preferably, the polypeptide fusions provided herein between CSMD1 and NRG1 are aligned so that the portion spanning the N-terminal to the fusion junction is the polypeptide sequence from CSMD1, and the portion spanning the fusion junction to the C-terminus Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing CSMD1-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. PTN-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of PTN exon 4 (or its allelic variant) and a portion of NRG1 exon 2 (or its allelic variant). The polypeptide encoded by exon 4 of PTN preferably comprises or consists of SEQ ID NO: 323 or an allele variant of SEQ ID NO: 323. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises SEQ ID NO: 321 and/or 322 or an allele variant of SEQ ID NO: 321 and/or 322, and preferably further comprises SEQ ID NO: 141-151 , or any allele variant of SEQ ID NO: 141-151. SEQ ID NO: 321, 322 and 323 correspond to the individual polypeptide sequences encoded by exons 2, 3 and 4 of PTN, respectively. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by exon 4 of the PTN comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 323 or an allele variant of SEQ ID NO: 323 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 323, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any PTN-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 314 or an allele variant thereof. SEQ ID NO: 314 contains a fusion junction between PTN and NRG1 between the amino acid at position 33 (with the amino acids at positions 1-32 of the stalk of PTN) and between position 35 Amino acids (which tie together with the amino acids at positions 36-67 of the handle of NRG1). At position 34, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with PTN. Preferably, the PTN-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 314 or its allele variant, at least including positions 33, 34 and 35 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 314, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 314 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 33, 34 and 35. The polypeptide sequence has at least 85% identity to SEQ ID NO: 314, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any PTN-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 314, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 314. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 314 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 314 : Any amino acid of the polypeptide of 314. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 314 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 314 of any amino acid.

Preferably, the polypeptide fusions provided herein between PTN and NRG1 are aligned such that the portion spanning the N-terminus to the fusion junction is a polypeptide sequence from PTN, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the PTN-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. ST14-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of ST14 exon 11 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 11 of ST14 preferably comprises or consists of SEQ ID NO: 362 or an allele variant of SEQ ID NO: 362. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 352-361, or any allele variant of SEQ ID NO: 352-361, and preferably further comprises SEQ ID NO : 145-151 or any allele variant of SEQ ID NO: 145-151. SEQ ID NOs: 352-361 correspond to individual polypeptide sequences encoded by exons 1-10 of ST14, respectively. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by the exon 11 part of ST14 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive allele variants from SEQ ID NO: 362 or SEQ ID NO: 362 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 362, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any ST14-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 331 or its allele variant. SEQ ID NO: 331 contains a fusion junction between ST14 and NRG1 between the amino acid at position 31 (together with the amino acids at positions 1-30 of the stalk of ST14) and position 33 Amino acids (which tie together with the amino acids at positions 34-60 of the handle of NRG1). At position 32, a proline (P, pro) residue was present due to an unexpected in-frame fusion of NRG1 with ST14. Preferably, the ST14-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 331 or its allele variant, including at least positions 31, 32 and 33 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 331, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 331 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 31, 32 and 33. The polypeptide sequence has at least 85% identity to SEQ ID NO: 455, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any ST14-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 331, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 331. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 331 having 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 331 : Any amino acid of the polypeptide of 331. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 331 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 331 of any amino acid.

Preferably, the polypeptide fusions provided herein between ST14 and NRG1 are aligned so that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from ST14, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the ST14-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. THBS1-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of THBS1 exon 9 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 9 of THBS1 preferably comprises or consists of SEQ ID NO: 396 or an allele variant of SEQ ID NO: 396. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 389-395, or any allele variant of SEQ ID NO: 389-395, and preferably further comprises SEQ ID NO : 145-151 or any allele variant of SEQ ID NO: 145-151. SEQ ID NOs: 389-395 correspond to individual polypeptide sequences encoded by exons 2-8 of THBS1, respectively. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by exon 9 of THBS1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 396 or the allele variant of SEQ ID NO: 396 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 396, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any THBS1-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 377 or its allele variant. SEQ ID NO: 377 contains a fusion junction between THBS1 and NRG1 between the amino acid at position 18 (together with the amino acids at positions 1-16 of the handle of THBS1) and between position 20 Amino acids (which tie together with amino acids at positions 20-48 of the handle of NRG1). At position 19, a threonine (T, Thr) residue was present due to an unexpected in-frame fusion of NRG1 with THBS1. Preferably, the THBS1-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 377 or its allele variant, including at least positions 18, Amino acids 19 and 20.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 377, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 377 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 18, 19 and 20. The polypeptide sequence has at least 85% identity to SEQ ID NO: 377, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any THBS1-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 377, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 377. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 377 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 377. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 377 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 377 of any amino acid.

Preferably, the polypeptide fusions provided herein between THBS1 and NRG1 are aligned so that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from THBS1, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing THBS1-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. AGRN-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of AGRN exon 12 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 12 of AGRN preferably comprises or consists of SEQ ID NO: 430 or an allele variant of SEQ ID NO: 430. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 419-429, or any allele variant of SEQ ID NO: 419-429, and preferably further comprises SEQ ID NO : 145-151 or any allele variant of SEQ ID NO: 145-151. SEQ ID NO: 419-429 correspond to individual polypeptide sequences encoded by AGRN exons 1-11, respectively. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by the exon 12 part of AGRN comprises 8, 9, 10, 11, 12, 13 or 14 consecutive allele variants from SEQ ID NO: 430 or SEQ ID NO: 430 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 430, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any AGRN-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 404 or an allele variant thereof. SEQ ID NO: 404 contains a fusion junction between AGRN and NRG1 between the amino acid at position 35 (together with the amino acids at positions 1-34 of the stalk of AGRN) and position 37 Amino acids (which tie together with the amino acids at positions 38-69 of the handle of NRG1). At position 36, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with AGRN. Preferably, the AGRN-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 404 or its allele variant, including at least positions 35, 36 and 37 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 404, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 404 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 35, 36 and 37. The polypeptide sequence has at least 85% identity to SEQ ID NO: 404, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any AGRN-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 404, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 404. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 404 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 404. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 404 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 404 of any amino acid.

Preferably, the polypeptide fusions provided herein between AGRN and NRG1 are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from AGRN, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the AGRN-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. PVALB-NRG1 polypeptide fusion

According to the present disclosure, there is also provided a polypeptide fusion encoded by a polynucleotide comprising a PVALB nucleic acid sequence (or a part of the PVALB nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of the NRG1 nucleic acid sequence). The PVALB nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 445-449 (or an allele variant of any one of these SEQ ID NOs) or derived from its constituent sequences. The NRG1 nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 139-152 (or an allele variant of any one of these SEQ ID NOs) or derived from its constituent sequences.

The PVALB allele variant of any one of SEQ ID NOs: 445-449 preferably has at least 85% sequence identity to these sequences, more preferably 90%, 92%, 94%, 96% thereto Or even better at least 98% sequence identity. The NRG1 allele variant of any one of SEQ ID NOs: 139-152 preferably has at least 85% sequence identity to these sequences, more preferably 90%, 92%, 94%, 96% thereto Or even better at least 98% sequence identity.

Preferably, the PVALB nucleic acid sequence part of the fusion is a polypeptide part of coding PVALB, and this polypeptide part comprises any one (or any one of SEQ ID NOs: 445-449) from SEQ ID NO: 445-449 or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of Preferably, the NRG1 nucleic acid sequence part of the fusion is a polypeptide part of encoding NRG1, and this polypeptide part comprises any one (or any one of SEQ ID NOs: 139-152) from SEQ ID NO: 139-152 or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of

Preferably, any PVALB-NRG1 polypeptide fusion of the present disclosure comprises the polypeptide sequence of any one of SEQ ID NO: 445-449, and this polypeptide sequence has one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutation to add, delete or replace any amino acid of the polypeptide of SEQ ID NO: 445-449. Preferably, the polypeptide fusion comprises the polypeptide sequence of any one of SEQ ID NO: 445-449, and this polypeptide sequence has 1, 2, 3, 4 or 5 point mutations to add, delete or replace SEQ ID NO : Any amino acid of the polypeptide of 445-449. More preferably, the polynucleotide fusion comprises the polypeptide sequence of any one of SEQ ID NO: 445-449, and this polypeptide sequence has 1, 2 or 3 point mutations added, deleted or substituted for SEQ ID NO: 445 Any amino acid of the polypeptide of -449.

In a preferred embodiment, there is also provided a polynucleoside comprising a part of exon 4 of PVALB (or its allele variant) and a part of NRG1 exon 6 (or its allele variant) Acid-encoded polypeptide fusion. The polypeptide encoded by exon 4 of PVALB preferably comprises or consists of SEQ ID NO: 447 or an allele variant of SEQ ID NO: 447. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NOs: 445 and 446, and any one of SEQ ID NOs: 141-151, or any pair of SEQ ID NOs: 141-151 genetic variants. SEQ ID NOs: 145-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be according to SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by exon 4 of PVALB comprises 8, 9, 10, 11, 12, 13 or 14 contiguous sequences from SEQ ID NO: 447 or an allele variant of SEQ ID NO: 447 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 447, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any PVALB-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 438 or its allele variant. SEQ ID NO: 438 contains a fusion junction between PVALB and NRG1 between the amino acid at position 33 (together with the amino acids at positions 1-32 of the stalk of PVALB) and position 35 Amino acids (which tie together with the amino acids at positions 36-75 of the handle of NRG1). At position 34, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with PVALB. Preferably, the PVALB-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 438 or its allele variant, at least including positions 33, 34 and 35 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 438, or a polypeptide comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 438 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 33, 34 and 35. The polypeptide sequence has at least 85% identity to SEQ ID NO: 438, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any PVALB-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 438, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 438. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 438 having 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 438. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 438 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 438 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and PVALB are aligned so that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from PVALB, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the PVALB-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. APP-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of APP exon 14 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 14 of APP preferably comprises or consists of SEQ ID NO: 519 or the allele variant of SEQ ID NO: 519. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 506-518, or any allele variant of SEQ ID NO: 506-518, and preferably further comprises SEQ ID NO : 145-151 or any allele variant of SEQ ID NO: 145-151. SEQ ID NO: 506-518 correspond to the individual polypeptide sequences encoded by APP exons 1-3, respectively. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by exon 14 of the APP comprises 8, 9, 10, 11, 12, 13 or 14 consecutive allele variants from SEQ ID NO: 519 or SEQ ID NO: 519 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 519, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any APP-NRG1 polypeptide fusion of the present disclosure comprises a polypeptide sequence such as SEQ ID NO: 487 or its allele variant. SEQ ID NO: 487 contains a fusion junction between APP and NRG1 between the amino acid at position 17 (together with the amino acids at positions 1-16 of the handle of APP) and position 19 Amino acids (which tie together with the amino acids at positions 20-46 of the handle of NRG1). At position 18, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with APP. Preferably, the APP-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 487 or its allele variant, including at least positions 17, 18 and 19 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 487, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 487 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 17, 18 and 19. The polypeptide sequence has at least 85% identity to SEQ ID NO: 487, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any APP-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 487, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 487. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 487 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 487. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 487 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 487 of any amino acid.

Preferably, the polypeptide fusions provided herein between APP and NRG1 are aligned so that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from APP, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the APP-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. WRN-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of WRN exon 33 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 33 of WRN preferably comprises or consists of SEQ ID NO: 597 or an allele variant of SEQ ID NO: 597. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 566-596, or any allele variant of SEQ ID NO: 566-596, and preferably further comprises SEQ ID NO : 145-151 or any allele variant of SEQ ID NO: 145-151. SEQ ID NOs: 566-596 correspond to individual polypeptide sequences encoded by WRN exons 2-32. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by the exon 33 portion of WRN comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 597 or an allele variant of SEQ ID NO: 597 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 597, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any WRN-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 528 or an allele variant thereof. SEQ ID NO: 528 contains a fusion junction between WRN and NRG1 between the amino acid at position 31 (together with the amino acids at positions 1-30 of the stalk of WRN) and position 33 Amino acids (which tie together with the amino acids at positions 34-60 of the handle of NRG1). At position 32, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 to WRN. Preferably, the WRN-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 528 or its allele variant, including at least positions 31, 32 and 33 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 528, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 528 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 31, 32 and 33. The polypeptide sequence has at least 85% identity to SEQ ID NO: 528, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any WRN-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 528, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 528. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 528 having 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 528. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 528 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 528 of any amino acid.

Preferably, the polypeptide fusions provided herein between WRN and NRG1 are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from WRN, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the WRN-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. ASPH-NRG1 polypeptide fusion

According to the present disclosure, there is also provided a polypeptide fusion encoded by a polynucleotide comprising an ASPH nucleic acid sequence (or a part of the ASPH nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of the NRG1 nucleic acid sequence). The ASPH nucleic acid sequence (or part thereof) preferably encodes a DNA comprising any one of SEQ ID NOs: 663-688 (or an allele variant of any one of these SEQ ID NOs) or is derived from its constituent sequences. The NRG1 nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 139-152 (or an allele variant of any one of these SEQ ID NOs) or derived from its constituent sequences.

ASPH allele variants of any one of SEQ ID NO: 663-688 preferably have at least 85% sequence identity with these sequences, more preferably 90%, 92%, 94%, 96% therewith Or even better at least 98% sequence identity. The NRG1 allele variant of any one of SEQ ID NOs: 139-152 preferably has at least 85% sequence identity to these sequences, more preferably 90%, 92%, 94%, 96% thereto Or even better at least 98% sequence identity.

Preferably, the ASPH nucleic acid sequence portion of the fusion is a polypeptide portion encoding ASPH, and this polypeptide portion comprises any one of SEQ ID NOs: 663-688 (or any one of SEQ ID NOs: 663-688) or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of Preferably, the NRG1 nucleic acid sequence part of the fusion is a polypeptide part of encoding NRG1, and this polypeptide part comprises any one (or any one of SEQ ID NOs: 139-152) from SEQ ID NO: 139-152 or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of

Preferably, any ASPH-NRG1 polypeptide fusion of the present disclosure includes the polypeptide sequence of any one of SEQ ID NO: 663-688, and this polypeptide sequence has one or more (ie 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutation to add, delete or replace any amino acid of the polypeptide of SEQ ID NO: 663-688. Preferably, the polypeptide fusion comprises the polypeptide sequence of any one of SEQ ID NO: 663-688, and this polypeptide sequence has 1, 2, 3, 4 or 5 point mutations to add, delete or replace SEQ ID NO : Any amino acid of the polypeptide of 663-688. More preferably, the polynucleotide fusion includes the polypeptide sequence of any one of SEQ ID NO: 663-688, and this polypeptide sequence has 1, 2 or 3 point mutations to add, delete or replace SEQ ID NO: 663 Any amino acid of the polypeptide of -688.

In a preferred embodiment, there is also provided a polynucleoside comprising a part of ASPH exon 22 (or its allele variant) and a part of NRG1 exon 2 (or its allele variant) Acid-encoded polypeptide fusion. The polypeptide encoded by exon 22 of ASPH preferably comprises or consists of SEQ ID NO: 684 or an allele variant of SEQ ID NO: 684. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 663-683 and any one of SEQ ID NO: 141-151, or SEQ ID NO: 663-683 or SEQ ID NO : Any allele variant of 141-151. SEQ ID NOs: 663-683 correspond to individual polypeptide sequences encoded by ASPH exons 1-21, respectively, and SEQ ID NOs: 141-151 respectively correspond to individual polypeptide sequences encoded by NRG1 exons 3-13. The part of exon 2 of NRG1 can also be according to SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 3-13.

Preferably, the ASPH exon 22 encoded polypeptide comprises 8, 9, 10, 11, 12, 13 or 14 contiguous sequences from SEQ ID NO: 684 or an allele variant of SEQ ID NO: 684 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 684, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any ASPH-NRG1 polypeptide fusion of the present disclosure comprises a polypeptide sequence such as SEQ ID NO: 636 or an allele variant thereof. SEQ ID NO: 636 contains a fusion junction between ASPH and NRG1 between the amino acid at position 24 (with the amino acids at positions 1-23 of the stalk of ASPH) and between position 26 between the amino acids (which tie together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with ASPH. Preferably, the ASPH-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 636 or an allele variant thereof, at least including positions 24, 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 636, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 636 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 636, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any ASPH-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 636, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 636. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 636 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 636 : Any amino acid of the polypeptide of 636. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 636 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 636 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and ASPH are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from ASPH, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the ASPH-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. NOTCH2-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of NOTCH2 exon 6 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 6 of NOTCH2 preferably comprises or consists of SEQ ID NO: 709 or an allele variant of SEQ ID NO: 709. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 704-708, or any allele variant of SEQ ID NO: 704-708, and preferably further comprises SEQ ID NO : 145-151 or any allele variant of SEQ ID NO: 145-151. SEQ ID NOs: 566-596 correspond to individual polypeptide sequences encoded by exons 1-5 of NOTCH2. SEQ ID NO: 141-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by exon 6 of NOTCH2 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 709 or an allele variant of SEQ ID NO: 709 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 709, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any NOTCH2-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 694 or an allele variant thereof. SEQ ID NO: 694 contains a fusion junction between NOTCH2 and NRG1 between the amino acid at position 24 (together with the amino acids at positions 1-23 of the stalk of NOTCH2) and between position 26 between the amino acids (which tie together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with NOTCH2. Preferably, the NOTCH2-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 694 or its allele variant, including at least positions 24, 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 694, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 694 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 694, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any NOTCH2-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 694, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 694. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 694 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 694. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 694 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 694 of any amino acid.

Preferably, the polypeptide fusions provided herein between NOTCH2 and NRG1 are aligned such that the portion spanning the N-terminus to the fusion junction is a polypeptide sequence from NOTCH2, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the NOTCH2-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. CD74-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of CD74 exon 2 (or its allogeneic variant) and a portion of NRG1 exon 2 (or its allogeneic variant). The polypeptide encoded by exon 2 of CD74 preferably comprises or consists of SEQ ID NO: 730 or an allele variant of SEQ ID NO: 730. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 729 or SEQ ID NO: 141-151, or any allele of SEQ ID NO: 729 or SEQ ID NO: 141-151 variant. SEQ ID NO: 729 corresponds to the polypeptide sequence encoded by exon 1 of CD74. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 2 part of CD74 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 730 or the allele variant of SEQ ID NO: 730 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 730, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CD74-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 718 or its allele variant. SEQ ID NO: 718 contains a fusion junction between CD74 and NRG1 between the amino acid at position 24 (together with the amino acids at positions 1-23 of the stalk of CD74) and position 26 between the amino acids (which tie together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, a proline (P, pro) residue was present due to an unexpected in-frame fusion of NRG1 with CD74. Preferably, the CD74-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 718 or its allele variant, including at least positions 24, 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 718, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 718 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 718, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any CD74-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 718, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 718. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 718 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 718 : Any amino acid of the polypeptide of 718. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 718 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 718 of any amino acid.

Preferably, the polypeptide fusions provided herein between CD74 and NRG1 are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from CD74, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the CD74-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. SDC4-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of SDC4 exon 2 (or its allogeneic variant) and a portion of NRG1 exon 2 (or its allogeneic variant). The polypeptide encoded by exon 2 of SDC4 preferably comprises or consists of SEQ ID NO: 752 or an allele variant of SEQ ID NO: 752. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 751 or SEQ ID NO: 141-151, or any allele of SEQ ID NO: 751 or SEQ ID NO: 141-151 variant. SEQ ID NO: 751 corresponds to the polypeptide sequence encoded by exon 1 of SDC4. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 2 part of SDC4 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 752 or an allele variant of SEQ ID NO: 752 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 752, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any SDC4-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 744 or an allele variant thereof. SEQ ID NO: 744 contains a fusion junction between SDC4 and NRG1 between the amino acid at position 24 (together with the amino acids at positions 1-23 of the stalk of SDC4) and position 26 between the amino acids (which tie together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with SDC4. Preferably, the SDC4-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 744 or its allele variant, including at least positions 24, 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 744, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 744 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 744, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any SDC4-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 744, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 744. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 744 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 744. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 744 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 744 of any amino acid.

Preferably, the polypeptide fusions provided herein between SDC4 and NRG1 are aligned so that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from SDC4, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the SDC4-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein.

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of SDC4 exon 4 (or its allogeneic variant) and a portion of NRG1 exon 2 (or its allogeneic variant). The polypeptide encoded by exon 4 of SDC4 preferably comprises or consists of SEQ ID NO: 754 or an allele variant of SEQ ID NO: 754. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 751-753 or SEQ ID NO: 141-151, or one of SEQ ID NO: 751-753 or SEQ ID NO: 141-151 Either allele variant. SEQ ID NO: 751-753 correspond to the individual polypeptide sequences encoded by exons 1-3 of SDC4. SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be composed of SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 4 part of SDC4 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 754 or the allele variant of SEQ ID NO: 754 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 754, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any SDC4-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 825 or an allele variant thereof. SEQ ID NO: 825 contains a fusion junction between SDC4 and NRG1 between the amino acid at position 24 (together with the amino acids at positions 1-23 of the stalk of SDC4) and position 26 between the amino acids (which tie together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with SDC4. Preferably, the SDC4-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 825 or its allele variant, including at least positions 24, 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 825, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 825 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 825, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any SDC4-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 825, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 825. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 825 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 825 : Any amino acid of the polypeptide of 825. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 825 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 825 of any amino acid.

Preferably, the polypeptide fusions provided herein between SDC4 and NRG1 are aligned so that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from SDC4, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the SDC4-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. SLC4A4-NRG1 polypeptide fusion

Also provided is a polypeptide fusion encoded by a polynucleotide comprising a portion of SLC4A4 exon 14 (or its allogeneic variant) and a portion of NRG1 exon 6 (or its allogeneic variant). The polypeptide encoded by exon 14 of SLC4A4 preferably comprises or consists of SEQ ID NO: 806 or an allele variant of SEQ ID NO: 806. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 794-805 or any allele variant of SEQ ID NO: 794-805, and preferably further comprises SEQ ID NO: 145 -151 or any allele variant of SEQ ID NO: 145-151. SEQ ID NOs: 794-805 correspond to individual polypeptide sequences encoded by exons 2-13 of SLC4A4. SEQ ID NOs: 145-151 correspond to individual polypeptide sequences encoded by exons 7-13 of NRG1, respectively. The part of exon 6 of NRG1 can also be composed of SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by the exon 14 part of SLC4A4 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 806 or the allele variant of SEQ ID NO: 806 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 806, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any SLC4A4-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 766 or an allele variant thereof. SEQ ID NO: 766 contains a fusion junction between SLC4A4 and NRG1 between the amino acid at position 24 (together with the amino acids at positions 1-23 of the stalk of SLC4A4) and between position 26 between the amino acids (which tie together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with SLC4A4. Preferably, the SLC4A4-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 766 or its allele variant, including at least positions 24, 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 766, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 766 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 766, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any SLC4A4-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 766, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 766. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 766 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: : Any amino acid of the polypeptide of 766. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 766 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 766 of any amino acid.

Preferably, the polypeptide fusions provided herein between SLC4A4 and NRG1 are aligned so that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from SLC4A4, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the SLC4A4-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. ZFAT-NRG1 polypeptide fusion

According to the disclosure, there is also provided a polypeptide fusion encoded by a polynucleotide comprising a ZFAT nucleic acid sequence (or a part of the ZFAT nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of the NRG1 nucleic acid sequence). The ZFAT nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 847-863 (or any allele variant of any one of these SEQ ID NOs) or is composed of its constituent sequences. The NRG1 nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 139-152 (or an allele variant of any one of these SEQ ID NOs) or derived from its constituent sequences.

The ZFAT allele variant of any one of SEQ ID NOs: 847-863 preferably has at least 85% sequence identity to these sequences, more preferably 90%, 92%, 94%, 96% thereto Or even better at least 98% sequence identity. The NRG1 allele variant of any one of SEQ ID NOs: 139-152 preferably has at least 85% sequence identity to these sequences, more preferably 90%, 92%, 94%, 96% thereto Or even better at least 98% sequence identity.

Preferably, the ZFAT nucleic acid sequence part of the fusion is a polypeptide part of coding ZFAT, and this polypeptide part comprises any one (or any one of SEQ ID NOs: 847-863) from SEQ ID NO: 847-863 or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of Preferably, the NRG1 nucleic acid sequence part of the fusion is a polypeptide part of encoding NRG1, and this polypeptide part comprises any one (or any one of SEQ ID NOs: 139-152) from SEQ ID NO: 139-152 or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of

Preferably, any ZFAT-NRG1 polypeptide fusion of the present disclosure includes the polypeptide sequence of any one of SEQ ID NO: 847-863, and this polypeptide sequence has one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutation to add, delete or replace any amino acid of the polypeptide of SEQ ID NO: 847-863. Preferably, the polypeptide fusion comprises the polypeptide sequence of any one of SEQ ID NO: 847-863, and this polypeptide sequence has 1, 2, 3, 4 or 5 point mutations to add, delete or replace SEQ ID NO : Any amino acid of the polypeptide of 847-863. More preferably, the polynucleotide fusion comprises the polypeptide sequence of any one of SEQ ID NO: 847-863, and this polypeptide sequence has 1, 2 or 3 point mutations added, deleted or substituted for SEQ ID NO: 847 Any amino acid of the polypeptide of -863.

In a preferred embodiment, a polynucleoside comprising a part of ZFAT exon 12 (or its allogeneic variant) and a part of NRG1 exon 6 (or its allogeneic variant) is also provided Acid-encoded polypeptide fusion. The polypeptide encoded by exon 12 of ZFAT preferably comprises or consists of SEQ ID NO: 858 or an allele variant of SEQ ID NO: 858. The polypeptide encoded by exon 6 of NRG1 preferably comprises or consists of SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 847-857 and any one of SEQ ID NO: 145-151, or SEQ ID NO: 847-857 or SEQ ID NO : Any allele variant of 145-151. SEQ ID NOs: 847-857 correspond to individual polypeptide sequences encoded by ZFAT exons 1-11, respectively, and SEQ ID NOs: 145-151 respectively correspond to individual polypeptide sequences encoded by NRG1 exons 7-13. The part of exon 6 of NRG1 can also be according to SEQ ID NO: 156 or an allele variant of SEQ ID NO: 156, and its sequence corresponds to the polypeptide sequence encoded by all exons 6-13.

Preferably, the polypeptide encoded by exon 12 of the ZFAT comprises 8, 9, 10, 11, 12, 13 or 14 consecutive allele variants from SEQ ID NO: 858 or SEQ ID NO: 858 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 858, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 6 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 144 or an allele variant of SEQ ID NO: 144 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 144, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any ZFAT-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 829 or an allele variant thereof. SEQ ID NO: 829 contains a fusion junction between ZFAT and NRG1 between the amino acid at position 24 (with the amino acids at positions 1-23 of the handle of ZFAT) and between position 26 between the amino acids (which tie together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion of NRG1 with ZFAT. Preferably, the ZFAT-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 829 or its allele variant, including at least positions 24, 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 829, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 829 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 829, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any ZFAT-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 829, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 829. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 829 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 829 : Any amino acid of the polypeptide of 829. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 829 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 829 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and ZFAT are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from ZFAT, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the ZFAT-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein. DSCAML1-NRG1 polypeptide fusion

According to the present disclosure, there is also provided a polypeptide fusion encoded by a polynucleotide comprising a fusion of DSCAML1 nucleic acid sequence (or a part of DSCAML1 nucleic acid sequence) and NRG1 nucleic acid sequence (or a part of NRG1 nucleic acid sequence). The DSCAML1 nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 904-937 (or an allele variant of any one of these SEQ ID NOs) or derived from its constituent sequences. The NRG1 nucleic acid sequence (or part thereof) preferably encodes a sequence comprising any one of SEQ ID NOs: 139-152 (or an allele variant of any one of these SEQ ID NOs) or derived from its constituent sequences.

The DSCAML1 allele variant of any one of SEQ ID NOs: 904-937 preferably has at least 85% sequence identity to these sequences, more preferably 90%, 92%, 94%, 96% thereto Or even better at least 98% sequence identity. The NRG1 allele variant of any one of SEQ ID NOs: 139-152 preferably has at least 85% sequence identity to these sequences, more preferably 90%, 92%, 94%, 96% thereto Or even better at least 98% sequence identity.

Preferably, the DSCAML1 nucleic acid sequence portion of the fusion is a polypeptide portion encoding DSCAML1, and this polypeptide portion comprises any one of SEQ ID NOs: 904-937 (or any one of SEQ ID NOs: 904-937) or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of Preferably, the NRG1 nucleic acid sequence part of the fusion is a polypeptide part of encoding NRG1, and this polypeptide part comprises any one (or any one of SEQ ID NOs: 139-152) from SEQ ID NO: 139-152 or consist of 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids of an allele variant of

Preferably, any DSCAML1-NRG1 polypeptide fusion of the present disclosure includes the polypeptide sequence of any one of SEQ ID NO: 904-937, and this polypeptide sequence has one or more (ie 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutation to add, delete or replace any amino acid of the polypeptide of SEQ ID NO: 904-937. Preferably, the polypeptide fusion comprises the polypeptide sequence of any one of SEQ ID NO: 904-937, and this polypeptide sequence has 1, 2, 3, 4 or 5 point mutations to add, delete or replace SEQ ID NO : Any amino acid of the polypeptide of 904-937. More preferably, the polynucleotide fusion includes the polypeptide sequence of any one of SEQ ID NO: 904-937, and this polypeptide sequence has 1, 2 or 3 point mutations to add, delete or replace SEQ ID NO: 904 Any amino acid of the polypeptide of -937.

In a preferred embodiment, there is also provided a part comprising DSCAML1 exon 3 (or its allogeneic variant) and NRG1 or its exon 2 (or its allogeneic variant) Polypeptide fusions encoded by polynucleotides. The polypeptide encoded by exon 3 of DSCAML1 preferably comprises or consists of SEQ ID NO: 906 or an allele variant of SEQ ID NO: 906. The polypeptide encoded by exon 2 of NRG1 preferably comprises or consists of SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140. Preferably, the polypeptide fusion further comprises any one of SEQ ID NO: 904-905 and any one of SEQ ID NO: 141-151, or SEQ ID NO: 904-905 or SEQ ID NO : Any allele variant of 141-151. SEQ ID NOs: 904-905 correspond to individual polypeptide sequences encoded by exons 1-2 of DSCAML1, respectively, while SEQ ID NOs: 141-151 correspond to individual polypeptide sequences encoded by exons 3-13 of NRG1, respectively. The part of exon 2 of NRG1 can also be according to SEQ ID NO: 154 or an allele variant of SEQ ID NO: 154, and its sequence corresponds to the polypeptide sequence encoded by all exons 2-13.

Preferably, the polypeptide encoded by the exon 3 part of DSCAML1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive sequences from SEQ ID NO: 906 or the allele variant of SEQ ID NO: 906 Amino acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 906, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto. Additionally, the polypeptide encoded by the exon 2 portion of NRG1 comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amine groups from SEQ ID NO: 140 or an allele variant of SEQ ID NO: 140 Acids, or consisting of them. The allele variant has at least 85% identity to SEQ ID NO: 140, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any DSCAML1-NRG1 polypeptide fusion of the present disclosure includes a polypeptide sequence such as SEQ ID NO: 869 or its allele variant. SEQ ID NO: 869 contains a fusion junction between DSCAML1 and NRG1 between the amino acid at position 24 (together with the amino acids at positions 1-23 of the handle of DSCAML1) and between position 26 between the amino acids (which tie together with the amino acids at positions 27-49 of the handle of NRG1). At position 25, an alanine (A, Ala) residue was present due to an unexpected in-frame fusion between NRG1 and DSCAML1. Preferably, the DSCAML1-NRG1 polypeptide fusion comprises 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids from SEQ ID NO: 869 or its allele variants, including at least positions 24, 25 and 26 amino acids.

In a preferred embodiment, it provides a polypeptide sequence according to SEQ ID NO: 869, or a polypeptide sequence comprising 8, 9, 10, 11, 12, 13 from SEQ ID NO: 869 or its allele variants Or a polypeptide of 14 or all consecutive amino acids, at least including amino acids at positions 24, 25 and 26. The polypeptide sequence has at least 85% identity to SEQ ID NO: 869, preferably at least 90% identity, 92%, 94%, 96% or more preferably at least 98% sequence identity thereto.

Preferably, any DSCAML1-NRG1 polypeptide fusion of the present disclosure includes SEQ ID with one or more (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) point mutations The polypeptide sequence of NO: 869, and the point mutation adds, deletes or replaces any amino acid of the polypeptide comprising SEQ ID NO: 869. Preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 869 with 1, 2, 3, 4 or 5 point mutations, and the point mutations add, delete or replace the polypeptide sequence comprising SEQ ID NO: 869 : Any amino acid of the polypeptide of 869. More preferably, the polypeptide fusion comprises the polypeptide sequence of SEQ ID NO: 869 with 1, 2 or 3 point mutations, and the point mutations add, delete or replace the polypeptide comprising SEQ ID NO: 869 of any amino acid.

Preferably, the polypeptide fusions provided herein between NRG1 and DSCAML1 are aligned such that the portion spanning the N-terminus to the fusion junction is the polypeptide sequence from DSCAML1, and the portion spanning the fusion junction to the C-terminus is Part of it is the NRG1 polypeptide sequence. Preferably, the NRG1 polypeptide sequence comprises or encodes an EGF-like domain. The EGF-like domain containing the DSCAML1-NRG1 polypeptide fusion is preferably composed of the abnormal cells mentioned herein.

Each polynucleotide fusion containing NRG1 mentioned herein includes VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, DAAM1-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4- NRG1, SLC4A4-NRG1, ZFAT-NRG1 and DSCAML1-NRG1, are preferably isolated. Any method of the invention preferably comprises isolating one or more polypeptide-containing fractions from the sample. The one or more polypeptide-containing components are typically isolated from any cells or cellular material in the sample. Assays for detecting or identifying NRG1 fusions

Generally, any polynucleotide or polypeptide fusion to be tested is obtained or derived from an abnormal cell expressing a polynucleotide fusion comprising the EGF-like domain of NRG1. The detection assay may not be directed to identifying the presence or absence of an EGF-like domain, as it need only detect the actual fusion junction to indicate the presence of a polynucleotide or polypeptide further containing the EGF-like domain of NRG1. The presence of an EGF-like domain can be inferred from the specific detection or identification of in-frame polynucleotide fusions between NRG1 and either fusion partner, such fusion junctions would be in the EGF-like domain of NRG1 5' found.

Those skilled in the art can employ a variety of different techniques to detect known polynucleotide or polypeptide fusions in samples obtained from human subjects, each of which typically includes a binding agent that specifically binds a target of interest. Such a binding agent refers to a reagent, such as a primer, a pair of primers, a probe, or an antibody, that selectively binds to a target sequence to achieve specific detection of the target. Said binding involves hybridization or adhesion to polynucleotide sequences, usually for the purpose of amplifying and/or detecting the target, or by binding an epitope with high affinity and specificity antibodies to enable detection of the target.

Techniques based on the use of primers, primer pairs or probes that specifically bind to polynucleotide fusions are well known in the art. Likewise, techniques for the detection of polypeptides based on binding agents are well known in the art, and in particular polypeptides that specifically bind polypeptides may be used.

Other ways of using the disclosed primers, primer pairs, or probes include next-generation sequencing (NGS), or using panels that include multiplex immunoassay techniques (e.g., using Anchored Multiplex PCR (AMP™) technology to target Fusions are detected to the Archer FusionPlex™ Custom Solid Panel) with known exons, or droplet digital PCR (ddPCR™) such as using the QX200™ AutoDG™ Droplet Digital PCR System (supplied by BioRad). Other approaches include the use of molecular beacons or quantitative PCR (Q-PCR) using TaqMan™ probes or chimeric fluorescent dyes such as SYBR™ Green, fluorescence in situ hybridization (FISH), next-generation sequencing ( NGS), ddPCR™, Anchored Multiplex PCR, semi-quantitative PCR, or quantitative PCR.

There are other methods using the probes of the present disclosure to detect polynucleotide fusions of NRG1 and fusion partners mentioned herein, such as IHC or FISH (such as fracture separation FISH), wherein the two ends of the gene of interest are linked Marked in different colors. To detect NRG1 containing fusions mentioned herein, the main strand hg38 chr8:31,639,222-32,764,405 was used to design appropriate probes to label both ends of the NRG1 gene to enable detection of any fusions.

The present disclosure provides a nucleic acid probe, primer or pair of primers for detecting the polynucleotide fusions mentioned herein. Also provided is a detection assay comprising said nucleic acid probe, primer or pair of primers for detecting the presence of a polynucleotide fusion referred to herein. Such nucleic acid probes, primers or primer pairs are of a length such that they detect the polynucleotide of interest, but are preferably about 10 to about 40 nucleotides in length.

Preferably, any nucleic acid probe, primer or pair of primers used to detect polynucleotide fusions includes a detectable label as described herein.

Preferably, the detection is selected from VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14- or Any nucleic acid probe, primer or primer pair is used in the assay for the presence or absence of polynucleotide fusions of DSCAML1-NRG1, particularly assays for detecting the presence or absence of fusion junctions in the polynucleotide fusions disclosed herein Law.

Preferably, any of the multiples mentioned herein are detected by using said probes, primers or primer pairs spanning the nucleic acid junction between NRG1 and its fusion partner resulting in amplification and detection of the fusion junction. The presence or absence of nucleotide fusions. Primers or probes for use in assays for detecting VAPB-NRG1 fusions

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a polynucleotide fusion comprising a VAPB nucleic acid sequence (or a part of a VAPB nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of an NRG1 nucleic acid sequence) . Preferably, the nucleic acid probe, primer or primer pair is specifically compatible with the polynucleotide according to SEQ ID NO: 23 (or the allele variant of SEQ ID NO: 23) and the multinuclear polynucleotide according to SEQ ID NO: 138 nucleotide (or the allele variant of SEQ ID NO: 138), or have 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with these sequences and over about 12 to 40 nucleotides in length.

In addition, the present disclosure provides a nucleic acid primer, primer pair or probe for detecting a VAPB-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 3, and the sequence includes nucleic acids at positions 43 and 44. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 3 (or the allele variant of SEQ ID NO: 3), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to about 40 nucleotides in length, and preferably includes positions 43 and 44 nucleic acid.

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of VAPB and NRG1 is specifically associated with a sequence consisting of exon 1 of VAPB (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 1 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of VAPB and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 17 (or the allele variant of SEQ ID NO: 17), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 1 line from VAPB comprises or consists of SEQ ID NO: 17 or its allele variant. Primers or probes for use in assays for detecting CADM1-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a CADM1-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 7, and the sequence includes the nucleic acids at positions 53 and 54. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 7 (or the allele variant of SEQ ID NO: 7), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 53 and 54 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting a fusion of CADM1 and NRG1 is specifically associated with a sequence consisting of exon 7 of CADM1 (such as used in a gain-of-function allele assay sequence), a sequence located 5' of exon 7 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of CADM1 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 57 (or the allele variant of SEQ ID NO: 57), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 7 line from CADM1 comprises or consists of SEQ ID NO: 39 or its allele variant. Primers or probes for use in assays for detecting CD44-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a CD44-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 11, and the sequence includes nucleic acids at positions 52 and 53. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 11 (or the allele variant of SEQ ID NO: 11), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 52 and 53 .

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of CD44 and NRG1 is specific to a sequence consisting of exon 5 of CD44 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 5 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair for detecting the fusion of CD44 and NRG1 is specifically compatible with the sequence composed of SEQ ID NO: 99 (or the allele variant of SEQ ID NO: 99), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 5 line from CD44 comprises or consists of SEQ ID NO: 65 or its allele variant.

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a CD44-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 761, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 761 (or the allele variant of SEQ ID NO: 761), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of CD44 and NRG1 is specific to a sequence consisting of exon 5 of CD44 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 5 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair for detecting the fusion of CD44 and NRG1 is specifically compatible with the sequence composed of SEQ ID NO: 99 (or the allele variant of SEQ ID NO: 99), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 5 line from CD44 comprises or consists of SEQ ID NO: 65 or its allele variant. Primers or probes for use in assays for detecting SLC3A2 -NRG1 fusions

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a SLC3A2 transcript 6-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 15, and the sequence includes nucleic acids at positions 53 and 54 . Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 15 (or the allele variant of SEQ ID NO: 15), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 53 and 54 .

Preferably, the nucleic acid probe, primer or primer pair used to detect the fusion of SLC3A2 transcript 6 and NRG1 is specifically compatible with a sequence consisting of exon 1 of SLC3A2 (such as used for functional gain sequence in the allele assay), a sequence located 5' of exon 1 and/or a sequence consisting of exon 5 of NRG1, or a sequence located 3' of exon 5 ( Gene sequences such as NRG1) are heterozygous (or have 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and have a length of more than about 12 to about 40 nucleotides). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of SLC3A2 and NRG1 is specifically related to the sequence composed of SEQ ID NO: 103 (or the allele variant of SEQ ID NO: 103 ), and/or a sequence consisting of SEQ ID NO: 157 (or an allele variant of SEQ ID NO: 157), or 95%, 96%, 97%, 98%, 99% of these sequences Or preferably have 100% sequence identity and are over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, exon 1 from SLC3A2 transcript 6 comprises or consists of SEQ ID NO: 103 or its allele variant.

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a SLC3A2 transcript 6-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 454, and the sequence includes nucleic acids at positions 93 and 94 . Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 454 (or the allele variant of SEQ ID NO: 454), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 93 and 94 .

Preferably, the nucleic acid probe, primer or primer pair for detecting the fusion of SLC3A2 transcript 3 and NRG1 is specifically compatible with a sequence consisting of said SLC3A2 exon 2 (such as used for functional gain sequence in an allele assay), a sequence located 5' to exon 2 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' to exon 6 ( Gene sequences such as NRG1) are heterozygous (or have 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and have a length of more than about 12 to about 40 nucleotides). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of SLC3A2 and NRG1 is specific to the sequence composed of SEQ ID NO: 482 (or the allele variant of SEQ ID NO: 482 ), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155), or 95%, 96%, 97%, 98%, 99% of these sequences Or preferably have 100% sequence identity and are over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, exon 2 from SLC3A2 transcript 3 comprises or consists of SEQ ID NO: 457 or its allele variant. Primers or probes for use in assays for detecting VTCN1-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a VTCN1-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 166, and the sequence includes nucleic acids at positions 65 and 66. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 166 (or the allele variant of SEQ ID NO: 166), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 65 and 66 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting a fusion of VTCN1 and NRG1 is specifically associated with a sequence consisting of exon 2 of VTCN1 (such as used in a gain-of-function allele assay sequence), a sequence located 5' of exon 2 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of VTCN1 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 181 (or the allele variant of SEQ ID NO: 181), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 2 line from VTCN1 comprises or consists of SEQ ID NO: 169 or its allele variant. Primers or probes for use in assays for detecting CDH1-NRG1 fusions

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a CDH1-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 186, and the sequence includes nucleic acids at positions 119 and 120. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 186 (or the allele variant of SEQ ID NO: 186), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 119 and 120 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of CDH1 and NRG1 are specifically associated with a sequence consisting of exon 11 of CDH1 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 11 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of CDH1 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 213 (or the allele variant of SEQ ID NO: 213), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the line from exon 11 of CDH1 comprises or consists of SEQ ID NO: 198 or its allele variant. Primers or probes for use in assays for detecting CXADR-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a CXADR-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 217, and the sequence includes nucleic acids at positions 43 and 44. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 217 (or the allele variant of SEQ ID NO: 217), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 43 and 44 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of CXADR and NRG1 is specifically associated with a sequence consisting of exon 1 of CXADR (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 1 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair for detecting the fusion of CXADR and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 219 (or the allele variant of SEQ ID NO: 219), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 1 line from CXADR comprises or consists of SEQ ID NO: 219 or its allele variant. Primers or probes for use in assays for detecting GTF2E2-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a GTF2E2-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 233, and the sequence includes nucleic acids at positions 141 and 142. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 233 (or the allele variant of SEQ ID NO: 233), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 141 and 142 .

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of GTF2E2 and NRG1 is specifically associated with a sequence consisting of exon 2 of GTF2E2 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 2 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of GTF2E2 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 252 (or the allele variant of SEQ ID NO: 252), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 2 line from GTF2E2 comprises or consists of SEQ ID NO: 236 or its allele variant. Primers or probes for use in assays for detecting CSMD1-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a CSMD1-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 255, and the sequence includes nucleic acids at positions 88 and 89. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 255 (or the allele variant of SEQ ID NO: 255), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 88 and 89 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting a fusion of CSMD1 and NRG1 is specifically associated with a sequence consisting of exon 23 of CSMD1 (such as used in a gain-of-function allele assay sequence), a sequence located 5' of exon 23 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of CSMD1 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 309 (or the allele variant of SEQ ID NO: 309), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 23 line from CSMD1 comprises or consists of SEQ ID NO: 279 or its allele variant. Primers or probes for use in assays for detecting PTN-NRG1 fusions

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a PTN-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 313, and the sequence includes nucleic acids at positions 102 and 103. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 313 (or the allele variant of SEQ ID NO: 313), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 102 and 103 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of PTN and NRG1 is specifically associated with a sequence consisting of exon 4 of PTN (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 4 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of PTN and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 326 (or the allele variant of SEQ ID NO: 326), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 4 line from PTN comprises or consists of SEQ ID NO: 318 or its allele variant. Primers or probes for use in assays for detecting ST14-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a ST14-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 330, and the sequence includes nucleic acids at positions 95 and 96. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 330 (or the allele variant of SEQ ID NO: 330), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 95 and 96 .

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of ST14 and NRG1 is specifically associated with a sequence consisting of exon 11 of ST14 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 11 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of ST14 and NRG1 is specifically related to the sequence composed of SEQ ID NO: 372 (or the allele variant of SEQ ID NO: 372), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 11 line from ST14 comprises or consists of SEQ ID NO: 362 or its allele variant. Primers or probes for use in assays for detecting THBS1-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a THBS1-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 376, and the sequence includes nucleic acids at positions 56 and 57. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 376 (or the allele variant of SEQ ID NO: 376), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 56 and 57 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting a fusion of THBS1 and NRG1 is specifically associated with a sequence consisting of exon 9 of THBS1 (such as used in a gain-of-function allele assay sequence), a sequence located 5' of exon 9 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of THBS1 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 399 (or the allele variant of SEQ ID NO: 399), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 9 line from THBS1 comprises or consists of SEQ ID NO: 386 or its allele variant. Primers or probes for use in assays for detecting AGRN-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting an AGRN-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 403, and the sequence includes the nucleic acids at positions 106 and 107. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 403 (or the allele variant of SEQ ID NO: 403), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 106 and 107 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of AGRN and NRG1 are specifically associated with a sequence consisting of exon 12 of AGRN (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 12 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of AGRN and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 433 (or the allele variant of SEQ ID NO: 433), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 12 line from AGRN comprises or consists of SEQ ID NO: 416 or its allele variant. Primers or probes for use in assays for detecting PVALB-NRG1 fusions

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a polynucleotide fusion comprising a PVALB nucleic acid sequence (or a part of a PVALB nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of an NRG1 nucleic acid sequence) . Preferably, the nucleic acid probe, primer or primer pair is specifically compatible with the polynucleotide according to SEQ ID NO: 444 (or the allele variant of SEQ ID NO: 444) and the multinuclear polynucleotide according to SEQ ID NO: 138 nucleotide (or the allele variant of SEQ ID NO: 138), or have 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with these sequences and are greater than about 12 to about 40 nucleotides in length.

In addition, the present disclosure provides a nucleic acid primer, primer pair or probe for detecting a PVALB-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 437, and the sequence includes nucleic acids at positions 102 and 103. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 437 (or the allele variant of SEQ ID NO: 437), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 102 and 103 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of PVALB and NRG1 is specifically associated with a sequence consisting of exon 4 of PVALB (such as used in a gain-of-function allele assay sequence), a sequence located 5' of exon 4 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of PVALB and NRG1 is specifically related to the sequence composed of SEQ ID NO: 450 (or the allele variant of SEQ ID NO: 450), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 4 line from PVALB comprises or consists of SEQ ID NO: 442 or its allele variant. Primers or probes for use in assays for detecting APP-NRG1 fusions

The disclosure provides a nucleic acid primer, primer pair or probe for detecting an APP-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 486, and the sequence includes the nucleic acids at positions 54 and 55. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 486 (or the allele variant of SEQ ID NO: 486), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 54 and 55 .

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of APP and NRG1 is specific for a sequence consisting of exon 14 of APP (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 14 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of APP and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 524 (or the allele variant of SEQ ID NO: 524), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 14 line from APP comprises or consists of SEQ ID NO: 501 or its allele variant. Primers or probes for use in assays for detecting WRN-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a WRN-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 528, and the sequence includes nucleic acids at positions 96 and 97. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 528 (or the allele variant of SEQ ID NO: 528), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 96 and 97 .

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of WRN and NRG1 is specifically associated with a sequence consisting of exon 33 of WRN (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 33 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of WRN and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 601 (or the allele variant of SEQ ID NO: 601), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 33 line from WRN comprises or consists of SEQ ID NO: 562 or its allele variant. Primers or probes for use in assays for detecting DAAM1-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a DAAM1-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 605, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 605 (or the allele variant of SEQ ID NO: 605), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of DAAM1 and NRG1 is specifically associated with a sequence consisting of exon 1 of DAAM1 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 1 and/or a sequence consisting of exon 1 of NRG1, or a sequence located 3' of exon 1 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of DAAM1 and NRG1 is specifically related to the sequence composed of SEQ ID NO: 606 (or the allele variant of SEQ ID NO: 606), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 1 line from DAAM1 comprises or consists of SEQ ID NO: 606 or its allele variant. Primers or probes for use in assays for detecting ASPH-NRG1 fusions

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a polynucleotide fusion comprising an ASPH nucleic acid sequence (or a part of an ASPH nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of an NRG1 nucleic acid sequence) . Preferably, the nucleic acid probe, primer or primer pair is specifically compatible with the polynucleotide according to SEQ ID NO: 662 (or the allele variant of SEQ ID NO: 662) and the multinuclear polynucleotide according to SEQ ID NO: 138 nucleotide (or the allele variant of SEQ ID NO: 138), or have 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with these sequences and are greater than about 12 to about 40 nucleotides in length.

In addition, the present disclosure provides a nucleic acid primer, primer pair or probe for detecting an ASPH-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 635, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 635 (or the allele variant of SEQ ID NO: 635), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of ASPH and NRG1 is specific for a sequence consisting of exon 22 of ASPH (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 22 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of ASPH and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 689 (or the allele variant of SEQ ID NO: 689), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 22 line from ASPH comprises or consists of SEQ ID NO: 658 or its allele variant. Primers or probes for use in assays for detecting NOTCH2-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a NOTCH2-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 693, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 693 (or the allele variant of SEQ ID NO: 693), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting a fusion of NOTCH2 and NRG1 is specifically associated with a sequence consisting of exon 6 of NOTCH2 (such as used in a gain-of-function allele assay sequence), a sequence located 5' of exon 6 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of NOTCH2 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 713 (or the allele variant of SEQ ID NO: 713), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 6 line from NOTCH2 comprises or consists of SEQ ID NO: 700 or its allele variant. Primers or probes for use in assays for detecting CD74-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a CD74-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 717, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 717 (or the allele variant of SEQ ID NO: 717), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers used to detect fusions of CD74 and NRG1 is specific to a sequence consisting of exon 2 of CD74 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 2 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of CD74 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 739 (or the allele variant of SEQ ID NO: 739), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 2 line from CD74 comprises or consists of SEQ ID NO: 720 or its allele variant. Primers or probes for use in assays for detecting SDC4-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a SDC4-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 743, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 743 (or the allele variant of SEQ ID NO: 743), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of SDC4 and NRG1 is specifically associated with a sequence consisting of exon 2 of SDC4 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 2 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of SDC4 and NRG1 is specifically related to the sequence composed of SEQ ID NO: 757 (or the allele variant of SEQ ID NO: 757), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 2 line from SDC4 comprises or consists of SEQ ID NO: 746 or its allele variant.

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a SDC4-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 824, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 824 (or the allele variant of SEQ ID NO: 824), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of SDC4 and NRG1 is specifically associated with a sequence consisting of exon 4 of SDC4 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 4 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of SDC4 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 940 (or the allele variant of SEQ ID NO: 940), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 2 line from SDC4 comprises or consists of SEQ ID NO: 748 or its allele variant. Primers or probes for use in assays for detecting SLC4A4 -NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a SLC4A4-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 765, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 765 (or the allele variant of SEQ ID NO: 765), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of SLC4A4 and NRG1 is specifically associated with a sequence consisting of exon 14 of SLC4A4 (such as used in gain-of-function allele assays sequence), a sequence located 5' of exon 14 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or primer pair used for detecting the fusion of SLC4A4 and NRG1 is specifically related to the sequence composed of SEQ ID NO: 820 (or the allele variant of SEQ ID NO: 820), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 14 line from SLC4A4 comprises or consists of SEQ ID NO: 780 or its allele variant. Primers or probes for use in assays for detecting ZFAT-NRG1 fusions

The present disclosure provides a nucleic acid primer, primer pair or probe for detecting a polynucleotide fusion comprising a ZFAT nucleic acid sequence (or a part of a ZFAT nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of a NRG1 nucleic acid sequence) . Preferably, the nucleic acid probe, primer or primer pair is specifically compatible with the polynucleotide according to SEQ ID NO: 846 (or the allele variant of SEQ ID NO: 846) and the multinuclear polynucleotide according to SEQ ID NO: 138 nucleotide (or the allele variant of SEQ ID NO: 138), or have 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with these sequences and are greater than about 12 to about 40 nucleotides in length.

In addition, the present disclosure provides a nucleic acid primer, primer pair or probe for detecting a ZFAT-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 828, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 828 (or the allele variant of SEQ ID NO: 828), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting fusions of ZFAT and NRG1 is specifically associated with a sequence consisting of exon 12 of ZFAT (such as used in a gain-of-function allele assay sequence), a sequence located 5' of exon 12 and/or a sequence consisting of exon 6 of NRG1, or a sequence located 3' of exon 6 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of ZFAT and NRG1 is specifically related to the sequence composed of SEQ ID NO: 864 (or the allele variant of SEQ ID NO: 864), and/or a sequence consisting of SEQ ID NO: 155 (or an allele variant of SEQ ID NO: 155) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 12 line from ZFAT comprises or consists of SEQ ID NO: 841 or its allele variant. Primers or probes for use in assays for detecting DSCAML1-NRG1 fusions

The disclosure provides a nucleic acid primer, primer pair or probe for detecting a polynucleotide fusion comprising a DSCAML1 nucleic acid sequence (or a part of a DSCAML1 nucleic acid sequence) fused to an NRG1 nucleic acid sequence (or a part of an NRG1 nucleic acid sequence) . Preferably, the nucleic acid probe, primer or primer pair is specifically compatible with the polynucleotide according to SEQ ID NO: 903 (or the allele variant of SEQ ID NO: 903) and the polynucleotide according to SEQ ID NO: 138 nucleotide (or the allele variant of SEQ ID NO: 138), or have 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with these sequences and are greater than about 12 to about 40 nucleotides in length.

In addition, the present disclosure provides a nucleic acid primer, primer pair or probe for detecting a DSCAML1-NRG1 polynucleotide fusion comprising or consisting of SEQ ID NO: 868, and the sequence includes nucleic acids at positions 75 and 76. Preferably, the nucleic acid probe, primer or primer pair is specifically hybridized to the polynucleotide according to SEQ ID NO: 868 (or the allele variant of SEQ ID NO: 868), or is related to the sequence 95%, 96%, 97%, 98%, 99%, or preferably 100% sequence identity and over about 12 to 40 nucleotides in length, and the sequence preferably includes the nucleic acids at positions 75 and 76 .

Preferably, the nucleic acid probe, primer or pair of primers for detecting a fusion of DSCAML1 and NRG1 is specifically associated with a sequence consisting of exon 3 of DSCAML1 (such as used in a gain-of-function allele assay sequence), a sequence located 5' of exon 3 and/or a sequence consisting of exon 2 of NRG1, or a sequence located 3' of exon 2 (such as the gene sequence of NRG1 ) is heterozygous (or has 95%, 96%, 97%, 98%, 99% or preferably 100% sequence identity with such sequences and is longer than about 12 to about 40 nucleotides in length). Preferably, the nucleic acid probe, primer or pair of primers for detecting the fusion of DSCAML1 and NRG1 is specifically compatible with the sequence consisting of SEQ ID NO: 938 (or the allele variant of SEQ ID NO: 938), and/or a sequence consisting of SEQ ID NO: 153 (or an allele variant of SEQ ID NO: 153) is heterozygous, or is 95%, 96%, 97%, 98%, 99% or more Preferably there is 100% sequence identity and over about 12 to about 40 nucleotides in length. Also provided are nucleic acid probes, primers or primer pairs for detecting fusions involving allogenic variants of any of said exons.

Preferably, the exon 3 line from DSCAML1 comprises or consists of SEQ ID NO: 872 or its allele variant. Probes for in situ hybridization

Probes for use in in situ hybridization (ISH) assays to detect genes involved in VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, Any gene rearrangement of DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1. In particular, the probes are intended for use in fluorescence in situ hybridization (FISH) or fragmentation FISH. The gene rearrangement is preferably VAPB, CADM1, CD44, SLC3A2, VTCN1 CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, Gene fusions of ZFAT or DSCAML1 and NRG1, but because these ISH assays target the 5' and 3' sides of the fusion junctions disclosed herein, this ISH assay can be used to detect any gene duplication involving these genes. Row.

Accordingly, a first nucleic acid probe and a second nucleic acid probe are specifically provided for use in an in situ hybridization assay to detect VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, Gene rearrangements of THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1, where: - the first probe for detecting the gene rearrangement of VAPB is specifically hybridized with the VAPB sequence at the nucleic acid 5' at position 42 or 43 of SEQ ID NO: 1, and the second probe is specifically hybridized with the sequence at The VAPB sequence hybridization at the nucleic acid 3' of position 42 or 43 of SEQ ID NO: 1; - the first probe for detecting the gene rearrangement of CADM1 is specifically hybridized to the CADM1 sequence located at the nucleic acid 5' of position 53 of SEQ ID NO: 5, and the second probe is specifically hybridized to the sequence located at SEQ ID NO: CADM1 sequence hybridization at the 3' of the nucleic acid at position 53 of 5; - the first probe for detecting gene rearrangement of CD44 specifically hybridizes to the CD44 sequence at the nucleic acid 5' at position 52 of SEQ ID NO: 9, and the second probe specifically hybridizes to the sequence at SEQ ID NO: CD44 sequence hybridization at the 3' position of the nucleic acid at position 52 of 9; - the first probe for detecting gene rearrangement of CD44 specifically hybridizes to the CD44 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 759, and the second probe specifically hybridizes to the sequence at SEQ ID CD44 sequence hybridization at the 3' position of the nucleic acid at position 75 of NO: 759; - the first probe for detecting the gene rearrangement of SLC3A2 specifically hybridizes to the SLC3A2 sequence at the nucleic acid 5' at position 53 of SEQ ID NO: 13, and the second probe specifically hybridizes to the sequence at SEQ ID NO: SLC3A2 sequence hybridization at the 3' of the nucleic acid at position 53 of 13; - the first probe for detecting the gene rearrangement of VTCN1 is specifically hybridized with the VTCN1 sequence at the nucleic acid 5' at position 65 of SEQ ID NO: 164, and the second probe is specifically hybridized with the sequence at SEQ ID NO: VTCN1 sequence hybridization at the 3' position of the nucleic acid at position 65 of 164; - the first probe for detecting gene rearrangement of CDH1 specifically hybridizes to the CDH1 sequence at the nucleic acid 5' at position 119 of SEQ ID NO: 184, and the second probe specifically hybridizes to the sequence at SEQ ID NO: CDH1 sequence hybridization at the 3' position of the nucleic acid at position 119 of 184; - the first probe for detecting the gene rearrangement of CXADR is specifically hybridized with the CXADR sequence at the nucleic acid 5' at position 43 of SEQ ID NO: 215, and the second probe is specifically hybridized with the sequence at SEQ ID NO: CXADR sequence hybridization at the 3' position of the nucleic acid at position 43 of 215; - the first probe for detecting the gene rearrangement of GTF2E2 specifically hybridizes to the GTF2E2 sequence located at the nucleic acid 5' of position 141 of SEQ ID NO: 231, and the second probe specifically hybridizes to the sequence located at SEQ ID NO: GTF2E2 sequence hybridization at the 3' position of the nucleic acid at position 141 of 231; - the first probe for detecting the gene rearrangement of CSMD1 is specifically hybridized to the CSMD1 sequence at the nucleic acid 5' at position 88 of SEQ ID NO: 253, and the second probe is specifically hybridized to the sequence at SEQ ID NO: CSMD1 sequence hybridization at the 3' position of the nucleic acid at position 88 of 253; - the first probe for detecting the gene rearrangement of PTN is specifically hybridized with the PTN sequence at the nucleic acid 5' at position 102 of SEQ ID NO: 311, and the second probe is specifically hybridized with the sequence at the position of SEQ ID NO: PTN sequence hybridization at the 3' position of the nucleic acid at position 102 of 311; - the first probe for detecting the gene rearrangement of ST14 specifically hybridizes to the ST14 sequence at the nucleic acid 5' at position 95 of SEQ ID NO: 328, and the second probe specifically hybridizes to the sequence at SEQ ID NO: ST14 sequence hybridization at the 3' position of the nucleic acid at position 95 of 328; - the first probe for detecting gene rearrangement of THBS1 specifically hybridizes to the THBS1 sequence at the 5' of the nucleic acid at position 56 of SEQ ID NO: 374, and the second probe specifically hybridizes to the sequence at SEQ ID THBS1 sequence hybridization at the 3' position of the nucleic acid at position 56 of NO: 374; - the first probe for detecting the gene rearrangement of AGRN is specifically hybridized with the AGRN sequence at the nucleic acid 5' at position 106 of SEQ ID NO: 401, and the second probe is specifically hybridized with the sequence at the position of SEQ ID NO: AGRN sequence hybridization at the 3' of the nucleic acid at position 106 of 401; - the first probe for detecting the gene rearrangement of PVALB is specifically hybridized with the PVALB sequence located at the nucleic acid 5' of position 102 of SEQ ID NO: 435, and the second probe is specifically hybridized with the sequence located at SEQ ID NO: PVALB sequence hybridization at the 3' position of the nucleic acid at position 102 of 435; - the first probe for detecting gene rearrangement of SLC3A2 specifically hybridizes to the SLC3A2 sequence at the nucleic acid 5' at position 93 of SEQ ID NO: 452, and the second probe specifically hybridizes to the sequence at SEQ ID NO: SLC3A2 sequence hybridization at the 3' position of the nucleic acid at position 93 of 452; - the first probe for detecting gene rearrangement of APP specifically hybridizes to the APP sequence at the nucleic acid 5' at position 54 of SEQ ID NO: 484, and the second probe specifically hybridizes to the sequence at SEQ ID NO: APP sequence hybridization at the 3' position of the nucleic acid at position 54 of 484; - the first probe for detecting the gene rearrangement of WRN specifically hybridizes to the WRN sequence at the nucleic acid 5' at position 96 of SEQ ID NO: 526, and the second probe specifically hybridizes to the sequence at SEQ ID NO: WRN sequence hybridization at the 3' position of the nucleic acid at position 96 of 526; - the first probe for detecting gene rearrangement of DAAM1 specifically hybridizes to the DAAM1 sequence at the 5' of the nucleic acid at position 75 of SEQ ID NO: 603, and the second probe specifically hybridizes to the sequence at SEQ ID NO: DAAM1 sequence hybridization at the 3' position of the nucleic acid at position 75 of 603; - the first probe for detecting the gene rearrangement of ASPH specifically hybridizes to the ASPH sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 633, and the second probe specifically hybridizes to the sequence at SEQ ID ASPH sequence hybridization at the 3' of the nucleic acid at position 75 of NO: 633; - the first probe for detecting the gene rearrangement of NOTCH2 specifically hybridizes to the NOTCH2 sequence at the 5' of the nucleic acid at position 75 of SEQ ID NO: 691, and the second probe specifically hybridizes to the sequence at SEQ ID NO: Hybridization of the NOTCH2 sequence at the 3' of the nucleic acid at position 75 of 691; - the first probe for detecting gene rearrangement of CD74 specifically hybridizes to the CD74 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 715, and the second probe specifically hybridizes to the sequence at SEQ ID CD74 sequence hybridization at the 3' of the nucleic acid at position 75 of NO: 715; - the first probe for detecting the gene rearrangement of SDC4 specifically hybridizes to the SDC4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 741, and the second probe specifically hybridizes to the sequence at SEQ ID NO: SDC4 sequence hybridization at the 3' position of the nucleic acid at position 75 of 741; - the first probe for detecting the gene rearrangement of SDC4 specifically hybridizes to the SDC4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 822, and the second probe specifically hybridizes to the sequence at SEQ ID NO: SDC4 sequence hybridization at the 3' position of the nucleic acid at position 75 of 822; - the first probe for detecting the gene rearrangement of SLC4A4 specifically hybridizes to the SLC4A4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 763, and the second probe specifically hybridizes to the sequence at SEQ ID SLC4A4 sequence hybridization at the 3' position of the nucleic acid at position 75 of NO: 763; - the first probe for detecting the gene rearrangement of ZFAT is specifically hybridized with the ZFAT sequence at the 5' nucleic acid at position 75 of SEQ ID NO: 826, and the second probe is specifically hybridized with the sequence at SEQ ID ZFAT sequence hybridization at the 3' position of the nucleic acid at position 75 of NO: 826; or - the first probe for detecting the gene rearrangement of DSCAML1 specifically hybridizes to the DSCAML1 sequence at the 5' of the nucleic acid at position 75 of SEQ ID NO: 866, and the second probe specifically hybridizes to the sequence at SEQ ID The DSCAML1 sequence at the 3' of the nucleic acid at position 75 of NO: 866 hybridized.

Alternatively, a preferred ISH assay is provided wherein the assay is selected from the group consisting of VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1 , CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, DAAM1-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4 - any polynucleotide fusion of NRG1, SLC4A4-NRG1, ZFAT-NRG1 or DSCAML1-NRG1. The assay specifies the use of a first probe and a second probe, wherein if the first probe hybridizes to a sequence on the 5' side of the fusion junction, the second probe hybridizes to the sequence on the other side sequence hybridization, or if the first probe hybridizes to the sequence on the 3' side of the fusion junction, the second probe hybridizes to the sequence on the other side, and wherein the first probe is selected from VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1 sequence hybridization, and The second probe hybridizes to the NRG1 sequence and is preferably an EGF-like domain sequence such as mentioned herein. Inclusion of a probe that hybridizes to an EGF-like domain places the domain in the vicinity of the NRG1 fusion partner sequence.

Specifically provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect VAPB-NRG1 fusions, wherein the first probe is specifically at the position of SEQ ID NO: 3 The VAPB sequence at the nucleic acid 5' place of 42 or 43 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' place at position 43 or 44 of SEQ ID NO:3, such as the EGF of the present disclosure The sequence comprised by the structural domain, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect CADM1-NRG1 fusions, wherein the first probe is specifically linked to the sequence located between SEQ ID NO: 7 The CADM1 sequence at the 5' position of the nucleic acid at position 53 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the 3' position of the nucleic acid at position 54 of SEQ ID NO: 7, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect CD44-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 11 The CD44 sequence at the 5' position of the nucleic acid at position 52 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the 3' position of the nucleic acid at position 53 of SEQ ID NO: 11, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect CD44-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 761 The CD44 sequence at the 5' position of the nucleic acid at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the 3' position of the nucleic acid at position 76 of SEQ ID NO: 761, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect SLC3A2-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 15 The SLC3A2 sequence at the 5' position of the nucleic acid at position 53 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the 3' position of the nucleic acid at position 54 of SEQ ID NO: 15, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect VTCN1-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 166 The VTCN1 sequence at the 5' position of the nucleic acid at position 65 hybridizes, and the second probe specifically hybridizes with the VTCN1 sequence at the 3' position of the nucleic acid at position 66 of SEQ ID NO: 166, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect CDH1-NRG1 fusions, wherein the first probe is specifically related to the nucleic acid located between SEQ ID NO: 186 The CDH1 sequence at the 5' position of the nucleic acid at position 119 hybridizes, and the second probe specifically hybridizes with the CDH1 sequence at the 3' position of the nucleic acid at position 120 of SEQ ID NO: 186, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect CXADR-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 217 The CXADR sequence at the nucleic acid 5' at position 43 hybridizes, and the second probe specifically hybridizes with the CXADR sequence at the nucleic acid 3' at position 44 of SEQ ID NO: 217, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect GTF2E2-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 233 The GTF2E2 sequence at the 5' position of the nucleic acid at position 141 hybridizes, and the second probe specifically hybridizes with the GTF2E2 sequence at the 3' position of the nucleic acid at position 142 of SEQ ID NO: 233, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect CSMD1-NRG1 fusions, wherein the first probe is specifically linked to the sequence located between SEQ ID NO: 255 The CSMD1 sequence at the nucleic acid 5' at position 88 hybridizes, and the second probe specifically hybridizes with the CSMD1 sequence at the nucleic acid 3' at position 89 of SEQ ID NO: 255, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect PTN-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 313 The PTN sequence at the nucleic acid 5' at position 102 hybridizes, and the second probe specifically hybridizes with the PTN sequence at the nucleic acid 3' at position 103 of SEQ ID NO: 313, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect ST14-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 330 The ST14 sequence at the 5' position of the nucleic acid at position 95 hybridizes, and the second probe specifically hybridizes with the ST14 sequence at the 3' position of the nucleic acid at position 96 of SEQ ID NO: 330, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect THBS1-NRG1 fusions, wherein the first probe is specifically associated with the nucleic acid located between SEQ ID NO: 376 The THBS1 sequence at the 5' position of the nucleic acid at position 56 hybridizes, and the second probe specifically hybridizes with the THBS1 sequence at the 3' position of the nucleic acid at position 57 of SEQ ID NO: 376, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect AGRN-NRG1 fusions, wherein the first probe is specifically associated with the sequence located between SEQ ID NO: 403 The AGRN sequence at the nucleic acid 5' at position 106 hybridizes, and the second probe specifically hybridizes with the AGRN sequence at the nucleic acid 3' at position 107 of SEQ ID NO: 403, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect PVALB-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 437 The PVALB sequence at the nucleic acid 5' at position 102 hybridizes, and the second probe specifically hybridizes with the PVALB sequence at the nucleic acid 3' at position 103 of SEQ ID NO: 437, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect SLC3A2-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 454 The SLC3A2 sequence at the nucleic acid 5' at position 93 hybridizes, and the second probe specifically hybridizes with the SLC3A2 sequence at the nucleic acid 3' at position 94 of SEQ ID NO: 454, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect APP-NRG1 fusions, wherein the first probe is specifically related to the nucleic acid located between SEQ ID NO: 486 The APP sequence at the nucleic acid 5' at position 54 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 55 of SEQ ID NO: 486, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect WRN-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 528 The WRN sequence at the nucleic acid 5' at position 96 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 97 of SEQ ID NO: 528, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect DAAM1-NRG1 fusions, wherein the first probe is specifically linked to the sequence located between SEQ ID NO: 605 The DAAM1 sequence at the 5' position of the nucleic acid at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the 3' position of the nucleic acid at position 76 of SEQ ID NO: 605, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect ASPH-NRG1 fusions, wherein the first probe is specifically related to the nucleic acid located between SEQ ID NO: 635 The ASPH sequence at the nucleic acid 5' at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 76 of SEQ ID NO: 635, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in an in situ hybridization assay to detect a NOTCH2-NRG1 fusion, wherein the first probe is specifically related to the nucleic acid located between SEQ ID NO: 693 The NOTCH2 sequence at the 5' position of the nucleic acid at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the 3' position of the nucleic acid at position 76 of SEQ ID NO: 693, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect CD74-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 717 The CD74 sequence at the 5' position of the nucleic acid at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the 3' position of the nucleic acid at position 76 of SEQ ID NO: 717, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect SDC4-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 743 The SDC4 sequence at the nucleic acid 5' at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 76 of SEQ ID NO: 743, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect SDC4-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 824 The SDC4 sequence at the nucleic acid 5' at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 76 of SEQ ID NO: 824, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect SLC4A4-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 765 The SLC4A4 sequence at the nucleic acid 5' at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 76 of SEQ ID NO: 765, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect ZFAT-NRG1 fusions, wherein the first probe is specifically linked to the sequence located between SEQ ID NO: 828 The ZFAT sequence at the nucleic acid 5' at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 76 of SEQ ID NO: 828, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Also particularly provided is a first nucleic acid probe and a second nucleic acid probe for use in in situ hybridization assays to detect DSCAML1-NRG1 fusions, wherein the first probe is specifically related to the sequence located between SEQ ID NO: 868 The DSCAML1 sequence at the 5' position of the nucleic acid at position 75 hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the 3' position of the nucleic acid at position 76 of SEQ ID NO: 868, such as the EGF-like domain of the present disclosure. Sequences included, in particular the sequence of SEQ ID NO: 163.

Any one of the nucleic acid probes, primers or primer pairs mentioned herein is preferably used in the following identification or detection methods to detect the selected from VAPB-NRG1, CADM1-NRG1 CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, DAAM1- Any of polynucleotides, polypeptide fusions, partial or allogenic variants thereof of NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4-NRG1, SLC4A4-NRG1, ZFAT-NRG1 and DSCAML1-NRG1 . Assays for the Detection of NRG Polynucleotide Fusions

According to the present disclosure, there is provided a method of identifying in a sample a polynucleotide fusion as referred to herein, or a polypeptide encoded thereby, which method comprises testing a sample obtained from an individual to detect whether This fusion exists.

Also provided is a method of detecting the presence in a sample of a polynucleotide fusion, or a polypeptide encoded thereby, comprising examining a sample obtained from an individual to detect the presence of the fusion in the sample.

Also provided is a method of determining whether an abnormal cell from an individual comprises a polynucleotide fusion, or a polypeptide encoded thereby, said method comprising testing whether the polynucleotide or polypeptide content of the abnormal cell obtained from the individual is present in the sample This fusion exists.

Also provided is a method of identifying an individual carrying a polynucleotide fusion, or a polypeptide encoded thereby, comprising testing a sample obtained from an individual to detect the presence of the fusion in the sample. Preferably the test is followed by the step of associating the fusion detected in the sample with the individual carrying the fusion.

Preferably, the assay comprises the use of a binding agent that specifically binds to the polynucleotide, such as any nucleic acid probe, primer or primer pair mentioned herein, or specifically with any of the nucleic acid probes mentioned herein. Binding of a polypeptide encoded by a polynucleotide fusion, or alternatively utilizing a binding agent to bind to a polynucleotide comprising the polynucleotide fusion, to detect any of the polynucleotides mentioned herein or polypeptide fusions. The binding agent is utilized as part of the detection step or to enable detection as a subsequent step. Accordingly, assaying in any of the methods of the present disclosure preferably comprises the use of a binding agent that specifically binds to any polynucleotide fusion or any polypeptide encoded thereby to detect such fusions. The binding agent preferably comprises or consists of a primer, primer pair, probe or antibody. In addition, the binding agent preferably comprises a detectable label.

Alternatively, the assay comprises detecting the fusion using a binding agent that binds to the polynucleotide comprising the polynucleotide fusion. In this alternative, the binding agent binds to a polynucleotide located 5' and/or 3' to the polynucleotide junction and the polynucleotide junction contains the actual junction between NRG1 and its fusion partner . The polynucleotide to which the binding agent binds or hybridizes is ligated or otherwise attached to the polynucleotide fusion as an adapter, after which the fusion is detected. Such adapters preferably contain a tag or molecular barcode, such as used in sequencing methodologies, including next generation sequencing. Such adapters, preferably comprising a marker code or tag, are attached to the polynucleotide fusion so that the fusion is detectable after amplification. In particular, the binder can be used in Anchored Multiplex PCR (or AMP), where a target-enriched library for NGS is obtained after cDNA generation from mRNA.

Preferably, the binding agent is specifically related to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 231, SEQ ID NO: 232. SEQ ID NO:233, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:401, SEQ ID NO:402, SEQ ID NO:403, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:452, SEQ ID NO:453, SEQ ID NO:454, SEQ ID NO:484, SEQ ID NO:485, SEQ ID NO: 486, SEQ ID NO: 526, SEQ ID NO: 527, SEQ ID NO: 528, SEQ ID NO: 603, SEQ ID NO: 604, SEQ ID NO: 605, SEQ ID NO: 633, SEQ ID NO: 634, SEQ ID NO: 635, SEQ ID NO: 691, SEQ ID NO: 692, SEQ ID NO: 693, SEQ ID NO: 715, SEQ ID NO: 716, SEQ ID NO: 717, SEQ ID NO: 741, SEQ ID NO: 742, SEQ ID NO: 743, SEQ ID NO: 759, SEQ ID NO: 760, SEQ ID NO: 761, SEQ ID NO: 763, SEQ ID NO: 764, SEQ ID NO: 765, SEQ ID NO: 822, SEQ ID NO: 823, SEQ ID NO: 824, SEQ ID NO: 826, SEQ ID NO: 827, SEQ ID NO: 828, SEQ ID NO: 866, SEQ ID NO: 867 or SEQ ID NO: 868 combination of polynucleotide sequences of any of them. These sequences allow specific hybridization next to, or even contain, the fusion junction of interest, making them good candidates for binding by the binding agent.

Alternatively, the binding agent is specifically associated with a composition comprising according to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 231, SEQ ID NO: 232. SEQ ID NO:233, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:401, SEQ ID NO:402, SEQ ID NO:403, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:452, SEQ ID NO:453, SEQ ID NO:454, SEQ ID NO:484, SEQ ID NO:485, SEQ ID NO: 486, SEQ ID NO: 526, SEQ ID NO: 527, SEQ ID NO: 528, SEQ ID NO: 603, SEQ ID NO: 604, SEQ ID NO: 605, SEQ ID NO: 633, SEQ ID NO: 634, SEQ ID NO: 635, SEQ ID NO: 691, SEQ ID NO: 692, SEQ ID NO: 693, SEQ ID NO: 715, SEQ ID NO: 716, SEQ ID NO: 717, SEQ ID NO: 741, SEQ ID NO: 742, SEQ ID NO: 743, SEQ ID NO: 759, SEQ ID NO: 760, SEQ ID NO: 761, SEQ ID NO: 763, SEQ ID NO: 764, SEQ ID NO: 765, SEQ ID NO: 822, SEQ ID NO: 823, SEQ ID NO: 824, SEQ ID NO: 826, SEQ ID NO: 827, SEQ ID NO: 828, SEQ ID NO: 866, SEQ ID NO: 867 or SEQ ID NO: 868 A polynucleotide sequence of any sequence. In a preferred aspect of this alternative, the binding agent preferably binds or hybridizes to an adapter sequence to attach (preferably ligate) to the polynucleotide fusion sequence. Such adapters, preferably comprising a marker code or tag, are attached to the polynucleotide fusion so that the fusion is detectable after amplification. Additionally or alternatively, the binding agent comprises a gene-specific primer, pair of primers, or probe, either of which binds to a nucleotide sequence located 5' or 3' to the fusion breakpoint, allowing Amplifies NRG1 with VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or Junction of DSCAML1.

Furthermore, testing for the presence of any polynucleotide fusion of the present disclosure preferably comprises amplifying a polynucleotide bearing an NRG1 fusion or a portion thereof, preferably using a DNA polymerase, more preferably using a thermostable DNA polymerase or Taq polymerase.

Preferably, the binding agent comprises a first primer and a second primer to amplify the sequence containing NRG1 and VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN , PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or the nucleotide sequence of DSCAML1 sequence, and then detect any polynucleotide fusion mentioned herein. More preferably, there is provided a first primer which will hybridize or bind to a nucleotide sequence specific for the NRG1 sequence portion of the fusion, and which will bind to a nucleotide sequence selected from the group consisting of VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, Fusion partners of CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1 have specific nucleotide sequence hybridization or bonding The second primer. Preferably, the first and second primers are combined close to the fusion junction to amplify a part comprising NRG1 sequence and VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14 , THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or a portion of a DSCAML1 sequence. The first or second primer can also bind to a site spanning the fusion junction. Generally, the amplified sequence comprises up to 1000, 900, 800, 700, 600, 500, 400 or 300 base pairs. Generally, the amplified sequence will span the NRG1 fusion junction.

Therefore also provide a kind of binding agent, it is or comprises the nucleic acid probe or primer that is 10-40 nucleotides in length to be used for detecting VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1 of the present disclosure , PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or polynucleotide fusions of DSCAML1 and NRG1, wherein the fusions respectively comprise SEQ ID NO: 3 The nucleic acid of position 43 and 44, the nucleic acid of SEQ ID NO: 7 position 53 and 54, the nucleic acid of SEQ ID NO: 11 position 52 and 53, the nucleic acid of SEQ ID NO: 15 position 53 and 54, the nucleic acid of SEQ ID NO: 166 position 65 The nucleic acid of and 66, the nucleic acid of SEQ ID NO: 186 position 119 and 120, the nucleic acid of SEQ ID NO: 217 position 43 and 44, the nucleic acid of SEQ ID NO: 233 position 141 and 142, the nucleic acid of SEQ ID NO: 255 position 88 and 89 The nucleic acid of, the nucleic acid of SEQ ID NO: 313 positions 102 and 103, the nucleic acid of SEQ ID NO: 330 positions 95 and 96, the nucleic acid of SEQ ID NO: 376 positions 56 and 57, the nucleic acid of SEQ ID NO: 403 positions 106 and 107 , the nucleic acid of SEQ ID NO: 437 positions 102 and 103, or the nucleic acid of SEQ ID NO: 454 positions 93 and 94, the nucleic acid of SEQ ID NO: 486 positions 54 and 55, the nucleic acid of SEQ ID NO: 528 positions 96 and 97, The nucleic acid of SEQ ID NO: 605 positions 75 and 76, the nucleic acid of SEQ ID NO: 635 positions 75 and 76, the nucleic acid of SEQ ID NO: 693 positions 75 and 76, the nucleic acid of SEQ ID NO: 717 positions 75 and 76, SEQ ID NO: NO: the nucleic acid of 743 positions 75 and 76, the nucleic acid of SEQ ID NO: 761 positions 75 and 76, the nucleic acid of SEQ ID NO: 765 positions 75 and 76, the nucleic acid of SEQ ID NO: 824 positions 75 and 76, SEQ ID NO: Nucleic acid at positions 75 and 76 of 828, nucleic acid at positions 75 and 76 of SEQ ID NO: 868. Nucleic acids at these positions define breakpoints or fusion junctions between NRG1 and its fusion partner.

Preferably, the assay mentioned herein comprises amplifying or detecting a sequence for distinguishing the presence or absence of the polynucleotide fusion or the polypeptide encoded thereby.

In a preferred embodiment, the binding agent is a polypeptide and is preferably detected by flow cytometry (FC), fluorescence in situ hybridization (FISH), immunocytochemical staining (ICC), immunofluorescent staining method (IF) to detect its presence. Those skilled in the art can employ a variety of different techniques to detect NRG1 fusions of the present disclosure in samples using FC, IHC, FISH, ICC or IF. For example, a primary antibody targeting NRG1 may be used as well as a target antibody selected from the group consisting of VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, Secondary antibodies to ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT, or the NRG1 fusion partner of DSCAML1 were used for ICC. Colocalization of the signals of the primary and secondary antibodies, or the presence or absence of a polypeptide product of the desired size using a protein size-based discrimination assay, can indicate the presence or absence of a respective NRG1 fusion product. Preferably, the anti-NRG1 antibody targets the EGF-like domain of NRG1, while the second antibody targets such as VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1 , AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or the extracellular domain of the fusion partner of DSCAML1. An example of a FISH protocol is provided by Frithiof et al., OncoTargets and therapy Volume 9, 7095-7103, November 16, 2016. Alternatively, antibodies can be detected using two different fluorescent detection systems combined with two different channels in a fluorescent microscope. Results are illustrated based on the overlapping or non-overlapping appearance of the two fluorescent signals. The development of antibodies against polypeptides of known structure and sequence is well within the purview of those skilled in the art.

Preferably, the polynucleotide or polypeptide fusion to be detected is obtained from abnormal cells expressing the NRG1 EGF-like domain comprising the polynucleotide fusion. Preferably, any detection method of the present disclosure comprises the steps of obtaining a sample from an individual, and subsequently isolating the polynucleotide or the polypeptide encoded by it from the sample. Furthermore, the method preferably comprises the step of purifying or isolating the nucleotide or polypeptide from the sample.

Preferably, the sample is obtained from an individual suffering from, or suspected of having, cancer or tumor with abnormal cells. The sample can be a liquid sample, or a sample from a solid cancer or a solid tumor. The solid sample is preferably a formalin-embedded and paraffin-fixed sample containing any of abnormal cells, a portion of cancer, or a portion of tumor. Taking a sample from a solid cancer or tumor would severely compromise the physical integrity of the skin, and possibly internal organs, to access the tumor under investigation. Using liquid samples such as blood, serum, plasma, pleural effusion, saliva, urine, semen, sputum, vaginal fluid, amniotic fluid, peritoneal fluid, cerebrospinal fluid, bone marrow, acellular lavage fluid or another biological fluid, There can be more affordable, faster, more reliable and less invasive sampling than these methods. Therefore, preferably, the sample is a liquid sample. Antibody-Based Assays for Detecting or Identifying NRG1 Fusions

A polypeptide-based detection assay and antibodies for use therein are also provided. The detection assay is aimed at detecting the polypeptide NRG1 fusions of the present disclosure, in particular VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2 of the present disclosure -NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4-NRG1 , SLC4A4-NRG1 , ZFAT-NRG1 and DSCAML1-NRG1 fusions.

In particular provided is a first antibody or a first and a second antibody suitable for detecting any of the polypeptide fusions mentioned herein, preferably any polypeptide fusion encoded by any of the polynucleotide fusions mentioned herein Group. Those skilled in the art are well within the ability to design, develop and produce antibodies capable and suitable for specifically binding to the polypeptide fusions disclosed herein.

Where a primary antibody is used without the use of a secondary antibody, the primary antibody will specifically detect a unique epitope of the NRG1 polypeptide fusion. Such epitopes include epitopes that span the polypeptide fusion between NRG1 and its fusion partner. Alternatively, where the primary antibody is used without the secondary antibody, and the primary antibody is used in a detection assay (such as discussed further below), the assay includes a recognition of the non-fusion polypeptide steps (eg size or charge based separation steps such as CIEX or HPLC). Where primary and secondary antibodies are used, the primary antibody will detect a portion of the polypeptide fusion (i.e., VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT, or DSCAML1), and the secondary antibody detects the portion of the polypeptide fusion that includes NRG1.

More particularly, the present disclosure provides a first antibody or set of first and second antibodies for detecting a polypeptide encoded by a polynucleotide fusion comprising a VAPB (or VAPB's counterpart) Gene variant) protein sequence nucleic acid is fused to a nucleic acid encoding NRG1 (or allele variant of NRG1) protein sequence.

Preferably, the first antibody, or the first and second antibody sets, is used to detect a part of the polypeptide encoded by VAPB exon 1 or an allele variant of exon 1 and NRG1 exon Polypeptide fusions in which a portion of a polypeptide encoded by an allele variant of exon 2 or exon 2 is fused. Also provided is a detection assay comprising a first antibody or a set of first and second antibodies for detecting the presence of a polypeptide encoded by a polynucleotide fusion involving VAPB and NRG1, wherein the first antibody preferably binds VAPB-NRG1 polypeptide fusion, and the first and second antibody sets preferably bind VAPB and NRG1.

Also provided is a first antibody, or a set of first and second antibodies, for detecting a portion of a polypeptide comprising CADM1 exon 7 or an allele variant of exon 7 and NRG1 exon 6 or exon 7 A polypeptide fusion to which a portion of the polypeptide encoded by the allele variant of exon 6 is fused. Also provided is a method for detecting a part of the polypeptide encoded by CADM1 exon 7 or an allele variant of exon 7 and NRG1 exon 6 or an allele variant of exon 6 An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the CADM1-NRG1 polypeptide fusion, and the first and second antibodies The second set of antibodies preferably bind CADM1 and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising CD44 exon 5 or an allele variant of exon 5 and NRG1 exon 2 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of the polypeptide encoded by CD44 exon 5 or an allele variant of exon 5 and an allele variant of NRG1 exon 2 or exon 2. An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the CD44-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds CD44 and NRG1 respectively.

Also provided is a first antibody, or a set of first and second antibodies, for detecting a portion of a polypeptide comprising CD44 exon 5 or an allele variant of exon 5 and NRG1 exon 6 or exon 5 A polypeptide fusion to which a portion of the polypeptide encoded by the allele variant of exon 6 is fused. Also provided is a method comprising a part of the polypeptide encoded by CD44 exon 5 or the allele variant of exon 5 and NRG1 exon 6 or the allele variant of exon 6. An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the CD44-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds CD44 and NRG1 respectively.

Also provided is a primary antibody or a set of primary and secondary antibodies for detecting a portion of a polypeptide comprising exon 1 of SLC3A2 transcript 6 or an allele variant of exon 1 and NRG1 exon Polypeptide fusions in which a portion of a polypeptide encoded by exon 5 or an allogenic variant of exon 5 is fused. Also provided is a method comprising a part of the polypeptide encoded by the SLC3A2 exon 1 or the allele variant of exon 1 and the allele variant of NRG1 exon 5 or exon 5. Assay for the detection of the presence of a first antibody or a set of first and second antibody fusions to which a portion of the encoded polypeptide is fused, wherein the first antibody is preferably fused to a SLC3A2-NRG1 polypeptide that binds SLC3A2 transcript 6 The first and second antibody groups preferably bind to said SLC3A2 and NRG1, respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide encoded by an allele variant comprising VTCN1 exon 2 or exon 2 and NRG1 exon 2 or exon 2 A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of the polypeptide encoded by VTCN1 exon 2 or an allele variant of exon 2 and an allele variant of NRG1 exon 2 or exon 2. A detection assay for the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the VTCN1-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds to VTCN1 and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising exon 11 of CDH1 or an allele variant of exon 11 and exon 2 or exon 2 of NRG1 A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of the polypeptide encoded by CDH1 exon 11 or an allele variant of exon 11 and an allele variant of NRG1 exon 2 or exon 2. An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of a polypeptide is fused, wherein the first antibody preferably binds to the CDH1-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds CDH1 and NRG1 respectively.

Also provided is a primary antibody or a set of primary and secondary antibodies for detecting a portion of a polypeptide comprising CXADR exon 1 or an allele variant of exon 1 and NRG1 exon 2 or exon 1 A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of a polypeptide encoded by CXADR exon 1 or an allele variant of exon 1 and an allele variant of NRG1 exon 2 or exon 2. A detection assay for the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the CXADR-NRG1 polypeptide fusion, and the first and second antibodies The second set of antibodies preferably binds to CXADR and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising GFT2E2 exon 2 or an allele variant of exon 2 and NRG1 exon 2 or exon 2 A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of a polypeptide encoded by GFT2E2 exon 2 or an allele variant of exon 2 and an allele variant of NRG1 exon 2 or exon 2. A detection assay for the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the GFT2E2-NRG1 polypeptide fusion, and the first and second antibodies The second set of antibodies preferably binds GFT2E2 and NRG1 respectively.

Also provided is a primary antibody or a set of primary and secondary antibodies for detecting a portion of a polypeptide comprising CSMD1 exon 23 or an allogenic variant of exon 23 and NRG1 exon 6 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by CSMD1 exon 23 or an allele variant of exon 23 and an allele variant of NRG1 exon 6 or exon 6 A detection assay for the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the CSMD1-NRG1 polypeptide fusion, and the first and second antibodies The second set of antibodies preferably bind CSMD1 and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising PTN exon 4 or an allele variant of exon 4 and NRG1 exon 2 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of a polypeptide encoded by PTN exon 4 or an allele variant of exon 4 and an allele variant of NRG1 exon 2 or exon 2. An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the PTN-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds PTN and NRG1 respectively.

Also provided is a primary antibody or a set of primary and secondary antibodies for detecting a portion of a polypeptide comprising ST14 exon 11 or an allogenic variant of exon 11 and NRG1 exon 6 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by ST14 exon 11 or an allele variant of exon 11 and an allele variant of NRG1 exon 6 or exon 6 An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of a polypeptide is fused, wherein the first antibody preferably binds to the ST14-NRG1 polypeptide fusion, and the first and second antibodies The second set of antibodies preferably bind ST14 and NRG1 respectively.

Also provided is a primary antibody or a set of primary and secondary antibodies for detecting a portion of a polypeptide comprising THBS1 exon 9 or an allele variant of exon 9 and NRG1 exon 6 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by THBS1 exon 9 or an allele variant encoded by exon 9 and an allele variant encoded by NRG1 exon 6 or exon 6 An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of a polypeptide is fused, wherein the first antibody preferably binds to the THBS1-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds THBS1 and NRG1 respectively.

Also provided is a primary antibody or a set of primary and secondary antibodies for detecting a portion of a polypeptide comprising AGRN exon 12 or an allogenic variant of exon 12 and NRG1 exon 6 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by AGRN exon 12 or an allele variant of exon 12 and an allele variant of NRG1 exon 6 or exon 6 An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the AGRN-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds to AGRN and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising PVALB exon 4 or an allele variant of exon 4 and NRG1 exon 6 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by PVALB exon 4 or an allele variant encoded by exon 4 and an allele variant encoded by NRG1 exon 6 or exon 6 A detection assay for the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the PVALB-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds PVALB and NRG1 respectively.

Also provided is a first antibody, or a set of first and second antibodies, for detecting a portion of a polypeptide comprising exon 2 of transcript 3 of SLC3A2 or an allele variant of exon 2 and NRG1 exon Polypeptide fusions to which a portion of the polypeptide encoded by exon 6 or an allogenic variant of exon 6 is fused. Also provided is a method for detecting a part of the polypeptide encoded by the SLC3A2 exon 2 or the allele variant of exon 2 and NRG1 exon 6 or the allele variant of exon 6. Assay for the detection of the presence of a primary antibody or a set of primary and secondary antibodies to which a portion of the encoded polypeptide is fused, wherein the primary antibody is preferably a SLC3A2-NRG1 polypeptide fusion that binds transcript 3 , and the first and second antibody sets preferably bind to said SLC3A2 and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising APP exon 14 or an allele variant of exon 14 and NRG1 exon 6 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by exon 14 of APP or an allele variant of exon 14 and an allele variant of NRG1 exon 6 or exon 6. An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the APP-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds APP and NRG1 respectively.

Also provided is a primary antibody or a set of primary and secondary antibodies for detecting a portion of a polypeptide comprising WRN exon 33 or an allogenic variant of exon 33 and NRG1 exon 6 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by WRN exon 33 or an allele variant of exon 33 and an allele variant of NRG1 exon 6 or exon 6 A detection assay for the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the WRN-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds to WRN and NRG1 respectively.

The present disclosure also provides a first antibody or a set of first and second antibodies for detecting a polypeptide encoded by a polynucleotide fusion comprising an allele variant encoding ASPH (or ASPH) The nucleic acid of the protein sequence of NRG1 is fused with a nucleic acid encoding the protein sequence of NRG1 (or an allele variant of NRG1).

More particularly, there is provided a first antibody or a set of first and second antibodies for detecting a polypeptide fusion comprising a portion of ASPH exon 22 or an allele variant of exon 22 The encoded polypeptide is fused to a portion of the polypeptide encoded by exon 2 of NRG1 or an allele variant of exon 2. Also provided is a detection assay comprising a first antibody or a set of first and second antibodies for detecting the presence of a polypeptide comprising a portion encoded by ASPH exon 22 or an allele variant of exon 22 A polypeptide fusion fused to a portion of a polypeptide encoded by exon 2 of NRG1 or an allogenic variant of exon 2, wherein the first antibody preferably binds to the ASPH-NRG1 polypeptide fusion, and the first antibody Preferably bind ASPH and NRG1 respectively with the second antibody set.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising exon 6 of NOTCH2 or an allele variant of exon 6 and exon 6 or exon 6 of NRG1 A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by exon 6 of NOTCH2 or an allele variant of exon 6 and an allele variant of NRG1 exon 6 or exon 6 An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of a polypeptide is fused, wherein the first antibody preferably binds to the NOTCH2-NRG1 polypeptide fusion, and the first and second antibodies The second set of antibodies preferably bind NOTCH2 and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising CD74 exon 2 or an allele variant of exon 2 and NRG1 exon 2 or exon 2 A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of a polypeptide encoded by CD74 exon 2 or an allele variant of exon 2 and an allele variant of NRG1 exon 2 or exon 2. An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the CD74-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds CD74 and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising SDC4 exon 2 or an allele variant of exon 2 and NRG1 exon 2 or exon 2 A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of a polypeptide encoded by SDC4 exon 2 or an allele variant of exon 2 and an allele variant of NRG1 exon 2 or exon 2. A detection assay for the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the SDC4-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds to SDC4 and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising SDC4 exon 4 or an allele variant of exon 4 and NRG1 exon 2 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of Son 2 is fused. Also provided is a method comprising a part of the polypeptide encoded by SDC4 exon 4 or an allele variant of exon 4 and an allele variant of NRG1 exon 2 or exon 2. A detection assay for the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the SDC4-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds to SDC4 and NRG1 respectively.

Also provided is a first antibody or a set of first and second antibodies for detecting a portion of a polypeptide comprising SLC4A4 exon 14 or an allogenic variant of exon 14 and NRG1 exon 6 or exon A polypeptide fusion in which a portion of the polypeptide encoded by the allele variant of sub6 is fused. Also provided is a method comprising a part of a polypeptide encoded by exon 14 of SLC4A4 or an allele variant of exon 14 and an allele variant of NRG1 exon 6 or exon 6. An assay for the detection of the presence of a first antibody or a set of first and second antibodies to which a portion of the polypeptide is fused, wherein the first antibody preferably binds to the SLC4A4-NRG1 polypeptide fusion, and the first and second antibodies The second antibody set preferably binds SLC4A4 and NRG1 respectively.

The disclosure also provides a first antibody or a set of first and second antibodies for detecting a polypeptide encoded by a polynucleotide fusion comprising an allele variant encoding ZFAT (or ZFAT) The nucleic acid of the protein sequence of NRG1 is fused with a nucleic acid encoding the protein sequence of NRG1 (or an allele variant of NRG1).

More particularly, there is provided a first antibody or a set of first and second antibodies for detecting a polypeptide fusion comprising a portion of ZFAT exon 12 or an allele variant of exon 12 The encoded polypeptide is fused to a portion of the polypeptide encoded by exon 6 of NRG1 or an allele variant of exon 6. Also provided is a detection assay comprising a first antibody or a set of first and second antibodies for detecting the presence of a polypeptide comprising a portion encoded by ZFAT exon 12 or an allele variant of exon 12 A polypeptide fusion fused to a portion of a polypeptide encoded by NRG1 exon 6 or an allogenic variant of exon 6, wherein the first antibody preferably binds to the ZFAT-NRG1 polypeptide fusion, and the first antibody Preferably bind ZFAT and NRG1 respectively with the second antibody set.

The present disclosure also provides a first antibody or a set of first and second antibodies for detecting a polypeptide encoded by a polynucleotide fusion comprising an allele variant encoding DSCAML1 (or DSCAML1 The nucleic acid of the protein sequence of NRG1 is fused with a nucleic acid encoding the protein sequence of NRG1 (or an allele variant of NRG1).

More particularly, there is provided a first antibody or a set of first and second antibodies for detecting a polypeptide fusion comprising a portion of DSCAML1 exon 3 or an allele variant of exon 3 The encoded polypeptide is fused to a portion of the polypeptide encoded by an allele variant of exon or exon 2 of NRG1. Also provided is a detection assay comprising a first antibody or a set of first and second antibodies for detecting the presence of a polypeptide comprising a portion encoded by exon 3 or an allele variant of exon 3 of DSCAML1 A polypeptide fusion fused to a portion of a polypeptide encoded by NRG1 exon 2 or an allogenic variant of exon 2, wherein the first antibody preferably binds to the DSCAML1-NRG1 polypeptide fusion, and the first antibody Preferably bind DSCAML1 and NRG1 respectively with the second antibody panel.

Preferably, the anti-NRG1 antibody preferably binds to the EGF-like domain of NRG1. Detection of the presence of the EGF-like domain in the polypeptide fusions of the present disclosure is advantageous because it shows that the EGF-like domain is translated and thus associated with VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, In-frame fusion portions of CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT, or DSCAML1.

Anti-NRG1, VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, ASPH, NOTCH2, CD74, SDC4, SLC4A4, Antibodies against ZFAT or DSCAML1 can be used in flow cytometry (FC), fluorescence in situ hybridization (FISH), immunocytochemical staining (ICC), immunohistochemical staining (IHC) or immunofluorescence staining (IF). treatment method

Fusions of the present disclosure are present or have been identified in human patients with abnormal cells, especially patients diagnosed with cancer. The cancer of the present disclosure is especially pancreatic cancer, more particularly pancreatic ductal adenocarcinoma, sarcoma, bladder cancer, colorectal cancer, rectal cancer, colorectal cancer, gallbladder cancer, head and neck cancer, prostate cancer, uterine cancer, breast cancer, ovarian cancer , liver cancer, endometrial cancer, lung cancer, especially non-small cell lung cancer, or invasive mucinous adenocarcinoma.

In general, the present disclosure also provides methods of treating individuals with abnormal cells like cancers, tumors, wherein the cancers, tumors or abnormal cells, the cells, cancers or tumors comprise the NRG1 polynucleotide fusions of the present disclosure Or express an NRG1 polypeptide fusion as disclosed herein.

The current NRG1 fusion has been identified as part of a clinical trial and Early Access Program (NCT02912949 and NCT04100694, respectively) called eNRGy (called ). As of the cut-off date of April 12, 2022, a total of approximately 70% of registered and non-excluded patients with identified NRG1 fusions were observed by RECIST 1.1 criteria across fusion partners and across multiple different cancer types Demonstrate investigator-assessed responses. Investigator-assessed responses were observed in each category in Table 1. Indications in which responses were observed include pancreatic ductal adenocarcinoma, non-small cell lung cancer, breast cancer, and cholangiocarcinoma. Prevalence of NRG1 fusion partners NRG1 Fusion Partner Classes % of total CD74 31% SLC3A2 16% SDC4 9% RBPMS 4% CDH1 2% VTCN1 2% Others twenty three% Table 1: Overview of the percentage of NRG1 fusion partners found, expressed as a percentage of total number of identified fusion partners identified in clinical trial NCT02912949 in subjects until April 12, 2022 cutoff. Other NRG1-containing fusions identified by the cutoff date accounted for less than 2% of the total.

Preferably, the abnormal cell, cancer (or cancer cell) or tumor (or tumor cell) comprises the polynucleotide fusion of the present disclosure, and the polynucleotide fusion further comprises an in-frame fusion-coding NRG1 Coding sequence for the EGF-like domain.

The present disclosure also provides a treatment for ErbB-2 and/or ErbB-3 positive abnormal cells, cancer cells or A method for an individual with tumor cells, said method comprising detecting the presence or absence of any of the polynucleotide or polypeptide fusions mentioned herein, and then administering to the individual an effective amount of ErbB-2 and/or ErbB-3 targets agent to treat the individual's cancer. The presence of any of the NRG1 fusions of the present disclosure, either as polynucleotides or polypeptides translated therefrom, is indicative of cancer.

Also provided is a method of inhibiting the course of disease in a subject having an ErbB-2 and ErbB-3 positive cancer comprising or expressing an NRG1 polynucleotide fusion mentioned herein, said method It comprises detecting the presence of any one of the polynucleotide or polypeptide fusions mentioned herein, and then administering to the individual an effective amount of an ErbB-2 and/or ErbB-3 targeting agent.

Also provided is an ErbB for use in the treatment of an individual with an ErbB-2 and ErbB-3 positive cancer comprising an NRG1 polynucleotide fusion mentioned herein or expressing an NRG1 polypeptide fusion mentioned herein -2 and/or an ErbB-3 targeting agent, the treatment comprising detecting the presence of any polynucleotide or polypeptide fusion mentioned herein, then administering to the individual an effective amount of ErbB-2 and/or ErbB-3 targeting agent.

Also provided is the manufacture of a therapeutic medicament for use in an individual with an ErbB-2 and ErbB-3 positive cancer comprising an NRG1 polynucleotide fusion mentioned herein or expressing an NRG1 polypeptide fusion mentioned herein An ErbB-2 and/or ErbB-3 targeting agent in which the treatment comprises detecting the presence of any polynucleotide or polypeptide fusion mentioned herein, and then administering an effective amount of ErbB-2 to the individual and/or an ErbB-3 targeting agent.

Still further provided is a method of assessing whether an individual suffers from cancer or is prone to developing cancer, the method comprising testing a sample obtained from an individual to detect the presence of the NRG1 polynucleotide fusion or NRG1 polypeptide fusion mentioned herein in the sample and assessing that the individual suffers from the cancer or is predisposed to developing the cancer by identifying whether the fusion is present. The assay preferably comprises detecting the fusion using a binding agent that specifically binds to the polynucleotide or using a binding agent that binds to a polynucleotide comprising the polynucleotide fusion. Further details regarding binding agents that bind polynucleotides comprising such polynucleotide fusions are set forth below.

Preferably, the diagnostic methods mentioned herein comprise the step of correlating the detection of NRG1 fusions in a sample with cancers expressing the NRG1 polypeptides mentioned herein, to diagnose that the individual suffers from the expression of said NRG1 Cancer of polypeptide fusions. Detection of NRG1 fusion molecules allows identification of an individual with a cancer expressing the NRG1 fusion polypeptide, and diagnosis of such cancer in the individual. Knowledge of the underlying oncogenic drivers of cancer allows for the selection and prescribing of improved or better tailored treatments. Thus, detection of fusion molecules, such as fusion polypeptides or polynucleotides, in a sample of an individual makes it possible to improve the chances of survival of an individual suffering from NRG1-associated cancer.

The present disclosure thus provides a method of treating cancer. The cancer is preferably a recurrent cancer or a metastatic cancer. Recurrence generally refers to a local recurrence and means that the cancer is in the same place or very close to the original cancer. A tumor is generally said to be metastatic when it has migrated to lymph nodes or tissues near the original cancer, or spread to organs or tissues further away from the original cancer. In such cases, both representations can be used.

The cancer is especially pancreatic cancer, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, sarcoma, bladder cancer, colorectal cancer, gallbladder cancer, head and neck cancer, prostate cancer, uterine cancer, breast cancer, ovarian cancer, liver cancer, endometrial cancer Carcinoma, lung cancer such as non-small cell lung cancer, especially non-small cell lung cancer, more especially invasive mucinous adenocarcinoma. Preferably, the tumor gene body shows the presence or absence of mutations in one or more genes selected from the group consisting of EGFR, KRAS, cKIT-BRCA1-2, MET, ROS, RET, ALK, preferably KRAS .

The present disclosure contemplates the use of ErbB-2 and/or ErbB-3 targeting agents for the treatment of cancers expressing NRG1 fusion polypeptides. The targeting agent is selected from the group consisting of a first antigen binding site that binds the extracellular portion of ErbB-2 and a second antigen binding site that binds the extracellular portion of ErbB-3 Multispecific antibody, tyrosine kinase inhibitor of ErbB-2, monospecific bivalent antibody comprising an antigen-binding site binding to the extracellular part of ErbB-2, comprising an extracellular part binding to ErbB-3 A monospecific diabody with an antigen-binding site, or any combination thereof.

Also comprising administering one or more compounds selected from the group consisting of inhibitors that inhibit components in the PI3 kinase pathway, inhibitors that inhibit components in the MAPK pathway, microtubule disrupting drugs, and histones for the treatment of cancer Inhibitors of deacetylase (HDAC). The inhibitors preferably comprise tyrosine kinase inhibitors, PI3Ka inhibitors, Akt inhibitors, mTOR inhibitors or Src inhibitors. The tyrosine kinase inhibitor is preferably afatinib, lapatinib and/or neratinib. The PI3Ka inhibitor is preferably BYL719. In one embodiment, the Akt inhibitor is MK-2206. In a preferred embodiment, the mTOR inhibitor is everolimus. In a preferred embodiment, the Src inhibitor is saracatinib. In one disclosed embodiment, the microtubule disrupting drug is paclitaxel. In a preferred embodiment, the HDAC inhibitor is vorinostat. In one embodiment, the binding compound specific to ErbB 2 and ErbB 3 is MM 111 .

The ErbB-2 targeting agent is preferably a monospecific diabody comprising an antigen binding site that binds the extracellular portion of ErbB-2. Such antibodies are preferably trastuzumab, pertuzumab or trastuzumab-emtansine. ErbB-2 targeted therapy is preferably ErbB-2 TKI. The ErbB-2 TKI is preferably lapatinib, canertinib, neratinib, tucatinib (or irbinitinib), CP-724714, Dalo One or more of tarloxitinib, mubritinib, afatinib, varlitinib and dacomitinib, preferably afatinib Ni. ErbB-2 TKIs may also affect ErbB-1 signaling, but differ from ErbB-1 TKIs in that they have significant activity against ErbB-2. ErbB-3 targeted therapy is preferably with a monospecific diabody comprising an antigen binding site that binds the extracellular portion of ErbB-3. Such antibodies are preferably patritumab, seribantumab, lumretuzumab, elgemtumab, GSK2849330, KTN3379 or AV-203 .

Preferably, the monospecific bivalent antibody system comprising an antigen-binding site that binds to the extracellular part of ErbB-3 comprises palivizumab, seribumab, rumucumab, erg Timumab, GSK2849330, KTN3379, or AV-203.

The tyrosine kinase inhibitor is preferably afatinib, lapatinib and/or neratinib.

More preferably, the ErbB-2 and/or ErbB-3 targeting agent is a multispecific antibody, or more preferably a bispecific antibody, and it comprises a first antibody that binds to the extracellular part of ErbB-2. An antigen binding site and a second antigen binding site that binds to the extracellular portion of ErbB-3. In particular, the bispecific antibody is zenocutuzumab.

The antibody preferably reduces ligand-induced ErbB-3 receptor function in ErbB-2 and ErbB-3 positive cells. Furthermore, the antibody preferably reduces ligand-induced growth in ErbB-2 and ErbB-3 positive cells. The antibody is preferably a multispecific or bispecific antibody comprising a first antigen binding site that binds to the extracellular portion of ErbB-2 and a second antigen binding site that binds to the extracellular portion of ErbB-3 .

The individual is preferably a human individual. The individual is preferably a subject eligible for monoclonal antibody therapy with an ErbB-2-specific antibody, such as trastuzumab. In a preferred embodiment, the individual comprises a tumor/cancer, preferably an ErbB-2/ErbB-3 positive cancer, preferably an ErbB-2 treatment-resistant genotype and/or a heregulin-resistant genotype The tumor/cancer is preferably a tumor/cancer with a monoclonal antibody resistant genotype. Tumors involving such genotypes may escape treatment with current anti-HER2 treatment regimens such as, but not limited to, anti-ErbB-2 monoclonal antibody therapy.

In particular, the cancer comprises tumors that are metastatic tumors, preferably wherein the tumor has migrated to lymph nodes or tissues adjacent to the original cancer, or spread to organs or tissues more distant from the original cancer.

The present disclosure also includes in vivo models, such as xenograft or transgenic animal models of transplanted abnormal cells expressing in their genes or comprising the polynucleotide fusions mentioned herein, and/or expressing the genes encoded by them. and treatment of such models with ERB2 and/or Erb3 targeting agents or other targeting agents to assess the therapeutic activity of such agents. Preferably, the animal model is a non-human animal model.

In a disclosed embodiment, the in vivo animal model comprises a polynucleotide fusion as disclosed herein and/or expresses a polypeptide fusion encoded thereby, wherein the animal model consists of a polynucleotide fusion The drug or polypeptide fusion is preferably composed of transplanted abnormal cells present in the animal model, or is composed of the gene body of the animal model.

In disclosed embodiments, the present disclosure provides a method of treatment of said in vivo animal model using an ErbB-2 and/or ErbB-3 targeting agent selected from the group consisting of: Multispecific antibody comprising a first antigen binding site that binds the extracellular portion of ErbB-2 and a second antigen binding site that binds the extracellular portion of ErbB-3, a tyrosine kinase inhibitor of ErbB-2 , a monospecific diabody comprising an antigen-binding site that binds an extracellular portion of ErbB-2, a monospecific diabody comprising an antigen-binding site that binds an extracellular portion of ErbB-3, or any of these In combination, said method comprises administering said Erb2 and/or Erb3 targeting agent to said animal.

In disclosed embodiments, the disclosure provides an ErbB-2 and/or ErbB-3 targeting agent selected from the group consisting of a first antigen that binds an extracellular portion of ErbB-2 Multispecific antibody binding site and a second antigen binding site binding to the extracellular portion of ErbB-3, tyrosine kinase inhibitor of ErbB-2, antigen binding comprising an extracellular portion binding to ErbB-2 Monospecific diabodies of a site, monospecific diabodies comprising an antigen binding site that binds an extracellular portion of ErbB-3, or any combination thereof, for use in therapy of said in vivo animal model . The method preferably comprises administering to the animal said Erb2 and/or Erb3 targeting agent. Administration and administration

Actual dosage levels of the active ingredients in the disclosed pharmaceutical compositions or administered in any method of treatment may be varied to achieve a desired therapeutic response effective for a particular patient, composition, and mode of administration without toxicity to the patient. amount of active ingredient. The selected dosage level will depend on a variety of pharmacokinetic factors, including the activity of the particular composition of the present disclosure used, the route of administration, the time of administration, the rate of excretion of the particular compound used, the duration of treatment; the combination with the particular composition used other drugs, compounds, and/or substances; the age, sex, weight, condition, general health, and prior medical history of the patient being treated; and similar factors well known in the medical field. The active ingredient is preferably any Erb2 and/or Erb3 targeting agent disclosed herein. Any approved active ingredient or drug that is undergoing clinical trials, especially once it enters the second phase of clinical trials, may be considered by a physician for administration according to the approved dosage regimen or clinical trial dosage regimen.

The amount to be administered to any ErbB-2 and/or ErbB-3 targeting agent as mentioned herein is generally within the therapeutic range, which means using a sufficient amount to obtain a therapeutic effect while not exceeding the amount that would cause side effects threshold of unacceptable levels. The lower the amount of therapeutic substance required to achieve the desired therapeutic effect, the larger the therapeutic area will generally be. The selected dosage level will depend on various factors including the route of administration, time of administration, rate of excretion of the particular compound used, duration of treatment, other drugs, compounds and/or substances used in combination, age, sex, Weight, medical conditions, general health, and previous medical history; and similar factors well known in the medical field.

With regard to zetuzumab, it has a good safety profile at relatively high doses and thus offers a larger therapeutic latitude compared to other targeted or cytotoxic chemotherapeutic agents. The administration of the bispecific antibody of the present invention follows a weekly, biweekly, or triweekly administration regimen of 750 mg, preferably a biweekly dose of 750 mg. Administration is preferably for individuals with pancreatic cancer, NSCLC, or solid tumors, and includes any individual with a solid tumor with an NRG1 fusion, wherein such individuals have been administered chemotherapy standard of care, Or ErbB-2 or ErbB-3 targeting agents, or TKI progressed. Alternatively, the subsequent dosing regimen comprises a weekly fixed dose administration of 400 mg, preferably initiated after a single administration of 800 mg. Following this alternate dosing regimen, the bispecific antibody of the present disclosure is preferably administered at a dose of 400 mg once weekly for 3 weeks, followed by 1 week of no administration. Then, one or more four-week period cycles consisting of three once-weekly fixed doses of 400 mg followed by one week of no administration were followed. It is preferred to follow this pattern until a therapeutic effect is observed.

Dosing preferably involves two infusions of the bispecific antibody of the present disclosure by intravenous injection to achieve the full dose, preferably when >360 mg of antibody is administered. Alternatively, a single infusion of the complete dose may be given for lower doses, eg, when administering ≤ 360 mg of antibody. Dosing regimens may include back-up medications to slow down infusion-related reactions. general definition

The articles "a" and "an" herein refer to one or more (ie, one or at least one) of the grammatical object of the article.

Throughout this specification and the appended claims, the words "comprises," "includes," and "has" and variations thereof such as "comprises," "comprising," "includes," and "includes" are to be referred to as Interpreted as inclusive. That is, where the context allows, these words are intended to mean that other elements or integers not specifically listed may be included.

"Percent identity (%)" when referring to nucleic acid or amino acid sequences is defined as the residues in a candidate sequence that are identical to residues in the selected sequence after alignment of the sequences for optimal comparison purposes base percentage. To optimize the alignment, a gap can be introduced between the two sequences in either of the two sequences being compared. Such alignments can be performed over the full length of the sequences being compared. Alternatively, the alignment can be performed over shorter lengths, eg, over about 20, about 50, about 100 or more nucleic acids/bases or amino acids. Sequence identity is the reported percentage of identical matches between two sequences over an aligned region.

The comparison of sequences and the determination of percent sequence identity between two sequences can be accomplished using a mathematical algorithm. Those skilled in the art will be aware of the fact that several different computer programs are available for aligning two sequences and determining the identity between the two sequences (Kruskal, J. B. (1983) An overview of sequence comparison In D. Sankoff and J. B. Kruskal, (ed.), Time warps, string edits and macromolecules: the theory and practice of sequence comparison, pp. 1-44 Addison Wesley). The percent sequence identity between two amino acid sequences or nucleic acid sequences can be determined using the Needleman and Wunsch algorithm for the alignment of two sequences (Needleman, S. B. and Wunsch, C. D. (1970) J. Mol. Biol. 48, 443-453). The Nyon-Wong algorithm has been implemented in the computer program NEEDLE. For the purposes of this disclosure, the NEEDLE program from the EMBOSS software package was used to determine percent identity for amino acid and nucleic acid sequences (version 2.8.0 or later, EMBOSS: The European Molecular Biology Open Software Suite (2000) Rice , P. LongdenJ. and Bleasby, A. Trends in Genetics 16, (6) pp. 276-277, http://emboss.bioinformatics.nl/). For protein sequences, use EBLOSUM62 for the substitution matrix. For DNA sequences, use DNAFULL. The parameters used were a gap opening penalty of 10 and a gap extension penalty of 0.5.

After the alignment, the percent sequence identity between the query sequence and the sequences of the disclosure is calculated by the program NEEDLE as described above as follows: the number of alignments showing identical amino acids or identical nucleotides in the two sequences The number of corresponding positions is divided by the total length of the alignment after subtracting the total number of gaps in the alignment.

"Allogenic variant" means the naturally occurring allele of a specific sequence identified in a patient-derived sample, the identified sequence has been assigned a SEQ ID NO, and the variant falls into a defined within the range of variation. The variability is defined as having at least 85% sequence identity, preferably 90% identity, or 92%, 94%, 95%, 96% or better with the sequence indicating that it is an allogenic variant At least 98% sequence identity. Such a variant is considered an allele of the sequence it is being compared to, and thus still qualifies as its variant gene. If no relationship to a particular allele variant is explicitly mentioned herein, these percent sequence identities still apply to the allele variant referred to.

"Bispecific antibody" refers to an antibody having one antibody variable domain that binds to a first antigen and a second antibody variable domain that binds to a second antigen, wherein the first and second antigens are not identical. The term "bispecific antibody" also encompasses binary antibodies in which one antibody variable domain binds to a first epitope of an antigen and a second antibody variable domain binds to a second epitope of the same antigen. The term further includes antibodies in which at least one VH specifically recognizes a first antigen and a VL is paired with at least one VH in an immunoglobulin variable domain to specifically recognize a second antigen. The resulting VH/VL pair will bind to Antigen 1 or Antigen 2 and is called a "two-in-one antibody", for example in WO 2008/027236, WO 2010/108127 and Schaefer et al. (Cancer Cell 20, 472-486, October 2011 ) described in . Bispecific antibodies as disclosed herein are not limited to any particular bispecific format or method of producing them.

"Detectable label" means a chemical, biological or other modification, including but not limited to fluorescent, mass, residue, dye, radioisotope, tag or label modification, etc., which results in the detection of a molecule of interest (preferred herein is polynucleotide or polypeptide) is present. Preferably, the detectable label is a visible label, a fluorescent dye, a quencher, an ultraviolet light detectable label, a chromogenic label, a radioactive label, an electrochemical label, a label, and when combined with an enzyme or molecular barcode. An enzyme that produces a detectable label upon contact with a specific substrate. Exemplary fluorescent dyes include water-soluble rhodamine dyes, luciferin, 4,7-dichlorofluorescein, benzoxanthene dyes, and energy transfer dyes, as disclosed in the following references: Handbook of Molecular Probes and Research Reagents, 8th Edition (2002), Molecular Probes, Eugene, Oreg.; WO 2001/32783; US Patent Publication Nos. US 2002-0081616, US 2002-0086985; and Lee et al., 1997, Nucleic Acids Research 25:2816 -2822.

"Isolated" or "purified" means that a nucleic acid or amino acid sequence has been isolated or purified from its natural environment. An "isolated" nucleic acid molecule includes one that is separated from other nucleic acid molecules present in the natural source of the nucleic acid molecule. Furthermore, an "isolated" nucleic acid molecule, such as a cDNA molecule, includes a state free of other cellular material or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A "sample" herein refers to a sample obtained from an individual or patient. Such samples are biological samples or patient samples, and these terms are used interchangeably herein, as reference herein to a sample is a biological sample obtained from a patient. The term "sample" includes liquid specimen samples, samples taken from solid cancers or solid tumors, and which will contain polynucleotide fusions and/or polypeptide fusions before any processing is applied thereto. In particular, the sample contains abnormal cells, such as tumor cells or cancer cells.

The expression "free of other cellular material or culture medium" includes preparations of nucleic acid molecules in which the nucleic acid molecule is isolated from the cellular components of the cells from which the nucleic acid molecule was isolated or recombinantly produced.

"Primer" means a single-stranded nucleotide molecule of sufficient length to specifically hybridize to a nucleotide sequence of interest such that it binds to a defined nucleotide sequence of interest to be amplified in a polymerase chain reaction (PCR). The second primers of the region together specifically bind (also referred to herein as hybridizing or adhering) to a target or selected nucleotide sequence. Herein, the first and second primers, or pair of primers, are specifically designed to amplify a region of nucleotides spanning the NRG1 fusion junction. In particular, a combination of a first primer that hybridizes to a nucleotide sequence specific for the portion of the NRG1 sequence on one side of the fusion junction and a second primer that hybridizes is used and for the other side of the fusion junction selected from VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2 , CD74, SDC4, SLC4A4, ZFAT or DSCAML1 fusion partners have specific nucleotide sequence hybridization. Generally, the primers themselves do not contain a detectable label. The primer typically shares at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or at least Approximately 99% sequence identity. A polynucleotide primer is optimally complementary (100% sequence identity over its entire length) to its target sequence. In all instances herein, sequence identity is generally measured over the full length of the non-variant/target sequence.

A "probe" or "nucleic acid probe" refers to a single-stranded nucleotide molecule of sufficient length to specifically hybridize to a nucleotide sequence of interest. In particular, in the context of the present disclosure, the probes can detect genes that occur in VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, Fusions among ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1, especially selected from VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1 , GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, DAAM1-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74 - Fusions of NRG1, SDC4-NRG1, SLC4A4-NRG1, ZFAT-NRG1 and DSCAML1-NRG1. Probes typically contain one or two detectable labels. On the full length of the target sequence of NRG1 fusion polynucleotide, the polynucleotide probe usually shares at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% sequence identity. The polynucleotide primer is optimally complementary (100% sequence identity over its entire length) to its target sequence. In all instances herein, sequence identity is generally measured over the full length of the non-variant/target sequence.

The polynucleotide probe is preferably a DNA probe, a TaqMan probe, a molecular beacon, a scorpion probe or a probe used in FISH. DNA probes typically hybridize to a complementary target sequence and can then be detected using, for example, a detectable label. TaqMan probes are known in the art and are polynucleotides with a fluorescent dye attached to the 5' end and a quencher attached to the 3' end. The polymerase used in PCR cleaves the hybridized probe, rendering the fluorescent dye unquenchable and detectable. Molecular Beacon probes are known in the art and are similar to TaqMan probes except that they hybridize to the target sequence to separate the dye from the quencher (instead of using cleavage to separate the dye from the quencher). Scorpion probes are known in the art and are similar to molecular beacons, except that their 3' end also contains a sequence complementary to the 5' end of the extension product of the primer to open the hybridizing probe to the dye. detected. The polynucleotide probe is preferably a TaqMan probe. The polynucleotide probe is preferably a TaqMan probe and is used in any of the PCR methods described above.

Probes used in techniques like FISH or Fragmentation FISH are of suitable length and comprise a single detectable label. FISH involves the detection and visualization of highly specific DNA probes that have hybridized to interphase or metaphase chromosomes for detection using a fluorescent microscope. The break-separation FISH line is particularly suitable for detecting fusion breakpoints. In this case, the two ends of the gene of interest are marked with different colors, and when a translocation occurs to create a fusion, the two separate colors do not colocalize, but two primary colors are observed. In normal cells with a normal number of copies of the tagged gene of interest, the two colors will co-localize to produce a fusion signal.

Probes or primers used to identify fusion polynucleotides composed of cells can be isolated or purified using standard molecular biology techniques, or synthesized based on sequence information in database records described herein. Such nucleic acid molecules as described herein can be cloned using standard hybridization and cloning techniques (e.g., in Sambrook et al., eds., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) to separate. In addition, fusion polynucleotides can be isolated, purified or synthesized using any suitable standard molecular biology techniques. In some embodiments, the primers or probes are specific for cDNA. For example, in some embodiments, the primers or probes are specific for exon-exon junctions in cDNA.

"Polynucleotide fusion" means a covalently bonded linkage between two polynucleotides in which a nucleotide sequence from one gene is present on one side of the fusion junction and a nucleotide sequence is present on the other. There is a nucleotide sequence from another gene. In the context of polynucleotide fusions, the linkage is operably linked in a manner that permits transcription into a protein. On one side of the fusion junction, the nucleotide sequence is preferably from VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1, and preferably from NRG1 on the other side.

"Polypeptide fusion" means a covalently bonded linkage between two amino acids in which on one side of the fusion junction there is an amino acid sequence from one polypeptide and on the other side an amino acid sequence from The amino acid sequence of another polypeptide. On one side of the fusion junction, the amino acid sequence is preferably from VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, ASPH, NOTCH2, CD74, SDC4, SLC4A4, ZFAT or DSCAML1, and preferably from NRG1 on the other side.

"Fusion partner" refers to a gene or polypeptide that has been fused to an NRG1 gene or polypeptide due to gene rearrangement. In this disclosure, the fusion partners are VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74, One of SDC4, SLC4A4, ZFAT or DSCAML1. Generally, the fusion partner system is located upstream of the NRG1 gene (at the 5' end of the sense strand), and in-frame fusion results in translation into a gene comprising a portion of the fusion partner and an NRG1 portion. chimeric protein. A fusion gene resulting from the joining of two different gene portions with a fusion polypeptide is the translation product from such a fusion gene.

"Fusion point" refers to the position in an amino acid or nucleotide sequence where the NRG1 sequence occurs on one side and the NRG1 fusion partner sequence occurs on the other side. This is the junction or location where gene rearrangement occurs to form chimeric gene, mRNA and/or protein sequences. The term "fusion point" herein is interchangeable with "junction" or "fusion junction".

"Gene sequence located 3'" refers to any element (regulatory or not) located downstream or 3' of the gene in question and considered to be part of said gene. Regulatory elements herein include enhancers, silencers, response elements, insertions, exons, embedded promoters, and are specific to the gene in question such that they can be uniquely expressed due to their proximity to the fusion junction. way to amplify and identify the fusion. A gene sequence located 3' in this context also includes any gene sequence located between any regulatory elements that can be used to uniquely identify the fusion in question.

"Gene sequence located 5'" refers to any element (regulatory or not) located downstream or 5' of the gene in question and considered to be part of said gene. Regulatory elements herein include promoters, enhancers, silencers, response elements, inserts, exons, embedded promoters, and the elements are specific to the gene in question so that they can be Instead, the fusion is amplified and identified in a unique manner. A gene sequence located 5' in this context also includes any gene sequence located between any regulatory elements that can be used to uniquely identify the fusion in question.

As used herein, the term "ErbB-2" refers to the protein encoded by the ERBB-2 gene in humans. Alternative names for the gene or protein include CD340; HER-2; HER-2/neu; MLN 19; NEU; NGL; TKR1. The ERBB-2 gene is often referred to as HER2 (from human epidermal growth factor receptor 2). When ErbB-2 is referred to herein, this reference refers to human ErbB-2. Antibodies containing an ErbB-2-binding antigen-binding site bind to human ErbB-2. ErbB-2 antigen binding sites can also bind human and other mammalian xenologs due to sequence and tertiary structural similarities between such xenologs, but not necessarily so. The database access numbers of human ErbB-2 protein and its coding gene are (NP_001005862.1, NP_004439.2, NC_000017.10, NT_010783.15, NC_018928.2). The accession number is given primarily to provide a further means of identifying ErbB-2 as a target, the actual sequence of the ErbB-2 protein that binds the antibody may vary, for example due to mutations in the coding gene, such as occurs in some cancers or the like mutations in . ErbB-2 antigen binding sites bind ErbB-2 and its various variants, such as those expressed by some ErbB-2 positive tumor cells. The antigen binding site that binds ErbB-2 preferably binds to domain I of ErbB-2.

As used herein, the term "ErbB-3" refers to the protein encoded by the ERBB3 gene in humans. Alternative names for the gene or protein are HER3; LCCS2; MDA-BF-1; c-ErbB-3; c-ErbB3; ErbB3-S; When reference is made herein to ErbB-3, this reference refers to human ErbB-3. Antibodies containing an ErbB-3-binding antigen-binding site bind to human ErbB-3. ErbB-3 antigen binding sites can also bind human and other mammalian xenologs due to sequence and tertiary structural similarities between such xenologs, but not necessarily so. The database access numbers of human ErbB-3 protein and its coding gene are (NP_001005915.1, NP_001973.2, NC_000012.11, NC_018923.2, NT_029419.12). The accession number is given primarily to provide a further means of identifying ErbB-3 as a target, the actual sequence of the ErbB-3 protein to which the antibody binds may vary, for example due to mutations in the coding gene, such as occurs in some cancers or similar mutations in those. ErbB-3 antigen binding sites bind ErbB-3 and its various variants, such as those expressed by some ErbB-3 positive tumor cells. The antigen binding site that binds ErbB-3 preferably binds to domain III of ErbB-3.

When referring to ErbB-2 or ErbB-3 or alternative names thereof, the reference refers to human ErbB-2 or ErbB-3. The antibodies referred to herein bind to ErbB-2 or ErbB-3 and to many mutated ErbB-2 or ErbB-3 proteins as found in cancer.

Reference herein to any range of values for a SEQ ID NO expressly includes all individual SEQ ID NOs falling within the relevant range up to and including end values. Therefore, for the avoidance of doubt, if (for example) reference is made to SEQ ID NO: 17-23, it is intended to refer to and disclose SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23. terms

The following items describe exemplary embodiments. 1. A polynucleotide comprising: a VALB nucleic acid sequence or an allele variant of the VALB sequence fused with a NRG1 nucleic acid sequence or an allele variant of the NRG1 sequence. 2. The polynucleotide according to item 1, wherein the VAPB nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 17-23, or a pair comprising any one of SEQ ID NOs: 17-23 A gene variant or consists of it, and the NRG1 nucleic acid sequence comprises or consists of any one of SEQ ID NO: 125-138. 3. The polynucleotide according to item 1 or 2, wherein the VALB nucleic acid sequence (or its allele variant) is located at the 5' end of the NRG1 nucleic acid sequence (or its allele variant). 4. The polynucleotide according to any one of the preceding items, wherein the allele variant of the VAPB nucleic acid sequence is at least 85% identical to any one of SEQ ID NO: 17-23, preferably At least 90% identity, more preferably at least 95% sequence identity; and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, compared Preferably at least 90% identity, more preferably at least 95% sequence identity. 5. The polynucleotide of any one of the preceding items, wherein the fusion of the VALB nucleic acid and the NRG1 nucleic acid comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 3, preferably including positions 102 and Nucleic acid at 103 6. The polynucleotide according to any one of the preceding items, wherein the nucleic acid encoding the NRG1 protein sequence (or its allele variant) comprises or encodes an EGF-like domain of NRG1, preferably An EGF-like domain such as SEQ ID NO: 163. 7. A polynucleotide comprising: - a PVALB nucleic acid sequence or an allele variant of the PVALB sequence fused to a NRG1 nucleic acid sequence or an allele variant of the NRG1 sequence, or - an ASPH nucleic acid sequence or the allele variant An allele variant of an ASPH sequence fused to an NRG1 nucleic acid sequence or an allele variant of the NRG1 sequence, or - a DAAM1 nucleic acid sequence or an allele variant of the DAAM1 sequence fused to an NRG1 nucleic acid sequence or The allogenic variant fusion of the NRG1 sequence, or - a ZFAT nucleic acid sequence or the allogenic variant of the ZFAT sequence fused to a NRG1 nucleic acid sequence or the allogenic variant of the NRG1 sequence, or - a DACAML1 nucleic acid sequence Or the allogeneic variant of the DSCAML1 sequence fused to a NRG1 nucleic acid sequence or the allogeneic variant of the NRG1 sequence. 8. The polynucleotide according to item 7, wherein- the PVALB nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 439-444, or comprises any one of SEQ ID NOs: 439-444 An allele variant or consists of it, and the NRG1 nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 125-138; - the DAAM1 nucleic acid sequence comprises any one of SEQ ID NOs: 606-631 Or consist of, or comprise or consist of any allele variant of any one of SEQ ID NOs: 606-631, and the NRG1 nucleic acid sequence comprises any one of SEQ ID NOs: 125-138 or consist of it Composition; - the ZFAT nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 830-846, or comprises or consists of any allele variant of any one of SEQ ID NOs: 830-846, and The NRG1 nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 125-138; or - the DSCAML1 nucleic acid sequence comprises any one of SEQ ID NOs: 870-903 or consists of it, or comprises SEQ ID The allele variant of any one of NO: 870-903 or consists of it, and the NRG1 nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 125-138. 9. The polynucleotide according to item 7 or 8, wherein the PVALB, DAAM1, ZFAT or DSCAML1 nucleic acid sequence (or its allele variant) is located at the 5' end of the NRG1 nucleic acid sequence (or its allele variant). 10. The polynucleotide according to any one of clauses 7-9, wherein- the allele variant of the PVALB nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 439-444, compared to Preferably at least 90% identity, more preferably at least 95% sequence identity; and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138 , preferably at least 90% identity, more preferably at least 95% sequence identity; - the allele variant of the DAAM1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 606-631 Identity, preferably at least 90% identity, more preferably at least 95% sequence identity; and the allele variant of the NRG1 nucleic acid sequence has at least 85% of any one of SEQ ID NO: 125-138 % identity, preferably at least 90% identity, more preferably at least 95% sequence identity; - the allele variant of the ZFAT nucleic acid sequence has any one of them in SEQ ID NO: 830-846 At least 85% identity, preferably at least 90% identity, more preferably at least 95% sequence identity; and the allele variant of the NRG1 nucleic acid sequence is identical to any one of SEQ ID NO: 125-138 There is at least 85% identity, preferably at least 90% identity, more preferably at least 95% sequence identity; or- the allele variant of the DSCAML1 nucleic acid sequence is identical to that of SEQ ID NO: 870-903 Either one has at least 85% identity, preferably at least 90% identity, more preferably at least 95% sequence identity; and the allele variant of the NRG1 nucleic acid sequence is identical to SEQ ID NO: 125- Any of 138 have at least 85% identity, preferably at least 90% identity, more preferably at least 95% sequence identity. 11. The polynucleotide according to any one of clauses 7 to 10, wherein: - the fusion of the PVALB nucleic acid and the NRG1 nucleic acid comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 437, preferably including the nucleic acids at positions 102 and 103; - the fusion of the DAAM1 nucleic acid and the NRG1 nucleic acid comprises from 2 to about 40 contiguous nucleic acids from SEQ ID NO: 605, preferably including the nucleic acids at positions 75 and 76; - the The fusion of the ZFAT nucleic acid and the NRG1 nucleic acid comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 828, preferably including the nucleic acids at positions 75 and 76; or - the fusion of the DSCAML1 nucleic acid and the NRG1 nucleic acid comprises From 2 to about 40 contiguous nucleic acids from SEQ ID NO: 868, preferably including the nucleic acids at positions 75 and 76. 12. The polynucleotide according to any one of items 7 to 11, wherein the nucleic acid encoding the NRG1 protein sequence (or its allele variant) comprises or encodes the EGF-like domain of NRG1, preferably as SEQ EGF-like domain of ID NO: 163. 13. A polynucleotide comprising: - a part of exon 1 or an allogenic variant of exon 1 of VAPB fused to a part of exon 2 or an allogenic variant of exon 2 of NRG1 ; - CADM1 exon 7 or part of an allogenic variant of exon 7, and NRG1 exon 6 or part of an allogenic variant of exon 6; - CD44 exon 5 or part of an allogenic variant Part of the allele variant of exon 5, part of the allele variant of exon 2 or exon 2 of NRG1; - allele of exon 1 or exon 1 of transcript 6 of SLC3A2 Part of a variant, part of an allogenic variant with exon 5 or exon 5 of NRG1; - Part of an allogenic variant of exon 2 or exon 2 of VTCN1, part of an allogenic variant with exon 5 of NRG1 Exon 2 or part of an allele variant of exon 2; - part of an allele variant of exon 11 or exon 11 of CDH1, allele of exon 2 or exon 2 of NRG1 Part of a variant; - part of an allogenic variant of exon 1 or exon 1 of CXADR, part of an allogenic variant of exon 2 or exon 2 of NRG1; - exon 2 of GTF2E2 Exon 2 or part of an allele variant of exon 2, and part of an allele variant of NRG1 exon 2 or exon 2; - CSMD1 exon 23 or part of an allele of exon 23 Part of a variant, with NRG1 exon 6 or part of an allogenic variant of exon 6; - Part of a PTN exon 4 or part of an allogenic variant of exon 4, with NRG1 exon Exon 2 or part of an allele variant of exon 2; - ST14 exon 11 or part of an allele variant of exon 11, and NRG1 exon 6 or part of an allele variant of exon 6 part of a variant; - THBS1 exon 9 or part of an allogenic variant of exon 9, and NRG1 exon 6 or part of an allogenic variant of exon 6; - AGRN exon Exon 12 or part of an allele variant of exon 12, and NRG1 exon 6 or part of an allele variant of exon 6; - PVALB exon 4 or part of an allele variant of exon 4 Part of the variant, with NRG1 exon 6 or part of the allogenic variant of exon 6; - Transcript 3 exon 2 of SLC3A2 or part of the allogenic variant of exon 2, with NRG1 exon 6 or part of an allogenic variant of exon 6; - APP exon 14 or part of an allogenic variant of exon 14, and NRG1 exon 6 or part of an allogenic variant Part of an allogenic variant of exon 6; - WRN exon 33 or part of an allogenic variant of exon 33, and NRG1 exon 6 or part of an allogenic variant of exon 6; - DAAM1 exon 1 or part of an allogenic variant of exon 1, and NRG1 exon 1 or part of an allogenic variant of exon 1; - ASPH exon 22 or part of an allogenic variant Part of an allogenic variant of 22, with NRG1 exon 2 or part of an allogenic variant of exon 2; - NOTCH2 exon 6 or part of an allogenic variant of exon 6, with NRG1 exon 6 or part of an allogenic variant of exon 6; - part of an allogenic variant of CD74 exon 2 or exon 2, and NRG1 exon 2 or part of an allogenic variant part of an allogenic variant of exon 2 of SDC4; part of an allogenic variant of exon 2 or exon 2 of SDC4, and part of an allogenic variant of exon 2 or exon 2 of NRG1;- CD44 exon 5 or part of an allogenic variant of exon 5, and NRG1 exon 6 or part of an allogenic variant of exon 6; - SLC4A4 exon 14 or part of an allogenic variant Part of an allogenic variant of 14, and part of an allogenic variant of exon 6 or exon 6 of NRG1; - part of an allogenic variant of exon 4 or exon 4 of SDC4, and NRG1 exon 2 or part of an allogenic variant of exon 2; - ZFAT exon 12 or part of an allogenic variant of exon 12, with NRG1 exon 6 or part of an allogenic variant part of an allogenic variant of exon 6; or - part of an allogenic variant of exon 3 or exon 3 of DSCAML1 and part of an allogenic variant of exon 2 or exon 2 of NRG1. 14. The polynucleotide as in item 13, wherein exon 1 of VAPB is exon of SEQ ID NO: 17; exon 7 of CADM1 is exon of SEQ ID NO: 39; exon of CD44 Son 5 is the exon of SEQ ID NO: 65; SLC3A2 exon 1 is the exon of SEQ ID NO: 103; VTCN1 exon 2 is the exon of SEQ ID NO: 169; CDH1 Exon 11 is the exon of SEQ ID NO: 198; exon 1 of CXADR is the exon of SEQ ID NO: 219; exon 2 of GTF2E2 is the exon of SEQ ID NO: 236; the exon of CSMD1 Exon 23 is the exon of SEQ ID NO: 279; PTN exon 4 is the exon of SEQ ID NO: 318; ST14 exon 11 is the exon of SEQ ID NO: 342; THBS1 Exon 9 is the exon of SEQ ID NO: 386; AGRN exon 12 is the exon of SEQ ID NO: 416; PVALB exon 4 is the exon of SEQ ID NO: 442; SLC3A2 exon 2 is the exon of SEQ ID NO: 457; APP exon 14 is the exon of SEQ ID NO: 501; WRN exon 33 is the exon of SEQ ID NO: 562 ; DAAM1 exon 1 is the exon of SEQ ID NO: 606; ASPH exon 22 is the exon of SEQ ID NO: 658; NOTCH2 exon 6 is the exon of SEQ ID NO: 700 CD74 exon 2 is SEQ ID NO: 720 exon; SDC4 exon 2 is SEQ ID NO: 746 exon; CD44 exon 5 is SEQ ID NO: 65 outside Exon; SLC4A4 exon 14 is the exon of SEQ ID NO: 780; SDC4 exon 4 is the exon of SEQ ID NO: 748; ZFAT exon 12 is the exon of SEQ ID NO: 841 exons; DSCAML1 exon 3 is the exon of SEQ ID NO: 872, and NRG1 exons 1, 2, 5 and 6 are the exons of SEQ ID NO: 125, 126, 129 and 130, respectively son. 15. The polynucleotide according to any one of clauses 13 or 14, wherein: - the VAPB exon 1 or allogenic variant thereof is partly located in the NRG1 exon 2 or allogenic variant thereof The 5' end of the portion; - the CADM1 exon 7 or its allele variant portion is located at the 5' end of the NRG1 exon 6 or its allele variant portion; - the CD44 exon 5 or its allelic variant part is located at the 5' end of the NRG1 exon 2 or its allelic variant part; - the SLC3A2 exon 1 or its allelic variant part is located at the NRG1 exon The 5' end of exon 5 or its allele variant part; - the VTCN1 exon 2 or its allele variant part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - the CDH1 exon 11 or its allogenic variant part is located at the 5' end of the NRG1 exon 2 or its allogenic variant part; - the CXADR exon 1 or its allogenic variant part The part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - The GTF2E2 exon 2 or its allele variant part is located at the NRG1 exon 2 or its allele The 5' end of the variant part; - the CSMD1 exon 23 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allegene variant part; - the PTN exon Exon 4 or its allogenic variant part is located at the 5' end of the NRG1 exon 2 or its allogenic variant part; - the ST14 exon 11 or its allogenic variant part is located at the NRG1 5' of exon 6 or its allogenic variant part; - the THBS1 exon 9 or its allogenic variant part is located 5' of the NRG1 exon 6 or its allogenic variant part - the AGRN exon 12 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - the PVALB exon 4 or its allele The variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - the SCL3A2 exon 2 or its allele variant part is located at the NRG1 exon 6 or its the 5' end of the allogenic variant part; - the APP exon 14 or the allogenic variant part thereof is located at the 5' end of the NRG1 exon 6 or the allogenic variant part of exon 6; - the WRN exon 33 or its allogenic variant part is located at the 5' end of the NRG1 exon 6 or the allogenic variant part of exon 6; - the DAAM1 exon 1 or its The allogenic variant part is located at the 5' end of the NRG1 exon 1 or the allogenic variant part of exon 1; - the ASPH exon 22 or its allogenic variant part is located at the NRG1 Exon 2 or the 5' end of the allele variant part of exon 2; - the NOTCH2 exon 6 or the allele variant part is located at the NRG1 exon 6 or exon 6 the 5' end of the allogenic variant part; - the CD74 exon 2 or allogenic variant part thereof is located at the 5' end of the NRG1 exon 2 or the allogenic variant part of exon 2; - the SDC4 exon 2 or its allogenic variant part is located at the 5' end of the NRG1 exon 2 or exon 2 allogenic variant part; - the CD44 exon 5 or its allogenic variant part The allogenic variant part is located at the 5' end of exon 6 of the NRG1 or the allogenic variant part of exon 6; - the SLC4A4 exon 14 or its allogenic variant part is located at the NRG1 Exon 6 or the 5' end of the allele variant part of exon 6; - the SDC4 exon 4 or the allele variant part is located at the NRG1 exon 2 or exon 2 the 5' end of the allogenic variant part; - the ZFAT exon 12 or its allogenic variant part is located at the 5' end of the NRG1 exon 6 or the allogenic variant part of exon 6; and - the DSCAML1 exon 3 or allogenic variant portion thereof is located 5' to the NRG1 exon 2 or exon 2 allele variant portion. 16. The polynucleotide according to any one of clauses 13 to 15, wherein: - the allele variant of exon 1 of VAPB has at least 85% identity to SEQ ID NO: 17, preferably There is at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of CADM1 exon 7 has at least 85% identity to SEQ ID NO: 39, preferably There is at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 5 of CD44 has at least 85% identity with SEQ ID NO: 65, compared with Preferably at least 90% identity, more preferably at least 95% identity, or preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the SLC3A2 The allele variant of exon 1 has at least 85% identity to SEQ ID NO: 103, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - VTCN1 The allele variant of exon 2 has at least 85% identity to SEQ ID NO: 169, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the The allele variant of CDH1 exon 11 has at least 85% identity to SEQ ID NO: 198, preferably at least 90%, 92%, 94%, 96% or even 98% identity;- The allele variant of exon 2 of NRG1 is at least 85% identical to SEQ ID NO: 126, preferably at least 90%, 92%, 94%, 96% or even 98% identical; - the allele variant of exon 5 of NRG1 is at least 85% identical to SEQ ID NO: 129, preferably at least 90%, 92%, 94%, 96% or even 98% identical - the allele variant of exon 6 of NRG1 is at least 85% identical to SEQ ID NO: 130, preferably at least 90%, 92%, 94%, 96% or even 98% identical - the CXADR exon 1 allele variant has at least 85% identity to SEQ ID NO: 219, preferably at least 90%, 92%, 94%, 96% or even 98% identity Identity; - the allele variant of exon 2 of GTF2E2 has at least 85% identity to SEQ ID NO: 236, preferably at least 90%, 92%, 94%, 96% or even 98% - the allele variant of exon 23 of CSMD1 has at least 85% identity to SEQ ID NO: 279, preferably at least 90%, 92%, 94%, 96% or even 98% % identity; - the PTN exon 4 allele variant has at least 85% identity to SEQ ID NO: 318, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the ST14 exon 11 allele variant has at least 85% identity to SEQ ID NO: 342, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 9 of THBS1 has at least 85% identity to SEQ ID NO: 386, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 12 of AGRN has at least 85% identity to SEQ ID NO: 416, preferably at least 90%, 92%, 94%, 96% % or even 98% identity; - the allele variant of exon 4 of PVALB has at least 85% identity to SEQ ID NO: 442, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 2 of SCL3A2 has at least 85% identity, preferably at least 90%, 92%, 94% identity to SEQ ID NO: 457 , 96% or even 98% identity; - the APP exon 14 allele variant has at least 85% identity to SEQ ID NO: 501, preferably at least 90%, 92%, 94% %, 96% or even 98% identity; - the allele variant of exon 33 of the WRN has at least 85% identity to SEQ ID NO: 562, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 1 of DAAM1 has at least 85% identity, preferably at least 90%, 92% identity to SEQ ID NO: 606 , 94%, 96% or even 98% identity; - the allele variant of exon 1 of NRG1 has at least 85% identity, preferably at least 90%, 92% identity to SEQ ID NO: 125 %, 94%, 96% or even 98% identity; - the ASPH exon 22 allele variant has at least 85% identity to SEQ ID NO: 658, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 6 of NOTCH2 has at least 85% identity, preferably at least 90% identity to SEQ ID NO: 700 , 92%, 94%, 96% or even 98% identity; - the CD74 exon 2 allele variant has at least 85% identity to SEQ ID NO: 720, preferably at least 90% identity %, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 2 of SDC4 has at least 85% identity to SEQ ID NO: 746, preferably at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 5 of CD44 has at least 85% identity to SEQ ID NO: 65, preferably has At least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 14 of SLC4A4 has at least 85% identity to SEQ ID NO: 780, preferably There is at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 4 of SDC4 has at least 85% identity to SEQ ID NO: 748, preferably There is at least 90%, 92%, 94%, 96% or even 98% identity; - the allele variant of exon 12 of the ZFAT has at least 85% identity with SEQ ID NO: 841, compared with Preferably at least 90%, 92%, 94%, 96% or even 98% identity; and - the allele variant of exon 3 of DSCAML1 has at least 85% identity to SEQ ID NO: 872 , preferably at least 90%, 92%, 94%, 96% or even 98% concordance. 17. The polynucleotide according to any one of clauses 13 to 16, wherein: - the fusion of VAPB and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 3, including positions 43 and 44 -the fusion of CADM1 and NRG1 comprises from 2 to about 40 contiguous nucleic acids of SEQ ID NO: 7, including the nucleic acids at positions 53 and 54; -the fusion of CD44 and NRG1 comprises from SEQ ID NO: 2 to about 40 contiguous nucleic acids of 11, including those at positions 52 and 53; - the fusion of SLC3A2 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 15, including those at positions 53 and 54 Nucleic acid; - the fusion of VTCN1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 166, including nucleic acids at positions 65 and 66; - the fusion of CDH1 and NRG1 comprises nucleic acids from SEQ ID NO: 186 2 to about 40 contiguous nucleic acids, including nucleic acids at positions 119 and 120; - the fusion of CXADR and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 217, including nucleic acids at positions 43 and 44 - the fusion of GTF2E2 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 233, including the nucleic acids at positions 141 and 142; - the fusion of CSMD1 and NRG1 comprises nucleic acids from SEQ ID NO: 255 2 to about 40 contiguous nucleic acids, including the nucleic acids at positions 88 and 89; - the fusion of PTN and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 313, including the nucleic acids at positions 102 and 103; - the fusion of ST14 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 330, including the nucleic acids at positions 95 and 96; - the fusion of THBS1 and NRG1 comprises 2 nucleic acids from SEQ ID NO: 376 to about 40 contiguous nucleic acids, including nucleic acids at positions 56 and 57; - the fusion of AGRN and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 403, including nucleic acids at positions 106 and 107; - The fusion of PVALB and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 437, including the nucleic acids at positions 102 and 103; - the fusion of SLC3A2 and NRG1 comprises 2 to about 40 consecutive nucleic acids from SEQ ID NO: 454 About 40 contiguous nucleic acids, including nucleic acids at positions 93 and 94; - the fusion of APP and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 486, including nucleic acids at positions 54 and 55; - the The fusion of WRN and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 528, including the nucleic acids at positions 96 and 97; - the fusion of DAAM1 and NRG1 comprises 2 to about 40 consecutive nucleic acids from SEQ ID NO: 605 40 contiguous nucleic acids, including those at positions 75 and 76; - the fusion of ASPH and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 635, including those at positions 75 and 76; - the NOTCH2 The fusion with NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 693, including the nucleic acids at positions 75 and 76; - the fusion of CD74 and NRG1 comprises 2 to about 40 consecutive nucleic acids from SEQ ID NO: 717 contiguous nucleic acids, including nucleic acids at positions 75 and 76; - the fusion of SDC4 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 743, including nucleic acids at positions 75 and 76; - the CD44 and The fusion of NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 761, including the nucleic acids at positions 75 and 76; - the fusion of SLC4A4 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 765 Contiguous nucleic acids, including nucleic acids at positions 75 and 76; - the fusion of SDC4 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 824, including nucleic acids at positions 75 and 76; - the ZFAT and NRG1 The fusion comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 828, including nucleic acids at positions 75 and 76; and - the fusion of DSCAML1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 868 Contiguous nucleic acids, including nucleic acids at positions 75 and 76. 18. The polynucleotide according to any one of clauses 13 to 17, wherein: - the fusion of VAPB and NRG1 comprises SEQ ID NO: 3 or an allele variant thereof; - the fusion of CAD1 and NRG1 comprises SEQ ID NO: 7 or its allogeneic variant; - the fusion of CD44 and NRG1 comprising SEQ ID NO: 11 or its allogeneic variant; - the SLC3A2 and NRG1 fusion comprising SEQ ID NO: 15 or its allegiance a genetic variant; - the fusion of VTCN1 and NRG1 comprising SEQ ID NO: 166 or an allogenic variant thereof; - the fusion of CDH1 and NRG1 comprising SEQ ID NO: 186 or an allogenic variant thereof; - the CXADR and The fusion of NRG1 comprises SEQ ID NO: 217 or its allogeneic variant; - the fusion of GTF2E2 and NRG1 comprises SEQ ID NO: 233 or its allogeneic variant; - the fusion of CSMD1 and NRG1 comprises SEQ ID NO : 255 or its allogeneic variant; - the fusion of PTN and NRG1 comprising SEQ ID NO: 313 or its allogeneic variant; - the ST14 and NRG1 fusion comprising SEQ ID NO: 330 or its allogeneic variant - the fusion of THBS1 and NRG1 comprising SEQ ID NO: 376 or an allogeneic variant thereof; - the fusion of AGRN and NRG1 comprising SEQ ID NO: 403 or an allogeneic variant thereof; - the fusion of PVALB and NRG1 - the fusion of SLC3A2 and NRG1 comprises SEQ ID NO: 454 or an allogenic variant thereof; - the fusion of APP and NRG1 comprises SEQ ID NO: 486 or an allele variant thereof; - the fusion of WRN and NRG1 comprising SEQ ID NO: 528 or an allele variant thereof; - the fusion of DAAM1 and NRG1 comprising SEQ ID NO: 605 or an allele variant thereof; - the The fusion of ASPH and NRG1 comprises SEQ ID NO: 635 or its allogeneic variant; - the fusion of NOTCH2 and NRG1 comprises SEQ ID NO: 693 or its allogeneic variant; - the fusion of CD74 and NRG1 comprises SEQ ID NO: 693 or its allogeneic variant; ID NO: 717 or its allogeneic variant; - the fusion of SDC4 and NRG1 comprising SEQ ID NO: 743 or its allogeneic variant; - the CD44 and NRG1 fusion comprising SEQ ID NO: 761 or its allogene Variant; - the fusion of SLC4A4 and NRG1 comprises SEQ ID NO: 765 or an allogenic variant thereof; - the fusion of SDC4 and NRG1 comprises SEQ ID NO: 824 or an allogenic variant thereof; - the ZFAT and NRG1 the fusion of which comprises SEQ ID NO: 828 or an allogeneic variant thereof; and - the fusion of DSCAML1 and NRG1 comprises SEQ ID NO: 868 or an allogeneic variant thereof. 19. The polynucleotide according to any one of clauses 13 to 18, wherein: - the VAPB exon 1 portion is or comprises SEQ ID NO: 1 or an allele variant of SEQ ID NO: 1; - The CADM1 exon 7 portion is or comprises SEQ ID NO: 5 or an allele variant of SEQ ID NO: 5; - the CD44 exon 5 portion is or comprises SEQ ID NO: 9 or SEQ ID NO: The allele variant of 9; - the SLC3A2 exon 1 portion is or comprises SEQ ID NO: 13 or the allele variant of SEQ ID NO: 13; - the VTCN1 exon 2 portion is or comprises SEQ ID NO: 164 or the allele variant of SEQ ID NO: 164; - the CDH1 exon 11 portion is or comprises SEQ ID NO: 184 or the allele variant of SEQ ID NO: 184; - the CXADR exon the exon 1 portion is or comprises SEQ ID NO: 219 or an allele variant of SEQ ID NO: 219; - the GTF2E2 exon 2 portion is or comprises SEQ ID NO: 236 or an allele variant of SEQ ID NO: 236 - the CXADR exon 23 part is or comprises SEQ ID NO: 279 or an allele variant of SEQ ID NO: 279; - the PTN exon 4 part is or comprises SEQ ID NO: 318 or SEQ ID NO: 279 an allele variant of ID NO: 318; - the ST14 exon 11 portion is or comprises SEQ ID NO: 342 or an allele variant of SEQ ID NO: 342; - the THBS1 exon 9 portion is or an allele variant comprising SEQ ID NO: 385 or SEQ ID NO: 386; - the AGRN exon 12 portion is or comprises an allele variant of SEQ ID NO: 416 or SEQ ID NO: 416; - the PVALB the part of exon 4 is or comprises SEQ ID NO: 442 or an allele variant of SEQ ID NO: 442; - the part of exon 2 of SLC3A2 is or comprises SEQ ID NO: 457 or an allele variant of SEQ ID NO: 457 an allele variant; - the part of exon 2 of NRG1 is or comprises SEQ ID NO: 165 or an allele variant of SEQ ID NO: 165; - the part of exon 5 of NRG1 is or comprises SEQ ID NO: 14 or an allele variant of SEQ ID NO: 14; - the NRG1 exon 6 portion is or comprises SEQ ID NO: 6 or an allele variant thereof; - the APP exon 14 portion is or comprises SEQ ID NO: 484 or an allele variant thereof; - the WRN exon 33 portion is or comprises SEQ ID NO: 526 or an allele variant thereof; - the DAAM1 exon 1 portion is or comprises SEQ ID NO : 603 or an allogenic variant thereof; - the ASPH exon 22 portion is or comprises SEQ ID NO: 633 or an allele variant thereof; - the NOTCH2 exon 6 portion is or comprises SEQ ID NO: 691 or an allogenic variant thereof; - the CD74 exon 2 portion is or comprises SEQ ID NO: 715 or an allele variant thereof; - the SDC4 exon 2 portion is or comprises SEQ ID NO: 741 or an allogenic variant thereof; an allele variant; - the CD44 exon 5 portion is or comprises SEQ ID NO: 759 or an allele variant thereof; - the SLC4A4 exon 14 portion is or comprises SEQ ID NO: 763 or an allele variant thereof Variant; - the SDC4 exon 4 portion is or comprises SEQ ID NO: 822 or an allele variant thereof; - the ZFAT exon 12 portion is or comprises SEQ ID NO: 826 or an allele variant thereof ; - the portion of exon 3 of DSCAML1 is or comprises SEQ ID NO: 866 or an allegenic variant thereof; and - the portion of exon 1 of NRG1 is or comprises SEQ ID NO: 604 or an allegenic variant thereof. 20. The polynucleotide according to any one of clauses 13 to 18, wherein: - the fusion of VAPB and NRG1 comprises a fusion junction between exon 1 of VAPB and exon 2 of NRG1, compared to Preferably the junction between the nucleic acid at position 43 of VAPB of SEQ ID NO: 3 and the nucleic acid at position 44 of NRG1; - the fusion of CADM1 and NRG1 comprises a junction between exon 7 of CADM1 and exon 6 of NRG1 A fusion junction, preferably the junction between the nucleic acid at position 53 of CADM1 of SEQ ID NO: 7 and the nucleic acid at position 54 of NRG1; - the fusion of CD44 and NRG1 comprises a CD44 exon 5 and NRG1 exon The fusion junction between exon 2, preferably the junction between the nucleic acid at position 52 of CD44 of SEQ ID NO: 11 and the nucleic acid at position 53 of NRG1; The fusion junction with exon 5 of NRG1, preferably the junction between the nucleic acid at position 53 of SLC3A2 of SEQ ID NO: 15 and the nucleic acid at position 54 of NRG1; - the fusion of VTCN1 and NRG1 comprises a VTCN1 The fusion junction between exon 2 and NRG1 exon 2, preferably the junction between the nucleic acid at position 65 of VTCN1 of SEQ ID NO: 166 and the nucleic acid at position 66 of NRG1; - between CDH1 and NRG1 The fusion comprises a fusion junction between CDH1 exon 11 and NRG1 exon 2, preferably the junction between the nucleic acid at CDH1 position 119 of SEQ ID NO: 186 and the nucleic acid at NRG1 position 120; - the fusion of CXADR and NRG1 comprises a fusion junction between exon 1 of CXADR and exon 2 of NRG1, preferably between the nucleic acid at position 43 of CXADR of SEQ ID NO: 217 and the nucleic acid at position 44 of NRG1 - the fusion of GTF2E2 and NRG1 comprises a fusion junction between exon 2 of GTF2E2 and exon 2 of NRG1, preferably the nucleic acid at position 141 of GTF2E2 of SEQ ID NO: 233 and NRG1 The junction between the nucleic acid at position 142; - the fusion of CSMD1 and NRG1 comprises a fusion junction between CSMD1 exon 23 and NRG1 exon 6, preferably the CSMD1 position of SEQ ID NO: 255 The junction between the nucleic acid at 88 and the nucleic acid at position 89 of NRG1; - the fusion of PTN and NRG1 comprises a fusion junction between PTN exon 4 and NRG1 exon 2, preferably SEQ ID NO : the junction between the nucleic acid at PTN position 102 of 313 and the nucleic acid at position 103 of NRG1; - the fusion of ST14 and NRG1 comprises a fusion junction between ST14 exon 11 and NRG1 exon 6, compared Preferably the junction between the nucleic acid at position 95 of ST14 of SEQ ID NO: 330 and the nucleic acid at position 96 of NRG1; - the fusion of THBS1 and NRG1 comprises a junction between exon 9 of THBS1 and exon 6 of NRG1 The fusion junction, preferably the junction between the nucleic acid at position 56 of THBS1 of SEQ ID NO: 376 and the nucleic acid at position 57 of NRG1; - the fusion of AGRN and NRG1 comprises an exon 12 of AGRN and an exon of NRG1 The fusion junction between exon 6, preferably the junction between the nucleic acid at AGRN position 106 of SEQ ID NO: 403 and the nucleic acid at position 107 of NRG1; - the fusion of PVALB and NRG1 comprises a PVALB exon 4 The fusion junction with exon 6 of NRG1, preferably the junction between the nucleic acid at PVALB position 102 of SEQ ID NO: 437 and the nucleic acid at position 103 of NRG1; The fusion junction between exon 2 and exon 6 of NRG1, preferably the junction between the nucleic acid at position 93 of SLC3A2 of SEQ ID NO: 454 and the nucleic acid at position 94 of NRG1; - between APP and NRG1 The fusion comprises a fusion junction between APP exon 14 and NRG1 exon 6, preferably the junction between the nucleic acid at APP position 54 of SEQ ID NO: 486 and the nucleic acid at NRG1 position 55; - the fusion of WRN and NRG1 comprises a fusion junction between WRN exon 33 and NRG1 exon 6, preferably between the nucleic acid at WRN position 96 of SEQ ID NO: 528 and the nucleic acid at position 97 of NRG1 - the fusion of DAAM1 and NRG1 comprises a fusion junction between exon 1 of DAAM1 and exon 1 of NRG1, preferably nucleic acid 75 at the DAAM1 position of SEQ ID NO: 605 and NRG1 The junction between nucleic acid 76 at position; - the fusion of ASPH and NRG1 comprises a fusion junction between exon 22 of ASPH and exon 2 of NRG1, preferably the ASPH position of SEQ ID NO: 635 The junction between the nucleic acid at 75 and the nucleic acid at position 76 of NRG1; - the fusion of NOTCH2 and NRG1 comprises a fusion junction between NOTCH2 exon 6 and NRG1 exon 6, preferably SEQ ID NO : the junction between the nucleic acid at position 75 of NOTCH2 of 693 and the nucleic acid at position 76 of NRG1; - the fusion of CD74 and NRG1 comprises a fusion junction between exon 2 of CD74 and exon 2 of NRG1 Preferably the junction between the nucleic acid at position 75 of CD74 of SEQ ID NO: 717 and the nucleic acid at position 76 of NRG1; A fusion junction, preferably the junction between the nucleic acid at position 75 of SDC4 of SEQ ID NO: 743 and the nucleic acid at position 76 of NRG1; - the fusion of CD44 and NRG1 comprises a CD44 exon 5 and NRG1 exon The fusion junction between sub6, preferably the junction between the nucleic acid of VAPB position 75 of SEQ ID NO: 761 and the nucleic acid of NRG1 position 76; The fusion junction with exon 6 of NRG1, preferably the junction between the nucleic acid at position 75 of SLC4A4 of SEQ ID NO: 765 and the nucleic acid at position 76 of NRG1; - the fusion of SDC4 and NRG1 comprises a junction in SDC4 The fusion junction between exon 4 and NRG1 exon 2, preferably the junction between the nucleic acid at position 75 of SDC4 of SEQ ID NO: 824 and the nucleic acid at position 76 of NRG1; - between ZFAT and NRG1 The fusion comprises a fusion junction between ZFAT exon 12 and NRG1 exon 6, preferably the junction between the nucleic acid at ZFAT position 75 of SEQ ID NO: 828 and the nucleic acid at position 76 of NRG1; and - the fusion of DSCAML1 and NRG1 comprises a fusion junction between exon 3 of DSCAML1 and exon 2 of NRG1, preferably the nucleic acid at position 75 of DSCAML1 of SEQ ID NO: 868 and the nucleic acid at position 76 of NRG1 the junction between. 21. The polynucleotide according to any one of the preceding items, wherein the polynucleotide is isolated or purified. 22. The polynucleotide of any one of the preceding items, wherein any one of the fusions is an in-frame fusion. 23. The polynucleotide according to any one of the preceding items, wherein the polynucleotide is a mammalian polynucleotide, preferably a human polynucleotide. 24. A polypeptide fusion encoded by the polynucleotide of any one of the preceding items. 25. A vector comprising the polynucleotide according to any one of items 1 to 23. 26. A recombinant host cell comprising the polynucleotide according to any one of items 1 to 23 or the vector according to item 25. 27. A method for producing a polypeptide fusion as in item 24, comprising maintaining the host cell as in item 26 under conditions suitable for the expression of a polynucleotide contained in the host cell, thereby expressing the polynucleotide and producing a The polypeptide fusion, which is subsequently isolated or purified. 28. A method for producing a recombinant host cell, comprising introducing the vector according to item 25 into a host cell. 29. A detection assay comprising a nucleic acid probe, a primer or a pair of primers for detecting the presence of a polynucleotide fusion according to any one of items 1 to 23. 30. A nucleic acid probe, primer or primer pair for detecting the polynucleotide fusion of any one of items 1 to 23. 31. The nucleic acid probe, primer or primer pair according to item 30, which is 10 to 40 nucleotides in length. 32. The nucleic acid probe, primer or primer pair according to item 30 or 31, wherein the detected fusion comprises: - a fusion of VAPB and NRG1 comprising or consisting of SEQ ID NO: 3, and preferably Preferably comprising the nucleic acid at position 43 or 44; - a fusion of CADM1 and NRG1 comprising or consisting of SEQ ID NO: 7, and preferably comprising a nucleic acid at position 53 or 54; - a fusion of CD44 and NRG1 comprising A nucleic acid having or consisting of SEQ ID NO: 11, and preferably comprising position 52 or 53; - a fusion of SLC3A2 and NRG1, comprising or consisting of SEQ ID NO: 15, and preferably comprising position 53 or the nucleic acid of 54; - the fusion of VTCN1 and NRG1, comprising or consisting of SEQ ID NO: 166, and preferably comprising the nucleic acid of position 65 or 66; - the fusion of CDH1 and NRG1, comprising SEQ ID NO : 186 or consisting of it, and preferably comprising the nucleic acid of position 119 or 120; - a fusion of CXADR and NRG1 comprising or consisting of SEQ ID NO: 217, and preferably comprising the nucleic acid of position 43 or 44 - a fusion of GTF2E2 and NRG1 comprising or consisting of SEQ ID NO: 233, and preferably comprising the nucleic acid at position 141 or 142; - a fusion of CSMD1 and NRG1 comprising SEQ ID NO: 255 or consisting of It consists of, and preferably includes the nucleic acid at position 88 or 89; - a fusion of PTN and NRG1, comprising or consisting of SEQ ID NO: 313, and preferably including the nucleic acid at position 102 or 103; - ST14 and A fusion of NRG1 comprising or consisting of SEQ ID NO: 330, and preferably comprising the nucleic acid at position 95 or 96; - a fusion of THBS1 and NRG1 comprising or consisting of SEQ ID NO: 376, and Preferably comprising the nucleic acid at position 56 or 57; - a fusion of AGRN and NRG1 comprising or consisting of SEQ ID NO: 403, and preferably comprising the nucleic acid at position 106 or 107; - a fusion of PVALB and NRG1 , comprising or consisting of SEQ ID NO: 437, and preferably comprising the nucleic acid at position 102 or 103; - a fusion of SLC3A2 and NRG1, comprising or consisting of SEQ ID NO: 454, and preferably comprising The nucleic acid at position 93 or 94; - a fusion of APP and NRG1 comprising or consisting of SEQ ID NO: 486, and preferably comprising the nucleic acid at position 54 or 55; - a fusion of WRN and NRG1 comprising SEQ ID NO: 486 or consisting of ID NO: 528, and preferably comprising a nucleic acid at position 96 or 97; - a fusion of DAAM1 and NRG1 comprising or consisting of SEQ ID NO: 605, and preferably comprising position 75 or 76 -A fusion of ASPH and NRG1 comprising or consisting of SEQ ID NO: 635, and preferably comprising the nucleic acid at position 75 or 76; -A fusion of NOTCH2 and NRG1 comprising SEQ ID NO: 693 or consisting of, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of CD74 and NRG1 comprising or consisting of SEQ ID NO: 717, and preferably comprising the nucleic acid at position 75 or 76; - A fusion of SDC4 and NRG1 comprising or consisting of SEQ ID NO: 743, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of CD44 and NRG1 comprising or consisting of SEQ ID NO: 761 , and preferably comprising the nucleic acid at position 75 or 76; - a fusion of SLC4A4 and NRG1 comprising or consisting of SEQ ID NO: 765, and preferably comprising the nucleic acid at position 75 or 76; - SDC4 and NRG1 A fusion comprising or consisting of SEQ ID NO: 824, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of ZFAT and NRG1 comprising or consisting of SEQ ID NO: 828, and preferably preferably comprising the nucleic acid at position 75 or 76; and - a fusion of DSCAML1 and NRG1 comprising or consisting of SEQ ID NO: 868, and preferably comprising the nucleic acid at position 75 or 76. 33. The nucleic acid probe, primer or primer pair according to any one of clauses 30 to 32, wherein: - the probe, primer or primer pair used to detect the fusion of VAPB and NRG1 is specifically compatible with a A sequence consisting of exon 1 or a sequence located 5' of exon 1 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 2 of NRG1 or located 3' of exon 2 The sequence hybridizes, or has 95% or more complementary sequence identity to these sequences; - The probe, primer or primer pair used to detect the fusion of CADM1 and NRG1 is specifically related to a CADM1 expression A sequence consisting of exon 7 or a sequence located 5' of exon 7 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 6 of NRG1 or a sequence located 3' of exon 6 sequence hybridization, or has 95% or higher complementary sequence identity to such sequences; - the probe, primer or primer pair used to detect the fusion of CD44 and NRG1 is specific for a CD44 exon A sequence consisting of exon 5 or a sequence located 5' to exon 5 hybridizes, and/or specifically to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2 hybridize, or have 95% or greater complementary sequence identity to such sequences; - the probe, primer or primer pair for detecting the fusion of transcript 6 of SLC3A2 with NRG1 is specifically compatible with a sequence produced by SLC3A2 A sequence consisting of exon 1 or a sequence located 5' of exon 1 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 5 of NRG1 or located 3' of exon 5 The sequence hybridizes thereto, or has 95% or higher complementary sequence identity with such sequences; - The probe, primer or primer pair used to detect the fusion of VTCN1 and NRG1 is specifically compatible with a VTCN1 fusion A sequence consisting of exon 2 or a sequence located 5' of exon 2 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 2 of NRG1 or located 3' of exon 2 or have 95% or greater complementary sequence identity to such sequences; - the probe, primer or primer pair used to detect the fusion of CDH1 and NRG1 is specific for a CDH1-expressed A sequence consisting of exon 11 or a sequence located at 5' of exon 11 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 2 of NRG1 or located at 3' of exon 2 sequence hybridization, or has 95% or higher complementary sequence identity with such sequences; - the probe, primer or primer pair used to detect the fusion of CXADR and NRG1 is specific to a CXADR exon 1, or a sequence located 5' to exon 1, and/or specifically hybridizes to a sequence consisting of NRG1 exon 2, or a sequence located 3' to exon 2 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - the probe, primer or primer pair used to detect the fusion of GTF2E2 and NRG1 is specific to a GTF2E2 exon 2 A sequence consisting of or located 5' to exon 2 hybridizes, and/or specifically hybridizes to a sequence consisting of NRG1 exon 2 or a sequence located 3' to exon 2 , or have 95% or greater complementary sequence identity to such sequences; - the probe, primer or primer pair for detecting the fusion of CSMD1 and NRG1 is specific to a CSMD1 exon 23 A sequence consisting of or a sequence located 5' to exon 23 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or a complementary sequence identity of 95% or greater to such sequences; - the probe, primer or primer pair for detecting the fusion of PTN and NRG1 is specifically bound to a PTN exon 4 or a sequence located 5' to exon 4, and/or specifically hybridizes to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or greater complementary sequence identity to the sequences; - the probe, primer or primer pair used to detect the fusion of ST14 and NRG1 is specific to a sequence consisting of exon 11 of ST14 sequence or a sequence located 5' to exon 11, and/or specifically hybridizes to a sequence consisting of NRG1 exon 6 or a sequence located 3' to exon 6, or Complementary sequence identity of 95% or higher to the sequences; - The probe, primer or primer pair for detecting the fusion of THBS1 and NRG1 is specific to a sequence consisting of exon 9 of THBS1 or a sequence at the 5' of exon 9 hybridizes, and/or specifically hybridizes with a sequence consisting of exon 6 of NRG1 or at a sequence at 3' of exon 6, or with The sequences have 95% or higher complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of AGRN and NRG1 is specific to a sequence consisting of exon 12 of AGRN or A sequence located 5' of exon 12 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 6 of NRG1 or to a sequence located 3' of exon 6, or to the The same sequence has 95% or higher complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of PVALB and NRG1 is specific to a sequence consisting of exon 4 of PVALB or located in The sequence at the 5' of exon 4 hybridizes, and/or specifically hybridizes with a sequence consisting of exon 6 of NRG1 or at the 3' of exon 6, or with such The sequence has 95% or higher complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of the transcript 3 of SLC3A2 and NRG1 is specific to an exon 2 composed of SLC3A2 sequence or a sequence located 5' to exon 2, and/or specifically hybridizes to a sequence consisting of NRG1 exon 6 or a sequence located 3' to exon 6, or Complementary sequence identity of 95% or higher to the sequences; - the probe, primer or primer pair used to detect the fusion of APP and NRG1 is specific to a sequence consisting of exon 14 of APP or a sequence located 5' to exon 14, and/or specifically hybridizes to a sequence consisting of exon 6 of NRG1 or to a sequence located 3' to exon 6, or to The sequences have 95% or higher complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of WRN and NRG1 is specific to a sequence consisting of exon 33 of WRN or A sequence located 5' to exon 33 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 6 of NRG1 or to a sequence located 3' to exon 6, or to the The sequence has 95% or higher complementary sequence identity; - The probe, primer or primer pair used to detect the fusion of DAAM1 and NRG1 is specific to a sequence consisting of exon 1 of DAAM1 or located in The sequence at the 5' of exon 1 hybridizes, and/or specifically hybridizes with a sequence consisting of exon 1 of NRG1 or at the 3' of exon 1, or with such The sequence has 95% or higher complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of ASPH and NRG1 is specific to a sequence consisting of exon 22 of ASPH or located in exon The sequence at the 5' of exon 22 hybridizes, and/or specifically hybridizes to a sequence consisting of exon 2 of NRG1 or to a sequence located at the 3' of exon 2, or to these sequences Complementary sequence identity of 95% or higher; - The probe, primer or primer pair used to detect the fusion of NOTCH2 and NRG1 is specific to a sequence consisting of exon 6 of NOTCH2 or located in exon The sequence at the 5' place of exon 6 hybridizes, and/or specifically hybridizes with a sequence consisting of exon 6 of NRG1 or at the sequence at the 3' place of exon 6, or has a sequence with these sequences Complementary sequence identity of 95% or higher; - The probe, primer or primer pair used to detect the fusion of CD74 and NRG1 is specific to a sequence consisting of exon 2 of CD74 or located in exon 2, and/or specifically hybridize to a sequence consisting of exon 2 of NRG1 or to a sequence located at 3' of exon 2, or 95% to these sequences % or higher complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of SDC4 and NRG1 is specific to a sequence consisting of exon 2 of SDC4 or located in exon 2 and/or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or 95% of these sequences or higher complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of CD44 and NRG1 is specific to a sequence consisting of or located in exon 5 of CD44 The sequence at the 5' hybridizes, and/or specifically hybridizes to a sequence consisting of exon 6 of NRG1 or to a sequence at the 3' of exon 6, or 95% or Higher complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of SLC4A4 and NRG1 is specific to a sequence consisting of exon 14 of SLC4A4 or located at exon 5 of exon 14 ', and/or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or to 95% or more of these sequences High complementary sequence identity; - The probe, primer or primer pair used to detect the fusion of SDC4 and NRG1 is specific to a sequence consisting of exon 4 of SDC4 or located 5' of exon 4 and/or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or to 95% or more of these sequences Complementary sequence identity; - the probe, primer or primer pair used to detect the fusion of ZFAT and NRG1 is specific to a sequence consisting of exon 12 of ZFAT or located at the 5' position of exon 12 and/or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or to have 95% or more of these sequences Complementary sequence identity; or - the probe, primer or primer pair used to detect the fusion of DSCAML1 and NRG1 is specific to a sequence consisting of exon 3 of DSCAML1 or located at the 5' position of exon 3 and/or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or to a sequence that is 95% or higher Complementary sequence identity. 34. The nucleic acid probe, primer or primer pair according to item 33, wherein: - exon 1 from VAPB comprises or consists of SEQ ID NO: 17 or its allele variant; - is from outside CADM1 Exon 7 comprises or consists of SEQ ID NO: 39 or an allogenic variant thereof; - exon 5 from CD44 comprises or consists of SEQ ID NO: 65 or an allogenic variant thereof; - Exon 1 from SLC3A2 comprising or consisting of SEQ ID NO: 103 or an allogenic variant thereof; - exon 2 from VTCN1 comprising SEQ ID NO: 169 or an allogenic variant thereof, or consisting of It consists of; - from exon 11 of CDH1 comprising or consisting of SEQ ID NO: 198 or an allegenic variant thereof; - from CXADR exon 1 comprising SEQ ID NO: 219 or an allegenic variant thereof , or consists of; - from GTF2E2 exon 2 comprising SEQ ID NO: 236 or an allele variant thereof; - from CSMD1 exon 23 comprising SEQ ID NO: 279 or its An allele variant, or consisting of it; - from PTN exon 4 comprising SEQ ID NO: 318 or an allele variant thereof; - from ST14 exon 11 comprising SEQ ID NO : 342 or its allogenic variant, or consists of it; - from THBS1 exon 9 comprising or consisting of SEQ ID NO: 386 or its allele variant; - from AGRN exon 12 comprising, or consisting of, SEQ ID NO: 416 or an allogenic variant thereof; - from PVALB exon 4 comprising, or consisting of SEQ ID NO: 442 or an allogenic variant thereof; - from SLC3A2 Exon 2 comprises or consists of SEQ ID NO: 457 or an allogenic variant thereof; - from APP exon 14 comprises or consists of SEQ ID NO: 501 or an allogenic variant thereof; - from WRN exon 33 comprising or consisting of SEQ ID NO: 562 or an allogenic variant thereof; - from DAAM1 exon 1 comprising SEQ ID NO: 606 or an allogenic variant thereof, or Consists of; - from ASPH exon 22 comprising SEQ ID NO: 658 or an allegenic variant thereof; - from NOTCH2 exon 6 comprising SEQ ID NO: 700 or an allegenic variant thereof - from CD74 exon 2 comprising SEQ ID NO: 720 or an allele variant thereof, or consisting of it; - from SDC4 exon 2 comprising SEQ ID NO: 746 or An allele variant thereof, or consisting of it; - from exon 5 of CD44 comprising SEQ ID NO: 65 or an allele variant thereof; - from SLC4A4 exon 14 comprising SEQ ID NO: 780 or its allogenic variant, or consists of it; - from SDC4 exon 4 comprising, or consisting of SEQ ID NO: 748 or its allele variant; - from the ZFAT exon 12 comprises or consists of SEQ ID NO: 841 or its allogeneic variant; - from DSCAML1 exon 3 comprises or consists of SEQ ID NO: 872 or its allogeneic variant; and - from NRG1 exons 1, 2, 5 and 6 comprise or consist of SEQ ID NO: 125, 126, 129 and 130, or allelic variants thereof, respectively. 35. The nucleic acid probe, primer or primer pair according to item 33, wherein: - the probe, primer or primer pair used to detect the fusion of VAPB and NRG1 is specifically associated with a sequence consisting of SEQ ID NO: 17 Sequence hybridization or allele variant hybridization thereof, and/or hybridization specifically to a sequence consisting of SEQ ID NO: 153, or having 95% or greater complementary sequence identity to such sequences; - with The probe, primer or pair of primers to detect the fusion of CADM1 and NRG1 is specifically hybridized with a sequence consisting of SEQ ID NO: 57 or its allele variant hybridization, and/or specifically hybridized with a sequence composed of SEQ ID NO: 57 The sequence consisting of ID NO: 155 hybridizes, or has 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair used to detect the fusion of CD44 and NRG1 is specifically compatible with A sequence consisting of SEQ ID NO: 99 hybridizes or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 153, or 95% or higher complementary sequence identity; - the probe, primer or primer pair for detecting the fusion of SLC3A2 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 103 or its allele variants, And/or specifically hybridize to a sequence consisting of SEQ ID NO: 157, or have 95% or higher complementary sequence identity with these sequences; - a probe for detecting the fusion of VTCN1 and NRG1 , the primer or primer pair specifically hybridizes to a sequence consisting of SEQ ID NO: 181 or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 153, Or there is 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair for detecting the fusion of CDH1 and NRG1 is specifically related to a sequence consisting of SEQ ID NO: 213 Sequence hybridization or allele variant hybridization thereof, and/or hybridization specifically to a sequence consisting of SEQ ID NO: 153, or having 95% or greater complementary sequence identity to such sequences; - with The probe, primer or pair of primers to detect the fusion of CXADR and NRG1 is specifically hybridized with a sequence consisting of SEQ ID NO: 219 or its allele variant hybridization, and/or specifically hybridized with a sequence composed of SEQ ID NO: 219 The sequence consisting of ID NO: 153 hybridizes, or has 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair used to detect the fusion of GTF2E2 and NRG1 is specifically compatible with A sequence consisting of SEQ ID NO: 252 hybridizes or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 153, or 95% or higher complementary sequence identity; - the probe, primer or primer pair for detecting the fusion of CSMD1 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 309 or its allele variants, and/or specifically hybridize to a sequence consisting of SEQ ID NO: 155, or have 95% or higher complementary sequence identity with such sequences; - a probe for detecting the fusion of PTN and NRG1 , the primer or primer pair specifically hybridizes to a sequence consisting of SEQ ID NO: 326 or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 153, Or there is 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair for detecting the fusion of ST14 and NRG1 is specifically related to a sequence consisting of SEQ ID NO: 372 Sequence hybridization or allogenic variant hybridization thereof, and/or hybridization specifically to a sequence consisting of SEQ ID NO: 155, or having 95% or greater complementary sequence identity to such sequences; - with The probe, primer or pair of primers to detect the fusion of THBS1 and NRG1 is specifically hybridized to a sequence composed of SEQ ID NO: 399 or its allele variant hybridization, and/or specifically hybridized to a sequence composed of SEQ ID NO: 399 The sequence consisting of ID NO: 155 hybridizes, or has 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair used to detect the fusion of AGRN and NRG1 is specifically compatible with A sequence consisting of SEQ ID NO: 433 hybridizes or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 155, or 95% or higher complementary sequence identity; - the probe, primer or pair of primers for detecting the fusion of PVALB and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 450 or its allele variants, and/or specifically hybridize to a sequence consisting of SEQ ID NO: 155, or have 95% or higher complementary sequence identity with such sequences; - a probe for detecting the fusion of SLC3A2 and NRG1 , the primer or primer pair specifically hybridizes to a sequence consisting of SEQ ID NO: 482 or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 155, Or there is 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair for detecting the fusion of APP and NRG1 is specifically related to a sequence consisting of SEQ ID NO: 524 Sequence hybridization or allogenic variant hybridization thereof, and/or hybridization specifically to a sequence consisting of SEQ ID NO: 155, or having 95% or greater complementary sequence identity to such sequences; - with The probe, primer or pair of primers to detect the fusion of WRN and NRG1 is specifically hybridized to a sequence composed of SEQ ID NO: 601 or its allele variant hybridization, and/or specifically hybridized to a sequence composed of SEQ ID NO: 601 The sequence consisting of ID NO: 155 hybridizes, or has 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair used to detect the fusion of DAAM1 and NRG1 is specifically compatible with A sequence consisting of SEQ ID NO: 606 hybridizes or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 138, or 95% or higher complementary sequence identity; - probes, primers or primer pairs for detecting the fusion of ASPH and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 689 or its allele variants, and/or specifically hybridize to a sequence consisting of SEQ ID NO: 153, or have 95% or higher complementary sequence identity with such sequences; - a probe for detecting the fusion of NOTCH2 and NRG1 , the primer or primer pair specifically hybridizes to a sequence consisting of SEQ ID NO: 713 or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 155, Or there is 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair for detecting the fusion of CD74 and NRG1 is specifically related to a sequence consisting of SEQ ID NO: 739 Sequence hybridization or allele variant hybridization thereof, and/or hybridization specifically to a sequence consisting of SEQ ID NO: 153, or having 95% or greater complementary sequence identity to such sequences; - with The probe, primer or pair of primers to detect the fusion of SDC4 and NRG1 is specifically hybridized to a sequence consisting of SEQ ID NO: 757 or its allele variant hybridization, and/or specifically hybridized to a sequence composed of SEQ ID NO: 757 The sequence consisting of ID NO: 153 hybridizes, or has 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair used to detect the fusion of CD44 and NRG1 is specifically compatible with A sequence consisting of SEQ ID NO: 99 hybridizes or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 155, or 95% or higher complementary sequence identity; - the probe, primer or primer pair for detecting the fusion of SLC4A4 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 820 or its allele variants, and/or specifically hybridize to a sequence consisting of SEQ ID NO: 155, or have 95% or higher complementary sequence identity with such sequences; - a probe for detecting the fusion of SDC4 and NRG1 , the primer or primer pair specifically hybridizes to a sequence consisting of SEQ ID NO: 940 or its allele variant hybridizes, and/or specifically hybridizes to a sequence consisting of SEQ ID NO: 153, Or there is 95% or higher complementary sequence identity with these sequences; - the probe, primer or primer pair for detecting the fusion of ZFAT and NRG1 is specifically related to a sequence consisting of SEQ ID NO: 864 Sequences hybridize or allele variants thereof, and/or specifically hybridize to a sequence consisting of SEQ ID NO: 155, or have 95% or greater complementary sequence identity to such sequences; and- The probe, primer or primer pair used to detect the fusion of DSCAML1 and NRG1 is specifically hybridized with a sequence consisting of SEQ ID NO: 938 or its allele variant hybridization, and/or specifically hybridized with a sequence composed of A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences. 36. A first nucleic acid probe and a second nucleic acid probe for use in an in situ hybridization assay to detect the polynucleotide fusion of any one of items 1 to 23, - wherein the first probe is specific and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' of position 44 of SEQ ID NO: 3 -wherein the first probe is specifically hybridized to the CADM1 sequence at the nucleic acid 5' at position 53 of SEQ ID NO: 7, and the second probe is specifically at position 54 of SEQ ID NO: 7 -wherein the first probe specifically hybridizes to the CD44 sequence at the nucleic acid 5' at position 52 of SEQ ID NO: 11, and the second probe specifically hybridizes to The NRG1 sequence hybridization at the nucleic acid 3' place of position 53 of SEQ ID NO: 11; - wherein the first probe is specifically hybridized with the SLC3A2 sequence at the nucleic acid 5' position of position 53 of SEQ ID NO: 15, and The second probe is specifically hybridized to the NRG1 sequence at the 3' nucleic acid at position 54 of SEQ ID NO: 15; - wherein the first probe is specifically at the nucleic acid at position 65 of SEQ ID NO: 166 The VTCN1 sequence at the 5' hybridizes, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 66 of SEQ ID NO: 166; ID NO: The CDH1 sequence hybridization at the nucleic acid 5' place of the position 119 of 186, and the NRG1 sequence at the nucleic acid 3' place of the position 120 of the position of SEQ ID NO: 186 is specifically hybridized with the second probe; - wherein the first A probe specifically hybridizes to the CXADR sequence at the nucleic acid 5' at position 43 of SEQ ID NO: 217, and the second probe specifically hybridizes with the nucleic acid 3' at position 44 of SEQ ID NO: 217 NRG1 sequence hybridization; -wherein the first probe specifically hybridizes with the GTF2E2 sequence at the nucleic acid 5' of position 141 of SEQ ID NO: 233, and the second probe specifically hybridizes with the sequence located at SEQ ID NO: The NRG1 sequence hybridization at the nucleic acid 3' place of the position 142 of 233; - wherein the first probe is specifically hybridized with the CSMD1 sequence at the nucleic acid 5' position of the position 88 of SEQ ID NO: 255, and the second probe Specifically hybridize to the NRG1 sequence at the nucleic acid 3' at position 89 of SEQ ID NO: 255; -wherein the first probe is specifically at the PTN at the nucleic acid 5' at position 102 of SEQ ID NO: 313 Sequence hybridization, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 103 of SEQ ID NO: 313; - wherein the first probe is specifically at the position of SEQ ID NO: 330 The ST14 sequence hybridization at the nucleic acid 5' place at position 95, and the NRG1 sequence at the nucleic acid 3' place at position 96 of SEQ ID NO:330 is specifically hybridized with the second probe; -wherein the first probe specificity Hybridized with the THBS1 sequence at the nucleic acid 5' at position 56 of SEQ ID NO:376, and the second probe is specifically hybridized with the NRG1 sequence at the 3' nucleic acid at position 57 of SEQ ID NO:376; -wherein the first probe is specifically hybridized to the AGRN sequence at the nucleic acid 5' at position 106 of SEQ ID NO:403, and the second probe is specifically at position 107 of SEQ ID NO:403 The NRG1 sequence hybridization at the nucleic acid 3'place; -wherein the first probe specifically hybridizes with the PVALB sequence at the nucleic acid 5' position at position 102 of SEQ ID NO: 437, and the second probe specifically hybridizes with the nucleic acid at position 102 The NRG1 sequence hybridization at the nucleic acid 3' place of position 103 of SEQ ID NO: 437; - wherein the first probe is specifically hybridized with the SLC3A2 sequence at the nucleic acid 5' position of position 93 of SEQ ID NO: 454, and the The second probe is specifically hybridized with the NRG1 sequence at the nucleic acid 3' at position 94 of SEQ ID NO: 454; -wherein the first probe is specifically at the nucleic acid 5 at position 54 of SEQ ID NO: 486 ', and the second probe specifically hybridizes to the NRG1 sequence at the nucleic acid 3' at position 55 of SEQ ID NO: 486; -wherein the first probe specifically hybridizes to the sequence at SEQ ID NO: The WRN sequence hybridization at the nucleic acid 5' place of the position 96 of NO: 528, and the NRG1 sequence at the nucleic acid 3' place at the position 97 of SEQ ID NO: 528 is specifically hybridized with the second probe; - wherein the first The probe specifically hybridizes to the DAAM1 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 605, and the second probe specifically hybridizes with the nucleic acid 3' at position 76 of SEQ ID NO: 605. NRG1 sequence hybridization; - wherein the first probe specifically hybridizes to the ASPH sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 635, and the second probe specifically hybridizes to the sequence at SEQ ID NO: 635 The NRG1 sequence hybridization at the nucleic acid 3' place of position 76; -wherein the first probe is specifically hybridized with the NOTCH2 sequence at the nucleic acid 5' position at position 75 of SEQ ID NO: 693, and the second probe is specific Hybridization with the NRG1 sequence at the nucleic acid 3' at position 76 of SEQ ID NO: 693; -wherein the first probe is specifically at the CD74 sequence at the 5' nucleic acid at position 75 of SEQ ID NO: 717 Hybridization, and the second probe specifically hybridizes with the NRG1 sequence at the nucleic acid 3' at position 76 of SEQ ID NO: 717; - wherein the first probe is specifically at the position of SEQ ID NO: 743 The SDC4 sequence hybridization at the nucleic acid 5' place of 75, and the NRG1 sequence hybridization at the nucleic acid 3' place at the nucleic acid 3' place of position 76 of SEQ ID NO: 743 with this second probe specifically; - wherein the first probe specifically With the CD44 sequence hybridization at the nucleic acid 5' place of position 75 of SEQ ID NO:761, and the second probe is specifically hybridized with the NRG1 sequence at the nucleic acid 3' position of position 76 of SEQ ID NO:761;- Wherein the first probe specifically hybridizes with the SLC4A4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 765, and the second probe specifically hybridizes with the nucleic acid at position 76 of SEQ ID NO: 765 The NRG1 sequence at the 3'hybridizes; - wherein the first probe specifically hybridizes to the SDC4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 824, and the second probe specifically hybridizes to the sequence at SEQ ID NO: 824 ID NO: the NRG1 sequence hybridization at the nucleic acid 3' place of position 76 of 824; - wherein the first probe is specifically hybridized with the ZFAT sequence at the nucleic acid 5' position of position 75 of SEQ ID NO: 828, and the second The two probes are specifically hybridized to the NRG1 sequence at the 3' nucleic acid at position 76 of SEQ ID NO: 828; or- wherein the first probe is specifically at the nucleic acid 5 at position 75 of SEQ ID NO: 868 ', and the second probe specifically hybridizes to the NRG1 sequence at position 76 of SEQ ID NO: 868 at the nucleic acid 3'. 37. A first antibody or a pair of first and second antibodies for detecting a polypeptide encoded by the polynucleotide fusion of any one of items 1 to 23. 38. A detection assay comprising a first antibody or a set of first and second antibodies for detecting the presence of a polypeptide encoded by the polynucleotide fusion of any one of items 1 to 23, wherein the first The antibody or the first and second antibody group is preferably the first antibody or the first and second antibody group as described in item 34. 39. The first antibody or the set of first and second antibodies according to item 38, or the detection assay according to item 32, wherein the first antibody binds to a group selected from VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, ASPH- Polypeptide fusions of NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4-NRG1, SLC4A4-NRG1, ZFAT-NRG1 or DSCAML1-NRG1, and the first and second antibody sets respectively bind VAPB and NRG1 or CADM1 and NRG1, or CD44 and NRG1, SLC3A2 and NRG1, CDH1 and NRG1, CXADR and NRG1, GTF2E2 and NRG1, CSMD1 and NRG1, PTN and NRG1, ST14 and NRG1, THBS1 and NRG1, AGRN and NRG1, PVALB and NRG1, APP and NRG1, WRN and NRG1, ASPH and NRG1, NOTCH2 and NRG1, CD74 and NRG1, SDC4 and NRG1, SLC4A4 and NRG1, ZFAT and NRG1, or DSCAML1 and NRG1. 40. A method of identifying the polynucleotide fusion of any one of items 1 to 23, or a polypeptide encoded thereby, in a sample, said method comprising testing a sample obtained from an individual to detect the sample Whether the fusion exists in . 41. A method for detecting the presence of a polynucleotide fusion as in any one of items 1 to 23, or a polypeptide encoded by it, in a sample, said method comprising testing a sample obtained from an individual to detect the Whether the fusion is present in the sample. 42. A method for determining whether an abnormal cell from an individual comprises a fusion as in any one of items 1 to 23, or a polypeptide encoded by it, said method comprising examining polynucleosides obtained from the abnormal cell of the individual Whether acid or polypeptide content is present in the sample for the fusion. 43. A method for identifying an individual carrying a polynucleotide fusion as in any one of items 1 to 23, or a polypeptide encoded by it, said method comprising testing a sample obtained from an individual to detect Whether the fusion exists. 44. The method according to any one of items 37 to 40, wherein the test comprises using a nucleic acid probe such as any one of items 31 to 36, a primer or a binding agent of a primer pair to specifically bind the polynucleotide Either the fusion is detected by the polypeptide encoded by it, or the fusion is detected by using a binding agent that binds a polynucleotide comprising the polynucleotide fusion. 45. The method according to any one of items 40 to 44, wherein the test comprises amplifying or detecting a sequence for distinguishing the presence or absence of the polynucleotide fusion or the polypeptide encoded by it. 46. The method according to any one of items 41 to 45, wherein the polynucleotide fusion is obtained from an abnormal cell expressing a polynucleotide fusion comprising the EGF-like domain of NRG1. 47. The method according to any one of items 40 to 46, wherein the method comprises the step of obtaining a sample from an individual, followed by the step of isolating the polynucleotide or the polypeptide encoded thereby from the sample. 48. The method according to any one of items 40 to 47, wherein the method comprises the step of purifying or isolating the polynucleotide from the sample. 49. The method according to any one of items 40 to 48, wherein the binding agent is or comprises a primer, primer pair, probe or antibody. 50. The method according to any one of items 40 to 49, wherein the test is an in vitro method, preferably an in vitro method. 51. The method according to any one of clauses 40 to 50, wherein the binding agent comprises or is associated with a detectable label. 52. The method according to any one of items 40 to 51, wherein the sample is a liquid specimen or a solid sample, such as a formalin-fixed paraffin-embedded tissue (FFPE) sample. 53. The method according to any one of items 40 to 52, wherein the sample comprises blood, serum, plasma, pleural fluid, urine, semen, amniotic fluid or ascites. 54. The method according to any one of items 40 to 53, wherein the sample comprises mutant cells, such as tumor cells or cancer cells, or polynucleotide or polypeptide content thereof. 55. A method of treating an individual suffering from an ErbB-2 and/or ErbB-3 positive cancer or tumor comprising a polynucleotide fusion and/or expressing a fusion polypeptide encoded by it, said method comprising introducing the The subject is administered an effective amount of an ErbB-2 and/or ErbB-3 targeting agent, wherein the fusion is a fusion according to any one of items 1-23. 56. A method of inhibiting the course of an individual suffering from an ErbB-2 and ErbB-3 positive cancer or tumor comprising a polynucleotide fusion and/or expressing a fusion polypeptide encoded thereby, said method comprising administering to the individual Administering an effective amount of an ErbB-2 and/or ErbB-3 targeting agent, wherein the fusion is a fusion according to any one of items 1-23. 57. An ErbB-2 and/or ErbB-2 for use in the treatment of an individual suffering from an ErbB-2 and ErbB-3 positive cancer or tumor comprising a polynucleotide fusion and/or expressing a fusion polypeptide encoded thereby or an ErbB-3 targeting agent, the treatment comprising administering to the individual an effective amount of ErbB-2 and/or an ErbB-3 targeting agent, wherein the fusion is as in any one of items 1 to 23 fusion. 58. A method for diagnosing whether an individual has abnormal cells comprising a polynucleotide fusion as in any one of items 1 to 23 or a polypeptide encoded by it, the method comprising testing a sample obtained from an individual to detect the Whether the fusion is present in the sample. 59. The method according to item 58, wherein the test comprises using a binding agent such as the nucleic acid probe, primer or primer pair of any one of items 30 to 35 to specifically bind to the polynucleotide or the polynucleotide encoded by it A polypeptide is used to detect the fusion, or a binding agent that binds a polynucleotide comprising the polynucleotide fusion is used to detect the fusion. 60. A method of assessing whether an individual suffers from or is susceptible to cancer or tumor, the method comprising testing a sample obtained from an individual to detect the presence of the polynucleoside according to any one of items 1 to 23 in the sample An acid fusion or a polypeptide encoded thereby, and by identifying the presence or absence of the polynucleotide or polypeptide fusion, assessing that the individual suffers from the cancer or tumor or is susceptible to the cancer or tumor. 61. The method or use according to any one of items 55 to 58, wherein the ErbB-2 and/or ErbB-3 targeting agent is selected from the group consisting of: an extracellular protein that binds ErbB-2 A multispecific antibody that binds to the first antigen-binding site of a portion of the extracellular portion of ErbB-3 and a second antigen-binding site that binds to the extracellular portion of ErbB-3, a tyrosine kinase inhibitor of ErbB-2, comprising a cell that binds to ErbB-2 A monospecific diabody having an antigen binding site on the outer portion, a monospecific diabody comprising an antigen binding site that binds the extracellular portion of ErbB-3, or any combination thereof. 62. The method or use according to any one of items 55 to 58, or 61, wherein the ErbB-2 and/or ErbB-3 targeting agent is zenocutuzumab. 63. The method or use according to any one of items 41 to 62, wherein the abnormal cell, cancer cell or tumor cell line comprises or is encoded by a polynucleotide fusion as in any one of items 1 to 23 The polypeptide, and wherein the polynucleotide fusion comprised by the cell further comprises a coding sequence in-frame fused to an EGF-like domain encoding NRG1. 64. The method or use according to any one of items 41 to 63, wherein the abnormal cell line is from cancer, especially said cancer is adenocarcinoma, more especially mucinous adenocarcinoma, pancreatic cancer, more especially pancreatic adenocarcinoma Cancer, more especially pancreatic ductal adenocarcinoma, renal cell carcinoma, sarcoma, bladder cancer, colorectal cancer, rectal cancer, colorectal cancer, gallbladder cancer, head and neck cancer, prostate cancer, uterine cancer, breast cancer, ovarian cancer, liver cancer, uterine Endometrial cancer, lung cancer, preferably non-small cell lung cancer, preferably, more preferably invasive mucinous adenocarcinoma, primary cancer or metastatic cancer. 65. An in vivo animal model comprising the polynucleotide fusion according to any one of items 1 to 23 and/or expressing the polypeptide fusion encoded thereby, wherein the polynucleotide fusion composed of the animal model The drug or polypeptide fusion is preferably composed of transplanted abnormal cells present in the animal model, or is composed of the gene body of the animal model. 66. A method of treating the in vivo animal model of item 66 with an Erb2 and/or Erb3 targeting agent selected from the group consisting of an extracellular moiety that binds ErbB-2 Multispecific antibody with a first antigen-binding site and a second antigen-binding site that binds to the extracellular portion of ErbB-3, a tyrosine kinase inhibitor of ErbB-2, comprising an extracellular portion that binds to ErbB-2 A monospecific diabody comprising an antigen-binding site that binds an extracellular portion of ErbB-3, or any combination thereof, the method comprising administering to the animal The Erb2 and/or Erb3 targeting agent. 67. An in situ hybridization assay for use in the detection of VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1 CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, The first nucleic acid probe and the second nucleic acid probe of the gene rearrangement of CD74, SDC4, SLC4A4, ZFAT or DSCAML1, wherein: - the first probe for detecting the gene rearrangement of VAPB is specifically related to SEQ ID NO: The VAPB sequence at the nucleic acid 5' place of position 43 of 1 hybridizes, and the VAPB sequence at the nucleic acid 3' place of position 43 of SEQ ID NO: 1 is specifically hybridized with the second probe; - for detecting the gene of CADM1 The rearranged first probe specifically hybridizes to the CADM1 sequence at the nucleic acid 5' of position 53 of SEQ ID NO: 5, and the second probe specifically hybridizes to the nucleic acid at position 53 of SEQ ID NO: 5 The CADM1 sequence at the 3'hybridizes; - the first probe for detecting gene rearrangement of CD44 specifically hybridizes to the CD44 sequence at the nucleic acid 5' at position 52 of SEQ ID NO: 9, and the second probe Specifically hybridize to the CD44 sequence at the nucleic acid 3' of position 52 of SEQ ID NO:9; The SLC3A2 sequence at the nucleic acid 5' hybridizes, and the second probe specifically hybridizes with the SLC3A2 sequence at the nucleic acid 3' at position 53 of SEQ ID NO: 13; - the first gene rearrangement for detecting VTCN1 The probe specifically hybridizes with the VTCN1 sequence at the nucleic acid 5' at position 65 of SEQ ID NO: 164, and the second probe specifically hybridizes with the VTCN1 at the nucleic acid 3' at position 65 of SEQ ID NO: 164 Sequence hybridization; - the first probe for detecting gene rearrangement of CDH1 specifically hybridizes to the CDH1 sequence at the 5' position of the nucleic acid at position 119 of SEQ ID NO: 184, and the second probe specifically hybridizes to the sequence at The CDH1 sequence at the 3' position of the nucleic acid at position 119 of SEQ ID NO: 184 hybridizes; - the first probe for detecting the gene rearrangement of CXADR is specifically at the 5' position of the nucleic acid at position 43 of SEQ ID NO: 215 The CXADR sequence hybridizes, and the second probe specifically hybridizes to the CXADR sequence at the nucleic acid 3' at position 43 of SEQ ID NO: 215; - the first probe for detecting the gene rearrangement of GTF2E2 specifically With the GTF2E2 sequence hybridization at the nucleic acid 5' place of the position 141 of SEQ ID NO: 231, and the GTF2E2 sequence at the nucleic acid 3' position of the position 141 position of the second probe is specifically hybridized with SEQ ID NO: 231; - with The first probe for detecting gene rearrangement of CSMD1 specifically hybridizes with the CSMD1 sequence at the nucleic acid 5' of position 88 of SEQ ID NO: 253, and the second probe specifically hybridizes with the sequence located at SEQ ID NO: 253 The CSMD1 sequence hybridization at the 3' position of the nucleic acid at position 88; - the first probe for detecting the gene rearrangement of PTN specifically hybridizes with the PTN sequence at the 5' position of the nucleic acid at position 102 of SEQ ID NO: 311, and The second probe specifically hybridizes to the PTN sequence at the nucleic acid 3' of position 102 of SEQ ID NO: 311; The ST14 sequence hybridization at the nucleic acid 5' place of position 95 of 328, and the ST14 sequence at the nucleic acid 3' place of position 95 of SEQ ID NO: 328 is specifically hybridized with this second probe; - for detecting the gene of AGRN The rearranged first probe specifically hybridizes with the AGRN sequence at the nucleic acid 5' of position 106 of SEQ ID NO:401, and the second probe specifically hybridizes with the nucleic acid at position 106 of SEQ ID NO:401 The AGRN sequence at the 3'hybridizes; - the first probe for detecting the gene rearrangement of THBS1 specifically hybridizes to the THBS1 sequence at the 5' position of the nucleic acid at position 56 of SEQ ID NO: 374, and the second probe Specifically hybridizes to the THBS1 sequence at the 3' position of the nucleic acid at position 56 of SEQ ID NO: 374; - the first probe for detecting the gene rearrangement of PVALB is specifically at position 102 of SEQ ID NO: 435 The PVALB sequence at the 5' place of the nucleic acid hybridizes, and the second probe specifically hybridizes with the PVALB sequence at the 3' place of the nucleic acid at position 102 of SEQ ID NO: 435; - the first gene rearrangement for detecting SLC3A2 The probe specifically hybridizes with the SLC3A2 sequence at the nucleic acid 5' at position 93 of SEQ ID NO: 452, and the second probe specifically hybridizes with the SLC3A2 at the nucleic acid 3' at position 93 of SEQ ID NO: 452 Sequence hybridization; - the first probe for detecting gene rearrangement of APP specifically hybridizes to the APP sequence at the nucleic acid 5' of position 54 of SEQ ID NO: 484, and the second probe specifically hybridizes to the nucleic acid located at The APP sequence at the 3' position of the nucleic acid at position 54 of SEQ ID NO: 484 hybridizes; - the first probe for detecting the gene rearrangement of WRN is specifically at the 5' position of the nucleic acid at position 96 of SEQ ID NO: 526 The WRN sequence hybridizes, and the second probe specifically hybridizes to the WRN sequence at the 3' of the nucleic acid at position 96 of SEQ ID NO: 526; - the first probe for detecting the gene rearrangement of DAAM1 specifically Hybridization with the DAAM1 sequence at the nucleic acid 5' place of the position 75 of SEQ ID NO: 603, and the second probe is specifically hybridized with the DAAM1 sequence at the nucleic acid 3' position of the position 75 of SEQ ID NO: 603; - with The first probe for detecting gene rearrangement of ASPH specifically hybridizes to the ASPH sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 633, and the second probe specifically hybridizes to the sequence located at SEQ ID NO: 633 The ASPH sequence at the 3' position of the nucleic acid at position 75 hybridizes; - the first probe for detecting the gene rearrangement of NOTCH2 specifically hybridizes with the NOTCH2 sequence at the 5' position of the nucleic acid at position 75 of SEQ ID NO: 691, and The second probe specifically hybridizes to the NOTCH2 sequence at the nucleic acid 3' of position 75 of SEQ ID NO:691; The CD74 sequence hybridization at the nucleic acid 5' place of the position 75 of 715, and the CD74 sequence at the nucleic acid 3' place of the position 75 position of SEQ ID NO: 715 is specifically hybridized with this second probe; - for detecting the gene of SDC4 The rearranged first probe specifically hybridizes to the SDC4 sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 741, and the second probe specifically hybridizes to the nucleic acid at position 75 of SEQ ID NO: 741 The SDC4 sequence at the 3'hybridizes; - the first probe for detecting gene rearrangement of CD44 specifically hybridizes to the CD44 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 759, and the second probe Specifically hybridizes to the CD44 sequence at the 3' position of the nucleic acid at position 75 of SEQ ID NO: 759; - the first probe for detecting gene rearrangements of SLC4A4 is specifically at position 75 of SEQ ID NO: 763 The SLC4A4 sequence at the 5' place of the nucleic acid hybridizes, and the second probe specifically hybridizes with the SLC4A4 sequence at the 3' of the nucleic acid at position 75 of SEQ ID NO: 763; - the first gene rearrangement method for detecting SDC4 The probe specifically hybridizes with the SDC4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO:822, and the second probe specifically hybridizes with the SDC4 at the nucleic acid 3' at position 75 of SEQ ID NO:822 Sequence hybridization; - the first probe for detecting the gene rearrangement of ZFAT is specifically hybridized with the ZFAT sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 826, and the second probe is specifically hybridized with the position at The ZFAT sequence at the 3' position of the nucleic acid at position 75 of SEQ ID NO: 826 hybridizes; or - the first probe for detecting the gene rearrangement of DSCAML1 is specifically at the 5' position of the nucleic acid at position 75 of SEQ ID NO: 866 The DSCAML1 sequence hybridizes, and the second probe specifically hybridizes to the DSCAML1 sequence located 3' of the nucleic acid at position 75 of SEQ ID NO: 866. Example Example 1 : Test sample preparation

Liquid samples or specimens include blood, serum, plasma, pleural effusion, urine, semen, vaginal swab, amniotic fluid, peritoneal fluid, acellular lavage fluid, or other biological fluids.

When using blood as the starting material, blood can be collected in tubes treated with a cell stabilizer, such as cell-free DNA BCT tubes (Streck), which prevents hemocytes from rupturing after collection and will Contamination with wild-type DNA/RNA from normal cells is minimized. Example 2 : Purification of Circulating DNA from Plasma

Although the protocol in this example describes the isolation of cfDNA from a 1 ml plasma sample, the protocol is also suitable for isolation from other volumes when higher yields are desired and other sample types such as urine and serum. The protocol is based on the QIAamp® Circulating Nucleic Acid Kit (CNA) (Qiagen, Product #55114) and brochure (HB-0202-006) dated 10/2019.

Before starting, allow plasma samples from human subjects to equilibrate to room temperature, either from samples suitable for storage at refrigerated temperatures or drawn directly from the patient. All centrifugation steps were performed at room temperature. Sample volumes below 1 ml were adjusted to a total of 1 ml with phosphate-buffered saline (PBS), if necessary. Preparation of buffers and reagents

Buffers ACB, ACW1 and ACW2 were prepared according to the manufacturer's instructions. Briefly, 200 ml of isopropanol (100 v/v%) was added to 300 ml of Buffer ACB concentrate before use to obtain 500 ml of Buffer ACB. After the addition of isopropanol, the resulting buffer was mixed well. Before use, add 25 ml of ethanol 96–100 (v/v%) to 19 ml of Buffer ACW1 concentrate to obtain 44 ml of Buffer ACW1. The resulting liquid was mixed well after adding ethanol. Before use, 30 ml of ethanol (96–100%) was added to 13 ml of buffer ACW2 concentrate to obtain 43 ml of buffer, which was then mixed well. For example, to process 12 1 ml plasma samples, mix 10.6 ml buffer ACL with 67.5 μl AVE buffer containing vehicle. Isolation of cfDNA from plasma

Procedure: 100 µl of QIAGEN Proteinase K was aspirated into a 50 ml centrifuge tube and 1 ml of plasma was added to the 50 ml centrifuge tube. Add 0.8 ml ACL buffer (containing 1.0 µg carrier RNA), then close the cap and mix by pulse vortexing for 30 seconds while vortexing the tube. Thoroughly mix the sample and ACL buffer to produce a homogeneous solution. Samples were immediately lysed by incubating at 60°C for 30 minutes. 1.8 ml of ACB buffer was added to the lysate in a centrifuge tube, then the cap was closed and mixed thoroughly with pulse vortexing for 15 to 30 seconds. The lysate ACB buffer mixture was incubated in a centrifuge tube on ice for 5 minutes. Insert the QIAamp mini column (Mini column) into the vacuum connector (VacConnector) on the QIAvac 24 Plus, and set according to the manufacturer's instructions. Insert the 20 ml extension tube into the open QIAamp Mini Column. Insert the 20 ml extension tubing tightly into the QIAamp Mini Column.

After incubation on ice, the lysate-ACB buffer mixture was applied to the extension tube of the QIAamp Mini Column. The vacuum pump was turned on, and when all lysates had been completely drawn through the column, the vacuum pump was turned off and the pressure was released to 0 mbar. Carefully remove and discard the extension tube. If part of the QIAvac Connecting System, a Vacuum Regulator can be used. To avoid cross-contamination, do not move extension tubing over adjacent QIAamp mini-columns. Apply 600 µl of ACW1 buffer to the QIAamp Mini Column. Uncap the column and turn on the vacuum pump. After all of the ACW1 buffer had been pumped through the QIAamp mini-column, the vacuum pump was turned off and the pressure was released to 0 mbar. Apply 750 µl of ACW2 buffer to the QIAamp Mini Column. Uncap the column and turn on the vacuum pump. After all of the ACW2 buffer had been pumped through the QIAamp mini-column, the vacuum pump was turned off and the pressure was released to 0 mbar. Apply 750 µl of ethanol (96 v/v%) to the QIAamp Mini Column. Uncap the column and turn on the vacuum pump. After all the ethanol had been drawn through the QIAamp spin column, the vacuum pump was turned off and the pressure was released to 0 mbar. Cap the QIAamp mini column tightly, remove the column from the vacuum manifold and discard the vacuum fitting. Place the QIAamp Mini Column in a clean 2 ml collection tube and centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 minutes. Place the QIAamp Mini Column into a new 2 ml collection tube. The lid was removed and the assembly was incubated at 56°C for 10 minutes to completely dry the membrane. Place the QIAamp Mini Column in a clean 1.5 ml elution tube and discard the last used 2 ml collection tube. Carefully apply 20 µl of AVE Buffer to the center of the QIAamp Mini membrane. Cover tightly and incubate at room temperature for 3 minutes. Equilibrate elution buffer AVE to room temperature. The recovered eluent volume was about 5 µl, which is less than the eluent volume applied to the QIAamp Mini Column. Centrifuge the column at full speed (20,000 x g; 14,000 rpm) in a microcentrifuge for 1 minute to elute nucleic acids, resulting in cell-free DNA.

Free circulating cell-free DNA was lysed with AVE buffer, i.e. used in amplification reactions or stored at –30°C to –15°C. Purified nucleic acids are free of proteins, nucleases, and other impurities.

Next, nucleic acid concentration is determined according to the manufacturer's recommendations prior to amplification of the NRG1 fusion and detection assays, such as quantitative amplification assays.

Bill of Materials for Vacuum 1–24 QIAGEN Spin Chromatography Columns for the QIAvac 24 Plus System. QIAvac 24 Plus: Vacuum manifold for processing 1–24 centrifugal chromatography columns, including QIAvac 24 Plus vacuum manifold, Luer Plugs and Quick Couplings (Product No. 19413). Vacuum Adapter (500): Type 500 Disposable Adapter for use with QIAamp Mini Columns on a luer slot or VacValve (Product No. 19407). Vacuum Valves (24): 24 valves for use with the QIAvac 24 Plus (Product No. 19408). Vacuum Regulator: For use with the QIAvac manifold (Product No. 19530). Vacuum pump (230 V, 50 Hz): Universal vacuum pump (34 L/min capacity, 8 mbar absolute vacuum) (Product No. 84020). QIAvac Connecting System (Connecting System): A system used to connect vacuum manifolds and vacuum pumps: including trays, waste bottles, tubing, connecting tubes, valves, pressure gauges, and 24 vacuum valves (product number 19419). Example 3 : Circulating Tumor RNA (cfRNA) Purification of Circulating RNA from Plasma

Although the protocol in this example describes the isolation of circulating RNA from a 4 ml plasma sample, the protocol is also suitable for isolation from other volumes when higher yields are desired and other sample types such as urine and serum. The protocol is based on the QIAamp® Circulating Nucleic Acid Kit (CNA) (Qiagen, Product #55114) and brochure (HB-0202-006) dated 10/2019.

Before starting, allow plasma samples from human subjects to equilibrate to room temperature, either from samples suitable for storage at refrigerated temperatures or drawn directly from the patient. All centrifugation steps were performed at room temperature. Sample volumes below 4 ml were adjusted to a total of 4 ml with phosphate-buffered saline (PBS), if necessary. Preparation of buffers and reagents.

Buffers ACB, ACW1 and ACW2 were prepared according to the manufacturer's instructions. Briefly, 200 ml of isopropanol (100 v/v%) was added to 300 ml of Buffer ACB concentrate before use to obtain 500 ml of Buffer ACB. After the addition of isopropanol, the resulting buffer was mixed well. Before use, add 25 ml of ethanol 96–100 (v/v%) to 19 ml of Buffer ACW1 concentrate to obtain 44 ml of Buffer ACW1. The resulting liquid was mixed well after adding ethanol. Before use, 30 ml of ethanol (96–100%) was added to 13 ml of buffer ACW2 concentrate to obtain 43 ml of buffer, which was then mixed well. For example, to process twelve 4 ml plasma samples, mix 43 ml of buffer ACL with 67.5 μl of AVE buffer containing vehicle. Isolation of cfRNA from plasma

Procedure: 400 µl of QIAGEN Proteinase K was aspirated into a 50 ml centrifuge tube and 4 ml of plasma was added to the 50 ml centrifuge tube. Add 3.2 ml ACL buffer (containing 1.0 µg carrier RNA), then close the cap and mix by pulse vortexing for 30 seconds while vortexing the tube. Thoroughly mix the sample and ACL buffer to produce a homogeneous solution. Samples were immediately lysed by incubating at 60°C for 30 minutes. To this lysate was added 7.2 ml of ACB buffer in a centrifuge tube, after which the cap was closed and mixed thoroughly by pulse vortexing for 15 to 30 seconds. The lysate ACB buffer mixture was incubated in a centrifuge tube on ice for 5 minutes. Insert the QIAamp mini column (Mini column) into the vacuum connector (VacConnector) on the QIAvac 24 Plus, and set according to the manufacturer's instructions. Insert the 20 ml extension tube into the open QIAamp Mini Column. Insert the 20 ml extension tubing tightly into the QIAamp Mini Column.

After incubation on ice, the lysate-ACB buffer mixture was applied to the extension tube of the QIAamp Mini Column. The vacuum pump was turned on, and when all lysates had been completely drawn through the column, the vacuum pump was turned off and the pressure was released to 0 mbar. Carefully remove and discard the extension tube. If part of the QIAvac Connecting System, a Vacuum Regulator can be used. To avoid cross-contamination, do not move extension tubing over adjacent QIAamp mini-columns. Apply 600 µl of ACW1 buffer to the QIAamp Mini Column. Uncap the column and turn on the vacuum pump. After all of the ACW1 buffer had been pumped through the QIAamp mini-column, the vacuum pump was turned off and the pressure was released to 0 mbar. Apply 750 µl of ACW2 buffer to the QIAamp Mini Column. Uncap the column and turn on the vacuum pump. After all of the ACW2 buffer had been pumped through the QIAamp mini-column, the vacuum pump was turned off and the pressure was released to 0 mbar. Apply 750 µl of ethanol (96 v/v%) to the QIAamp Mini Column. Uncap the column and turn on the vacuum pump. After all the ethanol had been drawn through the QIAamp spin column, the vacuum pump was turned off and the pressure was released to 0 mbar. Cap the QIAamp mini column tightly, remove the column from the vacuum manifold and discard the vacuum fitting. Place the QIAamp Mini Column in a clean 2 ml collection tube and centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 minutes. Place the QIAamp Mini Column into a new 2 ml collection tube. The lid was removed and the assembly was incubated at 56°C for 10 minutes to completely dry the membrane. Place the QIAamp Mini Column in a clean 1.5 ml elution tube and discard the last used 2 ml collection tube. Carefully apply 20 µl of AVE Buffer to the center of the QIAamp Mini membrane. Cover tightly and incubate at room temperature for 3 minutes. Equilibrate elution buffer AVE to room temperature. The recovered eluent volume was about 5 µl, which is less than the eluent volume applied to the QIAamp Mini Column. Centrifuge the column at full speed (20,000 x g; 14,000 rpm) in a microcentrifuge for 1 minute to elute nucleic acids, resulting in cell-free RNA.

Free circulating cell-free RNA was lysed with AVE buffer, either for amplification reactions or stored at –30°C to –15°C. Purified nucleic acids are free of proteins, nucleases, and other impurities.

Next, nucleic acid concentration is determined according to the manufacturer's recommendations prior to amplification of the NRG1 fusion and detection assays, such as quantitative amplification assays.

Bill of Materials for Vacuum 1–24 QIAGEN Spin Chromatography Columns for the QIAvac 24 Plus System. QIAvac 24 Plus: Vacuum manifold for processing 1–24 centrifugal chromatography columns, including QIAvac 24 Plus vacuum manifold, Luer Plugs and Quick Couplings (Product No. 19413). Vacuum Adapter (500): Type 500 disposable adapter for use with QIAamp Mini Columns on a luer slot or VacValve (Product No. 19407). Vacuum Valves (24): 24 valves for use with the QIAvac 24 Plus (Product No. 19408). Vacuum Regulator: For use with the QIAvac manifold (Product No. 19530). Vacuum pump (230 V, 50 Hz): Universal vacuum pump (34 L/min capacity, 8 mbar absolute vacuum) (Product No. 84020). QIAvac Connecting System (Connecting System): A system used to connect vacuum manifolds and vacuum pumps: including trays, waste bottles, tubing, connecting tubes, valves, pressure gauges, and 24 vacuum valves (product number 19419).

To avoid loss of RNA from biological material during and after purification, first thoroughly clean any plastic or glassware to eliminate possible ribonuclease (RNase) contamination. By establishing and maintaining an RNase-free environment, you can avoid inadvertently introducing RNase into the separation process. Example 4 : Isolation of Circulating Tumor Cells

This protocol describes the isolation of circulating tumor cells from whole blood using the AdnaTest Breast CancerSelect Kit (ADNAGEN, Cat. No. T-1-508) allowing the generation of tumor cells immunomagnetically enriched for epithelial and tumor-associated antigens. Antibodies against epithelial and tumor-associated antigens were conjugated to magnetic beads (Dynabeads) to label tumor cells in peripheral blood. Labeled cell lines were extracted with magnetic particle harvesters (AdnaMag-L and AdnaMag-S) and subsequently lysed. mRNA was isolated from the resulting lysates and used to detect NRG1 fusions.

Whole blood (at least 5 ml, but possibly 10 ml) is collected in tubes containing EDTA (eg, 'S Monovette® Kalium EDTA', Sarstedt; 'BD Vacutainer® K3EDTA', Becton Dickinson) and immediately placed on ice on, then aspirate and dispose of within 4 hours.

Preparation of Select Beads: Thoroughly resuspend the BreastSelect Beads (provided in the kit) by aspiration. Calculate the volume of BreastSelect Beads required for the entire sample and transfer the calculated volume to a 1.5 ml reaction tube. The reaction tube was placed in an AdnaMag-S magnetic collector (AdnaGen GmbH, product number T-1-800). The supernatant was removed after 1 min. Wash the beads three times with 1 ml PBS (phosphate-buffered saline; pH 7.0 – 7.3). The reaction tube was removed from the AdnaMag-S and resuspended in 100 μl PBS.

Selection of Tumor Cells: First a 5 ml blood sample was drawn into a 15 ml tube. Add 100 μl of resuspended BreastSelect Beads to each blood sample. The tubes were spun slowly (approximately 5 rpm) on a tilt-and-rotate device for 30 minutes at room temperature. The tube was then placed in an AdnaMag-L (AdnaGen GmbH, Product No. T-1-700) without a magnetic slide and swung down to release the blood drop captured in the cap. Magnetic slides were then inserted and tubes were incubated at room temperature for 3 minutes. Remove the blood supernatant completely with a 10 ml suction tube without touching the magnetic beads. First remove the magnetic slide from the AdnaMag-L, add 5 ml of PBS to the tube, and gently resuspend the magnetic bead/cell complex to complete the three washes. The magnetic slide was placed back into the AdnaMag-L and the tube was incubated at room temperature for 1 minute before removing the supernatant with a suction tube. After washing, the magnetic slides were removed and the bead/cell complexes were resuspended in 1 ml PBS and transferred to 1.5 ml reaction tubes. Place the reaction tube inside the AdnaMag-S with the magnetic slide inserted. After 1 minute, all supernatants were removed for subsequent cell lysis.

The magnetic slides were removed from the AdnaMag-S, 200 μl of room temperature equilibrated lysis/binding buffer (provided in the kit) was added to each reaction tube, and then resuspended by pipetting five times. Insert the magnetic slide into the AdnaMag-S and incubate for 1 minute. The supernatant containing the cell lysate was transferred to a new 1.5 ml reaction tube, and the tube containing the magnetic beads was discarded. The cell lysate is suitable for mRNA isolation or stored at -20°C. mRNA from this lysate was isolated and transcribed into cDNA template in a reverse transcription (RT-PCR) reaction using an oligo-thymidine (Oligo (dT)) primer. NRG1 fusions were subsequently detected by PCR-mediated amplification. Example 5 : Extracellular Vesicles and Exocytosomes

Total vesicular RNA was obtained from blood using the ExoRNeasy Maxi Kit (Cat. No. 77023, QIAGEN GmbH, Hilden, Germany), which is isolated from cell-free biological fluids based on a membrane-based affinity binding procedure Cytosomes and other EVs.

Step 1 includes plasma separation and storage. Whole blood was collected in BD Vacutainer® Venous Blood Collection Tubes (Product No. 367525) containing EDTA (or Streck’s PAXgene® blood ccfDNA tubes [Product No. 768115] and cell-free DNA BCT® tubes, but not the RNA BCT tube). Store tubes at room temperature or 4°C and process within 1 hour. Blood samples were centrifuged in primary collection tubes at 1900 x g (3000 rpm) for 10 minutes at 4°C using a swinging bucket rotor. Carefully transfer the upper (yellow) plasma phase to a new tube (with conical bottom) without disturbing the middle buffy coat (containing leukocytes and platelets). Centrifuge plasma samples in conical tubes at 3000 x g for 15 min at 4°C (or at 16,000 x g for 10 min – see above) or pass through a 0.8 µm filter (Sartorius® Minisart® NML [Sartorius Prod. ]). Carefully transfer the clear supernatant to a new tube without disturbing the pellet. Plasma was stored at 2–8°C for 6 hours and processed the same day.

Step 2 describes the extraction and lysis of exosomes and other extracellular vesicles (EVs) from 4 ml of plasma. Add 4 ml of Binding Buffer XBP to 4 ml of plasma and immediately mix well by gently inverting the tube 5 times. The plasma/XBP mixture was added to an exoEasy spin column (a membrane affinity column that binds EVs to the membrane) and centrifuged at 500 x g for 1 min. Discard the flow-through and return the column to the same collection tube. Add 10 ml Wash Buffer XWP to the exoEasy Maxi Spin Column and centrifuge at 5000 x g for 5 minutes. Discard the effluent with the collection tube. Transfer the spin chromatography column to a new collection tube. Add 700 µl of QIAzol to the membrane to lyse the vesicles, centrifuge at 5000 x g for 5 min to collect the lysate, and transfer completely to a 2 ml tube.

Step 3 describes the isolation of total RNA from the lysate. Prepare buffers RWT and RPE according to the manufacturer's instructions. Tubes containing lysates were vortexed briefly and incubated at room temperature for 5 minutes. Then add 90 µl of chloroform to the tube and shake vigorously for 15 seconds. After incubation at room temperature for 2 to 3 minutes, the tubes were centrifuged at 12,000 x g for 15 minutes at 4°C. Transfer the upper aqueous phase to a new collection tube, add 2 volumes of 100% ethanol and mix thoroughly. Aspirate 700 µl of sample onto an RNeasy MinElute spin chromatography column in a 2 ml collection tube and centrifuge at ≥8000 x g (≥10,000 rpm) for 15 seconds. After discarding the run-off, repeat this step with the remaining sample. Add 700 µl Buffer RWT to the RNeasy MinElute spin column and centrifuge at ≥8000 x g (≥10,000 rpm) for 15 seconds, followed by 500 µl Buffer RPE and centrifuge at ≥8000 x g (≥10,000 rpm) for 15 seconds. Discard the liquid that escapes from each step. Finally, 500 µl of Buffer RPE was added to the RNeasy MinElute spin column and centrifuged at ≥8000 x g (≥10,000 rpm) for 2 minutes. Discard the collection tube along with the effluent.

Place the RNeasy MinElute spin chromatography column into a new 2 ml collection tube and centrifuge at full speed for 5 minutes with the cap open to dry the membrane. Discard the collection tube along with the effluent. 14 µl RNase-free water to elute the RNA, let the tube sit for 1 min, and centrifuge at full speed for 1 min. Example 6 : Tumor-Educated Platelets (TEP)

Tumor cells are known to transfer (mutated) RNA into platelets, which are subsequently used to detect tumor-associated RNA markers. This protocol minimizes platelet mRNA degradation and minimizes contamination with other cell types such as erythrocytes and leukocytes (Amisten S, Methods Mol Biol. 2012). RNA obtained from platelets was then used to amplify and detect NRG1 fusions.

Preparation of antibody-conjugated magnetic beads: Mix 1 ml Dynabead wash buffer (PBS with 0.1% (w/v) BSA, pH 7.4) with 250 μl Dynabead slurry (Dynabeads® Pan Mouse IgG, Invitrogen) and place Dynamag magnet (DynaMag™-2 or DynaMag™-15, Invitrogen) for 1 min, after which the liquid was removed. After another wash, the beads were removed from the magnet and resuspended in 250 μL of wash buffer. 15 μl of anti-CD235a antibody (mouse, anti-human CD235a, erythrocyte surface marker, BD Inc, NJ, USA) and 15 μl of anti-CD45 antibody (mouse anti-human CD45, leukocyte surface marker, BD Inc, NJ, USA) was added to the magnetic beads, mixed and incubated for at least 30 minutes with gentle tilting and rotation. The supernatant was removed by placing the tube in the magnet for 1 min, and the beads were resuspended in 250 μl wash buffer before storage at 4°C.

Collect blood cells and purify platelets: 18 ml ACD (sterile anticoagulant: citrate dextrose solution, Sigma Aldrich), 12 μl 1 mM PGE1 (Prostaglandin E1, 1 mM stock solution in ethanol, Sigma Aldrich), 120 μl A platelet inhibitory cocktail was prepared with 30 mM acetylsalicylic acid (30 mM stock solution in ethanol, Sigma Aldrich), and 480 μl of 0.5 M EDTA (Sigma Aldrich). 8.5 ml of blood were collected in tubes of 15 ml tubes further containing 1.5 ml of platelet inhibitory cocktail. After centrifugation at 200g for 20 minutes at room temperature, the upper 85% platelet rich (PRP) plasma was transferred to a new 15 ml tube. After another centrifugation (200g, 10 min, room temperature) to remove white and red blood cells, 85% of the PRP was transferred to a 50 ml tube. Then, PRP was filtered with AutoStop™ BC high-efficiency filter (Pall Company, product number ATSBC1E) to remove leukocytes, and the filtrate was mixed with antibody-conjugated magnetic beads and incubated while tilting and rotating at room temperature for 45 minutes. The PRP/magnetic bead mixture was placed in the DynaMag™-2 for 2 minutes, and the supernatant was transferred to a new tube for depleted PRP. After repeating the PRP depletion step, the supernatant was harvested by centrifugation at 800 g for 10 min at room temperature. Platelet pellets were weighed and dissolved in 1 ml TRIzol (Invitrogen) per 100 mg of pellet, with a minimum of 1 mL TRIzol for samples weighing less than 100 mg.

Isolation of platelet RNA: Platelet samples dissolved in TRIzol were incubated for 5 minutes at room temperature and 200 μl of chloroform (Sigma Aldrich) was added to each tube. After 15 to 30 minutes of vigorous shaking, the tubes were incubated at room temperature for 2 to 3 minutes and centrifuged at 12,000 g for 15 minutes at 4°C. Add 10 μg Ultra Pure Glycogen (UltraPure™ Glycogen, Invitrogen, Product No. 10814–010) to a new RNase-free tube. The aqueous phase of the TRIzol/chloroform mixture was carefully added to the tube containing glycogen, followed by 500 μl of cold isopropanol (Sigma Aldrich). The tubes were mixed and left overnight at –20°C. After centrifugation at 12,000g for 15 minutes at 4°C, the supernatant was removed and the RNA pellet was washed in 1 ml of 75% ethanol. The dried RNA pellet is dissolved in RNase-free water and can be further used for reverse transcription to cDNA. Example 7 : ddPCR nucleic acid amplification and fusion detection

Droplet digital polymerase chain reaction (ddPCR) was used to detect target nucleic acid fusions in cfDNA and cfRNA samples from liquid samples.

Use Bio-Rad's QX100 ^TM or QX200 ^TM Droplet Digital PCR System to perform droplet digital polymerase chain reaction (ddPCR) to enable detection of target nucleic acid fusions in DNA and/or RNA (cDNA) samples from liquid specimens things.

Primers and probes: Primers are designed near fusion junctions or breakpoints to amplify NRG1 fusion products with a size of 60-200 bp. The Primer3 program (Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology) was used to design primers with a GC content of 50-60% and _{a Tm} between 50 and 65°C (at 50 mM salt concentration and 300 nM oligonucleotide nucleotide concentration) to avoid secondary structures and primer-dimers.

Sequence-specific TaqMan ^™ hydrolysis probes fluorescently labeled with FAM, HEX, or VIC dyes were used. The probe sequence is selected between the two primers of the amplicon. The _Tm of the hydrolysis probe is 3-10°C higher than that of the primer with 30-80% GC content. The probes are less than 30 nucleotides in length.

Sample preparation: Use the A260 spectrometer to evaluate the concentration of input DNA/RNA to confirm that the target DNA/RNA concentration to be loaded is within the detection dynamic range. The recommended DNA dynamic range for the QX100 or QX200 system is 120,000 replicates per 20 μl reaction. Genomic DNA was also cut by restriction enzyme digestion using 4 Dicer or 6 Dicer with 10 units of enzyme per μg DNA according to the manufacturer's recommendations. Digested and cleaved DNA was stored at -20°C until further use.

When performing experiments using cfDNA as starting material, the fusion sequence includes the fusion site plus contiguous sequences of sufficient length on each side to encompass the PCR amplicon. The resulting nucleotide sequence is between 50-250 ntd. A T7 promoter sequence (5'-CAGAGATGCATAATACGACTCACTATAGGGAGA-3') was added to the 5' end of the target sequence. Synthetic sequences in the form of double-stranded deoxyribonucleic acid (DNA) fragments were ordered from IDT (www.idtdna.com) and rehydrated in Tris-EDTA (TE) buffer to a final concentration of 10 ng/μl.

When using RNA as starting material, first use RT-PCR to generate cDNA, for example using Bio-Rad's iScript ^TM Select cDNA synthesis for oligothymine (oligo(dT)) or gene-specific priming set. The cDNA concentration was reduced to an equivalent of approximately 0.2 ng/μl RNA, and 5 μl was used per droplet digital PCR reaction (total volume 20 μl).

To generate a positive control for cfRNA, 60 ng of synthetic DNA was converted to RNA using in vitro transcription and the resulting RNA transcript was purified using a phenol/guanidine based reagent. Add DNase I to remove residual template DNA. RNA quality was assessed by gel electrophoresis. The resulting RNA was diluted to concentrations ranging from 0.25 to 2.5 fg based on the desired number of replicates exported to the test sample. Aliquots of 10 μl of analyzed RNA for use in positive controls were stored at –80°C. Nuclease-free water was used as a negative control for cfDNA and cfRNA.

ddPCR reaction: Prepare 20 μl PCR mixture containing sample nucleic acid (1 μg DNA or cDNA, final concentration 50 ng/μl), 2x ddPCR supermix ((Bio-Rad, product number 1863023; excluding 2 '-deoxyuridine 5'-triphosphate) - 10 μl, 20x fusion-specific primer/probe set (450 nmol/L primer, 250 nmol/L FAM probe) - 1 μl, 20x control target primer /probe set (450 nmol/L primer, 250 nmol/L HEX probe) - 1 μl and nuclease-free water. Set up an initial reaction pool of slightly more than 20 μl (22-25 μl) to ensure that the 20 μl of the mixture was transferred to a DG8 cassette (Bio-Rad, product number 1864007). The reaction mixtures were combined and mixed well in a separate tube (not in the droplet generation cassette). Then the The reaction mixture was transferred to a DG8 cassette preloaded in a DG8 cassette holder (Bio-Rad, prod. no. 1863051).

After loading 20 μl of PCR reaction, 70 μl of droplet generation oil (Bio-Rad, prod. no. 1863005) was loaded into the bottom of each well of the DG8 cassette. Install a gasket on top of the DG8 cassette and place it into the QX200 Droplet Generator. The droplet generator generates about 20,000 oil droplets per sample for 8 samples in about 2.5 minutes. The oil droplets were then gently transferred by suction to a 96-well plate. PCR well plates were heat sealed using Bio-Rad's PX1™ PCR Plate Sealer and a pierceable heat seal foil. Then put the PCR well plate into a C1000 Touch ^TM thermal cycler (Thermal Cycler) with a 96-deep well reaction module for PCR. Thermal cycling conditions were as follows: Enzyme activation at 95°C (10 minutes, 1 cycle); 40 cycles of denaturation (94°C, 30 seconds) and adhesion/prolongation (55°C, 1 minute); enzyme at 98°C Inactivation, 10 minutes, 1 cycle. A ramp rate of 2°C per second was used.

After PCR amplification of the nucleic acid targets in the oil droplets, the plate containing the oil droplets is placed into a QX100 or QX200 droplet reader using QuantaSoft software using a two-color detection system (set to detect FAM and HEX) Each oil droplet is analyzed individually. Positive oil droplets containing at least one copy of the target DNA/RNA molecule exhibit increased fluorescence compared to negative oil droplets. Concentrations are reported as number of replicates per μl final 1x ddPCR reaction. Use the threshold tool to correctly indicate that the oil droplet populations are double negative (both FAM and HEX are negative), FAM positive, HEC positive, and double positive (both FAM and HEX are positive). Absolute quantification of the target was obtained in replicates per microliter and replicates per microdrop using ABS analysis. Example 8 : Anchored Multiplex PCR

Anchored multiplex PCR (AMP) was used to detect gene fusions and to detect multiple fusions to a gene of interest. The following experimental protocol is based on the Archer FusionPlex Solid Tumor Kit (ArcherDX, Product No. AB0005), and is carried out using RNA obtained from liquid specimens such as Example 6. Sample bank preparation:

Include a positive control group containing at least several confirmed gene fusions. A non-template control group was included as an additional sample for each run.

Random-primed, first and second strand cDNA synthesis: The input to the assay is 200 ng of RNA diluted in 10 mM Tris HCl, pH 8.0. Add 20 μl of diluted RNA to pre-chilled Random Priming Reagent Strips (provided in the kit). After mixing and a brief quick spin, the mixture was transferred to a 96-well PCR well plate, sealed with RT membrane (USA Scientific, prod. no. 2921-7800) and incubated at 65°C for 5 minutes on a thermal cycler aluminum block (lid heated Down).

The random priming products were transferred to the first reagent train tube (in a pre-cooled aluminum block) and mixed, spun briefly, and transferred to a 96-well PCR well plate. Use the following thermal cycler program: 25 °C for 10 min, 42 °C for 30 min, 80 °C for 20 min, hold at 4 °C (with lid heated).

A 1:10 dilution of the first strand was made in nuclease-free water in a new set of PCR reaction strips for use in the Pre-Seq quality control (QC) assay. The QC assay is primarily used to verify the absence of cDNA synthesis in the non-template control group. QC assays were performed according to the manufacturer's protocol.

For second-strand cDNA synthesis, add 21 μl of nuclease-free water to the remaining first-strand product, and add 40 μl of this product to the second-strand reagent strip (supplied in the kit, set in the pre- cold aluminum block). After mixing and a brief quick spin, the mixture was transferred to a 96-well PCR well plate and sealed. Insert the well plate into a thermal cycler aluminum block and use the following thermal cycler program: 16 °C for 60 min, 75 °C for 20 min, hold at 4 °C (with lid heated).

End Repair: Transfer 40 μl of the second-strand product to the End Repair Reagent Strip Reaction Tube (provided in the kit, placed in a pre-cooled aluminum block). After mixing and a brief quick spin, the reaction tube strips were incubated in a thermal cycler aluminum block at 25°C for 30 minutes and then held at 4°C. The end-repair product was added to purification beads (Agencourt AMPure XP Beads, Bechman Coulter, Product No. A63881 ) at room temperature. After mixing, the mixture was incubated at room temperature for 5 minutes, followed by incubation on a magnet (Alpaqua, Product No. A32782) for 5 minutes. The supernatant was discarded, and the beads were washed twice with 200 μl of 70% ethanol, incubated for 30 seconds and air-dried for 5 minutes. Beads were resuspended in 22 μl of 10 mM Tris HCl, pH 8.0, incubated for 3 minutes off the magnet, followed by 2 minutes on the magnet.

Ligation step 1: Transfer 20 μl from the end-repair bead purification plate into ligation step 1 run-through reaction tubes (provided in the kit, placed in a pre-cooled aluminum block). After mixing and a brief quick spin, the mixture was incubated in a 96-well PCR well plate in a thermal cycler aluminum block at 37°C for 15 minutes, then kept at 4°C (with lid heating). The full volume of ligation step 1 product was added to 50 μl of room temperature equilibrated beads. After mixing, the mixture was incubated at room temperature for 5 minutes, followed by incubation on the magnet for 5 minutes. The supernatant was discarded and the beads were washed twice with 200 μl of 70% ethanol with a 30 second incubation. After the final wash, all 70% ethanol was removed and the beads were air dried for 5 minutes. Beads were removed from the magnet and resuspended in 42 μl of 10 mM Tris HCl, pH 8.0, incubated for 3 minutes off the magnet, followed by 2 minutes on the magnet.

Ligation Step 2: Remove MBC Adapter Strip Reagents (provided in the kit) from 4°C storage and number them correctly. Specific indices of samples are also recorded for sequencing purposes.

Transfer 40 μl from the bead purification well plate of ligation step 1 to MBC adapter series reaction tubes (ArcherDX, product number AK0016-48, placed in a pre-cooled aluminum block). After mixing and a brief quick spin, transfer the mixture to the ligation step 2 reagent strip (supplied in the kit, also placed in a pre-chilled aluminum block). After mixing and a brief quick spin, the mixture was incubated in a thermal cycler at 22°C for 5 minutes, then held at 4°C.

Ligation Cleanup beads (room temperature equilibrated) were swirled and 50 μl added to a new PCR strip. After 1 minute incubation on the magnet, the supernatant was discarded. The reaction tube strips were removed from the magnet and resuspended in 50 μl of Ligation Cleanup Buffer.

The ligation step 2 product was added to the ligated clean-up bead strip reaction tube, vortexed and incubated at room temperature for 5 minutes. Mixing and incubation were repeated, after which the samples were incubated on the magnet for 1 min and the supernatant was discarded. 200 μl of ligation cleanup buffer was added to resuspend and the mixture was placed on the magnet for 1 min after a quick spin. Repeat the wash with ligation cleanup buffer. The same wash was performed with ultrapure water, after which the beads were resuspended in 20 μl of 5 mM NaOH and incubated in a PCR well plate in a thermal cycler aluminum block with the following conditions: 75°C for 10 minutes followed by a hold 4°C (with lid heated). Place the PCR well plate on the magnet for at least 3 minutes.

1st PCR: Add 2 μl of NRG1-specific primers (GSP1 primers) to each well in the 1st PCR Reagent Strip (provided in the kit) and combine with 18 μl of the conjugation step 2 cleanup product mix. After a brief quick spin, the mixture was incubated in a thermocycler with the following program: 95°C for 3 min, 15 cycles; 95°C for 30 sec - 65°C for 5 min (100% ramp rate); 72°C for 3 min min, followed by maintaining at 4 °C (with the lid heated).

20 μl of the first PCR product was added to 24 μl of room temperature equilibrated beads, mixed and incubated for 5 minutes at room temperature and 2 minutes on the magnet. The supernatant was then removed, the beads were washed twice with 200 μl of 70% ethanol incubated for 30 seconds and air-dried, and resuspended in 24 μl of 10 mM Tris HCl, pH 8.0. The second PCR and sample bank quantification

Add 2 μl of additional NRG1-specific primers (GSP2 primers) to each well in a properly labeled second PCR reagent strip reaction tube (supplied in the kit) on a cold aluminum block and mix with 18 μl of the first PCR cleanup product mix. After a brief quick spin, the mixture was incubated in a thermal cycler with the following conditions: 95°C for 3 min, 18 cycles; 95°C for 30 sec - 65°C for 5 min (100% ramp rate); 72°C for 3 min min, followed by maintaining at 4 °C (with the lid heated).

20 μl of the second PCR product was added to 24 μl of room temperature equilibrated beads, mixed and incubated for 5 minutes at room temperature and 2 minutes on the magnet. Afterwards, the supernatant was removed, and the beads were washed twice with 200 μl of 70% ethanol, incubated for 30 seconds and air-dried. After 2 minutes of incubation on the magnet, 20 μl of the second PCR product was transferred to a new PCR plate and quantified.

The concentration of each library was determined by qPCR using the Kapa Biosystems Library Quantification Kit (Library Quantification Kit) for the Illumina platform code KK4973 according to the manufacturer's instructions. The second PCR product was serially diluted with 10 mM Tris HCl pH 8.0 and 0.05% Tween. Add 6 μl per well of the library quantitation master mix (library quantitation master mix) (Kapa Biosystems, product number KK4973) to the 96-well optical reaction plate, and then add 4 μl of the appropriate dilution or standard (Kapa Biosystems, product number KK4906, KK4903). The following qPCR program was used: 1 cycle of 95°C for 5 minutes; 35 cycles of 95°C for 30 seconds (temperature ramp rate 4.4°C/sec) - 60°C for 45 seconds (temperature ramp rate 2.2°C/sec). After pool quantification was complete, all pools were normalized and 10 μl of each normalized pool pooled into a 1.5 ml microcentrifuge tube. Sequencing of sample banks:

Remove the sequencing reagent cartridge from the freezer and place in deionized water to the fill line for at least one hour. The sequencing reagent set (MiSeq Reagent Set v3 – 600 cycles; Illumina; Product No. MS-102-3003) was equilibrated to room temperature. 10 μl of the library pool was combined with 10 μl of 0.2N NaOH to make a denatured amplicon library (DAL) pool and incubated at room temperature for 5 minutes. 10 μl of 200 mM Tris HCl, pH 7.0 was added to the DAL, followed by 970 μl of HT1 buffer (provided in the kit).

Combine 300 μl of HT1, 25 μl of 20 pM PhiX, and 675 μl of the DAL pool to make the final fill tube. After mixing and a brief quick spin, add the full volume of the fill tube to the sample well of the sequencing reagent cartridge, and load the cartridge into the sequencer for sequencing with 2×151 bp reads and 2×8 indexes Data (index reads) were run (MiSeqDx System - Illumina).

RNA fusion data were analyzed using appropriate bioinformatics data analysis software. Example 9 : Next Generation Sequencing

Next-generation sequencing was performed on DNA samples using the MI-Exome assay (Caris Molecular Intelligence®, Caris Life Sciences), which uses DNA and provides tumor mutational profiling using custom human exome panels to detect mutations including Variants of single nucleotide polymorphisms, insertions/deletions, and DNA rearrangements and fusion events.

The following customized exosome panel (panel) is a mixed panel using five panels. The set was validated using the Illumina NovaSeq 6000 instrument. This hybrid kit consists of two off-the-shelf kits from Agilent and three optimized kits developed by Caris: Agilent Human All Exon V7 Kit (48 MB) Agilent SNP Backbone Kit (3 MB kit with 1 MB resolution) Caris 719-Gene Targeted Clinical Kit (1 MB) Caris Intronic Fusion Package (0.1 MB) Caris Pathogenic Package (0.1 MB)

For RNA starting material, next-generation sequencing is performed using whole-genome transcript assays, such as the MI TranscriptomeTM assay set (Caris Molecular Intelligence®, Caris Life Sciences). The assay was used to detect gene fusions and splice variants using the Agilent SureSelect Human All Exon set when sequencing on the Illumina NovaSeq instrument. Example 10 : Fluorescence in situ hybridization (FISH)

FISH is performed on circulating tumor cells (CTCs) obtained from plasma or blood or other liquid specimens using a fragmentation probe. For example, circulating tumor cell lines are purified from plasma, serum, etc. using the CellSearch® (Menarini silicon biosystems, Italy) or ISET® (Rarecells Diagnostics, Paris, France) system, and fixed on glass slides.

Briefly, CTCs concentrated from whole blood were mounted on separate glass slides (Frithiof, Henrik et al., OncoTargets and therapy Vol. 9, 7095-7103, Nov. 16, 2016). The CTC-containing solution (-900 μL) was transferred to a 1.5 mL Eppendorf tube and placed in a magnetic tray. After 10 minutes of incubation, unattached solvent was removed. Cells were resuspended in 10 μL of 1X phosphate buffered saline and mounted on superfrost slides (ThermoScientific, Germany) and incubated at 37°C for 30 minutes. Fix the slides by immersing them in 100% methanol for 5 min. Samples were stored at −20°C until further evaluation.

Cell pretreatment was accomplished using the ZytoLight® FISH-Tissue Implementation Kit (ZytoVision, Product No. Z-2028-5). Buffers PT1, ES1, WB1, WB2 and MT7 are provided in the kit.

Slides were incubated at 70 °C for 10 minutes, followed by 2 x 10 minutes in xylene. Slides were then rehydrated using a series of ethanol 100%, 100%, 90%, 70% ethanol for 5 minutes each, and finally washed 2 x 2 minutes in deionized or distilled water. Slides were incubated in pre-warmed Heat Pretreatment Solution Citric (PT1) for 15 minutes at 98°C and immediately transferred to deionized or distilled water for 2 x 2 minute washes. After the moisture was blotted, the sample was applied with pepsin solution (Pepsin Solution (ES1)) and incubated in a humidity chamber at 37°C for 15 minutes, and washed with washing buffer SSC (WB1) for 5 minutes. Slides were washed in deionized water for 1 min, dehydrated in a series of ethanol 70%, 90%, and 100% ethanol for 1 min each and air dried.

ZytoLight SPEC NRG1 dual-color break separation probe (PL140) is composed of polynucleotides labeled with green fluorescent dye (ZyGreen) and orange fluorescent dye (ZyOrange). These probes target the remote location that maps to a breakpoint occurring in a gene of interest such as VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, AGRN, THBS1, or PVALB. end and proximal sequences. 10 μl of probes were pipetted onto each pretreated sample, covered with a 22 mm x 22 mm coverslip and sealed. Place the slides in a hybridization instrument at 75°C for 10 minutes to complete denaturation, then transfer the slides to a humidified chamber and hybridize overnight at 37°C.

The next day, slides were immersed in 1 x Wash Buffer A (WB2) at 37°C for 1 to 3 minutes to remove coverslips, and washed an additional 2 x 5 minutes at 37°C with Wash Buffer A. Slides were incubated in 70%, 90% and 100% ethanol for 1 minute each and air dried. 25 μl of DAPI/DuraTect-solution (MT7) was pipetted onto the slide, covered with a coverslip and incubated for 15 minutes in the dark. Sample fluorescence was then evaluated with a fluorescence microscope using the appropriate ZyGreen (excitation 503 nm/emission 528 nm) and ZyOrange (excitation 580 nm/emission 599 nm) filters. Results are illustrated based on the overlapping or non-overlapping appearance of the green and orange signals. Example 11 : Immunocytochemical staining (ICC)

Perform immunocytochemical staining on circulating tumor cells obtained from plasma or blood or other liquid samples to detect the expression of NRG1 fusion protein. For example, circulating tumor cell lines are purified from plasma, serum, etc. using the CellSearch® (Menarini silicon biosystems, Italy) or ISET® (Rarecells Diagnostics, Paris, France) system, and fixed on glass slides.

Briefly, CTCs concentrated from whole blood were mounted on separate glass slides (Frithiof, Henrik et al., OncoTargets and therapy Vol. 9, 7095-7103, Nov. 16, 2016). The CTC-containing solution (-900 μL) was transferred to a 1.5 mL Eppendorf tube and placed in a magnetic tray. After 10 minutes of incubation, unattached solvent was removed. Cells were resuspended in 10 μL of 1X phosphate buffered saline and mounted on ultra-frozen slides (ThermoScientific, Germany) and incubated at 37°C for 30 minutes. Fix the slides by immersing them in 100% methanol for 5 min. Samples were stored at −20°C until further evaluation.

Following fixation, protein detection on slides is performed using an appropriate immunostaining system (eg, Ventana Discovery Automated Immunostaining System, Ventana Medical Systems, Tucson, AZ, USA). Briefly, cells mounted on ultra-frozen slides were pretreated in EDTA-based buffer at pH 8.0. Two primary antibodies were administered to the NRG1 fusions of the present disclosure. For example, an anti-NRG1 antibody targeting a region at a position C-terminal to the fusion junction such as the EGFR domain of NRG1, and another primary antibody targeting a CD44 epitope at a position N-terminal to the fusion junction or domain. Antibody dilution is performed with an appropriate diluent. These antibodies were detected using appropriate secondary antibodies and two different fluorescent detection systems. Immunostaining was visualized using different channels in a fluorescent microscope. Results are illustrated based on the overlapping or non-overlapping appearance of the two fluorescent signals. Example 12 : Treatment Experimental Protocol

Treatment with zetuzumab in patients diagnosed with each of the following fusions: VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2-NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR- NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, DAAM1-NRG1, ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SLC4A4-NRG1, SDC4-NRG1, ZFAT-NRG1, and DSCAML1-NRG1, were treated as follows.

According to the biweekly plan, the first infusion of 750 mg of zetuzumab lasted 4 hours, followed by infusions every other week for 2 hours, with a cycle of 4 weeks. Also included are prep medications for the management of IRR (Infusion-Related Reactions), which include antipyretics and antihistamines for all infusions. Corticosteroids were also included prior to Cycle 1 dosing on Day 1; thereafter, administered at the investigator's discretion to manage the IRR. Example 13 : Patient-derived VAPB-NRG1 fusion data

A paraffin-fixed tumor material sample with 60% neoplastic cells obtained from the right body wall pleura of a 68-year-old male patient diagnosed with lung adenocarcinoma was subjected to the following molecular biotechnology analysis.

An Archer FusionPlex ^™ panel that detects a panel of 14 genes (ALK, BRAF, EGFR, FGFR1, FGFR2, FGFR3, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3, RET, ROS1) was used. The library was prepared according to the manufacturer's instructions, and next-generation sequencing (NGS) was performed on an Illumina MiSeq sequencer, and sample analysis was completed using the Archer Analysis 6.0 site.

Samples positive for the VAPB-NRG1 fusion were tested in this panel. This sample was sequenced to allow the identification of the sequence as SEQ ID NO:3. It shows a fusion junction between exon 1 of VAPB and exon 2 of NRG1. The underlined sequence (nucleotides 1-43) corresponds to part of exon 1 of the gene encoding VAPB (NM_004738.4). Nucleotides 44-94 correspond to a portion of the gene encoding NRG1. CAGGTCCTGAGCCTCGAGCCGCAGCACGAGCTCAAATTCCGAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTT (SEQ ID NO: 3). Example 14 : Patient-derived CADM1-NRG1 fusion data

Formalin-fixed paraffin blocks of neoplastic material obtained from a male patient diagnosed with metastatic lung adenocarcinoma NOS were subjected to the following molecular biotechnological analyses.

Molecular testing was performed after harvesting of metastatic brain tissue by approved microdissection techniques. Candidate slides are examined under a microscope and the areas containing tumor cells (and, if required, isolated normal cells) are circled. A laboratory technician harvests and removes the target tissue from the marked area using a dissecting microscope. The marked and removed areas were remicroscopically examined on microdissected slides, and the adequacy of the microdissection was rechecked.

RNA-Seq (RNA sequencing) was performed on the cDNA obtained from this sample to allow the identification of the sequence as SEQ ID NO:7. It shows the presence of an in-frame fusion with a junction between exon 7 of the CADM1 gene and exon 6 of the NRG1 gene. The underlined sequence, namely nucleotides 1-53, corresponds to a part of exon 7 of CADM1 gene (NM_001301045.1). Nucleotides 54-85 correspond to part of the gene encoding NRG1 (NM_001159999.3). AGCTTCAAACATAGTGGGGAAAGCTCACTCGGATTATATGCTGTATGTATACGCTACATCTACATCCACCACTGGGACAAGCCAT (SEQ ID NO: 7).

Genome DNA isolated from formalin-fixed and paraffin-embedded tumor samples was analyzed for tumor mutational burden based on next-generation sequencing (NGS) analysis using the Illumina NextSeq platform. Tumor mutational burden was calculated using only missense mutations that had no previous reports of germline alterations. High mutational burden is a potential indicator of response to immunotherapy (Hellman et al., NEJM, 2018; Le et al., NEJM, 2015; Rizvi et al., Science, 2015; Rosenberg et al., Lancet 2016; Snyder et al., NEJM, 2014 ). The cutoff point in NSCLC was based on a large phase 3 trial that showed improved progression-free survival in patients with mutations in TMB of 10 or more per megabase when treated with immune checkpoint inhibitor combination therapy The period is longer than when treated with chemotherapy (Hellman et al., NEJM, 2018). High: greater than or equal to 10 mutations per megabase; low: less than or equal to 9 mutations per megabase. The patient sample had a TMB score of 9.

Samples were analyzed for microsatellite instability (MSI) by NGS, which showed stable MSI signatures. MSI status in NGS (MSI-NGS) is determined by direct analysis of known microsatellite regions sequenced in a panel of 592 known genes. To determine clinical thresholds, MSI-NGS results were compared to results from more than 2,000 matched clinical cases analyzed with conventional PCR-based methods. Genomic variants in the microsatellite base were detected using the same depth and frequency criteria as used for mutation detection. Only insertions and deletions that change the number of tandem repeats are considered in this assay. The total number of microsatellite variants in each sample was counted and divided into three categories: high, ambiguous, and stable. Results with low MSI are reported in the stable category.

Immunohistochemical staining performed on the samples showed negative results for ALK and PD-L1, and positive results for MLH1, MSH2, MSH6, PMS2, and PTEN.

No fusions or mutations of the following cancer type-associated biomarkers were detected in the obtained samples using NGS or RNA-Seq analysis: NTRK1, NTRK2, NTRK3, KRAS, ALK, DOR2, ErbB2, ErbB3, ErbB4, PIK3CA, TP53, MET, PD-L1, RET, ROS1, STKI1, TP53. Example 15 : Patient-derived CD44-NRG1 fusion data

The biological sample of neoplastic material obtained from the liver of a 46-year-old male patient was subjected to the following molecular biotechnology analysis.

Gene fusions in tumor samples were detected using the Archer FusionPlex ^TM Custom Solid kit, which utilizes Anchored Multiplex PCR (AMP ^TM ) technology to target 62 exons in a previously reported chromosomal rearrangement. Unidirectional gene-specific primers (GSP) were designed for these 62 target exons. GPS was combined with adapter-specific primers to amplify known and novel fusion transcripts. The enriched amplicons were sequenced on an Illumina MiSeq sequencer.

Samples in this study group tested positive for the CD44-NRG1 fusion. The sample was sequenced to allow identification of the sequence as SEQ ID NO: 11. It shows that there is an in-frame fusion with a fusion junction between exon 5 of CD44 and exon 2 of NRG1. The underlined sequence, nucleotides 1-52, corresponds to a part of exon 5 of the CD44 gene (NM_000610). Nucleotides 53-110 correspond to part of exon 2 of the gene encoding NRG1. GACGAAGACAGTCCCTGGATCACCGACAGCAGCAGACAGAATCCCTGCTACCACCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACT (SEQ ID NO: 11).

The sample tested negative in this clinical validation panel containing a total of 62 exon targets: ALK exon 20 (NM_004304), ERG exons 2,4,8 (NM_004449 ), EWSR1 exon 6,7,8,10,11 (NM_005243), FGFR3 exon 17,18 (NM_00142), FGFR2 exon 17 (NM_00141.4), FOXO1 exon 2 (NM_002015), NTRK3 exon 11,12,14,15 (NM_002530), RET exon 12 (NM_020975), ROS exon 34,35 (NM_002944), SS18 exon 10 (NM_001007559 ), STAT6 exon 16,17,19 (NM_001178078), TAF15 exon 6 (NM_139215), TFE3 exon 6 (NM_006521), BRAF exon 7,9,11 (NM_004333), NTRK1 exon 12 (NM_002529), FUS exon 5,8 (NM_004960), CIC exon 20 (NM_015125). Example 16 : Patient-derived SLC3A2 -NRG1 fusion data

Neoplastic material showing primary adenocarcinoma tissue obtained from left lower lobectomy of a female patient diagnosed with lung adenocarcinoma was subjected to the following molecular biotechnological analysis.

Molecular assays were performed using Archer Lung Fusion Plex, Illumina MiniSEQ after harvesting neoplastic cells by sequencing of the following target genes: ALK, BRAF, FGFR1, FGFR2, FGFR3, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3, RET , ROS1. The reference gene body is GRCh37/hg19.

RNA-Seq (RNA sequencing) was performed on the cDNA obtained from this sample to allow the identification of the sequence as SEQ ID NO: 15. It shows the presence of an in-frame fusion junction occurring between exon 1 of the SLC3A2 gene and exon 5 of the NRG1 gene. The underlined sequence, i.e. nucleotides 1-53, corresponds to a part of exon 1 of the gene encoding SLC3A2 ((NM_001013251). The remaining 35 nucleotides, i.e. nucleotides 54-88, correspond to the outside of the NRG1 gene Part of exon 5. CCGCATCGGCGACCTTCAGGCCTTCCAGGGCCACGGCGCGGGCAACCTGGCGG CATCTACATCTACATCCACCACTGGGACAAGCCAT (SEQ ID NO: 15). Example 17 : Patient-derived VTCN1-NRG1 fusion data

Metastatic neoplastic specimen material obtained from the right parasternal site of a patient diagnosed with lung adenocarcinoma was subjected to the following molecular biotechnological analysis of selected tissue blocks containing neoplastic cells.

After harvesting of neoplastic cells by sequencing and TNA extraction, molecular assays were performed on the obtained material using the Archer Fusion Plex RNA CTL_V6 (Archerdx) kit using flow cells via Nextseq pair end N°HFFJFAFX2 and Sophia DDM Version 5.7.4—b127-31a209c, Process (Pipeline) ID ILL1AM1R2 / v5.5.24.1 / GEN1GN1FSQ2 to achieve.

Refers to panels that detect mutations in the following regions of interest (and exons in brackets): AKT1 (3), ALK (22, 23, 24, 25), AXL (5, 11, 15, 17) , BRAF (11, 15), CTNNB1 (3), CYSLTR2 (6), DDR2 (17), EGFR (18, 19, 20, 21), ERBB2 (20), FGFR1 (2, 8, 9, 10, 17 ), FGFR2 (2, 5, 7, 8, 9, 10), FGFR3 (3, 5, 8, 9, 10), GNA11 (4,5), GNAS (8, 9), GNAQ (4,5) , HRAS (2, 3, 4), IDH1 (4), IDH2 (4), KEAP1 (all), KIT (11, 13, 17), KRAS (2, 3, 4), MAP2K1 (2, 3), MET (13 à 19), NRAS (2, 3, 4), PIK3CA (9, 20), POLE (9 à 14), RAF1 (4, 5, 6, 7, 9, 10, 11, 12 ), RET (11, 13, 14, 15, 16), ROS1 (38), STK11 (all), TP53 (all). The following transcriptional fusions were detected: ALK, AXL, BRAF, CCND1, EGFR, FGFR1, FGFR2, FGFR3, MAP2K1, MET, NRG1, NTRK1, NTRK2, NTRK3, PPARG, RAF1, RET, ROS1. And detect the following manifestations: ALK, CCND1, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, RET, ROS1.

No mutations were observed in exons 18-21 of the EGFR gene; no mutations were detected in exons 2 and 3 of the KRAS gene; no mutations were detected in exons 11 and 15 of the BRAF gene; No mutation detected in exon 20; no mutation detected in exon 9 and 20 of PIK3CA gene; no mutation detected in exon 14 of MET gene; mutation 395G>T detected in exon 4 of IDH1 gene , resulting in a R132L amino acid change and a transcriptional fusion was detected between exon 2 of VTCN1 and exon 2 of NRG1.

Transcriptional fusions involving the ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, and FGFR3 genes were not detected.

No ERBB2 or MET overexpression was detected.

RNA-Seq (RNA sequencing) was performed on the cDNA obtained from this sample to allow the identification of the sequence as SEQ ID NO: 166. It shows the presence of an in-frame fusion junction occurring between exon 2 of the VTCN1 gene and exon 2 of the NRG1 gene. The underlined sequence, nucleotides 1-65, corresponds to a part of exon 2 of the gene encoding VTCN1 (access code NM_024626.4). The remaining 28 nucleotides, nucleotides 66-93, correspond to part of exon 2 of NRG1. CATAATTAGCATCATCATTATTCTGGCTGGAGCAATTGCACTCATCATTGGCTTTGGTATTTCAGCCTTGCCTCCCCGATTGAAAGAGATGAA (SEQ ID NO: 166). Example 18 : Patient-derived CDH1-NRG1 fusion data

Tumor material obtained from female patients diagnosed with pancreatic adenocarcinoma was subjected to the following molecular biotechnological analyses. Automated RNA extraction was performed with the Maxwell (Promega) FFPE LEV kit.

Molecular assays were performed using the Archer Fusion Plex NGS. NGS (S5XL – Life Technologies) was performed on the Oncomine Comprehensive Assay V3 (OCAV3) panel containing 161 genes, of which 81 were considered hotspot genes and 48 were full-length genes, and 47 copy number genes. RNA-Seq (RNA sequencing) was performed on the cDNA obtained from this sample to allow the identification of the sequence as SEQ ID NO: 186.

It shows the presence of an in-frame fusion junction occurring between exon 11 of the CDH1 gene and exon 2 of the NRG1 gene. The underlined sequence, nucleotides 1-119, corresponds to a part of exon 11 of the gene encoding CDH1 (NM_001317185.2). The remaining 30 nucleotides, namely nucleotides 120-149, correspond to a part of exon 2 of the NRG1 gene. In addition, NGS revealed a mutation 1172C>T in exon 10 of the FGFR3 gene, causing an amino acid change of Ala391Val. CTGGCTGGAGATTAATCCGGACACTGGTGCCATTTCCACTCGGGCTGAGCTGGACAGGGAGGATTTTGAGCACGTGAAGAACAGCACGTACACAGCCCTAATCATAGCTACAGACAATGCCTTGCCTCCCCGATTGAAAGAGATGAAA (SEQ ID NO: 186). CCTTGCCTCCCCGATTGAAAGAGATGAAAA Example 19 : Patient-derived CXADR-NRG1 fusion data

Tumor material obtained from a male patient diagnosed with colorectal cancer was subjected to the following molecular biotechnological analysis. Total RNA was isolated from tumor regions of submitted tissue samples or microdissected slides from surrounding tissue using standard methods. The isolated RNA is reverse transcribed and double-stranded DNA is constructed. The sample was processed with universal tags and marker codes, and semi-nested multiplex PCR was performed using gene-specific primers and universal marker-specific primers (Archer FusionPlex Chemical Company). Products were prepared and sequenced using Illumina NextSeq v2 chemistry. Sequence data were analyzed using Archer analysis software v4.1. The assay sensitivity is approximately 5 RNA molecules encoding the fusion and depends on the specific fusion event that occurs. Fusions were compared to reported reference transcripts.

Molecular analysis revealed the presence of an in-frame fusion junction between exon 1 of the CXADR gene and exon 2 of NRG1. The underlined sequence, nucleotides 1-43, corresponds to a part of exon 1 of the gene encoding CXADR (NM_001207063.2). The remaining 58 nucleotides, nucleotides 44-101, correspond to a part of exon 2 of the NRG1 gene. ATGGCGCTCCTGCTGTGCTTCGTGCTCCTGTGCGGAGTAGTGGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACT (SEQ ID NO: 217). Example 20 : Patient-derived GTF2E2-NRG1 fusion data

Formalin-fixed paraffin blocks of neoplastic material obtained from female patients diagnosed with metastatic breast cancer NOS were subjected to the following molecular biotechnological analyses.

Molecular testing was performed after harvesting the tissue with approved microdissection techniques. Candidate slides are examined under a microscope and the areas containing tumor cells (and, if required, isolated normal cells) are circled. A laboratory technician harvests and removes the target tissue from the marked area using a dissecting microscope. The marked and removed areas were remicroscopically examined on microdissected slides, and the adequacy of the microdissection was rechecked.

Detection of gene fusions and variant transcripts was performed on mRNA isolated from formalin-fixed and paraffin-embedded tumor samples using Agilent SureSelectXT Low Input Library prep chemistry ), optimized for FFPE samples, combined with the SureSelect Human All Exon V7 capture probe set (bait panel) (48.2 Mb) and Illumina NovaSeq. This assay is designed to detect fusions that occur at known and novel breakpoints within the gene. This analysis led to the identification of a sequence such as SEQ ID NO: 233. It shows the presence of an in-frame fusion with a junction between exon 2 of the GTF2E2 gene and exon 2 of the NRG1 gene. The underlined sequence, nucleotides 1-141, corresponds to a part of exon 2 of the GTF2E2 gene (NM_002095.6). Nucleotides 142-268 correspond to part of the gene encoding NRG1 (NM_001159999.3). GGGAGCTGTTCAAAAAACGAGCTCTTTCTACTCCTGTAGTAGAAAAACGTTCAGCATTCTTCTGAGTCATCATCATCATCGTCAAAAGAAGAAGAAAACAAAGGTAGAACATGGAGGATCGTCAGGCTCTAAACAAAATTCTGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCT GAATACTCCTCTCTCCAGATTCAAGTGGTTCAAGAATGGGAATGA (SEQ ID NO: 233).

Genome DNA isolated from formalin-fixed and paraffin-embedded tumor samples was analyzed for tumor mutational burden based on next-generation sequencing (NGS) analysis using the Illumina NextSeq platform. Tumor mutational burden was calculated using only missense mutations that had not been previously reported as germline variants. Threshold levels of tumor mutational burden defined below were used and cut-off points were established: ● High: greater than or equal to 17 mutations per megabase (≥17 mutations/Mb). • Medium: greater than or equal to 7 but less than 17 mutations per megabase (≥7 and <17 mutations/Mb). ● Low: Less than or equal to 6 mutations per megabase (≤6 mutations/Mb). The patient sample indicated a TMB score of 9.

No microsatellite instability was detected by NGS using microsatellite instability (MSI) analysis.

Using NGS analysis, a frameshift mutation was detected in exon 6 of GATA3 (c.1305_1327del23, protein variant P436fs) and a disabling variant NTRK2 (protein variant p.Q172 c.514C>T, (NM_006180.4). Example 21 : Patient-derived CSMD1-NRG1 fusion data

Tumor material obtained from male patients diagnosed with colorectal cancer was subjected to the following molecular biotechnological analyses.

Hybrid capture next-generation sequencing was performed using a custom oncology panel consisting of 596 genes with single nucleotide variations, insertions and deletions (indels), and translocations. Whole-genome transcript RNA sequencing was performed using the IDT xGen Exome Research Kit v1.0 Hybridization Probes to allow unbiased detection of expressed fusion transcripts from rearranged genes.

It shows the presence of an in-frame fusion junction occurring between exon 23 of the CSMD1 gene and exon 6 of the NRG1 gene. The underlined sequence, nucleotides 1-88, corresponds to a part of exon 23 of the gene encoding CSMD1 (NM_033225.6). The remaining nucleotides, nucleotides 89-150, correspond to a portion of exon 6 of the NRG1 gene. Related patient reports mention afatinib and erlotinib as FDA-approved therapies associated with this CSMD1-NRG1 fusion, while mentioning GSK2849330 as an investigational study. In addition, the clinical trial TAPUR (NCT02693535) related to the CSMD1-NRG1 fusion is mentioned.

No pathogenic germline mutations were identified in patient material, nor were pathogenic single nucleotide polymorphisms identified in KRAS or NRAS. The following four somatic gene variants were identified in patient material: Y220C missense mutation in TP53, R564* stop gain mutation in APC, N1455fs frameshift mutation in APC, and G469A missense mutation in BRAF. The MSI status was determined to be stable and the tumor mutational burden was 4.6 m/MB.

Variants of unknown significance were identified, including: c.3332+1G>A splice region variant in APOB (NM_000384), c.425C>T p.S142L missense variant in GATA3 (NM_001002295), c.352C>T p.R118C missense variant in LZTR1 (NM_006767), c.227A>T p.H76L missense variant in CTC1 (NM_025099), c.239G> in CYP1B1 (NM_000104) A p.R80H missense variant, c.1099C>T p.R367W missense variant in RECQL4 (NM_004260), c.871A>G p.R291G missense variant in SOX2 (NM_003106), and In-frame deletion of c85_87del pE29del in TCF7L2 (NM_001146274).

The patient's previous treatment included fluorouracil, leucovorin, irinotecan, bevacizumab, and oxaliplatin. ATCCTAAACAGCACATCCAATCACCTGTGGCTAGAGTTCAACACCAATGGATCTGACACCGACCAAGGTTTTCAACTCACCTATACCACTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACT (SEQ ID NO: 255). Example 22 : Patient-derived PTN-NRG1 fusion data

Formalin-fixed paraffin blocks of neoplastic material obtained from female patients diagnosed with metastatic breast malignancy NOS were subjected to the following molecular biotechnological analyses.

Molecular testing was performed after harvesting the tissue with approved microdissection techniques. Candidate slides are examined under a microscope and the areas containing tumor cells (and, if required, isolated normal cells) are circled. A laboratory technician harvests and removes the target tissue from the marked area using a dissecting microscope. The marked and removed areas were remicroscopically examined on microdissected slides, and the adequacy of the microdissection was rechecked.

Detection of gene fusions and variant transcripts was performed on mRNA isolated from formalin-fixed and paraffin-embedded tumor samples using Agilent SureSelectXT Low Input Library prep chemistry ), optimized for FFPE samples, combined with the SureSelect Human All Exon V7 capture probe set (bait panel) (48.2 Mb) and Illumina NovaSeq. This assay is designed to detect fusions that occur at known and novel breakpoints within the gene. This analysis led to the identification of the sequence as SEQ ID NO: 313. It shows the presence of an in-frame fusion with a junction between exon 4 of the PTN gene and exon 2 of the NRG1 gene. The underlined sequence, nucleotides 1-102, corresponds to a part of exon 2 of the PTN gene (NM_001321386.2). Nucleotides 103-205 correspond to part of the gene encoding NRG1 (NM_001159999.3). CCAGAACTGGAAGTCTGAAGCGAGCCCTGCACAATGCCGAATGCCAGAAGACTGTCACCATCTCCAAGCCCTGTGGCAAACTGACCAAGCCCAAACCTCAAG CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCTGAATACTCCTCTCTCAGATT (SEQ ID NO: 31 3).

Genome DNA isolated from formalin-fixed and paraffin-embedded tumor samples was analyzed for tumor mutational burden based on next-generation sequencing (NGS) analysis using the Illumina NextSeq platform. Tumor mutational burden was calculated using only missense mutations that had not been previously reported as germline variants. Threshold levels of tumor mutational burden defined below were used and cut-off points were established: ● High: greater than or equal to 17 mutations per megabase (≥17 mutations/Mb). • Medium: greater than or equal to 7 but less than 17 mutations per megabase (≥7 and <17 mutations/Mb). ● Low: Less than or equal to 6 mutations per megabase (≤6 mutations/Mb). Patient samples showed low TMB scores.

No microsatellite instability was detected by NGS using microsatellite instability (MSI) analysis.

Using NGS analysis, the p.E336*, c.1006G>T mutation (NM_000546.5) was detected in exon 10 of TP53. No mutations were detected in NTRK1/2/3, AKT1, BRCA1/2, ERBB2, ESR1, PIK3CA, PTEN, and negative IHC results were obtained for the PD-L1 lineage (based on 22c3 and SP142). Example 23 : Patient-derived ST14-NRG1 fusion data

Molecular analysis of tumorous material obtained from patients diagnosed with non-small cell lung cancer revealed the presence of exon 11 and NRG1 of the ST14 gene contained in the sequence SEQ ID NO: 330 In-frame fusion junction between sub6. The underlined sequence, nucleotides 1-95, corresponds to a part of exon 11 of the gene encoding ST14 (NM_021978.4). The remaining 87 nucleotides, namely nucleotides 96-182, correspond to a part of exon 6 of the NRG1 gene. CAACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTCTCTCTACGACTCCAGTGACCCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCT (SEQ ID NO: 330). Example 24 : Patient-derived THBS1-NRG1 fusion data

Tumor DNA was extracted from fresh, frozen, or formalin-fixed paraffin blocks of neoplastic material obtained from patients diagnosed with pancreatic adenocarcinoma and subjected to the following molecular biotechnological analyses.

Exon DNA sequences of 447 cancer genes were investigated in the extracted DNA, and rearrangement was detected in 191 regions of 60 genes. DNA was isolated from tissues containing at least 20% tumor nuclei and analyzed by massively parallel sequencing using a solution-phase Agilent SureSelect hybrid capture kit and an Illumina HiSeq 2500 sequencer.

Molecular analysis revealed the presence of an in-frame fusion junction between exon 9 of the THBS1 gene and exon 6 of the NRG1 gene. The underlined sequence, nucleotides 1-56, corresponds to a part of exon 9 of the gene encoding THBS1 (NM_003246.4). Nucleotides 57-145 correspond to a part of exon 6 of the NRG1 gene. ACCCTGTGAAGGCGAAGCGCGGGAGACCAAAGCCTGCAAGAAAGACGCCTGCCCCACTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTC (SEQ ID NO: 376).

Further molecular analysis did not reveal fusions with ALK, NTRK1, NTRK2, NTRK3, ROS1, and no pathogenic mutations, copy number alterations, or structural variants involving BRCA1, BRCA2, or PALB2 were detected. The following mutations have been identified: c.783-10_787delinsCCTG in TP53, single copy deletion of TP53 at 17p13.1, c.*178T>A, exon 3 of CDKN1B, c.1205A in ERCC2 exon 12 >C (p.N402T), c.1858T>C (p.C620R) in FANCD2 exon 21, c.398A>C (p.N133T) in KIF1B exon 5, in NAB2 c.1092-7T>C, c.3245G>A in NOTCH1 exon 20 (p.R1082H), c.1798C>T in PTPN14 exon 13 (p.R600W), and outside RASA1 c.1273C>A in exon 9 (p.H425N). Pathogenic single nucleotide polymorphisms were also not identified in KRAS or NRAS. The following four somatic gene variants were identified in patient material: Y220C missense mutation in TP53, R564* stop gain mutation in APC, N1455fs frameshift mutation in APC, and G469A missense mutation in BRAF. The MSI status was determined to be stable and the tumor mutational burden was 4.6 m/MB. Example 25 : Patient-derived AGRN-NRG1 fusion data

Tumor material obtained from male patients diagnosed with pancreatic cancer (PDAC) was subjected to the following molecular biotechnological analyses.

Hybrid capture next-generation sequencing was performed using a custom oncology panel consisting of 648 genes with single nucleotide variations, insertions and deletions (indels), and translocations. Whole-genome transcript RNA sequencing can be performed with unbiased detection of expressed fusion transcripts from rearranged genes. The limits of the assay are a variant allele fraction (VAF) of 5% with a sensitivity of 98.2% for single nucleotide variants, a VAF of 5% for insertions and deletions with a sensitivity of 91.8%, and a sensitivity of 91.8% for translocations. The sensitivity is 91.7%.

This analysis led to the identification of a sequence such as SEQ ID NO: 403. It shows the presence of an in-frame fusion with a junction between exon 12 of the AGRN gene and exon 6 of the NRG1 gene. The underlined sequence, nucleotides 1-106, corresponds to a part of exon 12 of the AGRN gene (NM_001305275.2). Nucleotides 107-207 correspond to part of the gene encoding NRG1 (NM_001159999.3). GTGTGCGGCTCAGATGGGGTCACCTACAGCACCGAGTGTGAGCTGAAGAAGGCCAGGTGTGAGTCACAGCGAGGGCTCTACGTAGCGGCCCAGGGAGCCTGCCGAG CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTCATGGTGAAAGAC (SE Q ID NO: 403).

In addition, FGFR1 overexpression was also detected. Example 26 : Patient-derived PVALB-NRG1 fusion data

Molecular analysis of tumorous material obtained from patients diagnosed with non-small cell lung cancer revealed the presence of exon 4 and NRG1 of the PVALB gene contained in the sequence SEQ ID NO: 437 In-frame fusion junction between sub6. The underlined sequence, nucleotides 1-102, corresponds to a part of exon 4 of the gene encoding PVALB (NM_002854.3). Nucleotides 103-227 correspond to a part of exon 6 of the NRG1 gene. TAAAAGGCTTCTCCCCCAGATGCCAGAGACCTGTCTGCTAAAGAAACCAAGATGCTGATGGCTGCTGGAGACAAAGATGGGGACGGCAAAATTGGGGTTGACGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTCATGGTGAAAGACCTTT CAAACCCCTCGAGATACTTG (SEQ ID NO: 437). Example 27 : Patient-derived SLC3A2-NRG1 fusion data

The following molecular biotechnological analyzes were performed on tumorous material obtained from patients diagnosed with lung cancer. Total RNA was extracted from formalin-fixed paraffin blocks using Maxwell RSC followed by ReliaPrep™ FFPE Total RNA Promega Kit and Archer Dx CTL Fusionplex. Bioinformatic analysis was performed using Archer Analysis version 6.2.7.

This analysis revealed the presence of an in-frame fusion junction occurring between exon 2 of the SLC3A2 gene and exon 6 of the NRG1 gene as encompassed by the sequence of SEQ ID NO: 454. The underlined sequence, nucleotides 1-93, corresponds to a part of exon 2 of the gene encoding SLC3A2 (NM_002394.6). Nucleotides 94-121 correspond to a part of exon 6 of the NRG1 gene. AGTTGGGGTCTCACTGTGTTGCCCAGACTGGTCTCGAACTCTTGGCCTCAGGTGATCCTCTTCCCTCAGCTTCCCAGAATGCCGAGATGATAGCTACATCTACATCCACCACTGGGACAAG (SEQ ID NO: 454). Example 28 : Patient-derived APP-NRG1 fusion data

Molecular biotechnological analysis of tumorous material obtained from a patient diagnosed with pancreatic cancer revealed the presence of exon 14 of the APP gene and the NRG1 gene contained in the sequence of SEQ ID NO: 486 In-frame fusion junction between exon 6. The underlined sequence, nucleotides 1-54, corresponds to a part of exon 14 of the gene encoding APP (NM_001136130.3). Nucleotides 55-141 correspond to a part of exon 6 of the NRG1 gene. TTGAGCCTGTTGATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCT (SEQ ID NO: 486). Example 29 : Patient-derived WRN-NRG1 fusion data

Molecular biotechnological analysis of neoplastic material obtained from a patient diagnosed with breast cancer revealed the presence of exon 33 of the WRN gene and outside the NRG1 gene as contained in the sequence of SEQ ID NO: 528 In-frame fusion junction between exon 6. The underlined sequence, nucleotides 1-96, corresponds to a part of exon 33 of the gene encoding APP (NM_000553.6). Nucleotides 97-182 correspond to a part of exon 6 of the NRG1 gene. AAGCTGGCTGCCCCCTTGATTTGGAGCGAGCAGGCCTGACTCCAGAGGTTCAGAAGATTATTGCTGATGTTATCCGAAACCCTCCCGTCAACTCAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGC (SEQ ID NO: 528). Example 30 : Patient-derived DAAM1-NRG1 fusion data

Molecular biotechnological analysis of neoplastic material obtained from a patient diagnosed with breast cancer revealed the presence of a gene present outside exon 1 of the DAAM1 gene and NRG1 gene as contained in the sequence of SEQ ID NO: 605 In-frame fusion junction between exon 1. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 1 of the gene encoding DAAM1 (NM_001270520.2). Nucleotides 76-150 correspond to a portion of exon 1 of the NRG1 gene. GAAGGAAACTGTTTAACCGGATCCCATTGTACCCAGAGTGCAGAGCCGCCTTTCCAGCATGCAGGGGCTGCTCAGGACAGAGAGGGAGGAGGCGCGCGGGGACGGGGACGCCCAGGAGGACCCACTCGCGGGTCCCGCTCCGCTCCGGCA (SEQ ID NO: 605). Example 31 : Patient-derived ASPH-NRG1 fusion data

Molecular biotechnological analysis of neoplastic material obtained from a patient diagnosed with colorectal adenocarcinoma showed the presence of exon 22 of the ASPH gene contained in the sequence of SEQ ID NO: 635 and NRG1 In-frame fusion junction between exon 2 of the gene. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 1 of the gene encoding ASPH (NM_001164750.2). Nucleotides 76-150 correspond to part of exon 2 of the NRG1 gene. AAGGTCTCTTCCTGCCTGAGGATGAAAACCTGAGGGAAAAAGGGGACTGGAGCCAGTTCACGCTGTGGCAGCAAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA (SEQ ID NO: 635). Example 32 : Patient-derived NOTCH2-NRG1 fusion data

Molecular biotechnological analysis of neoplastic material obtained from a patient diagnosed with pancreatic cancer revealed the presence of exon 6 of the NOTCH2 gene and the NRG1 gene as contained in the sequence of SEQ ID NO: 693 In-frame fusion junction between exon 6. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 6 of the gene encoding NOTCH2 (NM_024408.4). Nucleotides 76-150 correspond to a part of exon 6 of the NRG1 gene. CCTCCTGTACTCCAGGCTCCACCTGCATCGACCGTGTGGCCTCCTTCTCTTGCATGTGCCCAGAGGGGAAGGCAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG (SEQ ID NO: 693). Example 33 : Patient-derived CD74-NRG1 fusion data

Molecular biotechnological analysis of tumorous material obtained from a patient diagnosed with lung cancer revealed the presence of exon 2 of the CD74 gene and the NRG1 gene as contained in the sequence of SEQ ID NO: 717 In-frame fusion junction between exon 2. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 2 of the gene encoding CD74 (NM_001025159.3). Nucleotides 76-150 correspond to part of exon 2 of the NRG1 gene. AGGGCCGGCTGGACAAACTGACAGTCACCTCCCAGAACCTGCAGCTGGAGAACCTGCGCATGAAGCTTCCCAAGCCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA (SEQ ID NO: 717). Example 34 : Patient-derived SDC4-NRG1 fusion data

Molecular biotechnological analysis of tumorous material obtained from a patient diagnosed with lung cancer revealed the presence of exon 2 of the SDC4 gene and outside the NRG1 gene as contained in the sequence of SEQ ID NO: 743 In-frame fusion junction between exon 2. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 2 of the gene encoding SDC4 (NM_002999.4). Nucleotides 76-150 correspond to part of exon 2 of the NRG1 gene. TACCAGACGATGAGGATGTAGTGGGGCCCGGGCAGGAATCTGATGACTTTGAGCTGTCTGGCTCTGGAGATCTGGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA (SEQ ID NO: 743). Example 35 : Patient-derived CD44-NRG1 fusion data

Molecular biotechnological analysis of neoplastic material obtained from a patient diagnosed with cancer revealed the presence of exon 5 of the CD44 gene and the NRG1 gene as contained in the sequence of SEQ ID NO: 761 In-frame fusion junction between exon 6. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 2 of the gene encoding CD44 (NM_000610.4). Nucleotides 76-150 correspond to a part of exon 6 of the NRG1 gene. TTTCTACTGTACACCCATCCCAGACGAAGACAGTCCCTGGATCACCGACAGCCAGACAGAATCCCTGCTACCACTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG (SEQ ID NO: 761). Example 36 : Patient-derived SLC4A4-NRG1 fusion data

Molecular biotechnological analysis of neoplastic material obtained from a patient diagnosed with pancreatic cancer revealed the presence of exon 14 of the SLC4A4 gene and the NRG1 gene as contained in the sequence of SEQ ID NO: 765 In-frame fusion junction between exon 6. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 14 of the gene encoding SLC4A4 (NM_001098484.3). Nucleotides 76-150 correspond to a part of exon 6 of the NRG1 gene. ACTACCCCATCAACTCCAACTTCAAAGTGGGCTACAACACTCTCTTTTCCTGTACCTGTGTGCCACCTGACCCAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG (SEQ ID NO: 765). Example 37 : Patient-derived SDC4-NRG1 fusion data

Molecular biotechnological analysis of tumorous material obtained from a patient diagnosed with lung cancer revealed the presence of exon 4 of the SDC4 gene as contained in the sequence of SEQ ID NO: 824 and outside of the NRG1 gene In-frame fusion junction between exon 2. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 4 of the gene encoding SDC4 (NM_002999.4). Nucleotides 76-150 correspond to part of exon 2 of the NRG1 gene. ATGTGTCCAACAAGGTGTCAATGTCCAGCACTGTGCAGGGCAGCAACATCTTTGAGAGAACGGAGGTCCTGGCAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA (SEQ ID NO: 824). Example 38 : Patient-derived ZFAT-NRG1 fusion data

Molecular biotechnological analysis of tumorous material obtained from a patient diagnosed with lung cancer revealed the presence of exon 12 of the ZFAT gene and outside of the NRG1 gene as contained in the sequence of SEQ ID NO: 828 In-frame fusion junction between exon 6. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 12 of the gene encoding ZFAT (NM_020863.4). Nucleotides 76-150 correspond to a part of exon 6 of the NRG1 gene. ACAGGAAGCACCCCTAATGAGGAGTATGCCAACGTGGGCACCGGGGAGCTGGCAGCGGAGGTGCTCATCCAGCAAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG (SEQ ID NO: 828). Example 39 : Patient-derived DSCAML1-NRG1 fusion data

Molecular biotechnological analysis of neoplastic material obtained from a patient diagnosed with pancreatic cancer revealed the presence of exon 3 of the DSCAML1 gene contained in the sequence SEQ ID NO: 868 and the NRG1 gene In-frame fusion junction between exon 2. The underlined sequence, nucleotides 1-75, corresponds to a part of exon 3 of the gene encoding DSCAML1 (NM_020693.4). Nucleotides 76-150 correspond to part of exon 2 of the NRG1 gene. GCCTCATCCCCTCTTCAGTGCAGGAATATGTTAGCGTTGTATCTTGGGAGAAAGACACAGTCTCCATCATCCCACCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA (SEQ ID NO: 868). Example 40 : PDX animal model

Preparation of a patient-derived xenograft (PDX) animal model containing implanted abnormal cells containing abnormal cells comprising a polynucleotide fusion and expressing a polypeptide fusion encoded thereby, using zetuzumab as ERB2 and/or Erb3 targeting agents were treated to assess their therapeutic activity.

PDX models can be generated from samples containing cancer or specimens, such as in this example a female patient diagnosed with pancreatic adenocarcinoma, and essentially as described in Puig et al., A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived The CDH1-NRG1 polynucleotide fusion described in Colon Cancer Initiating Cells, Clin Cancer Res; 19(24), 6787-6801 (2013) (see Example 18), the entirety of which is incorporated into this application.

For all mouse studies, female NOD.CB17/AlhnRj-Prkdcscid/Rj mice (Janvier Labs) between 6-8 weeks of age were used.

These models can be injected subcutaneously, or orthotopically in the pancreas of immunodeficient mice. Orthotopic models produce local and distant metastases in lymph nodes, liver, lung, or cancer, reproducing predisease in PDAC patients.

At week 6, all vehicle- or zeltuzumab-treated mice were sacrificed and analyzed for treatment efficacy.

A statistically relevant number of NOD-SCID mice can be injected orthotopically with 1*10^6 tumor cells from the PDX model. Beginning 15 days after injection, mice were monitored weekly with CT imaging and primary tumors in the pancreas were detected. Treatment was initiated after at least 80% of the animals had primary tumor growth in the pancreas.

Mice were excluded from the study based on failure to meet the following quality criteria, including death after surgery, absence of primary tumors, mice with excessively large tumors, underweight, and general signs of disease. Dosing and treatment regimens were carried out according to Example 12, however, using standard procedures and calculations, taking care to translate appropriately from human to mouse conditions.

of this disclosure sequence information VAPB sequence informationSEQ ID NO:1 VAPB exon 1 sequence at 5' of VAPB-NRG1 fusion CAGGTCCTGAGCCTCGAGCCGCAGCACGAGCTCAAATTCCGAG SEQ ID NO:2 NRG1 exon 2 sequence at 3' of VAPB-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTT SEQ ID NO:3 VAPB-NRG1 polynucleotide sequence CAGGTCCTGAGCCTCGAGCCGCAGCACGAGCTCAAATTCCGAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTT SEQ ID NO:4 VAPB-NRG1 polypeptide sequence QVLSLEPQHELKFRALPPRLKEMKSQESAAG SEQ ID NO:17 VAPB exon 1 AGTCCCCCGCCCCTGGAGCCGGCGGCGCAGGGCGCAGCTTCCCGCCGCCAGAGCGGGCCAGCCTGCTGCGTGCGTGCGTGTGTACGACTCTGCGTGCGTGCGTGCGTGCGTGCGTGCCGTCAGCTCGCCGGGCACCGCGGCCTCGCCCTCGCCCTCCGCCCCTGCGCCTGCACCGCGTAGACCGACCCCCCCCCAGCGCGCCCACCCGGTAGAGGACCCCGCGC CCGTGCCCCGACCGGTCCCCGCCTTTTTGTAAAACTTAAAGCGGGCGCAGCATTAACGCTTCCCGCCCCGGTGACCTCTCAGGGGTCTCCCCCGCCAAAGGTGCTCCGCCGCTAAGGAACATGGCGAAGGTGGAGCAGGTCCTGAGCCTCGAGCCGCAGCACGAGCTCAAATTCCGAG SEQ ID NO:18 VAPB exon 2 GTCCTTCACCGATGTTGTCACCACCAAACCTAAAGCTTGGCAACCCGACAGACCGAAATGTGTGTTTTAAGGTGAAGACTACAGCACCACGTAGGTACTGTGTGAGGCCCAACAGCGGAATCATCGATGCAGGGGCCTCAATTAATGTATCTG SEQ ID NO:19 VAPB exon 3 TGATGTTACAGCCTTTCGATTATGATCCCAATGAGAAAAGTAAACACAAGTTTTATGGTTCAGTCTATGTTTGCTCCAACTGACACTTCAGATATGGAAGCAGTA SEQ ID NO:20 VAPB exon 4 TGGAAGGAGGCAAAACCGGAAGACCTTATGGATTCAAAACTTAGATGTGTGTTTGAATTGCCAGCAGAGAATGATAAACCA SEQ ID NO:21 VAPB exon 5 CATGATGTAGAAATAAATAAAATTATATCCACAACTGCATCAAAGACAGAAACACCAATAGTGTCTAAGTCTCTGAGTTTCTTCTTTGGATGACACCGAAGTTAAGAAGGTTATGGAAGAATGTAAGAGGCTGCAAGGTGAAGTTCAGAGGCTACGGGAGGAGAACAAGCAGTTCAAG SEQ ID NO:22 VAPB exon 6 GAAGAAGATGGACTGCGGATGAGGAAGACAGTGCAGAGCAACAGCCCCATTTCAGCATTAGCCCCAACTGGGAAGGAAGAAGGCCTTAGCACCCGGCTCTTGGCTCTGGTGGTTTTGTTCTTTATCGTTGGTGTAATTATTGGGAAGATTGCCTTGTAGAGGTAGCATGCACAGGATGGTAAATTGGATTGGTGGATCCACCATATCATGG GATTTAAAATTTATCATAACCATGTGTAAAAAAGAAATTAATGTATGATGACATCTCACAGGTCTTGCCTTTAAATTACCCCTCCCCTGCACACACATACACAGATACACACACACAAATATAATGTAACGATCTTTTAGAAAGTTAAAAATGTATAGTAACTGATTGAGGGGGAAAAGAATGATCTTTTATTAATGACAAGGGAAACCATGAGTAATGCCACAATGGCATATT GTAAATGTCATTTTAAACATTGGTAGGCCTTGGTACATGATGCTGGATTACCTCTCTTAAAATGACACCCTTCCTCGCCTGTTGGTGCTGGCCCTTGGGGAGCTGGAGCCCAGCATGCTGGGGAGTGCGGTCAGCTCCACACAGTAGTCCCCACGTGGCCCACTCCCGGCCCAGGCTGCTTTCCGTGTCTTCAGTTCTGTCCAAGCCATCATCAGCTCCTT GGGACTGATGAACAGAGTCAGAAGCCCAAAGGAATTGCACTGTGGCAGCATCAGACGTACTCGTCATAAGTGAGAGGCGTGTGTTGACTGATTGACCCAGCGCTTTGGAAATAAATGGCAGTGCTTTGTTCACTTAAAGGGACCAGCTAAATTTGTATTGGTTCATGTAGTGAAGTCAAACTGTTATTCAGAGATGTTTAATGCATATTTAACTTATTTAAT GTATTTCATCTCATGTTTTTCTTATTTGTCACAAGAGTACAGTTAATGCTGCGTGCTGCTGAACTCTGTTGGGTGAACTGGTATTGCTGCTGGAGGGCTGTGGGCTCCTCTGTCCTCTGGAGAGTCTGGTCATGTGGAGGTGGGGTTTATTGGGATGCTGGAGAAGAGCTGCCAGGAAGTGTTTTTTCTGGGTCAGTAAATAACAACT CATAGGGAGGGAAATTCTCAGTAGTGACAGTCAACTCTAGGTTACCTTTTTTAATGAAGAGTAGTCAGTCTTCTAGATTGTTCTTATACCACCCTCTCAACCATTACTCACACTTCCAGCGCCCAGGTCCAAGTCTGAGCCTGACCTCCCTTGGGGACCTAGCCTGGAGTCAGGACAAATGGATCGGGCTGCAGAGGGTTAGAAGCGAGGGCACCAGCAGTTGTGT GGGTGGGGAGCAAGGGAAGAGAGAAACTCTTCAGCGAATCCTTCTAGTACTAGTTGAGAGTTTGACTGTGAATTAATTTTATGCCATAAAAGACCAACCCAGTTCTGTTTGACTATGTAGCATCTTGAAAAGAAAAATTATAATAAAGCCCCAAAATTTAAGAATTCTTTTGTCATTTTTGTCACATTTGCTCTATGGGGGGAATTATTATTTTATCATTTTTATTATTTTGC CATTGGAAGGTTAACTTTAAATGAGCCCTATCACTGAGAAATACGTGTTTCATGATTTAACTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATTTTTTTTTTGGTTGTCTTCAGCTGACAGTATGAAAAATGAAACTGCTGAAAAAAGCTGAGCACCTGGTCACCCTTGGCCTTCCATTGCTTTGGCCTTCAGTAAAAAGCAGCCTCCCTTTCTAGGTCAG GGAACCATGCCATTGAGACTAGTAACGGGCGTTCTGGGCACAGTCCCACTGTGCACAGGTTTGAGAGGACAAGTTCATCAGAAGGAAGGCAGTCCTTAGAAGTCACATACGTTGAGCCACGTTGCTCCTAAGCCTGGCTCTGTCCAAGCTGGGTCAGGGGCCTTGAAACTGGAGAAGTGGAAGTCTATGGTTGGTCTGAGTAAGTAACTTCCTGTCTTC ATGAAAAAAGTTGACTTTGAATCCCAGGTACTCACAGAAATGGTGAACAGACTTAGTTGTTACCCAGGCACCCATGGATTGTGTTGAGTGTGCAGACAGGGAGGCCACCCCAATAGGAATTCGTCTCCCAGGATTTTTCCCATGTGTCCCCAGTACTTATAAAAGGGAGTGAAAAGACCGAGCTGTAAGGCATGTGCCTTCTGCCACCTGACTTTCCGTGAGGGGACT AAAATTTACTAATTGTAGTTGCTGCCAGCCAGTTAAGTCCTGTAGCTTCCAGGCCCTCATGTCTTTGATAGGAGAGTGCTTAGGTGGTCCCAACAGTGCCTAGGGGTACAGTACAGTCCCATTACACTAGAGCAGGGCTCTATTTATTTTTAAAGGATATGGCCGTGTGTTTTGATAAAACTTTATTCACAAAACAGCCGGGTCATGGGATTTGGCTTGTGTGAGT CTGTAACAGTTCTTAAAAAGAATATCTGAGAAACTACTCTGTTTTGAGACCTTTGAAGGTGATTTAGAGTTTTGTGTACATCTAGGAGAAGGTGTTCAGCTTCTCAGAGGATGTGGACATTTTGGTTGCAGCTAAAAATCAGTCCTGAAGTCTCTCCCTTCTAGAGGTTAGGACTTGGTGAACATGTTTGTGGGCCTTTTGACTGAGTGGCAGAAGGAAACTGCTCAG GAAGAGAAACAGGTGACTGATGGGAAGGTTGATTATTTTCTCAGTCATCCTGGCAGCCAAAAATGTGCCAGGAAAAGAAAGAATGTGGAGCACGCGTGGCTCCTGGAGGACTTGGAGATGCATGCACATTTAGGGTGTTTTCCCTAGAATTACATAATGAAAAAAAGAATAAGGCAAAGAGGAGGTGAATATGGGGCCTGTCACAACGGCCTGCCCTGCCCCA AGAGGGTTAAGAGTCAGATAATCGGGACGAAACTGGCATGGAAAGAGCGAGCCTAGGGAGGATGCCGCTGGGCAGTGTGCATGGGGGAGCTGCTGCCAGGCTGCCCTCCAGTCTGCTCCTGTGGTTACTGGCTCCACAGCACCTCAGAGAGGGCGGCCCTGGCTTCAGAAATGCCAGCCATAGTGCTCACAAATGCAGAAGAGATGGAAGCG GTGACAGAATCCTGAAAGTTTTTATTGATTGAAGTTTTAAAATTGGTAACTTAAGCTTCCTGGCACGATACAAAATACCTCTTAAGACAGCAGGCTTTTTTATTTGTAGGTGTGAGGAACTGGCTTTAACTTTTTTCTCCTCCTAGTTTGCATGTTTTTCCTTCTCGTCTTCTGAACTGCTGGCACCAGCAGTAATACATACTGATAAAATCAAAATTGATTTTTAC CAGTGGCCAGTTTTATGGCTAGAGAGACGACTTATACCTCCATAACACAGAAGGGGGAAAAATGAAGACTCCAGTGATCCGTGAAAACCTAAACGCTTTCAAACAAATCCCAGGAACAGAATTGCTATCGAAAGATATCATTGCCCAGTTTGCAGGCTATGTTGAGTCAGATAGAACTGAATGTAGTGAGAGCTCAGAGCTACAGAGCCTTTCAGATGAATTTGAAAAC AGACTCTGTGTGTGTGTGCATGTGTGCATGTGTGCATGTGTGGCATATGTGCCGTATGTCAGTAGCTTGACAGTTTTTCAAATCGTGCCTATATTTTTTTTGCATACACAAAATTTTTGTGTTTGCAAACTCAGAATCCATGCCAAAATACAATGTTATATGTCATTTTCAGCTCCTTTCTAAAGGAATGGCCCATTTTCTCATTGTAGTTTGAGAAATACATGTATGAAGAGATAG GGGTCTTGGGCTTCCCAGTGTCACTTTGAACACCTGAATAACATTTAACTCCTGAGACCTTCTCGGTGTAGAGGCCACTGCTTCCCCCTGCTGGAGATGGCATTTCATTGAAGGGCCTCTCGTGGCTTTCCCTGCCCCCGGCTGTCTGGCCTGAAGAAGGAGAAAGAACCAAACTGAACTATGAAAAGTTACCACTCTGAGGAGACCCTCTCTTAATTAACACTT GGGGCCATGTTTGCTGTTGTTGAGAAGGAGTGTTCTCAAAGATGAGCTGGAATGGAATTGTATTTAGAAAGGCCCCTGCAAAGTATATAGATGGATGACTCTAGTTCATGACATACAAAATCCATAAGGCCAACGACCACTCTTCTGGAACACCAAGAGCAGCTCTGAGATCATGCTGGCCCTACGCGAATTGAGTTTCTGTGGCCTAATTGGATTTGGA GAACGCCTTCCCTGGCCCCTTTTCCTCAGACAGATCTGCTCTGATAGGAACCTTTTCAAGAAAGTTACTGTTGTTTCAATGCCACTCCTTACCTGTATAGAACATTTCCAAATACATTCGCTCATTGAACTTAATCCTTGCAACTGTGACTGGGGGGTAGATGGCTCTGTTTGCATACGAAGAAATAAAGGCTCCAGGAGGTTAAATCGGGCAACTTTTTAGAACTAA ATCAGTCTCTGTAAGGCCTACATTGCTAAGATACCATTTCAGCTCTGAAAATCTGCTTCAGGGAAGTGAGTGGATGAGGCCTTCCTGCCTCAGCTACTCTGCCCGTCTGTACATCTTTTGTGTCTGCCTCCGTACCTTATTTTTTCACACTAAAGTAAGTAGAATTAAGACTGTAGTTCAGATGCTTTTTCTTTTTCTGTTGGAAACTGAACACACTACAGACAGT GAAAAAAGGTACATATTCCATTTTCTCATTGCCTGAAGATCTCTGCTGATGCTCCTGGAGAATGACTTTGGGGGCTTTAGAAAGAATATTGCCAGTCCGTCTCGGCAAGGAGATGATGGGAGCGCTTTATATGGAGGCTTTACATGACTTGTAAATTAAATGTGAATGAGGGCAGTTGATTAAAATTGGTATTACAGAAGGGCCCTGCTGAGGTTTGA AAACAGCTGAGCTGCTGATGTCTCAGGCCTTTCCCTGAATTAGCACTGCGGTTTCCAGGATATCAGCAAAGAGGGCAAGTAATAGAAGCCCCTGATAAGGAGCGTCAGCCGACAGGCAAGCTTGGGAGGCTGTGGGAATGGGTCTGCCCCCAGCTTCACAGACCTCTTCCTCCAGCCCTCTGAATCCCATTAGCCACAGCCTAGAACATTAGCTGAGCTGCAC AAGCTCACCCACCCCTGTGCCAGGGGGCCCTGACCCTCCCTCCATGCCATGTTTTTGGCTGTATCTACGGCACTTAACAATAGGGGCTTTTTATTTTCATTACAGAGATATTTTGAAAAATTTAAAAGACATGAACTCACATAAACAGTTATGGATGATAGTTAAAAGAGAAACGGGTGGAGGTGGATGAGAGGTTGTCTTCATGAATAATTACTTGAGAT TTTTTTTTTCTTAATGGAATTAGTTTTATTAGAAAATGTCTGTGTTAAATCCGTAGAAAAGGAAGAAAAGTGTAGCAACAAAAATGTAGCCATTATCTAACTTGCCATAAATATTTGCAGTTATGATACCTTGGAATGTTGCCACGATATGGATTGCTTTGATTAAAAGATGTCAGTTGAATAAAACAGTACTGTGGGAGAATCGCTTTCTGCTGCTAGATAAATGCT GATGTTTATTTTTAAACCAGGAAACATTGATCCTGTAACAATGCCCGATTACAATTGCTTTATTACACCCCAGGGCTGATGGAGATGTAATCACTTGGCTAATGGATGTGGGTGCAGGACAGATGCTCGCTTGCTGGCCTGCTTTCCTGCTTGCATTCTGATGAGCTGCAGGAGTGCGCCTGGCCTTCTGCAGGTGGAGCTGCTGTCAGAGCTTCGTTTCA CTGATACCCAAAGCCATGTCTGACTGAAATAAAACAGGTTCCCTTTTTTTTTCCCTTTGGAAAATGCCAACTAAGGGAGACTAATCAGATATCTTAACACAATTTCATCCAGGCTTAGTGCTAACAAGATTGCGGGGCTTTTTAGGGTTTAAGAAGATGAGAAATGAGTGTGCACGTTTCACACGTTGACTTGCCGGTTTTTCCATGTCATACAAAAAAGTCCTGGCT GTTTCTCCGAACTGGCTGCCTGCATTCCCGTCTTTCTTTTGTTTTTAAGAAATAGACTGAATTCAGCTGTTAATCCTCTAGTACAGTATCCATGTTAAAATGTTTTTCCATTGCATCTTTTATGTGAATTCAAAGGTCAGAATTTATTGTCTGTGATATTGAGACCATGTGTACAAGAACTACTTTTTGTTTTCATCATTCACTCCTTAGCAAACGTTTCGTAAGTACCCTGT CTGTTTGCTACTATATGAGGTGCTGCGAAATTAGTGGGCGTGGCTTTTTATATTTTTCATTCGTGTGTAGCCTAAGTAAGGTGACTCAAGATGATACACCGAGAGAAAAATGCAAAATATTTGGTTCTCATTTCTGTTGCTGTCGTTTCCTTTTTTAAAGACGATTTATCAACTGCTGCCATTTGGAACTTCCTATAAGAAACTAAAAATGATCTATTTCAGTGTTC CTTTCGCCTTTCCTCTGCTTTCTGAATAAATGGTTTCAGTAACCCATGCTGTTTCTCCCTATTCTACGTCTTTCTCCTATGTTGAAAAAAGATTCCCACAGTTTCTGATGTGTGTGTTTATAGTCTTCAATGTATGTTAACATGTTAGGAACTGAGTATCTTAAGAGATGTCTTAGAATGCTTTAGTTTCATAATTTGTCCTTTATGTATTTTTCATTGTATTTGCTGT TTTGACATGGAAGTAATTTAAAAAGTTGGTGCAGGAAAGGACTCTTTACTGTTGCACATTTTGGTTTTCTGATATGTAATAAATTCATGGCTTGGCAGCTGACATGATGTTTCCCCAGAGAGAAGGAGATGTATTTCTGCAGGGTCCAGACCAAAAAGAGCCATTTACAGCATGTTCTCCCATGTTCCATTATCAGCTGATGAAACCTGCCCTGCCAAGGCATAA ACTTTTGTACTAGCTGTCTCCATATTATGTTCAATAAATTCTGTGCTCTGAATATATTTAAAAAAAAAAAAA SEQ ID NO:23 The polynucleotide sequence of all 6 exons 1-6 of VAPB arranged in order SEQ ID NO:24 Translated polypeptide sequence of VAPB exon 1 MAKVEQVLSLEPQHELKFR SEQ ID NO:25 Translated polypeptide sequence of VAPB exon 2 PFTDVVTTNLKLGNPTDRNVCFKVKTTAPRRYCVRPNSGIIDAGASINVS SEQ ID NO:26 Translated polypeptide sequence of exon 3 of VAPB MLQPFDYDPNEKSKHKFMVQSMFAPTDTSDMEAV SEQ ID NO:27 Translated polypeptide sequence of exon 4 of VAPB WKEAKPEDLMDSKLRCVFELPAENDKP SEQ ID NO:28 Translated polypeptide sequence of exon 5 of VAPB HDVEINKIISTTASKTETPIVSKSLSSSLDDTEVKKVMEECKRLQGEVQRLREENKQFK SEQ ID NO:29 Translated polypeptide sequence of exon 6 of VAPB EEDGLRMRKTVQSNSPISALAPTGKEEGLSTRLLALVVLFFIVGVIIGKIAL SEQ ID NO:30 VAPB polypeptide sequence MAKVEQVLSLEPQHELKFRGPFTDVVTTNLKLGNPTDRNVCFKVKTTAPRRYCVRPNSGIIDAGASINVSVMLQPFDYDPNEKSKHKFMVQSMFAPTDTSDMEAVWKEAKPEDLMDSKLRCVFELPAENDKPHDVEINKIISTTASKTETPIVSKSLSSSLDDTEVKKVMEECKRLQGEVQRLREENK QFKEEDGLRMRKTVQSNSPISALAPTGKEEGLSTRLLALVVLFFIVGVIIGKIAL CADM1 sequence informationSEQ ID NO:5 CADM1 exon 7 sequence at 5' of CADM1-NRG1 fusion AGCTTCAAACATAGTGGGGAAAGCTCACTCGGATTATATGCTGTATGTATACG SEQ ID NO:6 NRG1 exon 6 sequence at 3' of CADM1-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCAT SEQ ID NO:7 CADM1-NRG1 polynucleotide sequence AGCTTCAAACATAGTGGGGAAAGCTCACTCGGATTATATGCTGTATGTATACGCTACATCTACATCCACCACTGGGACAAGCCAT SEQ ID NO:8 CADM1-NRG1 polypeptide sequence ASNIVGKAHSDYMLYVYATSTSTTGTSH SEQ ID NO:33 CADM1 exon 1 GGTTGGGCTCGCGGCGCTGTGATTGGTCTGCCCGGACTCCGCCTCCAGCGCATGTCATTAGCATCTCATTAGCTGTCCGCTCGGGCTCCGGAGGCAGCCAACGCCGCCAGTCTGAGGCAGGTGCCCGACATGGCGAGTGTAGTGCTGCCGAGCGGATCCCAGTGTGCGGCGGCAGCGGCGGCGGCGGCGCCTCCCGGGCTCCGGCT CCGGCTTCTGCTGTTGCTCTTCTCCGCCGCGGCACTGATCCCCACAG SEQ ID NO:34 CADM1 exon 2 GTGATGGGCAGAATCTGTTTACGAAAGACGTGACAGTGATCGAGGGAGAGGTTGCGACCATCAGTTGCCAAGTCAATAAGAGTGACGACTCTGTGATTCAGCTACTGAATCCCAACAGGCAGACCATTTATTTCAGGGACTTCAGGC SEQ ID NO:35 CADM1 exon 3 CTTTGAAGGACAGCAGGTTTCAGTTGCTGAATTTTTTCTAGCAGTGAACTCAAAGTATCATTGACAAACGTCTCAATTTCTGATGAAGGAAGATACTTTTGCCAGTCCTATACCGATCCCCCACAGGAAAGTTACACCATCACAGTCCTGG SEQ ID NO:36 CADM1 exon 4 TCCCACCACGTAATCTGATGATCGATATCCAGAAAGACACTGCGGTGGAAGGTGAGGAGATTGAAGTCAACTGCACTGCTATGGCCAGCAAGCCAGCCACGACTATCAGGTGGTTCAAAGGGAACACAGAGCTAAAAG SEQ ID NO:37 CADM1 exon 5 GCAAATCGGAGGTGGAAGAGTGGTCAGACATGTACACTGTGACCAGTCAGCTGATGCTGAAGGTGCACAAGGAGGACGATGGGGTCCCAGTGATCTGCCAGGTGGAGCACCCTGCGGTCACTGGAAACCTGCAGACCCAGCGGTATCTAGAAGTACAGT SEQ ID NO:38 CADM1 exon 6 ATAAGCCTCAAGTGCACATTCAGATGACTTATCCTCTACAAGGCTTAACCCGGGAAGGGGACGCGCTTGAGTTAACATGTGAAGCCATCGGGAAGCCCCA SEQ ID NO:39 CADM1 exon 7 GCCTGTGATGGTAACTTGGGTGAGAGTCGATGATGAAATGCCTCAACACGCCGTACTGTCTGGGCCCAACCTGTTCATCAATAACCTAAACAAACAGATAATGGTACATACCGCTGTGAAGCTTCAAACATAGTGGGGAAAGCTCACTCGGATTATATGCTGTATGTATACG SEQ ID NO:40 Exon 8 of CADM1 ACACAACGGCGACGACAGAACCAGCAGTTCACG SEQ ID NO:41 CADM1 exon 9 GCCTTACTCAGTTGCCCAATTCCGCAGAAGAACTGGACAGTGAGGACCTCTCAG SEQ ID NO:42 Exon 10 of CADM1 ATTCCCGAGCAGGTGAAGAAGGCTCGATCAGGGCAGTGGATCATGCCGTGATCGGTGGCGTCGTGGCGGTGGTGGTGTTCGCCATGCTGTGCTTGCTCATCATTCTGGGGCGCTATTTTGCCAGACATAAAG SEQ ID NO:43 CADM1 exon 11 GTACATACTTCACTCATGAAGCCAAAGGAGCCGATGACGCAGCAGACGCAGACACAGCTATAATCAATGCAGAAGGAGGACAGAACAACTCCGAAGAAAAGAAAGAGTACTTCATCTAGATCAGCCTTTTTGTTTCAATGAGGTGTCCAACTGGCCCTATTTAGATGATAAAGAGACAGTGATATTGGAACTTGCGAGAAATTCGTGTGTTTTTTTATGAATGGGTG GAAAGGTGTGAGACTGGGAAGGCTTGGGATTTGCTGTGTAAAAAAAAAAAAAATGTTCTTTGGAAAGTACACTCTGCTGTTTGACACCTCTTTTTTCGTTTGTTTGTTTGTTTAATTTTTATTTCTTCCTACCAAGTCAAACTTGGATACTTGGATTTAGTTTCAGTAGATTGCAAAAATTCTGTGCCTTGTTTTTTGTTTGTTTGTTGCGTTCCTTTCTTC CCCCTTTGTGCACATTTATTTCCTCCCTCTACCCCAATTTCGGATTTTTTCCAAAATCTCCCATTTTGGAATTTGCCTGCTGGGATTCCTTAGACTCTTTTCCTTCCCTTTTCTGTTCTAGTTTTTTACTTTTGTTTTATTTTTATGGTAACTGCTTTCTGTTCCAAATTCAGTTTCATAAAAGGAGAACCAGCACAGCTTAGATTTCATAGTTCAGAATTTAGTGTATCCATA ATGCATTCTTCTCTGTTGTCGTAAAGATTTGGGTGAACAAACAATGAAAACTCTTTGCTGCTGCCCATGTTTCAAATACTTAGAGCAGTGAAGACTAGAAAATTAGACTGTGATTCAGAAAATGTTCTGTTTGCTGTGGAACTACATTACTGTACAGGGTTATCTGCAAGTGAGGTGTGTCACAATGAGATTGAATTTCACTGTCTTTAATTCTGTATCTGTAGACGGC TCAGTATAGATACCCTACGCTGTCCAGAAAGGTTTGGGGCAGAAAGGACTCCTCCTTTTTCCATGCCCTAAACAGACCTGACAGGTGAGGTCTGTTCCTTTTATAAGTGGACAAATTTTGAGTTGCCACAGGAGGGGAAGTAGGGAGGGGGGAAATACAGTTCTGCTCTGGTTGTTTCTGTTCCAAATGATTCCATCCACCTTTCCCAATCGGCCT TACTTCTCACTAATTTGTAGGAAAAAGCAAGTTCGTCTGTTGTGCGAATGACTGAATGGGACAGAGTTGATTTTTTTTTTTTTTCCTTTGTGCTTAGTTAGGAAGGCAGTAGGATGTGGCCTGCATGTACTGTATATTACAGATATTTGTCATGCTGGGATTTCCAACTCGAATCTGTGTGAAACTTTCATTCCTTCAGATTTGGCTTGACAAAGGCAGGAGGTACAA AAGAAGGGCTGGTATTGTTCTCACACTGGTCTGCTGTCGCTCTCAGTTCTCGATAGGTCAAGAGCAGAGGTGGAAAAACAGCATGTACGGATTTTCAGTTACTTAATCAAAACTCAAATGTGAGTGTTTTTTATCTTTTTACCTTTTCATACACTAGCCTTGCCTCTTTCCTCAGCCTTAAGAACCATCTGCCAAAAATTACTGATCCTCGCATGATGGCAGCCATAGT GCATAGCTACTAAAATCAGTGACCTTGAACATATCTTAGATGGGGAGCCTCGGGAAAAGGTAGAGGAGTCACGTTACCATTTACATGTTTTAAAAGAAAGAAGTGTGGGGATTTTCACTGAAACGTCTAGGAAATCTAGAAGTAGTCCTGAAGGACAGAAACTAAACTCTTACCATATGTTTGGTAAGACTCCAGACTCCAGCTAACAGTCCCTATGGAAAGATGGC ATCAAAAAAGATAGATCTATATATATATAAATATATTTCTATTACATTTTCAGTGAGTAATTTTGGATTTTGCAAGGTGCATTTTTACTATTGTTACATTATGTGGAAAACTTATGCTGATTTATTTAAGGGGGAAAAAGTGTCAACTCTTTGTTATTTGAAAACATGTTTATTTTTCTTGTCTTTTATTTTAACCTTTGATAGAACCATTGCAATATGGGGGCCTT TTGGGAACGGACTGGTATGTAAAAAGAAAATCCATTATCGAGCAGCATTTTATTTACCCCTCCCCTATCCCTAGGCACTTAACCAAAGACAAAAAGCCACAATGAACATCCCTTTTTCAATGAATTTTATAATCTGCAGCTCTATTCCGAGCCCTTAGCACCCATTCCGACCATAGTATAATCATATCAAAGGGTGAGAATCATTTAGCATGTTGTTGAAAGGTTTTTTTTTCAGTTGT TCTTTTTAGAAAAAAAGAAAAACAAAAAAAAAAACAAAAAAAAAAAATCACACCATTGCTCACAGAATTGGCATCTCATTTTTGGGACCTCCCATCTTTCTGTTTTGAAAAGTGTACAGTAGTGCAGTGTTCCTGATGTAACTTTATGGCTTACAATGTTGACATGTCTCAGGTTCATGTGTTGCGATTGGTGTTTTCCGTCTCAGGTAGATTGCAAAGTGTAGGC CCCACACATTGGAAAAAATAATAATAAAAAAAGCAAAAACAGGAAATTATGGATTTTAGTTGTATATTGGTTTATGTATTTTTTCTTAAGTATACAGTGCACTGTTTGAAATGTATTGTTGAGTATTACTTTGTACAGGTTGATCACTTTTTTAGAGTGAAGAAAGAACAAACTTGTTTTTTGTGTTTTTTTAAAGGAATATAAAATAATGAAGGATGTATAATTGATGC CAAATAAGCTTGTTCTTTTAGTCACACCGACGTCTTTATTTTTCCCTTTAGGCCAGTTCTGTTTTTAAGGTGTACATGGACAATGTTACAGTGTAAGAAACTCCATATCCATATGTTCCCATTCGCATTTTGTATTGGTTCATGTATACCATTTTTCAAAAAAAAAAAAAAAAAAAAGTAAGTACTATAAAATATCTGTCTTCTTAATAAAAAAAAAATTAATGTTACAAAGTGA SEQ ID NO:44 The polynucleotide sequence of all 11 exons 1-11 of CADM1 arranged in order SEQ ID NO:45 Translated polypeptide sequence of exon 1 of CADM1 MASVVLPSGSQCAAAAAAAPPGLRLRLLLLLFSAAALIPT SEQ ID NO:46 Translated polypeptide sequence of exon 2 of CADM1 DGQNLFTKDVTVIEGEVATISCQVNKSDDSVIQLLNPNRQTIYFRDFR SEQ ID NO:47 Translated polypeptide sequence of exon 3 of CADM1 LKDSRFQLLNFSSSELKVSLTNVSISDEGRYFCQLYTDPPQESYTTITVL SEQ ID NO:48 Translated polypeptide sequence of exon 4 of CADM1 PPRNLMIDIQKDTAVEGEEIEVNCTAMASKPATTIRWFKGNTELK SEQ ID NO:49 Translated polypeptide sequence of exon 5 of CADM1 KSEVEEWSDMYTVTSQLMLKVHKEDDGVPVICQVEHPAVTGNLQTQRYLEVQ SEQ ID NO:50 Translated polypeptide sequence of exon 6 of CADM1 KPQVHIQMTYPLQGLTREGDALELTCEAIGKP SEQ ID NO:51 Translated polypeptide sequence of exon 7 of CADM1 PVMVTWVRVDDEMPQHAVLSGPNLFINNLNKTDNGTYRCEASNIVGKAHSDYMLYVY SEQ ID NO:52 Translated polypeptide sequence of exon 8 of CADM1 TTATTEPAVH SEQ ID NO:53 Translated polypeptide sequence of exon 9 of CADM1 LTQLPNSAEELDSEDLS SEQ ID NO:54 Translated polypeptide sequence of exon 10 of CADM1 SRAGEEGSIRAVDHAVIGGVVAVVVFAMLCLIILGRYFARHK SEQ ID NO:55 Translated polypeptide sequence of exon 11 of CADM1 TYFTHEAKGADDAADADTAIINAEGGQNNSEEKKEYFI SEQ ID NO:56 CADM1 polypeptide sequence MASVVLPSGSQCAAAAAAAPPGLRLRLLLLLFSAAALIPTGDGQNLFTKDVTVIEGEVATISCQVNKSDDSVIQLLNPNRQTIYFRDFRPLKDSRFQLLNFSSSELKVSLTNVSISDEGRYFCQLYTDPPQESYTTITVLVPPRNLMIDIQKDTAVEGEEIEVNCTAMASKPATTIRWFKGNTELKG KSEVEEWSDMYTVTSQLMLKVHKEDDGVPVICQVEHPAVTGNLQTQRYLEVQYKPQVHIQMTYPLQGLTREGDALELTCEAIGKPQPVMVTWVRVDDEMPQHAVLSGPNLFINNLNKTDNGTYRCEASNIVGKAHSDYMLYVYDTTATTEPAVHGLTQLPNSAEELDSEDLSDSRAGEEGSIR AVDHAVIGGVVAVVVFAMLCLIILGRYFARHKGTYFTHEAKGADDAADADTAIINAEGGQNNSEEKKEYFI SEQ ID NO:57 The polynucleotide sequence of all seven exons 1-7 of CADM1 arranged in order SEQ ID NO:58 Translated polypeptide sequence of CADM1 exon 1-7 arranged in order MASVVLPSGSQCAAAAAAAPPGLRLRLLLLLFSAAALIPTGDGQNLFTKDVTVIEGEVATISCQVNKSDDSVIQLLNPNRQTIYFRDFRPLKDSRFQLLNFSSSELKVSLTNVSISDEGRYFCQLYTDPPQESYTTITVLVPPRNLMIDIQKDTAVEGEEIEVNCTAMASKPATTIRWFKGNTELKG KSEVEEWSDMYTVTSQLMLKVHKEDDGVPVICQVEHPAVTGNLQTQRYLEVQYKPQVHIQMTYPLQGLTREGDALELTCEAIGKPQPVMVTWVRVDDEMPQHAVLSGPNLFINNLNKTDNGTYRCEASNIVGKAHSDYMLYVY CD44 sequence informationSEQ ID NO:9 Sequence from CD44 exon 5 at 5' of CD44-NRG1 fusion GACGAAGACAGTCCCTGGATCACCGACAGCACAGACAGAATCCCTGCTACCA SEQ ID NO: 10 NRG1 exon 2 subsequence at CD44-NRG1 fusion 3' CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACT SEQ ID NO:11 CD44-NRG1 polynucleotide sequence GACGAAGACAGTCCCTGGATCACCGACAGCAGCAGACAGAATCCCTGCTACCACCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACT SEQ ID NO:12 CD44-NRG1 polypeptide sequence DEDSPWITDSTDRIPATTLPPRLKEMKSQESAAGSK SEQ ID NO:61 CD44 exon 1 CTCATTGCCCAGCGGACCCAGCCTCTGCCAGGTTCGGTCCGCCATCCTCGTCCCGTCCTCCGCCGGCCCCTGCCCCGCGCCCAGGGATCCTCCAGCTCCTTTCGCCCGCGCCCTCCGTTCGCTCCGGACACCATGGACAAGTTTTGGTGGCACGCAGCCTGGGGACTCTGCCTCGTGCCGCTGAGCCTGGCGCAGATCG SEQ ID NO:62 CD44 exon 2 ATTTGAATATAACCTGCCGCTTTGCAGGTGTATTCCACGTGGAGAAAAATGGTCGCTACAGCATCTCTCGGACGGAGGCCGCTGACCTCTGCAAGGCTTTCAATAGCACCTTGCCCACAATGGCCCAGATGGAGAAAGCTCTGAGCATCGGATTTGAGACCTGCAG SEQ ID NO:63 CD44 exon 3 GTATGGGTTCATAGAAGGGCACGTGGTGATTCCCCGGATCCACCCCAACTCCATCTGTGCAGCAAACAACACAGGGGTGTACATCCTCACATCCAACACCTCCAGTATGACACATATTGCTTCAATGCTTCAG SEQ ID NO:64 CD44 exon 4 CTCCACCTGAAGAAGATTGTACATCAGTCACAGACCTGCCCAATGCCTTTGATGGACCAATTACCATAA SEQ ID NO:65 CD44 exon 5 CTATTGTTAACCGTGATGGCACCCGCTATGTCCAGAAAGGAGAATACAGAACGAATCCTGAAGACATCTACCCCAGCAAACCCTACTGATGATGACGTGAGCAGCGGCTCTCCAGTGAAAGGAGCAGCACTTCAGGAGGTTACATTCTTTTACACCTTTTTACTGTACCACCATCCCAGACGAAGACAGTCCCTGGATCACCGACAGCCAGACAGAATCCCT GCTACCA SEQ ID NO:66 CD44 exon 6 CTTTGATGAGCACTAGTGCTACAGCAACTGAGACAGCAACCAAGAGGCAAGAAACCTGGGATTGGTTTTCATGGTTGTTTCTACCATCATCAGAGTCAAAGAATCATCTTCACACAACAACACAAATGGCTG SEQ ID NO:67 CD44 exon 7 GTACGTCTTCAAATACCATTCTCAGCAGGCTGGGAGCCAAATGAAGAAAATGAAGATGAAAGAGACAGACCTCCAGTTTTTCTGGATCAGGCATTGATGATGATGAAGATTTTATCTCCAGCACCA SEQ ID NO:68 CD44 exon 8 TTTCAACCACACCACGGGCTTTTGACCACACAAAACAGAACCAGGACTGGACCCAGTGGAACCCAAGCCATTCAAATCCGGAAGTGCTACTTCAGACAACCACAAGGATGACTG SEQ ID NO:69 CD44 exon 9 ATGTAGACAGAAATGGCACCACTGCTTATGAAGGAAACTGGAACCCAGAAGCACACCCTCCCTCATTCACCATGAGCATCATGAGGAAGAAGAGACCCCACATTCTACAAGCACAA SEQ ID NO:70 CD44 exon 10 TCCAGGCAACTCCTAGTAGTACAACGGAAGAAACAGCTACCCAGAAGGAACAGTGGTTTGGCAACAGATGGCATGAGGGATATCGCCAAACACCCAAAGAAGACTCCCATTCGACAACAGGGACAGCTG SEQ ID NO:71 CD44 exon 11 CAGCCTCAGCTCATACCAGCATCCAATGCAAGGAAGGACAACACCAAGCCCAGAGGACAGTTCCTGGACTGATTTCTTCAACCCAATCTCACACCCCATGGGACGAGGTCATCAAGCAGGAAGAAGGATGG SEQ ID NO:72 CD44 exon 12 ATATGGACTCCAGTCATAGTATAACGCTTCAGCCTACTGCAAATCCAAACACAGGTTTGGTGGAAGATTTGGACAGGACAGGACCTCTTTCAATGACAACGC SEQ ID NO:73 CD44 exon 13 AGCAGAGTAATTCTCAGAGCTTCTCTACATCACATGAAGGCTTGGAAGAAGATAAAGACCATCCAAACTTCTACTCTGACATCAAGCA SEQ ID NO:74 CD44 exon 14 ATAGGAATGATGTCACAGGTGGAAGAAGAGACCCAAAATCATTCTGAAGGCTCAACTACTTTACTGGAAGGTTATACCTCTCATTACCCACACACGAAGGAAAGCAGGACCTTCATCCCAGTGACCTCAGCTAAGACTGGGTCCTTTGGAGTTACTGCAGTTACTGTTGGAGATTCCAACTTCTAATGTCAATCGTTCCTTATCAG SEQ ID NO:75 CD44 exon 15 GAGACCAAGACACATTCCACCCCAGTGGGGGGTCCCATACCACTCATGGATCTGAATCAGATG SEQ ID NO:76 CD44 exon 16 GACACTCACATGGGAGTCAAGAAGGTGGAGCAAACACAACCTCTGGTCCTATAAGGACACCCCAAATTCCAG SEQ ID NO:77 CD44 exon 17 AATGGCTGATCATCTTGGCATCCCCTTGGCCTTGGCTTTGATTCTTGCAGTTTGCATTGCAGTCAACAGTCGAAGAAG SEQ ID NO:78 CD44 exon 18 GTGTGGGCAGAAGAAAAAGCTAGTGATCAACAGTGGCAATGGAGCTGTGGAGGACAGAAAGCCAAGTGGACTCAACGGAGAGGCCAGCAAGTCTCAGGAAATGGTGCATTTGGTGAACAAGGAGTCGTCAGAAACTCCAGACCAGTTTATGACAGCTTATGACAGCTGATGAGACAAGGAACCTGCAGAATGTGGACATGAAGATTGGGGTGTAACACCCTACACC ATTATCTTGGAAAGAAACAACCGTTGGAAACATAACCATTACAGGGAGCTGGGACACTTAACAGATGCAATGTGCTACTGATTGTTTCATTGCGAATCTTTTTTAGCATAAAATTTTCTACTCTTTTTGTTTTTTGTGTTTTGTTCTTTAAAAGTCAGGTCCAATTTGTAAAAACAGCATTGCTTTCTGAAATTAGGGCCCAATTAATAATCAGCAAGAATTTGATCGTTC CAGTTCCCCACTTGGAGGCCTTTCATCCCTCGGGTGTGCTATGGATGGCTTCTAACAAAAACTACACATATGTATTCCTGATCGCCAACCTTTCCCCACCAGCTAAGGACATTTCCCAGGGTTAATAGGGCCTGGTCCCTGGGAGGAAATTTGAATGGGTCCATTTTGCCCTTCCATAGCCTAATCCCTGGGCATTGCTTTCCACTGAGGTTGGGGGT TGGGGTGTACTAGTTACACATTCTTCAACAGACCCCCTCTAGAAATTTTTCAGATGCTTCTGGGAGACACCCAAAGGGTGAAGCTATTTATCTGTAGTAAACTATTTATCTGTGTTTTTGAAATATTAAAACCCTGGATCAGTCCTTTGATCAGTATAATTTTTTAAAGTTACTTTGTCAGAGGCACAAAAGGGTTTAAACTGATTCATAATAAATATCTGTACTTCTTCGATC TTCACCCTTTTGTGCTGTGATTCTTCAGTTTCTAAACCAGCACTGTCTGGGTCCCTACAATGTATCAGGAAGAGCTGAGAATGGTAAGGAGACTCTTCTAAGTCTTCATCTCAGAGACCCTGAGTTCCCACTCAGACCCACTCAGCCAAATCTCATGGAAGACCAAGGAGGGCAGCACTGTTTTTTGTTTTTTGTTTTTTGTTTTTTTTTTTTGACACTGTCCAAAGGTTTTC CATCCTGTCCTGGAATCAGAGTTGGAAGCTGAGGAGCTTCAGCCTCTTTTATGGTTTAATGGCCACCTGTTCTCTCCTGTGAAAGGCTTTGCAAAGTCACATTAAGTTTGCATGACCTGTTATCCCTGGGGCCCTATTTCATAGAGGCTGGCCCTATTAGTGATTTCCAAAAACAATATGGAAGTGCCTTTTGATGTCTTACAATAAGAAGAAGCCAAT GGAAATGAAAGAGATTGGCAAAGGGGAAGGATGATGCCATGTAGATCCTGTTTGACATTTTTATGGCTGTATTTGTAAACTTAAACACCCAGTGTCTGTTCTTGATGCAGTTGCTATTTAGGATGAGTTAAGTGCCTGGGGAGTCCCTCAAAAAGGTTAAAGGGATTCCCATCATTGGAATCTTATCACCAGATAGGCAAGTTTATGACCAACAAGAGAG TACTGGCTTTATCCTCTAACCTCATATTTCTCCCACTTGGCAAGTCCTTTGTGGCATTTATTCATCAGTCAGGGTGTCCGATTGGTCCTAGAACTTCCAAAGGCTGCTTGTCATAGAAGCCATTGCATCTATAAAAGCAACGGCTCCTGTTAAATGGTATCTCCTTTCTGAGGCTCCTACTAAAAGTCATTTGTTACCTAAACTTATGTGCTTAACAGGCAATGCTTCT CAGACCACAAAGCAGAAAGAAGAAGAAAAGCTCCTGACTAAATCAGGGCTGGGCTTAGACAGAGTTGATCTGTAGAATATCTTTAAAGGAGAGATGTCCAACTTTCTGCACTATTCCCCAGCCTCTGCTCCTCCCTGTCTACCTCTCCCCTCCCTCTCCCTCCACTTCACCCCCACAATCTTGAAAAACTTCCTTTTCTCTTCTGTGAACATCATTGGCCAGATCCATTTCAGT GGTCTGGATTTCTTTTTTATTTTCTTTTCAACTTGAAAGAAACTGGACATTAGGCCACTATGTGTTGTTACTGCCACTAGTGTTCAAGTGCCTCTTGTTTTTCCCAGAGAGATTTCCTGGGTCTGCCAGAGGCCCAGACAGGCTCACTCAAGCTTTAACTGAAAAGCAACAAGCCACTCCAGGACAAGGTTCAAAATGGTTACAACAGCCTCTACCTGTCGCCCCAGGGA GAAAGGGGTAGTGATACAAGTCTCATAGCCAGAGATGGTTTTCCACTCCTTCTAGATATTCCAAAAAGAGGCTGAGACAGGAGGTTATTTTCCAATTTTATTTTGGAATTAAATACTTTTTTCCTTTATTTACTGTTGTAGTCCCTCACTTGGATATACCCTGTTTTTCACGATAGAAATAAGGGAGGTCTAGAGCTTCTATTCCTTGGCCATTGTCAACGGAGAGCT GGCCAAGTCTTCACAAACCCTTGCAACATTGCCTGAAGTTTATGGAATAAGATGTATTTCTCACTCCTTGATCTCAAGGGCGTAACTCTGGAAGCACAGCTTGACTACACGTCATTTTTACCAATGATTTTCAGGTGACCTGGGCTAAGTCATTTTAAACTGGGTCTTTAAACTGGGTCTTTAAAAGTAAAAGGCCAACATTTAATTATTTTGCAAAGCAACCTAAGAGCTAAAGATGT AATTTTTTCTTGCAATTGTAAATCTTTTGTGTCTCCTGAAGACTTCCCCTTAAAATTAGCTCTGAGTGAAAAATCAAAAGAGACAAAAGACATCTTCGAATCCATATTTCAAGCCTGGTAGAATTGGCTTTTCTAGCAGAACCTTTCCAAAAGTTTTATATTGAGATTCATAACACACCAAGAATTGATTTTGTAGCCAACATTCATTCAATACTGTTATATCAGAGGAGTAGGAGAGA GGAAACATTTGACTTATCTGGAAAAGCAAAATGTACTTAAGAATAAGAATAACATGGTCCATTCACCTTTATGTTATAGATATGTCTTTGTGTAAATCATTTGTTTTGAGTTTTCAAAGAATAGCCCATTGTTCATTCTTGTGCTGTACAATGACCACTGTTATTGTTACTTTGACTTTCAGACACACCCTTCCTCTGGTTTTTTGTATATTTATTGATGGATCAAT AATAATGAGGAAAGCATGATATGTATATTGCTGAGTTGAAAGCACTTATTGGAAAATATTAAAAGGCTAACATTAAAAGACTAAAGGAAACAGA SEQ ID NO:79 The polynucleotide sequence of all 18 exons 1-18 of CD44 arranged in order SEQ ID NO:80 Translated polypeptide sequence of exon 1 of CD44 MDKFWWHAAWGLCLVPLSLAQI SEQ ID NO:81 Translated polypeptide sequence of exon 2 of CD44 LNITCRFAGVFHVEKNGRYSISRTEADLCKAFNSTLPTMAQMEKALSIGFETC SEQ ID NO:82 Translated polypeptide sequence of exon 3 of CD44 YGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNAS SEQ ID NO:83 Translated polypeptide sequence of exon 4 of CD44 PPEEDCTSVTDLPNAFDGPITI SEQ ID NO:84 Translated polypeptide sequence of exon 5 of CD44 IVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSSGSSSERSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPAT SEQ ID NO:85 Translated polypeptide sequence of exon 6 of CD44 LMSTSATATETATKRQETWDWFSWLFLPSESKNHLHTTTQMA SEQ ID NO:86 Translated polypeptide sequence of exon 7 of CD44 TSSNTISAGWEPNEENEDERDRHLSFSGSGIDDDDEDFISST SEQ ID NO:87 Translated polypeptide sequence of exon 8 of CD44 STTPRAFDHTKQNQDWTQWNPSHSNPEVLLQTTTRMT SEQ ID NO:88 Translated polypeptide sequence of exon 9 of CD44 VDRNGTTAYEGNWNPEAHPPLIHHEHHEEEEETPHSTST SEQ ID NO:89 Translated polypeptide sequence of exon 10 of CD44 QATPSSTTEETATQKEQWFGNRWHEGYRQTPKEDSHSTTGTA SEQ ID NO:90 Translated polypeptide sequence of exon 11 of CD44 ASAHTSHPMQGRTTPSPEDSSWTDFFNPISHPMGRGHQAGRRM SEQ ID NO:91 Translated polypeptide sequence of exon 12 of CD44 MDSSHSITLQPTANPNTGLVEDLDRTGPLSMTT SEQ ID NO:92 Translated polypeptide sequence of exon 13 of CD44 QSNSQSFSTSHEGLEEDKDHPTTSTLTSS SEQ ID NO:93 Translated polypeptide sequence of exon 14 of CD44 RNDVTGGRRDPNHSEGSTTLLEGYTSHYPHTKESRTFIPVTSAKTGSFGVTAVTVGDSNSNVNRSLS SEQ ID NO:94 Translated polypeptide sequence of exon 15 of CD44 DQDTFHPSGGSHTTHGSESD SEQ ID NO:95 Translated polypeptide sequence of exon 16 of CD44 HSHGSQEGGANTTSGPIRTPQIP SEQ ID NO:96 Translated polypeptide sequence of exon 17 of CD44 WLIILASLLALALILAVCIAVNSRR SEQ ID NO:97 Translated polypeptide sequence of exon 18 of CD44 CGQKKKLVINSGNGAVEDRKPSGLNGEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV SEQ ID NO:98 CD44 polypeptide sequence MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEADLCKAFNSTLPTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSSGSSSERSSTSGGYIFY TFSTVHPIPDEDSPWITDSTDRIPATTLMSTSATATETATKRQETWDWFSWLFLPSESKNHLHTTTQMAGTSSNTISAGWEPNEENEDERDRHLSFSGSGIDDDEDFISSSTISTTPRAFDHTKQNQDWTQWNPSHSNPEVLLQTTTRMTDVDRNGTTAYEGNWNPEAHPPLIHHEHEEEETPHSTSTIQATPSSTTEETATQK EQWFGNRWHEGYRQTPKEDSHSTTGTAAASAHTSHPMQGRTTPSPEDSSWTDFFNPISHPMGRGHQAGRRMDMDSSHSITLQPTANPNTGLVEDLDRTGPLSMTTQQSNSQSFSTSHEGLEEDKDHPTTSTLTSSNRNDVTGGRRDPNHSEGSTTLEGYTSHYPHTKESRTFIPVTSAKTGSFGVTAVTV GDSNSNVNRSLSGDQDTFHPSGGSHTTHGSESDGHSHGSQEGGANTTSGPIRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLNGEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV SEQ ID NO:99 The polynucleotide sequence of all five exons 1-5 of CD44 arranged in order SEQ ID NO:100 Translated polypeptide sequence of exon 1-5 of CD44 MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEADLCKAFNSTLPTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSSGSSSERSSTSGGYIFY TFSTVHPIPDEDSPWITDSTDRIPAT SLC3A2 transcript 6 sequence informationSEQ ID NO:13 SLC3A2 exon 1 sequence at 5' of SLC3A2-NRG1 fusion CCGCATCGGCGACCTTCAGGCCTTCCAGGGCCACGGCGCGGGCAACCTGGCGG SEQ ID NO:14 NRG1 exon 5 sequence at 3' of SLC3A2-NRG1 fusion CATCTACATCTACATCCACCACTGGGACAAGCCAT SEQ ID NO:15 SLC3A2-NRG1 polynucleotide sequence CCGCATCGGCGACCTTCAGGCCTTCCAGGGCCACGGCGCGGGCAACCTGGCGGCATCTACATCTACATCCACCACTGGGACAAGCCAT SEQ ID NO:16 SLC3A2-NRG1 polypeptide sequence RIGDLQAFQGHGAGNLAASTSTSTTGTSH SEQ ID NO:103 Exon 1 of SLC3A2 AGATGCAGTAGCCGAAACTGCGCGGAGGCACAGAGGCCGGGGAGAGCGTTCTGGGTCCGAGGGTCCAGGTAGGGGTTGAGCCACCATCTGACCGCAAGCTGCGTCGTGTCGCCGGTTCTGCAGGCACCATGAGCCAGGACACCGAGGTGGATATGAAGGAGGTGGAGCTGAATGAGTTAGAGCCCGAGAAGCAGCCGATGAACGCGGCGT CTGGGGCGGCCATGTCCCTGGCGGGAGCCGAGAAGAATGGTCTGGTGAAGATCAAGGTGGCGGAAGACGAGGCGGAGGCGGCAGCCGCGGCTAAGTTCACGGGCCTGTCCAAGGAGGAGCTGCTGAAGGTGGCAGGCAGCCCCGGCTGGGTACGCACCCGCTGGGCACTGCTGCTGCTCTTCTGGCTCGGCTGGCTCGGCATGC TTGCTGGTGCCGTGGTCATAATCGTGCGAGCGCCGCGTTGTCGCGAGCTACCGGCGCAGAAGTGGTGGCACACGGGCGCCCTCTACCGCATCGGCGACCTTCAGGCCTTCCAGGGCCACGGCGCGGGCAACCTGGCGG SEQ ID NO:104 Exon 2 of SLC3A2 GTCTGAAGGGGCGTCTCGATTACCTGAGCTCTCTGAAGGTGAAGGGCCTTGTGCTGGGTCCAATTCACAAGAACCAGAAGGATGATGTCGCTCCAGACTGACTTGCTGCAGATCGACCCCAATTTTGGCTCCAAGGAAGATTTTGACAGTCTCTTGCAATCGGCTAAAAAAAAAGA SEQ ID NO:105 Exon 3 of SLC3A2 GCATCCGTGTCATTCTGGACCTTACTCCCAACTACCGGGGTGAGAACTCGTGGTTTCCCACTCAGGTTGACACTGTGGCCACCAAGGTGAA SEQ ID NO:106 Exon 4 of SLC3A2 GATGCTCTGGAGTTTTGGCTGCAAGCTGGCGTGGATGGGTTCCAGGTTCGGGACATAGAGAATCTGAAG SEQ ID NO:107 Exon 5 of SLC3A2 GATGCATCCTCATTCTTGGCTGAGTGGCAAAATATCACCAAGGGCTTCAGTGAAGACAG SEQ ID NO:108 Exon 6 of SLC3A2 GCTCTTGATTGCGGGGACTAACTCCTCCGACCTTCAGCAGATCCTGAGCCTACTCGAATCCAACAAAGACTTGCTGTTGACTAGCTCATACCTGTCTGATTCTGGTTCTACTGGGGAGCATACAAAATCCTAGTCACACAGTTTGAATGCCACTGGCAATCGCTGGTGCAGCTGGAGT SEQ ID NO:109 Exon 7 of SLC3A2 TTGTCTCAGGCAAGGCTCCTGACTTCCTTCTTGCCGGCTCAACTTCTCCGACTCTACCAGCTGATGCTCTTCACCCTGCCAGGGACCCCTGTTTTTCAGCTACGGGGATGAGATTGGCCTGGATGCAGCTGCCCTTCCTGGACAG SEQ ID NO:110 Exon 8 of SLC3A2 CCTATGGAGGCTCCAGTCATGCTGTGGGATGAGTCCAGCTTCCCTGACATCCCAGGGGCTGTAAGTGCCAACATGACTGTGAAG SEQ ID NO:111 Exon 9 of SLC3A2 GGCCAGAGTGAAGACCCTGGCTCCCTCCTTTCCTTGTTCCGGCGGCTGAGTGACCAGCGGAGTAAGGAGCGCTCCCTACTGCATGGGGACTTCCACGCGTTCTCCGCTGGGCCTGGACTCTTCTCCTATATCCGCCACTGGGACCAGAATGAGCGTTTTCTGGTAGTGCTTAACTTTGGGGATGTGGGCCTCTCGGCTGGACTGCAGGC CTCCGACCTGCCTGCCAGCGCCAGCCTGCCAGCCAAGGCTGACCTCCTGCTCAGCACCCAGCCAGGCCGTGAGGAGGGCTCCCCTCTTGAGCTGGAACGCCTGAAACTGGAGCCTCACGAAGGGCTGCTGCTCCGCTTCCCCTACGCGGCCTGACTTCAGCCTGACATGGACCCCACTACCCTTCTCCTTTCCTTCCCAGGCCCTTTGGCTTCTGATTTTTCT CTTTTTTAAAAACAAACAAACAAACTGTTGCAGATTATGAGTGAACCCCCAAATAGGGTGTTTTCTGCCTTCAAATAAAAGTCACCCCTGCATGGTGAA SEQ ID NO:112 The polynucleotide sequence of all nine exons 1-9 of SLC3A2 arranged in order SEQ ID NO:113 Translated polypeptide sequence of exon 1 of SLC3A2 MSQDTEVDMKEVELNELEPEKQPMNAASGAAMSLAGAEKNGLVKIKVAEDEAEAAAAAKFTGLSKEELLKVAGSPGWVRTRWALLLLFWLGWLGMLAGAVVIIVRAPRCRELPAQKWWHTGALYRIGDLQAFQGHGAGNLA SEQ ID NO:114 Translated polypeptide sequence of exon 2 of SLC3A2 LKGRLDYLSSLKVKGLVLGPIHKNQKDDVAQTDLLQIDPNFGSKEDFDSLLQSAKKK SEQ ID NO:115 Translated polypeptide sequence of exon 3 of SLC3A2 IRVILDLTPNYRGENSWFSTQVDTVATKV SEQ ID NO:116 Translated polypeptide sequence of exon 4 of SLC3A2 DALEFWLQAGVDGFQVRDIENLK SEQ ID NO:117 Translated polypeptide sequence of exon 5 of SLC3A2 DASSFLAEWQNITKGFSED SEQ ID NO:118 Translated polypeptide sequence of exon 6 of SLC3A2 LLIAGTNSSDLQQILSLLESNKDLLLTSSYLSDSGSTGEHTKSLVTQYLNATGNRWCSWS SEQ ID NO:119 Translated polypeptide sequence of exon 7 of SLC3A2 LSQARLLTSFLPAQLLRLYQLMLFLTLPGTPVFSYGDEIGLDAAALPGQ SEQ ID NO:120 Translated polypeptide sequence of exon 8 of SLC3A2 PMEAPVMLWDESSFPDIPGAVSANMTVK SEQ ID NO:121 Translated polypeptide sequence of exon 9 of SLC3A2 GQSEDPGSLLSLFRRLSDQRSKERSLLHGDFHAFSAGGLFSYIRHWDQNERFLVVLNFGDVGLSAGLQASDLPASASLPAKADLLLSTQPGREEGSPLELERLKLEPHEGLLLRFPYAA SEQ ID NO:122 SLC3A2 polypeptide sequence MSQDTEVDMKEVELNELEPEKQPMNAASGAAMSLAGAEKNGLVKIKVAEDEAEAAAAAKFTGLSKEELLKVAGSPGWVRTRWALLLLFWLGWLGMLAGAVVIIVRAPRCRELPAQKWWHTGALYRIGDLQAFQGHGAGNLAGLKGRLDYLSSLKVKGLVLGPIHKNQKDDVAQTDLLQIDPNFGSKEDFDSLL QSAKKKSIRVILLDLTPNYRGENSWFSTQVDTVATKVKDALEFWLQAGVDGFQVRDIENLKDASSFLAEWQNITKGFSEDRLLIAGTNSSDLQQILSLLESNKDLLLTSSYLSDSGSTGEHTKSLVTQYLNATGNRWCSWSLSQARLLTSFLPAQLLRLYQLMLFLTLPGTPVFSYGDEIGLDAAALPGQPM EAPVMLWDESSFPDIPGAVSANMTVKGQSEDPGSLLSLFRRLSDQRSKERSLLHGDFHAFSAGGLFSYIRHWDQNERFLVVLNFGDVGLSAGLQASDLPASASLPAKADLLLSTQPGREEGSPLELERLKLEPHEGLLLRFPYAA NRG1 sequence informationSEQ ID NO: 125 NRG1 exon 1 AGTAAGCCTCCGCAGCCCACTCGGACTGCAGCCTGTTTGCCGCCCGTCCTCCCATTGCAGCACTCGGGGCGACAGAGAGGGAGGAGGCGCGCGGGGACGGGGACGCCCAGGAGGACCCACTCGCGGGTCCCGCTCCGCTCCGGCAGCAGCATGGGGAAAGGACGCGCGGG CCGAGTTGGCACCACAG SEQ ID NO: 126 Exon 2 of NRG1 CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCTGAATACTCCTCTCTCAGATTCAAGTGGTTCAAGAATGGGAATGAATTGAATCGAAAAAACAAACCAAAATATCAAGATACAAAAAAGCCAG G SEQ ID NO: 127 NRG1 exon 3 GAAGTCAGAACTTCGCATTAACAAAGCATCACTGGCTGATTCTGGAGAGTATATGTGCAAAGTGATCAGCAAATTAGGAAATGACAGTGCCTCTGCCAATATCACCATCGTGGAATCAAACG SEQ ID NO: 128 NRG1 exon 4 AGATCATCACTGGTATGCCAGCTCCAACTGAAGGA GCATATGTGTCTTCAG SEQ ID NO: 129 NRG1 exon 5 AGTCTCCCATTAGAATATCAGTATCCACAGAAGGAGCAAATACTTCTTCAT CCTCGAGATACTTGTGCAA SEQ ID NO: 131 NRG1 exon 7 GTGCCCAAATGAGTTTACTGGTGATCGCTGCCAAAACTACGTAATGGCCAGCTTCTACA SEQ ID NO: 132 NRG1 exon 8 AGCATCTTGGGATTGAATTTATGG SEQ ID NO: 133 NRG1 exon 9 AGGCGGAGGAGCTGTACCAGAAAGAGAGTGCTGACCATAACCGGCATCTGCATCGCCCTCCTTGTGGTCGGCATCATGTGTGTGGTGGCCTACTGCAAAACCAA SEQ ID NO: 134 NRG1 exon 10 GAAACAGCGGAAAAAGCTGCATGACCGTCTTCGGCAGAGCCTTCGGTCTGAACGA AACAATATGATGAACATTGCCAATGGGCCTCACCATCCTAACCCACCCCCGAGAATGTCCAGCTGGTGAAT SEQ ID NO: 135 NRG1 exon 11 CAATACGTATCTAAAAAACGTCATTCCAGTGAGCATATTGTTGAGAGAAGCAGAGACATCCTTTTCCACCAGTCACTATACTTCCACAGCCATCACTCCACTACTGTCACCCAGACTCCTAG CCACAG SEQ ID NO: 136 NRG1 exon 12 CTGGAGCAACGGACACACTGAAAGCATCCTTTCCGAAAGCCACTCTGTAATCGTGATGTCATCCGTAAAACAGTAGGCACAGCAGCCCAACTGGGGGCCCAAGAGGACGTCTTAATGGCACAGGAGGCCCTCGTGAATGTAACAGCTTCTCAGGCATGCCAGAGAAACCCCCTGATTCCTACC GAGACTCTCCTCATAGTGAAAG SEQ ID NO: 137 NRG1 Exon 13 GTATGTGTCAGCCATGACCACCCCCGGCTCGTATGTCACCTGTAGATTTCCACACGCCAAGCTCCCCCAAATCGCCCCCTTCGGAAATGTCTCCACCACCCGTGTCCAGCATGACGGTGTCCCATGCCTTCCATGGCGGTCAGCCCTTCATGGAAGAAGAGAGACCCTACTTCTCGTGACACCACCAAGGCTGCGGGAGAAGAAGTTTGACCATCA CCCTCAGCAGTTCAGCTCCTTCCACCACAACCCCGCGCATGACAGTAACAGCTCCCTGCTAGCCCCTTGAGGATAGTGGAGGATGAGGAGTATGAAACGACCCAAGAGTACGAGCCAGCCCAAGAGCCTGTTAAAGAAACTCGCCAATAGCCGGCGGGCCAAAAGAACCAAGCCCAATGGCCACATTGCTAACAGATTGGAAGTGGACAGCAACACAAGCTCCCAGAGC AGTAACTCAGAGAGTGAAACAGAAGATGAAAGAGTAGGTGAAGATACGCCTTTCCTGGGCATACAGAAACCCCCTGGCAGCCAGTCTTGAGGCAACACCTGCCTTCCGCCTGGCTGACAGCAGGACTAACCCAGCAGGCCGCTTCTCGACACAGGAAGAAATCCAGGCCAGGCTGTCTAGTGTAATTGCTAACCAAGACCCTATTGCTGTATAAAACCTAAATAAACAC ATAGATTCACCTGTAAAACTTTATTTATATAATAAAGTATTCCACCTTAAATTAAACAATTTATTTTATTTTAGCAGTTCTGCAAATAGAAAACAGGAAAAAACTTTTTATAAATTAAATATATGTATGTAAAAAATGTGTTATGTGCCATATGTAGCAATTTTTACAGTATTTCAAACGAGAAAGATATCAATGGTGCCTTTATGTTATGTTATGTCGAGAGCAAGTTTTGTA CAGTTACAGTGATTGCTTTTCCACAGTTTCTGCAAAACCTCTCATAGATTCAGTTTTTGCTGGCTTCTTGTGCATTGCATTATGATGTTGACTGGATGTATGATTTGCAAGACTTGCAACTGTCCCCTCTGTTTGCTTGTAGTAGCACCCGATCAGTATGTCTTGTAATGGCACATCCATCCAGATATGCCTCTCTTGTGTATGAAGTTTTCTTTGCTTTCAGAAT ATGAAATGAGTTGTGTCTACTCTGCCAGCCAAAGGTTTGCCTCATTGGGCTCTGAGATAATAGTAGATCCAACAGCATGCTACTATTAAATACAGCAAGAAACTGCATTAAGTAATGTTAAATATTAGGAAGAAAGTAATACTGTGATTTAAAAAAAACTATATTATTAATCAGAAGACAGCTTGCTCTTACTAAAAAGGAGCTCTCATTTACTTTATTTGATTTTTATTTTTCTT GACAAAAAGCAACAGTTTTAGGGATAGCTTAGAAAATGGGTTCTGGCTTGCTATCAGGGTAAATCTAACACCTTACAAGAGGACTGAGTGTCACTTTCTCTCTGGGGGAATGATCCAGCAGCTTATCTAGTTGACAATCAAAACACGGCTGATAAAGGTGCAATCATTTCTGACATGTATTTTTCACTGATTTTGAAGCTAGTGATTGGTTGTGTCTTCTTGG CTCAAAAAGAAGCATATTACGGCACAAAAAGCCCAGCCCAGACAGCACATGCAGCATTTTGTCTGAAATACTTCTAGAGTCAAACGTGCCTGCTGTACATAGCGATGACTTGTCATCATAGGGAAGTATTTCCATCGTAGAGTGTTCAGAAGGAGTGACTGTATAGGTGGAGAAGCTTAGTGACTCCGTTGAAATTTTAAAATGTGGATGACCACCCCTTTCTCCCCCT TATTTTTCTTTTATCTTTCCATGTTGCCTTGATCAGGTCATAACTATGCATGAACATTTTTTATCAGGAATGGCCGATGTGTATGTGATTTGTAATCACAAGTAATGATTCATCAGGAAATGTCAAATCCTGTTGGAAAGATTGCACCTTTACTTGCAGAAGTGACCCCCACCTGTGTCCTGACCTCTCATTTTCACAGGCTCTCACCCATTCCCCACCTCCTTTAAT TTTTGCTTTACTGTCATAAAGTAGGACTAAGATTGGTCTAAGCATTGCATGTTCTTTTGTGATGGTAAATCCAAAGGAAGGCCTATAAGTTAACATTTGAAATAACTGCTAATTCAGGAAAATGGAAGAAAAAAAATTATTTGAAACACAGAACCCATTTCATGGCCTGCCTGATATCTGTGAAATCAGGGCTGGAGCTTTACTTAGGATTCACATGGCCTCCTAGGA ACCATGGGACAAATGGGAAACAGGTTATCGGGGGATTCATGAAGTCAGTGAGAGTAATTGCTTCTTTTTTGCGGGTGAACTGAATGTATTTTCTTCACCAAATCTTGATGTTAACAATTAAAAAGAAGAAATGACATGCAAGTAGGTCTTAGCAGAAAAATGCAGGCTGGGCATGAGTCATGTTGTTACCCTCCCACATGCTCCTACAATCCACAGAGAT GCCTGTCTGCAGGTTCTTGAAGTTATTGTTAGTATTTGGTATCTCAATTTTTCGTCACTGTTCACATGCCACTTTCTCTGTGCACAGTGGTATCCTCATTTGCTTTTTAACCTACACTGAGGAGTCTTTGTCAGGTTGCACTGATTTTCCAATTCTGCAGTAATGAGTAAGCTCACGGCATGGGGAAGAAGACAGTCAGTCCAATGAAGTTCCTAAATTATTTAACATT GCCTTTGAAGGCCTTGACTCATCCTTAGCTATTTCAATGAAGAAATTCCTACCATGAATTTAAAACCCTAAAAATTCTGTTTCAAATTCTTTGGGCATTGGGGTACTCAGATATCCCATTGTGGAAGAATTTTAAGAATAAATAGAAGTTTCTGTTGAGAACCATGAGCAACATGTTTCTACAATGAGAATTGCTATGCATTTTAAAATTGCAAATATATATGAAAAT TGAAAGACAAGAGGAAATTGTATTTCTAACTTGATTCTGATCACTCACAGAGGTGGCATATTATATTATAGTTGGGACATCCTTTGCACCCTTCATAAAAAAGGCCAGCTGACTGCTCAGCATCACCTGCCAAGGCCACTAGATTTGTGTTTACAAGGGGTATCTCTGTGATGCTTGTCACATCACTCTTGACCACCTCTGTTAATAAATTCCGACAGTGCAGTGGCGATCGGAGT GTGAACTTATGTTCCCAGCATATGGAAAGCTATCTTAGGTTTTAAAGGTAGTAGAAATTGCCCAGGAGTTTGACAGCAACTTTGTTTCCCGGGTCTAAAAATCGTATCCCACTGAGGTGTATGCAGTGGAGCATAATACATGCAAATACATGCAAAACTCCTTTTGTTTCTACCTAAGATTCACTTTCTTCTTACTTTCCCTTCCTGCCTAGTGTGACTTTTGCCCCAAGAGTGC CTGGACAGCATTCTAGTTTCTACAAAATGGTCCTCTGTGTAGGTGAATGTGTCCCAAACCTGCTATCACTTTCTTGTTTCAGTGTGACTGTCTTGTTAGAGGTGAAGTTTATCCAGGGTAACTTGCTCACTAACTATTCCTTTTTATGGCCTGGGGTTAAAGGGCGCATGGCTCACACTGGTGAAAATAAGGAAGGCCTGGTCTTATCTTGTATTAATAATACT GGCTGCATTCCACCAGCCAGAGATTTCTATCTGCGAAGACCTATGAAACACTGAAGAGAAATGTAGGCAGAAGGAAATGGCCACATATCACACAGTTTCTATTATATTTCTTTTGTAAATACATATTGTATATTACTTGGATGTTTTTCTTATATCATTTACTGTCTTTTGAGTTAATGTCAGTTTTACTTCTCCAACTTACTATGTAACATTGTAAATAACATAATGTCCTTTAT TATTTATATTTAAGCATCTAACATATAGAGTTGTTTTTCATAAGTTTAAGATAAATGTCAAAAATATGTCAAAAATATATGTTCTTTTGTTTTTCTTTGCTTTAAAATTATGTATCTTTTCCTTTTCTTTTTTTAAGAATAATTTATTGTTCAGGAGAAAGAATGTATATGTAACTGAAACTATCTGAAGAATGCACATTGAAGGCCGTGAGGTACTGATAAACTAAAGAATTTATTATTCAAAAT ACTAAGCAATAAGTAATTGTGATTTATTTAAAGTTTTGTCCATTTTCCATGAAAGACATACTGCAATAAAAATGCTACTCTGTGGAGACCTGGGAGTGTTGCTCAGCAGACTACAGCTTCAGTCTGTTAGACCAGCACCTTTCATCTCATTCCCATAGTTATGCTAATTTAGGATTGTTGTTCCATGGACCCCATGATCACCTTGTCTATACGTTGCTTCTTGTCTGTCCAT TGCTTTTGCCCACCACCTGTTCTCAAATCATCTCCTCCCTACCAATGCTGTTTATCACTTTCTTCCTTTGTTGAAGAGGCCACAACCAGACAGTACTATGCTTCCTTTTTCCTCATACACAATAACAGAGAGAGAATATTTCTAGGGCATGACTGCCTGGATCCTGGCTGTTGCTATCTTTTGTAGTGGCAGTAAGAAACTCCTTCAGACTAATGAAAATGTCAACGTG CCATTCAATCACGAAAGGTAACGAAAAATGCTCTCATGGTTCAAATAGTCCAATGGCCCATAGTGGCCTAAAAGGCAGCCAGTTGACACCTGGCCATGCTAAGCTTCCTTACCATCCGCTAATGACTTTCCATTGGGCCCACAATTTACGGATTCATAATTTTAAAAGAGGAGAAGGCCAAGTTAGGTTCATTCCCCTTATTCTGTCAATAAACAAATCAAACTCAT GTCTATCTAACTGCTCAGGGAGGAGCCTTTGCATGAGAAAATTCTCATATTTCTAAGACTGAGTCATAGAAATGAGGGTATTACTTTTCTTACTGCAATTAACCTAAACAAAAGCCATATTTAACAAATAGATTTGCATGGTACCCTTCATATTCCAAAGCATTTCACTCATTATTCCAGGTAGGTTAAGAGCTTCTGAAGTGTATGAAGTAAAGGTCAGCAATCCTTG GGGTGAACAGTGGCCTCCTTTGGAGTTTGGGGGTAACCTGAGACTTCCCACCAATGTCCACCATCCATCTGTGTACCTAATTCCTATTACCTAGTTATGGCTCCTCTAGGATCATTTTCCAAACACTCTGGATGTCCAGGAAATTAATTGTAGCTTTTGACTGAGCTAGTTTTTCCTATTTATATTAATAAATTTTCAAAAATGCTTGAAAATCTTCACATTTGCAACAC ACTTTAGTTTTTCATGCACATACAAACACAGAGAGACAAAAATTCCAAACAGACACTCTCCAAAAGCCACCACACTTCTTTCACTTGTCCTATAGTCATTTAGCCAACCAGCCATGCAGAGAATATTTAAAACTTAAAGATTGAGACATTTTCTCAGTTTTTGCTGAGGCTTTGTAACGAAATTGAACACTATAAGCAGCTATTGTAGTAATTTTGGTTAAAATTGTTTGCCTGG GATATAGTATTTGAGGCAGAAGCACGTGTGTGAAGGAGGTGAGGTGGTTTGGAAAGAGTGAAGACTCGCAGCCAGATTGAATGTCTGGATAATTACTATAATTCTCCCCTTCTTGGTTGAAACCATGTTCTCTCTTGATTTTTAAACCCAGGCTGCCTCTGGAAACAAGCAAACCTGAGTCTTTCTAACCTGAGTCTCCCAATCATTAGATTTCTTTTCTGTCCTAACGAT GAATGATAAAAGGACTTGATGTTCACAATTTGGGGTTATAAGGCAGGTCTGAAATCTGGAGACTCAAGATGCTGGAAGGAGTGGAAAGTTTCGATGACTTTATATGAATCACTTTGCACTCTATGTTTGGCTTGTCCTCTTTGAAACTGATTTACTAAAATAAATGTAAGGGAACTATTACTCAAAAGATTAACTTGGCAGGAAATACCAATACTTTCAGTTTAT GAAAGACAAAACTGTCTTGTTGCTACAGGAAGCTGCAATGTTCCTAACCTTAAGGTTGGTGTTGAATAGGGTGGTCATGCCCTCCCCTGCAGGTATCTTTAGGCTCCTGTTGACCTCCTGGTACTATAACTGTTCGTCTTCTCTGGGTAGCTATTGATTTTGAACTTTAACATGCTTCAAAACTTTTATTCATCAGGGAAATAGGAAAAGAGTTTTGTTACCTG GAGGAAATCTATTGTGATCTACCTGAGCTTTTTAAAAACAGACCAGGAGAAGGAAACCAGTAATTTTTAAAGAAGAGACAGAGAATGGGATAATAGTTTCACCCAGGATCTCTTTCTAACCCTTTCCCTTCAAATGAACTTATTGGAACAGAATTGGAAAGAAGAAAGGACATCTCTGCCCACCCCACAGGATGCCAAAAAGGCTAAAGAATTACCCTCTGTAGATTTAAACAT CTTTAATGGCTTATGTATAGATTTGCTAATACAGAGAGAAATGAACTATTAAATAAAAATCACATTTTAATATTTTTTATGGCTTAAAACATCCTTTATCTCCTTTTTGTTCTCTCTACATGATATGGTAAGTGATGAGGAAAATTTAGGCTCAGGAAGGTTAAAATCTTTCTTGGAGTTACACATCTAAGAGAGCTGCAGAGCTGACACTTGTACCCCAGGTTTTCTGACT GCAAATCCAGTTTCTTTCTATTGCGTTCTTCCCCTTTCCCTGCCTCAAGCAGAAACAGGTTTTTATTTTCAACCTTTATGTATACAGTATGTTATGTTACATTCTACAGCTAAGTTTCTTTTTAGAAGAATGTGAGCCCTTCTAGCTTTGGTTTAGAGTGATTCTAGAAGCCAATTTCCTTGGCTTAGTGATTCTATGCACCTTTCCTAAACTTAGCTTTCTAAGGAAATGAAGT GTACGAGTGAGAATGAATTCACAATTTCGACATGTAGGTAGCATCCTAAAGTGAAAAGAGGAGGAAATTTGTGGTCAAAGCACTCTCCCACCACTTAGAAACTTACTGACTGTGGGCAGCTTCCTCCTCCAAGTTTCCTTCCTGATTTACAAGACCGTGGTGTGGTCAGGATTAAACTTGAATACATGTAAGGAAGCCTGAAAGTGTCTAACACATAGCGAGTATTCAAAT GCCACCCTTCTATTTGATCCTTCCCCTCCAGTTCCTTAAGTTTTGGAATCTAGGTTTCTCAGTTCCAAATGGATTGACATTTGCATATCCCCATTGCACAATGGATCAAATAAACTTTATGTTATCATTCTCTCAACATAGTGCCAGTAAGCAAATCCTTTTAATAACAACAGTATGTTGAGAAACATATCACCAAATAATATTTAACTTTGTAGCTTTGATAAGTTCTTTAGGT TTTGGTTTTGGTTTTGTTTTCTGAGACAGGGTCTTGATCTGTCACCCAGACTGGAGTGCAATGGTTCAATTTTAGCTCACTGCAACCTGTAACTCCTGAGCTCAAGTGATCCTCCCACCTCAGCCTCTCAAGTAGCTGGGACTACAGGTGTGCTCCACCATGCCCAGCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTGGTAGGGACAAGGTCTCGCTATGT TGCCCAGGCTGGTCTTCAATTCCTGGCCTTAAGTGATCCTCCTGCCTCGGCCTCCCAAAGTGCTGGAATTACAGGCATGAGCCACCACCCATAACTTTATGTTTGTTTTTTTTGATGCAGTATAAGTTCAGCTTGCTTCTTATGCAGCCATACCATCTGATTTTTAGCAGCTTATTACATTAGTGTTTACAGAAATTTACTA AACCATGACTCTGTAGAGTTTTTAATAATACTACCTCCAAACATCATTGCAAACATCTAGAAGAATGAACAAAAATGATCTTAGATCGACAGTATATCTGTTTGTCTTAGTTTCTACACACAGGATGTTCAGACATATTCCCATTTCTTTAAAAAAAAAATATATATATATATATATATAGGCCTGGCACGGTGGCTCATGACTGTAATCCCAGCACTTTGGGAGGCTTAGGCAGG CAAATCACCTGAGGTCAGGAGTTTGAGACTGGCCTGACCCAACATGGTGAAACCTCGTCTCTATTAAAATTACAAAAATTAGCCGGGCGTGGTGGCACATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCAGAGGTTGCAGTGAGTTGAGATCACGCCATTGCACTCCAGCCTTGGTGACAAGGTGAAACTCC GTCTCAAAAAAAAAAAAAAATATGTATATATATATATATATATATATATATATATATATATATATATAAAATCCCACCAAAAGTCTGCAGAGTGACCAAATTAGACGGCTCTGGTTTCAGATTAAATTCTAAATGTGAGAAACCACATAGCTCCCATGATCCATCCAATAATTCCTCACGTCCTCTTCACTCTTTACTCCATGCATAAACAGAATTTTTTTTCTCCTG GGTATGAAGCAATTAATAATTTACGGATTTAGCCTATTTGGATTCAATCCCTTCAAACTCCATACTACATCCAAGGTGGAAGTGACTTAAACTCTGATATCAATCATCAGGCTTGTAATAGGCTTTGTTAATGGCAGGAGAGTCTAATAAAACTTTCTGTTCCTTTATCCTTCATTTAAATGAAAAAACTTTTTTATTGAAAACAATCATAACTCTAGCTCATCATAAATAAATA ATTCATGAGGACATTTTATTATTTTTATATTAAGAAATAATATTATAGATGTAAACTTTGCACCTTTTCAATTATTATCATGAGTTAAGCTAATACTTGTCTTCTGGTCCCTAGATGATGATTCTTTTTTGCCTTACTGGAGGAGCCCTTGTCTTGAAGTGAGTTGCTTCAACAGCAGAGGACTTCTAGTTTCTCCCAGTTGAGCCTAAAGTGAACTTTTCATCTCT TCAGAGGAAGGGGCTTCCTTGATTTGTACTTTTGTGGCTCCTCAGATAACACAGACAATTTTATCTTGGATCCCAGGTTTCTTCACCATTAAGAATAAGAAAGAGAAAATGCTGTGCATGACAGCCCCCTACTCCAAACTACCCCAACCCCCTGTAACCTCAACGAGATGATTCTGCCCTCACTCAAGAGTCCCCCACAAAGATTCATTCTCCTTT ACTTTTTTATTTTTTATTTTTTTGCAAAACAAAGGCCTCCTTTAGTACCTCCTTAGTTTAACCCTTATCTTCCCAGCTCTTCCCTTCACTGATACCCTCTGATTTCAAAAAGTTCTGAAGTCGGAAGACCACACAATTTCAGACTGTGAACAGAAATTCAGTCAGAAATTATTGGAGTTAGAAAGAATTTAGAGAAATTGTATTGAACTAGAAAGTCCTCTTTGATTAGTGGTGGC CCTTTAGAAAGTTCTAGGGCAGAGTCCCATGGTGTTTCATTCTTTTCCATGATTTGCTTGACCAAAAACTTTTCTTTCACAACATGAAAATATGCTAATCCACCACACATTTTGGATTCTGCTCTGTTTGCCTGAGGTGTTAGATCTCTAGCCAGGACTGTGAAGGGAAGGAACTTGAATCCTTCCTATTGAGCTATTAATGCAGAGTCAGTGAGATGAAGGGTTCCACTCG GGGTCAAAATCATGTCAGTTACCCAAGCAAAGGAGCAAGTAAGGGGAAACATCTCCTCATCTGGTTAGTGGAGCCACATTTCACCCACTGATCAAGCCAGACCTGAGCAATAGTCTAGATTTCTCCCCTCCACATCTAATTGGTGACAATGGTGATTGTACCACTGACAGGTCACACCAAGTCCACACCCTCCTTCACAGCTCACTGCTTCGGCTCTTGTTTATGCTCTTAT CAGCATCTGTCACTAGGATCCATTTGTCTCCTGACTCATCTACTTCCTTTCACTCCCCTGGGCCATCCTTCACATCATGCTAGAAGACTGTGTCTAACTTGCAGAACTTATTGTGTCAATCTCCTGGTTACGGCCCCTCCATGGCTCCCCACCTGACATAGGAGGCCCTTCACAATCTGGCTTCTGTCACTCATAACTTGTCTCCAGTCTGATT TTATGGTTTTTCTAGTTCCCCAAATACCACACCAGTGTTTATGAAACCTAGTCATTGGCCTACGAACTTTATGATTATTGACATATTCATGTACCACCTGTATTTATTTTTTGCATAGTGTTTTATTTTAATTGACTACATTTTTAACTACAATAAAGTAATTTCAACTAAAA SEQ ID NO: 138 All 13 exons 1-13 of NRG1 in sequence Nucleotide sequence SEQ ID NO: 139 Translated polypeptide sequence of exon 1 of NRG1 MGKGRAGRVGTT SEQ ID NO: 140 Translated polypeptide sequence of exon 2 of NRG1 LPPRLKEMKSQESAAAGSKLVLRCETSSEYSSLRFKWFKNGNELNRKNKPQNIKIQKKP SEQ ID NO: 141 Translated polypeptide sequence of exon 3 of NRG1 KSELRINKASLADSGEYMCKVISKLGNDSASANITIVESN SEQ ID NO: 142 Exon of NRG1 The translated polypeptide sequence of 4 IITGMPASTEGAYVSS SEQ ID NO: 143 NRG1 Translated polypeptide sequence of exon 5 SPIRISVSTEGANTSS SEQ ID NO: 144 Translated polypeptide sequence of exon 6 of NRG1 TSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLC SEQ ID NO: 145 Translated polypeptide sequence of exon 7 of NRG1 CPNEFTGDRCQNYVMASFY SEQ ID NO: 146 Outside of NRG1 Translated polypeptide sequence of exon 8 HLGIEFM SEQ ID NO: 147 Translated polypeptide sequence of exon 9 of NRG1 AEELYQKRVLTITGICALLVVGIMCVVAYCKT SEQ ID NO: 148 Translated polypeptide sequence of exon 10 of NRG1 KQRKKLHDRLRQSLRSERNNMMNIANGPHHPNPPPENVQLVN SEQ ID NO: 149 N RG1 exon The translated polypeptide sequence of 11 QYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSH SEQ ID NO:150 The translated polypeptide sequence of NRG1 exon 12 WSNGHTESILSESHSVIVMSSVENSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSE SEQ ID NO:151 The translation of NRG1 exon 13 Peptide sequence YVSAMTTPARMSPVDFHTPSSPKSPPSEMSPVSSMTVSMPSMAVSPFMEEERPLLLVTPPRLREKKFDHHPQQFSSFHHNPAHDSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSSNSESETEDERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQAR LSSVIANQDPIAV SEQ ID NO:152 NRG1 polypeptide sequence SEQ ID NO: 153 The sequenced polynucleotide sequence of all 12 exons 2-13 of NRG1 SEQ ID NO: 154 The translated polypeptide sequence of NRG1 exons 2-13 SEQ ID NO: 155 All 8 exons of NRG1 6-13 polynucleotide sequence in sequence SEQ ID NO: 156 Translated polypeptide sequence of NRG1 exon 6-13 TSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMASFYKHLGIFMEAEELYQKRVLTITGICIALVVGIMCVVAYCKTKKQRKKLHDRLRQSLRSERNNMMNIAN GPHHPNPPPENVQLVNQYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSHSWSNGHTESILSESHVIVMSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPPARMSPVDFHTPSSPKSPPSEMSPVSSMTVSMPSMAVSPFMEEERPLLLVTPPRLREKKFDHHPQQF SSFHHNPAHDSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSSNSESETEDERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQARLSSVIANQDPIAV SEQ ID NO: 157 All 8 exons 6-13 of NRG1 sequenced multinucleated Nucleotide sequence (excluding the nucleotide CAT of exon 5) SEQ ID NO:158 Translated polypeptide sequence of exon 5+CAT and exon 6-13 of NRG1 STSTSTTGTSHLVKCAEKEKFFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMASFYKHLGIFMEAEELYQKRVLTITGICIALVVGIMCVVAYCKTKKQRKK LHDRLRQSLRSERNNMMNIANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSHSWSNGHTESILSESHSVIVMSSVENSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPARMSPVDFHTPSSPKSPPSEMSPVSSMTVSMPSMAVSPFMEEERP LLLVTPPRLREKKFDHHPQQFSSFHHNPAHDSSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSSNSESETEDERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQARLSSVIANQDPIAV SEQ ID NO: 161 All 5 of NRG1 Exons 1-5 sequenced polynucleotide sequence (excluding the nucleotide CAT of exon 5) AGTAAGCCTCCGCAGCCCACTCGGACTGCAGCCTGTTTGCCGCCCGTCCTCCCATTGCAGCACTCGGGGCGACAGAGAGGGAGGAGGCGCGCGGGGACGGGGACGCCCAGGAGGACCCACTCGCGGGTCCCGCTCCGCTCCGGCAGCAGCATGGGGAA AGGACGCGCGGGCCGAGTTGGCACCACAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCTGAATACTCCTCTCTCGAATTCAAGTGGTTCAAGAATGGGAATGAATTGAATCGAAAAAACAAACCACAAAATATCAAGATACAAAAAAAAGCCAGGGAAGTCAGAACTTCGCATTA ACAAAGCATCACTGGCTGATTCTGGAGAGTATATGTGCAAAGTGATCAGCAAATTAGGAAATGACAGTGCCTCTGCCAATATCACCATCGTGGAATCAAACGAGATCATCACTGGTATGCCAGCCTCAACTGAAGGAGCATATGTGTCTTCAGAGTCTCCCATTAGAATATCAGTATCCACAGAAGGAGCAAATACTTCTT SEQ ID NO: 162 NRG1 explicit Translated polypeptide sequences of subs 1-5, excluding translated The most C-terminal amino acid of exon 5 (S) MGKGRAGRVGTTALPPRLKEMKSQESAAAGSKLVLRCETSSEYSSLRFKWFKNGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTEGAYVSSESPIRISVSTEGANTS SEQ ID NO: 163 According to SEQ ID NO: 163 EGF-like domain of NRG1 sequence of ID NO: 152 HLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMASFVTCN1 sequence informationSEQ ID NO:164 VTCN1 exon 2 sequence at 5' of VTCN1-NRG1 fusion CATAATTAGCATCATCATTATTCTGGCTGGAGCAATTGCACTCATCATTGGCTTTGGTATTTCAG SEQ ID NO:165 NRG1 exon 2 sequence at 3' of VTCN1-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAA SEQ ID NO:166 VTCN1-NRG1 polynucleotide sequence CATAATTAGCATCATCATTATTCTGGCTGGAGCAATTGCACTCATCATTGGCTTTGGTATTTCAGCCTTGCCTCCCCGATTGAAAGAGATGAA SEQ ID NO:167 VTCN1-NRG1 polypeptide sequence IISIIIILAGAIALIIGFGISALPPRLKEM SEQ ID NO:168 VTCN1 exon 1 GTGAGTCACCAAGGAAGGCAGCGGCAGCTCCACTCAGCCAGTACCCAGATACGCTGGGAACCTTCCCCAGCCATGGCTTCCCTGGGGCAGATCCTCTTCTGGAG SEQ ID NO:169 Exon 2 of VTCN1 CATAATTAGCATCATCATTATTCTGGCTGGAGCAATTGCACTCATCATTGGCTTTGGTATTTCAG SEQ ID NO:170 Exon 3 of VTCN1 GGAGACACTCCATCACAGTCACTACTGTCGCCTCAGCTGGGAACATTGGGGAGGATGGAATCCTGAGCTGCACTTTTGAACCTGACATCAAACTTTCTGATATCGTGATACAATGGCTGAAGGAAGGTGTTTTAGGCTTGGTCCATGAGTTCAAAGAAGGCAAAGATGAGCTGTCGGAGCAGGATGAAATGTTCAGTGTTT GCTGATCAAGTGATAGTTGGCAATGCCTCTTTGCGGCTGAAAAACGTGCAACTCACAGATGCTGGCACCTACAAATGTTATATCATCACTTCTAAAGGCAAGGGGAATGCTAACCTTGAGTATAAAACTGGAG SEQ ID NO:171 Exon 4 of VTCN1 CCTTCAGCATGCCGGAAGTGAATGTGGACTATAATGCCAGCTCAGAGACCTTGCGGTGTGAGGCTCCCCGATGGTTCCCCCAGCCCAGTGGTCTGGGCATCCCAAGTTGACCAGGGAGCCAACTTCTCGGAAGTCTCCAATACCAGCTTTGAGCTGAACTCTGAGAATGTGACCATGAAGGTTGTGTCTGTGCTCTACAATGTTACGATCAACAACAC ATACTCCTGTATGATTGAAAATGACATTGCCAAAGCAACAGGGGATATCAAAGTGACAG SEQ ID NO:172 Exon 5 of VTCN1 AATCGGAGATCAAAAGGCGGAGTCACCTACAGCTGCTAAACTCAAAGGCTTCTCTGTGTGTCTCTTCTTTCTTTGCCATCAGCTGGGCACTTCTGCCTCTCAGCCCTTACCTGATGCTAAAATAATGTGCCTCGGCCACAAAAAAGCATGCAAAGTCATTGTTACAACAG SEQ ID NO:173 Exon 6 of VTCN1 GGATCTACAGAACTATTTTCACCACCAGATATGACCTAGTTTTATATTTCTGGGAGGAAATGAATTCATATCTAGAAGTCTGGAGTGAGCAAAACAAGAGCAAGAAACAAAAAAAGCAAAAGCAGAAGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATAATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAAT GCACGTGGAGACAAGTGCATCCCCAGATCTCAGGGACCTCCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGATAGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAAGCCCCTGGAAAGCCTCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGTATGTACCCTAAGACGCTGCTAATTGACT GCCACTTCGCAACTTCAGGGGCGGCTGCATTTTAGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTCCCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGTCGGCGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTTAAACAAAACAAATGCGGGTTTATTTCCAGAT GATGTTCATCCGTGAATGGTCCAGGGAAGGACCTTTCACCTTTGTCTATATGGCATTATGTCATCACAAGCTCTGAGGCTTCTCCTTTCCATCCTGCGTGGACAGCTAAGACCTCAGTTTTCAATAGCATCTAGAGCAGTGGGACTCAGCTGGGGTGATTTCGCCCCCCATCTCCGGGGGAATGTCTGAAGACAATTTTGGTTACCTCAATGAGGGAGTGGA GGAGGATACAGTGCTACTACCAACTAGTGGATAGAGGCCAGGGATGCTGCTCAACCTCCTACCATGTACAGGACGTCTCCCCCATTACAACTACCCAATCCGAAGTGTCAACTGTGTCAGGGCTAAGAAACCCTGGTTTTGAGTAGAAAAGGGCCTGGAAAGAGGGGAGCCAACAAATCTGTCTGCTTCCTCACATTAGTCATTGGCAAATAAGCATTCTGT CTCTTTGGCTGCTGCCTCAGCACAGAGAGCCAGAACTCTATCGGGCACCAGGATAACATCTCTCAGTGAACAGAGTTGACAAGGCCTATGGGAAATGCCTGATGGGATTATCTTCAGCTTGTTGAGCTTCTAAGTTTCTTCCCTTCATTCTACCCTGCAAGCCAAGTTCTGTAAGAGAAATGCCTGAGTTCTAGCTCAGGTTTCTTACTCTGAATTTAGATCTCCA GACCCTGCCTGGCCACAATTCAAATTAAGGCAACAAACATATACCTTCCATGAAGCACACACAGACTTTTGAAAGCAAGGACAATGACTGCTTGAATTGAGGCCTTGAGGAATGAAGCTTTGAAGGAAAAGAATACTTTGTTTCCAGCCCCCTTCCCACACTCTTCATGTGTTAACCACTGCCTTCCTGGACCTTGGAGCCACGGTGACTGTATTACATGTTGTTATAGAAA ACTGATTTTAGAGTTCTGATCGTTCAAGAGAATGATTAAATATACATTTCCTACACCA SEQ ID NO:174 The polynucleotide sequence of all 6 exons 1-6 of VTCN1 arranged in order SEQ ID NO:175 Translated polypeptide sequence of exon 1 of VTCN1 MASLGQILFW SEQ ID NO:176 Translated polypeptide sequence of exon 2 of VTCN1 IISIIIILAGAIALIIGFGIS SEQ ID NO:177 Translated polypeptide sequence of exon 3 of VTCN1 RHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTG SEQ ID NO:178 Translated polypeptide sequence of exon 4 of VTCN1 FSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVT SEQ ID NO:179 Translated polypeptide sequence of exon 5 of VTCN1 SEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK SEQ ID NO:180 VTCN1 polypeptide sequence MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQ GANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK SEQ ID NO:181 VTCN1 exons 1 and 2 GTGAGTCACCAAGGAAGGCAGCGGCAGCTCCACTCAGCCAGTACCCAGATACGCTGGGAACCTTCCCCAGCCATGGCTTCCCTGGGGCAGATCCTCTTCTGGAGCATAATTAGCATCATCATTATTCTGGCTGGAGCAATTGCACTCATTGGCTTTGGTATTTCAG SEQ ID NO:182 Translated polypeptide sequence of exons 1 and 2 of VTCN1 MASLGQILFWSIISIIIILAGAIALIIGFGIS CDH1 sequence informationSEQ ID NO: 184 CDH1 exon 11 sequence at 5' of CDH1-NRG1 fusion CTGGCTGGAGATTAATCCGGACACTGGTGCCATTTCCACTCGGGCTGAGCTGGACAGGGAGGATTTTGAGCACGTGAAGAACAGCACGTACACAGCCCTAATCATAGCTACAGACAATG SEQ ID NO: 185 NRG1 exon 2 sequence at 3' of CDH1-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAA SEQ ID NO: 186 CDH1-NRG1 polynucleotide sequence CTGGCTGGAGATTAATCCGGACACTGGTGCCATTTCCACTCGGGCTGAGCTGGACAGGGAGGATTTTGAGCACGTGAAGAACAGCACGTACACAGCCCTAATCATAGCTACAGACAATGCCTTGCCTCCCCGATTGAAAGAGATGAAA SEQ ID NO: 187 CDH1-NRG1 polypeptide sequence WLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNALPPRLKEMK SEQ ID NO: 188 CDH1 exon 1 AGTGGCGTCGGAACTGCAAAGCACCTGTGAGCTTGCGGAAGTCAGTTCAGACTCCAGCCGCTCCAGCCCGGCCCGACCCGACCGCACCCGGCGCCTGCCCTCGCTCGGCGTCCCCGCCAGCCATGGGCCCTTGGAGCCGCAGCCTCTCGGCGCTGCTGCTGCTGCTGCAG SEQ ID NO: 189 CDH1 exon 2 GTCTCCTCTTGGCTCTGCCAGGAGCCGGAGCCCTGCCACCCTGGCTTTGACGCCGAGAGCTACACGTTCACGGTGCCCCGGCGCCACCTGGAGAGAGGCCGCGTCCTGGGCAGAG SEQ ID NO: 190 CDH1 exon 3 TGAATTTTGAAGATTGCACCGGTCGACAAAGGACAGCCTATTTTTCCCTCGACACCCGATTCAAAGTGGGCACAGATGGTGTGATTACAGTCAAAAGGCCTCTACGGTTTCATAACCCACAGATCCATTTCTTGGTCTACGCCTGGGACTCCACCCTACAGAAAGTTTTCACCAAAGTCACGCTGAATACAGTGGGGCACCACCACCGCCCCCCGCCC CATCAG SEQ ID NO: 191 Exon 4 of CDH1 GCCTCCGTTTCTGGAATCCAAGCAGAATTGCTCACATTTCCCAACTCCTCTCCTGGCCTCAGAAGACAGAAGAGAGACTGGGTTATTCCTCCCATCAGCTGCCCAGAAAATGAAAAAGGCCCATTTCCTAAAAACCTGGTTCAG SEQ ID NO: 192 CDH1 exon 5 ATCAAATCCAACAAAGACAAAGAAGGCAAGGTTTTTCTACAGCATCACTGGCCAAGGAGCTGACACACCCCCTGTTGGTGTCTTTTATTATTGAAAGAGAAACAGGATGGCTGAAGGTGACAGAGCCTCTGGATAGAGAACGCATTGCCACATACACT SEQ ID NO: 193 Exon 6 of CDH1 CTCTTCTCTCACGCTGTGTCATCCAACGGGAATGCAGTTGAGGATCCAATGGAGATTTTGATCACGGTAACCGATCAGAATGACAACAAGCCCGAATTCACCCAGGAGGTCTTTAAGGGGTCTTGTCATGGAAGGTGCTCTTCCAG SEQ ID NO: 194 CDH1 exon 7 GAACCTCTGTGATGGAGGTCACAGCCACAGACGCGGACGATGATGTGAACACCTACAATGCCGCCATCGCTTACACCATCCTCAGCCAAGATCCTGAGCTCCCTGACAAAAATATGTTCACCATTAACAGGAACACAGGAGTCATCAGTGTGGTCACCACTGGGCTGGACCGAGAG SEQ ID NO: 195 Exon 8 of CDH1 AGTTTCCCCTACGTATACCCTGGTGGTTCAAGCTGCTGACCTTCAAGGTGAGGGGTTAAGCACAACAGCAACAGCTGTGATCACAGTCACTGACACCAACGATAATCCTCCGATCTTCAATCCCACCACG SEQ ID NO: 196 CDH1 exon 9 TACAAGGGTCAGGTGCCTGAGAACGAGGCTAACGTCGTAATCACCACACTGAAAGTGACTGATGCTGATGCCCCCAATACCCAGCGTGGGAGGCTGTATACCATATTGAATGATGGTGGACAATTTGTCGTCACCACAAAATCCAGTGAACAACGATGGCATTTTGAAAACAGCAAAGGTTTGTATGGTACCTGGCAAGATGCAGAAACT GGCATCCTCACAGCTGTTCATACCCTTGTCCCCTG SEQ ID NO: 197 Exon 10 of CDH1 GGCTTGGATTTTGAGGCCAAGCAGCAGTACATTCTACACGTAGCAGTGACGAATGTGGTACCTTTTGAGGTCTCTCTCACCACCTCCACAGCCACCGTCACCGTGGATGTGCTGGATGTGAATGAAGCCCCATCTTTGTGCCTCCTGAAAAGGAGTGGAAGTGTCCGAGGACTTTGGCGTGGGCCAGGAAATCACTCCTACACTGCCCAGGAGCCAG ACACATTTATGGAACAGAAAATAAC SEQ ID NO: 198 Exon 11 of CDH1 ATATCGGATTTGGAGAGACACTGCCAACTGGCTGGAGATTAATCCGGACACTGGTGCCATTTCCACTCGGGCTGAGCTGGACAGGGAGGATTTTGAGCACGTGAAGAACAGCACGTACACAGCCCTAATCATAGCTACAGACAATG SEQ ID NO: 199 Exon 12 of CDH1 GTTCTCCAGTTGCTACTGGAACAGGGACACTTCTGCTGATCCTGTCTGATGTGAATGACAACGCCCCCATACCAGAACCTCGAACTATATTTCTTCTGTGAGAGGAATCCAAAGCCTCAGGTCATAAACATCATTGATGCAGACCTTCCTCCCAATACATCTCCCCTTCACAGCAGAACTAACACACGGGGCGAGTGCCAACTGGACCATTCAGTACAACGACCCAA SEQ ID NO: 200 Exon 13 of CDH1 CCCAAGAATCTATCATTTTGAAGCCAAAGATGGCCTTAGAGGTGGGTGACTACAAAATCAATCTCAAGCTCATGGATAACCAGAATAAAGACCAAAGTGACCACCTTAGAGGTCAGCGTGTGTGACTGTGAAGGGGCCGCTGGCGTCTGTAGGAAGGCCAGCCTGTCGAAGCAGGATTGCAAATTCCTGCCATTCTGGGGATTCTTGGAGGAATTCTTGCT TTGCTAA SEQ ID NO: 201 CDH1 exon 14 TTCTGATTCTGCTGCTCTTGCTGTTTCTTCGGAGGAGAGCGGTGGTCAAAGAGCCCTACTGCCCCCAGAGGATGACACCCGGGACAACGTTTATTACTATGATGAAGAAGGAGGCGGAGAAGAGGACCAG SEQ ID NO: 202 Exon 15 of CDH1 GACTTTGACTTGAGCCAGCTGCACAGGGGCCTGGACGCTCGGCCTGAAGTGACTCGTAACGACGTTGCACCAACCCTCATGAGTGTCCCCCGGTATCTTCCCGCCCTGCCAATCCCGATGAAATTGGAAATTTTATTGATGAA SEQ ID NO: 203 Exon 16 of CDH1 AatctgaAgCGGCGATGACCCCCCCCCCCCCCCCCCCCCCCCCCTTCTCTCTGTTGAAGGGAGGGTCCGCTGCTGAgCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCCTCCCTCTTTCTCTCTCTCTCTCTCTCTCTCTCTCTTCCCCCC. CCAGGACTACTGACTACTGAACGAATGGGGGGGGCAATCGCGCTCAAGGGGGGGGCGCGCGCGCGACGACGGGGGGGGGCCCCCCCCCCCCCCCCTGGGAAAAAAATGCAGCAG AAATCACGTTGTGTGTGTGTGTGTTTTTTCAGCTCCCCCTTGAGAGAGAGAGGGGGGGGGGGGGGGAAAGAGAGGGTGTGCAGCAGTAGTACTCTTTTTTTTTTTTTTTTTTTTTTTA TGTTAGAAAAGTTTCGACGACGACGACGACTTTTTTTTTTTTTTTTTTTTTTCCCCCACTTTTTGTGTGTGTGTCCCCAAACCAACCAACAACAAGCAGAGTCACACCCCC CAGCACACACTTGCAGCAGCAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCAGCACTCTCTAGTCTAGTTTTTTTTTTTTTTTTGTGTGTCTCTCTCAC TaccTGGTGTGTGTGTGTGTCTCTGCTGCTTTTTTTTTTTTTTTTTTTTTCAGGTCTCTCGGCCCCGGGGCAGCATCATCTCTCCCTCTCTCTCTCTCTCTCTCTCTCTCTAGCTCTCTCCTCCTCTCCTCCTCAT TGCACCTCAGCCTCCCCAAGCTGGGGGACCACAGCACCCACCACTATGCATTTTTTTTTTTTTTTTGGGGGGGGTCCCCCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCCCAT CCTCCCATCTTGCTCCCCAGGGGGGGGGGGGACACACAGAGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC GATCATAGCTCTCTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGCAGCCCCCCCCCCTCTCTCTTTTTTTTTTTTTTTTCCCCCCCCCCCTCTCTCTCTCTCTCTCAAG is CAATCCTCTCTGCCCCCCCCCCCCCCCAAAGCTGGGGGGGCAGCTGCCCCCCCTCCTCTTCTCTCTCTCTCTCTGAAGCCCCCCCCCCCCCAGGGGAgggggggggggggggggggggAgCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC AgaAAAATTTTATTGGGGGCTTTTTTTTTTTTTTTTTTTTAGTTTTTGTTGTTTTGTGCCCACACACTGTACTCTGTGACTTTTTTCTCTCTGTGTGTGTGTGTACTGCAATGGGGG GCAGCTAGTCAGTGAGAGTGTTGAgTGTGTGTGTGTCATTTTTTTTTGAGAGAGAGAGACCCCCCCCCCCCCTGCTGCCCAGCAgCgcggaacttatg AAAAGGGGGGCTGAGAGGCAGGGGAGAGAGCTGTGAgCTGCAATTGCAACTGAGAGAGAGAGAGAGAGAGGTGTCTCTCTGAAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGgggggggggggggggggggggggga GTTTTCTGACACAAGAAGAAGAAGAAGTGTGTTTGTCCCCCCCCCCCCCCCCCCCCAAGCTGCTTGTGTGTACTGGGGGGGGGGGGGACCCCCCCCCCCCACACACACACACACACACACCCCCCCCCCCCCCCCCCCCCCCCCCTGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC GagaatttcaaaAAAAAAAAATTTTTTTTTTTTTTTTTTTTTTTAGAGAGAAGAAAAAAAATGCCTGCTAAGGGGGGGGGGGGGGGGGGGGTGGGAGGAGAGATTTTTTTTTGAAATTTCAAC TTTTGACAATCAAAAGAGACTTTTTTTGAAAATAGTTTTTTTCTCTCAAGGGGGGGGGGAAAAAACCCAATCAATCAATCAATTTTTTTTTCAGGCAGGCAGGAGAATC AGTTTTCTGTGTGTGTGTGTAGAATGTCTGTGTTTTTTTGGTGTACATGTGTGTGTGTGTGTGTTTTTTTGGGGGGGGGGGAAAACAAGAGAGAGAAGAAGAAGAAGAAGAGAAGAGAAGAAGAAGCAAGAAGAAGAAGAAGAAAGAAAGAAAGAAAAAAAAAAGAAAGAAGAAAAACAAAAC AAATTTTTTTTTTAAAAATTTTTTTAAAAAA SEQ ID NO: 204 The polynucleotide sequence of all 16 exons 1-16 of CDH1 arranged in order SEQ ID NO: 205 Translated polypeptide sequence of exon 10 of CDH1 MEQKI SEQ ID NO: 206 Translated polypeptide sequence of exon 11 of CDH1 YRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDN SEQ ID NO: 207 Translated polypeptide sequence of exon 12 of CDH1 SPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADDLPPNTSPFTAELTHGASANWTIQYNDP SEQ ID NO: 208 Translated polypeptide sequence of exon 13 of CDH1 QESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALL SEQ ID NO: 209 Translated polypeptide sequence of exon 14 of CDH1 LILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQ SEQ ID NO: 210 Translated polypeptide sequence of exon 15 of CDH1 DFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDE SEQ ID NO: 211 Translated polypeptide sequence of exon 16 of CDH1 NLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD SEQ ID NO: 212 CDH1 polypeptide sequence MEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCCDCEGAAGVCKAQPVEAGLQ IPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD SEQ ID NO: 213 The polynucleotide sequence of all 11 exons 1-11 of CDH1 arranged in order SEQ ID NO: 214 Translated polypeptide sequence of exons 1-11 MEQKIYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDN CXADR sequence informationSEQ ID NO: 215 CXADR exon 1 sequence at 5' of CXADR-NRG1 fusion ATGGCGCTCCTGCTGTGCTTCGTGCTCCTGTGCGGAGTAGTGG SEQ ID NO: 216 NRG1 exon 2 sequence at 3' of CXADR-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACT SEQ ID NO: 217 CXADR-NRG1 polynucleotide sequence ATGGCGCTCCTGCTGTGCTTCGTGCTCCTGTGCGGAGTAGTGGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACT SEQ ID NO: 218 CXADR-NRG1 polypeptide sequence MALLLCFVLLCGVVALPPRLKEMKSQESAAGSK SEQ ID NO:219 CXADR exon 1 AGTCGGGAGCGCGCGAGGCGCGGGGAGCCTGGGACCAGGAGCGAGAGCCGCCTACCTGCAGCCGCCGCCCACGGCACGGCAGCACCATGGCGCTCCTGCTGTGCTTCGTGCTCCTGTGCGGAGTAGTGG SEQ ID NO:220 CXADR exon 2 ATTTCGCCAGAAGTTTTGAGTATCACTACTCCTGAAGAGATGATTGAAAAAAGCCAAAGGGGAAACTGCCTATCTGCCATGCAAATTTACGCTTAGTCCCGAAGACCAGGGACCGCTGGACATCGAGTGGCTGATATCACCAGCTGATAATCAGAAGGTGGATCAAGTG SEQ ID NO:221 CXADR exon 3 ATTATTTTATATTCTGGAGACAAAATTTATGATGACTACTATCCAGATCTGAAAGGCCGAGTACATTTTACGAGTAATGATCTCAAATCTGGTGATGCATCAATAAATGTAACGAATTTACAACTGTCAGATATTGGCACATATCAGTGCAAAGTGAAAAAAGCTCCTGGTGTTGCAAATAAGAAGATTCATCTGGTAGTTCTTG SEQ ID NO:222 CXADR exon 4 TTAAGCCTTCAGGTGCGAGATGTTACGTTGATGGATCTGAAGAAATTGGAAGTGACTTTAAGATAAAATGTGAACCAAAGAAGGTTCACTTCCATTACAGTATGAGTGGCAAAAATTGTCTGACTCACAGAAAATGCCCACTTCATGGTTAGCAG SEQ ID NO:223 CXADR exon 5 GGAAGATGTGCCACCTCCAAAGAGCCGTACGTCCACTGCCAGAAGCTACATCGGCAGTAATCATTCATCCCTGGGGTCCATGTCTCCTTCCAACATGGAAGGATATTCCAAAGACTCAGTATAACCAAGTACCAAGTGAAGACTTTGAACGCACTCCTCAGGTCCCACCTGCTAAGGTAGCTGCCCCTAATCTAAGTCGAATGGGTGCGATTCCTGTG ATGATTCCCAGCACAGAGCAAGGATGGGTCTATAGTATAGAGCCTCCATATGTCTCATCTGTGCTCTCCGTGTTCCTTTCCTTTTTTTGATATATGAAAACCTATTCTGGTCTAAATTGTGTTACTAGCCTCAAAATACATCAAAAAATAAGTTAATCAGGAACTTTTTAAAAATTTTTGTTTGGTTATATCGAAATAGTTACAGGCACTAAAGTTA GTAAAGAAAAGTTTACCATCTGAAAAAGCTGGATTTTCTTTAAGAGGTTGATTATAAAGTTTTTCTAAATTTATCAGTACCTAAGTAAGATGTAGCGCTTTGAATATGAAATCATAGGTGAAGACATGGGTGAACTTACTTGCATACCAAGTTGATACTTGAATAACCATCTGAAAGTGGTACTTGATCATTTTTACCATTATTTTTAGGATGTGTATTTCATTTATTTATG GCCCACCAGTCTCCCCCAAATTAGTACAGAAATATCCATGACAAAATTACTTACGTATGTTTGTACTTGGTTTTCAGCTCCTTTGAAAACTCTGTGTTTGGAATATCCTAAAAACATAGAAAACACTACAGTGGTTTAGAAAATTACTAATTTTAACTTCTAAGTCATTCATAAACCTTGTCTATGAAATGACTTCTTAAATATTTAGTTGATAGACTGCTACAGGTAATAGG GACTTAGCAAGCTCTTTTATATGCTAAAGGAGCATCTATCAGATTAAGTTAGAACATTTGCTGTCAGCCACATATTGAGATGACACTAGGTGCAATAGCAGGGATAGATTTTGTTGGTGAGTAGTCTCATGCCTTGAGATCTGTGGTGGTCTTCAAAATGGTGGCCAGCCAGATCAAGGATGTAGTATCTCATAGTTCCCAAGGTGATATTTTTCTTATTAGAAAAATAT TATAACTCATTTGTTGTTGTTTGACACTTATAGATTGAAATTTCCTAATTTATTCTAAATTTTAAGTGGTTCTTTGGTTCCAGTGCTTTATGTTGTTGTTGTTTTTTGGATGGTGTTACATATTATATGTTCTAGAAACATGTAATCCTAAATTTACCCTCTTGAATATAATTCCCTTGGATGATATTTTTTTATCATAAATGCAGAATAATCAAATACATTTTAAGCAAGTTAA GTGTCCTCCAATTCTGTATTCCAGACTTGGGAGGATGTACAGTTGCTGTTGTGTGATCAAACATGTCTCTGTGTAGTTCAGCAAATCAAGCTGAGCTTTGAAAAAGTTTGTCTTAGTTTTGTGAAGGTGATTTATTCTTAAAAAAAAAAAAGAAAAAAAAAAAAAGATAAGAAGGAGGAGTAAAGGGACTACTCCTCCTTGCCAAATGTGCTAAATATCATTTTA GGAGAAAGAAAGTGGGTTTATTGTATTTCCCCTTAAGATTGTGAGGGAGTGTGGATACAGTAGAATGAGCCAACAGTTTCTTTAATAAATACGGTCTGCAATAAATTATTTCACTAGCTCTAAAACCTTTCCCTAGATTTAGTAGGGAGTTGGTTTCTGTTAATATCTTGGGTGCTGTGGTGGTAAATGCTATATTATGAACGGTGGCATGTATTTACAGTT AGAGTATTGTGTGTACACTTTTTTAATGGTAAACTTAAGCTGAATGTGTAATGGATTTGTGTATAGTTTTACATATTTGGAAGCATTTTAAAAACAGGTTTTAAACCTTTATGTAAAATTACTTTATACTCGTGTTAACATTTTCATCTGTGCCTTTTGGTAATTTAATTCTATTATGAATTTCTGGTGCCTATGAGCTAGCTATCACCTACCTGAAAGGTGCTTAGAGGTGAAG GTACTGTTTCTAAAAAACACATCACTGTGATACCTTTTCTATCCTCACATTTTCAAGCTTGCCTCTTTTCTGTTCTTTGTGGATATAACTTAAGCAATTGTGTTATTCATAAAGGTTTAGAAATTTCAATATTTCCCAACACTCTATGTTTCTGATTTTATAACAGTAGCCATTTTTGAAAGTCAGATGTTTGGCCTGTTTTATATGAATAAAGTTTTATAAAATATTATAAAAAAT AAGTAAATAAACAGAACATTAATAATAAAAGTTTTGGTTCTTCCTATTCCTGACTTTCATATAATGAAAATTATCCTATTGATCTAAGTAGAAGTTATCATAGAAAGTGGACACGTATAAGACTTTTCCTTCCTTTTTTTTTTAATAACATATGAGGAACAAGACTTCTCTTCCCATACTTCATATTTTGAGGACATTGTTTTAAAGGCTTATGTCTCACTGTAAAATCTGTCACT GCCAAATAGTACCAATACGTTTTCAAGTAGTTCTCACTGATAATTTAGTTGAACCAGAGATCAAATATTTGCTCCCGAATTACTACTGGTAATCAAGTAGTTGAACAAAAAATTACTAAAGCATTTCCGTTAGATCAGTCAAGGACAGTACTGCATCTTTTTTTTTTTTTTTTTTTTTTAAGACGGAGTCTCGGTCTGTCACCCAGGCTGGAGTGCAGTGGCGGGATCTCG GCTCACTGCAAGCTCCGCCTCCCAGGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGCAGCTGGGACTACAGGCTCCCATCACCACGCTCGGCTAAGTTTTTTGTAATTTTAGTAGAGACAGGGTTTCACCGTGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCTGCCTGCCTCGGCTCCCAAAGTGCTGGGATTACAGGCGTGAACCACTGCACCC GGCCCAGTACTGCATCTTAACAGCAAAGCCATTTTATTCTACTTTATAACTGAGAGACTTGATACCATCCATCTCTTTAGGTTACAGAGGATAATTTGAAGAGAAATGTTACTGTAGAATATAGTTCTGTACTTTTTTTTTTTTTTAAGAGATAGGGTTTCACTATTGCTCAGGCTGGTCTCAAACTGCTGGGCTCAGGAGATCCCTCCTGCCTTGGCCTCCCAATT GCTGGGATTACAGGTGTGAGCCGCAGCATCCAGCCAGTTCTGTACTTTGAATATGGAGTAGTTTACAGCTATTTTTTTTCTTACTGGTAATCTTAACTAATATGATTCCCTTGTTAGAGCCTCTCACTCCCCACCCCCAAAAATGTCTACTATTCATGACAGTAACCAATTATTCTGGACAAATTGCTTCTTTTTAATTTGAGCTATCTGCCATGGACTTTC TAAAATGGAAACACAGCCTGAGTGTATCTTAGGGAGAGTTTGATTGAAAAAATCCAAATCACTATCCATATAGATCATGGATATAAAGAGATACCTGATTTTTATTAAAAAGATACTTTTTTCAAATTTAAGAGTTAATCTTGGAAATTTGGAACAAGTAAAAGGGGCAAGTAAACCTTTTGATGAAATATAAAAGGAACTCATTGCATGAAGTTGACTATCAAATTCTGTG ATGTGTGGCTTCTTAAAAATATTCTCAGTGTCTTTTGTGTGCGTGCAGCATGTACATTTGATGTTATGTGAATGTTGAGTTTTTCTTTCTAATTTTCACTTCAGCAGTGTTTAGGCTTTCAGATGCCTTATTCCAGTGTGAACAGAAAAAGTTCATATTTTATGTGGTTAATGCTTTGATGTGTCACATAAAGAGTAGTTTTGTAGAAAATGTTGGCACAATTTTAACTT CTTAGTGGCTTGTGACATTATATATTATATATATATGTACATATCTTTAACATTCCTGTGTTTAGTAGTGTAAATGTTCTGGGCAAGTTTTTAATATTTTGAATGCCTTTGGATATTCCAGCAATAAAGGCATCATGTTCTGCAATAGGATTTCTTACTCATTTACCTATTTTAACACTAAAATAGACCAAACTGAGCACAAATTCCTTTATAAATGTTATAGAAG CAGGGAAGAATAATAAACACATTTGTGAATTGTGGTTCAGTTTTTATCTTTAGGGAAGGCTGATCATTTATCTTTATAGCAGATAACCCCAGCCTCTTATTCATTATGGTTAACTTTTATAAATTTATCTTTTTTATAATTTAAGAATATAGTACATATCAGTTGGGTTTGGTTTTGGTCATCGAGACTAAAAGCTCCATCAAAACAGAACTTTGTGTTTTCTGCTAAC TTATTTAATGACACAAGTTTTAAGAGAACCACAATTCATTGATTCACTTATTCTTTTCCCTAATTGTGAATTTTAGTGATAAATACACCTGTACTACTGAGGAAAATATTCTGACACTTCACGTGTGCAAAGTATAGAACTGACAGTGTCAGTTTCAGATTTTGTATGTACGATTTCTGGCTTATATCCAATGGTGCAGATTTTGAAATTTGTAAGAACAAAATTTGTTA AGAAAAACAACTTGCTCTAGTTTTGTGACCTTGTGTACTTTTGAAATAAAATCAAGAAAGCAGTTCTCTGCCTC SEQ ID NO:224 The polynucleotide sequence of all five exons 1-5 of CXADR arranged in order SEQ ID NO:225 Translated polypeptide sequence of exon 1 of CXADR MALLLCFVLLCGVV SEQ ID NO:226 Translated polypeptide sequence of exon 2 of CXADR FARSLSITTPEEMIEKAKGETAYLPCKFTLSPEDQGPLDIEWLISPADNQKVDQV SEQ ID NO:227 Translated polypeptide sequence of exon 3 of CXADR IILYSGDKIYDDYYPDLKGRVHFTSNDLKSGDASINVTNLQLSDIGTYQCKVKKAPGVANKKIHLVVL SEQ ID NO:228 Translated polypeptide sequence of exon 4 of CXADR KPSGARCYVDGSEEIGSDFKIKCEPKEGSLPLQYEWQKLSDSQKMPTSWLA SEQ ID NO:229 Translated polypeptide sequence of exon 5 of CXADR KMCHLQRAVRPLPEATSAVIIHPWGPCLLPTWKDIPRLSITKYQVKTLNALLRVRLSHLLR SEQ ID NO:230 CDAXR polypeptide sequence MALLLCFVLLCGVVDFARSLSITTPEEMIEKAKGETAYLPCKFTLSPEDQGPLDIEWLISPADNQKVDQVIILYSGDKIYDDYYPDLKGRVHFTSNDLKSGDASINVTNLQLSDIGTYQCKVKKAPGVANKKIHLVVLVKPSGARCYVDGSEEIGSDFKIKCEPKEGSLPLQYEWQ KLSDSQKMPTSWLAGKMCHLQRAVRPLPEATSAVIIHPWGPCLLPTWKDIPRLSITKYQVKTLNALLRVRLSHLLR GTF2E2 sequence informationSEQ ID NO: 231 GTF2E2 exon 2 sequence at 5' of GTF2E2-NRG1 fusion GGGAGCTGTTCAAAAAACGAGCTCTTTCTACTCCTGTAGTAGAAAAACGTTCAGCATTCTTCTGAGTCATCATCATCATCGTCAAAAGAAGAAGAAAACAAAGGTAGAACATGGAGGATCGTCAGGCTCTAAACAAAATTCTG SEQ ID NO: 232 NRG1 exon 2 sequence at 3' of GTF2E2-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCTGAATACTCCTCTCTCGAATTCAAGTGGTTCAAGAATGGGAATGA SEQ ID NO: 233 GTF2E2-NRG1 polynucleotide sequence GGGAGCTGTTCAAAAAACGAGCTCTTTCTACTCCTGTAGTAGAAAAACGTTCAGCATTCTTCTGAGTCATCATCATCATCGTCAAAAGAAGAAGAAAACAAAGGTAGAACATGGAGGATCGTCAGGCTCTAAACAAAATTCTGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCTGA ATACTCCTCTCTCAGATTCAAGTGGTTCAAGAATGGGAATGA SEQ ID NO: 234 GTF2E2-NRG1 polypeptide sequence ELFKKRALSTPVVEKRSASSESSSSSSKKKKTKVEHGGSSGSKQNSALPPRLKEMKSQESAAAGSKLVLRCETSSEYSSLRFKWFKNGN SEQ ID NO:235 Exon 1 of GTF2E2 ACTGAGCTCCTAGCACCCGATCGGGAAGTGGCGGGCGGAGTCCCGGGTCCAGTCGCCGCCTCAGCTACCGCCGCTGCCGCCGCCGCCGCCGCCACCGCCAGTGGTGAGACCCCGACCTGGCGGGTCAGCGCTGGGCGTGCGTGCGGGCAGGCGGGGGCGCTGACGAGAAGCAGGAAGAGGGTGCAGTGCCGGCGTGGGCG GCCGGCCGAGGCGGAGGCGCAGGAAGGGGGCGGCGAGTCGTGCGAGGCTGCCCTTCTCACTCAG SEQ ID NO:236 Exon 2 of GTF2E2 CATTATGGATCCAAGCCTGTTGAGAGAAAGGGAGCTGTTCAAAAAACGAGCTCTTTCTACTCCTGTAGTAGAAAAACGTTCAGCATCCTTCTGAGTCATCATCATCATCGTCAAAAGAAGAAGAAAACAAAGGTAGAACATGGAGGATCGTCAGGCTCTAAACAAAATTCTG SEQ ID NO:237 Exon 3 of GTF2E2 ATCATAGCAATGGATCATTTAACTTGAAAGCTTTGTCAGGAAGCTCTGGATATAAGTTTGGTGTTCTTGCTAAGATTGTGAATTACATGAAG SEQ ID NO:238 Exon 4 of GTF2E2 ACACGGCATCAGCGAGGAGATACGCATCCTCTAACCTTAGATGAAATTTTGGATGAAACACAACATTTAGATATTGGACTCAAGCAGAAACAATGGCTAATGACTGAG SEQ ID NO:239 Exon 5 of GTF2E2 GCTTTAGTCAAACAATCCCAAAATTGAAGTAATAGATGGGAAGTATGCTTTCAAGCCCAAGTACAACGTGAGAGATAAGAAGGCCCTACTTAGGCTCTTAGATCAGCATGACCAGCGAGGATTAGGAGGAATTCTTTTAGAAGACATAGAAGAAGCACTGCCCAATTCCCAGAAAGCTGTCAAG SEQ ID NO:240 Exon 6 of GTF2E2 GCTTTGGGGGACCAGATACTATTTGTAAATCGTCCCGATAAGAAGAAAATACTTTTCTTCAATGATAAGAGCTGTCAGTTTTCTGTGGATGAAG SEQ ID NO:241 Exon 7 of GTF2E2 AATTTCAGAAACTGTGGAGGAGTGTCACTGTAGATTCCATGGACGAGGAGAAAATTGAAGAATATCTGAAGCGACAGGGTATTTCTTCCATGCAGGAATCTGGACCAAAAGAAAGTG SEQ ID NO:242 Exon 8 of GTF2E2 GCCCCTATTCAGAGAAGGAAAAAGCCTGCTTCACAGAAAAAGCGACGCTTTAAGACTCATAACGAACACTTGGCTGGAGTGCTGAAGGATTACTCTGACATTACTTCCAGCAAATAGGGAACAGTTTTGCCCTGGAACAGAGTTACAGATACACAATCAAGGTGTTCTTGCTGATGCTCGGGGTCTGAAGACTGTCTTCCTATCTGCTTCTTGCGGCTGAG GAGAGGAGCAGTTCAGTTTACAAAACAAGTGCAAATTACCAAACTCAAAGCTTATTTGAGTAGAATGGGCTCATGGGCAATGTGATGTTCCCTGTTAAACCTTCTGTTACTCCCTGGGAGAAAGGCGCTGAGCGTGGCATGCAGGTGTCTTTGCTGTGTTTTTCTCACTTCTAAATGGTTCCTGGTTCCTTTCTTCCTCGTTTGTTACTTTAGAGCAAGTTTGC CCATAGTCTTGAATGCAATATTTGTTTATTCCAAAAGAACATATTTATAATAAAATCACTGTAGAAGGATTTTTAAGATGTTAGTGAATTCTGTTTCTTTTCATTCTCGGAAATGGCAGGAAGCAGCTCCAGTCTCTGGGTCACGTGCTGGGGATGTGATGAAGCCTGCAGTCTGCACTGTGTTGCTGAGCACATGGATTTCACCACTGGAAC ACAGGTGTGCTGCTTGTTAGCAAGCAGAGCAATAAAGATGTGCTGGATGTCA SEQ ID NO:243 The polynucleotide sequence of all eight exons 1-8 of GTF2E2 arranged in order SEQ ID NO:244 Translated polypeptide sequence of exon 2 of GTF2E2 MDPSLLRERELFKKRALSTPVVEKRSASSESSSSSSKKKKTKVEHGGSSGSKQNS SEQ ID NO:245 Translated polypeptide sequence of exon 3 of GTF2E2 HSNGSFNLKALSGSSGYKFGVLAKIVNYMK SEQ ID NO:246 Translated polypeptide sequence of exon 4 of GTF2E2 TRHQRGDTHPLTLDEILDETQHLDIGLKQKQWLMTE SEQ ID NO:247 Translated polypeptide sequence of exon 5 of GTF2E2 ALVNNPKIEVIDGKYAFKPKYNVRDKKALLRLLDQHDQRGLGGILLEDIEEALPNSQKAVK SEQ ID NO:248 Translated polypeptide sequence of exon 6 of GTF2E2 ALGDQILFVNRPDKKKILFFNDKSCQFSVDE SEQ ID NO:249 Translated polypeptide sequence of exon 7 of GTF2E2 FQKLWRSVTVDSMDEEKIEEYLKRQGISSMQESGPKKV SEQ ID NO:250 Translated polypeptide sequence of exon 8 of GTF2E2 APIQRRKKPASQKKRRFKTHNEHLAGVLKDYSDITSSK SEQ ID NO:251 Full protein sequence MDPSLLRERELFKKRALSTPVVEKRSASSESSSSSSKKKKTKVEHGGSSGSKQNSDHSNGSFNLKALSGSSGYKFGVLAKIVNYMKTRHQRGDTHPLTLDEILDETQHLDIGLKQKQWLMTEALVNNPKIEVIDGKYAFKPKYNVRDKKALLRLLDQHDQRGLGGILLEDIE EALPNSQKAVKALGDQILFVNRPDKKKILFFNDKSCQFSVDEEFQKLWRSVTVDSMDEEKIEEYLKRQGISSMQESGPKKVAPIQRRKKPASQKKRRFKTHNEHLAGVLKDYSDITSSK SEQ ID NO:252 exons 1-2 ACTGAGCTCCTAGCACCCGATCGGGAAGTGGCGGGCGGAGTCCCGGGTCCAGTCGCCGCCTCAGCTACCGCCGCTGCCGCCGCCGCCGCCGCCACCGCCAGTGGTGAGACCCCGACCTGGCGGGTCAGCGCTGGGCGTGCGTGCGGGCAGGCGGGGGCGCTGACGAGAAGCAGGAAGAGGGTGCAGTGCCGGCGTGGGCG GCCGGCCGAGGCGGAGGCGCAGGAAGGGGGCGGCGAGTCGTGCGAGGCTGCCCTTCTCACTCAGCATTATGGATCCAAGCCTGTTGAGAGAAAGGGAGCTGTTCAAAAAACGAGCTCTTTCTACTCCCTGTAGTAGAAAAACGTTCAGCATCTTCTGAGTCATCATCATCATCGTCAAAAGAAGAAGAAAACAAAGGTAGAACATGGAGGATCGTCAGGC TCTAAACAAAATTCTG CSMD1 sequence informationSEQ ID NO: 253 CSMD1 exon 23 sequence ATCCTAAACAGCACATCCAATCACCTGTGGCTAGAGTTCAACACCAATGGATCTGACACCGACCCAAGGTTTTCAACTCACCTATACCA at 5' of CSMD1-NRG1 fusion 5' SEQ ID NO: 254 NRG1 exon 6 sequence CTACATCTAC at 3' of CSMD1-NRG1 fusion ATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACT SEQ ID NO: 255 CSMD1-NRG1 Polynucleotide sequence ATCCTAAACAGCACATCCAATCACCTGTGGCTAGAGTTCAACACCAATGGATCTGACACCGACCAAGGTTTTCAACTCACCTATACCACTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACT SEQ ID NO: 256 CSMD1-NRG1 polypeptide sequence ILNSTSNHLWLEFNTNGSDTDQGF QLTYTTTSTSTTGTSHLVKCAEKEKT SEQ ID NO:257 CSMD1 Exon 1 CTCCACGGCAGCGGCTCCTTGTGCCACTAGCAGCCCTTCTTCTGCGCTCTCCGCCTTTTCTCTCTAGACTGGATCTCTCCCTCCCCCCCGCGCCCCCCTCCCCGCATCTCCCACTCGCTGGCTCTCTCTCCAGCTGCCTCCTCTCCAGGTCTCTCCTGG CTGCGCGCGCTCCTCTCCCCGCTTCTCCCCCTCCCGCAGCCTCGCCGCCTTGGTGCCTTCCTGCCCGGCTCGGCCGGCGCTCGTCCCCGGCCCCGGCCCCGCCAGCCCGGGTCTCCGCGCTCGGAGCAGCTCAGCCCTGCAGTGGCTCGGGACCCGATGCTATGAGAGGGAAGCGAGCCGGGCGCCCAGACCTTCAGGAGGCGTCGGATGCGC GGCGGGTCTTGGGACCGGGCTCCTCTCTCCGGCTCGCCTTGCCCTCGGGTGATTATTTGGCTCCGCTCATAGCCCTGCCTTCCTCGGAGGAGCCATCGGTGTCGCGTGCGTGTGGAGTATCTGCAGACATGACTGCGTGGAGGAGATTCCAGTCGCTGCTCCTGCTTCTCGGGCTGCTGGTGCTGTGCGCGAGGCTCCTCACTGCAGCGAAGG SEQ ID NO: 258 CSMD1 exon 2 GTCAGAACTGTGGAGGCTTAGTCCAGGGTCCCAATGGCACTATTGAGAGCCCAGGGTTTCCTCACGGGTATCCGAACTATGCCAACTGCACCTGGATCATCATCACGGGCGAGCGCAATAGGATAGTTCAGTTGTCCTTCCATACCTTTGCTCTTGAAGAAGATTTTGATATTTTATCATTTACGATGGACAGC CTCAACAAGGGAATTTAAAAGTGAG SEQ ID NO: 259 CSMD1 exons 3 ATTATCGGGATTTCAGCTGCCCTCCTCTATAGTGAGTACCAGGATCTATCTCACTCTGTGGTTCACGACAGACTTCGCTGTGAGTGCCCAAGGTTTCAAAGCATTATATGAAG SEQ ID NO: 260 CSMD1 Exon 4 TTTTACCTAGCCACACTTGTGGAAATCCTGGAGAAATCCTGAAAGGAGTTCTGCATGGAACGAGATTCAACATAG GAGACAAAATCCGGTACAGCTGCCTCCCTGGCTACATCTTGGAAGGCCACGCCATCCTGACCTGCATCGTCAGCCCAGGAAATGGTGCATCGTGGGACTTCCCAGCTCCCTTTTTGCAGAG SEQ ID NO: 261 CSMD1 exon 5 CTGAGGGAGCCTGCGGAGGAACCTTACGCGGGACCAGCAGCTCCATCCTCCAGCCCGCACTTCCCTTCA GAGTACGAGAACAACGCGGACTGCACCTGGACCATTCTGGCTGAGCCCGGGGACACCATTGCGCTGGTCTTCACTGACTTTCAGCTAGAAGAAGGATATGATTTCTTAGAGATCAGTGGCACGGAAGCTCCATCCATATG SEQ ID NO: 262 CSMD1 Exon 6 GCTAACTGGCATGAACCTCCCCTCTCCAGTTATTCAGTAGCAAGAATTG GCTACGACTCCATTTCACCTCTGACAGCAACCACCGACGCAAAGGATTTAACGCTCAGTTCCAAG SEQ ID NO: 263 CSMD1 exon 7 TGAAAAAGGCGATTGAGTTGAAGTCAAGAGGAGTCAAGATGCTGCCCAGCAAGGATGGAAGCCATAAAAACTCTGTCT SEQ ID NO: 264 CSMD1 exon 8 TGAGCCAAGGAGGTGTTGCATTGGTCTCTGACATGTGTCCAGATCCTGGGATTCCAGAAAATGGTAGAAGAGCAGGTTCCGACTTCAG SEQ ID NO: 265 CSMD1 exon 9 GGTTGGTGCAAATGTACAGTTTTTCATGTGAGGACAATTACGTGCTCCAGGGATCTAAAAGCATC ACCTGTCAGAGAGTTACAGACGCTCGCTGCTTGGAGTGACCACAGGCCCATCTGCCGAG SEQ ID NO: 266 CSMD1 exon 10 CGAGAACATGTGGATCCAATCTGCGTGGGCCCAGCGGCGTCATTACCTCCCCCTAATTATCCGGTTCAGTATGAAGATAATGCACACTGTGTGTGGGTCATCACCACCACCGACCCGGACAAG SE Q ID NO: 267 CSMD1 Exon 11 GTCATCAAGCTTGCCTTTGAAGAGTTTGAGCTGGAGCGAGGCTATGACACCCTGACGGTTGGTGATGCTGGGAAGGTGGGAGACACCCAGATCGGTCTTGTACGT SEQ ID NO:268 CSMD1 exon 12 GCTCACGGGATCCAGTGTTCCTGACCTCATTGTGAGCATGAGCAACCAGATGTGGCTACATCTGCAGTCGGATGATAGCATTGGCTCACCTGGGTTTAAAGCTGTTTACCAAG SEQ ID NO:269 CSMD1 exon 13 AAATTGAAAAGGGAGGGTGTGGGGATCCTGGAATCCCCGCCT ATGGGAAGCGGACGGGCAGCAGTTTCCTCCATGGAGATACACTCACCTTTGAATGCCCGGCGGCCTTTGAGCTGGTGGGGGAGAGAGTTATCACCTGTCAGCAGAACAATCAGTGGTCTGGCAACAAGCCCAGCTGTGTAT SEQ ID NO: 270 CSMD1 exon 14 TTTCATGTTTCTTCAACTTTACGGCATCATCTGGGATTA TTCTGTCACCCAAATTATCCAGAGGAATATGGGAACAACATGAACTGTGTCTGGTTGATTATCTCGGAGCCAGGAAGTCGAATTCACCTAATCTTTAATGATTTTGATGTTGAGCCTCAGTTTGACTTTCTCGCGGTCAAGGATGATGGCATTTCTGACATAACTGTCCTGGGTACTTTTTCTGGCAATGAAGTGCCTTCCCAGCTGGCCAGCAGTGG GCATATAGTTCGCTTGGAATTTCAGTCTGACCATTCCACTACTGGCAGAGGGTTCAACATCACTTACACCA SEQ ID NO: 271 CSMD1 exon 15 CATTTGGTCAGAATGAGTGCCATGATCCTGGCATTCCTATAAACGGACGACGTTTTGGTGACAGGTTTCTACTCGGGAGCTCGGTTCTTTCCACTGTGATGATGGCTTTGTCA AGACCCAGGGATCCGAGTCCATTACCTGCATACTGCAAGACGGGAACGTGGTCTGGAGCTCCACCGTGCCCCGCTGTGAAG SEQ ID NO: 272 CSMD1 exon 16 CTCCATGTGGTGGACATCTGACAGCGTCCAGCGGAGTCATTTTGCCTCCTGGATGGCCAGGATATTATAAGGATTCTTTACATTGTGAATGGATAATTGAAGCAAAACCAGGCCACTCTATCAAAATAACTTTTGACAG SEQ ID NO: 273 CSMD1 exon 17 ATTTCAGACAGAGGTCAATT ATGACACCTTGGAGGTCAGAGATGGGCCAGCCAGTTCGTCCCCACTGATCGGCGAGTACCACGGCACCCAGGCACCCAGTTCCTCATCAGCACCGGGAACTTCATGTACCTGCTGTTCACCACTGACAACAGCCGCTCCAGCATCGGCTTCCTCATCCACTATGAGA SEQ ID NO: 274 CSMD1 exon 18 GTGTGACGCTTGAGTCGG ATTCCTGCCTGGACCGGGCATCCCTGTGAACGGCCATCGCCACGGTGGAGACTTTGGCATCAGGTCCACAGTGACTTTCAGCTGTGACCCGGGGTACACACTAAGTGACGACGAGCCCCTCGTCTGTGAGAGGAACCACCAGTGGAACCACGCCTTGCCCAGCTGCGACG SEQ ID NO: 275 CSMD1 exon 19 CTCTATGT GGAGGCTACATCCAAGGGAAGAGTGGAACAGTCCTTTCTCCTGGGTTTCCAGATTTTTTATCCAAACTTCTCTAAACTGCACGTGGACCATTGAAGTGTCTCATGGGAAAG SEQ ID NO: 276 CSMD1 Exon 20 GAGTTCAAATGATCTTTCACACCTTTCATCTTGAGAGTTCCCACGACTATTTACTGATCACAGAGGATGGAAGTTTTTCCGAGCCCGTTGCCAGGCTCACCGGGTCGGTGTTGCCTCATACGATCAAGGCAGGCCTGTTTGGAAACTTCACTGCCCAGCTTCGGTTTATATCAGACTTCTCAATTTCGTACGAGGGCTCAATATCACAT TTTCAG SEQ ID NO: 277 CSMD1 exon 21 AATATGACCTGGAGCCATGTGATGATCCTGGAGTCCCTGCCTTCAGCCGAAGAATTGGTTTTCACTTTGGTGTGGGAGACTCTCTGACGTTTTCCTGCTTCCTGGGATATCGTTTAGAAGGTGCCACCAAGCTTACCTGCCTGGGTGGGGCCGCCGTGTGTGGAGTGCACCTGC CAAGGTGTGTGG SEQ ID NO: 278 CSMD1 exon 22 CCGAATGTGGAGCAAGTGTCAAAGGAAATGAAGGAACATTACTGTCTCCAAATTTTCCATCCAAATTATGATAATAACCATGAGTGTATCTATAAAATAGAAACAGAAGCCGGCAAGGGCATCCACCTTAGAACACGAAGCTTCCAGCTGTTTGAAGGAGATACTCTAAAG SEQ ID NO: 279 CSMD1 exon 23 GTATATGATGGAAAAGACAGTTCCTCACGTCCACTGGGCACGTTCACTAAAAATGAACTTCTGGGGCTGATCCTAAACAGCACATCCAATCACCTGTGGCTAGAGTTCAACACCAATGGATCTGACACCGACCAAGGTTTTCAACTCACCTATACCA SEQ ID NO: 280 CSMD1 exon Exon 24 GTTTTGATCTGGTAAAATGTGAGGATCCGGGCATCCCTAACTACGGCTATAGGATCCGTGATGAAGGCCACTTTACCGACACTGTAGTTCTGTACAGTTGCAACCCGGGGTACGCCATGCATGGCAGCAACACCCCTGACCTGTTTGAGTGGAGACAGGAGAGTGTGGGACAAACCACTACCTTCGTGCATAG SEQ ID NO: 2 81 The polynucleotide sequence of all 47 exons 24-70 of CSMD1 in sequence SEQ ID NO: 282 The polynucleotide sequence of all 70 exons 1-70 of CSMD1 in sequence Acid sequence SEQ ID NO: 283 Translated polypeptide sequence of exon 1 of CSMD1 MTAWRRFQSLLLLLGLLVLCARLLTAAK SEQ ID NO: 284 Translated polypeptide sequence of exon 2 of CSMD1 QNCGGLVQGPNGTIESPGFPHGYPNYANCTWIIITGERNRIQLSFHTFALEEDFDILSVYDGQPQQGNLKV SEQ ID NO: 285 The translated polypeptide sequence of CSMD1 exon 3 LSGFQLPSSIVSTGSILTLWFTTDFAVSAQGFKALYE SEQ ID NO:286 Translated polypeptide sequence of exon 4 of CSMD1 LPSHTCGNPGEILKGVLHGTRFNIGDKIRYSCLPGYILEGHAILTCIVSPGNGASWDFPAPFCR SEQ ID NO:287 Translated polypeptide sequence of exon 5 of CSMD1 EGACGGTLRGTSSSISPHFPSEYENNADCTWTILAEPGDTIALVFTDFQLEEGYDF LEISGTEAPSI SEQ ID NO:288 Translated polypeptide sequence of exon 6 of CSMD1 LTGMNLPSPVISSKNWLRLHFTSDSNHRRKGFNAQFQ SEQ ID NO: 289 Translated polypeptide sequence KKAIELKSRGVKMLPSKDGSHKNSV of exon 7 of CSMD1 LAAWSDHRPICR SEQ ID NO: 292 Translated polypeptide sequence of exon 10 of CSMD1 RTCGSNLRGPSGVITSPNYPVQYEDNAHCVWVITTTPDDK SEQ ID NO: 293 Translated polypeptide sequence of exon 11 of CSMD1 VIKLAFEEFELERGYDTLTVGDAGKVGDTRSVLY SEQ ID NO: 294 Translated polypeptide sequence of exon 12 of CSMD1 LTGSSVPDLIVSMSN QMWLHLQSDDSIGSPGFKAVYQ SEQ ID NO:295 CSMD1 Translated polypeptide sequence of exon 13 IEKGGCGDPGIPAYGKRTGSSFLHGDTTLTFECPAAFELVGERVITCQQNNQWSGNKPSCV SEQ ID NO: 296 Translated polypeptide sequence of CSMD1 exon 14 SCFFNFTASSGIILSPNYPEEYGNNMNCVWLIISEPGSRIHLIFNDFDVEPQFDFLAVKDDGISDITVLGTFSGNEV PSQLASSGHIVRLEFQSDHSTTGRGFNITYT SEQ ID NO: 297 Translated polypeptide sequence of CSMD1 exon 15 FGQNECHDPGIPINGRRFGDRFLLGSSVSFHCDDGFVKTQGSESITCILQDGNVVWSSTVPRCE SEQ ID NO: 298 CSMD1 Translated polypeptide sequence of exon 16 PCGGHLTASSGVILPPGWPGYYKDSLHCEWIIEAKPGHSIKITFD SEQ ID NO:299 Translated polypeptide sequence of exon 17 of CSMD1 FQTEVNYDTLEVRDGPASSSPLIGEYHGTQAPQFLISTGNFMYLLFTTDNRSRSSIGFLIHYE SEQ ID NO:300 Exon 18 of CSMD1 Translated polypeptide sequence VTLESDSCLDPGIPVNGHRHGGDFGIRSTVTFSCDPGYTLSDDEPLVCERNHQWNHALPSCD SEQ ID NO: 301 CSMD1 exon Translated polypeptide sequence of 19 LCGGYIQGKSGTVLSPGPDFYPNSLNCTWTIEVSHGK SEQ ID NO: 302 Translated polypeptide sequence of CSMD1 exon 20 VQMIFHTFHLESSHDYLLITEDGSFSEPVARLTGSVLPHTIKAGLFGNFTAQLRFIDFSISYEGFNITFS SEQ ID NO: 303 CSMD1 exon 2 The translated polypeptide sequence of 1 YDLEPCDDPGVPAFSRRIGFHFGVGDSLTFSCFLGYRLEGATKLTCLGGGRRVWSAPLPRCV SEQ ID NO: 304 CSMD1 exon 22 Translated polypeptide sequence ECGASVKGNEGTLLLSPNFPSNYDNNHECIYKIETEAGKGIHLRTRSFQLFEGDTLK SEQ ID NO: 305 Translated polypeptide sequence of CSMD1 exon 23 VYDGKDSSSRPLGTFTKNELLGLILNSTSNHLWLEFNTNGSDTDQGFQLTYT SEQ ID NO: 306 Translated polypeptide sequence of CSMD1 exon 24 FDLVKCEDPGIPNYGYRIRDEGHFTDTVVLYSCNPGYAMHGSNTTLTCLSGDRRVWDKPLPSCI SEQ ID NO: 307 All from exons 24-70 Translated polypeptide sequence of 47 exons sequenced SEQ ID NO:308 Whole protein sequence-SEQ ID NO:309 Polynucleotide sequence sequenced sequence of all 23 exons 1-23 of CSMD1 SEQ ID NO:310 Sequential translated polypeptide sequence from all 23 exons 1-23 of CSMD1PTN sequence informationSEQ ID NO: 311 PTN exon 4 sequence at 5' of PTN-NRG1 fusion CCAGAACTGGAAGTCTGAAGCGAGCCCTGCACAATGCCGAATGCCAGAAGACTGTCACCATCTCCAAGCCCTGTGGCAAACTGACCAAGCCCAAACCTCAAG SEQ ID NO: 312 NRG1 exon 2 sequence at 3' of PTN-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCTGAATACTCCTCTCTCCAGATT SEQ ID NO: 313 PTN-NRG1 polynucleotide sequence CCAGAACTGGAAGTCTGAAGCGAGCCCTGCACAATGCCGAATGCCAGAAGACTGTCACCATCTCCAAGCCCTGTGGCAAACTGACCAAGCCCAAACCTCAAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCTGAATACTCCTCTCTCGATT SEQ ID NO: 314 PTN-NRG1 polypeptide sequence RTGSLKRALHNAECQKTVTISKPCGKLTKPKPQALPPRLKEMKSQESAAAGSKLVLRCETSSEYSSLR SEQ ID NO:315 PTN exon 1 AAGGGGAAATAAGGGACAAGAGAGACCCTCTCATATTGTTTTATATTTTTCATACTCAGAAAAGGAAAGAGAAGCCAAACAAAAGGCAGGTAACCCGCGCCTAGGAACCAGACCCGAAACCAAGGAACCAGATCTGAAACCAGGCCTGGGCCTGCCTGACCTAAGCCTGGTAGTAAAAATTCCACCCCTGACCTGACCTGGCAACTGTTGTTATTCAGATTC CAGACATTGTATGGAAGGACACTGTGAAACCTCCCGTTCTGTTCTGTTTCACTCTGACCATCGGTGCTCACAGCCCCTATCACGTACCCCCTGGCTTGCTCAGTCGATCACGACCCTCTCACGTGGACCCCCTTAGAGTTGTTAGCCCTTAAAAGGGACAGAAGTTGAGCACCTGAGGAGCTCAGATTTTAAGACGCTAGGCTGCTGATGCTCCCAGCTGATTAAAGC CACTCCCTTCACTATCTCGGTGTCTCCTGTCCGCGGCTCGTCCTGCTACATTTCTTGGTTCCCTGACCGGCAAGCGAG SEQ ID NO:316 PTN exon 2 AATGCAGGCTCAACAGTACCAGCAGCGTCGAAAATTTGCAGCTGCCTTCTTGGCATTCATTTTCATACTGGCAGCTGTGGATACTGCTGAAGCAGGGAAGAAAGAGAAACCAG SEQ ID NO:317 PTN exon 3 AAAAAAAAGTGAAGAAGTCTGACTGTGGAGAATGGCAGTGGAGTGTGTGTGCCCACCAGTGGAGACTGTGGGCTGGGCACACGGGAGGGCACTCGGACTGGAGCTGAGTGCAAGCAAACCATGAAGACCCAGAGATGTAAGATCCCCCTGCAACTGGAAGAAGCAATTTGGCG SEQ ID NO:318 PTN exon 4 CGGAGTGCAAATACCAGTTCCAGGCCTGGGGAGAATGTGACCTGAACACAGCCCTGAAGACCAGAACTGGAAGTCTGAAGCGAGCCCTGCACAATGCCGAATGCCAGAAGACTGTCACCATCTCCAAGCCCTGTGGCAAACTGACCAAGCCCAAACCTCAAG SEQ ID NO:319 Exon 5 of PTN CAGAATCTAAGAAGAAGAAAAAGGAAGGCAAGAAACAGGAGAAGATGCTGGATTAAAAGATGTCACCTGTGGAACATAAAAAGGACATCAGCAAACAGGATCAGTTAACTATTGCATTTATATGTACCGTAGGCTTTGTATTCAAAAATTATCTATAGCTAAGTACACAATAAGCAAAAAACAAAAAGAAAAGAAAATTTTTGTAGTAGCGTTTTTTAAATGTATACTATAGT ACCAGTAGGGGCTTATAATAAAGGACTGTAATTCTTATTTAGGAAGTTGACTTATAGTACATGATAAATGATAGACAATTGAGGTAAGTTTTTTGAAATTATGTGACATTTTACATTAAATTTTTTTTACATTTTTTGGGCAGCAATTTAAATGTTATGACTATGTAAACTACTTCTCTTGTTAGGTAATTTTTTTCACCTAGATTTTTTTCCCAATTGAGAAAAAATATAC TAAACAAAATAGCAATAAAACATAATCACTCTATTTGAAGAAAATATCTTGTTTTCTGCCAATAGATTTTTTAAAATGTAGTCAGCAAAATGGGGGTGGGGAAGCAGAGCATGTCCTAGTTCAATGTTGACTTTTTTTTTTTAAAGAAAAGCATTAAGACATAAAATTCTTTCACTTTGGCAGAAGCATTTGTTTTCTTGATGAAATTATTTTTCCATCTGAGGAAAAAAA TACTAGGAAAATAAATCAAGGTGATGCTGAAAAAAAAA SEQ ID NO:320 The polynucleotide sequence of all five exons 1-5 of PTN arranged in order SEQ ID NO:321 Translated polypeptide sequence of PTN exon 2 MQAQQYQQQRRKFAAAFLAFIFILAAVDTAEAGKKEKP SEQ ID NO:322 Translated polypeptide sequence of PTN exon 3 KKVKKSDCGEWQWSVCVPTSGDCGLGTREGTRTGAECKQTMKTQRCKIPCNWKKQFG SEQ ID NO:323 Translated polypeptide sequence of PTN exon 4 ECKYQFQAWGECDLNTALKTRTGSLKRALHNAECQKTVTISKPCGKLTKPKPQ SEQ ID NO:324 Exon 5 of PTN ESKKKKKEGKKQEKMLD SEQ ID NO:325 full protein sequence MQAQQYQQQRRKFAAAFLAFIFILAAVDTAEAGKKEKPEKKVKKSDCGEWQWSVCVPTSGDCGLGTREGTRTGAECKQTMKTQRCKIPCNWKKQFGAECKYQFQAWGECDLNTALKTRTGSLKRALHNAECQKTVTISKPCGKLTKPKPQAESKKKKKEGKKQEKMLD SEQ ID NO:326 The polynucleotide sequence of all four exons 1-4 of PTN arranged in order SEQ ID NO:327 Translated polypeptide sequence of all three exons 2-4 of PTN arranged in order ST14 sequence informationSEQ ID NO: 328 ST14 exon 11 sequence at 5' of ST14-NRG1 fusion CAACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTCTTAGCTGAATACCTCTCCTACGACTCCAGTGACC SEQ ID NO: 329 NRG1 exon 6 sequence at 3' of ST14-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCT SEQ ID NO: 330 ST14-NRG1 polynucleotide sequence CAACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTCTTAGCTGAATACCTCTCCTACGACTCCAGTGACCCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCT SEQ ID NO: 331 ST14-NRG1 polypeptide sequence NSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPTTSTTGTSHLVKCAEKEKTFCVNGGEC SEQ ID NO:332 Exon 1 of ST14 GTGAGAGCGGAGCTGCAGCCGGAGAAAGAGGAAGAGGGAGAGAGAGCGCGCCAGGGCGAGGGCACCGCCGCCGGTCGGGCGCGCTGGGCCTGCCCGGAATCCCGCCGCCTGCGCCCCGCGCCCCGCGCCCTGCGGGCCATGGGAGCCGCCGCCGGCAGGGACGACGCCTGTGAGACCCGCGAGCGGCCTCGGGGACC ATGGGGAGCGATCGGGCCCGCAAGGGCGGAGGGGGCCCGAAGGACTTCGGCGCGGGACTCAAGTACAACTCCCGGCACGAG SEQ ID NO:333 ST14 exon 2 AAAGTGAATGGCTTGGAGGAAGGCGTGGAGTTCCTGCCAGTCAACAACGTCAAGAAGGTGGAAAAGCATGGCCCGGGGCGCTGGGTGGTGCTGGCAGCCGTGCTGATCGGCCTCCTCTTGGTCTTGCTGGGGATCGGCTTCCTGGTGTGGCATTTGCAGT SEQ ID NO:334 ST14 exon 3 ACCGGGACGTGCGTGTCCAGAAGGTCTTCAATGGCTACATGAGGATCACAAATGAGAATTTTGTGGATGCCTACGAGAACTCCAACTCCACTGAGTTTGTAAGCCTGGCCAGCAAGGTGAAGGACGCG SEQ ID NO:335 ST14 exon 4 CTGAAGCTGCTGTACAGCGGAGTCCCATTCCTGGGCCCCTACCACAAGGAGTCGGCTGTGACGGCCTTCAG SEQ ID NO:336 ST14 exon 5 CGAGGGCAGCGTCATCGCCTACTACTGGTCTGAGTTCAGCATCCCGCAGCACCTGGTGGAGGAGGCCGAGCGCGTCATGGCCGAGGAGCGCGTAGTCATGCTGCCCCCGCGGGCGCGCTCCCTGAAGTCCTTTGTGGTCACCTCAGTGGTGGCTTTCC SEQ ID NO:337 ST14 exon 6 CCACGGACTCCAAAACAGTACAGAGGACCCAGGACA SEQ ID NO:338 ST14 exon 7 ACAGCTGCAGCTTTGGCCTGCACGCCCGCGGTGTGGAGCTGATGCGCTTCACCACGCCCGGCTTCCCTGACAGCCCCTACCCCGCTCATGCCCGCTGCCAGTGGGCCCTGCGGGGGGACGCCGACTCAGTGCTGAGCCTCACCTTCCGCAGCTTTGACCTTGCGTCCTGCGACGAGCGCGCAGCGACCCTGGTGACGGTGTACAACCCCTGAG CCCCATGGAGCCCCACGCCCTGGTGCA SEQ ID NO:339 Exon 8 of ST14 GTTGTGTGGCACCTACCCCTCCCTCCTACAACCTGACCTTCCACTCCTCCCCAGAACGTCCTGCTCATCACACTGATAACCAACACTGAGCGGCGGCATCCCGGCTTTGAGGCCACCTTCTTCCAGCTGCCTAGGATGAGCA SEQ ID NO:340 Exon 9 of ST14 GCTGTGGAGGCCGCTTACGTAAAGCCCAGGGGACATTCAACAGCCCTACTACCCAGGCCACTACCCACCCAACATTGACTGCACATGGAACATTGAG SEQ ID NO:341 Exon 10 of ST14 GTGCCCAACAACCAGCATGTGAAGGTGCGCTTCAAATTCTTCTACCTGCTGGAGCCCGGCGTGCCTGCGGGCACCTGCCCCAAGGACTACGTGGAGATCAACGGGGAGAA SEQ ID NO:342 Exon 11 of ST14 ATACTGCGGAGAGAGGTCCCAGTTCGTCGTCACCAGCAACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTCTTAGCTGAATACCTCTCCTACGACTCCAGTGACC SEQ ID NO:343 Exon 12 of ST14 CATGCCCGGGGCAGTTCACGTGCCGCACGGGGCGGTGTATCCGGAAGGAGCTGCGCTGTGATGGCTGGGCCGACTGCACCGACCCACAGCGATGAGCTCAACTGCA SEQ ID NO:344 Exon 13 of ST14 GTTGCGACGCCGGCCACCAGTTCACGTGCAAGAACAAGTTCTGCAAGCCCCTCTTCTGGGTCTGCGACAGTGTGAACGACTGCGGAGACAACAGCGACGAGCAGGGGTGCA SEQ ID NO:345 Exon 14 of ST14 GTTGTCCGGCCCAGACCTTCAGGTGTTCCAATGGGAAGTGCCTCTCGAAAAGCCAGCAGTGCAATGGGAAGGACGACTGTGGGGACGGGTCCGACGAGGCCTCCTGCCCCAAGG SEQ ID NO:346 Exon 15 of ST14 TGAACGTCGTCACTTGTACCAAACACCCTACCGCTGCCTCAATGGGCTCTGCTTGAGCAAGGGCAACCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAGGACTGCG SEQ ID NO:347 Exon 16 of ST14 ACTGTGGGCTGCGGTCATTCACGAGACAGGCTCGTGTTGTTGGGGGCACGGATGCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATCTGCGGTGCTTCCCTCATCTCTCCCAACTGGCTGGTCTCTGCCGCACACTGCTACATCGATGACAGAGGATTCAG SEQ ID NO:348 Exon 17 of ST14 GTACTCAGACCCCACGCAGTGGACGGCCTTCCTGGGCTTGCACGACCAGGCCAGCGCAGCGCCCCTGGGGTGCAGGAGCGCAGGCTCAAGCGCATCATCTCCCACCCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTGGAGAAACCGGCAGAGTACAGCTCCATGGTGCGGCCCATCTGCCTGCCGGACGCCTCCCATGT CTTCCCTGCCGGCAAGGCCATCTGGGTCACGGGCTGGGGACACACCCAGTATGGAG SEQ ID NO:349 Exon 18 of ST14 GCACTGGCGCGCTGATCCTGCAAAAGGGTGAGATCCGCGTCATCAACCAGACCACCTGCGAGAACCTCCTGCCGCAGCAGATCACGCCGCGCATGATGTGCGTGGGCTTCCTCAGCGGCGGCGTGGACTCCTGCCAG SEQ ID NO:350 Exon 19 of ST14 GGTGATTCCGGGGGACCCCCTGTCCAGCGTGGAGGCGGATGGGCGGATCTTCCAGGCCGGTGTGGTGAGCTGGGGAGACGGCTGCGCTCAGAGGAACAAGCCAGGCGTGTACACAAGGCTCCCTCTGTTTCGGGACTGGATCAAAGAGAACACTGGGGTATAGGGGCCGGGGCCACCCAAATGTGTACACCTGCGGGGCCA CCCATCGTCCACCCCAGTGTGCACGCCTGCAGGCTGGAGACTGGACCGCTGACTGCACCAGCGCCCCAGAACATACACTGTGAACTCAATCTCCAGGGCTCAAATCTGCCTAGAAAACCTCTCGCTTCCTCAGCCTCCAAAGTGGAGCTGGGAGGTAGAAGGGGAGGACACTGGTGGTTCTACTGACCCAACTGGGGGCAAAGGTTTGAAGACACAGTC CCCCGCCAGCCCCAAGCTGGGCCGAGGCGCGTTTGTGCATATCTGCCTCCCCTGTCTCTAAGGAGCAGCGGGAACGGAGCTTCGGGGCTCTCTCAGTGAAGGTGGTGGGGCTGCCGGATCTGGGCTGTGGGGCCCTTGGGCCACGCTCTTGAGGAAGCCCAGGCTCGGAGGACCCTGGAAAACAGACGGGTCTGAGACTGAAATTGT TTTACCAGTCCCAGGGTGGACTTCAGTGTGTGTATTTGTGTAAATGAGTAAAACATTTTATTTCTTTTTA SEQ ID NO:351 full mRNA polynucleotide sequence SEQ ID NO:352 Translated polypeptide sequence of exon 1 of ST14 MGSDRARKGGGGPKDFGAGLKYNSRHE SEQ ID NO:353 Translated polypeptide sequence of ST14 exon 2 KVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAAVLIGLLLVLLGIGFLVWHLQ SEQ ID NO:354 Translated polypeptide sequence of exon 3 of ST14 RDVRVQKVFNGYMRITNENFVDAYENSNNSTEFVSLASKVKDA SEQ ID NO:355 Translated polypeptide sequence of exon 4 of ST14 LKLLYSGVPFLGPYHKESAVTAF SEQ ID NO:356 Translated polypeptide sequence of exon 5 of ST14 EGSVIAYYWSEFSIPQHLVEEAERVMAEERVVMLPPRARSLKSFVVTSVVAF SEQ ID NO:357 Translated polypeptide sequence of exon 6 of ST14 TDSKTVQRTQD SEQ ID NO:358 Translated polypeptide sequence of exon 7 of ST14 SCSFGLHARGVELMRFTTPGFPDSPYPAHARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALV SEQ ID NO:359 Translated polypeptide sequence of exon 8 of ST14 LCGTYPPSYNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMS SEQ ID NO:360 Translated polypeptide sequence of exon 9 of ST14 CGGRLRKAQGTFNSPYYPGHYPPNIDCTWNIE SEQ ID NO:361 Translated polypeptide sequence of exon 10 of ST14 VPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGE SEQ ID NO:362 Translated polypeptide sequence of exon 11 of ST14 YCGERSQFVVTSNSNKITVRFHSDQSYTDTGFLAEYLSYDSSD SEQ ID NO:363 Translated polypeptide sequence of exon 12 of ST14 NM_021978.4 CPGQFTCRTGRCIRKELRCDGWADCTDHSDELNC SEQ ID NO:364 Translated polypeptide sequence of exon 13 of ST14 CDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGC SEQ ID NO:365 Translated polypeptide sequence of exon 14 of ST14 CPAQTFRCSNGKCLSKSQQCNGKDDCGDGSDEASCPK SEQ ID NO:366 Translated polypeptide sequence of exon 15 of ST14 NVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEKDC SEQ ID NO:367 Translated polypeptide sequence of exon 16 of ST14 CGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYIDDRGF SEQ ID NO:368 Translated polypeptide sequence of exon 17 of ST14 YSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKPAEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYG SEQ ID NO:369 Translated polypeptide sequence of exon 18 of ST14 TGALILQKGEIRVINQTTCENLLPQQITPRMMCVGFLSGGVDSCQ SEQ ID NO:370 Translated polypeptide sequence of exon 19 of ST14 GDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYTRLPLFRDWIKENTGV SEQ ID NO:371 Full protein sequence MGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAAVLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKVKDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVMLPPR ARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPAHARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPSYNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHYPPNIDCTWNIEVPNNQ HVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTSNSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDHSDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSKSQQCNGKDDCGDGSDEASCPKVN VVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEKDCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYIDDRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKPAEYSSMVRPICLPDASHVFPAGKAIWVTGWG HTQYGGTGALILQKGEIRVINQTTCENLLPQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYTRLPLFRDWIKENTGV SEQ ID NO:372 The polynucleotide sequence of all 11 exons 1-11 of ST14 arranged in order SEQ ID NO:373 Translated polypeptide sequence of all 11 exons 1-11 of ST14 arranged in order THBS1 sequence informationSEQ ID NO: 374 THBS1 exon 9 sequence at 5' of THBS1-NRG1 fusion ACCCTGTGAAGGCGAAGCGCGGGAGACCAAAAGCCTGCAAGAAAGACGCCTGCCCCA SEQ ID NO: 375 NRG1 exon 6 sequence at 3' of THBS1-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTC SEQ ID NO: 376 THBS1-NRG1 polynucleotide sequence ACCCTGTGAAGGCGAAGCGCGGGAGACCAAAGCCTGCAAGAAAGACGCCTGCCCCACTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTC SEQ ID NO: 377 THBS1-NRG1 polypeptide sequence PCEGEARETKACKKDACPTTTSTTGTSHLVKCAEKEKTFCVNGGECF SEQ ID NO:378 Exon 1 of THBS1 AGCCGCTGCGCCCGAGCTGGCCTGCGAGTTCAGGGCTCCTGTCGCTCTCCAGGAGCAACCTCTACTCCGGACGCACAGGCATTCCCGCGCCCCCTCCAGCCCTCGCCGCCCTCGCCACCGCTCCCGGCCGCCGCGCTCCGGTACACACAG SEQ ID NO:379 Exon 2 of THBS1 GATCCCTGCTGGGCACCAACAGCTCCACCATGGGGCTGGCCTGGGGACTAGGCGTCCTGTTCCTGATGCATGTGTGTGGCACCAACCGCATTCCAG SEQ ID NO:380 Exon 3 of THBS1 AGTCTGGCGGAGACAACAGCGTGTTTGACATCTTTGAACTCACCGGGGCCGCCCGCAAGGGGTCTGGGCGCCGACTGGTGAAGGGCCCCGACCCTTCCAGCCCAGCTTTCCGCATCGAGGATGCCAACCTGATCCCCCCTGTGCCTGATGACAAGTTCCAAAGACCTGGTGGATGCTGTGCGGGCAGAAAAGGGTTTCCTCCTTCTGGCAT CCCTGAGGCAGATGAAGAAGACCCGGGGCACGCTGCTGGCCCTGGAAGACCACTCTGGCCAGGTCTTCAGCGTGGTGTCCAATGGCAAGGCGGGCACCCTGGACCCTCAGCCTGACCGTCCAAGGAAAAGCAGCACGTGGTGTCTGTGGAAGAAGCTCTCCTGGCAACCGGCCAGTGGAAGAGCATCCACCCTGTTTGTGCAGGAAGACAG GGCCCAGCTGTACATCGACTGTGAAAAGATGGAGAATGCTGAGTTGGACGTCCCCATCCAAAGCGTCTTCACCAGAGACCTGGCCAGCATCGCCAGACTCCGCATCGCAAAGGGGGGCGTCAATGACAATTTCCAG SEQ ID NO:381 Exon 4 of THBS1 GGGGTGCTGCAGAATGTGAGGTTTGTCTTTGGAACCACACCAGAAGACATCCTCAGGAACAAAGGCTGCTCCAGCT SEQ ID NO:382 Exon 5 of THBS1 CTACCAGTGTCCTCCTCACCCTTGACAACAACGTGGTGAATGGTTCCAGCCCTGCCATCCGCACTAACTACATTGGCCACAAGACAAAGGACTTGCAAGCCATCTGCGGCATCTCCTGTGATGAGCTGTCCAGCATGGTCCTGGAACTCAGGGGCCTGCGCACCATTGTGACCACGCTGCAGGACAGCATCCGCAAAGTG SEQ ID NO:383 Exon 6 of THBS1 ACTGAAGAGAACAAAGAGTTGGCCAATGAGCTGAGGCGGCCTCCCCTATGCTATCACAACGGAGTTCAGTACAGAAATAACGAGGAATGGACTGTTGATAGCTGCACTGAGTGTCACTGTCAG SEQ ID NO:384 Exon 7 of THBS1 AACTCAGTTACCATCTGCAAAAAGGTGTCCTGCCCCATCATGCCCTGCTCCAATGCCACAGTTCCTGATGGAGAATGCTGTCCTCGCTGTTGGC SEQ ID NO:385 Exon 8 of THBS1 CCAGCGACTCTGCGGACGATGGCTGGTCTCCATGGTCCGAGTGGACCTCCTGTTCTACGAGCTGTGGCAATGGAATTCAGCAGCGCGGCCGCTCCTGCGATAGCCTCAACAACCGATGTGAGGGCTCCTCGGTCCAGACACGGACCTGCCACATTCAGGAGTGTGACAAGAGAT SEQ ID NO:386 Exon 9 of THBS1 TTAAACAGGATGGTGGCTGGAGCCACTGGTCCCGTGGTCATCTTGTTCTGTGACATGTGGTGATGGTGTGATCACAAGGATCCGGCTCTGCAACTCTCCCAGCCCCCAGATGAACGGGAAACCCTGTGAAGGCGAAGCGCGGGAGACCAAAGCCTGCAAGAAAGACGCCTGCCCCA SEQ ID NO:387 The polynucleotide sequence of all 13 exons 10-22 of THBS1 arranged in order TTAAACAGGATGGTGGCTGGAGCCACTGGTCCCCGTGGTCATCTTGTTCTGTGACATGTGGTGATGGTGTGATCACAAGGATCCGGCTCTGCAACTCTCCCAGCCCCCAGATGAACGGGAAACCCTGTGAAGGCGAAGCGCGGGAGACCAAAGCTGCAAGAAAGACGCCTGCCCCATCAATGGAGGCTGGGGTCCTTGGTCACCATGG GACATCTGTTCTGTCACCTGTGGAGGAGGGGTACAGAAACGTAGTCGTCTCTGCAACAACCCCACACCCAGTTTGGAGGCAAGGACTGCGTTGGTGATGTAACAGAAAACCAGATCTGCAACAAGCAGGACTGTCCAATTGATGGATGCCTGTCCAATCCCTGCTTTGCCGGCGTGAAGTGTACTAGCTACCCTGATGGCAGCTGGAAATGTGGT GCTTGTCCCCCCTGGTTACAGTGGAAATGGCATCCAGTGCACAGATGTTGATGAGTGCAAAGAAGTGCCTGATGCCTGCTTCAACCACAATGGAGAGCACCGGTGTGAGAACACGGACCCCGGCTACAACTGCCTGCCCTGCCCCCCACGCTTCACCGGCTCACAGCCCTTCGGCCAGGGTGTCGAACATGCCACGGCCAACAAACAGGTGTGCAAGCCCCG TAACCCCTGCACGGATGGGACCCACGACTGCAACAAGAACGCCAAGTGCAACTACCTGGGCCACTATAGCGACCCCATGTACCGCTGCGAGTGCAAGCCTGGCTACGCTGGCAATGGCATCATCTGCGGGGAGGACACAGACCTGGATGGCTGCCCAATGAGAACCTGGTGTGCGTGGCCAATGCGACTTACCACTGCAAAAAGGATAATT GCCCCAACCTTCCCAACTCAGGGCAGGAAGACTATGACAAGGATGGAATTGGTGATGCCTGTGATGATGACGATGACAATGATAAAATTCCAGATGACAGGGACAACTGTCCATTCCATTACAACCCAGCTCAGTATGACTATGACAGAGATGATGTGGGAGACCGCTGTGACAACTGTCCCTACAACCACACCCAGATCAGGCAGACACAGACAACAATG GGGAAGGAGACGCCTGTGCTGCAGACATTGATGGAGACGGTATCCTCAATGAACGGGACAACTGCCAGTACGTCTACAATGTGGACCAGAGAGACACTGATATGGATGGGGTTGGAGATCAGTGTGACAATTGCCCCTTGGAACACAATCCGGATCAGCTGGACTCTCAGACCGCATTGGAGATACCTGTGACAACAATCAGGATATT GATGAAGATGGCCACCAGAACAATCTGGACAACTGTCCCTATGTGCCCAATGCCAACCAGGCTGACCATGACAAAGATGGCAAGGGAGATGCCTGTGACCACGATGATGACAACGATGGCATTCCTGATGACAAGGACAACTGCAGACTCGTGCCCAATCCCGACCAGAAGGACTCTGACGGCGATGGTCGAGGTGATGCCTGCAAAGATGATTTTGACC ATGACAGTGTGCCAGACATCGATGACATCTGTCCTGAGAATGTTGACATCAGTGAGACCGATTTCCGCCGATTCCAGATGATTCCTCTGGACCCCAAAGGGACATCCCCAAAATGACCTAACTGGGTTGTACGCCATCAGGGTAAAGAACTCGTCCAGACTGTCAACTGTGATCCTGGACTCGCTGTAGGTTATGATGAGTTTAATGCTGTGGACTTCA GTGGCACCTTCTTCATCAACACCGAAAGGGACGATGACTATGCTGGATTTGTCTTTGGCTACCAGTCCAGCAGCCGCTTTTATGTTGTGTGATGTGGAAGCAAGTCACCCAGTCCTACTGGGACACCAACCCCACGAGGGCTCAGGGATACTCGGGCCTTTCTGTGAAAGTTGTAAACTCCACACAGGGCCTGGCGAGCACCTGCGGAACGCCCTGTGGC ACACAGGAAACACCCCTGGCCAGGTGCGCACCCTGTGGCATGACCCTCGTCACATAGGCTGGAAAGATTTCACCGCCTACAGATGGCGTCTCAGCCACAGGCCAAAGACGGGTTTCATTAGAGTGGTGATGTATGAAGGGAAGAAAATCATGGCTGACTCAGGACCCATCTATGATAAAACCTATGCTGGTGGTAGACTAGGGTTGTTTGTCTCTC TCAAGAAATGGTGTTTCTTCTCTGACCTGAAATACGAATGTAGAGATCCCTAATCATCAAATTGTTGATTGAAAGACTGATCATAAACCAATGCTGGTATTGCACCTTCTGGAACTATGGGCTTGAGAAAACCCCCAGGATCACTTCTCTTGGCTTCCTTCTTTTCTGTGCTTGCATCAGTGTGGACTCCTAGAACGTGCGACCTGCCTCAAGAAAATGCAGTTTCA AAAACAGACTCAGCATTCAGCCTCCAATGAATAAGACATTCTCCAAGCATAAACAATTGCTTTGGTTCCTTTTGAAAAAGCATCTACTTGCTTCAGTTGGGAAGGTGCCCATTCCACTCTGCCTTTGTCACAGAGCAGGGTGCTATTGTGAGGCCATCTCTGAGCAGTGGACTCAAAAGCATTTTCAGGCATGTCAGAGAAGGGAGGACTCACTAGAATTAGCAAACAA ACCACCCTGACATCCTCCTTCAGGAACACGGGGAGCAGAGGCCAAAGCACTAAGGGGAGGGCGCATACCCGAGACGATTGTATGAAGAAAATATGGAGGAACTGTTACATGTTCGGTACTAAGTCATTTTCAGGGGATTGAAAGACTATTGCTGGATTTCATGATGCTGACTGGCGTTAGCTGATTAACCCATGTAAATAGGCACTTAAATAGAAGCAGGA AAGGGAGACAAAAGACTGGCTTCTGGACTTCCTCCCTGATCCCCACCTTACTCATCACCTGCAGTGGCCAGAATTAGGGAATCAGAATCAAACCAGTGTAAGGCAGTGCTGGCTGCCATTGCCTGGTCACATTGAAATTGGTGGCTTCATTCTAGATGTAGCTTGTGCAGATGTAGCAGGAAAATAGGAAAACCTACCATCTCAGTGAGCACCAGCTGCCTCCCA AAGGAGGGGCAGCCGTGCTTATATTTTTTATGGTTACAATGGCACAAAATTATTATCAACCTAACTAAAACATTCCTTTTCTCTTTTTTTCCTGAATTATCATGGAGTTTTTCTAATTCTCTCTTTTGGAATGTAGATTTTTTTTAAATGCTTTACGATGTAAAATATTTTTTTTACTTATTCTGGAAGATCTGGCTGAAGGATTATTCATGGAACAGGAAGAAGCGTA AAGACTATCCATGTCATCTTTGTTGAGAGTCTTCGTGACTGTAAGATTGTAAATACAGATTATTTATTAACTCTGTTCTGCCTGGAAATTTAGGCTTCATACGGAAAGTGTTTGAGAGCAAGTAGTTGACATTTATCAGCAAATCTCTTGCAAGAACAGCACAAGGAAAATCAGTCTAATAAGCTGCTCTGCCCCTTGTGCTCAGAGTGGATGTTATGGGATTCTTTTTTT CTCTGTTTTATTCTTTTCAAGTGGAATTAGTTGGTTATCCATTTGCAAATGTTTTAAAATTGCAAAGAAAGCCATGAGGTCTTCAATACTGTTTTACCCCATCCCTTGTGCATATTTCCAGGGAGAAGGAAAGCATATACACTTTTTTTTCTTCATTTTTCCAAAAGAAGAAAAAAAATGACAAAAGGTGAAACTTACATACAAATATTACTCATTTGTTGTGTGACTGAGTAAAGAAT TTTTGGATCAAGCGGAAAGAGTTTAAGTGTCTAACAAACTTAAAGCTACTGTAGTACCTAAAAAGTCAGTGTTGTACATAGCATAAAAACTCTGCAGAGAAGTATTCCCAATAAGGAAATAGCATTGAAATGTTAAATACAATTTCTGAAAGTTATGTTTTTTTTTCTATCATCTGGTATACCATTGCTTTATTTTTATAAATTTTTCTCATTGCCATTGGAATAGATATCTCAGA TTGTGTAGATATGCTATTTAAATAATTTATCAGGAAATACTGCCTGTAGAGTTAGTATTTCTATTTTATATAATGTTTGCACACTGAATTGAAGAATTGTTGGTTTTTCTTTTTTTTGTTTTGTTTTTTTTTTTTTTTTTTTTGCTTTTGACCTCCCATTTTTACTATTTGCCAATACCTTTTTCTAGGAATGTGCTTTTTTTTGTACACATTTTTATCCATTTACATTCTAAG CAGTGTAAGTTGTATATTACTGTTTCTTATGTACAAGGAACAACAATAAATCATATGGAAATTTATATTTTACTTACTGTATCCATGCTTATTTGTTCTCTACTGGCTTTATGTCATGAAGTATATGCGTAAATACCATTCATAAAATCAATATAGCATATACAAAAAATAAATTACAGTAAGTCATAGCAACATTCACAGTTTGTATGTGATTGAGAAAGACTGAGTTGCTCAG GCCTAGGCTTAGAATTTGCTGCGTTTGTGGAATAAAAGAACAAAATGATACATTAGCCTGCCATATCAA SEQ ID NO:388 full mRNA polynucleotide sequence SEQ ID NO:389 Translated polypeptide sequence of exon 2 of THBS1 MGLAWGLGVLFLMHVCGTNRIP SEQ ID NO:390 Translated polypeptide sequence of exon 3 of THBS1 SGGDNSVFDIFELTGAARKGSGRRLVKGPDPSSPAFRIEDANLIPPVPDDKFQDLVDAVRAEKGFLLLASLRQMKKTRGTLLALERKDHSGQVFSVVSNGKAGTLDLSLTVQGKQHVVSVEEALLATGQWKSITLFVQEDRAQLYIDCEKMENAELDVPIQSVFTRDLASIARLRIAKGGVNDNFQ SEQ ID NO:391 Translated polypeptide sequence of exon 4 of THBS1 GVLQNVRFVFGTTPEDILRNKGCSS SEQ ID NO:392 Translated polypeptide sequence of exon 5 of THBS1 TSVLLTLDNNVVNGSSPAIRTNYIGHKTKDLQAICGISCDELSSMVLELRGLRTIVTTLQDSIRKV SEQ ID NO:393 Translated polypeptide sequence of exon 6 of THBS1 TEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQ SEQ ID NO:394 Translated polypeptide sequence of exon 7 of THBS1 NSVTICKKVSCPIMPCSNATVPDGECCPRCW SEQ ID NO:395 Translated polypeptide sequence of exon 8 of THBS1 SDSADDGWSPWSEWTSCSTSCGNGIQQRGRSCDSLNNRCEGSSVQTRTCHIQECDKR SEQ ID NO:396 Translated polypeptide sequence of exon 9 of THBS1 KQDGGWSHWSPWSSCSVTCGDGVITRIRLCNSPSPQMNGKPCEGEARETKACKKDACP SEQ ID NO:397 The translated polypeptide sequence of all 13 exons 10-22 of THBS1 arranged in order KQDGGWSHWSPWSSCSVTCGDGVITRIRLCNSPSPQMNGKPCEGEARETKACKKDACPINGGWGPWSPWDICSVTCGGGVQKRSRLCNNNTPQFGGKDCVGDVTENQICNKQDCPIDGCLSNPCFAGVKCTSYPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDACFNHNGEHRCENTDPGY NCLCPPRFTGSQPFGQGVEHATANKQVCKPRNPCTDGTHDCNKNAKCNYLGHYSDPMYRCECKPGYAGNGIICGEDTDLDGWPNENLVCVANATYHCKKDNCPNLPNSGQEDYDKDGIGDACDDDDDNDKIPDDRDNCPFHYNPAQYDYDRDDVGDRCDNCPYNHNPDQADTDNNGEGDACAADIDGD GILNERDNCQYVYNVDQRDTMDDGVGDQCDNCPLEHNPDQLDSDSDRIGDTCDNNQDIDEDGHQNNLDNCPYVPNANQADHDKDGKGDACDHDDDNDGIPDDKDNCRLVPNPDQKDSDGDGRGDACKDDFDHDSVPDIDDICPENVDISETDFRRFQMIPLDPKGTSQNDPNWVVRHQGKELVQ TVNCDPGLAVGYDEFNAVDFSGTFFINTERDDDYAGFVFGYQSSSRFYVVMWKQVTQSYWDTNPTRAQGYSGLSVKVVNSTTGPGEHLRNALWHTGNTPGQVRTLWHDPRHIGWKDFTAYRWRLSHRPKTGFIRVVMYEGKKIMADSGPIYDKTYAGGRGLLFVFSQEMVFFSDL KYECRDP SEQ ID NO:398 Full protein sequence MGLAWGLGVLFLMHVCGTNRIPESGGDNSVFDIFELTGAARKGSGRRLVKGPDPSSPAFRIEDANLIPPVPDDKFQDLVDAVRAEKGFLLLASLRQMKKTRGTLLALERKDHSGQVFSVVSNGKAGTLDLSLTVQGKQHVVSVEEALLATGQWKSITLFVQEDRAQLYIDCEKMENAELDVPIQ SVFTRDLASIARLRIAKGGVNDNFQGVLQNVRFVFGTTPEDILRNKGCSSTSVLLTLDNNVVNGSSPAIRTNYIGHKTKDLQAICGISCDELSSMVLELRGLRTIVTTLQDSIRKVTEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQNSVTICKKVSCPIMPCSNATVPDGECCPRCWPSDSADD GWSPWSEWTSCSTSCGNGIQQRGRSCDSLNNRCEGSSVQTRTCHIQECDKRFKQDGGWSHWSPWSSCSVTCGDGVITRIRLCNSPSPQMNGKPCEGEARETKACKKDACPINGGWGPWSPWDICSVTCGGGVQKRSRLCNNPTPQFGGKDCVGDVTENQICNKQDCPIDGCLSNPCFAGVKCTS YPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDACFNHNGEHRCENTDPGYNCLPCPPRFTGSQPFGQGVEHATANKQVCKPRNPCTDGTHDCNKNAKCNYLGHYSDPMYRCECKPGYAGNGIICGEDTDLDGWPNENLVCVANATYHCKKDNCPNLPNSGQEDYDKDGIGDACDDDDDNDKIPDDRDNCPF HYNPAQYDYDRDDDVGDRCDNCPYNHNPDQADTDNNGEGDACAADIDGDGILNERDNCQYVYNVDQRDTDMDGVGDQCDNCPLEHNPDQLDSDSDRIGDTCDNNQDIDEDGHQNNLDNCPYVPNANQADHDKDGKGDACDHDDDNDGIPDDKDNCRLVPNPDQKDSDGDGRGDACKDDFDHD SVPDIDICPENVDISETDFRRFQMIPLDPKGTSQNDPNWVVRHQGKELVQTVNCDPGLAVGYDEFNAVDFSGTFFINTERDDDYAGFVFGYQSSSRFYVVMWKQVTQSYWDTNPTRAQGYSGLSVKVVNSTTGPGEHLRNALWHTGNTPGQVRTLWHDPRHIGWKDFTAYRWRLSHRPK TGFIRVVMYEGKKIMADSGPIYDKTYAGGRLGLFVFSQEMVFFSDLKYECRDP SEQ ID NO:399 The polynucleotide sequence of all nine exons 1-9 of THBS1 arranged in order SEQ ID NO:400 Translated polypeptide sequence of all 8 exons 2-9 of THBS1 arranged in order AGRN sequence informationSEQ ID NO: 401 AGRN exon 12 sequence at 5' of the AGRN-NRG1 fusion GTGTGCGGCTCAGATGGGGTCACCTACAGCACCGAGTGTGAGCTGAAGAAGGCCAGGTGTGAGTCACAGCGAGGGCTCTACGTAGCGGCCCAGGGAGCCTGCCGAG SEQ ID NO: 402 NRG1 exon 6 sequence at 3' of AGRN-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTCATGGTGAAAGAC SEQ ID NO:403 AGRN-NRG1 polynucleotide sequence GTGTGCGGCTCAGATGGGGTCACCTACAGCACCGAGTGTGAGCTGAAGAAGGCCAGGTGTGAGTCACAGCGAGGGCTCTACGTAGCGGCCCAGGGAGCCTGCCGAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTCATGGTGAAAGAC SEQ ID NO:404 AGRN-NRG1 polypeptide sequence VCGSDGVTYSTECELKKARCESQRGLYVAAQGACRATSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKD SEQ ID NO:405 AGRN exon 1 AGTCCCGTCCCCGGCGCGGCCCGCGCGCTCCTCCGCCGCCTCTCGCCTGCGCCATGGCCGGCCGGTCCCACCCGGGCCCGCTGCGGCCGCTGCTGCCGCTCCTTGTGGTGGCCGCGTGCGTCCTGCCCGGAGCCGGCGGGACATGCCCGGAGCGCGCGCTGGAGCGGCGCGAGGAGGAGGCGAACGTGGTGCTCACCGGG ACGGTGGAGGAGATCCTCAACGTGGACCCGGTGCAGCACACGTACTCCTGCAAG SEQ ID NO:406 AGRN exon 2 GTTCGGGTCTGGCGGTACTTGAAGGGCAAAGACCTGGTGGCCCGGGAGAGCCTGCTGGACGGCGGCAACAAGGTGGTGATCAGCGGCTTTGGAGACCCCCTCATCTGTGACAACCAGGTGTCCACTGGGGACACCAGGATCTTCTTTGTGAACCCCTGCACCCCCATACCTGTGGCCAGCCCACAAGAACGAGCTGATGCTCAACTCCAGCCTC ATGCGGATCACCCTGCGGAACCTGGAGGAGGTGGAGTTCTGTGTGGAAG SEQ ID NO:407 AGRN exon 3 ATAAACCCGGGACCCACTTCACTCCAGTGCCTCCGACGCCTCCTGATG SEQ ID NO:408 AGRN exon 4 CGTGCCGGGGAATGCTGTGCGGCTTCGGCGCCGTGTGCGAGCCCAACGCGGAGGGGCCGGGCCGGGCGTCCTGCGTCTGCAAGAAGAGCCCGTGCCCCAGCGTGGTGGCGCCTGTGTGTGGGTCGGACGCCTCCACCTACAGCAACGAATGCGAGCTGCAGCGGGCGCAGTGCAGCCAGCAGCGCCGCATCCGCCTGCTCAGCCGCG GGCCGTGCG SEQ ID NO:409 AGRN exon 5 GCTCGCGGGACCCCCTGCTCCAACGTGACCTGCAGCTTCGGCAGCACCTGTGCGCGCTCGGCCGACGGGCTGACGGCCTCGTGCCTGTGCCCCGCGACCTGCCGTGGCGCCCCCGAGGGGACCGTCTGCGGCAGCGACGGCGCCGACTACCCCGGCGAGTGCCAGCTCCTGCGCCGCGCCTGCGCCCGCCAGGAGAATGTCTTAAGAAGT TCGACGGCCCTTGTG SEQ ID NO:410 AGRN exon 6 ACCCCTGTCAGGGCGCCCTCCCTGACCCGAGCCGCAGCTGCCGTGTGAACCCGCGCACGCGGCGCCCTGAGATGCTCCTACGGCCCGAGAGCTGCCCTGCCCGGCAGGCGCCAGTGTGTGGGGACGACGGAGTCACCTACGAAAACGACTGTGTCATGGGCCGATCGGGGGCCGCCCGGGGTCTCCTCCTGCAGAAAGTGCGCTCCG GCCAGTGCCAGGGTCGAG SEQ ID NO:411 AGRN exon 7 ACCAGTGCCCGGAGCCCTGCCGGTTCAATGCCGTGTGCCTGTCCCGCCGTGGCCGTCCCCGCTGCTCCTGCGACCGCGTCACCTGTGACGGGGCCTACAGGCCCGTGTGTGCCCAGGACGGGCGCACGTATGACAGTGATTGCTGGCGGCAGCAGGCTGAGTGCCGGCAGCAGCGTGCCATCCCCAGCAAGCACCAGGGCCCGTGTG SEQ ID NO:412 AGRN exon 8 ACCAGGCCCCGTCCCCATGCCTCGGGGTGCAGTGTGCATTTGGGGCGACGTGTGCTGTGAAGAACGGGCAGGCAGCGTGTGAATGCCTGCAGGCGTGCTCGAGCCTCTACGATCCTGTGTGCGGCAGCGACGGCGTCACATACGGCAGCGCGTGCGAGCTGGAGGCCACGGCCTGTACCCTCGGGCGGGAGATCCAGGTGGCGCGCAAAG GACCCTGTG SEQ ID NO:413 AGRN exon 9 ACCGCTGCGGGCAGTGCCGCTTTGGAGCCCTGTGCGAGGCCGAGACCGGGCGCTGCGTGTGCCCCTCTGAATGCGTGGCTTTGCCCAGCCCGTGTGTGGCTCCGACGGGCACACGTACCCAGCGAGTGCATGCTGCACGTGCACGCCTGCACACACCAGATCAGCTGCACGTGGCCTCAGCTGGACCCTGTG SEQ ID NO:414 AGRN exon 10 AGACCTGTGGAGATGCCGTGTGTGCTTTTGGGGCTGTGTGCTCCGCAGGGCAGTGTGTGTGTCCCCGGTGTGAGCACCCCCCGCCCGGCCCCGTGTGTGGCAGCGACGGTGTCACCTACGGCAGTGCCTGCGAGCTACGGGAAGCCGCCTGCCTCCAGCAGACACAGATCGAGGAGGCCCGGGCAGGGCCGTGCGAGCAGG SEQ ID NO:415 AGRN exon 11 CCGAGTGCGGTTCCGGAGGCTCTGGCTCTGGGGAGGACGGTGACTGTGAGCAGGAGCTGTGCCGGCAGCGCGGTGGCATCTGGGACGAGGACTCGGAGGACGGGCCGTGTGTCTGTGACTTCAGCTGCCAGAGTGTCCCAGGCAGCCCG SEQ ID NO:416 AGRN exon 12 GTGTGCGGCTCAGATGGGGTCACCTACAGCACCGAGTGTGAGCTGAAGAAGGCCAGGTGTGAGTCACAGCGAGGGCTCTACGTAGCGGCCCAGGGAGCCTGCCGAG SEQ ID NO:417 The polynucleotide sequence of all 27 exons 13-39 of AGRN arranged in order GCCCCACCTTCGCCCCGCTGCCGCCTGTGGCCCCCTTACACTGTGCCCAGACGCCCTACGGCTGCTGCCAGGACAATATCACCGCAGCCCGGGGCGTGGGCCTGGCTGGCTGCCCCAGTGCCTGCCAGTGCAACCCCCATGGCTCTTACGGCGGCACCTGTGACCCAGCCACAGGCCAGTGCTCCTGCCGCCCAGGTGTGGGGGGCCTCAG GTGTGACCGCTGTGAGCCTGGCTTCTGGAACTTTCGAGGCATCGTCACCGATGGCCGGAGTGGCTGTACACCCTGCAGCTGTGATCCCCAAGGCGCCGTGCGGGATGACTGTGAGCAGATGACGGGGCTGTGCTCGTGTAAGCCCGGGGTGGCTGGACCCAAGTGTGGGCAGTGTCCAGACGGCCGTGCCCTGGGCCCCGCGGGCT GTGAAGCTGACGCTTCTGCGCCTGCGACCTGTGCGGAGATGCGCTGTGAGTTCGGTGCGCGGTGCGTGGAGGAGTCTGGCTCAGCCCACTGTGTCTGCCCGATGCTCACCTGTCCAGAGGCCAACGCTACCAAGGTCTGTGGGTCAGATGGAGTCACATACGGCAACGAGTGTCAGCTGAAGACCATCGCCTGCCGCCAGGGCCTGCAAATTCTATCCAGA GCCTGGGCCCGTGCCAGGAGGCTGTTGCTCCCAGCACTCACCCGACATCTGCCTCCGTGACTGTGACCACCCCAGGGCTCCTCCTGAGCCAGGCACTGCCGGCCCCCCCCGGCGCCCTCCCCCTGGCTCCCAGCAGTACCGCCACAGCCAGACCACCCCTCCGCCCTCATCACGACCTCGGACCACTGCCAGCGTCCCCAGGACCACGTGTGGCCCGT GCTGACGGTGCCCCCCACGGCACCCTCCCCTGCACCCAGCCTGGTGGCGTCCGCCTTTGGTGAATCTGGCAGCACTGATGGAAGCAGCGATGAGGAACTGAGCGGGGACCAGGAGGCCAGTGGGGGTGGCTCTGGGGGGCTCGAGCCCTTGGAGGGCAGCAGCGTGGCCACCCCTGGGCCACCTGTCGAGAGGGCTTCCTGCTA CAACTCCGCGTTGGGCTGCTGCTCTGATGGGAAGACGCCCTCGCTGGACGCAGAGGGCTCCAACTGCCCCGCCACCAAGGTGTTCCAGGGCGTCCTGGAGCTGGAGGGCGTCGAGGGCCAGGAGCTGTTCTACACGCCCGAGATGGCTGACCCCAAGTCAGAACTGTTCGGGGAGACAGCCAGGAGCATTGAGAGCACCCTGG ACGACCTCTTCCGGAATTCAGACGTCAAGAAGGATTTTCGGAGTGTCCGCTTGCGGGACCTGGGGCCCGGCAAATCCGTCCGCGCCATTGTGGATGTGCACTTTGACCCCACCACAGCCTTCAGGGCACCCGACGTGGCCCGGGCCCTGCTCCGGCAGATCCAGGTGTCCAGGCGCCGGTCCTTGGGGGTGAGGCGGCCGCTGCAGGAGCACGT GCGATTTATGGACTTTGACTGGTTTCCTGCGTTTATCACGGGGGCCACGTCAGGAGCCATTGCTGCGGGAGCCACGGCCAGAGCCACCACTGCATCGCGCCTGCCGTCCTCTGCTGTGACCCCTCGGGCCCCGCACCCCAGTCACACAAGCCAGCCGTTGCCAAGACCACGGCAGCCCCCACCACACGTCGGCCCCCCACCACTGCCCCCAGCC GTGTGCCCGGACGTCGGCCCCCGGCCCCCCAGCAGCCTCCAAAGCCCTGTGACTCACAGCCCTGCTTCCACGGGGGGACCTGCCAGGACTGGGCATTGGGCGGGGGCTTCACCTGCAGCTGCCCGGCAGGCAGGGGAGGCGCCGTCTGTGAGAAGGTGCTTGGCGCCCCTGTGCCGGCCTTCGAGGGCCGCTCCTTCCTGGCCTTCCCCA CTCTCCGCGCCTACCACACGCTGCGCCTGGCACTGGAATTCCGGGCGCTGGAGCCTCAGGGGCTGCTGCTGTACAATGGCAACGCCCGGGGCAAGGACTTCCTGGCATTGGCGCTGCTAGATGGCCGCGTGCAGCTCAGGTTTGACACAGGTTCGGGGCCGGCGGTGCTGACCAGTGCCGTGCCGGTAGAGCCGGGCCAGT GGCACCGCCTGGAGCTGTCCCGGCACTGGCGCCGGGGCACCCTCTCGGTGGATGGTGAGACCCCTGTTCTGGGCGAGAGTCCCAGTGGCACCGACGGCCTCAACCTGGACACAGACCTTTGTGGGCGGCGTACCCGAGGACCAGGCTGCCGTGGCGCTGGAGCGGACCTTCGTGGGCGCCGGCCTGAGGGGGTGCATCC GTTTGCTGGACGTCAACAACCAGCGCCTGGAGCTTGGCATTGGGCCGGGGGGCTGCCACCCGAGGCTCTGGCGTGGGCGAGTGCGGGGACCACCCCTGCCTGCCCAACCCCTGCCATGGCGGGGCCCCATGCCAGAACCTGGAGGCTGGAAGGTTCCATTGCCAGTGCCCGCCCGGCCGCGTCGGACCAACCTGTGCCGATGAGA AGAGCCCCTGCCAGCCCAACCCCTGCCATGGGGCGGCGCCCTGCCGTGTGCTGCCCGAGGGTGGTGCTCAGTGCGAGTGCCCCCTGGGGCGTGAGGGCACCTTCTGCCAGACAGCCTCGGGGCAGGACGGCTCTGGGCCCTTCCTGGCTGACTTCAACGGCTTCTCCCACCTGGAGCTGAGAGGCCTGCACACCTTTGCACGGG ACCTGGGGGAGAAGATGGCGCTGGAGGTCGTGTTCCTGGCACGAGGCCCCAGCGGCCTCCTGCTCTACAACGGGCAGAAGACGGACGGCAAGGGGGACTTCGTGTCGCTGGCACTGCGGGACCGCCGCCTGGAGTTCCGCTACGACCTGGGCAAGGGGGCAGCGGTCATCAGGAGCAGGGAGCCAGTCACCCTGGGAGCCT GGACCAGGGTCTCACTGGAGCGAAACGGCCGCAAGGGTGCCCTGCGTGTGGGCGACGGCCCCCGTGTGTTGGGGGAGTCCCCCGAAATCCCGCAAGGTTCCGCACACCGTCCTCAACCTGAAGGAGCCGCTCTACGTAGGGGGCGCTCCCGACTTCAGCAAGCTGGCCCGTGCTGCTGCCGTGTCCTCTGGCTTCGACGGTGCCATCCAG CTGGTCTCCCTCGGAGGCCGCCAGCTGCTGACCCCGGAGCACGTGCTGCGGCAGGTGGACGTCACGTCCTTTGCAGGTCACCCCTGCACCCGGGCCTCAGGCCACCCCTGCCTCAATGGGGCCTCCTGCGTCCCGAGGGAGGCTGCCTATGTGTGCCTGTGTCCCGGGGGATTCTCAGGACCGCACTGCGAGAAGGGGCTGGTGGA GAAGTCAGCGGGGGACGTGGATACCTTGGCCTTTGACGGGCGGACCTTGTCGAGTACCTCAACGCTGTGACCGAGAGCGAACTGGCCAATGAGATCCCCGTCCCCGAAACTCTGGATTCCGGGGCCCTTCACAGCGAGAAGGCACTGCAGAGCAACCACTTTGAACTGAGCCTGCGCACTGAGGCCACGCAGGGGCTGGTGCTCTGGAGTG GCAAGGCCACGGAGCGGGCAGACTATGTGGCACTGGCCATTGTGGACGGGCACCTGCAACTGAGCTACAACCTGGGCTCCCAGCCCGTGGTGCTGCGTTCCACCGTGCCCGTCAACACCAACCGCTGGTTGCGGGTCGTGGCACATAGGGAGCAGAGGGAAGGTTCCCTGCAGGTGGGCAATGAGGCCCCTGTGACCGGCTCCTCCCCGCT GGGCGCCACGCAGCTGGACACTGATGGAGCCCTGTGGCTTGGGGGCCTGCCGGAGCTGCCCGTGGGCCCAGCACTGCCCAAGGCCTACGGCACAGGCTTTGTGGGCTGCTTGCGGGACGTGGTGGTGGGCCGGCACCCGCTGCACCTGCTGGAGGACGCCGTCACCAAGCCAGAGCTGCGGCCCTGCCCCACCCCATGAGCTG GCACCAGAGCCCCGCGCCCGCTGTAATTATTTTCTATTTTTGTAAACTTGTTGCTTTTTGATATGATTTTCTTGCCTGAGTGTTGGCCGGAGGGACTGCTGGCCCGGCCTCCCTTCCGTCCAGGCAGCCGTGCTGCAGACAGACCTAGTGCCGAGGGATGGACAGGCGAGGTGGCAGCGTGGAGGGCTCGGCGTGGATGGCAGCCTCAGG ACACACACCCCTGCCTCAAGGTGCTGAGCCCCCGCCTTGCACTGCGCCTGCCCCACGGTGTCCCCGCCGGGAAGCAGCCCCGGCTCCTGAATCACCCTCGCTCCGTCAGGCGGGACTCGTGTCCCAGAGAGGAAGGGGCTGCTGAGGTCTGATGGGGCCCTTCCTCCGGGTGACCCCACAGGGCCTTTCCAAGCCCCCATTTGAGCTGCTCTCTC CTGTGTGTGCTCTGGGCCCTGCCTCGGCCTCCTGCGCCAATACTGTGACTTCCAAACAATGTTACTGCTGGGCACAGCTCTGCGTTGCTCCCGTGCTGCCTGCGCCAGCCCCAGGCTGCTGAGGAGCAGAGGCCAGACCAGGCCGATCTGGGTGTCCTGACCCTCAGCTGGCCCTGCCCAGCCACCCTGGACGTGACCGTATCCCTCTGCCACACC CCAGGCCCTGCGAGGGGCTATCGAGAGGAGCTCACTGTGGGATGGGGTTGACCCTCTGCCGCCTGCCTGGGTATCTGGGCCTGGCCATGGCTGTGTTCTTCATGTGTTGATTTTATTTGACCCCTGGAGTGGTGGGTCTCATCTTTCCCATCTCGCCTGAGAGCGGCTGAGGGCTGCCTCACTGCAAATCCTCCCCACAGCGTCAGTGAA AGTCGTCCTTGTCTCCAGAATGACCAGGGGCCAGCCAGTGTCTGACCAAGGTCAAGGGGCAGGTGCAGAGGTGGCAGGGATGGCTCCGAAGCCAGAAATGCCTTAAACTGCAACGTCCCGTCCCTCCCCACCCCCATCCCATCCCCACCCCCAGCCCCAGCCCAGTCTCCTAGGAGCAGGACCCGATGAAGCGGGCGGCGGTGGGGCTGGGTGCCGTGT TACTAACTCTAGTATGTTTCTGTGTCAATCGCTGTGAAATAAAGTCTGAAAACTTTAAAA SEQ ID NO:418 full mRNA polynucleotide sequence SEQ ID NO:419 Translated polypeptide sequence of exon 1 of AGRN MAGRSHGPPLRPLLPLLVVAACVLPGAGGTCPERALERREEEANVVLTGTVEEILNVDPVQHTYSCK SEQ ID NO:420 Translated polypeptide sequence of exon 2 of AGRN VRVWRYLKGKDLVARESLLDGGNKVVISGFGDPLICDNQVSTGDTRIFFVNPAPPYLWPAHKNELMLNSSLMRITLRNLEEVEFCVE SEQ ID NO:421 Translated polypeptide sequence of exon 3 of AGRN KPGTHFTPVPPTPPD SEQ ID NO:422 Translated polypeptide sequence of exon 4 of AGRN CRGMLCGFGAVCEPNAEGPGRASCVCKKSPCPSVVAPVCGSDASTYSNECELQRAQCSQQRRIRLLSRGPC SEQ ID NO:423 Translated polypeptide sequence of exon 5 of AGRN SRDPCSNVTCSFGSTCARSADGLTASCLCPATCRGAPEGTVCGSDGADYPGECQLLRRACARQENVFKKFDGPC SEQ ID NO:424 Translated polypeptide sequence of exon 6 of AGRN PCQGALPPDPSRSCRVNPRTRRPEMLLRPESCPARQAPVCGDDGVTYENDCVMGRSGAARGLLLQKVRSGQCQGR SEQ ID NO:425 Translated polypeptide sequence of exon 7 of AGRN QCPEPCRFNAVCLSRRGRPRCSCDRVTCDGAYRPVCAQDGRTYDSDCWRQQAECRQQRAIPSKHQGPC SEQ ID NO:426 Translated polypeptide sequence of exon 8 of AGRN QAPSPCLGVQCAFGATCAVKNGQAACECLQACSSLYDPVCGSDGVTYGSACELEATACTLGREIQVARKGPC SEQ ID NO:427 Translated polypeptide sequence of exon 9 of AGRN RCGQCRFGALCEAETGRCVCPSECVALAQPVCGSDGHTYPSECMLHVHACTHQISLHVASAGPC SEQ ID NO:428 Translated polypeptide sequence of exon 10 of AGRN TCGDAVCAFGAVCSAGQCVCPRCEHPPPGPVCGSDGVTYGSACELREAACLQQTQIEEARAGPCEQ SEQ ID NO:429 Translated polypeptide sequence of exon 11 of AGRN ECGSGGSGSGEDGDCEQELCRQRGGIWDEDSEDGPVCDFSCQSVPGSP SEQ ID NO:430 Translated polypeptide sequence of exon 12 of AGRN VCGSDGVTYSTECELKKARCESQRGLYVAAQGACR SEQ ID NO:431 The translated polypeptide sequence of all 27 exons 12-39 of AGRN arranged in order VCGSDGVTYSTECELKKARCESQRGLYVAAQGACRGPTFAPLPPVAPLHCAQTPYGCCQDNITAARGVGLAGCPSACQCNPHGSYGGTCDPATGQCSCRPGVGGLRCDRCEPGFWNFRGIVTDGRSGCTPCSCDPQGAVRDDCEQMTGLCSCKPGVAGPKCGQCPDGRALGPAGCEADASAPATCAEMRCEFGARCVE ESGSAHCVCPMLTCPEANATKVCGSDGVTYGNECQLKTIACRQGLQISIQSLGPCQEAVAPSTHPTSASVTVTTPGLLLSQALPAPPGALPLAPSSTAHSQTTPPPSSRPRTTASVPRTTVWPVLTVPPTAPSPAPSLVASAFGESGSTDGSSDEELSGDQEASGGGSGGLEPLEGSSVATPGPPVERASCYNSALGCCSDGKTPSLDA EGSNCPATKVFQGVLELEGVEGQELFYTPEMADPKSELFGETARSIESTLDDLFRNSDVKKDFRSVRLRDLPGGKSVRAIVDVHFDPTTAFRAPDVARALLRQIQVSRRRSLGVRRPLQEHVRFMDFDWFPAFITGATSGAIAAGATARATTASRLPSSAVTPRAPHPSHTSQPVAKTTAAPTTRRPPTAPSRVPGRRPP APQQPPKPCDSQPCFHGGTCQDWALGGGFTCSCPAGRGGAVCEKVLGAPVPAFEGRSFLAFPTLRAYHTRLLALEFRALEPQGLLLYNGNARGKDFLALALLDGRVQLRFDTGSGPAVLTSAVPVEPGQWHRLELSRHWRRGTLSVDGETPVLGESPSGTDGLNLDTDLFVGGVPEDQAAVALERTFV GAGLRGCIRLLDVNNQRLELEGPGGAATRGSGVGECGDHPCLPNPCHGGAPCQNLEAGRFHCQCPPGRVGPTCADEKSPCQPNPCHGAAPCRVLPEGGAQCECPLGREGTFCQTASGQDGSGPFLADFNGFSHLELRGLHTFARDLGEKMALEVVFLARGPSGLLLYNGQKTDGKGDFVSLALRDRRLEFRYDLG KGAAVIRSREPVTLGAWTRVSLERNGRKGALRVGDGPRVLGESPKSRKVPHTVLNLKEPLYVGGAPDFSKLARAAAVSSGFDGAIQLVSLGGRQLLTPEHVLRQVDVTSFAGHPCTRASGHPCLNGASCVPREAAYVCLCPGGFSGPHCEKGLVEKSAGDVDTLAFDGRTFVEYLNAVTESELANEIPV PETLDSGALHSEKALQSNHFELSLRTEATQGLVLWSGKATERADYVALAIVDGHLQLSYNLGSQPVVLRSTVPVNTNRWLRVVAHREQREGSLQVGNEAPVTGSSPLGATQLDTDGALWLGGLPELPVGPALPKAYGTGFVGCLRDVVVGRHPLHLLEDAVTKPELRPCPTP SEQ ID NO:432 Full protein sequence MAGRSHGPPLRPLLPLLVVAACVLPGAGGTCPERALERREEEANVVLTGTVEEILNVDPVQHTYSCKVRVWRYLKGKDLVARESLLDGGNKVVISGFGDPLICDNQVSTGDTRIFFVNPAPPYLWPAHKNELMLNSSLMRITLRNLEEVEFCVEDKPGTHFTPVPTPDACRGMLCGFGAVCEPNAEGPGRASCVCK KSPCPSVVAPVCGSDASTYSNECELQRAQCSQQRRIRLLSRGPCGSRDPCSNVTCSFGSTCARSADGLTASCLCPATCRGAPEGTVCGSDGADYPGECQLLRRACARQENVFKKFDGPCDPCQGALPDPRSCRVNPRTRRPEMLLRPESCPARQAPVCGDDGVTYENDCVMGRSGAARGLLLQKVRSGQCQGRDQCPEPCR FNAVCLSRRGRPRCSCDRVTCDGAYRPVCAQDGRTYDSDCWRQQAECRQQRAIPSKHQGPCDQAPSPCLGVQCAFGATCAVKNGQAACECLQACSSLYDPVCGSDGVTYGSACELEATLGREIQVARKGPCDRCGQCRFGALCEAETGRCVCPSECVALAQPVCGSDGHTYPSECMLHVHACTHQISLHVASAGP CETCGDAVCAFGAVCSAGQCVCPRCEHPPPGPVCGSDGVTYGSACELREAACLQQTQIEEARAGPCEQAECGSGGSGSGEDGDCEQELCRQRGGIWDEDSEDGPVCDFSCQSVPPGSPVCGSDGVTYSTECELKKARCESQRGLYVAAQGACRGPTFAPLPPVAPLHCAQTPYGCCQDNITAARGVGLAGCPSACQCN PHGSYGGTCDPATGQCSCRPGVGGLRCDRPGVGGLRCDRPGFWNFRGIVTDGRSGCTPCSCDPQGAVRDDCEQMTGLCSCKPGVAGPKCGQCPDGRALGPAGCEADASAPATCAEMRCEFGARCVEESGSAHCVCPMLTCPEANATKVCGSDGVTYGNECQLKTIACRQGLQISIQSLGPCQEAVAPSTHPTSASVTVTTPGLLLSQALPAPP GALPLAPSSTAHSQTTPPPSSSRPRTTASVPRTTVWPVLTVPTAPSPAPSLVASAFGESGSTDGSSDEELSGDQEASGGGSGGLEPLEGSSVATPGPPVERASCYNSALGCCSDGKTPSLDAEGSNCPATKVFQGVLELEGVEGQELFYTPEMADPKSELFGETARSIESTLDDLFRNSDVKKDFRSVRLRRLGPGKSVRAIVDV HFDPTTAFRAPDVARALLRQIQVSRRRSLGVRRPLQEHVRFMDFDWFPAFITGATSGAIAAGATARATTASRLPSSAVTPRAPHPSHTSQPVAKTTAAPTTRRPPTTAPSRVPGRRPAPQQPPKPCDSQPCFHGGTCQDWALGGGFTCSCPAGRGGAVCEKVLGAPVPAFEGRSFLAFPTLRAYHTLRLALEFRALEPQGLLL YNGNARGKDFLALALLDGRVQLRFDTGSGPAVLTSAVPVEPGQWHRLELSRHWRRGTLSVDGETPVLGESPSGTDGLNLDTDLFVGGVPEDQAAVALERTFVGAGLRGCIRLLDVNNQRLELEGPGGAATRGSGVGECGDHPCLPNPCHGGAPCQNLEAGRFHCQCPPGRVGPTCADEKSPCQPNP CHGAAPCRVLPEGGAQCECPLGREGTFCQTASGQDGSGPFLADFNGFSHLELRGLHTFARDLGEKMALEVVFLARGPSGLLLYNGQKTDGKGDFVSLALRDRRLEFRYDLGKGAAVIRSREPVTLGAWTRVSLERNGRKGALRVGDGPRVLGESPKSRKVPHTVLNLKEPLYVGGAPDFSKLARAAAVSSGFD GAIQLVSLGGRQLLTPEHVLRQVDVTSFAGHPCTRASGHPCLNGASCVPREAAYVCLCPGGFSGPHCEKGLVEKSAGDVDTLAFDGRTFVEYLNAVTESELANEIPVPETLDSGALHSEKALQSNHFELSLRTEATQGLVLWSGKATERADYVALAIVDGHLQLSYNLGSQPVVLRSTVPVNTNRWL RVVAHREQREGSLQVGNEAPVTGSSPLGATQLDTDGALWLGGLPELPVGPALPKAYGTGFVGCLRDVVVGRHPLHLLEDAVTKPELRPCPTP SEQ ID NO:433 The polynucleotide sequence of all 12 exons 1-12 of AGRN arranged in order SEQ ID NO:434 Translated polypeptide sequence of all 12 exons 1-12 of AGRN arranged in order PVALB sequence informationSEQ ID NO: 435 PVAPB exon 4 sequence at 5' of PVALB-NRG1 fusion TAAAAGGCTTCTCCCCAGATGCCAGAGACCTGTCTGCTAAAGAAACCAAGATGCTGATGGCTGCTGGAGACAAAGATGGGGACGGCAAAATTGGGGTTGACG SEQ ID NO: 436 NRG1 exon 6 sequence at 3' of PVALB-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTCATGGTGAAAGACCTTCAAACCCCTCGAGATACTTG SEQ ID NO:437 PVALB-NRG1 polynucleotide sequence TAAAAGGCTTCTCCCCCAGATGCCAGAGACCTGTCTGCTAAAGAAACCAAGATGCTGATGGCTGCTGGAGACAAAGATGGGGACGGCAAAATTGGGGTTGACGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCTTCATGGTGAAAGACCTTCA AACCCCTCGAGATACTTG SEQ ID NO:438 PVALB-NRG1 polypeptide sequence KGFSPDARDLSAKETKMLMAAGDKDGDGKIGVDATSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYL SEQ ID NO:439 PVALB exon 1 ACTTCCCGACAGGACTTCCCACCAGCCCCAGCCTTTCAGTGCAGGCTCCAGCCCTCCACCCCCACCCGAG SEQ ID NO:440 PVALB exon 2 TTGCAGGATGTCGATGACAGACTTGCTGAACGCTGAGGACATCAAGAAGGCGGTGGGAGCCTTTAGCG SEQ ID NO:441 PVALB exon 3 CTACCGACTCCTTCGACCACAAAAAGTTCTTCCAAATGGTCGGCCTGAAGAAAAAGAGTGCGGATGATGTGAAGAAGGTGTTTCACATGCTGGACAAGGACAAAAGTGGCTTCATCGAGGAGGATGAGCTGGG SEQ ID NO:442 PVALB exon 4 ATTCATCCTAAAAGGCTTCTCCCCAGATGCCAGAGACCTGTCTGCTAAAGAAACCAAGATGCTGATGGCTGCTGGAGACAAAGATGGGGACGGCAAAATTGGGGTTGACG SEQ ID NO:443 PVALB exon 5 AATTCTCCACTCTGGTGGCTGAAAGCTAAGAAGCACTGACTGCCCCTGGTCTTCCACCTCTCTGCCCTGAACACCCAATCTCGGCCCCTCTCGCCACCCTCCTGCATTTCTGTTCAGTTCGTTTTATGTTTTTTTTACTCCCCCATCCCCTGTGGCCCTCTCTAATGACACCATTCTTCTGGAAAATGCTGGAGAAGCAATAAAGGTTGTACCAGTCA SEQ ID NO:444 full mRNA polynucleotide sequence ACTTCCCGACAGGACTTCCCACCAGCCCAGCCTTTCAGTGCAGGCTCCAGCCCTCCACCCCCACCCGAGTTGCAGGATGTCGATGACAGACTTGCTGAACGCTGAGGACATCAAGAAGGCGGTGGGAGCCTTTAGCGCTACCGACTCCTTCGACCACAAAAAGTTCTTCCAAATGGTCGGCCTGAAGAAAAGAGTGCGGATGATGTGAAGAAGGTGT TTCACATGCTGGACAAGGACAAAAGTGGCTTCATCGAGGAGGATGAGCTGGGATTCATCCTAAAAGGCTTCTCCCCAGATGCCAGAGACCTGTCTGCTAAAGAAACCAAGATGCTGATGGCTGCTGGAGACAAAGATGGGGACGGCAAAATTGGGGTTGACGAATTCTCCACTCTGGTGGCTGAAAGCTAAAGAAGCACTGACTGCCCCTG GTCTTCCACCTCTCTGCCCTGAACACCCAATCTCGGCCCCTCTCGCCACCCTCCTGCATTTCTGTTCAGTTCGTTTATGTTTTTTACTCCCCCATCCCCTGTGGCCCTCTAATGACACCATTCTTCTGGAAAATGCTGGAGAAGCAATAAAGGTTGTACCAGTCA SEQ ID NO:445 Translated polypeptide sequence of exon 2 of PVALB MSMTDLLNAEDIKKAVGAFS SEQ ID NO:446 Translated polypeptide sequence of exon 3 of PVALB TDSFDHKKFFQMVGLKKKSADDVKKVFHMLDKDKSGFIEEDEL SEQ ID NO:447 Translated polypeptide sequence of exon 4 of PVALB FILKGFSPDARDLSAKETKMLMAAGDKDGDGKIGVD SEQ ID NO:448 Translated polypeptide sequence of exon 5 of PVALB FSTLVAES SEQ ID NO:449 Full protein sequence MSMTDLLNAEDIKKAVGAFSATDSFDHKKFFQMVGLKKKSADDVKKVFHMLDKDKSGFIEEDELGFILKGFSPDARDLSAKETKMLMAAGDKDGDGKIGVDEFSTLVAES SEQ ID NO:450 The polynucleotide sequence of all four exons 1-4 of PVALB arranged in order SEQ ID NO:451 The translated polypeptide sequence of all three exons 2-4 of PVALB arranged in order SLC3A2 transcript 3 sequence informationSEQ ID NO:452 SLC3A2 exon 2 sequence at 5' of SLC3A2-NRG1 fusion AGTTGGGGTCTCACTGTGTTGCCCAGACTGGTCTCGAACTTCTGGCCTCAGGTGATCCTCTTCCCTCAGCTTCCCAGAATGCCGAGATGATAG SEQ ID NO:453 NRG1 exon 6 sequence at 3' of SLC3A2-NRG1 fusion CTACATCTACATCCACCACTGGGACAAG SEQ ID NO:454 SLC3A2-NRG1 polynucleotide sequence AGTTGGGGTCTCACTGTGTTGCCCAGACTGGTCTCGAACTCTTGGCCTCAGGTGATCCTCTTCCCTCAGCTTCCCAGAATGCCGAGATGATAGCTACATCTACATCCACCACTGGGACAAG SEQ ID NO:455 SLC3A2-NRG1 polypeptide sequence LGSHCVAQTGLELLASGDPLPSASQNAEMIATSTSTTGT SEQ ID NO:456 Exon 1 of SLC3A2 GCATTGCGGCTTGGTTTTTCTCACCCAGTGCATGTGGCAGGAGCGGTGAGATCACTGCCTCACGGCGATCCTGGACTGACGGTCACGACTGCCTACCCTCTAACCCTGTTCTGAGCTGCCCCTTGCCCACACACCCCAAACCTGTGTGCAGGATCCGCCTCCATGGAGCTACAGCCTCCTGAAGCCTCGATCGCCGTCGTGTCGATTCCGCGCCAGTTGC CTGGCTCACATTCGGAGGCTGGTGTCCAGGGTCTCAGCGCGGGGGACGACTCAG SEQ ID NO:457 Exon 2 of SLC3A2 AGTTGGGGTCTCACTGTGTTGCCCAGACTGGTCTCGAACTTCTGGCCTCAGGTGATCCTCTTCCCTCAGCTTCCCAGAATGCCGAGATGATAG SEQ ID NO:458 Exon 3 of SLC3A2 AGACGGGGTCTGACTGTGTTACCCAGGCTGGTCTTCAACTCTTGGCCTCAAGTGATCCTCCTGCCTTAGCTTCCAAGAATGCTGAGGTTACAG SEQ ID NO:459 Exon 4 of SLC3A2 GCACCATGAGCCAGGACACCGAGGTGGATATGAAGGAGGTGGAGCTGAATGAGTTAGAGCCCGAGAAGCAGCCGATGAACGCGGCGTCTGGGGCGGCCATGTCCCTGGCGGGAGCCGAGAAGAATGGTCTGGTGAAGATCAAGGTGGCGGAAGACGAGGCGGAGGCGGCAGCCGCGGCTAAGTTCACGGGCCTGTCCAAGGAGGAGCT GCTGAAGGTGGCAGGCAGCCCCGGCTGGGTACGCACCCGCTGGGCACTGCTGCTGCTCTTCTGGCTCGGCTGGCTCGGCATGCTTGCTGGTGCCGTGGTCATAATCGTGCGAGCGCCGCGTTGTCGCGAGCTACCGGCGCAGAAGTGGTGGCACACGGGCGCCCTCTACCGCATCGGCGACCTTCAGGCCTTCCAGGCCACGGCGCG GGCAACCTGGCGG SEQ ID NO:460 Exon 5 of SLC3A2 GTCTGAAGGGGCGTCTCGATTACCTGAGCTCTCTGAAGGTGAAGGGCCTTGTGCTGGGTCCAATTCACAAGAACCAGAAGGATGATGTCGCTCCAGACTGACTTGCTGCAGATCGACCCCAATTTTGGCTCCAAGGAAGATTTTGACAGTCTCTTGCAATCGGCTAAAAAAAAAGA SEQ ID NO:461 Exon 6 of SLC3A2 GCATCCGTGTCATTCTGGACCTTACTCCCAACTACCGGGGTGAGAACTCGTGGTTTCCCACTCAGGTTGACACTGTGGCCACCAAGGTGAAG SEQ ID NO:462 Exon 7 of SLC3A2 GATGCTCTGGAGTTTTGGCTGCAAGCTGGCGTGGATGGGTTCCAGGTTCGGGACATAGAGAATCTGAAG SEQ ID NO:463 Exon 8 of SLC3A2 GATGCATCCTCATTCTTGGCTGAGTGGCAAAATATCACCAAGGGCTTCAGTGAAGACAG SEQ ID NO:464 Exon 9 of SLC3A2 GCTCTTGATTGCGGGGACTAACTCCTCCGACCTTCAGCAGATCCTGAGCCTACTCGAATCCAACAAAGACTTGCTGTTGACTAGCTCATACCTGTCTGATTCTGGTTCTACTGGGGAGCATACAAAATCCTAGTCACACAGTTTGAATGCCACTGGCAATCGCTGGTGCAGCTGGAGT SEQ ID NO:465 Exon 10 of SLC3A2 TTGTCTCAGGCAAGGCTCCTGACTTCCTTCTTGCCGGCTCAACTTCTCCGACTCTACCAGCTGATGCTCTTCACCCTGCCAGGGACCCCTGTTTTTCAGCTACGGGGATGAGATTGGCCTGGATGCAGCTGCCCTTCCTGGACAG SEQ ID NO:466 Exon 11 of SLC3A2 CCTATGGAGGCTCCAGTCATGCTGTGGGATGAGTCCAGCTTCCCTGACATCCCAGGGGCTGTAAGTGCCAACATGACTGTGAAG SEQ ID NO:467 Exon 12 of SLC3A2 GGCCAGAGTGAAGACCCTGGCTCCCTCCTTTCCTTGTTCCGGCGGCTGAGTGACCAGCGGAGTAAGGAGCGCTCCCTACTGCATGGGGACTTCCACGCGTTCTCCGCTGGGCCTGGACTCTTCTCCTATATCCGCCACTGGGACCAGAATGAGCGTTTTCTGGTAGTGCTTAACTTTGGGGATGTGGGCCTCTCGGCTGGACTGCAGGC CTCCGACCTGCCTGCCAGCGCCAGCCTGCCAGCCAAGGCTGACCTCCTGCTCAGCACCCAGCCAGGCCGTGAGGAGGGCTCCCCTCTTGAGCTGGAACGCCTGAAACTGGAGCCTCACGAAGGGCTGCTGCTCCGCTTCCCCTACGCGGCCTGACTTCAGCCTGACATGGACCCCACTACCCTTCTCCTTTCCTTCCCAGGCCCTTTGGCTTCTGATTTTTCT CTTTTTTAAAAACAAACAAACAAACTGTTGCAGATTATGAGTGAACCCCCAAATAGGGTGTTTTCTGCCTTCAAATAAAAGTCACCCCTGCATGGTGAA SEQ ID NO:468 The complete mRNA polynucleotide sequence of SLC3A2 SEQ ID NO:469 Translated polypeptide sequence of exon 1 of SLC3A2 MELQPPEASIAVVSIPRQLPGSHSEAGVQGLSAGDDS SEQ ID NO:470 Translated polypeptide sequence of exon 2 of SLC3A2 LGSHCVAQTGLELLASGDPLPSASQNAEMI SEQ ID NO:471 Translated polypeptide sequence of exon 3 of SLC3A2 TGSDCVTQAGLQLLASSDPPALASKNAEVT SEQ ID NO:472 Translated polypeptide sequence of exon 4 of SLC3A2 TMSQDTEVDMKEVELNELEPEKQPMNAASGAAMSLAGAEKNGLVKIKVAEDEAEAAAAAKFTGLSKEELLKVAGSPGWVRTRWALLLLFWLGWLGMLAGAVVIIVRAPRCRELPAQKWWHTGALYRIGDLQAFQGHGAGNLA SEQ ID NO:473 Translated polypeptide sequence of exon 5 of SLC3A2 LKGRLDYLSSLKVKGLVLGPIHKNQKDDVAQTDLLQIDPNFGSKEDFDSLLQSAKKK SEQ ID NO:474 Translated polypeptide sequence of exon 6 of SLC3A2 IRVILDLTPNYRGENSWFSTQVDTVATKVK SEQ ID NO:475 Translated polypeptide sequence of exon 7 of SLC3A2 DALEFWLQAGVDGFQVRDIENLK SEQ ID NO:476 Translated polypeptide sequence of exon 8 of SLC3A2 DASSFLAEWQNITKGFSED SEQ ID NO:477 Translated polypeptide sequence of exon 9 of SLC3A2 LLIAGTNSSDLQQILSLLESNKDLLLTSSYLSDSGSTGEHTKSLVTQYLNATGNRWCSWS SEQ ID NO:478 Translated polypeptide sequence of exon 10 of SLC3A2 LSQARLLTSFLPAQLLRLYQLMLFLTLPGTPVFSYGDEIGLDAAALPGQ SEQ ID NO:479 Translated polypeptide sequence of exon 11 of SLC3A2 PMEAPVMLWDESSFPDIPGAVSANMTVK SEQ ID NO:480 Translated polypeptide sequence of exon 12 of SLC3A2 GQSEDPGSLLSLFRRLSDQRSKERSLLHGDFHAFSAGGLFSYIRHWDQNERFLVVLNFGDVGLSAGLQASDLPASASLPAKADLLLSTQPGREEGSPLELERLKLEPHEGLLLRFPYAA The complete protein sequence of SEQ ID NO:481 SLC3A2 MELQPPEASIAVVSIPRQLPGSHSEAGVQGLSAGDDSELGSHCVAQTGLELLASGDPLPSASQNAEMIETGSDCVTQAGLQLLASSDPPALASKNAEVTGTMSQDTEVDMKEVELNELEPEKQPMNAASGAAMSLAGAEKNGLVKIKVAEDEAEAAAAAKFTGLSKEELLKVAGSPGWVRTRWALLLLFWLGWLGMLAGAVVIIV RAPRCRELPAQKWWHTGALYRIGDLQAFQGHGAGNLAGLKGRLDYLSSLKVKGLVLGPIHKNQKDDVAQTDLLQIDPNFGSKEDFDSLLQSAKKKSIRVILDLTPNYRGENSWFSTQVDTVATKVKDALEFWLQAGVDGFQVRDIENLKDASSFLAEWQNITKGFSEDRLLIAGTNSSDLQQIL SLLESNKDLLLLTSSYLSDSGSTGEHTKSLVTQYLNATGNRWCSWSLSQARLLTSFLPAQLLRLYQLMMLFTLPGTPVFSYGDEIGLDAAALPGQPMEAPVMLWDESSFPDIPGAVSANMTVKGQSEDPGSLLSLFRRLSDQRSKERSLLHGDFHAFSAGGLFSYIRHWDQNERFLVVLNFGDVGLSAGLQASDL PASASLPAKADLLLSTQPGREEGSPLELERLKLEPHEGLLLRFPYAA SEQ ID NO:482 The polynucleotide sequence of exons 1 and 2 of SLC3A2 arranged in sequence SEQ ID NO:483 SLC3A2 exon 1-2 translated polypeptide sequence arranged in order app sequence informationSEQ ID NO:484 Sequence from APP exon 14 at 5' of the APP-NRG1 fusion TTGAGCCTGTTGATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAG SEQ ID NO:485 NRG1 exon 6 sequence at 3' of APP-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCT SEQ ID NO:486 APP-NRG1 polynucleotide sequence TTGAGCCTGTTGATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCT SEQ ID NO:487 APP-NRG1 polypeptide sequence EPVDARPAADRGLTTRPATSTSTTTGTSHLVKCAEKEKTFCVNGGEC SEQ ID NO:488 APP exon 1 GTCAGTTTCCTCGGCAGCGGTAGGCGAGAGCACGCGGAGGAGCGTGCGCGGGGGCCCCGGGAGACGGCGGCGGTGGCGGCGCGGGCAGAGCAAGGACGCGGCGGATCCCACTCGCACAGCAGCGCACTCGGTGCCCCGCGCAGGGTCGCGATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCG CTGGAG SEQ ID NO:489 APP exon 2 GTCTACCCTGAACTGCAGATCACCAATGTGGTAGAAGCCAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGGGGCCGCAAGCAGTGCAAGACCCATCCCACTTTGTGATTCCCTACCGCTGCTTAG SEQ ID NO:490 APP exon 3 TTGGTGAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTACACCAGGAGAGGATGGATGTTTGCGAAACTCATTCTCACTGGCACACCGTCGCCAAAGAG SEQ ID NO:491 APP Exon 4 ACATGCAGTGAGAAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGACAAGTTCCGAGGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAATGTGGATTCTGCTGATGCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCAGACACAGACTATGCAGATGGGAG SEQ ID NO:492 APP exon 5 TGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTGGCTGAGGTGGAAGAAGAAGAAGCCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAACCCTACGAAGAAGCCAGAGAGAGAACCACCAGCATTGCCACCACCACCACCACCAGAGTCTGTGGAAGAGGTGGTTCGAG SEQ ID NO:493 APP exon 6 AGGTGTGCTCTGAACAAGCCGAGACGGGGCCGTGCCGAGCAATGATCTCCCGCTGGTACTTTGATGTGACTGAAGGGAAGTGTGCCCCATTCTTTTACGGCGGATGTGGCGGCAACCGGAACAACTTTGACACAGAAGAGTACTGCATGGCCGTGTGTGGCAGCGCCA SEQ ID NO:494 APP exon 7 TGTCCCAAAGTTTTACTCAAGACTACCCAGGAACCTCTTGCCCGAGATCCTGTTAAAC SEQ ID NO:495 APP Exon 8 TTCCTACAACAGCAGCCAGTACCCCTGATGCCGTTGACAAGTATCTCGAGACACCTGGGGATGAGAATGAACATGCCCATTTCCAGAAAGCCAAAGAGAGGCTTGAGGCCAAGCACCGAGAGAGAATGTCCCAG SEQ ID NO:496 APP Exon 9 GTCATGAGAGAATGGGAAGAGGCAGAACGTCAAGCAAAGAACTTGCCTAAAGCTGATAAGAAGGCAGTTATCCAG SEQ ID NO:497 APP Exon 10 CATTTCCAGGAGAAAGTGGAATCTTTGGAACAGGAAGCAGCCAACGAGAGACAGCAGCTGGTGGAGACACACATGGCCAGAGTGGAAGCCATGCTCAATGACCGCCGCCGCCTGGCCCTGGAGAACTACATCACCGCTCTGCAGGCTGTTCCTCCTCGG SEQ ID NO:498 APP Exon 11 CCTCGTCACGTGTTCAATATGCTAAAGAAGTATGTCCGCGCAGAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGCATGTGCGCATGGTGGATCCCAAGAAAGCCGCTCAGATCCGGTCCCAG SEQ ID NO:499 APP Exon 12 GTTATGACACACCTCCGTGTGATTTATGAGCGCATGAATCAGTCTCTCTCCCCTGCTCTACAACGTGCCTGCAGTGGCCGAGGAGATTCAGGATGAAGTTG SEQ ID NO:500 APP Exon 13 ATGAGCTGCTTCAGAAAGAGCAAAACTATTCAGATGACGTCTTGGCCAACATGATTAGTGAACCAAGGATCAGTTACGGAAACGATGCTCTCATGCCATCTTTGACCGAAACGAAAACCACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTGGACGATCTCCAGCCGTGGCATTCTTTTGGGGCTGACTCTGTGCCAGCCAACAGAAAACGA AG SEQ ID NO:501 APP Exon 14 TTGAGCCTGTTGATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAG SEQ ID NO:502 APP Exon 15 GTTCTGGGTTGACAAATATCAAGACGGAGGAGATCTCTGAAGTGAAGATGGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATCATCAAAAATTG SEQ ID NO:503 APP exon 16 GTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGTGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTGATCGTCATCACCTTGGTGATGCTGAAGAAGAAACAGTACACATCCATTCATCATGGTGTGGTGGAG SEQ ID NO:504 APP exon 17 GTTGACGCCGCTGTCACCCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAACGGCTACGAAAATCCAACCTACAAGTTCTTTGAGCAGATGCAGAACTAGACCCCCGCCACAGCAGCCTCTGAAGTTGGACAGCAAAACCATTGCTTCACTACCCCATCGGTGTCCATTTATAGAATAATGTGGGAAGAAACAAACCCGTTTTATGATTTACTCATTATCGCCTT TTGACAGCTGTGCTGTAACACAAGTAGATGCCTGAACTTGAATTAATCCACACACATCAGTAATGTATTTCTATCTCTCTTTACATTTTGGTCTCTATACTACATTATTAATGGGTTTTGTGTACTGTAAAGAATTTAGCTGTATCAAACTAGTGCATGAATAGATTCTCTCCTGATTATTTATCACATAGCCCCTTAGCCAGTTGTATATTATTCTTGTGGTTTGTGACCCAAT TAAGTCCTACTTTACATATGCTTTAAGAATCGATGGGGGATGCTTCATGTGAACGTGGGAGTTCAGCTGCTTCTCTTGCCTAAGTATTCCTTTCCTGATCACTATGCATTTTAAAGTTAACATTTTTAAGTATTTCAGATGCTTTAGAGAGATTTTTTTTCCATGACTGCATTTACTGTACAGATTGCTGCTTCTGCTATATTTGTGATATAGGAATTAAGAGGAT ACACACGTTTGTTTCTTCGTGCCTGTTTTATGTGCACACATTAGGCATTGAGACTTCAAGCTTTTCTTTTTTTGTCCACGTATCTTTGGGTCTTTGATAAAGAAAAGAATCCCTGTTCATTGTAAGCACTTTTACGGGGCGGGTGGGGAGGGGTGCTCTGCTGGTCTTCAATTACCAAGAATTCTCCAAAACAATTTTCTGCAGGATGATTGTACAGAATCA TTGCTTATGACATGATCGCTTTCTACACTGTATTACATAAATAAATTAAATAAAATAACCCCGGGCAAGACTTTTCTTGAAGGATGACTACAGACATTAAATAATCGAAGTAATTTTGGGTGGGGAGAAGAGGCAGATTCAATTTTCTTTAACCAGTCTGAAGTTTCATTTATGATACAAAAAGAAGATGAAAATGGAAGTGGCAATATAAGGGGATGAGAAG GCATGCCTGGACAAACCCTTCTTTTAAGATGTGTCTTCAATTTGTATAAAATGGTGTTTTCATGTAAATAAATACATTCTTGGAGGAGCA The complete mRNA polynucleotide sequence of SEQ ID NO:505 APP GTCAGTTTCCTCGGCAGCGGTAGGCGAGAGCACGCGGAGGAGCGTGCGCGGGGGCCCCGGGAGACGGCGGCGGTGGCGGCGCGGGCAGAGCAAGGACGCGGCGGATCCCACTCGCACAGCAGCGCACTCGGTGCCCCGCGCAGGGTCGCGATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCG CTGGAGGTCTACCCTGAACTGCAGATCACCAATGTGGTAGAAGCCAAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGGGGCCGCAAGCAGTGCAAGACCCATCCCACTTTGTGATTCCCTACCGCTGCTTAGTTGGTGAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTTACACCAGGAGAGGATGGATGTTTGCGAAACTCATC TTCACTGGCACACCGTCGCCAAAGAGACATGCAGTGAGAAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGACAAGTTCCGAGGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAATGTGGATTCTGCTGATGCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCAGACAGACTAT GCAGATGGGAGTGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTGGCTGAGGTGGAAGAAGAAGAAGCCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAACCCTACGAAGAAGCCACAGAGAGAACCACCAGCATTGCCACCACCACCACCACCAGAGTCTGTGGAAGAGGTGGTTCGAGAGGTGT GCTCTGAACAAGCCGAGACGGGGCCGTGCCGAGCAATGATCTCCCGCTGGTACTTTGATGTGACTGAAGGGAAGTGTGCCCCATTCTTTTACGGCGGATGTGGCGGCAACCGGAACAACTTTGACACAGAAGAGTACTGCATGGCCGTGTGTGGCAGCGCCATGTCCCAAAGTTTACTCAAGACTACCCAGGAACCTCTTGCCCGAGATCCTGTTAA ACTTCCCTACAACAGCAGCCAGTACCCTGATGCCGTTGACAAGTATCTCGAGACACCTGGGGATGAATGAACATGCCCATTTCCAGAAAGCCAAAGAGAGGCTTGAGGCCAAGCACCGAGAGAGAATGTCCCAGGTCATGAGAGAATGGGAAGAGGCAGAACGTCCAAGCAAAGAACTTGCCTAAAAGCTGATAAGAAGGCAGTTATTCCAGCATTTCCAGGAGAAAGTG GAATCTTTGGAACAGGAAGCAGCCAACGAGAGACAGCAGCTGGTGGAGACACACATGGCCAGAGTGGAAGCCATGCTCAATGACCGCCGCCGCCTGGCCCTGGAGAACTACATCACCGCTCTGCAGGCTGTTCCTCCTCGGCCTCGTCACGTGTTCAATATGCTAAAGAAGTATGTCCGCAGAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGCAT GTGCGCATGGTGGATCCCAAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGTGTGATTTATGAGCGCATGAATCAGTCTCTCTCCTGCTCTACAACGTGCCTGCAGTGGCCGAGGAGATTCAGGATGAAGTTGATGAGCTGCTTCAGAAAGAGCAAAACTATTCAGATGACGTCTTGGCCAACATGATTAGTGAACCAAGGATCAGTTACGGA AACGATGCTCTCATGCCATCTTTGACCGAAACGAAAACCACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTGGACGATCTCCAGCCGTGGCATTCTTTTGGGGCTGACTCTGTGCCAGCCAACACAGAAAACGAAGTTGAGCCTGTTGATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAGGTTCTGGGTTGACAAATATCAAG ACGGAGGAGATCTCTGAAGTGAAGATGGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATCATCAAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGTGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTGATCGTCATCACCTTGGTGATGCTGAAGAAGAAACAGTACACATCCATTCATCATGGTGT GGTGGAGGTTGACGCCGCTGTCACCCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAACGGCTACGAAAATCCAACCTACAAGTTCTTTGAGCAGATGCAGAACTAGACCCCCGCCACAGCAGCCTCTGAAGTTGGACAGCAAAACCATTGCTTCACTACCCCATCGGTGTCCATTTATAGAATAATGTGGGAAGAAACAAACCCGTTTTATGATTTACTCATTA TCGCCTTTTGACAGCTGTGCTGTAACACAAGTAGATGCCTGAACTTGAATTAATCCACACATCAGTAATGTATTTCTATCTCTCTTTACATTTTGGTCTCTATACTACATTATTAATGGGTTTTGTGTACTGTAAAGAATTTAGCTGTATCAAACTAGTGCATGAATAGATTCTCTCCTGATTATTTATCACATAGCCCCTTAGCCAGTTGTATATTATTCTTGTGGTTTGT GACCCAATTAAGTCCTACTTTACATATGCTTTAAGAATCGATGGGGGATGCTTCATGTGAACGTGGGAGTTCAGCTGCTTCTCTTGCCTAAGTATTCCTTTCCTGATCACTATGCATTTTAAAGTTAAAACATTTTTAAGTATTTCAGATGCTTTAGAGAGATTTTTTTTCCATGACTGCATTTTTACTGTACAGATTGCTGCTTCTGCTATATTTGTGATATAGGAATTA AGAGGATACACACGTTTGTTTCTTCGTGCCTGTTTTATGTGCACACATTAGGCATTGAGACTTCAAGCTTTTCTTTTTTTGTCCACGTATCTTTGGGTCTTTGATAAAGAAAAGAATCCCTGTTCATTGTAAGCACTTTTACGGGGCGGGTGGGAGGGGTGCTCTGCTGGTCTTCAATTACCAAGAATTCTCCAAAACAATTTTCTGCAGGATGATTGTA CAGAATCATTGCTTATGACATGATCGCTTTCTACACTGTATTACATAAATAAATTAAATAAAATAACCCCGGGCAAGACTTTTCTTTGAAGGATGACTACAGACATTAAATAATCGAAGTAATTTTGGGTGGGGAGAAGAGGCAGATTCAATTTTCTTTAACCAGTCTGAAGTTTCATTTATGATACAAAAAGAAGATGAAAATGGAAGTGGCAATATAAGGGGAT GAGGAAGGCATGCCTGGACAAAACCCTTCTTTTAAGATGTGTCTTCAATTTGTATAAAATGGTGTTTTCATGTAAATAAATACATTCTTGGAGGAGCA SEQ ID NO:506 Translated polypeptide sequence of APP exon 1 MLPGLALLLLAAWTARALE SEQ ID NO:507 Translated polypeptide sequence of APP exon 2 VYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCL SEQ ID NO:508 Translated polypeptide sequence of APP exon 3 GEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKE SEQ ID NO:509 Translated polypeptide sequence of APP exon 4 TCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADG SEQ ID NO:510 Translated polypeptide sequence of APP exon 5 EDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVR SEQ ID NO:511 Translated polypeptide sequence of APP exon 6 VCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSA SEQ ID NO:512 Translated polypeptide sequence of APP exon 7 SQSLLKTTQEPLARDPVK SEQ ID NO:513 Translated polypeptide sequence of APP exon 8 PTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQ SEQ ID NO:514 Translated polypeptide sequence of APP exon 9 VMREWEEAERQAKNLPKADKKAVIQ SEQ ID NO:515 Translated polypeptide sequence of APP exon 10 HFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRRLALENYITALQAVPPR SEQ ID NO:516 Translated polypeptide sequence of APP exon 11 PRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQ SEQ ID NO:517 Translated polypeptide sequence of APP exon 12 VMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEV SEQ ID NO:518 Translated polypeptide sequence of APP exon 13 ELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENE SEQ ID NO:519 Translated polypeptide sequence of APP exon 14 EPVDARPAADRGLTTRP SEQ ID NO:520 Translated polypeptide sequence of APP exon 15 SGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKL SEQ ID NO:521 Translated polypeptide sequence of APP exon 16 VFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVE SEQ ID NO:522 Translated polypeptide sequence of APP exon 17 VDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN The complete protein sequence of SEQ ID NO:523 APP MLPGLALLLLAAWTARALEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDE DGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKV ESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADS VPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN SEQ ID NO:524 The polynucleotide sequence of all exons 1-14 of APP arranged in order SEQ ID NO:525 The translated polypeptide sequence of all exons 1-14 of APP arranged in order WRN sequence informationSEQ ID NO:526 Sequence from WRN exon 33 at 5' of WRN-NRG1 fusion AAGCTGGCTGCCCCCTTGATTTGGAGCGAGCAGGCCTGACTCCAGAGGTTCAGAAGATTATTGCTGATGTTATCCGAAACCCTCCCGTCAACTCAG SEQ ID NO:527 Sequence of NRG1 exon 6 at 3' of WRN-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGCT SEQ ID NO: 528 WRN - NRG1 polynucleotide sequence AAGCTGGCTGCCCCCTTGATTTGGAGCGAGCAGGCCTGACTCCAGAGGTTCAGAAGATTATTGCTGATGTTATCCGAAACCCTCCCGTCAACTCAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATGGAGGGGAGTGC SEQ ID NO: 529 WRN - NRG1 polypeptide sequence AGCPLDLERAGLTPEVQKIIADVIRNPPVNSATSTSTTGTSHLVKCAEKEKTFCVNGGEC SEQ ID NO: 530 WRN exon 1 GTGTACTGTGTGCGCCGGGGAGGCGCCGGCTTGTACTCGGCAGCGCGGGAATAAAGTTTGCTGATTTGGTGTCTAGCCTGGATGCCTGGGTTGCAGGCCCTGC TTGTGGTGGCGCTCCACAGTCATCCGGCTGAAGAAGACCTGTTGGACTGGATCTTCTCGGG SEQ ID NO: 531 WRN exon 2 TTTTCTTTCAGATATTGTTTTGTTTTACCCATGAAGACATTGTTTTTTGGACTCTGCAAATAGGACATTTCAAAGATGAGTGAAAAAAATTGGAAACAACTGCACAGCAGCGGAAATGTCCTGA ATGGATGAATGTGCAGAATAAAAGATGTGCTGTAGAAGAAAGAAAG SEQ ID NO:532 other than WRN Exon 3 GCATGTGTTCGGAAGAGTGTTTTTGAAGATGACCTCCCCTTCTTAGAATTCACTGGATCCATTGTGTATAGTTACGATGCTAGTGATTGCTCTTTCCTGTCAGAAGATATTAG SEQ ID NO: 533 WRN Exon 4 CATGAGTCTATCAGATGGGGATGTGGTGGGATTTGACATGGAGTGGCCACCATTATACAATAGAGGGA AACTTGGCAAAGTTGCACTAATTCAGTTGTGTGTTTCTGAGAGCAAATGTTACTTGTTCCACGTTTCTTCCATGTCAG SEQ ID NO: 534 WRN Exon 5 TTTTTCCCCAGGGATTAAAAATGTTGCTTGAAAATAAAAGCAGTTAAAAAGGCAGGTGTAGGAATTGAAGGAGATCAGTGGAAACTTCTACGTGACTTTGATATCAAATTGAAGAATTTT GTGGAGTTGACAGATGTTGCCAATAAAAAG SEQ ID NO:535 WRN exon 6 CTGAAATGCACAGAGACCTGGAGCCTTAACAGTCTGGTTAAACACCCTCTTAGGTAAACAGCTCCTGAAAGACAAGTCTATCCGCTGTAGCAATTGGAGTAAGCAATTGGAGTAAGAAACTGTATGCAGCCACTGATGCTTAT SEQ ID NO :536 WRN exons 7 GCTGGTTTTATTATTTACCGAAATTTAGAGATTTTGGATGATACTGTGCAAAGGTTTGCTATAAATAAAG SEQ ID NO: 537 WRN exon 8 AGGAAGAAATCCTACTTAGCGACATGAACAAACAGTTGACTTCAATCTCTGAGGAAGTGATGGATCTGGCTAAGCATCTTCCTCATGCTTTCAGTAAATTGGAAAACCCACGGAG SEQ ID NO: 538 WRN exon 9 GGTTTCTATCTTACTAAAGGATATTTCAGAAATCTATATTCACTGAGGAGGATGATAATTGGGTCTACTAACATTGAGACTGAACTGAGGCCCAGCAATAATTTAAACTTATTTATCCTTTGAAGATTCAACTACTGGGGGAGTACAACAGAAACAAATTAGAGAACATGAAGTTTTAATTCACGTTGAAGATGA AACATGGGACCCAACACTTGATCATTTAGCTAAACATGATGGAGAAGATGTACTTGGAAATAAAGTGGAACGAAAAGAAGATGGATTTGAAGATGGAGTAGAAGACAACAAATTGAAAGAGAATATGGAAAGAGCTTGTTTGATGTCGTTAGATATCAGAACATGAACTCCAATTTTGGAACAGCAGTCTCAGGAAGAATATCTTAGTGATATTGCTTATAAA TCTACTGAG SEQ ID NO: 539 WRN exon 10 CATTTATCTCCCAATGATAATGAAAACGATACGTCCTATGTAATTGAGAGTGATGAAGATTTAGAAATGGAGATGCTTAAG SEQ ID NO: 540 WRN exon 11 CATTTATCTCCCAATGATAATGAAAACGATACGTCCTATGTAATTGAGAGTGATGAAGATTTAGAAATGGA GATGCTTAAG SEQ ID NO: 541 WRN exon 12 TCTTTAGAAAACCTCAATAGTGGCACGGTAGAACCAACTTCTAAATGCTTAAAAATGGAAAGAAATCTGGGTCTTCCTACTAAAGAAGAAGAAGAAGATGATGAAAATGAAGCTAATGAAGGGGAAGAAGATGATGATAAGG SEQ ID NO: 542 WRN exon 13 ACTTTTT GTGGCCAGCACCCCAATGAAGAGCAAGTTACTTGCCTCAAGATGTACTTTGGCCATTCCAGTTTAAACC SEQ ID NO: 543 WRN exon 14 AGTTCAGTGGAAAGTGATTCATTCAGTATTAGAAGAAAGAAGAGATAATGTTGCTGTCATGGCAACTG SEQ ID NO: 544 WRN exon 15 GATATGGAAAGAGTTTGTGCT TCCAGTATCCACCTGTTTATGTAGGCAAGATTGGCCTTGTTATTCTCCCCCTTATTTCTCTGATGGAAGACCAAGTGCTACAGCTTAA SEQ ID NO: 545 WRN exon 16 AATGTCCAACATCCCAGCTTGCTTCCTTGGATCAGCACAGTCAGAAAATGTTCTAACAGATATTAATT SEQ ID NO: 546 WRN exon 17 AGGTAAATACCGGATTGTATACGTAACTCCAGAATACTGTTCAGGTAACATGGGCCTGCTCCAGCAACTTGAGGCTGATATTG SEQ ID NO: 547 WRN exon 18 GTATCACGCTCATTGCTGTGGATGAGGCTCACTGTATTTCTGAGTGGGGGCATGATTTTAGGGATTCATTCAGGAAGTTGGGCTCCCTAAAGACAGCACTGCCAATG SEQ ID NO: 548 WRN exon 19 GTTCCAATCGTTGCACTTACTGCTACTGCAAGTTTCTTCAATCCGGGAAGACATTGTAC GTTGCTTAAATCTGAGAAATCCTCAGATCACCTGTACTGGTTTTGATCGACCAAACCTGTATTTAGAAGTTAGGCGAAAAACAGGGAATATCCTTCAGGATCTGCAGCCATTTCTTGTCAAAACAAG SEQ ID NO: 549 WRN exon 20 TTCCCACTGGGAATTTGAAGGTCCAACATCATCTACTGTCCTTCTAGAAAAATGACACAACAAGTTACAGGTGAACTTAGGAAACTGAATCTATCCTGTGGAACATACCATGCGGGCATGAGTTTTAGCACAAGGAAAGACATTCATCATAGGTTTGTAAGAGATGAAATTCAG SEQ ID NO: 550 WRN exon 21 TGTGTCATAGCTACCATAGCTTTTGGAATGGGCATTAATAAAGCTGACATTCGCCAAGTCATTCATTACGGTGCTCCTAAGGACATGGAATCATATTATTCAGGAGATTGGTAGAGCTGGTCGTGATGGACTTCAAAGTTCTTGTCACGTCCTCTGGGCTCCTGCAGACATTAACTTAAATAG SEQ ID NO: 551 WRN exon 22 G CACCTTCTTACTGAGATACGTAATGAGAAGTTTCGATTATACAAATTAAAGATGATGGCAAAGATGGAAAAATATCTTCATTCTAGCAGATGTAGGAGACA SEQ ID NO: 552 WRN exon 23 AATCATCTTGTCTCATTTTGAGGACAAACAAGTACAAAAAGCCTCCTTGGGAATTATGGGAACTGAAAAATGCTGTGATAATTGCAGGTCC AG SEQ ID NO:553 WRN Exon 24 ATTGGATCATTGCTATTCCATGGATGACTCAGAGGATACATCCTGGGACTTTGGTCCACAAGCATTTAAGCTTTTGTCTGCTGTGGACATCTTAGGCGAAAAATTTGGAATTGGGCTTCCAATTTTATTTCTCCGAGGATCT SEQ ID NO: 554 WRN Exon 25 AATTCTCAGCGTCTTGCCGATCAATATCGCAG GCACAGTTTTATTTGGCACTGGCAAGGATCAAACAGAGAGTTGGTGGAAGGCTTTTTCCCGTCAGCTGATCACTGAGGGATTCTTGGTAGAAGTTTCTCGGTATAACAAATTTATGAAGATTTGCGCCCTTACGAAAAAG SEQ ID NO: 555 WRN exon 26 GGTAGAAATTGGCTTCATAAAGCTAATACAGAATCTCAGAGCTCATCCT TCAAGCTAATGAAGAATTGTGTCCAAAGAAGTTGCTTCTGCCTAG SEQ ID NO: 556 Outside of WRN Exon 27 TTCGAAAACTGTATCTTCGGGCACCAAAGAGCATTGTTATAATCAAGTACCAGTTGAATTAAGTACAGAGAAGAAG SEQ ID NO: 557 Outside of WRN Exon 28 TCTAACTTGGAGAAGTTATATTTCTTATAAACCATGTGATAAGATTTCTTCTGGGAGTAACATTTCTAAAAAAAG SEQ ID NO: 558 WRN exon 29 TATCATGGTACAGTCACCAGAAAAAAGCTTACAGTTCCTCACAGCTGTTATTTCGGCACAAGAGCAGGAGACTCAG SEQ ID NO: 559 WRN exon 3 0 ATTGTGTTATATGGCAAATTGGTAGAAGCTAGGCAGAAACATGCCAATAAAATGGATGTTCCCCCAGCTATTCTGGCAACAAACAAGATACTGGTGGATATGGCCAAAATGAG SEQ ID NO: 560 WRN exon 31 ACCAACTACGGTTGAAAACGTAAAAAGGATTGATGGTGTTTCTGAAGGCAAAGCTGCCATGTTGGCCCCT CTGTTGGAAGTCATCAAACATTTCTGCCAAACAAATAGTGTTCAG SEQ ID NO: 561 WRN exon 32 ACAGACCCTTTTCAAGTACAAACCTCAAGAAGAACAGAAGACGAGTCTGGTAGCAAAAAATAAAATATGCACACTTTCACAGTCTATGGCCATCACATACTCTTTATTCCAAGAAAAGAAGATGCCTTTG SEQ ID NO: 562 WRN exon 33 AAGAGCATAGCTGAGAGCAGGATTCTGCCTCTCATGACAATTGGCATGCACTTATC CCAAGCGGTGAAAGCTGGCTGCCCCCTTGATTTGGAGCGAGCAGGCCTGACTCCAGAGGTTCAGAAGATTATTGCTGATGTTATCCGAAACCCTCCCGTCAACTCAG SEQ ID NO: 563 WRN exon 34 ATATGAGTAAAAATTAGCCTAATCAGAATGTTAGTTCCTGAAAACATTGACACGTACCTTATCCACATGGCAATTGAGATCCTTAA ACATGGTCCTGACAGCGGACTTCAACCTTCATGTGATGTCAACAAAAGGAGATGTTTTCCCGGTTCTGAAGAGATCTGTTCAAGTTTCTAAGAGAAGCAAGGAAGAAGTAGGCATCAATACTGAG SEQ ID NO: 564 WRN exon 35 ACTTCATCTGCAGAGAGAAAAGAGACGATTACCTGTGTGGTTTGCCAAAGGAAGTGATACCAGCAAGAAAT TAATGGACAAAACGAAAAGGGGAGGTCTTTTTTTAGTTAAGCTGGCAATTACCAGAACAATTATGTTTCTTGCTGTATTATAAGAGGATAGCTATATTTTATTTCTGAAGAGTAAGGAGTAGTATTTTGGCTTAAAAATCATTCTAATTACAAAAGTTCACTGTTTATTGAAGAACTGGCATCTTAAATCAGCCTTCCGCAATTCATGTAGTTTCTGGGTCTTCTGGGA GCCTACGTGAGTACATCACCCTAACAGAATATTAAATTAGACTTCCTGTAAGATTGCTTTAAGAAACTGTTACTGTCCTGTTTTTCTAATCTCTTTATTAAAACAGTGTATTTGGAAAATGTTATGTGCTCTGATTTGATATAGATAACAGATTAGTAGTTACATGGTAATTATGTGATATAAAATATTTCATATATTTCAAAATTCTGTTTTGTAAATGTAAGAAGCATAGTTATTT TACAAATTGTTTTTACTGTCTTTTGAAGAAGTTCTTAAATACGTTGTTAAATGGTATTAGTTGACCAGGGCAGTGAAAATGAAACCGCATTTTGGGTGCCATTAAATAGGGAAAAAACATGTAAAAAATGTAAAATGGAGACCAATTGCACTAGGCAAGTGTATATTTTGTATTTTATACAATTTCTATTTTTTTCAAGTAATAAACAATGTTTTTCACTGA ATATTATATATATATTTTTTAGCTTTTCATTTACTTAATTATTTTAAGTACCTTTTATTTTTCCAGGATGTCAGAATTTGATTCAATCTCTCTTATGTAGCACATGTGACTTAATTTAAACCTATACTGTGACACAGAGTTGGGTAAACGATGATTATTTAACTTTAAGCAGTTCACCATCCATTTCAAAGCCTTTGATTGGCTTTTTTGTAAATAAAAATAACTTGTTAAGAAAC AAATATATCTGTCATAGAAGAACTAGAAAATCCAGGGAAGTGAGAAAAATGAAAATAAAATCATTCATAGTTTTACTAGTAGCTAATCACAGTCAAACCTCTTTGTGTATCCACCAGACTTTTTTTATATTCATTTGTTTTTAGTTAAAAATAAAAGTCTCGTATATTCCCCATTTTTCTGCATTGCATTACCCAGAAGGTAGTGGCGCCTATTAAATATGTGATATGTTGTT GTCCAGCCATGGCTTCTGCATTTGCATGCTTTTGTGTGTGCATCTGCAATACCCTGTGAATACCCTGTGTGATGGAGTGGCAAGTACGCACAGACACGTCTGCTGCATGCCTAGGTACGAGGCTGTCTCCAGGAGAAGCACTTGTTTGATTATTTGAGTTGCCAATTGAATTTGCTGCTTTTTTTCATGGCTTGCCATTTTCACTGAAAAGAATGACTAATGAAAAACG ATGATTGGTTATTAGATTTGGATGTTTGGCAGACATTTTCTCAAAATTGAACTAAGTTGGCCTCTTCACGGAAAACAACTGGTATTTGTTGTGCCAATGATAAAATTGGAGATTTCTAGCAAAATGTATAATTTTGGAAAAGTTGTGTTCCTCCACTGGAAGCTTGACAGCTTTCCTTAACATAAAGACTTCTCTTTCTCTCGCTTTCACTACTACTACTACTAATTCT TCTTCTGATTCTTCTTCTTCTCCTTCTTCCTTCTTCCTTCCTTCCTCCTCCTCCTCCTTCTTCTTCCTCTTCCTCTTCTTTCTCTCTCTTTCCTTCCTTCCCTTCCCTTCCCCTTCCTTCCTTCCTTCCTCCCTCCCTCCCTCCCTCCCTCCTCCTCCTCCTTCCTTTTCCTCCTCCTTCTTTCTTTCTCTCTCCTTCTTCTTCTTTCTCTCTCCTCTCTTCTTCTTTTCTTTCTCTTCTTTTTTTTT CTTTCAAGCAGTCCTCCCGCCTCAGTCCCCCAAAAATAGTGGGATTACAGGTGTGAGCCACCATGCACAGCCTTACATAAAGCCTTTTCTAATGAGATGGATAGTAATTAACAAATGTGAGTTTTTGATATTATATAAAGATTTTTTCTGTGTTTCGAAGATCCGTATAACTCAGTGAATCAGTATGTTCTGGATGACTAATATGTGATGTTAAGAAATCATGACTGAGG CCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGATCAGGAGATCGAGACCACCCCTGGCCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCTGGGTGTGTTGGTGCGTGCCTATAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACTCAGGAGGCGGAGATTG CAGTGAGCTGAGACTGCGCCACTGCACCCCAGCCTGGCGACAGAGCAAGACTCCGTCTCAAAAAAAAAAAGAAATCATGACTGGGTAAAAGATCTGTTCAGAGTACAAGATGGACCAATGGATTTGATATATTTGAATAACAGAGTGAAAAAAGTTTATTGATATAGTTTCACACTGCAACTAATCTTTAAGAAACTATTACTTGTCCACTTTTTGGTAA AATTTCAGAGAACAATGTCCACCATTATCTGAACAGGCTATTAAAATCTTCTCTTTTCCAACTACGTGCCTGTGCAAAGTCAGATTTTTTCATACTTCAGCCAAAACAGCATATCAAAATGGATTGAATGCAGAAGTAGATCTGAGAATACAGCCACTTTTGTTAAAGCCAGACAATGAGATTTGCAAAATGTAAACAATGCTGCTGTTCTCAGTTTTTAAAAAATATGTTTTT TAAAAGTATTTATGTTAATGTGTACTTGGTTTACTACTGCTATTTTTAAATAAAACAAGAAACATTTTTAAATGTCTGTTTTATTTTCTAAAGTGGTAGTGATAGATATAACCCATATTAATAAAAGCTCTTTGGGGTCCTCAGTGATTTTTTTTTAAGAGTATGGAAGGGTTCTCAGACCTAAGAGATTGAGAAATGCTGATGTAATGTTTTTATTATAAAGGTGTA CCATGAATTATGTACCTTACTTCATATTGTTGGACATTAAAGTTGCTTTCAGTTTTTTTTGTTTTAAAA SEQ ID NO:565 WRN full mRNA polynucleotide Sequence SEQ ID NO:566 Translated polypeptide sequence of WRN exon 2 MSEKKLETTAQQRKCPEWMNVQNKRCAVEERK SEQ ID NO:567 Translated polypeptide sequence of WRN exon 3 ACVRKSVFEDDLPFLEFTGSIVYSYDASDCSFLSEDI SEQ ID NO:568 Translated polypeptide sequence of WRN exon 4 MSLSDGDVVGFDME WPPLYNRGKLGKVALIQLCVSESKCYLFHVSSMS SEQ ID NO:569 The translated polypeptide sequence of exon 5 of WRN FPQGLKMLLENKAVKKAGVGIEGDQWKLLRDFDIKLKNFVELTDVANKK SEQ ID NO:570 The translated polypeptide sequence of exon 6 of WRN LKCTETWSLNSLVKHLLGKQLLKDKSIRCSNWSKFPLTEDQKLYAATDAY SEQ ID NO:571 WRN Translated polypeptide sequence of exon 7 AGFIIYRNLEILDDTVQRFAINK SEQ ID NO :572 Translated polypeptide sequence of exon 8 of WRN EEILLSDMNKQLTSISEEEVMDLAKHLPHAFSKLENPR SEQ ID NO:573 Translated polypeptide sequence of exon 9 of WRN VSILLKDISENLYSLRRMIIGSTNIETELRPSNNLNLLSFEDSTTGGVQQKQIREHEVLIHVEDETWDPTLDHLAKHDGEDVLGNKVERKED GFEDGVEDNKLKENMERACLMSLDITEHELQILEQQSQEEYLSDIAYKSTE SEQ ID NO:574 Translated polypeptide sequence of WRN exon 10 HLSPNDNENDTSYVIESDEDLEMEMLK SEQ ID NO:575 The translated polypeptide sequence of WRN exon 11 HLSPNDNENDTSYVIESDEDLEMEMLK SEQ ID NO:576 The translated polypeptide sequence of WRN exon 12 SLENLNSGTVEPTHSKCLKMERNLGLPTKEEEEDDENEANEGEEDDDK SEQ ID NO:577 The translated polypeptide sequence of WRN exon 13 FLWPAPNEEQVTCLKMYFGHSSFK SEQ ID NO:578 of WRN Translated polypeptide sequence of exon 14 VQWKVIHSVLEERRDNVAVMAT SEQ ID NO: 579 Translated polypeptide sequence of exon 15 of WRN YGKSLCFQYPPVYVGKIGLVISPLISLMEDQVLQL SEQ ID NO: 580 Translated polypeptide sequence of exon 16 of WRN MSNIPACFLGSAQSENVLTDIK SEQ ID NO: 581 WR N explicit Translated polypeptide sequence of exon 17 GKYRIVYVTPEYCSGNMGLLQQLEADI SEQ ID NO: 582 Translated polypeptide sequence of exon 18 of WRN ITLIAVDEAHCISEWGHDFRDSFRKLGSLKTALPM SEQ ID NO: 583 Translated polypeptide sequence of exon 19 of WRN VPIVALTATASSSIREDIVRCLNLRNPQITCTGFDRPNLYLE VRRKTGNILQDLQPFLVKT SEQ ID NO: 584 WRN exon 20 Translated polypeptide sequence SHWEFEGPTIIYCPSRKMTQQVTGELRKLNLSCGTYHAGMFSSTRKDIHHRFVRDEIQ SEQ ID NO:585 WRN exon 21 translated polypeptide sequence CVIATIAFGMGINKADIRQVIHYGAPKDMESYYQEIGRAGRDGLQSSCHVLWAPADINLN SEQ ID NO:586 WRN exon Translated polypeptide sequence of exon 22 HLLTEIRNEKFRLYKLKMMAKMEKYLHSSRCRR SEQ ID NO:587 Translation of WRN exon 23 Peptide sequence IILSHFEDKQVQKASLGIMGTEKCCDNCRS SEQ ID NO: 588 Translated polypeptide sequence of WRN exon 24 LDHCYSMDDSEDTSWDFGPQAFKLLSAVDILGEKFGIGLPILFLRGS SEQ ID NO: 589 Translated polypeptide sequence of WRN exon 25 NSQRLADQYRRHSLFGTGKDQSWTEWKAFSR QLITEGFLVEVSRYNKFMKICALTKK SEQ ID NO:590 Translated polypeptide sequence of exon 26 of WRN GRNWLHKANTESQSLILQANEELCPKKLLLP SEQ ID NO:591 The translated polypeptide sequence of WRN exon 27 SKTVSSGTKEHCYNQVPVELSTEKK SEQ ID NO:592 The translated polypeptide sequence of WRN exon 28 SNLEKLYSYKPCDKISSGSNISKK SEQ ID NO:593 The translation of WRN exon 29 Translate polypeptide sequence IMVQSPEKAYSSSQPVISAQEQETQ SEQ ID NO: 594 Translated polypeptide sequence of exon 30 of WRN IVLYGKLVEARQKHANKMDVPPAILATNKILVDMAKM SEQ ID NO: 595 Translated polypeptide sequence of exon 31 of WRN PTTVENVKRIDGVSEGKAAMLAPLLEVIKHFCQTNSVQ SEQ ID NO: 596 Translated polypeptide sequence of exon 32 of WRN TDLFSSTK PQEEQKTSLVAKNKICTLSQSMAITYSLFQEKKMPL SEQ ID NO : 597 The translated polypeptide sequence of WRN exon 33 KSIAESRILPLMTIGMHLSQAVKAGCPLDLERAGLTPEVQKIIADVIRNPPVNS SEQ ID NO: 598 The translated polypeptide sequence of WRN exon 34 MSKISLIRMLVPENIDTYLIHMAIEILKHGPDSGLQPSCDVNKRRCFPGSEEICSSSKRSKEEVGINTE SEQ ID NO: Translated polypeptide sequence of exon 35 of 599 WRN TSSAERKRRLPVWFAKGSDTSKKLMDKTKRGGLFS SEQ ID NO:600 Whole protein sequence of WRN SEQ ID NO:601 Polynucleotide sequence of all exons 1-33 of WRN in sequence SEQ ID NO:602 Translated polypeptide sequence of all exons 1-33 of WRN in sequenceDAAM1 sequence informationSEQ ID NO:603 Sequence from 5' UTR/exon 1 of DAAM1 at 5' of DAAM1-NRG1 fusion GAAGGAAACTGTTTAACCGGATCCCATTGTACCCAGAGTGCAGAGCCGCCTTTCCAGCATGCAGGGGCTGCTCAG SEQ ID NO:604 5' UTR/exon 1 sequence of NRG1 at 3' of DAAM1-NRG1 fusion GACAGAGAGGGAGGAGGCGCGCGGGGACGGGGACGCCCAGGAGGACCCACTCGCGGGTCCCGCTCCGCTCCGGCA SEQ ID NO:605 DAAM1-NRG1 polynucleotide sequence GAAGGAAACTGTTTAACCGGATCCCATTGTACCCAGAGTGCAGAGCCGCCTTTCCAGCATGCAGGGGCTGCTCAGGACAGAGAGGGAGGAGGCGCGCGGGGACGGGGACGCCCAGGAGGACCCACTCGCGGGTCCCGCTCCGCTCCGGCA SEQ ID NO:606 DAAM1 exon 1 GCGAGTTAGTAACCTACGAGCGGCTGTGAAGGAAACTGTTTAACCGGATCCCATTGTACCCAGAGTGCAGAGCCGCCTTTCCAGCATGCAGGGGCTGCTCAG SEQ ID NO:607 DAAM1 exon 2 CGTTTTTAGTCACACACAAGAAAATACACACATCAGCCCCCCCCCCCCCCCCCAAGGGGGGGGGGGGGGGTCATTCATTTTTCCCCCCCCCCCCCCCGGCGGCGCGCGAAATGATA is GcaacttttgCTCAGACACACACACACAGCACCCCCCCCCCCCCCCTGGGGGGGGGTCATGTCAGTGAACTGGGTGTG SEQ ID NO:608 DAAM1 exon 3 GATGAACTGGACCTCCACAGACAAACACAGAGAAGCCATGTTTGCACTTCCAGCTGAGAAAAAATGGCAAATATACTGTAGCAAGAAAAAAG SEQ ID NO:609 DAAM1 exon 4 GACCAGGAAGAAAACAAGGGAGCTACAAGTTGGCCTGAATTCTACATTGATCAGCTCAATTCCATGGCTGCT SEQ ID NO:610 DAAM1 exon 5 AGAAAATCTCTGCTGGCTTTAGAGAAGGAAGAAGAAGAAGAAAGAAGTAAAACTATAGAGAGTTTAAAGACAGCACTGAGGACAAAACCAATGAG SEQ ID NO:611 DAAM1 exon 6 GTTTGTAACCAGATTCATCGACTTGGATGGCCTATCATGTATCCTCAACTTTTCTAAAGACCATGGACTACGAGACCTCAGAGTCTCGAATACATACTTCTCTCATTGGCTGTATAAAGGCGTTAATGAACAACTCTCAAGGCCGGGCTCACGTCCTGGCTCATTCTGAGAGTATTAATGTAATTGCTCAGAGTCTGAGCACAGAGAACATTAAAACGAAGGTG GCCGTGCTGGAAATCTTGGGCGCCGTGTGCCTGGTTCCCGGGGGCCACAAGAAGGTTCTGCAGGCCATGCTGCACTACCAGAAGTATGCCAGCGAAAGGACCCGCTTTCAG SEQ ID NO:612 DAAM1 exon 7 ACATTAATTAACGACTTGGATAAAAGCACTGGGCGGTATCGAGATGAAGTGAGTCTCAAGACTGCCATCATGTCCTTCATTAATGCAGTGCTCCAGCCAAGGTGCAGGAGTG SEQ ID NO:613 DAAM1 exon 8 GAGAGTTTGGACTTTAGACTTCATCTTCGCTATGAATTTCTGATGTTAGGAATTCAACCTGTAATAGATAAATTAAGGGAACACGAAAATTCAACATTAGATAG SEQ ID NO:614 DAAM1 exon 9 GCATTTAGACTTTTTTGAAATGCTCCGAAATGAAGATGAACTAGAATTTGCCAAAAGATTTGAACTG SEQ ID NO:615 DAAM1 exon 10 GTTCACATAGACACAAAAAAGTGCAACTCAGATGTTTGAGCTGACCAGGAAGAGGCTGACACATAGTGAAGCTTACCCGCATTTCATGTCCATCCTGCACCACTGCCTCCAAATGCCTT SEQ ID NO:616 DAAM1 exon 11 ACAAGAGGAGTGGCAACACTGTTCAGTACTGGCTACTACTAGATAGAATTATACAGCAGATAGTTATTCCAGAATGACAAAGGACAGGACCCTGACTCCACACCTTTGGAAAACTTTAATATTAAGAATGTCGTACGAAT SEQ ID NO:617 DAAM1 exon 12 GTTGGTTAATGAAAATGAAGTTAAGCAGTGGAAAGAACAAGCGGAAAAAATGAGAAAAG SEQ ID NO:618 DAAM1 exon 13 AGCACAATGAGCTACAACAGAAACTGGAAAAGAAAGAACGAGAATGTGATGCTAAGACTCAAGAGAAGGAAGAGATGATGCAGACCTTAAATAAAATGAAAGAGAAACTTGAAAAGGAGACTACTGAGCATAAGCAAGTCAAGCAGCAGGTGGCGGACCTCACAGCACAGCTCCATGAGCTCAGTCAGG SEQ ID NO:619 DAAM1 exon 14 AGGGCCGTCTGTGCTTCAATCCCAGGTGGACCCTCGCCTGGAGCACCAGGAGGGCCCTTTCCTTCCTCTGTGCCTGGATCTCTCCTTCCTCCCACCACCCCCACCTCTACCAGGTGGGATGCTTCCCCCTCCACCGCCTCCCCTCCCTCCAGGTGGCCCTCCTCCTCCCCCAGGGCCTCCTCCCTTAGGGGCAATCATGCCACCTCCTGGTGCTCCAAT GGGCCTAGCACTGAAGAAGAAAAGCATTCCTCCAGCCCACAAATGCCCTGAAATCCTTCAACTGGTCTAAACTGCCCGAG SEQ ID NO:620 DAAM1 exon 15 AACAAACTGGAAGGAACAGTATGGACCGAAATTGATGATACAAAAGTCTTCAAAATTCTAGATCTTGAAGACCTGGAAAGAACCTTCTCTGCCTATCAAAGACAGCAG SEQ ID NO:621 DAAM1 exon 16 AAAGAAGCAGATGCCATTGATGACACTCTGAGTTCCAAACTTAAAGTTAAAGAGCTTTCGGTGATTGATGGTCGGAGAGCTCAGAATTGCAACATCCTTCTATCGAG SEQ ID NO:622 DAAM1 exon 17 GTTGAAATTATCCAATGACGAAATCAAACGGGCAATTCTAACAATGGACGAACAGGAAGATCTGCCCAAGGACATGTTGGAACAG SEQ ID NO:623 DAAM1 exon 18 CTCTTGAAATTTGTTCCTGAAAAAAGTGACATTGACCTATTGGAGGAACATAAACACGAACTGGATCGGATGGCCAAGGCTGATAGGTTCCTTTTTGAGATGAGCCG SEQ ID NO:624 DAAM1 exon 19 AATTAATCACTATCAGCAAAGGTTGCAATCGCTGTACTTCAAAAAGAGTTTGCAGAGCGTGTGGCAGAAGTGAAACCTAAAGTGGAAG SEQ ID NO:625 DAAM1 exon 20 CAATTCGTTCTGGCTCAGAAGAGGTGTTTAGGAGTGGTGCCCTCAAGCAGTTGCTGGAGGTGGTTTTGGCATTTGGAAATTATATGAATAAAGGTCAAAGAGGGAATGCATATGGATTCAAGATATCTAGCCTAAACAAAATTGCTGACACAAAATCCAGCATCGACAA SEQ ID NO:626 DAAM1 exon 21 AAACATTACCCTTTTGCACTATCTCATCACTATTGTGGAAAATAAGTACCCCAGTGTTCCAAATCTAAATGAAGAATTGCGAGATATTCCTCAAAGCTGCGAAAGTAAA SEQ ID NO:627 DAAM1 exon 22 CATGACTGAGCTGGACAAAGAAATAAGTACCTTGAGAAGTGGCTTGAAAGCAGTAGAGACA SEQ ID NO:628 DAAM1 exon 23 GAGCTGGAATATCAGAAGTCTCAGCCCCCACAGCCCGGAGATAAGTTTGTGTCTGTTGTCAGCCAGTTCATCACAGTAGCCAGCTTCAGCTTCCTGATGTTGAAGACCTTCTAGCAGAAGCTAAAGACCTG SEQ ID NO:629 DAAM1 exon 24 TTTACTAAAGCAGTGAAGCACTTTGGGGAAGAGGCTGGCAAAATACAACCAGATGAGTTCTTTGGCATTTTTGATCAATTTCTTCAAGCTGTGTCAGAAGCCAAACAAGAAAACGAAAATATGAGAAAGAAAAAGGAGGAAGAAGAACGTCGAGCTCGCATGGAAGCTCAG SEQ ID NO:630 DAAM1 exon 25 CTCAAAGAACAACGTGAAAGGGAACGTAAAATGAGAAAAGCTAAAGAATAGTGAAGAAAGCGGAGAGTTTGATGACCTTGTTTCAGCTTTACGCTCAGGAGAAGTGTTTGACAAAGACCTTTCTAAATTGAAACGGAATCGCAAACGTATTACCAACCAGATGACTGACAGCAGCAGAGAGAGACCAATCACAAACTTAATTTCTAATTTTTTTTTTT AGAAAAGCTCATTAGCAGCCCTCTAAAGTGACTAGAACGTTTCATTACACTGCCTTGCAATCCAAACAGTGGCAATTTTTTCCTTCATCTGTGAGTGAATGTGTGAACGTGTGTATGTAAATGTATGTGTGTATATATTAAAAAATGTATAGATGTCTGAGTGTTGTCTGGAGACCTATACGTATGGTTAAAAAAGATTTATGTTAATGTATGTGCTCCAAAACCTTTCGTGTAT GCATTCACATTGAGTGTGGCCTTCATTTCTTTCCCCGAACGCCATGACTGTTCAGAAGCACAATACTATTCTCCTGAAAGAGATAAGAGACATTCCCTAGATTCAAAGGCAAAACAGAAGAAACAAACAAACAAAAAAAAAAGCTTGCAAAATATTTTATGGTTTCCAAGCTTGATATCCTTTTAAAATTTTTCATTGATGGAACTGGAGTTGTTGGAAAAACATAGATT TAAAATGATTTTTGATAGCTGACATTGTGATGTTGATGTATCACATCAGTAATAGGACCAGCTTTGAATTTCTGACATTGGTGTGGGGATACAGTCTGTAAATGTTTATTGAGAACATCTTGCACACAATTTGAATTATGTAGAATGTCAATCAAGTTTTTGTATATTTAAAAGTTGGACATCAATTTTTCCCCTGATTTCATCAAGTTATCTCTGCCAAGTGC TTGATAATTTCTTCAGATTTTTGGAAAAAAACACTATAAATGCAATCCATGCTTTTTTTAAAGAACAACATTGCCAGAGTATGCTTGTTTCTAACAATATAGATATATAAACCTTAAAAATAAAATATCTCCACCCAAGACTTAAAGGAAGAATTCTCTGAAGGGATAAAGATTACTAAAAAAAAAAAAAAAAAAAAAATTAATGGGGTGCCTTTTTTTGTTATAGTTTCTATTTT CTGTTTTGTAGGACAAGCTGCATTTTCTGTAAATATAGGTCTGGACTAAAGGATACATAAAGAATGCACAAAATGTCAACATCAGCAGAGATGCCCAGATCTATTTTCTAAGTATTTGAAGTGATTGCTGTTTATATGTTGTCATTTAAAATTGTGTGTCAGTAAAGCTACCTGTAAATTTCAGTCCAAAAAATAAAGCTCTCAGGGAGACATGAATAAAATCAATGA ACATTAGAAAATAAAATATAGATGCTTACCATTAACCTACCAACTCTTAATATCCTTAAATTATGTGATATAAAGAGGACTGTTACTTTTTACTTTTTTTTTTTTTTTTTTTTTTTTTTTGGCTTTGCTTTATTTATTTGTAGTTGGGGGCTAACGTTTTTCTTTTTCTTCTTATTGATCCTGTTGTGGTTGGGTTTCCTGTGGAGAGAGTAGTTTGTCCTGT TGCACTAGAACATTTATTTACTCACTAAATTGAGTTTTCAGTCAATTAACAAATATTTTATTAAGTTCCTACTATGTACCAGGCATAGTAGGGCTACAATGGTAAGCAAGACAGGTCCCTGCCCCCAAAAGAGCTTATATTCTAATGGGGATATTAGGGATGAATAGAATACCAATGTGTGCACTGTACAGGAATCATACTATTTAAAAATAATTTGTATAAACTATAAT GCTTAGCACAGATGGCGAGTTATCTGTGCTATGTGAAAGCTGTGAAATAGTGCTCTAAGAGTTGTCAAGAGCTGTGGTTTTACATCTTTTCCTCATTGCAAATTTAGTGACTTTTCACACACTATATGGAAATAAATGACTAGCAAATAAAACAGTCATAAATACAAAGCAGAGGTTGCACTCCCCAATCCCGAGTTAACCCAGGTCTGCAATAACCCATGTTAAAGGT GCAGATAGAGACTTGGCTCAAAAAGGCTTGGAGATGAGGAAGATTGGAATATAATGATGGTTTTGTCTGTTCCTTAACTAAAGTGCCTCTATGTATATTTCTTTTCTATTTGTAGCAGGATAAATTTGGTCTGGCTCAGTTTTGGAACTGTATTTTGAAAATGGCTTTGTCTTACAGTTTAAGGAATAGACAGGTGGAGGGAAAGTCACATAAAGGAGCAAGT TTGTGTAGCTGTCCCTCTTGCCCCTTTTAATCATCCTCCTTTGATATGGCCATCCTGGTGGGCCTCCTTTGCCATTTCCATTTTTGGTTTCTTCCCTGAAAACTGTGTGCAGGTAATTCCATGTGCCATTGTTGAAAAGAAAAAAAAAAAACAAAAAAAACCTACTTTTTGATTGGTGCTGGTGTAAGTAGCCACTTTTCTCTCTTGGGTGTGTATTTAAACT TTTTTTGTTTTTTTAAATTAATGCCAAAAAGAAAATGCATAATTTGTAAACTTAATTATATGTCTTATATCTTATTAGCTTAGTAGTTGGAACCACTTAGTCTTTAGGTGCAAGACTGTTGTTGTTAGATAGTACTGAGAAAAAAAAGTATGTGTTATGAGACTGTACATGTTTTTTAAAAATAGCAATATGCAATAAAGAGATGAATTCATTGGGTGTA SEQ ID NO:631 The complete mRNA polynucleotide sequence of DAAM1 GCGAGTTAGTAACCTACGAGCGGCTGTGAAGGAAACTGTTTAACCGGATCCCATTGTACCCAGAGTGCAGAGCCGCCTTTCCAGCATGCAGGGGCTGCTCCAGCGTTTAGTCACATCAAGAAATAGAACAGAATTCAGCCATGGCCCCAAGAAAGAGAGGTGGACGAGGTATTTCATTCATTTTTGCTGTTTCCAGAAATAATGATCACCCGAAATCACGTATC GGCTGCGAAATGATAGCAACTTTGCGCTTCAGACCATGGAACCAGCATTGCCCATGCCCCCTGTGGAGGAGCTGGATGTCATGTTCAGTGAACTGGTGGATGAACTGGACCTCCACAGACAAACACAGAGAAGCCATGTTTGCACTTCCAGCTGAGAAAAAATGGCAAATATACTGTAGCAAAAAAAGGACCAGGAAGAAAACAAGGGAGCTACAAGTTGGC CTGAATTCTACATTGATCAGCTCAATTCCATGGCTGCTAGAAAATCTCTGCTGGCTTTAGAGAAGGAAGAAGAAGAAGAAAGAAGTAAAACTATAGAGAGTTTAAAGACAGCACTGAGGACAAAACCAATGAGGTTTGTAACCAGATTCATCGACTTGGATGGCCTATCATGTATCCTCAACTTTTCTAAAGACCATGGACTACGAGACCTCAGAGTCGAATACATACTT CTCTCATTGGCTGTATAAAGGCGTTAATGAACAACTCTCAAGGCCGGGCTCACGTCCTGGCTCATTCTGAGAGTATTAATGTAATTGCTCAGAGTCTGAGCACAGAGAACATTAAAACGAAGGTGGCCGTGCTGGAAATCTTGGGCGCCGTGTGCCTGGTTCCCGGGGGCCACAAGAAGGTTCTGCAGGCCATGCTGCACTACCAGAGAGTATGCCAGCGA AAGGACCCGCTTTCAGACATTAATTAACGACTTGGATAAAAGCACTGGGCGGTATCGAGATGAAGTGAGTCTCAAGACTGCCATCATGTCCTTCATTAATGCAGTGCTCCAGCCAAGGTGCAGGAGTGGAGAGTTTGGACTTTAGACTTCATCTTCGCTATGAATTTCTGATGTTAGGAATTCAACCTGTAATAGATAAATTAAGGGAACACGAAAATTCAACAC TTAGATAGGCATTTAGACTTTTTTTGAAATGCTCCGAAATGAAGATGAACTAGAATTTGCCAAAAGATTTGAACTGGTTCACATAGACACAAAAAGTGCAACTCAGATGTTTGAGCTGACCAGGAAGAGGCTGACACATAGTGAAGCTTACCCCGCATTTCATGTCCATCCTGCACCACTGCCTCCAAATGCCTTACAAGAGGAGTGGCAACACTGTTCAGTACTGGCTACTAC TAGATAGAATTATACAGCAGATAGTTATTCCAGAATGACAAAGGACAGGACCCTGACTCCACACCTTTGGAAAACTTTAATATTAAGAATGTCGTACGAATGTTGGTTAATGAAAATGAAGTTAAAGCAGTGGAAAGAACAAGCGGAAAAAATGAGAAAAGAGCACAATGAGCTACAACAGAAACTGGAAAAGAAAGAACGAGAATGTGATGCTAAGACTCAAGAGAAGGAAG AGATGATGCAGACCTTAAATAAAATGAAAGAGAAACTTGAAAAGGAGACTACTGAGCATAAGCAAGTCAAGCAGCAGGTGGCGGACCTCACAGCACAGCTCCATGAGCTCAGCAGGAGGGCCGTCTGTGCTTCAATCCCAGGTGGACCCTCGCCTGGAGCACCAGGAGGGCCCTTTCCTTCCTCTGTGCCTGGATCTCTCCTTCCTCCCCACCCACCCACCTACTAC CAGGTGGGATGCTTCCCCCTCCACCGCCTCCCCTCCCTCCAGGTGGCCCTCCTCCTCCCCCAGGGCCTCCTCCCTTAGGGGCAATCATGCCACCTCCTGGTGCTCCAATGGGCCTAGCACTGAAGAAGAAAAGCATTCCTCAGCCCACAAATGCCCTGAAATCCTTCAACTGGTCTAAACTGCCCGAGAACAAACTGGAAGGAACAGTATGGACCGAAATTGAT GATACAAAAGTCTTCAAAATTCTAGATCTTGAAGACCTGGAAAGAACCTTCTCTGCCTATCAAAGACAGCAGAAAGAAGCAGATGCCATTGATGACACTCTGAGTTCCAAACTTAAAGTTAAAGAGCTTTCGGTGATTGATGGTCGGAGAGCTCAGAATTGCAACATCCTTCTATCGAGGTTGAAATTATCCAATGACGAAATCAAACGGGCAATTCTAACAATGGACGA ACAGGAAGATCTGCCCAAGGACATGTTGGAACAGCTCTTGAAATTTGTTCCTGAAAAAAGTGACATTGACCTATTGGAGGAACATAAACACGAACTGGATCGGATGGCCAAGGCTGATAGGTTCCTTTTTGAGATGAGCCGAATTAATCACTATCAGCAAAGGTTGCAATCGCTGTACTTCAAAAAGTAAGTTTGCAGAGCGTGTGGCAGAAGTGAAACCTAAA GTGGAAGCAATTCGTTCTGGCTCAGAAGAGGTGTTTAGGAGTGGTGCCCTCAAGCAGTTGCTGGAGGTGGTTTTGGCATTTGGAAATTATATGAATAAAGGTCAAAGGGGAATGCATATGGATTCAAGATATCTAGCCTAAACAAAATTGCTGACACAAAATCCAGCATCGACAAAAACATTACCCTTTTGCACTATCTCATCACTATTGTGGAAAATAAGTACCC CAGTGTTCTCAATCTAAATGAAGAATTGCGAGATATTCCTCCAAGCTGCGAAAGTAAACATGACTGAGCTGGACAAAGAAATAAGTACCTTGAGAAGTGGCTTGAAAGCAGTAGAGACAGAGCTGGAATATCAGAAGTCTCAGCCCCCACAGCCCGGAGATAAGTTTGTGTCTGTTGTCAGCCAGTTCATCACAGTAGCCAGCTTCAGCTTCTCTGATGTTGAAGACCTTCTA GCAGAAGCTAAAGACCTGTTTACTAAAGCAGTGAAGCACTTTGGGGAAGAGGCTGGCAAAATACAACCAGATGAGTTCTTTGGCATTTTTGATCAATTTCTTCAAGCTGTGTCAGAAGCCAAACAAGAAAACGAAAATATGAGAAAGAAAAAAGGAGGAAGAAGAACGTCGAGCTCGCATGGAAGCTCAGCTCAAAGAACAACGTGAAAGGGAACGTAAAATGAGAAAAG CTAAAGGAATAGTGAAGAAAGCGGAGAGTTTGATGACCTTGTTTCAGCTTTACGCTCAGGAGAAGTGTTTGACAAAGACCTTTCTAAATTGAAACGGAATCGCAAACGTATTACCAACCAGATGACTGACAGCAGCAGAGAGAGACCAATCACAAACTTAATTTCTAATTTTCCATGAATACTTTTTTTAAAGCTCATTAGCAGCCCTCTAAAGTGACTAGAACGTTTCAT TACACTGCCTTGCAATCCAAACAGTGGCAATTTTTTCCTTCATCTGTGAGTGAATGTGTGAACGTGTGTATGTAAATGTATGTGTATATTAAAAAATGTATATAGATGTCTGAGTGTTGTCTGGAGACCTATACGTATGGTTAAAAAAGATTTATGTTAATGTGCTCCAAAACCTTTCGTGTATGCATTCACATTGAGTGTGGCTCATTTTCTTCCCCGAACGCC ATGACTGTTCAGAAGCACAATACTATTCTCCTGAAAGAGATAAGAGACATTCCCTAGATTCAAAGGCAAAACAGAAGAAACAAACAAACAAACAAAAAAAGCTTGCAAAATATTTTATGGTTTCCAAGCTTGATATCCTTTAAAATTTTTCATTGATGGAACTGGAGTTGTTGGAAAACATAGATTTAAAATGATTTTTGATAGCTGACATTGTGATGTTGATGTAT CACATCAGTAATAGGACCAGCTTTGAATTTCTGACATTGGTGTGGGGATACAGTCTGTAAATGTTTATTGAGAACATCTTGCACACAATTTGAATTATGTAGAATGTCAATCAAGTTTTTTGTATATTTAAAAGTTGGACATCAATTTTTTCCCCTGATTTCATCAAGTTATCTCTGCCAAGTGCTCTTGATAATTTCTTCAGATTTTTGGAAAAAAACACTATATAAATG CAATCCATGCTTTTTTTAAAGAACAACATTGCCAGAGTATGCTTGTTCTAACAATATAGATATATAAACCTTAAAAATAATAAAATATCTCACCCCAAGACTTAAAGGAAGAATTCTCTGAAGGGATAAAGATTACTAAAAAAAAAAAAAAAAAAAAAAAAAATGGGTGCCTTTTTGTTTAGTTTCTATTTTCTGTTTTGTAGGACAAGCTGCATTTTCTGTAAATAGGTCTG GACTAAAGGATACATAAAGAATGCACAAAATGTCAACATCAGCAGAGATGCCCAGATCTATTTTCTCTAAGTATTTGAAGTGATTGCTGTTTATATGTTGTCATTTTAAAAATTGTGTGTCAGTAAAGCTACCTGTAAAATTTCAGTCCAAAAAAAATAAAGCTCTCAGGGAGACATGAATAAAATCAATGAACATTAGAAAATAAAATATAGATGCTTACCATTAACCTACCAAC TCTTAATATCCTTAAATTATGTGATATATAAAGAGGACTGTTACTTTTTACTTTTTTTTTTTTTTTTTTTTTTTTTGGCTTTGCTTTATTTATTTGTAGTTGGGGGCTAACGTTTTTCTCTTTTCTTCTATTGATCCTGTTGTGGTTGGGTTTCCTGTGGAGAGAGTAGTTTGTCCTGTTGCACTAGAACATTTACTCACTAAATTGAGTTTTCAGTC ATTAACAAATATTTTATTAAGTTCCTACTATGTACCAGGCATAGTAGGGCTACAATGGTAAGCAAGACAGGTCCCTGCCCCCAAAGAGCTTATATTCTAATGGGGATATTAAGGGATGAATAGAATACCAGTGTGCACTGTACAGGAATCATACTATTTAAAAATAATTTGTATAAAAACTATAATGCTTAGCACAGATGGCGAGTTATCTGTGCTATGTGAAAGCT GTGAAATAGTGCTCTAAGAGTTGTCCAAGAGCTGTGGTTTTACATCTTTTCCTCATTGCAAATTTAGTGACTTTTCACACACTATATGGAAATAAATGACTAGCAAATAAAACAGTCATAAATACAAAGCAGAGGTTGCACTCCCCAATCCCGAGTTAACCCAGGTCTGCAATAACACCATGTTAAAGGTGCAGATAGAGACTTGGCTCAAAAAGGCTTGGAGATGAGGAAG ATTGGAATATAATGATGGTTTTGTCTGTTCCTTAACTAAAAGTGCCTCTATGTATATTTCTTTTCTATTTGTAGCAGGATAAATTTGGTCTGGCTCAGTTTTGGAACTGTATTTTGAAAATGGCTTTGTCTTACAGTTTAAGGAATAGACAGGTGGAGGGAAAGTCACATAAAGGAGCAAGTTTGTGTAGCTGTCCCTCTTGCCCCTTTTAATCATCCTCCTTTG ATATGGCCATCCTGGTGGGCCTCCTTTGCCATTTCCATTTTTGGTTTCTTTTCCCTGAAAACTGTGTGCAGGTAATTCCATGTGCCATTGTTGAAAAGAAAAAAAAAAAAAAAAAAAAACCTACTTTTTGATTGGTGCTGGTGTAAGTAGCCACTTTTCTCTCTTGGGTGTGTATTTAAACTTTTTTTGTTTTTTAAATTAATGCCAAAAAAAAATGCATAATTT GTAAACTTAATTATATGTCTTATATCTTATTAGCTTAGTAGTTGGAACCACTTAGTCTTTAGGTGCAAGACTGTTGTTAGATAGTACTGAGAAAAAAAAGTATGTGTTATGAGACTGTACATGTTTTTTAAAAATAGCAATATGCAATAAAGAGATGAATTCATTGGGTGTA The complete protein sequence of SEQ ID NO:632 DAAM1 MAPRKRGGRGISFIFCCFRNNDHPEITYRLRNDSNFALQTMEPALPPMPPVEELDVMFSELVDELDLTDKHREAMFALPAEKKWQIYCSKKKDQEENKGATSWPEFYIDQLNSMAARKSLLALEKEEEEERSKTIESLKTALRTKPMRFVTRFIDLDGLSCILNFLKTMDYETSESRIHTSLIGCIKAL MNNSQGRAHVLAHSESINVIAQSLSTENIKTKVAVLEILGAVCLVPGGHKKVLQAMLHYQKYASERTRFQTLINDLDKSTGRYRDEVSLKTAIMSFINAVLSQGAGVESLDFRLHLRYEFLMLGIQPVIDKLREHENSTLDRHLDFEMLRNEDELEFAKRFELVHIDTKSATQMFELTRKRLT HSEAYPHFMSILHHCLQMPYKRSGNTVQYWLLLDRIIQQIVIQNDKGQDPDSTPLENFNIKNVVRMLVNENEVKQWKEQAEKMRKEHNELQQKLEKKERECDAKTQEKEEMMQTLNKMKEKLEKETTEHKQVKQQVADLTAQLHELSRRAVCASIPGGPSPGAPGGPFPSSVPGSLLPPPPPP PLPGGMLPPPPPLPPGGPPPPPGPPPLGAIMPPPPGAPMGLALKKKSIPQPTNALKSFNWSKLPENKLEGTVWTEIDDTKVFKILDLEDLERTFSAYQRQQKEADAIDDTLSSKLKVKELSVIDGRRAQNCNILLSRLKLSNDEIKRAILTMDEQEDLPKDMLEQLLKFVPEKSDIDLLEEHKHELDRMAKADRFL FEMSRINHYQQRLQSLYFKKKFAERVAEVKPKVEAIRSGSEEVFRSGALKQLLEVVLAFGNYMNKGQRGNAYGFKISSLNKIADTKSSIDKNITLLHYLITIVENKYPSVLNLNEELRDIPQAAKVNMTELDKEISTLRSGLKAVETELEYQKSQPPQPGDKFVSVVSQFITVASFSF SDVEDLLAEAKDLFTKAVKHFGEEAGKIQPDEFFGIFDQFLQAVSEAKQENENMRKKKEEEERRARMEAQLKEQRERERKMRKAKENSEESGEFDDLVSALRSGEVFDKDLSKLKRNRKRITNQMTDSSRERPITKLNF ASPH sequence informationSEQ ID NO:633 Sequence from ASPH exon 22 at 5' of the ASPH-NRG1 fusion AAGGTCTCTTCCTGCCTGAGGATGAAAACCTGAGGGAAAAAGGGGACTGGAGCCAGTTCACGCTGTGGCAGCAAG SEQ ID NO:634 NRG1 exon 2 sequence at 3' of the ASPH-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO:635 ASPH-NRG1 polynucleotide sequence AAGGTCTCTTCCTGCCTGAGGATGAAAACCTGAGGGAAAAAGGGGACTGGAGCCAGTTCACGCTGTGGCAGCAAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO:636 ASPH-NRG1 polypeptide sequence GLFLPEDENLREKGDWSQFTLWQQALPPRLKEMKSQESAAAGSKLVLRCE SEQ ID NO:637 ASPH exon 1 AGTCTCAAAGCTCTGGTAGGCAAGTGCATGCAGTGTGCCTAAAACCTGCCAGCAGTACTTTTTGAGTTTTTTTTTTTTGTTTTGTTTTACTTTAGCATTTATTATTCATGGATTGAAGAAATCAAAATGGCTGAAGATAAAG SEQ ID NO:638 ASPH exon 2 AGACAAAGCATGGAGGACACAAGAATGGGAGGAAAGGCGGACTCTCAGGAACTTCATTCTTCACGTGGTTTATGGTGATTGCATTGCTGGGCGTCTGGACATCTGTAGCTGTCGTTTGGTTTGATCTTGTTGACTATGAGGAAGTTCTAG SEQ ID NO:639 ASPH exon 3 GAAAACTAGGAATCTATGATGCTGATGGTGATGGAGATTTTGATGTGGATGATGCCAAAGTTTTTATTAG SEQ ID NO:640 ASPH exon 4 GACTTAAAGAGAGATCTACTTCAGAGCCAGCAGTCCCGCCAGAAGAGGCTGAGCCACACACTGAGCCCGAGGAGCAGGTTCCTGTGGAGGCAG SEQ ID NO:641 ASPH exon 5 AACCCCAGAATATCGAAGATGAAGCAAAAAGAACAAATTCAGTCCCTTCTCCATGAAATGGTACACGCAGAACATG SEQ ID NO:642 ASPH exon 6 TTGAGGGAGAAGACTTGCAACAAGAAGATGGACCCACAGGAGAACCACAACAAGAGGATGATGAGTTTCTTATGGCGACTGATGTAGATGATAGATTTGAGACCCTGGAACCTGAAGTATCTCATGAAG SEQ ID NO:643 ASPH exon 7 AAACCGAGCATAGTTACCACGTGGAAGAGACAG SEQ ID NO:644 ASPH exon 8 TTTCACAAGACTGTAATCAGGATATGGAAGAGATGATGTCTGAGCAGGAAAATCCAG SEQ ID NO:645 ASPH exon 9 ATTCCAGTGAACCAGTAGTAGAAGATGAAAGATTGCACCATGATACAG SEQ ID NO:646 ASPH exon 10 ATGATGTAACATACCAAGTCTATGAGGAACAAG SEQ ID NO:647 ASPH exon 11 CAGTATATGAACCTCTAGAAAATGAAGGGATAGAAATCACAG SEQ ID NO:648 ASPH exon 12 AAGTAACTGCTCCCCCTGAGGATAATCCTGTAGAAGATTCACAGGTAATTGTAGAAG SEQ ID NO:649 ASPH exon 13 AAGTAAGCATTTTTCCTGTGGAAGAACAGCAGGAAGTACCACCAG SEQ ID NO:650 ASPH exon 14 AAACAAATAGAAAAACAGATGATCCAGAACAAAAAGCAAAAG SEQ ID NO:651 ASPH exon 15 TTAAGAAAAAAGAAGCCTAAACTTTTAAATAAATTTGATAAGACTATTAAAGCTGAACTTGATGCTGCAGAAAAACTCCGTAAAAGG SEQ ID NO:652 ASPH exon 16 GGAAAAATTGAGGAAGCAGTGAATGCATTTAAAGAACTAGTACGCAAATACCCTCAGAGTCCACGAGCAAGATATGGGAAGGCGCAG SEQ ID NO:653 ASPH exon 17 TGTGAGGATGATTTGGCTGAGAAGAGGAGAAGTAATGAGGTGCTACGTGGAGCCATCGAGACCTACCAAGAGGTGGCCAGCCTACCTGATGTCCCCTGCAGACCTGCTGAAGCTGAGTTTGAAGCGTCGCTCAGACAGGCAACAATTTCTAG SEQ ID NO:654 ASPH exon 18 GTCATATGAGAGGTTCCCTGCTTACCCTGCAGAGATTAGTTCAACTATTTCCCAATGATACTTCCTTAAAAAATGACCTTGGCGTGGGATACCTCTTGATAGGAGATAATGACAATGCAAAGAAAGTTTTATGAAGAG SEQ ID NO:655 ASPH exon 19 GTGCTGAGTGTGACACCTAATGATGGCTTTGCTAAAGTCCATTATGGCTTCATCCTGAAGGCACAGAACAAAATTGCTGAGAGCATCCATATTTAAAG SEQ ID NO:656 ASPH exon 20 GAAGGAATAGAATCCGGAGATCCTGGCACTGATGATGGGAGATTTTATTTCCACCTGGGGGATGCCATGCAGAGGGTTGGGAACAAAGAG SEQ ID NO:657 ASPH exon 21 GCATATAAGTGGTATGAGCTTGGGCACAAGAGAGGACACTTTGCATCTGTCTGGCAACGCTCACTCTACAATGTGAATGGACTGAAAGCACAGCCTTGGTGGACCCCAAAAAGAAACGGGCTACACAGAGTTAGTAAAG SEQ ID NO:658 ASPH exon 22 TCTTTAGAAAGAAACTGGAAGTTAATCCGAGATGAAGGCCTTGCAGTGATGGATAAAGCCAAAGGTCTCTTCCTGCCTGAGGATGAAAACCTGAGGGAAAAAGGGGACTGGAGCCAGTTCACGCTGTGGCAGCAAG SEQ ID NO:659 ASPH exon 23 GAAGAAGAAATGAAAATGCCTGCAAAGGAGCTCCTAAAACCTGTACCTTACTAGAAAAGTTCCCCGAGACAACAGGATGCAGAAGAGGACAG SEQ ID NO:660 ASPH exon 24 ATCAAATATTCCATCATGCACCCCGGGACTCACGTGTGGCCGCACACAGGGCCCACAAACTGCAGGCTCCGAATGCACCTGGGCTTGGTGATTCCCAAGGAAGGCTGCAAGATTCGATGTGCCAACGAGACCAA SEQ ID NO:661 ASPH exon 25 GACCTGGGAGGAAGGCAAGGTGCTCATCTTTGATGACTCCTTTGAGCACGAGGTATGGCAGGATGCCTCATCTTTCCGGCTGATATTCATCGTGGATGTGTGGCATCCGGAACTGACACCACAGCAGAGACGCAGCCTTCCAGCAATTTAGCATGAATTCATGCAAGCTTGGGAAACTCTGGAGAGAGGCTGCCTTTCTGGTTCCATTCTCTTGG GTGTGAGGATAGAATTTCGAACACCAAGAGTCAATTCCCTTGACTTGCAGCCCGAGTAATTCAAAGCCTCTCCTAGGGTCAGAAGACACTAAAGGGAATATTGCCTCGCTGCAATTCATTTAGGAAACACCCTGCTGTGTGTCATCTCATGACAGCACTGGTCTTCTGCCAGTATTTAAGGTGAACATTTGATAGCTTCTACCTTACCAGCCAAAGATATTTTTCCA CATAGAATAGGTCTAATTCAATGTATAATGAGAACATATGTAGAAACTGTGAATGGATTGCTTTAGTTTGTAATTTTTCTATGCAGTTATATTTTTCTAGTGTAGCTAGACTATTTTTGTCATCATGTACCACTACATTTTTGTTTATTTTAATGACAAGCTGTATAAATGCTTTACTTCTAGCTATTTAATGGTAGCATTACTGGGGAACTCAGACTTCCCCTTTTAATTCTTCT TAGTAAAAGATACTCATGAAAAAAGCAGTTTTTATTTTCCTAACAAAAAAGAAAGAGCTCATTATGTCAGTGTCTATGAACTGTACCCATCCCAACTTCTCAAATCGTTTGGTTTTTTTTTATCTTGATTGAGATCCTTCTCACTATGCTAGTGGTGGAGATATTGACAAAATCCTATTTCTTTCAAAGAGGAACTTTCACACCGAAAAAAGGAGCATGGAATTATTTTATATTGT TATAAAAATCCCAGATGCAAATTTTTTTAATGCCAATTATTAGAGCTTCTGGGGAAAAAGTATAGTTCACGGAAATAAAACTATGTTCTTTCAGGGTTGGGTGGATAGGTGGCTGCTAGGGTGTCTGGCTCCTGGCGGCTTTGCCATCCATGAGGCAAGGGCTGGGAACACAGTGTCTTTGCCTATGGTAGATCCATGTGAATGTCAGGAAGCC AGCTCTTCAGTCTTGGAGATGATTTCTGCTACAATTCTGTAGAAAGATTAAGGATGGCAGAGTAAAAGGTTACCAAGAATGCCAGGATGTTTTTCTTGGGCGTAGGAGGTCCAGATTACTTTTCCTTTTTGATGAAAGAGTTTGGAAGACTGTCCCATCTCTCTGGCTTGAAAATCTCTGCCATTTTAAACATCACTGTGAAATAGCAATTATTATCATCTGTATT TAGTTTTTAACATTACCCACAACATAGAAATAATAGGTAAAAATCGTCTTGCCTACTCATTCCAAAGATGATCAAGTCATTAATCTAGCAAAGTATTCATGTATCAGATTTTGTATATTTTGAATCAAAGCTAACTAGGAATGTTAGATATAAGAATGTAATGATATTCATGCACTGAATTCTAAGCCAATATGAACAAAAATGCTGCATGAATGGCACATAGGTCACCA AAGTTCATTCACAGGTAGAAAAAACTTGTGCTTTCTTTTCCATCTAAAAACAAAAGGAGACTTTCTTTATCTCATTTAAAGAACAGCTCTTTGAAATTGAAATTGACCCTTTTTGCTTGACCTTAAGGAGATTAGCTTCCAGTAGATGAGTTTGCAAAATACTTTTCCTGTTCTTTTGTTTTGCTGGTATTGAAAACTCCCACTAATCAGATGAAGAGGCATGGGAGGAAAA ATATCCAAATTAATTACTAAAATCGAGAAGAGAAGGCAAACTCTTGAAAAGTAAAAAGGTGTTTGTGACCTTCAGTATTTATTGAACAGAGGAAATAACTGACAAGGGCAATACAATTCAATGTTCATGTAGTAACATTCATGTCACTTGTTGAATTTGGTTCTCATATGTATATTGCATACACATAAATTCAAACTATAAGTCGTCATTTTTGAGCCATCATCTTACATTCAT GTAATGAAATTATGGAAGAGAGTAAAAACTAGCTCTTAACTTAGTAAATAATATGGTATTTAAAATCAGGTCACTACAGTAAGGTTCTAAGTATTGCCAATTGAAAAGCTAGAAATGGTATTACTGTTGCAAAGTGTTGTCAATAATTGACTCCAATAGCATTGTAAATACTTGTATCCCAACTATTTAAACCCAAGCAATAAAATGGATTTTCTAATTCACTTCAATTC TTTATTTTCTCTTACCTATCTATGTCTTGGTACATAAGAAAAGTGTTTCCATCACTGCATTGGTAGAATTATTTCAGTGTTATTTATTTTTGTGATTTCGTATGTCTACACAAAAATGAATTAGTTTAATTTATATTGTGATACAGTTGTTTGAGAAATATTTTTAATTCTGTTTCAACTTTTATTTCTCCAAGTGTATATATAAAAATTACTTCTGTTATTGTTCTCTACCAATAGG GGAAAAAATTAAAACATTAGATCCATTGAGAAAGAGATGATGTAATAAATAATTAAGATTAGTAATAATATTATCAGGGGTGATTATGACCAGTTGAATAATCTCTTTCCCTTGAATTATTTAGCTAACAAATTAACTTCCCAAATATTTAAAATAATGTAAAATCTATATTTTACTGCCCATTATTAACTAAAATATTTTGTTTGACTTTGAGCACCAACTGGTAATACTAATAA ATACCCATGTCATGCAGATGGCTGGGCGAATAAGAGATGTCTAAAAATATGCACTGGTCTTGGAAAACATGGCACAAGTAAGGATATCATATATGATGTCTGTTTATTTTATGTCTGATTTCTTTTGAATGAGTAGTTGGGGACTCCATTTCTAAGGAGACTAGGTAAATAAAATGACCTTTGACATTTCA SEQ ID NO:662 The complete mRNA polynucleotide sequence of ASPH AGTCTCAAAGCTCTGGTAGGCAAGTGCATGCAGTGTGCCTAAAACCTGCCAGTCAGTTTTTTTGAGTTTTTTTTTTTTGTTTTGTTTTACTTTAGCATTTATTATTCATGGATTGAAGAAATCAAAATGGCTGAAGATAAAGAGACAAAGCATGGAGGACACAAGAATGGGAGGAAAGGCGGACTCTCAGGAACTTCATTCTTCACGTGGTTTATGGTGATTGCAT TGCTGGGCGTCTGGACATCTGTAGCTGTCGTTTGGTTTGATCTTGTTGACTATGAGGAAGTTCTAGGAAAACTAGGAATCTATGATGCTGATGGTGATGGAGATTTTGATGTGGATGATGCCAAAGTTTTTATTAGGACTTAAAGAGAGATCTACTTCAGAGCCAGCAGTCCCGCCAGAAGAGGCTGAGCCACACACTGAGCCCGAGGAGCAGGTTCCTGTG GAGGCAGAACCCCAGAATATCGAAGATGAAGCAAAAAGAACAAATTCAGTCCCTTCTCCATGAAATGGTACACGCAGAACATGTTGAGGGAGAAGACTTGCAACAAGAAGATGGACCACAGGAGAACCACAACAAGAGGATGATGAGTTTCTTATGGCGACTGATGTAGATGATAGATTTGAGACCCTGGAACCTGAAGTATCTCATGAAGAAACCGAGCATAGT TACCACGTGGAAGAGACAGTTTCACAAGACTGTAATCAGGATATGGAAGAGATGATGTCTGAGCAGGAAAATCCAGATTCCAGTGAACCAGTAGTAGAAGATGAAAGATTGCACCATGATACAGATGATGTAACATACCAAGTCTATGAGGAACAAGCAGTATATGAACCTCTAGAAAATGAAGGGATAGAAATCACAGAAGTAACTGCTCCCCCTGAGGATAATCCTGTA GAAGATTCACAGGTAATTGTAGAAGAAGTAAGCATTTTTCCTGTGGAAGAACAGCAGGAAGTACCACCAGAAACAAATAGAAAAACAGATGATCCAGAACAAAAAGCAAAAGTTAAGAAAAAGAAGCCTAAACTTTTAAATAAATTTGATAAGACTATTAAAGCTGAACTTGATGCTGCAGAAAAACTCCGTAAAAGGGGAAAAATTGAGGAAGCAGTGAATGCATTTAAGAAC TAGTACGCAAATACCCTCAGAGTCCACGAGCAAGATATGGGAAGGCGCAGTGTGAGGATGATTTGGCTGAGAAGAGGAGAAGTAATGAGGTGCTACGTGGAGCCATCGAGACCTACCAAAGAGGTGGCCAGCCTACCTGATGTCCCCTGCAGACCTGCTGAAGCTGAGTTTGAAGCGTCGCTCAGACAGGCAACAATTTCTTAGGTCATATGAGAGGTTCCCTGCT TACCCTGCAGAGATTAGTTCAACTATTTCCCAATGATACTTCCTTAAAAAATGACCTTGGCGTGGGATACCTCTTGATAGGAGATAATGACAATGCAAAGAAAGTTTTATGAAGAGGTGCTGAGTGTGACACCTAATGATGGCTTTGCTAAAGTCCATTATGGCTTCATCCTGAAGGCACAGAACAAAATTGCTGAGAGCATCCCATATTTAAAGGAAGGAATAGAATCCG GAGATCCTGGCACTGATGATGGGAGATTTTATTTCCACCTGGGGGATGCCATGCAGAGGGTTGGGAACAAAGAGGCATATAAGTGGTATGAGCTTGGGCACAAGAGAGGACACTTTGCATCTGTCTGGCAACGCTCACTCTACAATGTGAATGGACTGAAAGCACAGCCTTGGTGGACCCCAAAAAGAAACGGGCTACACAGAGTTAGTAAAGTCTTTA GAAAGAAACTGGAAGTTAATCCGAGATGAAGGCCTTGCAGTGATGGATAAAGCCAAAGGTCTCTTCCTGCCTGAGGATGAAAACCTGAGGGAAAAAAGGGGACTGGAGCCAGTTCACGCTGTGGCAGCAAGGAAGAAGAAATGAAAATGCAAAGGAGCTCCTAAACCTGTACCTTACTAGAAAAGTTCCCCGAGACAACAGGATGCAGAAGAGGACAGA TCAAATATTCCATCATGCACCCCGGGACTCACGTGTGGCCGCACACAGGGCCCACAAACTGCAGGCTCCGAATGCACCTGGGCTTGGTGATTCCCAAGGAAGGCTGCAAGATTCGATGTGCCAACGAGACCAAGACCTGGGAGGAAGGCAAGGTGCTCATCTTTGATGACTCCTTTGAGCACGAGGTATGGCAGGATGCCTCATCTTTCCGGCTGATA TTCATCGTGGATGTGTGGCATCCGGAACTGACACCACAGCAGAGACGCAGCCTTCCAGCAATTTAGCATGAATTCATGCAAGCTTGGGAAACTCTGGAGAGAGGCTGCCTTTCTGGTTCCATCCTTGGGTGTGAGGATAGAATTTCGAACACCAAGAGTCAATTCCCTTGACTTGCAGCCCGAGTAATTCAAAGCCTCTCCTAGGGTCAGAAGACACTAA AGGGAATATTTGCCTCGCTGCAATTCATTTAGGAAACACCCTGCTGTGTCATCTCATGACAGCACTGGTCTTCTGCCAGTATTTAAGGTGAACATTTGATAGCTTCTACCTTACCAGCCAAAGATATTTTTTCCACATAGAATAGGTCTAATTCAATGTATAATGAGAACATATGTAGAAACTGTGAATGGATTGCTTTAGTTTGTAATTTTTCTATGCAGTTATATTTT TCTAGTGTAGCTAGACTATTTTTGTCATCATGTACCACTACATTTTTGTTTTATTTTAATGACAAGCTGTATAAATGCTTTACTTCTAGCTATTTAATGGTAGCATTACTGGGGAACTCAGACTTCCCCTTTTTTAATTCTTCTTAGTAAAAGATACTCATGAAAAAAGCAGTTTTTTTTCCTAACAAAAAAGAAAGAGCTCATTATGTCAGTGTCTATGAACTGTACCCATCCCAACTC TCAAATCGTTTGGTTTTTTTTTATCTTGATTGAGATCCTTCTCACTATGCTAGTGGTGGAGATATTGACAAAATCCTATTTCTTTCAAAGAGGAACTTTCACACCGAAAAAAGAGCATGGAATTATTTTATATTGTTATAAAAATCCCAGATGCAAATTTTTTTTAATGCCAATTATTAGAGCTTCTGGGGAAAAAAGTATAGTTCACGGAAATAAAACTATGTTCTTTC AGGGTTGGGTGGATAGGTGGCTGCTAGGGTGTCTGGCTCCTGGCGGCTTTGCCATCCATGAGGCAAGGGCTGGGAACACAGTGTCTTTGCCTATGGTAGATCCATGTGAATGTCAGGAAGCCAGCTCTTCAGTCTTGGAGATGATTTCTGCTACAATTCTGTAGAAAGATTAAGGATGGCAGAGTAAAAGGTTACCAAGAATGCCAGGATGTTT TTCTTGGGCGTAGGAGGTCCAGATTACTTTCCTTTTTGATGAAAGAGTTTGGAAGACTGTCCCATCTCTCTGGCTTGAGAAATCTCTGCCATTTTAAACATCACTGTGAAATAGCAATTATTATCATCTGTATTTAGTTTTTAACATTACCCACAACATAGAAATAATAGGTAAAAATCGTCTTGCCTACTCATTCCAAAGATGATCAAGTCATTAATCTAGCAAAGTAT TCATGTATCAGATTTTGTATATTTTGAATCAAAGCTAACTAGGAATGTTAGATATAAGAATGTAATGATATTCATGCACTGAATTCTAAGCCAATATGAACAAAAATGCTGCATGAATGGCACATATAGGTCACCAAAGTTCATTCACAGGTAGAAAAAACTTGTGCTTTCTTTTCCATCTAAAAACAAAAGGAGACTTTCTTTATCTCATTTAAAGAACAGCTCTTTGAAATT GAAATTGACCCTTTTTGCTTGACCTTAAGGAGATTAGCTTCCAGTAGATGAGTTTGCAAAATACTTTTCCTGTTCTTTTGTTTTGCTGGTATTGAAAACATCCACTAAATCAGATGAAGAGGCATGGGAGGAAAAAATATCCAATTAATTACTAAAATCGAGAAGAGAAGGCAAACTCTTGAAAAGTAAAAAAGGTGTTTGTGACCTTCAGTATTTATTGAACAGAGGAAAT AACTGACAAGGGCAATACAATTCAATGTTCATGTAGTAACATTCATGTCACTTGTTGAATTTGGTTCTCATATGTATATTGCATACACATAAATTCAAACTATAAGTCGTCATTTTTGAGCCATCATCTTACATTCATGTAATGAAATTATGGAAGAGTAAAAACTAGCTCTTAACTTAGTAAATAATATGGTATTAAAATCAGGTCACTACAGTAAGGTTCTAAGTATT GCCAATTGAAAAGCTAGAAATGGTATTACTGTTGCAAAGTGTTGTCAATAATTGACTCCAATAGCATTGTAAATACTTGTATCCCACAACTATTTAAACCCAAGCAATAAAATGGATTTTCTAATTCACTTCAATTCTTTATTTCTCTTACCTATCTATGTCTTGGTACAATAAGAAAGTGTTTCCATCACTGCATTGGTAGAATTTTCAGTGTTATTATTTTTGTGATT TCGTATGTCTAACACAAAAATGAATTAGTTTAATTTATATTGTGATACAGTTGTTTGAGAAATATTTTTAATTCTGTTTCAACTTTATTTTCTCCAAGTGTATAATATAAAAATTACTTCTGTTATTGTTCTCTACCAATAGGGGAAAAAATTAAAACATTAGATCCATTGAGAAAGAGATGATGTAATAAATAATTAAGATTAGTAATAATATTATTCAGGGGTGATTATGACCAGTT GAATAATCTCTTTCCCTTGAATTATTTAGCTAACAAATTAACTTCCCAAATATTTAAAATAATGTAAAATCATATTTTACTGCCCATTATTAACTAAAATATTTTGTTTGACTTTGAGCACCAACTGGTAATACTAATAAATACCCATGTCATGCAGATGGCTGGGCGAATAAGAGATGTCTAAAAATATGCACTGGTCTTGGAAAACATGGCACAAGTAAGGATATC ATATATGATGTCTGTTTATTTTATGTCTGATTTCTTTTGAATGAGTAGTTGGGGACTCCATTTCTAAGGAGACTAGGTAAATAAAATGACCTTTGACATTTCA SEQ ID NO:663 Translated polypeptide sequence of ASPH exon 1 MAEDK SEQ ID NO:664 Translated polypeptide sequence of ASPH exon 2 TKHGGHKNGRKGGLSGTSFFTWFMVIALLGVWTSVAVVWFDLVDYEEVL SEQ ID NO:665 Translated polypeptide sequence of ASPH exon 3 KLGIYDADGDGDFDVDDAKVLL SEQ ID NO:666 Translated polypeptide sequence of ASPH exon 4 LKERSTSEPAVPPEEAEPHTEPEEQVPVEA SEQ ID NO:667 Translated polypeptide sequence of exon 5 of ASPH PQNIEDEAKEQIQSLLHEMVHAEH SEQ ID NO:668 Translated polypeptide sequence of exon 6 of ASPH EGEDLQQEDGPTGEPQQEDDEFLMATDVDDRFETLEPEVSHE SEQ ID NO:669 Translated polypeptide sequence of exon 7 of ASPH TEHSYHVEET SEQ ID NO:670 Translated polypeptide sequence of exon 8 of ASPH SQDCNQDMEEMMSEQENP SEQ ID NO:671 Translated polypeptide sequence of ASPH exon 9 SSEPVVEDERLHHDT SEQ ID NO:672 Translated polypeptide sequence of exon 10 of ASPH DVTYQVYEEQ SEQ ID NO:673 Translated polypeptide sequence of ASPH exon 11 VYEPLENEGIEIT SEQ ID NO:674 Translated polypeptide sequence of ASPH exon 12 VTAPPEDNPVEDSQVIVE SEQ ID NO:675 Translated polypeptide sequence of ASPH exon 13 VSIFPVEEQQEVPP SEQ ID NO:676 Translated polypeptide sequence of ASPH exon 14 TNRKTDDPEQKAK SEQ ID NO:677 Translated polypeptide sequence of exon 15 of ASPH KKKKPKLLNKFDKTIKAELDAAEKLRKR SEQ ID NO:678 Translated polypeptide sequence of exon 16 of ASPH GKIEEAVNAFKELVRKYPQSPRARYGKAQ SEQ ID NO:679 Translated polypeptide sequence of ASPH exon 17 CEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLKLSLKRRSDRQQFL SEQ ID NO:680 Translated polypeptide sequence of ASPH exon 18 HMRGSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEE SEQ ID NO:681 Translated polypeptide sequence of ASPH exon 19 VLSVTPNDGFAKVHYGFILKAQNKIAESIPYLK SEQ ID NO:682 Translated polypeptide sequence of ASPH exon 20 EGIESGDPGTDDGRFYFHLGDAMQRVGNKE SEQ ID NO:683 Translated polypeptide sequence of ASPH exon 21 AYKWYELGHKRGHFASVWQRSLYNVNGLKAQPWWTPKETGYTELVK SEQ ID NO:684 Translated polypeptide sequence of ASPH exon 22 SLERNWKLIRDEGLAVMDKAKGLFLPPEDENLREKGDWSQFTLWQQ SEQ ID NO:685 Translated polypeptide sequence of ASPH exon 23 RRNENACKGAPKTCTLLEKFPETTGCRRGQ SEQ ID NO:686 Translated polypeptide sequence of ASPH exon 24 IKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANET SEQ ID NO:687 Translated polypeptide sequence of ASPH exon 25 TWEEGKVLIFDDSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI The complete protein sequence of SEQ ID NO:688 ASPH MAEDKETKHGGHKNGRKGGLSGTSFFTWFMVIALLGVWTSVAVVWFDLVDYEEVLGKLGIYDADGDGDFDVDDAKVLLGLKERSEPAVPPEEAEPHTEPEEQVPVEAEPQNIEDEAKEQIQSLLHEMVHAEHVEGEDLQQEDGPTGEPQQEDDEFLMATDVDDRFETLEPEVSHEETEHSYHVEETVS QDCNQDMEEMMSEQENPDSSEPVVEDERLHHDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPEDNPVEDSQVIVEEVSIFPVEEQQEVPPETNRKTDDPEQKAKVKKKKPKLLNKFDKTIKAELDAAEKLRKRGKIEEAVNAFKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVL RGAIETYQEVASLPDVPADLLKLSLKRRSDRQQFLGHMRGSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEVLSVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPGTDDGRFYFHLGDAMQRVGNKEAYKWYELGHKRGHFASVWQRSLYNVNGLKAQP WWTPKETGYTELVKSLERNWKLIRDEGLAVMDKAKGLAFLPEDENLREKGDWSQFTLWQQGRRNENACKGAPKTCTLLEKFPETTGCRRGQIKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANETKTWEEGKVLIFDDSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI SEQ ID NO:689 The polynucleotide sequence of all exons 1-22 of ASPH arranged in order SEQ ID NO:690 Translated polypeptide sequence of all exons 1-22 of ASPH arranged in order NOTCH2 sequence informationSEQ ID NO:691 Sequence CCTCCTGTACTCCAGGCTCCACCTGCATCGACCGTGTGGCCTCCTTCTCTTGCATGTGCCCAGAGGGGAAGGCAG Sequence from NOTCH2 exon 6 at 5' of NOTCH2-NRG1 fusion GGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG SEQ ID NO:693 Notch2 - NRG1 polynucleotide sequence CCTCCTGTACTCCAGGCTCCACCTGCATCGACCGTGTGGCCTCCTTCTCTTGCATGTGCCCAGAGGGGAAGGCAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG SEQ ID NO: 694 Notch2-NRG1 polypeptide sequence SCTPGSTCIDRVASFSCMCP EGKAATSTSTTGTSHLVKCAEKEKTFCVN SEQ ID NO:695 NOTCH2 Exon 1 AGGCTGCTTCGTTGCACACCCGAGAAAGTTTCAGCCAAACTTCGGGCGGCGGCTGAGGCGGCGGCCGAGGAGCGGCGGACTCGGGGCGCGGGGAGTCGAGGCATTTGCGCCTGGGCTTCGGAGCGTAGCGCCAGGGCCTGA GCCTTTGAAGCAGGAGGAGGGGAGGAGAGAGTGGGGCTCCTCTATCGGGACCCCCTCCCCATGTGGATCTGCCCAGGCGGCGGCGGCGGCGGCGGAGGAGGAGGCGACCGAGAAGATGCCCGCCCTGCGCCCCGCTCTGCTGTGGGCGCTGCTGGCGCTCTGGCTGTGCTGCGCGGCCCCCGCGCATG SEQ ID NO: 696 NOTCH2 Exon 2 CATTGCAGTGTCGAGATGGCTATGAACCCTGTGTAAATGAAGGAATGTGTGTTACCTACCACAATGGCACAGGATACTGCAA SEQ ID NO:697 NOTCH2 Exon Exon 3 ATGTCCAGAAGGCTTCTTGGGGGAATATTGTCAACATCGAGACCCCTGTGAGAAGAACCGCTGCCAGAATGGTGGGACTTGTGTGGCCCAGGCCATGCTGGGGAAAGCCACGTGCCGATGTGCCTCAGGGTTTACAGGAGAGGACTGCCAGTACTCAACATCATCCATGCTTTGTGTCTCGACCCTGCCTGAATGGCGGCAC ATGCCATATGCTCAGCCGGGATACCTATGAGTGCACCTGTCAAGTCGGGTTTACAG SEQ ID NO:698 NOTCH2 exon 4 GTAAGGAGTGCCAATGGACGGATGCCTGCCTGTCTCATCCCTGTGCAAATGGAAGTACCTGTACCACTGTGGCCAACCAGTTCTCCTGCAAATGCCTCACAGGCTTCACAGGGCAGAAATGTGAGACTGATGTCA ATGAGTGTGACATTCCAGGACACTGCCAGCATGGTGGCACCTGCCTCAACCTGCCTGGTTCCTACCAGTGCCAGTGCCCTCAGGGCTTCACAGGCCAGTACTGTGACAGCCTGTATGTGCCCTGTGCACCCCTCACCTTGTGTCAATGGAGGCACCTGTCGGCAGACTGGTGACTTCACTTTTGAGTGCAACTGCCTTCCAG Other than 699 NOTCH2 Exon 5 GTTTTGAAGGGAGCACCTGTGAGAGGAATATTGATGACTGCCCTAACCACAGGTGTCAGAATGGAGGGGTTTGTGTGGATGGGGTCCAACACTTACAACTGCCGCTGTCCCCCCACAATGGACAG SEQ ID NO: 700 NOTCH2 exon 6 GACAGTTCTGCACAGAGGATGTGGATGAATGCCTGCTGCAGCCCAATGCCTGTCAAA ATGGGGGCACCTGTGCCAACCGCAATGGAGGCTATGGCTGTGTATGTGTCAACGGCTGGAGTGGAGATGACTGCAGTGAGAACATTGATGATTGTGCCTTCGCCTCCTGTACTCCAGGCTCCACCTGCATCGACCGTGTGGCCTCCTTCTCTTGCATGTGCCCAGAGGGGAAGGCAG 7 GTCTCCTGTGTCATCTGGATGATGCATGCATCAGCAATCCTTGCCACAAGGGGGCACTGTGTGACACCAACCCCTAAATGGGCAATATATTTGCACCTGCCCACAAGGCTACAAAGGGGCTGACTGCACAGAAGATGTGGATGAATGTGCCATGG SEQ ID NO: 702 NOTCH2 exon 8-34 CCAATAGCAATCCTTGT GAGCATGCAGGAAAATGTGTGAACACGGATGGCGCCTTCCACTGTGAGTGTCTGAAGGGTTATGCAGGACCTCGTTGTGAGATGGACATCAATGAGTGCCATTCAGACCCCTGCCAGAATGATGCTACCTGTCTGGATAAGATTGGAGGCTTCACATGTCTGTGCATGCCAGGTTTCAAAGGTGTGCATTGTGAATTAGAAATAAATGAATGTCAGAGCAACCC TTGTGTGAACAATGGGCAGTGTGTGGATAAAGTCAATCGTTTCCAGTGCCTGTGTCCTCCTGGTTTCACTGGGCCAGTTTGCCAGATTGATATTGATGACTGTTCCAGTACTCCGTGTCTGAATGGGGCAAAGTGTATCGATCACCCGAATGGCTATGAATGCCAGTGTGCCACAGGTTTCACTGGTGTGTTGTGTGAGGAGAACATTGACAACTGTGACC CCGATCCTTGCCACCATGGTCAGTGTCAGGATGGTATTGATTCCTACACCTGCATCTGCAATCCCGGGTACATGGGCGCCATCTGCAGTGACCAGATTGATGAATGTTACAGCAGCCCTTGCCTGAACGATGGTCGCTGCATTGACCTGGTCAATGGCTACCAGTGCAACTGCCAGCCAGGCACGTCAGGGGTTAATTGTGAAATTAATTTTGAT GACTGTGCAAGTAACCCTTGTATCCATGGAATCTGTATGGATGGCATTAATCGCTACAGTTGTGTCTGCTCACCAGGATTCACAGGGCAGAGATGTAACATTGACATTGATGAGTGTGCCTCCAATCCCTGTCGCAAGGGTGCAACATGTATCAACGGTGTGAATGGTTTCCGCTGTATATGCCCCGAGGGACCCCATCACCCCAGCTGCTACTCACAGGTGA ACGAATGCCTGAGCAATCCCTGCATCCATGGAAACTGTACTGGAGGTCTCAGTGGATATAAGTGTCTCTGTGATGCAGGCTGGGTTGGCATCAACTGTGAAGTGGACAAAAATGAATGCCTTTCGAATCCATGCCAGAATGGAGGAACTTGTGACAATCTGGTGAATGGATACAGGTGTACTTGCAAGAAGGGCTTTAAAGGCTATAACTGCCAGGTGA ATATTGATGAATGTGCCTCAAATCCATGCCTGAACCAAGGAACCTGCTTTGATGACATAAGTGGCTACACTTGCCACTGTGTGCTGCCATACAAGGCAAGAATTGTCAGACAGTATTGGCTCCCTGTTCCCCAAACCCTTGTGAGAATGCTGCTGTTTGCAAAGAGTCACCAAATTTTGAGAGTTATACTTGCTTGTGTGCTCCTGGCTGGCAAGGTCAGCG GTGTACCATTGACATTGACGAGTGTATCTCCAAGCCCTGCATGAACCATGGTCTCTGCCATAACACCCAGGGCAGCTACATGTGTGAATGTCCACCAGGCTTCAGTGGTATGGACTGTGAGGAGGACATTGATGACTGCCTTGCCAATCCTTGCCAGAATGGAGGTTCCTGTATGGATGGAGTGAATACTTTCCTGCCTCTGCCTTCCGGGTTTCACTGGG GATAAGTGCCAGACAGACATGAATGAGTGTCTGAGTGAACCCTGTAAGAATGGAGGGACCTGCTCTGACTACGTCAACAGTTACACTTGCAAGTGCCAGGCAGGATTTGATGGAGTCCATTGTGAGAACAACATCAATGAGTGCACTGAGAGCTCCTGTTTCAATGGTGGCACATGTGTTGATGGGATTAACTCCTTCTCTTGCTTGTGCCCTGTGGGTTT CACTGGATCCTTCTGCCTCCATGAGATCAATGAATGCAGCTCTCATCCATGCCTGAATGAGGGAACGTGTGTTGATGGCCTGGGTACCTACCGCTGCAGCTGCCCCCTGGGCTACACTGGGAAAAACTGTCAGACCCTGGTGAATCTCTGCAGTCGGTCTCCATGTAAAACAAAGGTACTTGCGTTCAGAAAAAAGCAGAGTCCCAGTGCCTATGTCCATCTG GATGGGCTGGTGCCTATTGTGACGTGCCCAATGTCTCTTGTGACATAGCAGCCTTCCAGGAGAGGTGTGCTTGTTGAACACTTGTGCCAGCACTCAGGTGTCTGCATCAATGCTGGCAACACGCATTACTGTCAGTGCCCCCTGGGCTATACTGGGAGCTACTGTGAGGAGCAACTCGATGAGTGTGCGTCCAACCCCTGCCAGCACGGGCAACATG CAGTGACTTCATTGGTGGATACAGATGCGAGTGTGTCCCAGGCTATCAGGGTGTCAACTGTGAGTATGAAGTGGATGAGTGCCAGAATCAGCCCTGCCAGAATGGAGGCACCTGTATTGACCTTGTGAACCATTTCAAGTGCTCTTGCCCACCAGGCACTCGGGGCCTACTCTGTGAAGAGAACATTGATGACTGTGCCCGGGGTCCCCATTGCCTTAATG GTGGTCAGTGCATGGATAGGATTGGAGGCTACAGTTGTCGCTGCTTGCCTGGCTTTGCTGGGGAGCGTTGTGAGGGAGACATCAACGAGTGCCTCTCCAACCCCTGCAGCTCTGAGGGCAGCCTGGACTGTATACAGCTCACCAATGACTACCTGTGTGTTTGCCGTAGTGCCTTTACTGGCCGGCACTGTGAAACCTTCGTCGATGTGTGT CCCCAGATGCCCTGCCTGAATGGAGGGACTTGTGCTGTGGCCAGTAACATGCCTGATGGTTTCATTTGCCGTTGTCCCCCGGGATTTTCCGGGGCAAGGTGCCAGAGCAGCTGTGGACAAGTGAAATGTAGGAAGGGGGAGCAGTGTGTGCACACCGCCTCTGGACCCCGCTGCTTCTGCCCCAGTCCCGGGACTGCGAGTCAGGCTGTG CCAGTAGCCCCTGCCAGCACGGGGGCAGCTGCCACCCTCAGCGCCAGCCTCCTTATTACTCCTGCCAGTGTCCCCACCATTCTCGGGTAGCCGCTGTGAACTCTACACGGCACCCCCCAGCACCCCTCCTGCCACCTGTCTGAGCCAGTATTGTGCCGACAAAGCTCGGGATGGCGTCTGTGATGAGGCCTGCAACAGCCATGCCTGCCAGTGGGATGG GGGTGACTGTTTCTCTCACCATGGAGAACCCCTGGGCCAACTGCTCCTCCCCACTTCCCTGCTGGGATTATATCAACAACCAGTGTGATGAGCTGTGCAACACGGTCGAGTGCCTGTTTGACAACTTTGAATGCCAGGGGAACAGCAAGACATGCAAGTATGACAAATACTGTGCAGACCACTTCAAAAGACAACCAGTGAGGA GTGTGGTTGGGATGGGCTGGACTGTGCTGCTGACCAACCTGAGAACCTGGCAGAAGGTACCCTGGTTATTGTGGTATTGATGCCACCTGAACAACTGCTCCAGGATGCTCGCAGCTTCTTGCGGGCACTGGGTACCCTGCTCCACACCAACCTGCGCATTAAGCGGGACTCCCAGGGGGAACTCATGGTGTACCCCTATTATGGTGA GAAGTCAGCTGCTATGAAGAAACAGAGGATGACACGCAGATCCCTTCCTGGTGAACAAGAACAGGAGGTGGCTGGCTCTAAAGTCTTTCTGGAAATTGACAACCGCCAGTGTGTTCAAGACTCAGACCACTGCTTCAAGAACACGGATGCAGCAGCAGCTCTCCTGGCCTCTCACGCCATACAGGGGACCCTGTCATACCCCTTGTGTCTGTCGTCAGTGAAT CCCTGACTCCAGAACGCACTCAGCTCCTCTATCTCCTTGCTGTTGCTGTTGTCATCATTCTGTTTATTATTCTGCTGGGGGTAATCATGGCAAAACGAAAGCGTAAGCATGGCTCTCTCTGGCTGCCTGAAGGTTTCACTCTTCGCCGAGATGCAAGCAATCACAAGCGTCGTGAGCCAGTGGGACAGGATGCTGTGGGGCTGAAAAATCTCTCA GTGCAAGTCTCAGAAGCTAACCTAATTGGTACTGGAACAAGTGAACACTGGGTCGATGATGAAGGGCCCCAGCCAAAGAAAGTAAAGGCTGAAGATGAGGCCTTACTCTCAGAAGAAGATGACCCCATTGATCGACGGCCATGGACACAGCAGCACCTTGAAGCTGCAGACATCCGTAGGACACCATCGCTGGCTCTCACCCCTCCTCAGGCAGAGCAGGAG GTGGATGTGTTAGATGTGAATGTCCGTGGCCCAGATGGCTGCACCCCATTGATGTTGGCTTCTCTCCGAGGAGGCAGCTCAGATTTGAGTGATGAAGATGAAGATGCAGAGGACTCTTCTGCTAACATCATCACAGACTTGGTCTACCAGGGTGCCAGCCTCCAGGCCCAGACAGACCGGACTGGTGAGATGGCCCTGCACCTTGCAGCCCGCTACTCAC GGGCTGATGCTGCCAAGCGTCTCCTGGATGCAGGTGCAGATGCCAATGCCCAGGACAACATGGGCCGCTGTCCACTCCATGCTGCAGTGGCAGCTGATGCCCAAGGTGTCTTCCAGATTCTGATTCGCAACCGAGTAACTGATCTAGATGCCAGGATGAATGATGGTACTACACCCCTGATCCTGGCTGCCCGCCTGGCTGTGGAGGGAATG GTGGCAGAACTGATCAACTGCCAAGCGGATGTGAATGCAGTGGATGACCATGGAAAATCTGCTCTTCACTGGGCAGCTGCTGTCAATAATGTGGAGGCAACTCTTTTGTTGTTGAAAAATGGGGCCAACCGAGACATGCAGGACAACAAGGAAGAGACCTCTGTTTCTTGCTGCCCGGGAGGGGAGCTATGAAGCAGCCAAGATCCTGTTA GACCATTTTTGCCCAATCGAGACATCCACAGACCATATGGATCGTCTTCCCCGGGATGTGGCTCGGGATCGCATGCACCATGACATTGTGCGCCTTCTGGATGAATACAATGTGACCCCAAAGCCCTCCAGGCACCGTGTTGACTTCTGCTCTCTCACCTGTCATCTGTGGGCCCAACAGATCTTTCCTCAGCCTGAAGCACCACCCCAATGGGCAAGAGTCT AGACGGCCCAGTGCCAAGAGTACCATGCCTACTAGCCTCCCTAACCTTGCCAAGGAGGCAAAGGATGCCAAGGGTAGTAGGAGGAAGAAGTCTCTGAGTGAGAAGGTCCAACTGTCTGAGAGTTCAGTAACTTTTCCCCTGTTGATTCCCTAGAATCTCCTCACACGTATGTTTCCGACACCACATCCTCTCCAATGATTACATCCCCCTGGGATCTTACAGGCCTCACCCAAC CCTATGTTGGCCACTGCCGCCCCTCCTGCCCCAGTCCATGCCCAGCATGCACTATTCTTTTTCTAACCTTCATGAAATGCAGCCTTTGGCACATGGGGCCAGCACTGTGCTTCCCTCAGTGAGCCAGTTGCTATCCCACCACCATTGTGTCTCCAGGCAGTGGCAGTGCTGGAAGCTTGAGTAGGCTCCATCCAGTCCCAGTCCCAGCAGATTGGATGAAC CGCATGGAGGTGAATGAGACCCAGTACAATGAGATGTTTGGTATGGTCCTGGCTCCAGCTGAGGGCACCCATCCTGGCATAGCTCCCAGAGCAGGCCACCTGAAGGGAAGCACATAACCACCCCTCGGGAGCCCTTGCCCCCCATTGTGACTTTCCAGCTCATCCCTAAAGGCAGTATTGCCCAACCAGCGGGGGCCTCCCCAGCCTCAGTCCACCTGCC CTCCAGCTGTTGCGGGCCCCCTGCCCACCATGTACCAGATTCCAGAAATGGCCCGTTTGCCCAGTGTGGCTTTCCCACTGCCATGATGCCCCAGCAGGACGGGCAGGTAGCTCAGCCATTCTCCCAGCCTATCATCCTTTCCCAGCCCTCTGTGGGCAAGTACCCCACCCCCTTCAGCACAGTTATGCTTCCTCAAATGCTGCTGAGCGAACACCCAGTCA CAGTGGTCACCTCCAGGGTGAGCATCCCTACCTGACACCATCCCCAGAGTCTCCTGACCAGTGGTCAAGTTCATCACCCACTCTGCTTCTGACTGGTCAGATGTGACCACCAGCCCTACCCCTGGGGGTGCTGGAGGAGGTCACGCGGGGACCTGGGACACACATGTCTGAGCCACCACACAACAACATGCAGGTTTATGCGTGAGAGAGTCCACCTCAGT GTAGAGACATAACTGACTTTTGTAAATGCTGCTGAGGAACAAATGAAGGTCATCCGGGAGAGAAATGAAGAAATCTCTGGAGCCAGCTTCTAGAGGTAGGAAAGAGAAGATGTTTCTTATTCAGATAATGCAAGAGAAGCAATTCGTCAGTTTCACTGGGTATCTGCAAGGCTTATTGATTATTCTAATCTAATAAGACAAGTTTGTGGAAATGCAAGATGAATACAAG CCTTGGGTCCATGTTTACTTCTCTTCTATTTGGAGAATAAGATGGATGCTTATTGAAGCCCAGACATTCTTGCAGCTTGGACTGCATTTTAAGCCCTGCAGGCTTCTGCCATATCCATGAGAAGATTCTACACTAGCGTCCTGTTGGGAATTATGCCCTGGAATTCTGCCTGAATTGACCTACGCATCTCCTCCTCCTTGGACATTCTTTTGTCTTCATTTG GTGCTTTTGGTTTTGCACCTCTCCGTGATTGTAGCCCTACCAGCATGTTATAGGGCAAGACCTTTGTGCTTTTGATCATTCTGGCCCATGAAAGCAACTTTGGTCTCCTTTCCCCTCCTGTCTTCCCGGTATCCCTTGGAGTCTCCAAGGTTTTACTTTGGTATGGTTCTCAGCACAAACCTTTCAAGTATGTTGTTTCTTTGGAAAATGGACATACTGTATTGTGT TCTCCTGCATATATCATTCCTGGAGAGAGAAGGGGAGAAGAATACTTTTCTTCAACAAATTTTGGGGGCAGGAGATCCCTTCAAGAGGCTGCACCTTAATTTTCTTGTCTGTGTGCAGGTCTTCATATAAACTTTACCAGGAAGAAGGGTGTGAGTTGTTGTTTTTCTGTGTATGGGCCTGGTCAGTGTAAAGTTTTATCCTTGATAGTCTAGTTACTATGACCCT CCCCACTTTTTTAAAACCAGAAAAAGGTTTGGAATGTTGGAATGACCAAGAGACAAGTTAACTCGTGCAAGAGCCAGTTACCCACCCACAGGTCCCCTACTTCCTGCCAAGCATTCCATTGACTGCCTGTATGGAACACATTTGTCCCAGATCTGAGCATTCTAGGCCTGTTTCACTCACTCACCCAGCATATGAAACTAGTCTTAACTGTTGAGCCTTTCCTTTCATATCCAC AGAAGACACTGTCTCAAATGTTGTACCCCTTGCCATTTAGGACTGAACTTTCCTTAGCCCAAGGGACCCAGTGACAGTTGTCTTCCGTTTGTCAGATGATCAGTCTCTACTGATTATCTTGCTGCTTAAAGGCCTGCTCACCAATCTTTTCTTCACACCGTGTGGTCCGTGTTACTGGTATACCCAGTATGTTCTCACTGAAGACATGGACTTTATATGTTCAAGTGCAGGA ATTGGAAAGTTGGACTTGTTTTCTATGATCCAAAACAGCCCTATAAGAAGGTTGGAAAAGGAGGAACTATATAGCAGCCTTTGCTATTTTCTGCTACCATTTCTTTTCCTCTGAAGCGGCCATGACATTCCCTTTGGCAACTAACGTAGAAACTCAACGAACATTTTCCTTTCCTAGAGTCACCTTTTAGATGATAATGGACAACTATAGACTTGCTCATTGTTCA GACTGATTGCCCCTCACCTGAATCCACTCTCTGTATTCATGCTCTTGGCAATTTCTTTGACTTTCTTTTAAGGGCAGAAGCATTTTAGTTAATTGTAGATAAAGAATAGTTTTTCTTCCTCTTCTCCTTGGGCCAGTTAATAATTGGTCCATGGCTACACTGCAACTTCCGTCCAGTGCTGTGATGCCCATGACACCTGCAAAATAAGTTCTGCCTGGGCATTTTGTAG ATATTAACAGGTGAATTCCCGACTCTTTTGGTTTGAATGACAGTTCTCATTCCTTCTATGGCTGCAAGTATGCATCAGTGCTTCCCACTTACCTGATTTGTCTGTCGGTGGCCCCATATGGAAACCCTGCGTGTCTGTTGGCATAATAGTTTTACAAATGGTTTTTCAGTCCTATCCAAATTTATTGAACCAACAAAAATAATTACTTCTGCCCTGAGATAAGCAGATT AAGTTTTGTTCATTCTCTGCTTTATTCTCTCCATGTGGCAACATTCTGTCAGCCTCTTTCATAGTGTGCAAACATTTTATCATTCTAAATGGTGACTCTCTGCCCTTGGACCCATTTATTATTCACAGATGGGGAGAACCTATCTGCATGGACCCTGTGGACCACAGCGTACCTGCCCCTTTCTGCCCTCCTGCTCCAGCCCCACTTCTGAAAGTATCAGCTACTGATCCAGC CACTGGATATTTTATATCCTCCCTTTTCCTTAAGCACAATGTCAGACCAAATTGCTTGTTTCTTTTTCTTGGACTACTTTTAATTTGGATCCTTTGGGTTTGGAGAAAGGGAATGTGAAAGCTGTCATTACAGACAACAGGTTTCAGTGATGAGGAGGACAACACTGCCTTTCAAACTTTTTACTGATCTCTTAGATTTTAAGAACTCTTGAATTGTGTGGTATCT AATAAAAGGGAAGGTAAGATGGATAATCACTTTCTCATTTGGGTTCTGAATTGGAGACTCAGTTTTTTATGAGACACATCTTTTATGCCATGTATAGATCCTCCCCTGCTATTTTTGGTTTATTTTTTATTGTTATAAATGCTTTCTTTCTTTGACTCCTCTTCTGCCTGCCTTTGGGGATAGGTTTTTTTTGTTTGTTTTATTTGCTTCCTCTGTTTTGTTTTAGCA TCATTTTCTTATGTGAGGTGGGGAAGGGAAAGGTATGAGGGAAAGAGAGTCTGAGAATTAAAATATTTAGTATAAGCAATTGGCTGTGATGCTCAAATCCATTGCATCCTCTTATTGAATTTGCCAATTTGTAATTTTTGCATAATAAAGAACCAAAGGTGTAATGTTTTGTTGAGAGGTGGTTTAGGGATTTTGGCCCTAACCAATACATTGAATGTATG ATGACTATTTGGGAGGACACATTTATGTACCCAGAGGCCCCCACTAATAAGTGGTACTATGGTTACTTCCTTGTGTACATTTCTCTAAAAGTGATATTATATCTGTTTGTATGAGAAACCCAGTAACCAATAAAATGACCGCATATTCCTGACTAAACGTAGTAAGGAAAATGCACACTTTGTTTTACTTTCCGTTTCATTCTAAAGGTAGTTAAGATGAAATTTATATGA AAGCATTTTTATCACAAATAAAAAAGGTTTGCCAAGCTCAGTGGTGTTGTATTTTTTTATTTCCAATACTGCATCCATGGCCTGGCAGTGTTACCTCATGATGTCATAATTTGCTGAGAGAGCAAATTTTCTTTTCTTTCTGAATCCCACAAAAGCCTAGCACCAAACTTCTTTTTTTCTTCCTTTAATTAGATCATAAATAAATGATCCTGGGGAAAAAGCATCTGTCAAAT AGGAAACATCACAAAACTGAGCACTTCTTCTGTGCACTAGCCATAGCTGGTGACAAACAGATGGTTGCTCAGGGACAAGGTGCCTTCCAATGGAAATGCGAAGTAGTTGCTATAGCAAGAATTGGGAACTGGGATATAAGTCATAATATTAATTATGCTGTTATGTAAATGATTGGTTTGTAACATTCCTTAAGTGAAATTTGTGTAGAACTTAATATACAGGATTA TAAAATAATATTTTGTGTATAAATTTGTTATAAGTTCACATTCATACATTTATTTATAAAGTCAGTGAGATATTTGAACATGAA SEQ ID NO:703 The complete mRNA polynucleotide sequence of NOTCH2 SEQ ID NO:704 The translated polypeptide sequence of NOTCH2 exon 1 MPALRPALLWALLALWLCCAAPAH SEQ ID NO:705 The translated polypeptide sequence of exon 2 of NOTCH2 LQCRDGYEPCVNEGMCVTYHNGTGYC SEQ ID NO:706 The translated polypeptide sequence of exon 3 of NOTCH2 CPEGFLGEYCQHRDPCEKNRCQNGGTCVAQAMLGKATCRCASGFTGEDCQYSTSHPCFVSRPCLNGGTCHMLSRDTYECTCQVGFT SEQ ID NO:707 NOTCH The translated polypeptide sequence of exon 4 KECQWTDACLSHPCANGSTCTTVANQFSCKCLTGFTGQKCETDVNECDIPGHCQHGGTCLNLPGSYQCQCPQGFTGQYCDSLYVPCAPSPCVNGGTCRQTGDFTFECNCLP SEQ ID NO: 708 of NOTCH2 Translated polypeptide sequence of exon 5 FEGSTCERNIDDCPNHRCQNGGVCVDGVNTYNCRCPPQWT SEQ ID NO: 709 Translated polypeptide sequence of exon 6 of NOTCH2 QFCTEDVDECLLQPNACQNGGTCANNRNGGYGCVCVNGWSGDDCSENIDDCAFASCTPGSTCIDRVASFSCMCPEGKA SEQ ID NO: 710 of exon 7 of NOTCH2 Translated polypeptide sequence LLCHLDDACISNPCHKGALCDTNPLNGQYICTCPQGYKGADCTEDVDECAM SEQ ID NO:711 NOTCH2 external expression The translated polypeptide sequence of sub-8-34 SEQ ID NO:712 The whole protein sequence of NOTCH2 SEQ ID NO:713 The whole exon 1-6 of NOTCH2 The polynucleotide sequence SEQ ID NO:714 The whole exon of NOTCH2 Translated polypeptide sequences of sub-1-6 in sequenceCD74 sequence informationSEQ ID NO:715 Sequence from CD74 exon 2 at 5' of CD74-NRG1 fusion AGGGCCGGCTGGACAAACTGACAGTCACCTCCCAGAACCTGCAGCTGGAGAACCTGCGCATGAAGCTTCCCAAGC SEQ ID NO:716 NRG1 exon 2 sequence at 3' of CD74-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO:717 CD74-NRG1 polynucleotide sequence AGGGCCGGCTGGACAAACTGACAGTCACCTCCCAGAACCTGCAGCTGGAGAACCTGCGCATGAAGCTTCCCAAGCCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO:718 CD74-NRG1 polypeptide sequence GRLDKLTVTSQNLQLENLRMKLPKPLPPRLKEMKSQESAAAGSKLVLRCE SEQ ID NO:719 CD74 exon 1 ATCCTGCCCCGCAAAAGGCAGCTTCACCAAAGTGGGGTATTTCCAGCCTTTGTAGCTTTCACTTCCATCTACCAAGTGGGCGGAGTGGCCTTCTGTGGACGAATCAGATTCCTCTCCAGCACCGACTTTAAGAGGCGAGCCGGGGGGTCCAGGGTCCCAGATGCACAGGAGGAGAAGCAGGAGCTGTCGGGAAGATCAGAAGCCAGTCATG GATGACCAGCGCGACCTTATCTCCAACAATGAGCAACTGCCCATGCTGGGCCGGCGCCCTGGGGCCCCGGAGAG SEQ ID NO:720 CD74 exon 2 CAAGTGCAGCCGCGGAGCCCTGTACACAGGCTTTTCCATCCTGGTGACTCTGCTCCTCGCTGGCCAGGCCACCACCGCCTACTTCCTGTACCAGCAGCAGGGCCGGCTGGACAAACTGACAGTCACCTCCCAGAACCTGCAGCTGGAGAACCTGCGCATGAAGCTTCCCAAGC SEQ ID NO:721 CD74 exon 3 CTCCCAAGCCTGTGAGCAAGATGCGCATGGCCACCCCGCTGCTGATGCAGGCGCTGCCCATGGGAGCCCTGCCCCAGGGG SEQ ID NO:722 CD74 exon 4 CCCATGCAGAATGCCACCAAGTATGGCAACATGACAGAGGACCATGTGATGCACCTGCTCCAG SEQ ID NO:723 CD74 exon 5 AATGCTGACCCCCTGAAGGTGTACCCGCCACTGAAGGGGAGCTTCCCGGAGAACCTGAGACACCTTAAGAACACCATGGAGACCATAGACTGGAAG SEQ ID NO:724 CD74 exon 6 GTCTTTGAGAGCTGGATGCACCATTGGCTCCTGTTTGAAATGAGCAGGCACTCCTTGGAGCAAAAGCCCACTGACGCTCCACCGAAAG SEQ ID NO:725 CD74 exon 7 TACTGACCAAGTGCCAGGAAGAGGTCAGCCACATCCCTGCTGTCCACCCGGGTTCATTCAGGCCCAAGTGCGACGAGAACGGCAACTATCTGCCACTCCAGTGCTATGGGAGCATCGGCTACTGCTGGTGTGTCTTCCCCAACGGCACGGAGGTCCCCAACACCAGAAGCCGCGGGCACCATAACTGCAGTG SEQ ID NO:726 CD74 exon 8 AGTCACTGGAACTGGAGGACCCGTCTTCTGGGCTGGGTGTGACCAAGCAGGATCTGGGCCCAG SEQ ID NO:727 CD74 exon 9 TCCCCATGTGAGAGCAGCAGAGGCGGTCTTCAACATCCTGCCAGCCCCACAGCTACAGCTTTCTTGCTCCCTTCAGCCCCCAGCCCCTCCCCCATCTCCCACCCTGTACCTCATCCCATGAGACCCTGGTGCCTGGCTCTTTCGTCACCCTTGGACAAGACAAACCAAGTCGGAACAGCAGATAACAATGCAGCAAGGCCCTGCTGCCCAATCTCCATCTGTCAACAGG GGCGTGAGGTCCCAGGAAGTGGCCAAAAGCTAGACAGATCCCCGTTCCTGACATCACAGCAGCCTCCAACACAAGGCTCCAAGACCTAGGCTCATGGACGAGATGGGAAGGCACAGGGAGAAGGGATAACCCTACACCCAGACCCCAGGCTGGACATGCTGTCCTCTCCCCTCCAGCCTTTGGCCTTGGCTTTTCTAGCCTATTTACCTGCAGGCTGAGC CACTCTTCTTCCCTTTCCCCAGCATCACTCCCCCAAGGAAGAGCCAATGTTTTCCACCCATAATCCTTTCTGCCGACCCCTAGTTCCCTCTGCTCAGCCAAGCTTGTTATCAGCTTTCAGGGCCATGGTTCACATTAGAATAAAAGGTAGTAATTAGAA SEQ ID NO:728 The complete mRNA polynucleotide sequence of CD74 ATCCTGCCCCGCAAAAGGCAGCTTCACCAAAGTGGGGTATTTCCAGCCTTTGTAGCTTTCACTTCCATCTACCAAGTGGGCGGAGTGGCCTTCTGTGGACGAATCAGATTCCTCTCCAGCACCGACTTTAAGAGGCGAGCCGGGGGGTCCAGGGTCCCAGATGCACAGGAGGAGAAGCAGGAGCTGTCGGGAAGATCAGAAGCCAGTCATG GATGACCAGCGCGACCTTATCTCCAACAATGAGCAACTGCCCATGCTGGGCCGGCGCCCTGGGGCCCCGGAGAGCAAGTGCAGCCGCGGAGCCCTGTACACAGGCTTTTCCATCCTGGTGACTCTGCTCCTCGCTGGCCAGGCCACCACCGCCTACTTCCTGTACCAGCAGCAGGGCCGGCTGGACAAACTGACAGTCACCTCCCAGAACCTGCAG CTGGAGAACCTGCGCATGAAGCTTCCCAAGCCTCCCAAGCCCTGTGAGCAAGATGCGCATGGCCACCCCGCTGCTGATGCAGGCGCTGCCCATGGGAGCCCTGCCCCAGGGGCCCATGCAGAATGCCACCAAGTATGGCAACATGACAGAGGACCATGTGATGCACCTGCTCCAGAATGCTGACCCCCTGAAGGTGTACCCGCCACTGAAGGGGAGCTTCCCG GAGAACCTGAGACACCTTAAGAACACCATGGAGACCATAGACTGGAAGGTCTTTGAGAGCTGGATGCACCATTGGCTCCTGTTTGAAATGAGCAGGCACTCCTTGGAGCAAAAGCCCCACTGACGCTCCACCGAAAGTACTGACCAAGTGCCAGGAAGAGGTCAGCCACATCCCTGCTGTCCACCCGGGTTCATTCAGGCCCAAGTGCGACGAGAACGGCAACTAT CTGCCACTCCAGTGCTATGGGAGCATCGGCTACTGCTGGTGTGTCTTCCCCAACGGCACGGAGGTCCCCAACACCAGAAGCCGCGGGCACCATAACTGCAGTGAGTCACTGGAACTGGAGGACCCGTCTTCTGGGCTGGGTGTGACCAAGCAGGATCTGGGCCCAGTCCCATGTGAGAGCAGCAGAGGCGGTCTTCACATCCTGCCAGCCC CACACAGCTACAGCTTTCTTGCTCCCTTCAGCCCCCAGCCCCTCCCCCATCTCCCACCCTGTACCTCATCCCATGAGACCCTGGTGCCTGGCTCTTTCGTCACCCTTGGACAAGACAAACCAAGTCGGAACAGCAGATAACAATGCAGCAAGGCCCTGCTGCCCAATCTCCATCTGTCCAACAGGGGCGTGAGGTCCCAGGAAGTGGCCAAAAGCTAGACAGATCCCCGTTC CTGACATCACAGCAGCCTCCAACACAAGGCTCCAAGACCTAGGCTCATGGACGAGATGGGAAGGCACAGGGAGAAGGGATAACCCTACACCCAGACCCCAGGCTGGACATGCTGACTGTCCTCTCCCCTCCAGCCTTTGGCCTTGGCTTTTCTAGCCTATTTACCTGCAGGCTGAGCCACTCTCTTCCCTTTCCCCAGCATCACTCCCAAGGAAGAGCCAATGTTT TCCACCCATAATCCTTTTCTGCCGACCCCTAGTTCCCTCTGCTCAGCCAAGCTTGTTATCAGCTTTCAGGGCCATGGTTCACATTAGAATAAAAGGTAGTAATTAGAA SEQ ID NO:729 Translated polypeptide sequence of exon 1 of CD74 MHRRRRSSCREDQKPVMDDQRDLISNNEQLPMLGRRPGAPE SEQ ID NO:730 Translated polypeptide sequence of exon 2 of CD74 KCSRGALYTGFSILVTLLLAGQATTAYFLYQQQGRLDKLTVTSQNLQLENLRMKLPK SEQ ID NO:731 Translated polypeptide sequence of exon 3 of CD74 PKPVSKMRMATPLLMQALPMGALPQG SEQ ID NO:732 Translated polypeptide sequence of exon 4 of CD74 PMQNATKYGNMTEDHVMHLLQ SEQ ID NO:733 Translated polypeptide sequence of exon 5 of CD74 NADPLKVYPPLKGSFPENLRHLKNTMETIDWK SEQ ID NO:734 Translated polypeptide sequence of exon 6 of CD74 VFESWMHHWLLFEMSRHSLEQKPTDAPPK SEQ ID NO:735 Translated polypeptide sequence of exon 7 of CD74 LTKCQEEVSHIPAVHPGSFRPKCDENGNYLPLQCYGSIGYCWCVFPNGTEVPNTRSRGHHNCS SEQ ID NO:736 Translated polypeptide sequence of exon 8 of CD74 SLELEDPSSGLGVTKQDLGP SEQ ID NO:737 Translated polypeptide sequence of exon 9 of CD74 PM SEQ ID NO:738 Full protein sequence of CD74 MHRRRRSCREDQKPVMDDQRDLISNNEQLPMLGRRPGAPESKCSRGALYTGFSILVTLLLAGQATTAYFLYQQQGRLDKLTVTSQNLQLENLRMKLPKPPKPVSKMRMATPLLMQALPMGALPQGPMQNATKYGNMTEDHVMHLLQNADPLKVYPPLKGSFPENLRHLKNTMETIDWKVFESWM HHWLLFEMSRHSLEQKPTDAPPKVLTKCQEEVSHIPAVHPGSFRPKCDENGNYLPLQCYGSIGYCWCVFPNGTEVPNTSRSRGHHNCSESLELEDPSSGLGVTKQDLGPVPM SEQ ID NO:739 The polynucleotide sequence of all exons 1-2 of CD74 arranged in order SEQ ID NO:740 Translated polypeptide sequence of all exons 1-2 of CD74 arranged in order SDC4 sequence informationSEQ ID NO:741 Sequence from SDC4 exon 2 at 5' of SDC4-NRG1 fusion TACCAGACGATGAGGATGTAGTGGGGCCCGGGCAGGAATCTGATGACTTTGAGCTGTCTGGCTCTGGAGATCTGG SEQ ID NO:742 NRG1 exon 2 sequence at 3' of SDC4-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO:743 SDC4-NRG1 polynucleotide sequence TACCAGACGATGAGGATGTAGTGGGGCCCGGGCAGGAATCTGATGACTTTGAGCTGTCTGGCTCTGGAGATCTGGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO:744 SDC4-NRG1 polypeptide sequence PDDEDVVGPGQESDDFELSGSGDLALPPRLKEMKSQESAAAGSKLVLRCE SEQ ID NO:745 Exon 1 of SDC4 ACTCGCCGCAGCCTGCGCGCCTTCTCCAGTCCGCGGTGCCATGGCCCCCGCCCGTCTGTTCGCGCTGCTGCTGTTCTTCGTAGGCGGAGTCGCCGAGTCG SEQ ID NO:746 Exon 2 of SDC4 ATCCGAGAGACTGAGGTCATCGACCCCCAGGACCTCCTAGAAGGCCGATACTTCTCCGGAGCCCTACCAGACGATGAGGATGTAGTGGGGCCCGGGCAGGAATCTGATGACTTTGAGCTGTCTGGCTCTGGAGATCTGG SEQ ID NO:747 Exon 3 of SDC4 ATGACTTGGAAGACTCCATGATCGGCCCTGAAGTTGTCCATCCCTTG SEQ ID NO:748 Exon 4 of SDC4 GTGCCTCTAGATAACCATATCCCCTGAGAGGGCAGGGTCTGGGAGCCAAGTCCCCACCGAACCCAAGAAACTAGAGGAGAATGAGGTTATTCCCCAAGAGAATCTCACCCGTTGAAGAGAGTGAGGATGTGTCCAACAAGGTGTCAATGTCCAGCACTGTGCAGGGCAGCAACATCTTTGAGAGAACGGAGGTCCTGGCAG SEQ ID NO:749 Exon 5 of SDC4 CTCTGATTGTGGGTGGCATCGTGGGCATCCTCTTTGCCGTCCTTCCTGATCCTACTGCTCATGTACCGTATGAAGAAGAAGGATGAAGGCAGCTATGACCTGGGCAAGAAACCCATCTACAAGAAAGCCCCCACCAATGAGTTCTACGCGTGAAGCTTGCTTGTGGGCACTGGCTTGGACTTTAGCGGGGAGGGAAGCCAGGGGATTTTGAAG GGTGGACATTAGGGTAGGGTGAGGTCAACCTAATACTGACTTGTCAGTATCTCCAGCTCTGATTACCTTTGAAGTGTTCAGAAGAGACATTGTCTTCTACTGTTCTGCCAGGTTCTTCTTGAGCTTTGGGCCTCAGTTGCCCTGGCAGAAAAATGGATTCAACTTGGCCTTTCTGAAGGCAAGACTGGGATTGGATCACTTCTTAAACTTCCAGTTAAGAATCT AGGTCCGCCCTCCAAGCCCATACTGACCATGCCTCATCCAGAGCTCCTCTGAAGCCAGGGGGCTAACGGATGTTGTGTGGAGTCCTGGCTGGAGGTCCTCCCCAGTGGCCTTCCTCCCTTCCTTCACAGCCGGTCTCCTGCCAGGAAATGGGGGAAGGAACTAGAACCACCTGCACCTTGAGATGTTTCTGTAAATGGGTACTTGTGATCACACT ACGGGAATCTCTGTGGTATATACCTGGGGCCATTCTAGGCTCTTTCAAGTGACTTTTGGAAATCAACCTTTTTTATTTGGGGGGGAGGATGGGGAAAAGAGCTGAGAGTTTATGCTGAAATGGATTTATAGAATATTTGTAAATCTATTTTTAGTGTGTTCGTTTTTTTAACTGTTCATTCCTTTGTGCAGAGTGTATATCTGCCTGGGCAAGAGT GTGGAGGTGCCGAGGTGTCTTCATTCTCTCGCACATTTTCCACAGCACCTGCTAAGTTTGTATTTAATGGTTTTTTGTTTTGTTTTTTGTTGTTTCTTGAAAATGAGAGAAGAGCCGGAGAGATGATTTTTATTAATTTTTTTTTTTTTTTTTTTTTACTATTTATAGCTTTAGATAGGGCCTCCCTTCCCCTTCTTTTCTTTGTTCTCTTTCATTAAACCCCTTCCCC AGTTTTTTTTTTATACTTTAAAACCCCGCTCCTCATGGCCTTGGCCCTTTCTGAAGCTGCTTCCTCTTATAAAATAGCTTTTGCCGAAACATAGTTTTTTTTTAGCAGATCCCAAAAATATAATGAAGGGGATGGTGGGATATTTGTGTCTGTGTTCTTATAATATATTATTTATTCTTCCTTGGTTCTAGAAAAATAGATAAATAATATTTTTTTCAGGAAATAGTGTGGTGT TTCCAGTTTGATGTTGCTGGGTGGTTGAGTGAGTGAATTTTCATGTGGCTGGGTGGGTTTTTTGCCTTTTTCTCTTGCCCTGTTCCTGGTGCCTTCTGATGGGGCTGGAATAGTTGAGGTGGATGGTTCTACCCTTTCTGCCTTCTGTTTGGGACCCAGCTGGTGTTCTTTGGTTTGCTTTCTTCAGGCTCTAGGGCTGTGCTATCCA ATACAGTAACCACATGCGGCTGTTTAAAAGTTAAGCCAATTAAAATCACATAAGATTAAAAATTCCTTCCTCAGTTGCACTAACCACGTTTCTAGAGGCGTCACTGTATGTAGTTCATGGCTACTGTACTGACAGCGAGAGCATGTCCATCTGTTGGACAGCACTATTCTAGAGAACTAAACTGGCTTAACGAGTCACAGCCTCAGCTGTGCTGGGACGACCTTGTCT CCCTGGGTAGGGGGGGGGAATGGGGGAGGGCTGATGAGGCCCCAGCTGGGGCCTGTTGTCTGGGACCTCCCTCTCCTGAGAGGGGAGGCCTGGTGGCTTAGCCTGGGCAGGTCGTGTCTCCTCCTGACCCCAGTGGCTGCGGTGAGGGGAACCACCTCCCTTGCTGCACCAGTGGCCATTAGCTCCCGTCACCA CTGCAACCCAGGGTCCCAGCTGGCTGGGTCCCTCTTCTGCCCCCAGTGCCCTTCCCCTTGGGCTGTGTTGGAGTGAGCACCTCCTCTGTAGGCACCTCTCACACTGTTGTCTGTTACTGATTTTTTTTGATAAAAAGATAATAAAACCTGGTACTTTCTAAA The complete mRNA polynucleotide sequence of SEQ ID NO:750 SDC4 ACTCGCCGCAGCCTGCGCGCCTTCTCCAGTCCGCGGTGCCATGGCCCCCGCCCGTCTGTTCGCGCTGCTGCTGTTCTTCGTAGGCGGAGTCGCCGAGTCGATCCGAGAGACTGAGGTCATCGACCCCCAGGACCTCCTAGAAGGCCGATACTTCTCCGGAGCCCTACCAGACGATGAGGATGTAGTGGGGCCCGGGCAGGAATCTGATGACT TTGAGCTGTCTGGCTCTGGAGATCTGGATGACTTGGAAGACTCCATGATCGGCCCTGAAGTTGTCCATCCCTTGGTGCCTCTAGATAACCATATCCCTGAGAGGGCAGGGTCTGGGAGCCAAGTCCCCACCGAACCCAAGAAACTAGAGGAGAATGAGGTTATTCCCCAAGAGAATCACCCGTTGAAGAGAGTGAGGATGTGTCCAACAAGGTGTCAATGT CCAGCACTGTGCAGGGCAGCAACATCTTTGAGAGAACGGAGGTCCTGGCAGCTCTGATTGTGGGTGGCATCGTGGGCATCCTCTTTGCCGTCTTCCTGATCCTACTGCTCATGTACCGTATGAAGAAGAAGGATGAAGGCAGCTATGACCTGGGCAAGAAACCCATCTACAAGAAAGCCCCCACCAATGAGTTTCTACGCGTGAAGCTTGCTTGTGGGCACT GGCTTGGACTTTAGCGGGGAGGGAAGCCAGGGGATTTTGAAGGGTGGACATTAGGGTAGGGTGAGGTCAACCTAACTGACTTGTCAGTATCTCAGCTCTGATTACCTTTGAAGTGTTCAGAAAGAGACATTGTCTTACTGTTCTGCCAGGTTCTTCTTGAGCTTTGGGCCTCAGTTGCCCTGGCAGAAAAATGGATTCAACTTGGCCTTTCTGA AGGCAAGACTGGGATTGGATCACTTCTCTAAACTTCCAGTTAAGAATCTAGGTCCGCCCTCCAAGCCCATACTGACCATGCCTCATCCAGAGCTCCTCTGAAGCCAGGGGGCTAACGGATGTTGTGTGGAGTCCTGGCTGGAGGTCCTCCCCAGTGGCCTTCCTCCCTTCCTTCACAGCCGGTCTCTCTGCCAGGAAATGGGGGAAGGAACTAGAACC ACCTGCACCTTGAGATGTTTCTGTAAATGGGTACTTGTGATCACACTACGGGAATCTCTGTGGTATATACCTGGGGCCATTCTAGGCTCTTTCAAGTGACTTTTGGAAATCAACCTTTTTTATTTGGGGGGAGGATGGGGAAAAGAGCTGAGAGTTTTATGCTGAAATGGATTTATAGAATATTTGTAAATCTATTTTGTGTTTGTTCGTTTTTTT AACTGTTCATTCCTTTGTGCAGAGTGTATATCCTCTGCCTGGGCAAGAGTGTGGAGGTGCCGAGGTGTCTTCATTCTCTCGCACATTTTCCACAGCACCTGCTAAGTTTGTATTTAATGGTTTTTGTTTTTGTTTTGTTTTGTTTCTTGAAAATGAGAGAAGAGCCGGAGAGATGATTTTTTTTTTTTTTTTTACTATTTATAGCTTTTAGATAGG GCCTCCCTTCCCCTCTTCTTTCTTTGTTCTCTTTCATTAAACCCCTTCCCCAGTTTTTTTTTTATACTTTAAACCCGCTCCTCATGGCCTTGGCCCTTTCTGAAGCTGCTTCCTCTTATAAAATAGCTTTTGCCGAAACATAGTTTTTTTAGCAGATCCCAAAAATAATGAAGGGGATGGTGGGATATTTGTGTCTGTGTTCTTATAATATTATTTATTCTTCCTT GGTTCTAGAAAAATAGATAAATATATTTTTTTCAGGAAATAGTGTGGTGTTTCCAGTTTGATGTTGCTGGGTGGTTGAGTGAGTGAATTTTCATGTGGCTGGGTGGGTTTTTTGCCTTTTTCTCTTGCCCTGTTCCTGGTGCCTTCTGATGGGGCTGGAATAGTTGAGGTGGATGGTTTCTACCCTTTCTGCCTTCTGTTTGGGACCCAGCTG GTGTTCTTTGGTTTGCTTTCTTCAGGCTCTAGGGCTGTGCTATCCAATACAGTAACCACATGCGGCTGTTTAAAAGTTAAGCCAATTAAAATCACATAAGATTAAAAATTCCTTCCTCAGTTGCACTAACCACGTTTCTAAGAGGCGTCACTGTATGTAGTACTGTACTGACAGCGAGAGCATGTCCATCTAGAGAACTAAACTG GCTTAACGAGTCACAGCCTCAGCTGTGCTGGGACGACCCTTTGTCTCCCCTGGGTAGGGGGGGGGAATGGGGGAGGGCTGATGAGGCCCCAGCTGGGGCCTGTTGTCTCGGGACCTCCCTCTCCTGAGAGGGGAGGCCTGGTGGCTTAGCCTGGGCAGGTCGTGTCTCCTCCTGACCCCAGTGGCTGCGGTGAGGG GAACCACCCTCCCTTGCTGCACCAGTGGCCATTAGCTCCCGTCACCCACTGCAACCCAGGGTCCCAGCTGGCTGGGTCCCTCTTCTGCCCCCAGTGCCCTTCCCCTTGGGCTGTGTTGGAGTGAGCACCTCCTCTGTAGGCACCTCTCACACTGTTGTCTGTTACTGATTTTTTTTGATAAAAAGATAATAAAACCTGGTACTTTTCTAAA SEQ ID NO:751 Translated polypeptide sequence of exon 1 of SDC4 MAPARLFALLLLFFVGGVAES SEQ ID NO:752 Translated polypeptide sequence of exon 2 of SDC4 IRETEVIDPQDLLEGRYFSGALPDDEDVVGPGQESDDFELSGSGDL SEQ ID NO:753 Translated polypeptide sequence of exon 3 of SDC4 DLEDSMIGPEVVHPL SEQ ID NO:754 Translated polypeptide sequence of exon 4 of SDC4 VPLDNHIPERAGSGSQVPTEPKKLEENEVIPKRISPVEESEDVSNKVSMSSTVQGSNIFERTEVLA SEQ ID NO:755 Translated polypeptide sequence of exon 5 of SDC4 LIVGGIVGILFAVFLILLLMYRMKKKDEGSYDLGKKPIYKKAPTNEFYA The complete protein sequence of SEQ ID NO:756 SDC4 MAPARLFALLLFFVGGVAESIRETEVIDPQDLLEGRYFSGALPDDEDVVGPGQESDDFELSGSGDLDDLEDSMIGPEVVHPLVPLDNHIPERAGSGSQVPTEPKKLEENEVIPKRISPVEESEDVSNKVSMSSTVQGSNIFERTEVLAALIVGGIVGILFAVFLILLLMYRMKKKDEGSYDLGKKPIYKKAPTNEFYA SEQ ID NO:757 The polynucleotide sequence of all exons 1-2 of SDC4 arranged in order SEQ ID NO:758 Translated polypeptide sequence of all exons 1-2 of SDC4 arranged in order CD44 (2) sequence informationSEQ ID NO:759 Sequence from CD44 exon 5 at 5' of CD44-NRG1 fusion TTTCTACTGTACACCCATCCCAGACGAAGACAGTCCCTGGATCACCGACAGCACAGACAGAATCCCTGCTACCA SEQ ID NO:760 NRG1 exon 6 sequence at 3' of CD44-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG SEQ ID NO:761 CD44-NRG1 polynucleotide sequence TTTCTACTGTACACCCATCCCAGACGAAGACAGTCCCTGGATCACCGACAGCACAGACAGAATCCCTGCTACCACTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG SEQ ID NO:762 CD44-NRG1 polypeptide sequence STVHPIPDEDSPWITDSTDRIPATTTSTSTTGTSHLVKCAEKEKTFCVN SLC4A4 sequence informationSEQ ID NO:763 Sequence ACTACCCCATCAACTCCAACTTCAAAGTGGGCTACAACACTCTCTTTTCCTGTACCTGTGTGCCACCTGACCCAG Sequence ACTACCCCATCAACTCCAACTTCAAAGTGGGCTACAACACTCTCTTTTCCTGTACCTGTGTGCCACCTGACCCAG Sequence from SLC4A4-NRG1 fusion 5' of SLC4A4-NRG1 fusion 5' of SLC4A4 exon 14 SEQ ID NO:764 SLC4A4-NRG1 fusion 3' of NRG1 exon 6 sequence CTACATCTACATCC ACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG SEQ ID NO: 765 SCL4A4 - NRG1 polynucleotide sequence ACTACCCCCATCAACTCCAACTTCAAAGTGGGCTACAACACTCTCTTTTCCTGTACCTGTGTGCCACCTGACCCAGCCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG SEQ ID NO: 766 SCL4A4-NRG1 polypeptide sequence YPINSNFKVGYNTLFS CTCVPPDPATSTSTTGTSHLVKCAEKEKTFCVN SEQ ID NO:767 SLC4A4 exon 1 GGCGGCGCGCCGGGCAGCGCTTCGGTGGCGGCGGCGGCCGCGGTGGCAGCGAAGGCGGCGGCGGCGGCGGCAGTGGCAGTGGCCGCTGCAGCCCCACACTCCGCCGCCAAACTGGAGGAGCGACGGAAGCCAGAC CCCAGGAG SEQ ID NO: 768 SLC4A4 exon 2 GATGGAGGATGAAGCTGTCCTGGACAGAGGGGCTTCCTTCCTCAAGCATGTGTGTGATGAAGAAGAAGTAGAAG SEQ ID NO: 769 SLC4A4 exon Exon 3 GCCACCATACCATTTTACATCGGAGTCCATGTGCCGAAGAGTTACAGGAGAAGGAGACGTCACAAGAGAAAGACAGGGCACAAAGAAAAGAAGGAAAAGGAGAGAATCTCTGAGAACTACTCTGACAAAATCAGATATTGAAAATGCTGATGAATCCAGCAGCAGCATCCTAAAACCTCTCA SEQ ID NO: 770 SLC4A4 exon 4 TCTCTC CTGCTGCAGAACGCATCCGATTCATCTTGGGAGAGGAGGATGACAGCCCAGCTCCCCTCAGCTCTTCACGGAACTGGATGAGCTGCTGGCCGTGGATGGGCAGGAGATGGAGTGGAAGGAAACAGCCAG SEQ ID NO: 771 SLC4A4 exon 5 GTGGATCAAGTTTGAAGAAAAAGTGGAACAGGGTGGGGAAAGAT GGAGCAAGCCCCATGTGGCCACATTGTCCCTTCATAGTTTATTTGAGCTGAGGACATGTATGGAGAAAGGATCCATCATGCTTGATCGGGAGGCTTCTTCTCTCCCACAGTTGGTGG SEQ ID NO: 772 SLC4A4 exon 6 AGATGATTGTTGACCATCAGATTGAGACAGGCCTATTGAAACCTGAACTTAAGGATAAGGTGACCTATA CTTTGCTCCGGAAGCACCGGCATCAAACCAAGAAATCCAACCTTCGGTCCCTGGCTGACATTGGGAAGACAGTCTCCAGTGCAAGTAGGATGTTTACCAACCCTGATAATG SEQ ID NO: 773 Exon of SLC4A4 7 GTAGCCCAGCCATGACCCATAGGAATCTGACTTCCTCCAGTCTGAATGACATTTCTGATAAACCGGAGAAGGACCAG SEQ ID NO: 774 SLC4A4 exon 8 CTGAAGAATAAGTTCATGAAAAAATTGCCACGTGATGCAGAAGCTTCCAACGTGCTTGTTGGGGAGGTTGACTTTTTGGATACTCCTTTCATTGCCTTTGTTAG GCTACAGCAGGCTGTCATGCTGGGTGCCCTGACTGAAGTTCCTGTGCCCACAAG SEQ ID NO: 775 SLC4A4 exon 9 GTTCTTGTTCATTCTCTTAGGTCCTAAGGGGAAAGCCAAGTCCTACCACGAGATTGGCAGAGCCATTGCCACCCTGATGTCTGATGAG SEQ ID NO: 776 SLC4A4 exon 10 GTGTTC CATGACATTGCTTATAAAGCAAAAGACAGGCACGACCTGATTGCTGGTATTGATGAGTTCCTAGATGAAGTCATCGTCCTTCCACCTGGGGAATGGGATCCAGCAATTAGGATAGAGCCTCCTAAGAGTCTTCCATCCTCTGACAAAAG SEQ ID NO: 777 SLC4A4 exon 11 AAAGAATATGTACTCAGGTGGAGAGAATGTTCAGATGAATG GGGATACGCCCCATGATGGAGGTCACGGAGGAGGAGGACATGGGGATTGTGAAGAATTGCAGCGAACTGGACG SEQ ID NO: 778 SLC4A4 exon 12 GTTCTGTGGTGGACTAATTAAAGACATAAAGAGGAAAGCGCCATTTTTTGCCAGTGATTTTTATGATGCTTTAAATATTCAAGCTCTTTCGGCAATTCCTTCATTTATCTGGCAACTGTAACTAATGCTATCACTTTTGGAGGACTGCTTGGGGATGCCACTGACAACATGCAG SEQ ID NO: 779 SLC4A4 exon 13 GGCGTGTTGGAGAGTTTCCTGGGCACTGCTGTCTCTGGAGCCATCTTTTGCCTTTTTGCTGGTCAACCACTCACTATTCTGAGCAGCACCGGACCTGTCCTAGTTTTGAGAGGCTTCTATTTAATTTCAGCAA SEQ ID NO: 780 SLC4A4 exon 14 GGACAATAATTTTGACTATTTGGAGTT TCGCCTTTGGATTGGCCTGTGGTCCGCCTTCCTATGTCTCATTTTTGGTAGCCACTGATGCCAGCTTCTTGGTTCAATACTTCACACGTTTCACGGAGGAGGGCTTTTCCTCTCTGATTAGCTTCATCTTTATCTATGATGCTTTCAAGAAGATGATCAAGCTTGCAGATTACTACCCCCATCAACTCCAACTTCAAAGTGGGCTACAACACTCTCTTTTCCTGTACCT GTGTGCCACCTGACCCAG SEQ ID NO:781 SLC4A4 Exon 15 CTAATATCTCAATATCTAATGACACCACACTGGCCCCAGAGTATTTGCCAACTATGTCTTCTACTGACATG SEQ ID NO:782 SLC4A4 exon 16 TACCATAATACTACCTTTGACTGGGCATTTTTGTCGAAGAAGGAGTGTTCAAAATACGGAGGAAACCTCGTCGGGAACAACTGTAATTTTGTTCCTGATATCACACTCATGTCTTTTTATCCTCTTCTTGGGAACCTACACCTCTCCATGGCTCTGAAAAAATTCAAAACTAGTCCTTATTTCCAACCACA SEQ ID NO: 783 SLC4A4 exon 17 GCAAGAAAACTGATCAGTGATTTTGCCATTATCTTGTCCATTCTCATCTTTTGTGTAATAGATGCCCTAGTAGGCGTGGACACCCCAAAAACTAATTGTGCCAAGTGAGTTCAAG SEQ ID NO: 784 SLC4A4 exon 18 CCAACAAGTCCAAACCGAGGTTGGTTCGTTCCACCGTTTG GAGAAAACCCCTGGTGGGTGTGCCTTGCTGCTGCTATCCCGGCTTTGTTGGTCACTATACTGATTTTCATGGACCAACAAATTACAGCTGTGATTGTAAACAGGAAAGAACATAAACTCAAG SEQ ID NO: 785 SLC4A4 exon 19 AAAGGAGCAGGGTATCACTTGGATCTCTTTTGGGTGGCCATCCTCATGGTTATATGCTC CCTCATGGCTCTTCCGTGGTATGTAGCTGCTACGGTCATTCCATTGCTCACATCGACAGTTTGAAGATGGAGACAGAGACTTCTGCACCTGGAGAACAACCAAAGTTTCTAGGAGTGAG SEQ ID NO: 786 SLC4A4 exon 20 GGAACAAAAGAGTCACTGGAACCCTTGTGTTTATTCTGACTGGTCTGTCAGTCTTTATGGCTCCCATCTTGAAG SEQ ID NO: 787 SLC4A4 exon 21 GTTTATACCCATGCCTGTACTCTATGGTGTGTTCCTGTATATGGGAGTAGCATCCCTTAATGGTGTGCAG SEQ ID NO: 78 8 SLC4A4 exon 22 TTCATGGATCGTCTGAAGCTGCTTCTGATGCCTCTGAAGCATCAGCTGACTTCATCTACCTGCGTCATGTTCCTCTGCGCAGAGTCCACCTGTTCACTTTCCTGCAGGTGTTGTGTCTGGCCCTGCTTTGGATCCTCAAGTCAACGGTGGCTGCTATCATTTTTCCAGTAATG SEQ ID NO: 789 SLC4A4 exon Sub 23 ATCTTGGCACTTGTAGCTGTCAGAAAAGGCATGGACTACCTCTTCTCCCAGCACGACCTCAGCTTCCTGGATGATGTCATTCCAGAAAAGGACAAGAAAAAGAAGGAGGATGAGAAGAAAAAGAAAAAGAAGAAGGGAAGTCTGGACAGTGACAATGATGAT SEQ ID NO: 790 SLC4A4 In addition, Xianzi 24 TCTGACTGCCCCATACAGAAAAGTTTCCAAGTAAAAAAAAATTCCAACAACACACACACACTTTTTCTTCTTCGAACTCACTCACTGACTGACACTGACACTGACACTGACACAACAACTTCACAACAACAACAACAACAACAACAACAACAACAACACAACACACACACACATAT AAGAGACACAACACAACATTGACCACCACACACACACATCTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAOAAAAAAOOAAAAAAAAAAAAAOEation CaaAATTATAGAAAAACTGAACTGAACAATGAATGAATTTTTTTGGGGGGGGGGGAACAACAACTACTGTGTGTTTTTTTTTTTTGACACATGATTTCATTTCATTTTTTTT CTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCGTCTTTTTTTTTTTCAGCCAAATACAGCGCTCTCTCTCTTCTTGCAATCAATCACACCAAAACAGC AtcttgagaatcccccccccccccccccccccccccccccccccccccccccccccccccccccccCCCCCCCTTTTTTTTTTTTTTTTTCAGTGTGTTGAACCAAAACTCAGACACACACACACACACACCCCCTTCTTCTTAGAGAGGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTCACACACACATCTCAACCAAC GATTTTTTGTGTGTGTTTTTTTTTTTTTTTTGAAGGAAGGAACTTTAACTTTTTTTTTTTTGGTGTGTGGGGGGTTTTGTGGGGGGAACCCCCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCCCTCCTCCCTCCCTCCCTCT AtagagCTCTCTCCATCTGGGAAAAAGCTGCTGCTTTTTTTTTTGCTTTGTTGTAAATCTTTCAAAGAAAAAACTGTGTGTCCTCTCTCTCTCCCAACCAACCAACCAACCAACCAACCCCCCATC AttgtagcaagTGGGGAATGTCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTTGTGTGAAGAATTTTTTTTTTTTTTTTTTTTTTTTTTTT CCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTGTGTGAAAAAATGAATTTTTTGCAGCAGAACAACAACATTTTTTCTTTTTGCAGGCTTTTGTAAAAAAAAA AATTGTGTGTGTATATAATTGATTTTTTTTTTTTTTTACACACACACACAAATACAATCTAGGTAGCCAGCAAGCAGCAGAGAGAGAAAAAAACCCAAGCAgCAgCAgCAgCAgCAgCAgCAGCAGCAGCAGCAGCAGCAGCCAGCCAGCCAGCAGCCAGCAGCAGCAGCAGCAGCAGCAGCAGCACCACCACCCCAAGCCACCCACCCCACCCACCCACCCACCCCACAC TTACTGTGTTCTTCTAGGAGAGAGAGGGGGAGAGAGAGAGACAACTCTCTCATGAATGATGATGTGTGATGCAGTAGTAGTGTGTGTCAATCAATCAATCATCAATCATCAAT AgACACATTTTTTCATTTGAAAAATTTTGTGTGTTGTGTGTGTGTGCCATGGGGGGTGTGTGTGTGCAAGCAAAGGCAGGCAAGGCAAGGAAGAAGTCTTCTTATTCTTCTAT TTTCAAAAAAAAAACCCAACCACACATGAAAAAAAAAAAAAATCAAGGGTCCAAGTCAAGTGTGTCAAAAAAAAAAATGTAAAAAAATATTTTTCCCCCAGTCAACTAACTGCAAAAAAATC AtaggagtatttaatgccccccattTACACAAAAAAATGGGGGGGGGCAGCAGCGCAGCAGTGTGTGTCTCTCTCAATTTTTTTTTTTTTTTTTTTTTTTTTTCAGCAAAAGCAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGAT AATATTTGTGTGTGTGTGTGTGTACATTATGTTCACACACACACACAAAAAACACACCAACCAAACCAACGTTGTTTTTTTTTTTTTTTTTTAATACATGAAAACACAAACACAACACAAACATT TTAAAAAATGTTTAAAAAATAATTTTCAGATTCATACACACAACAACAACTGTGAACTACTACCAGTTGGGGGGGGTAGAGAAGAACCACACACACACACATTTTGCACTCCCCCAC TCATTGTTTTTTTTAATAAGTTTTTTTTTTCTCTCTTGTTTTTTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTTGAGTTTTTTTACTCTCTCTTTTTTTTTTAAAATCAATAATAAT GACCCCCAATTTTTTTTTTTTTTTTTTTTTTAAAATAATGTGTGAATTATTTGTTGTTGTCTCTCCAAAAAAAAAATTGGGGGGGGTTTTCTTCTTCTAGTAGTTCTTTCTTTCTTACCCCC CTAATATAACTGGTGTGTGTGTGTGAAGAGACTTTTTTTTTTTTTTTTTTTTTTTTTTGGGAAGCAATTTTTTTTTTTTTTTTTAACCAAAAAAAAACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTT AAGCTCTAGAAAAAAAAAAAAAAAAAAAACTTTTTTTTTGATGAATCAAGTCTGTGTCATGCCTCTCTTCTTCTCTCTCTGAACTCAGAGAGAGTGAGTAGTAGTAGTAGTAGTAGTAGAGTAGAGAGAGTCAACTCTCTCTCTCTCTCTCTCCCCCCCCTCTCTCAAGAAT AtGTGTGTGTCTCTGTTTTTTTTTCCCATTGACACACACACACATACATACTACTTGCTACAGACAGTAAAAAAATCCAACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAACAAC TTCAAAGAACAGAGTAGTTTACAACTAACAACAAAAAAAAAAAACTGACTGACTGACCAAAAAAAAAATCGGGTTGAATGACCCCCCAACCAGACCAGAGAGAGAGACAGAGAGACACCAACCCCCAACCACCACCACCTGACTGGACTGACTGACTGACTGACTGACTGACTGACTGACTGACTGACTGACTGACTGACTGACAT GTTTTCTATGCAACAACACACAAAAACAACAACAACAGTTTTTTTTTTTTTTTCTCTCTCCCATGTCCCCCGGGAAAGAAGAAGCAGTCTCTCTCGTCTCGTCGTGTGTTGTCTCTCTCTCTCCCCTCTCCTCCTCCATGATGATGAT GaaAgTCTCTGGTGTGTGTGTGCAGACACACTGTGTGGAAGAGAGAGAGAGAAGTCAAGTGTGTGCTAAAGCAAAAAAAAAAAAAAAATGCTGGGGGGGGGGGGCACA CtgtttttttttttgataaaAgtcartTCTCTCTCTGTGAATGAATGAATTGAATTTTGCCAGGGGGGGGGGGGGGTCCTCCCCAATCAAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG AgaggACTTACTACTTTTAAGAAGTAGAAAAAAAAAAAAAAAAAACCTCTCTCCCCCCCCCCCCCCAGAGGAAAAAAACAGTTGTGTGTGTTGTTTTTTTTTTTCTCTCTCTCTCTCTC CaccaaccatacAggtaAAAAAATTTTTTTTTTTTTGTGTGTGTTTTTTTAATGAATGATGTCCGAGAGAGAGAGGGGGGTTTTTTGTTTGAATGTGACTGACTGACTGACTGACTGATGACTGACTGATGATGACTGATGATGATGATGATGAATTGAATTTT TTAAAAAAAAAAAAAATGATTTTGAGAGTTGTTACAGGTGACACAGGGGGGGGGGGGGGGGGGGCAAGCCAATCATTTCATTTTTTTGCACTGACTGACTGATGATTGATTTGATTGATTGATTTTTTTT CatgatttttcACATTTTTTCACAGCAGCAgCCCCCCCCCCAAAAAAATGGGGGGGGGGGGGGGTGTGTTGTCTCTCTCTGCCCCCAGCCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTTC is AttgCAGCTGAAAAAAAAAAAAAGTGTGTGTGTGTGTGCCAACCAGTCAGTCAGTGTTTTTTTGCCAGAGAGTCCAATCCTCTCTCTCTACTAAAGCAGAAGAAGAATTT CTGTTTTTTTTTCTCTAGCAACAACAACTCAACTCGGGGGGGTCAAGTCCCAACCAACCCCCCCCCCCCCAACCCCCCCCCCTAAAAGAAGAAGAAGAAGAATGCTTTTTTTTTTTTTGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC AtgctggtacatatATCGTACGCATTTTTTTTTTTTTTTCAATCATACGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT AtggtggaacaaaaaaaaaAgaacagaAAAAAAACATTTCAATTAATAATAATTTTTTTTTTTTTCCTCTCTCTACTACTACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT AtgaagAgAgATGAGAGAGAGCATTTTTTTTTTTTTTTTTTTAAAAAAAAACTTTTTTTTTTT NO: 793 SLC4A4 The whole mRNA polynucleotide sequence SEQ ID NO: 794 SLC4A4 of SLC4A4 Translated polypeptide sequence of exon 2 MEDEAVLDRGASFLKHVCDEEEVE SEQ ID NO:795 Translated polypeptide sequence of exon 3 of SLC4A4 HHTIYIGVHVPKSYRRRRHKRKRKTGHKEKKEKERISENYSDKSDIENADESSSSILKPL SEQ ID NO:796 Translated polypeptide sequence of exon 4 of SLC4A4 SPAAERIRFILG EEDDSPAPPQLFTELDELLAVDGQEMEWKETA SEQ ID NO:797 SLC4A4 External display Translated polypeptide sequence of exon 5 WIKFEEKVEQGGERWSKPHVATLSLHSLFELRTCMEKGSIMLDREASSLPQLV SEQ ID NO: 798 SLC4A4 Translated polypeptide sequence of exon 6 MIVDHQIETGLLKPELKDKVTYTLLRKHRHQTKKSNLRSLADIGKTVSSASRMFTNPDN SEQ ID NO: 799 SLC4A4 Translated polypeptide sequence of exon 7 SPAMTHRNLTSSSLNDISDKPEKDQ SEQ ID NO: 800 SLC4A4 exon 8 Translated polypeptide sequence LKNKFMKKLPRDAEASNVLVGEVDFLDTPFIAFVRLQQAVMLGALTEVPVPT SEQ ID NO: 801 Translated polypeptide sequence of exon 9 of SLC4A4 FLFILLGPKGKAKSYHEIGRAIATLMSDE SEQ ID NO: 802 Translated polypeptide sequence of exon 10 of SLC4A4 VFHDIAYKAKDRHDLIAGIDEFLDEVIVLPP GEWDPAIRIEPPKSLPSSDK SEQ ID NO:803 Translation of exon 11 of SLC4A4 Peptide sequence KNMYSGGENVQMNGDTPHDGGHGGGGHGDCEELQRTG SEQ ID NO: 804 Translated polypeptide sequence of exon 12 of SLC4A4 FCGGLIKDIKRKAPFFASDFYDALNIQALSAILFIYLATVTNAITFGGLLGDATDNMQ SEQ ID NO: 805 Translated polypeptide sequence of exon 13 of SLC4A4 G VLESFLGTAVSGAIFCLFAGQPLTILSSTGPVLVFERLLFNFS SEQ ID NO: 806 Translated polypeptide sequence of exon 14 of SLC4A4 DNNFDYLEFRLWIGLWSAFLCLILVATDASFLVQYFTRFTEEGFSSLISFIFIYDAFKKMIKLADYYPINSNFKVGYNTLFSCTCVPPDP SEQ ID NO: 807 Translated polypeptide sequence of exon 15 of SLC4A4 NISISNDTTLAPEYLPTMSSTDM SEQ ID NO: 808 Translated polypeptide sequence of exon 16 of SLC4A4 YHNT TFDWAFLSKKECSKYGGNLVGNNCNFVPDITLMSFILFLGTYTSSMALKKFKTSPYFPTT SEQ ID NO:809 Translated polypeptide sequence of exon 17 of SLC4A4 ARKLISDFAIILSILIFCVIDALVGVDTPKLIVPSEFK SEQ ID NO: 810 Translated polypeptide sequence of exon 18 of SLC4A4 PTSPNRGWFVPPFGENPWWVCLAAAIPALLVTILIFMDQQITAVIVNRKEHKLK SEQ ID NO: 811 Translated polypeptide sequence of exon 19 of SLC4A4 KGAGYHLLDLFWVAILMVICSLMALPWYVAATVISIAHIDSLKMETETSAPAGEQPKFLGV SEQ ID NO:812 Translated polypeptide sequence of exon 20 of SLC4A4 EQRVTGTLVFILTGLSVFMAPILK SEQ ID NO :813 The translated polypeptide sequence of exon 21 of SLC4A4 FIPMPVLYGVFLYMGVASLNGVQ SEQ ID NO:814 The translated polypeptide sequence of exon 22 of SLC4A4 FMDRLKLLLMPLKHQPDFIYLRHVPLRRVHLFTFLQVLCLALLWILKSTVAAIFPVM SEQ ID NO:815 The translated polypeptide sequence of exon 23 of SLC4A4 Translated polypeptide sequence ILALVAVRKGMDYLFSQHDLSFLDDVIPEKDKKKKEDEKKKKKKKGSLDSDNDD SEQ ID NO: 816 The translated polypeptide sequence of exon 24 of SLC4A4 SDCPYSEKVPSIKIPMDIMEQQPFLSDSKPSD SEQ ID NO:817 The translated polypeptide sequence of exon 25 of SLC4A4 ERSPTFLERHTSC SEQ ID NO:819 The complete protein sequence of SLC4A4 SEQ ID NO:820 The entire exon 1- of SLC4A4 14 Sequentially arranged polynucleotide sequence SEQ ID NO: 821 SLC4A4 all exons 1-14 Sequentially arranged translated polypeptide sequenceSDC4 (2) sequence informationSEQ ID NO:822 Sequence from SDC4 exon 4 at 5' of SDC4-NRG1 fusion ATGTGTCCAACAAGGTGTCAATGTCCAGCACTGTGCAGGGCAGCAACATCTTTGAGAGAACGGAGGTCCTGGCAG SEQ ID NO:823 NRG1 exon 2 sequence at 3' of SDC4-NRG1 fusion CCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO:824 SDC4-NRG1 polynucleotide sequence ATGTGTCCAACAAGGTGTCAATGTCCAGCACTGTGCAGGGCAGCAACATCTTTGAGAGAACGGAGGTCCTGGCAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO:825 SDC4-NRG1 polypeptide sequence VSNKVSMSSTVQGSNIFERTEVLAALPPRLKEMKSQESAAAGSKLVLRCE SEQ ID NO:940 The polynucleotide sequence of all exons 1-4 of SDC4 arranged in order SEQ ID NO:941 The translated polypeptide sequence of all exons 1-4 of SDC4 arranged in order ZFAT sequence informationSEQ ID NO:826 Sequence from ZFAT exon 12 at 5' of ZFAT-NRG1 fusion ACAGGAAGCACCCTAATGAGGAGTATGCCAACGTGGGCACCGGGGAGCTGGCAGCGGAGGTGCTCATCCAGCAAG SEQ ID NO:827 NRG1 exon 6 sequence at 3' of ZFAT-NRG1 fusion CTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG SEQ ID NO:828 ZFAT-NRG1 polynucleotide sequence ACAGGAAGCACCCCTAATGAGGAGTATGCCAACGTGGGCACCGGGGAGCTGGCAGCGGAGGTGCTCATCCAGCAAGCTACATCTACATCCACCACTGGGACAAGCCATCTTGTAAAATGTGCGGAGAAGGAGAAAACTTTCTGTGTGAATG SEQ ID NO:829 ZFAT-NRG1 polypeptide sequence RKHPNEEYANVGTGELAAEVLIQQATSTSTTGTSHLVKCAEKEKTFCVN SEQ ID NO:830 ZFAT exon 1 ATCCGCCATGTTGGATGCCGCAGATTCGCCATAACCTCGCCGGCTCTTTTCTTAAAAAAATAAAAATAAAAAGCGAAGCGTCAGCAGGGCGCCCCGCCCCCTCGGTCGGCACGGGAGGGGGCCCGGAAGAGCCCGAGGCTTTTTTTTCCTCCGCGGTGGGGCGTTGCCATGGAGACGCGGGCGGCAG SEQ ID NO:831 ZFAT exon 2 AAAACACGGCCATCTTTATGTGTAAATGTTGTAACCTCTTCTCACCAAATCAGTCGGAACTCCTCTCCCACGTTTCAGAGAAGCACATGGAAGAAGGGGTTAATGTTGATGAGATTATTATTCCCCTTAGGCCTCTGAGTACACCTGAACCCCCCAACTCAAGCAAAAACCGGAGATG SEQ ID NO:832 ZFAT exon 3 AGTTTTTGGTCATGAAGAGGAAGAGAGGCAGGCCTAAGGGGTCCACGAAGAAGTCCAGCACAGAAGAGGAGCTGGCAGAAAACATCGTGAGTCCGACTGAGGACAGCCCGCTGGCTCCGGAGGAAGGGAACAGCCTGCCTCCAAGCAGCTTGGAGTGTAGCAAGTGCTGTCGGAAGTTCTCCAACACGCGCCAGCTGCGGAAGCACATCTGCATTATC GTGCTGAATTTGGGTGAGGAGGAAGGAGAAGCAG SEQ ID NO:833 ZFAT exon 4 GTAACGAGTCTGACCTTGAACTAGAAAAGAAGTGTAAGGAAGATGATCGGGAAAAAGCCTCGAAAAGACCACGGTCACAGAAAACAGAGAAAGTCCAGAAGATCTCAGGAAAGGAGGCCAGACAGCTTTCTGGGGCGAAGAAACCCATCATAAGTGTGGTTTTTAACTGCACACGAAGCAATTCCAG SEQ ID NO:834 ZFAT exon 5 GTGCTACCAAGATTGTGCCAGTGGAGGCTGGGCCCCCTGAAACAGGAGCTACAAATTCTGAGACCACTTCAAGCAGACCTGGTGCCTCGGAGAGGCTACCAGGAATACGCCATTCAGCAGACACCTTATGAGCAACCAATGAAGTCAAGCAG SEQ ID NO:835 ZFAT exon 6 GCTAGGTCCCACTCAGCTCAAAAATCTTCACTTGTGAATACTGCAACAAGGTCTTCAAGTTCAAGCACTCGCTGCAGGCCCACCTGAGGATCCACACCAATGAAAAGCCATACAAGTGCCCCAGTGCAGCTATGCCAGTGCCATCAAGGCCAACCTCAATGTGCACCTGCGCAAGCACACTGGAGAGAAGTTCGCCTGCGACTATTGCTCGTTCACCTGCCTGAGCAAGG GCCACCTCAAGGTGCACATCGAGCGAGTGCACAAGAAGATCAAGCAGCACTGCCGCTTCTGCAAGAAGAAGTACTCTGACGTCAAGAACCTCATCAAGCACATCCGAGACGCGCATGACCCACAGGACAAGAAGGTCAAAGGGCCTTGGACGAGCTCTGCCTGATGACGAGGGAGGGCAAGCGGCAGCTGCTCTATGACTGCCACATCTGTGAGCGCAAGT TCAAGAACGAGCTGGACCGTGACCGCCATATGCTGGTCCACGGAGACAAGTGGCCTTTTGCCTGTGAGCTCTGTGGCCATGGGGCCACCAAGTACCAGGCGCTGGAACTGCATGTCAGGAAGCACCCCCTTCGTGTACGTCTGTGCCGTCTGCCGCAAGAAGTTCGTCAGTCCATCAGGCTGCGCACCCACATCAAAGAGGTGCACGGGGCTGCCC AGGAGGCCTTGGTCTTCACCAGTTCCATCAACCAGAGCTTCTGCCTCCTGGAACCTGGTGGGGACATCCAGCAAGAAGCTCTGGGGGACCAGCTACAGCTGGTGGAAGAGGAGTTTGCCCTCCAGGGCGTGAATGCACTCAAGGAAGAGGCCTGTCCTGGGGACACTCAGCTGGAGGAGGGCCGGAAGGAGCCGGAGGCCCCTGGGGAA ATGCCTGCCCCAGCTGTGCACCTGGCCTCCCCGCAGGCCGAAAGCACAGCCCTGCCACCCTGTGAGCTGGAAACCACCGTGGTCTCTCTCTCCAGACCTGCATTCTCCAAGAGGTGGTTTCAGATGATTTTTTGTTGAAAAATGATACCTCCTCCGCAGAGGCTCATGCTGCTCCTGAGAAGCCCCCAGACATGCAGCACAGAAGCTCAGTCCAGACGCAAGGTGAAGTGA TCACACTACTGCTGTCCAAGGCCCAGAGTGCTGGGTCAGATCAGGAAAGCCATGGCGCCCAGAGCCCCCTAGGGGAAGGGCAGAACATGGCTGTGCTTTCAGCTGGTGACCCAGATCCCAGCAGGTGTCTCAGGTCAAACCCAGCTGAGGCCTCAGACCTCCTCCCTCCAGTAGCTGGTGGTGGGGACCCATCACACATCAGCCTGACTCTTGCAAAG CTGCCCCTGAGCACCGGTCAGGCATCACCGCTTTCATGAAGGTCCTGAACAGTTTACAGAAGAAGCAAATGAACACCAGCTTGTGTGAGCGGATCCGGAAGGTTTATGGAGACCTGGAGTGTGAATACTGTG SEQ ID NO:836 ZFAT exon 7 GCAAACTTTTTGGTACCAAGTGCATTTTGATATGCATGTCCGCACCCACACCCGGGAACATCTGTATTGCTCTCAGTGTCATTATTCTTCCATCACCAAAACTGCCTTAAACGCCACGTAATTCAGAAACACAGTAACATCTTGCTGAAGTGTCCCACCGATGGCTGTGACTACTCAACTCCGATAAATATAAGCTACAGGCACATCTTAAAGTTCAC ACAGCACTG SEQ ID NO:837 ZFAT exon 8 GACAAAAGGAGTTATTCTTGTCCTGTTTGTGAAAAGTCTTTTTCAGAGGATCGATTGATAAAGTCACATATCAAGACCAACCATCCTG SEQ ID NO:838 ZFAT exon 9 AGGTCTCCATGAGCACCATTTCTGAGGTTCTCGGGAGGAGGGTTCAGCTGAAAGGGCTAATTGGAAAGAGAGCCATGAAATGCCCATATTGTGACTTTTATTTCATGAAGAATGGCTCAGACCTTCAGCGTCATATTTGGGCTCATGAAG SEQ ID NO:839 ZFAT exon 10 GTGTGAAGCCCTTCAAGTGTTCTTTGTGTGAGTATGCAACTCGTAGCAAGAGTAACCTCAAGGCTCATATGAATCGTCACAGCACTGAGAAAACCCACCTATGTGACATGTGTGGCAAGAAATTCAAATCAAAAGGGACACTGAAAAGTCACAAACTCCTTCACACTGCAGATG SEQ ID NO:840 ZFAT exon 11 GGAAGCAGTTTAAGTGCACGGTGTGTGACTACACACAGCGGCCCAGAAGCCACAGCTGCTGCGGCACATGGAACAGCATGTCTCCTTCAAG SEQ ID NO:841 ZFAT exon 12 CCTTTCCGCTGTGCCCATTGCCATTACTCCTGCAACATATCTGGCTCTCTGAAGCGGCACTACAACAGGAAGCACCCTAATGAGGAGTATGCCAACGTGGGCACCGGGGAGCTGGCAGCGGAGGTGCTCATCCAGCAAG SEQ ID NO:842 ZFAT exon 13 GTGGTTTGAAGTGTCCTGTTTGCAGCTTTGTATATGGCACCAAATGGGAGTTCAATAGGCACTTGAAGAACAAACATGGCTTGAAGGTGGTGGAAATTGATGGAGACCCCAAGTGGGAG SEQ ID NO:843 ZFAT exon 14 ACAGCAACAGAAGCTCCTGAGGAGCCCTCCACCCAGTATCCTCCACATCACAGAGGCCGAAGAAGACGTTCAAGGGACACAGGCAGCGGTGGCCGCGCTCCAGGACCTGAGATACACCCTCTGAGAGTG SEQ ID NO:844 ZFAT exon 15 GCGACCGACTGGACCCCACGGCCGTGAACATCCTGCAGCAGATCATTGAGCTGGGCGCCGAGACCCATGACGCCACTGCCCTTGCCTCGGTGGTTGCCATGGCACCAGGGACGGTGACTGTGGTTAAGCAG SEQ ID NO:845 ZFAT exon 16 GTCACCGAGGAGGAGCCCAGCTCCAACCACACGGTCATGATCCAGGAGACGGTCCAGCAAGCGTCCGTGGAGCTTGCCGAGCAGCACCACCTGGTGGTGTCCTCCGACGACGTGGAGGGCATTGAGACGGTGACTGTCTACACGCAGGGCGGGGAGGCCTCGGAGTTCATCGTCTACGTGCAGGAGGCCATGCAGCCTGTGGAGGAGC AGGCTGTGGAGCAGCCGGCCCAGGAACTCTAGAGGACATGTGGCATCGGATGGCCACAGGGCGGGGCTGCCAGGCTCTGCAGGCACCCAGGGTGGGGAGGCCACCCTTCCTGCCCTACCCGCAGAATGGTGCTCTCCTTTGCCCTCCCTGCCCAGCAGCCTGATAGGACTCTCCTAGTCCAACTTGGGGTGGGCAAGGCAGTCAGCATCAC CAGCAATACCACAGGACCCTCACCCCAGCATAGACACACACCCCCTGACCCTTACCATCTGCTTCCTGAAAGACTTCAGTGTCAGTCCCCTACACACACACCCACCCTTCACCCCTTGCTTCAAGATTCAAACAGAGACTCCAGTCCCCCTCAGCATCTTCCCTGAATCACAGCCCCAGCTCCTTGACCCCCATCTAGGTGCCAAATGTTCATCTGCAACCGCTATGCAGTCTGGT GAGAGGGAGACAGCCATCACATAGAAAGTGACCGTACGGGTTTTTAATCACTGCTGGGTGGGGTGGGGGTAGGGGGATTGTCCTGGCTTTGTCGACAAAGTCCCACTTCCCCGAGTATTAAGGGCCCTTGGTATCAAGTGAGGTAAATTCACCATCAGGGTCTCGCCCTACCATCCTGGAATTATTTCACTTTTAAGATAAATGCACT ATTTCACTGTTCGCCTCCCATTCTAAGGAGGTGAGGTGGTTGGAATAAAAAACAGTTCCTGTCTGAA SEQ ID NO:846 The complete mRNA polynucleotide sequence of ZFAT ATCCGCCATGTTGGATGCCGCAGATTCGCCATAACCTCGCCGGCTCTTTTCTTAAAAAAATAAAAATAAAAAGCGAAGCGTCAGCAGGGCGCCCCGCCCCCTCGGTCGGCACGGGAGGGGGCCCGGAAGAGCCCGAGGCTTTTTTTTCCTCCGCGGTGGGGCGTTGCCATGGAGACGCGGGCGGCAGAAAACACGGCCATCTTT ATGTGTAAAATGTTGTAACCTCTTCTCACCAAATCAGTCGGAACTCCTCTCCCACGTTTCCAGAGAAGCACATGGAAGAAGGGGTTAATGTTGATGAGATTATTATTCCCCTTAGGCCTCTGAGTATCACCTGAACCCCCCAACTCAAGCAAAAACCGGAGATGAGTTTTTGGTCATGAAGAGGAAGAGAGGCAGGCCTAAGGGGTCCACGAAGAAGTCCAGCAGCAGAAGAG GAGCTGGCAGAAAACATCGTGAGTCCGACTGAGGACAGCCCGCTGGCTCCGGAGGAAGGGAACAGCCTGCCTCCAAGCAGCTTGGAGTGTAGCAAGTGCTGTCGGAAGTTCTCCAACACGCGCCAGCTGCGGAAGCACATCTGCATTATCGTGCTGAATTTGGGTGAGGAGGAAGGAAGCAGGTAACGAGTCTGACCTTGAACTAGAAAAGAGTG TAAGGAAGATGATCGGGAAAAAAGCCTCGAAAGACCACGGTCACAGAAAACAGAGAAAGTCCAGAAGATCTCAGGAAAGGAGGCCAGACAGCTTTCTGGGGCGAAGAAACCCATCATAAGTGTGGTTTTTAACTGCACACGAAGCAATTCCAGGTGCTACCAAGATTGTGCCAGTGGAGGCTGGGCCCCCTGAAACAGGAGCTACAAATTCTGAGACCACTTCA GCAGACCTGGTGCCTCGGAGAGGCTACCAGGAATACGCCATTCAGCAGACACCTTATGAGCAACCAATGAAGTCAAGCAGGCTAGGTCCCACTCAGCTCAAAATCTTCACTTGTGAATACTGCAACAAGGTCTTCAAGTTCAAGCACTCGCTGCAGGCCCACCTGAGGATCCACACCAATGAAAAGCCATACAAGTGCCCCCAGTGCAGCTATGCCAGTGCCATCAAGGCC ACCTCAATGTGCACCTGCGCCAAGCACACTGGAGAGAAGTTCGCCTGCGACTATTGCTCGTTCACCTGCCTGAGCAAGGGCCACCTCAAGGTGCACATCGAGCGAGTGCACAAGAAGATCAAGCAGCACTGCCGCTTCTGCAAGAAGAAGTACCTCATCAAGCACATCCGAGACGCGCATGACCCACAGGACAAGAAGGTCAAAGAGGCCTTG GACGAGCTCTGCCTGATGACGAGGGAGGGCAAGCGGCAGCTGCTCTATGACTGCCACATCTGTGAGCGCAAGTTCAAGAACGAGCTGGACCGTGACCGCCATATGCTGGTCCACGGAGACAAGTGGCCTTTTGCCTGTGAGCTCTGTGGCCATGGGGCCACCAAGTACCAGGCGCTGGAACTGCATGTCAGGAAGCCACCCCTTCGTGTACGTCT GTGCCGTCTGCCGCAAGAAGTTCGTCAGTCCATCAGGCTGCGCACCCACATCAAAGAGGTGCACGGGGCTGCCCAGGAGGCCTTGGTCTTCACCAGTTCCATCAACCAGAGCTTCTGCCTCCTGGAACCTGGTGGGGACATCCAGCAAGAAGCTCTGGGGGACCAGCTACAGCTGGTGGAAGAGGAGTTTGCCCTCCAGGGCGTGAATGCACTCAAG GAAGAGGCCTGTCCTGGGGACACTCAGCTGGAGGAGGGCCGGAAGGAGCCGGAGGCCCCTGGGGAAATGCCTGCCCCAGCTGTGCACCTGGCCTCCCCGCAGGCCGAAAGCACAGCCCTGCCACCCTGTGAGCTGGAAACCCACCGTGGTCTCTCCTCAGACCTGCATTCTCCAAGAGGTGGTTTCAGATGATTTTTTGTTGAAAAATGATACCTC CTCCGCAGAGGCTCATGCTGCTCCTGAGAAGCCCCCAGACATGCAGCACAGAAGCTCAGTCCAGACGCAAGGTGAAGTGATCACACTACTGCTGTCCAAGGCCCAGAGTGCTGGGTCCAGATCAGGAAAGCCATGGCGCCCAGAGCCCCCTAGGGGAAGGGCAGAACATGGCTGTGCTTTCAGCTGGTGACCCAGATCCCAGCAGGTGTCTCAGGTCAAACCCAG CTGAGGCCTCAGACCTCCTCCCTCCAGTAGCTGGTGGTGGGGAACACCATCACACATCAGCCTGACTCTTGCAAAGCTGCCCCTGAGCACCGGTCAGGCATCACCGCTTTCATGAAGGTCCTGAACAGTTTACAGAAGAAGCAAATGAACACCAGCTTGTGTGAGCGGATCCGGAAGGTTTATGGAGACCTGGAGTGTGAATACTGTGGCAAACTTTTTTGGTAC CAAGTGCATTTTGATATGCATGTCCGCACCCACACCCGGGAACATCTGTATTATTGCTCTCAGTGTCATTATTCTTCCATCACCAAAACTGCCTTAAACGCCACGTAATTCAGAAACACAGTAACATCTTGCTGAAGTGTCCCACCGATGGCTGTGACTACTCAACTCCGATAAATATAAGCTACAGGCACATCTTAAAGTTCACACAGCACTGGACAAAAGGAGT TATTCTTGTCCTGTTTGTGAAAAGTCTTTTTCAGAGGATCGATTGATAAAGTCACATATCAAGACCAACCATCCTGAGGTCTCCATGAGCACCATTTCTGAGGTTCTCGGGAGGAGGGTTCAGCTGAAAGGGCTAATTGGAAAGAGAGCCATGAAATGCCCATATTGTGACTTTTATTTCATGAAGAATGGCTCAGACCTTCAGCGTCATATTTGGGCTCAT GAAGGTGTGAAGCCCTTCAAGTGTTCTTTGTGTGAGTATGCAACTCGTAGCAAGAGTAACCTCAAGGCTCATATGAATCGTCACAGCACTGAGAAAACCCACCTATGTGACATGTGTGGCAAGAAATTCAAATCAAAAGGGACACTGAAAAGTCACAAACTCCTTCACACTGCAGATGGGAAGCAGTTTAAGTGCACGGTGTGTGACTACACACAGCGCCCAGAAGCCACAG CTGCTGCGGCACATGGAACAGCATGTCTCTCTTCAAGCCTTTTCCGCTGTGCCCATTGCCATTACTCCTGCAACATATCTGGCTCTCTGAAGCGGCACTACAACAGGAAGCACCCTAATGAGGAGTATGCCAACGTGGGCACCGGGGAGCTGCAGCGGAGGTGCTCATCCAGCAAGGTGGTTTGAAGTGTCCTGTTTGCAGCTTTGTATATGGCACCA AATGGGAGTTCAATAGGCACTTGAAGAACAAACATGGCTTGAAGGTGGTGGAAATTGATGGAGACCCCAAGTGGGAGACCCAAGCAACAGAAGCTCCTGAGGAGCCCTCACCCAGTATCCTCCACATCACAGAGGCCGAAGAAGACGTTCAAGGGACACAGGCAGCGGTGGCCGCGCTCCAGGACCTGAGATACCACCTCTGAGAGTGGCGACCGACTGGA CCCCACGGCCGTGAACATCCTGCAGCAGATCATTGAGCTGGGCGCCGAGACCCATGACGCCACTGCCCTTGCCTCGGTGGTTGCCATGGCACCAGGGACGGTGACTGTGGTTAAGCAGGTCACCGAGGAGGAGCCCAGCTCCAACCACACGGTCATGATCCAGGAGACGGTCCAGCAAGCGTCCGTGGAGCTTGCCGAGCAGCACCACCTGGT GGTGTCCTCCGACGACGTGGAGGGCATTGAGACGGTGACTGTCTACACGCAGGGCGGGAGGCCTCGGAGTTCATCGTCTACGTGCAGGAGGCCATGCAGCCTGTGGAGGAGCAGGCTGTGGAGCAGCCGGCCCAGGAACTCTAGAGGACATGTGGCATCGGATGGCCACAGGGCGGGGCTGCCAGGCTCTGCAGGCACCCAGG GTGGGGAGGCCACCCTTCCTGCCCTACCCGCAGAATGGTGCTCTCCTTTGCCCTCCCTGCCCAGCAGCCTGATAGGACTCTCCTAGTCCAACTTGGGGTGGCAAGGCAGTCAGCATCACCAGCAATACCACAGGACCCTCACCCCAGCATAGACACACACCCCCTGACCCTTACCATCTGCTTCCTGAAAGACTTCAGTGTCAGTCCCCTACACACACCCCACC TTCACCCCCTTGCTTCAAGATTCAAACAGAGACTCCCAAGTCCCCCTCAGCATCTTCCCTGAATCACAGCCCCAGCTCCTTGACCCCCATCTAGGTGCCAAATGTTCATCTGCAACCGCTATGCAGTCTGGTGAGAGGGAGACAGCCATCACATAGAAAGTGACCGTACGGGTTTTTAATCACTGCTGGGTGGGGTGGGGGTAGGGGGATTGTCCTGGCT TTGTCGACAAAGTCCCACTTCCCCGAGTATTAAGGGCCCTTGGTATCAAGTGAGGTAAATTCACCCATCACAGGGTCTCGCCCTACCATCCTGGAATTATTTCACTTTTAAGATAAATGCACTATTTCACTGTTCGCCTCCCATTCTAAGGAGGTGAGGTGGTTGGAATAAAAACAGTTCCTGTCTGAA SEQ ID NO:847 Translated polypeptide sequence of ZFAT exon 1 METRA SEQ ID NO:848 Translated polypeptide sequence of ZFAT exon 2 NTAIFMCKCCNLFSPNQSELLSHVSEKHMEEGVNVDEIIIPLRPLSTPEPPNSSKTGD SEQ ID NO:849 Translated polypeptide sequence of ZFAT exon 3 FLVMKRKRGRPKGSTKKSSTEEELAENIVSPTEDSPLAPEEGNSLPPSSLECSKCCRKFSNTRQLRKHICIIVLNLGEEEGEA SEQ ID NO:850 Translated polypeptide sequence of ZFAT exon 4 NESDLELEKKCKEDDREKASKRPRSQKTEKVQKISGKEARQLSGAKKPIISVVLTAHEAIP SEQ ID NO:851 Translated polypeptide sequence of ZFAT exon 5 ATKIVPVEAGPPETGATNSETTSADLVPRRGYQEYAIQQTPYEQPMKSS SEQ ID NO:852 Translated polypeptide sequence of ZFAT exon 6 LGPTQLKIFTCEYCNKVFKFKHSLQAHLRIHTNEKPYKCPQCSYASAIKANLNVHLRKHTGEKFACDYCSFTCLSKGHLKVHIERVHKKIKQHCRFCKKKYSDVKNLIKHIRDAHDPQDKKVKEALDELCLMTREGKRQLLYDCHICERKFKNELDRDRHMLVHGDK WPFACELCGHGATKYQALELHVRKHPFVYVCAVCRKKFVSSIRLRTHIKEVHGAAQEALVFTSSINQSFCLLEPGGDIQQEALGDQLQLVEEEFALQGVNALKEEACPGDTQLEEGRKEPEAPGEMPAPAVHLASPQAESTALPPCELETTVVSSSDLHSQEVVSDDFLLKNDTSSAEAHAAPEKPPDMQHRSSV QTQGEVITLLLSKAQSAGSDQESHGAQSPLGEGQNMAVLSAGDPDPSRCLRSNPEAEASDLLPPVAGGGDTITHQPDSCKAAPEHRSGITAFMKVLNSLQKKQMNTSLCERIRKVYGDLECEYC SEQ ID NO:853 Translated polypeptide sequence of ZFAT exon 7 KLFWYQVHFDMHVRTHTREHLYYCSQCHYSSITKNCLKRHVIQKHSNILLKCPTDGCDYSTPDKYKLQAHLKVHTAL SEQ ID NO:854 Translated polypeptide sequence of ZFAT exon 8 DKRSYSCPCEKSFSEDRLIKSHIKTNHP SEQ ID NO:855 Translated polypeptide sequence of ZFAT exon 9 VSMSTISEVLGRRVQLKGLIGKRAMKCPYCDFYFMKNGSDLQRHIWAHE SEQ ID NO:856 Translated polypeptide sequence of ZFAT exon 10 VKPFKCSLCEYATRSKSNLKAHMNRHSTEKTHLCDMCGKKFKSKGTLKSHKLLHTAD SEQ ID NO:857 Translated polypeptide sequence of ZFAT exon 11 KQFKCTVCDYTAAQKPQLLRHMEQHVSFK SEQ ID NO:858 Translated polypeptide sequence of ZFAT exon 12 PFRCAHCHYSCNISGSLKRHYNRKHPNEEYANVGTGELAAEVLIQQ SEQ ID NO:859 Translated polypeptide sequence of ZFAT exon 13 GLKCPVCSFVYGTKWEFNRHLKNKHGLKVVEIDGDPKWE SEQ ID NO:860 Translated polypeptide sequence of ZFAT exon 14 TATEAPEEPSTQYLHITEAEEDVQGTQAAVAALQDLRYTSES SEQ ID NO:861 Translated polypeptide sequence of ZFAT exon 15 DRLDPTAVNILQQIIELGAETHDATALASVVAMAPGTVTVVKQ SEQ ID NO:862 Translated polypeptide sequence of ZFAT exon 16 VTEEEPSSNHTVMIQETVQQASVELAEQHHLVVSSDDVEGIETVTVYTQGGEASEFIVYVQEAMQPVEEQAVEQPAQEL SEQ ID NO:863 Full protein sequence of ZFAT METRAAENTAIFMCKCCNLFSPNQSELLSHVSEKHMEEGVNVDEIIIPLRPPLSTPEPPNSSKTGDEFLVMKRKRGRPKGSTKKSSTEEELAENIVSPTEDSPLAPEEGNSLPPSSLECSKCCRKFSNTRQLRKHICIIVLNLGEEEGEAGNESDLELEKKCKEDDREKASKRPRSQKTEKVQKISGKEARQLSGA KKPIISVVLTAHEAIPGATKIVPVEAGPPETGATNSETTSADLVPRRGYQEYAIQQTPYEQPMKSSRLGPTQLKIFTCEYCNKVFKFKHSLQAHLRIHTNEKPYKCPQCSYASAIKANLNVHLRKHTGEKFACDYCSFTCLSKGHLKVHIERVHKKIKQHCRFCKKKYSDVKNLIK HIRDAHDPQDKKVKEALDELCLMTREGKRQLLYDCHICERKFKNELDRDRHMLVHGDKWPFACELCGHGATKYQALELHVRKHPFVYVCAVCRKKFVSSIRLRTHIKEVHGAAQEALVFTSSINQSFCLLEPGGDIQQEALGDQLQLVEEEFALQGVNALKEEACPGDTQLEEGRKEAP GEMPAPAVHLASPQAESTALPPCELETTVVSSSDLHSQEVVSDDFLLKNDTSSAEAHAAPEKPPDMQHRSSVQTQGEVITLLLSKAQSAGSDQESHGAQSPLGEGQNMAVLSAGDPDPSRCLRSNPEAEASDLLPPVAGGGDTITHQPDSCKAAPHRSGITAFMKVLNSLQKKQMNTSLCERIRKVYGDLECEYCGK LFWYQVHFDMHVRTHTREHLYYCSQCHYSSITKNCLKRHVIQKHSNILLKCPTDGCDYSTPDKYKLQAHLKVHTALDKRSYSCPCEKSFSEDRLIKSHIKTNHPEVSMSTISEVLGRRVQLKGLIGKRAMKCPYCDFYFMKNGSDLQRHIWAHEGVKPFKCSLCEYATRSKSNL KAHMNRHSTEKTHLCDMCGKKFKSKGTLKSHKLLHTADGKQFKCTVCDYTAAQKPQLLRHMEQHVSFKPFRCAHCHYSCNISGSLKRHYNRKHPNEEYANVGTGELAAEVLIQQGGLKCPVCSFVYGTKWEFNRHLKNKHGLKVVEIDGDPKWETATEAPEEEPSTQYLHITEAE EDVQGTQAAVAALQDLRYTSESGDRLDPTAVNILQQIIELGAETHDATALASVVAMAPGTVTVVKQVTEEEPSSNHTVMIQETVQQQASVELAEQHHLVVSSDDVEGIETVTVYTQGGEASEFIVYVQEAMQPVEEQAVEQPAQEL SEQ ID NO:864 The polynucleotide sequence of all exons 1-12 of ZFAT arranged in order SEQ ID NO:865 The translated polypeptide sequence of all exons 1-12 of ZFAT arranged in order DSCAML1 sequence informationSEQ ID NO:866 Sequence from DSCAML1 exon 3 at 5' of DSCAML1-NRG1 fusion GCCTCATCCCCTCTTCAGTGCAGGAATATGTTAGCGTTGTATCTTGGGAGAAAGACACAGTCTCCATCATCCCAG SEQ ID NO:867 Sequence of NRG1 exon 2 at 3' of DSCAML1-NRG1 fusion CCTTGCCTCCCCGATTGAAA GAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO: 868 DSCAML1 - NRG1 polynucleotide sequence GCCTCATCCCCTCTTCAGTGCAGGAATATGTTAGCGTTGTATCTTGGGAGAAAGACACAGTCTCCATCATCCAGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAA SEQ ID NO: 869 DSCAML1-NRG1 polypeptide sequence LIPSSVQEYVSVVSWEKD TVSIIPALPPRLKEMKSQESAAAGSKLVLRCE SEQ ID NO:870 DSCAML1 exon 1 AGCCGAGCGCTGGGCTGAGGAGCAGAGAGAGCGGGGCGCCGAGTGCGGGCGGCTGGGAGCGCGCTGAGCGGGGGAGAGGCGCTGCCGCACGGCCGGCCACAGGACCACCTCCCCGGAGAATAGGGCCTCTTTATG GCATGTGGCTGGTAACTTTCCTCCTGCTCCTGGACTCTTTACACAAAG SEQ ID NO:871 DSCAML1 exon 2 CCCGCCCTGAAGATGTTGGCACCAGCCCTACTTTGTAAATGACTCCTTGCAGCAGGTGACCTTTTCCAGCTCCGTGGGGGTGGTGGTGCCCTGCCCGGCCGCGGGCTCCCCCAGCGCGGCCCTTCGATGGTAC DSCAML1 Exon 3 TTTTCAGGGAACCCTACACCGTCCGGGTGGAGGATCAAAGGTCAATGCGTGGCAACGTGGCCGTCTTTCAAGTGCCTCATCCCCTCTTCAGTGCAGGAATATGTTAGCGTTGTATCTTGGGAGAAAGACACAGTCTCCATCATCCAG SEQ ID NO: 873 DSCAML1 exon 4 AACACAGGTTTTTTATTACCTACCACGGCGG GCTGTACATCCTCTGACGTACAGAAGGAGGACGCCCTCTCCACCTATCGCTGCATCACCAAGCACAAGTATAGCGGGGAGACCCGGCAGAGCAATGGGCACGCCTCTCTGTGACAG SEQ ID NO: 874 DSCAML1 Exon 5 ACCCTGCTGAGTCGATCCCCACCATCCTGGATGGCTTCCACTCCCAGGAAGTGTGGGCCGGCCA CACCGTGGAGCTGCCCTGCACCGCCTCGGGCTACCCTATCCCCGCCATCCGCTGGCTCAAGGATGGCCGGCCCCTCCCGGCTGACAGCCGCTGGACCAAGCGCATCACAGGGCTGACCATCAGCGACTTGCGGACCGAGGACAGCGGCACCTACATTTGTGAGGTCACCAACACCTTCGGTTCGGCAGAGGCCACAGGCATCCTCATGGTCA TTG SEQ ID NO: 875 DSCAML1 exon 6 ATCCCCTTCATGTGACCCTGACACCAAAGAAGCTGAAGACCGGCATTGGCAGCACGGTCATCCTCTCCTGTGCCCTGACGGGCTCCCCAGAGTTCACCATCCGCTGGTATCGCAACACGGAGCTGGTGCTGCCTGACGAGGCCATCTCCATCCGCGGGCTCAGCAACGAGACGCT GCTCATCACCTCGGCCCAGAAGAGCCATTCCGGGGCCTACCAGTGCTTCGCTACCCGCAAGGCCCAGACCGCCCAGGACTTTGCCATCATTGCACTTGAGG SEQ ID NO: 876 Exon of DSCAML1 7 ATGGCACGCCCCGCATCGTCTCGTCCTTCAGCGAGAAGGTGGTCAACCCCGGGGAGCAGTTCTCACTGATGTGTGCGGCCAAGGGCGCCCCGCCCCCCACGGTCACCTGGGCCCTCGACGATGAGCCCATCGTGCGGGATGGCACCACCGCACCAACCAGTACACCATGTCGGACGGCACCACCATCAGCCACATGAACGTCACA GGCCCCCAGATCCGCGACGGGGGCGTGTACCGGTGCACAGCGCGGAACTTGGTGGGCAGTGCTGAATATCAGGCGCGAATAAACGTAAGAG SEQ ID NO: 877 DSCAML1 exon 8 GCCCACCCAGCATCCGGGCTATGCGGAACATCACAGCAGTCGCCGGGCGGGACACCCTTATCAACTGCAGGGTCATCGGCTATCCCTA CTACTCCATCAAGTGGTACAAGGATGCCCTGCTGCTGCCAGACAACCACCGCCAGGTGGTGTTTGAGAATGGGACCCTCAAGCTGACTGACGTGCAGAAGGGCATGGATGAGGGGGAGTACCTGTGCAGTGTCCTCATCCAGCCCCAGCTCTCCATCAGCCAGAGCGTTCACGTAGCCGTCAAAG SEQ ID NO: 878 DSCAML1 exon 9 T GCCCCCTCTGATCCAGCCCTTCGAATTCCCACCCGCCTCCATCGGCCAGCTGCTCTACATTCCCTGTGTGGTGTCCTCGGGGGACATGCCCATCCGTATCACCTGGAGGAAGGACGGACAGGTGATCATCTCAGGCTCGGGCGTGACCATCGAGAGCAAGGAATTCATGAGCTCCCTGCAGATCTCTAGCGTCTCCCTCAAGCACAACGGCAACTATACAT GCATCGCCAGCAACGCAGCCGCCACCGTGAGCCGGGAGCGCCAGCTCCATCGTGCGTG SEQ ID NO: 879 DSCAML1 exon 10 TGCCCCCTCGATTTGTGGTGCAACCCAACAACCAGGATGGCATCTACGGCAAAGCTGGTGTGTCCAACTGCTCGGTGGACGCTACCCCCCACCCAAGGTCATGTGGAAGCATGCCAAGG SEQ ID NO: 880 DSCAML1 exon 11 GGAGCGGGAACCCCCAGCAGTACCACCCCTGTGCCCCTCACTGGCCGCATCCAGATCCTGCCCAACAGCTCGCTGCTGATCCGCCACGTCCTAGAAGAGGACATCGGCTACTACCTCTGCCAGGCCAGCAACGGCGTAGGCACCGACATCAGCAAGTCCATGTTCCTCACAGTCAAGA SEQ ID NO: 881 DSCAML1 exon 12 TCCCGGCCATGATCACTTCCCACCCCCAACACCACCATCGCCATCAAGGGCCATGCGAAGGAGCTAAACTGCACGGCACGGGGTGAGCGGCCCATCATCATCCGCTGGGAGAAGGGGGACACAGTCATCGACCCTGACCGCGTCATGCGGTATGCCATCGCCACCAAGGACAACGGCGACGA GGTCGTCTCCACACTGAAG SEQ ID NO:882 DSCAML1 exon 13 CTCAAGCCCGCTGACCGTGGGGACTCTGTGTTTCTCAGCTGCCATGCCATCAACTCGTATGGGGAGGACCGGGGCTTGATCCAACTCACTGTGCAAG SEQ ID NO:883 DSCAML1 exon 14 AGCCCCCCGACCCCCCAGAGCTGGAG ATCCGGGAGGTGAAGGCCCGGAGCATGAACCTGCGCTGGACCCAGCGATTCGACGGGAACAGCATCATCACGGGCTTCGACATTGAATACAAGAACAAATCAG SEQ ID NO: 884 DSCAML1 Exon 15 ATTCCTGGGACTTCAAGCAGTCCACACGCAACATCTCCCCCACCATCAACCAGGCCAACATTGTGGACTTGCACCCGGC ATCTGTGTACAGCATCCGCATGTACTCTTTCAACAAGATTGGCCGCAGTGAACCAAGCAAGGAGCTCACCATCAGCACTGAGGAGGCCG SEQ ID NO: 885 DSCAML1 exon 16 CTCCCGATGGGCCCCCCATGGATGTTACCTTGCAGCCAGTGACCTCACAGAGCATCCAGGTGACCTGGAAG GGGCAGTACAGCATCGTGGAGATGAAGGCCACGGGGGACAGCGAGGTCTACACCCTGGACAACCTCAAGAAGTTCGCCCAGTATGGGGTGGTGGTCCAAGCCTTCAATCGGGCTGGCACGGGGCCCTCTTCCAGCGAGATCAATGCCACCACTCTGGAGGATG SEQ ID NO: 887 DSCAML1 exon 18 TGCCCAGCC AGCCCCCTGAGAACGTCCGGGCCCTGTCCATCACTTCTGACGTGGCCGTCATCTCCTGGTCAGAGCCCCCGCGCAGCACCCTCAATGGCGTCCTCAAAGGCTATCGGGTCATCTTCTGGTCCCCTCTATGTTGATGGGG SEQ ID NO: 888 DSCAML1 Exon 19 AGTGGGGCGAGATGCAGAACATCACCACCCACGCGGGAGCGG GTGGAGCTGCGGGGCATGGAGAAGTTCCACCAACTACAGCGTCCAGGTGCTGGCCTACACCCAGGCTGGGGACGGCGTACGCAGCAGTGTGCTCTACATCCAGACCAAGGAGGACG SEQ ID NO: 889 DSCAML1 exon 20 TTCCAGGTCCCCCCTGCTGGCATCAAAGCTGTCCCCTTCATCAGCTAGCAGTGTGGTTGTGTCTTGGCTCCCCCCTACCAAGCCCAACGGGGTGATCCGAAGTACACCATCCTTCTGTTCCAGCCCCGGGTCTGGCCAGCCG SEQ ID NO: 890 DSCAML1 exon 21 GCTCCCAGCGAGTAC GAGACGAGTCCAGAGCAGCTCTTCTACCGGATCGCCCACCTAAACCGCGGTCAGCAGTATCTGCTGTGGGTGGCCGCCGTCACCTCTGCCGGCCGGGGCAACAGCAGCGAGAAGGTGACCATCGAGCCTGCTGGCAAGG SEQ ID NO: 891 DSCAML1 Exon 22 CCCCAGCAAAGATCATCTCCTTTGGGGGCACCGTGA CAACACCTTGGATGAAAGATGTTCGGCTGCCTTGCAATTCAGTGGGAGATCCAGCCCCTGCTGTGAAGTGGACCAAGGACAG SEQ ID NO: 892 DSCAML1 exon 23 TGAAGACTCGGCCATTCCAGTGTCCATGGATGGGCACCGGCTCATCCACACCAATGGCACACTGCTGCTGCGTGCAGTGAAGGCTGAGGACTCT GGCTACTACACGTGCACGGCCACCAACACTGGTGGCTTTGACACCATCATCGTCAAACCTTCTGGTGCAAG SEQ ID NO: 893 DSCAML1 Exon 24 TTCCCCCGGACCAGCCCCGCCTCACTGTCTCCAAAAACCTCAGCTTCGTCCATCACCCTGACCTGGATTCCAGGTGACAATGGGGGCAGCTCCATCCGAG SEQ ID NO: 894 DSCAML1 exon 25 GCTTCGTGCTACAGTACTCGGTGGACAACAGCGAGGAGTGGAAGGATGTGTTCATCAGCTCCAGCGAGCGCTCCTT CAAGCTGGACAGCCTCAAGTGTGGCACGTGGTACAAGGTGAAGCTGGCAGCCAAGAACAGCGTGGGCTCTGGGCGCATCAGCGAGATCATCGAGGCCAAGACCCACGGGCGGG SEQ ID NO: 895 DSCAML1 Exon 26 AGCCCCTCCTTCAGCAAAGACCAACACCTCTTCACCCACATCAACTCCACGCATGCTCGGCTTAACCTGC AGGGCTGGAACAATGGGGGCTGCCCTATCACAGCCATCGTTCTGGAGTACCGGCCCAAGGGGACCTGGGCCTGGCAGGGCCTCCGGGCCAACAGCTCCGGGGAGGTGTTTCTGACGGAACTGCGAGAGGCCACGTGGTACGAGCTGCGCATGAGGGCTTGCAACAGTGCGGGCTGCGGCAATGAAACAGCCCAGTTCGCCACC CTGGACTACGATGGCA SEQ ID NO: 896 DSCAML1 exon 27 GCACCATTCCACCCATCAAGTCTGCTCAAGGTGAAGGGGATGATGTGAAGAAGCTGTTCACCATCGGCTGCCCTGTCATCCTGGCCACACTGGGGGTGGCACTGCTCTTCATCGTACGCAAGAAGAGGAAGGAGAAACGGCTGAAGCGACTCCGAG SEQ ID NO:897 other than DSCAML1 Exon 28 ATGCAAAGAGTTTGGCAGAAATGTTGATAAG SEQ ID NO: 898 DSCAML1 exon 29 CAAGAACAATAGAAGCTTTGACACCCCTGTGAAAGGGCCACCCCAGGGCCCACGGCTACACATTGACATCCCCAGGGTCCAGCTGCTCATCGAGGACAAAGAAGGCATCAAGCAACTGG SEQ ID NO: 899 DSCA ML1 exon 30 GAGATGACAAGGCCACCATCCCTGTGACAGATGCTGAGTTCAGCCAAGCTGTCCAACCAGAGCTTCTGTACTGGCGTCTCCTTGCACCACCCAACCCTCATCCAGAGCACAGGACCCCTCATCGACATGTCTGACATCCGGCCAGGAACCA SEQ ID NO: 900 DSCAML1 exon 31 ATCCAGTGTCCAGGAAGAATGTGA AGTCAGCCCACAGCACCCGGAACCGGTACTCAAGCCAGTGGACCCTGACCAAGTGCCAGGCCTCCACACCTGCCCGCACCCTCACCTCCGACTGGCGCACCGTGGGCTCCCAGCATGGTGTCACGGTCACTGAGAGTGACAGCTACAGTGCCAGCCTGTCCCAGGACACAG SEQ ID NO: 901 exon of DSCAML1 32 ACAAAGGAAGGAACAGCATGGTGTCCACTGAGAGTGCCTCTTCCACCTACGAGGAGCTGGCCCGGGCCTATGAGCATGCCAAGCTGGAGGAGCAGCTGCAGCACGCCAAGTTTGAGATCACCGAGTGCTTCATCTCTGACAGTTCCCTGACCAGATGACCACAGGCACCAACGAGAACGCCGACAGCATGACATCCATGAGCACACCCTCCAGAGCCT GGCATCTGCCGCTTTACCGCCTCACCACCCAAGCCCCAGGATGCGGACCGGGGCAAAAACGTGGCTGTGCCCATCCCTCACCGGGCCAACAAGA SEQ ID NO: 902 DSCAML1 Exon 33 GTGACTACTGCAACCTGCCCCTGTATGCCAAGTCAGAGGCCTTCTTTCGAAAGGCAGATGGACGTGAGCCCTGCCCCGTGGTCCCACCCCC GTGAGGCCTCCATCCGGAACCTGGCTCGAACCTACCACCCAGGCTCGCCACCTGACCCTGGACCCTGCCAGCAAGTCCTTGGGCCTTCCCCCACCCGGGGCCCCCGCTGCCGCCTCCACAGCCACCTTACCTCAGAGGACTCTGGCCATGCCAGCCCCCCCAGCCGGCACAGCCCCCCCAGCCCCCGGCCCCACCCCTGCTGAGCCACCCCACCGCCCCCAGCG CTGCCCCTCCGGCCCCCAGCACCGAGCCTCCACGAGCCGGGGGCCCACACACCAAAATGGGGGGCTCCAGGGACTCGCTTCTCGAGATGAGCACATCGGGGGTAGGGAGGTCTCCAGAAGCAGGGGGCCGGGGCCTACTCCAAATCCTACACCCTGGTGTAGGGCCCGCAGGAAGAGCAGCCACGCCTGGACCGCGCCGCGCCGCAGCC CCACACGCCAGCTCGGCTGTTTTTTCTGCATTATTATATTCAACTGACAGACAAAAAACCAACCAACGACAAAACAAAAACCCCCAATCATGAACGCCTGTACATAGAACTCTTTTGTACAAATGAAACTATTTTTCTTCTTCTCCATGAAGCCAGGCACAAAGAATTTGACAGTACAAGTCAATCCCCCACCCCAAAATATGTGTGGAGATATATATACATATAGACAGAC AGGAACGCGTCCACGAGCTATATATCTATATATTTCTCTCACCCTATTTTGAGACAGAGGCACAAAGACTCAGCAATTTTTTTTCCCTCCTCCTCACCTTCCCCCAGTCTAGGTGGTTTTGACAAAGACCAAAATCCCAACTCAGAGACACTGCATGCGATTTTACTGTTCCAAAAACCAGGAGTTGCTTCAATTTGCAGATGCTTATGTGTTAATACCTTTTTTCTATGAAAAAAGAC CCAGCGCCGTGTGCAATAAAGGTTATGTTTCTA SEQ ID NO:903 The complete mRNA polynucleotide sequence of DSCAML1 SEQ ID NO:904 The translated polypeptide sequence of exon 1 of DSCAML1 MWLVTFLLLLDSLHK SEQ ID NO:905 The translated polypeptide sequence of DSCAML1 The translated polypeptide sequence of exon 2 RPEDVGTSLYFVNDSLQQVTFSSSVGVVVPCPAAGSPSAALRWYLATGDDIYDVPHIRHVHANGTLQLYPFSPSAFNSFIHDNDYFCTAENAAGKIRSPNIRVKA SEQ ID NO: 906 The translated polypeptide sequence of exon 3 of DSCAML1 FREPYTVRVEDQRSMRGNVAVFKCLIPSSV QEYVSVVSWEKDTVSIIP SEQ ID NO:907 Translated polypeptide sequence of exon 4 of DSCAML1 HRFFITYHGGLYISDVQKEDALSTYRCITKHKYSGETRQSNGARLSVT SEQ ID NO:908 Exon of DSCAML1 Translated polypeptide sequence of exon 5 PAESIPTILDGFHSQEVWAGHHTVELPCTASGYPIPAIRWLKDGRPLPADSRWTKRITGLTISDLRTEDSGTYICEVTNTFGSAEATGILMVI SEQ ID NO: 909 Translated polypeptide sequence of exon 6 of DSCAML1 PLHVTLTPKKLKTGIGSTVILSCALTGSPEFTIRWYRNTELVLPDEAISIRG LSNETLLITSAQKSHSGAYQCFATRKAQTAQDFAIIALE SEQ ID NO:910 Translated polypeptide sequence of exon 7 of DSCAML1 GTPRIVSSFSEKVVNPGEQFSLMCAAKGAPPPPTVTWALDDEPIVRDGSHRTNQYTMSDGTTISHMNVTGPQIRDGGVYRCTARNLVGSAEYQARINVR SEQ ID NO:911 DSCAML1 exon 8 Translated polypeptide sequence PPSIRAMRNITAVAGRDTLINCRVIGYPYYSIKWYKDALLLPDNHRQVVFENGTLKLTDVQKGMDEGEYLCSVLIQPQLSISQSVHVAVK SEQ ID NO: 912 Translated polypeptide sequence PPLIQPFEFPPASIGQLLYIPCVVSSGDMPIRITWRKDGQVIISGSGVTI ESKEFMSSLQISSVSLKHNGNYTCIASNAAATVSRERQLIVR SEQ ID NO:913 Translated polypeptide sequence of exon 10 of DSCAML1 PPRFVVQPNNQDGIYGKAGVLNCSVDGYPPPKVMWKHAK SEQ ID NO:914 Translation of exon 11 of DSCAML1 Peptide sequence SGNPQQYHPVPLTGRIQILPNSSLLIRHVLEEDIGYYLCQASNGVGTDISKSMFLTVK SEQ ID NO:915 Translated polypeptide sequence of exon 12 of DSCAML1 PAMITSHPNTTIAIKGHAKELNCTARGERPIIIRWEKGDTVIDPDRVMRYAIATKDNGDEVVSTLK SEQ ID NO:916 DSCAML1 exon Translated polypeptide sequence of exon 13 LKPADRGDSVFFSCHAINSYGEDRGLIQLTVQ SEQ ID NO: 917 Translated polypeptide sequence of exon 14 of DSCAML1 PPDPPELEIREVKARSMNLRWTQRFDGNSIITGFDIEYKNKS SEQ ID NO:918 Translated polypeptide sequence of exon 15 of DSCAML1 SWDFKQSTRNISPTINQANIVDLHPASVYSIRMYSFNKIGRSEPSKELTISTEEA SEQ ID NO:919 Translated polypeptide sequence of exon 16 of DSCAML1 PDGPPMDVTLQ PVTSQSIQVTWK SEQ ID NO:920 Translated polypeptide sequence of exon 17 of DSCAML1 APKKELQNGVIRGYQIGYRENSPGSNGQYSIVEMKATGDSEVYTLDNLKKFAQYGVVVQAFNRAGTGPSSSEINATTLED SEQ ID NO:921 Translated polypeptide sequence of exon 18 of DSCAML1 PSQPPENVRALSITSDVAVISWSEPPRSTLNGVLKGYRVIFWSLYVDG SEQ ID NO:922 Translated polypeptide sequence of exon 19 of DSCAML1 WGEMQNITTTRERVELRGMEKFTNYSVQVLAYTQAGDGVRSSVLYIQTKED SEQ ID NO:9 23 Translated polypeptide sequence of exon 20 of DSCAML1 PGPPAGIKAVPSSASSVVVSWLPPTKPNGVIRKYTIFCSSPGSGQP SEQ ID NO :924 The translated polypeptide sequence of exon 21 of DSCAML1 APSEYETSPEQLFYRIAHLNRGQQYLLWVAAVTSAGRGNSSEKVTIEPAGK SEQ ID NO:925 The translated polypeptide sequence of exon 22 of DSCAML1 PAKIISFGGTVTTPWMKDVRLPCNSVGDPAPAVKWTKD SEQ ID NO:926 Outside of DSCAML1 Translated polypeptide sequence of exon 23 EDSAIPVSMDGHRLIHTNGTLLLRAVKAEDSGYYTCTATNTGGFDTIIVNLLVQ SEQ ID NO:927 Translated polypeptide sequence of exon 24 of DSCAML1 PPDQPRLTVSKTSASSITLTWIPGDNGGSSIR SEQ ID NO: 928 Translated polypeptide sequence of exon 25 of DSCAML1 FVLQYSVDNSEEWKDVFISSSERSFKLDSLKCGTWYKVKLAAKNSVGSGRISEIIEAKTHGR SEQ ID NO: 929 Translated polypeptide sequence PSFSKDQHLFTHINSTHARLNLQGWNNGGCPITAIVLEYRPKGTWAWQGLRANSSGEVFLTELREATWYELRMRACNSAGCGNETAQFATLDYDG SEQ ID NO: 930 of DSCAML1 Translated polypeptide sequence of exon 27 TIPPIKSAQGEGDDVKKLFTIGCPVILATLGVALLFIVRKKRKEKRLKRLR SEQ ID NO:931 Translated polypeptide sequence of exon 28 of DSCAML1 AKSLAEMLI SEQ ID NO:932 Translated polypeptide sequence of exon 29 of DSCAML1 KNNRSFDTPVKGPPQGPRLHIDIPRVQ LLIEDKEGIKQL SEQ ID NO:933 DSCAML1 epitope Translated polypeptide sequence of exon 30 DDKATIPVTDAEFSQAVNPQSFCTGVSLHHPTLIQSTGPLIDMSDIRPGT SEQ ID NO:934 Translated polypeptide sequence of exon 31 of DSCAML1 PVSRKNVKSAHSTRNRYSSQWTLTKCQASTPARTLTSDWRTVGSQHGVTVTESDSYSASLSQDT SEQ ID NO:935 DS Translated polypeptide sequence of CAML1 exon 32 KGRNSMVSTESASSTYEELARAYEHAKLEEQLQHAKFEITECFISDSSSDQMTTGTNENADSMTSMSTPSEPGICRFTASPPKPQDADRGKNVAVPIPHRANK SEQ ID NO: 936 DSCAML1 exon 33 The translated polypeptide sequence of DYCNLPLYAKSEAFFRKADGREPCPVVPPREASIRNLARTYHTQARHLTLDPASKSLGLPGAPAAASTATLPQRTLAMPAPPAGTAPPAPGPTPAEPPTAPSAAPPAPSTEPPRAGGPHTKMGGSRDSLLEMSTSGVGRSQKQGAGAYSKSYTLV SEQ ID NO:937 The complete protein sequence of DSCAML1 SEQ ID NO:9 38 Polynucleotide sequence of all exons 1-3 of DSCAML1 arranged in order SEQ ID NO: 939 All exons 1-3 of DSCAML1 3 Translated polypeptide sequences in sequence

         
           <![CDATA[ <110> MERUS N.V.]]>
           <![CDATA[ <120> Novel NRG1 fusions, fusion junctions and methods of detecting them]]>
           <![CDATA[ <140> TW 111120470]]>
           <![CDATA[ <141> 2022-06-01]]>
           <![CDATA[ <150> NL 2028384]]>
           <![CDATA[ <151> 2021-06-03]]>
           <![CDATA[ <150> NL 2030006]]>
           <![CDATA[ <151> 2021-12-03]]>
           <![CDATA[ <160> 942 ]]>
           <![CDATA[ <170> PatentIn version 3.5]]>
           <![CDATA[ <210> 1]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 1]]>
          caggtcctga gcctcgagcc gcagcacgag ctcaaattcc gag 43
           <![CDATA[ <210> 2]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 2]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt t 51
           <![CDATA[ <210> 3]]>
           <![CDATA[ <211> 94]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 3]]>
          caggtcctga gcctcgagcc gcagcacgag ctcaaattcc gagccttgcc tccccgattg 60
          aaagagatga aaagccagga atcggctgca ggtt 94
           <![CDATA[ <210> 4]]>
           <![CDATA[ <211> 31]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 4]]>
          Gln Val Leu Ser Leu Glu Pro Gln His Glu Leu Lys Phe Arg Ala Leu
          1 5 10 15
          Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly
                      20 25 30
           <![CDATA[ <210> 5]]>
           <![CDATA[ <211> 53]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 5]]>
          agcttcaaac atagtgggga aagctcactc ggattatatg ctgtatgtat acg 53
           <![CDATA[ <210> 6]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 6]]>
          ctacatctac atccaccact gggacaagcc at 32
           <![CDATA[ <210> 7]]>
           <![CDATA[ <211> 85]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 7]]>
          agcttcaaac atagtgggga aagctcactc ggattatatg ctgtatgtat acgctacatc 60
          tacatccacc actgggacaa gccat 85
           <![CDATA[ <210> 8]]>
           <![CDATA[ <211> 28]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 8]]>
          Ala Ser Asn Ile Val Gly Lys Ala His Ser Asp Tyr Met Leu Tyr Val
          1 5 10 15
          Tyr Ala Thr Ser Thr Ser Thr Thr Gly Thr Ser His
                      20 25
           <![CDATA[ <210> 9]]>
           <![CDATA[ <211> 52]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 9]]>
          gacgaagaca gtccctggat caccgacagc acagacagaa tccctgctac ca 52
           <![CDATA[ <210> 10]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 10]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaact 58
           <![CDATA[ <210> 11]]>
           <![CDATA[ <211> 110]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 11]]>
          gacgaagaca gtccctggat caccgacagc acagacagaa tccctgctac caccttgcct 60
          ccccgattga aagagatgaa aagccaggaa tcggctgcag gttccaaact 110
           <![CDATA[ <210> 12]]>
           <![CDATA[ <211> 36]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 12]]>
          Asp Glu Asp Ser Pro Trp Ile Thr Asp Ser Thr Asp Arg Ile Pro Ala
          1 5 10 15
          Thr Thr Leu Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala
                      20 25 30
          Ala Gly Ser Lys
                  35
           <![CDATA[ <210> 13]]>
           <![CDATA[ <211> 53]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 13]]>
          ccgcatcggc gaccttcagg ccttccaggg ccacggcgcg ggcaacctgg cgg 53
           <![CDATA[ <210> 14]]>
           <![CDATA[ <211> 35]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 14]]>
          catctacatc tacatccacc actgggacaa gccat 35
           <![CDATA[ <210> 15]]>
           <![CDATA[ <211> 88]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 15]]>
          ccgcatcggc gaccttcagg ccttccaggg ccacggcgcg ggcaacctgg cggcatctac 60
          atctacatcc accactggga caagccat 88
           <![CDATA[ <210> 16]]>
           <![CDATA[ <211> 29]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 16]]>
          Arg Ile Gly Asp Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn Leu
          1 5 10 15
          Ala Ala Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His
                      20 25
           <![CDATA[ <210> 17]]>
           <![CDATA[ <211> 399]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 17]]>
          agtccccgcc cctggagccg gcggcgcagg gcgcagcttc ccgccgccag agcgggccag 60
          cctgctgcgt gcgtgcgtgt gtacgactct gcgtgcgtgc gtgcgtgcgt gcgtgccgtc 120
          agctcgccgg gcaccgcggc ctcgccctcg ccctccgccc ctgcgcctgc accgcgtaga 180
          ccgacccccc cccagcgcgc ccaccccggta gaggaccccc gcccgtgccc cgaccggtcc 240
          ccgccttttt gtaaaactta aagcgggcgc agcattaacg cttcccgccc cggtgacctc 300
          tcaggggtct ccccgccaaa ggtgctccgc cgctaaggaa catggcgaag gtggagcagg 360
          tcctgagcct cgagccgcag cacgagctca aattccgag 399
           <![CDATA[ <210> 18]]>
           <![CDATA[ <211> 153]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 18]]>
          gtcccttcac cgatgttgtc accaccaacc taaagcttgg caacccgaca gaccgaaatg 60
          tgtgttttaa ggtgaagact acagcaccac gtaggtactg tgtgaggccc aacagcggaa 120
          tcatcgatgc aggggcctca attaatgtat ctg 153
           <![CDATA[ <210> 19]]>
           <![CDATA[ <211> 104]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 19]]>
          tgatgttaca gcctttcgat tatgatccca atgagaaaag taaacacaag tttatggttc 60
          agtctatgtt tgctccaact gacacttcag atatggaagc agta 104
           <![CDATA[ <210> 20]]>
           <![CDATA[ <211> 81]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 20]]>
          tggaaggagg caaaaccgga agaccttatg gattcaaaac ttagatgtgtgtttgaattg 60
          ccagcagaga atgataaacc a 81
           <![CDATA[ <210> 21]]>
           <![CDATA[ <211> 177]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 21]]>
          catgatgtag aaataaataa aattatatcc acaactgcat caaagacaga aacaccaata 60
          gtgtctaagt ctctgagttc ttctttggat gacaccgaag ttaagaaggt tatggaagaa 120
          tgtaagaggc tgcaaggtga agttcagagg ctacgggagg agaacaagca gttcaag 177
           <![CDATA[ <210> 22]]>
           <![CDATA[ <211> 7035]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 22]]>
          gaagaagatg gactgcggat gaggaagaca gtgcagagca acagccccat ttcagcatta 60
          gccccaactg ggaaggaaga aggccttagc acccggctct tggctctggt ggttttgttc 120
          tttatcgttg gtgtaattat tgggaagatt gccttgtaga ggtagcatgc acaggatggt 180
          aaattggatt ggtggatcca ccatatcatg ggatttaaat ttatcataac catgtgtaaa 240
          aagaaattaa tgtatgatga catctcacag gtcttgcctt taaattaccc ctccctgcac 300
          acacatacac agatacacac acacaaatat aatgtaacga tcttttagaa agttaaaaat 360
          gtatagtaac tgattgaggg ggaaaagaat gatctttat aatgacaagg gaaaccatga 420
          gtaatgccac aatggcatat tgtaaatgtc attttaaaca ttggtaggcc ttggtacatg 480
          atgctggatt acctctctta aaatgacacc cttcctcgcc tgttggtgct ggcccttggg 540
          gagctggagc ccagcatgct ggggagtgcg gtcagctcca cacagtagtc cccacgtggc 600
          ccactcccgg cccaggctgc tttccgtgtc ttcagttctg tccaagccat cagctccttg 660
          ggactgatga acagagtcag aagcccaaag gaattgcact gtggcagcat cagacgtact 720
          cgtcataagt gagaggcgtg tgttgactga ttgacccagc gctttggaaa taaatggcag 780
          tgctttgttc acttaaaggg accaagctaa atttgtattg gttcatgtag tgaagtcaaa 840
          ctgttattca gagatgttta atgcatattt aacttattta atgtatttca tctcatgttt 900
          tcttattgtc acaagagtac agttaatgct gcgtgctgct gaactctgtt gggtgaactg 960
          gtattgctgc tggagggctg tgggctcctc tgtctctgga gagtctggtc atgtggaggt 1020
          ggggtttatt gggatgctgg agaagagctg ccaggaagtg ttttttctgg gtcagtaaat 1080
          aacaactgtc atagggaggg aaattctcag tagtgacagt caactctagg ttaccttttt 1140
          taatgaagag tagtcagtct tctagattgt tcttatacca cctctcaacc attackcaca 1200
          cttccagcgc ccaggtccaa gtctgagcct gacctcccct tggggaccta gcctggagtc 1260
          aggacaaatg gatcgggctg cagagggtta gaagcgaggg caccagcagt tgtgggtggg 1320
          gagcaaggga agagagaaac tcttcagcga atccttctag tactagttga gagtttgact 1380
          gtgaattaat tttatgccat aaaagaccaa cccagttctg tttgactatg tagcatcttg 1440
          aaaagaaaaa ttataataaa gccccaaaat taagaattct tttgtcattt tgtcacattt 1500
          gctctatggg gggaattatt attttatcat ttttattatt ttgccattgg aaggttaact 1560
          ttaaaatgag ccctatcact gagaaatacg tgtttcatga tttaactctg tgtgtgtgtg 1620
          tgtgtgtgtg tgtgtgtgtg tgtgtatttt ttttttggtt gtcttcagct gacagtatga 1680
          aaaatgaaac tgctgaaaaa gctgagcacc tggtcaccct tggccttcca ttgctttggc 1740
          cttcagtaaa aagcagcctc ccttctaggt cagggaacca tgccattgag actagtaacg 1800
          ggcgttctgg gcacagtccc actgtgcaca ggtttgagag gacaagttca tcagaaggaa 1860
          ggcagtcctt agaagtcaca tacgttgagc cacgttgctc ctaagcctgg ctctgtcaag 1920
          ctgggtcagg ggccttgaaa ctggagaagt ggaagtctat ggttggtctg agtaagtaac 1980
          ttcctgtctt catgaaaaaa gttgactttg aatcccaggt actcacagaa atggtgaaca 2040
          gacttagttg ttacccaggc acccatggat tgtgttgagt gtgcagacag ggaggccacc 2100
          ccaataggaa ttcgtctcca ggatttttcc catgtgtccc ccagtactta taaaagggag 2160
          tgaaaagacc gagctgtaag gcatgtgcct tctgccacct gactttccgt gaggggacta 2220
          aaatttacta attgtagttg ctgcagccag ttaagtcctg tagcttccag gccctcatgt 2280
          ctttgatagg agagtgctta ggtggtcccc aacagtgcct aggggtacag tacagtccca 2340
          ttacactaga gcagggctct atttattttt aaaggatatg gccgtgtgtt ttgataaaac 2400
          tttattcaca aaaacagccg ggtcatggga tttggcttgt gagtctgtaa cagttcttaa 2460
          aaagaatatc tgagaaacta ctctgtttta gacctttgaa ggtgatttag agttttgtgt 2520
          acatctagga gaaggtgttc agcttctcag aggatgtgga cattttggtt gcagctaaaa 2580
          atcagtctct gaagtctctc tcccttctag aggttaggac ttggtgaaca tgtttgtggg 2640
          ccttttgact gagtggcaga aggaaactgc tcaggaagag aaacaggtga ctgatgggaa 2700
          ggttgattat tttctcagtc atcctggcag ccaaaaatgt gccaggaaaa gaaagaatgt 2760
          ggagcacgcg tggctcctgg aggacttgga gatgcatgca catttagggt gttttcccta 2820
          gaattacata atgaaaaaaa gaataaggca aagaggaggt gaatatgggg cctgtcacaa 2880
          cggcctgccc tgccccaaga gggttaagag tcagataatc gggacgaaac tggcatggaa 2940
          agagcgagcc tagggaggat gccgctgggc agtgtgcatg ggggagctgc tgccaggctg 3000
          ccctccagtc tgctcctgtg gttactggct ccacagcacc tcagagaggg cggccctggc 3060
          ttcagaaatg ccagccatag tgctcacaaa tgcagaagag atggaagcgg tgacagaatc 3120
          ctgaaagttt ttattgattg aagttttaaa ttggtaactt aagcttcctt ggcacgatac 3180
          aaaatacctc ttaaagacag caggcttttt tatttgtagg tgtgaggaac tggctttaac 3240
          ttttttctcc tcctagtttg catgttttcc ttctctcgtc ttctgaactg ctggcaccag 3300
          cagtaataca tactgataaa atcaaaattg atttttacca gtggccagtt tatggctaga 3360
          gagaacgactt atacctccat aacacagaag ggggaaaaat gaagaacctc cagtgatccg 3420
          tgaaaaccta aacgctttca aacaaatccc aggaacagaa ttgctatcga aagatatcat 3480
          tgcccagttt gcaggctatg ttgagtcaga tagaactgaa tgtagtgaga gctcagagct 3540
          acagagcctt tcagatgaat ttgaaaacag actctgtgtg tgtgtgcatg tgtgcatgtg 3600
          tgcatgtgtg gcatatgtgc cgtatgtcag tagcttgaca gttttcaaat cgtgcctata 3660
          tttttttgca tacacaaatt tttgtgtttg caaactcaga atccatgcca aaatacaatg 3720
          ttatatgtca ttttcagctc cttctctaaa ggaatggccc atttctcatt gtagtttgag 3780
          aaatacatgt atgaagagat aggggtcttg ggcttcccag tgtcactttg aacacctgaa 3840
          taacatttaa ctcctgagac cttctcggtg tagaggccac tgcttccccc tgctggagat 3900
          ggcatttcat tgaagggcct ctcgtggctt tccctgcccc cggctgtctg gcctgaagaa 3960
          ggagaaagaa ccaaactgaa ctatgaaaag ttaccactct gaggagacct ctcttaatta 4020
          acacttgggg ccatgtttgc tgttgttgag aaggagtgtt ctcaaagatg agctggaatg 4080
          gaattgtatt tagaaaggcc cctgcaaagt atatagatgg atgactctag ttcatgacat 4140
          acaaatccca taaggccaac gaccactctt ctggaacacc aagagcagct ctgagatcat 4200
          gctggcccta cgcgaattga gtttctgtgg cctaattgga tttggagaac gccttccctg 4260
          gccccttttc ctcagacaga tctgctctga taggaacctt ttcaagaaag ttactgttgt 4320
          ttcaatgcca ctccttacct gtatagaaca tttccaatac attcgctcat tgaacttaat 4380
          ccttgcaact gtgactgggg ggtagatggc tctgtttgca tacgaagaaa taaaggctcc 4440
          aggagggttaa atcgggcaac tttttagaac taaatcagtc tctgtaaggc ctacattgct 4500
          aagataccat ttcagctctg aaaatctgct tcagggaagt gagtggatga ggccttcctg 4560
          cctcagctac tctgcccgtc tgtacatctt ttgtgtctgc ctccgtacct tattcagtta 4620
          ttttcacact aaagtaagta gaattaagac tgtagttcag atgctttttc tttttctgtt 4680
          ggaaactgaa cacactacag acagtgaaaa aaggtacata ttccattttc tcattgcctg 4740
          aagatctctg ctgatgctcc tggagaatga ctttgggggc tttagaaaga atattgccag 4800
          tccgtctcgg caaggagatg atgggagcgc tttatatgga ggctttacat gacttgtaaa 4860
          ttaaatgtga atgagggcag ttgattaaaa ttggtattac agaagggccc tgctgaggtt 4920
          tgaaaacagc tgagctgctg atgtctcagg cctttccctg aattagcact gcggttctcc 4980
          aggatatcag caaagagggc aagtaataga agcccctgat aaggagcgtc agccgacagg 5040
          caagcttggg aggctgtggg aatgggtctg cccccagctt cacagacctc ttcctccagc 5100
          ctctgaatcc cattagccac agcctagaac attagctgag ctgcacaagc tcacccaccc 5160
          ctgtgccagg gggccctgac ctccctccat gccatgtttt tggctgtatc tacggcactt 5220
          aacaataggg gctttttatt ttcattacag agatattttg aaaaatttaa aagacatgaa 5280
          ctcacataaa cagttatgga tgatagttaa aagagaaacg ggtggaggtg gatgagaggt 5340
          tgtcttcatg aatataatta cttgagattt ttttttctta atggaattag tttattagaa 5400
          aatgtctgtg ttaaatccgt agaaaaggaa gaaaagtgta gcaacaaaaa tgtagccatt 5460
          atctaacttg ccataaatat ttgcagttat gataccttgg aatgttgcca cgatatggat 5520
          tgctttgatt aaaagatgtc agttgaataa aacagtactg tgggagaatc gctttctgct 5580
          gctagataaa tgctgatgtt tatttttaaa ccaggaaaca ttgatcctgt aacaatgccc 5640
          gattacaatt gctttattac accccagggc tgatggagat gtaatcactt ggctaatgga 5700
          tgtgggtgca ggacagatgc tcgcttgctg gcctgctttc ctgcttgcat tctgatgagc 5760
          tgcaggagtg cgcctggcct tctgcaggtg gagctgctgt cagagcttcg tttcactgat 5820
          acccaaagcc atgtctgact gaaataaaac aggttccctt tttttttccc tttggaaaat 5880
          gccaactaag ggagactaat cagatatctt aacacaattt catccaggct tagtgctaac 5940
          aagattgcgg ggctttttag ggtttaagaa gatgagaaat gagtgtgcac gtttcacacg 6000
          ttgacttgcc ggtttttcca tgtcatacaa aaaagtcctg gctgtttctc cgaactggct 6060
          gcctgcattc ccgtctttct tttgttttta agaaatagac tgaattcagc tgttaatcct 6120
          ctagtacagt atccatgtta aaatgttttt ccattgcatc ttttatgtga attcaaaggt 6180
          cagaatttt tgtctgtgat attgagacca tgtgtacaag aactactttt tgcttttcat 6240
          cattcactcc ttagcaaacg tttcgtaagt accctctgtc tgtttgctac tatatgaggt 6300
          gctgcgaaat tagtgggcgt ggctttttat atttttcatt cgtgtgtagc ctaagtaagg 6360
          tgactcaaga tgatacaccg agagaaaaat gcaaaatata tttggttctc atttctgttg 6420
          ctgtcgtttc ctttttaaag acgatttatc aactgctgcc atttggaact tcctataaga 6480
          aactaaaaat gatctatttc agtgttcctt tcgcctttcc tctgctttct gaataaatgg 6540
          tttcagtaac ccatgctgtt ctctccctat tctacgtctt tctccctatg ttgaaaaaag 6600
          attcccacag tttctgatgt gtgtgtttat agtcttcaat gtatgttaac atgttaggaa 6660
          ctgagtatct taagagatgt cttagaatgc tttagttttc ataatttgtc ctttatgtat 6720
          ttttcattgt atttgctgtt ttgacatgga agtaatttaa aaagttggtg caggaaagga 6780
          ctctttactg ttgcacattt tggttttctg atatgtaata aattcatggc ttggcagctg 6840
          acatgatgtt tccccagagag aaggagatgt atttctgcag ggtccagacc aaaagagcca 6900
          tttacagcat gttctcccat gttccattat cagcctgatg aaacctgccc tgccaaggca 6960
          taaacttttg tactagctgt ctccatatta tgttcaataa attctgtgct ctgaatatat 7020
          ttaaaaaaaaaaaaa 7035
           <![CDATA[ <210> 23]]>
           <![CDATA[ <211> 7949]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 23]]>
          agtccccgcc cctggagccg gcggcgcagg gcgcagcttc ccgccgccag agcgggccag 60
          cctgctgcgt gcgtgcgtgt gtacgactct gcgtgcgtgc gtgcgtgcgt gcgtgccgtc 120
          agctcgccgg gcaccgcggc ctcgccctcg ccctccgccc ctgcgcctgc accgcgtaga 180
          ccgacccccc cccagcgcgc ccaccccggta gaggaccccc gcccgtgccc cgaccggtcc 240
          ccgccttttt gtaaaactta aagcgggcgc agcattaacg cttcccgccc cggtgacctc 300
          tcaggggtct ccccgccaaa ggtgctccgc cgctaaggaa catggcgaag gtggagcagg 360
          tcctgagcct cgagccgcag cacgagctca aattccgagg tcccttcacc gatgttgtca 420
          ccaccaacct aaagcttggc aacccgacag accgaaatgt gtgttttaag gtgaagacta 480
          cagcaccacg taggtactgt gtgaggccca acagcggaat catcgatgca ggggcctcaa 540
          ttaatgtatc tgtgatgtta cagcctttcg attatgatcc caatgagaaa agtaaacaca 600
          agtttatggt tcagtctatg tttgctccaa ctgacacttc agatatggaa gcagtatgga 660
          aggaggcaaa accggaagac cttatggatt caaaacttag atgtgtgttt gaattgccag 720
          cagagaatga taaaccacat gatgtagaaa taaataaaat tatatccaca actgcatcaa 780
          agacagaaac accaatagtg tctaagtctc tgagttcttc tttggatgac accgaagtta 840
          agaaggttat ggaagaatgt aagaggctgc aaggtgaagt tcagaggcta cgggaggaga 900
          acaagcagtt caaggaagaa gatggactgc ggatgaggaa gacagtgcag agcaacagcc 960
          ccatttcagc attagcccca actgggaagg aagaaggcct tagcacccgg ctcttggctc 1020
          tggtggtttt gttctttatc gttggtgtaa ttatgggaa gattgccttg tagaggtagc 1080
          atgcacagga tggtaaattg gattggtgga tccaccatat catgggattt aaatttatca 1140
          taaccatgtg taaaaagaaa ttaatgtatg atgacatctc acaggtcttg cctttaaatt 1200
          acccctccct gcacacacat acacagatac acacacacaa atataatgta acgatctttt 1260
          agaaagttaa aaatgtatag taactgattg agggggaaaa gaatgatctt tattaatgac 1320
          aagggaaacc atgagtaatg ccacaatggc atattgtaaa tgtcatttta aacattggta 1380
          ggccttggta catgatgctg gattacctct cttaaaatga cacccttcct cgcctgttgg 1440
          tgctggccct tggggagctg gagcccagca tgctggggag tgcggtcagc tccacacagt 1500
          agtccccacg tggcccactc ccggcccagg ctgctttccg tgtcttcagt tctgtccaag 1560
          ccatcagctc cttgggactg atgaacagag tcagaagccc aaaggaattg cactgtggca 1620
          gcatcagacg tactcgtcat aagtgagagg cgtgtgttga ctgattgacc cagcgctttg 1680
          gaaataaatg gcagtgcttt gttcacttaa agggaccaag ctaaatttgt attggttcat 1740
          gtagtgaagt caaactgtta ttcagagatg tttaatgcat atttaactta tttaatgtat 1800
          ttcatctcat gttttcttat tgtcacaaga gtacagttaa tgctgcgtgc tgctgaactc 1860
          tgttgggtga actggtattg ctgctgggagg gctgtgggct cctctgtctc tggagagtct 1920
          ggtcatgtgg aggtggggtt tattgggatg ctggagaaga gctgccagga agtgtttttt 1980
          ctgggtcagt aaataacaac tgtcatagggg agggaaattc tcagtcagtga cagtcaactc 2040
          taggttacct tttttaatga agagtagtca gtcttctaga ttgttcttat accacctctc 2100
          aaccattact cacacttcca gcgcccaggt ccaagtctga gcctgacctc cccttgggga 2160
          cctagcctgg agtcaggaca aatggatcgg gctgcagagg gttagaagcg agggcaccag 2220
          cagttgtggg tggggagcaa gggaagagag aaactcttca gcgaatcctt ctagtactag 2280
          ttgagagttt gactgtgaat taattttatg ccataaaaga ccaacccagt tctgtttgac 2340
          tatgtagcat cttgaaaaga aaaattataa taaagcccca aaattaagaa ttcttttgtc 2400
          attttgtcac atttgctcta tggggggaat tattatttta tcatttttat tattttgcca 2460
          ttggaaggtt aactttaaaa tgagccctat cactgagaaa tacgtgtttc atgatttaac 2520
          tctgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtgta tttttttttt ggttgtcttc 2580
          agctgacagt atgaaaaatg aaactgctga aaaagctgag cacctggtca cccttggcct 2640
          tccattgctt tggccttcag taaaaagcag cctcccttct aggtcaggga accatgccat 2700
          tgagactagt aacgggcgtt ctgggcacag tcccactgtg cacaggtttg agaggacaag 2760
          ttcatcagaa ggaaggcagt ccttagaagt cacatacgtt gagccacgtt gctcctaagc 2820
          ctggctctgt caagctgggt caggggcctt gaaactggag aagtggaagt ctatggttgg 2880
          tctgagtaag taacttcctg tcttcatgaa aaaagttgac tttgaatccc aggtactcac 2940
          agaaatggtg aacagactta gttgttaccc aggcacccat ggattgtgtt gagtgtgcag 3000
          acagggaggc caccccaata ggaattcgtc tccaggattt ttcccatgtg tcccccagta 3060
          ccttataaaag ggagtgaaaa gaccgagctg taaggcatgt gccttctgcc acctgacttt 3120
          ccgtgagggg actaaaattt actaattgta gttgctgcag ccagttaagt cctgtagctt 3180
          ccaggccctc atgtctttga taggagtg cttaggtggt ccccaacagt gcctaggggt 3240
          acagtacagt cccattacac tagagcaggg ctctatttat ttttaaagga tatggccgtg 3300
          tgttttgata aaactttat cacaaaaaca gccgggtcat gggatttggc ttgtgagtct 3360
          gtaacagttc ttaaaaagaa tatctgagaa actactctgt tttagacctt tgaaggtgat 3420
          ttagagtttt gtgtacatct aggagaaggt gttcagcttc tcagaggatg tggacatttt 3480
          ggttgcagct aaaaatcagt ctctgaagtc tctctccctt ctagaggtta ggacttggtg 3540
          aacatgtttg tgggcctttt gactgagtgg cagaaggaaa ctgctcagga agagaaacag 3600
          gtgactgatg ggaaggttga ttattttctc agtcatcctg gcagccaaaa atgtgccagg 3660
          aaaagaaaga atgtggagca cgcgtggctc ctggaggact tggagatgca tgcacattta 3720
          gggtgttttc cctagaatta cataatgaaa aaaagaataa ggcaaagagg aggtgaatat 3780
          ggggcctgtc acaacggcct gccctgcccc aagagggtta agagtcagat aatcgggacg 3840
          aaactggcat ggaaagagcg agcctaggga ggatgccgct gggcagtgtg catgggggag 3900
          ctgctgccag gctgccctcc agtctgctcc tgtggttact ggctccacag cacctcagag 3960
          agggcggccc tggcttcaga aatgccagcc atagtgctca caaatgcaga agagatggaa 4020
          gcggtgacag aatcctgaaa gtttttattg attgaagttt taaattggta acttaagctt 4080
          ccttggcacg atacaaaata cctcttaaag acagcaggct tttttatttg taggtgtgag 4140
          gaactggctt taactttttt ctcctcctag tttgcatgtt ttccttctct cgtcttctga 4200
          actgctggca ccagcagtaa tacatactga taaaatcaaa attgattttt accagtggcc 4260
          agtttatggc tagagagacg acttatacct ccataacaca gaagggggaa aaatgaagaa 4320
          cctccagtga tccgtgaaaa cctaaacgct ttcaaacaaa tcccaggaac agaattgcta 4380
          tcgaaagata tcattgccca gtttgcaggc tatgttgagt cagatagaac tgaatgtagt 4440
          gagagctcag agctacagag cctttcagat gaatttgaaa acagactctg tgtgtgtgtg 4500
          catgtgtgca tgtgtgcatg tgtggcatat gtgccgtatg tcagtagctt gacagttttc 4560
          aaatcgtgcc tatatttttt tgcatacaca aatttttgtg tttgcaaact cagaatccat 4620
          gccaaaatac aatgttatat gtcattttca gctccttctc taaaggaatg gcccatttct 4680
          cattgtagtt tgagaaatac atgtatgaag agataggggt cttgggcttc ccagtgtcac 4740
          tttgaacacc tgaataacat ttaactcctg agaccttctc ggtgtagagg ccactgcttc 4800
          cccctgctgg agatggcatt tcattgaagg gcctctcgtg gctttccctg cccccggctg 4860
          tctggcctga agaaggagaa agaaccaaac tgaactatga aaagttacca ctctgaggag 4920
          acctctctta attaacactt ggggccatgt ttgctgttgt tgagaaggag tgttctcaaa 4980
          gatgagctgg aatggaattg tattagaaa ggcccctgca aagtatatag atggatgact 5040
          ctagttcatg acatacaaat cccataaggc caacgaccac tcttctggaa caccaagagc 5100
          agctctgaga tcatgctggc cctacgcgaa ttgagtttct gtggcctaat tggatttgga 5160
          gaacgccttc cctggcccct tttcctcaga cagatctgct ctgataggaa ccttttcaag 5220
          aaagttactg ttgtttcaat gccactcctt acctgtatag aacatttcca atacattcgc 5280
          tcattgaact taatccttgc aactgtgact ggggggtaga tggctctgtt tgcatacgaa 5340
          gaaataaagg ctccaggagg ttaaatcggg caacttttta gaactaaatc agtctctgta 5400
          aggcctacat tgctaagata ccatttcagc tctgaaaatc tgcttcaggg aagtgagtgg 5460
          atgaggcctt cctgcctcag ctactctgcc cgtctgtaca tcttttgtgt ctgcctccgt 5520
          accttattca gttattttca cactaaagta agtagaatta agactgtagt tcagatgctt 5580
          tttctttttc tgttggaaac tgaacacact acagacagtg aaaaaaggta catattccat 5640
          tttctcattg cctgaagatc tctgctgatg ctcctggaga atgactttgg gggctttaga 5700
          aagaatattg ccagtccgtc tcggcaagga gatgatggga gcgctttata tggaggcttt 5760
          acatgacttg taaattaaat gtgaatgagg gcagttgatt aaaattggta ttacagaagg 5820
          gccctgctga ggtttgaaaa cagctgagct gctgatgtct caggcctttc cctgaattag 5880
          cactgcggtt ctccaggata tcagcaaaga gggcaagtaa tagaagcccc tgataaggag 5940
          cgtcagccga caggcaagct tgggaggctg tgggaatggg tctgccccca gcttcacaga 6000
          cctcttcctc cagcctctga atcccattag ccacagccta gaacattagc tgagctgcac 6060
          aagctcaccc acccctgtgc cagggggccc tgacctccct ccatgccatg tttttggctg 6120
          tatctacggc acttaacaat aggggctttt tattttcatt acagagatat tttgaaaaat 6180
          ttaaaagaca tgaactcaca taaacagtta tggatgatag ttaaaagaga aacgggtgga 6240
          ggtggatgag aggttgtctt catgaatata attacttgag attttttttt cttaatggaa 6300
          ttagtttatt agaaaatgtc tgtgttaaat ccgtagaaaa ggaagaaaag tgtagcaaca 6360
          aaaatgtagc cattatctaa cttgccataa atatttgcag ttatgatacc ttggaatgtt 6420
          gccacgatat ggattgcttt gattaaaaga tgtcagttga ataaaacagt actgtggggag 6480
          aatcgctttc tgctgctaga taaatgctga tgtttatttt taaaccagga aacattgatc 6540
          ctgtaacaat gcccgattac aattgcttta ttacacccca gggctgatgg agatgtaatc 6600
          acttggctaa tggatgtggg tgcaggacag atgctcgctt gctggcctgc tttcctgctt 6660
          gcattctgat gagctgcagg agtgcgcctg gccttctgca ggtggagctg ctgtcagagc 6720
          ttcgtttcac tgatacccaa agccatgtct gactgaaata aaacaggttc cctttttttt 6780
          tccctttgga aaatgccaac taagggagac taatcagata tcttaacaca atttcatcca 6840
          ggcttagtgc taacaagatt gcggggcttt ttagggttta agaagatgag aaatgagtgt 6900
          gcacgtttca cacgttgact tgccggtttt tccatgtcat acaaaaaagt cctggctgtt 6960
          tctccgaact ggctgcctgc attcccgtct ttcttttgtt tttaagaaat agactgaatt 7020
          cagctgttaa tcctctagta cagtatccat gttaaaatgt ttttccattg catcttttat 7080
          gtgaattcaa aggtcagaat ttaattgtctg tgatattgag accatgtgta caagaactac 7140
          tttttgcttt tcatcattca ctccttagca aacgtttcgt aagtaccctc tgtctgtttg 7200
          ctactatatg aggtgctgcg aaattagtgg gcgtggcttt ttatattttt cattcgtgtg 7260
          tagcctaagt aaggtgactc aagatgatac accgagagaa aaatgcaaaa tatatttggt 7320
          tctcatttct gttgctgtcg tttccttttt aaagacgatt tatcaactgc tgccatttgg 7380
          aacttcctat aagaaactaa aaatgatcta tttcagtgtt cctttcgcct ttcctctgct 7440
          ttctgaataa atggtttcag taacccatgc tgttctctcc ctattctacg tctttctccc 7500
          tatgttgaaa aaagattccc acagtttctg atgtgtgtgt ttatagtctt caatgtatgt 7560
          taacatgtta ggaactgagt atcttaagag atgtcttaga atgctttagt tttcataatt 7620
          tgtcctttat gtatttttca tgtattttgc tgttttgaca tggaagtaat ttaaaaagtt 7680
          ggtgcaggaa aggactcttt actgttgcac attttggttt tctgatatgt aataaattca 7740
          tggcttggca gctgacatga tgtttcccag agagaaggag atgtatttct gcagggtcca 7800
          gaccaaaaga gccattaca gcatgttctc ccatgttcca ttatcagcct gatgaaacct 7860
          gccctgccaa ggcataaact tttgtactag ctgtctccat attatgttca ataaattctg 7920
          tgctctgaat atatttaaaaaaaaaaaaa 7949
           <![CDATA[ <210> 24]]>
           <![CDATA[ <211> 19]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 24]]>
          Met Ala Lys Val Glu Gln Val Leu Ser Leu Glu Pro Gln His Glu Leu
          1 5 10 15
          Lys Phe Arg
           <![CDATA[ <210> 25]]>
           <![CDATA[ <211> 50]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 25]]>
          Pro Phe Thr Asp Val Val Thr Thr Asn Leu Lys Leu Gly Asn Pro Thr
          1 5 10 15
          Asp Arg Asn Val Cys Phe Lys Val Lys Thr Thr Ala Pro Arg Arg Tyr
                      20 25 30
          Cys Val Arg Pro Asn Ser Gly Ile Ile Asp Ala Gly Ala Ser Ile Asn
                  35 40 45
          Val Ser
              50
           <![CDATA[ <210> 26]]>
           <![CDATA[ <211> 34]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 26]]>
          Met Leu Gln Pro Phe Asp Tyr Asp Pro Asn Glu Lys Ser Lys His Lys
          1 5 10 15
          Phe Met Val Gln Ser Met Phe Ala Pro Thr Asp Thr Ser Asp Met Glu
                      20 25 30
          Ala Val
           <![CDATA[ <210> 27]]>
           <![CDATA[ <211> 27]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 27]]>
          Trp Lys Glu Ala Lys Pro Glu Asp Leu Met Asp Ser Lys Leu Arg Cys
          1 5 10 15
          Val Phe Glu Leu Pro Ala Glu Asn Asp Lys Pro
                      20 25
           <![CDATA[ <210> 28]]>
           <![CDATA[ <211> 59]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 28]]>
          His Asp Val Glu Ile Asn Lys Ile Ile Ser Thr Thr Ala Ser Lys Thr
          1 5 10 15
          Glu Thr Pro Ile Val Ser Lys Ser Leu Ser Ser Ser Leu Asp Asp Thr
                      20 25 30
          Glu Val Lys Lys Val Met Glu Glu Cys Lys Arg Leu Gln Gly Glu Val
                  35 40 45
          Gln Arg Leu Arg Glu Glu Asn Lys Gln Phe Lys
              50 55
           <![CDATA[ <210> 29]]>
           <![CDATA[ <211> 52]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 29]]>
          Glu Glu Asp Gly Leu Arg Met Arg Lys Thr Val Gln Ser Asn Ser Pro
          1 5 10 15
          Ile Ser Ala Leu Ala Pro Thr Gly Lys Glu Glu Gly Leu Ser Thr Arg
                      20 25 30
          Leu Leu Ala Leu Val Val Leu Phe Phe Ile Val Gly Val Ile Ile Gly
                  35 40 45
          Lys Ile Ala Leu
              50
           <![CDATA[ <210> 30]]>
           <![CDATA[ <211> 243]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 30]]>
          Met Ala Lys Val Glu Gln Val Leu Ser Leu Glu Pro Gln His Glu Leu
          1 5 10 15
          Lys Phe Arg Gly Pro Phe Thr Asp Val Val Thr Thr Asn Leu Lys Leu
                      20 25 30
          Gly Asn Pro Thr Asp Arg Asn Val Cys Phe Lys Val Lys Thr Thr Ala
                  35 40 45
          Pro Arg Arg Tyr Cys Val Arg Pro Asn Ser Gly Ile Ile Asp Ala Gly
              50 55 60
          Ala Ser Ile Asn Val Ser Val Met Leu Gln Pro Phe Asp Tyr Asp Pro
          65 70 75 80
          Asn Glu Lys Ser Lys His Lys Phe Met Val Gln Ser Met Phe Ala Pro
                          85 90 95
          Thr Asp Thr Ser Asp Met Glu Ala Val Trp Lys Glu Ala Lys Pro Glu
                      100 105 110
          Asp Leu Met Asp Ser Lys Leu Arg Cys Val Phe Glu Leu Pro Ala Glu
                  115 120 125
          Asn Asp Lys Pro His Asp Val Glu Ile Asn Lys Ile Ile Ser Thr Thr
              130 135 140
          Ala Ser Lys Thr Glu Thr Pro Ile Val Ser Lys Ser Leu Ser Ser Ser Ser
          145 150 155 160
          Leu Asp Asp Thr Glu Val Lys Lys Val Met Glu Glu Cys Lys Arg Leu
                          165 170 175
          Gln Gly Glu Val Gln Arg Leu Arg Glu Glu Asn Lys Gln Phe Lys Glu
                      180 185 190
          Glu Asp Gly Leu Arg Met Arg Lys Thr Val Gln Ser Asn Ser Pro Ile
                  195 200 205
          Ser Ala Leu Ala Pro Thr Gly Lys Glu Glu Gly Leu Ser Thr Arg Leu
              210 215 220
          Leu Ala Leu Val Val Leu Phe Phe Ile Val Gly Val Ile Ile Gly Lys
          225 230 235 240
          Ile Ala Leu
           <![CDATA[ <210> 31]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 31]]>
          000
           <![CDATA[ <210> 32]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 32]]>
          000
           <![CDATA[ <210> 33]]>
           <![CDATA[ <211> 253]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 33]]>
          ggttgggctc gcggcgctgt gattggtctg cccggactcc gcctccagcg catgtcatta 60
          gcatctcatt agctgtccgc tcgggctccg gaggcagcca acgccgccag tctgaggcag 120
          gtgcccgaca tggcgagtgt agtgctgccg agcggatccc agtgtgcggc ggcagcggcg 180
          gcggcggcgc ctcccgggct ccggctccgg cttctgctgt tgctcttctc cgccgcggca 240
          ctgatcccca cag 253
           <![CDATA[ <210> 34]]>
           <![CDATA[ <211> 147]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 34]]>
          gtgatgggca gaatctgttt acgaaagacg tgacagtgat cgaggggagag gttgcgacca 60
          tcagttgcca agtcaataag agtgacgact ctgtgattca gctactgaat cccaacaggc 120
          agaccattta tttcagggac ttcaggc 147
           <![CDATA[ <210> 35]]>
           <![CDATA[ <211> 153]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 35]]>
          ctttgaagga cagcaggttt cagttgctga atttttctag cagtgaactc aaagtatcat 60
          tgacaaacgt ctcaatttct gatgaaggaa gatacttttg ccagctctat accgatcccc 120
          cacaggaaag ttacaccacc atcacagtcc tgg 153
           <![CDATA[ <210> 36]]>
           <![CDATA[ <211> 138]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 36]]>
          tcccaccacg taatctgatg atcgatatcc agaaagacac tgcggtggaa ggtgaggaga 60
          ttgaagtcaa ctgcactgct atggccagca agccagccac gactatcagg tggttcaaag 120
          ggaacacaga gctaaaag 138
           <![CDATA[ <210> 37]]>
           <![CDATA[ <211> 159]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 37]]>
          gcaaatcgga ggtggaagag tggtcagaca tgtacactgt gaccagtcag ctgatgctga 60
          aggtgcacaa ggaggacgat gggtcccag tgatctgcca ggtggagcac cctgcggtca 120
          ctggaaacct gcagacccag cggtatctag aagtacagt 159
           <![CDATA[ <210> 38]]>
           <![CDATA[ <211> 100]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 38]]>
          ataagcctca agtgcacatt cagatgactt atcctctaca aggcttaacc cgggaagggg 60
          acgcgcttga gttaacatgt gaagccatcg ggaagcccca 100
           <![CDATA[ <210> 39]]>
           <![CDATA[ <211> 173]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 39]]>
          gcctgtgatg gtaacttggg tgagagtcga tgatgaaatg cctcaacacg ccgtactgtc 60
          tgggcccaac ctgttcatca ataacctaaa caaaacagat aatggtacat accgctgtga 120
          agcttcaaac atagtgggga aagctcactc ggattatatg ctgtatgtat acg 173
           <![CDATA[ <210> 40]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 40]]>
          acacaacggc gacgacagaa ccagcagttc acg 33
           <![CDATA[ <210> 41]]>
           <![CDATA[ <211> 54]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 41]]>
          gccttactca gttgcccaat tccgcagaag aactggacag tgaggacctc tcag 54
           <![CDATA[ <210> 42]]>
           <![CDATA[ <211> 132]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 42]]>
          attcccgagc aggtgaagaa ggctcgatca gggcagtgga tcatgccgtg atcggtggcg 60
          tcgtggcggt ggtggtgttc gccatgctgt gcttgctcat cattctgggg cgctattttg 120
          ccagacataa ag 132
           <![CDATA[ <210> 43]]>
           <![CDATA[ <211> 2968]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 43]]>
          gtacatactt cactcatgaa gccaaaggag ccgatgacgc agcagacgca gacacagcta 60
          taatcaatgc agaaggagga cagaacaact ccgaagaaaa gaaagagtac ttcatctaga 120
          tcagcctttt tgtttcaatg aggtgtccaa ctggccctat ttagatgata aagagacagt 180
          gatattggaa cttgcgagaa attcgtgtgtgtttttttatga atgggtggaa aggtgtgaga 240
          ctgggaaggc ttgggaatttg ctgtgtaaaa aaaaaaaaaa tgttctttgg aaagtacact 300
          ctgctgtttg acacctcttt tttcgtttgt ttgtttgttt aatttttatt tcttcctacc 360
          aagtcaaact tggatacttg gatttagttt cagtagattg cagaaaattc tgtgccttgt 420
          tttttgtttg tttgttgcgt tcctttcttt tccccctttg tgcacattta tttcctccct 480
          ctaccccaat ttcggatttt ttccaaaatc tcccattttg gaatttgcct gctgggattc 540
          cttagactct tttccttccc ttttctgttc tagtttttta cttttgttta tttttatggt 600
          aactgctttc tgttccaaat tcagtttcat aaaaggagaa ccagcacagc ttagatttca 660
          tagttcagaa tttagtgtat ccataatgca ttcttctctg ttgtcgtaaa gatttgggtg 720
          aacaaacaat gaaaactctt tgctgctgcc catgtttcaa atacttagag cagtgaagac 780
          tagaaaatta gactgtgatt cagaaaatgt tctgtttgct gtggaactac attackgtac 840
          agggttatct gcaagtgagg tgtgtcacaa tgagattgaa tttcactgtc tttaattctg 900
          tatctgtaga cggctcagta tagataccct acgctgtcca gaaaggtttg gggcagaaag 960
          gactcctcct ttttccatgc cctaaacaga cctgacaggt gaggtctgtt ccttttatat 1020
          aagtggaca attttgagtt gccacaggag gggaagtagg gaggggggaa atacagttct 1080
          gctctggttg tttctgttcc aaatgattcc atccaccttt cccaatcggc cttacttctc 1140
          actaatttgt aggaaaaagc aagttcgtct gttgtgcgaa tgactgaatg ggacagagtt 1200
          gatttttttt tttttttcct ttgtgcttag ttaggaaggc agtaggatgt ggcctgcatg 1260
          tactgtatat tacagatatt tgtcatgctg ggatttccaa ctcgaatctg tgtgaaactt 1320
          tcattccttc agatttggct tgacaaaggc aggaggtaca aaagaagggc tggtattgtt 1380
          ctcacactgg tctgctgtcg ctctcagttc tcgataggtc agagcagagg tggaaaaaca 1440
          gcatgtacgg attttcagtt acttaatcaa aactcaaatg tgagtgtttt tatcttttta 1500
          cctttcatac actagccttg gcctctttcc tcagccttaa gaaccatctg ccaaaaatta 1560
          ctgatcctcg catgatggca gccatagtgc atagctacta aaatcagtga ccttgaacat 1620
          atcttagatg gggagcctcg ggaaaaggta gaggagtcac gttaccattt acatgtttta 1680
          aagaaagaag tgtggggatt ttcactgaaa cgtctaggaa atctagaagt agtcctgaag 1740
          gacagaaact aaactcttac catatgtttg gtaagactcc agactccagc taacagtccc 1800
          tatggaaaga tggcatcaaa aaagatagat ctatatatat atataaatat atattctatt 1860
          acattttcag tgagtaattt tggattttgc aaggtgcatt tttactattg ttacattatg 1920
          tggaaaactt atgctgattt atttaagggg gaaaaagtgt caactctttg ttatttgaaa 1980
          acatgtttatttttcttgtc tttattttaa cctttgatag aaccattgca atatgggggc 2040
          cttttgggaa cggactggta tgtaaaagaa aatccattat cgagcagcat tttattacc 2100
          cctcccctat ccctaggcac ttaaccaaga caaaaagcca caatgaacat ccctttttca 2160
          atgaatttta taatctgcag ctctattccg agcccttagc acccattccg accatagtat 2220
          aatcatatca aagggtgaga atcatttagc atgttgttga aaggtttttt ttcagttgtt 2280
          ctttttagaaaaaaagaaaaaaaaaacaaaaacaaaaaaaaaaaatcac accattgctc 2340
          acagaattgg catctcattt ttgggacctc ccatctttct gttttgaaaa gtgtacagta 2400
          gtgcagtgtt cctgatgtaa ctttatggct tacaatgttg acatgtctca ggttcatgtg 2460
          ttgcgattgg tgttttccgt ctcaggtaga ttgcaaagtg taggccccac aattggaaa 2520
          aaataataat aaaacaaagc aaaaacagga aattatggat tttagttgta tattggttta 2580
          tgtatttttt cttaagtata cagtgcactg tttgaaatgt attgttgagt attactttgt 2640
          acaggttgat cacttttttt agagtgaaga aagaacaaac ttgttttttg tgttttttaa 2700
          aggaatataa aataatgaag gatgtataat tgatgccaaa taagcttgtt ctttagtcac 2760
          accgacgtct tatttttccc tttaggccag ttctgttttt aaggtgtaca tggacaatgt 2820
          tacagtgtaa gaaactccat atccatatgt tcccattcgc attttgtatt ggttcatgta 2880
          taccattttt acaaaaaaaaaaagaaaaaaaagaagtact ataaaatatc tgtcttctta 2940
          ataaaaaaaa attaatgtta caaagtga 2968
           <![CDATA[ <210> 44]]>
           <![CDATA[ <211> 4310]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 44]]>
          ggttgggctc gcggcgctgt gattggtctg cccggactcc gcctccagcg catgtcatta 60
          gcatctcatt agctgtccgc tcgggctccg gaggcagcca acgccgccag tctgaggcag 120
          gtgcccgaca tggcgagtgt agtgctgccg agcggatccc agtgtgcggc ggcagcggcg 180
          gcggcggcgc ctcccgggct ccggctccgg cttctgctgt tgctcttctc cgccgcggca 240
          ctgatcccca caggtgatgg gcagaatctg tttacgaaag acgtgacagt gatcgaggga 300
          gaggttgcga ccatcagttg ccaagtcaat aagagtgacg actctgtgat tcagctactg 360
          aatcccaaca ggcagaccat ttatttcagg gacttcaggc ctttgaagga cagcaggttt 420
          cagttgctga atttttctag cagtgaactc aaagtatcat tgacaaacgt ctcaatttct 480
          gatgaaggaa gatacttttg ccagctctat accgatcccc cacaggaaag ttacaccacc 540
          atcacagtcc tggtcccacc acgtaatctg atgatcgata tccagaaaga cactgcggtg 600
          gaaggtgagg agattgaagt caactgcact gctatggcca gcaagccagc cacgactatc 660
          aggtggttca aagggaacac agagctaaaa ggcaaatcgg aggtggaaga gtggtcagac 720
          atgtacactg tgaccagtca gctgatgctg aaggtgcaca aggaggacga tggggtccca 780
          gtgatctgcc aggtggagca ccctgcggtc actggaaacc tgcagaccca gcggtatcta 840
          gaagtacagt ataagcctca agtgcacatt cagatgactt atcctctaca aggcttaacc 900
          cgggaagggg acgcgcttga gttaacatgt gaagccatcg ggaagcccca gcctgtgatg 960
          gtaacttggg tgagagtcga tgatgaaatg cctcaacacg ccgtactgtc tgggcccaac 1020
          ctgttcatca ataacctaaa caaaacagat aatggtacat accgctgtga agcttcaaac 1080
          atagtgggga aagctcactc ggattatatg ctgtatgtat acgacacaac ggcgacgaca 1140
          gaaccagcag ttcacggcct tactcagttg cccaattccg cagaagaact ggacagtgag 1200
          gacctctcag attcccgagc aggtgaagaa ggctcgatca gggcagtgga tcatgccgtg 1260
          atcggtggcg tcgtggcggt ggtggtgttc gccatgctgt gcttgctcat cattctgggg 1320
          cgctattttg ccagacataa aggtacatac ttcactcatg aagccaaagg agccgatgac 1380
          gcagcagacg cagacacagc tataatcaat gcagaaggag gacagaacaa ctccgaagaa 1440
          aagaaagagt acttcatcta gatcagcctt tttgtttcaa tgaggtgtcc aactggccct 1500
          atttagatga taaagagaca gtgatattgg aacttgcgag aaattcgtgtgtttttttat 1560
          gaatgggtgg aaaggtgtga gactgggaag gcttgggat tgctgtgtaa aaaaaaaaaa 1620
          aatgttcttt ggaaagtaca ctctgctgtt tgacacctct tttttcgttt gtttgtttgt 1680
          ttaattttta tttcttccta ccaagtcaaa cttggatact tggatttagt ttcagtagat 1740
          tgcagaaaat tctgtgcctt gttttttgtt tgtttgttgc gttcctttct tttccccctt 1800
          tgtgcacatt tatttcctcc ctctacccca atttcggatt ttttccaaaa tctcccattt 1860
          tggaatttgc ctgctgggat tccttagact cttttccttc ccttttctgt tctagttttt 1920
          tacttttgtt tatttttatg gtaactgctt tctgttccaa attcagtttc ataaaaggag 1980
          aaccagcaca gcttagattt catagttcag aatttaggtgt atccataatg cattcttctc 2040
          tgttgtcgta aagatttggg tgaacaaaca atgaaaactc tttgctgctg cccatgtttc 2100
          aaatacttag agcagtgaag actagaaaat tagactgtga ttcagaaaat gttctgtttg 2160
          ctgtggaact aattactgt acagggttat ctgcaagtga ggtgtgtcac aatgagattg 2220
          aatttcactg tctttaattc tgtatctgta gacggctcag tatagatacc ctacgctgtc 2280
          cagaaaggtt tggggcagaa aggactcctc ctttttccat gccctaaaca gacctgacag 2340
          gtgaggtctg ttccttttat ataagtggac aaattttgag ttgccacagg agggggaagta 2400
          gggagggggg aaatacagtt ctgctctggt tgtttctgtt ccaaatgatt ccatccacct 2460
          ttcccaatcg gccttacttc tcactaattt gtaggaaaaa gcaagttcgt ctgttgtgcg 2520
          aatgactgaa tgggacagag ttgatttttttttttttttc ctttgtgctt agttaggaag 2580
          gcagtaggat gtggcctgca tgtactgtat attacagata tttgtcatgc tgggatttcc 2640
          aactcgaatc tgtgtgaaac tttcattcct tcagatttgg cttgacaaag gcaggaggta 2700
          caaaagaagg gctggtattg ttctcacact ggtctgctgt cgctctcagt tctcgatagg 2760
          tcagagcaga ggtggaaaaa cagcatgtac ggattttcag ttacttaatc aaaactcaaa 2820
          tgtgagtgtt tttatctttt tacctttcat aacactagcct tggcctcttt cctcagcctt 2880
          aagaaccatc tgccaaaaat tactgatcct cgcatgatgg cagccatagt gcatagctac 2940
          taaaatcagt gaccttgaac atatcttaga tggggagcct cgggaaaagg tagagaggtc 3000
          acgttaccat ttacatgttt taaagaaaga agtgtggggga ttttcactga aacgtctagg 3060
          aaatctagaa gtagtcctga aggacagaaa ctaaactctt accatatgtt tggtaagact 3120
          ccagactcca gctaacagtc cctatggaaa gatggcatca aaaaagatag atctatatat 3180
          atatataaat atatattcta ttacattttc agtgagtaat tttggatttt gcaaggtgca 3240
          tttttactat tgttacatta tgtggaaaac ttatgctgat ttattaagg gggaaaaagt 3300
          gtcaactctt tgttatttga aaacatgttt atttttcttg tctttattt aacctttgat 3360
          agaaccattg caatatgggg gccttttgggg aacggactgg tatgtaaaag aaaatccatt 3420
          atcgagcagc attttatta cccctcccct atccctaggc acttaaccaa gacaaaaagc 3480
          cacaatgaac atcccttttt caatgaattt tataatctgc agctctattc cgagccctta 3540
          gcacccattc cgaccatagt ataatcatat caaagggtga gaatcattta gcatgttgtt 3600
          gaaaggttttttttcagttg ttctttttag aaaaaaagaaaaacaaaaac aaaaacaaaa 3660
          aaaaaaaatc acaccattgc tcacagaatt ggcatctcat ttttgggacc tcccatcttt 3720
          ctgttttgaa aagtgtacag tagtgcagtg ttcctgatgt aactttatgg cttacaatgt 3780
          tgacatgtct caggttcatg tgttgcgatt ggtgttttcc gtctcaggta gattgcaaag 3840
          tgtaggcccc acacattgga aaaaataata ataaaacaaa gcaaaaacag gaaattatgg 3900
          attttagttg tatattggtt tatgtattttttcttaagta tacagtgcac tgtttgaaat 3960
          gtattgttga gtattacttt gtacaggttg atcacttttt ttagagtgaa gaaagaacaa 4020
          acttgttttttgtgtttttt aaaggaatat aaaataatga aggatgtata attgatgcca 4080
          aataagcttg ttctttagtc acaccgacgt cttatttttc cctttaggcc agttctgttt 4140
          ttaaggtgta catggacaat gttacagtgt aagaaactcc atatccatat gttcccattc 4200
          gcattttgta ttggttcatg tataccattt ttacaaaaaaaaaaagaaaaaaaagaagta 4260
          ctataaaata tctgtcttct taataaaaaa aaattaatgt tacaaagtga 4310
           <![CDATA[ <210> 45]]>
           <![CDATA[ <211> 41]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 45]]>
          Met Ala Ser Val Val Leu Pro Ser Gly Ser Gln Cys Ala Ala Ala Ala
          1 5 10 15
          Ala Ala Ala Ala Pro Pro Gly Leu Arg Leu Arg Leu Leu Leu Leu Leu Leu
                      20 25 30
          Phe Ser Ala Ala Ala Leu Ile Pro Thr
                  35 40
           <![CDATA[ <210> 46]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 46]]>
          Asp Gly Gln Asn Leu Phe Thr Lys Asp Val Thr Val Ile Glu Gly Glu
          1 5 10 15
          Val Ala Thr Ile Ser Cys Gln Val Asn Lys Ser Asp Asp Ser Val Ile
                      20 25 30
          Gln Leu Leu Asn Pro Asn Arg Gln Thr Ile Tyr Phe Arg Asp Phe Arg
                  35 40 45
           <![CDATA[ <210> 47]]>
           <![CDATA[ <211> 50]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 47]]>
          Leu Lys Asp Ser Arg Phe Gln Leu Leu Asn Phe Ser Ser Ser Ser Glu Leu
          1 5 10 15
          Lys Val Ser Leu Thr Asn Val Ser Ile Ser Asp Glu Gly Arg Tyr Phe
                      20 25 30
          Cys Gln Leu Tyr Thr Asp Pro Gln Glu Ser Tyr Thr Thr Ile Thr
                  35 40 45
          Val Leu
              50
           <![CDATA[ <210> 48]]>
           <![CDATA[ <211> 45]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 48]]>
          Pro Pro Arg Asn Leu Met Ile Asp Ile Gln Lys Asp Thr Ala Val Glu
          1 5 10 15
          Gly Glu Glu Ile Glu Val Asn Cys Thr Ala Met Ala Ser Lys Pro Ala
                      20 25 30
          Thr Thr Ile Arg Trp Phe Lys Gly Asn Thr Glu Leu Lys
                  35 40 45
           <![CDATA[ <210> 49]]>
           <![CDATA[ <211> 52]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 49]]>
          Lys Ser Glu Val Glu Glu Trp Ser Asp Met Tyr Thr Val Thr Ser Gln
          1 5 10 15
          Leu Met Leu Lys Val His Lys Glu Asp Asp Gly Val Pro Val Ile Cys
                      20 25 30
          Gln Val Glu His Pro Ala Val Thr Gly Asn Leu Gln Thr Gln Arg Tyr
                  35 40 45
          Leu Glu Val Gln
              50
           <![CDATA[ <210> 50]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 50]]>
          Lys Pro Gln Val His Ile Gln Met Thr Tyr Pro Leu Gln Gly Leu Thr
          1 5 10 15
          Arg Glu Gly Asp Ala Leu Glu Leu Thr Cys Glu Ala Ile Gly Lys Pro
                      20 25 30
           <![CDATA[ <210> 51]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 51]]>
          Pro Val Met Val Thr Trp Val Arg Val Asp Asp Glu Met Pro Gln His
          1 5 10 15
          Ala Val Leu Ser Gly Pro Asn Leu Phe Ile Asn Asn Leu Asn Lys Thr
                      20 25 30
          Asp Asn Gly Thr Tyr Arg Cys Glu Ala Ser Asn Ile Val Gly Lys Ala
                  35 40 45
          His Ser Asp Tyr Met Leu Tyr Val Tyr
              50 55
           <![CDATA[ <210> 52]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 52]]>
          Thr Thr Ala Thr Thr Glu Pro Ala Val His
          1 5 10
           <![CDATA[ <210> 53]]>
           <![CDATA[ <211> 17]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 53]]>
          Leu Thr Gln Leu Pro Asn Ser Ala Glu Glu Leu Asp Ser Glu Asp Leu
          1 5 10 15
          Ser
           <![CDATA[ <210> 54]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 54]]>
          Ser Arg Ala Gly Glu Glu Gly Ser Ile Arg Ala Val Asp His Ala Val
          1 5 10 15
          Ile Gly Gly Val Val Ala Val Val Val Phe Ala Met Leu Cys Leu Leu
                      20 25 30
          Ile Ile Leu Gly Arg Tyr Phe Ala Arg His Lys
                  35 40
           <![CDATA[ <210> 55]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 55]]>
          Thr Tyr Phe Thr His Glu Ala Lys Gly Ala Asp Asp Ala Ala Asp Ala
          1 5 10 15
          Asp Thr Ala Ile Ile Asn Ala Glu Gly Gly Gln Asn Asn Ser Glu Glu
                      20 25 30
          Lys Lys Glu Tyr Phe Ile
                  35
           <![CDATA[ <210> 56]]>
           <![CDATA[ <211> 443]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 56]]>
          Met Ala Ser Val Val Leu Pro Ser Gly Ser Gln Cys Ala Ala Ala Ala
          1 5 10 15
          Ala Ala Ala Ala Pro Pro Gly Leu Arg Leu Arg Leu Leu Leu Leu Leu Leu
                      20 25 30
          Phe Ser Ala Ala Ala Ala Leu Ile Pro Thr Gly Asp Gly Gln Asn Leu Phe
                  35 40 45
          Thr Lys Asp Val Thr Val Ile Glu Gly Glu Val Ala Thr Ile Ser Cys
              50 55 60
          Gln Val Asn Lys Ser Asp Asp Ser Val Ile Gln Leu Leu Asn Pro Asn
          65 70 75 80
          Arg Gln Thr Ile Tyr Phe Arg Asp Phe Arg Pro Leu Lys Asp Ser Arg
                          85 90 95
          Phe Gln Leu Leu Asn Phe Ser Ser Ser Glu Leu Lys Val Ser Leu Thr
                      100 105 110
          Asn Val Ser Ile Ser Asp Glu Gly Arg Tyr Phe Cys Gln Leu Tyr Thr
                  115 120 125
          Asp Pro Pro Gln Glu Ser Tyr Thr Thr Ile Thr Val Leu Val Pro Pro
              130 135 140
          Arg Asn Leu Met Ile Asp Ile Gln Lys Asp Thr Ala Val Glu Gly Glu
          145 150 155 160
          Glu Ile Glu Val Asn Cys Thr Ala Met Ala Ser Lys Pro Ala Thr Thr
                          165 170 175
          Ile Arg Trp Phe Lys Gly Asn Thr Glu Leu Lys Gly Lys Ser Glu Val
                      180 185 190
          Glu Glu Trp Ser Asp Met Tyr Thr Val Thr Ser Gln Leu Met Leu Lys
                  195 200 205
          Val His Lys Glu Asp Asp Gly Val Pro Val Ile Cys Gln Val Glu His
              210 215 220
          Pro Ala Val Thr Gly Asn Leu Gln Thr Gln Arg Tyr Leu Glu Val Gln
          225 230 235 240
          Tyr Lys Pro Gln Val His Ile Gln Met Thr Tyr Pro Leu Gln Gly Leu
                          245 250 255
          Thr Arg Glu Gly Asp Ala Leu Glu Leu Thr Cys Glu Ala Ile Gly Lys
                      260 265 270
          Pro Gln Pro Val Met Val Thr Trp Val Arg Val Asp Asp Glu Met Pro
                  275 280 285
          Gln His Ala Val Leu Ser Gly Pro Asn Leu Phe Ile Asn Asn Leu Asn
              290 295 300
          Lys Thr Asp Asn Gly Thr Tyr Arg Cys Glu Ala Ser Asn Ile Val Gly
          305 310 315 320
          Lys Ala His Ser Asp Tyr Met Leu Tyr Val Tyr Asp Thr Thr Ala Thr
                          325 330 335
          Thr Glu Pro Ala Val His Gly Leu Thr Gln Leu Pro Asn Ser Ala Glu
                      340 345 350
          Glu Leu Asp Ser Glu Asp Leu Ser Asp Ser Arg Ala Gly Glu Glu Gly
                  355 360 365
          Ser Ile Arg Ala Val Asp His Ala Val Ile Gly Gly Val Val Ala Val
              370 375 380
          Val Val Phe Ala Met Leu Cys Leu Leu Ile Ile Leu Gly Arg Tyr Phe
          385 390 395 400
          Ala Arg His Lys Gly Thr Tyr Phe Thr His Glu Ala Lys Gly Ala Asp
                          405 410 415
          Asp Ala Ala Asp Ala Asp Thr Ala Ile Ile Asn Ala Glu Gly Gly Gln
                      420 425 430
          Asn Asn Ser Glu Glu Lys Lys Glu Tyr Phe Ile
                  435 440
           <![CDATA[ <210> 57]]>
           <![CDATA[ <211> 1123]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 57]]>
          ggttgggctc gcggcgctgt gattggtctg cccggactcc gcctccagcg catgtcatta 60
          gcatctcatt agctgtccgc tcgggctccg gaggcagcca acgccgccag tctgaggcag 120
          gtgcccgaca tggcgagtgt agtgctgccg agcggatccc agtgtgcggc ggcagcggcg 180
          gcggcggcgc ctcccgggct ccggctccgg cttctgctgt tgctcttctc cgccgcggca 240
          ctgatcccca caggtgatgg gcagaatctg tttacgaaag acgtgacagt gatcgaggga 300
          gaggttgcga ccatcagttg ccaagtcaat aagagtgacg actctgtgat tcagctactg 360
          aatcccaaca ggcagaccat ttatttcagg gacttcaggc ctttgaagga cagcaggttt 420
          cagttgctga atttttctag cagtgaactc aaagtatcat tgacaaacgt ctcaatttct 480
          gatgaaggaa gatacttttg ccagctctat accgatcccc cacaggaaag ttacaccacc 540
          atcacagtcc tggtcccacc acgtaatctg atgatcgata tccagaaaga cactgcggtg 600
          gaaggtgagg agattgaagt caactgcact gctatggcca gcaagccagc cacgactatc 660
          aggtggttca aagggaacac agagctaaaa ggcaaatcgg aggtggaaga gtggtcagac 720
          atgtacactg tgaccagtca gctgatgctg aaggtgcaca aggaggacga tggggtccca 780
          gtgatctgcc aggtggagca ccctgcggtc actggaaacc tgcagaccca gcggtatcta 840
          gaagtacagt ataagcctca agtgcacatt cagatgactt atcctctaca aggcttaacc 900
          cgggaagggg acgcgcttga gttaacatgt gaagccatcg ggaagcccca gcctgtgatg 960
          gtaacttggg tgagagtcga tgatgaaatg cctcaacacg ccgtactgtc tgggcccaac 1020
          ctgttcatca ataacctaaa caaaacagat aatggtacat accgctgtga agcttcaaac 1080
          atagtgggga aagctcactc ggattatatg ctgtatgtat acg 1123
           <![CDATA[ <210> 58]]>
           <![CDATA[ <211> 331]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 58]]>
          Met Ala Ser Val Val Leu Pro Ser Gly Ser Gln Cys Ala Ala Ala Ala
          1 5 10 15
          Ala Ala Ala Ala Pro Pro Gly Leu Arg Leu Arg Leu Leu Leu Leu Leu Leu
                      20 25 30
          Phe Ser Ala Ala Ala Ala Leu Ile Pro Thr Gly Asp Gly Gln Asn Leu Phe
                  35 40 45
          Thr Lys Asp Val Thr Val Ile Glu Gly Glu Val Ala Thr Ile Ser Cys
              50 55 60
          Gln Val Asn Lys Ser Asp Asp Ser Val Ile Gln Leu Leu Asn Pro Asn
          65 70 75 80
          Arg Gln Thr Ile Tyr Phe Arg Asp Phe Arg Pro Leu Lys Asp Ser Arg
                          85 90 95
          Phe Gln Leu Leu Asn Phe Ser Ser Ser Glu Leu Lys Val Ser Leu Thr
                      100 105 110
          Asn Val Ser Ile Ser Asp Glu Gly Arg Tyr Phe Cys Gln Leu Tyr Thr
                  115 120 125
          Asp Pro Pro Gln Glu Ser Tyr Thr Thr Ile Thr Val Leu Val Pro Pro
              130 135 140
          Arg Asn Leu Met Ile Asp Ile Gln Lys Asp Thr Ala Val Glu Gly Glu
          145 150 155 160
          Glu Ile Glu Val Asn Cys Thr Ala Met Ala Ser Lys Pro Ala Thr Thr
                          165 170 175
          Ile Arg Trp Phe Lys Gly Asn Thr Glu Leu Lys Gly Lys Ser Glu Val
                      180 185 190
          Glu Glu Trp Ser Asp Met Tyr Thr Val Thr Ser Gln Leu Met Leu Lys
                  195 200 205
          Val His Lys Glu Asp Asp Gly Val Pro Val Ile Cys Gln Val Glu His
              210 215 220
          Pro Ala Val Thr Gly Asn Leu Gln Thr Gln Arg Tyr Leu Glu Val Gln
          225 230 235 240
          Tyr Lys Pro Gln Val His Ile Gln Met Thr Tyr Pro Leu Gln Gly Leu
                          245 250 255
          Thr Arg Glu Gly Asp Ala Leu Glu Leu Thr Cys Glu Ala Ile Gly Lys
                      260 265 270
          Pro Gln Pro Val Met Val Thr Trp Val Arg Val Asp Asp Glu Met Pro
                  275 280 285
          Gln His Ala Val Leu Ser Gly Pro Asn Leu Phe Ile Asn Asn Leu Asn
              290 295 300
          Lys Thr Asp Asn Gly Thr Tyr Arg Cys Glu Ala Ser Asn Ile Val Gly
          305 310 315 320
          Lys Ala His Ser Asp Tyr Met Leu Tyr Val Tyr
                          325 330
           <![CDATA[ <210> 59]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 59]]>
          000
           <![CDATA[ <210> 60]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 60]]>
          000
           <![CDATA[ <210> 61]]>
           <![CDATA[ <211> 200]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 61]]>
          ctcattgccc agcggacccc agcctctgcc aggttcggtc cgccatcctc gtcccgtcct 60
          ccgccggccc ctgccccgcg cccagggatc ctccagctcc tttcgcccgc gccctccgtt 120
          cgctccggac accatggaca agttttggtg gcacgcagcc tggggactct gcctcgtgcc 180
          gctgagcctg gcgcagatcg 200
           <![CDATA[ <210> 62]]>
           <![CDATA[ <211> 166]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 62]]>
          atttgaatat aacctgccgc tttgcaggtg tattccacgt ggagaaaaat ggtcgctaca 60
          gcatctctcg gacggaggcc gctgacctct gcaaggcttt caatagcacc ttgcccacaa 120
          tggccccagat ggagaaagct ctgagcatcg gatttgagac ctgcag 166
           <![CDATA[ <210> 63]]>
           <![CDATA[ <211> 134]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 63]]>
          gtatgggttc atagaagggc acgtggtgat tccccggatc caccccaact ccatctgtgc 60
          agcaaacaac acagggggtgt acatcctcac atccaacacc tccccagtatg acacatattg 120
          cttcaatgct tcag 134
           <![CDATA[ <210> 64]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 64]]>
          ctccacctga agaagattgt acatcagtca cagacctgcc caatgccttt gatggaccaa 60
          ttaccataa 69
           <![CDATA[ <210> 65]]>
           <![CDATA[ <211> 231]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 65]]>
          ctattgttaa ccgtgatggc acccgctatg tccagaaagg agaatacaga acgaatcctg 60
          aagacatcta ccccagcaac cctactgatg atgacgtgag cagcggctcc tccagtgaaa 120
          ggagcagcac ttcaggaggt tacatctttt acaccttttc tactgtacac cccatcccag 180
          acgaagacag tccctggatc accgacagca cagacagaat ccctgctacc a 231
           <![CDATA[ <210> 66]]>
           <![CDATA[ <211> 129]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 66]]>
          ctttgatgag cactagtgct acagcaactg agacagcaac caagaggcaa gaaacctggg 60
          attggttttc atggttgttt ctaccatcag agtcaaagaa tcatcttcac acaacaacac 120
          aaatggctg 129
           <![CDATA[ <210> 67]]>
           <![CDATA[ <211> 126]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 67]]>
          gtacgtcttc aaataccatc tcagcaggct gggagccaaa tgaagaaaat gaagatgaaa 60
          gagacagaca cctcagtttt tctggatcag gcattgatga tgatgaagat tttatctcca 120
          gcacca 126
           <![CDATA[ <210> 68]]>
           <![CDATA[ <211> 114]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 68]]>
          tttcaaccac accacgggct tttgaccaca caaaacagaa ccaggactgg acccagtgga 60
          acccaagcca ttcaaatccg gaagtgctac ttcagacaac cacaaggatg actg 114
           <![CDATA[ <210> 69]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 69]]>
          atgtagacag aaatggcacc actgcttatg aaggaaactg gaacccagaa gcacaccctc 60
          ccctcattca ccatgagcat catgaggaag aagagacccc aattctaca agcacaa 117
           <![CDATA[ <210> 70]]>
           <![CDATA[ <211> 129]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 70]]>
          tccaggcaac tcctagtagt acaacggaag aaacagctac ccagaaggaa cagtggtttg 60
          gcaacagatg gcatgaggga tatcgccaaa cacccaaaga agactcccat tcgacaacag 120
          ggacagctg 129
           <![CDATA[ <210> 71]]>
           <![CDATA[ <211> 132]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 71]]>
          cagcctcagc tcataccagc catccaatgc aaggaaggac aacaccaagc ccagaggaca 60
          gttcctggac tgatttcttc aacccaatct cacaccccat gggacgaggt catcaagcag 120
          gaagaaggat gg 132
           <![CDATA[ <210> 72]]>
           <![CDATA[ <211> 102]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 72]]>
          atatggactc cagtcatagt ataacgcttc agcctactgc aaatccaaac acaggtttgg 60
          tggaagattt ggacaggaca ggacctcttt caatgacaac gc 102
           <![CDATA[ <210> 73]]>
           <![CDATA[ <211> 90]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 73]]>
          agcagagtaa ttctcagagc ttctctacat cacatgaagg cttggaagaa gataaagacc 60
          atccaacaac ttctactctg acatcaagca 90
           <![CDATA[ <210> 74]]>
           <![CDATA[ <211> 204]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 74]]>
          ataggaatga tgtcacaggt ggaagaagag acccaaatca ttctgaaggc tcaactactt 60
          tactggaagg ttatacctct cattacccac acacgaagga aagcaggacc ttcatcccag 120
          tgacctcagc taagactggg tcctttggag ttactgcagt tactgttgga gattccaact 180
          ctaatgtcaa tcgttcctta tcag 204
           <![CDATA[ <210> 75]]>
           <![CDATA[ <211> 63]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 75]]>
          gagaccaaga cacattccac cccagtgggg ggtcccatac cactcatgga tctgaatcag 60
          atg 63
           <![CDATA[ <210> 76]]>
           <![CDATA[ <211> 72]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400>]]> 76
          gacactcaca tgggagtcaa gaaggtggag caaacacaac ctctggtcct ataaggacac 60
          cccaaattcc ag 72
           <![CDATA[ <210> 77]]>
           <![CDATA[ <211> 79]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 77]]>
          aatggctgat catcttggca tccctcttgg ccttggcttt gattcttgca gtttgcattg 60
          cagtcaacag tcgaagaag 79
           <![CDATA[ <210> 78]]>
           <![CDATA[ <211> 3274]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 78]]>
          gtgtgggcag aagaaaaagc tagtgatcaa cagtggcaat ggagctgtgg aggacagaaa 60
          gccaagtgga ctcaacggag aggccagcaa gtctcaggaa atggtgcatt tggtgaacaa 120
          ggagtcgtca gaaactccag accagtttat gacagctgat gagacaagga acctgcagaa 180
          tgtggacatg aagattgggg tgtaacacct acaccattat cttggaaaga aacaaccgtt 240
          ggaaacataa ccattacagg gagctgggac acttaacaga tgcaatgtgc tactgattgt 300
          ttcattgcga atctttttta gcataaaatt ttctactctt tttgtttttt gtgttttgtt 360
          ctttaaagtc aggtccaatt tgtaaaaaca gcattgcttt ctgaaattag ggcccaatta 420
          ataatcagca agaatttgat cgttccagtt cccacttgga ggcctttcat ccctcgggtg 480
          tgctatggat ggcttctaac aaaaactaca catatgtatt cctgatcgcc aacctttccc 540
          ccaccagcta aggacatttc ccagggttaa tagggcctgg tccctgggag gaaatttgaa 600
          tgggtccatt ttgcccttcc atagcctaat ccctgggcat tgctttccac tgaggttggg 660
          ggttggggtg tactagttac acatcttcaa cagaccccct ctagaaattt ttcagatgct 720
          tctgggagac acccaaaggg tgaagctatt tatctgtagt aaactattta tctgtgtttt 780
          tgaaatatta aaccctggat cagtcctttg atcagtataa ttttttaaag ttactttgtc 840
          agaggcacaa aagggtttaa actgattcat aataaatatc tgtacttctt cgatcttcac 900
          cttttgtgct gtgattcttc agtttctaaa ccagcactgt ctgggtccct acaatgtatc 960
          aggaagagct gagaatggta aggagactct tctaagtctt catctcagag accctgagtt 1020
          cccactcaga cccactcagc caaatctcat ggaagaccaa ggagggcagc actgtttttg 1080
          ttttttgttt tttgttttttttttttgaca ctgtccaaag gttttccatc ctgtcctgga 1140
          atcagagttg gaagctgagg agcttcagcc tcttttatgg tttaatggcc acctgttctc 1200
          tcctgtgaaa ggctttgcaa agtcacatta agtttgcatg acctgttatc cctggggccc 1260
          tatttcatag aggctggccc tattagtgat ttccaaaaac aatatggaag tgccttttga 1320
          tgtcttacaa taagagaaga agccaatgga aatgaaagag attggcaaag gggaaggatg 1380
          atgccatgta gatcctgttt gacatttta tggctgtatt tgtaaactta aacacaccag 1440
          tgtctgttct tgatgcagtt gctatttagg atgagttaag tgcctgggga gtccctcaaa 1500
          aggttaaagg gattcccatc attggaatct tatcaccaga taggcaagtt tatgaccaaa 1560
          caagagagta ctggctttat cctctaacct catattttct cccacttggc aagtcctttg 1620
          tggcatttat tcatcagtca gggtgtccga ttggtcctag aacttccaaa ggctgcttgt 1680
          catagaagcc attgcatcta taaagcaacg gctcctgtta aatggtatct cctttctgag 1740
          gctcctacta aaagtcattt gttacctaaa cttatgtgct taacaggcaa tgcttctcag 1800
          accacaaagc agaaagaaga agaaaagctc ctgactaaat cagggctggg cttagacaga 1860
          gttgatctgt agaatatctt taaaggagag atgtcaactt tctgcactat tcccagcctc 1920
          tgctcctccc tgtctaccct ctcccctccc tctctccctc cacttcaccc cacaatcttg 1980
          aaaaacttcc tttctcttct gtgaacatca ttggccagat ccattttcag tggtctggat 2040
          ttctttttat tttcttttca acttgaaaga aactggacat taggccacta tgtgttgtta 2100
          ctgccactag tgttcaagtg cctcttgttt tcccagagat ttcctgggtc tgccagaggc 2160
          ccagacaggc tcactcaagc tctttaactg aaaagcaaca agccactcca ggacaaggtt 2220
          caaaatggtt acaacagcct ctacctgtcg ccccaggggag aaaggggtag tgatacaagt 2280
          ctcatagcca gagatggttt tccactcctt ctagatattc ccaaaaagag gctgagacag 2340
          gaggttattt tcaattttat tttggaatta aatacttttt tccctttatt actgttgtag 2400
          tccctcactt ggatatacct ctgttttcac gatagaaata aggggaggtct agagcttcta 2460
          ttccttggcc attgtcaacg gagagctggc caagtcttca caaacccttg caacattgcc 2520
          tgaagtttat ggaataagat gtattctcac tcccttgatc tcaagggcgt aactctggaa 2580
          gcacagcttg actacacgtc atttttacca atgattttca ggtgacctgg gctaagtcat 2640
          ttaaactggg tctttataaa agtaaaaggc caacatttaa ttatttgca aagcaaccta 2700
          agagctaaag atgtaatttt tcttgcaatt gtaaatcttt tgtgtctcct gaagacttcc 2760
          cttaaaatta gctctgagtg aaaaatcaaa agagacaaaa gacatcttcg aatccatatt 2820
          tcaagcctgg tagaattggc ttttctagca gaacctttcc aaaagtttta tattgagatt 2880
          cataacaaca ccaagaattg attttgtagc caacattcat tcaatactgt tatatcagag 2940
          gagtaggaga gaggaaacat ttgacttatc tggaaaagca aaatgtactt aagaataaga 3000
          ataacatggt ccattcacct ttatgttata gatatgtctt tgtgtaaatc atttgttttg 3060
          agttttcaaa gaatagccca ttgttcattc ttgtgctgta caatgaccac tgttattgtt 3120
          actttgactt ttcagagcac acccttcctc tggtttttgt atatttattg atggatcaat 3180
          aataatgagg aaagcatgat atgtatattg ctgagttgaa agcacttatt ggaaaatatt 3240
          aaaaggctaa cattaaaaga ctaaaggaaa caga 3274
           <![CDATA[ <210> 79]]>
           <![CDATA[ <211> 5431]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 79]]>
          ctcattgccc agcggacccc agcctctgcc aggttcggtc cgccatcctc gtcccgtcct 60
          ccgccggccc ctgccccgcg cccagggatc ctccagctcc tttcgcccgc gccctccgtt 120
          cgctccggac accatggaca agttttggtg gcacgcagcc tggggactct gcctcgtgcc 180
          gctgagcctg gcgcagatcg atttgaatat aacctgccgc tttgcaggtg tattccacgt 240
          ggagaaaaat ggtcgctaca gcatctctcg gacggaggcc gctgacctct gcaaggcttt 300
          caatagcacc ttgcccacaa tggcccagat ggagaaagct ctgagcatcg gatttgagac 360
          ctgcaggtat gggttcatag aagggcacgt ggtgattccc cggatccacc ccaactccat 420
          ctgtgcagca aacaacacag gggtgtacat cctcacatcc aacacctccc agtatgacac 480
          atattgcttc aatgcttcag ctccacctga agaagattgt acatcagtca cagacctgcc 540
          caatgccttt gatggaccaa ttaccataac tattgttaac cgtgatggca cccgctatgt 600
          ccagaaagga gaatacagaa cgaatcctga agacatctac cccagcaacc ctactgatga 660
          tgacgtgagc agcggctcct ccagtgaaag gagcagcact tcaggaggtt acatctttta 720
          caccttttct actgtacacc ccatcccaga cgaagacagt ccctggatca ccgacagcac 780
          agacagaatc cctgctacca ctttgatgag cactagtgct acagcaactg agacagcaac 840
          caagaggcaa gaaacctggg atggttttc atggttgttt ctaccatcag agtcaaagaa 900
          tcatcttcac acaacaacac aaatggctgg tacgtcttca aataccatct cagcaggctg 960
          ggagccaaat gaagaaaatg aagatgaaag aagacagacac ctcagttttt ctggatcagg 1020
          cattgatgat gatgaagatt ttatctccag caccatttca accacacac gggcttttga 1080
          ccacacaaaa cagaaccagg actggaccca gtggaaccca agccatcaa atccggaagt 1140
          gctacttcag acaaccacaa ggatgactga tgtagacaga aatggcacca ctgcttatga 1200
          aggaaactgg aacccagaag cacaccctcc cctcattcac catgagcatc atgaggaaga 1260
          agagacccca cattctacaa gcacaatcca ggcaactcct agtagtacaa cggaagaaac 1320
          agctacccag aaggaacagt ggtttggcaa cagatggcat gagggatatc gccaaacacc 1380
          caaagaagac tcccattcga caacagggac agctgcagcc tcagctcata ccagccatcc 1440
          aatgcaagga aggacaacac caagcccaga ggacagttcc tggactgatt tcttcaaccc 1500
          aatctcacac cccatgggac gaggtcatca agcaggaaga aggatggata tggactccag 1560
          tcatagtata acgcttcagc ctactgcaaa tccaaacaca ggtttggtgg aagatttgga 1620
          caggacagga cctctttcaa tgacaacgca gcagagtaat tctcagagct tctctacatc 1680
          acatgaaggc ttggaagaag ataaagacca tccaacaact tctactctga catcaagcaa 1740
          taggaatgat gtcacaggtg gaagaagaga cccaaatcat tctgaaggct caactacttt 1800
          actggaaggt tatacctctc attacccaca cacgaaggaa agcaggacct tcatcccagt 1860
          gacctcagct aagactgggt cctttggagt tactgcagtt actgttggag attccaactc 1920
          taatgtcaat cgttccttat caggagacca agaacacattc caccccagtg gggggtccca 1980
          taccactcat ggatctgaat cagatggaca ctcacatggg agtcaagaag gtggagcaaa 2040
          cacaacctct ggtcctataa ggacacccca aattccagaa tggctgatca tcttggcatc 2100
          cctcttggcc ttggctttga ttcttgcagt ttgcattgca gtcaacagtc gaagaaggtg 2160
          tgggcagaag aaaaagctag tgatcaacag tggcaatgga gctgtggagg acagaaagcc 2220
          aagtggactc aacggagagg ccagcaagtc tcaggaaatg gtgcatttgg tgaacaagga 2280
          gtcgtcagaa actccagacc agtttatgac agctgatgag acaaggaacc tgcagaatgt 2340
          ggacatgaag attggggtgt aacacctaca ccattatctt ggaaagaaac aaccgttgga 2400
          aacataacca ttacaggggag ctgggacact taacagatgc aatgtgctac tgattgtttc 2460
          attgcgaatc ttttttagca taaaattttc tactcttttt gttttttgtg ttttgttctt 2520
          taaagtcagg tccaatttgt aaaaacagca ttgctttctg aaattagggc ccaattaata 2580
          atcagcaaga atttgatcgt tccagttccc acttggaggc ctttcatccc tcgggtgtgc 2640
          tatggatggc ttctaacaaa aactacacat atgtattcct gatcgccaac ctttccccca 2700
          ccagctaagg aatttccca gggttaatag ggcctggtcc ctgggagga atttgaatgg 2760
          gtccattttg cccttccata gcctaatccc tgggcattgc tttccactga ggttgggggt 2820
          tggggtgtac tagttacaca tcttcaacag accccctcta gaaatttttc agatgcttct 2880
          gggagacacc caaagggtga agctatttat ctgtagtaaa ctatttatct gtgtttttga 2940
          aatattaaac cctggatcag tcctttgatc agtataattt tttaaagtta ctttgtcaga 3000
          ggcacaaaag ggtttaaact gattcataat aaatatctgt acttcttcga tcttcacctt 3060
          ttgtgctgtg attcttcagt ttctaaacca gcactgtctg ggtccctaca atgtatcagg 3120
          aagagctgag aatggtaagg agactcttct aagtcttcat ctcagagacc ctgagttccc 3180
          actcagaccc actcagccaa atctcatgga agaccaagga gggcagcact gtttttgttt 3240
          tttgtttttt gttttttttt tttgacactg tccaaaggtt ttccatcctg tcctggaatc 3300
          agagttggaa gctgaggagc ttcagcctct tttatggttt aatggccacc tgttctctcc 3360
          tgtgaaaggc tttgcaaagt cacattaagt ttgcatgacc tgttatccct ggggccctat 3420
          ttcatagagg ctggccctat tagtgatttc caaaaacaat atggaagtgc cttttgatgt 3480
          cttacaataa gagaagaagc caatggaaat gaaagagatt ggcaaaagggg aaggatgatg 3540
          ccatgtagat cctgtttgac atttttatgg ctgtatttgt aaacttaaac acaccagtgt 3600
          ctgttcttga tgcagttgct atttaggatg agttaagtgc ctggggagtc cctcaaaagg 3660
          ttaaagggat tcccatcatt ggaatcttat caccagatag gcaagtttat gaccaaacaa 3720
          gagagtactg gctttatcct ctaacctcat attttctccc acttggcaag tcctttgtgg 3780
          catttatca tcagtcaggg tgtccgattg gtcctagaac ttccaaaggc tgcttgtcat 3840
          agaagccatt gcatctataa agcaacggct cctgttaaat ggtatctcct ttctgaggct 3900
          cctactaaaa gtcatttgtt acctaaactt atgtgcttaa caggcaatgc ttctcagacc 3960
          acaaagcaga aagaagaagaaaagctcctg actaaatcag ggctgggctt agacagagtt 4020
          gatctgtaga atatctttaa aggagagatg tcaactttct gcactattcc cagcctctgc 4080
          tcctccctgt ctacccctctc ccctccctct ctccctccac ttcaccccac aatcttgaaa 4140
          aacttccttt ctcttctgtg aacatcattg gccagatcca ttttcagtgg tctggatttc 4200
          tttttatttt cttttcaact tgaaagaaac tggacattag gccactatgt gttgttactg 4260
          ccactagtgt tcaagtgcct cttgttttcc cagagatttc ctgggtctgc cagaggccca 4320
          gacaggctca ctcaagctct ttaactgaaa agcaacaagc cactccagga caaggttcaa 4380
          aatggttaca acagcctcta cctgtcgccc cagggagaaa ggggtagtga tacaagtctc 4440
          atagccagag atggttttcc actccttcta gatattccca aaaagaggct gagacaggag 4500
          gttattttca attttatttt ggaattaaat acttttttcc ctttattact gttgtagtcc 4560
          ctcacttgga tatacctctg ttttcacgat agaaataagg gaggtctaga gcttctattc 4620
          cttggccatt gtcaacggag agctggccaa gtcttcacaa acccttgcaa cattgcctga 4680
          agtttatgga ataagatgta ttctcactcc cttgatctca agggcgtaac tctggaagca 4740
          cagcttgact aacacgtcatt tttaccaatg attttcaggt gacctgggct aagtcattta 4800
          aactgggtct ttataaaagt aaaaggccaa catttaatta ttttgcaaag caacctaaga 4860
          gctaaagatg taatttttct tgcaattgta aatcttttgt gtctcctgaa gacttccctt 4920
          aaaattagct ctgagtgaaa aatcaaaaga gacaaaagac atcttcgaat ccatatttca 4980
          agcctggtag aattggcttt tctagcagaa cctttccaaa agttttatat tgagattcat 5040
          aacaacacca agaattgatt ttgtagccaa cattcattca atactgttat atcagaggag 5100
          taggagagag gaaacatttg acttatctgg aaaagcaaaa tgtacttaag aataagaata 5160
          acatggtcca ttcaccttta tgttatagat atgtctttgt gtaaatcatt tgttttgagt 5220
          tttcaaagaa tagcccattg ttcattcttg tgctgtacaa tgaccactgt tattgttact 5280
          ttgacttttc agagcacacc cttcctctgg tttttgtata tttattgatg gatcaataat 5340
          aatgaggaaa gcatgatatg tatattgctg agttgaaagc acttattgga aaatattaaa 5400
          aggctaacat taaaagacta aaggaaacag a 5431
           <![CDATA[ <210> 80]]>
           <![CDATA[ <211> 22]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 80]]>
          Met Asp Lys Phe Trp Trp His Ala Ala Trp Gly Leu Cys Leu Val Pro
          1 5 10 15
          Leu Ser Leu Ala Gln Ile
                      20
           <![CDATA[ <210> 81]]>
           <![CDATA[ <211> 54]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 81]]>
          Leu Asn Ile Thr Cys Arg Phe Ala Gly Val Phe His Val Glu Lys Asn
          1 5 10 15
          Gly Arg Tyr Ser Ile Ser Arg Thr Glu Ala Ala Asp Leu Cys Lys Ala
                      20 25 30
          Phe Asn Ser Thr Leu Pro Thr Met Ala Gln Met Glu Lys Ala Leu Ser
                  35 40 45
          Ile Gly Phe Glu Thr Cys
              50
           <![CDATA[ <210> 82]]>
           <![CDATA[ <211> 44]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 82]]>
          Tyr Gly Phe Ile Glu Gly His Val Val Ile Pro Arg Ile His Pro Asn
          1 5 10 15
          Ser Ile Cys Ala Ala Asn Asn Thr Gly Val Tyr Ile Leu Thr Ser Asn
                      20 25 30
          Thr Ser Gln Tyr Asp Thr Tyr Cys Phe Asn Ala Ser
                  35 40
           <![CDATA[ <210> 83]]>
           <![CDATA[ <211> 22]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 83]]>
          Pro Pro Glu Glu Asp Cys Thr Ser Val Thr Asp Leu Pro Asn Ala Phe
          1 5 10 15
          Asp Gly Pro Ile Thr Ile
                      20
           <![CDATA[ <210> 84]]>
           <![CDATA[ <211> 76]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 84]]>
          Ile Val Asn Arg Asp Gly Thr Arg Tyr Val Gln Lys Gly Glu Tyr Arg
          1 5 10 15
          Thr Asn Pro Glu Asp Ile Tyr Pro Ser Asn Pro Thr Asp Asp Asp Val
                      20 25 30
          Ser Ser Gly Ser Ser Ser Glu Arg Ser Ser Thr Ser Gly Gly Tyr Ile
                  35 40 45
          Phe Tyr Thr Phe Ser Thr Val His Pro Ile Pro Asp Glu Asp Ser Pro
              50 55 60
          Trp Ile Thr Asp Ser Thr Asp Arg Ile Pro Ala Thr
          65 70 75
           <![CDATA[ <210> 85]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 85]]>
          Leu Met Ser Thr Ser Ala Thr Ala Thr Glu Thr Ala Thr Lys Arg Gln
          1 5 10 15
          Glu Thr Trp Asp Trp Phe Ser Trp Leu Phe Leu Pro Ser Glu Ser Lys
                      20 25 30
          Asn His Leu His Thr Thr Thr Gln Met Ala
                  35 40
           <![CDATA[ <210> 86]]>
           <![CDATA[ <211> 41]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 86]]>
          Thr Ser Ser Asn Thr Ile Ser Ala Gly Trp Glu Pro Asn Glu Glu Asn
          1 5 10 15
          Glu Asp Glu Arg Asp Arg His Leu Ser Phe Ser Gly Ser Gly Ile Asp
                      20 25 30
          Asp Asp Glu Asp Phe Ile Ser Ser Thr
                  35 40
           <![CDATA[ <210> 87]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 87]]>
          Ser Thr Thr Pro Arg Ala Phe Asp His Thr Lys Gln Asn Gln Asp Trp
          1 5 10 15
          Thr Gln Trp Asn Pro Ser His Ser Asn Pro Glu Val Leu Leu Gln Thr
                      20 25 30
          Thr Thr Arg Met Thr
                  35
           <![CDATA[ <210> 88]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 88]]>
          Val Asp Arg Asn Gly Thr Thr Ala Tyr Glu Gly Asn Trp Asn Pro Glu
          1 5 10 15
          Ala His Pro Pro Leu Ile His His Glu His His Glu Glu Glu Glu Thr
                      20 25 30
          Pro His Ser Thr Ser Thr
                  35
           <![CDATA[ <210> 89]]>
           <![CDATA[ <211> 4]]>2
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 89]]>
          Gln Ala Thr Pro Ser Ser Thr Thr Glu Glu Thr Ala Thr Gln Lys Glu
          1 5 10 15
          Gln Trp Phe Gly Asn Arg Trp His Glu Gly Tyr Arg Gln Thr Pro Lys
                      20 25 30
          Glu Asp Ser His Ser Thr Thr Gly Thr Ala
                  35 40
           <![CDATA[ <210> 90]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 90]]>
          Ala Ser Ala His Thr Ser His Pro Met Gln Gly Arg Thr Thr Pro Ser
          1 5 10 15
          Pro Glu Asp Ser Ser Trp Thr Asp Phe Phe Asn Pro Ile Ser His Pro
                      20 25 30
          Met Gly Arg Gly His Gln Ala Gly Arg Arg Met
                  35 40
           <![CDATA[ <210> 91]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 91]]>
          Met Asp Ser Ser His Ser Ile Thr Leu Gln Pro Thr Ala Asn Pro Asn
          1 5 10 15
          Thr Gly Leu Val Glu Asp Leu Asp Arg Thr Gly Pro Leu Ser Met Thr
                      20 25 30
          Thr
           <![CDATA[ <210> 92]]>
           <![CDATA[ <211> 29]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 92]]>
          Gln Ser Asn Ser Gln Ser Phe Ser Thr Ser His Glu Gly Leu Glu Glu
          1 5 10 15
          Asp Lys Asp His Pro Thr Thr Ser Ser Thr Leu Thr Ser Ser
                      20 25
           <![CDATA[ <210> 93]]>
           <![CDATA[ <211> ]]> 67
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 93]]>
          Arg Asn Asp Val Thr Gly Gly Arg Arg Asp Pro Asn His Ser Glu Gly
          1 5 10 15
          Ser Thr Thr Leu Leu Glu Gly Tyr Thr Ser His Tyr Pro His Thr Lys
                      20 25 30
          Glu Ser Arg Thr Phe Ile Pro Val Thr Ser Ala Lys Thr Gly Ser Phe
                  35 40 45
          Gly Val Thr Ala Val Thr Val Gly Asp Ser Asn Ser Asn Val Asn Arg
              50 55 60
          Ser Leu Ser
          65
           <![CDATA[ <210> 94]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 94]]>
          Asp Gln Asp Thr Phe His Pro Ser Gly Gly Ser His Thr Thr His Gly
          1 5 10 15
          Ser Glu Ser Asp
                      20
           <![CDATA[ <210> 95]]>
           <![CDATA[ <211> 23]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 95]]>
          His Ser His Gly Ser Gln Glu Gly Gly Ala Asn Thr Thr Ser Gly Pro
          1 5 10 15
          Ile Arg Thr Pro Gln Ile Pro
                      20
           <![CDATA[ <210> 96]]>
           <![CDATA[ <211> 25]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 96]]>
          Trp Leu Ile Ile Leu Ala Ser Leu Leu Ala Leu Ala Leu Ile Leu Ala
          1 5 10 15
          Val Cys Ile Ala Val Asn Ser Arg Arg
                      20 25
           <![CDATA[ <210> 97]]>
           <![CDATA[ <211> 67]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 97]]>
          Cys Gly Gln Lys Lys Lys Leu Val Ile Asn Ser Gly Asn Gly Ala Val
          1 5 10 15
          Glu Asp Arg Lys Pro Ser Gly Leu Asn Gly Glu Ala Ser Lys Ser Gln
                      20 25 30
          Glu Met Val His Leu Val Asn Lys Glu Ser Ser Glu Thr Pro Asp Gln
                  35 40 45
          Phe Met Thr Ala Asp Glu Thr Arg Asn Leu Gln Asn Val Asp Met Lys
              50 55 60
          Ile Gly Val
          65
           <![CDATA[ <210> 98]]>
           <![CDATA[ <211> 742]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 98]]>
          Met Asp Lys Phe Trp Trp His Ala Ala Trp Gly Leu Cys Leu Val Pro
          1 5 10 15
          Leu Ser Leu Ala Gln Ile Asp Leu Asn Ile Thr Cys Arg Phe Ala Gly
                      20 25 30
          Val Phe His Val Glu Lys Asn Gly Arg Tyr Ser Ile Ser Arg Thr Glu
                  35 40 45
          Ala Ala Asp Leu Cys Lys Ala Phe Asn Ser Thr Leu Pro Thr Met Ala
              50 55 60
          Gln Met Glu Lys Ala Leu Ser Ile Gly Phe Glu Thr Cys Arg Tyr Gly
          65 70 75 80
          Phe Ile Glu Gly His Val Val Ile Pro Arg Ile His Pro Asn Ser Ile
                          85 90 95
          Cys Ala Ala Asn Asn Thr Gly Val Tyr Ile Leu Thr Ser Asn Thr Ser
                      100 105 110
          Gln Tyr Asp Thr Tyr Cys Phe Asn Ala Ser Ala Pro Pro Glu Glu Asp
                  115 120 125
          Cys Thr Ser Val Thr Asp Leu Pro Asn Ala Phe Asp Gly Pro Ile Thr
              130 135 140
          Ile Thr Ile Val Asn Arg Asp Gly Thr Arg Tyr Val Gln Lys Gly Glu
          145 150 155 160
          Tyr Arg Thr Asn Pro Glu Asp Ile Tyr Pro Ser Asn Pro Thr Asp Asp
                          165 170 175
          Asp Val Ser Ser Gly Ser Ser Ser Glu Arg Ser Ser Thr Ser Gly Gly
                      180 185 190
          Tyr Ile Phe Tyr Thr Phe Ser Thr Val His Pro Ile Pro Asp Glu Asp
                  195 200 205
          Ser Pro Trp Ile Thr Asp Ser Thr Asp Arg Ile Pro Ala Thr Thr Leu
              210 215 220
          Met Ser Thr Ser Ala Thr Ala Thr Glu Thr Ala Thr Lys Arg Gln Glu
          225 230 235 240
          Thr Trp Asp Trp Phe Ser Trp Leu Phe Leu Pro Ser Glu Ser Lys Asn
                          245 250 255
          His Leu His Thr Thr Thr Gln Met Ala Gly Thr Ser Ser Asn Thr Ile
                      260 265 270
          Ser Ala Gly Trp Glu Pro Asn Glu Glu Asn Glu Asp Glu Arg Asp Arg
                  275 280 285
          His Leu Ser Phe Ser Gly Ser Gly Ile Asp Asp Asp Glu Asp Phe Ile
              290 295 300
          Ser Ser Thr Ile Ser Thr Thr Pro Arg Ala Phe Asp His Thr Lys Gln
          305 310 315 320
          Asn Gln Asp Trp Thr Gln Trp Asn Pro Ser His Ser Asn Pro Glu Val
                          325 330 335
          Leu Leu Gln Thr Thr Thr Arg Met Thr Asp Val Asp Arg Asn Gly Thr
                      340 345 350
          Thr Ala Tyr Glu Gly Asn Trp Asn Pro Glu Ala His Pro Pro Leu Ile
                  355 360 365
          His His Glu His His Glu Glu Glu Glu Thr Pro His Ser Thr Ser Thr
              370 375 380
          Ile Gln Ala Thr Pro Ser Ser Thr Thr Glu Glu Thr Ala Thr Gln Lys
          385 390 395 400
          Glu Gln Trp Phe Gly Asn Arg Trp His Glu Gly Tyr Arg Gln Thr Pro
                          405 410 415
          Lys Glu Asp Ser His Ser Thr Thr Gly Thr Ala Ala Ala Ser Ala His
                      420 425 430
          Thr Ser His Pro Met Gln Gly Arg Thr Thr Pro Ser Pro Glu Asp Ser
                  435 440 445
          Ser Trp Thr Asp Phe Phe Asn Pro Ile Ser His Pro Met Gly Arg Gly
              450 455 460
          His Gln Ala Gly Arg Arg Met Asp Met Asp Ser Ser His Ser Ile Thr
          465 470 475 480
          Leu Gln Pro Thr Ala Asn Pro Asn Thr Gly Leu Val Glu Asp Leu Asp
                          485 490 495
          Arg Thr Gly Pro Leu Ser Met Thr Thr Gln Gln Ser Asn Ser Gln Ser
                      500 505 510
          Phe Ser Thr Ser His Glu Gly Leu Glu Glu Asp Lys Asp His Pro Thr
                  515 520 525
          Thr Ser Thr Leu Thr Ser Ser Asn Arg Asn Asp Val Thr Gly Gly Arg
              530 535 540
          Arg Asp Pro Asn His Ser Glu Gly Ser Thr Thr Leu Leu Glu Gly Tyr
          545 550 555 560
          Thr Ser His Tyr Pro His Thr Lys Glu Ser Arg Thr Phe Ile Pro Val
                          565 570 575
          Thr Ser Ala Lys Thr Gly Ser Phe Gly Val Thr Ala Val Thr Val Gly
                      580 585 590
          Asp Ser Asn Ser Asn Val Asn Arg Ser Leu Ser Gly Asp Gln Asp Thr
                  595 600 605
          Phe His Pro Ser Gly Gly Ser His Thr Thr His Gly Ser Glu Ser Asp
              610 615 620
          Gly His Ser His Gly Ser Gln Glu Gly Gly Ala Asn Thr Thr Ser Gly
          625 630 635 640
          Pro Ile Arg Thr Pro Gln Ile Pro Glu Trp Leu Ile Ile Leu Ala Ser
                          645 650 655
          Leu Leu Ala Leu Ala Leu Ile Leu Ala Val Cys Ile Ala Val Asn Ser
                      660 665 670
          Arg Arg Arg Cys Gly Gln Lys Lys Lys Leu Val Ile Asn Ser Gly Asn
                  675 680 685
          Gly Ala Val Glu Asp Arg Lys Pro Ser Gly Leu Asn Gly Glu Ala Ser
              690 695 700
          Lys Ser Gln Glu Met Val His Leu Val Asn Lys Glu Ser Ser Ser Glu Thr
          705 710 715 720
          Pro Asp Gln Phe Met Thr Ala Asp Glu Thr Arg Asn Leu Gln Asn Val
                          725 730 735
          Asp Met Lys Ile Gly Val
                      740
           <![CDATA[ <210> 99]]>
           <![CDATA[ <211> 800]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 99]]>
          ctcattgccc agcggacccc agcctctgcc aggttcggtc cgccatcctc gtcccgtcct 60
          ccgccggccc ctgccccgcg cccagggatc ctccagctcc tttcgcccgc gccctccgtt 120
          cgctccggac accatggaca agttttggtg gcacgcagcc tggggactct gcctcgtgcc 180
          gctgagcctg gcgcagatcg atttgaatat aacctgccgc tttgcaggtg tattccacgt 240
          ggagaaaaat ggtcgctaca gcatctctcg gacggaggcc gctgacctct gcaaggcttt 300
          caatagcacc ttgcccacaa tggcccagat ggagaaagct ctgagcatcg gatttgagac 360
          ctgcaggtat gggttcatag aagggcacgt ggtgattccc cggatccacc ccaactccat 420
          ctgtgcagca aacaacacag gggtgtacat cctcacatcc aacacctccc agtatgacac 480
          atattgcttc aatgcttcag ctccacctga agaagattgt acatcagtca cagacctgcc 540
          caatgccttt gatggaccaa ttaccataac tattgttaac cgtgatggca cccgctatgt 600
          ccagaaagga gaatacagaa cgaatcctga agacatctac cccagcaacc ctactgatga 660
          tgacgtgagc agcggctcct ccagtgaaag gagcagcact tcaggaggtt acatctttta 720
          caccttttct actgtacacc ccatcccaga cgaagacagt ccctggatca ccgacagcac 780
          agacagaatc cctgctacca 800
           <![CDATA[ <210> 100]]>
           <![CDATA[ <211> 222]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 100]]>
          Met Asp Lys Phe Trp Trp His Ala Ala Trp Gly Leu Cys Leu Val Pro
          1 5 10 15
          Leu Ser Leu Ala Gln Ile Asp Leu Asn Ile Thr Cys Arg Phe Ala Gly
                      20 25 30
          Val Phe His Val Glu Lys Asn Gly Arg Tyr Ser Ile Ser Arg Thr Glu
                  35 40 45
          Ala Ala Asp Leu Cys Lys Ala Phe Asn Ser Thr Leu Pro Thr Met Ala
              50 55 60
          Gln Met Glu Lys Ala Leu Ser Ile Gly Phe Glu Thr Cys Arg Tyr Gly
          65 70 75 80
          Phe Ile Glu Gly His Val Val Ile Pro Arg Ile His Pro Asn Ser Ile
                          85 90 95
          Cys Ala Ala Asn Asn Thr Gly Val Tyr Ile Leu Thr Ser Asn Thr Ser
                      100 105 110
          Gln Tyr Asp Thr Tyr Cys Phe Asn Ala Ser Ala Pro Pro Glu Glu Asp
                  115 120 125
          Cys Thr Ser Val Thr Asp Leu Pro Asn Ala Phe Asp Gly Pro Ile Thr
              130 135 140
          Ile Thr Ile Val Asn Arg Asp Gly Thr Arg Tyr Val Gln Lys Gly Glu
          145 150 155 160
          Tyr Arg Thr Asn Pro Glu Asp Ile Tyr Pro Ser Asn Pro Thr Asp Asp
                          165 170 175
          Asp Val Ser Ser Gly Ser Ser Ser Glu Arg Ser Ser Thr Ser Gly Gly
                      180 185 190
          Tyr Ile Phe Tyr Thr Phe Ser Thr Val His Pro Ile Pro Asp Glu Asp
                  195 200 205
          Ser Pro Trp Ile Thr Asp Ser Thr Asp Arg Ile Pro Ala Thr
              210 215 220
           <![CDATA[ <210> 101]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 101]]>
          000
           <![CDATA[ <210> 102]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 102]]>
          000
           <![CDATA[ <210> 103]]>
           <![CDATA[ <211> 552]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 103]]>
          agatgcagta gccgaaactg cgcggaggca cagaggccgg ggagagcgtt ctgggtccga 60
          gggtccaggt aggggttgag ccaccacatctg accgcaagct gcgtcgtgtc gccggttctg 120
          caggcaccat gagccaggac accgaggtgg atatgaagga ggtggagctg aatgagttag 180
          agcccgagaa gcagccgatg aacgcggcgt ctggggcggc catgtccctg gcgggagccg 240
          agaagaatgg tctggtgaag atcaaggtgg cggaagacga ggcggaggcg gcagccgcgg 300
          ctaagttcac gggcctgtcc aaggaggagc tgctgaaggt ggcaggcagc cccggctggg 360
          tacgcacccg ctgggcactg ctgctgctct tctggctcgg ctggctcggc atgcttgctg 420
          gtgccgtggt cataatcgtg cgagcgccgc gttgtcgcga gctaccggcg cagaagtggt 480
          ggcacacggg cgccctctac cgcatcggcg accttcaggc cttccagggc cacggcgcgg 540
          gcaacctggc gg 552
           <![CDATA[ <210> 104]]>
           <![CDATA[ <211> 174]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 104]]>
          gtctgaaggg gcgtctcgat tacctgagct ctctgaaggt gaagggcctt gtgctgggtc 60
          caattcacaa gaaccagaag gatgatgtcg ctcagactga cttgctgcag atcgacccca 120
          atttggctc caaggaagat tttgacagtc tcttgcaatc ggctaaaaaa aaga 174
           <![CDATA[ <210> 105]]>
           <![CDATA[ <211> 91]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 105]]>
          gcatccgtgt cattctggac cttactccca actaccgggg tgagaactcg tggttctcca 60
          ctcaggttga cactgtggcc accaaggtga a 91
           <![CDATA[ <210> 106]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 106]]>
          gatgctctgg agttttggct gcaagctggc gtggatgggt tccaggttcg ggacatagag 60
          aatctgaag 69
           <![CDATA[ <210> 107]]>
           <![CDATA[ <211> 59]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 107]]>
          gatgcatcct cattcttggc tgagtggcaa aatatcacca agggcttcag tgaagacag 59
           <![CDATA[ <210> 108]]>
           <![CDATA[ <211> 181]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 108]]>
          gctcttgatt gcggggacta actcctccga ccttcagcag atcctgagcc tactcgaatc 60
          caacaaagac ttgctgttga ctagctcata cctgtctgat tctggttcta ctggggagca 120
          tacaaaatcc ctagtcacac agtatttgaa tgccactggc aatcgctggt gcagctggag 180
          t 181
           <![CDATA[ <210> 109]]>
           <![CDATA[ <211> 144]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 109]]>
          ttgtctcagg caaggctcct gacttccttc ttgccggctc aacttctccg actctaccag 60
          ctgatgctct tcaccctgcc agggacccct gttttcagct acggggatga gattggcctg 120
          gatgcagctg cccttcctgg acag 144
           <![CDATA[ <210> 110]]>
           <![CDATA[ <211> 84]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 110]]>
          cctatggagg ctccagtcat gctgtggggat gagtccagct tccctgacat cccaggggct 60
          gtaagtgcca acatgactgt gaag 84
           <![CDATA[ <210> 111]]>
           <![CDATA[ <211> 530]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 111]]>
          ggccagagtg aagaccctgg ctccctcctt tccttgttcc ggcggctgag tgaccagcgg 60
          agtaaggagc gctccctact gcatggggac ttccacgcgt tctccgctgg gcctggactc 120
          ttctcctata tccgccactg ggaccagaat gagcgttttc tggtagtgct taactttggg 180
          gatgtgggcc tctcggctgg actgcaggcc tccgacctgc ctgccagcgc cagcctgcca 240
          gccaaggctg acctcctgct cagcacccag ccaggccgtg aggagggctc ccctcttgag 300
          ctggaacgcc tgaaactgga gcctcacgaa gggctgctgc tccgcttccc ctacgcggcc 360
          tgacttcagc ctgacatgga cccactaccc ttctcctttc cttcccaggc cctttggctt 420
          ctgatttttc tcttttttaa aaacaaacaa acaaactgtt gcagattatg agtgaacccc 480
          caaatagggt gttttctgcc ttcaaataaa agtcacccct gcatggtgaa 530
           <![CDATA[ <210> 112]]>
           <![CDATA[ <211> 1884]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 112]]>
          agatgcagta gccgaaactg cgcggaggca cagaggccgg ggagagcgtt ctgggtccga 60
          gggtccaggt aggggttgag ccaccacatctg accgcaagct gcgtcgtgtc gccggttctg 120
          caggcaccat gagccaggac accgaggtgg atatgaagga ggtggagctg aatgagttag 180
          agcccgagaa gcagccgatg aacgcggcgt ctggggcggc catgtccctg gcgggagccg 240
          agaagaatgg tctggtgaag atcaaggtgg cggaagacga ggcggaggcg gcagccgcgg 300
          ctaagttcac gggcctgtcc aaggaggagc tgctgaaggt ggcaggcagc cccggctggg 360
          tacgcacccg ctgggcactg ctgctgctct tctggctcgg ctggctcggc atgcttgctg 420
          gtgccgtggt cataatcgtg cgagcgccgc gttgtcgcga gctaccggcg cagaagtggt 480
          ggcacacggg cgccctctac cgcatcggcg accttcaggc cttccagggc cacggcgcgg 540
          gcaacctggc gggtctgaag gggcgtctcg attacctgag ctctctgaag gtgaagggcc 600
          ttgtgctggg tccaattcac aagaaccaga aggatgatgt cgctcagact gacttgctgc 660
          agatcgaccc caattttggc tccaaggaag attttgacag tctcttgcaa tcggctaaaa 720
          aaaagagcat ccgtgtcatt ctggacctta ctcccaacta ccggggtgag aactcgtggt 780
          tctccactca ggttgacact gtggccacca aggtgaagat gctctggagt tttggctgca 840
          agctggcgtg gatgggttcc aggttcggga catagagaat ctgaaggatg catcctcatt 900
          cttggctgag tggcaaaata tcaccaaggg cttcagtgaa gacaggctct tgattgcggg 960
          gactaactcc tccgaccttc agcagatcct gagcctactc gaatccaaca aagacttgct 1020
          gttgactagc tcatacctgt ctgattctgg ttctactggg gagcatacaa aatccctagt 1080
          cacacagtat ttgaatgcca ctggcaatcg ctggtgcagc tggagtttgt ctcaggcaag 1140
          gctcctgact tccttcttgc cggctcaact tctccgactc taccagctga tgctcttcac 1200
          cctgccaggg acccctgttt tcagctacgg ggatgagatt ggcctggatg cagctgccct 1260
          tcctggacag cctatgggagg ctccagtcat gctgtgggat gagtccagct tccctgacat 1320
          cccaggggct gtaagtgcca acatgactgt gaagggccag agtgaagacc ctggctccct 1380
          cctttccttg ttccggcggc tgagtgacca gcggagtaag gagcgctccc tactgcatgg 1440
          ggacttccac gcgttctccg ctgggcctgg actcttctcc tatatccgcc actgggacca 1500
          gaatgagcgt tttctggtag tgcttaactt tggggatgtg ggcctctcgg ctggactgca 1560
          ggcctccgac ctgcctgcca gcgccagcct gccagccaag gctgacctcc tgctcagcac 1620
          ccagccaggc cgtgaggagg gctcccctct tgagctggaa cgcctgaaac tggagcctca 1680
          cgaagggctg ctgctccgct tcccctacgc ggcctgactt cagcctgaca tggacccact 1740
          acccttctcc tttccttccc aggccctttg gcttctgatt tttctctttt ttaaaaacaa 1800
          acaaacaaac tgttgcagat tatgagtgaa cccccaaata gggtgttttc tgccttcaaa 1860
          taaaagtcac ccctgcatgg tgaa 1884
           <![CDATA[ <210> 113]]>
           <![CDATA[ <211> 141]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 113]]>
          Met Ser Gln Asp Thr Glu Val Asp Met Lys Glu Val Glu Leu Asn Glu
          1 5 10 15
          Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala Ala Met
                      20 25 30
          Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala
                  35 40 45
          Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu Ser
              50 55 60
          Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr
          65 70 75 80
          Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met Leu
                          85 90 95
          Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg Glu Leu
                      100 105 110
          Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu Tyr Arg Ile Gly Asp
                  115 120 125
          Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn Leu Ala
              130 135 140
           <![CDATA[ <210> 114]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 114]]>
          Leu Lys Gly Arg Leu Asp Tyr Leu Ser Ser Leu Lys Val Lys Gly Leu
          1 5 10 15
          Val Leu Gly Pro Ile His Lys Asn Gln Lys Asp Asp Val Ala Gln Thr
                      20 25 30
          Asp Leu Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu Asp Phe Asp
                  35 40 45
          Ser Leu Leu Gln Ser Ala Lys Lys Lys Lys
              50 55
           <![CDATA[ <210> 115]]>
           <![CDATA[ <211> 29]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 115]]>
          Ile Arg Val Ile Leu Asp Leu Thr Pro Asn Tyr Arg Gly Glu Asn Ser
          1 5 10 15
          Trp Phe Ser Thr Gln Val Asp Thr Val Ala Thr Lys Val
                      20 25
           <![CDATA[ <210> 116]]>
           <![CDATA[ <211> 23]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 116]]>
          Asp Ala Leu Glu Phe Trp Leu Gln Ala Gly Val Asp Gly Phe Gln Val
          1 5 10 15
          Arg Asp Ile Glu Asn Leu Lys
                      20
           <![CDATA[ <210> 117]]>
           <![CDATA[ <211> 19]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 117]]>
          Asp Ala Ser Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe
          1 5 10 15
          Ser Glu Asp
           <![CDATA[ <210> 118]]>
           <![CDATA[ <211> 60]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 118]]>
          Leu Leu Ile Ala Gly Thr Asn Ser Ser Asp Leu Gln Gln Ile Leu Ser
          1 5 10 15
          Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu Thr Ser Ser Tyr Leu Ser
                      20 25 30
          Asp Ser Gly Ser Thr Gly Glu His Thr Lys Ser Leu Val Thr Gln Tyr
                  35 40 45
          Leu Asn Ala Thr Gly Asn Arg Trp Cys Ser Trp Ser
              50 55 60
           <![CDATA[ <210> 119]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 119]]>
          Leu Ser Gln Ala Arg Leu Leu Thr Ser Phe Leu Pro Ala Gln Leu Leu
          1 5 10 15
          Arg Leu Tyr Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro Val Phe
                      20 25 30
          Ser Tyr Gly Asp Glu Ile Gly Leu Asp Ala Ala Ala Leu Pro Gly Gln
                  35 40 45
           <![CDATA[ <210> 120]]>
           <![CDATA[ <211> 28]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 120]]>
          Pro Met Glu Ala Pro Val Met Leu Trp Asp Glu Ser Ser Phe Pro Asp
          1 5 10 15
          Ile Pro Gly Ala Val Ser Ala Asn Met Thr Val Lys
                      20 25
           <![CDATA[ <210> 121]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 121]]>
          Gly Gln Ser Glu Asp Pro Gly Ser Leu Leu Ser Leu Phe Arg Arg Leu
          1 5 10 15
          Ser Asp Gln Arg Ser Lys Glu Arg Ser Leu Leu His Gly Asp Phe His
                      20 25 30
          Ala Phe Ser Ala Gly Pro Gly Leu Phe Ser Tyr Ile Arg His Trp Asp
                  35 40 45
          Gln Asn Glu Arg Phe Leu Val Val Leu Asn Phe Gly Asp Val Gly Leu
              50 55 60
          Ser Ala Gly Leu Gln Ala Ser Asp Leu Pro Ala Ser Ala Ser Leu Pro
          65 70 75 80
          Ala Lys Ala Asp Leu Leu Leu Ser Thr Gln Pro Gly Arg Glu Glu Gly
                          85 90 95
          Ser Pro Leu Glu Leu Glu Arg Leu Lys Leu Glu Pro His Glu Gly Leu
                      100 105 110
          Leu Leu Arg Phe Pro Tyr Ala Ala
                  115 120
           <![CDATA[ <210> 122]]>
           <![CDATA[ <211> 529]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 122]]>
          Met Ser Gln Asp Thr Glu Val Asp Met Lys Glu Val Glu Leu Asn Glu
          1 5 10 15
          Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala Ala Met
                      20 25 30
          Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala
                  35 40 45
          Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu Ser
              50 55 60
          Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr
          65 70 75 80
          Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met Leu
                          85 90 95
          Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg Glu Leu
                      100 105 110
          Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu Tyr Arg Ile Gly Asp
                  115 120 125
          Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn Leu Ala Gly Leu Lys
              130 135 140
          Gly Arg Leu Asp Tyr Leu Ser Ser Leu Lys Val Lys Gly Leu Val Leu
          145 150 155 160
          Gly Pro Ile His Lys Asn Gln Lys Asp Asp Val Ala Gln Thr Asp Leu
                          165 170 175
          Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu Asp Phe Asp Ser Leu
                      180 185 190
          Leu Gln Ser Ala Lys Lys Lys Ser Ile Arg Val Ile Leu Asp Leu Thr
                  195 200 205
          Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser Thr Gln Val Asp Thr
              210 215 220
          Val Ala Thr Lys Val Lys Asp Ala Leu Glu Phe Trp Leu Gln Ala Gly
          225 230 235 240
          Val Asp Gly Phe Gln Val Arg Asp Ile Glu Asn Leu Lys Asp Ala Ser
                          245 250 255
          Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe Ser Glu Asp
                      260 265 270
          Arg Leu Leu Ile Ala Gly Thr Asn Ser Ser Asp Leu Gln Gln Ile Leu
                  275 280 285
          Ser Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu Thr Ser Ser Tyr Leu
              290 295 300
          Ser Asp Ser Gly Ser Thr Gly Glu His Thr Lys Ser Leu Val Thr Gln
          305 310 315 320
          Tyr Leu Asn Ala Thr Gly Asn Arg Trp Cys Ser Trp Ser Leu Ser Gln
                          325 330 335
          Ala Arg Leu Leu Thr Ser Phe Leu Pro Ala Gln Leu Leu Arg Leu Tyr
                      340 345 350
          Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro Val Phe Ser Tyr Gly
                  355 360 365
          Asp Glu Ile Gly Leu Asp Ala Ala Ala Leu Pro Gly Gln Pro Met Glu
              370 375 380
          Ala Pro Val Met Leu Trp Asp Glu Ser Ser Phe Pro Asp Ile Pro Gly
          385 390 395 400
          Ala Val Ser Ala Asn Met Thr Val Lys Gly Gln Ser Glu Asp Pro Gly
                          405 410 415
          Ser Leu Leu Ser Leu Phe Arg Arg Leu Ser Asp Gln Arg Ser Lys Glu
                      420 425 430
          Arg Ser Leu Leu His Gly Asp Phe His Ala Phe Ser Ala Gly Pro Gly
                  435 440 445
          Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn Glu Arg Phe Leu Val
              450 455 460
          Val Leu Asn Phe Gly Asp Val Gly Leu Ser Ala Gly Leu Gln Ala Ser
          465 470 475 480
          Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys Ala Asp Leu Leu Leu
                          485 490 495
          Ser Thr Gln Pro Gly Arg Glu Glu Gly Ser Pro Leu Glu Leu Glu Arg
                      500 505 510
          Leu Lys Leu Glu Pro His Glu Gly Leu Leu Leu Arg Phe Pro Tyr Ala
                  515 520 525
          Ala
           <![CDATA[ <210> 123]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 123]]>
          000
           <![CDATA[ <210> 124]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 124]]>
          000
           <![CDATA[ <210> 125]]>
           <![CDATA[ <211> 187]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 125]]>
          agtaagcctc cgcagcccac tcggactgca gcctgtttgc cgcccgtcct cccattgcag 60
          cactcggggc gacagagagg gaggaggcgc gcggggacgg ggacgcccag gaggacccac 120
          tcgcgggtcc cgctccgctc cggcagcagc atggggaaag gacgcgcggg ccgagttggc 180
          accacag 187
           <![CDATA[ <210> 126]]>
           <![CDATA[ <211> 178]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 126]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60
          tccttcggtg tgaaaccagt tctgaatact cctctctcag attcaagtgg ttcaagaatg 120
          ggaatgaatt gaatcgaaaa aacaaaccac aaaatatcaa gatacaaaaa aagccagg 178
           <![CDATA[ <210> 127]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 127]]>
          gaagtcagaa cttcgcatta acaaagcatc actggctgat tctggagagt atatgtgcaa 60
          agtgatcagc aaattaggaa atgacagtgc ctctgccaat atcaccatcg tggaatcaaa 120
          cg 122
           <![CDATA[ <210> 128]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 128]]>
          agatcatcac tggtatgcca gcctcaactg aaggagcata tgtgtcttca g 51
           <![CDATA[ <210> 129]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 129]]>
          agtctcccat tagaatatca gtatccacag aaggagcaaa tacttcttca t 51
           <![CDATA[ <210> 130]]>
           <![CDATA[ <211> 1]]>30
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 130]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgt gaatggaggg gagtgcttca tggtgaaaga cctttcaaac ccctcgagat 120
          acttgtgcaa 130
           <![CDATA[ <210> 131]]>
           <![CDATA[ <211> 59]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 131]]>
          gtgcccaaat ggtttactg gtgatcgctg ccaaaactac gtaatggcca gcttctaca 59
           <![CDATA[ <210> 132]]>
           <![CDATA[ <211> 24]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 132]]>
          agcatcttgg gattgaattt atgg 24
           <![CDATA[ <210> 133]]>
           <![CDATA[ <211> 103]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 133]]>
          aggcggagga gctgtaccag aagagagtgc tgaccataac cggcatctgc atcgccctcc 60
          ttgtggtcgg catcatgtgt gtggtggcct actgcaaaac caa 103
           <![CDATA[ <210> 134]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 134]]>
          gaaacagcgg aaaaagctgc atgaccgtct tcggcagagc cttcggtctg aacgaaacaa 60
          tatgatgaac attgccaatg ggcctcacca tcctaaccca ccccccgaga atgtccagct 120
          ggtgaat 127
           <![CDATA[ <210> 135]]>
           <![CDATA[ <211> 131]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 135]]>
          caatacgtat ctaaaaacgt catctccagt gagcatattg ttgagagaga agcagagaca 60
          tccttttcca ccagtcacta tacttccaca gcccatcact ccactactgt cacccagact 120
          cctagccaca g 131
           <![CDATA[ <210> 136]]>
           <![CDATA[ <211> 207]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 136]]>
          ctggagcaac ggacacactg aaagcatcct ttccgaaagc cactctgtaa tcgtgatgtc 60
          atccgtagaa aacagtaggc acagcagccc aactgggggc ccaagaggac gtcttaatgg 120
          cacaggaggc cctcgtgaat gtaacagctt cctcaggcat gccagagaaa cccctgattc 180
          ctaccgagac tctcctcata gtgaaag 207
           <![CDATA[ <210> 137]]>
           <![CDATA[ <211> 10299]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 137]]>
          gtatgtgtca gccatgacca ccccggctcg tatgtcacct gtagatttcc acacgccaag 60
          ctcccccaaa tcgccccctt cggaaatgtc tccacccgtg tccagcatga cggtgtccat 120
          gccttccatg gcggtcagcc ccttcatgga agaagagaga cctctacttc tcgtgacacc 180
          accaaggctg cgggagaaga agtttgacca tcaccctcag cagttcagct ccttccacca 240
          caaccccgcg catgacagta acagcctccc tgctagcccc ttgaggatag tggaggatga 300
          ggagtatgaa acgacccaag agtacgagcc agcccaagag cctgttaaga aactcgccaa 360
          tagccggcgg gccaaaagaa ccaagcccaa tggccacatt gctaacagat tggaagtgga 420
          cagcaacaca agctccccaga gcagtaactc agagagtgaa acagaagatg aaagagtagg 480
          tgaagatacg cctttcctgg gcatacagaa ccccctggca gccagtcttg aggcaacacc 540
          tgccttccgc ctggctgaca gcaggactaa cccagcaggc cgcttctcga cacaggaaga 600
          aatccaggcc aggctgtcta gtgtaattgc taaccaagac cctattgctg tataaaacct 660
          aaataaacac atagattcac ctgtaaaact ttattattata taataaagta ttccacctta 720
          aattaaacaa tttattttat tttagcagtt ctgcaaatag aaaacaggaa aaaaactttt 780
          ataaattaaa tatatgtatg taaaaatgtg ttatgtgcca tatgtagcaa ttttttacag 840
          tatttcaaaa cgagaaagat atcaatggtg cctttatgtt atgttatgtc gagagcaagt 900
          tttgtacagt tacagtgatt gcttttccac agtatttctg caaaacctct catagattca 960
          gtttttgctg gcttcttgtg cattgcatta tgatgttgac tggatgtatg atttgcaaga 1020
          cttgcaactg tccctctgtt tgcttgtagt agcacccgat cagtatgtct tgtaatggca 1080
          catccatcca gatatgcctc tcttgtgtat gaagttttct ttgctttcag aatatgaaat 1140
          gagttgtgtc tactctgcca gccaaaggtt tgcctcattg ggctctgaga taatagtaga 1200
          tccaacagca tgctactatt aaatacagca agaaactgca ttaagtaatg ttaaatatta 1260
          ggaagaaagt aatactgtga tttaaaaaaa actatattat taatcagaag acagcttgct 1320
          cttactaaaa ggagctctca tttactttat ttgattttat ttttcttgac aaaaagcaac 1380
          agttttaggg atagcttaga aaatgggttc tggcttgcta tcagggtaaa tctaacacct 1440
          tacaagagga ctgagtgtca ctttctctct gggggaatga tccagcagct tatctagttg 1500
          acaatcaaaa cacggctgat aaaggtgcaa tcatttctga catgtatttt tcactgattt 1560
          tgaagctagt gattggttgt gtcttcttgg ctcaaaaaga agcatattac ggcacaaaaa 1620
          gcccagccca gacagcacat gcagcatttt gtctgaaata cttctagagt caaacgtgcc 1680
          tgctgtacat agcgatgact tgtcatcata gggaagtatt tccatcgtag agtgttcaga 1740
          aggagtgact gtataggtgg agagaagctt agtgactccg ttgaaatttt aaaatgtgga 1800
          tgaccacccc tttctccccc ttatttttct tttatctttc catgttgcct tgatcaggtc 1860
          ataactatgc atgaacattt tttatcagga atggccgatg tgtatgtgat ttgtaatcac 1920
          aagtaatgat tcatcaggaa atgtcaatcc tgttggaaag attgcacctt tacttgcaga 1980
          agtgaccccc acctgtgtcc tgacctctcc atttacaggc tctctcaccc atttccccca 2040
          cctcctttaa tttttgcttt actgtcataa agtaggacta agattggtct aagcattgca 2100
          tgttcttttg tgatggtaaa tccaaaggaa ggcctataag tattaacatt tgaaataact 2160
          gctaattcag gaaaatggaa gaaaaaaaat tatttgaaac acagaaccca tttcatggcc 2220
          tgcctgatat ctgtgaaatc agggctggag ctttacttag gattcacatg gcctcctagg 2280
          aaccatggga caaatgggaa acaggttatc gggggattca tgaagtcagt gagagtaatt 2340
          gcttcttttt tgcgggtgaa ctgaatgtat ttcttcacca aatcttgatg ttaacaatta 2400
          aaaagaagaa atgacatgca agtaggtctt agcagaaaaa tgcaggctgg gcatgagtca 2460
          tgttgttacc ctcccacatg ctcctacaat ccacagagat gcctgtctgc aggttcttga 2520
          agttattgtt agtatttggt atctcaaatt tttcgtcact gttcacatgc cactttctct 2580
          gtgcacagtg gtatcctcat ttgcttttta acctacactg aggagtcttt gtcaggttgc 2640
          actgattttc caattctgca gtaatgagta agctcacggc atggggaaga agacagtcag 2700
          tccaatgaag ttctctaaat tattttaaca ttgcctttga aggccttgac tcatccttag 2760
          ctatttcaat gaagaaattc ctaccatgaa tttaaaaccc taaaaattct gtttcaaatt 2820
          ctttgggcat tggggtactc agatatccca ttgtggaaga attttaagaa taaatagaag 2880
          tttctgttga gaaccatgag caacatgttt cttacaatga gaattgctat gcattttaaa 2940
          attgcaaata tatatgaaaa ttgaagacaa gaggaaattg tatttctaac ttgattctga 3000
          tcactcacag aggtggcata ttattatagt tgggacatcc tttgcaccct tcataaaaaa 3060
          ggccagctga ctgctcagca tcacctgcca aggccactag atttgtgttt acaggggtat 3120
          ctctgtgatg cttgtcacat cactcttgac cacctctgtt aataaattcc gacagtgcag 3180
          tggcgatcgg agtgtgaact tatgttccca gcatatggaa agctatctta ggttttaagg 3240
          tagtagaaat tgcccaggag tttgacagca actttgtttc ccgggtctaa aatcgtatcc 3300
          cactgaggtg tatgcagtgg agcataatac atgcaaatac atgcaaaact ccttttgttt 3360
          cacctaagat tcactttcta tcttactttc ccttcctgcc tagtgtgact tttgccccca 3420
          agagtgcctg gacagcattc tagtttctac aaaatggtcc tctgtgtagg tgaatgtgtc 3480
          ccaaacctgc tatcactttc ttgtttcagt gtgactgtct tgttagaggt gaagtttatc 3540
          cagggtaact tgctcactaa ctattccttt ttatggcctg gggttaaagg gcgcatggct 3600
          cacactggtg aaaataagga aggcctggtc ttatcttgta ttaataatac tggctgcatt 3660
          ccaccagcca gagatttcta tctgcgaaga cctatgaaac actgaagaga aatgtaggca 3720
          gaaggaaatg gccacatatc acaagttcta ttatatattc ttttgtaaat acatattgta 3780
          tattacttgg atgttttctt atatcattta ctgtcttttt gagttaatgt cagtttttac 3840
          tctctcaact tactatgtaa cattgtaaat aacataatgt cctttattat ttatatttaa 3900
          gcatctaaca tatagagttg ttttcatata agtttaagat aaatgtcaaa aatatatgtt 3960
          cttttgtttt tctttgcttt aaaattatgt atcttttcct tttctttttt ttaagaataa 4020
          tttattgttc aggagaaaga atgtatatgt aactgaaact atctgaagaa tgcacattga 4080
          aggccgtgag gtactgataa actaaagaat ttattattca aaatactaag caataagtaa 4140
          ttgtgattta tttaaagttt tgtccatttt ccatgaaaga catactgcaa taaaaatgct 4200
          actctgtgga gacctgggag tgttgctcag cagactacag cttcagtctg ttagaccagc 4260
          acctttcatc tcattcccat agttatgcta atttaggatt gtgttccatg gaccccatga 4320
          tcaccttgtc tatacgttgc ttcttgtctg tccattgctt ttgccacacc acctgttctc 4380
          aaatcatctc ctccctacca atgctgttta tcactttctt ccttgttgaa gaggccaacac 4440
          aaccagacag tactatgctt cctttttcct ccatacacaa taacagagag agaatattct 4500
          agggcatgac tgcctggatc ctggctgttg ctatcttttg tagtggcagt aagaaactcc 4560
          ttcagactaa tgaaaatgtc aacgtgccat tcaatcacga aaggtaacga aaaatgctct 4620
          catggttcaa atagtccaat ggcccatagt ggcctaaaag gcagccagtt gacacctggc 4680
          catgctaagc ttccttatac catccgctaa tgactttcca ttgggcccac aatttacgga 4740
          ttcataattt taaaagagga gaaggccaag ttaggttcat tccccttat ctgtcaataa 4800
          aacaaatcaa actcatgtct atctaactgc tcaggggagga gcctttgcat gagaaaattc 4860
          tcatattcta agactgagtc atagaaatga gggtattact tttcttactg caattaacct 4920
          aaacaaaagc catattttaa caaatagata tttgcatggt acccttcata tattccaagc 4980
          atttcactca ttattccagg taggttaaga gcttctgaag tgtatgaagt aaaggtcagc 5040
          aatcctttgg ggtgaacagt ggcctccttt gagtttggg ggtaacctga gacttcccac 5100
          caatgtccac ctccatctgt gtacctaatt cctattacct agttatggct cctctaggat 5160
          catttccaaa cactctggat gtccaggaaa tttaaattgt agcttttgac tgagctagtt 5220
          tttcctattt atattaataa attttcaaaa atgcttgaaa tcttcacatt tgcaacaact 5280
          ttagttttca tgcacataca aacacagaga gacaaaaatt ccaaacagac actctccaaa 5340
          agccaccaca ctctttcact tgctctatag tcatttagcc aaccagccat gcagagaata 5400
          tttaaaactt aaagattgag aattattct cagtttttgc tgaggctttg taacgaaatt 5460
          gaacactata agcagctatt gtagtaattt tggttaaaat tgtttgcctg ggatatagta 5520
          tttgaggcag aagcacgtgt gtgaaggagg tgaggtggtt tggaaagagt gaagactcgc 5580
          agccagattg aatgtctgga taattactat aattctccct tcttggttga aaccatgttc 5640
          tctcttgatt tttaaaccca ggctgcctct ggaaacaagc aaacctgagt ctttctaacc 5700
          tgagtcttcc caatcattag atttcttttc tgtcctaacg atgaatgata aaaggacttg 5760
          atgttcacaa tttggggtta taaggcaggt ctgaaatctg gagactcaag atgctggaag 5820
          gagtggaaag tttcgatgac tttatatgaa tcactttgca ctctatgttt ggcttgtcct 5880
          ctttgaaact gatttactaa aataaatgta agggaactat tactccaaaa gatttaacttg 5940
          gcaggaaata ccaatacttt cagtttatga aagacaaaac tgtcttgttg ctacaggaag 6000
          ctgcaatgtt cctaaccttt aaggttggtg ttgaataggg tggtcatgcc ctcccctgca 6060
          ggtatcttta ggctcctgtt gacctcctgg tactataact gttcgtcttc tctgggtagc 6120
          tattgatttt gaactttaac atgcttcaaa actttatca tcagggaaat aggaaaagag 6180
          ttttgttacc tggaggaaat ctattgtgat ctacctgagc tttttaaaaa cagaccagga 6240
          gaaggaaacc agtaattttt aaagaagaga cagagaatgg gataatagtt tcacccagga 6300
          tctctttcta accctttccc ttcaaatgaa cttattggaa cagaattgga aagaagaaag 6360
          gacatctctg cccaccccac aggatgccaa aaaggctaaa gaattacctc tgtagattta 6420
          aacatcttta atggcttatg tatagatttg ctaatacaga gagaaatgaa ctattaaata 6480
          aaaatcacat tttataatat ttttatggct taaaacatcc tttatctcct ttttgttctc 6540
          tctacatgat atggtaagtg atgaggaaaa ttaggctca ggaaggttaa aatctttctt 6600
          ggagttacac atctaagaga gctgcagagc tgacacttgt accccaggttt tctgactgca 6660
          aatccagttt ctttctattg cgttcttccc ctttccctgc ctcaagcaga aacaggtttt 6720
          ttattttcaa cctttatgta tacagtatgt tatgttacat ctacagctaa gtttcttttt 6780
          agaagaatgt gagcccttct agctttggtt tagagtgatt ctagaagcca atttccttgg 6840
          cttagtgatt ctatgcacct ttcctaaact tagctttcta aggaaatgaa gtgtacgagt 6900
          gagaatgaat tcacaatttc gacatgtagg tagcatccta aagtgaaaag aggaggaaat 6960
          ttgtggtcaa agcactctcc ccaccactta gaaacttact gactgtgggc agcttcctcc 7020
          tccaagtttc cttcctgatt tacaagaccg tggtgtggtc aggattaaac ttgaatacat 7080
          gtaaggaagc ctgaaagtgt ctaacacata gcgagtattc aaatgccacc ttctatttga 7140
          tccttcccct ccagttccctt aagttttgga atctaggttt ctcagttcca aatggattga 7200
          catttgcata tccccattgc acaatggatc aaataaactt tatgttatca tttctccaac 7260
          atagtgccag taagcaaatc ctttttaata acaacagtat gttgagaaac atatcaccaa 7320
          ataatatta actttgtagc tttgataagt tctttaggtt ttggttttgg ttttgttttc 7380
          tgagacagggg tcttgatctg tcacccagac tggagtgcaa tggttcaatt ttagctcact 7440
          gcaacctgta actcctgagc tcaagtgatc ctccccacctc agcctctcaa gtagctggga 7500
          ctacaggtgt gctccaccat gcccagcgat ttttttttttttttttttttttttttttgg 7560
          tagggacaag gtctcgctat gttgcccagg ctggtcttca attcctggcc ttaagtgatc 7620
          ctcctgcctc ggcctcccaa agtgctggaa ttacaggcat gagccaccac ccataacttt 7680
          atgtttgttt ttttgatgca gtataagttc agcttgcttc ttatgcagcc ataccatttc 7740
          atgttaactc tgatttttag cagcttatta cattagtgtt ttattattaa tataatttta 7800
          cagaaattta ctaaaccatg actctgtaga gttttaataa tactacctcc aaacatcatt 7860
          gcaaacatct agaagaatga acaaaaatga tcttagatcg acagtatatc tgtttgtctt 7920
          agtttctaca caggatgttc agacatattc catttcttta aaaaaaaaat atatatatat 7980
          atatatatat ataggcctgg cacggtggct catgactgta atcccagcac tttgggaggc 8040
          ttaggcaggc aaatcacctg aggtcaggag tttgagactg gcctgaccaa catggtgaaa 8100
          cctcgtctct attaaaatta caaaaattag ccgggcgtgg tggcacatgc ctgtaatccc 8160
          agctactcgg gaggctgagg caggagaatc acttgaacct gggaggcaga ggttgcagtg 8220
          agttgagatc acgccattgc actccagcct tggtgacaag agtgaaactc cgtctcaaaa 8280
          aaaaaaaaaa tatgtatata tatatatata tatatatata tatatatata tatatatata 8340
          taaaatccca ccaaaagtct gcagagtgac caaattagac ggctctggtt tcagattaaa 8400
          ttctaaatgt gagaaaccac atagctccca tgatccatcc aataattcct cacgtcctct 8460
          tcactcttta ctccatgcat aaaacagaat ttttttttct catcctgggt atgaagcaat 8520
          taataattta cggatttagc ctatttggat tcaatccctt caaactccat actacatcca 8580
          aggtggaagt gacttaaact ctgatatcaa tcatcaggct tgtaatatag gctttgttaa 8640
          tggcaggaga gtctaataaa actttctgtt ccttatcctt catttaaatg aaaaactttt 8700
          tattgaaaac aatcataact ctagctcatc ataaatataa ttcatgagga cattttatta 8760
          tttttatatt aaagaaataa tattatagat gtaaactttg cacctttcta attattatca 8820
          tgagttaagc taatacttgt cttctggtcc ctagatgatg attctttttt gccttactgg 8880
          aggagccctt gtcttgaagt gagttgcttc aacagcagag gacttctagt ttctcccagt 8940
          tgagcctaaa gtgaactttt catcttcttc agaggaaggg gcttccttga tttgtacttt 9000
          tgtggctcct cagataacac agacaatttt atcttggatc ccaggttctc ttcaccatta 9060
          agaataagaa agagagaaaa tgctgtgcat gacagccacc tactccaaac tacccaaccc 9120
          cctgtaacca ggtaccttcc aacaacgaga tgattctgcc ctcactcaag agtctccccc 9180
          acaaagattc cattctccct ttacttttta ttttttatttttttgcaaaa caaaggcctc 9240
          ctttagtacc tccttagttt ataaccctta tcttcccagc tcttcccttc actgatacct 9300
          ctgatttcaa aagttctgaa gtcggaagac cacacaattt cagactgtga acagaaattc 9360
          agtcagaaat tattggagtt agaaagaatt tagagaaatt gtattgaact agaaagtcct 9420
          ctttgattag tggtggccct ttagaaagtt ctagggcaga gtcccatggt gtttcatctt 9480
          ttccatgatt tgcttgacca aaaacttttc tttcacaaca tgaaaatatg ctaatccacc 9540
          aacacattttg gattctgctc tgtttgcctg aggtgttaga tctctagcca ggactgtgaa 9600
          gggaaggaac ttgaatcctt cctattgagc tattaatgca gagtcagtga gatgaagggt 9660
          tccactcggg gtcaaaatca tgtcagttac caagcaaagg agcaagtaag gggaaacatc 9720
          tcctcatctg gttagtggag ccacatttca cccactgatc aagccagacc tgagcaatag 9780
          tctagatttc tccctccaca tctaattggt gacaatggtg attgtaccac tgacaggtca 9840
          cacaagtcca caccctcctt cacagcctca ctgcttcggc tcttgtttat gctcttatca 9900
          gcatctgtca ctaggatcca tttgtctcct gactcatcta cttcctttca ctcccctggg 9960
          ccatccttca catcatgcta gaagactgtg tctaacttgc agaacttatt gtgtcaatct 10020
          cctggttacg gcccctccat ggctccccac ctgacatagg aggcccttca caatctggct 10080
          tctgtcactc ataacttgtc tccagccttc attcttcagt ctgattttat ggttttctag 10140
          ttccccaata caccacacca gtgtttatga aaccctagtc attggcctac gaactttatg 10200
          attattgaca tattcatgta ccacctgtat tattttttgc atagtgttta tttttaattg 10260
          actacatttt taactacaat aaagtaattt caactaaaa 10299
           <![CDATA[ <210> 138]]>
           <![CDATA[ <211> 11669]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 138]]> agtaagcctc cgcagcccac tcggactgca gcctgtttgc cgcccgtcct cccattgcag 60 cactcggggc gacagagagg gaggaggcgc gcggggacgg ggacgcccag gaggacccac 120 tcgcgggtcc cgctccgctc cggcagcagc atggggaaag gacgcgcggg ccgagttggc 180 accacagcct tgcctccccg attgaaagag atgaaaagcc aggaatcggc tgcaggttcc 240 aaactagtcc ttcggtgtga aaccagttct gaatactcct ctctcagatt caagtggttc 300 aagaatggga atgaattgaa tcgaaaaaac aaaccaaa atatcaagat acaaaaaaag 360 ccagggaagt cagaacttcg cattaacaaa gcatcactgg ctgattctgg agagtatatg 420 tgcaaagtga tcagcaaatt aggaaatgac agtgcctctg ccaatatcac catcgtggaa 480 tcaaacgaga tcatcactgg tatgccagcc tcaactgaag gagcatatgt gtcttcagag 540 t ctcccatta gaatatcagt atccacagaa ggagcaaata cttcttcatc tacatctaca 600 tccaccactg ggacaagcca tcttgtaaaa tgtgcggaga aggagaaaac tttctgtgtg 660 aatggagggg agtgcttcat ggtgaaagac ctttcaaacc cctcgagata cttgtgcaag 720 tgcccaaatg agtttactgg tgatcgctgc caaaactacg taatggccag cttctacaag 780 catcttggga ttgaatttat ggaggcggag gagctgtacc agaagagagt gctgaccata 840 accggcatct gcatcgccct ccttgtggtc ggcatcatgt gtgtggtggc ctactgcaaa 900 accaagaaac agcggaaaaa gctgcatgac cgtcttcggc agagccttcg gtctgaacga 960 aaca atatga tgaacattgc caatgggcct caccatccta accaccccc cgagaatgtc 1020 cagctggtga atcaatacgt atctaaaaac gtcatctcca gtgagcatat tgttgagaga 1080 gaagcagaga catccttttc caccagtcac tatacttcca cagcccatca ctccactact 1 140 gtcacccaga ctcctagcca cagctggagc aacggacaca ctgaaagcat cctttccgaa 1200 agccactctg taatcgtgat gtcatccgta gaaaacagta ggcacagcag cccaactggg 1260 ggcccaagag gacgtcttaa tggcacagga ggccctcgtg aatgtaacag cttcctcagg 1320 catgccagag aaacccctga ttcctaccga gactctcctc atagtgaaag gtatgtgtca 1380 gccatgacca cc ccggctcg tatgtcacct gtagatttcc acacgccaag ctcccccaaa 1440 tcgccccctt cggaaatgtc tccaccgtg tccagcatga cggtgtccat gccttccatg 1500 gcggtcagcc ccttcatgga agaagagaga cctctacttc tcgtgacacc accaaggctg 1560 cgggagaaga agtttgacca tcaccctcag cagttcagct ccttccacca caacccgcg 1620 catgacagta acagcctccc tgctagcccc ttgaggatag tggaggatga ggagtatgaa 1680 acgacccaag agtacgagcc agcccaagag cctgttaaga aactcgccaa tagccggcgg 1740 gccaaaagaa ccaagcccaa tggccacatt gctaacagat tggaagtgga cagcaacaca 1800 agctcccaga gcagtaactc agagagt gaa acagaagatg aaagagtagg tgaagatacg 1860 cctttcctgg gcatacagaa ccccctggca gccagtcttg aggcaacacc tgccttccgc 1920 ctggctgaca gcaggactaa cccagcaggc cgcttctcga cacaggaaga aatccaggcc 1980 aggctgtcta gtgta attgc taaccaagac cctattgctg tataaaacct aaataaacac 2040 atagattcac ctgtaaaact ttaattttata taataaagta ttccacctta aattaaacaa 2100 tttattttat tttagcagtt ctgcaaatag aaaacaggaa aaaaactttt ataaattaaa 2160 tatatgtatg taaaaatgtg ttatgtgcca tatgtagcaa ttttttacag tatttcaaaa 2220 cgagaaagat atcaat ggtg cctttatgtt atgttatgtc gagagcaagt tttgtacagt 2280 tacagtgatt gcttttccac agtatttctg caaaacctct catagattca gtttttgctg 2340 gcttcttgtg cattgcatta tgatgttgac tggatgtatg atttgcaaga ctt gcaactg 2400 tccctctgtt tgcttgtagt agcacccgat cagtatgtct tgtaatggca catccatcca 2460 gatatgcctc tcttgtgtat gaagttttct ttgctttcag aatatgaaat gagttgtgtc 2520 tactctgcca gccaaaaggtt tgcctcattg ggctctgaga taatagtaga tccaacagca 2580 tgctactatt aaatacagca agaaactgca ttaagtaatg ttaaatatta ggaagaaagt 2640 aatactgtga tttaaaaaa actatattat taatcagaag acagcttg ct cttactaaaa 2700 ggagctctca tttactttat ttgattttat ttttcttgac aaaaagcaac agttttaggg 2760 atagcttaga aaatgggttc tggcttgcta tcagggtaaa tctaacacct tacaagagga 2820 ctgagtgtca ctttctctct gggggaatga tccagcagct tatctagttg acaatcaaaa 2880 cacggctgat aaaggtgcaa tcatttctga catgtatttt tcactgattt tgaagctagt 2940 gattggttgt gtcttcttgg ctcaaaaaga agcatattac ggcacaaaaa gcccagccca 3000 gacagcacat gcagcatttt gtctgaaata cttctagagt caaacgtgcc tgctgtacat 3060 agcgatgact tgtcatcata gggaagtatt tccatcgtag agtgtt caga aggagtgact 3120 gtataggtgg agagaagctt agtgactccg ttgaaatttt aaaatgtgga tgaccacccc 3180 tttctccccc ttatttttct tttatctttc catgttgcct tgatcaggtc ataactatgc 3240 atgaacattt tttatcagga atggcc gatg tgtatgtgat ttgtaatcac aagtaatgat 3300 tcatcaggaa atgtcaatcc tgttggaaag attgcacctt tacttgcaga agtgaccccc 3360 acctgtgtcc tgacctctcc atttacaggc tctctcaccc atttccccca cctcctttaa 3420 tttttgcttt actgtcataa agtaggacta agattggtct aagcattgca tgttcttttg 3480 tgatggtaaa tccaaaggaa ggcctataag tattaacatt tgaaataact gctaattcag 3 540 gaaaatggaa gaaaaaaaat tatttgaaac acagaaccca tttcatggcc tgcctgatat 3600 ctgtgaaatc agggctggag ctttacttag gattcacatg gcctcctagg aaccatggga 3660 caaatgggaa acaggttatc gggggattca tgaagtcagt gagagta att gcttcttttt 3720 tgcgggtgaa ctgaatgtat ttcttcacca aatcttgatg ttaacaatta aaaagaagaa 3780 atgacatgca agtaggtctt agcagaaaaa tgcaggctgg gcatgagtca tgttgttacc 3840 ctcccacatg ctcctacaat ccacagagat gcctgtctgc aggttcttga agttattgtt 3900 agtatttggt atctcaaatt tttcgtcact gttcacatgc cactttctct gtgcacagtg 3960 gtatcctcat ttgcttttta acctacactg aggagtcttt gtcaggttgc actgattttc 4020 caattctgca gtaatgagta agctcacggc atggggaaga agacagtcag tccaatgaag 4080 ttctctaaat tattttaaca ttgcctttga aggccttgac tcatccttag ctatttcaat 4140 gaagaaattc ctaccatgaa tttaaaaccc taaaaattct gtttcaaatt ctttgggcat 4200 tggggtactc agatatccca ttgtggaaga attttaagaa taaatagaag tttctgttga 4260 gaaccatgag caacatgttt cttacaatga gaattgctat gcattttaaa attgcaaata 4320 tatatgaaaa ttgaagacaa gaggaaattg tatttctaac ttgattctga tcactcacag 4380 aggtggcata ttat atagt tgggacatcc tttgcaccct tcataaaaaa ggccagctga 4440 ctgctcagca tcacctgcca aggccactag atttgtgttt acagggggtat ctctgtgatg 4500 cttgtcacat cactcttgac cacctctgtt aataaattcc gacagtgcag tggcgatcgg 4 560 agtgtgaact tatgttccca gcatatggaa agctatctta ggttttaagg tagtagaaat 4620 tgcccaggag tttgacagca actttgtttc ccgggtctaa aatcgtatcc cactgaggtg 4680 tatgcagtgg agcataatac atgcaaatac atgcaaaact ccttttgttt cacctaagat 4740 tcactttcta tcttactttc ccttcctgcc tagtgtgact tttgccccca agagtgcctg 4800 gacagcattc tagt ttctac aaaatggtcc tctgtgtagg tgaatgtgtc ccaaacctgc 4860 tatcactttc ttgtttcagt gtgactgtct tgttagaggt gaagtttatc cagggtaact 4920 tgctcactaa ctattccttt ttatggcctg gggttaaagg gcgcatggct cacact ggtg 4980 aaaataagga aggcctggtc ttatcttgta ttaataatac tggctgcatt ccaccagcca 5040 gagatttcta tctgcgaaga cctatgaaac actgaagaga aatgtaggca gaaggaaatg 5100 gccacatatc acaagttcta ttatatattc ttttgtaaat acatattgta tattacttgg 5160 atgttttctt atatcattta ctgtcttttt gagttaatgt cagtttttac tctctcaact 5220 tactatgtaa cattgtaaat aacataatgt c ctttattat ttatatttaa gcatctaaca 5280 tatagagttg ttttcataagat aaatgtcaaa aatatatgtt cttttgtttt 5340 tctttgcttt aaaattatgt atcttttcct tttctttttt ttaagaataa tttatgttc 5400 aggagaaaga atgtatatgt aactgaaact atctgaagaa tgcacattga aggccgtgag 5460 gtactgataa actaaagaat ttattatca aaatactaag caataagtaa ttgtgattaa 5520 tttaaagttt tgtccatttt ccatgaaaga catactgcaa taaaaatgct actctgtgga 5580 gacctgggag tgttgctcag cagactacag cttcagtctg ttagaccagc acctttcatc 5640 tcattcccat agttatgcta atttaggatt gtgttccat g gaccccatga tcaccttgtc 5700 tatacgttgc ttcttgtctg tccattgctt ttgccacacc acctgttctc aaatcatctc 5760 ctccctacca atgctgttta tcactttctt ccttgttgaa gaggccaacac aaccagacag 5820 tactatgctt ccttt ttcct ccatacacaa taacagagag agaatattct agggcatgac 5880 tgcctggatc ctggctgttg ctatcttttg tagtggcagt aagaaactcc ttcagactaa 5940 tgaaaatgtc aacgtgccat tcaatcacga aaggtaacga aaaatgctct catggttcaa 6000 atagtccaat ggcccatagt ggcctaaaag gcagccagtt gacacctggc catgctaagc 6060 ttccttatac catccgctaa tgactttcca ttgggcccac aattta cgga ttcataattt 6120 taaaagagga gaaggccaag ttaggttcat tccccttat ctgtcaataa aacaaatcaa 6180 actcatgtct atctaactgc tcagggagga gcctttgcat gagaaaattc tcatattcta 6240 agactgagtc atagaaatga gggtattact ttt cttactg caattaacct aaacaaaagc 6300 catattttaa caaaagata tttgcatggt acccttcata tattccaagc atttcactca 6360 ttatccagg taggttaaga gcttctgaag tgtatgaagt aaaggtcagc aatcctttgg 6420 ggtgaacagt ggcctccttt gagtttggg ggtaacctga gacttcccac caatgtccac 6480 ctccatctgt gtacctaatt cctattacct agttatggct cctctaggat catttcca aa 6540 cactctggat gtccaggaaa tttaaattgt agcttttgac tgagctagtt tttcctatttt 6600 atattaataa attttcaaaa atgcttgaaa tcttcacatt tgcaacaact ttagttttca 6660 tgcacataca aacacagaga gacaaaaatt ccaaac agac actctccaaa agccaccaca 6720 ctctttcact tgctctatag tcatttagcc aaccagccat gcagagaata tttaaaactt 6780 aaagattgag aattattct cagtttttgc tgaggctttg taacgaaatt gaacactata 6840 agcagctatt gtagtaattt tggttaaaat tgtttgcctg ggatatagta tttgaggcag 6900 aagcacgtgt gtgaaggagg tgaggtggtt tggaaagagt gaagactcgc agccagattg 69 60 aatgtctgga taattactat aattctccct tcttggttga aaccatgttc tctcttgatt 7020 tttaaaccca ggctgcctct ggaaacaagc aaacctgagt ctttctaacc tgagtcttcc 7080 caatcattag atttcttttc tgtcctaacg atgaatgata aaagg acttg atgttcacaa 7140 tttggggtta taaggcaggt ctgaaatctg gagactcaag atgctggaag gagtggaaag 7200 tttcgatgac tttatatgaa tcactttgca ctctatgttt ggcttgtcct ctttgaaact 7260 gatttactaa aataaatgta agggaactat tactccaaaa gattaacttg gcaggaaata 7320 ccaatacttt cagtttatga aagacaaaac tgtcttgttg ctacaggaag ctgcaatgtt 7380 cctaacct tt aaggttggtg ttgaataggg tggtcatgcc ctcccctgca ggtatcttta 7440 ggctcctgtt gacctcctgg tactataact gttcgtcttc tctgggtagc tattgatttt 7500 gaactttaac atgcttcaaa actttattca tcagggaaat aggaaaagag tttt gttacc 7560 tggaggaaat ctattgtgat ctacctgagc tttttaaaaa cagaccagga gaaggaaacc 7620 agtaattttt aaagaagaga cagagaatgg gataatagtt tcacccagga tctctttcta 7680 accctttccc ttcaaatgaa cttattggaa cagaattgga aagaagaaag gacatctctg 7740 cccaccccac aggatgccaa aaaggctaaa gaattacctc tgtagattta aacatcttta 7800 atggcttatg tatagatttg cta atacaga gagaaatgaa cttattaaata aaaatcacat 7860 tttataatat ttttatggct taaaacatcc tttatctcct ttttgttctc tctacatgat 7920 atggtaagtg atgaggaaaa tttaggctca ggaaggttaa aatctttctt ggagttacac 7980 at ctaagaga gctgcagagc tgacacttgt accccaggttt tctgactgca aatccagttt 8040 ctttctattg cgttcttccc ctttccctgc ctcaagcaga aacaggtttt ttattttcaa 8100 cctttatgta tacagtatgt tatgttacat ctacagctaa gtttcttttt agaagaatgt 8160 gagcccttct agctttggtt tagagtgatt ctagaagcca atttccttgg cttagtgatt 8220 ctatgcacct ttcctaaact tagctt tcta aggaaatgaa gtgtacgagt gagaatgaat 8280 tcacaatttc gacatgtagg tagcatccta aagtgaaaag aggaggaaat ttgtggtcaa 8340 agcactctcc ccaccactta gaaacttact gactgtgggc agcttcctcc tccaagtttc 8400 cttcctgatt tacaagaccg tggtgtggtc aggattaaac ttgaatacat gtaaggaagc 8460 ctgaaagtgt ctaacacata gcgagtattc aaatgccacc ttctatttga tccttcccct 8520 ccagttcctt aagttttgga atctaggttt ctcagttcca aatggattga catttgcata 8580 tccccattgc acaatggatc aaataaactt tatgttatca tttctccaac atagtgccag 8640 taagcaaatc ctttttaata acaacagtat gttgaga aac atatcaccaa ataatatta 8700 actttgtagc tttgataagt tctttaggtt ttggttttgg ttttgttttc tgagacaggg 8760 tcttgatctg tcacccagac tggagtgcaa tggttcaatt ttagctcact gcaacctgta 8820 actcctgagc tcaag tgatc ctccccacctc agcctctcaa gtagctggga ctacaggtgt 8880 gctccaccat gcccagcgat ttttttttttttttttttttttttttttgg tagggacaag 8940 gtctcgctat gttgcccagg ctggtcttca attcctggcc ttaagtgatc ctcctgcctc 9000 ggcctcccaa agtgctggaa ttacaggcat gagccaccac ccataacttt atgtttgttt 9060 ttttgatgca gtataagttc agcttgcttc ttatgc agcc ataccatttc atgttaactc 9120 tgatttttag cagcttatta cattagtgtt ttattattaa tataatttta cagaaattta 9180 ctaaaccatg actctgtaga gttttaataa tactacctcc aaacatcatt gcaaacatct 9240 agaagaatga acaaaaatga tcttagatc g acagtatatc tgtttgtctt agtttctaca 9300 caggatgttc agacatattc catttcttta aaaaaaaaat atatatatat atatatatat 9360 ataggcctgg cacggtggct catgactgta atcccagcac tttgggaggc ttaggcaggc 9420 aaatcacctg aggtcaggag tttgagactg gcctgaccaa catggtgaaa cctcgtctct 9480 attaaaatta caaaaattag ccgggcgtgg tggcacatgc ctgtaatccc agctact cgg 9540 gaggctgagg caggagaatc acttgaacct gggaggcaga ggttgcagtg agttgagatc 9600 acgccattgc actccagcct tggtgacaag agtgaaactc cgtctcaaaa aaaaaaaaaa 9660 tatgtatata tatatatata tatatatata tatatata tatatatata taaaatccca 9720 ccaaaagtct gcagagtgac caaattagac ggctctggtt tcagattaaa ttctaaatgt 9780 gagaaaccac atagctccca tgatccatcc aataattcct cacgtcctct tcactcttta 9840 ctccatgcat aaaacagaat ttttttttct catcctgggt atgaagcaat taataattta 9900 cggatttagc ctatttggat tcaatccctt caaactccat actacatcca aggtggaagt 9960 gacttaaact ctgatatcaa tcatcaggct tgtaatatag gctttgttaa tggcaggaga 10020 gtctaataaa actttctgtt ccttatcctt catttaaatg aaaaactttt tattgaaaac 10080 aatcataact ctagctcatc ataaatataa ttcatgagga cattttatta tttttatatt 1 0140 aaagaaataa tattatagat gtaaactttg cacctttcta attattatca tgagttaagc 10200 taatacttgt cttctggtcc ctagatgatg attctttttt gccttactgg aggagccctt 10260 gtcttgaagt gagttgcttc aacagcagag gacttctagt ttctcccagt tgagcctaaa 10320 gtgaactttt catcttcttc agaggaaggg gcttccttga tttgtacttt tgtggctcct 10380 c agataacac agacaatttt atcttggatc ccaggttctc ttcaccatta agaataagaa 10440 agagagaaaa tgctgtgcat gacagccacc tactccaaac tacccaaccc cctgtaacca 10500 ggtaccttcc aacaacgaga tgattctgcc ctcactcaag agtctccccc acaaagatt c 10560 cattctccct ttacttttta ttttttattt ttttgcaaaa caaaggcctc ctttagtacc 10620 tccttagttt ataaccctta tcttcccagc tcttcccttc actgatacct ctgatttcaa 10680 aagttctgaa gtcggaagac cacacaattt cagactgtga acagaaattc agtcagaaat 10740 tattggagtt agaaagaatt tagagaaatt gtattgaact agaaagtcct ctttgattag 10800 tggtggccct ttagaaagtt ct agggcaga gtcccatggt gtttcatctt ttccatgatt 10860 tgcttgacca aaaacttttc tttcacaaca tgaaaatatg ctaatccacc acaattttg 10920 gattctgctc tgtttgcctg aggtgttaga tctctagcca ggactgtgaa gggaaggaac 1098 0 ttgaatcctt cctattgagc tattaatgca gagtcagtga gatgaagggt tccactcggg 11040 gtcaaaatca tgtcagttac caagcaaagg agcaagtaag gggaaacatc tcctcatctg 11100 gttagtggag ccacatttca cccactgatc aagccagacc tgagcaatag tctagatttc 11160 tccctccaca tctaattggt gacaatggtg attgtaccac tgacaggtca cacaagtcca 11220 caccctcctt cacagcctca ctgcttcggc tct tgtttat gctcttatca gcatctgtca 11280 ctaggatcca tttgtctcct gactcatcta cttcctttca ctcccctggg ccatccttca 11340 catcatgcta gaagactgtg tctaacttgc agaacttatt gtgtcaatct cctggttacg 11400 gcccctccat gg ctccccac ctgacatagg aggcccttca caatctggct tctgtcactc 11460 ataacttgtc tccagccttc attcttcagt ctgattttat ggttttctag ttccccaata 11520 caccacacca gtgtttatga aaccctagtc attggcctac gaactttatg attattgaca 11580 tattcatgta ccacctgtat tattttttgc atagtgttta tttttaattg actacatttt 11640 taactacaat aaagtaattt caactaaaa 1166 9 <![CDATA[ <210> 139]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 139]]>
          Met Gly Lys Gly Arg Ala Gly Arg Val Gly Thr Thr
          1 5 10
           <![CDATA[ <210> 140]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 140]]>
          Leu Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly
          1 5 10 15
          Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu
                      20 25 30
          Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys Asn Lys
                  35 40 45
          Pro Gln Asn Ile Lys Ile Gln Lys Lys Pro
              50 55
           <![CDATA[ <210> 141]]>
           <![CDATA[ <211> 40]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 141]]>
          Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala Asp Ser Gly Glu
          1 5 10 15
          Tyr Met Cys Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala
                      20 25 30
          Asn Ile Thr Ile Val Glu Ser Asn
                  35 40
           <![CDATA[ <210> 142]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 142]]>
          Ile Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser
          1 5 10 15
           <![CDATA[ <210> 143]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 143]]>
          Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr Ser Ser
          1 5 10 15
           <![CDATA[ <210> 144]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 144]]>
          Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala Glu
          1 5 10 15
          Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe Met Val Lys
                      20 25 30
          Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys
                  35 40
           <![CDATA[ <210> 145]]>
           <![CDATA[ <211> 19]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 145]]>
          Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala
          1 5 10 15
          Ser Phe Tyr
           <![CDATA[ <210> 146]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 146]]>
          His Leu Gly Ile Glu Phe Met
          1 5
           <![CDATA[ <210> 147]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 147]]>
          Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys
          1 5 10 15
          Ile Ala Leu Leu Val Val Gly Ile Met Cys Val Val Ala Tyr Cys Lys
                      20 25 30
          Thr
           <![CDATA[ <210> 148]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 148]]>
          Lys Gln Arg Lys Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser
          1 5 10 15
          Glu Arg Asn Asn Met Met Asn Ile Ala Asn Gly Pro His His Pro Asn
                      20 25 30
          Pro Pro Pro Glu Asn Val Gln Leu Val Asn
                  35 40
           <![CDATA[ <210> 149]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 149]]>
          Gln Tyr Val Ser Lys Asn Val Ile Ser Ser Glu His Ile Val Glu Arg
          1 5 10 15
          Glu Ala Glu Thr Ser Phe Ser Thr Ser His Tyr Thr Ser Thr Ala His
                      20 25 30
          His Ser Thr Thr Val Thr Gln Thr Pro Ser His
                  35 40
           <![CDATA[ <210> 150]]>
           <![CDATA[ <211> 68]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 150]]>
          Trp Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser His Ser Val
          1 5 10 15
          Ile Val Met Ser Ser Val Glu Asn Ser Arg His Ser Ser Pro Thr Gly
                      20 25 30
          Gly Pro Arg Gly Arg Leu Asn Gly Thr Gly Gly Pro Arg Glu Cys Asn
                  35 40 45
          Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser
              50 55 60
          Pro His Ser Glu
          65
           <![CDATA[ <210> 151]]>
           <![CDATA[ <211> 217]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 151]]>
          Tyr Val Ser Ala Met Thr Thr Pro Ala Arg Met Ser Pro Val Asp Phe
          1 5 10 15
          His Thr Pro Ser Ser Pro Lys Ser Pro Pro Ser Glu Met Ser Pro Pro
                      20 25 30
          Val Ser Ser Met Thr Val Ser Met Pro Ser Met Ala Val Ser Pro Phe
                  35 40 45
          Met Glu Glu Glu Arg Pro Leu Leu Leu Val Thr Pro Pro Arg Leu Arg
              50 55 60
          Glu Lys Lys Phe Asp His His Pro Gln Gln Phe Ser Ser Phe His His
          65 70 75 80
          Asn Pro Ala His Asp Ser Asn Ser Leu Pro Ala Ser Pro Leu Arg Ile
                          85 90 95
          Val Glu Asp Glu Glu Tyr Glu Thr Thr Gln Glu Tyr Glu Pro Ala Gln
                      100 105 110
          Glu Pro Val Lys Lys Leu Ala Asn Ser Arg Arg Ala Lys Arg Thr Lys
                  115 120 125
          Pro Asn Gly His Ile Ala Asn Arg Leu Glu Val Asp Ser Asn Thr Ser
              130 135 140
          Ser Gln Ser Ser Asn Ser Glu Ser Glu Thr Glu Asp Glu Arg Val Gly
          145 150 155 160
          Glu Asp Thr Pro Phe Leu Gly Ile Gln Asn Pro Leu Ala Ala Ser Leu
                          165 170 175
          Glu Ala Thr Pro Ala Phe Arg Leu Ala Asp Ser Arg Thr Asn Pro Ala
                      180 185 190
          Gly Arg Phe Ser Thr Gln Glu Glu Ile Gln Ala Arg Leu Ser Ser Ser Val
                  195 200 205
          Ile Ala Asn Gln Asp Pro Ile Ala Val
              210 215
           <![CDATA[ <210> 152]]>
           <![CDATA[ <211> 624]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 152]]>
          Met Gly Lys Gly Arg Ala Gly Arg Val Gly Thr Thr Ala Leu Pro Pro
          1 5 10 15
          Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu
                      20 25 30
          Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu Arg Phe Lys
                  35 40 45
          Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn
              50 55 60
          Ile Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys
          65 70 75 80
          Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys
                          85 90 95
          Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn
                      100 105 110
          Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser
                  115 120 125
          Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr
              130 135 140
          Ser Ser Ser Thr Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys
          145 150 155 160
          Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe
                          165 170 175
          Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys Lys Cys Pro
                      180 185 190
          Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe
                  195 200 205
          Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu Leu Tyr Gln
              210 215 220
          Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val
          225 230 235 240
          Gly Ile Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys
                          245 250 255
          Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn
                      260 265 270
          Met Met Asn Ile Ala Asn Gly Pro His His Pro Asn Pro Pro Pro Glu
                  275 280 285
          Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Val Ile Ser Ser
              290 295 300
          Glu His Ile Val Glu Arg Glu Ala Glu Thr Ser Phe Ser Thr Ser His
          305 310 315 320
          Tyr Thr Ser Thr Ala His His Ser Thr Thr Val Thr Gln Thr Pro Ser
                          325 330 335
          His Ser Trp Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser His
                      340 345 350
          Ser Val Ile Val Met Ser Ser Ser Val Glu Asn Ser Arg His Ser Ser Pro
                  355 360 365
          Thr Gly Gly Pro Arg Gly Arg Leu Asn Gly Thr Gly Gly Pro Arg Glu
              370 375 380
          Cys Asn Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr Arg
          385 390 395 400
          Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Met Thr Thr Pro Ala
                          405 410 415
          Arg Met Ser Pro Val Asp Phe His Thr Pro Ser Ser Pro Lys Ser Pro
                      420 425 430
          Pro Ser Glu Met Ser Pro Pro Val Ser Ser Met Thr Val Ser Met Pro
                  435 440 445
          Ser Met Ala Val Ser Pro Phe Met Glu Glu Glu Arg Pro Leu Leu Leu
              450 455 460
          Val Thr Pro Pro Arg Leu Arg Glu Lys Lys Phe Asp His His Pro Gln
          465 470 475 480
          Gln Phe Ser Ser Phe His His Asn Pro Ala His Asp Ser Asn Ser Leu
                          485 490 495
          Pro Ala Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr
                      500 505 510
          Gln Glu Tyr Glu Pro Ala Gln Glu Pro Val Lys Lys Leu Ala Asn Ser
                  515 520 525
          Arg Arg Ala Lys Arg Thr Lys Pro Asn Gly His Ile Ala Asn Arg Leu
              530 535 540
          Glu Val Asp Ser Asn Thr Ser Ser Gln Ser Ser Asn Ser Glu Ser Glu
          545 550 555 560
          Thr Glu Asp Glu Arg Val Gly Glu Asp Thr Pro Phe Leu Gly Ile Gln
                          565 570 575
          Asn Pro Leu Ala Ala Ser Leu Glu Ala Thr Pro Ala Phe Arg Leu Ala
                      580 585 590
          Asp Ser Arg Thr Asn Pro Ala Gly Arg Phe Ser Thr Gln Glu Glu Ile
                  595 600 605
          Gln Ala Arg Leu Ser Ser Val Ile Ala Asn Gln Asp Pro Ile Ala Val
              610 615 620
           <![CDATA[ <210> 153]]>
           <![CDATA[ <211> 11482]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 153]]> ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60 tccttcggtg tgaaaccagt tctgaatact cctctctcag attcaagtgg ttcaagaatg 120 ggaatgaatt gaatcgaaaa aacaaaccac aaaat atcaa gatacaaaaa aagccaggga 180 agtcagaact tcgcattaac aaagcatcac tggctgattc tggagagtat atgtgcaaag 240 tgatcagcaa attaggaaat gacagtgcct ctgccaatat caccatcgtg gaatcaaacg 300 agatcatcac tggtatgcca gcct caactg aaggagcata tgtgtcttca gagtctccca 360 ttagaatatc agtatccaca gaaggagcaa atacttcttc atctacatct acatccacca 420 ctgggacaag ccatcttgta aaatgtgcgg agaaggagaa aactttctgt gtgaatggag 480 gggagtgctt catggtgaaa gacctttcaa accctcgag atacttgtgc aagtgcccaa 540 atgagtttac tggtgatcgc tgccaaaact acgtaatggc cagcttctac aagcatcttg 600 ggattgaatt tatggaggcg gaggagctgt accagaagag agtgctgacc ataaccggca 660 tctgcatcgc cctccttgtg gtcggcatca tgtgtgtggt ggcctactgc aaaaccaaga 720 aacagcggaa aaagctgcat gaccgtcttc ggcagagcct tcggtctgaa cgaaacaata 780 tgatgaacat tgccaatggg cctcaccatc ctaacccacc ccccgagaat gtccagctgg 840 tgaatcaata cgtatctaaa aacgtcatct ccagtgagca tattgttgag agagaagcag 900 agacatcctt ttccaccagt cactatactt ccacagccca tcactccact actgtcaccc 960 agactcctag ccacagct gg agcaacggac acactgaaag catcctttcc gaaagccact 1020 ctgtaatcgt gatgtcatcc gtagaaaaca gtaggcacag cagcccaact gggggcccaa 1080 gaggacgtct taatggcaca ggaggccctc gtgaatgtaa cagcttcctc aggcatgcca 1140 gagaaac ccc tgattcctac cgagactctc ctcatagtga aaggtatgtg tcagccatga 1200 ccaccccggc tcgtatgtca cctgtagatt tccaacacgcc aagctccccc aaatcgcccc 1260 cttcggaaat gtctccaccc gtgtccagca tgacggtgtc catgccttcc atggcggtca 1320 gccccttcat ggaagaagag agacctctac ttctcgtgac accaccaagg ctgcggggaga 1380 agaagttt ga ccatcaccct cagcagttca gctccttcca ccacaacccc gcgcatgaca 1440 gtaacagcct ccctgctagc cccttgagga tagtggagga tgaggagtat gaaacgaccc 1500 aagagtacga gccagcccaa gagcctgtta agaaactcgc caatagccgg cgggccaaaa 1 560 gaaccaagcc caatggccac attgctaaca gattggaagt ggacagcaac acaagctccc 1620 agagcagtaa ctcagagagt gaaacagaag atgaaagagt aggtgaagat acgcctttcc 1680 tgggcataca gaaccccctg gcagccagtc ttgaggcaac acctgccttc cgcctggctg 1740 acagcaggac taacccagca ggccgcttct cgacacagga agaaatccag gccaggctgt 1800 ctagtgtaat tgctaaccaa gaccctattg ctgtataaaa cctaaataaa cacatagatt 1860 cacctgtaaa actttatttt atataataaa gtattccacc ttaaattaaa caatttattt 1920 tattttagca gttctgcaaa tagaaaacag gaaaaaaact tttataaatt aaatatatgt 1980 atgtaaaaat gtgttatgtg ccatatgtag caatttttta cagtatttca aaacgagaaa 2040 gatatcaatg gtgcctttat gttatgttat gtcgagagca agttttgtac agttacagtg 2100 attgcttttc cacagtattt ctgcaaaacc tctcatagat tcagtttttg ctggcttctt 2160 gtgcattgca ttatgatgtt gactggatgt atgatttgca agacttgcaa ctgtccctct 2220 gtttgcttgt agtagc accc gatcagtatg tcttgtaatg gcacatccat ccagatatgc 2280 ctctcttgtg tatgaagttt tctttgcttt cagaatatga aatgagttgt gtctactctg 2340 ccagccaaag gtttgcctca ttgggctctg agataatagt agatccaaca gcatgctact 2 400 attaaataca gcaagaaact gcattaagta atgttaaata ttaggaagaa agtaatactg 2460 tgatttaaaa aaaactatat tattaatcag aagacagctt gctcttacta aaaggagctc 2520 tcatttactt tatttgattt tatttttctt gacaaaaagc aacagtttta gggatagctt 2580 agaaaatggg ttctggcttg ctatcagggt aaatctaaca ccttacaaga ggactgagtg 2640 tcactttctc tctgggggaa tgatccagca gcttatctag t tgacaatca aaacacggct 2700 gataaaggtg caatcatttc tgacatgtat ttttcactga ttttgaagct agtgattggt 2760 tgtgtcttct tggctcaaaa agaagcatat tacggcacaa aaagcccagc ccagacagca 2820 catgcagcat tttgtctgaa atact tctag agtcaaacgt gcctgctgta catagcgatg 2880 acttgtcatc atagggaagt atttccatcg tagagtgttc agaaggagtg actgtatagg 2940 tggagagaag cttagtgact ccgttgaaat tttaaaatgt ggatgaccac ccctttctcc 3000 cccttatttt tcttttatct ttccatgttg ccttgatcag gtcataacta tgcatgaaca 3060 ttttttca ggaatggccg atgtgtatgt gatttgtaat cacaagtaat gattcatcag 3120 gaaatgtcaa tcctgttgga aagattgcac ctttacttgc agaagtgacc cccacctgtg 3180 tcctgacctc tccattaca ggctctctca cccatttccc ccacctcctt taatttttgc 3240 tttactgtca taaagtagga c taagattgg tctaagcatt gcatgttctt ttgtgatggt 3300 aaatccaaag gaaggcctat aagtattaac atttgaaata actgctaatt caggaaaatg 3360 gaagaaaaaa aattatttga aacacagaac ccatttcatg gcctgcctga tatctgtgaa 3420 atcagggctg gagctttact taggattcac atggcctcct aggaaccatg ggacaaatgg 3480 gaaacaggtt atcgggggat tcatgaagtc agtgagagta attgcttctt ttttgcggg t 3540 gaactgaatg tatttcttca ccaaatcttg atgttaacaa ttaaaaagaa gaaatgacat 3600 gcaagtaggt cttagcagaa aaatgcaggc tgggcatgag tcatgttgtt accctcccac 3660 atgctcctac aatccacaga gatgcctgtc tgcaggt tct tgaagttat gttagtattt 3720 ggtatctcaa atttttcgtc actgttcaca tgccactttc tctgtgcaca gtggtatcct 3780 catttgcttt ttaacctaca ctgaggagtc tttgtcaggt tgcactgatt ttccaattct 3840 gcagtaatga gtaagctcac ggcatgggga agaagacagt cagtccaatg aagttctcta 3900 aattatttta aattgcctt tgaaggcctt gactcatcct tagctatttc aatgaagaaa 3960 ttcctac cat gaatttaaaa ccctaaaaat tctgtttcaa attctttggg cattggggta 4020 ctcagattc ccattgtgga agaattttaa gaataaatag aagtttctgt tgagaaccat 4080 gagcaacatg tttcttacaa tgagaattgc tatgcatttt aaaattgcaa atatatatga 4140 aaattgaaga caagaggaaa ttgtatttct aacttgattc tgatcactca cagaggtggc 4200 atattattat agttgggaca tcctttgcac ccttcataaa aaaggccagc tgactgctca 4260 gcatcacctg ccaaggccac tagatttgtg tttacagggg tatctctgtg atgcttgtca 4320 catcactctt gaccacctct gttaataaat tccgacagtg cagtggcgat cggagtgtga 4380 acttatgttc ccagcatatg gaaagctatc ttaggtttta aggtagtaga aattgcccag 4440 gagtttgaca gcaactttgt ttcccgggtc taaaatcgta tcccactgag gtgtatgcag 4500 tggagcataa tacatgcaaa tacatgcaaa actccttttg tttcacctaa gatt cacttt 4560 ctatcttact ttcccttcct gcctagtgtg acttttgccc ccaagagtgc ctggacagca 4620 ttctagtttc tacaaaatgg tcctctgtgt aggtgaatgt gtcccaaacc tgctatcact 4680 ttcttgtttc agtgtgactg tcttgttaga ggtgaagttt atccagggta acttgctcac 4740 taactattcc tttttatggc ctggggttaa agggcgcatg gctcacactg gtgaaaataa 4800 ggaaggcctg gt cttatctt gtattaataa tactggctgc attccaccag ccagagattt 4860 ctatctgcga agacctatga aacactgaag agaaatgtag gcagaaggaa atggccacat 4920 atcacaagtt ctattatata ttcttttgta aatacatatt gtatattact tggatgtttt 4980 cttatat cat ttactgtctt tttgagttaa tgtcagtttt tactctctca acttactatg 5040 taacattgta aataacataa tgtcctttat tattatatt taagcatcta acatatagag 5100 ttgttttcat ataagtttaa gataaatgtc aaaaatatat gttcttttgt ttttctttgc 5160 tttaaaatta tgtatctttt ccttttcttt tttttaagaa taatttattg ttcaggagaa 5220 agaatgtata tgtaactga a actatctgaa gaatgcacat tgaaggccgt gaggtactga 5280 taaactaaag aatttattat tcaaaatact aagcaataag taattgtgat ttattaaag 5340 ttttgtccat tttccatgaa agacatactg caataaaaat gctactctgt ggagacctgg 5400 gagtgttg ct cagcagacta cagcttcagt ctgttagacc agcacctttc atctcattcc 5460 catagttatg ctaatttagg attgtgttcc atggaccccca tgatcacctt gtctatacgt 5520 tgcttcttgt ctgtccattg cttttgccac accacctgtt ctcaaatcat ctcctcccta 5580 ccaatgctgt ttatcacttt cttccttgtt gaagaggcca cacaaccaga cagtactatg 5640 cttccttttt cctccataca caataacaga ga gagaatat tctagggcat gactgcctgg 5700 atcctggctg ttgctatctt ttgtagtggc agtaagaaac tccttcagac taatgaaaat 5760 gtcaacgtgc cattcaatca cgaaaggtaa cgaaaaatgc tctcatggtt caaatagtcc 5820 aatggcccat agtgg cctaa aaggcagcca gttgacacct ggccatgcta agcttcctta 5880 taccatccgc taatgacttt ccattgggcc cacaatttac ggattcataa ttttaaaaga 5940 ggagaaggcc aagttaggtt cattcccctt attctgtcaa taaaacaaat caaactcatg 6000 tctatctaac tgctcaggga ggagcctttg catgagaaaa ttctcatatt ctaagactga 6060 gtcatagaaa tgagggtatt acttttctta ctgcaattaa ctaaacaaa agccatattt 6120 taacaaatag atatttgcat ggtacccttc atatattcca agcatttcac tcattattcc 6180 aggtaggtta agagcttctg aagtgtatga agtaaaggtc agcaatcctt tggggtgaac 6240 agtggcctcc tttggagttt gggggtaacc tg agacttcc caccaatgtc cacctccatc 6300 tgtgtaccta attcctatta cctagttatg gctcctctag gatcattcc aaacactctg 6360 gatgtccagg aaatttaaat tgtagctttt gactgagcta gtttttccta tttatattaa 6420 taaattttca aaaatgcttg aaatcttcac atttgcaaca actttagttt tcatgcacat 6480 acaaacacag agagacaaaa attccaaaca gacactctcc aaaagccacc acact ctttc 6540 acttgctcta tagtcattta gccaaccagc catgcagaga atatttaaaa cttaaagatt 6600 gagacattat tctcagtttt tgctgaggct ttgtaacgaa attgaacact ataagcagct 6660 attgtagtaa ttttggttaa aattgtttgc ctgggat ata gtatttgagg cagaagcacg 6720 tgtgtgaagg aggtgaggtg gtttggaaag agtgaagact cgcagccaga ttgaatgtct 6780 ggataattac tataattctc ccttcttggt tgaaaccatg ttctctcttg atttttaaac 6840 ccaggctgcc tctggaaaca agcaaacctg agtctttcta acctgagtct tcccaatcat 6900 tagatttctt ttctgtccta acgatgaatg ataaaaggac ttgatgttca caatttgggg 696 0 ttataaggca ggtctgaaat ctggagactc aagatgctgg aaggagtgga aagtttcgat 7020 gactttatat gaatcacttt gcactctatg tttggcttgt cctctttgaa actgatttac 7080 taaaataaat gtaagggaac tattactcca aaagattaac ttggcaggaa ataccaatac 7140 tttcagttta tgaaagacaa aactgtcttg ttgctacagg aagctgcaat gttcctaacc 7200 tttaaggttg gtgttgaata gggtggtcat gccctcccct gcaggtatct ttaggctcct 7260 gttgacctcc tggtactata actgttcgtc ttctctgggt agctattgat tttgaacttt 7320 aacatgcttc aaaactttat tcatcaggga aataggaaaa gagttttgtt acctggagga 7380 aatctattgt g atctacctg agctttttaa aaacagacca ggagaaggaa accagtaatt 7440 tttaaagaag agacagagaa tgggataata gtttcaccca ggatctcttt ctaacccttt 7500 cccttcaaat gaacttattg gaacagaatt ggaaagaaga aaggacatct ctgcccaccc 7560 cacaggatgc caaaaaggct aaagaattac ctctgtagat ttaaacatct ttaatggctt 7620 atgtatagat ttgctaatac agagagaaat gaactattaa ataaaaatca cattttaggc tcaggaaggt taaaatcttt cttggagtta cacatctaag 7800 agagctgcag agctg acact tgtacccagg ttttctgact gcaaatccag tttctttcta 7860 ttgcgttctt cccctttccc tgcctcaagc agaaacaggt tttttttt caacctttat 7920 gtatacagta tgttatgtta catctacagc taagtttctt tttagaagaa tgtg agccct 7980 tctagctttg gtttagagtg attctagaag ccaatttcct tggcttagtg attctatgca 8040 cctttcctaa acttagcttt ctaaggaaat gaagtgtacg agtgagaatg aattcacaat 8100 ttcgacatgt aggtagcatc ctaaagtgaa aagaggagga aatttgtggt caaagcactc 8160 tccccaccac ttagaaactt actgactgtg ggcagcttcc tcctccaagt ttccttcctg 8220 atttacaaga ccgtggtgtg gtcaggatta aacttgaata catgtaagga agcctgaaag 8280 tgtctaacac atagcgagta ttcaaatgcc accttctatt tgatccttcc cctccagttc 8340 cttaagtttt ggaatctagg tttctcagtt ccaaatggat tgacatttgc atatccccat 8400 tgcacaatgg at caaataaa ctttatgtta tcatttctcc aacatagtgc cagtaagcaa 8460 atccttttta ataacaacag tatgttgaga aacatatcac caaataatat ttaactttgt 8520 agctttgata agttctttag gttttggttt tggttttgtt ttctgagaca gggtcttgat 8580 ctgtcaccca gactggagtg caatggttca attttagctc actgcaacct gtaactcctg 8640 agctcaagtg atcctcccac ctcagcctct caagtagctg ggactacagg tgtgctccac 8700 catgcccagc gatttttttttttttttttttttttttttttggtagggac aaggtctcgc 8760 tatgttgccc aggctggtct tcaattcctg gccttaagtg atcctcctgc ctcggcctcc 88 20 caaagtgctg gaattacagg catgagccac cacccataac tttatgtttg tttttttgat 8880 gcagtataag ttcagcttgc ttcttatgca gccataccat ttcatgttaa ctctgatttt 8940 tagcagctta ttacattagt gttttattat taatataatt ttacagaaat ttactaaacc 9000 atgactctgt agagttttaa taatactacc tccaaacatc attgcaaaca tctagaagaa 9060 tgaacaaaaa tgatcttaga tcgacagtat atctgtttgt ctta gtttct acacaggatg 9120 ttcagacata ttccatttct ttaaaaaaaa aatatatata tatatata tatataggcc 9180 tggcacggtg gctcatgact gtaatcccag cactttggga ggcttaggca ggcaaatcac 9240 ctgaggtcag gagtttgaga ctggcctgac ca acatggtg aaacctcgtc tctattaaaa 9300 ttacaaaaat tagccgggcg tggtggcaca tgcctgtaat cccagctact cgggaggctg 9360 aggcaggaga atcacttgaa cctgggaggc agaggttgca gtgagttgag atcacgccat 9420 tgcactccag ccttggtgac aagagtgaaa ctccgtctca aaaaaaaaaa aaatatgtat 9480 atatatatat atatatatat atatatatat atatatatat atataaaatc ccaccaaaag 9540 tctgcagagt gaccaaatta gacggctctg gtttcagatt aaattctaaa tgtgagaaac 9600 cacatagctc ccatgatcca tccaataatt cctcacgtcc tcttcactct ttactccatg 9660 cataaaacag aatttttttttctcatcctg ggtatgaag c aattaataat ttacggattt 9720 agcctatttg gattcaatcc cttcaaactc catactacat ccaaggtgga agtgacttaa 9780 actctgatat caatcatcag gcttgtaata taggctttgt taatggcagg agagtctaat 9840 aaaactttct gttccttatc cttcatttaa atgaaaaact ttttattgaa aacaatcata 9900 actctagctc atcataaata taattcatga ggacatttta ttatttttat attaaagaaa 9960 taatattata gatgtaaact ttgcaccttt ctaattatta tcatgagtta agctaatact 10020 tgtcttctgg tccctagatg atgattcttt tttgccttac tggaggagcc cttgtcttga 10080 agtgagttgc ttcaacagca gaggacttct agtttctccc agtt gagcct aaagtgaact 10140 tttcatcttc ttcagaggaa ggggcttcct tgatttgtac ttttgtggct cctcagataa 10200 cacagacaat tttatcttgg atcccaggtt ctcttcacca ttaagaataa gaaagagaga 10260 aaatgctgtg catgacagcc acctactcca aactacccaa ccccctgtaa ccaggtacct 10320 tccaacaacg agatgattct gccctcactc aagagtctcc cccacaaaga ttccattctc 10380 cctttacttt ttatttttta tttttttgca aaacaaaggc ctcctttagt acctccttag 10440 tttataaccc ttatcttccc agctcttccc ttcactgata cctctgattt caaaagttct 10500 gaagtcggaa gaccacacaa tttcagactg tgaacagaaa ttcag tcaga aattattgga 10560 gttagaaaga atttagagaa attgtattga actagaaagt cctctttgat tagtggtggc 10620 cctttagaaa gttctagggc agagtcccat ggtgtttcat cttttccatg atttgcttga 10680 ccaaaaactt ttctttcaca acatgaaaat atgctaatcc accacacatt ttggattctg 10740 ctctgtttgc ctgaggtgtt agatctctag ccaggactgt gaagggaagg aacttgaatc 10800 cttcctattg ag ctattaat gcagagtcag tgagatgaag ggttccactc ggggtcaaaa 10860 tcatgtcagt taccaagcaa aggagcaagt aaggggaaac atctcctcat ctggttagtg 10920 gagccacatt tcacccactg atcaagccag acctgagcaa tagtctagat ttctccctcc 109 80 acatctaatt ggtgacaatg gtgattgtac cactgacagg tcacacaagt ccacaccctc 11040 cttcacagcc tcactgcttc ggctcttgtt tatgctctta tcagcatctg tcactaggat 11100 ccatttgtct cctgactcat ctacttccctt tcactcccct gggccatcct tcacatcatg 11160 ctagaagact gtgtctaact tgcagaactt attgtgtcaa tctcctggtt acggcccctc 11220 catggctccc cacctgacat aggaggccct tcacaatct g gcttctgtca ctcataactt 11280 gtctccagcc ttcattcttc agtctgattt tatggttttc tagttcccca atacaccaca 11340 ccagtgttta tgaaacccta gtcattggcc tacgaacttt atgattattg acatattcat 11400 gtaccacctg tattattttt tg catagtgt ttatttttaa ttgactacat ttttaactac 11460 aataaagtaa tttcaactaa aa 11482 <![CDATA[ <210> 154]]>
           <![CDATA[ <211> 611]]>
           <![CDATA[ <212>]]> PRT
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 154]]>
          Leu Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly
          1 5 10 15
          Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu
                      20 25 30
          Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys Asn Lys
                  35 40 45
          Pro Gln Asn Ile Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg
              50 55 60
          Ile Asn Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val
          65 70 75 80
          Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val
                          85 90 95
          Glu Ser Asn Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala
                      100 105 110
          Tyr Val Ser Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly
                  115 120 125
          Ala Asn Thr Ser Ser Ser Thr Ser Thr Ser Thr Thr Thr Gly Thr Ser His
              130 135 140
          Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly
          145 150 155 160
          Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys
                          165 170 175
          Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met
                      180 185 190
          Ala Ser Phe Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu
                  195 200 205
          Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu
              210 215 220
          Leu Val Val Gly Ile Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys
          225 230 235 240
          Gln Arg Lys Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu
                          245 250 255
          Arg Asn Asn Met Met Asn Ile Ala Asn Gly Pro His His Pro Asn Pro
                      260 265 270
          Pro Pro Glu Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Val
                  275 280 285
          Ile Ser Ser Glu His Ile Val Glu Arg Glu Ala Glu Thr Ser Phe Ser
              290 295 300
          Thr Ser His Tyr Thr Ser Thr Ala His His Ser Thr Thr Val Thr Gln
          305 310 315 320
          Thr Pro Ser His Ser Trp Ser Asn Gly His Thr Glu Ser Ile Leu Ser
                          325 330 335
          Glu Ser His Ser Val Ile Val Met Ser Ser Val Glu Asn Ser Arg His
                      340 345 350
          Ser Ser Pro Thr Gly Gly Pro Arg Gly Arg Leu Asn Gly Thr Gly Gly
                  355 360 365
          Pro Arg Glu Cys Asn Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp
              370 375 380
          Ser Tyr Arg Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Met Thr
          385 390 395 400
          Thr Pro Ala Arg Met Ser Pro Val Asp Phe His Thr Pro Ser Ser Ser Pro
                          405 410 415
          Lys Ser Pro Pro Ser Glu Met Ser Pro Pro Val Ser Ser Met Thr Val
                      420 425 430
          Ser Met Pro Ser Met Ala Val Ser Pro Phe Met Glu Glu Glu Arg Pro
                  435 440 445
          Leu Leu Leu Val Thr Pro Pro Arg Leu Arg Glu Lys Lys Phe Asp His
              450 455 460
          His Pro Gln Gln Phe Ser Ser Ser Phe His His Asn Pro Ala His Asp Ser
          465 470 475 480
          Asn Ser Leu Pro Ala Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr
                          485 490 495
          Glu Thr Thr Gln Glu Tyr Glu Pro Ala Gln Glu Pro Val Lys Lys Leu
                      500 505 510
          Ala Asn Ser Arg Arg Ala Lys Arg Thr Lys Pro Asn Gly His Ile Ala
                  515 520 525
          Asn Arg Leu Glu Val Asp Ser Asn Thr Ser Ser Gln Ser Ser Asn Ser
              530 535 540
          Glu Ser Glu Thr Glu Asp Glu Arg Val Gly Glu Asp Thr Pro Phe Leu
          545 550 555 560
          Gly Ile Gln Asn Pro Leu Ala Ala Ser Leu Glu Ala Thr Pro Ala Phe
                          565 570 575
          Arg Leu Ala Asp Ser Arg Thr Asn Pro Ala Gly Arg Phe Ser Thr Gln
                      580 585 590
          Glu Glu Ile Gln Ala Arg Leu Ser Ser Val Ile Ala Asn Gln Asp Pro
                  595 600 605
          Ile Ala Val
              610
           <![CDATA[ <210> 155]]>
           <![CDATA[ <211> 11080]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 155]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgt gaatggaggg gagtgcttca tggtgaaaga cctttcaaac ccctcgagat 120
          acttgtgcaa gtgcccaaat gagtttactg gtgatcgctg ccaaaactac gtaatggcca 180
          gcttctacaa gcatcttggg attgaattta tggaggcgga ggagctgtac cagaagagag 240
          tgctgaccat aaccggcatc tgcatcgccc tccttgtggt cggcatcatg tgtgtggtgg 300
          cctactgcaa aaccaagaaa cagcggaaaa agctgcatga ccgtcttcgg cagagccttc 360
          ggtctgaacg aaacaatatg atgaacattg ccaatgggcc tcaccatcct aacccacccc 420
          ccgagaatgt ccagctggtg aatcaatacg tatctaaaaa cgtcatctcc agtgagcata 480
          ttgttgagag agaagcagag acatcctttt ccaccagtca ctatacttcc acagcccatc 540
          actccactac tgtcacccag actcctagcc acagctggag caacggacac actgaaagca 600
          tcctttccga aagccactct gtaatcgtga tgtcatccgt agaaaacagt aggcacagca 660
          gcccaactgg gggcccaaga ggacgtctta atggcacagg aggccctcgt gaatgtaaca 720
          gcttcctcag gcatgccaga gaaacccctg attcctaccg agactctcct catagtgaaa 780
          ggtatgtgtc agccatgacc accccggctc gtatgtcacc tgtagatttc cacacgccaa 840
          gctcccccaa atcgccccct tcggaaatgt ctccacccgt gtccagcatg acggtgtcca 900
          tgccttccat ggcggtcagc cccttcatgg aagaagagag acctctactt ctcgtgacac 960
          caccaaggct gcgggagaag aagtttgacc atcaccctca gcagttcagc tccttccacc 1020
          acaaccccgc gcatgacagt aacagcctcc ctgctagccc cttgaggata gtggaggatg 1080
          aggagtatga aacgacccaa gagtacgagc cagcccaaga gcctgttaag aaactcgcca 1140
          atagccggcg ggccaaaaga accaagccca atggccacat tgctaacaga ttggaagtgg 1200
          acagcaacac aagctccccag agcagtaact cagagagtga aacagaagat gaaagagtag 1260
          gtgaagatac gcctttcctg ggcatacaga accccctggc agccagtctt gaggcaacac 1320
          ctgccttccg cctggctgac agcaggacta acccagcagg ccgcttctcg acacaggaag 1380
          aaatccaggc caggctgtct agtgtaattg ctaaccaaga ccctattgct gtataaaacc 1440
          taaataaaca catagattca cctgtaaaac tttattttat ataataaagt attccacctt 1500
          aaattaaaca atttatttta ttttagcagt tctgcaaata gaaaacagga aaaaaacttt 1560
          tataaattaa atatatgtat gtaaaaatgt gttatgtgcc atatgtagca attttttaca 1620
          gtatttcaaa acgagaaaga tatcaatggt gcctttatgt tatgttatgt cgagagcaag 1680
          ttttgtacag ttacagtgat tgcttttcca cagtatttct gcaaaacctc tcatagattc 1740
          agtttttgct ggcttcttgt gcattgcatt atgatgttga ctggatgtat gatttgcaag 1800
          acttgcaact gtccctctgt ttgcttgtag tagcacccga tcagtatgtc ttgtaatggc 1860
          acatccatcc agatatgcct ctcttgtgta tgaagttttc tttgctttca gaatatgaaa 1920
          tgagttgtgt ctactctgcc agccaaaggt ttgcctcatt gggctctgag ataatagtag 1980
          atccaacagc atgctactat taaatacagc aagaaactgc attaagtaat gttaaatatt 2040
          aggaagaaag taatactgtg atttaaaaaa aactatatta ttaatcagaa gacagcttgc 2100
          tcttactaaa aggagctctc atttacttta tttgatttta tttttcttga caaaaagcaa 2160
          cagttttagg gatagcttag aaaatgggtt ctggcttgct atcagggtaa atctaacacc 2220
          ttacaagagg actgagtgtc actttctctc tgggggaatg atccagcagc ttatctagtt 2280
          gacaatcaaa acacggctga taaaggtgca atcatttctg acatgtattt ttcactgatt 2340
          ttgaagctag tgattggttg tgtcttcttg gctcaaaaag aagcatatta cggcacaaaa 2400
          agcccagccc agacagcaca tgcagcattt tgtctgaaat acttctagag tcaaacgtgc 2460
          ctgctgtaca tagcgatgac ttgtcatcat agggaagtat ttccatcgta gagtgttcag 2520
          aaggagtgac tgtataggtg gagagaagct tagtgactcc gttgaaattt taaaatgtgg 2580
          atgaccaccc ctttctcccc cttatttttc ttttatcttt ccatgttgcc ttgatcaggt 2640
          cataactatg catgaacatt ttttatcagg aatggccgat gtgtatgtga tttgtaatca 2700
          caagtaatga ttcatcagga aatgtcaatc ctgttggaaa gattgcacct ttacttgcag 2760
          aagtgacccc cacctgtgtc ctgacctctc catttacagg ctctctcacc catttccccc 2820
          acctccttta atttttgctt tactgtcata aagtaggact aagattggtc taagcattgc 2880
          atgttctttt gtgatggtaa atccaaagga aggcctataa gtattaacat ttgaaataac 2940
          tgctaattca ggaaaatgga agaaaaaaaa ttatttgaaa cacagaaccc atttcatggc 3000
          ctgcctgata tctgtgaaat cagggctgga gctttactta ggattcacat ggcctcctag 3060
          gaaccatggg acaaatggga aacaggttat cggggattc atgaagtcag tgagagtaat 3120
          tgcttctttt ttgcgggtga actgaatgta tttcttcacc aaatcttgat gttaacaatt 3180
          aaaaagaaga aatgacatgc aagtaggtct tagcagaaaa atgcaggctg ggcatgagtc 3240
          atgttgttac cctcccacat gctcctacaa tccacagaga tgcctgtctg caggttcttg 3300
          aagttatgt tagtatttgg tatctcaaat ttttcgtcac tgttcacatg ccactttctc 3360
          tgtgcacagt ggtatcctca tttgcttttt aacctacact gaggagtctt tgtcaggttg 3420
          cactgatttt ccaattctgc agtaatgagt aagctcacgg catggggaag aagacagtca 3480
          gtccaatgaa gttctctaaa ttattttaac attgcctttg aaggccttga ctcatcctta 3540
          gctatttcaa tgaagaaatt cctaccatga atttaaaacc ctaaaaattc tgtttcaaat 3600
          tctttgggca ttggggtact cagatatccc attgtggaag aattttaaga ataaatagaa 3660
          gtttctgttg agaaccatga gcaacatgtt tcttacaatg agaattgcta tgcattttaa 3720
          aattgcaaat atatatgaaa attgaagaca agaggaaatt gtatttctaa cttgattctg 3780
          atcactcaca gaggtggcat atttattatag ttgggacatc ctttgcaccc ttcataaaaa 3840
          aggccagctg actgctcagc atcacctgcc aaggccacta gatttgtgtt tacaggggta 3900
          tctctgtgat gcttgtcaca tcactcttga ccaccctctgt taataaattc cgacagtgca 3960
          gtggcgatcg gagtgtgaac ttatgttccc agcatatgga aagctatctt aggttttaag 4020
          gtagtagaaa ttgcccagga gtttgacagc aactttgttt cccgggtcta aaatcgtatc 4080
          ccactgaggt gtatgcagtg gagcataata catgcaaata catgcaaaac tccttttgtt 4140
          tcacctaaga ttcactttct atcttacttt cccttcctgc ctagtgtgac ttttgccccc 4200
          aagagtgcct ggacagcatt ctagtttcta caaaatggtc ctctgtgtag gtgaatgtgt 4260
          cccaaacctg ctatcacttt cttgtttcag tgtgactgtc ttgttagagg tgaagtttat 4320
          ccagggtaac ttgctcacta actattcctt tttatggcct ggggttaaag ggcgcatggc 4380
          tcacactggt gaaaataagg aaggcctggt cttatcttgt attaataata ctggctgcat 4440
          tccaccagcc agagatttct atctgcgaag acctatgaaa cactgaagag aaatgtaggc 4500
          agaaggaaat ggccacatat cacaagttct atttatatt cttttgtaaa tacatattgt 4560
          atattacttg gatgttttct tatatcattt actgtctttt tgagttaatg tcagttttta 4620
          ctctctcaac ttactatgta acattgtaaa taacataatg tcctttatta ttattattatta 4680
          agcatctaac atatagagtt gttttcatat aagtttaaga taaatgtcaa aaatatatgt 4740
          tcttttgtttttctttgctt taaaattatg tatcttttcc ttttcttttttttaagaata 4800
          atttattgtt caggagaaag aatgtatatg taactgaaac tatctgaaga atgcacattg 4860
          aaggccgtga ggtactgata aactaaagaa tttaattattc aaaatactaa gcaataagta 4920
          attgtgattt atttaaagtt ttgtccattt tccatgaaag acatactgca ataaaaatgc 4980
          tactctgtgg agacctggga gtgttgctca gcagactaca gcttcagtct gttagaccag 5040
          cacctttcat ctcattccca tagttatgct aatttaggat tgtgttccat ggaccccatg 5100
          atcaccttgt ctatacgttg cttcttgtct gtccattgct tttgccaacac cacctgttct 5160
          caaatcatct cctccctacc aatgctgttt atcactttct tccttgttga agaggccaca 5220
          caaccagaca gtactatgct tcctttttcc tccatacaca ataacagaga gagaatattc 5280
          tagggcatga ctgcctggat cctggctgtt gctatctttt gtagtggcag taagaaactc 5340
          cttcagacta atgaaaatgt caacgtgcca ttcaatcacg aaaggtaacg aaaaatgctc 5400
          tcatggttca aatagtccaa tggcccatag tggcctaaaa ggcagccagt tgacacctgg 5460
          ccatgctaag cttccttata ccatccgcta atgactttcc attgggccca caatttacgg 5520
          attcataatt ttaaaagagg agaaggccaa gttaggttca ttccccttat tctgtcaata 5580
          aaacaaatca aactcatgtc tatctaactg ctcagggagg agcctttgca tgagaaaatt 5640
          ctcatattct aagactgagt catagaaatg agggtattac ttttcttact gcaattaacc 5700
          taaacaaaag ccatatttta acaaatagat atttgcatgg tacccttcat atattccaag 5760
          catttcactc attattccag gtaggttaag agcttctgaa gtgtatgaag taaaggtcag 5820
          caatcctttg gggtgaacag tggcctcctt tggagtttgg gggtaacctg agacttccca 5880
          ccaatgtcca cctccatctg tgtacctaat tccttattacc tagttatggc tcctctagga 5940
          tcatttccaa acactctgga tgtccaggaa atttaaattg tagcttttga ctgagctagt 6000
          ttttcctatt tatattaata aattttcaaa aatgcttgaa atcttcacat ttgcaacaac 6060
          tttagttttc atgcacatac aaacacagag agacaaaaat tccaaacaga cactctccaa 6120
          aagccaccac actctttcac ttgctctata gtcatttagc caaccagcca tgcagagaat 6180
          atttaaaact taaagattga gacattattc tcagtttttg ctgaggcttt gtaacgaaat 6240
          tgaacactat aagcagctat tgtagtaatt ttggttaaaa ttgtttgcct gggatatagt 6300
          atttgaggca gaagcacgtg tgtgaaggag gtgaggtggt ttggaaagag tgaagactcg 6360
          cagccagatt gaatgtctgg ataattacta taattctccc ttcttggttg aaaccatgtt 6420
          ctctcttgat ttttaaaccc aggctgcctc tggaaacaag caaacctgag tctttctaac 6480
          ctgagtcttc ccaatcatta gatttctttt ctgtcctaac gatgaatgat aaaaggactt 6540
          gatgttcaca atttggggtt ataaggcagg tctgaaatct ggagactcaa gatgctggaa 6600
          ggagtggaaa gtttcgatga ctttatatga atcactttgc actctatgtt tggcttgtcc 6660
          tctttgaaac tgattacta aaataaatgt aagggaacta ttactccaaa agattaactt 6720
          ggcaggaaat accaatactt tcagtttatg aaagacaaaa ctgtcttgtt gctacaggaa 6780
          gctgcaatgt tcctaacctt taaggttggt gttgaatagg gtggtcatgc cctcccctgc 6840
          aggtatcttt aggctcctgt tgacctcctg gtactataac tgttcgtctt ctctgggtag 6900
          ctattgattt tgaactttaa catgcttcaa aactttattc atcagggaaa taggaaaaga 6960
          gttttgttac ctggaggaaa tctattgtga tctacctgag ctttttaaaa acagaccagg 7020
          agaaggaaac cagtaatttt taaagaagag acagagaatg ggataatagt ttcacccagg 7080
          atctctttct aaccctttcc cttcaaatga acttattgga acagaattgg aaagaagaaa 7140
          ggacatctct gcccacccca caggatgcca aaaaggctaa agaattacct ctgtagattt 7200
          aaacatcttt aatggcttat gtatagattt gctaatacag agagaaatga actattaaat 7260
          aaaaatcaca ttttataata tttttatggc ttaaaacatc ctttatctcc tttttgttct 7320
          ctctacatga tatggtaagt gatgaggaaa atttaggctc aggaaggtta aaatctttct 7380
          tggagttaca catctaagag agctgcagag ctgacacttg tacccaggtt ttctgactgc 7440
          aaatccagtt tctttctatt gcgttcttcc cctttccctg cctcaagcag aaacaggttt 7500
          tttattttca acctttatgt atacagtatg ttatgttaca tctacagcta agtttctttt 7560
          tagaagaatg tgagcccttc tagctttggt ttagagtgat tctagaagcc aatttccttg 7620
          gcttagtgat tctatgcacc tttcctaaac ttagctttct aaggaaatga agtgtacgag 7680
          tgagaatgaa ttcacaattt cgacatgtag gtagcatcct aaagtgaaaa gaggaggaaa 7740
          tttgtggtca aagcactctc cccaccactt agaaacttac tgactgtggtcagcttcctc 7800
          ctccaagttt ccttcctgat ttacaagacc gtggtgtggt caggattaaa cttgaataca 7860
          tgtaaggaag cctgaaagtg tctaacacat agcgagtatt caaatgccac cttctatttg 7920
          atccttcccc tccagttcct taagttttgg aatctaggtt tctcagttcc aaatggattg 7980
          acatttgcat atccccattg cacaatggat caaataaact ttatgttatc atttctccaa 8040
          catagtgcca gtaagcaaat cctttttaat aacaacagta tgttgagaaa catatcacca 8100
          aataatattt aactttgtag ctttgataag ttctttaggt tttggttttg gttttgtttt 8160
          ctgagacagg gtcttgatct gtcacccaga ctggagtgca atggttcaat tttagctcac 8220
          tgcaacctgt aactcctgag ctcaagtgat cctcccacct cagcctctca agtagctggg 8280
          actacaggtg tgctccacca tgcccagcga tttttttttttttttttttttttttttttg 8340
          gtagggacaa ggtctcgcta tgttgcccag gctggtcttc aattcctggc cttaagtgat 8400
          cctcctgcct cggcctccca aagtgctgga attacaggca tgagccacca cccataactt 8460
          tatgtttgtt tttttgatgc agtataagtt cagcttgctt cttatgcagc cataccattt 8520
          catgttaact ctgattttta gcagcttatt aacttagtgt tttattatta atataatttt 8580
          acagaaattt actaaaccat gactctgtag agttttaata atactacctc caaacatcat 8640
          tgcaaacatc tagaagaatg aacaaaaatg atcttagatc gacagtatat ctgtttgtct 8700
          tagtttctac acaggatgtt cagacatatt ccatttcttt aaaaaaaaaa tatatatata 8760
          tatatatata tataggcctg gcacggtggc tcatgactgt aatcccagca ctttgggagg 8820
          cttaggcagg caaatcacct gaggtcagga gtttgagact ggcctgacca acatggtgaa 8880
          acctcgtctc tattaaaatt acaaaaatta gccgggcgtg gtggcacatg cctgtaatcc 8940
          cagctactcg ggaggctgag gcaggagaat cacttgaacc tgggaggcag aggttgcagt 9000
          gagttgagat cacgccattg cactccagcc ttggtgacaa gagtgaaact ccgtctcaaa 9060
          aaaaaaaaaa atatgtatat atatatatat atatatatat atatatatat atatatatat 9120
          ataaaatccc accaaaagtc tgcagagtga ccaaattaga cggctctggt ttcagattaa 9180
          attctaaatg tgagaaacca catagctccc atgatccatc caataattcc tcacgtcctc 9240
          ttcactcttt actccatgca taaaacagaa tttttttttc tcatcctggg tatgaagcaa 9300
          ttaataattt acggatttag cctatttgga ttcaatccct tcaaactcca tactacatcc 9360
          aaggtggaag tgacttaaac tctgatatca atcatcaggc ttgtaatata ggctttgtta 9420
          atggcaggag agtctaataa aactttctgt tccttatcct tcatttaaat gaaaaacttt 9480
          ttattgaaaa caatcataac tctagctcat cataaatata attcatgagg aattttatt 9540
          atttttatat taaagaaata atattataga tgtaaacttt gcacctttct aattattatc 9600
          atgagttaag ctaatacttg tcttctggtc cctagatgat gattcttttt tgccttactg 9660
          gaggagccct tgtcttgaag tgagttgctt caacagcaga ggacttctag tttctcccag 9720
          ttgagcctaa agtgaacttt tcatcttctt cagaggaagg ggcttccttg atttgtactt 9780
          ttgtggctcc tcagataaca cagacaattt tatcttggat cccaggttct cttcaccatt 9840
          aagaataaga aagagagaaa atgctgtgca tgacagccac ctactccaaa ctacccaacc 9900
          ccctgtaacc aggtaccttc caacaacgag atgattctgc cctcactcaa gagtctcccc 9960
          cacaaagatt ccattctccc tttacttttt attttttttttttgcaaa acaaaggcct 10020
          cctttagtac ctccttagtt tataaccctt atcttcccag ctcttccctt cactgatacc 10080
          tctgatttca aaagttctga agtcggaaga ccacacaatt tcagactgtg aacagaaatt 10140
          cagtcagaaa ttattggagt tagaaagaat ttagagaaat tgtattgaac tagaaagtcc 10200
          tctttgatta gtggtggccc tttagaaagt tctagggcag agtcccatgg tgtttcatct 10260
          tttccatgat ttgcttgacc aaaaactttt ctttcacaac atgaaaatat gctaatccac 10320
          caacacatttt ggattctgct ctgtttgcct gaggtgttag atctctagcc aggactgtga 10380
          agggaaggaa cttgaatcct tcctattgag ctattaatgc agagtcagtg agatgaaggg 10440
          ttccactcgg ggtcaaaatc atgtcagtta ccaagcaaag gagcaagtaa ggggaaacat 10500
          ctcctcatct ggttagtgga gccacatttc accactgat caagccagac ctgagcaata 10560
          gtctagattt ctccctccac atctaattgg tgacaatggt gattgtacca ctgacaggtc 10620
          acacaagtcc acaccctcct tcacagcctc actgcttcgg ctcttgttta tgctcttatc 10680
          agcatctgtc actaggatcc atttgtctcc tgactcatct acttccctttc actcccctgg 10740
          gccatccttc acatcatgct agaagactgt gtctaacttg cagaacttat tgtgtcaatc 10800
          tcctggttac ggcccctcca tggctcccca cctgacatag gaggcccttc acaatctggc 10860
          ttctgtcact cataacttgt ctccagcctt cattcttcag tctgatttta tggttttcta 10920
          gttccccaat acaccacacc agtgtttatg aaaccctagt cattggccta cgaactttat 10980
          gattattgac atattcatgt accacctgta ttattttttg catagtgttt atttttaatt 11040
          gactacattt ttaactacaa taaagtaatt tcaactaaaa 11080
           <![CDATA[ <210> 156]]>
           <![CDATA[ <211> 477]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> person]]> class
           <![CDATA[ <400> 156]]>
          Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala Glu
          1 5 10 15
          Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe Met Val Lys
                      20 25 30
          Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu Phe
                  35 40 45
          Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe Tyr Lys His
              50 55 60
          Leu Gly Ile Glu Phe Met Glu Ala Glu Glu Leu Tyr Gln Lys Arg Val
          65 70 75 80
          Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val Gly Ile Met
                          85 90 95
          Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Lys Lys Leu His
                      100 105 110
          Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn Met Met Asn
                  115 120 125
          Ile Ala Asn Gly Pro His His Pro Asn Pro Pro Pro Glu Asn Val Gln
              130 135 140
          Leu Val Asn Gln Tyr Val Ser Lys Asn Val Ile Ser Ser Ser Glu His Ile
          145 150 155 160
          Val Glu Arg Glu Ala Glu Thr Ser Phe Ser Thr Ser His Tyr Thr Ser
                          165 170 175
          Thr Ala His His Ser Thr Thr Val Thr Gln Thr Pro Ser His Ser Trp
                      180 185 190
          Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser His Ser Ser Val Ile
                  195 200 205
          Val Met Ser Ser Val Glu Asn Ser Arg His Ser Ser Pro Thr Gly Gly
              210 215 220
          Pro Arg Gly Arg Leu Asn Gly Thr Gly Gly Pro Arg Glu Cys Asn Ser
          225 230 235 240
          Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro
                          245 250 255
          His Ser Glu Arg Tyr Val Ser Ala Met Thr Thr Pro Ala Arg Met Ser
                      260 265 270
          Pro Val Asp Phe His Thr Pro Ser Ser Pro Lys Ser Pro Pro Ser Glu
                  275 280 285
          Met Ser Pro Pro Val Ser Ser Met Thr Val Ser Met Pro Ser Met Ala
              290 295 300
          Val Ser Pro Phe Met Glu Glu Glu Arg Pro Leu Leu Leu Val Thr Pro
          305 310 315 320
          Pro Arg Leu Arg Glu Lys Lys Phe Asp His His Pro Gln Gln Phe Ser
                          325 330 335
          Ser Phe His His Asn Pro Ala His Asp Ser Asn Ser Leu Pro Ala Ser
                      340 345 350
          Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr Gln Glu Tyr
                  355 360 365
          Glu Pro Ala Gln Glu Pro Val Lys Lys Leu Ala Asn Ser Arg Arg Ala
              370 375 380
          Lys Arg Thr Lys Pro Asn Gly His Ile Ala Asn Arg Leu Glu Val Asp
          385 390 395 400
          Ser Asn Thr Ser Ser Ser Gln Ser Ser Asn Ser Glu Ser Glu Thr Glu Asp
                          405 410 415
          Glu Arg Val Gly Glu Asp Thr Pro Phe Leu Gly Ile Gln Asn Pro Leu
                      420 425 430
          Ala Ala Ser Leu Glu Ala Thr Pro Ala Phe Arg Leu Ala Asp Ser Arg
                  435 440 445
          Thr Asn Pro Ala Gly Arg Phe Ser Thr Gln Glu Glu Ile Gln Ala Arg
              450 455 460
          Leu Ser Ser Val Ile Ala Asn Gln Asp Pro Ile Ala Val
          465 470 475
           <![CDATA[ <210> 157]]>
           <![CDATA[ <211> 11083]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 157]]>
          catctacatc tacatccacc actgggacaa gccatcttgt aaaatgtgcg gagaaggaga 60
          aaactttctg tgtgaatgga ggggagtgct tcatggtgaa agacctttca aacccctcga 120
          gatacttgtg caagtgccca aatgagttta ctggtgatcg ctgccaaaac tacgtaatgg 180
          ccagcttcta caagcatctt gggattgaat ttatggaggc ggaggagctg taccagaaga 240
          gagtgctgac cataaccggc atctgcatcg ccctccttgt ggtcggcatc atgtgtgtgg 300
          tggcctactg caaaaccaag aaacagcgga aaaagctgca tgaccgtctt cggcagagcc 360
          ttcggtctga acgaaacaat atgatgaaca ttgccaatgg gcctcaccat cctaacccac 420
          cccccgagaa tgtccagctg gtgaatcaat acgtatctaa aaacgtcatc tccagtgagc 480
          atattgttga gagagaagca gagacatcct tttccaccag tcactatact tccacagccc 540
          atcactccac tactgtcacc cagactccta gccacagctg gagcaacgga cacactgaaa 600
          gcatcctttc cgaaagccac tctgtaatcg tgatgtcatc cgtagaaaac agtaggcaca 660
          gcagcccaac tgggggccca agaggacgtc ttaatggcac aggaggccct cgtgaatgta 720
          acagcttcct caggcatgcc agagaaaccc ctgattccta ccgagactct cctcatagtg 780
          aaaggtatgt gtcagccatg accacccccgg ctcgtatgtc acctgtagat ttccaacacgc 840
          caagctcccc caaatcgccc ccttcggaaa tgtctccacc cgtgtccagc atgacggtgt 900
          ccatgccttc catggcggtc agccccttca tggaagaaga gagacctcta cttctcgtga 960
          caccaccaag gctgcggggag aagaagtttg accatcacccc tcagcagttc agctccttcc 1020
          accacaaccc cgcgcatgac agtaacagcc tccctgctag ccccttgagg atagtggagg 1080
          atgaggagta tgaaacgacc caagagtacg agccagccca agagcctgtt aagaaactcg 1140
          ccaatagccg gcgggccaaa agaaccaagc ccaatggcca cattgctaac agatggaag 1200
          tggacagcaa cacaagctcc cagagcagta actcagagag tgaaacagaa gatgaaagag 1260
          taggtgaaga tacgcctttc ctgggcatac agaaccccct ggcagccagt cttgaggcaa 1320
          cacctgcctt ccgcctggct gacagcagga ctaacccagc aggccgcttc tcgacacagg 1380
          aagaaatcca ggccaggctg tctagtgtaa ttgctaacca agaccctatt gctgtataaa 1440
          acctaaataa acacatagat tcacctgtaa aactttattt tatataataa agtattccac 1500
          cttaaattaa acaatttatt ttattttagc agttctgcaa atagaaaaca ggaaaaaaac 1560
          ttttataaat taaatatatg tatgtaaaaa tgtgttatgt gccatatgta gcaatttttt 1620
          acagtatttc aaaacgagaa agatatcaat ggtgccttta tgttatgtta tgtcgagagc 1680
          aagttttgta cagttacagt gattgctttt ccacagtatt tctgcaaaac ctctcataga 1740
          ttcagttttt gctggcttct tgtgcattgc attatgatgt tgactggatg tatgatttgc 1800
          aagacttgca actgtccctc tgtttgcttg tagtagcacc cgatcagtat gtcttgtaat 1860
          ggcacatcca tccagatatg cctctcttgt gtatgaagtt ttctttgctt tcagaatatg 1920
          aaatgagttg tgtctactct gccagccaaa ggtttgcctc attgggctct gagataatag 1980
          tagatccaac agcatgctac tattaaatac agcaagaaac tgcattaagt aatgttaaat 2040
          attaggaaga aagtaatact gtgattaaa aaaaactata ttattaatca gaagacagct 2100
          tgctcttact aaaaggagct ctcatttact ttatttgatt ttatttttct tgacaaaaag 2160
          caacagtttt agggatagct tagaaaatgg gttctggctt gctatcaggg taaatctaac 2220
          accttacaag aggactgagt gtcactttct ctctggggga atgatccagc agcttatcta 2280
          gttgacaatc aaaacacggc tgataaaggt gcaatcattt ctgacatgta tttttcactg 2340
          attttgaagc tagtgattgg ttgtgtcttc ttggctcaaa aagaagcata ttacggcaca 2400
          aaaagcccag cccagacagc acatgcagca ttttgtctga aatacttcta gagtcaaacg 2460
          tgcctgctgt acatagcgat gacttgtcat catagggaag tatttccatc gtagaggtgtt 2520
          cagaaggagt gactgtatag gtggagagaa gcttagtgac tccgttgaaa ttttaaaatg 2580
          tggatgacca cccctttctc ccccttatttttcttttatc tttccatgtt gccttgatca 2640
          ggtcataact atgcatgaac attttttatc aggaatggcc gatgtgtatg tgatttgtaa 2700
          tcacaagtaa tgattcatca ggaaatgtca atcctgttgg aaagattgca cctttacttg 2760
          cagaagtgac ccccacctgt gtcctgacct ctccattac aggctctctc accccatttcc 2820
          cccacctcct ttaatttttg ctttactgtc ataaagtagg actaagattg gtctaagcat 2880
          tgcatgttct tttgtgatgg taaatccaaa ggaaggccta taagtattaa catttgaaat 2940
          aactgctaat tcaggaaaat ggaagaaaaa aaattatttg aaacacagaa cccatttcat 3000
          ggcctgcctg atatctgtga aatcagggct ggagctttac ttaggattca catggcctcc 3060
          taggaaccat gggacaaatg ggaaacaggt tatcggggga ttcatgaagt cagtgagagt 3120
          aattgcttct tttttgcggg tgaactgaat gtatttcttc accaaatctt gatgttaaca 3180
          attaaaaaga agaaatgaca tgcaagtagg tcttagcaga aaaatgcagg ctgggcatga 3240
          gtcatgttgt taccctccca catgctccta caatccacag agatgcctgt ctgcaggttc 3300
          ttgaagttat tgttagtatt tggtatctca aatttttcgt cactgttcac atgccacttt 3360
          ctctgtgcac agtggtatcc tcatttgctt tttaacctac actgaggagt ctttgtcagg 3420
          ttgcactgat tttccaattc tgcagtaatg agtaagctca cggcatgggg aagaagacag 3480
          tcagtccaat gaagttctct aaattatttt aacattgcct ttgaaggcct tgactcatcc 3540
          ttagctattt caatgaagaa attcctacca tgaatttaaa accctaaaaa ttctgtttca 3600
          aattctttgg gcattggggt actcagatat cccattgtgg aagaatttta agaataaata 3660
          gaagtttctg ttgagaacca tgagcaacat gtttcttaca atgagaattg ctatgcattt 3720
          taaaattgca aatatatatg aaaattgaag acaagaggaa attgtatttc taacttgatt 3780
          ctgatcactc acagaggtgg catattatta tagttgggac atcctttgca cccttcataa 3840
          aaaaggccag ctgactgctc agcatcacct gccaaggcca ctagatttgt gtttacaggg 3900
          gtatctctgt gatgcttgtc acatcactct tgaccacctc tgttaataaa ttccgacagt 3960
          gcagtggcga tcggagtgtg aacttatgtt cccagcatat ggaaagctat cttaggtttt 4020
          aaggtagtag aaattgccca ggagtttgac agcaactttg tttcccgggt ctaaaatcgt 4080
          atcccactga ggtgtatgca gtggagcata atacatgcaa atacatgcaa aactcctttt 4140
          gtttcaccta agattcactt tctatcttac tttcccttcc tgcctagtgt gacttttgcc 4200
          cccaagagtg cctggacagc attctagttt ctacaaaatg gtcctctgtg taggtgaatg 4260
          tgtcccaaac ctgctatcac tttcttgttt cagtgtgact gtcttgttag aggtgaagtt 4320
          tatccagggt aacttgctca ctaactattc ctttttatgg cctggggtta aagggcgcat 4380
          ggctcacact ggtgaaaata aggaaggcct ggtcttatct tgtattaata atactggctg 4440
          cattccacca gccagagatt tctatctgcg aagacctatg aaacactgaa gagaaatgta 4500
          ggcagaagga aatggccaca tatcacaagt tctattatat attcttttgt aaatacatat 4560
          tgtatattac ttggatgttt tcttatatca tttactgtct ttttgagtta atgtcagttt 4620
          ttactctctc aacttactat gtaacattgt aaataacata atgtccttta ttattatatat 4680
          ttaagcatct aacatataga gttgttttca tataagttta agataaatgt caaaaatata 4740
          tgttcttttg tttttctttg ctttaaaatt atgtatcttt tccttttctt ttttttaaga 4800
          ataatttatt gttcaggaga aagaatgtat atgtaactga aactatctga agaatgcaca 4860
          ttgaaggccg tgaggtactg ataaactaaa gaattttatta ttcaaaatac taagcaataa 4920
          gtaattgtga tttattaaa gttttgtcca ttttccatga aagacatact gcaataaaaa 4980
          tgctactctg tggagacctg ggagtgttgc tcagcagact acagcttcag tctgttagac 5040
          cagcaccttt catctcattc ccatagttat gctaatttag gattgtgttc catggaccccc 5100
          atgatcacct tgtctatacg ttgcttcttg tctgtccatt gcttttgcca caccacctgt 5160
          tctcaaatca tctcctccct accaatgctg tttatcactt tcttccttgt tgaagaggcc 5220
          acacaaccag acagtactat gcttcctttt tcctccatac acaataacag agagagaata 5280
          ttctagggca tgactgcctg gatcctggct gttgctatct tttgtagtgg cagtaagaaa 5340
          ctccttcaga ctaatgaaaa tgtcaacgtg ccattcaatc acgaaaggta acgaaaaatg 5400
          ctctcatggt tcaaatagtc caatggccca tagtggccta aaaggcagcc agttgacacc 5460
          tggccatgct aagcttcctt ataccatccg ctaatgactt tccatgggc ccacaattta 5520
          cggattcata attttaaaag aggagaaggc caagttaggt tcattcccct tattctgtca 5580
          ataaaacaaa tcaaactcat gtctatctaa ctgctcaggg aggagccttt gcatgagaaa 5640
          attctcatat tctaagactg agtcatagaa atgagggtat tacttttctt actgcaatta 5700
          acctaaacaa aagccatatt ttaacaaata gatatttgca tggtaccctt catatattcc 5760
          aagcatttca ctcattattc caggtaggtt aagagcttct gaagtgtatg aagtaaaggt 5820
          cagcaatcct ttggggtgaa cagtggcctc ctttggagtt tgggggtaac ctgagacttc 5880
          ccaccaatgt ccacctccat ctgtgtacct aattcctatt acctagttat ggctcctcta 5940
          ggatcatttc caaacactct ggatgtccag gaaatttaaa ttgtagcttt tgactgagct 6000
          agtttttcct atttatatta ataaattttc aaaaatgctt gaaatcttca catttgcaac 6060
          aactttagtt ttcatgcaca tacaaacaca gagagacaaa aattccaaac agacactctc 6120
          caaaagccac cacactcttt cacttgctct atagtcattt agccaaccag ccatgcagag 6180
          aatatttaaa acttaaagat tgagacatta ttctcagttt ttgctgaggc tttgtaacga 6240
          aattgaacac tataagcagc tattgtagta attttggtta aaattgtttg cctgggatat 6300
          agtatttgag gcagaagcac gtgtgtgaag gaggtgaggt ggtttggaaa gagtgaagac 6360
          tcgcagccag attgaatgtc tggataatta ctataattct cccttcttgg ttgaaaccat 6420
          gttctctctt gatttttaaa cccaggctgc ctctggaaac aagcaaacct gagtctttct 6480
          aacctgagtc ttcccaatca ttagatttct tttctgtcct aacgatgaat gataaaagga 6540
          cttgatgttc acaatttggg gttataaggc aggtctgaaa tctggagact caagatgctg 6600
          gaaggagtgg aaagtttcga tgactttata tgaatcactt tgcactctat gtttggcttg 6660
          tcctctttga aactgattaa ctaaaataaa tgtaagggaa ctattactcc aaaagattaa 6720
          cttggcagga aataccaata ctttcagttt atgaaagaca aaactgtctt gttgctacag 6780
          gaagctgcaa tgttcctaac ctttaaggtt ggtgttgaat agggtggtca tgccctcccc 6840
          tgcaggtatc tttaggctcc tgttgacctc ctggtactat aactgttcgt cttctctggg 6900
          tagctattga ttttgaactt taacatgctt caaaacttta ttcatcaggg aaataggaaa 6960
          agagttttgt tacctggagg aaatctattg tgatctacct gagcttttta aaaacagacc 7020
          aggagaagga aaccagtaat ttttaaagaa gagacagaga atgggataat agtttcaccc 7080
          aggatctctt tctaaccctt tcccttcaaa tgaacttatt ggaacagaat tggaaagaag 7140
          aaaggacatc tctgcccacc ccacaggatg ccaaaaaggc taaagaatta cctctgtaga 7200
          tttaaacatc tttaatggct tatgtataga tttgctaata cagagagaaa tgaactatta 7260
          aataaaaatc aattttata atatttttat ggcttaaaac atcctttatc tcctttttgt 7320
          tctctctaca tgatatggta agtgatgagg aaaatttagg ctcaggaagg ttaaaatctt 7380
          tcttggagtt acacatctaa gagagctgca gagctgacac ttgtacccag gttttctgac 7440
          tgcaaatcca gtttctttct attgcgttct tcccctttcc ctgcctcaag cagaaacagg 7500
          ttttttattt tcaaccttta tgtatacagt atgttatgtt acatctacag ctaagtttct 7560
          ttttagaaga atgtgagccc ttctagcttt ggtttagagt gattctagaa gccaatttcc 7620
          ttggcttagt gattctatgc acctttccta aacttagctt tctaaggaaa tgaagtgtac 7680
          gagtgagaat gaattcacaa tttcgacatg taggtagcat cctaaagtga aaagaggagg 7740
          aaatttgtgg tcaaagcact ctccccacca cttagaaact tactgactgt gggcagcttc 7800
          ctcctccaag tttccttcct gatttacaag accgtggtgt ggtcaggatt aaacttgaat 7860
          acatgtaagg aagcctgaaa gtgtctaaca catagcgagt attcaaatgc caccttctat 7920
          ttgatccttc ccctccagtt ccttaagttt tggaatctag gtttctcagt tccaaatgga 7980
          ttgacatttg catatcccca ttgcacaatg gatcaaataa actttatgtt atcatttctc 8040
          caacatagtg ccagtaagca aatccttttt aataacaaca gtatgttgag aaacatatca 8100
          ccaaataata tttaactttg tagctttgat aagttcttta ggttttggtt ttggttttgt 8160
          tttctgagac agggtcttga tctgtcaccc agactggagt gcaatggttc aattttagct 8220
          cactgcaacc tgtaactcct gagctcaagt gatcctccca cctcagcctc tcaagtagct 8280
          gggactacag gtgtgctcca ccatgcccag cgattttttttttttttttttttttttttt 8340
          ttggtaggga caaggtctcg ctatgttgcc caggctggtc ttcaattcct ggccttaagt 8400
          gatcctcctg cctcggcctc ccaaagtgct ggaattacag gcatgagcca ccacccataa 8460
          ctttatgttt gtttttttga tgcagtataa gttcagcttg cttcttatgc agccatacca 8520
          tttcatgtta actctgattt ttagcagctt attacattag tgttttatta ttaatataat 8580
          tttacagaaa tttactaaac catgactctg tagagtttta ataatactac ctccaaacat 8640
          cattgcaaac atctagaaga atgaacaaaa atgatcttag atcgacagta tatctgtttg 8700
          tcttagtttc tacacaggat gttcagacat attccatttc tttaaaaaaaaaatatatat 8760
          atatatatat atatataggc ctggcacggt ggctcatgac tgtaatccca gcactttggg 8820
          aggcttaggc aggcaaatca cctgaggtca ggagtttgag actggcctga ccaacatggt 8880
          gaaacctcgt ctctattaaa attacaaaaa ttagccgggc gtggtggcac atgcctgtaa 8940
          tcccagctac tcgggaggct gaggcaggag aatcacttga acctgggagg cagaggttgc 9000
          agtgagttga gatcacgcca ttgcactcca gccttggtga caagagtgaa actccgtctc 9060
          aaaaaaaaaa aaaatatgta tatatatata tatatatata tatatatata tatatatata 9120
          tatataaaat cccaccaaaa gtctgcagag tgaccaaatt agacggctct ggtttcagat 9180
          taaattctaa atgtgagaaa ccacatagct cccatgatcc atccaataat tcctcacgtc 9240
          ctcttcactc tttactccat gcataaaaca gaattttttt ttctcatcct gggtatgaag 9300
          caattaataa tttacggatt tagcctattt ggattcaatc ccttcaaact ccatactaca 9360
          tccaaggtgg aagtgactta aactctgata tcaatcatca ggcttgtaat ataggctttg 9420
          ttaatggcag gagagtctaa taaaactttc tgttccttat ccttcattta aatgaaaaac 9480
          tttttattga aaacaatcat aactctagct catcataaat ataattcatg aggacatttt 9540
          attattttta tattaaagaa ataatattat agatgtaaac tttgcacctt tctaattatt 9600
          atcatgagtt aagctaatac ttgtcttctg gtccctagat gatgattctt ttttgcctta 9660
          ctggaggagc ccttgtcttg aagtgagttg cttcaacagc agaggacttc tagtttctcc 9720
          cagttgagcc taaagtgaac ttttcatctt cttcagagga aggggcttcc ttgatttgta 9780
          cttttgtggc tcctcagata acacagacaa ttttatcttg gatcccaggt tctcttcacc 9840
          attaagaata agaaagagag aaaatgctgt gcatgacagc cacctactcc aaactaccca 9900
          accccctgta accaggtacc ttccaacaac gagatgattc tgccctcact caagagtctc 9960
          ccccacaaag attccattct ccctttactt tttatttttt atttttttgc aaaacaaagg 10020
          cctcctttag tacctcctta gtttataacc cttatcttcc cagctcttcc cttcactgat 10080
          acctctgatt tcaaaagttc tgaagtcgga agaccacaca atttcagact gtgaacagaa 10140
          attcagtcag aaattattgg agttagaaag aatttagaga aattgtattg aactagaaag 10200
          tcctctttga ttagtggtgg ccctttagaa agttctaggg cagagtccca tggtgtttca 10260
          tcttttccat gatttgcttg accaaaaact tttctttcac aacatgaaaa tatgctaatc 10320
          caccacacat tttggattct gctctgtttg cctgaggtgt tagatctcta gccaggactg 10380
          tgaagggaag gaacttgaat ccttcctatt gagctattaa tgcagagtca gtgagatgaa 10440
          gggttccact cggggtcaaa atcatgtcag ttaccaagca aaggagcaag taaggggaaa 10500
          catctcctca tctggttagt ggagccacat ttcacccact gatcaagcca gacctgagca 10560
          atagtctaga tttctccctc cacatctaat tggtgacaat ggtgattgta ccactgacag 10620
          gtcacacaag tccacaccct ccttcacagc ctcactgctt cggctcttgt ttatgctctt 10680
          atcagcatct gtcactagga tccattgtc tcctgactca tctacttcct ttcactcccc 10740
          tgggccatcc ttcacatcat gctagaagac tgtgtctaac ttgcagaact tattgtgtca 10800
          atctcctggt tacggcccct ccatggctcc ccacctgaca taggaggccc ttcacaatct 10860
          ggcttctgtc actcataact tgtctccagc cttcattctt cagtctgatt ttatggtttt 10920
          ctagttcccc aatacaccac accagtgttt atgaaaccct agtcattggc ctacgaactt 10980
          tatgattatt gacatattca tgtaccacct gtattatttt ttgcatagtg tttattttta 11040
          attgactaca tttttaacta caataaagta atttcaacta aaa 11083
           <![CDATA[ <210> 158]]>
           <![CDATA[ <211> 478]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 158]]>
          Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala
          1 5 10 15
          Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe Met Val
                      20 25 30
          Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu
                  35 40 45
          Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe Tyr Lys
              50 55 60
          His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu Leu Tyr Gln Lys Arg
          65 70 75 80
          Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val Gly Ile
                          85 90 95
          Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Lys Lys Leu
                      100 105 110
          His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn Met Met
                  115 120 125
          Asn Ile Ala Asn Gly Pro His His Pro Asn Pro Pro Pro Glu Asn Val
              130 135 140
          Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Val Ile Ser Ser Ser Glu His
          145 150 155 160
          Ile Val Glu Arg Glu Ala Glu Thr Ser Phe Ser Thr Ser His Tyr Thr
                          165 170 175
          Ser Thr Ala His His Ser Thr Thr Val Thr Gln Thr Pro Ser His Ser
                      180 185 190
          Trp Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser His Ser Val
                  195 200 205
          Ile Val Met Ser Ser Val Glu Asn Ser Arg His Ser Ser Pro Thr Gly
              210 215 220
          Gly Pro Arg Gly Arg Leu Asn Gly Thr Gly Gly Pro Arg Glu Cys Asn
          225 230 235 240
          Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser
                          245 250 255
          Pro His Ser Glu Arg Tyr Val Ser Ala Met Thr Thr Pro Ala Arg Met
                      260 265 270
          Ser Pro Val Asp Phe His Thr Pro Ser Ser Pro Lys Ser Pro Pro Ser
                  275 280 285
          Glu Met Ser Pro Pro Val Ser Ser Met Thr Val Ser Met Pro Ser Met
              290 295 300
          Ala Val Ser Pro Phe Met Glu Glu Glu Arg Pro Leu Leu Leu Val Thr
          305 310 315 320
          Pro Pro Arg Leu Arg Glu Lys Lys Phe Asp His His Pro Gln Gln Phe
                          325 330 335
          Ser Ser Phe His His Asn Pro Ala His Asp Ser Asn Ser Leu Pro Ala
                      340 345 350
          Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr Gln Glu
                  355 360 365
          Tyr Glu Pro Ala Gln Glu Pro Val Lys Lys Leu Ala Asn Ser Arg Arg
              370 375 380
          Ala Lys Arg Thr Lys Pro Asn Gly His Ile Ala Asn Arg Leu Glu Val
          385 390 395 400
          Asp Ser Asn Thr Ser Ser Gln Ser Ser Asn Ser Glu Ser Glu Thr Glu
                          405 410 415
          Asp Glu Arg Val Gly Glu Asp Thr Pro Phe Leu Gly Ile Gln Asn Pro
                      420 425 430
          Leu Ala Ala Ser Leu Glu Ala Thr Pro Ala Phe Arg Leu Ala Asp Ser
                  435 440 445
          Arg Thr Asn Pro Ala Gly Arg Phe Ser Thr Gln Glu Glu Ile Gln Ala
              450 455 460
          Arg Leu Ser Ser Val Ile Ala Asn Gln Asp Pro Ile Ala Val
          465 470 475
           <![CDATA[ <210> 159]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 159]]>
          000
           <![CDATA[ <210> 160]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 160]]>
          000
           <![CDATA[ <210> 161]]>
           <![CDATA[ <211> 586]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 161]]>
          agtaagcctc cgcagcccac tcggactgca gcctgtttgc cgcccgtcct cccattgcag 60
          cactcggggc gacagagagg gaggaggcgc gcggggacgg ggacgcccag gaggacccac 120
          tcgcgggtcc cgctccgctc cggcagcagc atggggaaag gacgcgcggg ccgagttggc 180
          accacagcct tgcctccccg attgaaagag atgaaaagcc aggaatcggc tgcaggttcc 240
          aaactagtcc ttcggtgtga aaccagttct gaatactcct ctctcagatt caagtggttc 300
          aagaatggga atgaattgaa tcgaaaaaac aaaccacaaa atatcaagat acaaaaaaag 360
          ccagggaagt cagaacttcg cattaacaaa gcatcactgg ctgattctgg agagtatatg 420
          tgcaaagtga tcagcaaatt aggaaatgac agtgcctctg ccaatatcac catcgtggaa 480
          tcaaacgaga tcatcactgg tatgccagcc tcaactgaag gagcatatgt gtcttcagag 540
          tctcccatta gaatatcagt atccacagaa ggagcaaata cttctt 586
           <![CDATA[ <210> 162]]>
           <![CDATA[ <211> 145]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 162]]>
          Met Gly Lys Gly Arg Ala Gly Arg Val Gly Thr Thr Ala Leu Pro Pro
          1 5 10 15
          Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu
                      20 25 30
          Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu Arg Phe Lys
                  35 40 45
          Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn
              50 55 60
          Ile Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys
          65 70 75 80
          Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys
                          85 90 95
          Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn
                      100 105 110
          Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser
                  115 120 125
          Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr
              130 135 140
          Ser
          145
           <![CDATA[ <210> 163]]>
           <![CDATA[ <211> 52]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 163]]>
          His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly
          1 5 10 15
          Gly Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu
                      20 25 30
          Cys Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val
                  35 40 45
          Met Ala Ser Phe
              50
           <![CDATA[ <210> 164]]>
           <![CDATA[ <211> 65]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 164]]>
          cataattagc atcatcatta ttctggctgg agcaattgca ctcatcattg gctttggtat 60
          ttcag 65
           <![CDATA[ <210> 165]]>
           <![CDATA[ <211> 28]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 165]]>
          ccttgcctcc ccgattgaaa gagatgaa 28
           <![CDATA[ <210> 166]]>
           <![CDATA[ <211> 93]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 166]]>
          cataattagc atcatcatta ttctggctgg agcaattgca ctcatcattg gctttggtat 60
          ttcagccttg cctccccgat tgaaagagat gaa 93
           <![CDATA[ <210> ]]>167
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 167]]>
          Ile Ile Ser Ile Ile Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile
          1 5 10 15
          Gly Phe Gly Ile Ser Ala Leu Pro Pro Arg Leu Lys Glu Met
                      20 25 30
           <![CDATA[ <210> 168]]>
           <![CDATA[ <211> 104]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 168]]>
          gtgagtcacc aaggaaggca gcggcagctc cactcagcca gtacccagat acgctgggaa 60
          ccttccccag ccatggcttc cctggggcag atcctcttct ggag 104
           <![CDATA[ <210> 169]]>
           <![CDATA[ <211> 65]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 169]]>
          cataattagc atcatcatta ttctggctgg agcaattgca ctcatcattg gctttggtat 60
          ttcag 65
           <![CDATA[ <210> 170]]>
           <![CDATA[ <211> 348]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 170]]>
          ggagacactc catcacagtc actactgtcg cctcagctgg gaacattggg gaggatggaa 60
          tcctgagctg cacttttgaa cctgacatca aactttctga tatcgtgata caatggctga 120
          aggaaggtgt tttaggcttg gtccatgagt tcaaagaagg caaagatgag ctgtcggagc 180
          aggatgaaat gttcagaggc cggacagcag tgtttgctga tcaagtgata gttggcaatg 240
          cctctttgcg gctgaaaaac gtgcaactca cagatgctgg cacctacaaa tgttatatca 300
          tcacttctaa aggcaagggg aatgctaacc ttgagtataa aactggag 348
           <![CDATA[ <210> 171]]>
           <![CDATA[ <211> 279]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 171]]>
          ccttcagcat gccggaagtg aatgtggact ataatgccag ctcagagacc ttgcggtgtg 60
          aggctccccg atggttcccc cagcccacag tggtctgggc atcccaagtt gaccaggggag 120
          ccaacttctc ggaagtctcc aataccagct ttgagctgaa ctctgagaat gtgaccatga 180
          aggttgtgtc tgtgctctac aatgttacga tcaacaacac atactcctgt atgattgaaa 240
          atgacattgc caaagcaaca ggggatatca aagtgacag 279
           <![CDATA[ <210> 172]]>
           <![CDATA[ <211> 170]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 172]]>
          aatcggagat caaaaggcgg agtcacctac agctgctaaa ctcaaaggct tctctgtgtg 60
          tctcttcttt ctttgccatc agctgggcac ttctgcctct cagcccttac ctgatgctaa 120
          aataatgtgc ctcggccaca aaaaagcatg caaagtcatt gttacaacag 170
           <![CDATA[ <210> 173]]>
           <![CDATA[ <211> 1639]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 173]]>
          ggatctacag aactatttca ccaccagata tgacctagtt ttatatttct gggaggaaat 60
          gaattcatat ctagaagtct ggagtgagca aacaagagca agaaacaaaa agaagccaaa 120
          agcagaaggc tccaatatga acaagataaa tctatcttca aagacatatt agaagttggg 180
          aaaataattc atgtgaacta gacaagtgtg ttaagagtga taagtaaaat gcacgtggag 240
          acaagtgcat ccccagatct cagggacctc cccctgcctg tcacctgggg agtgagagga 300
          caggatagtg catgttcttt gtctctgaat ttttagttat atgtgctgta atgttgctct 360
          gaggaagccc ctggaaagtc tatcccaaca tatccacatc ttatattcca caaattaagc 420
          tgtagtatgt accctaagac gctgctaatt gactgccact tcgcaactca ggggcggctg 480
          cattttagta atgggtcaaa tgattcactt tttatgatgc ttccaaaggt gccttggctt 540
          ctcttcccaa ctgacaaatg ccaaagttga gaaaaatgat cataatttta gcataaacag 600
          agcagtcggc gacaccgatt ttataaataa actgagcacc ttctttttaa acaaacaaat 660
          gcgggtttat ttctcagatg atgttcatcc gtgaatggtc cagggaagga cctttcacct 720
          tgtctatatg gcattatgtc atcacaagct ctgaggcttc tcctttccat cctgcgtgga 780
          cagctaagac ctcagttttc aatagcatct agagcagtgg gactcagctg gggtgatttc 840
          gccccccatc tccgggggaa tgtctgaaga caattttggt tacctcaatg agggagtgga 900
          ggaggataca gtgctactac caactagtgg atagaggcca gggatgctgc tcaacctcct 960
          accatgtaca ggacgtctcc ccattacaac tacccaatcc gaagtgtcaa ctgtgtcagg 1020
          gctaagaaac cctggttttg agtagaaaag ggcctggaaa gaggggagcc aacaaatctg 1080
          tctgcttcct cacattagtc attggcaaat aagcattctg tctctttggc tgctgcctca 1140
          gcacagagag ccagaactct atcgggcacc aggataacat ctctcagtga acagagttga 1200
          caaggcctat gggaaatgcc tgatggggatt atcttcagct tgttgagctt ctaagtttct 1260
          ttcccttcat tctaccctgc aagccaagtt ctgtaagaga aatgcctgag ttctagctca 1320
          ggttttctta ctctgaattt agatctccag accctgcctg gccacaattc aaattaaggc 1380
          aacaaacata taccttccat gaagcacaca cagacttttg aaagcaagga caatgactgc 1440
          ttgaattgag gccttgagga atgaagcttt gaaggaaaag aatactttgt ttccagcccc 1500
          cttcccacac tcttcatgtg ttaaccactg ccttcctgga ccttggagcc acggtgactg 1560
          tattacatgt tgttatagaa aactgatttt agagttctga tcgttcaaga gaatgattaa 1620
          atatacattt cctacacca 1639
           <![CDATA[ <210> 174]]>
           <![CDATA[ <211> 2605]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 174]]>
          gtgagtcacc aaggaaggca gcggcagctc cactcagcca gtacccagat acgctgggaa 60
          ccttccccag ccatggcttc cctggggcag atcctcttct ggagcataat tagcatcatc 120
          attattctgg ctggagcaat tgcactcatc attggctttg gtatttcagg gagacactcc 180
          atcacagtca ctactgtcgc ctcagctggg aacattgggg aggatggaat cctgagctgc 240
          acttttgaac ctgacatcaa actttctgat atcgtgatac aatggctgaa ggaaggtgtt 300
          ttaggcttgg tccatgagtt caaagaaggc aaagatgagc tgtcggagca ggatgaaatg 360
          ttcagaggcc ggacagcagt gtttgctgat caagtgatag ttggcaatgc ctctttgcgg 420
          ctgaaaaacg tgcaactcac agatgctggc acctacaaat gttatatcat cacttctaaa 480
          ggcaagggga atgctaacct tgagtataaa actggagcct tcagcatgcc ggaagtgaat 540
          gtggactata atgccagctc agagaccttg cggtgtgagg ctccccgatg gttcccccag 600
          cccacagtgg tctgggcatc ccaagttgac cagggagcca acttctcgga agtctccaat 660
          accagctttg agctgaactc tgagaatgtg accatgaagg ttgtgtctgt gctctacaat 720
          gttacgatca acaacacata ctcctgtatg attgaaaatg aattgccaa agcaacaggg 780
          gatatcaaag tgacagaatc ggagatcaaa aggcggagtc acctacagct gctaaactca 840
          aaggcttctc tgtgtgtctc ttctttcttt gccatcagct gggcacttct gcctctcagc 900
          ccttacctga tgctaaaata atgtgcctcg gccacaaaaa agcatgcaaa gtcattgtta 960
          caacagggat ctacagaact atttcaccac cagatatgac ctagttttat atttctggga 1020
          ggaaatgaat tcatatctag aagtctggag tgagcaaaca agagcaagaa acaaaaagaa 1080
          gccaaaagca gaaggctcca atatgaacaa gataaatcta tcttcaaaga catattagaa 1140
          gttgggaaaa taattcatgt gaactagaca agtgtgttaa gagtgataag taaaatgcac 1200
          gtggagacaa gtgcatcccc agatctcagg gacctccccc tgcctgtcac ctggggagtg 1260
          agaggacagg atagtgcatg ttctttgtct ctgaattttt agttatatgt gctgtaatgt 1320
          tgctctgagg aagcccctgg aaagtctatc ccaacatatc cacatcttat attccacaaa 1380
          ttaagctgta gtatgtaccc taagacgctg ctaattgact gccacttcgc aactcagggg 1440
          cggctgcatt ttagtaatgg gtcaaatgat tcacttttta tgatgcttcc aaaggtgcct 1500
          tggcttctct tcccaactga caaatgccaa agttgagaaa aatgatcata attttagcat 1560
          aaacagagca gtcggcgaca ccgattttat aaataaactg agcaccttct ttttaaacaa 1620
          acaaatgcgg gtttatttct cagatgatgt tcatccgtga atggtccagg gaaggacctt 1680
          tcaccttgtc tatatggcat tatgtcatca caagctctga ggcttctcct ttccatcctg 1740
          cgtggacagc taagacctca gttttcaata gcatctagag cagtggggact cagctggggt 1800
          gatttcgccc cccatctccg ggggaatgtc tgaagacaat tttggttacc tcaatgaggg 1860
          agtgggaggag gatacagtgc tactaccaac tagtggatag aggccaggga tgctgctcaa 1920
          cctcctacca tgtacaggac gtctccccat tacaactacc caatccgaag tgtcaactgt 1980
          gtcagggcta agaaaccctg gttttgagta gaaaagggcc tggaaagagg ggagccaaca 2040
          aatctgtctg cttcctcaca ttagtcattg gcaaataagc attctgtctc tttggctgct 2100
          gcctcagcac agagagccag aactctatcg ggcaccagga taacatctct cagtgaacag 2160
          agttgacaag gcctatggga aatgcctgat gggattatct tcagcttgtt gagcttctaa 2220
          gtttctttcc cttcattcta ccctgcaagc caagttctgt aagagaaatg cctgagttct 2280
          agctcaggtt ttcttactct gaatttagat ctccagaccc tgcctggcca caattcaaat 2340
          taaggcaaca aacatatacc ttccatgaag cacacacaga cttttgaaag caaggacaat 2400
          gactgcttga attgaggcct tgaggaatga agctttgaag gaaaagaata ctttgtttcc 2460
          agcccccttc ccacactctt catgtgttaa ccactgcctt cctggacctt ggagccacgg 2520
          tgactgtatt acatgttgtt atagaaaact gattttagag ttctgatcgt tcaagagaat 2580
          gattaaatat aatttccta cacca 2605
           <![CDATA[ <210> 175]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 175]]>
          Met Ala Ser Leu Gly Gln Ile Leu Phe Trp
          1 5 10
           <![CDATA[ <210> 176]]>
           <![CDATA[ <211> 21]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 176]]>
          Ile Ile Ser Ile Ile Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile
          1 5 10 15
          Gly Phe Gly Ile Ser
                      20
           <![CDATA[ <210> 177]]>
           <![CDATA[ <211> 115]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 177]]>
          Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile Gly
          1 5 10 15
          Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu Ser
                      20 25 30
          Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val His
                  35 40 45
          Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met Phe
              50 55 60
          Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn Ala
          65 70 75 80
          Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr Lys
                          85 90 95
          Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu Tyr
                      100 105 110
          Lys Thr Gly
                  115
           <![CDATA[ <210> 178]]>
           <![CDATA[ <211> 92]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 178]]>
          Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn Ala Ser Ser Glu Thr
          1 5 10 15
          Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln Pro Thr Val Val Trp
                      20 25 30
          Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser Glu Val Ser Asn Thr
                  35 40 45
          Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met Lys Val Val Ser Val
              50 55 60
          Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser Cys Met Ile Glu Asn
          65 70 75 80
          Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val Thr
                          85 90
           <![CDATA[ <210> 179]]>
           <![CDATA[ <211> 40]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 179]]>
          Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser Lys Ala
          1 5 10 15
          Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu Leu Pro
                      20 25 30
          Leu Ser Pro Tyr Leu Met Leu Lys
                  35 40
           <![CDATA[ <210> 180]]>
           <![CDATA[ <211> 282]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 180]]>
          Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
          1 5 10 15
          Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser
                      20 25 30
          Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile
                  35 40 45
          Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu
              50 55 60
          Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val
          65 70 75 80
          His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met
                          85 90 95
          Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn
                      100 105 110
          Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr
                  115 120 125
          Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu
              130 135 140
          Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn
          145 150 155 160
          Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln
                          165 170 175
          Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser
                      180 185 190
          Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met
                  195 200 205
          Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser
              210 215 220
          Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val
          225 230 235 240
          Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser
                          245 250 255
          Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu
                      260 265 270
          Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys
                  275 280
           <![CDATA[ <210> 181]]>
           <![CDATA[ <211> 169]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 181]]>
          gtgagtcacc aaggaaggca gcggcagctc cactcagcca gtacccagat acgctgggaa 60
          ccttccccag ccatggcttc cctggggcag atcctcttct ggagcataat tagcatcatc 120
          attattctgg ctggagcaat tgcactcatc attggctttg gtatttcag 169
           <![CDATA[ <210> 182]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 182]]>
          Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
          1 5 10 15
          Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser
                      20 25 30
           <![CDATA[ <210> 183]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 183]]>
          000
           <![CDATA[ <210> 184]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 184]]>
          ctggctggag attaatccgg acactggtgc catttccact cgggctgagc tggacaggga 60
          ggattttgag cacgtgaaga acagcacgta cacagcccta atcatagcta cagacaatg 119
           <![CDATA[ <210> 185]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 185]]>
          ccttgcctcc ccgattgaaa gagatgaaaa 30
           <![CDATA[ <210> 186]]>
           <![CDATA[ <211> 148]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 186]]>
          ctggctggag attaatccgg acactggtgc catttccact cgggctgagc tggacaggga 60
          ggattttgag cacgtgaaga acagcacgta cacagcccta atcatagcta cagacaatgc 120
          cttgcctccc cgattgaaag agatgaaa 148
           <![CDATA[ <210> 187]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 187]]>
          Trp Leu Glu Ile Asn Pro Asp Thr Gly Ala Ile Ser Thr Arg Ala Glu
          1 5 10 15
          Leu Asp Arg Glu Asp Phe Glu His Val Lys Asn Ser Thr Tyr Thr Ala
                      20 25 30
          Leu Ile Ile Ala Thr Asp Asn Ala Leu Pro Pro Arg Leu Lys Glu Met
                  35 40 45
          Lys
           <![CDATA[ <210> 188]]>
           <![CDATA[ <211> 172]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 188]]>
          agtggcgtcg gaactgcaaa gcacctgtga gcttgcggaa gtcagttcag actccagccc 60
          gctccagccc ggcccgaccc gaccgcaccc ggcgcctgcc ctcgctcggc gtccccggcc 120
          agccatgggc ccttggagcc gcagcctctc ggcgctgctg ctgctgctgc ag 172
           <![CDATA[ <210> 189]]>
           <![CDATA[ <211> 115]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 189]]>
          gtctcctctt ggctctgcca ggagccggag ccctgccacc ctggctttga cgccgagagc 60
          tacacgttca cggtgccccg gcgccacctg gagagaggcc gcgtcctggg cagag 115
           <![CDATA[ <210> 190]]>
           <![CDATA[ <211> 224]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 190]]>
          tgaattttga agattgcacc ggtcgacaaa ggacagccta tttttccctc gacacccgat 60
          tcaaagtggg cacagatggt gtgattacag tcaaaaggcc tctacggttt cataacccac 120
          agatccattt cttggtctac gcctgggact ccacctacag aaagttttcc accaaagtca 180
          cgctgaatac agtggggcac caccaccgcc ccccgcccca tcag 224
           <![CDATA[ <210> 191]]>
           <![CDATA[ <211> 144]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 191]]>
          gcctccgttt ctggaatcca agcagaattg ctcacatttc ccaactcctc tcctggcctc 60
          agaagacaga agagagactg ggttattcct cccatcagct gcccagaaaa tgaaaaaggc 120
          ccatttccta aaaacctggt tcag 144
           <![CDATA[ <210> 192]]>
           <![CDATA[ <211> 156]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 192]]>
          atcaaatcca acaaagacaa agaaggcaag gttttctaca gcatcactgg ccaaggagct 60
          gacacacccc ctgttggtgt ctttattatt gaaagagaaa caggatggct gaaggtgaca 120
          gagcctctgg atagagaacg cattgccaca tacact 156
           <![CDATA[ <210> 193]]>
           <![CDATA[ <211> 145]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 193]]>
          ctcttctctc acgctgtgtc atccaacggg aatgcagttg aggatccaat ggagattttg 60
          atcacggtaa ccgatcagaa tgacaacaag cccgaattca cccaggaggt ctttaagggg 120
          tctgtcatgg aaggtgctct tccag 145
           <![CDATA[ <210> 194]]>
           <![CDATA[ <211> 176]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 194]]>
          gaacctctgt gatggaggtc acagccacag acgcggacga tgatgtgaac acctacaatg 60
          ccgccatcgc ttacaccatc ctcagccaag atcctgagct ccctgacaaa aatatgttca 120
          ccattaacag gaacacagga gtcatcagtg tggtcaccac tgggctggac cgagag 176
           <![CDATA[ <210> 195]]>
           <![CDATA[ <211> 129]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 195]]>
          agtttcccta cgtataccct ggtggttcaa gctgctgacc ttcaaggtga ggggttaagc 60
          acaacagcaa cagctgtgat cacagtcact gacaccaacg ataatcctcc gatcttcaat 120
          cccaccacg 129
           <![CDATA[ <210> 196]]>
           <![CDATA[ <211> 250]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 196]]>
          tacaagggtc aggtgcctga gaacgaggct aacgtcgtaa tcaccacact gaaagtgact 60
          gatgctgatg cccccaatac cccagcgtgg gaggctgtat acaccatatt gaatgatgat 120
          ggtggacaat ttgtcgtcac cacaaatcca gtgaacaacg atggcatttt gaaaacagca 180
          aaggtttgta tggtacctgg caagatgcag aaactggcat cctcacagct gttcataccc 240
          ttgtcccctg 250
           <![CDATA[ <210> 197]]>
           <![CDATA[ <211> 245]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 197]]>
          ggcttggatt ttgaggccaa gcagcagtac attctacacg tagcagtgac gaatgtggta 60
          ccttttgagg tctctctcac cacctccaca gccaccgtca ccgtggatgt gctggatgtg 120
          aatgaagccc ccatctttgt gcctcctgaa aagagagtgg aagtgtccga ggactttggc 180
          gtgggccagg aaatcacatc ctacactgcc caggagccag acacatttat ggaacagaaa 240
          ataac 245
           <![CDATA[ <210> 198]]>
           <![CDATA[ <211> 146]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 198]]>
          atatcggatt tggagagaca ctgccaactg gctggagatt aatccggaca ctggtgccat 60
          ttccactcgg gctgagctgg acaggggagga ttttgagcac gtgaagaaca gcacgtacac 120
          agccctaatc atagctacag acaatg 146
           <![CDATA[ <210> 199]]>
           <![CDATA[ <211> 225]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 199]]>
          gttctccagt tgctactgga acagggacac ttctgctgat cctgtctgat gtgaatgaca 60
          acgcccccat accagaacct cgaactatat tcttctgtga gaggaatcca aagcctcagg 120
          tcataaacat cattgatgca gaccttcctc ccaatacatc tcccttcaca gcagaactaa 180
          cacacggggc gagtgccaac tggaccattc agtacaacga cccaa 225
           <![CDATA[ <210> 200]]>
           <![CDATA[ <211> 228]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 200]]>
          cccaagaatc tatcattttg aagccaaaga tggccttaga ggtgggtgac tacaaaatca 60
          atctcaagct catggataac cagaataaag accaagtgac caccttagag gtcagcgtgt 120
          gtgactgtga aggggccgct ggcgtctgta ggaaggcaca gcctgtcgaa gcaggattgc 180
          aaattcctgc cattctgggg attcttggag gaattcttgc tttgctaa 228
           <![CDATA[ <210> 201]]>
           <![CDATA[ <211> 131]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 201]]>
          ttctgattct gctgctcttg ctgtttcttc ggaggagagc ggtggtcaaa gagcccttac 60
          tgccccccaga ggatgacacc cgggacaacg tttattaacta tgatgaagaa ggaggcggag 120
          aagaggacca g 131
           <![CDATA[ <210> 202]]>
           <![CDATA[ <211> 144]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 202]]>
          gactttgact tgagccagct gcacaggggc ctggacgctc ggcctgaagt gactcgtaac 60
          gacgttgcac caaccctcat gagtgtcccc cggtatcttc cccgccctgc caatcccgat 120
          gaaattggaa attttattga tgaa 144
           <![CDATA[ <210> 203]]>
           <![CDATA[ <211> 2248]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 203]]>
          aatctgaaag cggctgatac tgaccccaca gccccgcctt atgattctct gctcgtgttt 60
          gactatgaag gaagcggttc cgaagctgct agtctgagct ccctgaactc ctcagagtca 120
          gacaaagacc aggactatga ctacttgaac gaatggggca atcgcttcaa gaagctggct 180
          gacatgtacg gaggcggcga ggacgactag gggactcgag agaggcgggc cccagaccca 240
          tgtgctggga aatgcagaaa tcacgttgct ggtggttttt cagctccctt cccttgagat 300
          gagtttctgg ggaaaaaaaa gagactggtt agtgatgcag ttagtatagc tttatactct 360
          ctccacttta tagctctaat aagtttgtgttagaaaagtt tcgacttatt tcttaaagct 420
          tttttttttt tcccatcact ctttacatgg tggtgatgtc caaaagatac ccaaatttta 480
          atattccaga agaacaactt tagcatcaga aggttcaccc agcaccttgc agattttctt 540
          aaggaatttt gtctcacttt taaaaagaag gggagaagtc agctactcta gttctgttgt 600
          tttgtgtata taatttttta aaaaaaattt gtgtgcttct gctcattact acactggtgt 660
          gtccctctgc cttttttttt tttttaagac agggtctcat tctatcggcc aggctggagt 720
          gcagtggtgc aatcacagct cactgcagcc ttgtcctccc aggctcaagc tatccttgca 780
          cctcagcctc ccaagtagct gggaccacag gcatgcacca ctacgcatga ctaatttttt 840
          aaatatttga gacggggtct ccctgtgtta cccaggctgg tctcaaactc ctggggctcaa 900
          gtgatcctcc catcttggcc tcccagagta ttgggattac agacatgagc cactgcacct 960
          gcccagctcc ccaactccct gccatttttt aagagacagt ttcgctccat cgcccaggcc 1020
          tgggatgcag tgatgtgatc atagctcact gtaacctcaa actctggggc tcaagcagtt 1080
          ctcccaccag cctccttttt atttttttgt acagatgggg tcttgctatg ttgcccaagc 1140
          tggtcttaaa ctcctggcct caagcaatcc ttctgccttg gccccccaaa gtgctgggat 1200
          tgtgggcatg agctgctgtg cccagcctcc atgttttaat atcaactctc actcctgaat 1260
          tcagttgctt tgcccaagat aggagttctc tgatgcagaa attattgggc tcttttaggg 1320
          taagaagttt gtgtctttgt ctggccacat cttgactagg tattgtctac tctgaagacc 1380
          tttaatggct tccctctttc atctcctgag tatgtaactt gcaatgggca gctatccagt 1440
          gacttgttct gagtaagtgt gttcattaat gtttattag ctctgaagca agagtgatat 1500
          actccaggac ttagaatagt gcctaaagtg ctgcagccaa agacagagcg gaactatgaa 1560
          aagtggggctt ggagatggca ggagagcttg tcattgagcc tggcaattta gcaaactgat 1620
          gctgaggatg attgaggtgg gtctacctca tctctgaaaa ttctggaagg aatggaggag 1680
          tctcaacatg tgtttctgac acaagatccg tggtttgtac tcaaagccca gaatccccaa 1740
          gtgcctgctt ttgatgatgt ctacagaaaa tgctggctga gctgaacaca tttgcccaat 1800
          tccaggtgtg cacagaaaac cgagaatatt caaaattcca aatttttttc ttaggagcaa 1860
          gaagaaaatg tggccctaaa ggggggttagt tgaggggtag ggggtagtga ggatcttgat 1920
          ttggatctct ttttatttaa atgtgaattt caacttttga caatcaaaga aaagactttt 1980
          gttgaaatag ctttactgtt tctcaagtgt tttggagaaa aaaatcaacc ctgcaatcac 2040
          tttttggaat tgtcttgatt tttcggcagt tcaagctata tcgaatatag ttctgtgtag 2100
          agaatgtcac tgtagttttg agtgtataca tgtgtgggtg ctgataattg tgtattttct 2160
          ttgggggtgg aaaaggaaaa caattcaagc tgagaaaagt attctcaaag atgcattttt 2220
          ataaatttta ttaaacaatt ttgttaaa 2248
           <![CDATA[ <210> 204]]>
           <![CDATA[ <211> 4878]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 204]]>
          agtggcgtcg gaactgcaaa gcacctgtga gcttgcggaa gtcagttcag actccagccc 60
          gctccagccc ggcccgaccc gaccgcaccc ggcgcctgcc ctcgctcggc gtccccggcc 120
          agccatgggc ccttggagcc gcagcctctc ggcgctgctg ctgctgctgc aggtctcctc 180
          ttggctctgc caggagccgg agccctgcca ccctggcttt gacgccgaga gctacacgtt 240
          cacggtgccc cggcgccacc tggagagagg ccgcgtcctg ggcagagtga attttgaaga 300
          ttgcaccggt cgacaaagga cagcctatttttccctcgac acccgattca aagtgggcac 360
          agatggtgtg attacagtca aaaggcctct acggtttcat aacccacaga tccattctt 420
          ggtctacgcc tgggactcca cctacagaaa gttttccacc aaagtcacgc tgaatacagt 480
          ggggcaccac caccgccccc cgccccatca ggcctccgtt tctggaatcc aagcagaatt 540
          gctcacattt cccaactcct ctcctggcct cagaagacag aagagagact gggttatcc 600
          tcccatcagc tgcccagaaa atgaaaaagg cccatttcct aaaaacctgg ttcagatcaa 660
          atccaacaaa gacaaagaag gcaaggtttt ctacagcatc actggccaag gagctgacac 720
          accccctgtt ggtgtcttta ttattgaaag agaaacagga tggctgaagg tgacagagcc 780
          tctggataga gaacgcattg ccacatacac tctcttctct cacgctgtgt catccaacgg 840
          gaatgcagtt gaggatccaa tggagatttt gatcacggta accgatcaga atgacaacaa 900
          gcccgaattc acccaggagg tctttaaggg gtctgtcatg gaaggtgctc ttccaggaac 960
          ctctgtgatg gaggtcacag ccacagacgc ggacgatgat gtgaacacct acaatgccgc 1020
          catcgcttac accatcctca gccaagatcc tgagctccct gacaaaaata tgttcaccat 1080
          taacaggaac acaggaggtca tcagtgtggt caccactggg ctggaccgag agagtttccc 1140
          tacgtatacc ctggtggttc aagctgctga ccttcaaggt gaggggttaa gcacaacagc 1200
          aacagctgtg atcacagtca ctgacaccaa cgataatcct ccgatcttca atcccaccac 1260
          gtacaagggt caggtgcctg agaacgaggc taacgtcgta atcaccacac tgaaagtgac 1320
          tgatgctgat gcccccaata ccccagcgtg ggaggctgta tacaccatat tgaatgatga 1380
          tggtggacaa tttgtcgtca ccacaaatcc agtgaacaac gatggcattt tgaaaacagc 1440
          aaaggtttgt atggtacctg gcaagatgca gaaactggca tcctcacagc tgttcatacc 1500
          cttgtcccct gggcttggat tttgaggcca agcagcagta cattctacac gtagcagtga 1560
          cgaatgtggt accttttgag gtctctctca ccacctccac agccaccgtc accgtggatg 1620
          tgctggatgt gaatgaagcc cccatctttg tgcctcctga aaagagagtg gaagtgtccg 1680
          aggactttgg cgtggggccag gaaatcacat cctacactgc ccaggagcca gacacattta 1740
          tggaacagaa aataacatat cggatttgga gagacactgc caactggctg gagattaatc 1800
          cggacactgg tgccatttcc actcgggctg agctggacag ggaggatttt gagcacgtga 1860
          agaacagcac gtacacagcc ctaatcatag ctacagacaa tggttctcca gttgctactg 1920
          gaacagggac acttctgctg atcctgtctg atgtgaatga caacgccccc ataccagaac 1980
          ctcgaactat attcttctgt gagaggaatc caaagcctca ggtcataaac atcattgatg 2040
          cagaccttcc tcccaataca tctcccttca cagcagaact aacacacggg gcgagtgcca 2100
          actggaccat tcagtacaac gacccaaccc aagaatctat cattttgaag ccaaagatgg 2160
          ccttagaggt gggtgactac aaaatcaatc tcaagctcat ggataaccag aataaagacc 2220
          aagtgaccac cttagaggtc agcgtgtgtg actgtgaagg ggccgctggc gtctgtagga 2280
          aggcacagcc tgtcgaagca ggattgcaaa ttcctgccat tctggggatt cttggaggaa 2340
          ttcttgcttt gctaattctg attctgctgc tcttgctgtt tcttcggagg agagcggtgg 2400
          tcaaagagcc cttactgccc ccagaggatg acacccggga caacgtttat tactatgatg 2460
          aagaaggagg cggagaagag gaccaggact ttgacttgag ccagctgcac aggggcctgg 2520
          acgctcggcc tgaagtgact cgtaacgacg ttgcaccaac cctcatgagt gtcccccggt 2580
          atcttccccg ccctgccaat cccgatgaaa ttggaaattt tattgatgaa aatctgaaag 2640
          cggctgatac tgaccccaca gccccgcctt atgattctct gctcgtgttt gactatgaag 2700
          gaagcggttc cgaagctgct agtctgagct ccctgaactc ctcagagtca gacaaagacc 2760
          aggactatga ctacttgaac gaatggggca atcgcttcaa gaagctggct gacatgtacg 2820
          gaggcggcga ggacgactag gggactcgag agaggcgggc cccagaccca tgtgctggga 2880
          aatgcagaaa tcacgttgct ggtggttttt cagctccctt cccttgagat gagtttctgg 2940
          ggaaaaaaaa gagactggtt agtgatgcag ttagtatagc tttatactct ctccacttta 3000
          tagctctaat aagtttgtgttagaaaagtt tcgacttatt tcttaaagct tttttttttt 3060
          tcccatcact ctttacatgg tggtgatgtc caaaagatac ccaaatttta atattccaga 3120
          agaacaactt tagcatcaga aggttcaccc agcaccttgc aagattttctt aaggaatttt 3180
          gtctcacttt taaaaagaag gggagaagtc agctactcta gttctgttgt tttgtgtata 3240
          taatttttta aaaaaaattt gtgtgcttct gctcattact acactggtgt gtccctctgc 3300
          cttttttttt tttttaagac agggtctcat tctatcggcc aggctggagt gcagtggtgc 3360
          aatcacagct cactgcagcc ttgtcctccc aggctcaagc tatccttgca cctcagcctc 3420
          ccaagtagct gggaccacag gcatgcacca ctacgcatga ctaatttttt aaatatttga 3480
          gacggggtct ccctgtgtta cccaggctgg tctcaaactc ctggggctcaa gtgatcctcc 3540
          catcttggcc tcccagagta ttgggattac agacatgagc cactgcacct gcccagctcc 3600
          ccaactccct gccatttttt aagagacagt ttcgctccat cgcccaggcc tgggatgcag 3660
          tgatgtgatc atagctcact gtaacctcaa actctggggc tcaagcagtt ctcccaccag 3720
          cctccttttt atttttttgt acagatgggg tcttgctatg ttgcccaagc tggtcttaaa 3780
          ctcctggcct caagcaatcc ttctgccttg gccccccaaa gtgctgggat tgtgggcatg 3840
          agctgctgtg cccagcctcc atgttttaat atcaactctc actcctgaat tcagttgctt 3900
          tgcccaagat aggagttctc tgatgcagaa attattgggc tcttttaggg taagaagttt 3960
          gtgtctttgt ctggccacat cttgactagg tattgtctac tctgaagacc tttaatggct 4020
          tccctctttc atctcctgag tatgtaactt gcaatgggca gctatccagt gacttgttct 4080
          gagtaagtgt gttcattaat gtttatttag ctctgaagca agagtgatat actccaggac 4140
          ttagaatagt gcctaaagtg ctgcagccaa agacagagcg gaactatgaa aagtgggctt 4200
          ggagatggca ggagagcttg tcattgagcc tggcaattta gcaaactgat gctgaggatg 4260
          attgaggtgg gtctacctca tctctgaaaa ttctggaagg aatggaggag tctcaacatg 4320
          tgtttctgac acaagatccg tggtttgtac tcaaagccca gaatccccaa gtgcctgctt 4380
          ttgatgatgt ctacagaaaa tgctggctga gctgaacaca tttgcccaat tccaggtgtg 4440
          cacagaaaac cgagaatatt caaaattcca aatttttttc ttaggagcaa gaagaaaatg 4500
          tggccctaaa gggggttagt tgaggggtag ggggtagtga ggatcttgat ttggatctct 4560
          ttttatttaa atgtgaattt caacttttga caatcaaaga aaagactttt gttgaaatag 4620
          ctttactgtt tctcaagtgt tttggagaaa aaaatcaacc ctgcaatcac tttttggaat 4680
          tgtcttgatt tttcggcagt tcaagctata tcgaatatag ttctgtgtag agaatgtcac 4740
          tgtagttttg agtgtataca tgtgtgggtg ctgataattg tgtattttct ttgggggtgg 4800
          aaaaggaaaa caattcaagc tgagaaaagt attctcaaag atgcattttt ataaatttta 4860
          ttaaacaatt ttgttaaa 4878
           <![CDATA[ <210> 205]]>
           <![CDATA[ <211> 5]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 205]]>
          Met Glu Gln Lys Ile
          1 5
           <![CDATA[ <210> 206]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 206]]>
          Tyr Arg Ile Trp Arg Asp Thr Ala Asn Trp Leu Glu Ile Asn Pro Asp
          1 5 10 15
          Thr Gly Ala Ile Ser Thr Arg Ala Glu Leu Asp Arg Glu Asp Phe Glu
                      20 25 30
          His Val Lys Asn Ser Thr Tyr Thr Ala Leu Ile Ile Ala Thr Asp Asn
                  35 40 45
           <![CDATA[ <210> 207]]>
           <![CDATA[ <211> 74]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 207]]>
          Ser Pro Val Ala Thr Gly Thr Gly Thr Leu Leu Leu Ile Leu Ser Asp
          1 5 10 15
          Val Asn Asp Asn Ala Pro Ile Pro Glu Pro Arg Thr Ile Phe Phe Cys
                      20 25 30
          Glu Arg Asn Pro Lys Pro Gln Val Ile Asn Ile Ile Asp Ala Asp Leu
                  35 40 45
          Pro Pro Asn Thr Ser Pro Phe Thr Ala Glu Leu Thr His Gly Ala Ser
              50 55 60
          Ala Asn Trp Thr Ile Gln Tyr Asn Asp Pro
          65 70
           <![CDATA[ <210> 208]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 208]]>
          Gln Glu Ser Ile Ile Leu Lys Pro Lys Met Ala Leu Glu Val Gly Asp
          1 5 10 15
          Tyr Lys Ile Asn Leu Lys Leu Met Asp Asn Gln Asn Lys Asp Gln Val
                      20 25 30
          Thr Thr Leu Glu Val Ser Val Cys Asp Cys Glu Gly Ala Ala Gly Val
                  35 40 45
          Cys Arg Lys Ala Gln Pro Val Glu Ala Gly Leu Gln Ile Pro Ala Ile
              50 55 60
          Leu Gly Ile Leu Gly Gly Ile Leu Ala Leu Leu
          65 70 75
           <![CDATA[ <210> 209]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 209]]>
          Leu Ile Leu Leu Leu Leu Leu Leu Phe Leu Arg Arg Arg Arg Ala Val Val Lys
          1 5 10 15
          Glu Pro Leu Leu Pro Pro Glu Asp Asp Thr Arg Asp Asn Val Tyr Tyr
                      20 25 30
          Tyr Asp Glu Glu Gly Gly Gly Gly Glu Glu Asp Gln
                  35 40
           <![CDATA[ <210> 210]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 210]]>
          Asp Phe Asp Leu Ser Gln Leu His Arg Gly Leu Asp Ala Arg Pro Glu
          1 5 10 15
          Val Thr Arg Asn Asp Val Ala Pro Thr Leu Met Ser Val Pro Arg Tyr
                      20 25 30
          Leu Pro Arg Pro Ala Asn Pro Asp Glu Ile Gly Asn Phe Ile Asp Glu
                  35 40 45
           <![CDATA[ <210> 211]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 211]]>
          Asn Leu Lys Ala Ala Asp Thr Asp Pro Thr Ala Pro Pro Tyr Asp Ser
          1 5 10 15
          Leu Leu Val Phe Asp Tyr Glu Gly Ser Gly Ser Glu Ala Ala Ser Leu
                      20 25 30
          Ser Ser Leu Asn Ser Ser Glu Ser Asp Lys Asp Gln Asp Tyr Asp Tyr
                  35 40 45
          Leu Asn Glu Trp Gly Asn Arg Phe Lys Lys Leu Ala Asp Met Tyr Gly
              50 55 60
          Gly Gly Glu Asp Asp
          65
           <![CDATA[ <210> 212]]>
           <![CDATA[ <211> 366]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 212]]>
          Met Glu Gln Lys Ile Thr Tyr Arg Ile Trp Arg Asp Thr Ala Asn Trp
          1 5 10 15
          Leu Glu Ile Asn Pro Asp Thr Gly Ala Ile Ser Thr Arg Ala Glu Leu
                      20 25 30
          Asp Arg Glu Asp Phe Glu His Val Lys Asn Ser Thr Tyr Thr Ala Leu
                  35 40 45
          Ile Ile Ala Thr Asp Asn Gly Ser Pro Val Ala Thr Gly Thr Gly Thr
              50 55 60
          Leu Leu Leu Ile Leu Ser Asp Val Asn Asp Asn Ala Pro Ile Pro Glu
          65 70 75 80
          Pro Arg Thr Ile Phe Phe Cys Glu Arg Asn Pro Lys Pro Gln Val Ile
                          85 90 95
          Asn Ile Ile Asp Ala Asp Leu Pro Asn Thr Ser Pro Phe Thr Ala
                      100 105 110
          Glu Leu Thr His Gly Ala Ser Ala Asn Trp Thr Ile Gln Tyr Asn Asp
                  115 120 125
          Pro Thr Gln Glu Ser Ile Ile Leu Lys Pro Lys Met Ala Leu Glu Val
              130 135 140
          Gly Asp Tyr Lys Ile Asn Leu Lys Leu Met Asp Asn Gln Asn Lys Asp
          145 150 155 160
          Gln Val Thr Thr Leu Glu Val Ser Val Cys Asp Cys Glu Gly Ala Ala
                          165 170 175
          Gly Val Cys Arg Lys Ala Gln Pro Val Glu Ala Gly Leu Gln Ile Pro
                      180 185 190
          Ala Ile Leu Gly Ile Leu Gly Gly Ile Leu Ala Leu Leu Ile Leu Ile
                  195 200 205
          Leu Leu Leu Leu Leu Leu Phe Leu Arg Arg Arg Ala Val Val Lys Glu Pro
              210 215 220
          Leu Leu Pro Pro Glu Asp Asp Thr Arg Asp Asn Val Tyr Tyr Tyr Asp
          225 230 235 240
          Glu Glu Gly Gly Gly Glu Glu Asp Gln Asp Phe Asp Leu Ser Gln Leu
                          245 250 255
          His Arg Gly Leu Asp Ala Arg Pro Glu Val Thr Arg Asn Asp Val Ala
                      260 265 270
          Pro Thr Leu Met Ser Val Pro Arg Tyr Leu Pro Arg Pro Ala Asn Pro
                  275 280 285
          Asp Glu Ile Gly Asn Phe Ile Asp Glu Asn Leu Lys Ala Ala Asp Thr
              290 295 300
          Asp Pro Thr Ala Pro Pro Tyr Asp Ser Leu Leu Val Phe Asp Tyr Glu
          305 310 315 320
          Gly Ser Gly Ser Glu Ala Ala Ser Leu Ser Ser Leu Asn Ser Ser Glu
                          325 330 335
          Ser Asp Lys Asp Gln Asp Tyr Asp Tyr Leu Asn Glu Trp Gly Asn Arg
                      340 345 350
          Phe Lys Lys Leu Ala Asp Met Tyr Gly Gly Gly Glu Asp Asp
                  355 360 365
           <![CDATA[ <210> 213]]>
           <![CDATA[ <211> 1902]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 213]]>
          agtggcgtcg gaactgcaaa gcacctgtga gcttgcggaa gtcagttcag actccagccc 60
          gctccagccc ggcccgaccc gaccgcaccc ggcgcctgcc ctcgctcggc gtccccggcc 120
          agccatgggc ccttggagcc gcagcctctc ggcgctgctg ctgctgctgc aggtctcctc 180
          ttggctctgc caggagccgg agccctgcca ccctggcttt gacgccgaga gctacacgtt 240
          cacggtgccc cggcgccacc tggagagagg ccgcgtcctg ggcagagtga attttgaaga 300
          ttgcaccggt cgacaaagga cagcctatttttccctcgac acccgattca aagtgggcac 360
          agatggtgtg attacagtca aaaggcctct acggtttcat aacccacaga tccattctt 420
          ggtctacgcc tgggactcca cctacagaaa gttttccacc aaagtcacgc tgaatacagt 480
          ggggcaccac caccgccccc cgccccatca ggcctccgtt tctggaatcc aagcagaatt 540
          gctcacattt cccaactcct ctcctggcct cagaagacag aagagagact gggttatcc 600
          tcccatcagc tgcccagaaa atgaaaaagg cccatttcct aaaaacctgg ttcagatcaa 660
          atccaacaaa gacaaagaag gcaaggtttt ctacagcatc actggccaag gagctgacac 720
          accccctgtt ggtgtcttta ttattgaaag agaaacagga tggctgaagg tgacagagcc 780
          tctggataga gaacgcattg ccacatacac tctcttctct cacgctgtgt catccaacgg 840
          gaatgcagtt gaggatccaa tggagatttt gatcacggta accgatcaga atgacaacaa 900
          gcccgaattc acccaggagg tctttaaggg gtctgtcatg gaaggtgctc ttccaggaac 960
          ctctgtgatg gaggtcacag ccacagacgc ggacgatgat gtgaacacct acaatgccgc 1020
          catcgcttac accatcctca gccaagatcc tgagctccct gacaaaaata tgttcaccat 1080
          taacaggaac acaggaggtca tcagtgtggt caccactggg ctggaccgag agagtttccc 1140
          tacgtatacc ctggtggttc aagctgctga ccttcaaggt gaggggttaa gcacaacagc 1200
          aacagctgtg atcacagtca ctgacaccaa cgataatcct ccgatcttca atcccaccac 1260
          gtacaagggt caggtgcctg agaacgaggc taacgtcgta atcaccacac tgaaagtgac 1320
          tgatgctgat gcccccaata ccccagcgtg ggaggctgta tacaccatat tgaatgatga 1380
          tggtggacaa tttgtcgtca ccacaaatcc agtgaacaac gatggcattt tgaaaacagc 1440
          aaaggtttgt atggtacctg gcaagatgca gaaactggca tcctcacagc tgttcatacc 1500
          cttgtcccct gggcttggat tttgaggcca agcagcagta cattctacac gtagcagtga 1560
          cgaatgtggt accttttgag gtctctctca ccacctccac agccaccgtc accgtggatg 1620
          tgctggatgt gaatgaagcc cccatctttg tgcctcctga aaagagagtg gaagtgtccg 1680
          aggactttgg cgtggggccag gaaatcacat cctacactgc ccaggagcca gacacattta 1740
          tggaacagaa aataacatat cggatttgga gagacactgc caactggctg gagattaatc 1800
          cggacactgg tgccatttcc actcgggctg agctggacag ggaggatttt gagcacgtga 1860
          agaacagcac gtacacagcc ctaatcatag ctacagacaa tg 1902
           <![CDATA[ <210> 214]]>
           <![CDATA[ <211> 53]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 214]]>
          Met Glu Gln Lys Ile Tyr Arg Ile Trp Arg Asp Thr Ala Asn Trp Leu
          1 5 10 15
          Glu Ile Asn Pro Asp Thr Gly Ala Ile Ser Thr Arg Ala Glu Leu Asp
                      20 25 30
          Arg Glu Asp Phe Glu His Val Lys Asn Ser Thr Tyr Thr Ala Leu Ile
                  35 40 45
          Ile Ala Thr Asp Asn
              50
           <![CDATA[ <210> 215]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 215]]>
          atggcgctcc tgctgtgctt cgtgctcctg tgcggagtag tgg 43
           <![CDATA[ <210> 216]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 216]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaact 58
           <![CDATA[ <210> 217]]>
           <![CDATA[ <211> 101]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 217]]>
          atggcgctcc tgctgtgctt cgtgctcctg tgcggagtag tggccttgcc tccccgattg 60
          aaagagatga aaagccagga atcggctgca ggttccaaac t 101
           <![CDATA[ <210> 218]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 218]]>
          Met Ala Leu Leu Leu Cys Phe Val Leu Leu Cys Gly Val Val Ala Leu
          1 5 10 15
          Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser
                      20 25 30
          Lys
           <![CDATA[ <210> 219]]>
           <![CDATA[ <211> 130]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 219]]>
          agtcgggagc gcgcgaggcg cggggagcct gggaccagga gcgagagccg cctacctgca 60
          gccgccgccc acggcacggc agccaccatg gcgctcctgc tgtgcttcgt gctcctgtgc 120
          ggagtagtgg 130
           <![CDATA[ <210> 220]]>
           <![CDATA[ <211> 167]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 220]]>
          atttcgccag aagtttgagt atcactactc ctgaagagat gattgaaaaa gccaaagggg 60
          aaactgccta tctgccatgc aaatttacgc ttagtcccga agaccaggga ccgctggaca 120
          tcgagtggct gatatcacca gctgataatc agaaggtgga tcaagtg 167
           <![CDATA[ <210> 221]]>
           <![CDATA[ <211> 205]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 221]]>
          attattttat attctggaga caaaatttat gatgactact atccagatct gaaaggccga 60
          gtacatttta cgagtaatga tctcaaatct ggtgatgcat caataaatgt aacgaattta 120
          caactgtcag atattggcac atatcagtgc aaagtgaaaa aagctcctgg tgttgcaaat 180
          aagaagattc atctggtagt tcttg 205
           <![CDATA[ <210> 222]]>
           <![CDATA[ <211> 156]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 222]]>
          ttaagccttc aggtgcgaga tgttacgttg atggatctga agaaattgga agtgacttta 60
          agataaaatg tgaaccaaaa gaaggttcac ttccattaca gtatgagtgg caaaaattgt 120
          ctgactcaca gaaaatgccc acttcatggt tagcag 156
           <![CDATA[ <210> 223]]>
           <![CDATA[ <211> 4683]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 223]]>
          ggaagatgtg ccacctccaa agagccgtac gtccactgcc agaagctaca tcggcagtaa 60
          tcattcatcc ctggggtcca tgtctccttc caacatggaa ggatattcca agactcagta 120
          taaccaagta ccaagtgaag actttgaacg cactcctcag agtccgactc tcccacctgc 180
          taaggtagct gcccctaatc taagtcgaat gggtgcgatt cctgtgatga ttccagcaca 240
          gagcaaggat gggtctatag tatagagcct ccatatgtct catctgtgct ctccgtgttc 300
          ctttcctttt tttgatatat gaaaacctat tctggtctaa attgtgttac tagcctcaaa 360
          atacatcaaa aaataagtta atcaggaact gtacggaata tatttttaaa aatttttgtt 420
          tggttattc gaaatagtta caggcactaa agttagtaaa gaaaagttta ccatctgaaa 480
          aagctggatt ttctttaaga ggttgattat aaagttttct aaatttatca gtacctaagt 540
          aagatgtagc gctttgaata tgaaatcata ggtgaagaca tgggtgaact tacttgcata 600
          ccaagttgat acttgaataa ccatctgaaa gtggtacttg atcattttta ccattatttt 660
          taggatgtgt atttcattta tttatggccc accagtctcc cccaaattag tacagaaata 720
          tccatgacaa aattacttac gtatgtttgt acttggtttt acagctcctt tgaaaactct 780
          gtgtttggaa tatctctaaa aacatagaaa acactacagt ggtttagaaa ttactaattt 840
          tacttctaag tcattcataa accttgtcta tgaaatgact tcttaaatat ttagttgata 900
          gactgctaca ggtaataggg acttagcaag ctcttttata tgctaaagga gcatctatca 960
          gattaagtta gaacatttgc tgtcagccac atattgagat gacactaggt gcaatagcag 1020
          ggatagattt tgttggtgag tagtctcatg ccttgagatc tgtggtggtc ttcaaaatgg 1080
          tggccagcca gatcaaggat gtagtatctc atagttccca ggtgatattt ttcttattag 1140
          aaaaatatta taactcattt gttgtttgac acttatagat tgaaatttcc taatttattc 1200
          taaattttaa gtggttcttt ggttccagtg ctttatgttg ttgttgtttt tggatggtgt 1260
          tacatattat atgttctaga aacatgtaat cctaaattta ccctcttgaa tataatccct 1320
          ggatgatatt ttttatcata aatgcagaat aatcaaatac attttaagca agttaagtgt 1380
          cctccatcaa ttctgtattc cagacttggg aggatgtaca gttgctgttg tgtgatcaaa 1440
          catgtctctg tgtagttcca gcaaatcaag ctgagctttg aaaaagtttg tcttagtttt 1500
          gtgaaggtga tttattctta aaaaaaaaaa agaaagaaaa agaaaaaaag ataagaagga 1560
          ggagtaaagg gactactcct ccttgccaaa tgtgctaaat atcattttag gagaagaaag 1620
          tgggtttatt gtatttccct taagattgtg agggagtgtg gatacagtag aatgagccaa 1680
          cagtttcttt aataataaata cggtctgcaa taaattattt cactagctct aaaacctttc 1740
          cctagatttt agtaggggagt tggtttctgt taatatcttt gggtgctgtg gtggtaaatg 1800
          ctatattatg aacggtggca tgtatttaca gttagagagtat tgtgtgtaca ctttttaatg 1860
          gtaaacttaa gctgaatgtg taatggattt gtgtatagtt ttacatattt ggaagcattt 1920
          taaaaacagg ttttaacctt atgtaaaatt acttttatac tcgtgttaac attttcatct 1980
          gtgccttttg gtaatttaat ttctattatg aatttctggt gcctatgagc tagctatcac 2040
          ctacctgaaa ggtgcttaga ggtgaaggta ctgtttctaa aaacacatca ctgtgatacc 2100
          tttctatcct cacattttca agcttgcctc ttttctgttc tttgtggata taacttaagc 2160
          aattgtgtta ttcataaagg tttagaaatt tcaatattcc caacactcta tgtttctgat 2220
          tttataacag tagccatttt tgaaagtcag atgtttggcc tgttttatat gaataaagtt 2280
          tattataaa atattataaa aaataagtaa ataaacagaa cattaataat aaagttttgg 2340
          ttcttcctat tcctgacttt catataatga aaattatcct attgatctaa gtagaagtta 2400
          tcatagaaag tggacacgta taagactttc cttccttttt ttttttaata acatatgagg 2460
          aacaagactt ctcttcccat atacttcata ttttagagga cattgtttta aaggcttatg 2520
          tctcactgta aaattctgtc agccaaatag taccaatacg ttttcaagta gttctcactg 2580
          ataatttagt tgaaccagag atcaaatatt tgctcccgaa ttactactgg taatcaagta 2640
          gttgaacaaa aaattactaa agcatttccg ttagatcagt caaggacagt actgcatctt 2700
          ttttttttttttttttttta agacggagtc tcggtctgtc acccaggctg gagtgcagtg 2760
          gcgggatctc ggctcactgc aagctccgcc tcccaggttc acgccattct cctgcctcag 2820
          cctcccgagc agctgggact acaggctccc atcaccacgc tcggctaagt ttttgtaatt 2880
          ttagtagaga cagggtttca ccgtgttagc caggatggtc tcgatctcct gacctcgtga 2940
          tctgcctgcc tcggcctccc aaagtgctgg gattacaggc gtgaaccact gcacccggcc 3000
          cagtactgca tcttaacagc aaagccattt tattctactt tataactgag agacttgata 3060
          ccatccatct ctttaggtta cagaggataa tttgaagaga aatgttactg tagaatatat 3120
          agttctgtac tttttttttt tttttttaag agatagggtt tcactattgc tcaggctggt 3180
          ctcaaactgc tgggctcagg agatcctcct gccttggcct cccaaattgc tgggattaca 3240
          ggtgtgagcc gcagcatcca gccagttctg tactttgaat atggagtagt ttacagctat 3300
          ttttttttct tactggtaat cttaactaat atgattccct tgttagagag cctctcactc 3360
          ccccacccccc aaaaatgtct actattcatg acagtaacca attattctgg acaaattgct 3420
          tctttttaat ttgagctatc tgccatggac tttctaaaat ggaaacacag cctgagtgta 3480
          tcttagggag agtttgattg aaaaaatcca aatcactatc catatagatc atggatataa 3540
          agagatacct gatttttatt aaaaagatac tttttcaaat ttaagagtta atcttggaaa 3600
          tttggaacaa gtaaaggggc aagtaaacct tttgatgaaa tataaaagga actcattgca 3660
          tgaagttgac tatcaaattc tgtgatgtgt ggcttcttaa aaatattctc agtgtctttt 3720
          gtgtgcgtgc agcatgtaca tttgatgtta tgtgaatgtt gagttttttc ttctaatttt 3780
          cacttcagca gtgtttaggg ctttcagatg ccttattcca gtgtgaacag aaaaagttca 3840
          tattttatgt ggttaatgct ttgatgtgtc acataaagag tagtttgtag aaaatgttgg 3900
          cacaatttta acttcttagt ggcttgtgac attatatatt atatatatat atgtacatat 3960
          atctttataa cattcctgtg tttagtagtg taaatgttct gggcaagttt taatattttg 4020
          aatgcctttg gatattccag caataaaggc atcatgttct gcaataggat ttcttactca 4080
          tttacctatt ttaacactaa aatagaccac aactgagcac aaattccttt tataaatgtt 4140
          atagaagcag ggaagaataa taaacacatt tgtgaattgt ggttcagttt atttatcttt 4200
          agggaaggct gatcatttat cttatagcag ataacccccag cctcttattc attatggtta 4260
          acttttataa tttatcttat tttataattt aagaatatag tacatatcag ttgggtttgg 4320
          ttttggtcat cgagactaaa agctccatca aaacagaact ttgtgttttc tgctaactta 4380
          tttaatgaca caagttttaa gagaaccaca attcattgat tcacttattc ttttccctaa 4440
          ttgtgaattt tagtgataaa tacacctgta ctactgagga aaatattctg acacttcacg 4500
          tgtgcaaagt atagaactga cagtgtcagt ttcagatttt gtatgtacga tttctggctt 4560
          atatatccaa tggtgcagat tttgaaattt gtaagaacaa aatttgttaa gaaaaacaac 4620
          ttgctctagt tttgtgacct tgtgtacttt tgaaataaaa tcaagaaagc agttctctgc 4680
          ctc 4683
           <![CDATA[ <210> 224]]>
           <![CDATA[ <211> 5341]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 224]]>
          agtcgggagc gcgcgaggcg cggggagcct gggaccagga gcgagagccg cctacctgca 60
          gccgccgccc acggcacggc agccaccatg gcgctcctgc tgtgcttcgt gctcctgtgc 120
          ggagtagtgg atttcgccag aagtttgagt atcactactc ctgaagagat gattgaaaaa 180
          gccaaagggg aaactgccta tctgccatgc aaatttacgc ttagtcccga agaccaggga 240
          ccgctggaca tcgagtggct gatatcacca gctgataatc agaaggtgga tcaagtgatt 300
          attttatatt ctggagacaa aatttatgat gactactatc cagatctgaa aggccgagta 360
          cattttacga gtaatgatct caaatctggt gatgcatcaa taaatgtaac gaatttacaa 420
          ctgtcagata ttggcacata tcagtgcaaa gtgaaaaaag ctcctggtgt tgcaaataag 480
          aagattcatc tggtagttct tgttaagcct tcaggtgcga gatgttacgt tgatggatct 540
          gaagaaattg gaagtgactt taagataaaa tgtgaaccaa aagaaggttc acttccatta 600
          cagtatgagt ggcaaaaatt gtctgactca cagaaaatgc ccacttcatg gttagcaggg 660
          aagatgtgcc acctccaaag agccgtacgt ccactgccag aagctacatc ggcagtaatc 720
          attcatccct ggggtccatg tctccttcca acatggaagg atattccaag actcagtata 780
          accaagtacc aagtgaagac tttgaacgca ctcctcagag tccgactctc ccacctgcta 840
          aggtagctgc ccctaatcta agtcgaatgg gtgcgattcc tgtgatgatt ccagcacaga 900
          gcaaggatgg gtctatagta tagagcctcc atatgtctca tctgtgctct ccgtgttcct 960
          ttcctttttt tgatatatga aaacctattc tggtctaaat tgtgttacta gcctcaaaat 1020
          acatcaaaaa ataagttaat caggaactgt acggaatata tttttaaaaa tttttgtttg 1080
          gttatatcga aatagttaca ggcactaaag ttagtaaaga aaagtttacc atctgaaaaa 1140
          gctggatttt ctttaagagg ttgattataa agttttctaa atttatcagt acctaagtaa 1200
          gatgtagcgc tttgaatatg aaatcatagg tgaagacatg ggtgaactta cttgcatacc 1260
          aagttgatac ttgaataacc atctgaaagt ggtacttgat catttttacc attattttta 1320
          ggatgtgtat ttcatttatt tatggcccac cagtctcccc caaattagta cagaaatatc 1380
          catgacaaaa ttacttacgt atgtttgtac ttggttttac agctcctttg aaaactctgt 1440
          gtttggaata tctctaaaaa catagaaaac actacagtgg tttagaaatt actaatttta 1500
          cttctaagtc attcataaac cttgtctatg aaatgacttc ttaaatattt agttgataga 1560
          ctgctacagg taatagggac ttagcaagct cttttatatg ctaaaaggagc atctatcaga 1620
          ttaagttaga aatttgctg tcagccacat attgagatga cactaggtgc aatagcaggg 1680
          atagattttg ttggtgagta gtctcatgcc ttgagatctg tggtggtctt caaaatggtg 1740
          gccagccaga tcaaggatgt agtatctcat agttcccagg tgatattttt cttattagaa 1800
          aaatattata actcatttgt tgtttgacac ttatagattg aaatttccta atttattcta 1860
          aattttaagt ggttctttgg ttccagtgct ttatgttgtt gttgtttttg gatggtgtta 1920
          catattatat gttctagaaa catgtaatcc taaatttacc ctcttgaata taatccctgg 1980
          atgatatttt ttatcataaa tgcagaataa tcaaatacat ttaagcaag ttaagtgtcc 2040
          tccatcaatt ctgtattcca gacttgggag gatgtacagt tgctgttgtg tgatcaaaca 2100
          tgtctctgtg tagttccagc aaatcaagct gagctttgaa aaagtttgtc ttagttttgt 2160
          gaaggtgatt tattcttaaaaaaaaaaaag aaagaaaaag aaaaaaagat aagaaggagg 2220
          agtaaaggga ctactcctcc ttgccaaatg tgctaaatat cattttagga gaagaaagtg 2280
          ggtttattgt atttccctta agattgtgag ggagtgtgga tacagtagaa tgagccaaca 2340
          gtttctttat aataaatacg gtctgcaata aattatttca ctagctctaa aacctttccc 2400
          tagattttag tagggagttg gtttctgtta atatctttgg gtgctgtggt ggtaaatgct 2460
          atattatgaa cggtggcatg tattatcagt tagagtattg tgtgtacact ttttaatggt 2520
          aaacttaagc tgaatgtgta atggatttgt gtatagtttt acatatttgg aagcatttta 2580
          aaaacaggtt ttaaccttat gtaaaattac ttttatactc gtgttaacat tttcatctgt 2640
          gccttttggt aatttaattt ctattatgaa tttctggtgc ctatgagcta gctatcacct 2700
          acctgaaagg tgcttagagg tgaaggtact gtttctaaaa acacatcact gtgatacctt 2760
          tctatcctca cattttcaag cttgcctctt ttctgttctt tgtggatata acttaagcaa 2820
          ttgtgttatt cataaaggtt tagaaatttc aatattccca acactctatg tttctgattt 2880
          tataacagta gccatttttg aaagtcagat gtttggcctg ttttatatga ataaagttta 2940
          tttataaaat attataaaaa ataagtaaat aaacagaaca ttaataataa agttttggtt 3000
          cttcctattc ctgactttca tataatgaaa attatcctat tgatctaagt agaagttatc 3060
          atagaaagtg gacacgtata agactttcct tcctttttttttttaataac atatgaggaa 3120
          caagacttct cttcccatat acttcatatt ttagaggaca ttgttttaaa ggcttatgtc 3180
          tcactgtaaa attctgtcag ccaaatagta ccaatacgtt ttcaagtagt tctcactgat 3240
          aatttagttg aaccagagat caaatatttg ctcccgaatt actactggta atcaagtagt 3300
          tgaacaaaaa attackaaag catttccgtt agatcagtca aggacagtac tgcatctttt 3360
          tttttttttttttttttaag acggagtctc ggtctgtcac ccaggctgga gtgcagtggc 3420
          gggatctcgg ctcactgcaa gctccgcctc ccaggttcac gccattctcc tgcctcagcc 3480
          tcccgagcag ctgggactac aggctcccat caccacgctc ggctaagttt ttgtaatttt 3540
          agtagagaca gggtttcacc gtgttagcca ggatggtctc gatctcctga cctcgtgatc 3600
          tgcctgcctc ggcctcccaa agtgctggga ttacaggcgt gaaccactgc acccggccca 3660
          gtactgcatc ttaacagcaa agccatttta ttctacttta taactgagag acttgatacc 3720
          atccatctct ttaggttaca gaggataatt tgaagagaaa tgttactgta gaatatatag 3780
          ttctgtactt tttttttttt tttttaagag atagggtttc actattgctc aggctggtct 3840
          caaactgctg ggctcaggag atcctcctgc cttggcctcc caaattgctg ggattacagg 3900
          tgtgagccgc agcatccagc cagttctgta ctttgaatat ggagtagttt acagctattt 3960
          ttttttctta ctggtaatct taactaatat gattcccttg ttagagagcc tctcactccc 4020
          ccacccccaa aaatgtctac tattcatgac agtaaccaat tattctggac aaattgcttc 4080
          tttttaattt gagctatctg ccatggactt tctaaaatgg aaacacagcc tgagtgtatc 4140
          ttagggagag tttgattgaa aaaatccaaa tcactatcca tatagatcat ggatataaag 4200
          agatacctga tttttattaa aaagatactt tttcaaattt aagagttaat cttggaaatt 4260
          tggaacaagt aaaggggcaa gtaaaccttt tgatgaaata taaaaggaac tcattgcatg 4320
          aagttgacta tcaaattctg tgatgtgtgg cttcttaaaa atattctcag tgtcttttgt 4380
          gtgcgtgcag catgtacatt tgatgttatg tgaatgttga gttttttctt ctaattttca 4440
          cttcagcagt gtttagggct ttcagatgcc ttattccagt gtgaacagaa aaagttcata 4500
          ttttatgtgg ttaatgcttt gatgtgtcac ataaagagta gtttgtagaa aatgttggca 4560
          caattttaac ttcttagtgg cttgtgacat tatatattat atatatatat gtacatatat 4620
          ctttataaca ttcctgtgtt tagtagtgta aatgttctgg gcaagtttta atattttgaa 4680
          tgcctttgga tattccagca ataaaggcat catgttctgc aataggattt cttactcatt 4740
          tacctatttt aacactaaaa tagaccaa ctgagcacaa attcctttta taaatgttat 4800
          agaagcaggg aagaataata aacacatttg tgaattgtgg ttcagtttat ttatctttag 4860
          ggaaggctga tcatttatct tatagcagat aacccccagcc tcttattcat tatggttaac 4920
          ttttataatt tatcttattt tataatttaa gaatatagta catatcagtt gggtttggtt 4980
          ttggtcatcg agactaaaag ctccatcaaa acagaacttt gtgttttctg ctaacttatt 5040
          taatgacaca agttttaaga gaaccacaat tcattgattc acttattctt ttccctaatt 5100
          gtgaatttta gtgataaata cacctgtact actgaggaaa atattctgac acttcacgtg 5160
          tgcaaagtat agaactgaca gtgtcagttt cagattttgt atgtacgatt tctggcttat 5220
          atatccaatg gtgcagattt tgaaatttgt aagaacaaaa tttgttaaga aaaacaactt 5280
          gctctagttt tgtgaccttg tgtacttttg aaataaaatc aagaaagcag ttctctgcct 5340
          c 5341
           <![CDATA[ <210> 225]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 225]]>
          Met Ala Leu Leu Leu Cys Phe Val Leu Leu Cys Gly Val Val
          1 5 10
           <![CDATA[ <210> 226]]>
           <![CDATA[ <211> 55]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 226]]>
          Phe Ala Arg Ser Leu Ser Ile Thr Thr Pro Glu Glu Met Ile Glu Lys
          1 5 10 15
          Ala Lys Gly Glu Thr Ala Tyr Leu Pro Cys Lys Phe Thr Leu Ser Pro
                      20 25 30
          Glu Asp Gln Gly Pro Leu Asp Ile Glu Trp Leu Ile Ser Pro Ala Asp
                  35 40 45
          Asn Gln Lys Val Asp Gln Val
              50 55
           <![CDATA[ <210> 227]]>
           <![CDATA[ <211> 68]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 227]]>
          Ile Ile Leu Tyr Ser Gly Asp Lys Ile Tyr Asp Asp Tyr Tyr Pro Asp
          1 5 10 15
          Leu Lys Gly Arg Val His Phe Thr Ser Asn Asp Leu Lys Ser Gly Asp
                      20 25 30
          Ala Ser Ile Asn Val Thr Asn Leu Gln Leu Ser Asp Ile Gly Thr Tyr
                  35 40 45
          Gln Cys Lys Val Lys Lys Ala Pro Gly Val Ala Asn Lys Lys Ile His
              50 55 60
          Leu Val Val Leu
          65
           <![CDATA[ <210> 228]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 228]]>
          Lys Pro Ser Gly Ala Arg Cys Tyr Val Asp Gly Ser Glu Glu Ile Gly
          1 5 10 15
          Ser Asp Phe Lys Ile Lys Cys Glu Pro Lys Glu Gly Ser Leu Pro Leu
                      20 25 30
          Gln Tyr Glu Trp Gln Lys Leu Ser Asp Ser Gln Lys Met Pro Thr Ser
                  35 40 45
          Trp Leu Ala
              50
           <![CDATA[ <210> 229]]>
           <![CDATA[ <211> 61]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 229]]>
          Lys Met Cys His Leu Gln Arg Ala Val Arg Pro Leu Pro Glu Ala Thr
          1 5 10 15
          Ser Ala Val Ile Ile His Pro Trp Gly Pro Cys Leu Leu Pro Thr Trp
                      20 25 30
          Lys Asp Ile Pro Arg Leu Ser Ile Thr Lys Tyr Gln Val Lys Thr Leu
                  35 40 45
          Asn Ala Leu Leu Arg Val Arg Leu Ser His Leu Leu Arg
              50 55 60
           <![CDATA[ <210> 230]]>
           <![CDATA[ <211> 252]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 230]]>
          Met Ala Leu Leu Leu Cys Phe Val Leu Leu Cys Gly Val Val Asp Phe
          1 5 10 15
          Ala Arg Ser Leu Ser Ile Thr Thr Pro Glu Glu Met Ile Glu Lys Ala
                      20 25 30
          Lys Gly Glu Thr Ala Tyr Leu Pro Cys Lys Phe Thr Leu Ser Pro Glu
                  35 40 45
          Asp Gln Gly Pro Leu Asp Ile Glu Trp Leu Ile Ser Pro Ala Asp Asn
              50 55 60
          Gln Lys Val Asp Gln Val Ile Ile Leu Tyr Ser Gly Asp Lys Ile Tyr
          65 70 75 80
          Asp Asp Tyr Tyr Pro Asp Leu Lys Gly Arg Val His Phe Thr Ser Asn
                          85 90 95
          Asp Leu Lys Ser Gly Asp Ala Ser Ile Asn Val Thr Asn Leu Gln Leu
                      100 105 110
          Ser Asp Ile Gly Thr Tyr Gln Cys Lys Val Lys Lys Ala Pro Gly Val
                  115 120 125
          Ala Asn Lys Lys Ile His Leu Val Val Leu Val Lys Pro Ser Gly Ala
              130 135 140
          Arg Cys Tyr Val Asp Gly Ser Glu Glu Ile Gly Ser Asp Phe Lys Ile
          145 150 155 160
          Lys Cys Glu Pro Lys Glu Gly Ser Leu Pro Leu Gln Tyr Glu Trp Gln
                          165 170 175
          Lys Leu Ser Asp Ser Gln Lys Met Pro Thr Ser Trp Leu Ala Gly Lys
                      180 185 190
          Met Cys His Leu Gln Arg Ala Val Arg Pro Leu Pro Glu Ala Thr Ser
                  195 200 205
          Ala Val Ile Ile His Pro Trp Gly Pro Cys Leu Leu Pro Thr Trp Lys
              210 215 220
          Asp Ile Pro Arg Leu Ser Ile Thr Lys Tyr Gln Val Lys Thr Leu Asn
          225 230 235 240
          Ala Leu Leu Arg Val Arg Leu Ser His Leu Leu Arg
                          245 250
           <![CDATA[ <210> 231]]>
           <![CDATA[ <211> 141]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 231]]>
          gggagctgtt caaaaaacga gctctttcta ctcctgtagt agaaaaacgt tcagcatctt 60
          ctgagtcatc atcatcatcg tcaaagaaga agaaaacaaa ggtagaacat ggaggatcgt 120
          caggctctaa acaaaattct g 141
           <![CDATA[ <210> 232]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 232]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60
          tccttcggtg tgaaaccagt tctgaatact cctctctcag attcaagtgg ttcaagaatg 120
          ggaatga 127
           <![CDATA[ <210> 233]]>
           <![CDATA[ <211> 268]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 233]]>
          gggagctgtt caaaaaacga gctctttcta ctcctgtagt agaaaaacgt tcagcatctt 60
          ctgagtcatc atcatcatcg tcaaagaaga agaaaacaaa ggtagaacat ggaggatcgt 120
          caggctctaa acaaaattct gccttgcctc cccgattgaa agagatgaaa agccaggaat 180
          cggctgcagg ttccaaacta gtccttcggt gtgaaaccag ttctgaatac tcctctctca 240
          gattcaagtg gttcaagaat gggaatga 268
           <![CDATA[ <210> 234]]>
           <![CDATA[ <211> 88]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 234]]>
          Glu Leu Phe Lys Lys Arg Ala Leu Ser Thr Pro Val Val Glu Lys Arg
          1 5 10 15
          Ser Ala Ser Ser Ser Glu Ser Ser Ser Ser Ser Ser Ser Lys Lys Lys Lys Lys Thr
                      20 25 30
          Lys Val Glu His Gly Gly Ser Ser Ser Gly Ser Lys Gln Asn Ser Ala Leu
                  35 40 45
          Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser
              50 55 60
          Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu Arg
          65 70 75 80
          Phe Lys Trp Phe Lys Asn Gly Asn
                          85
           <![CDATA[ <210> 235]]>
           <![CDATA[ <211> 264]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 2]]>35
          actgagctcc tagcacccga tcgggaagtg gcgggcggag tcccgggtcc agtcgccgcc 60
          tcagctaccg ccgctgccgc cgccgccgcc gccaccgcca gtggtgagac cccgacctgg 120
          cgggtcagcg ctgggcgtgc gtgcgggcag gcgggggcgc tgacgagaag caggaagagg 180
          gtgcagtgcc ggcgtgggcg gccggccgag gcggaggcgc aggaaggggg cggcgagtcg 240
          tgcgaggctg cccttctcac tcag 264
           <![CDATA[ <210> 236]]>
           <![CDATA[ <211> 170]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 236]]>
          cattatggat ccaagcctgt tgagagaaag ggagctgttc aaaaaacgag ctctttctac 60
          tcctgtagta gaaaaacgtt cagcatcttc tgagtcatca tcatcatcgt caaagaagaa 120
          gaaaacaaag gtagaacatg gaggatcgtc aggctctaaa caaaattctg 170
           <![CDATA[ <210> 237]]>
           <![CDATA[ <211> 92]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 237]]>
          atcatagcaa tggatcattt aacttgaaag ctttgtcagg aagctctgga tataagtttg 60
          gtgttcttgc taagattgtg aattacatga ag 92
           <![CDATA[ <210> 238]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 238]]>
          acacggcatc agcgaggaga tacgcatcct ctaaccttag atgaaatttt ggatgaaaca 60
          caacatttag atattggact caagcagaaa caatggctaa tgactgag 108
           <![CDATA[ <210> 239]]>
           <![CDATA[ <211> 183]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 239]]>
          gctttagtca acaatcccaa aattgaagta atagatggga agtatgcttt caagcccaag 60
          tacaacgtga gagataagaa ggccctactt aggctcttag atcagcatga ccagcgagga 120
          ttaggaggaa ttcttttaga agacatagaa gaagcactgc ccaattccca gaaagctgtc 180
          aag 183
           <![CDATA[ <210> 240]]>
           <![CDATA[ <211> 94]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 240]]>
          gctttggggg accagatact atttgtaaat cgtcccgata agaagaaaat acttttcttc 60
          aatgataaga gctgtcagtt ttctgtggat gaag 94
           <![CDATA[ <210> 241]]>
           <![CDATA[ <211> 116]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 241]]>
          aatttcagaa actgtgggagg agtgtcactg tagattccat ggacgaggag aaaattgaag 60
          aatatctgaa gcgacagggt atttcttcca tgcaggaatc tggaccaaag aaagtg 116
           <![CDATA[ <210> 242]]>
           <![CDATA[ <211> 720]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 242]]>
          gcccctattc agagaaggaa aaagcctgct tcacagaaaa agcgacgctt taagactcat 60
          aacgaacact tggctggagt gctgaaggat tactctgaca ttacttccag caaataggga 120
          acagttttgc cctggaacag agttacagat acacaatcaa gagtgttctt gctgatgctc 180
          ggggtctgaa gactgtcttc ctatctgctt cttgcggctg aggagaggag cagttcagtt 240
          tacaaaacaa gtgcaaatta ccaaactcaa agcttatttg agtagaatgg gctcatgggc 300
          aatgtgatgt tccctgttaa ccttctgtta ctccctggga gaaaggcgct gagcgtggca 360
          tgcaggtgtc tttgctgtgtttttctccac ttctaaatgg ttcctggttc ctttcttcct 420
          cgtttgttac tttagagcaa gtttgcccat agtcttgaat gcaatatttg tttattccaa 480
          aagaacatat ttataataaa atcactgtag aaggattttt aagatgttag tgaattctgt 540
          ttcttttcat tctcggaaat ggcaggaagc agctccagtc tctgatttcc atgggtcacg 600
          tgctggggat gtgatgaagc ctgcagtctg cactgtgttg ctgagcacat ggatttcacc 660
          actggaacac aggtgtgctg cttgttagca agcagagcaa taaagatgtg ctggatgtca 720
           <![CDATA[ <210> 243]]>
           <![CDATA[ <211> 1747]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 243]]>
          actgagctcc tagcacccga tcgggaagtg gcgggcggag tcccgggtcc agtcgccgcc 60
          tcagctaccg ccgctgccgc cgccgccgcc gccaccgcca gtggtgagac cccgacctgg 120
          cgggtcagcg ctgggcgtgc gtgcgggcag gcgggggcgc tgacgagaag caggaagagg 180
          gtgcagtgcc ggcgtgggcg gccggccgag gcggaggcgc aggaaggggg cggcgagtcg 240
          tgcgaggctg cccttctcac tcagcatttat ggatccaagc ctgttgagag aaagggagct 300
          gttcaaaaaa cgagctcttt ctactcctgt agtagaaaaa cgttcagcat cttctgagtc 360
          atcatcatca tcgtcaaaga agaagaaaac aaaggtagaa catggaggat cgtcaggctc 420
          taaacaaaat tctgatcata gcaatggatc atttaacttg aaagctttgt caggaagctc 480
          tggatataag tttggtgttc ttgctaagat tgtgaattac atgaagacac ggcatcagcg 540
          aggagatacg catcctctaa ccttagatga aattttggat gaaacacaac atttagatat 600
          tggactcaag cagaaacaat ggctaatgac tgaggcttta gtcaacaatc ccaaaattga 660
          agtaatagat gggaagtatg ctttcaagcc caagtacaac gtgagagata agaaggccct 720
          acttaggctc ttagatcagc atgaccagcg aggattagga ggaattcttt tagaagacat 780
          agaagaagca ctgcccaatt cccagaaagc tgtcaaggct ttgggggacc agatactatt 840
          tgtaaatcgt cccgataaga agaaaatact tttcttcaat gataagagct gtcagttttc 900
          tgtggatgaa gaatttcaga aactgtggag gagtgtcact gtagattcca tggacgagga 960
          gaaaattgaa gaatatctga agcgacaggg tatttcttcc atgcaggaat ctggaccaaa 1020
          gaaagtggcc cctattcaga gaaggaaaaa gcctgcttca cagaaaaagc gacgctttaa 1080
          gactcataac gaacacttgg ctggagtgct gaaggattac tctgacatta cttccagcaa 1140
          atagggaaca gttttgccct ggaacagagt tacagataca caatcaagag tgttcttgct 1200
          gatgctcggg gtctgaagac tgtcttccta tctgcttctt gcggctgagg agaggagcag 1260
          ttcagtttac aaaacaagtg caaattacca aactcaaagc ttatttgagt agaatgggct 1320
          catgggcaat gtgatgttcc ctgttaacct tctgttactc cctgggagaa aggcgctgag 1380
          cgtggcatgc aggtgtcttt gctgtgtttt tctccacttc taaatggttc ctggttcctt 1440
          tcttcctcgt ttgttacttt agagcaagtt tgcccatagt cttgaatgca atatttgttt 1500
          attccaaaag aacatattta taataaaatc actgtagaag gatttttaag atgttagtga 1560
          attctgtttc ttttcattct cggaaatggc aggaagcagc tccagtctct gatttccatg 1620
          ggtcacgtgc tggggatgtg atgaagcctg cagtctgcac tgtgttgctg agcacatgga 1680
          tttcaccact ggaacacagg tgtgctgctt gttagcaagc agagcaataa agatgtgctg 1740
          gatgtca 1747
           <![CDATA[ <210> 244]]>
           <![CDATA[ <211> 55]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 244]]>
          Met Asp Pro Ser Leu Leu Arg Glu Arg Glu Leu Phe Lys Lys Arg Ala
          1 5 10 15
          Leu Ser Thr Pro Val Val Glu Lys Arg Ser Ala Ser Ser Glu Ser Ser
                      20 25 30
          Ser Ser Ser Ser Lys Lys Lys Lys Thr Lys Val Glu His Gly Gly Ser
                  35 40 45
          Ser Gly Ser Lys Gln Asn Ser
              50 55
           <![CDATA[ <210> 245]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 245]]>
          His Ser Asn Gly Ser Phe Asn Leu Lys Ala Leu Ser Gly Ser Ser Gly
          1 5 10 15
          Tyr Lys Phe Gly Val Leu Ala Lys Ile Val Asn Tyr Met Lys
                      20 25 30
           <![CDATA[ <210> 246]]>
           <![CDATA[ <211> 36]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 246]]>
          Thr Arg His Gln Arg Gly Asp Thr His Pro Leu Thr Leu Asp Glu Ile
          1 5 10 15
          Leu Asp Glu Thr Gln His Leu Asp Ile Gly Leu Lys Gln Lys Gln Trp
                      20 25 30
          Leu Met Thr Glu
                  35
           <![CDATA[ <210> 247]]>
           <![CDATA[ <211> 61]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 247]]>
          Ala Leu Val Asn Asn Pro Lys Ile Glu Val Ile Asp Gly Lys Tyr Ala
          1 5 10 15
          Phe Lys Pro Lys Tyr Asn Val Arg Asp Lys Lys Ala Leu Leu Arg Leu
                      20 25 30
          Leu Asp Gln His Asp Gln Arg Gly Leu Gly Gly Ile Leu Leu Glu Asp
                  35 40 45
          Ile Glu Glu Ala Leu Pro Asn Ser Gln Lys Ala Val Lys
              50 55 60
           <![CDATA[ <210> 248]]>
           <![CDATA[ <211> 31]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 248]]>
          Ala Leu Gly Asp Gln Ile Leu Phe Val Asn Arg Pro Asp Lys Lys Lys Lys
          1 5 10 15
          Ile Leu Phe Phe Asn Asp Lys Ser Cys Gln Phe Ser Val Asp Glu
                      20 25 30
           <![CDATA[ <210> 249]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 249]]>
          Phe Gln Lys Leu Trp Arg Ser Val Thr Val Asp Ser Met Asp Glu Glu
          1 5 10 15
          Lys Ile Glu Glu Tyr Leu Lys Arg Gln Gly Ile Ser Ser Met Gln Glu
                      20 25 30
          Ser Gly Pro Lys Lys Val
                  35
           <![CDATA[ <210> 250]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 250]]>
          Ala Pro Ile Gln Arg Arg Lys Lys Pro Ala Ser Gln Lys Lys Arg Arg
          1 5 10 15
          Phe Lys Thr His Asn Glu His Leu Ala Gly Val Leu Lys Asp Tyr Ser
                      20 25 30
          Asp Ile Thr Ser Ser Lys
                  35
           <![CDATA[ <210> 251]]>
           <![CDATA[ <211> 291]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 251]]>
          Met Asp Pro Ser Leu Leu Arg Glu Arg Glu Leu Phe Lys Lys Arg Ala
          1 5 10 15
          Leu Ser Thr Pro Val Val Glu Lys Arg Ser Ala Ser Ser Glu Ser Ser
                      20 25 30
          Ser Ser Ser Ser Lys Lys Lys Lys Thr Lys Val Glu His Gly Gly Ser
                  35 40 45
          Ser Gly Ser Lys Gln Asn Ser Asp His Ser Asn Gly Ser Phe Asn Leu
              50 55 60
          Lys Ala Leu Ser Gly Ser Ser Ser Gly Tyr Lys Phe Gly Val Leu Ala Lys
          65 70 75 80
          Ile Val Asn Tyr Met Lys Thr Arg His Gln Arg Gly Asp Thr His Pro
                          85 90 95
          Leu Thr Leu Asp Glu Ile Leu Asp Glu Thr Gln His Leu Asp Ile Gly
                      100 105 110
          Leu Lys Gln Lys Gln Trp Leu Met Thr Glu Ala Leu Val Asn Asn Pro
                  115 120 125
          Lys Ile Glu Val Ile Asp Gly Lys Tyr Ala Phe Lys Pro Lys Tyr Asn
              130 135 140
          Val Arg Asp Lys Lys Ala Leu Leu Arg Leu Leu Asp Gln His Asp Gln
          145 150 155 160
          Arg Gly Leu Gly Gly Ile Leu Leu Glu Asp Ile Glu Glu Ala Leu Pro
                          165 170 175
          Asn Ser Gln Lys Ala Val Lys Ala Leu Gly Asp Gln Ile Leu Phe Val
                      180 185 190
          Asn Arg Pro Asp Lys Lys Lys Lys Ile Leu Phe Phe Asn Asp Lys Ser Cys
                  195 200 205
          Gln Phe Ser Val Asp Glu Glu Phe Gln Lys Leu Trp Arg Ser Val Thr
              210 215 220
          Val Asp Ser Met Asp Glu Glu Lys Ile Glu Glu Tyr Leu Lys Arg Gln
          225 230 235 240
          Gly Ile Ser Ser Met Gln Glu Ser Gly Pro Lys Lys Val Ala Pro Ile
                          245 250 255
          Gln Arg Arg Lys Lys Pro Ala Ser Gln Lys Lys Arg Arg Phe Lys Thr
                      260 265 270
          His Asn Glu His Leu Ala Gly Val Leu Lys Asp Tyr Ser Asp Ile Thr
                  275 280 285
          Ser Ser Lys
              290
           <![CDATA[ <210> 252]]>
           <![CDATA[ <211> 434]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 252]]>
          actgagctcc tagcacccga tcgggaagtg gcgggcggag tcccgggtcc agtcgccgcc 60
          tcagctaccg ccgctgccgc cgccgccgcc gccaccgcca gtggtgagac cccgacctgg 120
          cgggtcagcg ctgggcgtgc gtgcgggcag gcgggggcgc tgacgagaag caggaagagg 180
          gtgcagtgcc ggcgtgggcg gccggccgag gcggaggcgc aggaaggggg cggcgagtcg 240
          tgcgaggctg cccttctcac tcagcatttat ggatccaagc ctgttgagag aaagggagct 300
          gttcaaaaaa cgagctcttt ctactcctgt agtagaaaaa cgttcagcat cttctgagtc 360
          atcatcatca tcgtcaaaga agaagaaaac aaaggtagaa catggaggat cgtcaggctc 420
          taaacaaaat tctg 434
           <![CDATA[ <210> 253]]>
           <![CDATA[ <211> 88]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 253]]>
          atcctaaaca gcacatccaa tcacctgtgg ctagagttca acaccaatgg atctgacacc 60
          gaccaaggtt ttcaactcac ctatacca 88
           <![CDATA[ <210> 254]]>
           <![CDATA[ <211> 62]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 254]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ct 62
           <![CDATA[ <210> 255]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 255]]>
          atcctaaaca gcacatccaa tcacctgtgg ctagagttca acaccaatgg atctgacacc 60
          gaccaaggtt ttcaactcac ctataccact acatctacat ccaccactgg gacaagccat 120
          cttgtaaaat gtgcggagaa ggagaaaact 150
           <![CDATA[ <210> 256]]>
           <![CDATA[ <211> 50]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 256]]>
          Ile Leu Asn Ser Thr Ser Asn His Leu Trp Leu Glu Phe Asn Thr Asn
          1 5 10 15
          Gly Ser Asp Thr Asp Gln Gly Phe Gln Leu Thr Tyr Thr Thr Thr Thr Ser
                      20 25 30
          Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala Glu Lys Glu
                  35 40 45
          Lys Thr
              50
           <![CDATA[ <210> 257]]>
           <![CDATA[ <211> 583]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 257]]>
          ctccacggca gcggctcctt gtgccactag cagcccttct tctgcgctct ccgccttttc 60
          tctctagact ggatctctcc tcccccccgc gcccccctcc ccgcatctcc cactcgctgg 120
          ctctctctcc agctgcctcc tctccaggtc tctcctggct gcgcgcgctc ctctccccgc 180
          ttctccccct cccgcagcct cgccgccttg gtgccttcct gcccggctcg gccggcgctc 240
          gtccccggcc ccggccccgc cagcccgggt ctccgcgctc ggagcagctc agccctgcag 300
          tggctcggga cccgatgcta tgagagggaa gcgagccggg cgcccagacc ttcaggaggc 360
          gtcggatgcg cggcgggtct tgggaccggg ctctctctcc ggctcgcctt gccctcgggt 420
          gattatttgg ctccgctcat agccctgcct tcctcggagg agccatcggt gtcgcgtgcg 480
          tgtggagtat ctgcagacat gactgcgtgg aggagattcc agtcgctgct cctgcttctc 540
          gggctgctgg tgctgtgcgc gaggctcctc actgcagcga agg 583
           <![CDATA[ <210> 258]]>
           <![CDATA[ <211> 217]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 258]]>
          gtcagaactg tggaggctta gtccagggtc ccaatggcac tattgagagc ccagggtttc 60
          ctcacgggta tccgaactat gccaactgca cctggatcat catcacgggc gagcgcaata 120
          ggatacagtt gtccttccat acctttgctc ttgaagaaga ttttgatatt ttatcagttt 180
          acgatggaca gcctcaacaa gggaatttaa aagtgag 217
           <![CDATA[ <210> 259]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 259]]>
          attatcggga tttcagctgc cctcctctat agtgagtaca ggatctatcc tcactctgtg 60
          gttcacgaca gacttcgctg tgagtgccca aggtttcaaa gcatttatg aag 113
           <![CDATA[ <210> 260]]>
           <![CDATA[ <211> 195]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 260]]>
          ttttacctag ccacacttgt ggaaatcctg gagaaatcct gaaaggagtt ctgcatggaa 60
          cgagattcaa cataggagac aaaatccggt acagctgcct ccctggctac atcttggaag 120
          gccacgccat cctgacctgc atcgtcagcc caggaaatgg tgcatcgtgg gacttcccag 180
          ctcccttttg cagag 195
           <![CDATA[ <210> 261]]>
           <![CDATA[ <211> 208]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 261]]>
          ctgagggagc ctgcggagga accttacgcg ggaccagcag ctccatctcc agcccgcact 60
          tcccttcaga gtacgagaac aacgcggact gcacctggac cattctggct gagcccgggg 120
          accacattgc gctggtcttc actgactttc agctagaaga aggatatgat ttcttagaga 180
          tcagtggcac ggaagctcca tccatatg 208
           <![CDATA[ <210> 262]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 262]]>
          gctaactggc atgaacctcc cctctccagt tatcagtagc aagaattggc tacgactcca 60
          tttcacctct gacagcaacc accgacgcaa aggatttaac gctcagttcc aag 113
           <![CDATA[ <210> 263]]>
           <![CDATA[ <211> 78]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 263]]>
          tgaaaaaggc gattgagttg aagtcaagag gagtcaagat gctgcccagc aaggatggaa 60
          gccataaaaa ctctgtct 78
           <![CDATA[ <210> 264]]>
           <![CDATA[ <211> 88]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 264]]>
          tgagccaagg aggtgttgca ttggtctctg acatgtgtcc agatcctggg attccagaaa 60
          atggtagaag agcaggttcc gacttcag 88
           <![CDATA[ <210> 265]]>
           <![CDATA[ <211> 125]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 265]]>
          ggttggtgca aatgtacagt tttcatgtga ggacaattac gtgctccagg gatctaaaag 60
          catcacctgt cagagagtta cagagacgct cgctgcttgg agtgaccaca ggcccatctg 120
          ccgag 125
           <![CDATA[ <210> 266]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 266]]>
          cgagaacatg tggatccaat ctgcgtgggc ccagcggcgt cattacctcc cctaattatc 60
          cggttcagta tgaagataat gcacactgtg tgtgggtcat caccaccacc gacccggaca 120
          ag 122
           <![CDATA[ <210> 267]]>
           <![CDATA[ <211> 104]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 267]]>
          gtcatcaagc ttgcctttga agagtttgag ctggagcgag gctatgacac cctgacggtt 60
          ggtgatgctg ggaaggtggg agacaccaga tcggtcttgt acgt 104
           <![CDATA[ <210> 268]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 268]]>
          gctcacggga tccagtgttc ctgacctcat tgtgagcatg agcaaccaga tgtggctaca 60
          tctgcagtcg gatgatagca ttggctcacc tgggtttaaa gctgtttacc aag 113
           <![CDATA[ <210> 269]]>
           <![CDATA[ <211> 183]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 269]]>
          aaattgaaaa gggagggtgt ggggatcctg gaatccccgc ctatgggaag cggacgggca 60
          gcagtttcct ccatggagat acactcacct ttgaatgccc ggcggccttt gagctggtgg 120
          gggagagagt tatcacctgt cagcagaaca atcagtggtc tggcaacaag cccagctgtg 180
          tat 183
           <![CDATA[ <210> 270]]>
           <![CDATA[ <211> 327]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 270]]>
          tttcatgttt cttcaacttt acggcatcat ctgggattat tctgtcacca aattatccag 60
          aggaatatgg gaacaacatg aactgtgtct ggttgattat ctcggagcca ggaagtcgaa 120
          ttcacctaat ctttaatgat tttgatgttg agcctcagtt tgactttctc gcggtcaagg 180
          atgatggcat ttctgacata actgtcctgg gtactttttc tggcaatgaa gtgccttccc 240
          agctggccag cagtggggcat atagttcgct tggaatttca gtctgaccat tccactactg 300
          gcagagggtt caacatcact tacacca 327
           <![CDATA[ <210> 271]]>
           <![CDATA[ <211> 195]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 271]]>
          catttggtca gaatgagtgc catgatcctg gcattcctat aaacggacga cgttttggtg 60
          acaggtttct actcgggagc tcggtttctt tccactgtga tgatggcttt gtcaagaccc 120
          agggatccga gtccattacc tgcatactgc aagacgggaa cgtggtctgg agctccaccg 180
          tgccccgctg tgaag 195
           <![CDATA[ <210> 272]]>
           <![CDATA[ <211> 139]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 272]]>
          ctccatgtgg tggacatctg acagcgtcca gcggagtcat tttgcctcct ggatggccag 60
          gatattataa ggattcttta cattgtgaat ggataattga agcaaaacca ggccactcta 120
          tcaaaataac ttttgacag 139
           <![CDATA[ <210> 273]]>
           <![CDATA[ <211> 188]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 273]]>
          atttcagaca gaggtcaatt atgacacctt ggaggtcaga gatgggccag ccagttcgtc 60
          cccactgatc ggcgagtacc acggcaccca ggcaccccag ttcctcatca gcaccgggaa 120
          cttcatgtac ctgctgttca ccactgacaa cagccgctcc agcatcggct tcctcatcca 180
          ctatgaga 188
           <![CDATA[ <210> 274]]>
           <![CDATA[ <211]]>> 189]]>
           <br/> &lt;![CDATA[ &lt;212&gt;DNA]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt;Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;274]]&gt;
           <br/> <![CDATA[gtgtgacgct tgagtcggat tcctgcctgg acccgggcat ccctgtgaac ggccatcgcc 60
          acggtggaga ctttggcatc aggtccacag tgactttcag ctgtgacccg gggtacacac 120
          taagtgacga cgagcccctc gtctgtgaga ggaaccacca gtggaaccac gccttgccca 180
          gctgcgacg 189
           <![CDATA[ <210> 275]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 275]]>
          ctctatgtgg aggctacatc caagggaaga gtggaacagt cctttctcct gggtttccag 60
          atttttatcc aaactctcta aactgcacgt ggaccattga agtgtctcat gggaaag 117
           <![CDATA[ <210> 276]]>
           <![CDATA[ <211> 216]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 276]]>
          gagttcaaat gatctttcac acctttcatc ttgagagttc ccacgactat ttactgatca 60
          cagaggatgg aagtttttcc gagcccgttg ccaggctcac cgggtcggtg ttgcctcata 120
          cgatcaaggc aggcctgttt ggaaacttca ctgcccagct tcggtttata tcagacttct 180
          caatttcgta cgagggcttc aatatcacat tttcag 216
           <![CDATA[ <210> 277]]>
           <![CDATA[ <211> 189]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 277]]>
          aatatgacct ggagccatgt gatgatcctg gagtccctgc cttcagccga agaattggtt 60
          ttcactttgg tgtgggagac tctctgacgt tttcctgctt cctgggatat cgtttagaag 120
          gtgccaccaa gcttacctgc ctgggtgggg gccgccgtgtgtggagtgca cctctgccaa 180
          ggtgtgtgg 189
           <![CDATA[ <210> 278]]>
           <![CDATA[ <211> 170]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 278]]>
          ccgaatgtgg agcaagtgtc aaaggaaatg aaggaacatt actgtctcca aattttccat 60
          ccaattatga taataaccat gagtgtatct ataaaataga aacagaagcc ggcaagggca 120
          tccaccttag aacacgaagc ttccagctgt ttgaaggaga tactctaaag 170
           <![CDATA[ <210> 279]]>
           <![CDATA[ <211> 157]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 279]]>
          gtatatgatg gaaaagacag ttcctcacgt ccactgggca cgttcactaa aaatgaactt 60
          ctggggctga tcctaaacag cacatccaat cacctgtggc tagagttcaa caccaatgga 120
          tctgacaccg accaaggttttcaactcacc tatacca 157
           <![CDATA[ <210> 280]]>
           <![CDATA[ <211> 192]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 280]]>
          gttttgatct ggtaaaatgt gaggatccgg gcatccctaa ctacggctat aggatccgtg 60
          atgaaggcca ctttaccgac actgtagttc tgtacagttg caacccgggg tacgccatgc 120
          atggcagcaa caccctgacc tgtttgagtg gagacaggag agtgtgggac aaaccactac 180
          cttcgtgcat ag 192
           <![CDATA[ <210> 281]]>
           <![CDATA[ <211> 10288]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 281]]>
          gttttgatct ggtaaaatgt gaggatccgg gcatccctaa ctacggctat aggatccgtg 60
          atgaaggcca ctttaccgac actgtagttc tgtacagttg caacccgggg tacgccatgc 120
          atggcagcaa caccctgacc tgtttgagtg gagacaggag agtgtgggac aaaccactac 180
          cttcgtgcat agcggaatgt ggtggtcaga tccatgcagc cacatcagga cgaatattgt 240
          cccctggcta tccagctccg tatgacaaca acctccactg cacctggatt atagaggcag 300
          acccaggaaa gacccattagc ctccatttca ttgttttcga cacggagatg gctcacgaca 360
          tcctcaaggt ctgggacggg ccggtggaca gtgacatcct gctgaaggag tggagtggct 420
          ccgcccttcc ggaggacatc cacagcacct tcaactcact caccctgcag ttcgacagcg 480
          acttcttcat cagcaagtct ggcttctcca tccagttctc cacctcaatt gcagccacct 540
          gtaacgatcc aggtatgccc caaaatggca cccgctatgg agacagcaga gaggctggag 600
          acaccgtcac attccagtgt gaccctggct atcagctcca aggacaagcc aaaatcacct 660
          gtgtgcagct gaataaccgg ttcttttggc aaccagaccc tcctacatgc atagctgctt 720
          gtggagggaa tctgacgggc ccagcaggtg ttattttgtc acccaactac ccacagccgt 780
          atcctcctgg gaaggaatgt gactggagag taaaagtgaa cccggacttt gtcatcgcct 840
          tgatattcaa aagtttcaac atggagccca gctatgactt cttacacatc tatgaagggg 900
          aagattccaa cagccccctc attgggagtt accagggctc tcaggcccca gaaagaatag 960
          agagtagcgg aaacagcctg tttctggcat ttcggagtga tgcctccgtg ggcctttcag 1020
          ggttcgccat tgaatttaaa gagaaaccac gggaagcttg ttttgaccca ggaaatataa 1080
          tgaatgggac aagagttgga acagacttca agcttggctc caccatcacc taccagtgtg 1140
          actctggcta taagattctt gacccctcat ccatcacctg tgtgattggg gctgatggga 1200
          aaccctcctg ggaccaagtg ctgccctcct gcaatgctcc ctgtggaggc cagtacacgg 1260
          gatcagaagg ggtagtttta tcaccaaact acccccataa ttacacagct ggtcaaatat 1320
          gcctctattc catcacggta ccaaaggaat tcgtggtctt tggacagttt gcctatttcc 1380
          agacagccct gaatgatttg gcagaattat ttgatggaac ccatgcacag gccagacttc 1440
          tcagctcact ctcggggtct cactcagggg aaacattgcc cttggctacg tcaaatcaaa 1500
          ttctgctccg attcagtgca aagagcggtg cctctgcccg cggcttccac ttcgtgtatc 1560
          aagctgttcc tcgtaccagt gacacccaat gcagctctgt ccccgagccc agatacggaa 1620
          ggagaattgg ttctgagttt tctgccggct ccatcgtccg attcgagtgc aacccgggat 1680
          acctgcttca gggttccacg gcgctccact gccagtccgt gcccaacgcc ttggcacagt 1740
          ggaacgacac gatccccagc tgtgtggtac cctgcagtgg caatttcact caacgaagag 1800
          gtacaatcct gtcccccggc taccctgagc catacggaaa caacttgaac tgtatatgga 1860
          agatcatagt tacggagggc tcgggaattc agatccaagt gatcagtttt gccacggagc 1920
          agaactggga ctcccttgag atccacgatg gtggggatgt gaccgcaccc agactgggaa 1980
          gcttctcagg caccacagta ccggcactgc tgaacagtac ttccaaccaa ctctacctgc 2040
          atttccagtc tgacattagt gtggcagctg ctggtttcca cctggaatac aaaactgtag 2100
          gtcttgctgc atgccaagaa ccagccctcc ccagcaacag catcaaaatc ggagatcggt 2160
          acatggtgaa cgacgtgctc tccttccagt gcgagcccgg gtacaccctg cagggccgtt 2220
          cccacatttc ctgtatgcca gggaccgttc gccgttggaa ctatccgtct cccctgtgca 2280
          ttgcaacctg tggagggacg ctgagcacct tgggtggtgt gatcctgagc cccggcttcc 2340
          caggttctta ccccaacaac ttagactgca cctggaggat ctcattaccc atcggctatg 2400
          gtgcacatat tcagtttctg aatttttcta ccgaagctaa tcatgacttc cttgaaattc 2460
          aaaatggacc ttaccacacc agccccatga ttggacaatt tagcggcacg gatctccccg 2520
          cggccctgct gagcacaacg catgaaaccc tcatccactt ttatagtgac cattcgcaaa 2580
          accggcaagg atttaaactt gcttaccaag cctatgaatt acagaactgt ccagatccac 2640
          ccccatttca gaatgggtac atgatcaact cggattacag cgtggggcaa tcagtatctt 2700
          tcgagtgtta tcctgggtac attctaatag gccatcctgt cctcacttgt cagcatggga 2760
          tcaacagaaa ctggaactac ccttttccaa gatgtgatgc cccttgtggg tacaacgtaa 2820
          cttctcagaa cggcaccatc tactcccctg gctttcctga tgagtatccg atcctgaagg 2880
          actgcatttg gctcatcacg gtgcctccag ggcacggagt ttacatcaac ttcaccctgt 2940
          tacagacgga agctgtcaac gattacattg ctgtttggga cggtcccgat cagaactcac 3000
          cccagctggg agttttcagt ggcaacacag ccctcgaaac ggcgtatagc tccaccaacc 3060
          aagtcctgct caagttccac agcgactttt caaatggagg cttctttgtc ctcaatttcc 3120
          acgcatttca gctcaagaaa tgtcaacctc ccccagcggt tccacaggca gaaatgctta 3180
          ctgaggatga tgatttcgaa ataggagatt ttgtgaagta ccagtgccac cccgggtaca 3240
          ccttggtggg gaccgacatt ctgacttgca agctcagttc ccagttgcag tttgagggtt 3300
          ctctcccaac atgtgaagca caatgcccag caaatgaagt ccggactgga tcatcggggag 3360
          tcattctcag tccagggtat ccgggtaatt attttaactc ccagacttgc tcttggagta 3420
          ttaaagtgga accaaactac aacattacca tctttgtgga cacatttcaa agtgaaaagc 3480
          agtttgatgc actggaagtg tttgatggtt cttctgggca aagtcctctg ctagtagtct 3540
          taagtgggaa tcatactgaa caatcaaatt ttacaagcag gagtaatcag ttatatctcc 3600
          gctggtccac tgaccatgcc accagtaaga aaggattcaa gattcgctat gcagcacctt 3660
          actgcagttt gacccacccc ctgaagaatg ggggtattct aaacaggact gcaggagcgg 3720
          ttggaagcaa agtgcattat ttttgcaagc ctggataccg aatggtcggc cacagcaatg 3780
          caacctgtag acgaaaccca cttggcatgt accagtggga ctccctcacg ccactctgcc 3840
          aggctgtgtc ctgtggaatc ccagaatccc caggaaacgg ttcatttacc gggaacgagt 3900
          tcactttgga cagtaaagtg gtctatgaat gtcatgaggg cttcaagctt gaatccagcc 3960
          agcaagcaac agccgtgtgt caagaagatg ggttgtggag taacaagggg aagccgccca 4020
          cgtgtaagcc ggtcgcttgc cccagcattg aagctcagct ctcagaacat gtcatctgga 4080
          ggctggtttc aggatccttg aatgagtacg gtgctcaagt attgctgagc tgcagtcctg 4140
          gttactactt agaaggctgg aggctcctgc ggtgccaggc caatgggacg tggaacatag 4200
          gagatgagag gccaagctgt cgagttatct cgtgtggaag cctttccttt cccccaaatg 4260
          gcaacaagat tggaacgttg acagtttatg gggccacagc tatatttacg tgcaacaccg 4320
          gctacacgct tgtggggtct catgtcagag agtgcttggc aaatgggctc tggagcggca 4380
          gcgaaactcg atgtctggct ggccactgcg gttccccaga cccgattgtg aacggtcaca 4440
          ttagtggaga tggcttcagt tacagagaca cggtggttta ccagtgcaat cctggtttcc 4500
          ggcttgtggg aacttccgtg aggatatgcc tgcaagacca caagtggtct ggacaaacgc 4560
          ctgtctgtgt ccccatcaca tgtggtcacc ctggaaaccc tgcccacgga ttcactaatg 4620
          gcagtgagtt caacctgaat gatgtcgtga atttcacctg caacacgggc tatttgctgc 4680
          agggcgtgtc tcgagcccag tgtcggagca acggccagtg gagtagccct ctgcccacgt 4740
          gtcgagtggt gaactgttct gatccaggct ttgtggaaaa tgccattcgt cacgggcaac 4800
          agaacttccc tgagagtttt gagtatggaa tgagtatcct gtaccattgc aagaagggat 4860
          tttacttgct gggatcttca gccttgacct gtatggcaaa tggcttatgg gaccgatccc 4920
          tgcccaagtg tttggctata tcgtgtggac accccagggggt ccctgccaac gccgtcctca 4980
          ctggagagct gtttacctat ggcgccgtcg tgcactactc ctgcagaggg agcgagagcc 5040
          tcataggcaa cgacacgaga gtgtgccagg aagacagtca ctggagcggg gcactgcccc 5100
          actgcacagg aaataatcct ggattctgtg gtgatccggg gaccccagca catgggtctc 5160
          ggcttggtga tgactttaag acaaagagtc ttctccgctt ctcctgtgaa atggggcacc 5220
          agctgagggg ctcccctgaa cgcacgtgtt tgctcaatgg gtcatggtca ggactgcagc 5280
          cggtgtgtga ggccgtgtcc tgtggcaacc ctggcacacc caccaacgga atgattgtca 5340
          gtagtgatgg cattctgttc tccagctcgg tcatctatgc ctgctgggaa ggctacaaga 5400
          cctcagggct catgacacgg cattgcacag ccaatgggac ctggacaggc actgctcccg 5460
          actgcacaat tataagttgt ggggatccag gcaacactagc aaatggcatc cagtttggga 5520
          ccgacttcac cttcaacaag actgtgagct atcagtgtaa cccaggctat gtcatggaag 5580
          cagtcacatc cgccactatt cgctgtacca aagacggcag gtggaatccg agcaaacctg 5640
          tctgcaaagc cgtgctgtgt cctcagccgc cgccggtgca gaatggaaca gtggagggaa 5700
          gtgatttccg ctggggctcc agcataagtt acagctgcat ggacggttac cagctctctc 5760
          actccgccat cctctcctgt gaaggtcgcg gggtgtggaa aggagagatc ccccagtgtc 5820
          tccctgtgtt ctgcggagac cctggcatcc ccgcagaagg gcgacttagt gggaaaagtt 5880
          tcacctataa gtccgaagtc ttcttccagt gcaaatctcc atttatactc gtgggatcct 5940
          ccagaagagt ctgccaagct gacggcacgt ggagcggcat acaacccacc tgcattgatc 6000
          ctgctcataa cacctgccca gaccctggta cgccaacactt tggaatacag aatagctcca 6060
          gaggctatga ggttggaagc acggtttttt tcaggtgcag aaaaggctac catattcaag 6120
          gttccacgac tcgcacctgc cttgccaatt taacatggag tgggatacag accgaatgta 6180
          tacctcatgc ctgcagacag ccagaaaccc cggcacacgc ggatgtgaga gccatcgatc 6240
          ttcctacttt cggctacacc ttagtgtaca cctgccatcc aggctttttc ctcgcagggg 6300
          gatctgagca cagaacatgt aaagcagaca tgaaatggac aggaaagtcg cctgtgtgta 6360
          aaagtaaagg agtgagagaa gttaatgaaa cagttactaa aactccagtt ccttcagatg 6420
          tctttttcgt caattcactg tggaaggggt attatgaata ttagggaaa agacaacccg 6480
          ccactctaac tgttgactgg ttcaatgcaa caagcagtaa ggtgaatgcc accttcagcg 6540
          aagcctcgcc agtggagctg aagttgacag gcatttacaa gaaggaggag gcccacttac 6600
          tcctgaaagc ttttcaaatt aaaggccagg cagatatttt tgtaagcaag ttcgaaaatg 6660
          acaactgggg actagatggt tatgtgtcat ctggacttga aagaggagga tttacttttc 6720
          aaggtgacat tcatggaaaa gactttggaa aatttaagct agaaaggcaa gatcctttaa 6780
          accccagatca agactcttcc agtcattacc acggcaccag cagtggctct gtggcggctg 6840
          ccattctggt tcctttcttt gctctaattt tatcagggtt tgcattttac ctctacaaac 6900
          acagaacgag accaaaagtt caatacaatg gctatgctgg gcatgaaaac agcaatggac 6960
          aagcatcgtt tgaaaaccccc atgtatgata caaacttaaa accccacagaa gccaaggctg 7020
          tgaggtttga cacaactctg aacacagtct gtacagtggt atagccctca gtgccccaac 7080
          aggactgatt catagccata cctctgatgg acaagcagtg attcctttgg tgccatatac 7140
          cactctccct tccactctgg ctttactgca gcgatcttca accttgtcta ctggcataag 7200
          tgcagcgggg atctctactc aaatgtgtca gggtcttcta cggatcaaac tacacatgcg 7260
          ttttcattcc aaaagtgggt tctaaatgcc tggctgcatc tgtatgaaat caaggcacac 7320
          tccaggaaga ctgccacgtc gcgccaacac gtcatactca atgcctcaga ctttcatatt 7380
          tctgtgttgc tgagatgcct ttcaatgcaa tcgtctgggc tcgtggatat gtccctcagg 7440
          tgcggtgaca gaatggtggc accacgatat gtgttctctt gtgttgtttt tcctttttaa 7500
          acccccatga acacgaatac tctgaaaaaa ataaaaagct ttctggaaga agaacaccttt 7560
          ctgatagagg ctcacaccta caaatgcttc actctgtcct tccgagacct gacaagcttt 7620
          gaggacctca cagctcccct gtgtgttcat ctctagggat gtttgcaatt tcccagtcag 7680
          ctgttctgtc gcagaatgtt taatgcacaa ttttttgcac tagtgtgtta tgaatgacta 7740
          agattctgat aaaaaaaata aattatttac acagggttta tacacactat ccattgtata 7800
          taagcattat ttcatattat caagctaaac attcccccat cagcttagtt gaggtgttag 7860
          ggaaaagtat tcctagatat ggcacagatt ttaaaaggaa atacagtatt gaagagattt 7920
          atttattat tgcttcaatt agctccattt acgtgttgaa ttcattgaag aggtccaatg 7980
          agaaaaaaac agaagcctcc ttatttcaca cgttttcctc ctttagtacc atcctcatcc 8040
          aattactgtc tctctgatac tacttaatag caggggggttt gcagaaattt ctgtttgcca 8100
          tgtaaaactg tgaatagtaa tttattttag atagtcgatg aacttgtggg ttttagctca 8160
          caatgcagcc ttcccttttg cagtgttttttttttgtttttttttttttttgtcttttac 8220
          tgtgccatcg atctttgata ttgcattgaa agacaatata ccacagtagc accttgaact 8280
          cagtgaaaat tgttcaggat caaaatacca agtgttcttt tagagggaag gaaaaagtac 8340
          acacactctc ctctcacaat gatatatttt atacattcat ttgttatttg tttcatgctt 8400
          tatgattcca gatggaaagg taatttcagt gacttttcaa gtttaaattc catttataggt 8460
          aaatgataag ttatgatgca aataaaatct ataagatccc cagggcaaat aaaaatcaaa 8520
          acatgaagta gaagatgtgg ccgtgaggta gtttatgtaa caaattcaaa gtgaaaatca 8580
          tgtttacttt tacttatact tatttgataa aaatattttt gaaacgatag tacttatttt 8640
          attatttgat atttcagttc ctattcaatt gtggcagatt ttctctgttt cacattttag 8700
          attggcgttg gtaatagaaa tgtcagaatg ttcaaattgg ccttcacgtt gtcggagtga 8760
          aacacattgac acctagcttt aagactgatt tatctgttgg tgtactgaag gtttccatgt 8820
          aggacttcaa atgtggaaaa ggaaaagcag tcaggaaaat ggggcattct ttggagagtc 8880
          acgcgttttg attcggacat ttccgtagag ctcggctccc agtgttgtgt tcctcggtcg 8940
          aaagggtctc tgctgtttgg ggactcactg gcctctccta gggactcctt tgtcttgtga 9000
          accccacgct gttggattct gtatcattat gctgaattct ctgcacagtt ttccctggcc 9060
          aacctgccca catccttgga gatttgcttt gccagtggga atccttacat tgctgtttca 9120
          cagtagacgg gacgaggtca gcgggagtcg tgctcctaac aacacacattg aacgaaacag 9180
          aagatgattg aaagtgtgag gaggctcgtg tgcaagggag aacagggtta ctatacatat 9240
          tagtgtatat atatacatac atatatatat atatatattg tacatatcta agtttgagtc 9300
          attcaaacta ggtgcaaaat gctgacttca gagtctgaat taacatctct gttcccatat 9360
          ccctgacctg ctccctggtc aacgatgcta tgaaatcctg aaatgacagg acatacatac 9420
          atacaagaaa ccacatatca aattagatat gattttcctt tgtgtgcaaa gtcaaactgt 9480
          cctagggttg ccagtttgaa gcatgttatt taaatgaaaa aaaaaatcag tgaaattctc 9540
          gtgtgagaat tctgcctagt ttcttcctaa ggttgtgtgc agtgttgaac ggcgtctccg 9600
          caaggtgttg gaggatctca ttttagggca gtcaggagct gtgcttgctg agttaggtct 9660
          agaagactct tccctgaagg caacgggaac acgcgtgagg gacgcgacca cacactaaca 9720
          gaggacacgt gcttcagagc tgtttaaaac tgctgcttgt tttacacaca catcttgcct 9780
          tttttcaggc tagctgcaat aatttttttc ttctgtaaaa tattttgtaa acaacaacaa 9840
          aaagctatta taaaaagggg gtaaaaaaaa gaacgctggc attatgatca ggaaaaccca 9900
          ttgtcatcgc cgaccctccc tcccgtccca ccaacacgctg ctgtcacgac gtaggtgcga 9960
          aagacctttt tgtacagaga tatatttttt atgaagaatt tgtaaaatta ttaaatatgc 10020
          tgtaattttt tgattaatgt aggtacattg ttaaaaaata aatgttttta caatacagaa 10080
          ctgtaatttt cccaataatg taaaatgtac catctctagc tgattttcag ttccaatcct 10140
          attacacatg tattaatatt aaagtggcct gttaaaatga acagtatctt ttttttgtca 10200
          aaaaaattat aaagagggtg taatatagcc tgtgcaatgc caccaatctt taaagcaaat 10260
          cagagttcta attaaatatt taatttta 10288
           <![CDATA[ <210> 282]]>
           <![CDATA[ <211> 14417]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 282]]>
          ctccacggca gcggctcctt gtgccactag cagcccttct tctgcgctct ccgccttttc 60
          tctctagact ggatctctcc tcccccccgc gcccccctcc ccgcatctcc cactcgctgg 120
          ctctctctcc agctgcctcc tctccaggtc tctcctggct gcgcgcgctc ctctccccgc 180
          ttctccccct cccgcagcct cgccgccttg gtgccttcct gcccggctcg gccggcgctc 240
          gtccccggcc ccggccccgc cagcccgggt ctccgcgctc ggagcagctc agccctgcag 300
          tggctcggga cccgatgcta tgagagggaa gcgagccggg cgcccagacc ttcaggaggc 360
          gtcggatgcg cggcgggtct tgggaccggg ctctctctcc ggctcgcctt gccctcgggt 420
          gattatttgg ctccgctcat agccctgcct tcctcggagg agccatcggt gtcgcgtgcg 480
          tgtggagtat ctgcagacat gactgcgtgg aggagattcc agtcgctgct cctgcttctc 540
          gggctgctgg tgctgtgcgc gaggctcctc actgcagcga agggtcagaa ctgtggaggc 600
          ttagtccagg gtcccaatgg cactattgag agcccagggt ttcctcacgg gtatccgaac 660
          tatgccaact gcacctggat catcatcacg ggcgagcgca ataggataca gttgtccttc 720
          catacctttg ctcttgaaga agattttgat attttatcag tttacgatgg acagcctcaa 780
          caagggaatt taaaagtgag attatcggga tttcagctgc cctcctctat agtgagtaca 840
          ggatctatcc tcactctgtg gttcacgaca gacttcgctg tgagtgccca aggtttcaaa 900
          gcatttatg aagttttacc tagccaacact tgtggaaatc ctggagaaat cctgaaagga 960
          gttctgcatg gaacgagatt caacatagga gacaaaatcc ggtacagctg cctccctggc 1020
          tacatcttgg aaggccacgc catcctgacc tgcatcgtca gcccaggaaa tggtgcatcg 1080
          tgggacttcc cagctccctt ttgcagagct gagggagcct gcggaggaac cttacgcggg 1140
          accagcagct ccatctccag cccgcacttc ccttcagagt acgagaacaa cgcggactgc 1200
          acctggacca ttctggctga gcccggggac accattgcgc tggtcttcac tgactttcag 1260
          ctagaagaag gatatgattt cttagagatc agtggcacgg aagctccatc catatggcta 1320
          actggcatga acctcccctc tccagttatc agtagcaaga attggctacg actccatttc 1380
          acctctgaca gcaaccaccg acgcaaagga tttaacgctc agttccaagt gaaaaaggcg 1440
          attgagttga agtcaagagg agtcaagatg ctgcccagca aggatggaag ccataaaaac 1500
          tctgtcttga gccaaggagg tgttgcattg gtctctgaca tgtgtccaga tcctggggatt 1560
          ccagaaaatg gtagaagagc aggttccgac ttcagggttg gtgcaaatgt acagttttca 1620
          tgtgaggaca attacgtgct ccagggatct aaaagcatca cctgtcagag agttacagag 1680
          acgctcgctg cttggagtga ccacaggccc atctgccgag cgagaacatg tggatccaat 1740
          ctgcgtgggc ccagcggcgt cattacctcc cctaattatc cggttcagta tgaagataat 1800
          gcacactgtg tgtgggtcat caccaccacc gacccggaca aggtcatcaa gcttgccttt 1860
          gaagagtttg agctggagcg aggctatgac accctgacgg ttggtgatgc tgggaaggtg 1920
          ggagacacca gatcggtctt gtacgtgctc acgggatcca gtgttcctga cctcattgtg 1980
          agcatgagca accagatgtg gctacatctg cagtcggatg atagcattgg ctcacctggg 2040
          tttaaagctg tttaccaaga aattgaaaag gggaggtgtggggatcctgg aatccccgcc 2100
          tatgggaagc ggacggggcag cagtttcctc catggagata cactcacctt tgaatgcccg 2160
          gcggcctttg agctggtggg ggagagagtt atcacctgtc agcagaacaa tcagtggtct 2220
          ggcaacaagc ccagctgtgt attttcatgt ttcttcaact ttacggcatc atctgggatt 2280
          attctgtcac caaattatcc agaggaatat gggaacaaca tgaactgtgt ctggttgatt 2340
          atctcggagc caggaagtcg aattcaccta atctttaatg attttgatgt tgagcctcag 2400
          tttgactttc tcgcggtcaa ggatgatggc atttctgaca taactgtcct gggtactttt 2460
          tctggcaatg aagtgccttc ccagctggcc agcagtgggc atatagttcg cttggaattt 2520
          cagtctgacc attccactac tggcagaggg ttcaacatca cttacaccac atttggtcag 2580
          aatgagtgcc atgatcctgg cattcctata aacggacgac gttttggtga caggtttcta 2640
          ctcggggagct cggtttcttt ccactgtgat gatggctttg tcaagaccca gggatccgag 2700
          tccattacct gcatactgca agacgggaac gtggtctgga gctccaccgt gccccgctgt 2760
          gaagctccat gtggtggaca tctgacagcg tccagcggag tcattttgcc tcctggatgg 2820
          ccaggatatt ataaggattc tttacattgt gaatggataa ttgaagcaaa accaggccac 2880
          tctatcaaaa taacttttga cagatttcag acagaggtca attatgacac cttggaggtc 2940
          agagatgggc cagccagttc gtccccactg atcggcgagt accacggcac ccaggcaccc 3000
          cagttcctca tcagcaccgg gaacttcatg tacctgctgt tcaccactga caacagccgc 3060
          tccagcatcg gcttcctcat ccactatgag agtgtgacgc ttgagtcgga ttcctgcctg 3120
          gacccgggca tccctgtgaa cggccatcgc cacggtggag actttggcat caggtccaca 3180
          gtgactttca gctgtgaccc ggggtacaca ctaagtgacg acgagcccct cgtctgtgag 3240
          aggaaccacc agtggaacca cgccttgccc agctgcgacg ctctatgtgg aggctacatc 3300
          caagggaaga gtggaacagt cctttctcct gggtttccag atttttatcc aaactctcta 3360
          aactgcacgt ggaccatga agtgtctcat gggaaaggag ttcaaatgat ctttcacacc 3420
          tttcatcttg agagttccca cgactattta ctgatcacag aggatggaag tttttccgag 3480
          cccgttgcca ggctcaccgg gtcggtgttg cctcatacga tcaaggcagg cctgtttgga 3540
          aacttcactg cccagcttcg gtttatatca gacttctcaa tttcgtacga gggcttcaat 3600
          atcacatttt cagaatatga cctggagcca tgtgatgatc ctggagtccc tgccttcagc 3660
          cgaagaattg gttttcactt tggtgtggga gactctctga cgttttcctg cttcctggga 3720
          tatcgtttag aaggtgccac caagcttacc tgcctgggtg ggggccgccg tgtgtggagt 3780
          gcacctctgc caaggtgtgt ggccgaatgt ggagcaagtg tcaaaggaaa tgaaggaaca 3840
          ttactgtctc caaattttcc atccaattat gataataacc atgagtgtat ctataaaata 3900
          gaaacagaag ccggcaaggg catccacctt agaacacgaa gcttccagct gtttgaagga 3960
          gatactctaa aggtatatga tggaaaagac agttcctcac gtccactggg cacgttcact 4020
          aaaaatgaac ttctggggct gatcctaaac agcacatcca atcacctgtg gctagagttc 4080
          aacaccaatg gatctgacac cgaccaaggt tttcaactca cctataccag ttttgatctg 4140
          gtaaaatgtg aggatccggg catccctaac tacggctata ggatccgtga tgaaggccac 4200
          tttaccgaca ctgtagttct gtacagttgc aacccggggt acgccatgca tggcagcaac 4260
          accctgacct gtttgagtgg agacaggaga gtgtgggaca aacccactacc ttcgtgcata 4320
          gcggaatgtg gtggtcagat ccatgcagcc acatcaggac gaatattgtc ccctggctat 4380
          ccagctccgt atgacaacaa cctccactgc acctggatta tagaggcaga cccaggaaag 4440
          accattagcc tccatttcat tgttttcgac acggagatgg ctcacgacat cctcaaggtc 4500
          tgggacgggc cggtggacag tgacatcctg ctgaaggagt ggagtggctc cgcccttccg 4560
          gaggacatcc acagcacctt caactcactc accctgcagt tcgacagcga cttcttcatc 4620
          agcaagtctg gcttctccat ccagttctcc acctcaattg cagccacctg taacgatcca 4680
          ggtatgcccc aaaatggcac ccgctatgga gacagcagag aggctggaga caccgtcaca 4740
          ttccagtgtg accctggcta tcagctccaa ggacaagcca aaatcacctg tgtgcagctg 4800
          aataaccggt tcttttggca accagaccct cctacatgca tagctgcttg tggagggaat 4860
          ctgacgggcc cagcaggtgttttttgtca cccaactacc cacagccgta tcctcctggg 4920
          aaggaatgtg actggagagt aaaagtgaac ccggactttg tcatcgcctt gatattcaaa 4980
          agtttcaaca tggagcccag ctatgacttc ctacacatct atgaagggga agattccaac 5040
          agccccctca ttggggagtta ccagggctct caggccccag aaagaataga gagtagcgga 5100
          aacagcctgt ttctggcatt tcggagtgat gcctccgtgg gcctttcagg gttcgccatt 5160
          gaatttaaag agaaaccacg ggaagcttgt tttgacccag gaaatataat gaatgggaca 5220
          agagttggaa cagacttcaa gcttggctcc accatcacct accacgtgtga ctctggctat 5280
          aagattcttg acccctcatc catcacctgt gtgattgggg ctgatgggaa accctcctgg 5340
          gaccaagtgc tgccctcctg caatgctccc tgtggaggcc agtacacggg atcagaaggg 5400
          gtagttttat caccaaacta cccccataat tacacagctg gtcaaatatg cctctattcc 5460
          atcacggtac caaaggaatt cgtggtcttt ggacagtttg cctatttcca gacagccctg 5520
          aatgatttgg cagaattatt tgatggaacc catgcacagg ccagacttct cagctcactc 5580
          tcggggtctc actcagggga aacattgccc ttggctacgt caaatcaaat tctgctccga 5640
          ttcagtgcaa agagcggtgc ctctgcccgc ggcttccact tcgtgtatca agctgttcct 5700
          cgtaccagtg acacccaatg cagctctgtc cccgagccca gatacggaag gagaattggt 5760
          tctgagtttt ctgccggctc catcgtccga ttcgagtgca acccgggata cctgcttcag 5820
          ggttccacgg cgctccactg ccagtccgtg cccaacgcct tggcacagtg gaacgacacg 5880
          atccccagct gtgtggtacc ctgcagtggc aatttcactc aacgaagagg tacaatcctg 5940
          tcccccggct accctgagcc atacggaaac aacttgaact gtatatggaa gatcatagtt 6000
          acggagggct cgggaattca gatccaagtg atcagttttg ccacggagca gaactgggac 6060
          tcccttgaga tccacgatgg tggggatgtg accgcaccca gactgggaag cttctcaggc 6120
          accacagtac cggcactgct gaacagtact tccaaccaac tctacctgca tttccagtct 6180
          gacattagtg tggcagctgc tggtttccac ctggaataca aaactgtagg tcttgctgca 6240
          tgccaagaac cagccctccc cagcaacagc atcaaaatcg gagatcggta catggtgaac 6300
          gacgtgctct ccttccagtg cgagcccggg tacaccctgc agggccgttc ccacatttcc 6360
          tgtatgccag ggaccgttcg ccgttggaac tatccgtctc ccctgtgcat tgcaacctgt 6420
          ggagggacgc tgagcacctt gggtggtgtg atcctgagcc ccggcttccc aggttcttac 6480
          cccaacaact tagactgcac ctggaggatc tcattaccca tcggctatgg tgcacatatt 6540
          cagtttctga atttttctac cgaagctaat catgacttcc ttgaaattca aaatggacct 6600
          taccacacca gccccatgat tggacaattt agcggcacgg atctccccgc ggccctgctg 6660
          agcacaacgc atgaaaccct catccacttt tatagtgacc attcgcaaaa ccggcaagga 6720
          tttaaacttg cttaccaagc ctatgaatta cagaactgtc cagatccacc cccatttcag 6780
          aatgggtaca tgatcaactc ggattacagc gtggggcaat cagtatcttt cgagtgttat 6840
          cctgggtaca ttctaatagg ccatcctgtc ctcacttgtc agcatgggat caacagaaac 6900
          tggaactacc cttttccaag atgtgatgcc ccttgtgggt acaacgtaac ttctcagaac 6960
          ggcaccatct actcccctgg ctttcctgat gagtatccga tcctgaagga ctgcatttgg 7020
          ctcatcacgg tgcctccagg gcacggagtt tacatcaact tcaccctgtt acagacggaa 7080
          gctgtcaacg attacattgc tgtttgggac ggtcccgatc agaactcacc ccagctggga 7140
          gttttcagtg gcaacacagc cctcgaaacg gcgtatagct ccaccaacca agtcctgctc 7200
          aagttccaca gcgacttttc aaatggaggc ttctttgtcc tcaatttcca cgcatttcag 7260
          ctcaagaaat gtcaacctcc cccagcggtt ccacaggcag aaatgcttac tgaggatgat 7320
          gatttcgaaa tagggagattt tgtgaagtac cagtgccacc ccgggtacac cttggtgggg 7380
          accgacattc tgacttgcaa gctcagttcc cagttgcagtttgagggttc tctcccaaca 7440
          tgtgaagcac aatgcccagc aaatgaagtc cggactggat catcgggagt cattctcagt 7500
          ccagggtatc cgggtaatta ttttaactcc cagacttgct cttggagtat taaagtggaa 7560
          ccaaactaca aattaccat ctttgtggac aatttcaaa gtgaaaagca gtttgatgca 7620
          ctggaagtgtttgatggttc ttctgggcaa agtcctctgc tagtagtctt aagtgggaat 7680
          catactgaac aatcaaattt tacaagcagg agtaatcagt tatatctccg ctggtccact 7740
          gaccatgcca ccagtaagaa aggattcaag attcgctatg cagcacctta ctgcagtttg 7800
          acccacccccc tgaagaatgg gggtattcta aacaggactg caggagcggt tggaagcaaa 7860
          gtgcattatt tttgcaagcc tggataccga atggtcggcc acagcaatgc aacctgtaga 7920
          cgaaacccac ttggcatgta ccagtgggac tccctcacgc cactctgcca ggctgtgtcc 7980
          tgtggaatcc cagaatcccc aggaaacggt tcatttaccg ggaacgagtt cactttggac 8040
          agtaaagtgg tctatgaatg tcatgagggc ttcaagcttg aatccagcca gcaagcaaca 8100
          gccgtgtgtc aagaagatgg gttgtggagt aacaagggga agccgcccac gtgtaagccg 8160
          gtcgcttgcc ccagcattga agctcagctc tcagaacatg tcatctggag gctggtttca 8220
          ggatccttga atgagtacgg tgctcaagta ttgctgagct gcagtcctgg ttactactta 8280
          gaaggctgga ggctcctgcg gtgccaggcc aatgggacgt ggaacatagg agatgagagg 8340
          ccaagctgtc gagttatctc gtgtggaagc ctttcctttc ccccaaatgg caacaagatt 8400
          ggaacgttga cagtttatgg ggccacagct atattacgt gcaacaccgg ctacacgctt 8460
          gtggggtctc atgtcagaga gtgcttggca aatggggctct ggagcggcag cgaaactcga 8520
          tgtctggctg gccactgcgg ttccccagac ccgattgtga acggtcacat tagtggagat 8580
          ggcttcagtt acagagacac ggtggtttac cagtgcaatc ctggtttccg gcttgtggga 8640
          acttccgtga ggatatgcct gcaagaccac aagtggtctg gacaaacgcc tgtctgtgtc 8700
          cccatcacat gtggtcaccc tggaaaccct gcccacggat tcactaatgg cagtgagttc 8760
          aacctgaatg atgtcgtgaa tttcacctgc aacacgggct atttgctgca gggcgtgtct 8820
          cgagcccagt gtcggagcaa cggccagtgg agtagccctc tgcccacgtg tcgagtggtg 8880
          aactgttctg atccaggctt tgtggaaaat gccattcgtc acgggcaaca gaacttccct 8940
          gagagttttg agtatggaat gagtatcctg taccatgca agaagggatt ttacttgctg 9000
          ggatcttcag ccttgacctg tatggcaaat ggcttatggg accgatccct gcccaagtgt 9060
          ttggctatat cgtgtggaca cccaggggtc cctgccaacg ccgtcctcac tggagagctg 9120
          tttacctatg gcgccgtcgt gcactactcc tgcagaggga gcgagagcct cataggcaac 9180
          gacacgagag tgtgccagga agacagtcac tggagcgggg cactgcccca ctgcacagga 9240
          aataatcctg gattctgtgg tgatccgggg accccagcac atgggtctcg gcttggtgat 9300
          gactttaaga caaagagtct tctccgcttc tcctgtgaaa tggggcacca gctgaggggc 9360
          tcccctgaac gcacgtgttt gctcaatggg tcatggtcag gactgcagcc ggtgtgtgag 9420
          gccgtgtcct gtggcaaccc tggcacaccc accaacggaa tgattgtcag tagtgatggc 9480
          attctgttct ccagctcggt catctatgcc tgctgggaag gctacaagac ctcagggctc 9540
          atgacacggc attgcacagc caatgggacc tggacaggca ctgctcccga ctgcacaatt 9600
          ataagttgtg gggatccagg caactagca aatggcatcc agtttgggac cgacttcacc 9660
          ttcaacaaga ctgtgagcta tcagtgtaac ccaggctatg tcatggaagc agtcacatcc 9720
          gccactattc gctgtaccaa agacggcagg tggaatccga gcaaacctgt ctgcaaagcc 9780
          gtgctgtgtc ctcagccgcc gccggtgcag aatggaacag tggagggaag tgatttccgc 9840
          tggggctcca gcataagtta cagctgcatg gacggttacc agctctctca ctccgccatc 9900
          ctctcctgtg aaggtcgcgg ggtgtggaaa ggagagatcc cccagtgtct ccctgtgttc 9960
          tgcggagacc ctggcatccc cgcagaaggg cgacttagtg ggaaaagttt cacctataag 10020
          tccgaagtct tcttccagtg caaatctcca tttatactcg tgggatcctc cagaagagtc 10080
          tgccaagctg acggcacgtg gagcggcata caacccacct gcattgatcc tgctcataac 10140
          acctgcccag accctggtac gccaacacttt ggaatacaga atagctccag aggctatgag 10200
          gttggaagca cggttttttt caggtgcaga aaaggctacc atattcaagg ttccacgact 10260
          cgcacctgcc ttgccaattt aacatggagt gggatacaga ccgaatgtat acctcatgcc 10320
          tgcagacagc cagaaaccccc ggcacacgcg gatgtgagag ccatcgatct tcctactttc 10380
          ggctacacct tagtgtacac ctgccatcca ggctttttcc tcgcagggggg atctgagcac 10440
          agaacatgta aagcagacat gaaatggaca ggaaagtcgc ctgtgtgtaa aagtaaagga 10500
          gtgagagaag ttaatgaaac agttactaaa actccagttc cttcagatgt ctttttcgtc 10560
          aattcactgt ggaaggggta ttatgaatat ttagggaaaa gacaacccgc cactctaact 10620
          gttgactggt tcaatgcaac aagcagtaag gtgaatgcca ccttcagcga agcctcgcca 10680
          gtggagctga agttgacagg catttacaag aaggaggagg cccacttact cctgaaagct 10740
          tttcaaatta aaggccaggc agatattttt gtaagcaagt tcgaaaatga caactgggga 10800
          ctagatggtt atgtgtcatc tggacttgaa agaggagat ttacttttca aggtgacatt 10860
          catggaaaag actttggaaa atttaagcta gaaaggcaag atcctttaaa cccagatcaa 10920
          gactcttcca gtcattacca cggcaccagc agtggctctg tggcggctgc cattctggtt 10980
          cctttctttg ctctaatttt atcagggttt gcattttacc tctacaaaca cagaacgaga 11040
          ccaaaagttc aatacaatgg ctatgctggg catgaaaaca gcaatggaca agcatcgttt 11100
          gaaaacccca tgtatgatac aaacttaaaa cccacagaag ccaaggctgt gaggtttgac 11160
          acaactctga acacagtctg tacagtggta tagccctcag tgccccaaca ggactgattc 11220
          atagccatac ctctgatgga caagcagtga ttcctttggt gccatatacc actctccctt 11280
          ccactctggc tttactgcag cgatcttcaa ccttgtctac tggcataagt gcagcgggga 11340
          tctctactca aatgtgtcag ggtcttctac ggatcaaact acacatgcgt tttcattcca 11400
          aaagtgggtt ctaaatgcct ggctgcatct gtatgaaatc aaggcacact ccaggaagac 11460
          tgccacgtcg cgccaacacg tcatactcaa tgcctcagac tttcatattt ctgtgttgct 11520
          gagatgcctt tcaatgcaat cgtctgggct cgtggatatg tccctcaggt gcggtgacag 11580
          aatggtggca ccacgatatg tgttctcttg tgttgttttt cctttttaaa cccccatgaa 11640
          cacgaatact ctgaaaaaaa taaaaagctt tctggaagaa gacacctttc tgatagaggc 11700
          tcacacctac aaatgcttca ctctgtcctt ccgagacctg acaagctttg aggacctcac 11760
          agctcccctg tgtgttcatc tctagggatg tttgcaattt cccagtcagc tgttctgtcg 11820
          cagaatgttt aatgcacaat tttttgcact agtgtgttat gaatgactaa gattctgata 11880
          aaaaaaataa atttattaca cagggtttat acacactatc cattgtatat aagcattatt 11940
          tcatattatc aagctaaaca ttcccccatc agcttagttg gagtgttagg gaaaagtatt 12000
          cctagatatg gcacagattt taaaaggaaa tacagtattg aagagatta ttttattatt 12060
          gcttcaatta gctccatta cgtgttgaat tcattgaaga ggtccaatga gaaaaaaaca 12120
          gaagcctcct tatttcacac gttttcctcc tttagtacca tcctcatcca attackgtct 12180
          ctctgatact acttaatagc agggggtttg cagaaatttc tgtttgccat gtaaaactgt 12240
          gaatagtaat ttattttaga tagtcgatga acttgtgggt tttagctcac aatgcagcct 12300
          tcccttttgc agtgttttttttttgtttttttttttttttgtcttttact gtgccatcga 12360
          tctttgatat tgcattgaaa gacaatatac cacagtagca ccttgaactc agtgaaaatt 12420
          gttcaggatc aaaataccaa gtgttctttt agagggaagg aaaaagtaca cacactctcc 12480
          tctcacaatg atatatttta tacattcatt tgttatttgt ttcatgcttt atgattccag 12540
          atggaaaggt aatttcagtg acttttcaag tttaaattcc attataggta aatgataagt 12600
          tatgatgcaa ataaaatcta taagatcccc agggcaaata aaaatcaaaa catgaagtag 12660
          aagatgtggc cgtgaggtag tttatgtaac aaattcaaag tgaaaatcat gtttactttt 12720
          acttatactt atttgataaa aatatttttg aaacgatagt acttatttta ttatttgata 12780
          tttcagttcc tattcaattg tggcagattt tctctgtttc aattttaga ttggcgttgg 12840
          taatagaaat gtcagaatgt tcaaattggc cttcacgttg tcggagtgaa cacattgaca 12900
          cctagcttta agactgattt atctgttggt gtactgaagg tttccatgta ggacttcaaa 12960
          tgtggaaaag gaaaagcagt caggaaaatg gggcattctt tggagagtca cgcgttttga 13020
          ttcggacatt tccgtagagc tcggctccca gtgttgtgtt cctcggtcga aagggtctct 13080
          gctgtttggg gactcactgg cctctcctag ggactccttt gtcttgtgaa ccccacgctg 13140
          ttggattctg tatcattatg ctgaattctc tgcacagttt tccctggcca acctgcccac 13200
          atccttggag atttgctttg ccagtgggaa tccttacatt gctgtttcac agtagacggg 13260
          acgaggtcag cgggagtcgt gctcctaaca caacacattga acgaaacaga agatgattga 13320
          aagtgtgagg aggctcgtgt gcaagggaga acagggttac tatacatatt agtgtatata 13380
          tatacataca tatatatata tatatattgt acatatctaa gtttgagtca ttcaaactag 13440
          gtgcaaaatg ctgacttcag agtctgaatt aacatctctg ttcccatatc cctgacctgc 13500
          tccctggtca acgatgctat gaaatcctga aatgacagga catacataca tacaagaaac 13560
          cacatatcaa attagatatg attttccttt gtgtgcaaag tcaaactgtc ctagggttgc 13620
          cagtttgaag catgttattt aaatgaaaaa aaaaatcagt gaaattctcg tgtgagaatt 13680
          ctgcctagtt tcttcctaag gttgtgtgca gtgttgaacg gcgtctccgc aaggtgttgg 13740
          aggatctcat tttagggcag tcaggagctg tgcttgctga gttaggtcta gaagactctt 13800
          ccctgaaggc aacgggaaca cgcgtgaggg acgcgaccac aactaacag aggacacgtg 13860
          cttcagagct gtttaaaact gctgcttgtt ttacacacac atcttgcctt ttttcaggct 13920
          agctgcaata atttttttct tctgtaaaat attttgtaaa caacaacaaa aagctattat 13980
          aaaaaggggg taaaaaaaag aacgctggca ttatgatcag gaaaacccat tgtcatcgcc 14040
          gaccctccct cccgtccccac cacacgctgc tgtcacgacg taggtgcgaa agaccttttt 14100
          gtacagagat atatttttta tgaagaattt gtaaaattat taaatatgct gtaatttttt 14160
          gattaatgta ggtacattgt taaaaaataa atgtttttac aatacagaac tgtaattttc 14220
          ccaataatgt aaaatgtacc atctctagct gattttcagt tccaatccta ttacacatgt 14280
          attaatatta aagtggcctg ttaaaatgaa cagtatcttt tttttgtcaa aaaaattata 14340
          aagagggtgt aatatagcct gtgcaatgcc accaatcttt aaagcaaatc agagttctaa 14400
          ttaaatattt aatttta 14417
           <![CDATA[ <210> 283]]>
           <![CDATA[ <211> 28]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 283]]>
          Met Thr Ala Trp Arg Arg Phe Gln Ser Leu Leu Leu Leu Leu Leu Gly Leu
          1 5 10 15
          Leu Val Leu Cys Ala Arg Leu Leu Thr Ala Ala Lys
                      20 25
           <![CDATA[ <210> 284]]>
           <![CDATA[ <211> 71]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 284]]>
          Gln Asn Cys Gly Gly Leu Val Gln Gly Pro Asn Gly Thr Ile Glu Ser
          1 5 10 15
          Pro Gly Phe Pro His Gly Tyr Pro Asn Tyr Ala Asn Cys Thr Trp Ile
                      20 25 30
          Ile Ile Thr Gly Glu Arg Asn Arg Ile Gln Leu Ser Phe His Thr Phe
                  35 40 45
          Ala Leu Glu Glu Asp Phe Asp Ile Leu Ser Val Tyr Asp Gly Gln Pro
              50 55 60
          Gln Gln Gly Asn Leu Lys Val
          65 70
           <![CDATA[ <210> 285]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 285]]>
          Leu Ser Gly Phe Gln Leu Pro Ser Ser Ile Val Ser Thr Gly Ser Ile
          1 5 10 15
          Leu Thr Leu Trp Phe Thr Thr Asp Phe Ala Val Ser Ala Gln Gly Phe
                      20 25 30
          Lys Ala Leu Tyr Glu
                  35
           <![CDATA[ <210> 286]]>
           <![CDATA[ <211> 64]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 286]]>
          Leu Pro Ser His Thr Cys Gly Asn Pro Gly Glu Ile Leu Lys Gly Val
          1 5 10 15
          Leu His Gly Thr Arg Phe Asn Ile Gly Asp Lys Ile Arg Tyr Ser Cys
                      20 25 30
          Leu Pro Gly Tyr Ile Leu Glu Gly His Ala Ile Leu Thr Cys Ile Val
                  35 40 45
          Ser Pro Gly Asn Gly Ala Ser Trp Asp Phe Pro Ala Pro Phe Cys Arg
              50 55 60
           <![CDATA[ <210> 287]]>
           <![CDATA[ <211> 68]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 287]]>
          Glu Gly Ala Cys Gly Gly Thr Leu Arg Gly Thr Ser Ser Ser Ser Ile Ser
          1 5 10 15
          Ser Pro His Phe Pro Ser Glu Tyr Glu Asn Asn Ala Asp Cys Thr Trp
                      20 25 30
          Thr Ile Leu Ala Glu Pro Gly Asp Thr Ile Ala Leu Val Phe Thr Asp
                  35 40 45
          Phe Gln Leu Glu Glu Gly Tyr Asp Phe Leu Glu Ile Ser Gly Thr Glu
              50 55 60
          Ala Pro Ser Ile
          65
           <![CDATA[ <210> 288]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 288]]>
          Leu Thr Gly Met Asn Leu Pro Ser Pro Val Ile Ser Ser Lys Asn Trp
          1 5 10 15
          Leu Arg Leu His Phe Thr Ser Asp Ser Asn His Arg Arg Lys Gly Phe
                      20 25 30
          Asn Ala Gln Phe Gln
                  35
           <![CDATA[ <210> 289]]>
           <![CDATA[ <211> 25]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 289]]>
          Lys Lys Ala Ile Glu Leu Lys Ser Arg Gly Val Lys Met Leu Pro Ser
          1 5 10 15
          Lys Asp Gly Ser His Lys Asn Ser Val
                      20 25
           <![CDATA[ <210> 290]]>
           <![CDATA[ <211> 28]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 290]]>
          Ser Gln Gly Gly Val Ala Leu Val Ser Asp Met Cys Pro Asp Pro Gly
          1 5 10 15
          Ile Pro Glu Asn Gly Arg Arg Ala Gly Ser Asp Phe
                      20 25
           <![CDATA[ <210> 291]]>
           <![CDATA[ <211> 41]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 291]]>
          Val Gly Ala Asn Val Gln Phe Ser Cys Glu Asp Asn Tyr Val Leu Gln
          1 5 10 15
          Gly Ser Lys Ser Ile Thr Cys Gln Arg Val Thr Glu Thr Leu Ala Ala
                      20 25 30
          Trp Ser Asp His Arg Pro Ile Cys Arg
                  35 40
           <![CDATA[ <210> 292]]>
           <![CDATA[ <211> 40]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 292]]>
          Arg Thr Cys Gly Ser Asn Leu Arg Gly Pro Ser Gly Val Ile Thr Ser
          1 5 10 15
          Pro Asn Tyr Pro Val Gln Tyr Glu Asp Asn Ala His Cys Val Trp Val
                      20 25 30
          Ile Thr Thr Thr Asp Pro Asp Lys
                  35 40
           <![CDATA[ <210> 293]]>
           <![CDATA[ <211> 34]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 293]]>
          Val Ile Lys Leu Ala Phe Glu Glu Phe Glu Leu Glu Arg Gly Tyr Asp
          1 5 10 15
          Thr Leu Thr Val Gly Asp Ala Gly Lys Val Gly Asp Thr Arg Ser Val
                      20 25 30
          Leu Tyr
           <![CDATA[ <210> 294]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 294]]>
          Leu Thr Gly Ser Ser Val Pro Asp Leu Ile Val Ser Met Ser Asn Gln
          1 5 10 15
          Met Trp Leu His Leu Gln Ser Asp Asp Ser Ile Gly Ser Pro Gly Phe
                      20 25 30
          Lys Ala Val Tyr Gln
                  35
           <![CDATA[ <210> 295]]>
           <![CDATA[ <211> 60]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 295]]>
          Ile Glu Lys Gly Gly Cys Gly Asp Pro Gly Ile Pro Ala Tyr Gly Lys
          1 5 10 15
          Arg Thr Gly Ser Ser Phe Leu His Gly Asp Thr Leu Thr Phe Glu Cys
                      20 25 30
          Pro Ala Ala Phe Glu Leu Val Gly Glu Arg Val Ile Thr Cys Gln Gln
                  35 40 45
          Asn Asn Gln Trp Ser Gly Asn Lys Pro Ser Cys Val
              50 55 60
           <![CDATA[ <210> 296]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 296]]>
          Ser Cys Phe Phe Asn Phe Thr Ala Ser Ser Gly Ile Ile Leu Ser Pro
          1 5 10 15
          Asn Tyr Pro Glu Glu Tyr Gly Asn Asn Met Asn Cys Val Trp Leu Ile
                      20 25 30
          Ile Ser Glu Pro Gly Ser Arg Ile His Leu Ile Phe Asn Asp Phe Asp
                  35 40 45
          Val Glu Pro Gln Phe Asp Phe Leu Ala Val Lys Asp Asp Gly Ile Ser
              50 55 60
          Asp Ile Thr Val Leu Gly Thr Phe Ser Gly Asn Glu Val Pro Ser Gln
          65 70 75 80
          Leu Ala Ser Ser Gly His Ile Val Arg Leu Glu Phe Gln Ser Asp His
                          85 90 95
          Ser Thr Thr Gly Arg Gly Phe Asn Ile Thr Tyr Thr
                      100 105
           <![CDATA[ <210> 297]]>
           <![CDATA[ <211> 64]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 297]]>
          Phe Gly Gln Asn Glu Cys His Asp Pro Gly Ile Pro Ile Asn Gly Arg
          1 5 10 15
          Arg Phe Gly Asp Arg Phe Leu Leu Gly Ser Ser Val Ser Phe His Cys
                      20 25 30
          Asp Asp Gly Phe Val Lys Thr Gln Gly Ser Glu Ser Ile Thr Cys Ile
                  35 40 45
          Leu Gln Asp Gly Asn Val Val Trp Ser Ser Thr Val Pro Arg Cys Glu
              50 55 60
           <![CDATA[ <210> 298]]>
           <![CDATA[ <211> 45]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 298]]>
          Pro Cys Gly Gly His Leu Thr Ala Ser Ser Gly Val Ile Leu Pro Pro
          1 5 10 15
          Gly Trp Pro Gly Tyr Tyr Lys Asp Ser Leu His Cys Glu Trp Ile Ile
                      20 25 30
          Glu Ala Lys Pro Gly His Ser Ile Lys Ile Thr Phe Asp
                  35 40 45
           <![CDATA[ <210> 299]]>
           <![CDATA[ <211> 62]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 299]]>
          Phe Gln Thr Glu Val Asn Tyr Asp Thr Leu Glu Val Arg Asp Gly Pro
          1 5 10 15
          Ala Ser Ser Ser Pro Leu Ile Gly Glu Tyr His Gly Thr Gln Ala Pro
                      20 25 30
          Gln Phe Leu Ile Ser Thr Gly Asn Phe Met Tyr Leu Leu Phe Thr Thr
                  35 40 45
          Asp Asn Ser Arg Ser Ser Ser Ile Gly Phe Leu Ile His Tyr Glu
              50 55 60
           <![CDATA[ <210> 300]]>
           <![CDATA[ <211> 62]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 300]]>
          Val Thr Leu Glu Ser Asp Ser Cys Leu Asp Pro Gly Ile Pro Val Asn
          1 5 10 15
          Gly His Arg His Gly Gly Asp Phe Gly Ile Arg Ser Thr Val Thr Phe
                      20 25 30
          Ser Cys Asp Pro Gly Tyr Thr Leu Ser Asp Asp Glu Pro Leu Val Cys
                  35 40 45
          Glu Arg Asn His Gln Trp Asn His Ala Leu Pro Ser Cys Asp
              50 55 60
           <![CDATA[ <210> 301]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 301]]>
          Leu Cys Gly Gly Tyr Ile Gln Gly Lys Ser Gly Thr Val Leu Ser Pro
          1 5 10 15
          Gly Phe Pro Asp Phe Tyr Pro Asn Ser Leu Asn Cys Thr Trp Thr Ile
                      20 25 30
          Glu Val Ser His Gly Lys
                  35
           <![CDATA[ <210> 302]]>
           <![CDATA[ <211> 71]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 302]]>
          Val Gln Met Ile Phe His Thr Phe His Leu Glu Ser Ser His Asp Tyr
          1 5 10 15
          Leu Leu Ile Thr Glu Asp Gly Ser Phe Ser Glu Pro Val Ala Arg Leu
                      20 25 30
          Thr Gly Ser Val Leu Pro His Thr Ile Lys Ala Gly Leu Phe Gly Asn
                  35 40 45
          Phe Thr Ala Gln Leu Arg Phe Ile Ser Asp Phe Ser Ile Ser Tyr Glu
              50 55 60
          Gly Phe Asn Ile Thr Phe Ser
          65 70
           <![CDATA[ <210> 303]]>
           <![CDATA[ <211> 62]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 303]]>
          Tyr Asp Leu Glu Pro Cys Asp Asp Pro Gly Val Pro Ala Phe Ser Arg
          1 5 10 15
          Arg Ile Gly Phe His Phe Gly Val Gly Asp Ser Leu Thr Phe Ser Cys
                      20 25 30
          Phe Leu Gly Tyr Arg Leu Glu Gly Ala Thr Lys Leu Thr Cys Leu Gly
                  35 40 45
          Gly Gly Arg Arg Val Trp Ser Ala Pro Leu Pro Arg Cys Val
              50 55 60
           <![CDATA[ <210> 304]]>
           <![CDATA[ <211> 56]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 304]]>
          Glu Cys Gly Ala Ser Val Lys Gly Asn Glu Gly Thr Leu Leu Ser Pro
          1 5 10 15
          Asn Phe Pro Ser Asn Tyr Asp Asn Asn His Glu Cys Ile Tyr Lys Ile
                      20 25 30
          Glu Thr Glu Ala Gly Lys Gly Ile His Leu Arg Thr Arg Ser Phe Gln
                  35 40 45
          Leu Phe Glu Gly Asp Thr Leu Lys
              50 55
           <![CDATA[ <210> 305]]>
           <![CDATA[ <211> 52]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 305]]>
          Val Tyr Asp Gly Lys Asp Ser Ser Ser Arg Pro Leu Gly Thr Phe Thr
          1 5 10 15
          Lys Asn Glu Leu Leu Gly Leu Ile Leu Asn Ser Thr Ser Asn His Leu
                      20 25 30
          Trp Leu Glu Phe Asn Thr Asn Gly Ser Asp Thr Asp Gln Gly Phe Gln
                  35 40 45
          Leu Thr Tyr Thr
              50
           <![CDATA[ <210> 306]]>
           <![CDATA[ <211> 63]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 306]]>
          Phe Asp Leu Val Lys Cys Glu Asp Pro Gly Ile Pro Asn Tyr Gly Tyr
          1 5 10 15
          Arg Ile Arg Asp Glu Gly His Phe Thr Asp Thr Val Val Leu Tyr Ser
                      20 25 30
          Cys Asn Pro Gly Tyr Ala Met His Gly Ser Asn Thr Leu Thr Cys Leu
                  35 40 45
          Ser Gly Asp Arg Arg Val Trp Asp Lys Pro Leu Pro Ser Cys Ile
              50 55 60
           <![CDATA[ <210> 307]]>
           <![CDATA[ <211> 2353]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 307]]> Phe Asp Leu Val Lys Cys Glu Asp Pro Gly Ile Pro Asn Tyr Gly Tyr 1 5 10 15 Arg Ile Arg Asp Glu Gly His Phe Thr Asp Thr Val Val Leu Tyr Ser 20 25 30 Cys Asn Pro Gly Tyr Ala Met His Gly Ser Asn Thr Leu Thr Cys Leu 35 40 45 Ser Gly Asp Arg Arg Val Trp Asp Lys Pro Leu Pro Ser Cys Ile Ala 50 55 60 Glu Cys Gly Gly Gln Ile His Ala Ala Thr Ser Gly Arg Ile Leu Ser 65 70 75 80 Pro Gly Tyr Pro Ala Pro Tyr Asp Asn Asn Leu His Cys Thr Trp Ile 85 90 95 Ile Glu Ala Asp Pro Gly Lys Thr Ile Ser Leu His Phe Ile Val Phe 100 105 110 Asp Thr Glu Met Ala His Asp Ile Leu LYS Val Trp Asp Gly Pro Val 115 120 125 ASP Serite Leu LEU LYS GLU TRP Serp Serge Serge Seru Glu 130 135 140 ASP ILE HIS THR Leu Thr Leu Gln PHE ASP SP S ER ASP 145 150 155 160 Phe Phe Ile Ser Lys Ser Gly Phe Ser Ile Gln Phe Ser Thr Ser Ile 165 170 175 Ala Ala Thr Cys Asn Asp Pro Gly Met Pro Gln Asn Gly Thr Arg Tyr 180 185 190 Gly Asp Ser Arg Glu Ala Gly Asp Thr Val Thr Phe Gln Cys Asp Pro 195 200 205 Gly Tyr Gln Leu Gln Gly Gln Ala Lys Ile Thr Cys Val Gln Leu Asn 210 215 220 Asn Arg Phe Phe Trp Gln Pro Asp Pro Pro Thr Cys Ile Ala Ala Cys 225 230 235 240 Gly Gly Asn Leu Thr Gly Pro Ala Gly Val Ile Leu Ser Pro Asn Tyr 245 250 255 Pro Gln Pro Tyr Pro Pro Gly Lys Glu Cys Asp Trp Arg Val Lys Val 260 265 270 Asn Pro Asp Phe Val Ile Ala Leu Ile Phe Lys Ser Phe Asn Met Glu 275 280 285 Pro Ser Tyr Asp Phe Leu His Ile Tyr Glu Gly Glu Asp Ser Asn Ser 290 295 300 Pro Leu Ile Gly Ser Tyr Gln Gly Ser Gln Ala Pro Glu Arg Ile Glu 305 310 315 320 Ser Ser Gly Asn Ser Leu Phe Leu Ala Phe Arg Ser Asp Ala Ser Val 325 330 335 Gly Leu Ser Gly Phe Ala Ile Glu Phe Lys Glu Lys Pro Arg Glu Ala 340 345 350 Cys Phe Asp Pro Gly Asn Ile Met Asn Gly Thr Arg Val Gly Thr Asp 355 360 365 Phe Lys Leu Gly Ser Thr Ile Thr Tyr Gln Cys Asp Ser Gly Tyr Lys 370 375 380 Ile Leu Asp Pro Ser Ser Ile Thr Cys Val Ile Gly Ala Asp Gly Lys 385 390 395 400 Pro Ser Trp Asp Gln Val Leu Pro Ser Cys Asn Ala Pro Cys Gly Gly 410 415 GLN TYR THR GLY Ser Gly Val Val Leu Sern Tyr Pro His 420 425 430 ASN TYR Ala Gln Ile Cys Leu Tyr Val Pro Lys 43 5 440 445 GLU PHE VAL VAL PHE Gly Gln Phe Ala Tyr Phe Gln Thr Ala Leu Asn 450 455 460 Asp Leu Ala Glu Leu Phe Asp Gly Thr His Ala Gln Ala Arg Leu Leu 465 470 475 480 Ser Ser Leu Ser Gly Ser His Ser Gly Glu Thr Leu Pro Leu Ala Thr 485 490 495 Ser Asn Gln Ile Leu Leu Arg Phe Ser Ala Lys Ser Gly Ala Ser Ala 500 505 510 Arg Gly Phe His Phe Val Tyr Gln Ala Val Pro Arg Thr Ser Asp Thr 515 520 525 Gln Cys Ser Ser Val Pro Glu Pro Arg Tyr Gly Arg Arg Ile Gly Ser 530 535 540 Glu Phe Ser Ala Gly Ser Ile Val Arg Phe Glu Cys Asn Pro Gly Tyr 545 550 555 560 Leu Leu Gln Gly Ser Thr Ala Leu His Cys Gln Ser Val Pro Asn Ala 565 570 575 Leu Ala Gln Trp Asn Asp Thr Ile Pro Ser Cys Val Val Pro Cys Ser 580 585 590 Gly Asn Phe Thr Gln Arg Arg Gly Thr Ile Leu Ser Pro Gly Tyr Pro 595 600 605 Glu Pro Tyr Gly Asn Asn Asn Leu Asn Cys Ile Trp Lys Ile Ile Val Thr 610 615 620 Glu Gly Ser Gly Ile Gln Ile Gln Val Ile Ser Phe Ala Thr Glu Gln 625 630 635 640 Asn Trp Asp Ser Leu Glu Ile His Asp Gly Gly Asp Val Thr Ala Pro 645 650 655 Arg Leu Gly Ser Phe Ser Gly Thr Thr Val Pro Ala Leu Leu Asn Ser 660 665 670 Thr Ser Asn Gln Leu Tyr Leu His Phe Gln Ser Asp Ile Ser Val Ala 675 680 685 Ala Ala Gly Phe His Leu Glu Tyr Lys Thr Val Gly Leu Ala Ala Cys 690 695 700 GLN GLU Pro Ala Leu Pro Sero Serite Gly ASP ARG TYR 705 710 715 720 Met Val Leu Seru Gln Gln Glu GLY TYR Leu 725 735 Gln Gly. ARG Ser His Ile Ser Cys Met Pro Gly Thr Val Arg Arg Trp 740 745 750 Asn Tyr Pro Ser Pro Leu Cys Ile Ala Thr Cys Gly Gly Thr Leu Ser 755 760 765 Thr Leu Gly Gly Val Ile Leu Ser Pro Gly Phe Pro Gly Ser Tyr Pro 770 775 780 Asn Asn Leu Asp Cys Thr Trp Arg Ile Ser Leu Pro Ile Gly Tyr Gly 785 790 795 800 Ala His Ile Gln Phe Leu Asn Phe Ser Thr Glu Ala Asn His Asp Phe 805 810 815 Leu Glu Ile Gln Asn Gly Pro Tyr His Thr Ser Pro Met Ile Gly Gln 820 825 830 Phe Ser Gly Thr Asp Leu Pro Ala Ala Leu Leu Ser Thr Thr His Glu 835 840 845 Thr Leu Ile His Phe Tyr Ser Asp His Ser Gln Asn Arg Gln Gly Phe 850 855 860 Lys Leu Ala Tyr Gln Ala Tyr Glu Leu Gln Asn Cys Pro Asp Pro Pro 865 870 875 880 Pro Phe Gln Asn Gly Tyr Met Ile Asn Ser Asp Tyr Ser Val Gly Gln 885 890 895 Ser Val Ser Phe Glu Cys Tyr Pro Gly Tyr Ile Leu Ile Gly His Pro 900 905 910 Val Leu ThR CYS GLN HIS GLY ILE Asn ARG Asn Trp Asn Tyr Pro PHE 915 920 925 Pro ARG CYS Asp Ala Pro Cys GLY TYR ASN GLN GLN GLN GLN GLN 935 940 Thr Ile Tyr Ser Pro Gly PHE Pro ASP GLU Tyr Pro Ile Leu Lys Asp 945 950 955 960 Cys Ile Trp Leu Ile Thr Val Pro Gly His Gly Val Tyr Ile Asn 965 970 975 Phe Thr Leu Leu Gln Thr Glu Ala Val Asn Asp Tyr Ile Ala Val Trp 980 985 990 A sp Gly Pro Asp Gln Asn Ser Pro Gln Leu Gly Val Phe Ser Gly Asn 995 1000 1005 Thr Ala Leu Glu Thr Ala Tyr Ser Ser Thr Asn Gln Val Leu Leu 1010 1015 1020 Lys Phe His Ser Asp Phe Ser Asn Gly Gly Phe Phe Val Leu Asn 1025 1030 1035 Phe His Ala Phe Gln Leu Lys Lys Cys Gln Pro Pro Pro Ala Val 1040 1045 1050 Pro Gln Ala Glu Met Leu Thr Glu Asp Asp Asp Phe Glu Ile Gly 1055 1060 1065 Asp Phe Val Lys Tyr Gln Cys His Pro Gly Tyr Thr Leu Val Gly 1070 1075 1080 Thr Asp Ile Leu Thr Cys Lys Leu Ser Ser Gln Leu Gln Phe Glu 1085 1090 1095 Gly Ser Leu Pro Thr Cys Glu Ala Gln Cys Pro Ala Asn Glu Val 1100 1105 1110 Arg Thr Gly S er Ser Gly Val Ile Leu Ser Pro Gly Tyr Pro Gly 1115 1120 1125 Asn Tyr Phe Asn Ser Gln Thr Cys Ser Trp Ser Ile Lys Val Glu 1130 1135 1140 Pro Asn Tyr Asn Ile Thr Ile Phe Val Asp Thr Phe Gln Ser Glu 1145 115 0 1155 Lys Gln Phe Asp Ala Leu Glu Val Phe Asp Gly Ser Ser Gly Gln 1160 1165 1170 Ser Pro Leu Leu Val Val Leu Ser Gly Asn His Thr Glu Gln Ser 1175 1180 1185 Asn Phe Thr Ser Arg Ser Asn Gln Leu Tyr Leu Arg Trp Ser Thr 1190 1195 1200 Asp His Ala Thr Ser Lys Lys Gly Phe Lys Ile Arg Tyr Ala Ala 1205 1210 1215 Pro Tyr Cys Ser Leu Thr His Pro Leu Lys Asn Gly Gly Ile Leu 1220 1225 1230 Asn Arg Thr Ala Gly Ala Val Gly Ser Lys Val His T yr Phe Cys 1235 1240 1245 Lys Pro Gly Tyr Arg Met Val Gly His Ser Asn Ala Thr Cys Arg 1250 1255 1260 Arg Asn Pro Leu Gly Met Tyr Gln Trp Asp Ser Leu Thr Pro Leu 1265 1270 1275 Cys Gln Ala Val S er Cys Gly Ile Pro Glu Ser Pro Gly Asn Gly 1280 1285 1290 Ser Phe Thr Gly Asn Glu Phe Thr Leu Asp Ser Lys Val Tyr 1295 1300 1305 Glu Cys His Glu Gly Phe Lys Leu Glu Ser Ser Gln Gln Ala Thr 1310 1315 1320 A la Val Cys Gln Glu Asp Gly Leu Trp Ser Asn Lys Gly Lys Pro 1325 1330 1335 Pro Thr Cys Lys Pro Val Ala Cys Pro Ser Ile Glu Ala Gln Leu 1340 1345 1350 Ser Glu His Val Ile Trp Arg Leu Val Ser Gly Ser Leu Asn Glu 1355 1360 1365 Tyr Gly Ala Gln Val Leu Leu Ser Cys Ser Pro Gly Tyr Tyr Leu 1370 1375 1380 Glu Gly Trp Arg Leu Leu Arg Cys Gln Ala Asn Gly Thr Trp Asn 1385 1390 1395 Ile Gly Asp Glu Arg Pro Ser Cys Arg Val Ile Ser Cys Gly Ser 1400 1405 1410 Leu Ser Phe Pro Pro Asn Gly Asn Lys Ile Gly Thr Leu Thr Val 1415 1420 1425 Tyr Gly Ala Thr Ala Ile Phe Thr Cys Asn Thr Gly Tyr Thr Leu 1430 1435 1440 Val Gly Ser His Val Arg Glu Cys Leu Ala Asn Gly Leu Trp Ser 1445 1450 1455 Gly Ser Glu Thr Arg Cys Leu Ala Gly His Cys Gly Ser Pro Asp 1460 1465 1470 Pro Ile Val Asn Gly His Ile Ser Gly Asp Gly Phe Ser Tyr Arg 1475 1480 1485 Asp Thr Val Val Tyr Gln Cys Asn Pro Gly Phe Arg Leu Val Gly 1490 1495 1500 Thr Ser Val Arg Ile Cys Leu Gln Asp His Lys Trp Ser Gly Gln 1505 1510 1515 Thr Pro Val Cys Val Pro Ile Thr Cys Gly His Pro Gly Asn Pro 1520 1525 1530 A la His Gly Phe Thr Asn Gly Ser Glu Phe Asn Leu Asn Asp Val 1535 1540 1545 Val Asn Phe Thr Cys Asn Thr Gly Tyr Leu Leu Gln Gly Val Ser 1550 1555 1560 Arg Ala Gln Cys Arg Ser Asn Gly Gln Trp Ser Ser Pro Leu Pro 1565 1570 1575 Thr Cys Arg Val Val Asn Cys Ser Asp Pro Gly Phe Val Glu Asn 1580 1585 1590 Ala Ile Arg His Gly Gln Gln Asn Phe Pro Glu Ser Phe Glu Tyr 1595 1600 1605 Gly Met Ser Ile Leu Tyr His Cys Lys Lys Gly Phe Tyr Leu Leu 1610 1615 1620 Gly Ser Ala Leu Thr Cys Met Ala Asn Gly Leu Trp Asp Arg 1625 1630 1635 Ser Leu Pro Lys Cys Leu Ala Ile Ser Cys Gly His Pro Gly Val 1640 1645 1650 Pro Ala Asn Ala Val Leu Th r Gly Glu Leu Phe Thr Tyr Gly Ala 1655 1660 1665 Val Val His Tyr Ser Cys Arg Gly Ser Glu Ser Leu Ile Gly Asn 1670 1675 1680 Asp Thr Arg Val Cys Gln Glu Asp Ser His Trp Ser Gly Ala Leu 1685 1690 1695 Pro His Cys Thr Gly Asn Asn Pro Gly Phe Cys Gly Asp Pro Gly 1700 1705 1710 Thr Pro Ala His Gly Ser Arg Leu Gly Asp Asp Phe Lys Thr Lys 1715 1720 1725 Ser Leu Leu Arg Phe Ser Cys Glu Met Gly His Gln Leu Arg Gly 1730 1735 1 740 Ser Pro Glu Arg Thr Cys Leu Leu Asn Gly Ser Trp Ser Gly Leu 1745 1750 1755 Gln Pro Val Cys Glu Ala Val Ser Cys Gly Asn Pro Gly Thr Pro 1760 1765 1770 Thr Asn Gly Met Ile Val Ser Ser Asp Gly Ile Leu Phe Ser Ser 1775 1780 1785 Ser Val Ile Tyr Ala Cys Trp Glu Gly Tyr Lys Thr Ser Gly Leu 1790 1795 1800 Met Thr Arg His Cys Thr Ala Asn Gly Thr Trp Thr Gly Thr Ala 1805 1810 1815 Pro Asp Cys Thr Ile Ile S er Cys Gly Asp Pro Gly Thr Leu Ala 1820 1825 1830 Asn Gly Ile Gln Phe Gly Thr Asp Phe Thr Phe Asn Lys Thr Val 1835 1840 1845 Ser Tyr Gln Cys Asn Pro Gly Tyr Val Met Glu Ala Val Thr Ser 1850 1855 1860 Ala Th r Ile Arg Cys Thr Lys Asp Gly Arg Trp Asn Pro Ser Lys 1865 1870 1875 Pro Val Cys Lys Ala Val Leu Cys Pro Gln Pro Pro Pro Val Gln 1880 1885 1890 Asn Gly Thr Val Glu Gly Ser Asp Phe Arg Trp Gly Ser Ser Ile 1895 1900 1905 S er Tyr Ser Cys Met Asp Gly Tyr Gln Leu Ser His Ser Ala Ile 1910 1915 1920 Leu Ser Cys Glu Gly Arg Gly Val Trp Lys Gly Glu Ile Pro Gln 1925 1930 1935 Cys Leu Pro Val Phe Cys Gly Asp Pro Gly Ile Pro Ala Glu Gly 1940 19 45 1950 Arg Leu Ser Gly Lys Ser Phe Thr Tyr Lys Ser Glu Val Phe Phe 1955 1960 1965 Gln Cys Lys Ser Pro Phe Ile Leu Val Gly Ser Ser Arg Arg Val 1970 1975 1980 Cys Gln Ala Asp Gly Thr Trp Ser Gly Ile Gln Pro Thr Cys Ile 1985 1990 1995 Asp Pro Ala His Asn Thr Cys Pro Asp Pro Gly Thr Pro His Phe 2000 2005 2010 Gly Ile Gln Asn Ser Ser Arg Gly Tyr Glu Val Gly Ser Thr Val 2015 2020 2025 Phe Phe Arg Cys Arg Lys G ly Tyr His Ile Gln Gly Ser Thr Thr 2030 2035 2040 Arg Thr Cys Leu Ala Asn Leu Thr Trp Ser Gly Ile Gln Thr Glu 2045 2050 2055 Cys Ile Pro His Ala Cys Arg Gln Pro Glu Thr Pro Ala His Ala 2060 2065 2070 Asp Val Arg Ala Ile Asp Leu Pro Thr Phe Gly Tyr Thr Leu Val 2075 2080 2085 Tyr Thr Cys His Pro Gly Phe Phe Leu Ala Gly Gly Ser Glu His 2090 2095 2100 Arg Thr Cys Lys Ala Asp Met Lys Trp Thr Gly Lys Ser Pro Val 2105 2110 2 115 Cys LYS Ser Lys Gly Val ARG Glu Val Asn Glu Thr Val THR LYS 2125 2130 THR Pro Val Pro Ser ASP Val PHE Val Asn Serou TRP LYS 2135 2145 GLY Tyr Tyr Glu Tyr Leu GLY LYS ARG GLN Pro Ala THR Leu ThR 2150 2155 2160 Val Asp Trp Phe Asn Ala Thr Ser Ser Lys Val Asn Ala Thr Phe 2165 2170 2175 Ser Glu Ala Ser Pro Val Glu Leu Lys Leu Thr Gly Ile Tyr Lys 2180 2185 2190 Lys Glu Glu Ala His Leu Leu Leu Lys Ala Phe Gln Ile Lys Gly 2195 2200 2205 Gln Ala Asp Ile Phe Val Ser Lys Phe Glu Asn Asp Asn Trp Gly 2210 2215 2220 Leu Asp Gly Tyr Val Ser Gly Leu Glu Arg Gly Gly Phe Thr 2225 2230 2235 Phe G ln Gly Asp Ile His Gly Lys Asp Phe Gly Lys Phe Lys Leu 2240 2245 2250 Glu Arg Gln Asp Pro Leu Asn Pro Asp Gln Asp Ser Ser Ser His 2255 2260 2265 Tyr His Gly Thr Ser Ser Ser Gly Ser Val Ala Ala Ala Ile Leu Val 2270 2275 228 0 Pro Phe Phe Ala Leu Ile Leu Ser Gly Phe Ala Phe Tyr Leu Tyr 2285 2290 2295 Lys His Arg Thr Arg Pro Lys Val Gln Tyr Asn Gly Tyr Ala Gly 2300 2305 2310 His Glu Asn Ser Asn Gly Gln Ala Ser Phe Glu Asn Pro Met Ty r 2315 2320 2325 Asp Thr Asn Leu Lys Pro Thr Glu Ala Lys Ala Val Arg Phe Asp 2330 2335 2340 Thr Thr Leu Asn Thr Val Cys Thr Val Val 2345 2350 <![CDATA[ <210> 308]]>
           <![CDATA[ <211> 3564]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 308]]>
          Met Thr Ala Trp Arg Arg Phe Gln Ser Leu Leu Leu Leu Leu Leu Gly Leu
          1 5 10 15
          Leu Val Leu Cys Ala Arg Leu Leu Thr Ala Ala Lys Gly Gln Asn Cys
                      20 25 30
          Gly Gly Leu Val Gln Gly Pro Asn Gly Thr Ile Glu Ser Pro Gly Phe
                  35 40 45
          Pro His Gly Tyr Pro Asn Tyr Ala Asn Cys Thr Trp Ile Ile Ile Thr
              50 55 60
          Gly Glu Arg Asn Arg Ile Gln Leu Ser Phe His Thr Phe Ala Leu Glu
          65 70 75 80
          Glu Asp Phe Asp Ile Leu Ser Val Tyr Asp Gly Gln Pro Gln Gln Gly
                          85 90 95
          Asn Leu Lys Val Arg Leu Ser Gly Phe Gln Leu Pro Ser Ser Ile Val
                      100 105 110
          Ser Thr Gly Ser Ile Leu Thr Leu Trp Phe Thr Thr Asp Phe Ala Val
                  115 120 125
          Ser Ala Gln Gly Phe Lys Ala Leu Tyr Glu Val Leu Pro Ser His Thr
              130 135 140
          Cys Gly Asn Pro Gly Glu Ile Leu Lys Gly Val Leu His Gly Thr Arg
          145 150 155 160
          Phe Asn Ile Gly Asp Lys Ile Arg Tyr Ser Cys Leu Pro Gly Tyr Ile
                          165 170 175
          Leu Glu Gly His Ala Ile Leu Thr Cys Ile Val Ser Pro Gly Asn Gly
                      180 185 190
          Ala Ser Trp Asp Phe Pro Ala Pro Phe Cys Arg Ala Glu Gly Ala Cys
                  195 200 205
          Gly Gly Thr Leu Arg Gly Thr Ser Ser Ser Ile Ser Ser Pro His Phe
              210 215 220
          Pro Ser Glu Tyr Glu Asn Asn Ala Asp Cys Thr Trp Thr Ile Leu Ala
          225 230 235 240
          Glu Pro Gly Asp Thr Ile Ala Leu Val Phe Thr Asp Phe Gln Leu Glu
                          245 250 255
          Glu Gly Tyr Asp Phe Leu Glu Ile Ser Gly Thr Glu Ala Pro Ser Ile
                      260 265 270
          Trp Leu Thr Gly Met Asn Leu Pro Ser Pro Val Ile Ser Ser Lys Asn
                  275 280 285
          Trp Leu Arg Leu His Phe Thr Ser Asp Ser Asn His Arg Arg Lys Gly
              290 295 300
          Phe Asn Ala Gln Phe Gln Val Lys Lys Ala Ile Glu Leu Lys Ser Arg
          305 310 315 320
          Gly Val Lys Met Leu Pro Ser Lys Asp Gly Ser His Lys Asn Ser Val
                          325 330 335
          Leu Ser Gln Gly Gly Val Ala Leu Val Ser Asp Met Cys Pro Asp Pro
                      340 345 350
          Gly Ile Pro Glu Asn Gly Arg Arg Ala Gly Ser Asp Phe Arg Val Gly
                  355 360 365
          Ala Asn Val Gln Phe Ser Cys Glu Asp Asn Tyr Val Leu Gln Gly Ser
              370 375 380
          Lys Ser Ile Thr Cys Gln Arg Val Thr Glu Thr Leu Ala Ala Trp Ser
          385 390 395 400
          Asp His Arg Pro Ile Cys Arg Ala Arg Thr Cys Gly Ser Asn Leu Arg
                          405 410 415
          Gly Pro Ser Gly Val Ile Thr Ser Pro Asn Tyr Pro Val Gln Tyr Glu
                      420 425 430
          Asp Asn Ala His Cys Val Trp Val Ile Thr Thr Thr Asp Pro Asp Lys
                  435 440 445
          Val Ile Lys Leu Ala Phe Glu Glu Phe Glu Leu Glu Arg Gly Tyr Asp
              450 455 460
          Thr Leu Thr Val Gly Asp Ala Gly Lys Val Gly Asp Thr Arg Ser Val
          465 470 475 480
          Leu Tyr Val Leu Thr Gly Ser Ser Val Pro Asp Leu Ile Val Ser Met
                          485 490 495
          Ser Asn Gln Met Trp Leu His Leu Gln Ser Asp Asp Ser Ile Gly Ser
                      500 505 510
          Pro Gly Phe Lys Ala Val Tyr Gln Glu Ile Glu Lys Gly Gly Cys Gly
                  515 520 525
          Asp Pro Gly Ile Pro Ala Tyr Gly Lys Arg Thr Gly Ser Ser Phe Leu
              530 535 540
          His Gly Asp Thr Leu Thr Phe Glu Cys Pro Ala Ala Phe Glu Leu Val
          545 550 555 560
          Gly Glu Arg Val Ile Thr Cys Gln Gln Asn Asn Gln Trp Ser Gly Asn
                          565 570 575
          Lys Pro Ser Cys Val Phe Ser Cys Phe Phe Asn Phe Thr Ala Ser Ser
                      580 585 590
          Gly Ile Ile Leu Ser Pro Asn Tyr Pro Glu Glu Tyr Gly Asn Asn Met
                  595 600 605
          Asn Cys Val Trp Leu Ile Ile Ser Glu Pro Gly Ser Arg Ile His Leu
              610 615 620
          Ile Phe Asn Asp Phe Asp Val Glu Pro Gln Phe Asp Phe Leu Ala Val
          625 630 635 640
          Lys Asp Asp Gly Ile Ser Asp Ile Thr Val Leu Gly Thr Phe Ser Gly
                          645 650 655
          Asn Glu Val Pro Ser Gln Leu Ala Ser Ser Gly His Ile Val Arg Leu
                      660 665 670
          Glu Phe Gln Ser Asp His Ser Thr Thr Gly Arg Gly Phe Asn Ile Thr
                  675 680 685
          Tyr Thr Thr Phe Gly Gln Asn Glu Cys His Asp Pro Gly Ile Pro Ile
              690 695 700
          Asn Gly Arg Arg Phe Gly Asp Arg Phe Leu Leu Gly Ser Ser Val Ser
          705 710 715 720
          Phe His Cys Asp Asp Gly Phe Val Lys Thr Gln Gly Ser Glu Ser Ile
                          725 730 735
          Thr Cys Ile Leu Gln Asp Gly Asn Val Val Trp Ser Ser Thr Val Pro
                      740 745 750
          Arg Cys Glu Ala Pro Cys Gly Gly His Leu Thr Ala Ser Ser Gly Val
                  755 760 765
          Ile Leu Pro Pro Gly Trp Pro Gly Tyr Tyr Lys Asp Ser Leu His Cys
              770 775 780
          Glu Trp Ile Ile Glu Ala Lys Pro Gly His Ser Ile Lys Ile Thr Phe
          785 790 795 800
          Asp Arg Phe Gln Thr Glu Val Asn Tyr Asp Thr Leu Glu Val Arg Asp
                          805 810 815
          Gly Pro Ala Ser Ser Ser Pro Leu Ile Gly Glu Tyr His Gly Thr Gln
                      820 825 830
          Ala Pro Gln Phe Leu Ile Ser Thr Gly Asn Phe Met Tyr Leu Leu Phe
                  835 840 845
          Thr Thr Asp Asn Ser Arg Ser Ser Ser Ile Gly Phe Leu Ile His Tyr Glu
              850 855 860
          Ser Val Thr Leu Glu Ser Asp Ser Cys Leu Asp Pro Gly Ile Pro Val
          865 870 875 880
          Asn Gly His Arg His Gly Gly Asp Phe Gly Ile Arg Ser Thr Val Thr
                          885 890 895
          Phe Ser Cys Asp Pro Gly Tyr Thr Leu Ser Asp Asp Glu Pro Leu Val
                      900 905 910
          Cys Glu Arg Asn His Gln Trp Asn His Ala Leu Pro Ser Cys Asp Ala
                  915 920 925
          Leu Cys Gly Gly Tyr Ile Gln Gly Lys Ser Gly Thr Val Leu Ser Pro
              930 935 940
          Gly Phe Pro Asp Phe Tyr Pro Asn Ser Leu Asn Cys Thr Trp Thr Ile
          945 950 955 960
          Glu Val Ser His Gly Lys Gly Val Gln Met Ile Phe His Thr Phe His
                          965 970 975
          Leu Glu Ser Ser His Asp Tyr Leu Leu Ile Thr Glu Asp Gly Ser Phe
                      980 985 990
          Ser Glu Pro Val Ala Arg Leu Thr Gly Ser Val Leu Pro His Thr Ile
                  995 1000 1005
          Lys Ala Gly Leu Phe Gly Asn Phe Thr Ala Gln Leu Arg Phe Ile
              1010 1015 1020
          Ser Asp Phe Ser Ile Ser Tyr Glu Gly Phe Asn Ile Thr Phe Ser
              1025 1030 1035
          Glu Tyr Asp Leu Glu Pro Cys Asp Asp Pro Gly Val Pro Ala Phe
              1040 1045 1050
          Ser Arg Arg Ile Gly Phe His Phe Gly Val Gly Asp Ser Leu Thr
              1055 1060 1065
          Phe Ser Cys Phe Leu Gly Tyr Arg Leu Glu Gly Ala Thr Lys Leu
              1070 1075 1080
          Thr Cys Leu Gly Gly Gly Arg Arg Val Trp Ser Ala Pro Leu Pro
              1085 1090 1095
          Arg Cys Val Ala Glu Cys Gly Ala Ser Val Lys Gly Asn Glu Gly
              1100 1105 1110
          Thr Leu Leu Ser Pro Asn Phe Pro Ser Asn Tyr Asp Asn Asn His
              1115 1120 1125
          Glu Cys Ile Tyr Lys Ile Glu Thr Glu Ala Gly Lys Gly Ile His
              1130 1135 1140
          Leu Arg Thr Arg Ser Phe Gln Leu Phe Glu Gly Asp Thr Leu Lys
              1145 1150 1155
          Val Tyr Asp Gly Lys Asp Ser Ser Ser Arg Pro Leu Gly Thr Phe
              1160 1165 1170
          Thr Lys Asn Glu Leu Leu Gly Leu Ile Leu Asn Ser Thr Ser Asn
              1175 1180 1185
          His Leu Trp Leu Glu Phe Asn Thr Asn Gly Ser Asp Thr Asp Gln
              1190 1195 1200
          Gly Phe Gln Leu Thr Tyr Thr Ser Phe Asp Leu Val Lys Cys Glu
              1205 1210 1215
          Asp Pro Gly Ile Pro Asn Tyr Gly Tyr Arg Ile Arg Asp Glu Gly
              1220 1225 1230
          His Phe Thr Asp Thr Val Val Leu Tyr Ser Cys Asn Pro Gly Tyr
              1235 1240 1245
          Ala Met His Gly Ser Asn Thr Leu Thr Cys Leu Ser Gly Asp Arg
              1250 1255 1260
          Arg Val Trp Asp Lys Pro Leu Pro Ser Cys Ile Ala Glu Cys Gly
              1265 1270 1275
          Gly Gln Ile His Ala Ala Thr Ser Gly Arg Ile Leu Ser Pro Gly
              1280 1285 1290
          Tyr Pro Ala Pro Tyr Asp Asn Asn Leu His Cys Thr Trp Ile Ile
              1295 1300 1305
          Glu Ala Asp Pro Gly Lys Thr Ile Ser Leu His Phe Ile Val Phe
              1310 1315 1320
          Asp Thr Glu Met Ala His Asp Ile Leu Lys Val Trp Asp Gly Pro
              1325 1330 1335
          Val Asp Ser Asp Ile Leu Leu Lys Glu Trp Ser Gly Ser Ala Leu
              1340 1345 1350
          Pro Glu Asp Ile His Ser Thr Phe Asn Ser Leu Thr Leu Gln Phe
              1355 1360 1365
          Asp Ser Asp Phe Phe Ile Ser Lys Ser Gly Phe Ser Ile Gln Phe
              1370 1375 1380
          Ser Thr Ser Ile Ala Ala Thr Cys Asn Asp Pro Gly Met Pro Gln
              1385 1390 1395
          Asn Gly Thr Arg Tyr Gly Asp Ser Arg Glu Ala Gly Asp Thr Val
              1400 1405 1410
          Thr Phe Gln Cys Asp Pro Gly Tyr Gln Leu Gln Gly Gln Ala Lys
              1415 1420 1425
          Ile Thr Cys Val Gln Leu Asn Asn Arg Phe Phe Trp Gln Pro Asp
              1430 1435 1440
          Pro Pro Thr Cys Ile Ala Ala Cys Gly Gly Asn Leu Thr Gly Pro
              1445 1450 1455
          Ala Gly Val Ile Leu Ser Pro Asn Tyr Pro Gln Pro Tyr Pro Pro
              1460 1465 1470
          Gly Lys Glu Cys Asp Trp Arg Val Lys Val Asn Pro Asp Phe Val
              1475 1480 1485
          Ile Ala Leu Ile Phe Lys Ser Phe Asn Met Glu Pro Ser Tyr Asp
              1490 1495 1500
          Phe Leu His Ile Tyr Glu Gly Glu Asp Ser Asn Ser Pro Leu Ile
              1505 1510 1515
          Gly Ser Tyr Gln Gly Ser Gln Ala Pro Glu Arg Ile Glu Ser Ser
              1520 1525 1530
          Gly Asn Ser Leu Phe Leu Ala Phe Arg Ser Asp Ala Ser Val Gly
              1535 1540 1545
          Leu Ser Gly Phe Ala Ile Glu Phe Lys Glu Lys Pro Arg Glu Ala
              1550 1555 1560
          Cys Phe Asp Pro Gly Asn Ile Met Asn Gly Thr Arg Val Gly Thr
              1565 1570 1575
          Asp Phe Lys Leu Gly Ser Thr Ile Thr Tyr Gln Cys Asp Ser Gly
              1580 1585 1590
          Tyr Lys Ile Leu Asp Pro Ser Ser Ile Thr Cys Val Ile Gly Ala
              1595 1600 1605
          Asp Gly Lys Pro Ser Trp Asp Gln Val Leu Pro Ser Cys Asn Ala
              1610 1615 1620
          Pro Cys Gly Gly Gln Tyr Thr Gly Ser Glu Gly Val Val Leu Ser
              1625 1630 1635
          Pro Asn Tyr Pro His Asn Tyr Thr Ala Gly Gln Ile Cys Leu Tyr
              1640 1645 1650
          Ser Ile Thr Val Pro Lys Glu Phe Val Val Phe Gly Gln Phe Ala
              1655 1660 1665
          Tyr Phe Gln Thr Ala Leu Asn Asp Leu Ala Glu Leu Phe Asp Gly
              1670 1675 1680
          Thr His Ala Gln Ala Arg Leu Leu Ser Ser Leu Ser Gly Ser His
              1685 1690 1695
          Ser Gly Glu Thr Leu Pro Leu Ala Thr Ser Asn Gln Ile Leu Leu
              1700 1705 1710
          Arg Phe Ser Ala Lys Ser Gly Ala Ser Ala Arg Gly Phe His Phe
              1715 1720 1725
          Val Tyr Gln Ala Val Pro Arg Thr Ser Asp Thr Gln Cys Ser Ser
              1730 1735 1740
          Val Pro Glu Pro Arg Tyr Gly Arg Arg Ile Gly Ser Glu Phe Ser
              1745 1750 1755
          Ala Gly Ser Ile Val Arg Phe Glu Cys Asn Pro Gly Tyr Leu Leu
              1760 1765 1770
          Gln Gly Ser Thr Ala Leu His Cys Gln Ser Val Pro Asn Ala Leu
              1775 1780 1785
          Ala Gln Trp Asn Asp Thr Ile Pro Ser Cys Val Val Pro Cys Ser
              1790 1795 1800
          Gly Asn Phe Thr Gln Arg Arg Gly Thr Ile Leu Ser Pro Gly Tyr
              1805 1810 1815
          Pro Glu Pro Tyr Gly Asn Asn Leu Asn Cys Ile Trp Lys Ile Ile
              1820 1825 1830
          Val Thr Glu Gly Ser Gly Ile Gln Ile Gln Val Ile Ser Phe Ala
              1835 1840 1845
          Thr Glu Gln Asn Trp Asp Ser Leu Glu Ile His Asp Gly Gly Asp
              1850 1855 1860
          Val Thr Ala Pro Arg Leu Gly Ser Phe Ser Gly Thr Thr Val Pro
              1865 1870 1875
          Ala Leu Leu Asn Ser Thr Ser Asn Gln Leu Tyr Leu His Phe Gln
              1880 1885 1890
          Ser Asp Ile Ser Val Ala Ala Ala Gly Phe His Leu Glu Tyr Lys
              1895 1900 1905
          Thr Val Gly Leu Ala Ala Cys Gln Glu Pro Ala Leu Pro Ser Asn
              1910 1915 1920
          Ser Ile Lys Ile Gly Asp Arg Tyr Met Val Asn Asp Val Leu Ser
              1925 1930 1935
          Phe Gln Cys Glu Pro Gly Tyr Thr Leu Gln Gly Arg Ser His Ile
              1940 1945 1950
          Ser Cys Met Pro Gly Thr Val Arg Arg Trp Asn Tyr Pro Ser Pro
              1955 1960 1965
          Leu Cys Ile Ala Thr Cys Gly Gly Thr Leu Ser Thr Leu Gly Gly
              1970 1975 1980
          Val Ile Leu Ser Pro Gly Phe Pro Gly Ser Tyr Pro Asn Asn Leu
              1985 1990 1995
          Asp Cys Thr Trp Arg Ile Ser Leu Pro Ile Gly Tyr Gly Ala His
              2000 2005 2010
          Ile Gln Phe Leu Asn Phe Ser Thr Glu Ala Asn His Asp Phe Leu
              2015 2020 2025
          Glu Ile Gln Asn Gly Pro Tyr His Thr Ser Pro Met Ile Gly Gln
              2030 2035 2040
          Phe Ser Gly Thr Asp Leu Pro Ala Ala Leu Leu Ser Thr Thr His
              2045 2050 2055
          Glu Thr Leu Ile His Phe Tyr Ser Asp His Ser Gln Asn Arg Gln
              2060 2065 2070
          Gly Phe Lys Leu Ala Tyr Gln Ala Tyr Glu Leu Gln Asn Cys Pro
              2075 2080 2085
          Asp Pro Pro Pro Phe Gln Asn Gly Tyr Met Ile Asn Ser Asp Tyr
              2090 2095 2100
          Ser Val Gly Gln Ser Val Ser Phe Glu Cys Tyr Pro Gly Tyr Ile
              2105 2110 2115
          Leu Ile Gly His Pro Val Leu Thr Cys Gln His Gly Ile Asn Arg
              2120 2125 2130
          Asn Trp Asn Tyr Pro Phe Pro Arg Cys Asp Ala Pro Cys Gly Tyr
              2135 2140 2145
          Asn Val Thr Ser Gln Asn Gly Thr Ile Tyr Ser Pro Gly Phe Pro
              2150 2155 2160
          Asp Glu Tyr Pro Ile Leu Lys Asp Cys Ile Trp Leu Ile Thr Val
              2165 2170 2175
          Pro Pro Gly His Gly Val Tyr Ile Asn Phe Thr Leu Leu Gln Thr
              2180 2185 2190
          Glu Ala Val Asn Asp Tyr Ile Ala Val Trp Asp Gly Pro Asp Gln
              2195 2200 2205
          Asn Ser Pro Gln Leu Gly Val Phe Ser Gly Asn Thr Ala Leu Glu
              2210 2215 2220
          Thr Ala Tyr Ser Ser Thr Asn Gln Val Leu Leu Lys Phe His Ser
              2225 2230 2235
          Asp Phe Ser Asn Gly Gly Phe Phe Val Leu Asn Phe His Ala Phe
              2240 2245 2250
          Gln Leu Lys Lys Cys Gln Pro Pro Pro Ala Val Pro Gln Ala Glu
              2255 2260 2265
          Met Leu Thr Glu Asp Asp Asp Phe Glu Ile Gly Asp Phe Val Lys
              2270 2275 2280
          Tyr Gln Cys His Pro Gly Tyr Thr Leu Val Gly Thr Asp Ile Leu
              2285 2290 2295
          Thr Cys Lys Leu Ser Ser Gln Leu Gln Phe Glu Gly Ser Leu Pro
              2300 2305 2310
          Thr Cys Glu Ala Gln Cys Pro Ala Asn Glu Val Arg Thr Gly Ser
              2315 2320 2325
          Ser Gly Val Ile Leu Ser Pro Gly Tyr Pro Gly Asn Tyr Phe Asn
              2330 2335 2340
          Ser Gln Thr Cys Ser Trp Ser Ile Lys Val Glu Pro Asn Tyr Asn
              2345 2350 2355
          Ile Thr Ile Phe Val Asp Thr Phe Gln Ser Glu Lys Gln Phe Asp
              2360 2365 2370
          Ala Leu Glu Val Phe Asp Gly Ser Ser Gly Gln Ser Pro Leu Leu
              2375 2380 2385
          Val Val Leu Ser Gly Asn His Thr Glu Gln Ser Asn Phe Thr Ser
              2390 2395 2400
          Arg Ser Asn Gln Leu Tyr Leu Arg Trp Ser Thr Asp His Ala Thr
              2405 2410 2415
          Ser Lys Lys Gly Phe Lys Ile Arg Tyr Ala Ala Pro Tyr Cys Ser
              2420 2425 2430
          Leu Thr His Pro Leu Lys Asn Gly Gly Ile Leu Asn Arg Thr Ala
              2435 2440 2445
          Gly Ala Val Gly Ser Lys Val His Tyr Phe Cys Lys Pro Gly Tyr
              2450 2455 2460
          Arg Met Val Gly His Ser Asn Ala Thr Cys Arg Arg Asn Pro Leu
              2465 2470 2475
          Gly Met Tyr Gln Trp Asp Ser Leu Thr Pro Leu Cys Gln Ala Val
              2480 2485 2490
          Ser Cys Gly Ile Pro Glu Ser Pro Gly Asn Gly Ser Phe Thr Gly
              2495 2500 2505
          Asn Glu Phe Thr Leu Asp Ser Lys Val Val Tyr Glu Cys His Glu
              2510 2515 2520
          Gly Phe Lys Leu Glu Ser Ser Gln Gln Ala Thr Ala Val Cys Gln
              2525 2530 2535
          Glu Asp Gly Leu Trp Ser Asn Lys Gly Lys Pro Pro Thr Cys Lys
              2540 2545 2550
          Pro Val Ala Cys Pro Ser Ile Glu Ala Gln Leu Ser Glu His Val
              2555 2560 2565
          Ile Trp Arg Leu Val Ser Gly Ser Leu Asn Glu Tyr Gly Ala Gln
              2570 2575 2580
          Val Leu Leu Ser Cys Ser Pro Gly Tyr Tyr Leu Glu Gly Trp Arg
              2585 2590 2595
          Leu Leu Arg Cys Gln Ala Asn Gly Thr Trp Asn Ile Gly Asp Glu
              2600 2605 2610
          Arg Pro Ser Cys Arg Val Ile Ser Cys Gly Ser Leu Ser Phe Pro
              2615 2620 2625
          Pro Asn Gly Asn Lys Ile Gly Thr Leu Thr Val Tyr Gly Ala Thr
              2630 2635 2640
          Ala Ile Phe Thr Cys Asn Thr Gly Tyr Thr Leu Val Gly Ser His
              2645 2650 2655
          Val Arg Glu Cys Leu Ala Asn Gly Leu Trp Ser Gly Ser Glu Thr
              2660 2665 2670
          Arg Cys Leu Ala Gly His Cys Gly Ser Pro Asp Pro Ile Val Asn
              2675 2680 2685
          Gly His Ile Ser Gly Asp Gly Phe Ser Tyr Arg Asp Thr Val Val
              2690 2695 2700
          Tyr Gln Cys Asn Pro Gly Phe Arg Leu Val Gly Thr Ser Val Arg
              2705 2710 2715
          Ile Cys Leu Gln Asp His Lys Trp Ser Gly Gln Thr Pro Val Cys
              2720 2725 2730
          Val Pro Ile Thr Cys Gly His Pro Gly Asn Pro Ala His Gly Phe
              2735 2740 2745
          Thr Asn Gly Ser Glu Phe Asn Leu Asn Asp Val Val Asn Phe Thr
              2750 2755 2760
          Cys Asn Thr Gly Tyr Leu Leu Gln Gly Val Ser Arg Ala Gln Cys
              2765 2770 2775
          Arg Ser Asn Gly Gln Trp Ser Ser Pro Leu Pro Thr Cys Arg Val
              2780 2785 2790
          Val Asn Cys Ser Asp Pro Gly Phe Val Glu Asn Ala Ile Arg His
              2795 2800 2805
          Gly Gln Gln Asn Phe Pro Glu Ser Phe Glu Tyr Gly Met Ser Ile
              2810 2815 2820
          Leu Tyr His Cys Lys Lys Lys Gly Phe Tyr Leu Leu Gly Ser Ser Ser Ala
              2825 2830 2835
          Leu Thr Cys Met Ala Asn Gly Leu Trp Asp Arg Ser Leu Pro Lys
              2840 2845 2850
          Cys Leu Ala Ile Ser Cys Gly His Pro Gly Val Pro Ala Asn Ala
              2855 2860 2865
          Val Leu Thr Gly Glu Leu Phe Thr Tyr Gly Ala Val Val His Tyr
              2870 2875 2880
          Ser Cys Arg Gly Ser Glu Ser Leu Ile Gly Asn Asp Thr Arg Val
              2885 2890 2895
          Cys Gln Glu Asp Ser His Trp Ser Gly Ala Leu Pro His Cys Thr
              2900 2905 2910
          Gly Asn Asn Pro Gly Phe Cys Gly Asp Pro Gly Thr Pro Ala His
              2915 2920 2925
          Gly Ser Arg Leu Gly Asp Asp Phe Lys Thr Lys Ser Leu Leu Arg
              2930 2935 2940
          Phe Ser Cys Glu Met Gly His Gln Leu Arg Gly Ser Pro Glu Arg
              2945 2950 2955
          Thr Cys Leu Leu Asn Gly Ser Trp Ser Gly Leu Gln Pro Val Cys
              2960 2965 2970
          Glu Ala Val Ser Cys Gly Asn Pro Gly Thr Pro Thr Asn Gly Met
              2975 2980 2985
          Ile Val Ser Ser Asp Gly Ile Leu Phe Ser Ser Ser Val Ile Tyr
              2990 2995 3000
          Ala Cys Trp Glu Gly Tyr Lys Thr Ser Gly Leu Met Thr Arg His
              3005 3010 3015
          Cys Thr Ala Asn Gly Thr Trp Thr Gly Thr Ala Pro Asp Cys Thr
              3020 3025 3030
          Ile Ile Ser Cys Gly Asp Pro Gly Thr Leu Ala Asn Gly Ile Gln
              3035 3040 3045
          Phe Gly Thr Asp Phe Thr Phe Asn Lys Thr Val Ser Tyr Gln Cys
              3050 3055 3060
          Asn Pro Gly Tyr Val Met Glu Ala Val Thr Ser Ala Thr Ile Arg
              3065 3070 3075
          Cys Thr Lys Asp Gly Arg Trp Asn Pro Ser Lys Pro Val Cys Lys
              3080 3085 3090
          Ala Val Leu Cys Pro Gln Pro Pro Pro Val Gln Asn Gly Thr Val
              3095 3100 3105
          Glu Gly Ser Asp Phe Arg Trp Gly Ser Ser Ile Ser Tyr Ser Cys
              3110 3115 3120
          Met Asp Gly Tyr Gln Leu Ser His Ser Ala Ile Leu Ser Cys Glu
              3125 3130 3135
          Gly Arg Gly Val Trp Lys Gly Glu Ile Pro Gln Cys Leu Pro Val
              3140 3145 3150
          Phe Cys Gly Asp Pro Gly Ile Pro Ala Glu Gly Arg Leu Ser Gly
              3155 3160 3165
          Lys Ser Phe Thr Tyr Lys Ser Glu Val Phe Phe Gln Cys Lys Ser
              3170 3175 3180
          Pro Phe Ile Leu Val Gly Ser Ser Arg Arg Val Cys Gln Ala Asp
              3185 3190 3195
          Gly Thr Trp Ser Gly Ile Gln Pro Thr Cys Ile Asp Pro Ala His
              3200 3205 3210
          Asn Thr Cys Pro Asp Pro Gly Thr Pro His Phe Gly Ile Gln Asn
              3215 3220 3225
          Ser Ser Arg Gly Tyr Glu Val Gly Ser Thr Val Phe Phe Arg Cys
              3230 3235 3240
          Arg Lys Gly Tyr His Ile Gln Gly Ser Thr Thr Arg Thr Cys Leu
              3245 3250 3255
          Ala Asn Leu Thr Trp Ser Gly Ile Gln Thr Glu Cys Ile Pro His
              3260 3265 3270
          Ala Cys Arg Gln Pro Glu Thr Pro Ala His Ala Asp Val Arg Ala
              3275 3280 3285
          Ile Asp Leu Pro Thr Phe Gly Tyr Thr Leu Val Tyr Thr Cys His
              3290 3295 3300
          Pro Gly Phe Phe Leu Ala Gly Gly Ser Glu His Arg Thr Cys Lys
              3305 3310 3315
          Ala Asp Met Lys Trp Thr Gly Lys Ser Pro Val Cys Lys Ser Lys
              3320 3325 3330
          Gly Val Arg Glu Val Asn Glu Thr Val Thr Lys Thr Pro Val Pro
              3335 3340 3345
          Ser Asp Val Phe Phe Val Asn Ser Leu Trp Lys Gly Tyr Tyr Glu
              3350 3355 3360
          Tyr Leu Gly Lys Arg Gln Pro Ala Thr Leu Thr Val Asp Trp Phe
              3365 3370 3375
          Asn Ala Thr Ser Ser Lys Val Asn Ala Thr Phe Ser Glu Ala Ser
              3380 3385 3390
          Pro Val Glu Leu Lys Leu Thr Gly Ile Tyr Lys Lys Glu Glu Ala
              3395 3400 3405
          His Leu Leu Leu Lys Ala Phe Gln Ile Lys Gly Gln Ala Asp Ile
              3410 3415 3420
          Phe Val Ser Lys Phe Glu Asn Asp Asn Trp Gly Leu Asp Gly Tyr
              3425 3430 3435
          Val Ser Ser Gly Leu Glu Arg Gly Gly Phe Thr Phe Gln Gly Asp
              3440 3445 3450
          Ile His Gly Lys Asp Phe Gly Lys Phe Lys Leu Glu Arg Gln Asp
              3455 3460 3465
          Pro Leu Asn Pro Asp Gln Asp Ser Ser Ser His Tyr His Gly Thr
              3470 3475 3480
          Ser Ser Gly Ser Val Ala Ala Ala Ile Leu Val Pro Phe Phe Ala
              3485 3490 3495
          Leu Ile Leu Ser Gly Phe Ala Phe Tyr Leu Tyr Lys His Arg Thr
              3500 3505 3510
          Arg Pro Lys Val Gln Tyr Asn Gly Tyr Ala Gly His Glu Asn Ser
              3515 3520 3525
          Asn Gly Gln Ala Ser Phe Glu Asn Pro Met Tyr Asp Thr Asn Leu
              3530 3535 3540
          Lys Pro Thr Glu Ala Lys Ala Val Arg Phe Asp Thr Thr Leu Asn
              3545 3550 3555
          Thr Val Cys Thr Val Val
              3560
           <![CDATA[ <210> 309]]>
           <![CDATA[ <211> 4129]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 309]]>
          ctccacggca gcggctcctt gtgccactag cagcccttct tctgcgctct ccgccttttc 60
          tctctagact ggatctctcc tcccccccgc gcccccctcc ccgcatctcc cactcgctgg 120
          ctctctctcc agctgcctcc tctccaggtc tctcctggct gcgcgcgctc ctctccccgc 180
          ttctccccct cccgcagcct cgccgccttg gtgccttcct gcccggctcg gccggcgctc 240
          gtccccggcc ccggccccgc cagcccgggt ctccgcgctc ggagcagctc agccctgcag 300
          tggctcggga cccgatgcta tgagagggaa gcgagccggg cgcccagacc ttcaggaggc 360
          gtcggatgcg cggcgggtct tgggaccggg ctctctctcc ggctcgcctt gccctcgggt 420
          gattatttgg ctccgctcat agccctgcct tcctcggagg agccatcggt gtcgcgtgcg 480
          tgtggagtat ctgcagacat gactgcgtgg aggagattcc agtcgctgct cctgcttctc 540
          gggctgctgg tgctgtgcgc gaggctcctc actgcagcga agggtcagaa ctgtggaggc 600
          ttagtccagg gtcccaatgg cactattgag agcccagggt ttcctcacgg gtatccgaac 660
          tatgccaact gcacctggat catcatcacg ggcgagcgca ataggataca gttgtccttc 720
          catacctttg ctcttgaaga agattttgat attttatcag tttacgatgg acagcctcaa 780
          caagggaatt taaaagtgag attatcggga tttcagctgc cctcctctat agtgagtaca 840
          ggatctatcc tcactctgtg gttcacgaca gacttcgctg tgagtgccca aggtttcaaa 900
          gcatttatg aagttttacc tagccaacact tgtggaaatc ctggagaaat cctgaaagga 960
          gttctgcatg gaacgagatt caacatagga gacaaaatcc ggtacagctg cctccctggc 1020
          tacatcttgg aaggccacgc catcctgacc tgcatcgtca gcccaggaaa tggtgcatcg 1080
          tgggacttcc cagctccctt ttgcagagct gagggagcct gcggaggaac cttacgcggg 1140
          accagcagct ccatctccag cccgcacttc ccttcagagt acgagaacaa cgcggactgc 1200
          acctggacca ttctggctga gcccggggac accattgcgc tggtcttcac tgactttcag 1260
          ctagaagaag gatatgattt cttagagatc agtggcacgg aagctccatc catatggcta 1320
          actggcatga acctcccctc tccagttatc agtagcaaga attggctacg actccatttc 1380
          acctctgaca gcaaccaccg acgcaaagga tttaacgctc agttccaagt gaaaaaggcg 1440
          attgagttga agtcaagagg agtcaagatg ctgcccagca aggatggaag ccataaaaac 1500
          tctgtcttga gccaaggagg tgttgcattg gtctctgaca tgtgtccaga tcctggggatt 1560
          ccagaaaatg gtagaagagc aggttccgac ttcagggttg gtgcaaatgt acagttttca 1620
          tgtgaggaca attacgtgct ccagggatct aaaagcatca cctgtcagag agttacagag 1680
          acgctcgctg cttggagtga ccacaggccc atctgccgag cgagaacatg tggatccaat 1740
          ctgcgtgggc ccagcggcgt cattacctcc cctaattatc cggttcagta tgaagataat 1800
          gcacactgtg tgtgggtcat caccaccacc gacccggaca aggtcatcaa gcttgccttt 1860
          gaagagtttg agctggagcg aggctatgac accctgacgg ttggtgatgc tgggaaggtg 1920
          ggagacacca gatcggtctt gtacgtgctc acgggatcca gtgttcctga cctcattgtg 1980
          agcatgagca accagatgtg gctacatctg cagtcggatg atagcattgg ctcacctggg 2040
          tttaaagctg tttaccaaga aattgaaaag gggaggtgtggggatcctgg aatccccgcc 2100
          tatgggaagc ggacggggcag cagtttcctc catggagata cactcacctt tgaatgcccg 2160
          gcggcctttg agctggtggg ggagagagtt atcacctgtc agcagaacaa tcagtggtct 2220
          ggcaacaagc ccagctgtgt attttcatgt ttcttcaact ttacggcatc atctgggatt 2280
          attctgtcac caaattatcc agaggaatat gggaacaaca tgaactgtgt ctggttgatt 2340
          atctcggagc caggaagtcg aattcaccta atctttaatg attttgatgt tgagcctcag 2400
          tttgactttc tcgcggtcaa ggatgatggc atttctgaca taactgtcct gggtactttt 2460
          tctggcaatg aagtgccttc ccagctggcc agcagtgggc atatagttcg cttggaattt 2520
          cagtctgacc attccactac tggcagaggg ttcaacatca cttacaccac atttggtcag 2580
          aatgagtgcc atgatcctgg cattcctata aacggacgac gttttggtga caggtttcta 2640
          ctcggggagct cggtttcttt ccactgtgat gatggctttg tcaagaccca gggatccgag 2700
          tccattacct gcatactgca agacgggaac gtggtctgga gctccaccgt gccccgctgt 2760
          gaagctccat gtggtggaca tctgacagcg tccagcggag tcattttgcc tcctggatgg 2820
          ccaggatatt ataaggattc tttacattgt gaatggataa ttgaagcaaa accaggccac 2880
          tctatcaaaa taacttttga cagatttcag acagaggtca attatgacac cttggaggtc 2940
          agagatgggc cagccagttc gtccccactg atcggcgagt accacggcac ccaggcaccc 3000
          cagttcctca tcagcaccgg gaacttcatg tacctgctgt tcaccactga caacagccgc 3060
          tccagcatcg gcttcctcat ccactatgag agtgtgacgc ttgagtcgga ttcctgcctg 3120
          gacccgggca tccctgtgaa cggccatcgc cacggtggag actttggcat caggtccaca 3180
          gtgactttca gctgtgaccc ggggtacaca ctaagtgacg acgagcccct cgtctgtgag 3240
          aggaaccacc agtggaacca cgccttgccc agctgcgacg ctctatgtgg aggctacatc 3300
          caagggaaga gtggaacagt cctttctcct gggtttccag atttttatcc aaactctcta 3360
          aactgcacgt ggaccatga agtgtctcat gggaaaggag ttcaaatgat ctttcacacc 3420
          tttcatcttg agagttccca cgactattta ctgatcacag aggatggaag tttttccgag 3480
          cccgttgcca ggctcaccgg gtcggtgttg cctcatacga tcaaggcagg cctgtttgga 3540
          aacttcactg cccagcttcg gtttatatca gacttctcaa tttcgtacga gggcttcaat 3600
          atcacatttt cagaatatga cctggagcca tgtgatgatc ctggagtccc tgccttcagc 3660
          cgaagaattg gttttcactt tggtgtggga gactctctga cgttttcctg cttcctggga 3720
          tatcgtttag aaggtgccac caagcttacc tgcctgggtg ggggccgccg tgtgtggagt 3780
          gcacctctgc caaggtgtgt ggccgaatgt ggagcaagtg tcaaaggaaa tgaaggaaca 3840
          ttactgtctc caaattttcc atccaattat gataataacc atgagtgtat ctataaaata 3900
          gaaacagaag ccggcaaggg catccacctt agaacacgaa gcttccagct gtttgaagga 3960
          gatactctaa aggtatatga tggaaaagac agttcctcac gtccactggg cacgttcact 4020
          aaaaatgaac ttctggggct gatcctaaac agcacatcca atcacctgtg gctagagttc 4080
          aacaccaatg gatctgacac cgaccaaggt tttcaactca cctatacca 4129
           <![CDATA[ <210> 310]]>
           <![CDATA[ <211> 1210]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 310]]>
          Met Thr Ala Trp Arg Arg Phe Gln Ser Leu Leu Leu Leu Leu Leu Gly Leu
          1 5 10 15
          Leu Val Leu Cys Ala Arg Leu Leu Thr Ala Ala Lys Gly Gln Asn Cys
                      20 25 30
          Gly Gly Leu Val Gln Gly Pro Asn Gly Thr Ile Glu Ser Pro Gly Phe
                  35 40 45
          Pro His Gly Tyr Pro Asn Tyr Ala Asn Cys Thr Trp Ile Ile Ile Thr
              50 55 60
          Gly Glu Arg Asn Arg Ile Gln Leu Ser Phe His Thr Phe Ala Leu Glu
          65 70 75 80
          Glu Asp Phe Asp Ile Leu Ser Val Tyr Asp Gly Gln Pro Gln Gln Gly
                          85 90 95
          Asn Leu Lys Val Arg Leu Ser Gly Phe Gln Leu Pro Ser Ser Ile Val
                      100 105 110
          Ser Thr Gly Ser Ile Leu Thr Leu Trp Phe Thr Thr Asp Phe Ala Val
                  115 120 125
          Ser Ala Gln Gly Phe Lys Ala Leu Tyr Glu Val Leu Pro Ser His Thr
              130 135 140
          Cys Gly Asn Pro Gly Glu Ile Leu Lys Gly Val Leu His Gly Thr Arg
          145 150 155 160
          Phe Asn Ile Gly Asp Lys Ile Arg Tyr Ser Cys Leu Pro Gly Tyr Ile
                          165 170 175
          Leu Glu Gly His Ala Ile Leu Thr Cys Ile Val Ser Pro Gly Asn Gly
                      180 185 190
          Ala Ser Trp Asp Phe Pro Ala Pro Phe Cys Arg Ala Glu Gly Ala Cys
                  195 200 205
          Gly Gly Thr Leu Arg Gly Thr Ser Ser Ser Ile Ser Ser Pro His Phe
              210 215 220
          Pro Ser Glu Tyr Glu Asn Asn Ala Asp Cys Thr Trp Thr Ile Leu Ala
          225 230 235 240
          Glu Pro Gly Asp Thr Ile Ala Leu Val Phe Thr Asp Phe Gln Leu Glu
                          245 250 255
          Glu Gly Tyr Asp Phe Leu Glu Ile Ser Gly Thr Glu Ala Pro Ser Ile
                      260 265 270
          Trp Leu Thr Gly Met Asn Leu Pro Ser Pro Val Ile Ser Ser Lys Asn
                  275 280 285
          Trp Leu Arg Leu His Phe Thr Ser Asp Ser Asn His Arg Arg Lys Gly
              290 295 300
          Phe Asn Ala Gln Phe Gln Val Lys Lys Ala Ile Glu Leu Lys Ser Arg
          305 310 315 320
          Gly Val Lys Met Leu Pro Ser Lys Asp Gly Ser His Lys Asn Ser Val
                          325 330 335
          Leu Ser Gln Gly Gly Val Ala Leu Val Ser Asp Met Cys Pro Asp Pro
                      340 345 350
          Gly Ile Pro Glu Asn Gly Arg Arg Ala Gly Ser Asp Phe Arg Val Gly
                  355 360 365
          Ala Asn Val Gln Phe Ser Cys Glu Asp Asn Tyr Val Leu Gln Gly Ser
              370 375 380
          Lys Ser Ile Thr Cys Gln Arg Val Thr Glu Thr Leu Ala Ala Trp Ser
          385 390 395 400
          Asp His Arg Pro Ile Cys Arg Ala Arg Thr Cys Gly Ser Asn Leu Arg
                          405 410 415
          Gly Pro Ser Gly Val Ile Thr Ser Pro Asn Tyr Pro Val Gln Tyr Glu
                      420 425 430
          Asp Asn Ala His Cys Val Trp Val Ile Thr Thr Thr Asp Pro Asp Lys
                  435 440 445
          Val Ile Lys Leu Ala Phe Glu Glu Phe Glu Leu Glu Arg Gly Tyr Asp
              450 455 460
          Thr Leu Thr Val Gly Asp Ala Gly Lys Val Gly Asp Thr Arg Ser Val
          465 470 475 480
          Leu Tyr Val Leu Thr Gly Ser Ser Val Pro Asp Leu Ile Val Ser Met
                          485 490 495
          Ser Asn Gln Met Trp Leu His Leu Gln Ser Asp Asp Ser Ile Gly Ser
                      500 505 510
          Pro Gly Phe Lys Ala Val Tyr Gln Glu Ile Glu Lys Gly Gly Cys Gly
                  515 520 525
          Asp Pro Gly Ile Pro Ala Tyr Gly Lys Arg Thr Gly Ser Ser Phe Leu
              530 535 540
          His Gly Asp Thr Leu Thr Phe Glu Cys Pro Ala Ala Phe Glu Leu Val
          545 550 555 560
          Gly Glu Arg Val Ile Thr Cys Gln Gln Asn Asn Gln Trp Ser Gly Asn
                          565 570 575
          Lys Pro Ser Cys Val Phe Ser Cys Phe Phe Asn Phe Thr Ala Ser Ser
                      580 585 590
          Gly Ile Ile Leu Ser Pro Asn Tyr Pro Glu Glu Tyr Gly Asn Asn Met
                  595 600 605
          Asn Cys Val Trp Leu Ile Ile Ser Glu Pro Gly Ser Arg Ile His Leu
              610 615 620
          Ile Phe Asn Asp Phe Asp Val Glu Pro Gln Phe Asp Phe Leu Ala Val
          625 630 635 640
          Lys Asp Asp Gly Ile Ser Asp Ile Thr Val Leu Gly Thr Phe Ser Gly
                          645 650 655
          Asn Glu Val Pro Ser Gln Leu Ala Ser Ser Gly His Ile Val Arg Leu
                      660 665 670
          Glu Phe Gln Ser Asp His Ser Thr Thr Gly Arg Gly Phe Asn Ile Thr
                  675 680 685
          Tyr Thr Thr Phe Gly Gln Asn Glu Cys His Asp Pro Gly Ile Pro Ile
              690 695 700
          Asn Gly Arg Arg Phe Gly Asp Arg Phe Leu Leu Gly Ser Ser Val Ser
          705 710 715 720
          Phe His Cys Asp Asp Gly Phe Val Lys Thr Gln Gly Ser Glu Ser Ile
                          725 730 735
          Thr Cys Ile Leu Gln Asp Gly Asn Val Val Trp Ser Ser Thr Val Pro
                      740 745 750
          Arg Cys Glu Ala Pro Cys Gly Gly His Leu Thr Ala Ser Ser Gly Val
                  755 760 765
          Ile Leu Pro Pro Gly Trp Pro Gly Tyr Tyr Lys Asp Ser Leu His Cys
              770 775 780
          Glu Trp Ile Ile Glu Ala Lys Pro Gly His Ser Ile Lys Ile Thr Phe
          785 790 795 800
          Asp Arg Phe Gln Thr Glu Val Asn Tyr Asp Thr Leu Glu Val Arg Asp
                          805 810 815
          Gly Pro Ala Ser Ser Ser Pro Leu Ile Gly Glu Tyr His Gly Thr Gln
                      820 825 830
          Ala Pro Gln Phe Leu Ile Ser Thr Gly Asn Phe Met Tyr Leu Leu Phe
                  835 840 845
          Thr Thr Asp Asn Ser Arg Ser Ser Ser Ile Gly Phe Leu Ile His Tyr Glu
              850 855 860
          Ser Val Thr Leu Glu Ser Asp Ser Cys Leu Asp Pro Gly Ile Pro Val
          865 870 875 880
          Asn Gly His Arg His Gly Gly Asp Phe Gly Ile Arg Ser Thr Val Thr
                          885 890 895
          Phe Ser Cys Asp Pro Gly Tyr Thr Leu Ser Asp Asp Glu Pro Leu Val
                      900 905 910
          Cys Glu Arg Asn His Gln Trp Asn His Ala Leu Pro Ser Cys Asp Ala
                  915 920 925
          Leu Cys Gly Gly Tyr Ile Gln Gly Lys Ser Gly Thr Val Leu Ser Pro
              930 935 940
          Gly Phe Pro Asp Phe Tyr Pro Asn Ser Leu Asn Cys Thr Trp Thr Ile
          945 950 955 960
          Glu Val Ser His Gly Lys Gly Val Gln Met Ile Phe His Thr Phe His
                          965 970 975
          Leu Glu Ser Ser His Asp Tyr Leu Leu Ile Thr Glu Asp Gly Ser Phe
                      980 985 990
          Ser Glu Pro Val Ala Arg Leu Thr Gly Ser Val Leu Pro His Thr Ile
                  995 1000 1005
          Lys Ala Gly Leu Phe Gly Asn Phe Thr Ala Gln Leu Arg Phe Ile
              1010 1015 1020
          Ser Asp Phe Ser Ile Ser Tyr Glu Gly Phe Asn Ile Thr Phe Ser
              1025 1030 1035
          Glu Tyr Asp Leu Glu Pro Cys Asp Asp Pro Gly Val Pro Ala Phe
              1040 1045 1050
          Ser Arg Arg Ile Gly Phe His Phe Gly Val Gly Asp Ser Leu Thr
              1055 1060 1065
          Phe Ser Cys Phe Leu Gly Tyr Arg Leu Glu Gly Ala Thr Lys Leu
              1070 1075 1080
          Thr Cys Leu Gly Gly Gly Arg Arg Val Trp Ser Ala Pro Leu Pro
              1085 1090 1095
          Arg Cys Val Ala Glu Cys Gly Ala Ser Val Lys Gly Asn Glu Gly
              1100 1105 1110
          Thr Leu Leu Ser Pro Asn Phe Pro Ser Asn Tyr Asp Asn Asn His
              1115 1120 1125
          Glu Cys Ile Tyr Lys Ile Glu Thr Glu Ala Gly Lys Gly Ile His
              1130 1135 1140
          Leu Arg Thr Arg Ser Phe Gln Leu Phe Glu Gly Asp Thr Leu Lys
              1145 1150 1155
          Val Tyr Asp Gly Lys Asp Ser Ser Ser Arg Pro Leu Gly Thr Phe
              1160 1165 1170
          Thr Lys Asn Glu Leu Leu Gly Leu Ile Leu Asn Ser Thr Ser Asn
              1175 1180 1185
          His Leu Trp Leu Glu Phe Asn Thr Asn Gly Ser Asp Thr Asp Gln
              1190 1195 1200
          Gly Phe Gln Leu Thr Tyr Thr
              1205 1210
           <![CDATA[ <210> 311]]>
           <![CDATA[ <211> 102]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 311]]>
          ccagaactgg aagtctgaag cgagccctgc acaatgccga atgccagaag actgtcacca 60
          tctccaagcc ctgtggcaaa ctgaccaagc ccaaacctca ag 102
           <![CDATA[ <210> 312]]>
           <![CDATA[ <211> 103]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 312]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60
          tccttcggtg tgaaaccagt tctgaatact cctctctcag att 103
           <![CDATA[ <210> 313]]>
           <![CDATA[ <211> 205]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 313]]>
          ccagaactgg aagtctgaag cgagccctgc acaatgccga atgccagaag actgtcacca 60
          tctccaagcc ctgtggcaaa ctgaccaagc ccaaacctca agccttgcct ccccgattga 120
          aagagatgaa aagccaggaa tcggctgcag gttccaaact agtccttcgg tgtgaaacca 180
          gttctgaata ctcctctctc agatt 205
           <![CDATA[ <210> 314]]>
           <![CDATA[ <211> 67]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 314]]>
          Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn Ala Glu Cys Gln Lys
          1 5 10 15
          Thr Val Thr Ile Ser Lys Pro Cys Gly Lys Leu Thr Lys Pro Lys Pro
                      20 25 30
          Gln Ala Leu Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala
                  35 40 45
          Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser
              50 55 60
          Ser Leu Arg
          65
           <![CDATA[ <210> 315]]>
           <![CDATA[ <211> 532]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 315]]>
          aaggggaaat aagggacaag agagaccctc tcatattgtt ttatattatt tcatactcag 60
          aaaaggaaag agaagccaaa caaaaggcag gtaacccagc gcctaggaac cagacccgaa 120
          accaaggaac cagatctgaa accaggcctg ggcctgcctg acctaagcct ggtagtaaaa 180
          attccacccc tgacctgacc tggcaactgt tgttatctac agattccaga cattgtatgg 240
          aaggacactg tgaaacctcc cgttctgttc tgtttcactc tgaccatcgg tgctcacagc 300
          ccctatcacg taccccctgg cttgctcagt cgatcacgac cctctcacgt ggaccccctt 360
          agagttgtta gcccttaaaa gggacagaag ttgagcacct gaggagctca gattttaaga 420
          cgctaggctg ctgatgctcc cagctgatta aagccactcc cttcactatc tcggtgtctc 480
          ctgtccgcgg ctcgtcctgc tacatttctt ggttccctga ccggcaagcg ag 532
           <![CDATA[ <210> 316]]>
           <![CDATA[ <211> 116]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 316]]>
          aatgcaggct caacagtacc agcagcagcg tcgaaaattt gcagctgcct tcttggcatt 60
          cattttcata ctggcagctg tggatactgc tgaagcaggg aagaaagaga aaccag 116
           <![CDATA[ <210> 317]]>
           <![CDATA[ <211> 174]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 317]]>
          aaaaaaaagt gaagaagtct gactgtggag aatggcagtg gagtgtgtgtgtgcccacca 60
          gtggagactg tgggctgggc acacgggagg gcactcggac tggagctgag tgcaagcaaa 120
          ccatgaagac ccagagatgt aagatcccct gcaactggaa gaagcaattt ggcg 174
           <![CDATA[ <210> 318]]>
           <![CDATA[ <211> 162]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 318]]>
          cggagtgcaa ataccagttc caggcctggg gagaatgtga cctgaacaca gccctgaaga 60
          ccagaactgg aagtctgaag cgagccctgc acaatgccga atgccagaag actgtcacca 120
          tctccaagcc ctgtggcaaa ctgaccaagc ccaaacctca ag 162
           <![CDATA[ <210> 319]]>
           <![CDATA[ <211> 735]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 319]]>
          cagaatctaa gaagaagaaa aaggaaggca agaaacagga gaagatgctg gattaaaaga 60
          tgtcacctgt ggaacataaa aaggacatca gcaaacagga tcagttaact attgcattta 120
          tatgtaccgt aggctttgta ttcaaaaatt atctatagct aagtacacaa taagcaaaaa 180
          caaaaagaaa agaaaatttt tgtagtagcg ttttttaaat gtatactata gtaccagtag 240
          gggcttataa taaaggactg taatcttatt taggaagttg acttatagta catgataaat 300
          gatagacaat tgaggtaagt tttttgaaat tatgtgacat tttacattaa atttttttta 360
          cattttttgg gcagcaattt aaatgttatg actatgtaaa ctacttctct tgttaggtaa 420
          tttttttcac ctagattttt ttcccaattg agaaaaatat atactaaaca aaatagcaat 480
          aaaacataat cactctattt gaagaaaata tcttgttttc tgccaataga ttttttaaaa 540
          tgtagtcagc aaaatggggg tggggaagca gagcatgtcc tagttcaatg ttgacttttt 600
          ttttttttaa agaaaagcat taagacataa aattctttca ctttggcaga agcatttgtt 660
          ttcttgatga aattattttt ccatctgagg aaaaaaatac taggaaaata aatcaaggtg 720
          atgctgaaaaaaaaa 735
           <![CDATA[ <210> 320]]>
           <![CDATA[ <211> 1719]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 320]]>
          aaggggaaat aagggacaag agagaccctc tcatattgtt ttatattatt tcatactcag 60
          aaaaggaaag agaagccaaa caaaaggcag gtaacccagc gcctaggaac cagacccgaa 120
          accaaggaac cagatctgaa accaggcctg ggcctgcctg acctaagcct ggtagtaaaa 180
          attccacccc tgacctgacc tggcaactgt tgttatctac agattccaga cattgtatgg 240
          aaggacactg tgaaacctcc cgttctgttc tgtttcactc tgaccatcgg tgctcacagc 300
          ccctatcacg taccccctgg cttgctcagt cgatcacgac cctctcacgt ggaccccctt 360
          agagttgtta gcccttaaaa gggacagaag ttgagcacct gaggagctca gattttaaga 420
          cgctaggctg ctgatgctcc cagctgatta aagccactcc cttcactatc tcggtgtctc 480
          ctgtccgcgg ctcgtcctgc tacatttctt ggttccctga ccggcaagcg agaatgcagg 540
          ctcaacagta ccagcagcag cgtcgaaaat ttgcagctgc cttcttggca ttcattttca 600
          tactggcagc tgtggatact gctgaagcag ggaagaaaga gaaaccagaa aaaaaagtga 660
          agaagtctga ctgtggagaa tggcagtgga gtgtgtgtgt gcccaccagt ggagactgtg 720
          ggctgggcac acgggagggc actcggactg gagctgagtg caagcaaacc atgaagaccc 780
          agagatgtaa gatcccctgc aactggaaga agcaatttgg cgcggagtgc aaataccagt 840
          tccaggcctg gggagaatgt gacctgaaca cagccctgaa gaccagaact ggaagtctga 900
          agcgagccct gcacaatgcc gaatgccaga agactgtcac catctccaag ccctgtggca 960
          aactgaccaa gcccaaacct caagcagaat ctaagaagaa gaaaaaggaa ggcaagaaac 1020
          aggagaagat gctggattaa aagatgtcac ctgtggaaca taaaaaggac atcagcaaac 1080
          aggatcagtt aactattgca tttatatgta ccgtaggctt tgtattcaaa aattatctat 1140
          agctaagtac acaataagca aaaacaaaaa gaaaagaaaa tttttgtagt agcgtttttt 1200
          aaatgtatac tatagtacca gtaggggctt ataataaagg actgtaatct tattaggaa 1260
          gttgacttat agtacatgat aaatgataga caattgaggt aagttttttg aaattatgtg 1320
          acattttaca ttaaattttt tttacatttt ttgggcagca atttaaatgt tatgactatg 1380
          taaactactt ctcttgttag gtaatttttt tcacctagat ttttttccca attgagaaaa 1440
          atatatacta aacaaaatag caataaaaca taatcactct atttgaagaa aatatcttgt 1500
          tttctgccaa tagatttttt aaaatgtagt cagcaaaatgggggtgggga agcagagcat 1560
          gtcctagttc aatgttgact tttttttttt ttaaagaaaa gcattaagac ataaaattct 1620
          ttcactttgg cagaagcatt tgttttcttg atgaaattat ttttccatct gaggaaaaaa 1680
          atactaggaa aataaatcaa ggtgatgctg aaaaaaaaa 1719
           <![CDATA[ <210> 321]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 321]]>
          Met Gln Ala Gln Gln Tyr Gln Gln Gln Arg Arg Lys Phe Ala Ala Ala
          1 5 10 15
          Phe Leu Ala Phe Ile Phe Ile Leu Ala Ala Val Asp Thr Ala Glu Ala
                      20 25 30
          Gly Lys Lys Glu Lys Pro
                  35
           <![CDATA[ <210> 322]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 322]]>
          Lys Lys Val Lys Lys Ser Asp Cys Gly Glu Trp Gln Trp Ser Val Cys
          1 5 10 15
          Val Pro Thr Ser Gly Asp Cys Gly Leu Gly Thr Arg Glu Gly Thr Arg
                      20 25 30
          Thr Gly Ala Glu Cys Lys Gln Thr Met Lys Thr Gln Arg Cys Lys Ile
                  35 40 45
          Pro Cys Asn Trp Lys Lys Gln Phe Gly
              50 55
           <![CDATA[ <210> 323]]>
           <![CDATA[ <211> 53]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 323]]>
          Glu Cys Lys Tyr Gln Phe Gln Ala Trp Gly Glu Cys Asp Leu Asn Thr
          1 5 10 15
          Ala Leu Lys Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn Ala
                      20 25 30
          Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro Cys Gly Lys Leu Thr
                  35 40 45
          Lys Pro Lys Pro Gln
              50
           <![CDATA[ <210> 324]]>
           <![CDATA[ <211> 17]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 324]]>
          Glu Ser Lys Lys Lys Lys Lys Lys Glu Gly Lys Lys Gln Glu Lys Met Leu
          1 5 10 15
          Asp
           <![CDATA[ <210> 325]]>
           <![CDATA[ <211> 168]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 325]]>
          Met Gln Ala Gln Gln Tyr Gln Gln Gln Arg Arg Lys Phe Ala Ala Ala
          1 5 10 15
          Phe Leu Ala Phe Ile Phe Ile Leu Ala Ala Val Asp Thr Ala Glu Ala
                      20 25 30
          Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys Ser Asp Cys Gly
                  35 40 45
          Glu Trp Gln Trp Ser Val Cys Val Pro Thr Ser Gly Asp Cys Gly Leu
              50 55 60
          Gly Thr Arg Glu Gly Thr Arg Thr Gly Ala Glu Cys Lys Gln Thr Met
          65 70 75 80
          Lys Thr Gln Arg Cys Lys Ile Pro Cys Asn Trp Lys Lys Gln Phe Gly
                          85 90 95
          Ala Glu Cys Lys Tyr Gln Phe Gln Ala Trp Gly Glu Cys Asp Leu Asn
                      100 105 110
          Thr Ala Leu Lys Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn
                  115 120 125
          Ala Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro Cys Gly Lys Leu
              130 135 140
          Thr Lys Pro Lys Pro Gln Ala Glu Ser Lys Lys Lys Lys Lys Lys Glu Gly
          145 150 155 160
          Lys Lys Gln Glu Lys Met Leu Asp
                          165
           <![CDATA[ <210> 326]]>
           <![CDATA[ <211> 984]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 326]]>
          aaggggaaat aagggacaag agagaccctc tcatattgtt ttatattatt tcatactcag 60
          aaaaggaaag agaagccaaa caaaaggcag gtaacccagc gcctaggaac cagacccgaa 120
          accaaggaac cagatctgaa accaggcctg ggcctgcctg acctaagcct ggtagtaaaa 180
          attccacccc tgacctgacc tggcaactgt tgttatctac agattccaga cattgtatgg 240
          aaggacactg tgaaacctcc cgttctgttc tgtttcactc tgaccatcgg tgctcacagc 300
          ccctatcacg taccccctgg cttgctcagt cgatcacgac cctctcacgt ggaccccctt 360
          agagttgtta gcccttaaaa gggacagaag ttgagcacct gaggagctca gattttaaga 420
          cgctaggctg ctgatgctcc cagctgatta aagccactcc cttcactatc tcggtgtctc 480
          ctgtccgcgg ctcgtcctgc tacatttctt ggttccctga ccggcaagcg agaatgcagg 540
          ctcaacagta ccagcagcag cgtcgaaaat ttgcagctgc cttcttggca ttcattttca 600
          tactggcagc tgtggatact gctgaagcag ggaagaaaga gaaaccagaa aaaaaagtga 660
          agaagtctga ctgtggagaa tggcagtgga gtgtgtgtgt gcccaccagt ggagactgtg 720
          ggctgggcac acgggagggc actcggactg gagctgagtg caagcaaacc atgaagaccc 780
          agagatgtaa gatcccctgc aactggaaga agcaatttgg cgcggagtgc aaataccagt 840
          tccaggcctg gggagaatgt gacctgaaca cagccctgaa gaccagaact ggaagtctga 900
          agcgagccct gcacaatgcc gaatgccaga agactgtcac catctccaag ccctgtggca 960
          aactgaccaa gcccaaacct caag 984
           <![CDATA[ <210> 327]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 327]]>
          Met Gln Ala Gln Gln Tyr Gln Gln Gln Arg Arg Lys Phe Ala Ala Ala
          1 5 10 15
          Phe Leu Ala Phe Ile Phe Ile Leu Ala Ala Val Asp Thr Ala Glu Ala
                      20 25 30
          Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys Ser Asp Cys Gly
                  35 40 45
          Glu Trp Gln Trp Ser Val Cys Val Pro Thr Ser Gly Asp Cys Gly Leu
              50 55 60
          Gly Thr Arg Glu Gly Thr Arg Thr Gly Ala Glu Cys Lys Gln Thr Met
          65 70 75 80
          Lys Thr Gln Arg Cys Lys Ile Pro Cys Asn Trp Lys Lys Gln Phe Gly
                          85 90 95
          Ala Glu Cys Lys Tyr Gln Phe Gln Ala Trp Gly Glu Cys Asp Leu Asn
                      100 105 110
          Thr Ala Leu Lys Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn
                  115 120 125
          Ala Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro Cys Gly Lys Leu
              130 135 140
          Thr Lys Pro Lys Pro Gln
          145 150
           <![CDATA[ <210> 328]]>
           <![CDATA[ <211> 95]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 328]]>
          caacagcaac aagatcacag ttcgcttcca ctcagatcag tcctacaccg acaccggctt 60
          cttagctgaa tacctctcct acgactccag tgacc 95
           <![CDATA[ <210> 329]]>
           <![CDATA[ <211> 87]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 329]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgt gaatggaggg gagtgct 87
           <![CDATA[ <210> 330]]>
           <![CDATA[ <211> 182]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 330]]>
          caacagcaac aagatcacag ttcgcttcca ctcagatcag tcctacaccg acaccggctt 60
          cttagctgaa taccctctcct acgactccag tgaccctaca tctacatcca ccactgggac 120
          aagccatctt gtaaaatgtg cggagaagga gaaaactttc tgtgtgaatg gaggggagtg 180
          ct 182
           <![CDATA[ <210> 331]]>
           <![CDATA[ <211> 60]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 331]]>
          Asn Ser Asn Lys Ile Thr Val Arg Phe His Ser Asp Gln Ser Tyr Thr
          1 5 10 15
          Asp Thr Gly Phe Leu Ala Glu Tyr Leu Ser Tyr Asp Ser Ser Ser Asp Pro
                      20 25 30
          Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala Glu
                  35 40 45
          Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys
              50 55 60
           <![CDATA[ <210> 332]]>
           <![CDATA[ <211> 279]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 332]]>
          gtgagagcgg agctgcagcc ggagaaagag gaagaggggag agagagcgcg ccagggcgag 60
          ggcaccgccg ccggtcgggc gcgctgggcc tgcccggaat cccgccgcct gcgccccgcg 120
          ccccgcgccc tgcgggccat gggagccggc cgccggcagg gacgacgcct gtgagacccg 180
          cgagcggcct cggggaccat ggggagcgat cgggcccgca agggcgggagg gggcccgaag 240
          gacttcggcg cgggactcaa gtacaactcc cggcacgag 279
           <![CDATA[ <210> 333]]>
           <![CDATA[ <211> 160]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 333]]>
          aaagtgaatg gcttggagga aggcgtggag ttcctgccag tcaacaacgt caagaaggtg 60
          gaaaagcatg gcccggggcg ctgggtggtg ctggcagccg tgctgatcgg cctcctcttg 120
          gtcttgctgg ggatcggctt cctggtgtgg catttgcagt 160
           <![CDATA[ <210> 334]]>
           <![CDATA[ <211> 128]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 334]]>
          accgggacgt gcgtgtccag aaggtcttca atggctacat gaggatcaca aatgagaatt 60
          ttgtggatgc ctacgagaac tccaactcca ctgagtttgt aagcctggcc agcaaggtga 120
          aggacgcg 128
           <![CDATA[ <210> 335]]>
           <![CDATA[ <211> 71]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 335]]>
          ctgaagctgc tgtacagcgg agtcccattc ctgggcccct accacaagga gtcggctgtg 60
          acggccttca g 71
           <![CDATA[ <210> 336]]>
           <![CDATA[ <211> 158]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 336]]>
          cgagggcagc gtcatcgcct actactggtc tgagttcagc atcccgcagc acctggtgga 60
          ggaggccgag cgcgtcatgg ccgaggagcg cgtagtcatg ctgcccccgc gggcgcgctc 120
          cctgaagtcc tttgtggtca cctcagtggt ggctttcc 158
           <![CDATA[ <210> 337]]>
           <![CDATA[ <211> 36]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 337]]>
          ccacggactc caaaacagta cagaggaccc aggaca 36
           <![CDATA[ <210> 338]]>
           <![CDATA[ <211> 241]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 338]]>
          acagctgcag ctttggcctg cacgcccgcg gtgtggagct gatgcgcttc accacgcccg 60
          gcttccctga cagcccctac cccgctcatg cccgctgcca gtgggccctg cggggggacg 120
          ccgactcagt gctgagcctc accttccgca gctttgacct tgcgtcctgc gacgagcgcg 180
          gcagcgacct ggtgacggtg tacaacaccc tgagccccat ggagccccac gccctggtgc 240
          a 241
           <![CDATA[ <210> 339]]>
           <![CDATA[ <211> 140]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 339]]>
          gttgtgtggc acctaccctc cctcctacaa cctgaccttc cactcctccc agaacgtcct 60
          gctcatcaca ctgataacca acactgagcg gcggcatccc ggctttgagg ccaccttctt 120
          ccagctgcct aggatgagca 140
           <![CDATA[ <210> 340]]>
           <![CDATA[ <211> 98]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 340]]>
          gctgtggagg ccgcttacgt aaagcccagg ggacattcaa cagcccctac tacccaggcc 60
          actacccacc caacattgac tgcacatgga actattgag 98
           <![CDATA[ <210> 341]]>
           <![CDATA[ <211> 110]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 341]]>
          gtgcccaaca accagcatgt gaaggtgcgc ttcaaattct tctacctgct ggagcccggc 60
          gtgcctgcgg gcacctgccc caaggactac gtggagatca acggggagaa 110
           <![CDATA[ <210> 342]]>
           <![CDATA[ <211> 131]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 342]]>
          atactgcgga gagaggtccc agttcgtcgt caccagcaac agcaacaaga tcacagttcg 60
          cttccactca gatcagtcct acaccgacac cggcttctta gctgaatacc tctcctacga 120
          ctccagtgac c 131
           <![CDATA[ <210> 343]]>
           <![CDATA[ <211> 105]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 343]]>
          catgcccggg gcagttcacg tgccgcacgg ggcggtgtat ccggaaggag ctgcgctgtg 60
          atggctgggc cgactgcacc gaccacagcg atgagctcaa ctgca 105
           <![CDATA[ <210> 344]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 344]]>
          gttgcgacgc cggccaccag ttcacgtgca agaacaagtt ctgcaagccc ctcttctggg 60
          tctgcgacag tgtgaacgac tgcggagaca acagcgacga gcaggggtgc a 111
           <![CDATA[ <210> 345]]>
           <![CDATA[ <211> 114]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 345]]>
          gttgtccggc ccagaccttc aggtgttcca atgggaagtg cctctcgaaa agccagcagt 60
          gcaatgggaa ggacgactgt ggggacgggt ccgacgaggc ctcctgcccc aagg 114
           <![CDATA[ <210> 346]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 346]]>
          tgaacgtcgt cacttgtacc aaacacacct accgctgcct caatgggctc tgcttgagca 60
          agggcaaccc tgagtgtgac gggaaggagg actgtagcga cggctcagat gagaaggact 120
          gcg 123
           <![CDATA[ <210> 347]]>
           <![CDATA[ <211> 187]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 347]]>
          actgtggggct gcggtcattc acgagacagg ctcgtgttgt tgggggcacg gatgcggatg 60
          agggcgagtg gccctggcag gtaagcctgc atgctctggg ccagggccac atctgcggtg 120
          cttccctcat ctctcccaac tggctggtct ctgccgcaca ctgctacatc gatgacagag 180
          gattcag 187
           <![CDATA[ <210> 348]]>
           <![CDATA[ <211> 275]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 348]]>
          gtactcagac cccacgcagt ggacggcctt cctgggcttg cacgaccaga gccagcgcag 60
          cgcccctggg gtgcaggagc gcaggctcaa gcgcatcatc tcccaccccct tcttcaatga 120
          cttcaccttc gactatgaca tcgcgctgct ggagctggag aaaccggcag agtacagctc 180
          catggtgcgg cccatctgcc tgccggacgc ctcccatgtc ttccctgccg gcaaggccat 240
          ctgggtcacg ggctggggac acacccagta tggag 275
           <![CDATA[ <210> 349]]>
           <![CDATA[ <211> 137]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 349]]>
          gcactggcgc gctgatcctg caaaagggtg agatccgcgt catcaaccag accacctgcg 60
          agaacctcct gccgcagcag atcacgccgc gcatgatgtg cgtgggcttc ctcagcggcg 120
          gcgtggactc ctgccag 137
           <![CDATA[ <210> 350]]>
           <![CDATA[ <211> 701]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 350]]>
          ggtgattccg ggggacccct gtccagcgtg gaggcggatg ggcggatctt ccaggccggt 60
          gtggtgagct ggggagacgg ctgcgctcag aggaacaagc caggcgtgta cacaaggctc 120
          cctctgtttc gggactggat caaagagaac actggggtat aggggccggg gccacccaaa 180
          tgtgtacaccc tgcggggcca cccatcgtcc accccagtgt gcacgcctgc aggctggaga 240
          ctggaccgct gactgcacca gcgcccccag aacataacact gtgaactcaa tctccagggc 300
          tccaaatctg cctagaaaac ctctcgcttc ctcagcctcc aaagtggagc tgggaggtag 360
          aagggggagga cactggtggt tctactgacc caactggggg caaaggtttg aagacacagc 420
          ctcccccgcc agccccaagc tgggccgagg cgcgtttgtg catatctgcc tcccctgtct 480
          ctaaggagca gcgggaacgg agcttcgggg cctcctcagt gaaggtggtg gggctgccgg 540
          atctgggctg tggggccctt gggccacgct cttgaggaag cccaggctcg gaggaccctg 600
          gaaaacagac gggtctgaga ctgaaattgt ttaccagct cccagggtgg acttcagtgt 660
          gtgtatttgt gtaaatgagt aaaacatttt atttcttttt a 701
           <![CDATA[ <210> 351]]>
           <![CDATA[ <211> 3305]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Whole mRNA polynucleotide sequence of ST14 ]]>
           <![CDATA[ <400> 351]]>
          gtgagagcgg agctgcagcc ggagaaagag gaagaggggag agagagcgcg ccagggcgag 60
          ggcaccgccg ccggtcgggc gcgctgggcc tgcccggaat cccgccgcct gcgccccgcg 120
          ccccgcgccc tgcgggccat gggagccggc cgccggcagg gacgacgcct gtgagacccg 180
          cgagcggcct cggggaccat ggggagcgat cgggcccgca agggcgggagg gggcccgaag 240
          gacttcggcg cgggactcaa gtacaactcc cggcacgaga aagtgaatgg cttggaggaa 300
          ggcgtggagt tcctgccagt caacaacgtc aagaaggtgg aaaagcatgg cccggggcgc 360
          tgggtggtgc tggcagccgt gctgatcggc ctcctcttgg tcttgctggg gatcggcttc 420
          ctggtgtggc atttgcagta ccgggacgtg cgtgtccaga aggtcttcaa tggctacatg 480
          aggatcacaa atgagaattt tgtggatgcc tacgagaact ccaactccac tgagtttgta 540
          agcctggcca gcaaggtgaa ggacgcgctg aagctgctgt acagcggagt cccattcctg 600
          ggcccctacc acaaggagtc ggctgtgacg gccttcagcg agggcagcgt catcgcctac 660
          tactggtctg agttcagcat cccgcagcac ctggtggagg aggccgagcg cgtcatggcc 720
          gaggagcgcg tagtcatgct gcccccgcgg gcgcgctccc tgaagtcctt tgtggtcacc 780
          tcagtggtgg ctttccccac ggactccaaa acagtacaga ggacccagga caacagctgc 840
          agctttggcc tgcacgcccg cggtgtggag ctgatgcgct tcaccacgcc cggcttccct 900
          gacagcccct accccgctca tgcccgctgc cagtgggccc tgcgggggga cgccgactca 960
          gtgctgagcc tcaccttccg cagctttgac cttgcgtcct gcgacgagcg cggcagcgac 1020
          ctggtgacgg tgtacaacac cctgagcccc atggagcccc acgccctggt gcagttgtgt 1080
          ggcacctacc ctccctccta caacctgacc ttccactcct cccagaacgt cctgctcatc 1140
          acactgataa ccaacactga gcggcggcat cccggctttg aggccacctt cttccagctg 1200
          cctaggatga gcagctgtgg aggccgctta cgtaaagccc aggggacatt caacagcccc 1260
          tactacccag gccactaccc acccaacatt gactgcacat ggaacattga ggtgcccaac 1320
          aaccagcatg tgaaggtgcg cttcaaattc ttctacctgc tggagcccgg cgtgcctgcg 1380
          ggcacctgcc ccaaggacta cgtggagatc aacggggaga aatactgcgg agagaggtcc 1440
          cagttcgtcg tcaccagcaa cagcaacaag atcacagttc gcttccactc agatcagtcc 1500
          tacaccgaca ccggcttctt agctgaatac ctctcctacg actccagtga cccatgcccg 1560
          gggcagttca cgtgccgcac ggggcggtgt atccggaagg agctgcgctg tgatggctgg 1620
          gccgactgca ccgaccacag cgatgagctc aactgcagtt gcgacgccgg ccaccagttc 1680
          acgtgcaaga acaagttctg caagcccctc ttctgggtct gcgacagtgt gaacgactgc 1740
          ggagacaaca gcgacgagca ggggtgcagt tgtccggccc agaccttcag gtgttccaat 1800
          gggaagtgcc tctcgaaaag ccagcagtgc aatgggaagg acgactgtgg ggacgggtcc 1860
          gacgaggcct cctgccccaa ggtgaacgtc gtcacttgta ccaaacacac ctaccgctgc 1920
          ctcaatgggc tctgcttgag caagggcaac cctgagtgtg acgggaagga ggactgtagc 1980
          gacggctcag atgagaagga ctgcgactgt gggctgcggt cattcacgag acaggctcgt 2040
          gttgttgggg gcacggatgc ggatgagggc gagtggccct ggcaggtaag cctgcatgct 2100
          ctgggccagg gccacatctg cggtgcttcc ctcatctctc ccaactggct ggtctctgcc 2160
          gcacactgct acatcgatga cagaggattc aggtactcag accccacgca gtggacggcc 2220
          ttcctgggct tgcacgacca gagccagcgc agcgcccctg gggtgcagga gcgcaggctc 2280
          aagcgcatca tctcccaccc cttcttcaat gacttcacct tcgactatga catcgcgctg 2340
          ctggagctgg agaaaccggc agagtacagc tccatggtgc ggcccatctg cctgccggac 2400
          gcctcccatg tcttccctgc cggcaaggcc atctgggtca cgggctgggg acacacccag 2460
          tatggaggca ctggcgcgct gatcctgcaa aagggtgaga tccgcgtcat caaccagacc 2520
          acctgcgaga acctcctgcc gcagcagatc acgccgcgca tgatgtgcgt gggcttcctc 2580
          agcggcggcg tggactcctg ccagggtgat tccgggggac ccctgtccag cgtgggaggcg 2640
          gatgggcgga tcttccaggc cggtgtggtg agctggggag acggctgcgc tcagaggaac 2700
          aagccaggcg tgtacacaag gctccctctg tttcgggact ggatcaaaga gaacactggg 2760
          gtataggggc cggggccacc caaatgtgta cacctgcggg gccacccatc gtccacccca 2820
          gtgtgcacgc ctgcaggctg gagactggac cgctgactgc accagcgccc ccagaacata 2880
          cactgtgaac tcaatctcca gggctccaaa tctgcctaga aaacctctcg cttcctcagc 2940
          ctccaaagtg gagctggggag gtagaagggg aggacactgg tggttctact gacccaactg 3000
          ggggcaaagg tttgaagaca cagcctcccc cgccagcccc aagctgggcc gaggcgcgtt 3060
          tgtgcatatc tgcctcccct gtctctaagg agcagcggga acggagcttc ggggcctcct 3120
          cagtgaaggt ggtggggctg ccggatctgg gctgtggggc ccttgggcca cgctcttgag 3180
          gaagcccagg ctcggaggac cctggaaaac agacgggtct gagactgaaa ttgttttacc 3240
          agctcccagg gtggacttca gtgtgtgtat ttgtgtaaat gagtaaaaca ttttatttct 3300
          TTTT 3305
           <![CDATA[ <210> 352]]>
           <![CDATA[ <211> 27]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 352]]>
          Met Gly Ser Asp Arg Ala Arg Lys Gly Gly Gly Gly Pro Lys Asp Phe
          1 5 10 15
          Gly Ala Gly Leu Lys Tyr Asn Ser Arg His Glu
                      20 25
           <![CDATA[ <210> 353]]>
           <![CDATA[ <211> 53]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 353]]>
          Lys Val Asn Gly Leu Glu Glu Gly Val Glu Phe Leu Pro Val Asn Asn
          1 5 10 15
          Val Lys Lys Val Glu Lys His Gly Pro Gly Arg Trp Val Val Leu Ala
                      20 25 30
          Ala Val Leu Ile Gly Leu Leu Leu Val Leu Leu Gly Ile Gly Phe Leu
                  35 40 45
          Val Trp His Leu Gln
              50
           <![CDATA[ <210> 354]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 354]]>
          Arg Asp Val Arg Val Gln Lys Val Phe Asn Gly Tyr Met Arg Ile Thr
          1 5 10 15
          Asn Glu Asn Phe Val Asp Ala Tyr Glu Asn Ser Asn Ser Thr Glu Phe
                      20 25 30
          Val Ser Leu Ala Ser Lys Val Lys Asp Ala
                  35 40
           <![CDATA[ <210> 355]]>
           <![CDATA[ <211> 23]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 355]]>
          Leu Lys Leu Leu Tyr Ser Gly Val Pro Phe Leu Gly Pro Tyr His Lys
          1 5 10 15
          Glu Ser Ala Val Thr Ala Phe
                      20
           <![CDATA[ <210> 356]]>
           <![CDATA[ <211> 52]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 356]]>
          Glu Gly Ser Val Ile Ala Tyr Tyr Trp Ser Glu Phe Ser Ile Pro Gln
          1 5 10 15
          His Leu Val Glu Glu Ala Glu Arg Val Met Ala Glu Glu Arg Val Val
                      20 25 30
          Met Leu Pro Pro Arg Ala Arg Ser Leu Lys Ser Phe Val Val Thr Ser
                  35 40 45
          Val Val Ala Phe
              50
           <![CDATA[ <210> 357]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 357]]>
          Thr Asp Ser Lys Thr Val Gln Arg Thr Gln Asp
          1 5 10
           <![CDATA[ <210> 358]]>
           <![CDATA[ <211> 79]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 35]]>8
          Ser Cys Ser Phe Gly Leu His Ala Arg Gly Val Glu Leu Met Arg Phe
          1 5 10 15
          Thr Thr Pro Gly Phe Pro Asp Ser Pro Tyr Pro Ala His Ala Arg Cys
                      20 25 30
          Gln Trp Ala Leu Arg Gly Asp Ala Asp Ser Val Leu Ser Leu Thr Phe
                  35 40 45
          Arg Ser Phe Asp Leu Ala Ser Cys Asp Glu Arg Gly Ser Asp Leu Val
              50 55 60
          Thr Val Tyr Asn Thr Leu Ser Pro Met Glu Pro His Ala Leu Val
          65 70 75
           <![CDATA[ <210> 359]]>
           <![CDATA[ <211> 46]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 359]]>
          Leu Cys Gly Thr Tyr Pro Pro Ser Tyr Asn Leu Thr Phe His Ser Ser
          1 5 10 15
          Gln Asn Val Leu Leu Ile Thr Leu Ile Thr Asn Thr Glu Arg Arg His
                      20 25 30
          Pro Gly Phe Glu Ala Thr Phe Phe Gln Leu Pro Arg Met Ser
                  35 40 45
           <![CDATA[ <210> 360]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 360]]>
          Cys Gly Gly Arg Leu Arg Lys Ala Gln Gly Thr Phe Asn Ser Pro Tyr
          1 5 10 15
          Tyr Pro Gly His Tyr Pro Pro Asn Ile Asp Cys Thr Trp Asn Ile Glu
                      20 25 30
           <![CDATA[ <210> 361]]>
           <![CDATA[ <211> 36]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 361]]>
          Val Pro Asn Asn Gln His Val Lys Val Arg Phe Lys Phe Phe Tyr Leu
          1 5 10 15
          Leu Glu Pro Gly Val Pro Ala Gly Thr Cys Pro Lys Asp Tyr Val Glu
                      20 25 30
          Ile Asn Gly Glu
                  35
           <![CDATA[ <210> 362]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 362]]>
          Tyr Cys Gly Glu Arg Ser Gln Phe Val Val Thr Ser Ser Asn Ser Asn Lys
          1 5 10 15
          Ile Thr Val Arg Phe His Ser Asp Gln Ser Tyr Thr Asp Thr Gly Phe
                      20 25 30
          Leu Ala Glu Tyr Leu Ser Tyr Asp Ser Ser Asp
                  35 40
           <![CDATA[ <210> 363]]>
           <![CDATA[ <211> 34]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 363]]>
          Cys Pro Gly Gln Phe Thr Cys Arg Thr Gly Arg Cys Ile Arg Lys Glu
          1 5 10 15
          Leu Arg Cys Asp Gly Trp Ala Asp Cys Thr Asp His Ser Asp Glu Leu
                      20 25 30
          Asn Cys
           <![CDATA[ <210> 364]]>
           <![CDATA[ <211> 36]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 36]]>4
          Cys Asp Ala Gly His Gln Phe Thr Cys Lys Asn Lys Phe Cys Lys Pro
          1 5 10 15
          Leu Phe Trp Val Cys Asp Ser Val Asn Asp Cys Gly Asp Asn Ser Asp
                      20 25 30
          Glu Gln Gly Cys
                  35
           <![CDATA[ <210> 365]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 365]]>
          Cys Pro Ala Gln Thr Phe Arg Cys Ser Asn Gly Lys Cys Leu Ser Lys
          1 5 10 15
          Ser Gln Gln Cys Asn Gly Lys Asp Asp Cys Gly Asp Gly Ser Asp Glu
                      20 25 30
          Ala Ser Cys Pro Lys
                  35
           <![CDATA[ <210> 366]]>
           <![CDATA[ <211> 40]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 366]]>
          Asn Val Val Thr Cys Thr Lys His Thr Tyr Arg Cys Leu Asn Gly Leu
          1 5 10 15
          Cys Leu Ser Lys Gly Asn Pro Glu Cys Asp Gly Lys Glu Asp Cys Ser
                      20 25 30
          Asp Gly Ser Asp Glu Lys Asp Cys
                  35 40
           <![CDATA[ <210> 367]]>
           <![CDATA[ <211> 61]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 367]]>
          Cys Gly Leu Arg Ser Phe Thr Arg Gln Ala Arg Val Val Gly Gly Thr
          1 5 10 15
          Asp Ala Asp Glu Gly Glu Trp Pro Trp Gln Val Ser Leu His Ala Leu
                      20 25 30
          Gly Gln Gly His Ile Cys Gly Ala Ser Leu Ile Ser Pro Asn Trp Leu
                  35 40 45
          Val Ser Ala Ala His Cys Tyr Ile Asp Asp Arg Gly Phe
              50 55 60
           <![CDATA[ <210> 368]]>
           <![CDATA[ <211> 91]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 368]]>
          Tyr Ser Asp Pro Thr Gln Trp Thr Ala Phe Leu Gly Leu His Asp Gln
          1 5 10 15
          Ser Gln Arg Ser Ala Pro Gly Val Gln Glu Arg Arg Leu Lys Arg Ile
                      20 25 30
          Ile Ser His Pro Phe Phe Asn Asp Phe Thr Phe Asp Tyr Asp Ile Ala
                  35 40 45
          Leu Leu Glu Leu Glu Lys Pro Ala Glu Tyr Ser Ser Met Val Arg Pro
              50 55 60
          Ile Cys Leu Pro Asp Ala Ser His Val Phe Pro Ala Gly Lys Ala Ile
          65 70 75 80
          Trp Val Thr Gly Trp Gly His Thr Gln Tyr Gly
                          85 90
           <![CDATA[ <210> 369]]>
           <![CDATA[ <211> 45]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 369]]>
          Thr Gly Ala Leu Ile Leu Gln Lys Gly Glu Ile Arg Val Ile Asn Gln
          1 5 10 15
          Thr Thr Cys Glu Asn Leu Leu Pro Gln Gln Ile Thr Pro Arg Met Met
                      20 25 30
          Cys Val Gly Phe Leu Ser Gly Gly Val Asp Ser Cys Gln
                  35 40 45
           <![CDATA[ <210> 370]]>
           <![CDATA[ <211> 53]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 370]]>
          Gly Asp Ser Gly Gly Pro Leu Ser Ser Val Glu Ala Asp Gly Arg Ile
          1 5 10 15
          Phe Gln Ala Gly Val Val Ser Trp Gly Asp Gly Cys Ala Gln Arg Asn
                      20 25 30
          Lys Pro Gly Val Tyr Thr Arg Leu Pro Leu Phe Arg Asp Trp Ile Lys
                  35 40 45
          Glu Asn Thr Gly Val
              50
           <![CDATA[ <210> 371]]>
           <![CDATA[ <211> 855]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 371]]>
          Met Gly Ser Asp Arg Ala Arg Lys Gly Gly Gly Gly Pro Lys Asp Phe
          1 5 10 15
          Gly Ala Gly Leu Lys Tyr Asn Ser Arg His Glu Lys Val Asn Gly Leu
                      20 25 30
          Glu Glu Gly Val Glu Phe Leu Pro Val Asn Asn Val Lys Lys Val Glu
                  35 40 45
          Lys His Gly Pro Gly Arg Trp Val Val Leu Ala Ala Val Leu Ile Gly
              50 55 60
          Leu Leu Leu Val Leu Leu Gly Ile Gly Phe Leu Val Trp His Leu Gln
          65 70 75 80
          Tyr Arg Asp Val Arg Val Gln Lys Val Phe Asn Gly Tyr Met Arg Ile
                          85 90 95
          Thr Asn Glu Asn Phe Val Asp Ala Tyr Glu Asn Ser Asn Ser Thr Glu
                      100 105 110
          Phe Val Ser Leu Ala Ser Lys Val Lys Asp Ala Leu Lys Leu Leu Tyr
                  115 120 125
          Ser Gly Val Pro Phe Leu Gly Pro Tyr His Lys Glu Ser Ala Val Thr
              130 135 140
          Ala Phe Ser Glu Gly Ser Val Ile Ala Tyr Tyr Trp Ser Glu Phe Ser
          145 150 155 160
          Ile Pro Gln His Leu Val Glu Glu Ala Glu Arg Val Met Ala Glu Glu
                          165 170 175
          Arg Val Val Met Leu Pro Pro Arg Ala Arg Ser Leu Lys Ser Phe Val
                      180 185 190
          Val Thr Ser Val Val Ala Phe Pro Thr Asp Ser Lys Thr Val Gln Arg
                  195 200 205
          Thr Gln Asp Asn Ser Cys Ser Phe Gly Leu His Ala Arg Gly Val Glu
              210 215 220
          Leu Met Arg Phe Thr Thr Pro Gly Phe Pro Asp Ser Pro Tyr Pro Ala
          225 230 235 240
          His Ala Arg Cys Gln Trp Ala Leu Arg Gly Asp Ala Asp Ser Val Leu
                          245 250 255
          Ser Leu Thr Phe Arg Ser Phe Asp Leu Ala Ser Cys Asp Glu Arg Gly
                      260 265 270
          Ser Asp Leu Val Thr Val Tyr Asn Thr Leu Ser Pro Met Glu Pro His
                  275 280 285
          Ala Leu Val Gln Leu Cys Gly Thr Tyr Pro Pro Ser Tyr Asn Leu Thr
              290 295 300
          Phe His Ser Ser Gln Asn Val Leu Leu Ile Thr Leu Ile Thr Asn Thr
          305 310 315 320
          Glu Arg Arg His Pro Gly Phe Glu Ala Thr Phe Phe Gln Leu Pro Arg
                          325 330 335
          Met Ser Ser Cys Gly Gly Arg Leu Arg Lys Ala Gln Gly Thr Phe Asn
                      340 345 350
          Ser Pro Tyr Tyr Pro Gly His Tyr Pro Pro Asn Ile Asp Cys Thr Trp
                  355 360 365
          Asn Ile Glu Val Pro Asn Asn Gln His Val Lys Val Arg Phe Lys Phe
              370 375 380
          Phe Tyr Leu Leu Glu Pro Gly Val Pro Ala Gly Thr Cys Pro Lys Asp
          385 390 395 400
          Tyr Val Glu Ile Asn Gly Glu Lys Tyr Cys Gly Glu Arg Ser Gln Phe
                          405 410 415
          Val Val Thr Ser Asn Ser Asn Lys Ile Thr Val Arg Phe His Ser Asp
                      420 425 430
          Gln Ser Tyr Thr Asp Thr Gly Phe Leu Ala Glu Tyr Leu Ser Tyr Asp
                  435 440 445
          Ser Ser Asp Pro Cys Pro Gly Gln Phe Thr Cys Arg Thr Gly Arg Cys
              450 455 460
          Ile Arg Lys Glu Leu Arg Cys Asp Gly Trp Ala Asp Cys Thr Asp His
          465 470 475 480
          Ser Asp Glu Leu Asn Cys Ser Cys Asp Ala Gly His Gln Phe Thr Cys
                          485 490 495
          Lys Asn Lys Phe Cys Lys Pro Leu Phe Trp Val Cys Asp Ser Val Asn
                      500 505 510
          Asp Cys Gly Asp Asn Ser Asp Glu Gln Gly Cys Ser Cys Pro Ala Gln
                  515 520 525
          Thr Phe Arg Cys Ser Asn Gly Lys Cys Leu Ser Lys Ser Gln Gln Cys
              530 535 540
          Asn Gly Lys Asp Asp Cys Gly Asp Gly Ser Asp Glu Ala Ser Cys Pro
          545 550 555 560
          Lys Val Asn Val Val Thr Cys Thr Lys His Thr Tyr Arg Cys Leu Asn
                          565 570 575
          Gly Leu Cys Leu Ser Lys Gly Asn Pro Glu Cys Asp Gly Lys Glu Asp
                      580 585 590
          Cys Ser Asp Gly Ser Asp Glu Lys Asp Cys Asp Cys Gly Leu Arg Ser
                  595 600 605
          Phe Thr Arg Gln Ala Arg Val Val Gly Gly Thr Asp Ala Asp Glu Gly
              610 615 620
          Glu Trp Pro Trp Gln Val Ser Leu His Ala Leu Gly Gln Gly His Ile
          625 630 635 640
          Cys Gly Ala Ser Leu Ile Ser Pro Asn Trp Leu Val Ser Ala Ala His
                          645 650 655
          Cys Tyr Ile Asp Asp Arg Gly Phe Arg Tyr Ser Asp Pro Thr Gln Trp
                      660 665 670
          Thr Ala Phe Leu Gly Leu His Asp Gln Ser Gln Arg Ser Ala Pro Gly
                  675 680 685
          Val Gln Glu Arg Arg Leu Lys Arg Ile Ile Ser His Pro Phe Phe Asn
              690 695 700
          Asp Phe Thr Phe Asp Tyr Asp Ile Ala Leu Leu Glu Leu Glu Lys Pro
          705 710 715 720
          Ala Glu Tyr Ser Ser Met Val Arg Pro Ile Cys Leu Pro Asp Ala Ser
                          725 730 735
          His Val Phe Pro Ala Gly Lys Ala Ile Trp Val Thr Gly Trp Gly His
                      740 745 750
          Thr Gln Tyr Gly Gly Thr Gly Ala Leu Ile Leu Gln Lys Gly Glu Ile
                  755 760 765
          Arg Val Ile Asn Gln Thr Thr Cys Glu Asn Leu Leu Pro Gln Gln Ile
              770 775 780
          Thr Pro Arg Met Met Cys Val Gly Phe Leu Ser Gly Gly Val Asp Ser
          785 790 795 800
          Cys Gln Gly Asp Ser Gly Gly Pro Leu Ser Ser Ser Val Glu Ala Asp Gly
                          805 810 815
          Arg Ile Phe Gln Ala Gly Val Val Ser Trp Gly Asp Gly Cys Ala Gln
                      820 825 830
          Arg Asn Lys Pro Gly Val Tyr Thr Arg Leu Pro Leu Phe Arg Asp Trp
                  835 840 845
          Ile Lys Glu Asn Thr Gly Val
              850 855
           <![CDATA[ <210> 372]]>
           <![CDATA[ <211> 1552]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 372]]>
          gtgagagcgg agctgcagcc ggagaaagag gaagaggggag agagagcgcg ccagggcgag 60
          ggcaccgccg ccggtcgggc gcgctgggcc tgcccggaat cccgccgcct gcgccccgcg 120
          ccccgcgccc tgcgggccat gggagccggc cgccggcagg gacgacgcct gtgagacccg 180
          cgagcggcct cggggaccat ggggagcgat cgggcccgca agggcgggagg gggcccgaag 240
          gacttcggcg cgggactcaa gtacaactcc cggcacgaga aagtgaatgg cttggaggaa 300
          ggcgtggagt tcctgccagt caacaacgtc aagaaggtgg aaaagcatgg cccggggcgc 360
          tgggtggtgc tggcagccgt gctgatcggc ctcctcttgg tcttgctggg gatcggcttc 420
          ctggtgtggc atttgcagta ccgggacgtg cgtgtccaga aggtcttcaa tggctacatg 480
          aggatcacaa atgagaattt tgtggatgcc tacgagaact ccaactccac tgagtttgta 540
          agcctggcca gcaaggtgaa ggacgcgctg aagctgctgt acagcggagt cccattcctg 600
          ggcccctacc acaaggagtc ggctgtgacg gccttcagcg agggcagcgt catcgcctac 660
          tactggtctg agttcagcat cccgcagcac ctggtggagg aggccgagcg cgtcatggcc 720
          gaggagcgcg tagtcatgct gcccccgcgg gcgcgctccc tgaagtcctt tgtggtcacc 780
          tcagtggtgg ctttccccac ggactccaaa acagtacaga ggacccagga caacagctgc 840
          agctttggcc tgcacgcccg cggtgtggag ctgatgcgct tcaccacgcc cggcttccct 900
          gacagcccct accccgctca tgcccgctgc cagtgggccc tgcgggggga cgccgactca 960
          gtgctgagcc tcaccttccg cagctttgac cttgcgtcct gcgacgagcg cggcagcgac 1020
          ctggtgacgg tgtacaacac cctgagcccc atggagcccc acgccctggt gcagttgtgt 1080
          ggcacctacc ctccctccta caacctgacc ttccactcct cccagaacgt cctgctcatc 1140
          acactgataa ccaacactga gcggcggcat cccggctttg aggccacctt cttccagctg 1200
          cctaggatga gcagctgtgg aggccgctta cgtaaagccc aggggacatt caacagcccc 1260
          tactacccag gccactaccc acccaacatt gactgcacat ggaacattga ggtgcccaac 1320
          aaccagcatg tgaaggtgcg cttcaaattc ttctacctgc tggagcccgg cgtgcctgcg 1380
          ggcacctgcc ccaaggacta cgtggagatc aacggggaga aatactgcgg agagaggtcc 1440
          cagttcgtcg tcaccagcaa cagcaacaag atcacagttc gcttccactc agatcagtcc 1500
          tacaccgaca ccggcttctt agctgaatac ctctcctacg actccagtga cc 1552
           <![CDATA[ <210> 373]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 373]]>
          Met Gly Ser Asp Arg Ala Arg Lys Gly Gly Gly Gly Pro Lys Asp Phe
          1 5 10 15
          Gly Ala Gly Leu Lys Tyr Asn Ser Arg His Glu Lys Val Asn Gly Leu
                      20 25 30
          Glu Glu Gly Val Glu Phe Leu Pro Val Asn Asn Val Lys Lys Val Glu
                  35 40 45
          Lys His Gly Pro Gly Arg Trp Val Val Leu Ala Ala Val Leu Ile Gly
              50 55 60
          Leu Leu Leu Val Leu Leu Gly Ile Gly Phe Leu Val Trp His Leu Gln
          65 70 75 80
          Tyr Arg Asp Val Arg Val Gln Lys Val Phe Asn Gly Tyr Met Arg Ile
                          85 90 95
          Thr Asn Glu Asn Phe Val Asp Ala Tyr Glu Asn Ser Asn Ser Thr Glu
                      100 105 110
          Phe Val Ser Leu Ala Ser Lys Val Lys Asp Ala Leu Lys Leu Leu Tyr
                  115 120 125
          Ser Gly Val Pro Phe Leu Gly Pro Tyr His Lys Glu Ser Ala Val Thr
              130 135 140
          Ala Phe Ser Glu Gly Ser Val Ile Ala Tyr Tyr Trp Ser Glu Phe Ser
          145 150 155 160
          Ile Pro Gln His Leu Val Glu Glu Ala Glu Arg Val Met Ala Glu Glu
                          165 170 175
          Arg Val Val Met Leu Pro Pro Arg Ala Arg Ser Leu Lys Ser Phe Val
                      180 185 190
          Val Thr Ser Val Val Ala Phe Pro Thr Asp Ser Lys Thr Val Gln Arg
                  195 200 205
          Thr Gln Asp Asn Ser Cys Ser Phe Gly Leu His Ala Arg Gly Val Glu
              210 215 220
          Leu Met Arg Phe Thr Thr Pro Gly Phe Pro Asp Ser Pro Tyr Pro Ala
          225 230 235 240
          His Ala Arg Cys Gln Trp Ala Leu Arg Gly Asp Ala Asp Ser Val Leu
                          245 250 255
          Ser Leu Thr Phe Arg Ser Phe Asp Leu Ala Ser Cys Asp Glu Arg Gly
                      260 265 270
          Ser Asp Leu Val Thr Val Tyr Asn Thr Leu Ser Pro Met Glu Pro His
                  275 280 285
          Ala Leu Val Gln Leu Cys Gly Thr Tyr Pro Pro Ser Tyr Asn Leu Thr
              290 295 300
          Phe His Ser Ser Gln Asn Val Leu Leu Ile Thr Leu Ile Thr Asn Thr
          305 310 315 320
          Glu Arg Arg His Pro Gly Phe Glu Ala Thr Phe Phe Gln Leu Pro Arg
                          325 330 335
          Met Ser Ser Cys Gly Gly Arg Leu Arg Lys Ala Gln Gly Thr Phe Asn
                      340 345 350
          Ser Pro Tyr Tyr Pro Gly His Tyr Pro Pro Asn Ile Asp Cys Thr Trp
                  355 360 365
          Asn Ile Glu Val Pro Asn Asn Gln His Val Lys Val Arg Phe Lys Phe
              370 375 380
          Phe Tyr Leu Leu Glu Pro Gly Val Pro Ala Gly Thr Cys Pro Lys Asp
          385 390 395 400
          Tyr Val Glu Ile Asn Gly Glu Lys Tyr Cys Gly Glu Arg Ser Gln Phe
                          405 410 415
          Val Val Thr Ser Asn Ser Asn Lys Ile Thr Val Arg Phe His Ser Asp
                      420 425 430
          Gln Ser Tyr Thr Asp Thr Gly Phe Leu Ala Glu Tyr Leu Ser Tyr Asp
                  435 440 445
          Ser Ser Asp
              450
           <![CDATA[ <210> 374]]>
           <![CDATA[ <211> 56]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 374]]>
          accctgtgaa ggcgaagcgc gggagaccaa agcctgcaag aaagacgcct gcccca 56
           <![CDATA[ <210> 375]]>
           <![CDATA[ <211> 89]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 375]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgt gaatggaggg gagtgcttc 89
           <![CDATA[ <210> 376]]>
           <![CDATA[ <211> 145]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 376]]>
          accctgtgaa ggcgaagcgc gggagaccaa agcctgcaag aaagacgcct gccccactac 60
          atctacatcc accactggga caagccatct tgtaaaatgt gcggagaagg agaaaacttt 120
          ctgtgtgaat ggaggggagt gcttc 145
           <![CDATA[ <210> 377]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 377]]>
          Pro Cys Glu Gly Glu Ala Arg Glu Thr Lys Ala Cys Lys Lys Asp Ala
          1 5 10 15
          Cys Pro Thr Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys
                      20 25 30
          Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe
                  35 40 45
           <![CDATA[ <210> 378]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 378]]>
          agccgctgcg cccgagctgg cctgcgagtt cagggctcct gtcgctctcc aggagcaacc 60
          tctactccgg acgcacaggc attccccgcg cccctccagc cctcgccgcc ctcgccaccg 120
          ctcccggccg ccgcgctccg gtacacacag 150
           <![CDATA[ <210> 379]]>
           <![CDATA[ <211> 96]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 379]]>
          gatccctgct gggcaccaac agctccacca tggggctggc ctggggacta ggcgtcctgt 60
          tcctgatgca tgtgtgtggc accaaccgca ttccag 96
           <![CDATA[ <210> 380]]>
           <![CDATA[ <211> 560]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 380]]>
          agtctggcgg agacaacagc gtgtttgaca tctttgaact caccggggcc gcccgcaagg 60
          ggtctgggcg ccgactggtg aagggccccg acccttccag cccagctttc cgcatcgagg 120
          atgccaacct gatcccccct gtgcctgatg acaagttcca agacctggtg gatgctgtgc 180
          gggcagaaaa gggtttcctc cttctggcat ccctgaggca gatgaagaag acccggggca 240
          cgctgctggc cctggagcgg aaagaccact ctggccaggt cttcagcgtg gtgtccaatg 300
          gcaaggcggg caccctggac ctcagcctga ccgtccaagg aaagcagcac gtggtgtctg 360
          tggaagaagc tctcctggca accggccagt ggaagagcat caccctgttt gtgcaggaag 420
          acagggccca gctgtacatc gactgtgaaa agatggagaa tgctgagttg gacgtcccca 480
          tccaaagcgt cttcaccaga gacctggcca gcatcgccag actccgcatc gcaaaggggg 540
          gcgtcaatga caatttccag 560
           <![CDATA[ <210> 381]]>
           <![CDATA[ <211> 76]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 381]]>
          ggggtgctgc agaatgtgag gtttgtcttt ggaaccacac cagaagacat cctcaggaac 60
          aaaggctgct ccagct 76
           <![CDATA[ <210> 382]]>
           <![CDATA[ <211> 200]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 382]]>
          ctaccagtgt cctcctcacc cttgacaaca acgtggtgaa tggttccagc cctgccatcc 60
          gcactaacta cattggccac aagacaaagg acttgcaagc catctgcggc atctcctgtg 120
          atgagctgtc cagcatggtc ctggaactca ggggcctgcg caccatgtg accacgctgc 180
          aggacagcat ccgcaaagtg 200
           <![CDATA[ <210> 383]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 383]]>
          actgaagaga acaaagagtt ggccaatgag ctgaggcggc ctcccctatg ctatcacaac 60
          ggagttcagt acagaaataa cgaggaatgg actgttgata gctgcactga gtgtcactgt 120
          cag 123
           <![CDATA[ <210> 384]]>
           <![CDATA[ <211> 94]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 384]]>
          aactcagtta ccatctgcaa aaaggtgtcc tgccccatca tgccctgctc caatgccaca 60
          gttcctgatg gagaatgctg tcctcgctgt tggc 94
           <![CDATA[ <210> 385]]>
           <![CDATA[ <211> 174]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 385]]>
          ccagcgactc tgcggacgat ggctggtctc catggtccga gtggacctcc tgttctacga 60
          gctgtggcaa tggaattcag cagcgcggcc gctcctgcga tagcctcaac aaccgatgtg 120
          agggctcctc ggtccagaca cggacctgcc aattcagga gtgtgacaag agat 174
           <![CDATA[ <210> 386]]>
           <![CDATA[ <211> 177]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 386]]>
          ttaaacagga tggtggctgg agccactggt ccccgtggtc atcttgttct gtgacatgtg 60
          gtgatggtgt gatcacaagg atccggctct gcaactctcc cagcccccag atgaacggga 120
          aaccctgtga aggcgaagcg cgggagacca aagcctgcaa gaaagacgcc tgcccca 177
           <![CDATA[ <210> 387]]>
           <![CDATA[ <211> 4547]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 387]]>
          ttaaacagga tggtggctgg agccactggt ccccgtggtc atcttgttct gtgacatgtg 60
          gtgatggtgt gatcacaagg atccggctct gcaactctcc cagcccccag atgaacggga 120
          aaccctgtga aggcgaagcg cgggagacca aagcctgcaa gaaagacgcc tgccccatca 180
          atggaggctg gggtccttgg tcaccatggg acatctgttc tgtcacctgt ggaggagggg 240
          tacagaaacg tagtcgtctc tgcaacaacc ccacacccca gtttggaggc aaggactgcg 300
          ttggtgatgt aacagaaaac cagatctgca acaagcagga ctgtccaatt gatggatgcc 360
          tgtccaatcc ctgctttgcc ggcgtgaagt gtactagcta ccctgatggc agctggaaat 420
          gtggtgcttg tccccctggt tacagtggaa atggcatcca gtgcacagat gttgatgagt 480
          gcaaagaagt gcctgatgcc tgcttcaacc acaatggaga gcaccggtgt gagaacacgg 540
          accccggcta caactgcctg ccctgccccc cacgcttcac cggctcacag cccttcggcc 600
          agggtgtcga acatgccacg gccaacaaac aggtgtgcaa gccccgtaac ccctgcacgg 660
          atgggaccca cgactgcaac aagaacgcca agtgcaacta cctgggccac tatagcgacc 720
          ccatgtaccg ctgcgagtgc aagcctggct acgctggcaa tggcatcatc tgcgggggagg 780
          acacagacct ggatggctgg cccaatgaga acctggtgtg cgtggccaat gcgacttacc 840
          actgcaaaaa ggataattgc cccaaccttc ccaactcagg gcaggaagac tatgacaagg 900
          atggaattgg tgatgcctgt gatgatgacg atgacaatga taaaattcca gatgacaggg 960
          acaactgtcc attccattac aacccagctc agtatgacta tgacagagat gatgtggggag 1020
          accgctgtga caactgtccc tacaaccaca accccagatca ggcagacaca gacaacaatg 1080
          gggaaggaga cgcctgtgct gcagacattg atggagacgg tatcctcaat gaacgggaca 1140
          actgccagta cgtctacaat gtggaccaga gagacactga tatggatggg gttggagatc 1200
          agtgtgacaa ttgccccttg gaacacaatc cggatcagct ggactctgac tcagaccgca 1260
          ttggagatac ctgtgacaac aatcaggata ttgatgaaga tggccaccag aacaatctgg 1320
          acaactgtcc ctatgtgccc aatgccaacc aggctgacca tgacaaagat ggcaagggag 1380
          atgcctgtga ccacgatgat gacaacgatg gcattcctga tgacaaggac aactgcagac 1440
          tcgtgcccaa tcccgaccag aaggactctg acggcgatgg tcgaggtgat gcctgcaaag 1500
          atgattttga ccatgacagt gtgccagaca tcgatgacat ctgtcctgag aatgttgaca 1560
          tcagtgagac cgatttccgc cgattccaga tgattcctct ggaccccaaa gggacatccc 1620
          aaaatgaccc taactgggtt gtacgccatc agggtaaaga actcgtccag actgtcaact 1680
          gtgatcctgg actcgctgta ggttatgatg agtttaatgc tgtggacttc agtggcacct 1740
          tcttcatcaa caccgaaagg gacgatgact atgctggatt tgtctttggc taccagtcca 1800
          gcagccgctt ttatgttgtg atgtggaagc aagtcaccca gtcctactgg gacaccaacc 1860
          ccacgagggc tcagggatac tcgggccttt ctgtgaaagt tgtaaactcc accacagggc 1920
          ctggcgagca cctgcggaac gccctgtggc acacaggaaa cacccctggc caggtgcgca 1980
          ccctgtggca tgaccctcgt cacataggct ggaaagattt caccgcctac agatggcgtc 2040
          tcagccacag gccaaagacg ggtttcatta gagtggtgat gtatgaaggg aagaaaatca 2100
          tggctgactc aggaccccatc tatgataaaa cctatgctgg tggtagacta gggttgtttg 2160
          tcttctctca agaaatggtg ttcttctctg acctgaaata cgaatgtaga gatccctaat 2220
          catcaaattg ttgattgaaa gactgatcat aaaccaatgc tggtattgca ccttctggaa 2280
          ctatggggctt gagaaaaccc ccaggatcac ttctccttgg cttccttctt ttctgtgctt 2340
          gcatcagtgt ggactcctag aacgtgcgac ctgcctcaag aaaatgcagt tttcaaaaac 2400
          agactcagca ttcagcctcc aatgaataag acatcttcca agcatataaa caattgcttt 2460
          ggtttccttttgaaaaagca tctacttgct tcagttggga aggtgcccat tccactctgc 2520
          ctttgtcaca gagcagggtg ctattgtgag gccatctctg agcagtggac tcaaaagcat 2580
          tttcaggcat gtcagagaag ggaggactca ctagaattag caaacaaaac caccctgaca 2640
          tcctccttca ggaacacggg gagcagaggc caaagcacta aggggagggc gcatacccga 2700
          gacgattgta tgaagaaaat atggaggaac tgttacatgt tcggtactaa gtcattttca 2760
          ggggattgaa agactattgc tggatttcat gatgctgact ggcgttagct gattaaccca 2820
          tgtaaatagg cacttaaata gaagcaggaa agggagacaa agactggctt ctggacttcc 2880
          tccctgatcc ccacccttac tcatcacctg cagtggccag aattagggaa tcagaatcaa 2940
          accagtgtaa ggcagtgctg gctgccattg cctggtcaca ttgaaattgg tggcttcatt 3000
          ctagatgtag cttgtgcaga tgtagcagga aaataggaaa acctaccatc tcagtgagca 3060
          ccagctgcct cccaaaggag gggcagccgt gcttatattt ttatggttac aatggcacaa 3120
          aattattatc aacctaacta aaacattcct tttctctttt ttcctgaatt atcatggagt 3180
          tttctaattc tctcttttgg aatgtagatt ttttttaaat gctttacgat gtaaaatatt 3240
          tattttttac ttattctgga agatctggct gaaggattat tcatggaaca ggaagaagcg 3300
          taaagactat ccatgtcatc tttgttgaga gtcttcgtga ctgtaagatt gtaaatacag 3360
          attatttatt aactctgttc tgcctggaaa tttaggcttc atacggaaag tgtttgagag 3420
          caagtagttg acatttatca gcaaatctct tgcaagaaca gcacaaggaa aatcagtcta 3480
          ataagctgct ctgccccttg tgctcagagt ggatgttatg ggattctttt tttctctgtt 3540
          ttatcttttc aagtggaatt agttggttat ccatttgcaa atgttttaaa ttgcaaagaa 3600
          agccatgagg tcttcaatac tgttttaccc catcccttgt gcatatttcc agggagaagg 3660
          aaagcatata cacttttttc tttcattttt ccaaaagaga aaaaaatgac aaaaggtgaa 3720
          acttacatac aaatattacc tcatttgttg tgtgactgag taaagaattt ttggatcaag 3780
          cggaaagagt ttaagtgtct aacaaactta aagctactgt agtacctaaa aagtcagtgt 3840
          tgtacatagc ataaaaactc tgcagagaag tattcccaat aaggaaatag cattgaaatg 3900
          ttaaatacaa tttctgaaag ttatgttttt tttctatcat ctggtatacc attgctttat 3960
          ttttataaat tattttctca ttgccattgg aatagatc tcagattgtg tagatatgct 4020
          atttaaataa tttatcagga aatactgcct gtagagttag tatttctatt tttatataat 4080
          gtttgcacac tgaattgaag aattgttggt tttttcttttttttgttttg tttttttttt 4140
          tttttttttttgcttttgac ctcccatttttactattttgc caatacctttttctaggaat 4200
          gtgctttttt ttgtacacat ttttatccat tttacattct aaagcagtgt aagttgtata 4260
          ttatgtttc ttatgtacaa ggaacaacaa taaatcatat ggaaatttat atttatactt 4320
          actgtatcca tgcttatttg ttctctactg gctttatgtc atgaagtata tgcgtaaata 4380
          ccattcataa atcaatatag catatacaaa aataaattac agtaagtcat agcaacattc 4440
          acagtttgta tgtgattgag aaagactgag ttgctcaggc ctaggcttag aatttgctgc 4500
          gtttgtggaa taaaagaaca aaatgataca ttagcctgcc atatcaa 4547
           <![CDATA[ <210> 388]]>
           <![CDATA[ <211> 6197]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Whole mRNA polynucleotide sequence of THBS1]]>
           <![CDATA[ <400> 388]]>
          agccgctgcg cccgagctgg cctgcgagtt cagggctcct gtcgctctcc aggagcaacc 60
          tctactccgg acgcacaggc attccccgcg cccctccagc cctcgccgcc ctcgccaccg 120
          ctcccggccg ccgcgctccg gtacacacag gatccctgct gggcaccaac agctccacca 180
          tggggctggc ctggggacta ggcgtcctgt tcctgatgca tgtgtgtggc accaaccgca 240
          ttccagagtc tggcggagac aacagcgtgt ttgacatctt tgaactcacc ggggccgccc 300
          gcaaggggtc tgggcgccga ctggtgaagg gccccgaccc ttccagccca gctttccgca 360
          tcgaggatgc caacctgatc ccccctgtgc ctgatgacaa gttccaagac ctggtggatg 420
          ctgtgcgggc agaaaagggt ttcctccttc tggcatccct gaggcagatg aagaagaccc 480
          ggggcacgct gctggccctg gagcggaaag accactctgg ccaggtcttc agcgtggtgt 540
          ccaatggcaa ggcgggcacc ctggacctca gcctgaccgt ccaaggaaag cagcacgtgg 600
          tgtctgtgga agaagctctc ctggcaaccg gccagtggaa gagcatcacc ctgtttgtgc 660
          aggaagacag ggcccagctg tacatcgact gtgaaaagat ggagaatgct gagttggacg 720
          tccccatcca aagcgtcttc accagagacc tggccagcat cgccagactc cgcatcgcaa 780
          aggggggcgt caatgacaat ttccagggggg tgctgcagaa tgtgaggttt gtctttggaa 840
          ccacaccaga agacatcctc aggaacaaag gctgctccag ctctaccagt gtcctcctca 900
          cccttgacaa caacgtggtg aatggttcca gccctgccat ccgcactaac tacattggcc 960
          acaagacaaa ggacttgcaa gccatctgcg gcatctcctg tgatgagctg tccagcatgg 1020
          tcctggaact caggggcctg cgcaccattg tgaccacgct gcaggacagc atccgcaaag 1080
          tgactgaaga gaacaaagag ttggccaatg agctgaggcg gcctccccta tgctatcaca 1140
          acggagttca gtacagaaat aacgaggaat ggactgttga tagctgcact gagtgtcact 1200
          gtcagaactc agttaccatc tgcaaaaagg tgtcctgccc catcatgccc tgctccaatg 1260
          ccacagttcc tgatggagaa tgctgtcctc gctgttggcc cagcgactct gcggacgatg 1320
          gctggtctcc atggtccgag tggacctcct gttctacgag ctgtggcaat ggaattcagc 1380
          agcgcggccg ctcctgcgat agcctcaaca accgatgtga gggctcctcg gtccagacac 1440
          ggacctgcca cattcaggag tgtgacaaga gatttaaaca ggatggtggc tggagccact 1500
          ggtccccgtg gtcatcttgt tctgtgacat gtggtgatgg tgtgatcaca aggatccggc 1560
          tctgcaactc tcccagcccc cagatgaacg ggaaaccctg tgaaggcgaa gcgcggggaga 1620
          ccaaagcctg caagaaagac gcctgcccca ttaaacagga tggtggctgg agccactggt 1680
          ccccgtggtc atcttgttct gtgacatgtg gtgatggtgt gatcacaagg atccggctct 1740
          gcaactctcc cagcccccag atgaacggga aaccctgtga aggcgaagcg cgggagacca 1800
          aagcctgcaa gaaagacgcc tgccccatca atggaggctg gggtccttgg tcaccatggg 1860
          acatctgttc tgtcacctgt ggaggagggg tacagaaacg tagtcgtctc tgcaacaacc 1920
          ccacacccca gtttggaggc aaggactgcg ttggtgatgt aacagaaaac cagatctgca 1980
          acaagcagga ctgtccaatt gatggatgcc tgtccaatcc ctgctttgcc ggcgtgaagt 2040
          gtactagcta ccctgatggc agctggaaat gtggtgcttg tccccctggt tacagtggaa 2100
          atggcatcca gtgcacagat gttgatgagt gcaaagaagt gcctgatgcc tgcttcaacc 2160
          acaatggaga gcaccggtgt gagaacacgg accccggcta caactgcctg ccctgccccc 2220
          cacgcttcac cggctcacag cccttcggcc agggtgtcga acatgccacg gccaacaaac 2280
          aggtgtgcaa gccccgtaac ccctgcacgg atgggaccca cgactgcaac aagaacgcca 2340
          agtgcaacta cctgggccac tatagcgacc ccatgtaccg ctgcgagtgc aagcctggct 2400
          acgctggcaa tggcatcatc tgcgggggagg acacagacct ggatggctgg cccaatgaga 2460
          acctggtgtg cgtggccaat gcgacttacc actgcaaaaa ggataattgc cccaaccttc 2520
          ccaactcagg gcaggaagac tatgacaagg atggaattgg tgatgcctgt gatgatgacg 2580
          atgacaatga taaaattcca gatgacagggg acaactgtcc attccattac aacccagctc 2640
          agtatgacta tgacagagat gatgtggggag accgctgtga caactgtccc tacaaccaca 2700
          accccagatca ggcagacaca gacaacaatg gggaaggaga cgcctgtgct gcagacattg 2760
          atggagacgg tatcctcaat gaacgggaca actgccagta cgtctacaat gtggaccaga 2820
          gagacactga tatggatggg gttggagatc agtgtgacaa ttgccccttg gaacacaatc 2880
          cggatcagct ggactctgac tcagaccgca ttggagatac ctgtgacaac aatcaggata 2940
          ttgatgaaga tggccaccag aacaatctgg acaactgtcc ctatgtgccc aatgccaacc 3000
          aggctgacca tgacaaagat ggcaagggag atgcctgtga ccacgatgat gacaacgatg 3060
          gcattcctga tgacaaggac aactgcagac tcgtgcccaa tcccgaccag aaggactctg 3120
          acggcgatgg tcgaggtgat gcctgcaaag atgattttga ccatgacagt gtgccagaca 3180
          tcgatgacat ctgtcctgag aatgttgaca tcagtgagac cgatttccgc cgattccaga 3240
          tgattcctct ggaccccaaa gggacatccc aaaatgaccc taactgggtt gtacgccatc 3300
          agggtaaaga actcgtccag actgtcaact gtgatcctgg actcgctgta ggttatgatg 3360
          agtttaatgc tgtggacttc agtggcacct tcttcatcaa caccgaaagg gacgatgact 3420
          atgctggatt tgtctttggc taccagtcca gcagccgctt ttatgttgtg atgtggaagc 3480
          aagtcaccca gtcctactgg gacaccaacc ccacgagggc tcagggatac tcgggccttt 3540
          ctgtgaaagt tgtaaactcc accacagggc ctggcgagca cctgcggaac gccctgtggc 3600
          acacaggaaa cacccctggc caggtgcgca ccctgtggca tgaccctcgt cacataggct 3660
          ggaaagattt caccgcctac agatggcgtc tcagccacag gccaaagacg ggtttcatta 3720
          gagtggtgat gtatgaaggg aagaaaatca tggctgactc aggaccccatc tatgataaaa 3780
          cctatgctgg tggtagacta gggttgtttg tcttctctca agaaatggtg ttcttctctg 3840
          acctgaaata cgaatgtaga gatccctaat catcaaattg ttgattgaaa gactgatcat 3900
          aaaccaatgc tggtattgca ccttctggaa ctatgggctt gagaaaaccc ccaggatcac 3960
          ttctccttgg cttccttctt ttctgtgctt gcatcagtgt ggactcctag aacgtgcgac 4020
          ctgcctcaag aaaatgcagt tttcaaaaac agactcagca ttcagcctcc aatgaataag 4080
          acatcttcca agcatataaa caattgcttt ggtttccttt tgaaaaagca tctacttgct 4140
          tcagttggga aggtgcccat tccactctgc ctttgtcaca gagcagggtg ctattgtgag 4200
          gccatctctg agcagtggac tcaaaagcat tttcaggcat gtcagagaag ggaggactca 4260
          ctagaattag caaacaaaac caccctgaca tcctccttca ggaacacggg gagcagaggc 4320
          caaagcacta aggggagggc gcatacccga gacgattgta tgaagaaaat atggaggaac 4380
          tgttacatgt tcggtactaa gtcattttca ggggattgaa agactattgc tggatttcat 4440
          gatgctgact ggcgttagct gattaaccca tgtaaatagg cacttaaata gaagcaggaa 4500
          agggagacaa agactggctt ctggacttcc tccctgatcc ccacccttac tcatcacctg 4560
          cagtggccag aattagggaa tcagaatcaa accagtgtaa ggcagtgctg gctgccattg 4620
          cctggtcaca ttgaaattgg tggcttcatt ctagatgtag cttgtgcaga tgtagcagga 4680
          aaataggaaa acctaccatc tcagtgagca ccagctgcct cccaaaggag gggcagccgt 4740
          gcttatattt ttatggttac aatggcacaa aattattatc aacctaacta aaacattcct 4800
          tttctctttt ttcctgaatt atcatggagt tttctaattc tctcttttgg aatgtagatt 4860
          ttttttaaat gctttacgat gtaaaatatt tattttttac ttatctgga agatctggct 4920
          gaaggattat tcatggaaca ggaagaagcg taaagactat ccatgtcatc tttgttgaga 4980
          gtcttcgtga ctgtaagatt gtaaatacag attatttatt aactctgttc tgcctggaaa 5040
          tttaggcttc atacggaaag tgtttgagag caagtagttg acatttatca gcaaatctct 5100
          tgcaagaaca gcacaaggaa aatcagtcta ataagctgct ctgccccttg tgctcagagt 5160
          ggatgttatg ggattctttt tttctctgtt ttatcttttc aagtggaatt agttggttat 5220
          ccatttgcaa atgttttaaa ttgcaaagaa agccatgagg tcttcaatac tgttttaccc 5280
          catcccttgt gcatatttcc agggagaagg aaagcatata cacttttttc tttcattttt 5340
          ccaaaagaga aaaaaatgac aaaaggtgaa acttacatac aaatattacc tcatttgttg 5400
          tgtgactgag taaagaattt ttggatcaag cggaaagagt ttaagtgtct aacaaactta 5460
          aagctactgt agtacctaaa aagtcagtgt tgtacatagc ataaaaactc tgcagagaag 5520
          tattcccaat aaggaaatag cattgaaatg ttaaatacaa tttctgaaag ttatgttttt 5580
          tttctatcat ctggtatacc attgctttat ttttataaat tattttctca ttgccattgg 5640
          aatagatatc tcagattgtg tagatatgct atttaaataa tttatcagga aatactgcct 5700
          gtagagttag tatttctatt tttatataat gtttgcacac tgaattgaag aattgttggt 5760
          tttttcttttttttgttttg tttttttttttttttttttttgcttttgac ctcccatttt 5820
          tactattttgc caataccttt ttctaggaat gtgctttttt ttgtacacat ttttatccat 5880
          tttacattct aaagcagtgt aagttgtata ttactgtttc ttatgtacaa ggaacaacaa 5940
          taaatcatat ggaaatttat atttatactt actgtatcca tgcttatttg ttctctactg 6000
          gctttatgtc atgaagtata tgcgtaaata ccattcataa atcaatatag catatacaaa 6060
          aataaattac agtaagtcat agcaacattc acagtttgta tgtgattgag aaagactgag 6120
          ttgctcaggc ctaggcttag aatttgctgc gtttgtggaa taaaagaaca aaatgataca 6180
          ttagcctgcc atatcaa 6197
           <![CDATA[ <210> 389]]>
           <![CDATA[ <211> 22]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 389]]>
          Met Gly Leu Ala Trp Gly Leu Gly Val Leu Phe Leu Met His Val Cys
          1 5 10 15
          Gly Thr Asn Arg Ile Pro
                      20
           <![CDATA[ <210> 390]]>
           <![CDATA[ <211> 186]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 390]]>
          Ser Gly Gly Asp Asn Ser Val Phe Asp Ile Phe Glu Leu Thr Gly Ala
          1 5 10 15
          Ala Arg Lys Gly Ser Gly Arg Arg Leu Val Lys Gly Pro Asp Pro Ser
                      20 25 30
          Ser Pro Ala Phe Arg Ile Glu Asp Ala Asn Leu Ile Pro Pro Val Pro
                  35 40 45
          Asp Asp Lys Phe Gln Asp Leu Val Asp Ala Val Arg Ala Glu Lys Gly
              50 55 60
          Phe Leu Leu Leu Ala Ser Leu Arg Gln Met Lys Lys Thr Arg Gly Thr
          65 70 75 80
          Leu Leu Ala Leu Glu Arg Lys Asp His Ser Gly Gln Val Phe Ser Val
                          85 90 95
          Val Ser Asn Gly Lys Ala Gly Thr Leu Asp Leu Ser Leu Thr Val Gln
                      100 105 110
          Gly Lys Gln His Val Val Ser Val Glu Glu Ala Leu Leu Ala Thr Gly
                  115 120 125
          Gln Trp Lys Ser Ile Thr Leu Phe Val Gln Glu Asp Arg Ala Gln Leu
              130 135 140
          Tyr Ile Asp Cys Glu Lys Met Glu Asn Ala Glu Leu Asp Val Pro Ile
          145 150 155 160
          Gln Ser Val Phe Thr Arg Asp Leu Ala Ser Ile Ala Arg Leu Arg Ile
                          165 170 175
          Ala Lys Gly Gly Val Asn Asp Asn Phe Gln
                      180 185
           <![CDATA[ <210> 391]]>
           <![CDATA[ <211> 25]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 391]]>
          Gly Val Leu Gln Asn Val Arg Phe Val Phe Gly Thr Thr Pro Glu Asp
          1 5 10 15
          Ile Leu Arg Asn Lys Gly Cys Ser Ser
                      20 25
           <![CDATA[ <210> 392]]>
           <![CDATA[ <211> 66]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 392]]>
          Thr Ser Val Leu Leu Thr Leu Asp Asn Asn Val Val Asn Gly Ser Ser
          1 5 10 15
          Pro Ala Ile Arg Thr Asn Tyr Ile Gly His Lys Thr Lys Asp Leu Gln
                      20 25 30
          Ala Ile Cys Gly Ile Ser Cys Asp Glu Leu Ser Ser Met Val Leu Glu
                  35 40 45
          Leu Arg Gly Leu Arg Thr Ile Val Thr Thr Leu Gln Asp Ser Ile Arg
              50 55 60
          Lys Val
          65
           <![CDATA[ <210> 393]]>
           <![CDATA[ <211> 41]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 393]]>
          Thr Glu Glu Asn Lys Glu Leu Ala Asn Glu Leu Arg Arg Pro Pro Leu
          1 5 10 15
          Cys Tyr His Asn Gly Val Gln Tyr Arg Asn Asn Glu Glu Trp Thr Val
                      20 25 30
          Asp Ser Cys Thr Glu Cys His Cys Gln
                  35 40
           <![CDATA[ <210> 394]]>
           <![CDATA[ <211> 31]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 394]]>
          Asn Ser Val Thr Ile Cys Lys Lys Val Ser Cys Pro Ile Met Pro Cys
          1 5 10 15
          Ser Asn Ala Thr Val Pro Asp Gly Glu Cys Cys Pro Arg Cys Trp
                      20 25 30
           <![CDATA[ <210> 395]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 395]]>
          Ser Asp Ser Ala Asp Asp Gly Trp Ser Pro Trp Ser Glu Trp Thr Ser
          1 5 10 15
          Cys Ser Thr Ser Cys Gly Asn Gly Ile Gln Gln Arg Gly Arg Ser Cys
                      20 25 30
          Asp Ser Leu Asn Asn Arg Cys Glu Gly Ser Ser Val Gln Thr Arg Thr
                  35 40 45
          Cys His Ile Gln Glu Cys Asp Lys Arg
              50 55
           <![CDATA[ <210> 396]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 396]]>
          Lys Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser
          1 5 10 15
          Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser
                      20 25 30
          Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu
                  35 40 45
          Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro
              50 55
           <![CDATA[ <210> 397]]>
           <![CDATA[ <211> 738]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 397]]>
          Lys Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser
          1 5 10 15
          Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser
                      20 25 30
          Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu
                  35 40 45
          Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro Ile Asn Gly Gly Trp Gly
              50 55 60
          Pro Trp Ser Pro Trp Asp Ile Cys Ser Val Thr Cys Gly Gly Gly Val
          65 70 75 80
          Gln Lys Arg Ser Arg Leu Cys Asn Asn Pro Thr Pro Gln Phe Gly Gly
                          85 90 95
          Lys Asp Cys Val Gly Asp Val Thr Glu Asn Gln Ile Cys Asn Lys Gln
                      100 105 110
          Asp Cys Pro Ile Asp Gly Cys Leu Ser Asn Pro Cys Phe Ala Gly Val
                  115 120 125
          Lys Cys Thr Ser Tyr Pro Asp Gly Ser Trp Lys Cys Gly Ala Cys Pro
              130 135 140
          Pro Gly Tyr Ser Gly Asn Gly Ile Gln Cys Thr Asp Val Asp Glu Cys
          145 150 155 160
          Lys Glu Val Pro Asp Ala Cys Phe Asn His Asn Gly Glu His Arg Cys
                          165 170 175
          Glu Asn Thr Asp Pro Gly Tyr Asn Cys Leu Pro Cys Pro Pro Arg Phe
                      180 185 190
          Thr Gly Ser Gln Pro Phe Gly Gln Gly Val Glu His Ala Thr Ala Asn
                  195 200 205
          Lys Gln Val Cys Lys Pro Arg Asn Pro Cys Thr Asp Gly Thr His Asp
              210 215 220
          Cys Asn Lys Asn Ala Lys Cys Asn Tyr Leu Gly His Tyr Ser Asp Pro
          225 230 235 240
          Met Tyr Arg Cys Glu Cys Lys Pro Gly Tyr Ala Gly Asn Gly Ile Ile
                          245 250 255
          Cys Gly Glu Asp Thr Asp Leu Asp Gly Trp Pro Asn Glu Asn Leu Val
                      260 265 270
          Cys Val Ala Asn Ala Thr Tyr His Cys Lys Lys Asp Asn Cys Pro Asn
                  275 280 285
          Leu Pro Asn Ser Gly Gln Glu Asp Tyr Asp Lys Asp Gly Ile Gly Asp
              290 295 300
          Ala Cys Asp Asp Asp Asp Asp Asn Asp Lys Ile Pro Asp Asp Arg Asp
          305 310 315 320
          Asn Cys Pro Phe His Tyr Asn Pro Ala Gln Tyr Asp Tyr Asp Arg Asp
                          325 330 335
          Asp Val Gly Asp Arg Cys Asp Asn Cys Pro Tyr Asn His Asn Pro Asp
                      340 345 350
          Gln Ala Asp Thr Asp Asn Asn Gly Glu Gly Asp Ala Cys Ala Ala Asp
                  355 360 365
          Ile Asp Gly Asp Gly Ile Leu Asn Glu Arg Asp Asn Cys Gln Tyr Val
              370 375 380
          Tyr Asn Val Asp Gln Arg Asp Thr Asp Met Asp Gly Val Gly Asp Gln
          385 390 395 400
          Cys Asp Asn Cys Pro Leu Glu His Asn Pro Asp Gln Leu Asp Ser Asp
                          405 410 415
          Ser Asp Arg Ile Gly Asp Thr Cys Asp Asn Asn Gln Asp Ile Asp Glu
                      420 425 430
          Asp Gly His Gln Asn Asn Leu Asp Asn Cys Pro Tyr Val Pro Asn Ala
                  435 440 445
          Asn Gln Ala Asp His Asp Lys Asp Gly Lys Gly Asp Ala Cys Asp His
              450 455 460
          Asp Asp Asp Asn Asp Gly Ile Pro Asp Asp Lys Asp Asn Cys Arg Leu
          465 470 475 480
          Val Pro Asn Pro Asp Gln Lys Asp Ser Asp Gly Asp Gly Arg Gly Asp
                          485 490 495
          Ala Cys Lys Asp Asp Phe Asp His Asp Ser Val Pro Asp Ile Asp Asp
                      500 505 510
          Ile Cys Pro Glu Asn Val Asp Ile Ser Glu Thr Asp Phe Arg Arg Phe
                  515 520 525
          Gln Met Ile Pro Leu Asp Pro Lys Gly Thr Ser Gln Asn Asp Pro Asn
              530 535 540
          Trp Val Val Arg His Gln Gly Lys Glu Leu Val Gln Thr Val Asn Cys
          545 550 555 560
          Asp Pro Gly Leu Ala Val Gly Tyr Asp Glu Phe Asn Ala Val Asp Phe
                          565 570 575
          Ser Gly Thr Phe Phe Ile Asn Thr Glu Arg Asp Asp Asp Tyr Ala Gly
                      580 585 590
          Phe Val Phe Gly Tyr Gln Ser Ser Ser Arg Phe Tyr Val Val Met Trp
                  595 600 605
          Lys Gln Val Thr Gln Ser Tyr Trp Asp Thr Asn Pro Thr Arg Ala Gln
              610 615 620
          Gly Tyr Ser Gly Leu Ser Val Lys Val Val Asn Ser Thr Thr Gly Pro
          625 630 635 640
          Gly Glu His Leu Arg Asn Ala Leu Trp His Thr Gly Asn Thr Pro Gly
                          645 650 655
          Gln Val Arg Thr Leu Trp His Asp Pro Arg His Ile Gly Trp Lys Asp
                      660 665 670
          Phe Thr Ala Tyr Arg Trp Arg Leu Ser His Arg Pro Lys Thr Gly Phe
                  675 680 685
          Ile Arg Val Val Met Tyr Glu Gly Lys Lys Ile Met Ala Asp Ser Gly
              690 695 700
          Pro Ile Tyr Asp Lys Thr Tyr Ala Gly Gly Arg Leu Gly Leu Phe Val
          705 710 715 720
          Phe Ser Gln Glu Met Val Phe Phe Ser Asp Leu Lys Tyr Glu Cys Arg
                          725 730 735
          Asp Pro
           <![CDATA[ <210> 398]]>
           <![CDATA[ <211> 1170]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 398]]>
          Met Gly Leu Ala Trp Gly Leu Gly Val Leu Phe Leu Met His Val Cys
          1 5 10 15
          Gly Thr Asn Arg Ile Pro Glu Ser Gly Gly Asp Asn Ser Val Phe Asp
                      20 25 30
          Ile Phe Glu Leu Thr Gly Ala Ala Arg Lys Gly Ser Gly Arg Arg Leu
                  35 40 45
          Val Lys Gly Pro Asp Pro Ser Ser Ser Pro Ala Phe Arg Ile Glu Asp Ala
              50 55 60
          Asn Leu Ile Pro Pro Val Pro Asp Asp Lys Phe Gln Asp Leu Val Asp
          65 70 75 80
          Ala Val Arg Ala Glu Lys Gly Phe Leu Leu Leu Ala Ser Leu Arg Gln
                          85 90 95
          Met Lys Lys Thr Arg Gly Thr Leu Leu Ala Leu Glu Arg Lys Asp His
                      100 105 110
          Ser Gly Gln Val Phe Ser Val Val Ser Asn Gly Lys Ala Gly Thr Leu
                  115 120 125
          Asp Leu Ser Leu Thr Val Gln Gly Lys Gln His Val Val Ser Val Glu
              130 135 140
          Glu Ala Leu Leu Ala Thr Gly Gln Trp Lys Ser Ile Thr Leu Phe Val
          145 150 155 160
          Gln Glu Asp Arg Ala Gln Leu Tyr Ile Asp Cys Glu Lys Met Glu Asn
                          165 170 175
          Ala Glu Leu Asp Val Pro Ile Gln Ser Val Phe Thr Arg Asp Leu Ala
                      180 185 190
          Ser Ile Ala Arg Leu Arg Ile Ala Lys Gly Gly Val Asn Asp Asn Phe
                  195 200 205
          Gln Gly Val Leu Gln Asn Val Arg Phe Val Phe Gly Thr Thr Pro Glu
              210 215 220
          Asp Ile Leu Arg Asn Lys Gly Cys Ser Ser Ser Thr Ser Val Leu Leu
          225 230 235 240
          Thr Leu Asp Asn Asn Val Val Asn Gly Ser Ser Pro Ala Ile Arg Thr
                          245 250 255
          Asn Tyr Ile Gly His Lys Thr Lys Asp Leu Gln Ala Ile Cys Gly Ile
                      260 265 270
          Ser Cys Asp Glu Leu Ser Ser Ser Met Val Leu Glu Leu Arg Gly Leu Arg
                  275 280 285
          Thr Ile Val Thr Thr Leu Gln Asp Ser Ile Arg Lys Val Thr Glu Glu
              290 295 300
          Asn Lys Glu Leu Ala Asn Glu Leu Arg Arg Pro Pro Leu Cys Tyr His
          305 310 315 320
          Asn Gly Val Gln Tyr Arg Asn Asn Glu Glu Trp Thr Val Asp Ser Cys
                          325 330 335
          Thr Glu Cys His Cys Gln Asn Ser Val Thr Ile Cys Lys Lys Val Ser
                      340 345 350
          Cys Pro Ile Met Pro Cys Ser Asn Ala Thr Val Pro Asp Gly Glu Cys
                  355 360 365
          Cys Pro Arg Cys Trp Pro Ser Asp Ser Ala Asp Asp Gly Trp Ser Pro
              370 375 380
          Trp Ser Glu Trp Thr Ser Cys Ser Thr Ser Cys Gly Asn Gly Ile Gln
          385 390 395 400
          Gln Arg Gly Arg Ser Cys Asp Ser Leu Asn Asn Asn Arg Cys Glu Gly Ser
                          405 410 415
          Ser Val Gln Thr Arg Thr Cys His Ile Gln Glu Cys Asp Lys Arg Phe
                      420 425 430
          Lys Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser
                  435 440 445
          Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser
              450 455 460
          Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu
          465 470 475 480
          Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro Ile Asn Gly Gly Trp Gly
                          485 490 495
          Pro Trp Ser Pro Trp Asp Ile Cys Ser Val Thr Cys Gly Gly Gly Val
                      500 505 510
          Gln Lys Arg Ser Arg Leu Cys Asn Asn Pro Thr Pro Gln Phe Gly Gly
                  515 520 525
          Lys Asp Cys Val Gly Asp Val Thr Glu Asn Gln Ile Cys Asn Lys Gln
              530 535 540
          Asp Cys Pro Ile Asp Gly Cys Leu Ser Asn Pro Cys Phe Ala Gly Val
          545 550 555 560
          Lys Cys Thr Ser Tyr Pro Asp Gly Ser Trp Lys Cys Gly Ala Cys Pro
                          565 570 575
          Pro Gly Tyr Ser Gly Asn Gly Ile Gln Cys Thr Asp Val Asp Glu Cys
                      580 585 590
          Lys Glu Val Pro Asp Ala Cys Phe Asn His Asn Gly Glu His Arg Cys
                  595 600 605
          Glu Asn Thr Asp Pro Gly Tyr Asn Cys Leu Pro Cys Pro Pro Arg Phe
              610 615 620
          Thr Gly Ser Gln Pro Phe Gly Gln Gly Val Glu His Ala Thr Ala Asn
          625 630 635 640
          Lys Gln Val Cys Lys Pro Arg Asn Pro Cys Thr Asp Gly Thr His Asp
                          645 650 655
          Cys Asn Lys Asn Ala Lys Cys Asn Tyr Leu Gly His Tyr Ser Asp Pro
                      660 665 670
          Met Tyr Arg Cys Glu Cys Lys Pro Gly Tyr Ala Gly Asn Gly Ile Ile
                  675 680 685
          Cys Gly Glu Asp Thr Asp Leu Asp Gly Trp Pro Asn Glu Asn Leu Val
              690 695 700
          Cys Val Ala Asn Ala Thr Tyr His Cys Lys Lys Asp Asn Cys Pro Asn
          705 710 715 720
          Leu Pro Asn Ser Gly Gln Glu Asp Tyr Asp Lys Asp Gly Ile Gly Asp
                          725 730 735
          Ala Cys Asp Asp Asp Asp Asp Asn Asp Lys Ile Pro Asp Asp Arg Asp
                      740 745 750
          Asn Cys Pro Phe His Tyr Asn Pro Ala Gln Tyr Asp Tyr Asp Arg Asp
                  755 760 765
          Asp Val Gly Asp Arg Cys Asp Asn Cys Pro Tyr Asn His Asn Pro Asp
              770 775 780
          Gln Ala Asp Thr Asp Asn Asn Gly Glu Gly Asp Ala Cys Ala Ala Asp
          785 790 795 800
          Ile Asp Gly Asp Gly Ile Leu Asn Glu Arg Asp Asn Cys Gln Tyr Val
                          805 810 815
          Tyr Asn Val Asp Gln Arg Asp Thr Asp Met Asp Gly Val Gly Asp Gln
                      820 825 830
          Cys Asp Asn Cys Pro Leu Glu His Asn Pro Asp Gln Leu Asp Ser Asp
                  835 840 845
          Ser Asp Arg Ile Gly Asp Thr Cys Asp Asn Asn Gln Asp Ile Asp Glu
              850 855 860
          Asp Gly His Gln Asn Asn Leu Asp Asn Cys Pro Tyr Val Pro Asn Ala
          865 870 875 880
          Asn Gln Ala Asp His Asp Lys Asp Gly Lys Gly Asp Ala Cys Asp His
                          885 890 895
          Asp Asp Asp Asn Asp Gly Ile Pro Asp Asp Lys Asp Asn Cys Arg Leu
                      900 905 910
          Val Pro Asn Pro Asp Gln Lys Asp Ser Asp Gly Asp Gly Arg Gly Asp
                  915 920 925
          Ala Cys Lys Asp Asp Phe Asp His Asp Ser Val Pro Asp Ile Asp Asp
              930 935 940
          Ile Cys Pro Glu Asn Val Asp Ile Ser Glu Thr Asp Phe Arg Arg Phe
          945 950 955 960
          Gln Met Ile Pro Leu Asp Pro Lys Gly Thr Ser Gln Asn Asp Pro Asn
                          965 970 975
          Trp Val Val Arg His Gln Gly Lys Glu Leu Val Gln Thr Val Asn Cys
                      980 985 990
          Asp Pro Gly Leu Ala Val Gly Tyr Asp Glu Phe Asn Ala Val Asp Phe
                  995 1000 1005
          Ser Gly Thr Phe Phe Ile Asn Thr Glu Arg Asp Asp Asp Tyr Ala
              1010 1015 1020
          Gly Phe Val Phe Gly Tyr Gln Ser Ser Ser Arg Phe Tyr Val Val
              1025 1030 1035
          Met Trp Lys Gln Val Thr Gln Ser Tyr Trp Asp Thr Asn Pro Thr
              1040 1045 1050
          Arg Ala Gln Gly Tyr Ser Gly Leu Ser Val Lys Val Val Asn Ser
              1055 1060 1065
          Thr Thr Gly Pro Gly Glu His Leu Arg Asn Ala Leu Trp His Thr
              1070 1075 1080
          Gly Asn Thr Pro Gly Gln Val Arg Thr Leu Trp His Asp Pro Arg
              1085 1090 1095
          His Ile Gly Trp Lys Asp Phe Thr Ala Tyr Arg Trp Arg Leu Ser
              1100 1105 1110
          His Arg Pro Lys Thr Gly Phe Ile Arg Val Val Met Tyr Glu Gly
              1115 1120 1125
          Lys Lys Ile Met Ala Asp Ser Gly Pro Ile Tyr Asp Lys Thr Tyr
              1130 1135 1140
          Ala Gly Gly Arg Leu Gly Leu Phe Val Phe Ser Gln Glu Met Val
              1145 1150 1155
          Phe Phe Ser Asp Leu Lys Tyr Glu Cys Arg Asp Pro
              1160 1165 1170
           <![CDATA[ <210> 399]]>
           <![CDATA[ <211> 1650]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 399]]>
          agccgctgcg cccgagctgg cctgcgagtt cagggctcct gtcgctctcc aggagcaacc 60
          tctactccgg acgcacaggc attccccgcg cccctccagc cctcgccgcc ctcgccaccg 120
          ctcccggccg ccgcgctccg gtacacacag gatccctgct gggcaccaac agctccacca 180
          tggggctggc ctggggacta ggcgtcctgt tcctgatgca tgtgtgtggc accaaccgca 240
          ttccagagtc tggcggagac aacagcgtgt ttgacatctt tgaactcacc ggggccgccc 300
          gcaaggggtc tgggcgccga ctggtgaagg gccccgaccc ttccagccca gctttccgca 360
          tcgaggatgc caacctgatc ccccctgtgc ctgatgacaa gttccaagac ctggtggatg 420
          ctgtgcgggc agaaaagggt ttcctccttc tggcatccct gaggcagatg aagaagaccc 480
          ggggcacgct gctggccctg gagcggaaag accactctgg ccaggtcttc agcgtggtgt 540
          ccaatggcaa ggcgggcacc ctggacctca gcctgaccgt ccaaggaaag cagcacgtgg 600
          tgtctgtgga agaagctctc ctggcaaccg gccagtggaa gagcatcacc ctgtttgtgc 660
          aggaagacag ggcccagctg tacatcgact gtgaaaagat ggagaatgct gagttggacg 720
          tccccatcca aagcgtcttc accagagacc tggccagcat cgccagactc cgcatcgcaa 780
          aggggggcgt caatgacaat ttccagggggg tgctgcagaa tgtgaggttt gtctttggaa 840
          ccacaccaga agacatcctc aggaacaaag gctgctccag ctctaccagt gtcctcctca 900
          cccttgacaa caacgtggtg aatggttcca gccctgccat ccgcactaac tacattggcc 960
          acaagacaaa ggacttgcaa gccatctgcg gcatctcctg tgatgagctg tccagcatgg 1020
          tcctggaact caggggcctg cgcaccattg tgaccacgct gcaggacagc atccgcaaag 1080
          tgactgaaga gaacaaagag ttggccaatg agctgaggcg gcctccccta tgctatcaca 1140
          acggagttca gtacagaaat aacgaggaat ggactgttga tagctgcact gagtgtcact 1200
          gtcagaactc agttaccatc tgcaaaaagg tgtcctgccc catcatgccc tgctccaatg 1260
          ccacagttcc tgatggagaa tgctgtcctc gctgttggcc cagcgactct gcggacgatg 1320
          gctggtctcc atggtccgag tggacctcct gttctacgag ctgtggcaat ggaattcagc 1380
          agcgcggccg ctcctgcgat agcctcaaca accgatgtga gggctcctcg gtccagacac 1440
          ggacctgcca cattcaggag tgtgacaaga gatttaaaca ggatggtggc tggagccact 1500
          ggtccccgtg gtcatcttgt tctgtgacat gtggtgatgg tgtgatcaca aggatccggc 1560
          tctgcaactc tcccagcccc cagatgaacg ggaaaccctg tgaaggcgaa gcgcggggaga 1620
          ccaaagcctg caagaaagac gcctgcccca 1650
           <![CDATA[ <210> 400]]>
           <![CDATA[ <211> 490]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 400]]>
          Met Gly Leu Ala Trp Gly Leu Gly Val Leu Phe Leu Met His Val Cys
          1 5 10 15
          Gly Thr Asn Arg Ile Pro Glu Ser Gly Gly Asp Asn Ser Val Phe Asp
                      20 25 30
          Ile Phe Glu Leu Thr Gly Ala Ala Arg Lys Gly Ser Gly Arg Arg Leu
                  35 40 45
          Val Lys Gly Pro Asp Pro Ser Ser Ser Pro Ala Phe Arg Ile Glu Asp Ala
              50 55 60
          Asn Leu Ile Pro Pro Val Pro Asp Asp Lys Phe Gln Asp Leu Val Asp
          65 70 75 80
          Ala Val Arg Ala Glu Lys Gly Phe Leu Leu Leu Ala Ser Leu Arg Gln
                          85 90 95
          Met Lys Lys Thr Arg Gly Thr Leu Leu Ala Leu Glu Arg Lys Asp His
                      100 105 110
          Ser Gly Gln Val Phe Ser Val Val Ser Asn Gly Lys Ala Gly Thr Leu
                  115 120 125
          Asp Leu Ser Leu Thr Val Gln Gly Lys Gln His Val Val Ser Val Glu
              130 135 140
          Glu Ala Leu Leu Ala Thr Gly Gln Trp Lys Ser Ile Thr Leu Phe Val
          145 150 155 160
          Gln Glu Asp Arg Ala Gln Leu Tyr Ile Asp Cys Glu Lys Met Glu Asn
                          165 170 175
          Ala Glu Leu Asp Val Pro Ile Gln Ser Val Phe Thr Arg Asp Leu Ala
                      180 185 190
          Ser Ile Ala Arg Leu Arg Ile Ala Lys Gly Gly Val Asn Asp Asn Phe
                  195 200 205
          Gln Gly Val Leu Gln Asn Val Arg Phe Val Phe Gly Thr Thr Pro Glu
              210 215 220
          Asp Ile Leu Arg Asn Lys Gly Cys Ser Ser Ser Thr Ser Val Leu Leu
          225 230 235 240
          Thr Leu Asp Asn Asn Val Val Asn Gly Ser Ser Pro Ala Ile Arg Thr
                          245 250 255
          Asn Tyr Ile Gly His Lys Thr Lys Asp Leu Gln Ala Ile Cys Gly Ile
                      260 265 270
          Ser Cys Asp Glu Leu Ser Ser Ser Met Val Leu Glu Leu Arg Gly Leu Arg
                  275 280 285
          Thr Ile Val Thr Thr Leu Gln Asp Ser Ile Arg Lys Val Thr Glu Glu
              290 295 300
          Asn Lys Glu Leu Ala Asn Glu Leu Arg Arg Pro Pro Leu Cys Tyr His
          305 310 315 320
          Asn Gly Val Gln Tyr Arg Asn Asn Glu Glu Trp Thr Val Asp Ser Cys
                          325 330 335
          Thr Glu Cys His Cys Gln Asn Ser Val Thr Ile Cys Lys Lys Val Ser
                      340 345 350
          Cys Pro Ile Met Pro Cys Ser Asn Ala Thr Val Pro Asp Gly Glu Cys
                  355 360 365
          Cys Pro Arg Cys Trp Pro Ser Asp Ser Ala Asp Asp Gly Trp Ser Pro
              370 375 380
          Trp Ser Glu Trp Thr Ser Cys Ser Thr Ser Cys Gly Asn Gly Ile Gln
          385 390 395 400
          Gln Arg Gly Arg Ser Cys Asp Ser Leu Asn Asn Asn Arg Cys Glu Gly Ser
                          405 410 415
          Ser Val Gln Thr Arg Thr Cys His Ile Gln Glu Cys Asp Lys Arg Phe
                      420 425 430
          Lys Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser
                  435 440 445
          Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser
              450 455 460
          Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu
          465 470 475 480
          Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro
                          485 490
           <![CDATA[ <210> 401]]>
           <![CDATA[ <211> 106]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 401]]>
          gtgtgcggct cagatggggt cacctacagc accgagtgtg agctgaagaa ggccagggtgt 60
          gagtcacagc gagggctcta cgtagcggcc cagggagcct gccgag 106
           <![CDATA[ <210> 402]]>
           <![CDATA[ <211> 101]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 402]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgt gaatggaggg gagtgcttca tggtgaaaga c 101
           <![CDATA[ <210> 403]]>
           <![CDATA[ <211> 207]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 403]]>
          gtgtgcggct cagatggggt cacctacagc accgagtgtg agctgaagaa ggccagggtgt 60
          gagtcacagc gagggctcta cgtagcggcc cagggagcct gccgagctac atctacatcc 120
          accactggga caagccatct tgtaaaatgt gcggagaagg agaaaacttt ctgtgtgaat 180
          ggaggggagt gcttcatggt gaaagac 207
           <![CDATA[ <210> 404]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 404]]>
          Val Cys Gly Ser Asp Gly Val Thr Tyr Ser Thr Glu Cys Glu Leu Lys
          1 5 10 15
          Lys Ala Arg Cys Glu Ser Gln Arg Gly Leu Tyr Val Ala Ala Gln Gly
                      20 25 30
          Ala Cys Arg Ala Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val
                  35 40 45
          Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys
              50 55 60
          Phe Met Val Lys Asp
          65
           <![CDATA[ <210> 405]]>
           <![CDATA[ <211> 254]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 405]]>
          agtcccgtcc ccggcgcggc ccgcgcgctc ctccgccgcc tctcgcctgc gccatggccg 60
          gccggtccca cccgggcccg ctgcggccgc tgctgccgct ccttgtggtg gccgcgtgcg 120
          tcctgcccgg agccggcggg acatgcccgg agcgcgcgct ggagcggcgc gaggaggagg 180
          cgaacgtggt gctcaccggg acggtggagg agatcctcaa cgtggacccg gtgcagcaca 240
          cgtactcctg caag 254
           <![CDATA[ <210> 406]]>
           <![CDATA[ <211> 262]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 406]]>
          gttcgggtct ggcggtactt gaagggcaaa gacctggtgg cccggggagag cctgctggac 60
          ggcggcaaca aggtggtgat cagcggcttt ggagacccccc tcatctgtga caaccaggtg 120
          tccactgggg acaccaggat cttctttgtg aaccctgcac ccccatacct gtggccagcc 180
          cacaagaacg agctgatgct caactccagc ctcatgcgga tcaccctgcg gaacctggag 240
          gaggtggagt tctgtgtgga ag 262
           <![CDATA[ <210> 407]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 407]]>
          ataaacccgg gacccacttc actccagtgc ctccgacgcc tcctgatg 48
           <![CDATA[ <210> 408]]>
           <![CDATA[ <211> 216]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 408]]>
          cgtgccgggg aatgctgtgc ggcttcggcg ccgtgtgcga gcccaacgcg gaggggccgg 60
          gccgggcgtc ctgcgtctgc aagaagagcc cgtgccccag cgtggtggcg cctgtgtgtg 120
          ggtcggacgc ctccacctac agcaacgaat gcgagctgca gcgggcgcag tgcagccagc 180
          agcgccgcat ccgcctgctc agccgcgggc cgtgcg 216
           <![CDATA[ <210> 409]]>
           <![CDATA[ <211> 225]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 409]]>
          gctcgcggga cccctgctcc aacgtgacct gcagcttcgg cagcacctgt gcgcgctcgg 60
          ccgacgggct gacggcctcg tgcctgtgcc ccgcgacctg ccgtggcgcc cccgaggggga 120
          ccgtctgcgg cagcgacggc gccgactacc ccggcgagtg ccagctcctg cgccgcgcct 180
          gcgcccgcca ggagaatgtc ttcaagaagt tcgacggccc ttgtg 225
           <![CDATA[ <210> 410]]>
           <![CDATA[ <211> 225]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 410]]>
          accccctgtca gggcgccctc cctgacccga gccgcagctg ccgtgtgaac ccgcgcacgc 60
          ggcgccctga gatgctccta cggcccgaga gctgccctgc ccggcaggcg ccagtgtgtg 120
          gggacgacgg agtcacctac gaaaacgact gtgtcatggg ccgatcgggg gccgcccggg 180
          gtctcctcct gcagaaagtg cgctccggcc agtgccaggg tcgag 225
           <![CDATA[ <210> 411]]>
           <![CDATA[ <211> 207]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 411]]>
          accagtgccc ggagccctgc cggttcaatg ccgtgtgcct gtcccgccgt ggccgtcccc 60
          gctgctcctg cgaccgcgtc acctgtgacg gggcctacag gcccgtgtgt gcccaggacg 120
          ggcgcacgta tgacagtgat tgctggcggc agcaggctga gtgccggcag cagcgtgcca 180
          tccccagcaa gcaccagggc ccgtgtg 207
           <![CDATA[ <210> 412]]>
           <![CDATA[ <211> 219]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 412]]>
          accaggcccc gtccccatgc ctcggggtgc agtgtgcatt tggggcgacg tgtgctgtga 60
          agaacgggca ggcagcgtgt gaatgcctgc aggcgtgctc gagcctctac gatcctgtgt 120
          gcggcagcga cggcgtcaca tacggcagcg cgtgcgagct ggaggccacg gcctgtaccc 180
          tcgggcggga gatccaggtg gcgcgcaaag gaccctgtg 219
           <![CDATA[ <210> 413]]>
           <![CDATA[ <211> 195]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 413]]>
          accgctgcgg gcagtgccgc tttggagccc tgtgcgaggc cgagaccggg cgctgcgtgt 60
          gcccctctga atgcgtggct ttggcccagc ccgtgtgtgg ctccgacggg cacacgtacc 120
          ccagcgagtg catgctgcac gtgcacgcct gcacacacca gatcagcctg cacgtggcct 180
          cagctggacc ctgtg 195
           <![CDATA[ <210> 414]]>
           <![CDATA[ <211> 201]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 414]]>
          agacctgtgg agatgccgtg tgtgcttttg gggctgtgtg ctccgcaggg cagtgtgtgt 60
          gtccccggtg tgagcacccc ccgcccggcc ccgtgtgtgg cagcgacggt gtcacctacg 120
          gcagtgcctg cgagctacgg gaagccgcct gcctccagca gacacagatc gaggaggccc 180
          gggcagggcc gtgcgagcag g 201
           <![CDATA[ <210> 415]]>
           <![CDATA[ <211> 149]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 415]]>
          ccgagtgcgg ttccggaggc tctggctctg gggaggacgg tgactgtgag caggagctgt 60
          gccggcagcg cggtggcatc tgggacgagg actcggagga cgggccgtgt gtctgtgact 120
          tcagctgcca gagtgtccca ggcagcccg 149
           <![CDATA[ <210> 416]]>
           <![CDATA[ <211> 106]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 416]]>
          gtgtgcggct cagatggggt cacctacagc accgagtgtg agctgaagaa ggccagggtgt 60
          gagtcacagc gagggctcta cgtagcggcc cagggagcct gccgag 106
           <![CDATA[ <210> 417]]>
           <![CDATA[ <211> 5088]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 417]]>
          gccccacctt cgccccgctg ccgcctgtgg cccccttaca ctgtgcccag acgccctacg 60
          gctgctgcca ggacaatatc accgcagccc ggggcgtggg cctggctggc tgccccagtg 120
          cctgccagtg caacccccat ggctcttacg gcggcacctg tgacccagcc acaggccagt 180
          gctcctgccg cccaggtgtg gggggcctca ggtgtgaccg ctgtgagcct ggcttctgga 240
          actttcgagg catcgtcacc gatggccgga gtggctgtac accctgcagc tgtgatcccc 300
          aaggcgccgt gcgggatgac tgtgagcaga tgacggggct gtgctcgtgt aagcccgggg 360
          tggctggacc caagtgtggg cagtgtccag acggccgtgc cctgggcccc gcgggctgtg 420
          aagctgacgc ttctgcgcct gcgacctgtg cggagatgcg ctgtgagttc ggtgcgcggt 480
          gcgtggagga gtctggctca gcccactgtg tctgcccgat gctcacctgt ccagaggcca 540
          acgctaccaa ggtctgtggg tcagatggag tcacatacgg caacgagtgt cagctgaaga 600
          ccatcgcctg ccgccagggc ctgcaaatct ctatccagag cctgggcccg tgccaggagg 660
          ctgttgctcc cagcactcac ccgacatctg cctccgtgac tgtgaccacc ccagggctcc 720
          tcctgagcca ggcactgccg gccccccccg gcgccctccc cctggctccc agcagtaccg 780
          cacacagcca gaccacccct ccgccctcat cacgacctcg gaccactgcc agcgtcccca 840
          ggaccaccgt gtggcccgtg ctgacggtgc cccccacggc accctcccct gcacccagcc 900
          tggtggcgtc cgcctttggt gaatctggca gcactgatgg aagcagcgat gaggaactga 960
          gcggggacca ggaggccagt gggggtggct ctggggggct cgagcccttg gagggcagca 1020
          gcgtggccac ccctgggcca cctgtcgaga gggcttcctg ctacaactcc gcgttgggct 1080
          gctgctctga tgggaagacg ccctcgctgg acgcagagggg ctccaactgc cccgccacca 1140
          aggtgttcca gggcgtcctg gagctggagg gcgtcgaggg ccaggagctg ttctacacgc 1200
          ccgagatggc tgaccccaag tcagaactgt tcggggagac agccaggagc attgagagca 1260
          ccctggacga cctcttccgg aattcagacg tcaagaagga ttttcggagt gtccgcttgc 1320
          gggacctggg gcccggcaaa tccgtccgcg ccattgtgga tgtgcacttt gaccccacca 1380
          cagccttcag ggcacccgac gtggcccggg ccctgctccg gcagatccag gtgtccaggc 1440
          gccggtcctt gggggtgagg cggccgctgc aggagcacgt gcgattatg gactttgact 1500
          ggtttcctgc gtttatcacg ggggccacgt caggagccat tgctgcggga gccacggcca 1560
          gagccaccac tgcatcgcgc ctgccgtcct ctgctgtgac ccctcgggcc ccgcacccca 1620
          gtcacacaag ccagccccgtt gccaagacca cggcagcccc caccaacacgt cggcccccca 1680
          ccactgcccc cagccgtgtg cccggacgtc ggcccccggc cccccagcag cctccaaagc 1740
          cctgtgactc acagccctgc ttccacgggg ggacctgcca ggactgggca ttgggcgggg 1800
          gcttcacctg cagctgcccg gcaggcaggg gaggcgccgt ctgtgagaag gtgcttggcg 1860
          cccctgtgcc ggccttcgag ggccgctcct tcctggcctt ccccactctc cgcgcctacc 1920
          acacgctgcg cctggcactg gaattccggg cgctggagcc tcaggggctg ctgctgtaca 1980
          atggcaacgc ccggggcaag gacttcctgg cattggcgct gctagatggc cgcgtgcagc 2040
          tcaggtttga cacaggttcg gggccggcgg tgctgaccag tgccgtgccg gtagagccgg 2100
          gccagtggca ccgcctggag ctgtcccggc actggcgccg gggcaccctc tcggtggatg 2160
          gtgagacccc tgttctgggc gagagtccca gtggcaccga cggcctcaac ctggacacag 2220
          acctctttgt gggcggcgta cccgaggacc aggctgccgt ggcgctggag cggaccttcg 2280
          tgggcgccgg cctgaggggg tgcatccgtt tgctggacgt caacaaccag cgcctggagc 2340
          ttggcattgg gccgggggct gccacccgag gctctggcgt gggcgagtgc ggggaccacc 2400
          cctgcctgcc caacccctgc catggcgggg ccccatgcca gaacctggag gctggaaggt 2460
          tccattgcca gtgcccgccc ggccgcgtcg gaccaacctg tgccgatgag aagagcccct 2520
          gccagcccaa cccctgccat ggggcggcgc cctgccgtgt gctgcccgag ggtggtgctc 2580
          agtgcgagtg ccccctgggg cgtgagggca ccttctgcca gacagcctcg gggcaggacg 2640
          gctctgggcc cttcctggct gacttcaacg gcttctccca cctggagctg agaggcctgc 2700
          acacctttgc acgggacctg ggggagaaga tggcgctgga ggtcgtgttc ctggcacgag 2760
          gccccagcgg cctcctgctc tacaacgggc agaagacgga cggcaagggg gacttcgtgt 2820
          cgctggcact gcgggaccgc cgcctggagt tccgctacga cctgggcaag ggggcagcgg 2880
          tcatcaggag cagggagcca gtcaccctgg gagcctggac cagggtctca ctggagcgaa 2940
          acggccgcaa gggtgccctg cgtgtgggcg acggcccccg tgtgttgggg gagtccccga 3000
          aatcccgcaa ggttccgcac accgtcctca acctgaagga gccgctctac gtagggggcg 3060
          ctcccgactt cagcaagctg gcccgtgctg ctgccgtgtc ctctggcttc gacggtgcca 3120
          tccagctggt ctccctcgga ggccgccagc tgctgacccc ggagcacgtg ctgcggcagg 3180
          tggacgtcac gtcctttgca ggtcacccct gcacccgggc ctcaggccac ccctgcctca 3240
          atggggcctc ctgcgtcccg agggaggctg cctatgtgtg cctgtgtccc gggggattct 3300
          caggaccgca ctgcgagaag gggctggtgg agaagtcagc gggggacgtg gataccttgg 3360
          cctttgacgg gcggaccttt gtcgagtacc tcaacgctgt gaccgagagc gaactggcca 3420
          atgagatccc cgtccccgaa actctggatt ccggggccct tcacagcgag aaggcactgc 3480
          agagcaacca ctttgaactg agcctgcgca ctgaggccac gcaggggctg gtgctctgga 3540
          gtggcaaggc cacggagcgg gcagactatg tggcactggc cattgtggac gggcacctgc 3600
          aactgagcta caacctgggc tcccagcccg tggtgctgcg ttccaccgtg cccgtcaaca 3660
          ccaaccgctg gttgcgggtc gtggcacata gggagcagag ggaaggttcc ctgcaggtgg 3720
          gcaatgaggc ccctgtgacc ggctcctccc cgctgggcgc cacgcagctg gacactgatg 3780
          gagccctgtg gcttgggggc ctgccggagc tgcccgtggg cccagcactg cccaaggcct 3840
          acggcacagg ctttgtgggc tgcttgcggg acgtggtggt gggccggcac ccgctgcacc 3900
          tgctggagga cgccgtcacc aagccagagc tgcggccctg ccccacccca tgagctggca 3960
          ccagagcccc gcgcccgctg taattatttt ctatttttgt aaacttgttg ctttttgata 4020
          tgattttctt gcctgagtgttggccggagg gactgctggc ccggcctccc ttccgtccag 4080
          gcagccgtgc tgcagacaga cctagtgccg agggatggac aggcgaggtg gcagcgtgga 4140
          gggctcggcg tggatggcag cctcaggaca cacacccctg cctcaaggtg ctgagccccc 4200
          gccttgcact gcgcctgccc cacggtgtcc ccgccgggaa gcagccccgg ctcctgaatc 4260
          accctcgctc cgtcaggcgg gactcgtgtc ccagagagga aggggctgct gaggtctgat 4320
          ggggcccttc ctccgggtga ccccacagggg cctttccaag cccccatttg agctgctcct 4380
          tcctgtgtgt gctctgggcc ctgcctcggc ctcctgcgcc aatactgtga cttccaaaca 4440
          atgttactgc tgggcacagc tctgcgttgc tcccgtgctg cctgcgccag ccccaggctg 4500
          ctgaggagca gaggccagac cagggccgat ctgggtgtcc tgaccctcag ctggccctgc 4560
          ccagccacccc tggacgtgac cgtatccctc tgccacacccc caggccctgc gaggggctat 4620
          cgagaggagc tcactgtggg atggggttga cctctgccgc ctgcctgggt atctgggcct 4680
          ggccatggct gtgttcttca tgtgttgatt ttatttgacc cctggagtgg tgggtctcat 4740
          ctttcccatc tcgcctgaga gcggctgagg gctgcctcac tgcaaatcct ccccacagcg 4800
          tcagtgaaag tcgtccttgt ctcagaatga ccaggggcca gccagtgtct gaccaaggtc 4860
          aaggggcagg tgcagaggtg gcagggatgg ctccgaagcc agaaatgcct taaactgcaa 4920
          cgtcccgtcc cttccccacc cccatcccat ccccacccccc agccccagcc cagtcctcct 4980
          aggagcagga cccgatgaag cgggcggcgg tggggctggg tgccgtgtta ctaactctag 5040
          tatgtttctg tgtcaatcgc tgtgaaataa agtctgaaaa ctttaaaa 5088
           <![CDATA[ <210> 418]]>
           <![CDATA[ <211> 7395]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> The complete mRNA polynucleotide sequence of AGRN]]>
           <![CDATA[ <400> 418]]>
          agtcccgtcc ccggcgcggc ccgcgcgctc ctccgccgcc tctcgcctgc gccatggccg 60
          gccggtccca cccgggcccg ctgcggccgc tgctgccgct ccttgtggtg gccgcgtgcg 120
          tcctgcccgg agccggcggg acatgcccgg agcgcgcgct ggagcggcgc gaggaggagg 180
          cgaacgtggt gctcaccggg acggtggagg agatcctcaa cgtggacccg gtgcagcaca 240
          cgtactcctg caaggttcgg gtctggcggt acttgaaggg caaagacctg gtggcccggg 300
          agagcctgct ggacggcggc aacaaggtgg tgatcagcgg ctttggagac cccctcatct 360
          gtgacaacca ggtgtccact ggggaccacca ggatcttctt tgtgaaccct gcacccccat 420
          acctgtggcc agcccacaag aacgagctga tgctcaactc cagcctcatg cggatcaccc 480
          tgcggaacct gaggaggtg gagttctgtg tggaagataa acccgggacc cacttcactc 540
          cagtgcctcc gacgcctcct gatgcgtgcc ggggaatgct gtgcggcttc ggcgccgtgt 600
          gcgagcccaa cgcggagggg ccgggccggg cgtcctgcgt ctgcaagaag agcccgtgcc 660
          ccagcgtggt ggcgcctgtg tgtgggtcgg acgcctccac ctacagcaac gaatgcgagc 720
          tgcagcgggc gcagtgcagc cagcagcgcc gcatccgcct gctcagccgc gggccgtgcg 780
          gctcgcggga cccctgctcc aacgtgacct gcagcttcgg cagcacctgt gcgcgctcgg 840
          ccgacgggct gacggcctcg tgcctgtgcc ccgcgacctg ccgtggcgcc cccgagggga 900
          ccgtctgcgg cagcgacggc gccgactacc ccggcgagtg ccagctcctg cgccgcgcct 960
          gcgcccgcca ggagaatgtc ttcaagaagt tcgacggccc ttgtgacccc tgtcagggcg 1020
          ccctccctga cccgagccgc agctgccgtg tgaacccgcg cacgcggcgc cctgagatgc 1080
          tcctacggcc cgagagctgc cctgcccggc aggcgccagt gtgtggggac gacggagtca 1140
          cctacgaaaa cgactgtgtc atgggccgat cgggggccgc ccggggtctc ctcctgcaga 1200
          aagtgcgctc cggccagtgc cagggtcgag accagtgccc ggagccctgc cggttcaatg 1260
          ccgtgtgcct gtcccgccgt ggccgtcccc gctgctcctg cgaccgcgtc acctgtgacg 1320
          gggcctacag gcccgtgtgt gcccaggacg ggcgcacgta tgacagtgat tgctggcggc 1380
          agcaggctga gtgccggcag cagcgtgcca tccccagcaa gcaccagggc ccgtgtgacc 1440
          aggccccgtc cccatgcctc ggggtgcagt gtgcattgg ggcgacgtgt gctgtgaaga 1500
          acgggcaggc agcgtgtgaa tgcctgcagg cgtgctcgag cctctacgat cctgtgtgcg 1560
          gcagcgacgg cgtcacatac ggcagcgcgt gcgagctgga ggccacggcc tgtaccctcg 1620
          ggcggggagat ccaggtggcg cgcaaaggac cctgtgaccg ctgcggggcag tgccgctttg 1680
          gagccctgtg cgaggccgag accgggcgct gcgtgtgccc ctctgaatgc gtggctttgg 1740
          cccagcccgt gtgtggctcc gacgggcaca cgtaccccag cgagtgcatg ctgcacgtgc 1800
          acgcctgcac acaccagatc agcctgcacg tggcctcagc tggaccctgt gagacctgtg 1860
          gagatgccgt gtgtgctttt ggggctgtgt gctccgcagg gcagtgtgtg tgtccccggt 1920
          gtgagcaccc cccgcccggc cccgtgtgtg gcagcgacgg tgtcacctac ggcagtgcct 1980
          gcgagctacg ggaagccgcc tgcctccagc agacacagat cgaggaggcc cgggcagggc 2040
          cgtgcgagca ggccgagtgc ggttccggag gctctggctc tggggaggac ggtgactgtg 2100
          agcaggagct gtgccggcag cgcggtggca tctgggacga ggactcggag gacgggccgt 2160
          gtgtctgtga cttcagctgc cagagtgtcc caggcagccc ggtgtgcggc tcagatgggg 2220
          tcacctacag caccgagtgt gagctgaaga aggccaggtg tgagtcacag cgagggctct 2280
          acgtagcggc ccagggagcc tgccgaggcc ccaccttcgc cccgctgccg cctgtggccc 2340
          ccttacactg tgcccagacg ccctacggct gctgccagga caatatcacc gcagcccggg 2400
          gcgtgggcct ggctggctgc cccagtgcct gccagtgcaa cccccatggc tcttacggcg 2460
          gcacctgtga cccagccaca ggccagtgct cctgccgccc aggtgtgggg ggcctcaggt 2520
          gtgaccgctg tgagcctggc ttctggaact ttcgaggcat cgtcaccgat ggccggagtg 2580
          gctgtacacc ctgcagctgt gatccccaag gcgccgtgcg ggatgactgt gagcagatga 2640
          cggggctgtg ctcgtgtaag cccggggtgg ctggacccaa gtgtggggcag tgtccagacg 2700
          gccgtgccct gggccccgcg ggctgtgaag ctgacgcttc tgcgcctgcg acctgtgcgg 2760
          agatgcgctg tgagttcggt gcgcggtgcg tggaggagtc tggctcagcc cactgtgtct 2820
          gcccgatgct cacctgtcca gaggccaacg ctaccaaggt ctgtgggtca gatggagtca 2880
          catacggcaa cgagtgtcag ctgaagacca tcgcctgccg ccagggcctg caaatctcta 2940
          tccagagcct gggcccgtgc caggaggctg ttgctcccag cactcacccg acatctgcct 3000
          ccgtgactgt gaccacccca gggctcctcc tgagccaggc actgccggcc ccccccggcg 3060
          ccctccccct ggctcccagc agtaccgcac acagccagac cacccctccg ccctcatcac 3120
          gacctcggac cactgccagc gtccccagga ccaccgtgtg gcccgtgctg acggtgcccc 3180
          ccacggcacc ctcccctgca cccagcctgg tggcgtccgc ctttggtgaa tctggcagca 3240
          ctgatggaag cagcgatgag gaactgagcg gggaccagga ggccagtggg ggtggctctg 3300
          gggggctcga gcccttggag ggcagcagcg tggccacccc tgggccacct gtcgagaggg 3360
          cttcctgcta caactccgcg ttgggctgct gctctgatgg gaagacgccc tcgctggacg 3420
          cagagggctc caactgcccc gccaccaagg tgttccaggg cgtcctggag ctggagggcg 3480
          tcgagggcca ggagctgttc tacacgcccg agatggctga ccccaagtca gaactgttcg 3540
          gggagacagc caggagcatt gagagcaccc tggacgacct cttccggaat tcagacgtca 3600
          agaaggattt tcggagtgtc cgcttgcggg acctggggcc cggcaaatcc gtccgcgcca 3660
          ttgtggatgt gcactttgac cccaccacag ccttcagggc acccgacgtg gcccgggccc 3720
          tgctccggca gatccaggtg tccaggcgcc ggtccttggg ggtgaggcgg ccgctgcagg 3780
          agcacgtgcg atttatggac tttgactggt ttcctgcgtt tatcacgggg gccacgtcag 3840
          gagccattgc tgcggggagcc acggccagag ccaccactgc atcgcgcctg ccgtcctctg 3900
          ctgtgacccc tcgggccccg caccccagtc acacaagcca gcccgttgcc aagaccacgg 3960
          cagcccccac cacacgtcgg cccccacca ctgcccccag ccgtgtgccc ggacgtcggc 4020
          ccccggcccc ccagcagcct ccaaagccct gtgactcaca gccctgcttc cacggggggga 4080
          cctgccagga ctgggcattg ggcggggggct tcacctgcag ctgcccggca ggcaggggag 4140
          gcgccgtctg tgagaaggtg cttggcgccc ctgtgccggc cttcgagggc cgctccttcc 4200
          tggccttccc cactctccgc gcctaccaca cgctgcgcct ggcactggaa ttccgggcgc 4260
          tggagcctca ggggctgctg ctgtacaatg gcaacgcccg gggcaaggac ttcctggcat 4320
          tggcgctgct agatggccgc gtgcagctca ggtttgacac aggttcgggg ccggcggtgc 4380
          tgaccagtgc cgtgccggta gagccgggcc agtggcaccg cctggagctg tcccggcact 4440
          ggcgccgggg caccctctcg gtggatggtg agaccccctgt tctgggcgag agtccccagtg 4500
          gcaccgacgg cctcaacctg gacacagacc tctttgtggg cggcgtaccc gaggaccagg 4560
          ctgccgtggc gctggagcgg accttcgtgg gcgccggcct gagggggtgc atccgtttgc 4620
          tggacgtcaa caaccagcgc ctggagcttg gcattgggcc gggggctgcc acccgaggct 4680
          ctggcgtggg cgagtgcggg gaccacccct gcctgcccaa cccctgccat ggcggggccc 4740
          catgccagaa cctggaggct ggaaggttcc attgccagtg cccgcccggc cgcgtcggac 4800
          caacctgtgc cgatgagaag agcccctgcc agcccaaccc ctgccatggg gcggcgccct 4860
          gccgtgtgct gcccgagggt ggtgctcagt gcgagtgccc cctggggcgt gagggcacct 4920
          tctgccagac agcctcgggg caggacggct ctgggccctt cctggctgac ttcaacggct 4980
          tctcccacct ggagctgaga ggcctgcaca cctttgcacg ggacctgggg gagaagatgg 5040
          cgctggaggt cgtgttcctg gcacgaggcc ccagcggcct cctgctctac aacgggcaga 5100
          agacggacgg caagggggac ttcgtgtcgc tggcactgcg ggaccgccgc ctggagttcc 5160
          gctacgacct gggcaagggg gcagcggtca tcaggagcag ggagccagtc accctgggag 5220
          cctggaccag ggtctcactg gagcgaaacg gccgcaaggg tgccctgcgt gtgggcgacg 5280
          gcccccgtgtgttgggggag tccccgaaat cccgcaaggt tccgcacacc gtcctcaacc 5340
          tgaaggagcc gctctacgta gggggcgctc ccgacttcag caagctggcc cgtgctgctg 5400
          ccgtgtcctc tggcttcgac ggtgccatcc agctggtctc cctcggaggc cgccagctgc 5460
          tgaccccgga gcacgtgctg cggcaggtgg acgtcacgtc ctttgcaggt cacccctgca 5520
          cccgggcctc aggccacccc tgcctcaatg gggcctcctg cgtcccgagg gaggctgcct 5580
          atgtgtgcct gtgtcccgggg ggattctcag gaccgcactg cgagaagggg ctggtggaga 5640
          agtcagcggg ggacgtggat accttggcct ttgacgggcg gacctttgtc gagtacctca 5700
          acgctgtgac cgagagcgaa ctggccaatg agatccccgt ccccgaaact ctggattccg 5760
          gggcccttca cagcgagaag gcactgcaga gcaaccactt tgaactgagc ctgcgcactg 5820
          aggccacgca ggggctggtg ctctggagtg gcaaggccac ggagcgggca gactatgtgg 5880
          cactggccat tgtggacggg cacctgcaac tgagctacaa cctgggctcc cagcccgtgg 5940
          tgctgcgttc caccgtgccc gtcaacacca accgctggtt gcgggtcgtg gcacataggg 6000
          agcagaggga aggttccctg caggtgggca atgaggcccc tgtgaccggc tcctccccgc 6060
          tgggcgccac gcagctggac actgatggag ccctgtggct tgggggcctg ccggagctgc 6120
          ccgtgggccc agcactgccc aaggcctacg gcacaggctt tgtgggctgc ttgcgggacg 6180
          tggtggtggg ccggcacccg ctgcacctgc tggaggacgc cgtcaccaag ccagagctgc 6240
          ggccctgccc caccccatga gctggcacca gagccccgcg cccgctgtaa ttattttcta 6300
          tttttgtaaa cttgttgctt tttgatatga ttttcttgcc tgagtgttgg ccggagggac 6360
          tgctggcccg gcctcccttc cgtccaggca gccgtgctgc agacagacct agtgccgagg 6420
          gatggacagg cgaggtggca gcgtggaggg ctcggcgtgg atggcagcct caggacacac 6480
          acccctgcct caaggtgctg agcccccgcc ttgcactgcg cctgccccac ggtgtccccg 6540
          ccgggaagca gccccggctc ctgaatcacc ctcgctccgt caggcgggac tcgtgtccca 6600
          gagaggaagg ggctgctgag gtctgatggg gcccttcctc cgggtgaccc cacagggcct 6660
          ttccaagccc ccatttgagc tgctccttcc tgtgtgtgct ctgggccctg cctcggcctc 6720
          ctgcgccaat actgtgactt ccaaacaatg ttactgctgg gcacagctct gcgttgctcc 6780
          cgtgctgcct gcgccagccc caggctgctg aggagcagag gccagaccag ggccgatctg 6840
          ggtgtcctga ccctcagctg gccctgccca gccaccctgg acgtgaccgt atccctctgc 6900
          cacaccccag gccctgcgag gggctatcga gaggagctca ctgtgggatg gggttgacct 6960
          ctgccgcctg cctgggtatc tgggcctggc catggctgtg ttcttcatgt gttgatttta 7020
          tttgacccct ggagtggtgg gtctcatctt tcccatctcg cctgagagcg gctgagggct 7080
          gcctcactgc aaatcctccc cacagcgtca gtgaaagtcg tccttgtctc agaatgacca 7140
          ggggccagcc agtgtctgac caaggtcaag gggcaggtgc agaggtggca gggatggctc 7200
          cgaagccaga aatgccttaa actgcaacgt cccgtccctt ccccacccccc atcccatccc 7260
          cacccccagc cccagcccag tcctcctagg agcaggaccc gatgaagcgg gcggcggtgg 7320
          ggctgggtgc cgtgttacta actctagtat gtttctgtgt caatcgctgt gaaataaagt 7380
          ctgaaaactt taaaa 7395
           <![CDATA[ <210> 419]]>
           <![CDATA[ <211> 67]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 419]]>
          Met Ala Gly Arg Ser His Pro Gly Pro Leu Arg Pro Leu Leu Pro Leu
          1 5 10 15
          Leu Val Val Ala Ala Cys Val Leu Pro Gly Ala Gly Gly Thr Cys Pro
                      20 25 30
          Glu Arg Ala Leu Glu Arg Arg Glu Glu Glu Glu Ala Asn Val Val Leu Thr
                  35 40 45
          Gly Thr Val Glu Glu Ile Leu Asn Val Asp Pro Val Gln His Thr Tyr
              50 55 60
          Ser Cys Lys
          65
           <![CDATA[ <210> 420]]>
           <![CDATA[ <211> 87]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 420]]>
          Val Arg Val Trp Arg Tyr Leu Lys Gly Lys Asp Leu Val Ala Arg Glu
          1 5 10 15
          Ser Leu Leu Asp Gly Gly Asn Lys Val Val Ile Ser Gly Phe Gly Asp
                      20 25 30
          Pro Leu Ile Cys Asp Asn Gln Val Ser Thr Gly Asp Thr Arg Ile Phe
                  35 40 45
          Phe Val Asn Pro Ala Pro Pro Tyr Leu Trp Pro Ala His Lys Asn Glu
              50 55 60
          Leu Met Leu Asn Ser Ser Leu Met Arg Ile Thr Leu Arg Asn Leu Glu
          65 70 75 80
          Glu Val Glu Phe Cys Val Glu
                          85
           <![CDATA[ <210> 421]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 421]]>
          Lys Pro Gly Thr His Phe Thr Pro Val Pro Pro Thr Pro Pro Asp
          1 5 10 15
           <![CDATA[ <210> 422]]>
           <![CDATA[ <211> 71]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 422]]>
          Cys Arg Gly Met Leu Cys Gly Phe Gly Ala Val Cys Glu Pro Asn Ala
          1 5 10 15
          Glu Gly Pro Gly Arg Ala Ser Cys Val Cys Lys Lys Ser Pro Cys Pro
                      20 25 30
          Ser Val Val Ala Pro Val Cys Gly Ser Asp Ala Ser Thr Tyr Ser Asn
                  35 40 45
          Glu Cys Glu Leu Gln Arg Ala Gln Cys Ser Gln Gln Arg Arg Ile Arg
              50 55 60
          Leu Leu Ser Arg Gly Pro Cys
          65 70
           <![CDATA[ <210> 423]]>
           <![CDATA[ <211> 74]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 423]]>
          Ser Arg Asp Pro Cys Ser Asn Val Thr Cys Ser Phe Gly Ser Thr Cys
          1 5 10 15
          Ala Arg Ser Ala Asp Gly Leu Thr Ala Ser Cys Leu Cys Pro Ala Thr
                      20 25 30
          Cys Arg Gly Ala Pro Glu Gly Thr Val Cys Gly Ser Asp Gly Ala Asp
                  35 40 45
          Tyr Pro Gly Glu Cys Gln Leu Leu Arg Arg Ala Cys Ala Arg Gln Glu
              50 55 60
          Asn Val Phe Lys Lys Phe Asp Gly Pro Cys
          65 70
           <![CDATA[ <210> 424]]>
           <![CDATA[ <211> 74]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 424]]>
          Pro Cys Gln Gly Ala Leu Pro Asp Pro Ser Arg Ser Cys Arg Val Asn
          1 5 10 15
          Pro Arg Thr Arg Arg Pro Glu Met Leu Leu Arg Pro Glu Ser Cys Pro
                      20 25 30
          Ala Arg Gln Ala Pro Val Cys Gly Asp Asp Gly Val Thr Tyr Glu Asn
                  35 40 45
          Asp Cys Val Met Gly Arg Ser Gly Ala Ala Arg Gly Leu Leu Leu Gln
              50 55 60
          Lys Val Arg Ser Gly Gln Cys Gln Gly Arg
          65 70
           <![CDATA[ <210> 425]]>
           <![CDATA[ <211> 68]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 425]]>
          Gln Cys Pro Glu Pro Cys Arg Phe Asn Ala Val Cys Leu Ser Arg Arg
          1 5 10 15
          Gly Arg Pro Arg Cys Ser Cys Asp Arg Val Thr Cys Asp Gly Ala Tyr
                      20 25 30
          Arg Pro Val Cys Ala Gln Asp Gly Arg Thr Tyr Asp Ser Asp Cys Trp
                  35 40 45
          Arg Gln Gln Ala Glu Cys Arg Gln Gln Arg Ala Ile Pro Ser Lys His
              50 55 60
          Gln Gly Pro Cys
          65
           <![CDATA[ <210> 426]]>
           <![CDATA[ <211> 72]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 426]]>
          Gln Ala Pro Ser Pro Cys Leu Gly Val Gln Cys Ala Phe Gly Ala Thr
          1 5 10 15
          Cys Ala Val Lys Asn Gly Gln Ala Ala Cys Glu Cys Leu Gln Ala Cys
                      20 25 30
          Ser Ser Leu Tyr Asp Pro Val Cys Gly Ser Asp Gly Val Thr Tyr Gly
                  35 40 45
          Ser Ala Cys Glu Leu Glu Ala Thr Ala Cys Thr Leu Gly Arg Glu Ile
              50 55 60
          Gln Val Ala Arg Lys Gly Pro Cys
          65 70
           <![CDATA[ <210> 427]]>
           <![CDATA[ <211> 64]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 427]]>
          Arg Cys Gly Gln Cys Arg Phe Gly Ala Leu Cys Glu Ala Glu Thr Gly
          1 5 10 15
          Arg Cys Val Cys Pro Ser Glu Cys Val Ala Leu Ala Gln Pro Val Cys
                      20 25 30
          Gly Ser Asp Gly His Thr Tyr Pro Ser Glu Cys Met Leu His Val His
                  35 40 45
          Ala Cys Thr His Gln Ile Ser Leu His Val Ala Ser Ala Gly Pro Cys
              50 55 60
           <![CDATA[ <210> 428]]>
           <![CDATA[ <211> 66]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 428]]>
          Thr Cys Gly Asp Ala Val Cys Ala Phe Gly Ala Val Cys Ser Ala Gly
          1 5 10 15
          Gln Cys Val Cys Pro Arg Cys Glu His Pro Pro Pro Gly Pro Val Cys
                      20 25 30
          Gly Ser Asp Gly Val Thr Tyr Gly Ser Ala Cys Glu Leu Arg Glu Ala
                  35 40 45
          Ala Cys Leu Gln Gln Thr Gln Ile Glu Glu Ala Arg Ala Gly Pro Cys
              50 55 60
          Glu Gln
          65
           <![CDATA[ <210> 429]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 429]]>
          Glu Cys Gly Ser Gly Gly Ser Gly Ser Gly Glu Asp Gly Asp Cys Glu
          1 5 10 15
          Gln Glu Leu Cys Arg Gln Arg Gly Gly Ile Trp Asp Glu Asp Ser Glu
                      20 25 30
          Asp Gly Pro Cys Val Cys Asp Phe Ser Cys Gln Ser Val Pro Gly Ser
                  35 40 45
          Pro
           <![CDATA[ <210> 430]]>
           <![CDATA[ <211> 35]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 430]]>
          Val Cys Gly Ser Asp Gly Val Thr Tyr Ser Thr Glu Cys Glu Leu Lys
          1 5 10 15
          Lys Ala Arg Cys Glu Ser Gln Arg Gly Leu Tyr Val Ala Ala Gln Gly
                      20 25 30
          Ala Cys Arg
                  35
           <![CDATA[ <210> 431]]>
           <![CDATA[ <211> 1352]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 431]]>
          Val Cys Gly Ser Asp Gly Val Thr Tyr Ser Thr Glu Cys Glu Leu Lys
          1 5 10 15
          Lys Ala Arg Cys Glu Ser Gln Arg Gly Leu Tyr Val Ala Ala Gln Gly
                      20 25 30
          Ala Cys Arg Gly Pro Thr Phe Ala Pro Leu Pro Pro Val Ala Pro Leu
                  35 40 45
          His Cys Ala Gln Thr Pro Tyr Gly Cys Cys Gln Asp Asn Ile Thr Ala
              50 55 60
          Ala Arg Gly Val Gly Leu Ala Gly Cys Pro Ser Ala Cys Gln Cys Asn
          65 70 75 80
          Pro His Gly Ser Tyr Gly Gly Thr Cys Asp Pro Ala Thr Gly Gln Cys
                          85 90 95
          Ser Cys Arg Pro Gly Val Gly Gly Leu Arg Cys Asp Arg Cys Glu Pro
                      100 105 110
          Gly Phe Trp Asn Phe Arg Gly Ile Val Thr Asp Gly Arg Ser Gly Cys
                  115 120 125
          Thr Pro Cys Ser Cys Asp Pro Gln Gly Ala Val Arg Asp Asp Cys Glu
              130 135 140
          Gln Met Thr Gly Leu Cys Ser Cys Lys Pro Gly Val Ala Gly Pro Lys
          145 150 155 160
          Cys Gly Gln Cys Pro Asp Gly Arg Ala Leu Gly Pro Ala Gly Cys Glu
                          165 170 175
          Ala Asp Ala Ser Ala Pro Ala Thr Cys Ala Glu Met Arg Cys Glu Phe
                      180 185 190
          Gly Ala Arg Cys Val Glu Glu Ser Gly Ser Ala His Cys Val Cys Pro
                  195 200 205
          Met Leu Thr Cys Pro Glu Ala Asn Ala Thr Lys Val Cys Gly Ser Asp
              210 215 220
          Gly Val Thr Tyr Gly Asn Glu Cys Gln Leu Lys Thr Ile Ala Cys Arg
          225 230 235 240
          Gln Gly Leu Gln Ile Ser Ile Gln Ser Leu Gly Pro Cys Gln Glu Ala
                          245 250 255
          Val Ala Pro Ser Thr His Pro Thr Ser Ala Ser Val Thr Val Thr Thr
                      260 265 270
          Pro Gly Leu Leu Leu Ser Gln Ala Leu Pro Ala Pro Pro Gly Ala Leu
                  275 280 285
          Pro Leu Ala Pro Ser Ser Thr Ala His Ser Gln Thr Thr Pro Pro Pro
              290 295 300
          Ser Ser Arg Pro Arg Thr Thr Ala Ser Val Pro Arg Thr Thr Val Trp
          305 310 315 320
          Pro Val Leu Thr Val Pro Pro Thr Ala Pro Ser Pro Ala Pro Ser Leu
                          325 330 335
          Val Ala Ser Ala Phe Gly Glu Ser Gly Ser Thr Asp Gly Ser Ser Asp
                      340 345 350
          Glu Glu Leu Ser Gly Asp Gln Glu Ala Ser Gly Gly Gly Ser Gly Gly
                  355 360 365
          Leu Glu Pro Leu Glu Gly Ser Ser Val Ala Thr Pro Gly Pro Pro Val
              370 375 380
          Glu Arg Ala Ser Cys Tyr Asn Ser Ala Leu Gly Cys Cys Ser Asp Gly
          385 390 395 400
          Lys Thr Pro Ser Leu Asp Ala Glu Gly Ser Asn Cys Pro Ala Thr Lys
                          405 410 415
          Val Phe Gln Gly Val Leu Glu Leu Glu Gly Val Glu Gly Gln Glu Leu
                      420 425 430
          Phe Tyr Thr Pro Glu Met Ala Asp Pro Lys Ser Glu Leu Phe Gly Glu
                  435 440 445
          Thr Ala Arg Ser Ile Glu Ser Thr Leu Asp Asp Leu Phe Arg Asn Ser
              450 455 460
          Asp Val Lys Lys Asp Phe Arg Ser Val Arg Leu Arg Asp Leu Gly Pro
          465 470 475 480
          Gly Lys Ser Val Arg Ala Ile Val Asp Val His Phe Asp Pro Thr Thr
                          485 490 495
          Ala Phe Arg Ala Pro Asp Val Ala Arg Ala Leu Leu Arg Gln Ile Gln
                      500 505 510
          Val Ser Arg Arg Arg Ser Leu Gly Val Arg Arg Pro Leu Gln Glu His
                  515 520 525
          Val Arg Phe Met Asp Phe Asp Trp Phe Pro Ala Phe Ile Thr Gly Ala
              530 535 540
          Thr Ser Gly Ala Ile Ala Ala Gly Ala Thr Ala Arg Ala Thr Thr Ala
          545 550 555 560
          Ser Arg Leu Pro Ser Ser Ala Val Thr Pro Arg Ala Pro His Pro Ser
                          565 570 575
          His Thr Ser Gln Pro Val Ala Lys Thr Thr Ala Ala Pro Thr Thr Arg
                      580 585 590
          Arg Pro Pro Thr Thr Ala Pro Ser Arg Val Pro Gly Arg Arg Pro Pro
                  595 600 605
          Ala Pro Gln Gln Pro Pro Lys Pro Cys Asp Ser Gln Pro Cys Phe His
              610 615 620
          Gly Gly Thr Cys Gln Asp Trp Ala Leu Gly Gly Gly Phe Thr Cys Ser
          625 630 635 640
          Cys Pro Ala Gly Arg Gly Gly Ala Val Cys Glu Lys Val Leu Gly Ala
                          645 650 655
          Pro Val Pro Ala Phe Glu Gly Arg Ser Phe Leu Ala Phe Pro Thr Leu
                      660 665 670
          Arg Ala Tyr His Thr Leu Arg Leu Ala Leu Glu Phe Arg Ala Leu Glu
                  675 680 685
          Pro Gln Gly Leu Leu Leu Tyr Asn Gly Asn Ala Arg Gly Lys Asp Phe
              690 695 700
          Leu Ala Leu Ala Leu Leu Asp Gly Arg Val Gln Leu Arg Phe Asp Thr
          705 710 715 720
          Gly Ser Gly Pro Ala Val Leu Thr Ser Ala Val Pro Val Glu Pro Gly
                          725 730 735
          Gln Trp His Arg Leu Glu Leu Ser Arg His Trp Arg Arg Gly Thr Leu
                      740 745 750
          Ser Val Asp Gly Glu Thr Pro Val Leu Gly Glu Ser Pro Ser Gly Thr
                  755 760 765
          Asp Gly Leu Asn Leu Asp Thr Asp Leu Phe Val Gly Gly Val Pro Glu
              770 775 780
          Asp Gln Ala Ala Val Ala Leu Glu Arg Thr Phe Val Gly Ala Gly Leu
          785 790 795 800
          Arg Gly Cys Ile Arg Leu Leu Asp Val Asn Asn Gln Arg Leu Glu Leu
                          805 810 815
          Gly Ile Gly Pro Gly Ala Ala Thr Arg Gly Ser Gly Val Gly Glu Cys
                      820 825 830
          Gly Asp His Pro Cys Leu Pro Asn Pro Cys His Gly Gly Ala Pro Cys
                  835 840 845
          Gln Asn Leu Glu Ala Gly Arg Phe His Cys Gln Cys Pro Pro Gly Arg
              850 855 860
          Val Gly Pro Thr Cys Ala Asp Glu Lys Ser Pro Cys Gln Pro Asn Pro
          865 870 875 880
          Cys His Gly Ala Ala Pro Cys Arg Val Leu Pro Glu Gly Gly Ala Gln
                          885 890 895
          Cys Glu Cys Pro Leu Gly Arg Glu Gly Thr Phe Cys Gln Thr Ala Ser
                      900 905 910
          Gly Gln Asp Gly Ser Gly Pro Phe Leu Ala Asp Phe Asn Gly Phe Ser
                  915 920 925
          His Leu Glu Leu Arg Gly Leu His Thr Phe Ala Arg Asp Leu Gly Glu
              930 935 940
          Lys Met Ala Leu Glu Val Val Phe Leu Ala Arg Gly Pro Ser Gly Leu
          945 950 955 960
          Leu Leu Tyr Asn Gly Gln Lys Thr Asp Gly Lys Gly Asp Phe Val Ser
                          965 970 975
          Leu Ala Leu Arg Asp Arg Arg Leu Glu Phe Arg Tyr Asp Leu Gly Lys
                      980 985 990
          Gly Ala Ala Val Ile Arg Ser Arg Glu Pro Val Thr Leu Gly Ala Trp
                  995 1000 1005
          Thr Arg Val Ser Leu Glu Arg Asn Gly Arg Lys Gly Ala Leu Arg
              1010 1015 1020
          Val Gly Asp Gly Pro Arg Val Leu Gly Glu Ser Pro Lys Ser Arg
              1025 1030 1035
          Lys Val Pro His Thr Val Leu Asn Leu Lys Glu Pro Leu Tyr Val
              1040 1045 1050
          Gly Gly Ala Pro Asp Phe Ser Lys Leu Ala Arg Ala Ala Ala Val
              1055 1060 1065
          Ser Ser Gly Phe Asp Gly Ala Ile Gln Leu Val Ser Leu Gly Gly
              1070 1075 1080
          Arg Gln Leu Leu Thr Pro Glu His Val Leu Arg Gln Val Asp Val
              1085 1090 1095
          Thr Ser Phe Ala Gly His Pro Cys Thr Arg Ala Ser Gly His Pro
              1100 1105 1110
          Cys Leu Asn Gly Ala Ser Cys Val Pro Arg Glu Ala Ala Tyr Val
              1115 1120 1125
          Cys Leu Cys Pro Gly Gly Phe Ser Gly Pro His Cys Glu Lys Gly
              1130 1135 1140
          Leu Val Glu Lys Ser Ala Gly Asp Val Asp Thr Leu Ala Phe Asp
              1145 1150 1155
          Gly Arg Thr Phe Val Glu Tyr Leu Asn Ala Val Thr Glu Ser Glu
              1160 1165 1170
          Leu Ala Asn Glu Ile Pro Val Pro Glu Thr Leu Asp Ser Gly Ala
              1175 1180 1185
          Leu His Ser Glu Lys Ala Leu Gln Ser Asn His Phe Glu Leu Ser
              1190 1195 1200
          Leu Arg Thr Glu Ala Thr Gln Gly Leu Val Leu Trp Ser Gly Lys
              1205 1210 1215
          Ala Thr Glu Arg Ala Asp Tyr Val Ala Leu Ala Ile Val Asp Gly
              1220 1225 1230
          His Leu Gln Leu Ser Tyr Asn Leu Gly Ser Gln Pro Val Val Leu
              1235 1240 1245
          Arg Ser Thr Val Pro Val Asn Thr Asn Arg Trp Leu Arg Val Val
              1250 1255 1260
          Ala His Arg Glu Gln Arg Glu Gly Ser Leu Gln Val Gly Asn Glu
              1265 1270 1275
          Ala Pro Val Thr Gly Ser Ser Pro Leu Gly Ala Thr Gln Leu Asp
              1280 1285 1290
          Thr Asp Gly Ala Leu Trp Leu Gly Gly Leu Pro Glu Leu Pro Val
              1295 1300 1305
          Gly Pro Ala Leu Pro Lys Ala Tyr Gly Thr Gly Phe Val Gly Cys
              1310 1315 1320
          Leu Arg Asp Val Val Val Gly Arg His Pro Leu His Leu Leu Glu
              1325 1330 1335
          Asp Ala Val Thr Lys Pro Glu Leu Arg Pro Cys Pro Thr Pro
              1340 1345 1350
           <![CDATA[ <210> 432]]>
           <![CDATA[ <211> 2068]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 432]]> Met Ala Gly Arg Ser His Pro Gly Pro Leu Arg Pro Leu Leu Pro Leu 1 5 10 15 Leu Val Val Ala Ala Cys Val Leu Pro Gly Ala Gly Gly Thr Cys Pro 20 25 30 Glu Arg Ala Leu Glu Arg Arg Glu Glu Glu Ala Asn Val Leu Thr 35 40 45 Gly Thr Val Glu Glu Ile Leu Asn Val Asp Pro Val Gln His Thr Tyr 50 55 60 Ser Cys Lys Val Arg Val Trp Arg Tyr Leu Lys Gly Lys Asp Leu Val 65 70 75 80 Ala Arg Glu Ser Leu Leu Asp Gly Gly Asn Lys Val Val Ile Ser Gly 85 90 95 Phe Gly Asp Pro Leu Ile Cys Asp Asn Gln Val Ser Thr Gly Asp Thr 100 105 110 Arg Ile Phe Phe Val Asn Pro Ala Pro Pro Tyr Leu Trp Pro Ala His 115 120 125 Lys Asn Glu Leu Met Leu Asn Ser Ser Leu Met Arg Ile Thr Leu Arg 130 135 140 Asn Leu Glu Glu Val Glu Phe Cys Val Glu Asp Lys Pro Gly Thr His 145 150 155 160 Phe Thr Pro Val Pro Pro Thr Pro Pro Asp Ala Cys Arg Gly Met Leu 165 170 175 Cys Gly Phe Gly Ala Val Cys Glu Pro Asn Ala Glu Gly Pro Gly Arg 180 185 190 Ala Ser Cys Val Cys Lys Lys Lys Ser Pro Cys Pro Ser Val Val Ala Pro 195 200 205 Val Cys Gly Ser Asp Ala Ser Thr Tyr Ser Asn Glu Cys Glu Leu Gln 210 215 220 Arg Ala Gln Cys Ser Gln Gln Arg Arg Ile Arg Leu Leu Ser Arg Gly 225 230 235 240 Pro Cys Gly Ser Arg Asp Pro Cys Ser Asn Val Thr Cys Ser Phe Gly 245 250 255 Ser Thr Cys Ala Arg Ser Ala Asp Gly Leu Thr Ala Ser Cys Leu Cys 260 265 270 Pro Ala Thr Cys Arg Gly Ala Pro Glu Gly Thr Val Cys Gly Ser Asp 275 280 285 Gly Ala Asp Tyr Pro Gly Glu Cys Gln Leu Leu Arg Arg Ala Cys Ala 290 295 300 Arg Gln Glu Asn Val Phe Lys Lys Phe Asp Gly Pro Cys Asp Pro Cys 305 310 315 320 Gln Gly Ala Leu Pro Asp Pro Ser Arg Ser Cys Arg Val Asn Pro Arg 325 330 335 Thr Arg Arg Pro Glu Met Leu Leu Arg Pro Glu Ser Cys Pro Ala Arg 340 345 350 Gln Ala Pro Val Cys Gly Asp Asp Gly Val Thr Tyr Glu Asn Asp Cys 355 360 365 Val Met Gly Arg Ser Gly Ala Ala Arg Gly Leu Leu Leu Gln Lys Val 370 375 380 Arg Ser Gly Gln Cys Gln Gly Arg Asp Gln Cys Pro Glu Pro Cys Arg 385 390 395 400 Phe Asn Ala Val Cys Leu Ser Arg Arg Gly Arg Pro Arg Cys Ser Cys 405 410 415 Asp Arg Val Thr Cys Asp Gly Ala Tyr Arg Pro Val Cys Ala Gln Asp 420 425 430 Gly Arg Thr Tyr Asp Ser Asp Cys Trp Arg Gln Gln Ala Glu Cys Arg 435 440 445 Gln Gln Arg A la ile Pro Ser Lys His Gln Gly Pro Cys Asp Gln Ala 450 455 460 Pro Ser Pro Cys Leu Gly Val Gln Cys Ala Phe Gly Ala Thr Cys Ala 465 470 475 480 Val Lys Asn Gly Gln Ala Ala Cys Glu Cys Leu Gln Ala Cys Ser Ser 485 490 495 Leu Tyr Asp Pro Val Cys Gly Ser Asp Gly Val Thr Tyr Gly Ser Ala 500 505 510 Cys Glu Leu Glu Ala Thr Ala Cys Thr Leu Gly Arg Glu Ile Gln Val 515 520 525 Ala Arg Lys Gly Pro Cys Asp Arg Cys Gly Gln Cys Arg Phe Gly Ala 530 535 540 Leu Cys Glu Ala Glu Thr Gly Arg Cys Val Cys Pro Ser Glu Cys Val 545 550 555 560 Ala Leu Ala Gln Pro Val Cys Gly Ser Asp Gly His Thr Tyr Pro Ser 565 570 575 Glu Cys Met Leu His Val His Ala Cys Thr His Gln Ile Ser Leu His 580 585 590 Val Ala Ser Ala Gly Pro Cys Glu Thr Cys Gly Asp Ala Val Cys Ala 595 600 605 Phe Gly Ala Val Cys Ser Ala Gly Gln Cys Val Cys Pro Arg Cys Glu 610 615 620 His Pro Pro Pro Gly Pro Val Cys Gly Ser Asp Gly Val Thr Tyr Gly 625 630 635 640 Ser Ala Cys Glu Leu Arg Glu Ala Ala Cys Leu Gln Gln Thr Gln Ile 645 650 655 Glu Glu Ala Arg Ala Gly Pro Cys Glu Gln Ala Glu Cys Gly Ser Gly 660 665 670 Gly Ser Gly Ser Gly Glu Asp Gly Asp Cys Glu Gln Glu Leu Cys Arg 675 680 685 Gln Arg Gly Gly Ile Trp Asp Glu Asp Ser Glu Asp Gly Pro Cys Val 690 695 700 Cys Asp Phe Ser Cys Gln Ser Val Pro Gly Ser Pro Val Cys Gly Ser 705 710 715 720 Asp Gly Val Thr Tyr Ser Thr Glu Cys Glu Leu Lys Lys Ala Arg Cys 725 730 735 Glu Ser Gln Arg Gly Leu Tyr Val Ala Ala Gln Gly Ala Cys Arg Gly 740 745 750 Pro Thr Phe Ala Pro Leu Pro Pro Val Ala Pro Leu His Cys Ala Gln 755 760 765 Thr Pro Tyr Gly Cys Cys Gln Asp Asn Ile Thr Ala Ala Arg Gly Val 770 775 780 Gly Leu Ala Gly Cys Pro Ser Ala Cys Gln Cys Asn Pro His Gly Ser 785 790 795 800 Tyr Gly Gly Thr Cys Asp Pro Ala Thr Gly Gln Cys Ser Cys Arg Pro 805 810 815 Gly Val Gly Gly Leu Arg Cys Asp Arg Cys Glu Pro Gly Phe Trp Asn 820 825 830 Phe Arg Gly Ile Val Thr Asp Gly Arg Ser Gly Cys Thr Pro Cys Ser 835 840 845 Cys Asp Pro Gln Gly Ala Val Arg Asp Asp Cys Glu Gln Met Thr Gly 850 855 860 Leu Cys Ser Cys Lys Pro Gly Val Ala Gly Pro Lys Cys Gly Gln Cys 865 870 875 880 Pro Asp Gly Arg Ala Leu Gly Pro Ala Gly Cys Glu Ala Asp Ala Ser 885 890 895 Ala Pro Ala Thr Cys Ala Glu Met Arg Cys Glu Phe Gly Ala Arg Cys 900 905 910 Val Glu Glu Ser Gly Ser Ala His Cys Val Cys Pro Met Leu Thr Cys 915 920 925 Pro Glu Ala Asn Ala Thr Lys Val Cys Gly Ser Asp Gly Val Thr Tyr 930 935 940 Gly Asn Glu Cys Gln Leu Lys Thr Ile Ala Cys Arg Gln Gly Leu Gln 945 950 955 960 Ile Ser Ile Gln Ser Leu Gly Pro Cys Gln Glu Ala Val Ala Pro Ser 965 970 975 Thr His Pro Thr Ser Ala Ser Val Thr Val Thr Pro Gly Leu Leu 980 985 990 Leu Ser Gln Ala Leu Pro Ala Pro Pro Gly Ala Leu Pro Leu Ala Pro 995 1000 1005 Ser Ser Thr Ala His Ser Gln Thr Thr Pro Pro Pro Ser Ser Arg 1010 1015 1020 Pro Arg Thr Thr Ala Ser Val Pro Arg Thr Thr Val Trp Pro Val 1025 1030 1035 Leu Thr Val Pro Pro Thr Ala Pro Ser Pro Ala Pro Ser Leu Val 1040 1045 1050 Ala Ser Ala Phe Gly Glu Ser Gly Ser Thr Asp Gly Ser Ser Asp 1055 1060 1065 Glu Glu Leu Ser Gly Asp Gln Glu Ala Ser G ly Gly Gly Ser Gly 1070 1075 1080 Gly Leu Glu Pro Leu Glu Gly Ser Ser Val Ala Thr Pro Gly Pro 1085 1090 1095 Pro Val Glu Arg Ala Ser Cys Tyr Asn Ser Ala Leu Gly Cys Cys 1100 1105 1110 Ser Asp Gly Lys Thr Pro Ser Leu Asp Ala Glu Gly Ser Asn Cys 1115 1120 1125 Pro Ala Thr Lys Val Phe Gln Gly Val Leu Glu Leu Glu Gly Val 1130 1135 1140 Glu Gly Gln Glu Leu Phe Tyr Thr Pro Glu Met Ala Asp Pro Lys 1145 1150 1155 Ser Glu Leu Phe Gly Glu Thr Ala Arg Ser Ile Glu Ser Leu 1160 1165 1170 Asp Asp Leu Phe Arg Asn Ser Asp Val Lys Lys Asp Phe Arg Ser 1175 1180 1185 Val Arg Leu Arg Asp Leu Gly Pro Gly Lys Ser Val Arg Ala Ile 1190 11 95 1200 Val Asp Val His Phe Asp Pro Thr Thr Ala Phe Arg Ala Pro Asp 1205 1210 1215 Val Ala Arg Ala Leu Leu Arg Gln Ile Gln Val Ser Arg Arg Arg 1220 1225 1230 Ser Leu Gly Val Arg Arg Pro Leu Gln Glu His Val Arg Phe Met 1235 1240 1245 Asp Phe Asp Trp Phe Pro Ala Phe Ile Thr Gly Ala Thr Ser Gly 1250 1255 1260 Ala Ile Ala Ala Gly Ala Thr Ala Arg Ala Thr Ala Ser Arg 1265 1270 1275 Leu Pro Ser Ser Ala Val Thr Pro Arg Ala Pro His Pro Ser His 1280 1285 1290 Thr Ser Gln Pro Val Ala Lys Thr Thr Ala Ala Pro Thr Thr Arg 1295 1300 1305 Arg Pro Pro Thr Thr Ala Pro Ser Arg Val Pro Gly Arg Arg Pro 1310 1315 1320 Pro Ala Pro Gln Gln Pro Pro Lys Pro Cys Asp Ser Gln Pro Cys 1325 1330 1335 Phe His Gly Gly Thr Cys Gln Asp Trp Ala Leu Gly Gly Gly Phe 1340 1345 1350 Thr Cys Ser Cys Pro Ala Gly Arg Gly Gly Ala Val Cys Glu Lys 1355 1360 136 5 Val Leu Gly Ala Pro Val Pro Ala Phe Glu Gly Arg Ser Phe Leu 1370 1375 1380 Ala Phe Pro Thr Leu Arg Ala Tyr His Thr Leu Arg Leu Ala Leu 1385 1390 1395 Glu Phe Arg Ala Leu Glu Pro Gln Gly Leu Leu Leu Tyr Asn Gly 1400 1405 1410 Asn Ala Arg Gly Lys Asp Phe Leu Ala Leu Ala Leu Leu Asp Gly 1415 1420 1425 Arg Val Gln Leu Arg Phe Asp Thr Gly Ser Gly Pro Ala Val Leu 1430 1435 1440 Thr Ser Ala Val Pro Val Glu Pro Gly Gln Trp His Arg Leu Glu 1445 1450 1455 Leu Ser Arg His Trp Arg Arg Gly Thr Leu Ser Val Asp Gly Glu 1460 1465 1470 Thr Pro Val Leu Gly Glu Ser Pro Ser Pro Ser Gly Thr Asp Gly Leu Asn 1475 1480 1485 Leu Asp Thr Asp Le u Phe Val Gly Gly Val Pro Glu Asp Gln Ala 1490 1495 1500 Ala Val Ala Leu Glu Arg Thr Phe Val Gly Ala Gly Leu Arg Gly 1505 1510 1515 Cys Ile Arg Leu Leu Asp Val Asn Asn Gln Arg Leu Glu Leu Gly 1520 1525 15 30 Ile Gly Pro Gly Ala Ala THR ALG GLY VAL VAL GLY GLU CYS 1535 1540 Gly Asp His Pro Cys Leu Pro ASN PRS HIS GLY GLY ALA PRO 155555 1560 CYS GLU GLU GLY ARG P HE HIS CYS GLN CYS Pro Pro 1565 1570 1575 Gly Arg Val Gly Pro Thr Cys Ala Asp Glu Lys Ser Pro Cys Gln 1580 1585 1590 Pro Asn Pro Cys His Gly Ala Ala Pro Cys Arg Val Leu Pro Glu 1595 1600 1605 Gly Gly Ala Gln Cys Glu Cys Pro Leu Gly Arg Glu Gly Thr Phe 1610 1615 1620 Cys Gln Thr Ala Ser Gly Gln Asp Gly Ser Gly Pro Phe Leu Ala 1625 1630 1635 Asp Phe Asn Gly Phe Ser His Leu Glu Leu Arg Gly Leu His Thr 1640 1645 1650 Phe Ala Arg Asp Leu G ly Glu Lys Met Ala Leu Glu Val Val Phe 1655 1660 1665 Leu Ala Arg Gly Pro Ser Gly Leu Leu Leu Tyr Asn Gly Gln Lys 1670 1675 1680 Thr Asp Gly Lys Gly Asp Phe Val Ser Leu Ala Leu Arg Asp Arg 1685 1690 1695 Arg Le u Glu Phe Arg Tyr Asp Leu Gly Lys Gly Ala Ala Val Ile 1700 1705 1710 Arg Ser Arg Glu Pro Val Thr Leu Gly Ala Trp Thr Arg Val Ser 1715 1720 1725 Leu Glu Arg Asn Gly Arg Lys Gly Ala Leu Arg Val Gly Asp Gly 1730 1735 1740Pro Arg Val Leu Gly Glu Ser Pro Lys Ser Arg Lys Val Pro His 1745 1750 1755 Thr Val Leu Asn Leu Lys Glu Pro Leu Tyr Val Gly Gly Ala Pro 1760 1765 1770 Asp Phe Ser Lys Leu Ala Arg Ala Ala Ala Val Ser Ser Gly Phe 1775 1780 1785 Asp Gly Ala Ile Gln Leu Val Ser Leu Gly Gly Arg Gln Leu Leu 1790 1795 1800 Thr Pro Glu His Val Leu Arg Gln Val Asp Val Thr Ser Phe Ala 1805 1810 1815 Gly His Pro Cys Thr Arg Ala Ser Gly His Pro Cys Leu Asn Gly 1820 1825 1830 Ala Ser Cys Val Pro Arg Glu Ala Ala Tyr Val Cys Leu Cys Pro 1835 1840 1845 Gly Gly Phe Ser Gly Pro His Cys Glu Lys Gly Leu Val Glu Lys 1850 1855 1860 Ser Ala Gly Asp Val Asp Thr Leu Ala Phe Asp Gly Arg Thr Phe 1865 1870 1875 Val Glu Tyr Leu Asn Ala Val Thr Glu Ser Glu Leu Ala Asn Glu 1880 1885 1890 Ile Pro Val Pro Glu Thr Leu Asp Ser Gly Ala Leu His Ser Glu 1895 1900 1905 Lys Ala Leu Gln Ser Asn His Phe Glu Leu Ser Leu Arg Thr Glu 1910 1915 1920 Ala Thr Gln Gly Leu Val Leu Trp Ser Gly Lys Ala Thr Glu Arg 1925 1930 1935 Ala Asp Tyr Val Ala Leu Ala Ile Val Asp Gly His Leu Gln Leu 1 940 1945 1950 Ser Tyr Asn Leu Gly Ser Gln Pro Val Val Leu Arg Ser Thr Val 1955 1960 1965 Pro Val Asn Thr Asn Arg Trp Leu Arg Val Val Ala His Arg Glu 1970 1975 1980 Gln Arg Glu Gly Ser Leu Gln Val Gly Asn Glu Ala Pro Val Thr 1985 1990 1995 Gly Ser Pro Leu Gly Ala Thr Gln Leu Asp Thr Asp Gly Ala 2000 2005 2010 Leu Trp Leu Gly Gly Leu Pro Glu Leu Pro Val Gly Pro Ala Leu 2015 2020 2025 Pro Lys Ala Tyr Gly Thr Gly P he Val Gly Cys Leu Arg Asp Val 2030 2035 2040 Val Val Gly Arg His Pro Leu His Leu Leu Glu Asp Ala Val Thr 2045 2050 2055 Lys Pro Glu Leu Arg Pro Cys Pro Thr Pro 2060 2065 <![CDATA[ <210> 433]]>
           <![CDATA[ <211> 2307]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 433]]>
          agtcccgtcc ccggcgcggc ccgcgcgctc ctccgccgcc tctcgcctgc gccatggccg 60
          gccggtccca cccgggcccg ctgcggccgc tgctgccgct ccttgtggtg gccgcgtgcg 120
          tcctgcccgg agccggcggg acatgcccgg agcgcgcgct ggagcggcgc gaggaggagg 180
          cgaacgtggt gctcaccggg acggtggagg agatcctcaa cgtggacccg gtgcagcaca 240
          cgtactcctg caaggttcgg gtctggcggt acttgaaggg caaagacctg gtggcccggg 300
          agagcctgct ggacggcggc aacaaggtgg tgatcagcgg ctttggagac cccctcatct 360
          gtgacaacca ggtgtccact ggggaccacca ggatcttctt tgtgaaccct gcacccccat 420
          acctgtggcc agcccacaag aacgagctga tgctcaactc cagcctcatg cggatcaccc 480
          tgcggaacct gaggaggtg gagttctgtg tggaagataa acccgggacc cacttcactc 540
          cagtgcctcc gacgcctcct gatgcgtgcc ggggaatgct gtgcggcttc ggcgccgtgt 600
          gcgagcccaa cgcggagggg ccgggccggg cgtcctgcgt ctgcaagaag agcccgtgcc 660
          ccagcgtggt ggcgcctgtg tgtgggtcgg acgcctccac ctacagcaac gaatgcgagc 720
          tgcagcgggc gcagtgcagc cagcagcgcc gcatccgcct gctcagccgc gggccgtgcg 780
          gctcgcggga cccctgctcc aacgtgacct gcagcttcgg cagcacctgt gcgcgctcgg 840
          ccgacgggct gacggcctcg tgcctgtgcc ccgcgacctg ccgtggcgcc cccgaggggga 900
          ccgtctgcgg cagcgacggc gccgactacc ccggcgagtg ccagctcctg cgccgcgcct 960
          gcgcccgcca ggagaatgtc ttcaagaagt tcgacggccc ttgtgacccc tgtcagggcg 1020
          ccctccctga cccgagccgc agctgccgtg tgaacccgcg cacgcggcgc cctgagatgc 1080
          tcctacggcc cgagagctgc cctgcccggc aggcgccagt gtgtggggac gacggagtca 1140
          cctacgaaaa cgactgtgtc atgggccgat cgggggccgc ccggggtctc ctcctgcaga 1200
          aagtgcgctc cggccagtgc cagggtcgag accagtgccc ggagccctgc cggttcaatg 1260
          ccgtgtgcct gtcccgccgt ggccgtcccc gctgctcctg cgaccgcgtc acctgtgacg 1320
          gggcctacag gcccgtgtgt gcccaggacg ggcgcacgta tgacagtgat tgctggcggc 1380
          agcaggctga gtgccggcag cagcgtgcca tccccagcaa gcaccagggc ccgtgtgacc 1440
          aggccccgtc cccatgcctc ggggtgcagt gtgcattgg ggcgacgtgt gctgtgaaga 1500
          acgggcaggc agcgtgtgaa tgcctgcagg cgtgctcgag cctctacgat cctgtgtgcg 1560
          gcagcgacgg cgtcacatac ggcagcgcgt gcgagctgga ggccacggcc tgtaccctcg 1620
          ggcggggagat ccaggtggcg cgcaaaggac cctgtgaccg ctgcggggcag tgccgctttg 1680
          gagccctgtg cgaggccgag accgggcgct gcgtgtgccc ctctgaatgc gtggctttgg 1740
          cccagcccgt gtgtggctcc gacgggcaca cgtaccccag cgagtgcatg ctgcacgtgc 1800
          acgcctgcac acaccagatc agcctgcacg tggcctcagc tggaccctgt gagacctgtg 1860
          gagatgccgt gtgtgctttt ggggctgtgt gctccgcagg gcagtgtgtg tgtccccggt 1920
          gtgagcaccc cccgcccggc cccgtgtgtg gcagcgacgg tgtcacctac ggcagtgcct 1980
          gcgagctacg ggaagccgcc tgcctccagc agacacagat cgaggaggcc cgggcagggc 2040
          cgtgcgagca ggccgagtgc ggttccggag gctctggctc tggggaggac ggtgactgtg 2100
          agcaggagct gtgccggcag cgcggtggca tctgggacga ggactcggag gacgggccgt 2160
          gtgtctgtga cttcagctgc cagagtgtcc caggcagccc ggtgtgcggc tcagatgggg 2220
          tcacctacag caccgagtgt gagctgaaga aggccaggtg tgagtcacag cgagggctct 2280
          acgtagcggc ccagggagcc tgccgag 2307
           <![CDATA[ <210> 434]]>
           <![CDATA[ <211> 751]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 434]]>
          Met Ala Gly Arg Ser His Pro Gly Pro Leu Arg Pro Leu Leu Pro Leu
          1 5 10 15
          Leu Val Val Ala Ala Cys Val Leu Pro Gly Ala Gly Gly Thr Cys Pro
                      20 25 30
          Glu Arg Ala Leu Glu Arg Arg Glu Glu Glu Glu Ala Asn Val Val Leu Thr
                  35 40 45
          Gly Thr Val Glu Glu Ile Leu Asn Val Asp Pro Val Gln His Thr Tyr
              50 55 60
          Ser Cys Lys Val Arg Val Trp Arg Tyr Leu Lys Gly Lys Asp Leu Val
          65 70 75 80
          Ala Arg Glu Ser Leu Leu Asp Gly Gly Asn Lys Val Val Ile Ser Gly
                          85 90 95
          Phe Gly Asp Pro Leu Ile Cys Asp Asn Gln Val Ser Thr Gly Asp Thr
                      100 105 110
          Arg Ile Phe Phe Val Asn Pro Ala Pro Pro Tyr Leu Trp Pro Ala His
                  115 120 125
          Lys Asn Glu Leu Met Leu Asn Ser Ser Leu Met Arg Ile Thr Leu Arg
              130 135 140
          Asn Leu Glu Glu Val Glu Phe Cys Val Glu Asp Lys Pro Gly Thr His
          145 150 155 160
          Phe Thr Pro Val Pro Pro Thr Pro Pro Asp Ala Cys Arg Gly Met Leu
                          165 170 175
          Cys Gly Phe Gly Ala Val Cys Glu Pro Asn Ala Glu Gly Pro Gly Arg
                      180 185 190
          Ala Ser Cys Val Cys Lys Lys Ser Pro Cys Pro Ser Val Val Ala Pro
                  195 200 205
          Val Cys Gly Ser Asp Ala Ser Thr Tyr Ser Asn Glu Cys Glu Leu Gln
              210 215 220
          Arg Ala Gln Cys Ser Gln Gln Arg Arg Ile Arg Leu Leu Ser Arg Gly
          225 230 235 240
          Pro Cys Gly Ser Arg Asp Pro Cys Ser Asn Val Thr Cys Ser Phe Gly
                          245 250 255
          Ser Thr Cys Ala Arg Ser Ala Asp Gly Leu Thr Ala Ser Cys Leu Cys
                      260 265 270
          Pro Ala Thr Cys Arg Gly Ala Pro Glu Gly Thr Val Cys Gly Ser Asp
                  275 280 285
          Gly Ala Asp Tyr Pro Gly Glu Cys Gln Leu Leu Arg Arg Ala Cys Ala
              290 295 300
          Arg Gln Glu Asn Val Phe Lys Lys Phe Asp Gly Pro Cys Asp Pro Cys
          305 310 315 320
          Gln Gly Ala Leu Pro Asp Pro Ser Arg Ser Cys Arg Val Asn Pro Arg
                          325 330 335
          Thr Arg Arg Pro Glu Met Leu Leu Arg Pro Glu Ser Cys Pro Ala Arg
                      340 345 350
          Gln Ala Pro Val Cys Gly Asp Asp Gly Val Thr Tyr Glu Asn Asp Cys
                  355 360 365
          Val Met Gly Arg Ser Gly Ala Ala Arg Gly Leu Leu Leu Gln Lys Val
              370 375 380
          Arg Ser Gly Gln Cys Gln Gly Arg Asp Gln Cys Pro Glu Pro Cys Arg
          385 390 395 400
          Phe Asn Ala Val Cys Leu Ser Arg Arg Gly Arg Pro Arg Cys Ser Cys
                          405 410 415
          Asp Arg Val Thr Cys Asp Gly Ala Tyr Arg Pro Val Cys Ala Gln Asp
                      420 425 430
          Gly Arg Thr Tyr Asp Ser Asp Cys Trp Arg Gln Gln Ala Glu Cys Arg
                  435 440 445
          Gln Gln Arg Ala Ile Pro Ser Lys His Gln Gly Pro Cys Asp Gln Ala
              450 455 460
          Pro Ser Pro Cys Leu Gly Val Gln Cys Ala Phe Gly Ala Thr Cys Ala
          465 470 475 480
          Val Lys Asn Gly Gln Ala Ala Cys Glu Cys Leu Gln Ala Cys Ser Ser
                          485 490 495
          Leu Tyr Asp Pro Val Cys Gly Ser Asp Gly Val Thr Tyr Gly Ser Ala
                      500 505 510
          Cys Glu Leu Glu Ala Thr Ala Cys Thr Leu Gly Arg Glu Ile Gln Val
                  515 520 525
          Ala Arg Lys Gly Pro Cys Asp Arg Cys Gly Gln Cys Arg Phe Gly Ala
              530 535 540
          Leu Cys Glu Ala Glu Thr Gly Arg Cys Val Cys Pro Ser Glu Cys Val
          545 550 555 560
          Ala Leu Ala Gln Pro Val Cys Gly Ser Asp Gly His Thr Tyr Pro Ser
                          565 570 575
          Glu Cys Met Leu His Val His Ala Cys Thr His Gln Ile Ser Leu His
                      580 585 590
          Val Ala Ser Ala Gly Pro Cys Glu Thr Cys Gly Asp Ala Val Cys Ala
                  595 600 605
          Phe Gly Ala Val Cys Ser Ala Gly Gln Cys Val Cys Pro Arg Cys Glu
              610 615 620
          His Pro Pro Pro Gly Pro Val Cys Gly Ser Asp Gly Val Thr Tyr Gly
          625 630 635 640
          Ser Ala Cys Glu Leu Arg Glu Ala Ala Cys Leu Gln Gln Thr Gln Ile
                          645 650 655
          Glu Glu Ala Arg Ala Gly Pro Cys Glu Gln Ala Glu Cys Gly Ser Gly
                      660 665 670
          Gly Ser Gly Ser Gly Glu Asp Gly Asp Cys Glu Gln Glu Leu Cys Arg
                  675 680 685
          Gln Arg Gly Gly Ile Trp Asp Glu Asp Ser Glu Asp Gly Pro Cys Val
              690 695 700
          Cys Asp Phe Ser Cys Gln Ser Val Pro Gly Ser Pro Val Cys Gly Ser
          705 710 715 720
          Asp Gly Val Thr Tyr Ser Thr Glu Cys Glu Leu Lys Lys Ala Arg Cys
                          725 730 735
          Glu Ser Gln Arg Gly Leu Tyr Val Ala Ala Gln Gly Ala Cys Arg
                      740 745 750
           <![CDATA[ <210> 435]]>
           <![CDATA[ <211> 102]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 435]]>
          taaaaggctt ctccccagat gccagagacc tgtctgctaa agaaaccaag atgctgatgg 60
          ctgctggaga caaagatggg gacggcaaaa ttggggttga cg 102
           <![CDATA[ <210> 436]]>
           <![CDATA[ <211> 125]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 436]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgt gaatggaggg gagtgcttca tggtgaaaga cctttcaaac ccctcgagat 120
          acttg 125
           <![CDATA[ <210> 437]]>
           <![CDATA[ <211> 227]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 437]]>
          taaaaggctt ctccccagat gccagagacc tgtctgctaa agaaaccaag atgctgatgg 60
          ctgctggaga caaagatggg gacggcaaaa ttggggttga cgctacatct acatccacca 120
          ctgggacaag ccatcttgta aaatgtgcgg agaaggagaa aactttctgt gtgaatggag 180
          gggagtgctt catggtgaaa gacctttcaa accccctcgag atacttg 227
           <![CDATA[ <210> 438]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 438]]>
          Lys Gly Phe Ser Pro Asp Ala Arg Asp Leu Ser Ala Lys Glu Thr Lys
          1 5 10 15
          Met Leu Met Ala Ala Gly Asp Lys Asp Gly Asp Gly Lys Ile Gly Val
                      20 25 30
          Asp Ala Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys
                  35 40 45
          Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe Met
              50 55 60
          Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu
          65 70 75
           <![CDATA[ <210> 439]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 439]]>
          acttcccgac aggacttccc accagcccag cctttcagtg caggctccag ccctccaccc 60
          ccacccgag 69
           <![CDATA[ <210> 440]]>
           <![CDATA[ <211> 68]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 440]]>
          ttgcaggatg tcgatgacag acttgctgaa cgctgaggac atcaagaagg cggtgggagc 60
          ctttagcg68
           <![CDATA[ <210> 441]]>
           <![CDATA[ <211> 133]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 441]]>
          ctaccgactc cttcgaccac aaaaagttct tccaaatggt cggcctgaag aaaaagagtg 60
          cggatgatgt gaagaaggtg tttcacatgc tggacaagga caaaagtggc ttcatcgagg 120
          aggatgagct ggg 133
           <![CDATA[ <210> 442]]>
           <![CDATA[ <211> 110]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 442]]>
          attcatccta aaaggcttct ccccagatgc cagagacctg tctgctaaag aaaccaagat 60
          gctgatggct gctggagaca aagatgggga cggcaaaatt ggggttgacg 110
           <![CDATA[ <210> 443]]>
           <![CDATA[ <211> 216]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 443]]>
          aattctccac tctggtggct gaaagctaag aagcactgac tgcccctggt cttccacctc 60
          tctgccctga acacccaatc tcggcccctc tcgccaccct cctgcatttc tgttcagttc 120
          gtttatgtta ttttttactc ccccatcccc tgtggccctc taatgacacc attcttctgg 180
          aaaatgctgg agaagcaata aaggttgtac cagtca 216
           <![CDATA[ <210> 444]]>
           <![CDATA[ <211> 596]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> The complete mRNA polynucleotide sequence of PVALB]]>
           <![CDATA[ <400> 444]]>
          acttcccgac aggacttccc accagcccag cctttcagtg caggctccag ccctccaccc 60
          ccaccccgagt tgcaggatgt cgatgacaga cttgctgaac gctgaggaca tcaagaaggc 120
          ggtgggagcc tttagcgcta ccgactcctt cgaccacaaa aagttcttcc aaatggtcgg 180
          cctgaagaaa aagagtgcgg atgatgtgaa gaaggtgttt cacatgctgg acaaggacaa 240
          aagtggcttc atcgaggagg atgagctggg attcatccta aaaggcttct ccccagatgc 300
          cagagacctg tctgctaaag aaaccaagat gctgatggct gctggagaca aagatgggga 360
          cggcaaaatt ggggttgacg aattctccac tctggtggct gaaagctaag aagcactgac 420
          tgcccctggt cttccacctc tctgccctga acacccaatc tcggcccctc tcgccaccct 480
          cctgcatttc tgttcagttc gtttatgtta ttttttactc ccccatcccc tgtggccctc 540
          taatgacacc attcttctgg aaaatgctgg agaagcaata aaggttgtac cagtca 596
           <![CDATA[ <210> 445]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 445]]>
          Met Ser Met Thr Asp Leu Leu Asn Ala Glu Asp Ile Lys Lys Ala Val
          1 5 10 15
          Gly Ala Phe Ser
                      20
           <![CDATA[ <210> 446]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 446]]>
          Thr Asp Ser Phe Asp His Lys Lys Phe Phe Gln Met Val Gly Leu Lys
          1 5 10 15
          Lys Lys Ser Ala Asp Asp Val Lys Lys Val Phe His Met Leu Asp Lys
                      20 25 30
          Asp Lys Ser Gly Phe Ile Glu Glu Asp Glu Leu
                  35 40
           <![CDATA[ <210> 447]]>
           <![CDATA[ <211> 36]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 447]]>
          Phe Ile Leu Lys Gly Phe Ser Pro Asp Ala Arg Asp Leu Ser Ala Lys
          1 5 10 15
          Glu Thr Lys Met Leu Met Ala Ala Gly Asp Lys Asp Gly Asp Gly Lys
                      20 25 30
          Ile Gly Val Asp
                  35
           <![CDATA[ <210> 448]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 448]]>
          Phe Ser Thr Leu Val Ala Glu Ser
          1 5
           <![CDATA[ <210> 449]]>
           <![CDATA[ <211> 110]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 449]]>
          Met Ser Met Thr Asp Leu Leu Asn Ala Glu Asp Ile Lys Lys Ala Val
          1 5 10 15
          Gly Ala Phe Ser Ala Thr Asp Ser Phe Asp His Lys Lys Phe Phe Gln
                      20 25 30
          Met Val Gly Leu Lys Lys Lys Ser Ala Asp Asp Val Lys Lys Val Phe
                  35 40 45
          His Met Leu Asp Lys Asp Lys Ser Gly Phe Ile Glu Glu Asp Glu Leu
              50 55 60
          Gly Phe Ile Leu Lys Gly Phe Ser Pro Asp Ala Arg Asp Leu Ser Ala
          65 70 75 80
          Lys Glu Thr Lys Met Leu Met Ala Ala Gly Asp Lys Asp Gly Asp Gly
                          85 90 95
          Lys Ile Gly Val Asp Glu Phe Ser Thr Leu Val Ala Glu Ser
                      100 105 110
           <![CDATA[ <210> 450]]>
           <![CDATA[ <211> 380]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 450]]>
          acttcccgac aggacttccc accagcccag cctttcagtg caggctccag ccctccaccc 60
          ccaccccgagt tgcaggatgt cgatgacaga cttgctgaac gctgaggaca tcaagaaggc 120
          ggtgggagcc tttagcgcta ccgactcctt cgaccacaaa aagttcttcc aaatggtcgg 180
          cctgaagaaa aagagtgcgg atgatgtgaa gaaggtgttt cacatgctgg acaaggacaa 240
          aagtggcttc atcgaggagg atgagctggg attcatccta aaaggcttct ccccagatgc 300
          cagagacctg tctgctaaag aaaccaagat gctgatggct gctggagaca aagatgggga 360
          cggcaaaatt ggggttgacg 380
           <![CDATA[ <210> 451]]>
           <![CDATA[ <211> 101]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 451]]>
          Met Ser Met Thr Asp Leu Leu Asn Ala Glu Asp Ile Lys Lys Ala Val
          1 5 10 15
          Gly Ala Phe Ser Ala Thr Asp Ser Phe Asp His Lys Lys Phe Phe Gln
                      20 25 30
          Met Val Gly Leu Lys Lys Lys Ser Ala Asp Asp Val Lys Lys Val Phe
                  35 40 45
          His Met Leu Asp Lys Asp Lys Ser Gly Phe Ile Glu Glu Asp Glu Leu
              50 55 60
          Gly Phe Ile Leu Lys Gly Phe Ser Pro Asp Ala Arg Asp Leu Ser Ala
          65 70 75 80
          Lys Glu Thr Lys Met Leu Met Ala Ala Gly Asp Lys Asp Gly Asp Gly
                          85 90 95
          Lys Ile Gly Val Asp
                      100
           <![CDATA[ <210> 452]]>
           <![CDATA[ <211> 93]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 452]]>
          agttggggtc tcactgtgtt gcccagactg gtctcgaact cttggcctca ggtgatcctc 60
          ttccctcagc ttcccagaat gccgagatga tag 93
           <![CDATA[ <210> 453]]>
           <![CDATA[ <211> 28]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 453]]>
          ctacatctac atccaccact gggacaag 28
           <![CDATA[ <210> 454]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 454]]>
          agttggggtc tcactgtgtt gcccagactg gtctcgaact cttggcctca ggtgatcctc 60
          ttccctcagc ttcccagaat gccgagatga tagctacatc tacatccacc actgggacaa 120
          g 121
           <![CDATA[ <210> 455]]>
           <![CDATA[ <211> 39]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 455]]>
          Leu Gly Ser His Cys Val Ala Gln Thr Gly Leu Glu Leu Leu Ala Ser
          1 5 10 15
          Gly Asp Pro Leu Pro Ser Ala Ser Gln Asn Ala Glu Met Ile Ala Thr
                      20 25 30
          Ser Thr Ser Thr Thr Gly Thr
                  35
           <![CDATA[ <210> 456]]>
           <![CDATA[ <211> 273]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 456]]>
          gcattgcggc ttggttttct cacccagtgc atgtggcagg agcggtgaga tcactgcctc 60
          acggcgatcc tggactgacg gtcacgactg cctaccctct aaccctgttc tgagctgccc 120
          cttgcccaca caccccaaac ctgtgtgcag gatccgcctc catggagcta cagcctcctg 180
          aagcctcgat cgccgtcgtg tcgattccgc gccagttgcc tggctcacat tcggaggctg 240
          gtgtccaggg tctcagcgcg ggggacgact cag 273
           <![CDATA[ <210> 457]]>
           <![CDATA[ <211> 93]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 457]]>
          agttggggtc tcactgtgtt gcccagactg gtctcgaact cttggcctca ggtgatcctc 60
          ttccctcagc ttcccagaat gccgagatga tag 93
           <![CDATA[ <210> 458]]>
           <![CDATA[ <211> 93]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 458]]>
          agacggggtc tgactgtgtt acccaggctg gtcttcaact cttggcctca agtgatcctc 60
          ctgccttagc ttccaagaat gctgaggtta cag 93
           <![CDATA[ <210> 459]]>
           <![CDATA[ <211> 429]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 459]]>
          gcaccatgag ccaggacacc gaggtggata tgaaggaggt ggagctgaat gagttagagc 60
          ccgagaagca gccgatgaac gcggcgtctg gggcggccat gtccctggcg ggagccgaga 120
          agaatggtct ggtgaagatc aaggtggcgg aagacgaggc ggaggcggca gccgcggcta 180
          agttcacggg cctgtccaag gaggagctgc tgaaggtggc aggcagcccc ggctgggtac 240
          gcacccgctg ggcactgctg ctgctcttct ggctcggctg gctcggcatg cttgctggtg 300
          ccgtggtcat aatcgtgcga gcgccgcgtt gtcgcgagct accggcgcag aagtggtggc 360
          acacgggcgc cctctaccgc atcggcgacc ttcaggcctt ccagggccac ggcgcgggca 420
          acctggcgg 429
           <![CDATA[ <210> 460]]>
           <![CDATA[ <211> 174]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 460]]>
          gtctgaaggg gcgtctcgat tacctgagct ctctgaaggt gaagggcctt gtgctgggtc 60
          caattcacaa gaaccagaag gatgatgtcg ctcagactga cttgctgcag atcgacccca 120
          atttggctc caaggaagat tttgacagtc tcttgcaatc ggctaaaaaa aaga 174
           <![CDATA[ <210> 461]]>
           <![CDATA[ <211> 92]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 461]]>
          gcatccgtgt cattctggac cttactccca actaccgggg tgagaactcg tggttctcca 60
          ctcaggttga cactgtggcc accaaggtga ag 92
           <![CDATA[ <210> 462]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 462]]>
          gatgctctgg agttttggct gcaagctggc gtggatgggt tccaggttcg ggacatagag 60
          aatctgaag 69
           <![CDATA[ <210> 463]]>
           <![CDATA[ <211> 59]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 463]]>
          gatgcatcct cattcttggc tgagtggcaa aatatcacca agggcttcag tgaagacag 59
           <![CDATA[ <210> 464]]>
           <![CDATA[ <211> 181]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 464]]>
          gctcttgatt gcggggacta actcctccga ccttcagcag atcctgagcc tactcgaatc 60
          caacaaagac ttgctgttga ctagctcata cctgtctgat tctggttcta ctggggagca 120
          tacaaaatcc ctagtcacac agtatttgaa tgccactggc aatcgctggt gcagctggag 180
          t 181
           <![CDATA[ <210> 465]]>
           <![CDATA[ <211> 144]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 465]]>
          ttgtctcagg caaggctcct gacttccttc ttgccggctc aacttctccg actctaccag 60
          ctgatgctct tcaccctgcc agggacccct gttttcagct acggggatga gattggcctg 120
          gatgcagctg cccttcctgg acag 144
           <![CDATA[ <210> 466]]>
           <![CDATA[ <211> 84]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 466]]>
          cctatggagg ctccagtcat gctgtggggat gagtccagct tccctgacat cccaggggct 60
          gtaagtgcca acatgactgt gaag 84
           <![CDATA[ <210> 467]]>
           <![CDATA[ <211> 530]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 467]]>
          ggccagagtg aagaccctgg ctccctcctt tccttgttcc ggcggctgag tgaccagcgg 60
          agtaaggagc gctccctact gcatggggac ttccacgcgt tctccgctgg gcctggactc 120
          ttctcctata tccgccactg ggaccagaat gagcgttttc tggtagtgct taactttggg 180
          gatgtgggcc tctcggctgg actgcaggcc tccgacctgc ctgccagcgc cagcctgcca 240
          gccaaggctg acctcctgct cagcacccag ccaggccgtg aggagggctc ccctcttgag 300
          ctggaacgcc tgaaactgga gcctcacgaa gggctgctgc tccgcttccc ctacgcggcc 360
          tgacttcagc ctgacatgga cccactaccc ttctcctttc cttcccaggc cctttggctt 420
          ctgatttttc tcttttttaa aaacaaacaa acaaactgtt gcagattatg agtgaacccc 480
          caaatagggt gttttctgcc ttcaaataaa agtcacccct gcatggtgaa 530
           <![CDATA[ <210> 468]]>
           <![CDATA[ <211> 2221]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Full mRNA polynucleotide sequence of SLC3A2]]>
           <![CDATA[ <400> 468]]>
          gcattgcggc ttggttttct cacccagtgc atgtggcagg agcggtgaga tcactgcctc 60
          acggcgatcc tggactgacg gtcacgactg cctaccctct aaccctgttc tgagctgccc 120
          cttgcccaca caccccaaac ctgtgtgcag gatccgcctc catggagcta cagcctcctg 180
          aagcctcgat cgccgtcgtg tcgattccgc gccagttgcc tggctcacat tcggaggctg 240
          gtgtccaggg tctcagcgcg ggggacgact cagagttggg gtctcactgt gttgcccaga 300
          ctggtctcga actcttggcc tcaggtgatc ctcttccctc agcttcccag aatgccgaga 360
          tgatagagac gggtctgac tgtgttaccc aggctggtct tcaactcttg gcctcaagtg 420
          atcctcctgc cttagcttcc aagaatgctg aggttacagg caccatgagc caggacaccg 480
          aggtggatat gaaggaggtg gagctgaatg agttagagcc cgagaagcag ccgatgaacg 540
          cggcgtctgg ggcggccatg tccctggcgg gagccgagaa gaatggtctg gtgaagatca 600
          aggtggcgga agacgaggcg gaggcggcag ccgcggctaa gttcacgggc ctgtccaagg 660
          aggagctgct gaaggtggca ggcagccccg gctgggtacg cacccgctgg gcactgctgc 720
          tgctcttctg gctcggctgg ctcggcatgc ttgctggtgc cgtggtcata atcgtgcgag 780
          cgccgcgttg tcgcgagcta ccggcgcaga agtggtggca cacgggcgcc ctctaccgca 840
          tcggcgacct tcaggccttc cagggccacg gcgcgggcaa cctggcgggt ctgaaggggc 900
          gtctcgatta cctgagctct ctgaaggtga agggccttgt gctgggtcca attcacaaga 960
          accagaagga tgatgtcgct cagactgact tgctgcagat cgaccccaat tttggctcca 1020
          aggaagattt tgacagtctc ttgcaatcgg ctaaaaaaaa gagcatccgt gtcattctgg 1080
          accttactcc caactaccgg ggtgagaact cgtggttctc cactcaggtt gacactgtgg 1140
          ccaccaaggt gaaggatgct ctggagtttt ggctgcaagc tggcgtggat gggttccagg 1200
          ttcgggacat agagaatctg aaggatgcat cctcattctt ggctgagtgg caaaatatca 1260
          ccaagggctt cagtgaagac aggctcttga ttgcggggac taactcctcc gaccttcagc 1320
          agatcctgag cctactcgaa tccaacaaag acttgctgtt gactagctca tacctgtctg 1380
          attctggttc tactggggag catacaaaat ccctagtcac acagtatttg aatgccactg 1440
          gcaatcgctg gtgcagctgg agtttgtctc aggcaaggct cctgacttcc ttcttgccgg 1500
          ctcaacttct ccgactctac cagctgatgc tcttcaccct gccagggacc cctgttttca 1560
          gctacgggga tgagattggc ctggatgcag ctgcccttcc tggacagcct atggaggctc 1620
          cagtcatgct gtgggatgag tccagcttcc ctgacatccc aggggctgta agtgccaaca 1680
          tgactgtgaa gggccagagt gaagaccctg gctccctcct ttccttgttc cggcggctga 1740
          gtgaccagcg gagtaaggag cgctccctac tgcatgggga cttccacgcg ttctccgctg 1800
          ggcctggact cttctcctat atccgccact gggaccagaa tgagcgtttt ctggtagtgc 1860
          ttaactttgg ggatgtgggc ctctcggctg gactgcaggc ctccgacctg cctgccagcg 1920
          ccagcctgcc agccaaggct gacctcctgc tcagcaccca gccaggccgt gaggagggct 1980
          cccctcttga gctggaacgc ctgaaactgg agcctcacga agggctgctg ctccgcttcc 2040
          cctacgcggc ctgacttcag cctgacatgg acccactacc cttctccttt ccttcccagg 2100
          ccctttggct tctgattttt ctctttttta aaaacaaaca aacaaactgt tgcagattat 2160
          gagtgaaccc ccaaataggg tgttttctgc cttcaaataa aagtcacccc tgcatggtga 2220
          a 2221
           <![CDATA[ <210> 469]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 469]]>
          Met Glu Leu Gln Pro Pro Glu Ala Ser Ile Ala Val Val Ser Ile Pro
          1 5 10 15
          Arg Gln Leu Pro Gly Ser His Ser Glu Ala Gly Val Gln Gly Leu Ser
                      20 25 30
          Ala Gly Asp Asp Ser
                  35
           <![CDATA[ <210> 470]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> ]]> PRT
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 470]]>
          Leu Gly Ser His Cys Val Ala Gln Thr Gly Leu Glu Leu Leu Ala Ser
          1 5 10 15
          Gly Asp Pro Leu Pro Ser Ala Ser Gln Asn Ala Glu Met Ile
                      20 25 30
           <![CDATA[ <210> 471]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 471]]>
          Thr Gly Ser Asp Cys Val Thr Gln Ala Gly Leu Gln Leu Leu Ala Ser
          1 5 10 15
          Ser Asp Pro Pro Ala Leu Ala Ser Lys Asn Ala Glu Val Thr
                      20 25 30
           <![CDATA[ <210> 472]]>
           <![CDATA[ <211> 142]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 472]]>
          Thr Met Ser Gln Asp Thr Glu Val Asp Met Lys Glu Val Glu Leu Asn
          1 5 10 15
          Glu Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala Ala
                      20 25 30
          Met Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val
                  35 40 45
          Ala Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu
              50 55 60
          Ser Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg
          65 70 75 80
          Thr Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met
                          85 90 95
          Leu Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg Glu
                      100 105 110
          Leu Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu Tyr Arg Ile Gly
                  115 120 125
          Asp Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn Leu Ala
              130 135 140
           <![CDATA[ <210> 473]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 473]]>
          Leu Lys Gly Arg Leu Asp Tyr Leu Ser Ser Leu Lys Val Lys Gly Leu
          1 5 10 15
          Val Leu Gly Pro Ile His Lys Asn Gln Lys Asp Asp Val Ala Gln Thr
                      20 25 30
          Asp Leu Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu Asp Phe Asp
                  35 40 45
          Ser Leu Leu Gln Ser Ala Lys Lys Lys Lys
              50 55
           <![CDATA[ <210> 474]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 474]]>
          Ile Arg Val Ile Leu Asp Leu Thr Pro Asn Tyr Arg Gly Glu Asn Ser
          1 5 10 15
          Trp Phe Ser Thr Gln Val Asp Thr Val Ala Thr Lys Val Lys
                      20 25 30
           <![CDATA[ <210> 475]]>
           <![CDATA[ <211> 23]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 475]]>
          Asp Ala Leu Glu Phe Trp Leu Gln Ala Gly Val Asp Gly Phe Gln Val
          1 5 10 15
          Arg Asp Ile Glu Asn Leu Lys
                      20
           <![CDATA[ <210> 476]]>
           <![CDATA[ <211> 19]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 476]]>
          Asp Ala Ser Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe
          1 5 10 15
          Ser Glu Asp
           <![CDATA[ <210> 477]]>
           <![CDATA[ <211> 60]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 477]]>
          Leu Leu Ile Ala Gly Thr Asn Ser Ser Asp Leu Gln Gln Ile Leu Ser
          1 5 10 15
          Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu Thr Ser Ser Tyr Leu Ser
                      20 25 30
          Asp Ser Gly Ser Thr Gly Glu His Thr Lys Ser Leu Val Thr Gln Tyr
                  35 40 45
          Leu Asn Ala Thr Gly Asn Arg Trp Cys Ser Trp Ser
              50 55 60
           <![CDATA[ <210> 478]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 478]]>
          Leu Ser Gln Ala Arg Leu Leu Thr Ser Phe Leu Pro Ala Gln Leu Leu
          1 5 10 15
          Arg Leu Tyr Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro Val Phe
                      20 25 30
          Ser Tyr Gly Asp Glu Ile Gly Leu Asp Ala Ala Ala Leu Pro Gly Gln
                  35 40 45
           <![CDATA[ <210> 479]]>
           <![CDATA[ <211> 28]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 479]]>
          Pro Met Glu Ala Pro Val Met Leu Trp Asp Glu Ser Ser Phe Pro Asp
          1 5 10 15
          Ile Pro Gly Ala Val Ser Ala Asn Met Thr Val Lys
                      20 25
           <![CDATA[ <210> 480]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 480]]>
          Gly Gln Ser Glu Asp Pro Gly Ser Leu Leu Ser Leu Phe Arg Arg Leu
          1 5 10 15
          Ser Asp Gln Arg Ser Lys Glu Arg Ser Leu Leu His Gly Asp Phe His
                      20 25 30
          Ala Phe Ser Ala Gly Pro Gly Leu Phe Ser Tyr Ile Arg His Trp Asp
                  35 40 45
          Gln Asn Glu Arg Phe Leu Val Val Leu Asn Phe Gly Asp Val Gly Leu
              50 55 60
          Ser Ala Gly Leu Gln Ala Ser Asp Leu Pro Ala Ser Ala Ser Leu Pro
          65 70 75 80
          Ala Lys Ala Asp Leu Leu Leu Ser Thr Gln Pro Gly Arg Glu Glu Gly
                          85 90 95
          Ser Pro Leu Glu Leu Glu Arg Leu Lys Leu Glu Pro His Glu Gly Leu
                      100 105 110
          Leu Leu Arg Phe Pro Tyr Ala Ala
                  115 120
           <![CDATA[ <210> 481]]>
           <![CDATA[ <211> 630]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 481]]>
          Met Glu Leu Gln Pro Pro Glu Ala Ser Ile Ala Val Val Ser Ile Pro
          1 5 10 15
          Arg Gln Leu Pro Gly Ser His Ser Glu Ala Gly Val Gln Gly Leu Ser
                      20 25 30
          Ala Gly Asp Asp Ser Glu Leu Gly Ser His Cys Val Ala Gln Thr Gly
                  35 40 45
          Leu Glu Leu Leu Ala Ser Gly Asp Pro Leu Pro Ser Ala Ser Gln Asn
              50 55 60
          Ala Glu Met Ile Glu Thr Gly Ser Asp Cys Val Thr Gln Ala Gly Leu
          65 70 75 80
          Gln Leu Leu Ala Ser Ser Asp Pro Pro Ala Leu Ala Ser Lys Asn Ala
                          85 90 95
          Glu Val Thr Gly Thr Met Ser Gln Asp Thr Glu Val Asp Met Lys Glu
                      100 105 110
          Val Glu Leu Asn Glu Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala
                  115 120 125
          Ser Gly Ala Ala Met Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val
              130 135 140
          Lys Ile Lys Val Ala Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Ala Lys
          145 150 155 160
          Phe Thr Gly Leu Ser Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro
                          165 170 175
          Gly Trp Val Arg Thr Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly
                      180 185 190
          Trp Leu Gly Met Leu Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro
                  195 200 205
          Arg Cys Arg Glu Leu Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu
              210 215 220
          Tyr Arg Ile Gly Asp Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn
          225 230 235 240
          Leu Ala Gly Leu Lys Gly Arg Leu Asp Tyr Leu Ser Ser Leu Lys Val
                          245 250 255
          Lys Gly Leu Val Leu Gly Pro Ile His Lys Asn Gln Lys Asp Asp Val
                      260 265 270
          Ala Gln Thr Asp Leu Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu
                  275 280 285
          Asp Phe Asp Ser Leu Leu Gln Ser Ala Lys Lys Lys Lys Ser Ile Arg Val
              290 295 300
          Ile Leu Asp Leu Thr Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser
          305 310 315 320
          Thr Gln Val Asp Thr Val Ala Thr Lys Val Lys Asp Ala Leu Glu Phe
                          325 330 335
          Trp Leu Gln Ala Gly Val Asp Gly Phe Gln Val Arg Asp Ile Glu Asn
                      340 345 350
          Leu Lys Asp Ala Ser Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys
                  355 360 365
          Gly Phe Ser Glu Asp Arg Leu Leu Ile Ala Gly Thr Asn Ser Ser Asp
              370 375 380
          Leu Gln Gln Ile Leu Ser Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu
          385 390 395 400
          Thr Ser Ser Tyr Leu Ser Asp Ser Gly Ser Thr Gly Glu His Thr Lys
                          405 410 415
          Ser Leu Val Thr Gln Tyr Leu Asn Ala Thr Gly Asn Arg Trp Cys Ser
                      420 425 430
          Trp Ser Leu Ser Gln Ala Arg Leu Leu Thr Ser Phe Leu Pro Ala Gln
                  435 440 445
          Leu Leu Arg Leu Tyr Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro
              450 455 460
          Val Phe Ser Tyr Gly Asp Glu Ile Gly Leu Asp Ala Ala Ala Leu Pro
          465 470 475 480
          Gly Gln Pro Met Glu Ala Pro Val Met Leu Trp Asp Glu Ser Ser Phe
                          485 490 495
          Pro Asp Ile Pro Gly Ala Val Ser Ala Asn Met Thr Val Lys Gly Gln
                      500 505 510
          Ser Glu Asp Pro Gly Ser Leu Leu Ser Leu Phe Arg Arg Leu Ser Asp
                  515 520 525
          Gln Arg Ser Lys Glu Arg Ser Leu Leu His Gly Asp Phe His Ala Phe
              530 535 540
          Ser Ala Gly Pro Gly Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn
          545 550 555 560
          Glu Arg Phe Leu Val Val Leu Asn Phe Gly Asp Val Gly Leu Ser Ala
                          565 570 575
          Gly Leu Gln Ala Ser Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys
                      580 585 590
          Ala Asp Leu Leu Leu Ser Thr Gln Pro Gly Arg Glu Glu Gly Ser Pro
                  595 600 605
          Leu Glu Leu Glu Arg Leu Lys Leu Glu Pro His Glu Gly Leu Leu Leu
              610 615 620
          Arg Phe Pro Tyr Ala Ala
          625 630
           <![CDATA[ <210> 482]]>
           <![CDATA[ <211> 366]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 482]]>
          gcattgcggc ttggttttct cacccagtgc atgtggcagg agcggtgaga tcactgcctc 60
          acggcgatcc tggactgacg gtcacgactg cctaccctct aaccctgttc tgagctgccc 120
          cttgcccaca caccccaaac ctgtgtgcag gatccgcctc catggagcta cagcctcctg 180
          aagcctcgat cgccgtcgtg tcgattccgc gccagttgcc tggctcacat tcggaggctg 240
          gtgtccaggg tctcagcgcg ggggacgact cagagttggg gtctcactgt gttgcccaga 300
          ctggtctcga actcttggcc tcaggtgatc ctcttccctc agcttcccag aatgccgaga 360
          tgatag 366
           <![CDATA[ <210> 483]]>
           <![CDATA[ <211> 68]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 483]]>
          Met Glu Leu Gln Pro Pro Glu Ala Ser Ile Ala Val Val Ser Ile Pro
          1 5 10 15
          Arg Gln Leu Pro Gly Ser His Ser Glu Ala Gly Val Gln Gly Leu Ser
                      20 25 30
          Ala Gly Asp Asp Ser Glu Leu Gly Ser His Cys Val Ala Gln Thr Gly
                  35 40 45
          Leu Glu Leu Leu Ala Ser Gly Asp Pro Leu Pro Ser Ala Ser Gln Asn
              50 55 60
          Ala Glu Met Ile
          65
           <![CDATA[ <210> 484]]>
           <![CDATA[ <211> 54]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 484]]>
          ttgagcctgt tgatgcccgc cctgctgccg accgaggact gaccactcga ccag 54
           <![CDATA[ <210> 485]]>
           <![CDATA[ <211> 87]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 485]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgt gaatggaggg gagtgct 87
           <![CDATA[ <210> 486]]>
           <![CDATA[ <211> 141]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 486]]>
          ttgagcctgt tgatgcccgc cctgctgccg accgaggact gaccactcga ccagctacat 60
          ctacatccac cactgggaca agccatcttg taaaatgtgc ggagaaggag aaaactttct 120
          gtgtgaatgg aggggagtgc t 141
           <![CDATA[ <210> 487]]>
           <![CDATA[ <211> 46]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 487]]>
          Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg
          1 5 10 15
          Pro Ala Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys
                      20 25 30
          Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys
                  35 40 45
           <![CDATA[ <210> 488]]>
           <![CDATA[ <211> 207]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 488]]>
          gtcagtttcc tcggcagcgg taggcgagag cacgcggagg agcgtgcgcg ggggccccgg 60
          gagacggcgg cggtggcggc gcgggcagag caaggacgcg gcggatccca ctcgcacagc 120
          agcgcactcg gtgccccgcg cagggtcgcg atgctgcccg gtttggcact gctcctgctg 180
          gccgcctgga cggctcgggc gctggag 207
           <![CDATA[ <210> 489]]>
           <![CDATA[ <211> 130]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 489]]>
          gtctaccctg aactgcagat caccaatgtg gtagaagcca accaaccagt gaccatccag 60
          aactggtgca agcggggccg caagcagtgc aagacccatc cccactttgt gattccctac 120
          cgctgcttag 130
           <![CDATA[ <210> 490]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 490]]>
          ttggtgagtt tgtaagtgat gcccttctcg ttcctgacaa gtgcaaattc ttacaccagg 60
          agaggatgga tgtttgcgaa actcatcttc actggcacac cgtcgccaaa gag 113
           <![CDATA[ <210> 491]]>
           <![CDATA[ <211> 194]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 491]]>
          acatgcagtg agaagagtac caacttgcat gactacggca tgttgctgcc ctgcggaatt 60
          gacaagttcc gaggggtaga gtttgtgtgt tgcccactgg ctgaagaaag tgacaatgtg 120
          gattctgctg atgcggagga ggatgactcg gatgtctggt ggggcggagc agacacagac 180
          tatgcagatgggag 194
           <![CDATA[ <210> 492]]>
           <![CDATA[ <211> 203]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 492]]>
          tgaagacaaa gtagtagaag tagcagagga ggaagaagtg gctgaggtgg aagaagaaga 60
          agccgatgat gacgaggacg atgaggatgg tgatgaggta gaggaagagg ctgaggaacc 120
          ctacgaagaa gccacagaga gaaccaccag cattgccacc accaccacca ccaccacaga 180
          gtctgtggaa gaggtggttc gag 203
           <![CDATA[ <210> 493]]>
           <![CDATA[ <211> 168]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 493]]>
          aggtgtgctc tgaacaagcc gagacggggc cgtgccgagc aatgatctcc cgctggtact 60
          ttgatgtgac tgaagggaag tgtgccccat tcttttacgg cggatgtggc ggcaaccgga 120
          acaactttga cacagaagag tactgcatgg ccgtgtgtgg cagcgcca 168
           <![CDATA[ <210> 494]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 494]]>
          tgtcccaaag tttactcaag actacccagg aacctcttgc ccgagatcct gttaaac 57
           <![CDATA[ <210> 495]]>
           <![CDATA[ <211> 134]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 495]]>
          ttcctacaac agcagccagt acccctgatg ccgttgacaa gtatctcgag acacctgggg 60
          atgagaatga acatgcccat ttccagaaag ccaaagagag gcttgaggcc aagcaccgag 120
          agagaatgtc ccag 134
           <![CDATA[ <210> 496]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> ]]> 496
          gtcatgagag aatgggaaga ggcagaacgt caagcaaaga acttgcctaa agctgataag 60
          aaggcagtta tccag 75
           <![CDATA[ <210> 497]]>
           <![CDATA[ <211> 159]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 497]]>
          catttccagg agaaagtgga atctttggaa caggaagcag ccaacgagag acagcagctg 60
          gtggagacac acatggccag agtggaagcc atgctcaatg accgccgccg cctggccctg 120
          gagaactaca tcaccgctct gcaggctgtt cctcctcgg 159
           <![CDATA[ <210> 498]]>
           <![CDATA[ <211> 129]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 498]]>
          cctcgtcacg tgttcaatat gctaaagaag tatgtccgcg cagaacagaa ggacagacag 60
          cacaccctaa agcatttcga gcatgtgcgc atggtggatc ccaagaaagc cgctcagatc 120
          cggtcccag 129
           <![CDATA[ <210> 499]]>
           <![CDATA[ <211> 100]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 499]]>
          gttatgacac acctccgtgt gatttatgag cgcatgaatc agtctctctc cctgctctac 60
          aacgtgcctg cagtggccga ggagattcag gatgaagttg 100
           <![CDATA[ <210> 500]]>
           <![CDATA[ <211> 222]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <21]]>3> Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;500]]&gt;
           <br/> <![CDATA[atgagctgct tcagaaagag caaaactatt cagatgacgt cttggccaac atgattagtg 60
          aaccaaggat cagttacgga aacgatgctc tcatgccatc tttgaccgaa acgaaaacca 120
          ccgtggagct ccttcccgtg aatggagagt tcagcctgga cgatctccag ccgtggcatt 180
          cttttggggc tgactctgtg ccagccaaca cagaaaacga ag 222
           <![CDATA[ <210> 501]]>
           <![CDATA[ <211> 54]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 501]]>
          ttgagcctgt tgatgcccgc cctgctgccg accgaggact gaccactcga ccag 54
           <![CDATA[ <210> 502]]>
           <![CDATA[ <211> 101]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 502]]>
          gttctgggtt gacaaatatc aagacggagg agatctctga agtgaagatg gatgcagaat 60
          tccgacatga ctcaggatat gaagttcatc atcaaaaatt g 101
           <![CDATA[ <210> 503]]>
           <![CDATA[ <211> 147]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 503]]>
          gtgttctttg cagaagatgt gggttcaaac aaaggtgcaa tcattggact catggtgggc 60
          ggtgttgtca tagcgacagt gatcgtcatc accttggtga tgctgaagaa gaaacagtac 120
          acatccattc atcatggtgt ggtggag 147
           <![CDATA[ <210> 504]]>
           <![CDATA[ <211> 1222]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 504]]>
          gttgacgccg ctgtcacccc agaggagcgc cacctgtcca agatgcagca gaacggctac 60
          gaaaatccaa cctacaagtt ctttgagcag atgcagaact agaccccccgc cacagcagcc 120
          tctgaagttg gacagcaaaa ccattgcttc actacccatc ggtgtccatt tatagaataa 180
          tgtgggaaga aacaaacccg ttttatgatt tactcattat cgccttttga cagctgtgct 240
          gtaacacaag tagatgcctg aacttgaatt aatccacaca tcagtaatgt attctatctc 300
          tctttacatt ttggtctcta tactacatta ttaatgggtt ttgtgtactg taaagaattt 360
          agctgtatca aactagtgca tgaatagatt ctctcctgat tattatcac atagcccctt 420
          agccagttgt atattattct tgtggtttgt gacccaatta agtcctactt tacatatgct 480
          ttaagaatcg atgggggatg cttcatgtga acgtgggagt tcagctgctt ctcttgccta 540
          agtattcctt tcctgatcac tatgcatttt aaagttaaac atttttaagt atttcagatg 600
          ctttagagag attttttttc catgactgca ttttactgta cagattgctg cttctgctat 660
          atttgtgata taggaattaa gaggatacac acgtttgttt cttcgtgcct gttttatgtg 720
          cacacattag gcattgagac ttcaagcttt tctttttttg tccacgtatc tttgggtctt 780
          tgataaagaa aagaatccct gttcattgta agcactttta cggggcgggt ggggaggggt 840
          gctctgctgg tcttcaatta ccaagaattc tccaaaacaa ttttctgcag gatgattgta 900
          cagaatcatt gcttatgaca tgatcgcttt ctacactgta ttacataaat aaattaaata 960
          aaataacccc gggcaagact tttctttgaa ggatgactac agacattaaa taatcgaagt 1020
          aattttgggt ggggagaaga ggcagattca attttcttta accagtctga agtttcattt 1080
          atgatacaaa agaagatgaa aatggaagtg gcaatataag gggatgagga aggcatgcct 1140
          ggacaaaccc ttcttttaag atgtgtcttc aatttgtata aaatggtgtt ttcatgtaaa 1200
          taaatacatt cttggaggag ca 1222
           <![CDATA[ <210> 505]]>
           <![CDATA[ <211> 3415]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> The complete mRNA polynucleotide sequence of APP]]>
           <![CDATA[ <400> 505]]>
          gtcagtttcc tcggcagcgg taggcgagag cacgcggagg agcgtgcgcg ggggccccgg 60
          gagacggcgg cggtggcggc gcgggcagag caaggacgcg gcggatccca ctcgcacagc 120
          agcgcactcg gtgccccgcg cagggtcgcg atgctgcccg gtttggcact gctcctgctg 180
          gccgcctgga cggctcgggc gctggaggtc taccctgaac tgcagatcac caatgtggta 240
          gaagccaacc aaccagtgac catccagaac tggtgcaagc ggggccgcaa gcagtgcaag 300
          acccatcccc actttgtgat tccctaccgc tgcttagttg gtgagtttgt aagtgatgcc 360
          cttctcgttc ctgacaagtg caaattctta caccaggaga ggatggatgt ttgcgaaact 420
          catcttcact ggcacaccgt cgccaaagag acatgcagtg agaagagtac caacttgcat 480
          gactacggca tgttgctgcc ctgcggaatt gacaagttcc gaggggtaga gtttgtgtgt 540
          tgcccactgg ctgaagaaag tgacaatgtg gattctgctg atgcggagga ggatgactcg 600
          gatgtctggt ggggcggagc agacacagac tatgcagatg ggagtgaaga caaagtagta 660
          gaagtagcag aggaggaaga agtggctgag gtggaagaag aagaagccga tgatgacgag 720
          gacgatgagg atggtgatga ggtagaggaa gaggctgagg aaccctacga agaagccaca 780
          gagagaacca ccagcattgc caccaccacc accacccacca cagagtctgt ggaagaggtg 840
          gttcgagagg tgtgctctga acaagccgag acggggccgt gccgagcaat gatctcccgc 900
          tggtactttg atgtgactga agggaagtgt gccccattct tttacggcgg atgtggcggc 960
          aaccggaaca actttgacac agaagagtac tgcatggccg tgtgtggcag cgccatgtcc 1020
          caaagtttac tcaagactac ccaggaacct cttgcccgag atcctgttaa acttcctaca 1080
          acagcagcca gtacccctga tgccgttgac aagtatctcg agaacacctgg ggatgagaat 1140
          gaacatgccc atttccagaa agccaaagag aggcttgagg ccaagcaccg agagaatg 1200
          tcccaggtca tgagagaatg ggaagaggca gaacgtcaag caaagaactt gcctaaagct 1260
          gataagaagg cagttatcca gcatttccag gagaaagtgg aatctttgga acaggaagca 1320
          gccaacgaga gacagcagct ggtggagaca cacatggcca gagtggaagc catgctcaat 1380
          gaccgccgcc gcctggccct ggagaactac atcaccgctc tgcaggctgt tcctcctcgg 1440
          cctcgtcacg tgttcaatat gctaaagaag tatgtccgcg cagaacagaa ggacagacag 1500
          cacaccctaa agcatttcga gcatgtgcgc atggtggatc ccaagaaagc cgctcagatc 1560
          cggtcccagg ttatgacaca cctccgtgtg atttatgagc gcatgaatca gtctctctcc 1620
          ctgctctaca acgtgcctgc agtggccgag gagattcagg atgaagttga tgagctgctt 1680
          cagaaagagc aaaactattc agatgacgtc ttggccaaca tgattagtga accaaggatc 1740
          agttacggaa acgatgctct catgccatct ttgaccgaaa cgaaaaccac cgtggagctc 1800
          cttcccgtga atggagagtt cagcctggac gatctccagc cgtggcattc ttttggggct 1860
          gactctgtgc cagccaacac agaaaacgaa gttgagcctg ttgatgcccg ccctgctgcc 1920
          gaccgaggac tgaccactcg accaggttct gggttgacaa atatcaagac ggaggagatc 1980
          tctgaagtga agatggatgc agaattccga catgactcag gatatgaagt tcatcatcaa 2040
          aaattggtgt tctttgcaga agatgtgggt tcaaacaaag gtgcaatcat tggactcatg 2100
          gtgggcggtg ttgtcatagc gacagtgatc gtcatcacct tggtgatgct gaagaagaaa 2160
          cagtacacat ccattcatca tggtgtggtg gaggttgacg ccgctgtcac cccagaggag 2220
          cgccacctgt ccaagatgca gcagaacggc tacgaaaatc caacctacaa gttctttgag 2280
          cagatgcaga actagacccc cgccacagca gcctctgaag ttggacagca aaaccattgc 2340
          ttcactaccc atcggtgtcc atttatagaa taatgtggga agaaacaaac ccgttttatg 2400
          atttactcat tatcgccttt tgacagctgt gctgtaacac aagtagatgc ctgaacttga 2460
          attaatccac acatcagtaa tgtattctat ctctctttac attttggtct ctatactaca 2520
          ttattaatgg gttttgtgta ctgtaaagaa tttagctgta tcaaactagt gcatgaatag 2580
          attctctcct gattatttt cacatagccc cttagccagt tgtatattat tcttgtggtt 2640
          tgtgacccaa ttaagtccta ctttacatat gctttaagaa tcgatggggg atgcttcatg 2700
          tgaacgtggg agttcagctg cttctcttgc ctaagtattc ctttcctgat cactatgcat 2760
          tttaaagtta aacattttta agtatttcag atgctttaga gagattttttttccatgact 2820
          gcattttact gtacagattg ctgcttctgc tatatttgtg atatagggaat taagaggata 2880
          cacacgtttg tttcttcgtg cctgttttat gtgcacacat taggcattga gacttcaagc 2940
          ttttcttttt ttgtccacgt atctttgggt ctttgataaa gaaaagaatc cctgttcatt 3000
          gtaagcactt ttacggggcg ggtggggagg ggtgctctgc tggtcttcaa ttaccaagaa 3060
          ttctccaaaa caattttctg caggatgatt gtacagaatc attgcttatg acatgatcgc 3120
          tttctacact gtattacata aataaattaa ataaaataac cccgggcaag acttttcttt 3180
          gaaggatgac tacagacatt aaataatcga agtaattttg ggtggggaga agaggcagat 3240
          tcaattttct ttaaccagtc tgaagtttca tttatgatac aaaagaagat gaaaatggaa 3300
          gtggcaatat aaggggatga ggaaggcatg cctggacaaa cccttctttt aagatgtgtc 3360
          ttcaatttgt ataaaatggt gttttcatgt aaataaatac attcttggag gagca 3415
           <![CDATA[ <210> 506]]>
           <![CDATA[ <211> 19]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 506]]>
          Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
          1 5 10 15
          Ala Leu Glu
           <![CDATA[ <21]]>0> 507]]&gt;
           <br/> &lt;![CDATA[ &lt;211&gt;43]]&gt;
           <br/> &lt;![CDATA[ &lt;212&gt;PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt;Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;507]]&gt;
           <br/>
           <br/> <![CDATA[Val Tyr Pro Glu Leu Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro
          1 5 10 15
          Val Thr Ile Gln Asn Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr
                      20 25 30
          His Pro His Phe Val Ile Pro Tyr Arg Cys Leu
                  35 40
           <![CDATA[ <210> 508]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 508]]>
          Gly Glu Phe Val Ser Asp Ala Leu Leu Val Pro Asp Lys Cys Lys Phe
          1 5 10 15
          Leu His Gln Glu Arg Met Asp Val Cys Glu Thr His Leu His Trp His
                      20 25 30
          Thr Val Ala Lys Glu
                  35
           <![CDATA[ <210> 509]]>
           <![CDATA[ <211> 64]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 509]]>
          Thr Cys Ser Glu Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu
          1 5 10 15
          Pro Cys Gly Ile Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro
                      20 25 30
          Leu Ala Glu Glu Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp
                  35 40 45
          Asp Ser Asp Val Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly
              50 55 60
           <![CDATA[ <210> 510]]>
           <![CDATA[ <211> 67]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 510]]>
          Glu Asp Lys Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val
          1 5 10 15
          Glu Glu Glu Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu
                      20 25 30
          Val Glu Glu Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr
                  35 40 45
          Thr Ser Ile Ala Thr Thr Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu
              50 55 60
          Val Val Arg
          65
           <![CDATA[ <210> 511]]>
           <![CDATA[ <211> 55]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 511]]>
          Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile Ser
          1 5 10 15
          Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe Tyr
                      20 25 30
          Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr Cys
                  35 40 45
          Met Ala Val Cys Gly Ser Ala
              50 55
           <![CDATA[ <210> 512]]>
           <![CDATA[ <211> 18]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 512]]>
          Ser Gln Ser Leu Leu Lys Thr Thr Gln Glu Pro Leu Ala Arg Asp Pro
          1 5 10 15
          Val Lys
           <![CDATA[ <210> 513]]>
           <![CDATA[ <211> 44]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 513]]>
          Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu
          1 5 10 15
          Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu
                      20 25 30
          Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln
                  35 40
           <![CDATA[ <210> 514]]>
           <![CDATA[ <211> 25]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 514]]>
          Val Met Arg Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro
          1 5 10 15
          Lys Ala Asp Lys Lys Ala Val Ile Gln
                      20 25
           <![CDATA[ <210> 515]]>
           <![CDATA[ <211> 53]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 515]]>
          His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn Glu
          1 5 10 15
          Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met Leu
                      20 25 30
          Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu Gln
                  35 40 45
          Ala Val Pro Pro Arg
              50
           <![CDATA[ <210> 516]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 516]]>
          Pro Arg His Val Phe Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln
          1 5 10 15
          Lys Asp Arg Gln His Thr Leu Lys His Phe Glu His Val Arg Met Val
                      20 25 30
          Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser Gln
                  35 40
           <![CDATA[ <210> 517]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 517]]>
          Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser Leu
          1 5 10 15
          Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp Glu
                      20 25 30
          Val
           <![CDATA[ <210> 518]]>
           <![CDATA[ <211> 73]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 518]]>
          Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn
          1 5 10 15
          Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala Leu Met Pro
                      20 25 30
          Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro Val Asn Gly
                  35 40 45
          Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp
              50 55 60
          Ser Val Pro Ala Asn Thr Glu Asn Glu
          65 70
           <![CDATA[ <210> 519]]>
           <![CDATA[ <211> 17]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 519]]>
          Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg
          1 5 10 15
          Pro
           <![CDATA[ <210> 520]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 520]]>
          Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met
          1 5 10 15
          Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
                      20 25 30
          Leu
           <![CDATA[ <210> 521]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 521]]>
          Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
          1 5 10 15
          Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
                      20 25 30
          Val Met Leu Lys Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
                  35 40 45
          Glu
           <![CDATA[ <210> 522]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 522]]>
          Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met Gln
          1 5 10 15
          Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met Gln
                      20 25 30
          Asn
           <![CDATA[ <210> 523]]>
           <![CDATA[ <211> 714]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 523]]>
          Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
          1 5 10 15
          Ala Leu Glu Val Tyr Pro Glu Leu Gln Ile Thr Asn Val Val Glu Ala
                      20 25 30
          Asn Gln Pro Val Thr Ile Gln Asn Trp Cys Lys Arg Gly Arg Lys Gln
                  35 40 45
          Cys Lys Thr His Pro His Phe Val Ile Pro Tyr Arg Cys Leu Val Gly
              50 55 60
          Glu Phe Val Ser Asp Ala Leu Leu Val Pro Asp Lys Cys Lys Phe Leu
          65 70 75 80
          His Gln Glu Arg Met Asp Val Cys Glu Thr His Leu His Trp His Thr
                          85 90 95
          Val Ala Lys Glu Thr Cys Ser Glu Lys Ser Thr Asn Leu His Asp Tyr
                      100 105 110
          Gly Met Leu Leu Pro Cys Gly Ile Asp Lys Phe Arg Gly Val Glu Phe
                  115 120 125
          Val Cys Cys Pro Leu Ala Glu Glu Ser Asp Asn Val Asp Ser Ala Asp
              130 135 140
          Ala Glu Glu Asp Asp Ser Asp Val Trp Trp Gly Gly Ala Asp Thr Asp
          145 150 155 160
          Tyr Ala Asp Gly Ser Glu Asp Lys Val Val Glu Val Ala Glu Glu Glu Glu
                          165 170 175
          Glu Val Ala Glu Val Glu Glu Glu Glu Ala Asp Asp Asp Glu Asp Asp
                      180 185 190
          Glu Asp Gly Asp Glu Val Glu Glu Glu Ala Glu Glu Pro Tyr Glu Glu
                  195 200 205
          Ala Thr Thr Glu Arg Thr Thr Ser Ile Ala Thr Thr Thr Thr Thr Thr Thr Thr Thr
              210 215 220
          Glu Ser Val Glu Glu Val Val Arg Glu Val Cys Ser Glu Gln Ala Glu
          225 230 235 240
          Thr Gly Pro Cys Arg Ala Met Ile Ser Arg Trp Tyr Phe Asp Val Thr
                          245 250 255
          Glu Gly Lys Cys Ala Pro Phe Phe Tyr Gly Gly Cys Gly Gly Asn Arg
                      260 265 270
          Asn Asn Phe Asp Thr Glu Glu Tyr Cys Met Ala Val Cys Gly Ser Ala
                  275 280 285
          Met Ser Gln Ser Leu Leu Lys Thr Thr Gln Glu Pro Leu Ala Arg Asp
              290 295 300
          Pro Val Lys Leu Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp
          305 310 315 320
          Lys Tyr Leu Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln
                          325 330 335
          Lys Ala Lys Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln
                      340 345 350
          Val Met Arg Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro
                  355 360 365
          Lys Ala Asp Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu
              370 375 380
          Ser Leu Glu Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr
          385 390 395 400
          His Met Ala Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala
                          405 410 415
          Leu Glu Asn Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Pro Arg Pro Arg
                      420 425 430
          His Val Phe Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp
                  435 440 445
          Arg Gln His Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro
              450 455 460
          Lys Lys Ala Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val
          465 470 475 480
          Ile Tyr Glu Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro
                          485 490 495
          Ala Val Ala Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys
                      500 505 510
          Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro
                  515 520 525
          Arg Ile Ser Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr
              530 535 540
          Lys Thr Thr Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp
          545 550 555 560
          Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn
                          565 570 575
          Thr Glu Asn Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg
                      580 585 590
          Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu
                  595 600 605
          Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly
              610 615 620
          Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly
          625 630 635 640
          Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile
                          645 650 655
          Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr
                      660 665 670
          Thr Ser Ile His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro
                  675 680 685
          Glu Glu Arg His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro
              690 695 700
          Thr Tyr Lys Phe Phe Glu Gln Met Gln Asn
          705 710
           <![CDATA[ <210> 524]]>
           <![CDATA[ <211> 1945]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 524]]>
          gtcagtttcc tcggcagcgg taggcgagag cacgcggagg agcgtgcgcg ggggccccgg 60
          gagacggcgg cggtggcggc gcgggcagag caaggacgcg gcggatccca ctcgcacagc 120
          agcgcactcg gtgccccgcg cagggtcgcg atgctgcccg gtttggcact gctcctgctg 180
          gccgcctgga cggctcgggc gctggaggtc taccctgaac tgcagatcac caatgtggta 240
          gaagccaacc aaccagtgac catccagaac tggtgcaagc ggggccgcaa gcagtgcaag 300
          acccatcccc actttgtgat tccctaccgc tgcttagttg gtgagtttgt aagtgatgcc 360
          cttctcgttc ctgacaagtg caaattctta caccaggaga ggatggatgt ttgcgaaact 420
          catcttcact ggcacaccgt cgccaaagag acatgcagtg agaagagtac caacttgcat 480
          gactacggca tgttgctgcc ctgcggaatt gacaagttcc gaggggtaga gtttgtgtgt 540
          tgcccactgg ctgaagaaag tgacaatgtg gattctgctg atgcggagga ggatgactcg 600
          gatgtctggt ggggcggagc agacacagac tatgcagatg ggagtgaaga caaagtagta 660
          gaagtagcag aggaggaaga agtggctgag gtggaagaag aagaagccga tgatgacgag 720
          gacgatgagg atggtgatga ggtagaggaa gaggctgagg aaccctacga agaagccaca 780
          gagagaacca ccagcattgc caccaccacc accacccacca cagagtctgt ggaagaggtg 840
          gttcgagagg tgtgctctga acaagccgag acggggccgt gccgagcaat gatctcccgc 900
          tggtactttg atgtgactga agggaagtgt gccccattct tttacggcgg atgtggcggc 960
          aaccggaaca actttgacac agaagagtac tgcatggccg tgtgtggcag cgccatgtcc 1020
          caaagtttac tcaagactac ccaggaacct cttgcccgag atcctgttaa acttcctaca 1080
          acagcagcca gtacccctga tgccgttgac aagtatctcg agaacacctgg ggatgagaat 1140
          gaacatgccc atttccagaa agccaaagag aggcttgagg ccaagcaccg agagaatg 1200
          tcccaggtca tgagagaatg ggaagaggca gaacgtcaag caaagaactt gcctaaagct 1260
          gataagaagg cagttatcca gcatttccag gagaaagtgg aatctttgga acaggaagca 1320
          gccaacgaga gacagcagct ggtggagaca cacatggcca gagtggaagc catgctcaat 1380
          gaccgccgcc gcctggccct ggagaactac atcaccgctc tgcaggctgt tcctcctcgg 1440
          cctcgtcacg tgttcaatat gctaaagaag tatgtccgcg cagaacagaa ggacagacag 1500
          cacaccctaa agcatttcga gcatgtgcgc atggtggatc ccaagaaagc cgctcagatc 1560
          cggtcccagg ttatgacaca cctccgtgtg atttatgagc gcatgaatca gtctctctcc 1620
          ctgctctaca acgtgcctgc agtggccgag gagattcagg atgaagttga tgagctgctt 1680
          cagaaagagc aaaactattc agatgacgtc ttggccaaca tgattagtga accaaggatc 1740
          agttacggaa acgatgctct catgccatct ttgaccgaaa cgaaaaccac cgtggagctc 1800
          cttcccgtga atggagagtt cagcctggac gatctccagc cgtggcattc ttttggggct 1860
          gactctgtgc cagccaacac agaaaacgaa gttgagcctg ttgatgcccg ccctgctgcc 1920
          gaccgaggac tgaccactcg accag 1945
           <![CDATA[ <210> 525]]>
           <![CDATA[ <211> 598]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 525]]>
          Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
          1 5 10 15
          Ala Leu Glu Val Tyr Pro Glu Leu Gln Ile Thr Asn Val Val Glu Ala
                      20 25 30
          Asn Gln Pro Val Thr Ile Gln Asn Trp Cys Lys Arg Gly Arg Lys Gln
                  35 40 45
          Cys Lys Thr His Pro His Phe Val Ile Pro Tyr Arg Cys Leu Val Gly
              50 55 60
          Glu Phe Val Ser Asp Ala Leu Leu Val Pro Asp Lys Cys Lys Phe Leu
          65 70 75 80
          His Gln Glu Arg Met Asp Val Cys Glu Thr His Leu His Trp His Thr
                          85 90 95
          Val Ala Lys Glu Thr Cys Ser Glu Lys Ser Thr Asn Leu His Asp Tyr
                      100 105 110
          Gly Met Leu Leu Pro Cys Gly Ile Asp Lys Phe Arg Gly Val Glu Phe
                  115 120 125
          Val Cys Cys Pro Leu Ala Glu Glu Ser Asp Asn Val Asp Ser Ala Asp
              130 135 140
          Ala Glu Glu Asp Asp Ser Asp Val Trp Trp Gly Gly Ala Asp Thr Asp
          145 150 155 160
          Tyr Ala Asp Gly Ser Glu Asp Lys Val Val Glu Val Ala Glu Glu Glu Glu
                          165 170 175
          Glu Val Ala Glu Val Glu Glu Glu Glu Ala Asp Asp Asp Glu Asp Asp
                      180 185 190
          Glu Asp Gly Asp Glu Val Glu Glu Glu Ala Glu Glu Pro Tyr Glu Glu
                  195 200 205
          Ala Thr Thr Glu Arg Thr Thr Ser Ile Ala Thr Thr Thr Thr Thr Thr Thr Thr Thr
              210 215 220
          Glu Ser Val Glu Glu Val Val Arg Glu Val Cys Ser Glu Gln Ala Glu
          225 230 235 240
          Thr Gly Pro Cys Arg Ala Met Ile Ser Arg Trp Tyr Phe Asp Val Thr
                          245 250 255
          Glu Gly Lys Cys Ala Pro Phe Phe Tyr Gly Gly Cys Gly Gly Asn Arg
                      260 265 270
          Asn Asn Phe Asp Thr Glu Glu Tyr Cys Met Ala Val Cys Gly Ser Ala
                  275 280 285
          Met Ser Gln Ser Leu Leu Lys Thr Thr Gln Glu Pro Leu Ala Arg Asp
              290 295 300
          Pro Val Lys Leu Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp
          305 310 315 320
          Lys Tyr Leu Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln
                          325 330 335
          Lys Ala Lys Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln
                      340 345 350
          Val Met Arg Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro
                  355 360 365
          Lys Ala Asp Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu
              370 375 380
          Ser Leu Glu Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr
          385 390 395 400
          His Met Ala Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala
                          405 410 415
          Leu Glu Asn Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Pro Arg Pro Arg
                      420 425 430
          His Val Phe Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp
                  435 440 445
          Arg Gln His Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro
              450 455 460
          Lys Lys Ala Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val
          465 470 475 480
          Ile Tyr Glu Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro
                          485 490 495
          Ala Val Ala Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys
                      500 505 510
          Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro
                  515 520 525
          Arg Ile Ser Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr
              530 535 540
          Lys Thr Thr Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp
          545 550 555 560
          Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn
                          565 570 575
          Thr Glu Asn Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg
                      580 585 590
          Gly Leu Thr Thr Arg Pro
                  595
           <![CDATA[ <210> 526]]>
           <![CDATA[ <211> 96]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 526]]>
          aagctggctg cccccttgat ttggagcgag caggcctgac tccagaggtt cagaagatta 60
          ttgctgatgt tatccgaaac cctcccgtca actcag 96
           <![CDATA[ <210> 527]]>
           <![CDATA[ <211> 87]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 527]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgt gaatggaggg gagtgct 87
           <![CDATA[ <210> 528]]>
           <![CDATA[ <211> 182]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 528]]>
          aagctggctg cccccttgat ttggagcgag caggcctgac tccagaggtt cagaagatta 60
          ttgctgatgt tatccgaaac cctcccgtca actcagctac atctacatcc accactggga 120
          caagccatct tgtaaaatgt gcggagaagg agaaaacttt ctgtgtgaat ggaggggagt 180
          gc 182
           <![CDATA[ <210> 529]]>
           <![CDATA[ <211> 60]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 529]]>
          Ala Gly Cys Pro Leu Asp Leu Glu Arg Ala Gly Leu Thr Pro Glu Val
          1 5 10 15
          Gln Lys Ile Ile Ala Asp Val Ile Arg Asn Pro Pro Val Asn Ser Ala
                      20 25 30
          Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala Glu
                  35 40 45
          Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys
              50 55 60
           <![CDATA[ <210> 530]]>
           <![CDATA[ <211> 164]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 530]]>
          gtgtactgtg tgcgccgggg aggcgccggc ttgtactcgg cagcgcggga ataaagtttg 60
          ctgatttggt gtctagcctg gatgcctggg ttgcaggccc tgcttgtggt ggcgctccac 120
          agtcatccgg ctgaagaaga cctgttggac tggatcttct cggg 164
           <![CDATA[ <210> 531]]>
           <![CDATA[ <211> 172]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 531]]>
          ttttctttca gatattgttt tgtatttacc catgaagaca ttgttttttg gactctgcaa 60
          ataggacatt tcaaagatga gtgaaaaaaa attggaaaca actgcacagc agcggaaatg 120
          tcctgaatgg atgaatgtgc agaataaaag atgtgctgta gaagaaagaa ag 172
           <![CDATA[ <210> 532]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 532]]>
          gcatgtgttc ggaagagtgt ttttgaagat gacctcccct tcttagaatt cactggatcc 60
          attgtgtata gttacgatgc tagtgattgc tctttcctgt cagaagatat tag 113
           <![CDATA[ <210> 533]]>
           <![CDATA[ <211> 146]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 533]]>
          catgagtcta tcagatgggg atgtggtgggg atttgacatg gagtggccac cattatacaa 60
          tagagggaaa cttggcaaag ttgcactaat tcagttgtgtgtttctgaga gcaaatgtta 120
          cttgttccac gtttcttcca tgtcag 146
           <![CDATA[ <210> 534]]>
           <![CDATA[ <211> 149]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 534]]>
          tttttcccca gggattaaaa atgttgcttg aaaataaagc agttaaaaag gcaggtgtag 60
          gaattgaagg agatcagtgg aaacttctac gtgactttga tatcaaattg aagaattttg 120
          tggagttgac agatgttgcc aataaaaag 149
           <![CDATA[ <210> 535]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 535]]>
          ctgaaatgca cagagacctg gagccttaac agtctggtta aacacctctt aggtaaacag 60
          ctcctgaaag acaagtctat ccgctgtagc aattggagta aatttcctct cactgaggac 120
          cagaaactgt atgcagccac tgatgcttat 150
           <![CDATA[ <210> 536]]>
           <![CDATA[ <211> 70]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 536]]>
          gctggtttta ttattaccg aaatttagag attttggatg atactgtgca aaggtttgct 60
          ataaataaag 70
           <![CDATA[ <210> 537]]>
           <![CDATA[ <211> 115]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 537]]>
          aggaagaaat cctacttagc gacatgaaca aacagttgac ttcaatctct gaggaagtga 60
          tggatctggc taagcatctt cctcatgctt tcagtaaatt ggaaaaccca cggag 115
           <![CDATA[ <210> 538]]>
           <![CDATA[ <211> 430]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 538]]>
          ggtttctatc ttactaaagg atatttcaga aaatctatat tcactgagga ggatgataat 60
          tgggtctact aacattgaga ctgaactgag gcccagcaat aatttaaact tattatcctt 120
          tgaagattca actactgggg gagtacaaca gaaacaaatt agagaacatg aagttttaat 180
          tcacgttgaa gatgaaacat gggacccaac acttgatcat ttagctaaac atgatggaga 240
          agatgtactt ggaaataaag tggaacgaaa agaagatgga tttgaagatg gagtagaaga 300
          caacaaattg aaagagaata tggaaagagc ttgtttgatg tcgttagata ttacagaaca 360
          tgaactccaa attttggaac agcagtctca ggaagaatat cttagtgata ttgcttataa 420
          atctactgag 430
           <![CDATA[ <210> 539]]>
           <![CDATA[ <211> 81]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 539]]>
          catttatctc ccaatgataa tgaaaacgat acgtcctatg taattgagag tgatgaagat 60
          ttagaaatgg agatgcttaa g 81
           <![CDATA[ <210> 540]]>
           <![CDATA[ <211> 81]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 540]]>
          catttatctc ccaatgataa tgaaaacgat acgtcctatg taattgagag tgatgaagat 60
          ttagaaatgg agatgcttaa g 81
           <![CDATA[ <210> 541]]>
           <![CDATA[ <211> 145]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 541]]>
          tctttagaaa acctcaatag tggcacggta gaaccaactc attctaaatg cttaaaaatg 60
          gaaagaaatc tgggtcttcc tactaaagaa gaagaagaag atgatgaaaa tgaagctaat 120
          gaaggggaag aagatgatga taagg 145
           <![CDATA[ <210> 542]]>
           <![CDATA[ <211> 76]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 542]]>
          actttttgtg gccagcaccc aatgaagagc aagttacttg cctcaagatg tactttggcc 60
          attccagttt taaacc 76
           <![CDATA[ <210> 543]]>
           <![CDATA[ <211> 68]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 543]]>
          agttcagtgg aaagtgattc attcagtatt agaagaaaga agagataatg ttgctgtcat 60
          ggcaactg 68
           <![CDATA[ <210> 544]]>
           <![CDATA[ <211> 109]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <21]]>3> Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;544]]&gt;
           <br/> <![CDATA[gatatggaaa gagtttgtgc ttccagtatc cacctgttta tgtaggcaag attggccttg 60
          ttatctctcc ccttatttct ctgatggaag accaagtgct acagcttaa 109
           <![CDATA[ <210> 545]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 545]]>
          aatgtccaac atcccagctt gcttccttgg atcagcacag tcagaaaatg ttctaacaga 60
          Tattaaatt 69
           <![CDATA[ <210> 546]]>
           <![CDATA[ <211> 83]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 546]]>
          aggtaaatac cggattgtat acgtaactcc agaatactgt tcaggtaaca tgggcctgct 60
          ccagcaactt gaggctgata ttg 83
           <![CDATA[ <210> 547]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 547]]>
          gtatcacgct cattgctgtg gatgaggctc actgtatttc tgagtggggg catgatttta 60
          gggattcatt caggaagttg ggctccctaa aagacagcact gccaatg 107
           <![CDATA[ <210> 548]]>
           <![CDATA[ <211> 185]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 548]]>
          gttccaatcg ttgcacttac tgctactgca agttcttcaa tccgggaaga cattgtacgt 60
          tgcttaaatc tgagaaatcc tcagatcacc tgtactggtt ttgatcgacc aaacctgtat 120
          ttagaagtta ggcgaaaaac agggaatatc cttcaggatc tgcagccatt tcttgtcaaa 180
          acaag 185
           <![CDATA[ <210> 549]]>
           <![CDATA[ <211> 175]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 549]]>
          ttcccactgg gaatttgaag gtccaacaat catctactgt ccttctagaa aaatgacaca 60
          acaagttaca ggtgaactta ggaaactgaa tctatcctgt ggaacatacc atgcgggcat 120
          gagttttagc acaaggaaag acattcatca taggtttgta agagatgaaa ttcag 175
           <![CDATA[ <210> 550]]>
           <![CDATA[ <211> 182]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 550]]>
          tgtgtcatag ctaccatagc ttttggaatg ggcattaata aagctgacat tcgccaagtc 60
          attcattacg gtgctcctaa ggacatggaa tcatattatc aggagattgg tagagctggt 120
          cgtgatggac ttcaaagttc ttgtcacgtc ctctgggctc ctgcagacat taacttaaat 180
          ag 182
           <![CDATA[ <210> 551]]>
           <![CDATA[ <211> 102]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 551]]>
          gcaccttctt actgagatac gtaatgagaa gtttcgatta tacaaattaa agatgatggc 60
          aaagatggaa aaatatcttc attctagcag atgtaggaga ca 102
           <![CDATA[ <210> 552]]>
           <![CDATA[ <211> 93]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 552]]>
          aatcatcttg tctcattttg aggacaaaca agtacaaaaa gcctccttgg gaattatggg 60
          aactgaaaaa tgctgtgata attgcaggtc cag 93
           <![CDATA[ <210> 553]]>
           <![CDATA[ <211> 142]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 553]]>
          attggatcat tgctattcca tggatgactc agaggataca tcctgggact ttggtccaca 60
          agcatttaag cttttgtctg ctgtggacat cttaggcgaa aaatttggaa ttgggcttcc 120
          aattttattt ctccgaggat ct 142
           <![CDATA[ <210> 554]]>
           <![CDATA[ <211> 171]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 554]]>
          aattctcagc gtcttgccga tcaatatcgc aggcacagtttatttggcac tggcaaggat 60
          caaacagaga gttggtggaa ggctttttcc cgtcagctga tcactgaggg attcttggta 120
          gaagtttctc ggtataacaa atttatgaag atttgcgccc ttacgaaaaa g 171
           <![CDATA[ <210> 555]]>
           <![CDATA[ <211> 95]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 555]]>
          ggtagaaatt ggcttcataa agctaataca gaatctcaga gcctcatcct tcaagctaat 60
          gaagaattgt gtccaaagaa gttgcttctg cctag 95
           <![CDATA[ <210> 556]]>
           <![CDATA[ <211> 76]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 556]]>
          ttcgaaaact gtatcttcgg gcaccaaaga gcattgttat aatcaagtac cagttgaatt 60
          aagtacagag aagaag 76
           <![CDATA[ <210> 557]]>
           <![CDATA[ <211> 74]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 557]]>
          tctaacttgg agaagttata ttcttataaa ccatgtgata agatttcttc tgggagtaac 60
          atttctaaaaaaag 74
           <![CDATA[ <210> 558]]>
           <![CDATA[ <211> 76]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 558]]>
          tatcatggta cagtcaccag aaaaagctta cagttcctca cagcctgtta tttcggcaca 60
          agagcaggag actcag 76
           <![CDATA[ <210> 559]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 559]]>
          attgtgttat atggcaaatt ggtagaagct aggcagaaac atgccaataa aatggatgtt 60
          cccccagcta ttctggcaac aaacaagata ctggtggata tggccaaaat gag 113
           <![CDATA[ <210> 560]]>
           <![CDATA[ <211> 115]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 560]]>
          accaactacg gttgaaaacg taaaaaggat tgatggtgtt tctgaaggca aagctgccat 60
          gttggcccct ctgttggaag tcatcaaaca tttctgccaa acaaatagtg ttcag 115
           <![CDATA[ <210> 561]]>
           <![CDATA[ <211> 132]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 561]]>
          acagacctct tttcaagtac aaaacctcaa gaagaacaga agacgagtct ggtagcaaaa 60
          aataaaatat gcacactttc acagtctatg gccatcacat actctttatt ccaagaaaag 120
          aagatgcctt tg 132
           <![CDATA[ <210> 562]]>
           <![CDATA[ <211> 163]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 562]]>
          aagagcatag ctgagagcag gattctgcct ctcatgacaa ttggcatgca cttatcccaa 60
          gcggtgaaag ctggctgccc ccttgatttg gagcgagcag gcctgactcc agaggttcag 120
          aagattattg ctgatgttat ccgaaaccct cccgtcaact cag 163
           <![CDATA[ <210> 563]]>
           <![CDATA[ <211> 209]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 563]]>
          atatgagtaa aattagccta atcagaatgt tagttcctga aaacattgac acgtacctta 60
          tccacatggc aattgagatc cttaaacatg gtcctgacag cggacttcaa ccttcatgtg 120
          atgtcaacaa aaggagatgt tttcccggtt ctgaagagat ctgttcaagt tctaagagaa 180
          gcaaggaaga agtaggcatc aatactgag 209
           <![CDATA[ <210> 564]]>
           <![CDATA[ <211> 3144]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 564]]>
          acttcatctg cagagagaaa gagacgatta cctgtgtggt ttgccaaagg aagtgatacc 60
          agcaagaaat taatggacaa aacgaaaagg ggaggtcttt ttagttaagc tggcaattac 120
          cagaacaatt atgtttcttg ctgtattata agaggatagc tatattttattctgaagag 180
          taaggagtag tattttggct taaaaatcat tctaattaca aagttcactg tttattgaag 240
          aactggcatc ttaaatcagc cttccgcaat tcatgtagtt tctgggtctt ctgggagcct 300
          acgtgagtac atcacctaac agaatattaa attagacttc ctgtaagatt gctttaagaa 360
          actgttactg tcctgttttc taatctcttt attaaaacag tgtatttgga aaatgttatg 420
          tgctctgatt tgatatagat aacagattag tagttacatg gtaattatgt gatataaaat 480
          attcatatat tatcaaaatt ctgttttgta aatgtaagaa agcatagtta ttttacaaat 540
          tgtttttact gtcttttgaa gaagttctta aatacgttgt taaatggtat tagttgacca 600
          gggcagtgaa aatgaaaccg cattttgggt gccattaaat agggaaaaaa catgtaaaaa 660
          atgtaaaatg gagaccaatt gcactaggca agtgtatatt ttgtatttta tatacaattt 720
          ctattatttt tcaagtaata aaacaatgtt tttcatactg aatattatat atatattttt 780
          tagctttcat ttacttaatt attttaagta cctttattt tccaggatgt cagaatttga 840
          ttctaatctc tcttatgtag cacatgtgac ttaatttaaa acctatactg tgacacagag 900
          ttgggtaaac gatgattatt taactttaag cagttcacca tccatttcaa agcctttgat 960
          tggctttttt gtaaataaaa ataacttgtt aagaaacaaa tatatctgtc atagaagaac 1020
          tagaaaatcc agggaagtga gaaaaatgaa aataaaaatc attcatagtt ttactagtag 1080
          ctaatcacag tcaacctctt ttgtgtatcc caccagactt ttttatattc atttgttttt 1140
          agttaaaata taaaagtctc gtatattccc atttttctgc attgcattac cagaaggtag 1200
          tggcgcctat taaatatgtg atatgttgtt gtccagccat ggcttctgca tttgcatgct 1260
          tttgtgtgtg catctgcaat accctgtgaa tatcctgtgt gatggagtgg caagtacgca 1320
          cagacacgtc tgctgcatgc ctaggtacga ggctgtctcc aggagaagca cttgtttgat 1380
          tatttgagtt gccaattgaa tttgctgctt tttttcatgg cttgccattt tcactgaaaa 1440
          gaatgactaa tgaaaaacga tgattggtta ttagatttgg atgtttggca gacattttct 1500
          caaaattgaa ctaagttggc ctcttcacgg aaaacaactg gtatttgttg tgccaatgat 1560
          aaaattggag atttctagca aaatgtataa ttttggaaaa gttgtgttcc tccactggaa 1620
          gcttgacagc tttccttaac ataaagactt ctctttctct tcgctttcac tactactact 1680
          actaattctt cttctgattc ttcttcttct ccttcttcct tcttccttcc ttcctcctcc 1740
          tcctccttct tcttcctctt cctcttcttc tttctctctt tccttccttc ccttcccttc 1800
          cccttccttc cttccttcct tccttcctcc ctccctccctccctccctcc ctccctcctt 1860
          tctttttctt tctctttctt tctttctttc tctctctctc tctctttctt tctttttctt 1920
          tctctttttc tttctttcaa gcagtcctcc cgcctcagtc ccccaaaata gtgggattac 1980
          aggtgtgagc caccatgcac agccttacat aaagcctttt ctaatgagat ggatagtaat 2040
          taacaaatgt gagtttttga tattatataa agattttttc tgtgtttcga agatccgtat 2100
          aactcagtga atcagtatgt tctggatgac taatatgtga tgttaagaaa tcatgactga 2160
          ggccgggcgc ggtggctcac gcctgtaatc ccagcacttt gggaggccga ggcgggcgga 2220
          tcacgagatc aggagatcga gaccaccctg gccaacatgg tgaaaccccg tctctactaa 2280
          aaatacaaaa attagctggg tgtgttggtg cgtgcctata atcccagcta ctcgggaggc 2340
          tgaggcagga gaatcgcttg aactcaggag gcggagattg cagtgagctg agactgcgcc 2400
          actgcacccc agcctggcga cagagcaaga ctccgtctca aaaataaaaa aagaaatcat 2460
          gactgggtaa aagatctgtt cagagtacaa gatggaccaa tggatttgat atatttgaat 2520
          ataacagagt atgaaaaagt ttattgatat agtttcagat tacacactgc aactaatctt 2580
          taagaaacta ttacttgtcc actttttggt aaaatttcag agaacaatgt ccaccattat 2640
          ctgaacaggc tattaaaata ctcttctctt ttccaactac gtgcctgtgc aaagtcagat 2700
          ttttttcata tacttcagcc aaaacagcat atcaaaatgg attgaatgca gaagtagatc 2760
          tgagaataca gccacttttg ttaagccaga caatgagatt tgcaaaatgt aaacaatgct 2820
          gctgttctca gtttttaaaa atatgttttt taaaagtatt tatgttaatg tgtacttggt 2880
          ttactactgc tatttttaaa taaaacaaga aacattttta aatgtctgtt ttaatttcta 2940
          aagtggtagt gatagatata acccatatta ataaaagctc tttggggtcc tcagtgattt 3000
          ttttttaaga gtatggaagg gttctcagac ctaagagatt gagaaatgct gatgtaatgt 3060
          tttattataa aggtgtacca tgaattatgt accttacttc atattgttgg acattaaagt 3120
          tgctttcagtttttttgttt taaa 3144
           <![CDATA[ <210> 565]]>
           <![CDATA[ <211> 7575]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223>WRN full mRNA polynucleotide sequence]]>
           <![CDATA[ <400> 565]]>
          gtgtactgtg tgcgccgggg aggcgccggc ttgtactcgg cagcgcggga ataaagtttg 60
          ctgatttggt gtctagcctg gatgcctggg ttgcaggccc tgcttgtggt ggcgctccac 120
          agtcatccgg ctgaagaaga cctgttggac tggatcttct cgggttttct ttcagatatt 180
          gttttgtatt tacccatgaa gacattgttt tttggactct gcaaataggga catttcaaag 240
          atgagtgaaa aaaaattgga aacaactgca cagcagcgga aatgtcctga atggatgaat 300
          gtgcagaata aaagatgtgc tgtagaagaa agaaaggcat gtgttcggaa gagtgttttt 360
          gaagatgacc tccccttctt agaattcact ggatccattg tgtatagtta cgatgctagt 420
          gattgctctt tcctgtcaga agatattagc atgagtctat cagatgggga tgtggtggga 480
          tttgacatgg agtggccacc attatacaat agagggaaac ttggcaaagt tgcactaatt 540
          cagttgtgtg tttctgagag caaatgttac ttgttccacg tttcttccat gtcagttttt 600
          ccccagggat taaaaatgtt gcttgaaaat aaagcagtta aaaaggcagg tgtaggaatt 660
          gaaggagatc agtggaaact tctacgtgac tttgatatca aattgaagaa ttttgtggag 720
          ttgacagatg ttgccaataa aaagctgaaa tgcacagaga cctggagcct taacagtctg 780
          gttaaacacc tcttaggtaa acagctcctg aaagacaagt ctatccgctg tagcaattgg 840
          agtaaatttc ctctcactga ggaccagaaa ctgtatgcag ccactgatgc ttatgctggt 900
          tttattattt accgaaattt agagattttg gatgatactg tgcaaaggtt tgctataaat 960
          aaagaggaag aaatcctact tagcgacatg aacaaacagt tgacttcaat ctctgaggaa 1020
          gtgatggatc tggctaagca tcttcctcat gctttcagta aattggaaaa cccacggagg 1080
          gtttctatct tactaaagga tatttcagaa aatctatatt cactgaggag gatgataatt 1140
          gggtctacta acattgagac tgaactgagg cccagcaata atttaaactt attatccttt 1200
          gaagattcaa ctactggggg agtacaacag aaacaaatta gagaacatga agttttaatt 1260
          cacgttgaag atgaaacatg ggacccaaca cttgatcatt tagctaaaca tgatggagaa 1320
          gatgtacttg gaaataaagt ggaacgaaaa gaagatggat ttgaagatgg agtagaagac 1380
          aacaaattga aagagaatat ggaaagagct tgtttgatgt cgttagatat tacagaacat 1440
          gaactccaaa ttttggaaca gcagtctcag gaagaatatc ttagtgatat tgcttataaa 1500
          tctactgagc atttatctcc caatgataat gaaaacgata cgtcctatgt aattgagagt 1560
          gatgaagatt tagaaatgga gatgcttaag catttatctc ccaatgataa tgaaaacgat 1620
          acgtcctatg taattgagag tgatgaagat ttagaaatgg agatgcttaa gtctttagaa 1680
          aacctcaata gtggcacggt agaaccaact cattctaaat gcttaaaaat ggaaagaaat 1740
          ctgggtcttc ctactaaaga agaagaagaa gatgatgaaa atgaagctaa tgaaggggaa 1800
          gaagatgatg ataaggactt tttgtggcca gcacccaatg aagagcaagt tacttgcctc 1860
          aagatgtact ttggccattc cagttttaaa ccagttcagt ggaaagtgat tcattcagta 1920
          ttagaagaaa gaagagataa tgttgctgtc atggcaactg gatatggaaa gagtttgtgc 1980
          ttccagtatc cacctgttta tgtaggcaag attggccttg ttatctctcc ccttatttct 2040
          ctgatggaag accaagtgct acagcttaaa atgtccaaca tcccagcttg cttccttgga 2100
          tcagcacagt cagaaaatgt tctaacagat attaaattag gtaaataccg gattgtatac 2160
          gtaactccag aatactgttc aggtaacatg ggcctgctcc agcaacttga ggctgatatt 2220
          ggtatcacgc tcattgctgt ggatgaggct cactgtattt ctgagtgggg gcatgatttt 2280
          agggattcat tcaggaagtt gggctcccta aagacagcac tgccaatggt tccaatcgtt 2340
          gcacttactg ctactgcaag ttcttcaatc cgggaagaca ttgtacgttg cttaaatctg 2400
          agaaatcctc agaatcacctg tactggtttt gatcgaccaa acctgtattt agaagttagg 2460
          cgaaaaacag ggaatatcct tcaggatctg cagccatttc ttgtcaaaac aagttcccac 2520
          tgggaatttg aaggtccaac aatcatctac tgtccttcta gaaaaatgac acaacaagtt 2580
          acaggtgaac ttaggaaact gaatctatcc tgtggaacat accatgcggg catgagtttt 2640
          agcacaagga aagacattca tcataggtt gtaagagatg aaattcagtg tgtcatagct 2700
          accatagctt ttggaatggg cattaataaa gctgacattc gccaagtcat tcattacggt 2760
          gctcctaagg acatggaatc atattatcag gagattggta gagctggtcg tgatggactt 2820
          caaagttctt gtcacgtcct ctgggctcct gcagacatta acttaaatag gcaccttctt 2880
          actgagatac gtaatgagaa gtttcgatta tacaaattaa agatgatggc aaagatggaa 2940
          aaatatcttc attctagcag atgtaggaga caaatcatct tgtctcattt tgaggacaaa 3000
          caagtacaaa aagcctcctt gggaattatg ggaactgaaa aatgctgtga taattgcagg 3060
          tccagattgg atcattgcta ttccatggat gactcagagg atacatcctg ggactttggt 3120
          ccacaagcat ttaagctttt gtctgctgtg gacatcttag gcgaaaaatt tggaattggg 3180
          cttccaattt tatttctccg aggatctaat tctcagcgtc ttgccgatca atatcgcagg 3240
          cacagtttat ttggcactgg caaggatcaa acagagagtt ggtggaaggc tttttcccgt 3300
          cagctgatca ctgagggatt cttggtagaa gtttctcggt ataacaaatt tatgaagatt 3360
          tgcgccctta cgaaaaaggg tagaaattgg cttcataaag ctaatacaga atctcagagc 3420
          ctcatccttc aagctaatga agaattgtgt ccaaagaagt tgcttctgcc tagttcgaaa 3480
          actgtatctt cgggcaccaa agagcattgt tataatcaag taccagttga attaagtaca 3540
          gagaagaagt ctaacttgga gaagttatat tcttataaac catgtgataa gatttcttct 3600
          gggagtaaca tttctaaaaa aagtatcatg gtacagtcac cagaaaaagc ttacagttcc 3660
          tcacagcctg ttatttcggc acaagagcag gagactcaga ttgtgttata tggcaaattg 3720
          gtagaagcta ggcagaaaca tgccaataaa atggatgttc ccccagctat tctggcaaca 3780
          aacaagatac tggtggatat ggccaaaatg agaccaacta cggttgaaaa cgtaaaaagg 3840
          attgatggtg tttctgaagg caaagctgcc atgttggccc ctctgttgga agtcatcaaa 3900
          catttctgcc aaacaaatag tgttcagaca gacctctttt caagtacaaa acctcaagaa 3960
          gaacagaaga cgagtctggt agcaaaaaat aaaatatgca cactttcaca gtctatggcc 4020
          atcacatact ctttattcca agaaaagaag atgcctttga agagcatagc tgagagcagg 4080
          attctgcctc tcatgacaat tggcatgcac ttatcccaag cggtgaaagc tggctgcccc 4140
          cttgatttgg agcgagcagg cctgactcca gaggttcaga agattattgc tgatgttatc 4200
          cgaaaccctc ccgtcaactc agatatgagt aaaattagcc taatcagaat gttagttcct 4260
          gaaaacattg acacgtacct tatccacatg gcaattgaga tccttaaaca tggtcctgac 4320
          agcggacttc aaccttcatg tgatgtcaac aaaaggagat gttttcccgg ttctgaagag 4380
          atctgttcaa gttctaagag aagcaaggaa gaagtaggca tcaatactga gacttcatct 4440
          gcagagagaa agagacgatt acctgtgtgg tttgccaaag gaagtgatac cagcaagaaa 4500
          ttaatggaca aaacgaaaag gggaggtctt tttagttaag ctggcaatta ccagaacaat 4560
          tatgtttctt gctgtattat aagaggatag ctatatttta tttctgaaga gtaaggagta 4620
          gtattttggc ttaaaaatca ttctaattac aaagttcact gtttattgaa gaactggcat 4680
          cttaaatcag ccttccgcaa ttcatgtagt ttctgggtct tctgggagcc tacgtgagta 4740
          catcacctaa cagaatatta aattagactt cctgtaagat tgctttaaga aactgttact 4800
          gtcctgtttt ctaatctctt tattaaaaca gtgtatttgg aaaatgttat gtgctctgat 4860
          ttgatataga taacagatta gtagttacat ggtaattatg tgatataaaa tattcatata 4920
          ttatcaaaat tctgttttgt aaatgtaaga aagcatagtt attttacaaa ttgtttttac 4980
          tgtcttttga agaagttctt aaatacgttg ttaaatggta ttagttgacc agggcagtga 5040
          aaatgaaacc gcattttggg tgccattaaa tagggaaaaa acatgtaaaa aatgtaaaat 5100
          ggagaccaat tgcactaggc aagtgtatat tttgtatttt atatacaatt tctattattt 5160
          ttcaagtaat aaaacaatgt ttttcatact gaatattata tatatatttt ttagctttca 5220
          tttacttaat tattttaagt acctttattt ttccaggatg tcagaatttg attctaatct 5280
          ctcttatgta gcacatgtga cttaatttaa aacctatact gtgacacaga gttgggtaaa 5340
          cgatgattat ttaactttaa gcagttcacc atccatttca aagcctttga ttggcttttt 5400
          tgtaaataaa aataacttgt taagaaacaa atatatctgt catagaagaa ctagaaaatc 5460
          cagggaagtg agaaaaatga aaataaaaat cattcatagt tttactagta gctaatcaca 5520
          gtcaacctct tttgtgtatc ccaccagact tttttatatt catttgtttt tagttaaaat 5580
          ataaaagtct cgtatattcc catttttctg cattgcatta ccagaaggta gtggcgccta 5640
          ttaaatatgt gatatgttgt tgtccagcca tggcttctgc atttgcatgc ttttgtgtgtgt 5700
          gcatctgcaa taccctgtga atatcctgtg tgatggagtg gcaagtacgc acagacacgt 5760
          ctgctgcatg cctaggtacg aggctgtctc caggagaagc acttgtttga ttatttgagt 5820
          tgccaattga atttgctgct ttttttcatg gcttgccatt ttcactgaaa agaatgacta 5880
          atgaaaaacg atgattggtt attagatttg gatgtttggc agacattttc tcaaaattga 5940
          actaagttgg cctcttcacg gaaaacaact ggtatttgtt gtgccaatga taaaattgga 6000
          gatttctagc aaaatgtata attttggaaa agttgtgttc ctccactgga agcttgacag 6060
          ctttccttaa cataaagact tctctttctc ttcgctttca ctactactac tactaattct 6120
          tcttctgatt cttcttcttc tccttcttcc ttcttccttc cttcctcctc ctcctccttc 6180
          ttcttcctct tcctcttctt ctttctctct ttccttccctt cccttccctt ccccttcctt 6240
          ccttccttcc ttccttcctc cctccctccc tccctccctc cctccctcct ttctttttct 6300
          ttctctttct ttctttcttt ctctctctct ctctctttct ttctttttct ttctcttttt 6360
          ctttctttca agcagtcctc ccgcctcagt cccccaaaat agtgggatta caggtgtgag 6420
          ccaccatgca cagccttaca taaagccttt tctaatgaga tggatagtaa ttaacaaatg 6480
          tgagtttttg atattatata aagatttttt ctgtgtttcg aagatccgta taactcagtg 6540
          aatcagtatg ttctggatga ctaatatgtg atgttaagaa atcatgactg aggccgggcg 6600
          cggtggctca cgcctgtaat cccagcactt tgggaggccg aggcgggcgg atcacgagat 6660
          caggagatcg agaccaccct ggccaacatg gtgaaaccccc gtctctacta aaaatacaaa 6720
          aattagctgg gtgtgttggt gcgtgcctat aatcccagct actcgggagg ctgaggcagg 6780
          agaatcgctt gaactcagga ggcggagatt gcagtgagct gagactgcgc cactgcaccc 6840
          cagcctggcg acagagcaag actccgtctc aaaaataaaa aaagaaatca tgactgggta 6900
          aaagatctgt tcagagtaca agatggacca atggatttga tatatttgaa tataacagag 6960
          tatgaaaaag tttattgata tagtttcaga ttacacactg caactaatct ttaagaaact 7020
          attacktgtc cactttttgg taaaatttca gagaacaatg tccaccatta tctgaacagg 7080
          ctattaaaat actcttctct tttccaacta cgtgcctgtg caaagtcaga tttttttcat 7140
          atacttcagc caaaacagca tatcaaaatg gattgaatgc agaagtagat ctgagaatac 7200
          agccactttt gttaagccag acaatgagat ttgcaaaatg taaacaatgc tgctgttctc 7260
          agtttttaaa aatatgtttt ttaaaagtat ttatgttaat gtgtacttgg tttactactg 7320
          ctatttttaa ataaaacaag aaacattttt aaatgtctgt tttaatttct aaagtggtag 7380
          tgatagatat aacccatatt aataaaagct ctttggggtc ctcagtgatt tttttttaag 7440
          agtatggaag ggttctcaga cctaagagat tgagaaatgc tgatgtaatg ttttattata 7500
          aaggtgtacc atgaattatg taccttactt catattgttg gacattaaag ttgctttcag 7560
          tttttttgtt ttaaa 7575
           <![CDATA[ <210> 566]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 566]]>
          Met Ser Glu Lys Lys Leu Glu Thr Thr Ala Gln Gln Arg Lys Cys Pro
          1 5 10 15
          Glu Trp Met Asn Val Gln Asn Lys Arg Cys Ala Val Glu Glu Arg Lys
                      20 25 30
           <![CDATA[ <210> 567]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 567]]>
          Ala Cys Val Arg Lys Ser Val Phe Glu Asp Asp Leu Pro Phe Leu Glu
          1 5 10 15
          Phe Thr Gly Ser Ile Val Tyr Ser Tyr Asp Ala Ser Asp Cys Ser Phe
                      20 25 30
          Leu Ser Glu Asp Ile
                  35
           <![CDATA[ <210> 568]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 568]]>
          Met Ser Leu Ser Asp Gly Asp Val Val Gly Phe Asp Met Glu Trp Pro
          1 5 10 15
          Pro Leu Tyr Asn Arg Gly Lys Leu Gly Lys Val Ala Leu Ile Gln Leu
                      20 25 30
          Cys Val Ser Glu Ser Lys Cys Tyr Leu Phe His Val Ser Ser Met Ser
                  35 40 45
           <![CDATA[ <210> 569]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 569]]>
          Phe Pro Gln Gly Leu Lys Met Leu Leu Glu Asn Lys Ala Val Lys Lys
          1 5 10 15
          Ala Gly Val Gly Ile Glu Gly Asp Gln Trp Lys Leu Leu Arg Asp Phe
                      20 25 30
          Asp Ile Lys Leu Lys Asn Phe Val Glu Leu Thr Asp Val Ala Asn Lys
                  35 40 45
          Lys
           <![CDATA[ <210> 570]]>
           <![CDATA[ <211> 50]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 570]]>
          Leu Lys Cys Thr Glu Thr Trp Ser Leu Asn Ser Leu Val Lys His Leu
          1 5 10 15
          Leu Gly Lys Gln Leu Leu Lys Asp Lys Ser Ile Arg Cys Ser Asn Trp
                      20 25 30
          Ser Lys Phe Pro Leu Thr Glu Asp Gln Lys Leu Tyr Ala Ala Thr Asp
                  35 40 45
          Ala Tyr
              50
           <![CDATA[ <210> 571]]>
           <![CDATA[ <211> 23]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 571]]>
          Ala Gly Phe Ile Ile Tyr Arg Asn Leu Glu Ile Leu Asp Asp Thr Val
          1 5 10 15
          Gln Arg Phe Ala Ile Asn Lys
                      20
           <![CDATA[ <210> 572]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 572]]>
          Glu Glu Ile Leu Leu Ser Asp Met Asn Lys Gln Leu Thr Ser Ile Ser
          1 5 10 15
          Glu Glu Val Met Asp Leu Ala Lys His Leu Pro His Ala Phe Ser Lys
                      20 25 30
          Leu Glu Asn Pro Arg
                  35
           <![CDATA[ <210> 573]]>
           <![CDATA[ <211> 143]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 573]]>
          Val Ser Ile Leu Leu Lys Asp Ile Ser Glu Asn Leu Tyr Ser Leu Arg
          1 5 10 15
          Arg Met Ile Ile Gly Ser Thr Asn Ile Glu Thr Glu Leu Arg Pro Ser
                      20 25 30
          Asn Asn Leu Asn Leu Leu Ser Phe Glu Asp Ser Thr Thr Gly Gly Val
                  35 40 45
          Gln Gln Lys Gln Ile Arg Glu His Glu Val Leu Ile His Val Glu Asp
              50 55 60
          Glu Thr Trp Asp Pro Thr Leu Asp His Leu Ala Lys His Asp Gly Glu
          65 70 75 80
          Asp Val Leu Gly Asn Lys Val Glu Arg Lys Glu Asp Gly Phe Glu Asp
                          85 90 95
          Gly Val Glu Asp Asn Lys Leu Lys Glu Asn Met Glu Arg Ala Cys Leu
                      100 105 110
          Met Ser Leu Asp Ile Thr Glu His Glu Leu Gln Ile Leu Glu Gln Gln
                  115 120 125
          Ser Gln Glu Glu Tyr Leu Ser Asp Ile Ala Tyr Lys Ser Thr Glu
              130 135 140
           <![CDATA[ <210> 574]]>
           <![CDATA[ <211> 27]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 574]]>
          His Leu Ser Pro Asn Asp Asn Glu Asn Asp Thr Ser Tyr Val Ile Glu
          1 5 10 15
          Ser Asp Glu Asp Leu Glu Met Glu Met Leu Lys
                      20 25
           <![CDATA[ <210> 575]]>
           <![CDATA[ <211> 27]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 575]]>
          His Leu Ser Pro Asn Asp Asn Glu Asn Asp Thr Ser Tyr Val Ile Glu
          1 5 10 15
          Ser Asp Glu Asp Leu Glu Met Glu Met Leu Lys
                      20 25
           <![CDATA[ <210> 576]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 576]]>
          Ser Leu Glu Asn Leu Asn Ser Gly Thr Val Glu Pro Thr His Ser Lys
          1 5 10 15
          Cys Leu Lys Met Glu Arg Asn Leu Gly Leu Pro Thr Lys Glu Glu Glu Glu
                      20 25 30
          Glu Asp Asp Glu Asn Glu Ala Asn Glu Gly Glu Glu Asp Asp Asp Lys
                  35 40 45
           <![CDATA[ <210> 577]]>
           <![CDATA[ <211> 24]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 577]]>
          Phe Leu Trp Pro Ala Pro Asn Glu Glu Gln Val Thr Cys Leu Lys Met
          1 5 10 15
          Tyr Phe Gly His Ser Ser Phe Lys
                      20
           <![CDATA[ <210> 578]]>
           <![CDATA[ <211> 22]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 578]]>
          Val Gln Trp Lys Val Ile His Ser Val Leu Glu Glu Arg Arg Asp Asn
          1 5 10 15
          Val Ala Val Met Ala Thr
                      20
           <![CDATA[ <210> 579]]>
           <![CDATA[ <211> 35]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 579]]>
          Tyr Gly Lys Ser Leu Cys Phe Gln Tyr Pro Pro Val Tyr Val Gly Lys
          1 5 10 15
          Ile Gly Leu Val Ile Ser Pro Leu Ile Ser Leu Met Glu Asp Gln Val
                      20 25 30
          Leu Gln Leu
                  35
           <![CDATA[ <210> 580]]>
           <![CDATA[ <211> 22]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 580]]>
          Met Ser Asn Ile Pro Ala Cys Phe Leu Gly Ser Ala Gln Ser Glu Asn
          1 5 10 15
          Val Leu Thr Asp Ile Lys
                      20
           <![CDATA[ <210> 581]]>
           <![CDATA[ <211> 27]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 581]]>
          Gly Lys Tyr Arg Ile Val Tyr Val Thr Pro Glu Tyr Cys Ser Gly Asn
          1 5 10 15
          Met Gly Leu Leu Gln Gln Leu Glu Ala Asp Ile
                      20 25
           <![CDATA[ <210> 582]]>
           <![CDATA[ <211> 35]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 58]]>2
          Ile Thr Leu Ile Ala Val Asp Glu Ala His Cys Ile Ser Glu Trp Gly
          1 5 10 15
          His Asp Phe Arg Asp Ser Phe Arg Lys Leu Gly Ser Leu Lys Thr Ala
                      20 25 30
          Leu Pro Met
                  35
           <![CDATA[ <210> 583]]>
           <![CDATA[ <211> 61]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 583]]>
          Val Pro Ile Val Ala Leu Thr Ala Thr Ala Ser Ser Ser Ile Arg Glu
          1 5 10 15
          Asp Ile Val Arg Cys Leu Asn Leu Arg Asn Pro Gln Ile Thr Cys Thr
                      20 25 30
          Gly Phe Asp Arg Pro Asn Leu Tyr Leu Glu Val Arg Arg Lys Thr Gly
                  35 40 45
          Asn Ile Leu Gln Asp Leu Gln Pro Phe Leu Val Lys Thr
              50 55 60
           <![CDATA[ <210> 584]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 584]]>
          Ser His Trp Glu Phe Glu Gly Pro Thr Ile Ile Tyr Cys Pro Ser Arg
          1 5 10 15
          Lys Met Thr Gln Gln Val Thr Gly Glu Leu Arg Lys Leu Asn Leu Ser
                      20 25 30
          Cys Gly Thr Tyr His Ala Gly Met Ser Phe Ser Thr Arg Lys Asp Ile
                  35 40 45
          His His Arg Phe Val Arg Asp Glu Ile Gln
              50 55
           <![CDATA[ <210> 585]]>
           <![CDATA[ <211> 60]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 585]]>
          Cys Val Ile Ala Thr Ile Ala Phe Gly Met Gly Ile Asn Lys Ala Asp
          1 5 10 15
          Ile Arg Gln Val Ile His Tyr Gly Ala Pro Lys Asp Met Glu Ser Tyr
                      20 25 30
          Tyr Gln Glu Ile Gly Arg Ala Gly Arg Asp Gly Leu Gln Ser Ser Cys
                  35 40 45
          His Val Leu Trp Ala Pro Ala Asp Ile Asn Leu Asn
              50 55 60
           <![CDATA[ <210> 586]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 586]]>
          His Leu Leu Thr Glu Ile Arg Asn Glu Lys Phe Arg Leu Tyr Lys Leu
          1 5 10 15
          Lys Met Met Ala Lys Met Glu Lys Tyr Leu His Ser Ser Arg Cys Arg
                      20 25 30
          Arg
           <![CDATA[ <210> 587]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 587]]>
          Ile Ile Leu Ser His Phe Glu Asp Lys Gln Val Gln Lys Ala Ser Leu
          1 5 10 15
          Gly Ile Met Gly Thr Glu Lys Cys Cys Asp Asn Cys Arg Ser
                      20 25 30
           <![CDATA[ <210> 588]]>
           <![CDATA[ <211> 47]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 588]]>
          Leu Asp His Cys Tyr Ser Met Asp Asp Ser Glu Asp Thr Ser Trp Asp
          1 5 10 15
          Phe Gly Pro Gln Ala Phe Lys Leu Leu Ser Ala Val Asp Ile Leu Gly
                      20 25 30
          Glu Lys Phe Gly Ile Gly Leu Pro Ile Leu Phe Leu Arg Gly Ser
                  35 40 45
           <![CDATA[ <210> 589]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 589]]>
          Asn Ser Gln Arg Leu Ala Asp Gln Tyr Arg Arg His Ser Leu Phe Gly
          1 5 10 15
          Thr Gly Lys Asp Gln Thr Glu Ser Trp Trp Lys Ala Phe Ser Arg Gln
                      20 25 30
          Leu Ile Thr Glu Gly Phe Leu Val Glu Val Ser Arg Tyr Asn Lys Phe
                  35 40 45
          Met Lys Ile Cys Ala Leu Thr Lys Lys
              50 55
           <![CDATA[ <210> 590]]>
           <![CDATA[ <211> 31]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 590]]>
          Gly Arg Asn Trp Leu His Lys Ala Asn Thr Glu Ser Gln Ser Leu Ile
          1 5 10 15
          Leu Gln Ala Asn Glu Glu Leu Cys Pro Lys Lys Leu Leu Leu Pro
                      20 25 30
           <![CDATA[ <210> 591]]>
           <![CDATA[ <211> 25]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 591]]>
          Ser Lys Thr Val Ser Ser Gly Thr Lys Glu His Cys Tyr Asn Gln Val
          1 5 10 15
          Pro Val Glu Leu Ser Thr Glu Lys Lys
                      20 25
           <![CDATA[ <210> 592]]>
           <![CDATA[ <211> 24]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 592]]>
          Ser Asn Leu Glu Lys Leu Tyr Ser Tyr Lys Pro Cys Asp Lys Ile Ser
          1 5 10 15
          Ser Gly Ser Asn Ile Ser Lys Lys
                      20
           <![CDATA[ <210> 593]]>
           <![CDATA[ <211> 25]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 593]]>
          Ile Met Val Gln Ser Pro Glu Lys Ala Tyr Ser Ser Ser Gln Pro Val
          1 5 10 15
          Ile Ser Ala Gln Glu Gln Glu Thr Gln
                      20 25
           <![CDATA[ <210> 594]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 594]]>
          Ile Val Leu Tyr Gly Lys Leu Val Glu Ala Arg Gln Lys His Ala Asn
          1 5 10 15
          Lys Met Asp Val Pro Pro Ala Ile Leu Ala Thr Asn Lys Ile Leu Val
                      20 25 30
          Asp Met Ala Lys Met
                  35
           <![CDATA[ <210> 595]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 595]]>
          Pro Thr Thr Val Glu Asn Val Lys Arg Ile Asp Gly Val Ser Glu Gly
          1 5 10 15
          Lys Ala Ala Met Leu Ala Pro Leu Leu Glu Val Ile Lys His Phe Cys
                      20 25 30
          Gln Thr Asn Ser Val Gln
                  35
           <![CDATA[ <210> 596]]>
           <![CDATA[ <211> 44]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 596]]>
          Thr Asp Leu Phe Ser Ser Thr Lys Pro Gln Glu Glu Gln Lys Thr Ser
          1 5 10 15
          Leu Val Ala Lys Asn Lys Ile Cys Thr Leu Ser Gln Ser Met Ala Ile
                      20 25 30
          Thr Tyr Ser Leu Phe Gln Glu Lys Lys Met Pro Leu
                  35 40
           <![CDATA[ <210> 597]]>
           <![CDATA[ <211> 54]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 597]]>
          Lys Ser Ile Ala Glu Ser Arg Ile Leu Pro Leu Met Thr Ile Gly Met
          1 5 10 15
          His Leu Ser Gln Ala Val Lys Ala Gly Cys Pro Leu Asp Leu Glu Arg
                      20 25 30
          Ala Gly Leu Thr Pro Glu Val Gln Lys Ile Ile Ala Asp Val Ile Arg
                  35 40 45
          Asn Pro Pro Val Asn Ser
              50
           <![CDATA[ <210> 598]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 598]]>
          Met Ser Lys Ile Ser Leu Ile Arg Met Leu Val Pro Glu Asn Ile Asp
          1 5 10 15
          Thr Tyr Leu Ile His Met Ala Ile Glu Ile Leu Lys His Gly Pro Asp
                      20 25 30
          Ser Gly Leu Gln Pro Ser Cys Asp Val Asn Lys Arg Arg Cys Phe Pro
                  35 40 45
          Gly Ser Glu Glu Ile Cys Ser Ser Ser Lys Arg Ser Lys Glu Glu Val
              50 55 60
          Gly Ile Asn Thr Glu
          65
           <![CDATA[ <210> 599]]>
           <![CDATA[ <211> 35]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 599]]>
          Thr Ser Ser Ala Glu Arg Lys Arg Arg Leu Pro Val Trp Phe Ala Lys
          1 5 10 15
          Gly Ser Asp Thr Ser Lys Lys Leu Met Asp Lys Thr Lys Arg Gly Gly
                      20 25 30
          Leu Phe Ser
                  35
           <![CDATA[ <210> 600]]>
           <![CDATA[ <211> 1432]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 600]]>
          Met Ser Glu Lys Lys Leu Glu Thr Thr Ala Gln Gln Arg Lys Cys Pro
          1 5 10 15
          Glu Trp Met Asn Val Gln Asn Lys Arg Cys Ala Val Glu Glu Arg Lys
                      20 25 30
          Ala Cys Val Arg Lys Ser Val Phe Glu Asp Asp Leu Pro Phe Leu Glu
                  35 40 45
          Phe Thr Gly Ser Ile Val Tyr Ser Tyr Asp Ala Ser Asp Cys Ser Phe
              50 55 60
          Leu Ser Glu Asp Ile Ser Met Ser Leu Ser Asp Gly Asp Val Val Gly
          65 70 75 80
          Phe Asp Met Glu Trp Pro Pro Leu Tyr Asn Arg Gly Lys Leu Gly Lys
                          85 90 95
          Val Ala Leu Ile Gln Leu Cys Val Ser Glu Ser Lys Cys Tyr Leu Phe
                      100 105 110
          His Val Ser Ser Met Ser Val Phe Pro Gln Gly Leu Lys Met Leu Leu
                  115 120 125
          Glu Asn Lys Ala Val Lys Lys Ala Gly Val Gly Ile Glu Gly Asp Gln
              130 135 140
          Trp Lys Leu Leu Arg Asp Phe Asp Ile Lys Leu Lys Asn Phe Val Glu
          145 150 155 160
          Leu Thr Asp Val Ala Asn Lys Lys Leu Lys Cys Thr Glu Thr Trp Ser
                          165 170 175
          Leu Asn Ser Leu Val Lys His Leu Leu Gly Lys Gln Leu Leu Lys Asp
                      180 185 190
          Lys Ser Ile Arg Cys Ser Asn Trp Ser Lys Phe Pro Leu Thr Glu Asp
                  195 200 205
          Gln Lys Leu Tyr Ala Ala Thr Asp Ala Tyr Ala Gly Phe Ile Ile Tyr
              210 215 220
          Arg Asn Leu Glu Ile Leu Asp Asp Thr Val Gln Arg Phe Ala Ile Asn
          225 230 235 240
          Lys Glu Glu Glu Ile Leu Leu Ser Asp Met Asn Lys Gln Leu Thr Ser
                          245 250 255
          Ile Ser Glu Glu Val Met Asp Leu Ala Lys His Leu Pro His Ala Phe
                      260 265 270
          Ser Lys Leu Glu Asn Pro Arg Arg Val Ser Ile Leu Leu Lys Asp Ile
                  275 280 285
          Ser Glu Asn Leu Tyr Ser Leu Arg Arg Met Ile Ile Gly Ser Thr Asn
              290 295 300
          Ile Glu Thr Glu Leu Arg Pro Ser Asn Asn Leu Asn Leu Leu Ser Phe
          305 310 315 320
          Glu Asp Ser Thr Thr Gly Gly Val Gln Gln Lys Gln Ile Arg Glu His
                          325 330 335
          Glu Val Leu Ile His Val Glu Asp Glu Thr Trp Asp Pro Thr Leu Asp
                      340 345 350
          His Leu Ala Lys His Asp Gly Glu Asp Val Leu Gly Asn Lys Val Glu
                  355 360 365
          Arg Lys Glu Asp Gly Phe Glu Asp Gly Val Glu Asp Asn Lys Leu Lys
              370 375 380
          Glu Asn Met Glu Arg Ala Cys Leu Met Ser Leu Asp Ile Thr Glu His
          385 390 395 400
          Glu Leu Gln Ile Leu Glu Gln Gln Ser Gln Glu Glu Tyr Leu Ser Asp
                          405 410 415
          Ile Ala Tyr Lys Ser Thr Glu His Leu Ser Pro Asn Asp Asn Glu Asn
                      420 425 430
          Asp Thr Ser Tyr Val Ile Glu Ser Asp Glu Asp Leu Glu Met Glu Met
                  435 440 445
          Leu Lys His Leu Ser Pro Asn Asp Asn Glu Asn Asp Thr Ser Tyr Val
              450 455 460
          Ile Glu Ser Asp Glu Asp Leu Glu Met Glu Met Leu Lys Ser Leu Glu
          465 470 475 480
          Asn Leu Asn Ser Gly Thr Val Glu Pro Thr His Ser Lys Cys Leu Lys
                          485 490 495
          Met Glu Arg Asn Leu Gly Leu Pro Thr Lys Glu Glu Glu Glu Asp Asp
                      500 505 510
          Glu Asn Glu Ala Asn Glu Gly Glu Glu Asp Asp Asp Lys Asp Phe Leu
                  515 520 525
          Trp Pro Ala Pro Asn Glu Glu Gln Val Thr Cys Leu Lys Met Tyr Phe
              530 535 540
          Gly His Ser Ser Phe Lys Pro Val Gln Trp Lys Val Ile His Ser Val
          545 550 555 560
          Leu Glu Glu Arg Arg Asp Asn Val Ala Val Met Ala Thr Gly Tyr Gly
                          565 570 575
          Lys Ser Leu Cys Phe Gln Tyr Pro Pro Val Tyr Val Gly Lys Ile Gly
                      580 585 590
          Leu Val Ile Ser Pro Leu Ile Ser Leu Met Glu Asp Gln Val Leu Gln
                  595 600 605
          Leu Lys Met Ser Asn Ile Pro Ala Cys Phe Leu Gly Ser Ala Gln Ser
              610 615 620
          Glu Asn Val Leu Thr Asp Ile Lys Leu Gly Lys Tyr Arg Ile Val Tyr
          625 630 635 640
          Val Thr Pro Glu Tyr Cys Ser Gly Asn Met Gly Leu Leu Gln Gln Leu
                          645 650 655
          Glu Ala Asp Ile Gly Ile Thr Leu Ile Ala Val Asp Glu Ala His Cys
                      660 665 670
          Ile Ser Glu Trp Gly His Asp Phe Arg Asp Ser Phe Arg Lys Leu Gly
                  675 680 685
          Ser Leu Lys Thr Ala Leu Pro Met Val Pro Ile Val Ala Leu Thr Ala
              690 695 700
          Thr Ala Ser Ser Ser Ile Arg Glu Asp Ile Val Arg Cys Leu Asn Leu
          705 710 715 720
          Arg Asn Pro Gln Ile Thr Cys Thr Gly Phe Asp Arg Pro Asn Leu Tyr
                          725 730 735
          Leu Glu Val Arg Arg Lys Thr Gly Asn Ile Leu Gln Asp Leu Gln Pro
                      740 745 750
          Phe Leu Val Lys Thr Ser Ser His Trp Glu Phe Glu Gly Pro Thr Ile
                  755 760 765
          Ile Tyr Cys Pro Ser Arg Lys Met Thr Gln Gln Val Thr Gly Glu Leu
              770 775 780
          Arg Lys Leu Asn Leu Ser Cys Gly Thr Tyr His Ala Gly Met Ser Phe
          785 790 795 800
          Ser Thr Arg Lys Asp Ile His His Arg Phe Val Arg Asp Glu Ile Gln
                          805 810 815
          Cys Val Ile Ala Thr Ile Ala Phe Gly Met Gly Ile Asn Lys Ala Asp
                      820 825 830
          Ile Arg Gln Val Ile His Tyr Gly Ala Pro Lys Asp Met Glu Ser Tyr
                  835 840 845
          Tyr Gln Glu Ile Gly Arg Ala Gly Arg Asp Gly Leu Gln Ser Ser Cys
              850 855 860
          His Val Leu Trp Ala Pro Ala Asp Ile Asn Leu Asn Arg His Leu Leu
          865 870 875 880
          Thr Glu Ile Arg Asn Glu Lys Phe Arg Leu Tyr Lys Leu Lys Met Met
                          885 890 895
          Ala Lys Met Glu Lys Tyr Leu His Ser Ser Arg Cys Arg Arg Gln Ile
                      900 905 910
          Ile Leu Ser His Phe Glu Asp Lys Gln Val Gln Lys Ala Ser Leu Gly
                  915 920 925
          Ile Met Gly Thr Glu Lys Cys Cys Asp Asn Cys Arg Ser Arg Leu Asp
              930 935 940
          His Cys Tyr Ser Met Asp Asp Ser Glu Asp Thr Ser Trp Asp Phe Gly
          945 950 955 960
          Pro Gln Ala Phe Lys Leu Leu Ser Ala Val Asp Ile Leu Gly Glu Lys
                          965 970 975
          Phe Gly Ile Gly Leu Pro Ile Leu Phe Leu Arg Gly Ser Asn Ser Gln
                      980 985 990
          Arg Leu Ala Asp Gln Tyr Arg Arg His Ser Leu Phe Gly Thr Gly Lys
                  995 1000 1005
          Asp Gln Thr Glu Ser Trp Trp Lys Ala Phe Ser Arg Gln Leu Ile
              1010 1015 1020
          Thr Glu Gly Phe Leu Val Glu Val Ser Arg Tyr Asn Lys Phe Met
              1025 1030 1035
          Lys Ile Cys Ala Leu Thr Lys Lys Gly Arg Asn Trp Leu His Lys
              1040 1045 1050
          Ala Asn Thr Glu Ser Gln Ser Leu Ile Leu Gln Ala Asn Glu Glu Glu
              1055 1060 1065
          Leu Cys Pro Lys Lys Leu Leu Leu Pro Ser Ser Lys Thr Val Ser
              1070 1075 1080
          Ser Gly Thr Lys Glu His Cys Tyr Asn Gln Val Pro Val Glu Leu
              1085 1090 1095
          Ser Thr Glu Lys Lys Ser Asn Leu Glu Lys Leu Tyr Ser Tyr Lys
              1100 1105 1110
          Pro Cys Asp Lys Ile Ser Ser Gly Ser Asn Ile Ser Lys Lys Ser
              1115 1120 1125
          Ile Met Val Gln Ser Pro Glu Lys Ala Tyr Ser Ser Ser Ser Gln Pro
              1130 1135 1140
          Val Ile Ser Ala Gln Glu Gln Glu Thr Gln Ile Val Leu Tyr Gly
              1145 1150 1155
          Lys Leu Val Glu Ala Arg Gln Lys His Ala Asn Lys Met Asp Val
              1160 1165 1170
          Pro Pro Ala Ile Leu Ala Thr Asn Lys Ile Leu Val Asp Met Ala
              1175 1180 1185
          Lys Met Arg Pro Thr Thr Val Glu Asn Val Lys Arg Ile Asp Gly
              1190 1195 1200
          Val Ser Glu Gly Lys Ala Ala Met Leu Ala Pro Leu Leu Glu Val
              1205 1210 1215
          Ile Lys His Phe Cys Gln Thr Asn Ser Val Gln Thr Asp Leu Phe
              1220 1225 1230
          Ser Ser Thr Lys Pro Gln Glu Glu Gln Lys Thr Ser Leu Val Ala
              1235 1240 1245
          Lys Asn Lys Ile Cys Thr Leu Ser Gln Ser Met Ala Ile Thr Tyr
              1250 1255 1260
          Ser Leu Phe Gln Glu Lys Lys Met Pro Leu Lys Ser Ile Ala Glu
              1265 1270 1275
          Ser Arg Ile Leu Pro Leu Met Thr Ile Gly Met His Leu Ser Gln
              1280 1285 1290
          Ala Val Lys Ala Gly Cys Pro Leu Asp Leu Glu Arg Ala Gly Leu
              1295 1300 1305
          Thr Pro Glu Val Gln Lys Ile Ile Ala Asp Val Ile Arg Asn Pro
              1310 1315 1320
          Pro Val Asn Ser Asp Met Ser Lys Ile Ser Leu Ile Arg Met Leu
              1325 1330 1335
          Val Pro Glu Asn Ile Asp Thr Tyr Leu Ile His Met Ala Ile Glu
              1340 1345 1350
          Ile Leu Lys His Gly Pro Asp Ser Gly Leu Gln Pro Ser Cys Asp
              1355 1360 1365
          Val Asn Lys Arg Arg Cys Phe Pro Gly Ser Glu Glu Ile Cys Ser
              1370 1375 1380
          Ser Ser Lys Arg Ser Lys Glu Glu Val Gly Ile Asn Thr Glu Thr
              1385 1390 1395
          Ser Ser Ala Glu Arg Lys Arg Arg Leu Pro Val Trp Phe Ala Lys
              1400 1405 1410
          Gly Ser Asp Thr Ser Lys Lys Leu Met Asp Lys Thr Lys Arg Gly
              1415 1420 1425
          Gly Leu Phe Ser
              1430
           <![CDATA[ <210> 601]]>
           <![CDATA[ <211> 4222]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 601]]>
          gtgtactgtg tgcgccgggg aggcgccggc ttgtactcgg cagcgcggga ataaagtttg 60
          ctgatttggt gtctagcctg gatgcctggg ttgcaggccc tgcttgtggt ggcgctccac 120
          agtcatccgg ctgaagaaga cctgttggac tggatcttct cgggttttct ttcagatatt 180
          gttttgtatt tacccatgaa gacattgttt tttggactct gcaaataggga catttcaaag 240
          atgagtgaaa aaaaattgga aacaactgca cagcagcgga aatgtcctga atggatgaat 300
          gtgcagaata aaagatgtgc tgtagaagaa agaaaggcat gtgttcggaa gagtgttttt 360
          gaagatgacc tccccttctt agaattcact ggatccattg tgtatagtta cgatgctagt 420
          gattgctctt tcctgtcaga agatattagc atgagtctat cagatgggga tgtggtggga 480
          tttgacatgg agtggccacc attatacaat agagggaaac ttggcaaagt tgcactaatt 540
          cagttgtgtg tttctgagag caaatgttac ttgttccacg tttcttccat gtcagttttt 600
          ccccagggat taaaaatgtt gcttgaaaat aaagcagtta aaaaggcagg tgtaggaatt 660
          gaaggagatc agtggaaact tctacgtgac tttgatatca aattgaagaa ttttgtggag 720
          ttgacagatg ttgccaataa aaagctgaaa tgcacagaga cctggagcct taacagtctg 780
          gttaaacacc tcttaggtaa acagctcctg aaagacaagt ctatccgctg tagcaattgg 840
          agtaaatttc ctctcactga ggaccagaaa ctgtatgcag ccactgatgc ttatgctggt 900
          tttattattt accgaaattt agagattttg gatgatactg tgcaaaggtt tgctataaat 960
          aaagaggaag aaatcctact tagcgacatg aacaaacagt tgacttcaat ctctgaggaa 1020
          gtgatggatc tggctaagca tcttcctcat gctttcagta aattggaaaa cccacggagg 1080
          gtttctatct tactaaagga tatttcagaa aatctatatt cactgaggag gatgataatt 1140
          gggtctacta acattgagac tgaactgagg cccagcaata atttaaactt attatccttt 1200
          gaagattcaa ctactggggg agtacaacag aaacaaatta gagaacatga agttttaatt 1260
          cacgttgaag atgaaacatg ggacccaaca cttgatcatt tagctaaaca tgatggagaa 1320
          gatgtacttg gaaataaagt ggaacgaaaa gaagatggat ttgaagatgg agtagaagac 1380
          aacaaattga aagagaatat ggaaagagct tgtttgatgt cgttagatat tacagaacat 1440
          gaactccaaa ttttggaaca gcagtctcag gaagaatatc ttagtgatat tgcttataaa 1500
          tctactgagc atttatctcc caatgataat gaaaacgata cgtcctatgt aattgagagt 1560
          gatgaagatt tagaaatgga gatgcttaag catttatctc ccaatgataa tgaaaacgat 1620
          acgtcctatg taattgagag tgatgaagat ttagaaatgg agatgcttaa gtctttagaa 1680
          aacctcaata gtggcacggt agaaccaact cattctaaat gcttaaaaat ggaaagaaat 1740
          ctgggtcttc ctactaaaga agaagaagaa gatgatgaaa atgaagctaa tgaaggggaa 1800
          gaagatgatg ataaggactt tttgtggcca gcacccaatg aagagcaagt tacttgcctc 1860
          aagatgtact ttggccattc cagttttaaa ccagttcagt ggaaagtgat tcattcagta 1920
          ttagaagaaa gaagagataa tgttgctgtc atggcaactg gatatggaaa gagtttgtgc 1980
          ttccagtatc cacctgttta tgtaggcaag attggccttg ttatctctcc ccttatttct 2040
          ctgatggaag accaagtgct acagcttaaa atgtccaaca tcccagcttg cttccttgga 2100
          tcagcacagt cagaaaatgt tctaacagat attaaattag gtaaataccg gattgtatac 2160
          gtaactccag aatactgttc aggtaacatg ggcctgctcc agcaacttga ggctgatatt 2220
          ggtatcacgc tcattgctgt ggatgaggct cactgtattt ctgagtgggg gcatgatttt 2280
          agggattcat tcaggaagtt gggctcccta aagacagcac tgccaatggt tccaatcgtt 2340
          gcacttactg ctactgcaag ttcttcaatc cgggaagaca ttgtacgttg cttaaatctg 2400
          agaaatcctc agaatcacctg tactggtttt gatcgaccaa acctgtattt agaagttagg 2460
          cgaaaaacag ggaatatcct tcaggatctg cagccatttc ttgtcaaaac aagttcccac 2520
          tgggaatttg aaggtccaac aatcatctac tgtccttcta gaaaaatgac acaacaagtt 2580
          acaggtgaac ttaggaaact gaatctatcc tgtggaacat accatgcggg catgagtttt 2640
          agcacaagga aagacattca tcataggtt gtaagagatg aaattcagtg tgtcatagct 2700
          accatagctt ttggaatggg cattaataaa gctgacattc gccaagtcat tcattacggt 2760
          gctcctaagg acatggaatc atattatcag gagattggta gagctggtcg tgatggactt 2820
          caaagttctt gtcacgtcct ctgggctcct gcagacatta acttaaatag gcaccttctt 2880
          actgagatac gtaatgagaa gtttcgatta tacaaattaa agatgatggc aaagatggaa 2940
          aaatatcttc attctagcag atgtaggaga caaatcatct tgtctcattt tgaggacaaa 3000
          caagtacaaa aagcctcctt gggaattatg ggaactgaaa aatgctgtga taattgcagg 3060
          tccagattgg atcattgcta ttccatggat gactcagagg atacatcctg ggactttggt 3120
          ccacaagcat ttaagctttt gtctgctgtg gacatcttag gcgaaaaatt tggaattggg 3180
          cttccaattt tatttctccg aggatctaat tctcagcgtc ttgccgatca atatcgcagg 3240
          cacagtttat ttggcactgg caaggatcaa acagagagtt ggtggaaggc tttttcccgt 3300
          cagctgatca ctgagggatt cttggtagaa gtttctcggt ataacaaatt tatgaagatt 3360
          tgcgccctta cgaaaaaggg tagaaattgg cttcataaag ctaatacaga atctcagagc 3420
          ctcatccttc aagctaatga agaattgtgt ccaaagaagt tgcttctgcc tagttcgaaa 3480
          actgtatctt cgggcaccaa agagcattgt tataatcaag taccagttga attaagtaca 3540
          gagaagaagt ctaacttgga gaagttatat tcttataaac catgtgataa gatttcttct 3600
          gggagtaaca tttctaaaaa aagtatcatg gtacagtcac cagaaaaagc ttacagttcc 3660
          tcacagcctg ttatttcggc acaagagcag gagactcaga ttgtgttata tggcaaattg 3720
          gtagaagcta ggcagaaaca tgccaataaa atggatgttc ccccagctat tctggcaaca 3780
          aacaagatac tggtggatat ggccaaaatg agaccaacta cggttgaaaa cgtaaaaagg 3840
          attgatggtg tttctgaagg caaagctgcc atgttggccc ctctgttgga agtcatcaaa 3900
          catttctgcc aaacaaatag tgttcagaca gacctctttt caagtacaaa acctcaagaa 3960
          gaacagaaga cgagtctggt agcaaaaaat aaaatatgca cactttcaca gtctatggcc 4020
          atcacatact ctttattcca agaaaagaag atgcctttga agagcatagc tgagagcagg 4080
          attctgcctc tcatgacaat tggcatgcac ttatcccaag cggtgaaagc tggctgcccc 4140
          cttgatttgg agcgagcagg cctgactcca gaggttcaga agattattgc tgatgttatc 4200
          cgaaaccctc ccgtcaactc ag 4222
           <![CDATA[ <210> 602]]>
           <![CDATA[ <211> 1327]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 602]]>
          Met Ser Glu Lys Lys Leu Glu Thr Thr Ala Gln Gln Arg Lys Cys Pro
          1 5 10 15
          Glu Trp Met Asn Val Gln Asn Lys Arg Cys Ala Val Glu Glu Arg Lys
                      20 25 30
          Ala Cys Val Arg Lys Ser Val Phe Glu Asp Asp Leu Pro Phe Leu Glu
                  35 40 45
          Phe Thr Gly Ser Ile Val Tyr Ser Tyr Asp Ala Ser Asp Cys Ser Phe
              50 55 60
          Leu Ser Glu Asp Ile Ser Met Ser Leu Ser Asp Gly Asp Val Val Gly
          65 70 75 80
          Phe Asp Met Glu Trp Pro Pro Leu Tyr Asn Arg Gly Lys Leu Gly Lys
                          85 90 95
          Val Ala Leu Ile Gln Leu Cys Val Ser Glu Ser Lys Cys Tyr Leu Phe
                      100 105 110
          His Val Ser Ser Met Ser Val Phe Pro Gln Gly Leu Lys Met Leu Leu
                  115 120 125
          Glu Asn Lys Ala Val Lys Lys Ala Gly Val Gly Ile Glu Gly Asp Gln
              130 135 140
          Trp Lys Leu Leu Arg Asp Phe Asp Ile Lys Leu Lys Asn Phe Val Glu
          145 150 155 160
          Leu Thr Asp Val Ala Asn Lys Lys Leu Lys Cys Thr Glu Thr Trp Ser
                          165 170 175
          Leu Asn Ser Leu Val Lys His Leu Leu Gly Lys Gln Leu Leu Lys Asp
                      180 185 190
          Lys Ser Ile Arg Cys Ser Asn Trp Ser Lys Phe Pro Leu Thr Glu Asp
                  195 200 205
          Gln Lys Leu Tyr Ala Ala Thr Asp Ala Tyr Ala Gly Phe Ile Ile Tyr
              210 215 220
          Arg Asn Leu Glu Ile Leu Asp Asp Thr Val Gln Arg Phe Ala Ile Asn
          225 230 235 240
          Lys Glu Glu Glu Ile Leu Leu Ser Asp Met Asn Lys Gln Leu Thr Ser
                          245 250 255
          Ile Ser Glu Glu Val Met Asp Leu Ala Lys His Leu Pro His Ala Phe
                      260 265 270
          Ser Lys Leu Glu Asn Pro Arg Arg Val Ser Ile Leu Leu Lys Asp Ile
                  275 280 285
          Ser Glu Asn Leu Tyr Ser Leu Arg Arg Met Ile Ile Gly Ser Thr Asn
              290 295 300
          Ile Glu Thr Glu Leu Arg Pro Ser Asn Asn Leu Asn Leu Leu Ser Phe
          305 310 315 320
          Glu Asp Ser Thr Thr Gly Gly Val Gln Gln Lys Gln Ile Arg Glu His
                          325 330 335
          Glu Val Leu Ile His Val Glu Asp Glu Thr Trp Asp Pro Thr Leu Asp
                      340 345 350
          His Leu Ala Lys His Asp Gly Glu Asp Val Leu Gly Asn Lys Val Glu
                  355 360 365
          Arg Lys Glu Asp Gly Phe Glu Asp Gly Val Glu Asp Asn Lys Leu Lys
              370 375 380
          Glu Asn Met Glu Arg Ala Cys Leu Met Ser Leu Asp Ile Thr Glu His
          385 390 395 400
          Glu Leu Gln Ile Leu Glu Gln Gln Ser Gln Glu Glu Tyr Leu Ser Asp
                          405 410 415
          Ile Ala Tyr Lys Ser Thr Glu His Leu Ser Pro Asn Asp Asn Glu Asn
                      420 425 430
          Asp Thr Ser Tyr Val Ile Glu Ser Asp Glu Asp Leu Glu Met Glu Met
                  435 440 445
          Leu Lys His Leu Ser Pro Asn Asp Asn Glu Asn Asp Thr Ser Tyr Val
              450 455 460
          Ile Glu Ser Asp Glu Asp Leu Glu Met Glu Met Leu Lys Ser Leu Glu
          465 470 475 480
          Asn Leu Asn Ser Gly Thr Val Glu Pro Thr His Ser Lys Cys Leu Lys
                          485 490 495
          Met Glu Arg Asn Leu Gly Leu Pro Thr Lys Glu Glu Glu Glu Asp Asp
                      500 505 510
          Glu Asn Glu Ala Asn Glu Gly Glu Glu Asp Asp Asp Lys Asp Phe Leu
                  515 520 525
          Trp Pro Ala Pro Asn Glu Glu Gln Val Thr Cys Leu Lys Met Tyr Phe
              530 535 540
          Gly His Ser Ser Phe Lys Pro Val Gln Trp Lys Val Ile His Ser Val
          545 550 555 560
          Leu Glu Glu Arg Arg Asp Asn Val Ala Val Met Ala Thr Gly Tyr Gly
                          565 570 575
          Lys Ser Leu Cys Phe Gln Tyr Pro Pro Val Tyr Val Gly Lys Ile Gly
                      580 585 590
          Leu Val Ile Ser Pro Leu Ile Ser Leu Met Glu Asp Gln Val Leu Gln
                  595 600 605
          Leu Lys Met Ser Asn Ile Pro Ala Cys Phe Leu Gly Ser Ala Gln Ser
              610 615 620
          Glu Asn Val Leu Thr Asp Ile Lys Leu Gly Lys Tyr Arg Ile Val Tyr
          625 630 635 640
          Val Thr Pro Glu Tyr Cys Ser Gly Asn Met Gly Leu Leu Gln Gln Leu
                          645 650 655
          Glu Ala Asp Ile Gly Ile Thr Leu Ile Ala Val Asp Glu Ala His Cys
                      660 665 670
          Ile Ser Glu Trp Gly His Asp Phe Arg Asp Ser Phe Arg Lys Leu Gly
                  675 680 685
          Ser Leu Lys Thr Ala Leu Pro Met Val Pro Ile Val Ala Leu Thr Ala
              690 695 700
          Thr Ala Ser Ser Ser Ile Arg Glu Asp Ile Val Arg Cys Leu Asn Leu
          705 710 715 720
          Arg Asn Pro Gln Ile Thr Cys Thr Gly Phe Asp Arg Pro Asn Leu Tyr
                          725 730 735
          Leu Glu Val Arg Arg Lys Thr Gly Asn Ile Leu Gln Asp Leu Gln Pro
                      740 745 750
          Phe Leu Val Lys Thr Ser Ser His Trp Glu Phe Glu Gly Pro Thr Ile
                  755 760 765
          Ile Tyr Cys Pro Ser Arg Lys Met Thr Gln Gln Val Thr Gly Glu Leu
              770 775 780
          Arg Lys Leu Asn Leu Ser Cys Gly Thr Tyr His Ala Gly Met Ser Phe
          785 790 795 800
          Ser Thr Arg Lys Asp Ile His His Arg Phe Val Arg Asp Glu Ile Gln
                          805 810 815
          Cys Val Ile Ala Thr Ile Ala Phe Gly Met Gly Ile Asn Lys Ala Asp
                      820 825 830
          Ile Arg Gln Val Ile His Tyr Gly Ala Pro Lys Asp Met Glu Ser Tyr
                  835 840 845
          Tyr Gln Glu Ile Gly Arg Ala Gly Arg Asp Gly Leu Gln Ser Ser Cys
              850 855 860
          His Val Leu Trp Ala Pro Ala Asp Ile Asn Leu Asn Arg His Leu Leu
          865 870 875 880
          Thr Glu Ile Arg Asn Glu Lys Phe Arg Leu Tyr Lys Leu Lys Met Met
                          885 890 895
          Ala Lys Met Glu Lys Tyr Leu His Ser Ser Arg Cys Arg Arg Gln Ile
                      900 905 910
          Ile Leu Ser His Phe Glu Asp Lys Gln Val Gln Lys Ala Ser Leu Gly
                  915 920 925
          Ile Met Gly Thr Glu Lys Cys Cys Asp Asn Cys Arg Ser Arg Leu Asp
              930 935 940
          His Cys Tyr Ser Met Asp Asp Ser Glu Asp Thr Ser Trp Asp Phe Gly
          945 950 955 960
          Pro Gln Ala Phe Lys Leu Leu Ser Ala Val Asp Ile Leu Gly Glu Lys
                          965 970 975
          Phe Gly Ile Gly Leu Pro Ile Leu Phe Leu Arg Gly Ser Asn Ser Gln
                      980 985 990
          Arg Leu Ala Asp Gln Tyr Arg Arg His Ser Leu Phe Gly Thr Gly Lys
                  995 1000 1005
          Asp Gln Thr Glu Ser Trp Trp Lys Ala Phe Ser Arg Gln Leu Ile
              1010 1015 1020
          Thr Glu Gly Phe Leu Val Glu Val Ser Arg Tyr Asn Lys Phe Met
              1025 1030 1035
          Lys Ile Cys Ala Leu Thr Lys Lys Gly Arg Asn Trp Leu His Lys
              1040 1045 1050
          Ala Asn Thr Glu Ser Gln Ser Leu Ile Leu Gln Ala Asn Glu Glu Glu
              1055 1060 1065
          Leu Cys Pro Lys Lys Leu Leu Leu Pro Ser Ser Lys Thr Val Ser
              1070 1075 1080
          Ser Gly Thr Lys Glu His Cys Tyr Asn Gln Val Pro Val Glu Leu
              1085 1090 1095
          Ser Thr Glu Lys Lys Ser Asn Leu Glu Lys Leu Tyr Ser Tyr Lys
              1100 1105 1110
          Pro Cys Asp Lys Ile Ser Ser Gly Ser Asn Ile Ser Lys Lys Ser
              1115 1120 1125
          Ile Met Val Gln Ser Pro Glu Lys Ala Tyr Ser Ser Ser Ser Gln Pro
              1130 1135 1140
          Val Ile Ser Ala Gln Glu Gln Glu Thr Gln Ile Val Leu Tyr Gly
              1145 1150 1155
          Lys Leu Val Glu Ala Arg Gln Lys His Ala Asn Lys Met Asp Val
              1160 1165 1170
          Pro Pro Ala Ile Leu Ala Thr Asn Lys Ile Leu Val Asp Met Ala
              1175 1180 1185
          Lys Met Arg Pro Thr Thr Val Glu Asn Val Lys Arg Ile Asp Gly
              1190 1195 1200
          Val Ser Glu Gly Lys Ala Ala Met Leu Ala Pro Leu Leu Glu Val
              1205 1210 1215
          Ile Lys His Phe Cys Gln Thr Asn Ser Val Gln Thr Asp Leu Phe
              1220 1225 1230
          Ser Ser Thr Lys Pro Gln Glu Glu Gln Lys Thr Ser Leu Val Ala
              1235 1240 1245
          Lys Asn Lys Ile Cys Thr Leu Ser Gln Ser Met Ala Ile Thr Tyr
              1250 1255 1260
          Ser Leu Phe Gln Glu Lys Lys Met Pro Leu Lys Ser Ile Ala Glu
              1265 1270 1275
          Ser Arg Ile Leu Pro Leu Met Thr Ile Gly Met His Leu Ser Gln
              1280 1285 1290
          Ala Val Lys Ala Gly Cys Pro Leu Asp Leu Glu Arg Ala Gly Leu
              1295 1300 1305
          Thr Pro Glu Val Gln Lys Ile Ile Ala Asp Val Ile Arg Asn Pro
              1310 1315 1320
          Pro Val Asn Ser
              1325
           <![CDATA[ <210> 603]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 603]]>
          gaaggaaact gtttaaccgg atcccattgt accccagagtg cagagccgcc tttccagcat 60
          gcaggggctg ctcag 75
           <![CDATA[ <210> 604]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 604]]>
          gacagagagg gaggaggcgc gcggggacgg ggacgcccag gaggacccac tcgcgggtcc 60
          cgctccgctc cggca 75
           <![CDATA[ <210> 605]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 605]]>
          gaaggaaact gtttaaccgg atcccattgt accccagagtg cagagccgcc tttccagcat 60
          gcaggggctg ctcaggacag aggggagga ggcgcgcggg gacggggacg cccaggagga 120
          cccactcgcg ggtcccgctc cgctccggca 150
           <![CDATA[ <210> 606]]>
           <![CDATA[ <211> 102]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 606]]>
          gcgagttagt aacctacgag cggctgtgaa ggaaactgtt taaccggatc ccattgtacc 60
          cagagtgcag agccgccttt ccagcatgca ggggctgctc ag 102
           <![CDATA[ <210> 607]]>
           <![CDATA[ <211> 220]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 607]]>
          cgtttagtca catcaagaaa tagaacagaa ttcagccatg gccccaagaa agagaggtgg 60
          acgaggtatt tcattcatct tttgctgttt ccgaaataat gatcacccag aaatcacgta 120
          tcggctgcga aatgatagca actttgcgct tcagaccatg gaaccagcat tgcccatgcc 180
          ccctgtggag gagctggatg tcatgttcag tgaactggtg 220
           <![CDATA[ <210> 608]]>
           <![CDATA[ <211> 90]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 608]]>
          gatgaactgg acctcacaga caaacacaga gaagccatgt ttgcacttcc agctgagaaa 60
          aaatggcaaa tatactgtag caagaaaaag 90
           <![CDATA[ <210> 609]]>
           <![CDATA[ <211> 72]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 609]]>
          gaccaggaag aaaacaaggg agctacaagt tggcctgaat tctacattga tcagctcaat 60
          tccatggctg ct 72
           <![CDATA[ <210> 610]]>
           <![CDATA[ <211> 9]]>5
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 610]]>
          agaaaatctc tgctggcttt agagaaggaa gaagaagaag aaagaagtaa aactatagag 60
          agtttaaaga cagcactgag gacaaaacca atgag 95
           <![CDATA[ <210> 611]]>
           <![CDATA[ <211> 334]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 611]]>
          gtttgtaacc agattcatcg acttggatgg cctatcatgt atcctcaact ttctaaagac 60
          catggactac gagacctcag agtctcgaat acatacttct ctcattggct gtataaaggc 120
          gttaatgaac aactctcaag gccgggctca cgtcctggct cattctgaga gttattaatgt 180
          aattgctcag agtctgagca cagagaacat taaaacgaag gtggccgtgc tggaaatctt 240
          gggcgccgtg tgcctggttc ccgggggcca caagaaggtt ctgcaggcca tgctgcacta 300
          ccagaagtat gccagcgaaa ggacccgctt tcag 334
           <![CDATA[ <210> 612]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 612]]>
          acattaatta acgacttgga taaaagcact gggcggtatc gagatgaagt gagtctcaag 60
          actgccatca tgtccttcat taatgcagtg ctcagccaag gtgcaggagt g 111
           <![CDATA[ <210> 613]]>
           <![CDATA[ <211> 104]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 613]]>
          gagagtttgg actttagact tcatcttcgc tatgaatttc tgatgttagg aattcaacct 60
          gtaatagata aattaaggga acacgaaaat tcaacattag atag 104
           <![CDATA[ <210> 614]]>
           <![CDATA[ <211> 67]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 614]]>
          gcatttagac ttttttgaaa tgctccgaaa tgaagatgaa ctagaatttg ccaaaagatt 60
          tgaactg 67
           <![CDATA[ <210> 615]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 615]]>
          gttcacatag acacaaaaag tgcaactcag atgtttgagc tgaccaggaa gaggctgaca 60
          catagtgaag cttacccgca tttcatgtcc atcctgcacc actgcctcca aatgcctt 118
           <![CDATA[ <210> 616]]>
           <![CDATA[ <211> 139]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 616]]>
          acaagaggag tggcaacact gttcagtact ggctactact agatagaatt atacagcaga 60
          tagttatcca gaatgacaaa ggacaggacc ctgactccac acctttggaa aactttaata 120
          ttaagaatgt cgtacgaat 139
           <![CDATA[ <210> 617]]>
           <![CDATA[ <211> 59]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 617]]>
          gttggttaat gaaaatgaag ttaagcagtg gaaagaacaa gcggaaaaaa tgagaaaag 59
           <![CDATA[ <210> 618]]>
           <![CDATA[ <211> 188]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 618]]>
          agcacaatga gctacaacag aaactggaaa agaaagaacg agaatgtgat gctaagactc 60
          aagagaagga agagatgatg cagaccttaa ataaaatgaa agagaaactt gaaaaggaga 120
          ctactgagca taagcaagtc aagcagcagg tggcggacct cacagcacag ctccatgagc 180
          tcagcagg 188
           <![CDATA[ <210> 619]]>
           <![CDATA[ <211> 300]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 619]]>
          agggccgtct gtgcttcaat cccaggtgga ccctcgcctg gagcaccagg agggcccttt 60
          ccttcctctg tgcctggatc tctccttcct cccccaccac ccccacctct accagtggg 120
          atgcttcccc ctccaccgcc tcccctccct ccaggtggcc ctcctcctcc cccagggcct 180
          cctcccttag gggcaatcat gccacctcct ggtgctccaa tgggcctagc actgaagaag 240
          aaaagcattc ctcagcccac aaatgccctg aaatccttca actggtctaa actgcccgag 300
           <![CDATA[ <210> 620]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 620]]>
          aacaaactgg aaggaacagt atggaccgaa attgatgata caaaagtctt caaaattcta 60
          gatcttgaag acctggaaag aaccttctct gcctatcaaa gacagcag 108
           <![CDATA[ <210> 621]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 621]]>
          aaagaagcag atgccattga tgacactctg agttccaaac ttaaagttaa agagctttcg 60
          gtgattgatg gtcggagagc tcagaattgc aacatccttc tatcgag 107
           <![CDATA[ <210> 622]]>
           <![CDATA[ <211> 85]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 622]]>
          gttgaaatta tccaatgacg aaatcaaacg ggcaattcta acaatggacg aacaggaaga 60
          tctgcccaag gacatgttgg aacag 85
           <![CDATA[ <210> 623]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 623]]>
          ctcttgaaat ttgttcctga aaaaagtgac attgacctat tggaggaaca taaacacgaa 60
          ctggatcgga tggccaaggc tgataggttc ctttttgaga tgagccg 107
           <![CDATA[ <210> 6]]>24
           <![CDATA[ <211> 89]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 624]]>
          aattaatcac tatcagcaaa ggttgcaatc gctgtacttc aaaaagaagt ttgcagagcg 60
          tgtggcagaa gtgaaaccta aagtggaag 89
           <![CDATA[ <210> 625]]>
           <![CDATA[ <211> 169]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 625]]>
          caattcgttc tggctcagaa gaggtgttta ggagtggtgc cctcaagcag ttgctggagg 60
          tggttttggc atttggaaat tatatgaata aaggtcaaag agggaatgca tatggattca 120
          agatatctag cctaaacaaa attgctgaca caaaatccag catcgacaa 169
           <![CDATA[ <210> 626]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 626]]>
          aaacattacc cttttgcact atctcatcac tattgtggaa aataagtacc ccagtgttct 60
          caatctaaat gaagaattgc gagatattcc tcaagctgcg aaagtaaa 108
           <![CDATA[ <210> 627]]>
           <![CDATA[ <211> 61]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 627]]>
          catgactgag ctggacaaag aaataagtac cttgagaagt ggcttgaaag cagtagagac 60
          a 61
           <![CDATA[ <210> 628]]>
           <![CDATA[ <211> 132]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 628]]>
          gagctggaat atcagaagtc tcagccccca cagcccggag ataagtttgt gtctgttgtc 60
          agccagttca tcacagtagc cagcttcagc ttctctgatg ttgaagacct tctagcagaa 120
          gctaaagacc tg 132
           <![CDATA[ <210> 629]]>
           <![CDATA[ <211> 171]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 629]]>
          tttactaaag cagtgaagca ctttggggaa gaggctggca aaatacaacc agatgagttc 60
          tttggcattt ttgatcaatt tcttcaagct gtgtcagaag ccaaacaaga aaacgaaaat 120
          atgagaaaga aaaaggagga agaagaacgt cgagctcgca tggaagctca g 171
           <![CDATA[ <210> 630]]>
           <![CDATA[ <211> 2754]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 630]]>
          ctcaaagaac aacgtgaaag ggaacgtaaa atgagaaaag ctaaagagaa tagtgaagaa 60
          agcggagagt ttgatgacct tgtttcagct ttacgctcag gagaagtgtt tgacaaagac 120
          ctttctaaat tgaaacggaa tcgcaaacgt attaccaacc agatgactga cagcagcaga 180
          gagagaccaa tcacaaaact taatttctaa ttttccatga atactttttt ttagaaagct 240
          cattagcagc cctctaaagt gactagaacg tttcattaca ctgccttgca atccaaacag 300
          tggcaatttt ttccttcatc tgtgagtgaa tgtgtgaacg tgtgtatgta aatgtatgtg 360
          tgtatatatt aaaaaatgta tatagatgtc tgagtgttgt ctggagacct atacgtatgg 420
          ttaaaaagat ttatgttaat gtatgtgctc caaaaccttt cgtgtatgca ttcacattga 480
          gtgtggctca ttttctttcc ccgaacgcca tgactgttca gaagcacaat actatctcct 540
          gaaagagata agagacattc cctagattca aaggcaaaac agaagaaaca aacaaacaaa 600
          caaaaaaagc ttgcaaaata ttttatggtt tccaagcttg atatccttta aaattatttt 660
          cattgatgga actggagttg ttggaaaaac atagatttaa aatgattttt gatagctgac 720
          attgtgatgt tgatgtatca catcagtaat aggaccagct ttgaatttct gacattggtg 780
          tggggataca gtctgtaaat gtttattgag aacatcttgc acacaatttg aattatgtag 840
          aatgtcaatc aagtttttgt atatttaaaa gttggacatc aattttttcc cctgatttca 900
          tcaagttatc tctgccaagt gctcttgata atttcttcag atttttggaaaaaaacacta 960
          tataaatgca atccatgctt tttttaaaga acaacattgc cagagtatgc ttgttctaac 1020
          aatatagata tataaacctt aaaaataata aaatatctca cccaagactt aaaggaagaa 1080
          ttctctgaag ggataaagat tactaaaaaaaaaaaaaaaaaaaaaaaatt aatggggtgc 1140
          ctttttgtta tagtttctat tttctgtttt gtaggacaag ctgcattttc tgtaaatata 1200
          ggtctggact aaaggataca taaagaatgc acaaaatgtc aacatcagca gagatgccca 1260
          gatctattta tctctaagta tattgaagt gattgctgtt tatatgttgt cattttaaaa 1320
          ttgtgtgtca gtaaagctac ctgtaaaatt tcagtccaaa aaaataaagc tctcagggag 1380
          acatgaataa aatcaatgaa cattagaaaa taaaatatag atgcttacca ttaacctacc 1440
          aactcttaat atccttaaat tatgtgatat ataaagagga ctgttacttttttacttttt 1500
          tttttttttttttttttttttggctttgct ttatttattt gtagttgggg gctaacgttt 1560
          tctcttttct ttctattgat cctgttgtgg ttgggtttcc tgtggagaga gtagtttgtc 1620
          ctgttgcact agaacattat ttactcacta aattgagttt ttcagtcaat taacaaatat 1680
          ttattaagtt cctactatgt accaggcata gtagggctac aatggtaagc aagacagagt 1740
          ccctgccccc aaagagctta tattctaatg gggatattaa gggatgaata gaataccaat 1800
          gtgtgcactg tacaggaatc atactattta aaaataattt gtataaacta taatgcttag 1860
          cacagatggc gagttatctg tgctatgtga aagctgtgaa atagtgctct aagagttgtc 1920
          aagagctgtg gttttacatc ttttcctcat tgcaaattta gtgactttct acacactata 1980
          tggaaataaa tgactagcaa ataaaacagt cataaataca aagcagaggt tgcactcccc 2040
          caatcccgag ttaacccagg tctgcaataa caccatgtta aaggtgcaga tagagacttg 2100
          gctcaaaaag gcttggagat gaggaagatt ggaatataat gatggttttg tctgttcctt 2160
          aactaaagtg cctctatgta tattcttttc tatttgtagc aggataaatt tggtctggct 2220
          cagttttgga actgtatttt gaaaatggct ttgtcttaca gtttaaggaa tagacaggtg 2280
          gagggaaagt cacataaagg agcaagtttg tgtagctgtc cctcttgccc cttttaatca 2340
          tcctcctttg atatggccat cctggtgggc ctcctttgcc atttccattt ttggtttctt 2400
          tccctgaaaa ctgtgtgcag gtaattccat gtgccattgt tgaaaagaaaaaaaaaaaac 2460
          aaaaaaaaaa cctacttttt agattggtgc tggtgtaagt agccactttt ctctcttggg 2520
          tgtgtatttt aaactttttt tgttttttta aattaatgcc aaaaagaaaa tgcataattt 2580
          gtaaacttaa ttatatgtct tatatcttat tagcttagta gttggaacca cttagtcttt 2640
          aggtgcaaga ctgttgttag atagtactga gaaaaaaaaa gtatgtgtta tgagactgta 2700
          catgtttttt taaaaatagc aatatgcaat aaagagatga attcattggg tgta 2754
           <![CDATA[ <210> 631]]>
           <![CDATA[ <211> 5890]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> The complete mRNA polynucleotide sequence of DAAM1]]>
           <![CDATA[ <400> 631]]>
          gcgagttagt aacctacgag cggctgtgaa ggaaactgtt taaccggatc ccattgtacc 60
          cagagtgcag agccgccttt ccagcatgca ggggctgctc agcgtttagt cacatcaaga 120
          aatagaacag aattcagcca tggccccaag aaagagaggt ggacgaggta tttcattcat 180
          cttttgctgt ttccgaaata atgatcaccc agaaatcacg tatcggctgc gaaatgatag 240
          caactttgcg cttcagacca tggaaccagc attgcccatg ccccctgtgg aggagctgga 300
          tgtcatgttc agtgaactgg tggatgaact ggacctcaca gacaaacaca gagaagccat 360
          gtttgcactt ccagctgaga aaaaatggca aatatactgt agcaagaaaa aggaccagga 420
          agaaaacaag ggagctacaa gttggcctga attctacatt gatcagctca attccatggc 480
          tgctagaaaa tctctgctgg ctttagagaa ggaagaagaa gaagaaagaa gtaaaactat 540
          agagagttta aagacagcac tgaggacaa accaatgagg tttgtaacca gattcatcga 600
          cttggatggc ctatcatgta tcctcaactt tctaaagacc atggactacg agacctcaga 660
          gtctcgaata catacttctc tcattggctg tataaaggcg ttaatgaaca actctcaagg 720
          ccgggctcac gtcctggctc attctgagag tattaatgta attgctcaga gtctgagcac 780
          agagaacatt aaaacgaagg tggccgtgct ggaaatcttg ggcgccgtgt gcctggttcc 840
          cgggggccac aagaaggttc tgcaggccat gctgcactac cagaagtatg ccagcgaaag 900
          gacccgcttt cagacattaa ttaacgactt ggataaaagc actgggcggt atcgagatga 960
          agtgagtctc aagactgcca tcatgtccctt cattaatgca gtgctcagcc aaggtgcagg 1020
          agtggagagt ttggacttta gacttcatct tcgctatgaa tttctgatgt taggaattca 1080
          acctgtaata gataaattaa gggaacacga aaattcaaca ttagataggc atttagactt 1140
          ttttgaaatg ctccgaaatg aagatgaact agaatttgcc aaaagatttg aactggttca 1200
          catagacaca aaaagtgcaa ctcagatgtt tgagctgacc aggaagaggc tgacacatag 1260
          tgaagcttac ccgcatttca tgtccatcct gcaccactgc ctccaaatgc cttacaagag 1320
          gagtggcaac actgttcagt actggctact actagataga atttacagc agatagttat 1380
          ccagaatgac aaaggacagg accctgactc cacacctttg gaaaacttta atattaagaa 1440
          tgtcgtacga atgttggtta atgaaaatga agttaagcag tggaaagaac aagcggaaaa 1500
          aatgagaaaa gagcacaatg agctacaaca gaaactggaa aagaaagaac gagaatgtga 1560
          tgctaagact caagagaagg aagagatgat gcagacctta aataaaatga aagagaaact 1620
          tgaaaaggag actactgagc ataagcaagt caagcagcag gtggcggacc tcacagcaca 1680
          gctccatgag ctcagcagga gggccgtctg tgcttcaatc ccaggtggac cctcgcctgg 1740
          agcaccagga gggccctttc cttcctctgt gcctggatct ctccttcctc ccccaccacc 1800
          cccaccctcta ccaggtggga tgcttccccc tccaccgcct cccctccctc caggtggccc 1860
          tcctcctccc ccagggcctc ctcccttagg ggcaatcatg ccacctcctg gtgctccaat 1920
          gggcctagca ctgaagaaga aaagcattcc tcagcccaca aatgccctga aatccttcaa 1980
          ctggtctaaa ctgcccgaga acaaactgga aggaacagta tggaccgaaa ttgatgatac 2040
          aaaagtcttc aaaattctag atcttgaaga cctggaaaga accttctctg cctatcaaag 2100
          acagcagaaa gaagcagatg ccattgatga cactctgagt tccaaactta aagttaaaga 2160
          gctttcggtg attgatggtc ggagagctca gaattgcaac atccttctat cgaggttgaa 2220
          attatccaat gacgaaatca aacgggcaat tctaacaatg gacgaacagg aagatctgcc 2280
          caaggacatg ttggaacagc tcttgaaatt tgttcctgaa aaaagtgaca ttgacctatt 2340
          ggaggaacat aaacacgaac tggatcggat ggccaaggct gtaggttcc tttttgagat 2400
          gagccgaatt aatcactatc agcaaaggtt gcaatcgctg tacttcaaaa agaagtttgc 2460
          agagcgtgtg gcagaagtga aacctaaagt ggaagcaatt cgttctggct cagaagaggt 2520
          gtttaggagt ggtgccctca agcagttgct ggaggtggtt ttggcatttg gaaattatat 2580
          gaataaaggt caaagaggga atgcatatgg attcaagata tctagcctaa acaaaattgc 2640
          tgacacaaaa tccagcatcg acaaaaacat tacccttttg cactatctca tcactattgt 2700
          ggaaaataag taccccagtg ttctcaatct aaatgaagaa ttgcgagata ttcctcaagc 2760
          tgcgaaagta aacatgactg agctggacaa agaaataagt accttgagaa gtggcttgaa 2820
          agcagtagag acagagctgg aatatcagaa gtctcagccc ccacagcccg gagataagtt 2880
          tgtgtctgtt gtcagccagt tcatcacagt agccagcttc agcttctctg atgttgaaga 2940
          ccttctagca gaagctaaag acctgtttac taaagcagtg aagcactttg gggaagaggc 3000
          tggcaaaata caaccagatg agttctttgg catttttgat caatttcttc aagctgtgtc 3060
          agaagccaaa caagaaaacg aaaatatgag aaagaaaaag gaggaagaag aacgtcgagc 3120
          tcgcatggaa gctcagctca aagaacaacg tgaaagggaa cgtaaaatga gaaaagctaa 3180
          agagaatagt gaagaaagcg gagagtttga tgaccttgtt tcagctttac gctcaggaga 3240
          agtgtttgac aaagaccttt ctaaattgaa acggaatcgc aaacgtatta ccaaccagat 3300
          gactgacagc agcagagaga gaccaatcac aaaacttaat ttctaatttt ccatgaatac 3360
          ttttttttag aaagctcatt agcagccctc taaagtgact agaacgtttc attacactgc 3420
          cttgcaatcc aaacagtggc aattttttcc ttcatctgtg agtgaatgtg tgaacgtgtg 3480
          tatgtaaatg tatgtgtgtgta tatattaaaa aatgtatata gatgtctgag tgttgtctgg 3540
          agacctatac gtatggttaa aaagatttat gttaatgtat gtgctccaaa acctttcgtg 3600
          tatgcattca cattgagtgt ggctcatttt ctttccccga acgccatgac tgttcagaag 3660
          cacaatacta tctcctgaaa gagataagag aattcccta gattcaaagg caaaacagaa 3720
          gaaacaaaca aacaaacaaa aaaagcttgc aaaatatttt atggtttcca agcttgatat 3780
          cctttaaaat tattttcatt gatggaactg gagttgttgg aaaaacatag atttaaaatg 3840
          atttttgata gctgacattg tgatgttgat gtatcacatc agtaatagga ccagctttga 3900
          atttctgaca ttggtgtggg gatacagtct gtaaatgttt attgagaaca tcttgcacac 3960
          aatttgaatt atgtagaatg tcaatcaagt ttttgtatat ttaaaagttg gacatcaatt 4020
          ttttcccctg atttcatcaa gttatctctg ccaagtgctc ttgataattt cttcagattt 4080
          ttggaaaaaa acactatata aatgcaatcc atgctttttt taaagaacaa cattgccaga 4140
          gtatgcttgt tctaacaata tagatatata aaccttaaaa ataataaaat atctcaccca 4200
          agacttaaag gaagaattct ctgaagggat aaagattact aaaaaaaaaaaaaaaaaaaa 4260
          aaaattaatg gggtgccttt ttgttatagt ttctattttc tgttttgtag gacaagctgc 4320
          attttctgta aatataggtc tggactaaag gatacataaa gaatgcacaa aatgtcaaca 4380
          tcagcagaga tgccccagatc tattattctc taagtatatt tgaagtgatt gctgtttata 4440
          tgttgtcatt ttaaaattgt gtgtcagtaa agctacctgt aaaatttcag tccaaaaaaa 4500
          taaagctctc agggagacat gaataaaatc aatgaacatt agaaaataaa atatagatgc 4560
          ttaccattaa cctaccaact cttaatatcc ttaaattatg tgatatataa agaggactgt 4620
          tactttttta cttttttttttttttttttttttttttggc tttgctttatttatttgtag 4680
          ttgggggcta acgttttctc ttttctttct attgatcctg ttgtggttgg gtttcctgtg 4740
          gagagagtag tttgtcctgt tgcactagaa catttattac tcactaaatt gagtttttca 4800
          gtcaattaac aaatatttat taagttccta ctatgtacca ggcatagtag ggctacaatg 4860
          gtaagcaaga cagagtccct gcccccaaag agcttatatt ctaatgggga tattaaggga 4920
          tgaatagaat accaatgtgt gcactgtaca ggaatcatac tatttaaaaa taatttgtat 4980
          aaactataat gcttagcaca gatggcgagt tatctgtgct atgtgaaagc tgtgaaatag 5040
          tgctctaaga gttgtcaaga gctgtggttt tacatctttt cctcattgca aatttagtga 5100
          ctttctacac actatatgga aataaatgac tagcaaataa aacagtcata aatacaaagc 5160
          agaggttgca ctcccccaat cccgagttaa cccaggtctg caataacaccc atgttaaagg 5220
          tgcagataga gacttggctc aaaaaggctt ggagatgagg aagattggaa tataatgatg 5280
          gttttgtctg ttccttaact aaagtgcctc tatgtatatt cttttctatt tgtagcagga 5340
          taaatttggt ctggctcagt tttggaactg tattttgaaa atggctttgt cttacagttt 5400
          aaggaataga caggtggagg gaaagtcaca taaaggagca agtttgtgta gctgtccctc 5460
          ttgccccttt taatcatcct cctttgatat ggccatcctg gtgggcctcc tttgccattt 5520
          ccatttttgg tttctttccc tgaaaactgt gtgcaggtaa ttccatgtgc cattgttgaa 5580
          aagaaaaaaaaaaaacaaaaaaaaaaccta ctttttagat tggtgctggt gtaagtagcc 5640
          acttttctct cttgggtgtg tattttaaac tttttttgtt tttttaaatt aatgccaaaa 5700
          agaaaatgca taatttgtaa acttaattat atgtcttata tcttattagc ttagtagttg 5760
          gaaccactta gtctttaggt gcaagactgt tgttagatag tactgagaaa aaaaaagtat 5820
          gtgttatgag actgtacatg tttttttaaa aatagcaata tgcaataaag agatgaattc 5880
          attgggtgta 5890
           <![CDATA[ <210> 632]]>
           <![CDATA[ <211> 1068]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 632]]>
          Met Ala Pro Arg Lys Arg Gly Gly Arg Gly Ile Ser Phe Ile Phe Cys
          1 5 10 15
          Cys Phe Arg Asn Asn Asp His Pro Glu Ile Thr Tyr Arg Leu Arg Asn
                      20 25 30
          Asp Ser Asn Phe Ala Leu Gln Thr Met Glu Pro Ala Leu Pro Met Pro
                  35 40 45
          Pro Val Glu Glu Leu Asp Val Met Phe Ser Glu Leu Val Asp Glu Leu
              50 55 60
          Asp Leu Thr Asp Lys His Arg Glu Ala Met Phe Ala Leu Pro Ala Glu
          65 70 75 80
          Lys Lys Trp Gln Ile Tyr Cys Ser Lys Lys Lys Lys Asp Gln Glu Glu Asn
                          85 90 95
          Lys Gly Ala Thr Ser Trp Pro Glu Phe Tyr Ile Asp Gln Leu Asn Ser
                      100 105 110
          Met Ala Ala Arg Lys Ser Leu Leu Ala Leu Glu Lys Glu Glu Glu Glu Glu
                  115 120 125
          Glu Arg Ser Lys Thr Ile Glu Ser Leu Lys Thr Ala Leu Arg Thr Lys
              130 135 140
          Pro Met Arg Phe Val Thr Arg Phe Ile Asp Leu Asp Gly Leu Ser Cys
          145 150 155 160
          Ile Leu Asn Phe Leu Lys Thr Met Asp Tyr Glu Thr Ser Glu Ser Arg
                          165 170 175
          Ile His Thr Ser Leu Ile Gly Cys Ile Lys Ala Leu Met Asn Asn Ser
                      180 185 190
          Gln Gly Arg Ala His Val Leu Ala His Ser Glu Ser Ile Asn Val Ile
                  195 200 205
          Ala Gln Ser Leu Ser Thr Glu Asn Ile Lys Thr Lys Val Ala Val Leu
              210 215 220
          Glu Ile Leu Gly Ala Val Cys Leu Val Pro Gly Gly His Lys Lys Val
          225 230 235 240
          Leu Gln Ala Met Leu His Tyr Gln Lys Tyr Ala Ser Glu Arg Thr Arg
                          245 250 255
          Phe Gln Thr Leu Ile Asn Asp Leu Asp Lys Ser Thr Gly Arg Tyr Arg
                      260 265 270
          Asp Glu Val Ser Leu Lys Thr Ala Ile Met Ser Phe Ile Asn Ala Val
                  275 280 285
          Leu Ser Gln Gly Ala Gly Val Glu Ser Leu Asp Phe Arg Leu His Leu
              290 295 300
          Arg Tyr Glu Phe Leu Met Leu Gly Ile Gln Pro Val Ile Asp Lys Leu
          305 310 315 320
          Arg Glu His Glu Asn Ser Thr Leu Asp Arg His Leu Asp Phe Phe Glu
                          325 330 335
          Met Leu Arg Asn Glu Asp Glu Leu Glu Phe Ala Lys Arg Phe Glu Leu
                      340 345 350
          Val His Ile Asp Thr Lys Ser Ala Thr Gln Met Phe Glu Leu Thr Arg
                  355 360 365
          Lys Arg Leu Thr His Ser Glu Ala Tyr Pro His Phe Met Ser Ile Leu
              370 375 380
          His His Cys Leu Gln Met Pro Tyr Lys Arg Ser Gly Asn Thr Val Gln
          385 390 395 400
          Tyr Trp Leu Leu Leu Asp Arg Ile Ile Gln Gln Ile Val Ile Gln Asn
                          405 410 415
          Asp Lys Gly Gln Asp Pro Asp Ser Thr Pro Leu Glu Asn Phe Asn Ile
                      420 425 430
          Lys Asn Val Val Arg Met Leu Val Asn Glu Asn Glu Val Lys Gln Trp
                  435 440 445
          Lys Glu Gln Ala Glu Lys Met Arg Lys Glu His Asn Glu Leu Gln Gln
              450 455 460
          Lys Leu Glu Lys Lys Glu Arg Glu Cys Asp Ala Lys Thr Gln Glu Lys
          465 470 475 480
          Glu Glu Met Met Gln Thr Leu Asn Lys Met Lys Glu Lys Leu Glu Lys
                          485 490 495
          Glu Thr Thr Glu His Lys Gln Val Lys Gln Gln Val Ala Asp Leu Thr
                      500 505 510
          Ala Gln Leu His Glu Leu Ser Arg Arg Ala Val Cys Ala Ser Ile Pro
                  515 520 525
          Gly Gly Pro Ser Pro Gly Ala Pro Gly Gly Pro Phe Pro Ser Ser Val
              530 535 540
          Pro Gly Ser Leu Leu Pro Pro Pro Pro Pro Pro Pro Pro Pro Leu Pro Gly Gly
          545 550 555 560
          Met Leu Pro Pro Pro Pro Pro Pro Leu Pro Pro Gly Gly Pro Pro Pro
                          565 570 575
          Pro Pro Gly Pro Pro Pro Leu Gly Ala Ile Met Pro Pro Pro Gly Ala
                      580 585 590
          Pro Met Gly Leu Ala Leu Lys Lys Lys Ser Ile Pro Gln Pro Thr Asn
                  595 600 605
          Ala Leu Lys Ser Phe Asn Trp Ser Lys Leu Pro Glu Asn Lys Leu Glu
              610 615 620
          Gly Thr Val Trp Thr Glu Ile Asp Asp Thr Lys Val Phe Lys Ile Leu
          625 630 635 640
          Asp Leu Glu Asp Leu Glu Arg Thr Phe Ser Ala Tyr Gln Arg Gln Gln
                          645 650 655
          Lys Glu Ala Asp Ala Ile Asp Asp Thr Leu Ser Ser Lys Leu Lys Val
                      660 665 670
          Lys Glu Leu Ser Val Ile Asp Gly Arg Arg Ala Gln Asn Cys Asn Ile
                  675 680 685
          Leu Leu Ser Arg Leu Lys Leu Ser Asn Asp Glu Ile Lys Arg Ala Ile
              690 695 700
          Leu Thr Met Asp Glu Gln Glu Asp Leu Pro Lys Asp Met Leu Glu Gln
          705 710 715 720
          Leu Leu Lys Phe Val Pro Glu Lys Ser Asp Ile Asp Leu Leu Glu Glu
                          725 730 735
          His Lys His Glu Leu Asp Arg Met Ala Lys Ala Asp Arg Phe Leu Phe
                      740 745 750
          Glu Met Ser Arg Ile Asn His Tyr Gln Gln Arg Leu Gln Ser Leu Tyr
                  755 760 765
          Phe Lys Lys Lys Phe Ala Glu Arg Val Ala Glu Val Lys Pro Lys Val
              770 775 780
          Glu Ala Ile Arg Ser Gly Ser Glu Glu Val Phe Arg Ser Gly Ala Leu
          785 790 795 800
          Lys Gln Leu Leu Glu Val Val Leu Ala Phe Gly Asn Tyr Met Asn Lys
                          805 810 815
          Gly Gln Arg Gly Asn Ala Tyr Gly Phe Lys Ile Ser Ser Leu Asn Lys
                      820 825 830
          Ile Ala Asp Thr Lys Ser Ser Ile Asp Lys Asn Ile Thr Leu Leu His
                  835 840 845
          Tyr Leu Ile Thr Ile Val Glu Asn Lys Tyr Pro Ser Val Leu Asn Leu
              850 855 860
          Asn Glu Glu Leu Arg Asp Ile Pro Gln Ala Ala Lys Val Asn Met Thr
          865 870 875 880
          Glu Leu Asp Lys Glu Ile Ser Thr Leu Arg Ser Gly Leu Lys Ala Val
                          885 890 895
          Glu Thr Glu Leu Glu Tyr Gln Lys Ser Gln Pro Pro Gln Pro Gly Asp
                      900 905 910
          Lys Phe Val Ser Val Val Ser Gln Phe Ile Thr Val Ala Ser Phe Ser
                  915 920 925
          Phe Ser Asp Val Glu Asp Leu Leu Ala Glu Ala Lys Asp Leu Phe Thr
              930 935 940
          Lys Ala Val Lys His Phe Gly Glu Glu Ala Gly Lys Ile Gln Pro Asp
          945 950 955 960
          Glu Phe Phe Gly Ile Phe Asp Gln Phe Leu Gln Ala Val Ser Glu Ala
                          965 970 975
          Lys Gln Glu Asn Glu Asn Met Arg Lys Lys Lys Glu Glu Glu Glu Arg
                      980 985 990
          Arg Ala Arg Met Glu Ala Gln Leu Lys Glu Gln Arg Glu Arg Glu Arg
                  995 1000 1005
          Lys Met Arg Lys Ala Lys Glu Asn Ser Glu Glu Ser Gly Glu Phe
              1010 1015 1020
          Asp Asp Leu Val Ser Ala Leu Arg Ser Gly Glu Val Phe Asp Lys
              1025 1030 1035
          Asp Leu Ser Lys Leu Lys Arg Asn Arg Lys Arg Ile Thr Asn Gln
              1040 1045 1050
          Met Thr Asp Ser Ser Arg Glu Arg Pro Ile Thr Lys Leu Asn Phe
              1055 1060 1065
           <![CDATA[ <210> 633]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 633]]>
          aaggtctctt cctgcctgag gatgaaaacc tgagggaaaa aggggactgg agccagttca 60
          cgctgtggca gcaag 75
           <![CDATA[ <210> 634]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 634]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60
          tccttcggtg tgaaa 75
           <![CDATA[ <210> 635]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 635]]>
          aaggtctctt cctgcctgag gatgaaaacc tgagggaaaa aggggactgg agccagttca 60
          cgctgtggca gcaagccttg cctccccgat tgaaagagat gaaaagccag gaatcggctg 120
          caggttccaa actagtcctt cggtgtgaaa 150
           <![CDATA[ <210> 636]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> person]]> class
           <![CDATA[ <400> 636]]>
          Gly Leu Phe Leu Pro Glu Asp Glu Asn Leu Arg Glu Lys Gly Asp Trp
          1 5 10 15
          Ser Gln Phe Thr Leu Trp Gln Gln Ala Leu Pro Pro Arg Leu Lys Glu
                      20 25 30
          Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys
                  35 40 45
          Glu
           <![CDATA[ <210> 637]]>
           <![CDATA[ <211> 139]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 637]]>
          agtctcaagc tctggtaggc aagtgcatgc agtgtgccta aaacctgcca gcagtacttt 60
          tgagtttttt tttttgtttt gttttacttt agcatttatt attcatggat tgaagaaatc 120
          aaaatggctg aagataaag 139
           <![CDATA[ <210> 638]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 638]]>
          agacaaagca tggaggacac aagaatggga ggaaaggcgg actctcagga acttcattct 60
          tcacgtggtt tatggtgatt gcattgctgg gcgtctggac atctgtagct gtcgtttggt 120
          ttgatcttgt tgactatgag gaagttctag 150
           <![CDATA[ <210> 639]]>
           <![CDATA[ <211> 69]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 639]]>
          gaaaactagg aatctatgat gctgatggtg atggagattt tgatgtggat gatgccaaag 60
          tttttag 69
           <![CDATA[ <210> 640]]>
           <![CDATA[ <211> 93]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 640]]>
          gacttaaaga gagatctact tcagagccag cagtcccgcc agaagaggct gagccacaca 60
          ctgagcccga ggagcaggtt cctgtggagg cag 93
           <![CDATA[ <210> 641]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 641]]>
          aaccccagaa tatcgaagat gaagcaaaag aacaaattca gtcccttctc catgaaatgg 60
          tacacgcaga acatg 75
           <![CDATA[ <210> 642]]>
           <![CDATA[ <211> 129]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 642]]>
          ttgaggggaga agacttgcaa caagaagatg gacccacagg agaaccacaa caagaggatg 60
          atgagtttct tatggcgact gatgtagatg atagatttga gaccctggaa cctgaagtat 120
          ctcatgaag 129
           <![CDATA[ <210> 643]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 643]]>
          aaaccgagca tagttaccac gtggaagaga cag 33
           <![CDATA[ <210> 644]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 644]]>
          tttcacaaga ctgtaatcag gatatggaag agatgatgtc tgagcaggaa aatccag 57
           <![CDATA[ <210> 645]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 645]]>
          attccagtga accagtagta gaagatgaaa gattgcacca tgatacag 48
           <![CDATA[ <210> 646]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 646]]>
          atgatgtaac ataccaagtc tatgaggaac aag 33
           <![CDATA[ <210> 647]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 647]]>
          cagtatatga acctctagaa aatgaaggga tagaaatcac ag 42
           <![CDATA[ <210> 648]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 648]]>
          aagtaactgc tccccctgag gataatcctg tagaagattc acaggtaatt gtagaag 57
           <![CDATA[ <210> 649]]>
           <![CDATA[ <211> 45]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 649]]>
          aagtaagcat ttttcctgtg gaagaacagc aggaagtacc accag 45
           <![CDATA[ <210> 650]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 650]]>
          aaacaaatag aaaaacagat gatccagaac aaaaagcaaa ag 42
           <![CDATA[ <210> 651]]>
           <![CDATA[ <211> 86]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 651]]>
          ttaagaaaaa gaagcctaaa cttttaaata aatttgataa gactattaaa gctgaacttg 60
          atgctgcaga aaaactccgt aaaagg 86
           <![CDATA[ <210> 652]]>
           <![CDATA[ <211> 87]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 652]]>
          ggaaaaattg aggaagcagt gaatgcattt aaagaactag tacgcaaata ccctcagagt 60
          ccacgagcaa gatatgggaa ggcgcag 87
           <![CDATA[ <210> 653]]>
           <![CDATA[ <211> 151]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 653]]>
          tgtgaggatg atttggctga gaagaggaga agtaatgagg tgctacgtgg agccatcgag 60
          acctaccaag aggtggccag cctacctgat gtccctgcag acctgctgaa gctgagtttg 120
          aagcgtcgct cagacaggca acaatttcta g 151
           <![CDATA[ <210> 654]]>
           <![CDATA[ <211> 137]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 654]]>
          gtcatatgag aggttccctg cttaccctgc agagattagt tcaactattt cccaatgata 60
          cttccttaaa aaatgacctt ggcgtggggat acctcttgat aggagataat gacaatgcaa 120
          agaaagttta tgaagag 137
           <![CDATA[ <210> 655]]>
           <![CDATA[ <211> 99]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 655]]>
          gtgctgagtg tgacacctaa tgatggcttt gctaaagtcc attatggctt catcctgaag 60
          gcacagaaca aaattgctga gagcatccca tattaaag 99
           <![CDATA[ <210> 656]]>
           <![CDATA[ <211> 90]]>
           <![CDATA[ <212> ]]> DNA
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 656]]>
          gaaggaatag aatccggaga tcctggcact gatgatggga gattttattt ccacctgggg 60
          gatgccatgc agagggttgg gaacaaagag 90
           <![CDATA[ <210> 657]]>
           <![CDATA[ <211> 138]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 657]]>
          gcatataagt ggtatgagct tgggcacaag agaggacact ttgcatctgt ctggcaacgc 60
          tcactctaca atgtgaatgg actgaaagca cagccttggt ggaccccaaa agaaacgggc 120
          tacacagagt tagtaaag 138
           <![CDATA[ <210> 658]]>
           <![CDATA[ <211> 136]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 658]]>
          tctttagaaa gaaactggaa gttaatccga gatgaaggcc ttgcagtgat ggataaagcc 60
          aaaggtctct tcctgcctga ggatgaaaac ctgagggaaa aaggggactg gagccagttc 120
          acgctgtggc agcaag 136
           <![CDATA[ <210> 659]]>
           <![CDATA[ <211> 92]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 659]]>
          gaagaagaaa tgaaaatgcc tgcaaaggag ctcctaaaac ctgtacctta ctagaaaagt 60
          tccccgagac aacaggatgc agaagaggac ag 92
           <![CDATA[ <210> 660]]>
           <![CDATA[ <211> 134]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 660]]>
          atcaaatatt ccatcatgca ccccggggact cacgtgtggc cgcacacagg gcccacaaac 60
          tgcaggctcc gaatgcacct gggcttggtg attcccaagg aaggctgcaa gattcgatgt 120
          gccaacgaga ccaa 134
           <![CDATA[ <210> 661]]>
           <![CDATA[ <211> 2954]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 661]]>
          gacctggggag gaaggcaagg tgctcatctt tgatgactcc tttgagcacg aggtatggca 60
          ggatgcctca tctttccggc tgatattcat cgtggatgtg tggcatccgg aactgacacc 120
          acagcagaga cgcagccttc cagcaattta gcatgaattc atgcaagctt gggaaactct 180
          ggagagaggc tgcctttctg gttccatctc cttgggtgtg aggatagaat ttcgaacacc 240
          aagagtcaat tcccttgact tgcagcccga gtaattcaaa gcctcctcct agggtcagaa 300
          gacactaaag ggaatatttg cctcgctgca attcatttag gaaacaccct gctgtgtgtc 360
          atctcatgac agcactggtc ttctgccagt atttaaggtg aacatttgat agcttctacc 420
          ttaccagcca aagatatttt ttccacatag aataggtcta attcaatgta taatgagaac 480
          atatgtagaa actgtgaatg gattgcttta gtttgtaatt tttctatgca gttatatttt 540
          tctagtgtag ctagactatt ttgtcatcat gtaccactac atttttgttt attttaatga 600
          caagctgtat aaatgcttta cttctagcta tttaatggta gcattactgg ggaactcaga 660
          cttccctctt ttaattcttc ttagtaaaag atactcatga aaaaagcagt tttattttcc 720
          taacaaaaaa gaaagagctc attatgtcag tgtctatgaa ctgtacccat cccaactctc 780
          aaatcgtttg gtttttttta tcttgattga gatcctcttc tcactatgct agtggtggag 840
          atattgacaa aatcctattt ctttcaaaga ggaacttttc acaccgaaaa aagagcatgg 900
          aattatttta tattgttata aaaatcccag atgcaaattt ttttaatgcc aattattaga 960
          gcttctgggg aaaaagtata gttcacggaa ataaaactat gttctttcag ggttgggtgg 1020
          ataggtggct gctagggtgt ctggctcctg gcggctttgc catccatgag gcaagggctg 1080
          ggaacacagt gtctttgcct atggtagatc catgtgaatg tcaggaagcc agctcttcag 1140
          tcttggagat gatttctgct acaattctgt agaaagatta aggatggcag agtaaaaggt 1200
          taccaagaat gccaggatgt ttttcttggg cgtagggaggt ccagattact ttcctttttg 1260
          atgaaagagt ttggaagact gtcccatctc tctggcttga gaaatctctg ccattttaaa 1320
          catcactgtg aaatagcaat tattatcatc tgtatttagt tttaacatta cccacaacat 1380
          agaaataata ggtaaaaatc gtcttgccta ctcattccaa agatgatcaa gtcattaatc 1440
          tagcaaagta ttcatgtatc agattttgta tattttgaat caaagctaac taggaatgtt 1500
          agatataaga atgtaatgat attcatgcac tgaattctaa gccaatatga acaaaaatgc 1560
          tgcatgaatg gcacatatag gtcaccaaag ttcattcaca ggtagaaaaa acttgtgctt 1620
          tcttttccat ctaaaaacaa aaggagactt tctttatctc atttaaagaa cagctctttg 1680
          aaattgaaat tgaccctttt tgcttgacct taaggagatt agcttccagt agatgagttt 1740
          gcaaaatact tttcctgttc ttttgttttg ctggtattga aaacatccca ctaaatcaga 1800
          tgaagaggca tgggaggaaa aatatccaaa ttaattacta aaatcgagaa gagaaggcaa 1860
          actcttgaaa agtaaaaagg tgtttgtgac cttcagtatt tattgaacag aggaaataac 1920
          tgacaagggc aatacaattc aatgttcatg tagtaacatt catgtcactt gttgaatttg 1980
          gttctcatat gtatattgca tacacataaa ttcaaactat aagtcgtcat ttttgagcca 2040
          tcatcttaca ttcatgtaat gaaattatgg aagagagtaa aaactagctc ttaacttagt 2100
          aaatataata tggtatttaa aatcaggtca ctacagtaag gttctaagta ttgccaattg 2160
          aaaagctaga aatggtatta ctgttgcaaa gtgttgtcaa taattgactc caatagcatt 2220
          gtaaatactt gtatcccaca actattttaa acccaagcaa taaaatggat tttctaattc 2280
          acttcaattc tttatttctc ttacctatct atgtcttggt acataagaaa agtgtttcca 2340
          tcactgcatt ggtagaatta tttcagtgtt attatttttg tgatttcgta tgtctacaca 2400
          aaaatgaatt agtttaattt atattgtgat acagttgttt gagaaatatt tttaattctg 2460
          tttcaacttt atttctccaa gtgtataata taaaaattac ttctgttatt gttctctacc 2520
          aatagggggaa aaaattaaaa cattagatcc attgagaaag agatgatgta ataaataatt 2580
          aagattagta aataatattat caggggtgat tatgaccagt tgaataatct ctttcccttg 2640
          aattatttag ctaacaaatt aactctccca aatatttaaa ataatgtaaa atcatatttt 2700
          actgcccatt attaactaaa atatttttgt ttgactttga gcaccaactg gtaatactaa 2760
          taaataccca tgtcatgcag atggctgggc gaataagaga tgtctaaaaa tatgcactgg 2820
          tcttggaaaa catggcacaa gtaaggatat catatatgat gtctgtttat tttatgtctg 2880
          atttcttttg aatgagtagt tggggactcc atttctaagg agactaggta aataaaatga 2940
          cctttgacat ttca 2954
           <![CDATA[ <210> 662]]>
           <![CDATA[ <211> 5116]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Complete mRNA polynucleotide sequence of ASPH]]>
           <![CDATA[ <400> 662]]>
          agtctcaagc tctggtaggc aagtgcatgc agtgtgccta aaacctgcca gcagtacttt 60
          tgagtttttt tttttgtttt gttttacttt agcatttatt attcatggat tgaagaaatc 120
          aaaatggctg aagataaaga gacaaagcat ggaggacaca agaatggggag gaaaggcgga 180
          ctctcaggaa cttcattctt cacgtggttt atggtgattg cattgctggg cgtctggaca 240
          tctgtagctg tcgtttggtt tgatcttgtt gactatgagg aagttctagg aaaactagga 300
          atctatgatg ctgatggtga tggagatttt gatgtggatg atgccaaagt tttattagga 360
          cttaaagaga gatctacttc agagccagca gtcccgccag aagaggctga gccacacact 420
          gagcccgagg agcaggttcc tgtggaggca gaacccccaga atatcgaaga tgaagcaaaa 480
          gaacaaattc agtcccttct ccatgaaatg gtacacgcag aacatgttga gggagaagac 540
          ttgcaacaag aagatggacc cacaggagaa ccacaacaag aggatgatga gtttcttatg 600
          gcgactgatg tagatgatag atttgagacc ctggaacctg aagtatctca tgaagaaacc 660
          gagcatagtt accacgtgga agagacagtt tcacaagact gtaatcagga tatggaagag 720
          atgatgtctg agcaggaaaa tccagattcc agtgaaccag tagtagaaga tgaaagattg 780
          caccatgata cagatgatgt aacataccaa gtctatgagg aacaagcagt atatgaacct 840
          ctagaaaatg aagggataga aatcacagaa gtaactgctc cccctgagga taatcctgta 900
          gaagattcac aggtaattgt agaagaagta agcatttttc ctgtggaaga acagcaggaa 960
          gtaccaccag aaacaaatag aaaaacagat gatccagaac aaaaagcaaa agttaagaaa 1020
          aagaagccta aacttttaaa taaatttgat aagactatta aagctgaact tgatgctgca 1080
          gaaaaactcc gtaaaagggg aaaaattgag gaagcagtga atgcatttaa agaactagta 1140
          cgcaaatacc ctcagagtcc acgagcaaga tatgggaagg cgcagtgtga ggatgatttg 1200
          gctgagaaga ggagaagtaa tgaggtgcta cgtggagcca tcgagaccta ccaagaggtg 1260
          gccagcctac ctgatgtccc tgcagacctg ctgaagctga gtttgaagcg tcgctcagac 1320
          aggcaacaat ttctaggtca tatgagaggt tccctgctta ccctgcagag attagttcaa 1380
          ctatttccca atgatacttc cttaaaaaat gaccttggcg tgggatacct cttgatagga 1440
          gataatgaca atgcaaagaa agtttatgaa gaggtgctga gtgtgacacc taatgatggc 1500
          tttgctaaag tccattatgg cttcatcctg aaggcacaga acaaaattgc tgagagcatc 1560
          ccatatttaa aggaaggaat agaatccgga gatcctggca ctgatgatgg gagattttat 1620
          ttccacctgg gggatgccat gcagagggtt gggaacaaag aggcatataa gtggtatgag 1680
          cttgggcaca agagaggaca ctttgcatct gtctggcaac gctcactcta caatgtgaat 1740
          ggactgaaag cacagccttg gtggaccccca aaagaaacgg gctacacaga gttagtaaag 1800
          tctttagaaa gaaactggaa gttaatccga gatgaaggcc ttgcagtgat ggataaagcc 1860
          aaaggtctct tcctgcctga ggatgaaaac ctgagggaaa aaggggactg gagccagttc 1920
          acgctgtggc agcaaggaag aagaaatgaa aatgcctgca aaggagctcc taaaacctgt 1980
          accttactag aaaagttccc cgagacaaca ggatgcagaa gaggacagat caaatattcc 2040
          atcatgcacc ccgggactca cgtgtggccg cacacagggc ccacaaactg caggctccga 2100
          atgcacctgg gcttggtgat tcccaaggaa ggctgcaaga ttcgatgtgc caacgagacc 2160
          aagacctggg aggaaggcaa ggtgctcatc tttgatgact cctttgagca cgaggtatgg 2220
          caggatgcct catctttccg gctgatattc atcgtggatg tgtggcatcc ggaactgaca 2280
          ccacagcaga gacgcagcct tccagcaatt tagcatgaat tcatgcaagc ttgggaaact 2340
          ctggagagag gctgcctttc tggttccatc tccttgggtg tgaggataga atttcgaaca 2400
          ccaagagtca attcccttga cttgcagccc gagtaattca aagcctcctc ctagggtcag 2460
          aagacactaa agggaatatt tgcctcgctg caattcatt aggaaacacc ctgctgtgtg 2520
          tcatctcatg atagcactgg tcttctgcca gtatttaagg tgaacatttg atagcttcta 2580
          ccttaccagc caaagatatt ttttccacat agaataggtc taattcaatg tataatgaga 2640
          acatatgtag aaactgtgaa tggattgctt tagtttgtaa tttttctatg cagttatatt 2700
          tttctagtgt agctagacta ttttgtcatc atgtaccact aatttttgt ttaattttaat 2760
          gacaagctgt ataaatgctt tacttctagc tatttaatgg tagcattact ggggaactca 2820
          gacttccctc ttttaattct tcttagtaaa agatactcat gaaaaaagca gttttatttt 2880
          cctaacaaaa aagaaagagc tcatttatgtc agtgtctatg aactgtaccc atcccaactc 2940
          tcaaatcgtt tggttttttt tatcttgatt gagatcctct tctcactatg ctagtggtgg 3000
          agatattgac aaaatcctat ttctttcaaa gaggaacttt tcacaccgaa aaaagagcat 3060
          ggaattattt tatattgtta taaaaatccc agatgcaaat ttttttaatg ccaattatta 3120
          gagcttctgg ggaaaaagta tagttcacgg aaataaaact atgttctttc agggttgggt 3180
          ggataggtgg ctgctagggt gtctggctcc tggcggcttt gccatccatg aggcaagggc 3240
          tgggaacaca gtgtctttgc ctatggtaga tccatgtgaa tgtcaggaag ccagctcttc 3300
          agtcttggag atgatttctg ctacaattct gtagaaagat taaggatggc agagtaaaag 3360
          gttaccaaga atgccaggat gtttttcttg ggcgtaggag gtccagatta ctttcctttt 3420
          tgatgaaaga gtttggaaga ctgtcccatc tctctggctt gagaaatctc tgccatttta 3480
          aacatcactg tgaaatagca attattatca tctgtattta gttttaacat tacccacaac 3540
          atagaaataa taggtaaaaa tcgtcttgcc tactcattcc aaagatgatc aagtcattaa 3600
          tctagcaaag tatcatgta tcagattttg tatattttga atcaaagcta actaggaatg 3660
          ttagatataa gaatgtaatg atattcatgc actgaattct aagccaatat gaacaaaaat 3720
          gctgcatgaa tggcacatat aggtcaccaa agttcattca caggtagaaa aaacttgtgc 3780
          tttcttttcc atctaaaaac aaaaggagac tttctttatc tcatttaaag aacagctctt 3840
          tgaaattgaa attgaccctt tttgcttgac cttaaggaga ttagcttcca gtagatgagt 3900
          ttgcaaaata cttttcctgt tcttttgttt tgctggtatt gaaaacatcc cactaaatca 3960
          gatgaagagg catgggagga aaaatatcca aattaattac taaaatcgag aagagaaggc 4020
          aaactcttga aaagtaaaaa ggtgtttgtg accttcagta tttatgaac agaggaaata 4080
          actgacaagg gcaatacaat tcaatgttca tgtagtaaca ttcatgtcac ttgttgaatt 4140
          tggttctcat atgtatattg catacacata aattcaaact ataagtcgtc atttttgagc 4200
          catcatctta cattcatgta atgaaattat ggaagagagt aaaaactagc tcttaactta 4260
          gtaaatataa tatggtattt aaaatcaggt cactacagta aggttctaag tattgccaat 4320
          tgaaaagcta gaaatggtat tactgttgca aagtgttgtc aataattgac tccaatagca 4380
          ttgtaaatac ttgtatccca caactatttt aaacccaagc aataaaatgg attttctaat 4440
          tcacttcaat tctttatttc tcttacctat ctatgtcttg gtacataaga aaagtgtttc 4500
          catcactgca ttggtagaat tatttcagtg ttaattatttt tgtgatttcg tatgtctaca 4560
          caaaaatgaa ttagtttaat ttatattgtg atacagttgt ttgagaaata tttttaattc 4620
          tgtttcaact ttatttctcc aagtgtataa tataaaaatt acttctgtta ttgttctcta 4680
          ccaatagggg aaaaaattaa aacattagat ccattgagaa agagatgatg taataaataa 4740
          ttaagattag taataatatt atcaggggtg attatgacca gttgaataat ctctttccct 4800
          tgaattattt agctaacaaa ttaactctcc caaatatta aaataatgta aaatcatatt 4860
          ttactgccca ttattaacta aaatattttt gtttgacttt gagcaccaac tggtaatact 4920
          aataaatacc catgtcatgc agatggctgg gcgaataaga gatgtctaaa aatatgcact 4980
          ggtcttggaa aacatggcac aagtaaggat atcatatatg atgtctgttt attttatgtc 5040
          tgatttcttt tgaatgagta gttggggact ccatttctaa ggagactagg taaataaaat 5100
          gacctttgac atttca 5116
           <![CDATA[ <210> 663]]>
           <![CDATA[ <211> 5]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 663]]>
          Met Ala Glu Asp Lys
          1 5
           <![CDATA[ <210> 664]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 664]]>
          Thr Lys His Gly Gly His Lys Asn Gly Arg Lys Gly Gly Leu Ser Gly
          1 5 10 15
          Thr Ser Phe Phe Thr Trp Phe Met Val Ile Ala Leu Leu Gly Val Trp
                      20 25 30
          Thr Ser Val Ala Val Val Trp Phe Asp Leu Val Asp Tyr Glu Glu Val
                  35 40 45
          Leu
           <![CDATA[ <210> 665]]>
           <![CDATA[ <211> 22]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 665]]>
          Lys Leu Gly Ile Tyr Asp Ala Asp Gly Asp Gly Asp Phe Asp Val Asp
          1 5 10 15
          Asp Ala Lys Val Leu Leu
                      20
           <![CDATA[ <210> 666]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 666]]>
          Leu Lys Glu Arg Ser Thr Ser Glu Pro Ala Val Pro Pro Glu Glu Ala
          1 5 10 15
          Glu Pro His Thr Glu Pro Glu Glu Gln Val Pro Val Glu Ala
                      20 25 30
           <![CDATA[ <210> 667]]>
           <![CDATA[ <211> 24]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 667]]>
          Pro Gln Asn Ile Glu Asp Glu Ala Lys Glu Gln Ile Gln Ser Leu Leu
          1 5 10 15
          His Glu Met Val His Ala Glu His
                      20
           <![CDATA[ <210> 668]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 668]]>
          Glu Gly Glu Asp Leu Gln Gln Glu Asp Gly Pro Thr Gly Glu Pro Gln
          1 5 10 15
          Gln Glu Asp Asp Glu Phe Leu Met Ala Thr Asp Val Asp Asp Arg Phe
                      20 25 30
          Glu Thr Leu Glu Pro Glu Val Ser His Glu
                  35 40
           <![CDATA[ <210> 669]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 669]]>
          Thr Glu His Ser Tyr His Val Glu Glu Thr
          1 5 10
           <![CDATA[ <210> 670]]>
           <![CDATA[ <211> 18]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 670]]>
          Ser Gln Asp Cys Asn Gln Asp Met Glu Glu Met Met Ser Glu Gln Glu
          1 5 10 15
          Asn Pro
           <![CDATA[ <210> 671]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 671]]>
          Ser Ser Glu Pro Val Val Glu Asp Glu Arg Leu His His Asp Thr
          1 5 10 15
           <![CDATA[ <210> 672]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 672]]>
          Asp Val Thr Tyr Gln Val Tyr Glu Glu Gln
          1 5 10
           <![CDATA[ <210> 673]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 673]]>
          Val Tyr Glu Pro Leu Glu Asn Glu Gly Ile Glu Ile Thr
          1 5 10
           <![CDATA[ <210> 674]]>
           <![CDATA[ <211> 18]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 674]]>
          Val Thr Ala Pro Pro Glu Asp Asn Pro Val Glu Asp Ser Gln Val Ile
          1 5 10 15
          Val Glu
           <![CDATA[ <210> 675]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <21]]>3> Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;675]]&gt;
           <br/>
           <br/> <![CDATA[Val Ser Ile Phe Pro Val Glu Glu Gln Gln Glu Val Pro Pro
          1 5 10
           <![CDATA[ <210> 676]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 676]]>
          Thr Asn Arg Lys Thr Asp Asp Pro Glu Gln Lys Ala Lys
          1 5 10
           <![CDATA[ <210> 677]]>
           <![CDATA[ <211> 28]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 677]]>
          Lys Lys Lys Lys Pro Lys Leu Leu Asn Lys Phe Asp Lys Thr Ile Lys
          1 5 10 15
          Ala Glu Leu Asp Ala Ala Glu Lys Leu Arg Lys Arg
                      20 25
           <![CDATA[ <210> 678]]>
           <![CDATA[ <211> 29]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 678]]>
          Gly Lys Ile Glu Glu Ala Val Asn Ala Phe Lys Glu Leu Val Arg Lys
          1 5 10 15
          Tyr Pro Gln Ser Pro Arg Ala Arg Tyr Gly Lys Ala Gln
                      20 25
           <![CDATA[ <210> 679]]>
           <![CDATA[ <211> 50]]>
           <![CDATA[ <212> PR]]>T
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 679]]>
          Cys Glu Asp Asp Leu Ala Glu Lys Arg Arg Ser Asn Glu Val Leu Arg
          1 5 10 15
          Gly Ala Ile Glu Thr Tyr Gln Glu Val Ala Ser Leu Pro Asp Val Pro
                      20 25 30
          Ala Asp Leu Leu Lys Leu Ser Leu Lys Arg Arg Ser Asp Arg Gln Gln
                  35 40 45
          Phe Leu
              50
           <![CDATA[ <210> 680]]>
           <![CDATA[ <211> 45]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 680]]>
          His Met Arg Gly Ser Leu Leu Thr Leu Gln Arg Leu Val Gln Leu Phe
          1 5 10 15
          Pro Asn Asp Thr Ser Leu Lys Asn Asp Leu Gly Val Gly Tyr Leu Leu
                      20 25 30
          Ile Gly Asp Asn Asp Asn Ala Lys Lys Val Tyr Glu Glu
                  35 40 45
           <![CDATA[ <210> 681]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 681]]>
          Val Leu Ser Val Thr Pro Asn Asp Gly Phe Ala Lys Val His Tyr Gly
          1 5 10 15
          Phe Ile Leu Lys Ala Gln Asn Lys Ile Ala Glu Ser Ile Pro Tyr Leu
                      20 25 30
          Lys
           <![CDATA[ <210> 682]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 682]]>
          Glu Gly Ile Glu Ser Gly Asp Pro Gly Thr Asp Asp Gly Arg Phe Tyr
          1 5 10 15
          Phe His Leu Gly Asp Ala Met Gln Arg Val Gly Asn Lys Glu
                      20 25 30
           <![CDATA[ <210> 683]]>
           <![CDATA[ <211> 46]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 683]]>
          Ala Tyr Lys Trp Tyr Glu Leu Gly His Lys Arg Gly His Phe Ala Ser
          1 5 10 15
          Val Trp Gln Arg Ser Leu Tyr Asn Val Asn Gly Leu Lys Ala Gln Pro
                      20 25 30
          Trp Trp Thr Pro Lys Glu Thr Gly Tyr Thr Glu Leu Val Lys
                  35 40 45
           <![CDATA[ <210> 684]]>
           <![CDATA[ <211> 45]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <21]]>3> Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;684]]&gt;
           <br/>
           <br/> <![CDATA[Ser Leu Glu Arg Asn Trp Lys Leu Ile Arg Asp Glu Gly Leu Ala Val
          1 5 10 15
          Met Asp Lys Ala Lys Gly Leu Phe Leu Pro Glu Asp Glu Asn Leu Arg
                      20 25 30
          Glu Lys Gly Asp Trp Ser Gln Phe Thr Leu Trp Gln Gln
                  35 40 45
           <![CDATA[ <210> 685]]>
           <![CDATA[ <211> 30]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 685]]>
          Arg Arg Asn Glu Asn Ala Cys Lys Gly Ala Pro Lys Thr Cys Thr Leu
          1 5 10 15
          Leu Glu Lys Phe Pro Glu Thr Thr Gly Cys Arg Arg Gly Gln
                      20 25 30
           <![CDATA[ <210> 686]]>
           <![CDATA[ <211> 44]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 686]]>
          Ile Lys Tyr Ser Ile Met His Pro Gly Thr His Val Trp Pro His Thr
          1 5 10 15
          Gly Pro Thr Asn Cys Arg Leu Arg Met His Leu Gly Leu Val Ile Pro
                      20 25 30
          Lys Glu Gly Cys Lys Ile Arg Cys Ala Asn Glu Thr
                  35 40
           <![CDATA[ <210> 687]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 687]]>
          Thr Trp Glu Glu Gly Lys Val Leu Ile Phe Asp Asp Ser Phe Glu His
          1 5 10 15
          Glu Val Trp Gln Asp Ala Ser Ser Phe Arg Leu Ile Phe Ile Val Asp
                      20 25 30
          Val Trp His Pro Glu Leu Thr Pro Gln Gln Arg Arg Ser Leu Pro Ala
                  35 40 45
          Ile
           <![CDATA[ <210> 688]]>
           <![CDATA[ <211> 729]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 688]]>
          Met Ala Glu Asp Lys Glu Thr Lys His Gly Gly His Lys Asn Gly Arg
          1 5 10 15
          Lys Gly Gly Leu Ser Gly Thr Ser Phe Phe Thr Trp Phe Met Val Ile
                      20 25 30
          Ala Leu Leu Gly Val Trp Thr Ser Val Ala Val Val Trp Phe Asp Leu
                  35 40 45
          Val Asp Tyr Glu Glu Val Leu Gly Lys Leu Gly Ile Tyr Asp Ala Asp
              50 55 60
          Gly Asp Gly Asp Phe Asp Val Asp Asp Ala Lys Val Leu Leu Gly Leu
          65 70 75 80
          Lys Glu Arg Ser Thr Ser Glu Pro Ala Val Pro Pro Glu Glu Ala Glu
                          85 90 95
          Pro His Thr Glu Pro Glu Glu Gln Val Pro Val Glu Ala Glu Pro Gln
                      100 105 110
          Asn Ile Glu Asp Glu Ala Lys Glu Gln Ile Gln Ser Leu Leu His Glu
                  115 120 125
          Met Val His Ala Glu His Val Glu Gly Glu Asp Leu Gln Gln Glu Asp
              130 135 140
          Gly Pro Thr Gly Glu Pro Gln Gln Glu Asp Asp Glu Phe Leu Met Ala
          145 150 155 160
          Thr Asp Val Asp Asp Arg Phe Glu Thr Leu Glu Pro Glu Val Ser His
                          165 170 175
          Glu Glu Thr Glu His Ser Tyr His Val Glu Glu Thr Val Ser Gln Asp
                      180 185 190
          Cys Asn Gln Asp Met Glu Glu Met Met Ser Glu Gln Glu Asn Pro Asp
                  195 200 205
          Ser Ser Glu Pro Val Val Glu Asp Glu Arg Leu His His Asp Thr Asp
              210 215 220
          Asp Val Thr Tyr Gln Val Tyr Glu Glu Gln Ala Val Tyr Glu Pro Leu
          225 230 235 240
          Glu Asn Glu Gly Ile Glu Ile Thr Glu Val Thr Ala Pro Pro Glu Asp
                          245 250 255
          Asn Pro Val Glu Asp Ser Gln Val Ile Val Glu Glu Val Ser Ile Phe
                      260 265 270
          Pro Val Glu Glu Gln Gln Glu Val Pro Pro Glu Thr Asn Arg Lys Thr
                  275 280 285
          Asp Asp Pro Glu Gln Lys Ala Lys Val Lys Lys Lys Lys Lys Pro Lys Leu
              290 295 300
          Leu Asn Lys Phe Asp Lys Thr Ile Lys Ala Glu Leu Asp Ala Ala Glu
          305 310 315 320
          Lys Leu Arg Lys Arg Gly Lys Ile Glu Glu Ala Val Asn Ala Phe Lys
                          325 330 335
          Glu Leu Val Arg Lys Tyr Pro Gln Ser Pro Arg Ala Arg Tyr Gly Lys
                      340 345 350
          Ala Gln Cys Glu Asp Asp Leu Ala Glu Lys Arg Arg Ser Asn Glu Val
                  355 360 365
          Leu Arg Gly Ala Ile Glu Thr Tyr Gln Glu Val Ala Ser Leu Pro Asp
              370 375 380
          Val Pro Ala Asp Leu Leu Lys Leu Ser Leu Lys Arg Arg Ser Asp Arg
          385 390 395 400
          Gln Gln Phe Leu Gly His Met Arg Gly Ser Leu Leu Thr Leu Gln Arg
                          405 410 415
          Leu Val Gln Leu Phe Pro Asn Asp Thr Ser Leu Lys Asn Asp Leu Gly
                      420 425 430
          Val Gly Tyr Leu Leu Ile Gly Asp Asn Asp Asn Ala Lys Lys Val Tyr
                  435 440 445
          Glu Glu Val Leu Ser Val Thr Pro Asn Asp Gly Phe Ala Lys Val His
              450 455 460
          Tyr Gly Phe Ile Leu Lys Ala Gln Asn Lys Ile Ala Glu Ser Ile Pro
          465 470 475 480
          Tyr Leu Lys Glu Gly Ile Glu Ser Gly Asp Pro Gly Thr Asp Asp Gly
                          485 490 495
          Arg Phe Tyr Phe His Leu Gly Asp Ala Met Gln Arg Val Gly Asn Lys
                      500 505 510
          Glu Ala Tyr Lys Trp Tyr Glu Leu Gly His Lys Arg Gly His Phe Ala
                  515 520 525
          Ser Val Trp Gln Arg Ser Leu Tyr Asn Val Asn Gly Leu Lys Ala Gln
              530 535 540
          Pro Trp Trp Thr Pro Lys Glu Thr Gly Tyr Thr Glu Leu Val Lys Ser
          545 550 555 560
          Leu Glu Arg Asn Trp Lys Leu Ile Arg Asp Glu Gly Leu Ala Val Met
                          565 570 575
          Asp Lys Ala Lys Gly Leu Phe Leu Pro Glu Asp Glu Asn Leu Arg Glu
                      580 585 590
          Lys Gly Asp Trp Ser Gln Phe Thr Leu Trp Gln Gln Gly Arg Arg Asn
                  595 600 605
          Glu Asn Ala Cys Lys Gly Ala Pro Lys Thr Cys Thr Leu Leu Glu Lys
              610 615 620
          Phe Pro Glu Thr Thr Gly Cys Arg Arg Gly Gln Ile Lys Tyr Ser Ile
          625 630 635 640
          Met His Pro Gly Thr His Val Trp Pro His Thr Gly Pro Thr Asn Cys
                          645 650 655
          Arg Leu Arg Met His Leu Gly Leu Val Ile Pro Lys Glu Gly Cys Lys
                      660 665 670
          Ile Arg Cys Ala Asn Glu Thr Lys Thr Trp Glu Glu Gly Lys Val Leu
                  675 680 685
          Ile Phe Asp Asp Ser Phe Glu His Glu Val Trp Gln Asp Ala Ser Ser
              690 695 700
          Phe Arg Leu Ile Phe Ile Val Asp Val Trp His Pro Glu Leu Thr Pro
          705 710 715 720
          Gln Gln Arg Arg Ser Leu Pro Ala Ile
                          725
           <![CDATA[ <210> 689]]>
           <![CDATA[ <211> 1936]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 689]]>
          agtctcaagc tctggtaggc aagtgcatgc agtgtgccta aaacctgcca gcagtacttt 60
          tgagtttttt tttttgtttt gttttacttt agcatttatt attcatggat tgaagaaatc 120
          aaaatggctg aagataaaga gacaaagcat ggaggacaca agaatggggag gaaaggcgga 180
          ctctcaggaa cttcattctt cacgtggttt atggtgattg cattgctggg cgtctggaca 240
          tctgtagctg tcgtttggtt tgatcttgtt gactatgagg aagttctagg aaaactagga 300
          atctatgatg ctgatggtga tggagatttt gatgtggatg atgccaaagt tttattagga 360
          cttaaagaga gatctacttc agagccagca gtcccgccag aagaggctga gccacacact 420
          gagcccgagg agcaggttcc tgtggaggca gaacccccaga atatcgaaga tgaagcaaaa 480
          gaacaaattc agtcccttct ccatgaaatg gtacacgcag aacatgttga gggagaagac 540
          ttgcaacaag aagatggacc cacaggagaa ccacaacaag aggatgatga gtttcttatg 600
          gcgactgatg tagatgatag atttgagacc ctggaacctg aagtatctca tgaagaaacc 660
          gagcatagtt accacgtgga agagacagtt tcacaagact gtaatcagga tatggaagag 720
          atgatgtctg agcaggaaaa tccagattcc agtgaaccag tagtagaaga tgaaagattg 780
          caccatgata cagatgatgt aacataccaa gtctatgagg aacaagcagt atatgaacct 840
          ctagaaaatg aagggataga aatcacagaa gtaactgctc cccctgagga taatcctgta 900
          gaagattcac aggtaattgt agaagaagta agcatttttc ctgtggaaga acagcaggaa 960
          gtaccaccag aaacaaatag aaaaacagat gatccagaac aaaaagcaaa agttaagaaa 1020
          aagaagccta aacttttaaa taaatttgat aagactatta aagctgaact tgatgctgca 1080
          gaaaaactcc gtaaaagggg aaaaattgag gaagcagtga atgcatttaa agaactagta 1140
          cgcaaatacc ctcagagtcc acgagcaaga tatgggaagg cgcagtgtga ggatgatttg 1200
          gctgagaaga ggagaagtaa tgaggtgcta cgtggagcca tcgagaccta ccaagaggtg 1260
          gccagcctac ctgatgtccc tgcagacctg ctgaagctga gtttgaagcg tcgctcagac 1320
          aggcaacaat ttctaggtca tatgagaggt tccctgctta ccctgcagag attagttcaa 1380
          ctatttccca atgatacttc cttaaaaaat gaccttggcg tgggatacct cttgatagga 1440
          gataatgaca atgcaaagaa agtttatgaa gaggtgctga gtgtgacacc taatgatggc 1500
          tttgctaaag tccattatgg cttcatcctg aaggcacaga acaaaattgc tgagagcatc 1560
          ccatatttaa aggaaggaat agaatccgga gatcctggca ctgatgatgg gagattttat 1620
          ttccacctgg gggatgccat gcagagggtt gggaacaaag aggcatataa gtggtatgag 1680
          cttgggcaca agagaggaca ctttgcatct gtctggcaac gctcactcta caatgtgaat 1740
          ggactgaaag cacagccttg gtggaccccca aaagaaacgg gctacacaga gttagtaaag 1800
          tctttagaaa gaaactggaa gttaatccga gatgaaggcc ttgcagtgat ggataaagcc 1860
          aaaggtctct tcctgcctga ggatgaaaac ctgagggaaa aaggggactg gagccagttc 1920
          acgctgtggc agcaag 1936
           <![CDATA[ <210> 690]]>
           <![CDATA[ <211> 604]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 690]]>
          Met Ala Glu Asp Lys Glu Thr Lys His Gly Gly His Lys Asn Gly Arg
          1 5 10 15
          Lys Gly Gly Leu Ser Gly Thr Ser Phe Phe Thr Trp Phe Met Val Ile
                      20 25 30
          Ala Leu Leu Gly Val Trp Thr Ser Val Ala Val Val Trp Phe Asp Leu
                  35 40 45
          Val Asp Tyr Glu Glu Val Leu Gly Lys Leu Gly Ile Tyr Asp Ala Asp
              50 55 60
          Gly Asp Gly Asp Phe Asp Val Asp Asp Ala Lys Val Leu Leu Gly Leu
          65 70 75 80
          Lys Glu Arg Ser Thr Ser Glu Pro Ala Val Pro Pro Glu Glu Ala Glu
                          85 90 95
          Pro His Thr Glu Pro Glu Glu Gln Val Pro Val Glu Ala Glu Pro Gln
                      100 105 110
          Asn Ile Glu Asp Glu Ala Lys Glu Gln Ile Gln Ser Leu Leu His Glu
                  115 120 125
          Met Val His Ala Glu His Val Glu Gly Glu Asp Leu Gln Gln Glu Asp
              130 135 140
          Gly Pro Thr Gly Glu Pro Gln Gln Glu Asp Asp Glu Phe Leu Met Ala
          145 150 155 160
          Thr Asp Val Asp Asp Arg Phe Glu Thr Leu Glu Pro Glu Val Ser His
                          165 170 175
          Glu Glu Thr Glu His Ser Tyr His Val Glu Glu Thr Val Ser Gln Asp
                      180 185 190
          Cys Asn Gln Asp Met Glu Glu Met Met Ser Glu Gln Glu Asn Pro Asp
                  195 200 205
          Ser Ser Glu Pro Val Val Glu Asp Glu Arg Leu His His Asp Thr Asp
              210 215 220
          Asp Val Thr Tyr Gln Val Tyr Glu Glu Gln Ala Val Tyr Glu Pro Leu
          225 230 235 240
          Glu Asn Glu Gly Ile Glu Ile Thr Glu Val Thr Ala Pro Pro Glu Asp
                          245 250 255
          Asn Pro Val Glu Asp Ser Gln Val Ile Val Glu Glu Val Ser Ile Phe
                      260 265 270
          Pro Val Glu Glu Gln Gln Glu Val Pro Pro Glu Thr Asn Arg Lys Thr
                  275 280 285
          Asp Asp Pro Glu Gln Lys Ala Lys Val Lys Lys Lys Lys Lys Pro Lys Leu
              290 295 300
          Leu Asn Lys Phe Asp Lys Thr Ile Lys Ala Glu Leu Asp Ala Ala Glu
          305 310 315 320
          Lys Leu Arg Lys Arg Gly Lys Ile Glu Glu Ala Val Asn Ala Phe Lys
                          325 330 335
          Glu Leu Val Arg Lys Tyr Pro Gln Ser Pro Arg Ala Arg Tyr Gly Lys
                      340 345 350
          Ala Gln Cys Glu Asp Asp Leu Ala Glu Lys Arg Arg Ser Asn Glu Val
                  355 360 365
          Leu Arg Gly Ala Ile Glu Thr Tyr Gln Glu Val Ala Ser Leu Pro Asp
              370 375 380
          Val Pro Ala Asp Leu Leu Lys Leu Ser Leu Lys Arg Arg Ser Asp Arg
          385 390 395 400
          Gln Gln Phe Leu Gly His Met Arg Gly Ser Leu Leu Thr Leu Gln Arg
                          405 410 415
          Leu Val Gln Leu Phe Pro Asn Asp Thr Ser Leu Lys Asn Asp Leu Gly
                      420 425 430
          Val Gly Tyr Leu Leu Ile Gly Asp Asn Asp Asn Ala Lys Lys Val Tyr
                  435 440 445
          Glu Glu Val Leu Ser Val Thr Pro Asn Asp Gly Phe Ala Lys Val His
              450 455 460
          Tyr Gly Phe Ile Leu Lys Ala Gln Asn Lys Ile Ala Glu Ser Ile Pro
          465 470 475 480
          Tyr Leu Lys Glu Gly Ile Glu Ser Gly Asp Pro Gly Thr Asp Asp Gly
                          485 490 495
          Arg Phe Tyr Phe His Leu Gly Asp Ala Met Gln Arg Val Gly Asn Lys
                      500 505 510
          Glu Ala Tyr Lys Trp Tyr Glu Leu Gly His Lys Arg Gly His Phe Ala
                  515 520 525
          Ser Val Trp Gln Arg Ser Leu Tyr Asn Val Asn Gly Leu Lys Ala Gln
              530 535 540
          Pro Trp Trp Thr Pro Lys Glu Thr Gly Tyr Thr Glu Leu Val Lys Ser
          545 550 555 560
          Leu Glu Arg Asn Trp Lys Leu Ile Arg Asp Glu Gly Leu Ala Val Met
                          565 570 575
          Asp Lys Ala Lys Gly Leu Phe Leu Pro Glu Asp Glu Asn Leu Arg Glu
                      580 585 590
          Lys Gly Asp Trp Ser Gln Phe Thr Leu Trp Gln Gln
                  595 600
           <![CDATA[ <210> 691]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 691]]>
          cctcctgtac tccaggctcc acctgcatcg accgtgtggc ctccttctct tgcatgtgcc 60
          cagaggggaa ggcag 75
           <![CDATA[ <210> 692]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 692]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgtgaatg 75
           <![CDATA[ <210> 693]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 693]]>
          cctcctgtac tccaggctcc acctgcatcg accgtgtggc ctccttctct tgcatgtgcc 60
          cagaggggaa ggcagctaca tctacatcca ccactgggac aagccatctt gtaaaatgtg 120
          cggagaagga gaaaactttc tgtgtgaatg 150
           <![CDATA[ <210> 694]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 694]]>
          Ser Cys Thr Pro Gly Ser Thr Cys Ile Asp Arg Val Ala Ser Phe Ser
          1 5 10 15
          Cys Met Cys Pro Glu Gly Lys Ala Ala Thr Ser Thr Ser Thr Thr Gly
                      20 25 30
          Thr Ser His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val
                  35 40 45
          Asn
           <![CDATA[ <210> 695]]>
           <![CDATA[ <211> 329]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 695]]>
          aggctgcttc gttgcacacc cgagaaagtt tcagccaaac ttcgggcggc ggctgaggcg 60
          gcggccgagg agcggcggac tcggggcgcg gggagtcgag gcatttgcgc ctgggcttcg 120
          gagcgtagcg ccagggcctg agcctttgaa gcaggaggag gggaggagag agtggggctc 180
          ctctatcggg accccctccc catgtggatc tgcccaggcg gcggcggcgg cggcggagga 240
          ggaggcgacc gagaagatgc ccgccctgcg ccccgctctg ctgtgggcgc tgctggcgct 300
          ctggctgtgc tgcgcggccc ccgcgcatg 329
           <![CDATA[ <210> 696]]>
           <![CDATA[ <211> 82]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 696]]>
          cattgcagtg tcgagatggc tatgaaccct gtgtaaatga aggaatgtgt gttacctacc 60
          acaatggcac aggatactgc aa 82
           <![CDATA[ <210> 697]]>
           <![CDATA[ <211> 260]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 697]]>
          atgtccagaa ggcttcttgg gggaatattg tcaacatcga gacccctgtg agaagaaccg 60
          ctgccagaat ggtgggactt gtgtggccca ggccatgctg gggaaagcca cgtgccgatg 120
          tgcctcaggg tttacaggag aggactgcca gtactcaaca tctcatccat gctttgtgtc 180
          tcgaccctgc ctgaatggcg gcacatgcca tatgctcagc cgggatacct atgagtgcac 240
          ctgtcaagtc gggtttacag 260
           <![CDATA[ <210> 698]]>
           <![CDATA[ <211> 336]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 698]]>
          gtaaggagtg ccaatggacg gatgcctgcc tgtctcatcc ctgtgcaaat ggaagtacct 60
          gtaccactgt ggccaaccag ttctcctgca aatgcctcac aggcttcaca gggcagaaat 120
          gtgagactga tgtcaatgag tgtgacattc caggacactg ccagcatggt ggcacctgcc 180
          tcaacctgcc tggttcctac cagtgccagt gccctcaggg cttcacaggc cagtactgtg 240
          acagcctgta tgtgccctgt gcaccctcac cttgtgtcaa tggaggcacc tgtcggcaga 300
          ctggtgactt cacttttgag tgcaactgcc ttccag 336
           <![CDATA[ <210> 699]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 699]]>
          gttttgaagg gagcacctgt gagaggaata ttgatgactg ccctaaccac aggtgtcaga 60
          atggaggggt ttgtgtggat ggggtcaaca cttacaactg ccgctgtccc ccacaatgga 120
          cag 123
           <![CDATA[ <210> 700]]>
           <![CDATA[ <211> 234]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 700]]>
          gacagttctg cacagaggat gtggatgaat gcctgctgca gcccaatgcc tgtcaaaatg 60
          ggggcacctg tgccaaccgc aatggaggct atggctgtgt atgtgtcaac ggctggagtg 120
          gagatgactg cagtgagaac attgatgatt gtgccttcgc ctcctgtact ccaggctcca 180
          cctgcatcga ccgtgtggcc tccttctctt gcatgtgccc agagggggaag gcag 234
           <![CDATA[ <210> 701]]>
           <![CDATA[ <211> 156]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 701]]>
          gtctcctgtg tcatctggat gatgcatgca tcagcaatcc ttgccacaag ggggcactgt 60
          gtgacaccaa ccccctaaat gggcaatata tttgcacctg cccacaaggc tacaaagggg 120
          ctgactgcac agaagatgtg gatgaatgtg ccatgg 156
           <![CDATA[ <210> 702]]>
           <![CDATA[ <211> 9905]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 702]]>
          ccaatagcaa tccttgtgag catgcaggaa aatgtgtgaa cacggatggc gccttccact 60
          gtgagtgtct gaagggttat gcaggacctc gttgtgagat ggacatcaat gagtgccatt 120
          cagacccctg ccagaatgat gctacctgtc tggataagat tggaggcttc acatgtctgt 180
          gcatgccagg tttcaaaggt gtgcattgtg aattagaaat aaatgaatgt cagagcaacc 240
          cttgtgtgaa caatgggcag tgtgtggata aagtcaatcg tttccagtgc ctgtgtcctc 300
          ctggtttcac tgggccagtt tgccagattg atattgatga ctgttccagt actccgtgtc 360
          tgaatggggc aaagtgtatc gatcacccga atggctatga atgccagtgt gccacaggtt 420
          tcactggtgt gttgtgtgag gagaacattg acaactgtga ccccgatcct tgccaccatg 480
          gtcagtgtca ggatggtatt gattcctaca cctgcatctg caatcccggg tacatgggcg 540
          ccatctgcag tgaccagatt gatgaatgtt acagcagccc ttgcctgaac gatggtcgct 600
          gcattgacct ggtcaatggc taccagtgca actgccagcc aggcacgtca ggggttaatt 660
          gtgaaattaa ttttgatgac tgtgcaagta acccttgtat ccatggaatc tgtatggatg 720
          gcattaatcg ctacagttgtgtctgctcac caggattcac agggcagaga tgtaacattg 780
          acattgatga gtgtgcctcc aatccctgtc gcaagggtgc aacatgtatc aacggtgtga 840
          atggtttccg ctgtatatgc cccgagggac cccatcaccc cagctgctac tcacaggtga 900
          acgaatgcct gagcaatccc tgcatccatg gaaactgtac tggaggtctc agtggatata 960
          agtgtctctg tgatgcaggc tgggttggca tcaactgtga agtggacaaa aatgaatgcc 1020
          tttcgaatcc atgccagaat ggaggaactt gtgacaatct ggtgaatgga tacaggtgta 1080
          cttgcaagaa gggctttaaa ggctataact gccaggtgaa tattgatgaa tgtgcctcaa 1140
          atccatgcct gaaccaagga acctgctttg atgacataag tggctacact tgccactgtg 1200
          tgctgccata cacaggcaag aattgtcaga cagtattggc tccctgttcc ccaaaccctt 1260
          gtgagaatgc tgctgtttgc aaagagtcac caaattttga gagttatact tgcttgtgtg 1320
          ctcctggctg gcaaggtcag cggtgtacca ttgacattga cgagtgtatc tccaagccct 1380
          gcatgaacca tggtctctgc cataacaccc agggcagcta catgtgtgaa tgtccaccag 1440
          gcttcagtgg tatggactgt gaggaggaca ttgatgactg ccttgccaat ccttgccaga 1500
          atggaggttc ctgtatggat ggagtgaata ctttctcctg cctctgcctt ccgggtttca 1560
          ctggggataa gtgccagaca gacatgaatg agtgtctgag tgaaccctgt aagaatggag 1620
          ggacctgctc tgactacgtc aacagttaca cttgcaagtg ccaggcagga tttgatggag 1680
          tccattgtga gaacaacatc aatgagtgca ctgagagctc ctgtttcaat ggtggcacat 1740
          gtgttgatgg gattaactcc ttctcttgct tgtgccctgt gggtttcact ggatccttct 1800
          gcctccatga gatcaatgaa tgcagctctc atccatgcct gaatgaggga acgtgtgttg 1860
          atggcctggg tacctaccgc tgcagctgcc ccctgggcta cactgggaaa aactgtcaga 1920
          ccctggtgaa tctctgcagt cggtctccat gtaaaaacaa aggtacttgc gttcagaaaa 1980
          aagcagagtc ccagtgccta tgtccatctg gatgggctgg tgcctattgt gacgtgccca 2040
          atgtctcttg tgacatagca gcctccagga gaggtgtgct tgttgaacac ttgtgccagc 2100
          actcaggtgt ctgcatcaat gctggcaaca cgcattactg tcagtgcccc ctgggctata 2160
          ctgggagcta ctgtgaggag caactcgatg agtgtgcgtc caacccctgc cagcacgggg 2220
          caacatgcag tgacttcatt ggtggataca gatgcgagtg tgtcccaggc tatcagggtg 2280
          tcaactgtga gtatgaagtg gatgagtgcc agaatcagcc ctgccagaat ggaggcacct 2340
          gtattgacct tgtgaaccat ttcaagtgct cttgcccacc aggcactcgg ggcctactct 2400
          gtgaagagaa cattgatgac tgtgcccggg gtccccattg ccttaatggt ggtcagtgca 2460
          tggataggat tggaggctac agttgtcgct gcttgcctgg ctttgctggg gagcgttgtg 2520
          agggagacat caacgagtgc ctctccaacc cctgcagctc tgagggcagc ctggactgta 2580
          tacagctcac caatgactac ctgtgtgttt gccgtagtgc ctttactggc cggcactgtg 2640
          aaaccttcgt cgatgtgtgt ccccagatgc cctgcctgaa tggagggact tgtgctgtgg 2700
          ccagtaacat gcctgatggt ttcatttgcc gttgtccccc gggattttcc ggggcaaggt 2760
          gccagagcag ctgtggacaa gtgaaatgta ggaaggggga gcagtgtgtg cacaccgcct 2820
          ctggaccccg ctgcttctgc cccagtcccc gggactgcga gtcaggctgt gccagtagcc 2880
          cctgccagca cgggggcagc tgccaccctc agcgccagcc tccttattac tcctgccagt 2940
          gtgccccacc attctcgggt agccgctgtg aactctacac ggcacccccc agcaccccctc 3000
          ctgccacctg tctgagccag tattgtgccg acaaagctcg ggatggcgtc tgtgatgagg 3060
          cctgcaacag ccatgcctgc cagtgggatgggggtgactg ttctctcacc atggagaacc 3120
          cctgggccaa ctgctcctcc ccacttccct gctgggatta tatcaacaac cagtgtgatg 3180
          agctgtgcaa cacggtcgag tgcctgtttg acaactttga atgccagggg aacagcaaga 3240
          catgcaagta tgacaaatac tgtgcagacc acttcaaaga caaccactgt gaccaggggt 3300
          gcaacagtga ggagtgtggt tgggatgggc tggactgtgc tgctgaccaa cctgagaacc 3360
          tggcagaagg taccctggtt attgtggtat tgatgccacc tgaacaactg ctccaggatg 3420
          ctcgcagctt cttgcgggca ctgggtaccc tgctccacac caacctgcgc attaagcggg 3480
          actcccaggg ggaactcatg gtgtacccct attatggtga gaagtcagct gctatgaaga 3540
          aacagaggat gacacgcaga tcccttcctg gtgaacaaga acaggaggtg gctggctcta 3600
          aagtctttct ggaaattgac aaccgccagt gtgttcaaga ctcagaccac tgcttcaaga 3660
          acacggatgc agcagcagct ctcctggcct ctcacgccat acagggggacc ctgtcatacc 3720
          ctcttgtgtc tgtcgtcagt gaatccctga ctccagaacg cactcagctc ctctatctcc 3780
          ttgctgttgc tgttgtcatc attctgttta ttaattctgct gggggtaatc atggcaaaac 3840
          gaaagcgtaa gcatggctct ctctggctgc ctgaaggttt cactcttcgc cgagatgcaa 3900
          gcaatcacaa gcgtcgtgag ccagtgggac aggatgctgt ggggctgaaa aatctctcag 3960
          tgcaagtctc agaagctaac ctaattggta ctggaacaag tgaacactgg gtcgatgatg 4020
          aagggcccca gccaaagaaa gtaaaggctg aagatgaggc cttactctca gaagaagatg 4080
          accccattga tcgacggcca tggacacagc agcaccttga agctgcagac atccgtagga 4140
          caccatcgct ggctctcacc cctcctcagg cagagcagga ggtggatgtg ttagatgtga 4200
          atgtccgtgg cccagatggc tgcaccccat tgatgttggc ttctctccga ggaggcagct 4260
          cagatttgag tgatgaagat gaagatgcag aggactcttc tgctaacatc atcacagact 4320
          tggtctacca gggtgccagc ctccaggccc agacagaccg gactggtgag atggccctgc 4380
          accttgcagc ccgctactca cgggctgatg ctgccaagcg tctcctggat gcaggtgcag 4440
          atgccaatgc ccaggacaac atgggccgct gtccactcca tgctgcagtg gcagctgatg 4500
          cccaaggtgt cttccagatt ctgattcgca accgagtaac tgatctagat gccaggatga 4560
          atgatggtac tacacccctg atcctggctg cccgcctggc tgtggaggga atggtggcag 4620
          aactgatcaa ctgccaagcg gatgtgaatg cagtggatga ccatggaaaa tctgctcttc 4680
          actgggcagc tgctgtcaat aatgtgggagg caactctttt gttgttgaaa aatggggcca 4740
          accgagacat gcaggacaac aaggaagaga cacctctgtt tcttgctgcc cgggaggggga 4800
          gctatgaagc agccaagatc ctgttagacc attttgccaa tcgagacatc acagaccata 4860
          tggatcgtct tccccgggat gtggctcggg atcgcatgca ccatgacatt gtgcgccttc 4920
          tggatgaata caatgtgacc ccaagccctc caggcaccgt gttgacttct gctctctcac 4980
          ctgtcatctg tgggcccaac agatctttcc tcagcctgaa gcacacccca atgggcaaga 5040
          agtctagacg gcccagtgcc aagagtacca tgcctactag cctccctaac cttgccaagg 5100
          aggcaaagga tgccaagggt agtagggagga agaagtctct gagtgagaag gtccaactgt 5160
          ctgagagttc agtaacttta tcccctgttg attccctaga atctccctcac acgtatgttt 5220
          ccgacaccac atccctctcca atgattacat cccctgggat cttacaggcc tcacccaacc 5280
          ctatgttggc cactgccgcc cctcctgccc cagtccatgc ccagcatgca ctatcttttt 5340
          ctaaccttca tgaaatgcag cctttggcac atggggccag cactgtgctt ccctcagtga 5400
          gccagttgct atcccaccac cacattgtgt ctccaggcag tggcagtgct ggaagcttga 5460
          gtaggctcca tccagtccca gtcccagcag attggatgaa ccgcatggag gtgaatgaga 5520
          cccagtacaa tgagatgttt ggtatggtcc tggctccagc tgagggcacc catcctggca 5580
          tagctcccca gagcaggcca cctgaaggga agcacataac cacccctcgg gagcccttgc 5640
          cccccattgt gactttccag ctcatcccta aaggcagtat tgcccaacca gcgggggctc 5700
          cccagcctca gtccacctgc cctccagctg ttgcgggccc cctgcccacc atgtaccaga 5760
          ttccagaaat ggcccgtttg cccagtgtgg ctttccccac tgccatgatg ccccagcagg 5820
          acgggcaggt agctcagacc attctcccag cctatcatcc tttcccagcc tctgtgggca 5880
          agtaccccac acccccttca cagcacagtt atgcttcctc aaatgctgct gagcgaacac 5940
          ccagtcacag tggtcacctc cagggtgagc atccctacct gacaccatcc ccagagtctc 6000
          ctgaccagtg gtcaagttca tcaccccact ctgcttctga ctggtcagat gtgaccacca 6060
          gccctacccc tgggggtgct gggagggtc agcggggacc tgggacacac atgtctgagc 6120
          caccacacaa caacatgcag gtttatgcgt gagagagtcc acctccagtg tagagacata 6180
          actgactttt gtaaatgctg ctgaggaaca aatgaaggtc atccgggaga gaaatgaaga 6240
          aatctctgga gccagcttct agaggtagga aagagaagat gttcttattc agataatgca 6300
          agagaagcaa ttcgtcagtt tcactgggta tctgcaaggc ttattgatta ttctaatcta 6360
          ataagacaag tttgtggaaa tgcaagatga atacaagcct tgggtccatg tttactctct 6420
          tctatttgga gaataagatg gatgcttatt gaagccccaga cattcttgca gcttggactg 6480
          cattttaagc cctgcaggct tctgccatat ccatgagaag attctacact agcgtcctgt 6540
          tgggaattat gccctggaat tctgcctgaa ttgacctacg catctcctcc tccttggaca 6600
          ttcttttgtc ttcatttggt gcttttggtt ttgcacctct ccgtgattgt agccctacca 6660
          gcatgttata gggcaagacc tttgtgcttt tgatcattct ggcccatgaa agcaactttg 6720
          gtctcctttc ccctcctgtc ttcccggtat cccttggagt ctcacaaggt ttactttggt 6780
          atggttctca gcacaaacct ttcaagtatg ttgtttcttt ggaaaatgga catactgtat 6840
          tgtgttctcc tgcatatatc attcctggag agagaagggg agaagaatac ttttcttcaa 6900
          caaattttgg gggcaggaga tcccttcaag aggctgcacc ttaatttttc ttgtctgtgt 6960
          gcaggtcttc atataaactt taccaggaag aagggtgtga gtttgttgtt tttctgtgta 7020
          tgggcctggt cagtgtaaag ttttatcctt gtagtctag ttactatgac cctccccact 7080
          tttttaaaac cagaaaaagg tttggaatgt tggaatgacc aagagacaag ttaactcgtg 7140
          caagagccag ttacccaccc acaggtcccc ctacttcctg ccaagcattc cattgactgc 7200
          ctgtatggaa cacatttgtc ccagatctga gcattctagg cctgtttcac tcactcaccc 7260
          agcatatgaa actagtctta actgttgagc ctttcctttc atatccacag aagacactgt 7320
          ctcaaatgtt gtacccttgc catttaggac tgaactttcc ttagcccaag ggacccagtg 7380
          acagttgtct tccgtttgtc agatgatcag tctctactga ttatcttgct gcttaaaggc 7440
          ctgctcacca atctttcttt cacaccgtgt ggtccgtgtt actggtatac ccagtatgtt 7500
          ctcactgaag acatggactt tatatgttca agtgcaggaa ttggaaagtt ggacttgttt 7560
          tctatgatcc aaaacagccc tataagaagg ttggaaaagg aggaactata tagcagcctt 7620
          tgctattttc tgctaccatt tcttttcctc tgaagcggcc atgacattcc ctttggcaac 7680
          taacgtagaa actcaacaga aattttcct ttcctagagt caccttttag atgataatgg 7740
          acaactatag acttgctcat tgttcagact gattgcccct cacctgaatc cactctctgt 7800
          attcatgctc ttggcaattt ctttgacttt cttttaaggg cagaagcatt ttagttaatt 7860
          gtagataaag aatagttttc ttcctcttct ccttgggcca gttaataatt ggtccatggc 7920
          tacactgcaa cttccgtcca gtgctgtgat gcccatgaca cctgcaaaat aagttctgcc 7980
          tgggcatttt gtagatatta acaggtgaat tcccgactct tttggtttga atgacagttc 8040
          tcattccttc tatggctgca agtatgcatc agtgcttccc acttacctga tttgtctgtc 8100
          ggtggcccca tatggaaacc ctgcgtgtct gttggcataa tagtttacaa atggtttttt 8160
          cagtcctatc caaatttatt gaaccaacaa aaataattac ttctgccctg agataagcag 8220
          attaagtttg ttcattctct gctttatctct ctccatgtgg caacattctg tcagcctctt 8280
          tcatagtgtg caaacatttt atcattctaa atggtgactc tctgcccttg gacccatta 8340
          ttattcacag atggggagaa cctatctgca tggacctctg tggaccacag cgtacctgcc 8400
          cctttctgcc ctcctgctcc agccccactt ctgaaagtat cagctactga tccagccact 8460
          ggatatttta tatcctccct tttccttaag cacaatgtca gaccaaattg cttgtttctt 8520
          tttcttggac tactttaatt tggatccttt gggtttggag aaagggaatg tgaaagctgt 8580
          cattacagac aacaggtttc agtgatgagg aggacaacac tgcctttcaa actttttact 8640
          gatctcttag attttaagaa ctcttgaatt gtgtggtatc taataaaagg gaaggtaaga 8700
          tggataatca ctttctcatt tgggttctga attggagact cagtttttat gagacacatc 8760
          ttttatgcca tgtatagatc ctcccctgct atttttggtt tattttatt gttataaatg 8820
          ctttctttct ttgactcctc ttctgcctgc ctttggggat aggttttttt gtttgtttat 8880
          ttgcttcctc tgttttgttt taagcatcat tttcttatgt gaggtgggga agggaaaggt 8940
          atgagggaaa gagagtctga gaattaaaat attttagtat aagcaattgg ctgtgatgct 9000
          caaatccatt gcatcctctt attgaatttg ccaatttgta atttttgcat aataaagaac 9060
          caaaggtgta atgttttgtt gagaggtggt ttagggattt tggccctaac caatacattg 9120
          aatgtatgat gactatttgg gaggacacat ttatgtaccc agaggccccc actaataagt 9180
          ggtactatgg ttacttcctt gtgtacattt ctcttaaaag tgatattata tctgtttgta 9240
          tgagaaaccc agtaaccaat aaaatgaccg catattcctg actaaacgta gtaaggaaaa 9300
          tgcacacttt gtttttactt ttccgtttca ttctaaaggt agttaagatg aaatttatat 9360
          gaaagcattt ttatcacaaa ataaaaaagg tttgccaagc tcagtggtgt tgtatttttt 9420
          attttccaat actgcatcca tggcctggca gtgttacctc atgatgtcat aatttgctga 9480
          gagagcaaat tttcttttct ttctgaatcc cacaaagcct agcaccaaac ttcttttttt 9540
          cttcctttaa ttagatcata aataaatgat cctggggaaa aagcatctgt caaataggaa 9600
          acatcacaaa actgagcact cttctgtgca ctagccatag ctggtgacaa acagatggtt 9660
          gctcagggac aaggtgcctt ccaatggaaa tgcgaagtag ttgctatagc aagaattggg 9720
          aactgggata taagtcataa tattaattat gctgttatgt aaatgattgg tttgtaacat 9780
          tccttaagtg aaatttgtgt agaacttaat atacaggatt ataaaataat attttgtgta 9840
          taaatttgtt ataagttcac attcatacat ttattataa agtcagtgag atatttgaac 9900
          atgaa 9905
           <![CDATA[ <210> 703]]>
           <![CDATA[ <211> 11425]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> The complete mRNA polynucleotide sequence of NOTCH2]]>
           <![CDATA[ <400> 703]]>
          aggctgcttc gttgcacacc cgagaaagtt tcagccaaac ttcgggcggc ggctgaggcg 60
          gcggccgagg agcggcggac tcggggcgcg gggagtcgag gcatttgcgc ctgggcttcg 120
          gagcgtagcg ccagggcctg agcctttgaa gcaggaggag gggaggagag agtggggctc 180
          ctctatcggg accccctccc catgtggatc tgcccaggcg gcggcggcgg cggcggagga 240
          ggaggcgacc gagaagatgc ccgccctgcg ccccgctctg ctgtgggcgc tgctggcgct 300
          ctggctgtgc tgcgcggccc ccgcgcatgc attgcagtgt cgagatggct atgaaccctg 360
          tgtaaatgaa ggaatgtgtg ttacctacca caatggcaca ggatactgca aatgtccaga 420
          aggcttcttg ggggaatatt gtcaacatcg agaccccctgt gagaagaacc gctgccagaa 480
          tggtgggact tgtgtggccc aggccatgct ggggaaagcc acgtgccgat gtgcctcagg 540
          gtttacagga gaggactgcc agtactcaac atctcatcca tgctttgtgt ctcgaccctg 600
          cctgaatggc ggcacatgcc atatgctcag ccgggatacc tatgagtgca cctgtcaagt 660
          cgggtttaca ggtaaggagt gccaatggac ggatgcctgc ctgtctcatc cctgtgcaaa 720
          tggaagtacc tgtaccactg tggccaacca gttctcctgc aaatgcctca caggcttcac 780
          agggcagaaa tgtgagactg atgtcaatga gtgtgacatt ccaggacact gccagcatgg 840
          tggcacctgc ctcaacctgc ctggttccta ccagtgccag tgccctcagg gcttcacagg 900
          ccagtactgt gacagcctgt atgtgccctg tgcaccctca ccttgtgtca atggaggcac 960
          ctgtcggcag actggtgact tcacttttga gtgcaactgc cttccaggtt ttgaagggag 1020
          cacctgtgag aggaatattg atgactgccc taaccacagg tgtcagaatg gaggggtttg 1080
          tgtggatggg gtcaacactt acaactgccg ctgtccccca caatggacag gacagttctg 1140
          cacagaggat gtggatgaat gcctgctgca gcccaatgcc tgtcaaaatg ggggcacctg 1200
          tgccaaccgc aatggaggct atggctgtgt atgtgtcaac ggctggagtg gagatgactg 1260
          cagtgagaac attgatgatt gtgccttcgc ctcctgtact ccaggctcca cctgcatcga 1320
          ccgtgtggcc tccttctctt gcatgtgccc agagggggaag gcaggtctcc tgtgtcatct 1380
          ggatgatgca tgcatcagca atccttgcca caagggggca ctgtgtgaca ccaaccccct 1440
          aaatgggcaa tatatttgca cctgcccaca aggctacaaa ggggctgact gcacagaaga 1500
          tgtggatgaa tgtgccatgg ccaatagcaa tccttgtgag catgcaggaa aatgtgtgaa 1560
          cacggatggc gccttccact gtgagtgtct gaagggttat gcaggacctc gttgtgagat 1620
          ggacatcaat gagtgccatt cagacccctg ccagaatgat gctacctgtc tggataagat 1680
          tggaggcttc acatgtctgt gcatgccagg tttcaaaggt gtgcattgtg aattagaaat 1740
          aaatgaatgt cagagcaacc cttgtgtgaa caatgggcag tgtgtggata aagtcaatcg 1800
          tttccagtgc ctgtgtcctc ctggtttcac tgggccagtt tgccagattg atattgatga 1860
          ctgttccagt actccgtgtc tgaatggggc aaagtgtatc gatcacccga atggctatga 1920
          atgccagtgt gccacaggtt tcactggtgt gttgtgtgag gagaacattg acaactgtga 1980
          ccccgatccttgccaccatg gtcagtgtca ggatggtatt gattcctaca cctgcatctg 2040
          caatcccggg tacatgggcg ccatctgcag tgaccagatt gatgaatgtt acagcagccc 2100
          ttgcctgaac gatggtcgct gcattgacct ggtcaatggc taccagtgca actgccagcc 2160
          aggcacgtca ggggttaatt gtgaaattaa ttttgatgac tgtgcaagta acccttgtat 2220
          ccatggaatc tgtatggatg gcattaatcg ctacagttgt gtctgctcac caggattcac 2280
          agggcagaga tgtaacattg acattgatga gtgtgcctcc aatccctgtc gcaagggtgc 2340
          aacatgtatc aacggtgtga atggtttccg ctgtatatgc cccgagggac cccatcaccc 2400
          cagctgctac tcacaggtga acgaatgcct gagcaatccc tgcatccatg gaaactgtac 2460
          tggaggtctc agtggatata agtgtctctg tgatgcaggc tgggttggca tcaactgtga 2520
          agtggacaaa aatgaatgcc tttcgaatcc atgccagaat ggaggaactt gtgacaatct 2580
          ggtgaatgga tacaggtgta cttgcaagaa gggctttaaa ggctataact gccaggtgaa 2640
          tattgatgaa tgtgcctcaa atccatgcct gaaccaagga acctgctttg atgacataag 2700
          tggctacact tgccactgtg tgctgccata cacaggcaag aattgtcaga cagtattggc 2760
          tccctgttcc ccaaaccctt gtgagaatgc tgctgtttgc aaagagtcac caaattttga 2820
          gagttatact tgcttgtgtg ctcctggctg gcaaggtcag cggtgtacca ttgacattga 2880
          cgagtgtatc tccaagccct gcatgaacca tggtctctgc cataacaccc agggcagcta 2940
          catgtgtgaa tgtccaccag gcttcagtgg tatggactgt gaggaggaca ttgatgactg 3000
          ccttgccaat ccttgccaga atggaggttc ctgtatggat ggagtgaata ctttctcctg 3060
          cctctgcctt ccgggtttca ctggggataa gtgccagaca gacatgaatg agtgtctgag 3120
          tgaaccctgt aagaatggag ggacctgctc tgactacgtc aacagttaca cttgcaagtg 3180
          ccaggcagga tttgatggag tccatgtga gaacaacatc aatgagtgca ctgagagctc 3240
          ctgtttcaat ggtggcacat gtgttgatgg gattaactcc ttctcttgct tgtgccctgt 3300
          gggtttcact ggatccttct gcctccatga gatcaatgaa tgcagctctc atccatgcct 3360
          gaatgaggga acgtgtgttg atggcctggg tacctaccgc tgcagctgcc ccctgggcta 3420
          cactgggaaa aactgtcaga ccctggtgaa tctctgcagt cggtctccat gtaaaaacaa 3480
          aggtacttgc gttcagaaaa aagcagagtc ccagtgccta tgtccatctg gatgggctgg 3540
          tgcctattgt gacgtgccca atgtctcttg tgacatagca gcctccagga gaggtgtgct 3600
          tgttgaacac ttgtgccagc actcaggtgt ctgcatcaat gctggcaaca cgcattactg 3660
          tcagtgcccc ctgggctata ctgggagcta ctgtgaggag caactcgatg agtgtgcgtc 3720
          caacccctgc cagcacgggg caacatgcag tgacttcatt ggtggataca gatgcgagtg 3780
          tgtcccaggc tatcagggtg tcaactgtga gtatgaagtg gatgagtgcc agaatcagcc 3840
          ctgccagaat ggaggcacct gtattgacct tgtgaaccat ttcaagtgct cttgcccacc 3900
          aggcactcgg ggccctactct gtgaagagaa cattgatgac tgtgcccggg gtccccattg 3960
          ccttaatggt ggtcagtgca tggataggat tggaggctac agttgtcgct gcttgcctgg 4020
          ctttgctggg gagcgttgtg agggagacat caacgagtgc ctctccaacc cctgcagctc 4080
          tgagggcagc ctggactgta tacagctcac caatgactac ctgtgtgttt gccgtagtgc 4140
          ctttactggc cggcactgtg aaaccttcgt cgatgtgtgt ccccagatgc cctgcctgaa 4200
          tggagggact tgtgctgtgg ccagtaacat gcctgatggt ttcatttgcc gttgtccccc 4260
          gggattttcc ggggcaaggt gccagagcag ctgtggacaa gtgaaatgta ggaaggggga 4320
          gcagtgtgtg cacaccgcct ctggaccccg ctgcttctgc cccagtcccc gggactgcga 4380
          gtcaggctgt gccagtagcc cctgccagca cgggggcagc tgccaccctc agcgccagcc 4440
          tccttaattac tcctgccagt gtgccccacc attctcgggt agccgctgtg aactctacac 4500
          ggcacccccc agcaccccctc ctgccacctg tctgagccag tattgtgccg acaaagctcg 4560
          ggatggcgtc tgtgatgagg cctgcaacag ccatgcctgc cagtgggatgggggtgactg 4620
          ttctctcacc atggagaacc cctgggccaa ctgctcctcc ccacttccct gctgggatta 4680
          tatcaacaac cagtgtgatg agctgtgcaa cacggtcgag tgcctgtttg acaactttga 4740
          atgccagggg aacagcaaga catgcaagta tgacaaatac tgtgcagacc acttcaaaga 4800
          caaccactgt gaccaggggt gcaacagtga ggagtgtggt tgggatgggc tggactgtgc 4860
          tgctgaccaa cctgagaacc tggcagaagg taccctggtt attgtggtat tgatgccacc 4920
          tgaacaactg ctccaggatg ctcgcagctt cttgcgggca ctgggtaccc tgctccaacac 4980
          caacctgcgc attaagcggg actcccaggg ggaactcatg gtgtacccct attatggtga 5040
          gaagtcagct gctatgaaga aacagaggat gacacgcaga tcccttcctg gtgaacaaga 5100
          acaggaggtg gctggctcta aagtctttct ggaaattgac aaccgccagt gtgttcaaga 5160
          ctcagaccac tgcttcaaga acacggatgc agcagcagct ctcctggcct ctcacgccat 5220
          acaggggacc ctgtcatacc ctcttgtgtc tgtcgtcagt gaatccctga ctccagaacg 5280
          cactcagctc ctctatctcc ttgctgttgc tgttgtcatc attctgttta ttaattctgct 5340
          gggggtaatc atggcaaaac gaaagcgtaa gcatggctct ctctggctgc ctgaaggttt 5400
          cactcttcgc cgagatgcaa gcaatcacaa gcgtcgtgag ccagtgggac aggatgctgt 5460
          ggggctgaaa aatctctcag tgcaagtctc agaagctaac ctaattggta ctggaacaag 5520
          tgaacactgg gtcgatgatg aagggcccca gccaaagaaa gtaaaggctg aagatgaggc 5580
          cttactctca gaagaagatg accccattga tcgacggcca tggacacagc agcaccttga 5640
          agctgcagac atccgtagga caccatcgct ggctctcacc cctcctcagg cagagcagga 5700
          ggtggatgtg ttagatgtga atgtccgtgg cccagatggc tgcaccccat tgatgttggc 5760
          ttctctccga ggaggcagct cagatttgag tgatgaagat gaagatgcag aggactcttc 5820
          tgctaacatc atcacagact tggtctacca gggtgccagc ctccaggccc agacagaccg 5880
          gactggtgag atggccctgc accttgcagc ccgctactca cgggctgatg ctgccaagcg 5940
          tctcctggat gcaggtgcag atgccaatgc ccaggacaac atgggccgct gtccactcca 6000
          tgctgcagtg gcagctgatg cccaaggtgt cttccagatt ctgattcgca accgagtaac 6060
          tgatctagat gccaggatga atgatggtac tacacccctg atcctggctg cccgcctggc 6120
          tgtggaggga atggtggcag aactgatcaa ctgccaagcg gatgtgaatg cagtggatga 6180
          ccatggaaaa tctgctcttc actgggcagc tgctgtcaat aatgtggagg caactctttt 6240
          gttgttgaaa aatggggcca accgagacat gcaggacaac aaggaagaga cacctctgtt 6300
          tcttgctgcc cgggaggggga gctatgaagc agccaagatc ctgttagacc attttgccaa 6360
          tcgagacatc acagaccata tggatcgtct tccccgggat gtggctcggg atcgcatgca 6420
          ccatgacatt gtgcgccttc tggatgaata caatgtgacc ccaagccctc caggcaccgt 6480
          gttgacttct gctctctcac ctgtcatctg tgggcccaac agatctttcc tcagcctgaa 6540
          gcacacccca atgggcaaga agtctagacg gcccagtgcc aagagtacca tgcctactag 6600
          cctccctaac cttgccaagg aggcaaagga tgccaagggt agtagggagga agaagtctct 6660
          gagtgagaag gtccaactgt ctgagagttc agtaacttta tcccctgttg attccctaga 6720
          atctcctcac acgtatgttt ccgacaccac atcctctcca atgattacat cccctgggat 6780
          ccttacaggcc tcacccaacc ctatgttggc cactgccgcc cctcctgccc cagtccatgc 6840
          ccagcatgca ctatcttttt ctaaccttca tgaaatgcag cctttggcac atggggccag 6900
          cactgtgctt ccctcagtga gccagttgct atcccaccac cacattgtgt ctccaggcag 6960
          tggcagtgct ggaagcttga gtaggctcca tccagtccca gtcccagcag attggatgaa 7020
          ccgcatggag gtgaatgaga cccagtacaa tgagatgttt ggtatggtcc tggctccagc 7080
          tgagggcacc catcctggca tagctcccca gagcaggcca cctgaaggga agcacataac 7140
          cacccctcgg gagcccttgc cccccattgt gactttccag ctcatcccta aaggcagtat 7200
          tgcccaacca gcgggggctc cccagcctca gtccacctgc cctccagctg ttgcgggccc 7260
          cctgcccacc atgtaccaga ttccagaaat ggcccgtttg cccagtgtgg ctttccccac 7320
          tgccatgatg ccccagcagg acgggcaggt agctcagacc attctcccag cctatcatcc 7380
          tttcccagcc tctgtgggca agtaccccac acccccttca cagcacagtt atgcttcctc 7440
          aaatgctgct gagcgaacac ccagtcacag tggtcacctc cagggtgagc atccctacct 7500
          gacaccatcc ccagagtctc ctgaccagtg gtcaagttca tcaccccact ctgcttctga 7560
          ctggtcagat gtgaccacca gccctacccc tgggggtgct ggaggaggtc agcggggacc 7620
          tgggacacac atgtctgagc caccacacaa caacatgcag gtttatgcgt gagagagtcc 7680
          acctccagtg tagagacata actgactttt gtaaatgctg ctgaggaaca aatgaaggtc 7740
          atccggggaga gaaatgaaga aatctctgga gccagcttct agaggtagga aagagaagat 7800
          gttcttattc agataatgca agagaagcaa ttcgtcagtt tcactgggta tctgcaaggc 7860
          ttattgatta ttctaatcta ataagacaag tttgtggaaa tgcaagatga atacaagcct 7920
          tgggtccatg tttactctct tctatttgga gaataagatg gatgcttatt gaagcccaga 7980
          cattcttgca gcttggactg cattttaagc cctgcaggct tctgccatat ccatgagaag 8040
          attctacact agcgtcctgt tgggaattat gccctggaat tctgcctgaa ttgacctacg 8100
          catctcctcc tccttggaca ttcttttgtc ttcatttggt gcttttggtt ttgcacctct 8160
          ccgtgattgt agccctacca gcatgttata gggcaagacc tttgtgcttt tgatcattct 8220
          ggcccatgaa agcaactttg gtctcctttc ccctcctgtc ttcccggtat cccttggagt 8280
          ctcacaaggt ttactttggt atggttctca gcacaaacct ttcaagtatg ttgtttcttt 8340
          ggaaaatgga catactgtat tgtgttctcc tgcatatac attcctggag agagaagggg 8400
          agaagaatac ttttcttcaa caaattttgg gggcaggaga tcccttcaag aggctgcacc 8460
          ttaatttttc ttgtctgtgt gcaggtcttc atataaactt taccaggaag aagggtgtga 8520
          gtttgttgtt tttctgtgta tgggcctggt cagtgtaaag ttttatcctt gtagtctag 8580
          ttactatgac cctccccact tttttaaaac cagaaaaagg tttggaatgt tggaatgacc 8640
          aagagacaag ttaactcgtg caagagccag ttaccaccc acaggtcccc ctacttcctg 8700
          ccaagcattc cattgactgc ctgtatggaa cacatttgtc ccagatctga gcattctagg 8760
          cctgtttcac tcactcaccc agcatatgaa actagtctta actgttgagc ctttcctttc 8820
          atatccacag aagacactgt ctcaaatgtt gtacccttgc catttaggac tgaactttcc 8880
          ttagcccaag ggacccagtg acagttgtct tccgtttgtc agatgatcag tctctactga 8940
          ttatcttgct gcttaaaggc ctgctcacca atctttcttt cacaccgtgt ggtccgtgtt 9000
          actggtatac ccagtatgtt ctcactgaag acatggactt tatatgttca agtgcaggaa 9060
          ttggaaagtt ggacttgttt tctatgatcc aaaacagccc tataagaagg ttggaaaagg 9120
          aggaactata tagcagcctt tgctattttc tgctaccatt tcttttcctc tgaagcggcc 9180
          atgacattcc ctttggcaac taacgtagaa actcaacaga attttcct ttcctagagt 9240
          caccttttag atgataatgg acaactatag acttgctcat tgttcagact gattgcccct 9300
          cacctgaatc cactctctgt attcatgctc ttggcaattt ctttgacttt cttttaaggg 9360
          cagaagcatt ttagttaatt gtagataaag aatagttttc ttcctcttct ccttgggcca 9420
          gttaataatt ggtccatggc tacactgcaa cttccgtcca gtgctgtgat gcccatgaca 9480
          cctgcaaaat aagttctgcc tgggcatttt gtagatatta acaggtgaat tcccgactct 9540
          tttggtttga atgacagttc tcattccttc tatggctgca agtatgcatc agtgcttccc 9600
          acttacctga tttgtctgtc ggtggcccca tatggaaacc ctgcgtgtct gttggcataa 9660
          tagtttacaa atggtttttt cagtcctatc caaatttatt gaaccaacaa aaataattac 9720
          ttctgccctg agataagcag attaagtttg ttcattctct gctttattct ctccatgtgg 9780
          caacattctg tcagcctctt tcatagtgtg caaacatttt atcattctaa atggtgactc 9840
          tctgcccttg gacccattatta ttatcacag atggggagaa cctatctgca tggacctctg 9900
          tggaccacag cgtacctgcc cctttctgcc ctcctgctcc agccccactt ctgaaagtat 9960
          cagctactga tccagccact ggatatttta tatcctccct tttccttaag cacaatgtca 10020
          gaccaaattg cttgtttctt tttcttggac tactttaatt tggatccttt gggtttggag 10080
          aaagggaatg tgaaagctgt cattacagac aacaggtttc agtgatgagg aggacaacac 10140
          tgcctttcaa actttttact gatctcttag attttaagaa ctcttgaatt gtgtggtatc 10200
          taataaaagg gaaggtaaga tggataatca ctttctcatt tgggttctga attggagact 10260
          cagtttttat gagacacatc ttttatgcca tgtatagatc ctcccctgct atttttggtt 10320
          tatttttatt gttataaatg ctttctttct ttgactcctc ttctgcctgc ctttggggat 10380
          aggttttttt gtttgtttat ttgcttcctc tgttttgttt taagcatcat tttcttatgt 10440
          gaggtgggga agggaaaggt atgagggaaa gagagtctga gaattaaaat attttagtat 10500
          aagcaattgg ctgtgatgct caaatccatt gcatcctctt attgaatttg ccaatttgta 10560
          atttttgcat aataaagaac caaaggtgta atgttttgtt gagaggtggt ttaggggattt 10620
          tggccctaac caatacattg aatgtatgat gactatttgg gaggacacat ttatgtaccc 10680
          agaggccccc actaataagt ggtactatgg ttacttcctt gtgtacattt ctcttaaaag 10740
          tgatattata tctgtttgta tgagaaaccc agtaaccaat aaaatgaccg catattcctg 10800
          actaaacgta gtaaggaaaa tgcacacttt gtttttacttttccgtttca ttctaaaggt 10860
          agttaagatg aaatttatat gaaagcattt ttatcacaaa ataaaaagg tttgccaagc 10920
          tcagtggtgt tgtatttttt attttccaat actgcatcca tggcctggca gtgttacctc 10980
          atgatgtcat aatttgctga gagagcaaat tttcttttct ttctgaatcc cacaaagcct 11040
          agcaccaaac ttcttttttt cttcctttaa ttagatcata aataaatgat cctggggaaa 11100
          aagcatctgt caaataggaa acatcacaaa actgagcact cttctgtgca ctagccatag 11160
          ctggtgacaa acagatggtt gctcagggac aaggtgcctt ccaatggaaa tgcgaagtag 11220
          ttgctatagc aagaattggg aactgggata taagtcataa tattaattat gctgttatgt 11280
          aaatgattgg tttgtaacat tccttaagtg aaatttgtgt agaacttaat atacaggatt 11340
          ataaaataat attttgtgta taaatttgtt ataagttcac attcatacat ttattattataa 11400
          agtcagtgag atatttgaac atgaa 11425
           <![CDATA[ <210> 704]]>
           <![CDATA[ <211> 24]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 704]]>
          Met Pro Ala Leu Arg Pro Ala Leu Leu Trp Ala Leu Leu Ala Leu Trp
          1 5 10 15
          Leu Cys Cys Ala Ala Pro Ala His
                      20
           <![CDATA[ <210> 705]]>
           <![CDATA[ <211> 26]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 705]]>
          Leu Gln Cys Arg Asp Gly Tyr Glu Pro Cys Val Asn Glu Gly Met Cys
          1 5 10 15
          Val Thr Tyr His Asn Gly Thr Gly Tyr Cys
                      20 25
           <![CDATA[ <210> 706]]>
           <![CDATA[ <211> 86]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 706]]>
          Cys Pro Glu Gly Phe Leu Gly Glu Tyr Cys Gln His Arg Asp Pro Cys
          1 5 10 15
          Glu Lys Asn Arg Cys Gln Asn Gly Gly Thr Cys Val Ala Gln Ala Met
                      20 25 30
          Leu Gly Lys Ala Thr Cys Arg Cys Ala Ser Gly Phe Thr Gly Glu Asp
                  35 40 45
          Cys Gln Tyr Ser Thr Ser His Pro Cys Phe Val Ser Arg Pro Cys Leu
              50 55 60
          Asn Gly Gly Thr Cys His Met Leu Ser Arg Asp Thr Tyr Glu Cys Thr
          65 70 75 80
          Cys Gln Val Gly Phe Thr
                          85
           <![CDATA[ <210> 707]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 707]]>
          Lys Glu Cys Gln Trp Thr Asp Ala Cys Leu Ser His Pro Cys Ala Asn
          1 5 10 15
          Gly Ser Thr Cys Thr Thr Val Ala Asn Gln Phe Ser Cys Lys Cys Leu
                      20 25 30
          Thr Gly Phe Thr Gly Gln Lys Cys Glu Thr Asp Val Asn Glu Cys Asp
                  35 40 45
          Ile Pro Gly His Cys Gln His Gly Gly Thr Cys Leu Asn Leu Pro Gly
              50 55 60
          Ser Tyr Gln Cys Gln Cys Pro Gln Gly Phe Thr Gly Gln Tyr Cys Asp
          65 70 75 80
          Ser Leu Tyr Val Pro Cys Ala Pro Ser Pro Cys Val Asn Gly Gly Thr
                          85 90 95
          Cys Arg Gln Thr Gly Asp Phe Thr Phe Glu Cys Asn Cys Leu Pro
                      100 105 110
           <![CDATA[ <210> 708]]>
           <![CDATA[ <211> 40]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 708]]>
          Phe Glu Gly Ser Thr Cys Glu Arg Asn Ile Asp Asp Cys Pro Asn His
          1 5 10 15
          Arg Cys Gln Asn Gly Gly Val Cys Val Asp Gly Val Asn Thr Tyr Asn
                      20 25 30
          Cys Arg Cys Pro Pro Gln Trp Thr
                  35 40
           <![CDATA[ <210> 709]]>
           <![CDATA[ <211> 77]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 709]]>
          Gln Phe Cys Thr Glu Asp Val Asp Glu Cys Leu Leu Gln Pro Asn Ala
          1 5 10 15
          Cys Gln Asn Gly Gly Thr Cys Ala Asn Arg Asn Gly Gly Tyr Gly Cys
                      20 25 30
          Val Cys Val Asn Gly Trp Ser Gly Asp Asp Cys Ser Glu Asn Ile Asp
                  35 40 45
          Asp Cys Ala Phe Ala Ser Cys Thr Pro Gly Ser Thr Cys Ile Asp Arg
              50 55 60
          Val Ala Ser Phe Ser Cys Met Cys Pro Glu Gly Lys Ala
          65 70 75
           <![CDATA[ <210> 710]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 710]]>
          Leu Leu Cys His Leu Asp Asp Ala Cys Ile Ser Asn Pro Cys His Lys
          1 5 10 15
          Gly Ala Leu Cys Asp Thr Asn Pro Leu Asn Gly Gln Tyr Ile Cys Thr
                      20 25 30
          Cys Pro Gln Gly Tyr Lys Gly Ala Asp Cys Thr Glu Asp Val Asp Glu
                  35 40 45
          Cys Ala Met
              50
           <![CDATA[ <210> 711]]>
           <![CDATA[ <211> 2049]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 711]]> Asn Ser Asn Pro Cys Glu His Ala Gly Lys Cys Val Asn Thr Asp Gly 1 5 10 15 Ala Phe His Cys Glu Cys Leu Lys Gly Tyr Ala Gly Pro Arg Cys Glu 20 25 30 Met Asp Ile Asn Glu Cys His Ser Asp Pro Cys Gln Asn Asp Ala Thr 35 40 45 Cys Leu Asp Lys Ile Gly Gly Phe Thr Cys Leu Cys Met Pro Gly Phe 50 55 60 Lys Gly Val His Cys Glu Leu Glu Ile Asn Glu Cys Gln Ser Asn Pro 65 70 75 80 Cys Val Asn Asn Gly Gln Cys Val Asp Lys Val Asn Arg Phe Gln Cys 85 90 95 Leu Cys Pro Pro Gly Phe Thr Gly Pro Val Cys Gln Ile Asp Ile Asp 100 105 110 Asp Cys Ser Ser Ser Thr Pro Cys Leu Asn Gly Ala Lys Cys Ile Asp His 115 120 125 Pro Asn Gly Tyr Glu Cys Gln Cys Ala Thr Gly Phe Thr Gly Val Leu 130 135 140 Cys Glu Glu Asn Ile Asp Asn Cys Asp Pro Asp Pro Cys His His Gly 145 150 155 16 0 Gln Cys Gln Asp Gly Ile Asp Ser Tyr Thr Cys Ile Cys Asn Pro Gly 165 170 175 Tyr Met Gly Ala Ile Cys Ser Asp Gln Ile Asp Glu Cys Tyr Ser Ser 180 185 190 Pro Cys Leu Asn Asp Gly Arg Cys Ile Asp Leu Val Asn Gly Tyr Gln 195 200 205 Cys Asn Cys Gln Pro Gly Thr Ser Gly Val Asn Cys Glu Ile Asn Phe 210 215 220 Asp Asp Cys Ala Ser Asn Pro Cys Ile His Gly Ile Cys Met Asp Gly 225 230 235 240 Ile As n Arg Tyr Ser Cys Val Cys Ser Pro Gly Phe Thr Gly Gln Arg 245 250 255 Cys Asn Ile Asp Ile Asp Glu Cys Ala Ser Asn Pro Cys Arg Lys Gly 260 265 270 Ala Thr Cys Ile Asn Gly Val Asn Gly Phe Arg Cys Ile Cys Pro Glu 275 280 285 Gly Pro His His Pro Ser Cys Tyr Ser Gln Val Asn Glu Cys Leu Ser 290 295 300 Asn Pro Cys Ile His Gly Asn Cys Thr Gly Gly Leu Ser Gly Tyr Lys 305 310 315 320 Cys Leu Cys Asp Ala Gly Trp Val Gly Ile Asn Cys Glu Val Asp Lys 325 330 335 Asn Glu Cys Leu Ser Asn Pro Cys Gln Asn Gly Gly Thr Cys Asp Asn 340 345 350 Leu Val Asn Gly Tyr Arg Cys Thr Cys Lys Lys Gly Phe Lys Gly Tyr 355 360 3 65 Asn Cys Gln Val Asn Ile Asp Glu Cys Ala Ser Asn Pro Cys Leu Asn 370 375 380 Gln Gly Thr Cys Phe Asp Asp Ile Ser Gly Tyr Thr Cys His Cys Val 385 390 395 400 Leu Pro Tyr Thr Gly Lys Asn Cys Gln Thr Val Leu Ala Pro Cys Ser 405 410 415 Pro Asn Pro Cys Glu Asn Ala Ala Val Cys Lys Glu Ser Pro Asn Phe 420 425 430 Glu Ser Tyr Thr Cys Leu Cys Ala Pro Gly Trp Gln Gly Gln Arg Cys 435 440 445 Thr Ile Asp Ile Asp Glu Cys Ile Ser Lys Pro Cys Met Asn His Gly 450 455 460 Leu Cys His Asn Thr Gln Gly Ser Tyr Met Cys Glu Cys Pro Gly 465 470 475 480 Phe Ser Gly Met Asp Cys Glu Glu Asp Ile Asp Asp Cys Leu Ala Asn 485 490 495 Pro Cys Gln Asn Gly Gly Ser Cys Met Asp Gly Val Asn Thr Phe Ser 500 505 510 Cys Leu Cys Leu Pro Gly Phe Thr Gly Asp Lys Cys Gln Thr Asp Met 515 520 525 Asn Glu Cys Leu Ser Glu Pro Cys Lys Asn Gly Gly Thr Cys Ser Asp 530 535 540 Tyr Val Asn Ser Tyr Thr Cys Lys Cys Gln Ala Gly Phe Asp Gly Val 545 550 555 560 His Cys Glu Asn Asn Ile Asn Glu Cys Thr Glu Ser Ser Cys Phe Asn 565 57 0 575 Gly Gly Thr Cys Val Asp Gly Ile Asn Ser Phe Ser Cys Leu Cys Pro 580 585 590 Val Gly Phe Thr Gly Ser Phe Cys Leu His Glu Ile Asn Glu Cys Ser 595 600 605 Ser His Pro Cys Leu Asn Glu Gly Thr Cys Val Asp Gly Leu Gly Thr 610 615 620 Tyr Arg Cys Ser Cys Pro Leu Gly Tyr Thr Gly Lys Asn Cys Gln Thr 625 630 635 640 Leu Val Asn Leu Cys Ser Arg Ser Pro Cys Lys Asn Lys Gly Thr Cys 645 650 655 Val Gln Lys L ys Ala Glu Ser Gln Cys Leu Cys Pro Ser Gly Trp Ala 660 665 670 Gly Ala Tyr Cys Asp Val Pro Asn Val Ser Cys Asp Ile Ala Ala Ser 675 680 685 Arg Arg Gly Val Leu Val Glu His Leu Cys Gln His Ser Gly Val Cys 690 695 700 Ile Asn Ala Gly Asn Thr His Tyr Cys Gln Cys Pro Leu Gly Tyr Thr 705 710 715 720 Gly Ser Tyr Cys Glu Glu Gln Leu Asp Glu Cys Ala Ser Asn Pro Cys 725 730 735 Gln His Gly Ala Thr Cys Ser A sp Phe Ile Gly Gly Tyr Arg Cys Glu 740 745 750 Cys Val Pro Gly Tyr Gln Gly Val Asn Cys Glu Tyr Glu Val Asp Glu 755 760 765 Cys Gln Asn Gln Pro Cys Gln Asn Gly Gly Thr Cys Ile Asp Leu Val 770 775 780 Asn His Phe Lys Cys Ser Cys Pro Gly Thr Arg Gly Leu Leu Cys 785 790 795 800 Glu Glu Asn Ile Asp Asp Cys Ala Arg Gly Pro His Cys Leu Asn Gly 805 810 815 Gly Gln Cys Met Asp Arg Ile Gly Gly Tyr Ser Cys Arg Cys Leu Pro 820 825 830 Gly Phe Ala Gly Glu Arg Cys Glu Gly Asp Ile Asn Glu Cys Leu Ser 835 840 845 Asn Pro Cys Ser Ser Glu Gly Ser Leu Asp Cys Ile Gln Leu Thr Asn 850 855 860 Asp Tyr Leu Cys Val Cys Arg Ser Ala Phe Thr Gly Arg His Cys Glu 865 870 875 880 Thr Phe Val Asp Val Cys Pro Gln Met Pro Cys Leu Asn Gly Gly Thr 885 890 895 Cys Ala Val Ala Ser Asn Met Pro Asp Gly Phe Ile Cys Arg Cys Pro 900 905 910 Pro Gly Phe Ser Gly Ala Arg Cys Gln Ser Ser Cys Gly Gly Gln Val Lys 915 920 925 Cys Arg Lys Gly Glu Gln Cys Val His Thr Ala Ser Gly Pro Arg Cys 930 935 940 Phe Cys Pro Ser Pro Arg Asp Cys Glu Ser Gly Cys Ala Ser Ser Pro 945 950 955 960 Cys Gln His Gly Gly Ser Cys His Pro Gln Arg Gln Pro Pro Tyr Tyr 965 970 975 Ser Cys Gln Cys Ala Pro Pro Phe Ser Gly Ser Arg Cys Glu Leu Tyr 980 985 990 Thr Ala Pro Pro Ser Thr Pro Pro Ala Thr Cys Leu Ser Gln Tyr Cys 995 1000 1005 Ala Asp Lys Ala Arg Asp Gly Val Cys Asp Glu Ala Cys Asn Ser 1010 1015 1020 His Ala Cys Gln Trp Asp Gly Gly Asp Cys Ser Leu Thr Met Glu 1025 1030 1035 Asn Pro Trp Ala Asn Cys Ser Ser Pro Leu Pro Cys Trp Asp Tyr 1040 1045 1050 Ile Asn Asn Gln Cys Asp Glu Leu Cys Asn Thr Val Glu Cys Leu 1055 1060 1065 Phe Asp Asn Phe Glu Cys Gln Gly Asn Ser Lys Thr Cys Lys Tyr 1070 1075 1080 Asp Lys Tyr Cys Ala Asp His Phe Lys Asp Asn His Cys Asp Gln 1085 1090 1095 Gly Cys Asn Ser Glu Glu Cys Gly Trp Asp Gly Leu Asp Cys Ala 1100 1105 1110 Ala A sp Gln Pro Glu Asn Leu Ala Glu Gly Thr Leu Val Ile Val 1115 1120 1125 Val Leu Met Pro Pro Glu Gln Leu Leu Gln Asp Ala Arg Ser Phe 1130 1135 1140 Leu Arg Ala Leu Gly Thr Leu Leu His Thr Asn Leu Arg Ile Lys 1145 1150 1155 Arg Asp Ser Gln Gly Glu Leu Met Val Tyr Pro Tyr Tyr Gly Glu 1160 1165 1170 Lys Ser Ala Ala Met Lys Lys Gln Arg Met Thr Arg Arg Ser Leu 1175 1180 1185 Pro Gly Glu Gln Glu Gln Glu Val Ala Gly Ser Lys Val Phe Leu 11 90 1195 1200 Glu Ile Asp Asn Arg Gln Cys Val Gln Asp Ser Asp His Cys Phe 1205 1210 1215 Lys Asn Thr Asp Ala Ala Ala Ala Leu Leu Ala Ser His Ala Ile 1220 1225 1230 Gln Gly Thr Leu Ser Tyr Pro Leu Val Ser Val Val Ser Glu Ser 1235 1240 1245 Leu Thr Pro Glu Arg Thr Gln Leu Leu Tyr Leu Leu Ala Val Ala 1250 1255 1260 Val Val Ile Ile Leu Phe Ile Ile Leu Leu Gly Val Ile Met Ala 1265 1270 1275 Lys Arg Lys Arg Lys His Gly Ser Leu Trp Leu Pro Glu Gly Phe 1280 1285 1290 Thr Leu Arg Arg Asp Ala Ser Asn His Lys Arg Arg Glu Pro Val 1295 1300 1305 Gly Gln Asp Ala Val Gly Leu Lys Asn Leu Ser Val Gln Val Ser 1310 1315 1320 Glu Ala Asn Leu Ile Gly Thr Gly Thr Ser Glu His Trp Val Asp 1325 1330 1335 Asp Glu Gly Pro Gln Pro Lys Lys Val Lys Ala Glu Asp Glu Ala 1340 1345 1350 Leu Leu Ser Glu Asp Asp Pro Ile Asp Arg Arg Pro Trp Thr 1355 1360 13 65 Gln Gln His Leu Glu Ala Ala Asp Ile Arg Arg Thr Pro Ser Leu 1370 1375 1380 Ala Leu Thr Pro Pro Gln Ala Glu Gln Glu Val Asp Val Leu Asp 1385 1390 1395 Val Asn Val Arg Gly Pro Asp Gly Cys Thr Pro Leu Met Leu Ala 1400 1405 1410 Ser Leu Arg Gly Gly Ser Ser Asp Leu Ser Asp Glu Asp Glu Asp 1415 1420 1425 Ala Glu Asp Ser Ser Ala Asn Ile Ile Thr Asp Leu Val Tyr Gln 1430 1435 1440 Gly Ala Ser Leu Gln Ala G ln Thr Asp Arg Thr Gly Glu Met Ala 1445 1450 1455 Leu His Leu Ala Ala Arg Tyr Ser Arg Ala Asp Ala Ala Lys Arg 1460 1465 1470 Leu Leu Asp Ala Gly Ala Asp Ala Asn Ala Gln Asp Asn Met Gly 1475 1480 1485 Arg Cys Pro Leu His Ala Ala Val Ala Ala Asp Ala Gln Gly Val 1490 1495 1500 Phe Gln Ile Leu Ile Arg Asn Arg Val Thr Asp Leu Asp Ala Arg 1505 1510 1515 Met Asn Asp Gly Thr Thr Pro Leu Ile Leu Ala Ala Arg Leu Ala 1520 1525 15 30 Val Glu Gly Met Val Ala Glu Leu Ile Asn Cys Gln Ala Asp Val 1535 1540 1545 Asn Ala Val Asp Asp His Gly Lys Ser Ala Leu His Trp Ala Ala 1550 1555 1560 Ala Val Asn Asn Val Glu Ala Thr Leu Leu Leu Leu Lys Asn Gly 1565 1570 1575 Ala Asn Arg Asp Met Gln Asp Asn Lys Glu Glu Thr Pro Leu Phe 1580 1585 1590 Leu Ala Ala Arg Glu Gly Ser Tyr Glu Ala Ala Lys Ile Leu Leu 1595 1600 1605 Asp His Phe Ala Asn Arg Asp Ile Thr Asp His M et Asp Arg Leu 1610 1615 1620 Pro Arg Asp Val Ala Arg Asp Arg Met His His Asp Ile Val Arg 1625 1630 1635 Leu Leu Asp Glu Tyr Asn Val Thr Pro Ser Pro Pro Gly Thr Val 1640 1645 1650 Leu Thr Ser Ala Leu Ser Pro Val Ile Cys Gly Pro Asn Arg Ser 1655 1660 1665 Phe Leu Ser Leu Lys His Thr Pro Met Gly Lys Lys Ser Arg Arg 1670 1675 1680 Pro Ser Ala Lys Ser Thr Met Pro Thr Ser Leu Pro Asn Leu Ala 1685 1690 1695 Lys Glu Ala Lys Asp Ala Lys Gly Ser Arg Arg Lys Lys Ser Leu 1700 1705 1710 Ser Glu Lys Val Gln Leu Ser Glu Ser Ser Val Thr Leu Ser Pro 1715 1720 1725 Val Asp Ser Leu Glu Ser Pro His Thr Tyr Val Ser Asp Thr Thr 1730 1735 1 740 Ser Ser Pro Met Ile Thr Ser Pro Gly Ile Leu Gln Ala Ser Pro 1745 1750 1755 Asn Pro Met Leu Ala Thr Ala Ala Pro Pro Ala Pro Val His Ala 1760 1765 1770 Gln His Ala Leu Ser Phe Ser Asn Leu His Glu Met Gln Pro Leu 1775 1780 1785 Ala His Gly Ala Ser Thr Val Leu Pro Ser Val Ser Gln Leu Leu 1790 1795 1800 Ser His His His Ile Val Ser Pro Gly Ser Gly Ser Ala Gly Ser 1805 1810 1815 Leu Ser Arg Leu His Pro Val Pro Val Pro A la Asp Trp Met Asn 1820 1825 1830 Arg Met Glu Val Asn Glu Thr Gln Tyr Asn Glu Met Phe Gly Met 1835 1840 1845 Val Leu Ala Pro Ala Glu Gly Thr His Pro Gly Ile Ala Pro Gln 1850 1855 1860 Ser Arg Pro Pro Glu Gly Lys His Ile Thr Thr Pro Arg Glu Pro 1865 1870 1875 Leu Pro Pro Ile Val Thr Phe Gln Leu Ile Pro Lys Gly Ser Ile 1880 1885 1890 Ala Gln Pro Ala Gly Ala Pro Gln Pro Gln Ser Thr Cys Pro Pro 1895 1900 1905 Ala Val Ala Gly Pro Leu Pro Thr Met Tyr Gln Ile Pro Glu Met 1910 1915 1920 Ala Arg Leu Pro Ser Val Ala Phe Pro Thr Ala Met Met Pro Gln 1925 1930 1935 Gln Asp Gly Gln Val Ala Gln Thr Ile Leu Pro Ala Tyr His Pro 1940 194 5 1950 Phe Pro Ala Ser Val Gly Lys Tyr Pro Thr Pro Pro Ser Gln His 1955 1960 1965 Ser Tyr Ala Ser Ser Asn Ala Ala Glu Arg Thr Pro Ser His Ser 1970 1975 1980 Gly His Leu Gln Gly Glu His Pro Tyr Leu Thr Pro Ser Pro Glu 1985 1990 1995 Ser Pro Asp Gln Trp Ser Ser Ser Ser Ser Pro His Ser Ala Ser Asp 2000 2005 2010 Trp Ser Asp Val Thr Thr Ser Pro Thr Pro Gly Gly Ala Gly Gly 2015 2020 2025 Gly Gln Arg Gly Pro Gly Thr H is met Ser Glu Pro Pro His Asn 2030 2035 2040 Asn Met Gln Val Tyr Ala 2045 <![CDATA[ <210> 712]]>
           <![CDATA[ <211> 2471]]>
           <![CDATA[ <212>]]> PRT
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 712]]> Met Pro Ala Leu Arg Pro Ala Leu Leu Trp Ala Leu Leu Ala Leu Trp 1 5 10 15 Leu Cys Cys Ala Ala Pro Ala His Ala Leu Gln Cys Arg Asp Gly Tyr 20 25 30 Glu Pro Cys Val Asn Glu Gly Met Cys Val Thr Tyr His Asn Gly Thr 35 40 45 Gly Tyr Cys Lys Cys Pro Glu Gly Phe Leu Gly Glu Tyr Cys Gln His 50 55 60 Arg Asp Pro Cys Glu Lys Asn Arg Cys Gln Asn Gly Gly Thr Cys Val 65 70 75 80 Ala Gln Ala Met Leu Gly Lys Ala Thr Cys Arg Cys Ala Ser Gly Phe 85 90 95 Thr Gly Glu Asp Cys Gln Tyr Ser Thr Ser His Pro Cys Phe Val Ser 100 105 110 Arg Pro Cys Leu Asn Gly Gly Thr Cys His Met Leu Ser Arg Asp Thr 115 120 125 Tyr Glu Cys Thr Cys Gln Val Gly Phe Thr Gly Lys Glu Cys Gln Trp 130 135 140 Thr Asp Ala Cys Leu Ser His Pro Cys Ala Asn Gly Ser Thr Cys Thr 145 150 155 1 60 Thr Val Ala Asn Gln Phe Ser Cys Lys Cys Leu Thr Gly Phe Thr Gly 165 170 175 Gln Lys Cys Glu Thr Asp Val Asn Glu Cys Asp Ile Pro Gly His Cys 180 185 190 Gln His Gly Gly Thr Cys Leu Asn Leu Pro Gly Ser Tyr Gln Cys Gln 195 200 205 Cys Pro Gln Gly Phe Thr Gly Gln Tyr Cys Asp Ser Leu Tyr Val Pro 210 215 220 Cys Ala Pro Ser Pro Cys Val Asn Gly Gly Thr Cys Arg Gln Thr Gly 225 230 235 240 Asp Phe Th r Phe Glu Cys Asn Cys Leu Pro Gly Phe Glu Gly Ser Thr 245 250 255 Cys Glu Arg Asn Ile Asp Asp Cys Pro Asn His Arg Cys Gln Asn Gly 260 265 270 Gly Val Cys Val Asp Gly Val Asn Thr Tyr Asn Cys Arg Cys Pro Pro 275 280 285 Gln Trp Thr Gly Gln Phe Cys Thr Glu Asp Val Asp Glu Cys Leu Leu 290 295 300 Gln Pro Asn Ala Cys Gln Asn Gly Gly Thr Cys Ala Asn Arg Asn Gly 305 310 315 320 Gly Tyr Gly Cys Val Cys Val Asn Gly Trp Ser Gly Asp Asp Cys Ser 325 330 335 Glu Asn Ile Asp Asp Cys Ala Phe Ala Ser Cys Thr Pro Gly Ser Thr 340 345 350 Cys Ile Asp Arg Val Ala Ser Phe Ser Cys Met Cys Pro Glu Gly Lys 355 360 365 Ala Gly Leu Leu Cys His Leu Asp Asp Ala Cys Ile Ser Asn Pro Cys 370 375 380 His Lys Gly Ala Leu Cys Asp Thr Asn Pro Leu Asn Gly Gln Tyr Ile 385 390 395 400 Cys Thr Cys Pro Gln Gly Tyr Lys Gly Ala Asp Cys Thr Glu Asp Val 405 410 415 Asp Glu Cys Ala Met Ala Asn Ser Asn Pro Cys Glu His Ala Gly Lys 420 425 430 Cys Val Asn Thr Asp Gly Ala Phe His Cys Glu Cys Leu Lys Gly Tyr 435 440 445 Ala Gly Pro Arg Cys Glu Met Asp Ile Asn Glu Cys His Ser Asp Pro 450 455 460 Cys Gln Asp Ala Thr Cys Leu Asp Lys Ile Gly Gly Phe Thr Cys 465 470 475 480 Leu Cys Met Pro Gly Phe Lys Gly Val His Cys Glu Leu Glu Ile Asn 485 490 495 GLU CLN SER Asn Pro Cys Val Val ASN GLY GLN CYS Val Val ASP LYS 500 510 Val asn ARG PHE GLN CYS PRO Pro Gly PRY Pro Val 515 520525 CY s GLN ILE ASP ILE ASP ASP CYS Ser Ser Thr Pro Cys Leu Asn Gly 530 535 540 Ala Lys Cys Ile Asp His Pro Asn Gly Tyr Glu Cys Gln Cys Ala Thr 545 550 555 560 Gly Phe Thr Gly Val Leu Cys Glu Glu Asn Ile Asp Asn Cys Asp Pro 565 570 575 A sp Pro Cys His His Gly Gln Cys Gln Asp Gly Ile Asp Ser Tyr Thr 580 585 590 Cys Ile Cys Asn Pro Gly Tyr Met Gly Ala Ile Cys Ser Asp Gln Ile 595 600 605 Asp Glu Cys Tyr Ser Ser Pro Cys Leu Asn Asp Gly Arg Cys Ile Asp 610 615 620 Leu Val Asn Gly Tyr Gln Cys Asn Cys Gln Pro Gly Thr Ser Gly Val 625 630 635 640 Asn Cys Glu Ile Asn Phe Asp Asp Asp Cys Ala Ser Asn Pro Cys Ile His 645 650 655 Gly Ile Cys Met Asp Gly Ile Asn Arg Tyr Ser Cys Val Cys Ser Pro 660 665 670 Gly Phe Thr Gly Gln Arg Cys Asn Ile Asp Ile Asp Glu Cys Ala Ser 675 680 685 Asn Pro Cys Arg Lys Gly Ala Thr Cys Ile Asn Gly Val Asn Gly Phe 690 695 700 Arg Cys Ile Cys Pro Glu Gly Pro His His Pro Ser Cys Tyr Ser Gln 705 710 715 720 Val Asn Glu Cys Leu Ser Asn Pro Cys Ile His Gly Asn Cys Thr Gly 725 730 735 Gly Leu Ser Gly Tyr Lys Cys Leu Cys Asp Ala Gly Trp Val Gly Ile 740 745 750 Asn Cys Glu Val Asp Lys Asn Glu Cys Leu Ser Asn Pro Cys Gln Asn 755 760 765 Gly Gly Thr Cys Asp Asn Leu Val Asn Gly Tyr Arg Cys Thr Cys Lys 770 775 780 Lys Gly PHE LYS GLY TYR Asn Cys Gln Val Asn Ile Asp Glu Cys Ala 785 790 795 800 SER ASN GLN GLN GLN GLN GLS PHE ASP ILE Serle Serle Serle Serle Serite 805 815 TYR Cys His His Cys Cys Cys lu project Cys Gln Thr 820 825 830 Val Leu Ala Pro Cys Ser Pro Asn Pro Cys Glu Asn Ala Ala Val Cys 835 840 845 Lys Glu Ser Pro Asn Phe Glu Ser Tyr Thr Cys Leu Cys Ala Pro Gly 850 855 860 Trp Gln Gly Gln Arg Cys Thr Ile Asp Ile Asp Glu Cys Ile Ser Lys 865 870 875 880 Pro Cys Met Asn His Gly Leu Cys His Asn Thr Gln Gly Ser Tyr Met 885 890 895 Cys Glu Cys Pro Gly Phe Ser Gly Met Asp Cys Glu Glu Asp Ile 900 905 910 Asp Asp Cys Leu Ala Asn Pro Cys Gln Asn Gly Gly Ser Cys Met Asp 915 920 925 Gly Val Asn Thr Phe Ser Cys Leu Cys Leu Pro Gly Phe Thr Gly Asp 930 935 940 Lys Cys Gln Thr Asp Met Asn Glu Cys Leu Ser Glu Pro Cys Lys Asn 945 950 955 960 Gly Gly Thr Cys Ser Asp Tyr Val Asn Ser Tyr Thr Cys Lys Cys Gln 965 970 975 Ala Gly Phe Asp Gly Val His Cys Glu Asn Asn Ile Asn Glu Cys Thr 980 985 99 0 Glu Ser Ser Cys Phe Asn Gly Gly Thr Cys Val Asp Gly Ile Asn Ser 995 1000 1005 Phe Ser Cys Leu Cys Pro Val Gly Phe Thr Gly Ser Phe Cys Leu 1010 1015 1020 His Glu Ile Asn Glu Cys Ser Ser His Pro Cys Leu Asn Glu Gly 1025 1030 1035 Thr Cys Val Asp Gly Leu Gly Thr Tyr Arg Cys Ser Cys Pro Leu 1040 1045 1050 Gly Tyr Thr Gly Lys Asn Cys Gln Thr Leu Val Asn Leu Cys Ser 1055 1060 1065 Arg Ser Pro Cys Lys Asn L ys Gly Thr Cys Val Gln Lys Lys Ala 1070 1075 1080 Glu Ser Gln Cys Leu Cys Pro Ser Gly Trp Ala Gly Ala Tyr Cys 1085 1090 1095 Asp Val Pro Asn Val Ser Cys Asp Ile Ala Ala Ser Arg Arg Gly 1100 1105 1110 Val Leu Val Glu His Leu Cys Gln His Ser Gly Val Cys Ile Asn 1115 1120 1125 Ala Gly Asn Thr His Tyr Cys Gln Cys Pro Leu Gly Tyr Thr Gly 1130 1135 1140 Ser Tyr Cys Glu Glu Gln Leu Asp Glu Cys Ala Ser Asn Pro Cys 1145 115 0 1155 Gln His Gly Ala Thr Cys Ser Asp Phe Ile Gly Gly Tyr Arg Cys 1160 1165 1170 Glu Cys Val Pro Gly Tyr Gln Gly Val Asn Cys Glu Tyr Glu Val 1175 1180 1185 Asp Glu Cys Gln Asn Gln Pro Cys Gln Asn Gly Gly Thr Cys Ile 1190 1195 1200 ASP Leu Val As His PHE LYS CYS Ser Cys Pro Pro Gly THR ARG 1205 Gly Leu Leu Leu GLU GLU Asn Ile ASP CYS ALA ARG GLY PRE GLY GLN CYS MET ASP ARG Ile Gly Gly Tyr 1235 1240 1245 Ser Cys Arg Cys Leu Pro Gly Phe Ala Gly Glu Arg Cys Glu Gly 1250 1255 1260 Asp Ile Asn Glu Cys Leu Ser Asn Pro Cys Ser Ser Ser Glu Gly Ser 1265 1270 1275 Leu Asp Cys Ile Gln Le u Thr Asn Asp Tyr Leu Cys Val Cys Arg 1280 1285 1290 Ser Ala Phe Thr Gly Arg His Cys Glu Thr Phe Val Asp Val Cys 1295 1300 1305 Pro Gln Met Pro Cys Leu Asn Gly Gly Thr Cys Ala Val Ala Ser 1310 1315 1320 Asn M et Pro Asp Gly Phe Ile Cys Arg Cys Pro Gly Phe Ser 1325 1330 1335 Gly Ala Arg Cys Gln Ser Ser Cys Gly Gln Val Lys Cys Arg Lys 1340 1345 1350 Gly Glu Gln Cys Val His Thr Ala Ser Gly Pro Arg Cys Phe Cys 1355 1360 1 365 Pro Ser Pro Arg Asp Cys Glu Ser Gly Cys Ala Ser Ser Pro Cys 1370 1375 1380 Gln His Gly Gly Ser Cys His Pro Gln Arg Gln Pro Pro Tyr Tyr 1385 1390 1395 Ser Cys Gln Cys Ala Pro Pro Phe Ser Gly Ser Arg Cys Glu Leu 1400 1405 1410 Tyr Thr Ala Pro Pro Ser Thr Pro Pro Ala Thr Cys Leu Ser Gln 1415 1420 1425 Tyr Cys Ala Asp Lys Ala Arg Asp Gly Val Cys Asp Glu Ala Cys 1430 1435 1440 Asn Ser His Ala Cys Gln Trp A sp Gly Gly Asp Cys Ser Leu Thr 1445 1450 1455 Met Glu Asn Pro Trp Ala Asn Cys Ser Ser Pro Leu Pro Cys Trp 1460 1465 1470 Asp Tyr Ile Asn Asn Gln Cys Asp Glu Leu Cys Asn Thr Val Glu 1475 1480 1485 Cys Le u Phe Asp Asn Phe Glu Cys Gln Gly Asn Ser Lys Thr Cys 1490 1495 1500 Lys Tyr Asp Lys Tyr Cys Ala Asp His Phe Lys Asp Asn His Cys 1505 1510 1515 Asp Gln Gly Cys Asn Ser Glu Glu Cys Gly Trp Asp Gly Leu Asp 1520 15 25 1530 Cys Ala Ala Asp Gln Pro Glu Asn Leu Ala Glu Gly Thr Leu Val 1535 1540 1545 Ile Val Val Leu Met Pro Pro Glu Gln Leu Leu Gln Asp Ala Arg 1550 1555 1560 Ser Phe Leu Arg Ala Leu Gly Thr Leu Leu His Thr Asn Leu Arg 1565 1570 1575 Ile Lys Arg Asp Ser Gln Gly Glu Leu Met Val Tyr Pro Tyr Tyr 1580 1585 1590 Gly Glu Lys Ser Ala Ala Met Lys Lys Gln Arg Met Thr Arg Arg 1595 1600 1605 Ser Leu Pro Gly Glu Gln Glu Gln Glu Val Ala Gly Ser Lys Val 1610 1615 1620 Phe Leu Glu Ile Asp Asn Arg Gln Cys Val Gln Asp Ser Asp His 1625 1630 1635 Cys Phe Lys Asn Thr Asp Ala Ala Ala Ala Leu Leu Ala Ser His 1640 1645 1650 Ala Ile Gln Gly Thr Leu Ser Tyr Pro Leu Val Ser Val Val Ser 1655 1660 1665 Glu Ser Leu Thr Pro Glu Arg Thr Gln Leu Leu Tyr Leu Leu Ala 1670 1675 1680 Val Ala Val Val Ile Ile Leu Phe Ile Ile Leu Leu Gly Val Ile 1685 1690 1695 Met Ala Lys Arg Lys Arg Lys His Gly Ser Leu Trp Leu Pro Glu 1700 1705 1710 Gly Phe Thr Leu Arg Arg Asp Ala Ser Asn His Lys Arg Arg Glu 1715 1720 1725 Pro Val Gly Gln Asp Ala Val Gly Leu Lys Asn Leu Ser Val Gln 1730 173 5 1740 Val Ser Glu Ala Asn Leu Ile Gly Thr Gly Thr Ser Glu His Trp 1745 1750 1755 Val Asp Asp Glu Gly Pro Gln Pro Lys Lys Val Lys Ala Glu Asp 1760 1765 1770 Glu Ala Leu Leu Ser Glu Glu Asp Asp Pro Ile Asp Arg Arg Pro 1775 1780 1785 Trp Thr Gln Gln His Leu Glu Ala Ala Asp Ile Arg Arg Thr Pro 1790 1795 1800 Ser Leu Ala Leu Thr Pro Pro Gln Ala Glu Gln Glu Val Asp Val 1805 1810 1815 Leu Asp Val Asn Val Arg Gly Pro Asp Gly Cys Thr Pro Leu Met 1820 1825 1830 Leu Ala Ser Leu Arg Gly Gly Ser Ser Asp Leu Ser Asp Glu Asp 1835 1840 1845 Glu Asp Ala Glu Asp Ser Ser Ala Asn Ile Ile Thr Asp Leu Val 1850 1855 1860 Tyr Gln Gly A la Ser Leu Gln Ala Gln Thr Asp Arg Thr Gly Glu 1865 1870 1875 Met Ala Leu His Leu Ala Ala Arg Tyr Ser Arg Ala Asp Ala Ala 1880 1885 1890 Lys Arg Leu Leu Asp Ala Gly Ala Asp Ala Asn Ala Gln Asp Asn 1895 1900 1905 Met Gly Arg Cys Pro Leu His Ala Ala Val Ala Ala Asp Ala Gln 1910 1915 1920 Gly Val Phe Gln Ile Leu Ile Arg Asn Arg Val Thr Asp Leu Asp 1925 1930 1935 Ala Arg Met Asn Asp Gly Thr Thr Pro Leu Ile Leu Ala Ala Arg 1940 1945 1950 Leu Ala Val Glu Gly Met Val Ala Glu Leu Ile Asn Cys Gln Ala 1955 1960 1965 Asp Val Asn Ala Val Asp Asp His Gly Lys Ser Ala Leu His Trp 1970 1975 1980 Ala Ala Ala Val Asn Asn Val Glu Ala Thr Le u Leu Leu Leu Lys 1985 1990 1995 Asn Gly Ala Asn Arg Asp Met Gln Asp Asn Lys Glu Glu Thr Pro 2000 2005 2010 Leu Phe Leu Ala Ala Arg Glu Gly Ser Tyr Glu Ala Ala Lys Ile 2015 2020 2025 Leu Leu Asp His P he Ala Asn Arg Asp Ile Thr Asp His Met Asp 2030 2035 2040 Arg Leu Pro Arg Asp Val Ala Arg Asp Arg Met His His Asp Ile 2045 2050 2055 Val Arg Leu Leu Asp Glu Tyr Asn Val Thr Pro Ser Pro Pro Gly 2060 2065 2070 Thr Val Leu Th r Ser Ala Leu Ser Pro Val Ile Cys Gly Pro Asn 2075 2080 2085 Arg Ser Phe Leu Ser Leu Lys His Thr Pro Met Gly Lys Lys Ser 2090 2095 2100 Arg Arg Pro Ser Ala Lys Ser Thr Met Pro Thr Ser Leu Pro Asn 2105 2110 2115 Le u Ala Lys Glu Ala Lys Asp Ala Lys Gly Ser Arg Arg Lys Lys 2120 2125 2130 Ser Leu Ser Glu Lys Val Gln Leu Ser Glu Ser Ser Ser Val Thr Leu 2135 2140 2145 Ser Pro Val Asp Ser Leu Glu Ser Pro His Thr Tyr Val Ser Asp 2150 2155 2160 Thr Thr Ser Ser Pro Met Ile Thr Ser Pro Gly Ile Leu Gln Ala 2165 2170 2175 Ser Pro Asn Pro Met Leu Ala Thr Ala Ala Pro Pro Ala Pro Val 2180 2185 2190 His Ala Gln His Ala Leu Ser Phe Ser Asn Leu His Glu Met Gln 2195 2200 2205 Pro Leu Ala His Gly Ala Ser Thr Val Leu Pro Ser Val Ser Gln 2210 2215 2220 Leu Leu Ser His His His His Ile Val Ser Pro Gly Ser Gly Ser Ala 2225 2230 2235 Gly Ser Leu Ser Arg Leu His Pro Val Pro Val Pro Ala Asp Trp 2240 2245 2250 Met Asn Arg Met Glu Val Asn Glu Thr Gln Tyr Asn Glu Met Phe 2255 2260 2265 Gly Met Val Leu Ala Pro Ala Glu Gly Thr His Pro Gly Ile Ala 2270 2275 2280 Pro Gln Ser Arg Pro Pro Glu Gly Lys His Ile Thr Thr Pro Arg 2285 2290 2295 Glu Pro Leu Pro Pro Ile Val Thr Phe Gln Leu Ile Pro Lys Gly 2300 2305 2310 Ser Ile Ala Gln Pro Ala Gly Ala Pro Gln Pro Gln Ser Thr Cys 2315 2320 2325 Pro Pro Ala Val Ala Gly Pro Leu Pro Thr Met Tyr Gln Ile Pro 2330 2335 2340 Glu Met Ala Arg Leu Pro Ser Val Ala Phe Pro Thr Ala Met Met 2345 2350 2355 Pro Gln Gln Asp Gly Gln Val Ala Gln Thr Ile Leu Pro Ala Tyr 2360 2365 2370 His Pro Phe Pro Ala Ser Val Gly Lys Tyr Pro Thr Pro Pro Ser 2375 2380 2385 Gln His Ser Tyr Ala Ser Ser Asn Ala Ala Glu Arg Thr Pro Ser 2390 2395 2400 His Ser Gly His Leu Gln G Ly Glu His Pro Tyr Leu Thr Pro Ser 2405 2410 2415 Pro Glu Ser Pro Asp Gln Trp Ser Ser Ser Ser Ser Pro His Ser Ala 2420 2425 2430 Ser Asp Trp Ser Asp Val Thr Thr Ser Pro Thr Pro Gly Gly Ala 2435 2440 2445 Gly Gly Gly Gl n Arg Gly Pro Gly Thr His Met Ser Glu Pro Pro 2450 2455 2460 His Asn Asn Met Gln Val Tyr Ala 2465 2470 <![CDATA[ <210> 713]]>
           <![CDATA[ <211> 1364]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> person]]> class
           <![CDATA[ <400> 713]]>
          aggctgcttc gttgcacacc cgagaaagtt tcagccaaac ttcgggcggc ggctgaggcg 60
          gcggccgagg agcggcggac tcggggcgcg gggagtcgag gcatttgcgc ctgggcttcg 120
          gagcgtagcg ccagggcctg agcctttgaa gcaggaggag gggaggagag agtggggctc 180
          ctctatcggg accccctccc catgtggatc tgcccaggcg gcggcggcgg cggcggagga 240
          ggaggcgacc gagaagatgc ccgccctgcg ccccgctctg ctgtgggcgc tgctggcgct 300
          ctggctgtgc tgcgcggccc ccgcgcatgc attgcagtgt cgagatggct atgaaccctg 360
          tgtaaatgaa ggaatgtgtg ttacctacca caatggcaca ggatactgca aatgtccaga 420
          aggcttcttg ggggaatatt gtcaacatcg agaccccctgt gagaagaacc gctgccagaa 480
          tggtgggact tgtgtggccc aggccatgct ggggaaagcc acgtgccgat gtgcctcagg 540
          gtttacagga gaggactgcc agtactcaac atctcatcca tgctttgtgt ctcgaccctg 600
          cctgaatggc ggcacatgcc atatgctcag ccgggatacc tatgagtgca cctgtcaagt 660
          cgggtttaca ggtaaggagt gccaatggac ggatgcctgc ctgtctcatc cctgtgcaaa 720
          tggaagtacc tgtaccactg tggccaacca gttctcctgc aaatgcctca caggcttcac 780
          agggcagaaa tgtgagactg atgtcaatga gtgtgacatt ccaggacact gccagcatgg 840
          tggcacctgc ctcaacctgc ctggttccta ccagtgccag tgccctcagg gcttcacagg 900
          ccagtactgt gacagcctgt atgtgccctg tgcaccctca ccttgtgtca atggaggcac 960
          ctgtcggcag actggtgact tcacttttga gtgcaactgc cttccaggtt ttgaagggag 1020
          cacctgtgag aggaatattg atgactgccc taaccacagg tgtcagaatg gaggggtttg 1080
          tgtggatggg gtcaacactt acaactgccg ctgtccccca caatggacag gacagttctg 1140
          cacagaggat gtggatgaat gcctgctgca gcccaatgcc tgtcaaaatg ggggcacctg 1200
          tgccaaccgc aatggaggct atggctgtgt atgtgtcaac ggctggagtg gagatgactg 1260
          cagtgagaac attgatgatt gtgccttcgc ctcctgtact ccaggctcca cctgcatcga 1320
          ccgtgtggcc tccttctctt gcatgtgccc agagggggaag gcag 1364
           <![CDATA[ <210> 714]]>
           <![CDATA[ <211> 369]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 714]]>
          Met Pro Ala Leu Arg Pro Ala Leu Leu Trp Ala Leu Leu Ala Leu Trp
          1 5 10 15
          Leu Cys Cys Ala Ala Pro Ala His Ala Leu Gln Cys Arg Asp Gly Tyr
                      20 25 30
          Glu Pro Cys Val Asn Glu Gly Met Cys Val Thr Tyr His Asn Gly Thr
                  35 40 45
          Gly Tyr Cys Lys Cys Pro Glu Gly Phe Leu Gly Glu Tyr Cys Gln His
              50 55 60
          Arg Asp Pro Cys Glu Lys Asn Arg Cys Gln Asn Gly Gly Thr Cys Val
          65 70 75 80
          Ala Gln Ala Met Leu Gly Lys Ala Thr Cys Arg Cys Ala Ser Gly Phe
                          85 90 95
          Thr Gly Glu Asp Cys Gln Tyr Ser Thr Ser His Pro Cys Phe Val Ser
                      100 105 110
          Arg Pro Cys Leu Asn Gly Gly Thr Cys His Met Leu Ser Arg Asp Thr
                  115 120 125
          Tyr Glu Cys Thr Cys Gln Val Gly Phe Thr Gly Lys Glu Cys Gln Trp
              130 135 140
          Thr Asp Ala Cys Leu Ser His Pro Cys Ala Asn Gly Ser Thr Cys Thr
          145 150 155 160
          Thr Val Ala Asn Gln Phe Ser Cys Lys Cys Leu Thr Gly Phe Thr Gly
                          165 170 175
          Gln Lys Cys Glu Thr Asp Val Asn Glu Cys Asp Ile Pro Gly His Cys
                      180 185 190
          Gln His Gly Gly Thr Cys Leu Asn Leu Pro Gly Ser Tyr Gln Cys Gln
                  195 200 205
          Cys Pro Gln Gly Phe Thr Gly Gln Tyr Cys Asp Ser Leu Tyr Val Pro
              210 215 220
          Cys Ala Pro Ser Pro Cys Val Asn Gly Gly Thr Cys Arg Gln Thr Gly
          225 230 235 240
          Asp Phe Thr Phe Glu Cys Asn Cys Leu Pro Gly Phe Glu Gly Ser Thr
                          245 250 255
          Cys Glu Arg Asn Ile Asp Asp Cys Pro Asn His Arg Cys Gln Asn Gly
                      260 265 270
          Gly Val Cys Val Asp Gly Val Asn Thr Tyr Asn Cys Arg Cys Pro Pro
                  275 280 285
          Gln Trp Thr Gly Gln Phe Cys Thr Glu Asp Val Asp Glu Cys Leu Leu
              290 295 300
          Gln Pro Asn Ala Cys Gln Asn Gly Gly Thr Cys Ala Asn Arg Asn Gly
          305 310 315 320
          Gly Tyr Gly Cys Val Cys Val Asn Gly Trp Ser Gly Asp Asp Cys Ser
                          325 330 335
          Glu Asn Ile Asp Asp Cys Ala Phe Ala Ser Cys Thr Pro Gly Ser Thr
                      340 345 350
          Cys Ile Asp Arg Val Ala Ser Phe Ser Cys Met Cys Pro Glu Gly Lys
                  355 360 365
          Ala
           <![CDATA[ <210> 715]]>
           <![CDATA[ <211> 7]]>5
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 715]]>
          agggccggct ggacaaactg acagtcacct cccagaacct gcagctggag aacctgcgca 60
          tgaagcttcc caagc 75
           <![CDATA[ <210> 716]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 716]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60
          tccttcggtg tgaaa 75
           <![CDATA[ <210> 717]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 717]]>
          agggccggct ggacaaactg acagtcacct cccagaacct gcagctggag aacctgcgca 60
          tgaagcttcc caagcccttg cctccccgat tgaaagagat gaaaagccag gaatcggctg 120
          caggttccaa actagtcctt cggtgtgaaa 150
           <![CDATA[ <210> 718]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 718]]>
          Gly Arg Leu Asp Lys Leu Thr Val Thr Ser Gln Asn Leu Gln Leu Glu
          1 5 10 15
          Asn Leu Arg Met Lys Leu Pro Lys Pro Leu Pro Pro Arg Leu Lys Glu
                      20 25 30
          Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys
                  35 40 45
          Glu
           <![CDATA[ <210> 719]]>
           <![CDATA[ <211> 286]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 719]]>
          atcctgcccc gcaaaaggca gcttcaccaa agtggggtat ttccagcctt tgtagctttc 60
          acttccacat ctaccaagtg ggcggagtgg ccttctgtgg acgaatcaga ttcctctcca 120
          gcaccgactt taagaggcga gccggggggt cagggtccca gatgcacagg aggagaagca 180
          ggagctgtcg ggaagatcag aagccagtca tggatgacca gcgcgacctt atctccaaca 240
          atgagcaact gcccatgctg ggccggcgcc ctggggcccc ggagag 286
           <![CDATA[ <210> 720]]>
           <![CDATA[ <211> 173]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 720]]>
          caagtgcagc cgcggagccc tgtacacagg cttttccatc ctggtgactc tgctcctcgc 60
          tggccaggcc accaccgcct acttcctgta ccagcagcag ggccggctgg acaaactgac 120
          agtcacctcc cagaacctgc agctggagaa cctgcgcatg aagcttccca agc 173
           <![CDATA[ <210> 721]]>
           <![CDATA[ <211> 80]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 721]]>
          ctcccaagcc tgtgagcaag atgcgcatgg ccaccccgct gctgatgcag gcgctgccca 60
          tgggagccct gccccagggg 80
           <![CDATA[ <210> 722]]>
           <![CDATA[ <211> 63]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 722]]>
          cccatgcaga atgccaccaa gtatggcaac atgacagagg accatgtgat gcacctgctc 60
          cag 63
           <![CDATA[ <210> 723]]>
           <![CDATA[ <211> 96]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 723]]>
          aatgctgacc ccctgaaggt gtacccgcca ctgaagggga gcttcccgga gaacctgaga 60
          caccttaaga acaccatgga gaccatagac tggaag 96
           <![CDATA[ <210> 724]]>
           <![CDATA[ <211> 88]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 724]]>
          gtctttgaga gctggatgca ccattggctc ctgtttgaaa tgagcaggca ctccttggag 60
          caaaagccca ctgacgctcc accgaaag 88
           <![CDATA[ <210> 725]]>
           <![CDATA[ <211> 192]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 725]]>
          tactgaccaa gtgccaggaa gaggtcagcc acatccctgc tgtccacccg ggttcattca 60
          ggcccaagtg cgacgagaac ggcaactatc tgccactcca gtgctatggg agcatcggct 120
          actgctggtg tgtcttcccc aacggcacgg aggtccccaa caccagaagc cgcgggcacc 180
          ataactgcag tg 192
           <![CDATA[ <210> 726]]>
           <![CDATA[ <211> 63]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 726]]>
          agtcactgga actggaggac ccgtcttctg ggctgggtgt gaccaagcag gatctgggcc 60
          cag 63
           <![CDATA[ <210> 727]]>
           <![CDATA[ <211> 612]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 727]]>
          tccccatgtg agagcagcag aggcggtctt caacatcctg ccagccccac acagctacag 60
          ctttcttgct cccttcagcc cccagcccct cccccatctc ccaccctgta cctcatccca 120
          tgagaccctg gtgcctggct ctttcgtcac ccttggacaa gacaaaccaa gtcggaacag 180
          cagataacaa tgcagcaagg ccctgctgcc caatctccat ctgtcaacag gggcgtgagg 240
          tcccaggaag tggccaaaag ctagacagat ccccgttcct gacatcacag cagcctccaa 300
          cacaaggctc caagacctag gctcatggac gagatgggaa ggcacaggga gaagggataa 360
          ccctacaccc agaccccagg ctggacatgc tgactgtcct ctcccctcca gcctttggcc 420
          ttggcttttc tagcctattt acctgcaggc tgagccactc tcttcccttt ccccagcatc 480
          actccccaag gaagagccaa tgttttccac ccataatcct ttctgccgac ccctagttcc 540
          ctctgctcag ccaagcttgt tatcagcttt cagggccatg gttcacatta gaataaaagg 600
          tagtaattag aa 612
           <![CDATA[ <210> 728]]>
           <![CDATA[ <211> 1653]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> CD74 full mRNA polynucleotide sequence]]>
           <![CDATA[ <400> 728]]>
          atcctgcccc gcaaaaggca gcttcaccaa agtggggtat ttccagcctt tgtagctttc 60
          acttccacat ctaccaagtg ggcggagtgg ccttctgtgg acgaatcaga ttcctctcca 120
          gcaccgactt taagaggcga gccggggggt cagggtccca gatgcacagg aggagaagca 180
          ggagctgtcg ggaagatcag aagccagtca tggatgacca gcgcgacctt atctccaaca 240
          atgagcaact gcccatgctg ggccggcgcc ctggggcccc ggagagcaag tgcagccgcg 300
          gagccctgta cacaggcttt tccatcctgg tgactctgct cctcgctggc caggccacca 360
          ccgcctactt cctgtaccag cagcagggcc ggctggaca actgacagtc acctcccaga 420
          acctgcagct ggagaacctg cgcatgaagc ttcccaagcc tcccaagcct gtgagcaaga 480
          tgcgcatggc caccccgctg ctgatgcagg cgctgcccat gggagccctg ccccaggggc 540
          ccatgcagaa tgccaccaag tatggcaaca tgacagagga ccatgtgatg cacctgctcc 600
          agaatgctga ccccctgaag gtgtacccgc cactgaaggg gagcttcccg gagaacctga 660
          gacaccttaa gaacaccatg gagaccatag actggaaggt ctttgagagc tggatgcacc 720
          attggctcct gtttgaaatg agcaggcact ccttggagca aaagcccact gacgctccac 780
          cgaaagtact gaccaagtgc caggaagagg tcagccacat ccctgctgtc cacccgggtt 840
          cattcaggcc caagtgcgac gagaacggca actatctgcc actccagtgc tatgggagca 900
          tcggctactg ctggtgtgtc ttccccaacg gcacggaggt ccccaacacc agaagccgcg 960
          ggcaccataa ctgcagtgag tcactggaac tggaggaccc gtcttctggg ctgggtgtga 1020
          ccaagcagga tctgggccca gtccccatgt gagagcagca gaggcggtct tcaacatcct 1080
          gccagcccca cacagctaca gctttcttgc tcccttcagc ccccagcccc tcccccatct 1140
          cccaccctgt acctcatccc atgagaccct ggtgcctggc tctttcgtca cccttggaca 1200
          agacaaacca agtcggaaca gcagataaca atgcagcaag gccctgctgc ccaatctcca 1260
          tctgtcaaca ggggcgtgag gtcccaggaa gtggccaaaa gctagacaga tccccgttcc 1320
          tgacatcaca gcagcctcca acacaaggct ccaagaccta ggctcatgga cgagatggga 1380
          aggcacagggg agaagggata accctacacc cagaccccag gctggacatg ctgactgtcc 1440
          tctcccctcc agcctttggc cttggctttt ctagcctatt tacctgcagg ctgagccact 1500
          ctcttccctt tccccagcat cactccccaa ggaagagcca atgttttcca cccataatcc 1560
          tttctgccga cccctagttc cctctgctca gccaagcttg ttatcagctt tcagggccat 1620
          ggttcacatt agaataaaag gtagtaatta gaa 1653
           <![CDATA[ <210> 729]]>
           <![CDATA[ <211> 41]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 729]]>
          Met His Arg Arg Arg Ser Arg Ser Cys Arg Glu Asp Gln Lys Pro Val
          1 5 10 15
          Met Asp Asp Gln Arg Asp Leu Ile Ser Asn Asn Glu Gln Leu Pro Met
                      20 25 30
          Leu Gly Arg Arg Pro Gly Ala Pro Glu
                  35 40
           <![CDATA[ <210> 730]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 730]]>
          Lys Cys Ser Arg Gly Ala Leu Tyr Thr Gly Phe Ser Ile Leu Val Thr
          1 5 10 15
          Leu Leu Leu Ala Gly Gln Ala Thr Thr Ala Tyr Phe Leu Tyr Gln Gln
                      20 25 30
          Gln Gly Arg Leu Asp Lys Leu Thr Val Thr Ser Gln Asn Leu Gln Leu
                  35 40 45
          Glu Asn Leu Arg Met Lys Leu Pro Lys
              50 55
           <![CDATA[ <210> 731]]>
           <![CDATA[ <211> 26]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 731]]>
          Pro Lys Pro Val Ser Lys Met Arg Met Ala Thr Pro Leu Leu Met Gln
          1 5 10 15
          Ala Leu Pro Met Gly Ala Leu Pro Gln Gly
                      20 25
           <![CDATA[ <210> 732]]>
           <![CDATA[ <211> 21]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 732]]>
          Pro Met Gln Asn Ala Thr Lys Tyr Gly Asn Met Thr Glu Asp His Val
          1 5 10 15
          Met His Leu Leu Gln
                      20
           <![CDATA[ <210> 733]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 733]]>
          Asn Ala Asp Pro Leu Lys Val Tyr Pro Pro Leu Lys Gly Ser Phe Pro
          1 5 10 15
          Glu Asn Leu Arg His Leu Lys Asn Thr Met Glu Thr Ile Asp Trp Lys
                      20 25 30
           <![CDATA[ <210> 734]]>
           <![CDATA[ <211> 29]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 734]]>
          Val Phe Glu Ser Trp Met His His Trp Leu Leu Phe Glu Met Ser Arg
          1 5 10 15
          His Ser Leu Glu Gln Lys Pro Thr Asp Ala Pro Pro Lys
                      20 25
           <![CDATA[ <210> 735]]>
           <![CDATA[ <211> 63]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 735]]>
          Leu Thr Lys Cys Gln Glu Glu Val Ser His Ile Pro Ala Val His Pro
          1 5 10 15
          Gly Ser Phe Arg Pro Lys Cys Asp Glu Asn Gly Asn Tyr Leu Pro Leu
                      20 25 30
          Gln Cys Tyr Gly Ser Ile Gly Tyr Cys Trp Cys Val Phe Pro Asn Gly
                  35 40 45
          Thr Glu Val Pro Asn Thr Arg Ser Arg Gly His His Asn Cys Ser
              50 55 60
           <![CDATA[ <210> 736]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 736]]>
          Ser Leu Glu Leu Glu Asp Pro Ser Ser Ser Gly Leu Gly Val Thr Lys Gln
          1 5 10 15
          Asp Leu Gly Pro
                      20
           <![CDATA[ <210> 737]]>
           <![CDATA[ <211> 2]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 737]]>
          Pro Met
          1       
           <![CDATA[ <210> 738]]>
           <![CDATA[ <211> 296]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 738]]>
          Met His Arg Arg Arg Ser Arg Ser Cys Arg Glu Asp Gln Lys Pro Val
          1 5 10 15
          Met Asp Asp Gln Arg Asp Leu Ile Ser Asn Asn Glu Gln Leu Pro Met
                      20 25 30
          Leu Gly Arg Arg Pro Gly Ala Pro Glu Ser Lys Cys Ser Arg Gly Ala
                  35 40 45
          Leu Tyr Thr Gly Phe Ser Ile Leu Val Thr Leu Leu Leu Ala Gly Gln
              50 55 60
          Ala Thr Thr Ala Tyr Phe Leu Tyr Gln Gln Gln Gly Arg Leu Asp Lys
          65 70 75 80
          Leu Thr Val Thr Ser Gln Asn Leu Gln Leu Glu Asn Leu Arg Met Lys
                          85 90 95
          Leu Pro Lys Pro Pro Lys Pro Val Ser Lys Met Arg Met Ala Thr Pro
                      100 105 110
          Leu Leu Met Gln Ala Leu Pro Met Gly Ala Leu Pro Gln Gly Pro Met
                  115 120 125
          Gln Asn Ala Thr Lys Tyr Gly Asn Met Thr Glu Asp His Val Met His
              130 135 140
          Leu Leu Gln Asn Ala Asp Pro Leu Lys Val Tyr Pro Pro Leu Lys Gly
          145 150 155 160
          Ser Phe Pro Glu Asn Leu Arg His Leu Lys Asn Thr Met Glu Thr Ile
                          165 170 175
          Asp Trp Lys Val Phe Glu Ser Trp Met His His Trp Leu Leu Phe Glu
                      180 185 190
          Met Ser Arg His Ser Leu Glu Gln Lys Pro Thr Asp Ala Pro Pro Lys
                  195 200 205
          Val Leu Thr Lys Cys Gln Glu Glu Val Ser His Ile Pro Ala Val His
              210 215 220
          Pro Gly Ser Phe Arg Pro Lys Cys Asp Glu Asn Gly Asn Tyr Leu Pro
          225 230 235 240
          Leu Gln Cys Tyr Gly Ser Ile Gly Tyr Cys Trp Cys Val Phe Pro Asn
                          245 250 255
          Gly Thr Glu Val Pro Asn Thr Arg Ser Arg Gly His His Asn Cys Ser
                      260 265 270
          Glu Ser Leu Glu Leu Glu Asp Pro Ser Ser Gly Leu Gly Val Thr Lys
                  275 280 285
          Gln Asp Leu Gly Pro Val Pro Met
              290 295
           <![CDATA[ <210> 739]]>
           <![CDATA[ <211> 459]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 739]]>
          atcctgcccc gcaaaaggca gcttcaccaa agtggggtat ttccagcctt tgtagctttc 60
          acttccacat ctaccaagtg ggcggagtgg ccttctgtgg acgaatcaga ttcctctcca 120
          gcaccgactt taagaggcga gccggggggt cagggtccca gatgcacagg aggagaagca 180
          ggagctgtcg ggaagatcag aagccagtca tggatgacca gcgcgacctt atctccaaca 240
          atgagcaact gcccatgctg ggccggcgcc ctggggcccc ggagagcaag tgcagccgcg 300
          gagccctgta cacaggcttt tccatcctgg tgactctgct cctcgctggc caggccacca 360
          ccgcctactt cctgtaccag cagcagggcc ggctggaca actgacagtc acctcccaga 420
          acctgcagct ggagaacctg cgcatgaagc ttcccaagc 459
           <![CDATA[ <210> 740]]>
           <![CDATA[ <211> 99]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 740]]>
          Met His Arg Arg Arg Ser Arg Ser Cys Arg Glu Asp Gln Lys Pro Val
          1 5 10 15
          Met Asp Asp Gln Arg Asp Leu Ile Ser Asn Asn Glu Gln Leu Pro Met
                      20 25 30
          Leu Gly Arg Arg Pro Gly Ala Pro Glu Ser Lys Cys Ser Arg Gly Ala
                  35 40 45
          Leu Tyr Thr Gly Phe Ser Ile Leu Val Thr Leu Leu Leu Ala Gly Gln
              50 55 60
          Ala Thr Thr Ala Tyr Phe Leu Tyr Gln Gln Gln Gly Arg Leu Asp Lys
          65 70 75 80
          Leu Thr Val Thr Ser Gln Asn Leu Gln Leu Glu Asn Leu Arg Met Lys
                          85 90 95
          Leu Pro Lys
           <![CDATA[ <210> 741]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 741]]>
          taccagacga tgaggatgta gtggggcccg ggcaggaatc tgatgacttt gagctgtctg 60
          gctctggaga tctgg 75
           <![CDATA[ <210> 742]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 742]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60
          tccttcggtg tgaaa 75
           <![CDATA[ <210> 743]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 743]]>
          taccagacga tgaggatgta gtggggcccg ggcaggaatc tgatgacttt gagctgtctg 60
          gctctggaga tctggccttg cctccccgat tgaaagagat gaaaagccag gaatcggctg 120
          caggttccaa actagtcctt cggtgtgaaa 150
           <![CDATA[ <210> 744]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 744]]>
          Pro Asp Asp Glu Asp Val Val Gly Pro Gly Gln Glu Ser Asp Asp Phe
          1 5 10 15
          Glu Leu Ser Gly Ser Gly Asp Leu Ala Leu Pro Pro Arg Leu Lys Glu
                      20 25 30
          Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys
                  35 40 45
          Glu
           <![CDATA[ <210> 745]]>
           <![CDATA[ <211> 100]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 745]]>
          actcgccgca gcctgcgcgc cttctccagt ccgcggtgcc atggcccccg cccgtctgtt 60
          cgcgctgctg ctgttcttcg taggcggagt cgccgagtcg 100
           <![CDATA[ <210> 746]]>
           <![CDATA[ <211> 139]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 746]]>
          atccgagaga ctgaggtcat cgacccccag gacctcctag aaggccgata cttctccgga 60
          gccctaccag acgatgagga tgtagtgggg cccgggcagg aatctgatga ctttgagctg 120
          tctggctctg gagatctgg 139
           <![CDATA[ <210> 747]]>
           <![CDATA[ <211> 47]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 747]]>
          atgacttgga agactccatg atcggccctg aagttgtcca tcccttg 47
           <![CDATA[ <210> 748]]>
           <![CDATA[ <211> 199]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 748]]>
          gtgcctctag ataaccatat ccctgagagg gcagggtctg ggagccaagt ccccaccgaa 60
          cccaagaaac tagaggaa tgaggttatc cccaagagaa tctcacccgt tgaagagagt 120
          gaggatgtgt ccaacaaggt gtcaatgtcc agcactgtgc agggcagcaa catctttgag 180
          agaacggagg tcctggcag 199
           <![CDATA[ <210> 749]]>
           <![CDATA[ <211> 2128]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 749]]>
          ctctgattgt gggtggcatc gtgggcatcc tctttgccgt cttcctgatc ctactgctca 60
          tgtaccgtat gaagaagaag gatgaaggca gctatgacct gggcaagaaa cccatctaca 120
          agaaagcccc caccaatgag ttctacgcgt gaagcttgct tgtgggcact ggcttggact 180
          ttagcgggga gggaagccag gggattttga agggtggaca ttagggtagg gtgaggtcaa 240
          cctaatactg acttgtcagt atctccagct ctgattacct ttgaagtgtt cagaagagac 300
          attgtcttct actgttctgc caggttcttc ttgagctttg ggcctcagtt gccctggcag 360
          aaaaatggat tcaacttggc ctttctgaag gcaagactgg gattggatca cttcttaaac 420
          ttccagttaa gaatctaggt ccgccctcaa gcccatactg accatgcctc atccagagct 480
          cctctgaagc cagggggcta acggatgttg tgtggagtcc tggctggagg tcctccccca 540
          gtggccttcc tcccttcctt tcacagccgg tctctctgcc aggaaatggg ggaaggaact 600
          agaaccacct gcaccttgag atgtttctgt aaatgggtac ttgtgatcac actacgggaa 660
          tctctgtggt atatacctgg ggccattcta ggctctttca agtgactttt ggaaatcaac 720
          cttttttatt tggggggggag gatggggaaa agagctgaga gtttatgctg aaatggattt 780
          atagaatatt tgtaaatcta tttttagtgtttgttcgttt ttttaactgt tcattccttt 840
          gtgcagagtg tatatctctg cctgggcaag agtgtgggagg tgccgaggtg tcttcattct 900
          ctcgcacatt tccacagcac ctgctaagtt tgtatttaat ggtttttgtt tttgtttttg 960
          tttgtttctt gaaaatgaga gaagagccgg agagatgatt tttattaatt tttttttttt 1020
          tttttttttt ttactattta tagctttaga tagggcctcc cttcccctct tctttctttg 1080
          ttctctttca ttaaacccct tccccagttt tttttttata ctttaaaccc cgctcctcat 1140
          ggccttggcc ctttctgaag ctgcttcctc ttataaaata gcttttgccg aaacatagtt 1200
          tttttttagc agatcccaaa atataatgaa ggggatggtg ggatatttgt gtctgtgttc 1260
          ttataatata ttaattattct tccttggttc tagaaaaata gataaatata tttttttcag 1320
          gaaatagtgt ggtgtttcca gtttgatgtt gctgggtggt tgagtgagtg aattttcatg 1380
          tggctgggtg ggtttttgcc tttttctctt gccctgttcc tggtgccttc tgatggggct 1440
          ggaatagttg aggtggatgg ttctaccctt tctgccttct gtttgggacc cagctggtgt 1500
          tctttggttt gctttcttca ggctctaggg ctgtgctatc caatacagta accacatgcg 1560
          gctgtttaaa gttaagccaa ttaaaatcac ataagattaa aaattccttc ctcagttgca 1620
          ctaaccacgt ttctagaggc gtcactgtat gtagttcatg gctactgtac tgacagcgag 1680
          agcatgtcca tctgttggac agcactattc tagagaacta aactggctta acgagtcaca 1740
          gcctcagctg tgctgggacg acccttgtct ccctgggtag ggggggggga atgggggagg 1800
          gctgatgagg ccccagctgg ggcctgttgt ctgggaccct ccctctcctg agagggggagg 1860
          cctggtggct tagcctgggc aggtcgtgtc tcctcctgac cccagtggct gcggtgaggg 1920
          gaaccaccct cccttgctgc accagtggcc attagctccc gtcaccactg caacccaggg 1980
          tcccagctgg ctgggtcctc ttctgccccc agtgcccttc cccttgggct gtgttggagt 2040
          gagcacctcc tctgtaggca cctctcacac tgttgtctgt tactgatttt ttttgataaa 2100
          aagataataa aacctggtac tttctaaa 2128
           <![CDATA[ <210> 750]]>
           <![CDATA[ <211> 2613]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Full mRNA polynucleotide sequence of SDC4]]>
           <![CDATA[ <400> 750]]>
          actcgccgca gcctgcgcgc cttctccagt ccgcggtgcc atggcccccg cccgtctgtt 60
          cgcgctgctg ctgttcttcg taggcggagt cgccgagtcg atccgagaga ctgaggtcat 120
          cgacccccag gacctcctag aaggccgata cttctccgga gccctaccag acgatgagga 180
          tgtagtgggg cccgggcagg aatctgatga ctttgagctg tctggctctg gagatctgga 240
          tgacttggaa gactccatga tcggccctga agttgtccat cccttggtgc ctctagataa 300
          ccatatccct gagagggcag ggtctggggag ccaagtcccc accgaaccca agaaactaga 360
          ggagaatgag gttatcccca agagaatctc acccgttgaa gagagtgagg atgtgtccaa 420
          caaggtgtca atgtccagca ctgtgcaggg cagcaacatc tttgagagaa cggaggtcct 480
          ggcagctctg attgtgggtg gcatcgtggg catcctcttt gccgtcttcc tgatcctact 540
          gctcatgtac cgtatgaaga agaaggatga aggcagctat gacctgggca agaaacccat 600
          ctacaagaaa gccccccacca atgagttcta cgcgtgaagc ttgcttgtgg gcactggctt 660
          ggactttagc ggggagggaa gccaggggat tttgaagggt ggacattagg gtagggtgag 720
          gtcaacctaa tactgacttg tcagtatctc cagctctgat tacctttgaa gtgttcagaa 780
          gagacattgt cttctactgt tctgccaggt tcttcttgag ctttgggcct cagttgccct 840
          ggcagaaaaa tggattcaac ttggcctttc tgaaggcaag actgggattg gatcacttct 900
          taaacttcca gttaagaatc taggtccgcc ctcaagccca tactgaccat gcctcatcca 960
          gagctcctct gaagccagggg ggctaacgga tgttgtgtgg agtcctggct ggaggtcctc 1020
          ccccagtggc cttcctccct tcctttcaca gccggtctct ctgccaggaa atgggggaag 1080
          gaactagaac cacctgcacc ttgagatgtt tctgtaaatg ggtacttgtg atcacactac 1140
          gggaatctct gtggtatata cctggggcca ttctaggctc tttcaagtga cttttggaaa 1200
          tcaacctttt ttatttgggg gggaggatgg ggaaaagagc tgagagttta tgctgaaatg 1260
          gatttataga atatttgtaa atctattttt agtgtttgtt cgttttttta actgttcatt 1320
          cctttgtgca gagtgtatat ctctgcctgg gcaagagtgt ggaggtgccg aggtgtcttc 1380
          attctctcgc aatttccac agcacctgct aagtttgtat ttaatggttt ttgtttttgt 1440
          ttttgtttgt ttcttgaaaa tgagagaaga gccggagaga tgatttttat taattttttt 1500
          tttttttttttttttttact atttatagct ttagataggg cctcccttcc cctcttcttt 1560
          ctttgttctc tttcattaaa ccccttcccc agtttttttt ttatacttta aaccccgctc 1620
          ctcatggcct tggccctttc tgaagctgct tcctcttata aaatagcttt tgccgaaaca 1680
          tagttttttt ttagcagatc ccaaaatata atgaagggga tggtgggata tttgtgtctg 1740
          tgttcttata atatattatt attcttcctt ggttctagaa aaatagataa atatattttt 1800
          ttcaggaaat agtgtggtgt ttccagtttg atgttgctgg gtggttgagt gagtgaattt 1860
          tcatgtggct gggtgggttt ttgccttttt ctcttgccct gttcctggtg ccttctgatg 1920
          gggctggaat agttgaggtg gatggttcta ccctttctgc cttctgtttg ggacccagct 1980
          ggtgttcttt ggtttgcttt cttcaggctc tagggctgtg ctatccaata cagtaaccac 2040
          atgcggctgt ttaaagttaa gccaattaaa atcacataag attaaaaatt ccttcctcag 2100
          ttgcactaac cacgtttcta gaggcgtcac tgtatgtagt tcatggctac tgtactgaca 2160
          gcgagagcat gtccatctgt tggacagcac tattctagag aactaaactg gcttaacgag 2220
          tcacagcctc agctgtgctg ggacgaccct tgtctccctg ggtagggggg ggggaatggg 2280
          ggagggctga tgaggcccca gctggggcct gttgtctggg accctccctc tcctgagagg 2340
          ggaggcctgg tggcttagcc tgggcaggtc gtgtctcctc ctgaccccag tggctgcggt 2400
          gaggggaacc accctccctt gctgcaccag tggccattag ctcccgtcac cactgcaacc 2460
          cagggtccca gctggctggg tcctcttctg cccccagtgc ccttcccctt gggctgtgtt 2520
          ggagtgagca cctcctctgt aggcacctct cacactgttg tctgttactg attttttttg 2580
          ataaaaagat aataaaacct ggtactttct aaa 2613
           <![CDATA[ <210> 751]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 751]]>
          Met Ala Pro Ala Arg Leu Phe Ala Leu Leu Leu Phe Phe Val Gly Gly
          1 5 10 15
          Val Ala Glu Ser
                      20
           <![CDATA[ <210> 752]]>
           <![CDATA[ <211> 46]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 752]]>
          Ile Arg Glu Thr Glu Val Ile Asp Pro Gln Asp Leu Leu Glu Gly Arg
          1 5 10 15
          Tyr Phe Ser Gly Ala Leu Pro Asp Asp Glu Asp Val Val Gly Pro Gly
                      20 25 30
          Gln Glu Ser Asp Asp Phe Glu Leu Ser Gly Ser Gly Asp Leu
                  35 40 45
           <![CDATA[ <210> 753]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 753]]>
          Asp Leu Glu Asp Ser Met Ile Gly Pro Glu Val Val His Pro Leu
          1 5 10 15
           <![CDATA[ <210> 754]]>
           <![CDATA[ <211> 66]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 754]]>
          Val Pro Leu Asp Asn His Ile Pro Glu Arg Ala Gly Ser Gly Ser Gln
          1 5 10 15
          Val Pro Thr Glu Pro Lys Lys Leu Glu Glu Asn Glu Val Ile Pro Lys
                      20 25 30
          Arg Ile Ser Pro Val Glu Glu Ser Glu Asp Val Ser Asn Lys Val Ser
                  35 40 45
          Met Ser Ser Thr Val Gln Gly Ser Asn Ile Phe Glu Arg Thr Glu Val
              50 55 60
          Leu Ala
          65
           <![CDATA[ <210> 755]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 755]]>
          Leu Ile Val Gly Gly Ile Val Gly Ile Leu Phe Ala Val Phe Leu Ile
          1 5 10 15
          Leu Leu Leu Met Tyr Arg Met Lys Lys Lys Asp Glu Gly Ser Tyr Asp
                      20 25 30
          Leu Gly Lys Lys Pro Ile Tyr Lys Lys Ala Pro Thr Asn Glu Phe Tyr
                  35 40 45
          Ala
           <![CDATA[ <210> 756]]>
           <![CDATA[ <211> 198]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 756]]>
          Met Ala Pro Ala Arg Leu Phe Ala Leu Leu Leu Phe Phe Val Gly Gly
          1 5 10 15
          Val Ala Glu Ser Ile Arg Glu Thr Glu Val Ile Asp Pro Gln Asp Leu
                      20 25 30
          Leu Glu Gly Arg Tyr Phe Ser Gly Ala Leu Pro Asp Asp Glu Asp Val
                  35 40 45
          Val Gly Pro Gly Gln Glu Ser Asp Asp Phe Glu Leu Ser Gly Ser Gly
              50 55 60
          Asp Leu Asp Asp Leu Glu Asp Ser Met Ile Gly Pro Glu Val Val His
          65 70 75 80
          Pro Leu Val Pro Leu Asp Asn His Ile Pro Glu Arg Ala Gly Ser Gly
                          85 90 95
          Ser Gln Val Pro Thr Glu Pro Lys Lys Leu Glu Glu Asn Glu Val Ile
                      100 105 110
          Pro Lys Arg Ile Ser Pro Val Glu Glu Ser Glu Asp Val Ser Asn Lys
                  115 120 125
          Val Ser Met Ser Ser Ser Thr Val Gln Gly Ser Asn Ile Phe Glu Arg Thr
              130 135 140
          Glu Val Leu Ala Ala Leu Ile Val Gly Gly Ile Val Gly Ile Leu Phe
          145 150 155 160
          Ala Val Phe Leu Ile Leu Leu Leu Met Tyr Arg Met Lys Lys Lys Lys Asp
                          165 170 175
          Glu Gly Ser Tyr Asp Leu Gly Lys Lys Pro Ile Tyr Lys Lys Ala Pro
                      180 185 190
          Thr Asn Glu Phe Tyr Ala
                  195
           <![CDATA[ <210> 757]]>
           <![CDATA[ <211> 239]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 757]]>
          actcgccgca gcctgcgcgc cttctccagt ccgcggtgcc atggcccccg cccgtctgtt 60
          cgcgctgctg ctgttcttcg taggcggagt cgccgagtcg atccgagaga ctgaggtcat 120
          cgacccccag gacctcctag aaggccgata cttctccgga gccctaccag acgatgagga 180
          tgtagtgggg cccgggcagg aatctgatga ctttgagctg tctggctctg gagatctgg 239
           <![CDATA[ <210> 758]]>
           <![CDATA[ <211> 66]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 758]]>
          Met Ala Pro Ala Arg Leu Phe Ala Leu Leu Leu Phe Phe Val Gly Gly
          1 5 10 15
          Val Ala Glu Ser Ile Arg Glu Thr Glu Val Ile Asp Pro Gln Asp Leu
                      20 25 30
          Leu Glu Gly Arg Tyr Phe Ser Gly Ala Leu Pro Asp Asp Glu Asp Val
                  35 40 45
          Val Gly Pro Gly Gln Glu Ser Asp Asp Phe Glu Leu Ser Gly Ser Gly
              50 55 60
          Asp Leu
          65
           <![CDATA[ <210> 759]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 759]]>
          tttctactgt aacaccccatc ccagacgaag acagtccctg gatcaccgac agcacagaca 60
          gaatccctgc tacca 75
           <![CDATA[ <210> 760]]>
           <![CDATA[ <21]]>1> 75]]>
           <br/> &lt;![CDATA[ &lt;212&gt;DNA]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt;Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;760]]&gt;
           <br/> <![CDATA[ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgtgaatg 75
           <![CDATA[ <210> 761]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 761]]>
          tttctactgt aacaccccatc ccagacgaag acagtccctg gatcaccgac agcacagaca 60
          gaatccctgc taccactaca tctacatcca ccactgggac aagccatctt gtaaaatgtg 120
          cggagaagga gaaaactttc tgtgtgaatg 150
           <![CDATA[ <210> 762]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 762]]>
          Ser Thr Val His Pro Ile Pro Asp Glu Asp Ser Pro Trp Ile Thr Asp
          1 5 10 15
          Ser Thr Asp Arg Ile Pro Ala Thr Thr Thr Thr Ser Ser Thr Ser Thr Thr Gly
                      20 25 30
          Thr Ser His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val
                  35 40 45
          Asn
           <![CDATA[ <210> 763]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212> ]]>DNA
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 763]]>
          actaccccat caactccaac ttcaaagtgg gctacaacac tctcttttcc tgtacctgtg 60
          tgccacctga cccag 75
           <![CDATA[ <210> 764]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 764]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgtgaatg 75
           <![CDATA[ <210> 765]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 765]]>
          actaccccat caactccaac ttcaaagtgg gctacaacac tctcttttcc tgtacctgtg 60
          tgccacctga cccagctaca tctacatcca ccactgggac aagccatctt gtaaaatgtg 120
          cggagaagga gaaaactttc tgtgtgaatg 150
           <![CDATA[ <210> 766]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 766]]>
          Tyr Pro Ile Asn Ser Asn Phe Lys Val Gly Tyr Asn Thr Leu Phe Ser
          1 5 10 15
          Cys Thr Cys Val Pro Pro Asp Pro Ala Thr Ser Thr Ser Thr Thr Gly
                      20 25 30
          Thr Ser His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val
                  35 40 45
          Asn
           <![CDATA[ <210> 767]]>
           <![CDATA[ <211> 143]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 767]]>
          ggcggcgcgc cgggcagcgc ttcggtggcg gcggcggccg cggtggcagc gaaggcggcg 60
          gcggcggcgg cagtggcagt ggccgctgca gccccaacact ccgccgccaa actggaggag 120
          cgacggaagc cagaccccag gag 143
           <![CDATA[ <210> 768]]>
           <![CDATA[ <211> 74]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 768]]>
          gatggaggat gaagctgtcc tggacagagg ggcttccttc ctcaagcatg tgtgtgatga 60
          agaagaagta gaag 74
           <![CDATA[ <210> 769]]>
           <![CDATA[ <211> 180]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 769]]>
          gccaccacatac catttacatc ggagtccatg tgccgaagag ttacaggaga aggagacgtc 60
          acaagagaaa gacagggcac aaagaaaaga aggaaaagga gagaatctct gagaactact 120
          ctgacaaatc agatattgaa aatgctgatg aatccagcag cagcatccta aaacctctca 180
           <![CDATA[ <210> 770]]>
           <![CDATA[ <211> 136]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 770]]>
          tctctcctgc tgcagaacgc atccgattca tcttgggaga ggaggatgac agcccagctc 60
          cccctcagct cttcacggaa ctggatgagc tgctggccgt ggatgggcag gagatggagt 120
          ggaaggaaac agccag 136
           <![CDATA[ <210> 771]]>
           <![CDATA[ <211> 161]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 771]]>
          gtggatcaag tttgaagaaa aagtggaaca gggtggggaa agatggagca agccccatgt 60
          ggccacattg tcccttcata gtttatttga gctgaggaca tgtatggaga aaggatccat 120
          catgcttgat cgggaggctt cttctctccc acagttggtg g 161
           <![CDATA[ <210> 772]]>
           <![CDATA[ <211> 180]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 772]]>
          agatgattgt tgaccatcag attgagacag gcctattgaa acctgaactt aaggataagg 60
          tgacctatac tttgctccgg aagcaccggc atcaaaccaa gaaatccaac cttcggtccc 120
          tggctgacat tgggaagaca gtctccagtg caagtaggat gtttaccaac cctgataatg 180
           <![CDATA[ <210> 773]]>
           <![CDATA[ <211> 77]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 773]]>
          gtagcccagc catgacccat aggaatctga cttcctccag tctgaatgac atttctgata 60
          aaccggagaa ggaccag 77
           <![CDATA[ <210> 774]]>
           <![CDATA[ <211> 158]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 774]]>
          ctgaagaata agttcatgaa aaaattgcca cgtgatgcag aagcttccaa cgtgcttgtt 60
          gggggaggttg actttttgga tactcctttc attgcctttg ttaggctaca gcaggctgtc 120
          atgctgggtg ccctgactga agttcctgtg cccacaag 158
           <![CDATA[ <210> 775]]>
           <![CDATA[ <211> 88]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 775]]>
          gttcttgttc attctcttag gtcctaaggg gaaagccaag tcctaccacg agattggcag 60
          agccattgcc accctgatgt ctgatgag 88
           <![CDATA[ <210> 776]]>
           <![CDATA[ <211> 155]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 776]]>
          gtgttccatg acattgctta taaagcaaaa gacaggcacg acctgattgc tggtattgat 60
          gagttcctag atgaagtcat cgtccttcca cctggggaat gggatccagc aattaggata 120
          gagcctccta agagtcttcc atcctctgac aaaag 155
           <![CDATA[ <210> 777]]>
           <![CDATA[ <211> 114]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 777]]>
          aaagaatatg tactcaggtg gagagaatgt tcagatgaat ggggatacgc cccatgatgg 60
          aggtcacgga ggaggaggac atggggattg tgaagaattg cagcgaactg gacg 114
           <![CDATA[ <210> 778]]>
           <![CDATA[ <211> 175]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 778]]>
          gttctgtggt ggactaatta aagacataaa gaggaaagcg ccattttttg ccagtgattt 60
          ttatgatgct ttaaatattc aagctctttc ggcaattctc ttcatttatc tggcaactgt 120
          aactaatgct atcacttttg gaggactgct tggggatgcc actgacaaca tgcag 175
           <![CDATA[ <210> 779]]>
           <![CDATA[ <211> 134]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 779]]>
          ggcgtgttgg agagtttcct gggcactgct gtctctggag ccatcttttg cctttttgct 60
          ggtcaaccac tcactattct gagcagcacc ggacctgtcc tagtttttga gaggcttcta 120
          tttaatttca gcaa 134
           <![CDATA[ <210> 780]]>
           <![CDATA[ <211> 272]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 780]]>
          ggacaataat tttgactatt tggagtttcg cctttggatt ggcctgtggt ccgccttcct 60
          atgtctcatt ttggtagcca ctgatgccag cttcttggtt caatacttca cacgtttcac 120
          ggaggagggc ttttcctctc tgattagctt catctttatc tatgatgctt tcaagaagat 180
          gatcaagctt gcagattact acccccatcaa ctccaacttc aaagtgggct acaacactct 240
          cttttcctgt acctgtgtgc cacctgaccc ag 272
           <![CDATA[ <210> 781]]>
           <![CDATA[ <211> 71]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 781]]>
          ctaatatctc aatatctaat gacaccacac tggccccaga gtatttgcca actatgtctt 60
          ctactgacat g 71
           <![CDATA[ <210> 782]]>
           <![CDATA[ <211> 192]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 782]]>
          taccataata ctacctttga ctgggcattt ttgtcgaaga aggagtgttc aaaatacgga 60
          ggaaacctcg tcgggaacaa ctgtaatttt gttcctgata tcacactcat gtcttttatc 120
          ctcttcttgg gaacctacac ctcttccatg gctctgaaaa aattcaaaac tagtccttat 180
          tttccaacca ca 192
           <![CDATA[ <210> 783]]>
           <![CDATA[ <211> 114]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 783]]>
          gcaagaaaac tgatcagtga ttttgccatt atcttgtcca ttctcatctt ttgtgtaata 60
          gatgccctag taggcgtgga caccccaaaa ctaattgtgc caagtgagtt caag 114
           <![CDATA[ <210> 784]]>
           <![CDATA[ <211> 162]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 784]]>
          ccaacaagtc caaaccgagg ttggttcgtt ccaccgtttg gagaaaaccc ctggtgggtg 60
          tgccttgctg ctgctatccc ggctttgttg gtcactatac tgattttcat ggaccaacaa 120
          attacagctg tgattgtaaa caggaaagaa cataaactca ag 162
           <![CDATA[ <210> 785]]>
           <![CDATA[ <211> 179]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 785]]>
          aaaggagcag ggtatcactt ggatctcttt tgggtggcca tcctcatggt tatatgctcc 60
          ctcatggctc ttccgtggta tgtagctgct acggtcatct ccattgctca catcgacagt 120
          ttgaagatgg agacagagac ttctgcacct ggagaacaac caaagtttct aggagtgag 179
           <![CDATA[ <210> 786]]>
           <![CDATA[ <211]]>> 73]]>
           <br/> &lt;![CDATA[ &lt;212&gt;DNA]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt;Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;786]]&gt;
           <br/> <![CDATA[ggaacaaaga gtcactggaa cccttgtgtt tattctgact ggtctgtcag tctttatggc 60
          tcccatcttg aag 73
           <![CDATA[ <210> 787]]>
           <![CDATA[ <211> 70]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 787]]>
          gtttataccc atgcctgtac tctatggtgt gttcctgtat atgggagtag catcccttaa 60
          tggtgtgcag 70
           <![CDATA[ <210> 788]]>
           <![CDATA[ <211> 174]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 788]]>
          ttcatggatc gtctgaagct gcttctgatg cctctgaagc atcagcctga cttcatctac 60
          ctgcgtcatg ttcctctgcg cagagtccac ctgttcactt tcctgcaggt gttgtgtctg 120
          gccctgcttt ggatcctcaa gtcaacggtg gctgctatca tttttccagt aatg 174
           <![CDATA[ <210> 789]]>
           <![CDATA[ <211> 162]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 789]]>
          atcttggcac ttgtagctgt cagaaaaggc atggactacc tcttctccca gcacgacctc 60
          agcttcctgg atgatgtcat tccagaaaag gacaagaaaa agaaggagga tgagaagaaa 120
          aagaaaaaga agaagggaag tctggacagt gacaatgatg at 162
           <![CDATA[ <210> 790]]>
           <![CDATA[ <211> 97]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 790]]>
          tctgactgcc catactcaga aaaagttcca agtattaaaa ttccaatgga catcatggaa 60
          cagcaacctt tcctaagcga tagcaaacct tctgaca 97
           <![CDATA[ <210> 791]]>
           <![CDATA[ <211> 80]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 791]]>
          gagaaagatc accaacattc cttgaacgcc acacatcatg ctgataaaat tcctttcctt 60
          cagtcactcg gtatgccaag 80
           <![CDATA[ <210> 792]]>
           <![CDATA[ <211> 4296]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 792]]>
          tcctcctaga actccagtaa aagttgtgcc tcaaattaga atagaacttg aacctgaaga 60
          caatgattat ttctggagga gcaagggaac agaaactaca ttgtaacctg tttgtctttc 120
          ttaaaactga catttgttgt taatgtcatt tgtttttgtt tggctgtttg tttatttttt 180
          aacttttatt tcgtctcagt ttttggtcac aggccaaata atacagcgct ctctctgctt 240
          ctctcttgca tagacacaat caagacaata gtgcaccgtt ccttaaaaac agcatctgag 300
          gaatccccct tttgttctta aactttcaga tgtgtccttt gataaccaaa ttctgtcact 360
          caagacacag acacgcacag accctgtcct ttgcctctat taagcagagg atggaagtat 420
          taaggatttt gtaacacctt ttatgaaaat gttgaaggaa cttaaaactt tagctttgga 480
          gctgtgctta ctggcttgtc tttgtctggt agaacaaacc ttgacctcca gacagagtcc 540
          cttctcactt atagagctct ccaggactgg aaaaagtgct gctattttaa cttgctcttg 600
          cttgtaaatc ctaatcttag agttatcaaa agaagaaaaa actgaaggta ctttactccc 660
          tatagagaaa ccattgccat cattgtagca agtgctggaa tgtccctttt ttcctatgca 720
          acttttttta accctttaat gaacttatct gttgagtaca ttgaagaata tttttcttcc 780
          tagattttgt tgtttaaatt atggggccta acctgccact tattttttgt caatttttaa 840
          aacttttttt taattactgt aaagaaaatg aattttttcc tgcagcagga aacatagttt 900
          tgagtagttc tacctcttat ttgtagctgc caggctttct gtaaaaattg tattgtatat 960
          aatgtgattt ttacacatac atacacacac aaatacacaa tctctagggt aagccagaag 1020
          gcaagatcag attaaaaaca ccatgtttct aagcatccat ttttcccttt ctttaaaaga 1080
          aacttaactg ttctatgaag gagattgagg gagaagagac aaactcctat gtcatgagaa 1140
          taaccgatgt tctgataata gtagcatcta ggtacagatg ctggttgtat taccacgtca 1200
          atgtcctatg cagtattgtt agacattttc tcattttgaa atatttgtgtgtttgtgtat 1260
          gtgctctgtg ccatggctgg tgtatatatg tgcaatgtta gaaggcaaaa gagtgatggt 1320
          aggcagagggg caaagtcatt gaatctctta tgccagtttt cataaaaccc aaaccacata 1380
          tgaaaaaatc cattaagggt ccaagaagtc tgtccatatg aaaatgaggg taaatatagt 1440
          ttatttccca ggtatcagtc attataattg atataatagc tctaacatgc aatataaaat 1500
          tcataggagt attaatagcc catttacaca tctataaaat gtaatgggat tgcagagctg 1560
          cagagtacag tgtaacagta ctctcatgca atttttttca ggatgcaaag gcaattattc 1620
          tttgtaagcg ggacatttag aatatatttg tgtacatatt atatgtatgt atatttcaaa 1680
          gtaccacact gaaaattaga catttattaa ccaaatttaa cgtggtattt aaaggtaata 1740
          tttttaatat gatacattac atattgtgaa tgtatactaa aaaaacattt taaatgttaa 1800
          aattataatt tcagattcat ataaccacaa ctgtgatata tcctaactat aaccagttgt 1860
          tgaggggtat actagaagca gaatgaaacc aattttttg gtttgataat atgcacttat 1920
          tgactcccac tcattgttat gttaattaag ttaattattct gtctccttgt aattttgatt 1980
          acaaaaattt tattatcctg agttagctgt tacttttaca gtacctgata ctcctaaaac 2040
          ttttaactta tacaaattag tcaataatga ccccaatttt ttcattaaaa taatagtggt 2100
          gaattatatg ttaattgtgtt aaaacctcac ttgccaaatt ctggcttcac atttgtattt 2160
          agggctatcc ttaaaatgat gagtctatat tatctagctt tctattaccc taatataaac 2220
          tggtataaga agactttcct tttttcttta tgcatggaag catcaataaa ttgtttaaaa 2280
          accatgtata gtaaattcag cttaacccgt gatcttctta agttaaaggt acttttgttt 2340
          tataaaagct ctagataaaa ctttcttttc tgatcatgaa tcaagtatct gtggtttcat 2400
          gcccctctct atacctttca aagaactcct gaagcaactt aactcatcat ttcagcctct 2460
          gagtagaggt aaaacctatg tgtacttctg tttatgatcc atattgatat ttatgacatg 2520
          aacacagaat agtaccttac atttgctaaa cagacagtta atatcaaatc ctttcaatat 2580
          tctgggaacc cagggaagtt tttaaaaatg tcattacttt caaaggaaca gaagtagtta 2640
          accaaactaa caagcaaaac ctgaggttta cctagtgaca ccaaattatc ggtattttaa 2700
          ctgaatttac ccattgacta agaatgaacc agattggtg gtggttttgt ttctatgcaa 2760
          actggacaca aattacaaca gtaaattttt ttataagtgc ttctcccttc tccatgatgt 2820
          gacttccgga gataaaggat tcaaaagata aagacaaagt acgctcagag ttgttaacca 2880
          gaaagtcctg gctgtggttg cagaaacact gttggaagaa aagagatgac taagtcaagt 2940
          gtctgcctta tcaaaagagc aaaaatgcct ctggttttgt gtttgggaga aaagtatctt 3000
          ggacgcactg ttttcccttga taaaagtcat cttctctact gtgtgaaatg aatacttgga 3060
          attctaattg ttttgtgtgc caggggcagt aatgtccctg cctcttctcc caatcaaggt 3120
          tgaggagtgg ggctggggag aggacttaac tgacttaaga agtaggaaaa caaaaacctc 3180
          tctcctcagc cttccacctc caagagagga ggaaaaacag ttgtctgctg tctgtaattc 3240
          agtttgcgtg tattttatgc tcatgcacca acccatacag agtaaatctt ttatcaactg 3300
          tatactggtg tttaatagag aatgattgtc ttccgagttt tttggttcct tttttaactg 3360
          tgttaaagta cttgaaatgt attgactgct gactatattt taaaaacaaa atgaaataat 3420
          ttgagttgta ttacagaggt tgacattgtt cagggatggg acaaagcctt cttcaatcct 3480
          tttcatacta cttaatgatt ttggtgcagg aacctgagat tttctgattt atatttcatg 3540
          atatttcaca tttgctcttc acagcatgag catgaagccc agtggcacca aatggctggg 3600
          tacaatcaag tgatattttg tagcacctca ctatctgaaa ggccatgagt tttcagatga 3660
          tttcattgag cttcattgca gcctgaaatt ttaaaaaagt tgtgtaatac gccaaccagt 3720
          caagttgtgttttggccaga gatttagata tgtccaattt cctggctcat ttcattgtgc 3780
          tctatgggta cgtataaaaa gcaagaattc tgtttcctag gcaaacattg caactcaggg 3840
          ctaaagtcat ccagtgaaac ttttagagcc agaagtaact ttgtcccagt cctacaatgt 3900
          gaaaagagtg aatagttgcc tctttttagc cattttcatg gctggtacat attcgtacgc 3960
          attacktttc agaatcaata cgcactttca gatattctta tttttattct cttaagtctt 4020
          tattaacttt ggagagagaa atgatgcatc tttttatttt aaatgaagta gatcaacatg 4080
          gtggaacaaa atgataaaga acagaaaaca tttcaatata ttactaataa ctttttccaa 4140
          tataaatcct aaaattccta taacatagta ttttacagtt ttatgaagct ttctattgtg 4200
          acttttatgg aattaagaga tgaagaagat gagatatttt agcatttata tttttcaaaa 4260
          ttatatgtat acttaaaaat aaagtaactt tatgca 4296
           <![CDATA[ <210> 793]]>
           <![CDATA[ <211> 7716]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Full mRNA polynucleotide sequence of SLC4A4]]>
           <![CDATA[ <400> 793]]>
          ggcggcgcgc cgggcagcgc ttcggtggcg gcggcggccg cggtggcagc gaaggcggcg 60
          gcggcggcgg cagtggcagt ggccgctgca gccccaacact ccgccgccaa actggaggag 120
          cgacggaagc cagaccccag gaggatggag gatgaagctg tcctggacag aggggcttcc 180
          ttcctcaagc atgtgtgtga tgaagaagaa gtagaaggcc accataccat ttacatcgga 240
          gtccatgtgc cgaagagtta caggagaagg agacgtcaca agagaaagac agggcacaaa 300
          gaaaagaagg aaaaggagag aatctctgag aactactctg acaaatcaga tattgaaaat 360
          gctgatgaat ccagcagcag catcctaaaa cctctcatct ctcctgctgc agaacgcatc 420
          cgattcatct tgggagagga ggatgacagc ccagctcccc ctcagctctt cacggaactg 480
          gatgagctgc tggccgtgga tgggcaggag atggagtgga aggaaacagc caggtggatc 540
          aagtttgaag aaaaagtgga acagggtggg gaaagatgga gcaagcccca tgtggccaca 600
          ttgtcccttc atagtttatt tgagctgagg acatgtatgg agaaaggatc catcatgctt 660
          gatcgggagg cttcttctct cccacagttg gtggagatga ttgttgacca tcagattgag 720
          acaggcctat tgaaacctga acttaaggat aaggtgacct atactttgct ccggaagcac 780
          cggcatcaaa ccaagaaatc caaccttcgg tccctggctg aattgggaa gacagtctcc 840
          agtgcaagta ggatgtttac caaccctgat aatggtagcc cagccatgac ccataggaat 900
          ctgacttcct ccagtctgaa tgacatttct gataaaccgg agaaggacca gctgaagaat 960
          aagttcatga aaaaattgcc acgtgatgca gaagcttcca acgtgcttgt tggggaggtt 1020
          gactttttgg atactccttt cattgccttt gttaggctac agcaggctgt catgctgggt 1080
          gccctgactg aagttcctgt gcccacaagg ttcttgttca ttctcttagg tcctaagggg 1140
          aaagccaagt cctaccacga gattggcaga gccattgcca ccctgatgtc tgatgaggtg 1200
          ttccatgaca ttgcttataa agcaaaagac aggcacgacc tgattgctgg tattgatgag 1260
          ttcctagatg aagtcatcgt ccttccacct ggggaatggg atccagcaat taggatagag 1320
          cctcctaaga gtcttccatc ctctgacaaa agaaagaata tgtactcagg tggagagaat 1380
          gttcagatga atggggatac gccccatgat ggaggtcacg gaggaggagg acatggggat 1440
          tgtgaagaat tgcagcgaac tggacggttc tgtggtggac taattaaaga cataaagagg 1500
          aaagcgccat tttttgccag tgatttttat gatgctttaa atattcaagc tctttcggca 1560
          attctcttca tttatctggc aactgtaact aatgctatca cttttggagg actgcttggg 1620
          gatgccactg acaacatgca gggcgtgttg gagagtttcc tgggcactgc tgtctctgga 1680
          gccatctttt gcctttttgc tggtcaacca ctcactattc tgagcagcac cggacctgtc 1740
          ctagtttttg agaggcttct atttaatttc agcaaggaca ataattttga ctatttggag 1800
          tttcgccttt ggattggcct gtggtccgcc ttcctatgtc tcattttggt agccactgat 1860
          gccagcttct tggttcaata cttcacacgt ttcacggagg agggcttttc ctctctgatt 1920
          agcttcatct ttatctatga tgctttcaag aagatgatca agcttgcaga ttactaccccc 1980
          atcaactcca acttcaaagt gggctacaac actctctttt cctgtacctg tgtgccacct 2040
          gacccagcta atatctcaat atctaatgac accacactgg ccccagagta tttgccaact 2100
          atgtcttcta ctgacatgta ccataatact acctttgact gggcattttt gtcgaagaag 2160
          gagtgttcaa aatacggagg aaacctcgtc gggaacaact gtaattttgt tcctgattc 2220
          acactcatgt cttttatcct cttcttggga acctacacct cttccatggc tctgaaaaaa 2280
          ttcaaaacta gtccttattt tccaaccaca gcaagaaaac tgatcagtga ttttgccatt 2340
          atcttgtcca ttctcatctt ttgtgtaata gatgccctag taggcgtgga caccccaaaa 2400
          ctaattgtgc caagtgagtt caagccaaca agtccaaacc gaggttggtt cgttccaccg 2460
          tttggagaaa acccctggtgggtgtgcctt gctgctgcta tcccggcttt gttggtcact 2520
          atactgattt tcatggacca acaaattaca gctgtgattg taaacaggaa agaacataaa 2580
          ctcaagaaag gagcagggta tcacttggat ctcttttggg tggccatcct catggttata 2640
          tgctccctca tggctcttcc gtggtatgta gctgctacgg tcatctccat tgctcacatc 2700
          gacagtttga agatggagac agagacttct gcacctggag aacaaccaaa gtttctagga 2760
          gtgagggaac aaagagtcac tggaaccctt gtgtttattc tgactggtct gtcagtcttt 2820
          atggctccca tcttgaagtt tatacccatg cctgtactct atggtgtgtt cctgtatatg 2880
          ggagtagcat cccttaatgg tgtgcagttc atggatcgtc tgaagctgct tctgatgcct 2940
          ctgaagcatc agcctgactt catctacctg cgtcatgttc ctctgcgcag agtccacctg 3000
          ttcactttcc tgcaggtgtt gtgtctggcc ctgctttgga tcctcaagtc aacggtggct 3060
          gctatcattt ttccagtaat gatcttggca cttgtagctg tcagaaaagg catggactac 3120
          ctcttctccc agcacgacct cagcttcctg gatgatgtca ttccagaaaa ggacaagaaa 3180
          aagaaggagg atgagaagaa aaagaaaaag aagaagggaa gtctggacag tgacaatgat 3240
          gattctgact gcccatactc agaaaaagtt ccaagtatta aaattccaat ggacatcatg 3300
          gaacagcaac ctttcctaag cgatagcaaa ccttctgaca gagaaagatc accaacattc 3360
          cttgaacgcc acacatcatg ctgataaaat tcctttcctt cagtcactcg gtatgccaag 3420
          tcctcctaga actccagtaa aagttgtgcc tcaaattaga atagaacttg aacctgaaga 3480
          caatgattat ttctggagga gcaagggaac agaaactaca ttgtaacctg tttgtctttc 3540
          ttaaaactga catttgttgt taatgtcatt tgtttttgtt tggctgtttg tttatttttt 3600
          aacttttatt tcgtctcagt ttttggtcac aggccaaata atacagcgct ctctctgctt 3660
          ctctcttgca tagacacaat caagacaata gtgcaccgtt ccttaaaaac agcatctgag 3720
          gaatccccct tttgttctta aactttcaga tgtgtccttt gataaccaaa ttctgtcact 3780
          caagacacag acacgcacag accctgtcct ttgcctctat taagcagagg atggaagtat 3840
          taaggatttt gtaacacctt ttatgaaaat gttgaaggaa cttaaaactt tagctttgga 3900
          gctgtgctta ctggcttgtc tttgtctggt agaacaaacc ttgacctcca gacagagtcc 3960
          cttctcactt atagagctct ccaggactgg aaaaagtgct gctattttaa cttgctcttg 4020
          cttgtaaatc ctaatcttag agttatcaaa agaagaaaaa actgaaggta ctttactccc 4080
          tatagagaaa ccattgccat cattgtagca agtgctggaa tgtccctttt ttcctatgca 4140
          acttttttta accctttaat gaacttatct gttgagtaca ttgaagaata tttttcttcc 4200
          tagattttgt tgtttaaatt atggggccta acctgccact tatttttgt caatttttaa 4260
          aacttttttt taattactgt aaagaaaatg aattttttcc tgcagcagga aacatagttt 4320
          tgagtagttc tacctcttat ttgtagctgc caggctttct gtaaaaattg tattgtatat 4380
          aatgtgattt ttacacatac atacacacac aaatacacaa tctctagggt aagccagaag 4440
          gcaagatcag attaaaaaca ccatgtttct aagcatccat ttttcccttt ctttaaaaga 4500
          aacttaactg ttctatgaag gagattgagg gagaagagac aaactcctat gtcatgagaa 4560
          taaccgatgt tctgataata gtagcatcta ggtacagatg ctggttgtat taccacgtca 4620
          atgtcctatg cagtattgtt agacattttc tcattttgaa atatttgtgt gtttgtgtat 4680
          gtgctctgtg ccatggctgg tgtatatatg tgcaatgtta gaaggcaaaa gagtgatggt 4740
          aggcagagggg caaagtcatt gaatctctta tgccagtttt cataaaaccc aaaccacata 4800
          tgaaaaaatc cattaagggt ccaagaagtc tgtccatatg aaaatgaggg taaatatagt 4860
          ttatttccca ggtatcagtc attataattg atataatagc tctaacatgc aatataaaat 4920
          tcataggagt attaatagcc catttacaca tctataaaat gtaatgggat tgcagagctg 4980
          cagagtacag tgtaacagta ctctcatgca atttttttca ggatgcaaag gcaattattc 5040
          tttgtaagcg ggacatttag aatatatttg tgtacatatt atatgtatgt atatttcaaa 5100
          gtaccacact gaaaattaga catttattaa ccaaatttaa cgtggtattt aaaggtaata 5160
          tttttaatat gatacattac atattgtgaa tgtatactaa aaaaacattt taaatgttaa 5220
          aattataatt tcagattcat ataaccacaa ctgtgatata tcctaactat aaccagttgt 5280
          tgaggggtat actagaagca gaatgaaacc aattttttg gtttgataat atgcacttat 5340
          tgactcccac tcattgttat gttaattaag ttaattattct gtctccttgt aattttgatt 5400
          acaaaaattt tattatcctg agttagctgt tacttttaca gtacctgata ctcctaaaac 5460
          ttttaactta tacaaattag tcaataatga ccccaatttt ttcattaaaa taatagtggt 5520
          gaattatatg ttaattgtgtt aaaacctcac ttgccaaatt ctggcttcac atttgtattt 5580
          agggctatcc ttaaaatgat gagtctatat tatctagctt tctattaccc taatataaac 5640
          tggtataaga agactttcct tttttcttta tgcatggaag catcaataaa ttgtttaaaa 5700
          accatgtata gtaaattcag cttaacccgt gatcttctta agttaaaggt acttttgttt 5760
          tataaaagct ctagataaaa ctttcttttc tgatcatgaa tcaagtatct gtggtttcat 5820
          gcccctctct atacctttca aagaactcct gaagcaactt aactcatcat ttcagcctct 5880
          gagtagaggt aaaacctatg tgtacttctg tttatgatcc atattgatat ttatgacatg 5940
          aacacagaat agtaccttac atttgctaaa cagacagtta atatcaaatc ctttcaatat 6000
          tctgggaacc cagggaagtt tttaaaaatg tcattacttt caaaggaaca gaagtagtta 6060
          accaaactaa caagcaaaac ctgaggttta cctagtgaca ccaaattatc ggtattttaa 6120
          ctgaatttac ccattgacta agaatgaacc agattggtg gtggttttgt ttctatgcaa 6180
          actggacaca aattacaaca gtaaattttt ttataagtgc ttctcccttc tccatgatgt 6240
          gacttccgga gataaaggat tcaaaagata aagacaaagt acgctcagag ttgttaacca 6300
          gaaagtcctg gctgtggttg cagaaacact gttggaagaa aagagatgac taagtcaagt 6360
          gtctgcctta tcaaaagagc aaaaatgcct ctggttttgt gtttgggaga aaagtatctt 6420
          ggacgcactg ttttcccttga taaaagtcat cttctctact gtgtgaaatg aatacttgga 6480
          attctaattg ttttgtgtgc caggggcagt aatgtccctg cctcttctcc caatcaaggt 6540
          tgaggagtgg ggctggggag aggacttaac tgacttaaga agtaggaaaa caaaaacctc 6600
          tctcctcagc cttccacctc caagagagga ggaaaaacag ttgtctgctg tctgtaattc 6660
          agtttgcgtg tattttatgc tcatgcacca acccatacag agtaaatctt ttatcaactg 6720
          tatactggtg tttaatagag aatgattgtc ttccgagttt tttggttcct tttttaactg 6780
          tgttaaagta cttgaaatgt attgactgct gactatattt taaaaacaaa atgaaataat 6840
          ttgagttgta ttacagaggt tgacattgtt cagggatggg acaaagcctt cttcaatcct 6900
          tttcatacta cttaatgatt ttggtgcagg aacctgagat tttctgattt atatttcatg 6960
          atatttcaca tttgctcttc acagcatgag catgaagccc agtggcacca aatggctggg 7020
          tacaatcaag tgatattttg tagcacctca ctatctgaaa ggccatgagt tttcagatga 7080
          tttcattgag cttcattgca gcctgaaatt ttaaaaaagt tgtgtaatac gccaaccagt 7140
          caagttgtgttttggccaga gatttagata tgtccaattt cctggctcat ttcattgtgc 7200
          tctatgggta cgtataaaaa gcaagaattc tgtttcctag gcaaacattg caactcaggg 7260
          ctaaagtcat ccagtgaaac ttttagagcc agaagtaact ttgtcccagt cctacaatgt 7320
          gaaaagagtg aatagttgcc tctttttagc cattttcatg gctggtacat attcgtacgc 7380
          attacktttc agaatcaata cgcactttca gatattctta tttttattct cttaagtctt 7440
          tattaacttt ggagagagaa atgatgcatc tttttatttt aaatgaagta gatcaacatg 7500
          gtggaacaaa atgataaaga acagaaaaca tttcaatata ttactaataa ctttttccaa 7560
          tataaatcct aaaattccta taacatagta ttttacagtt ttatgaagct ttctattgtg 7620
          acttttatgg aattaagaga tgaagaagat gagatatttt agcatttata tttttcaaaa 7680
          ttatatgtat acttaaaaat aaagtaactt tatgca 7716
           <![CDATA[ <210> 794]]>
           <![CDATA[ <211> 24]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 794]]>
          Met Glu Asp Glu Ala Val Leu Asp Arg Gly Ala Ser Phe Leu Lys His
          1 5 10 15
          Val Cys Asp Glu Glu Glu Val Glu
                      20
           <![CDATA[ <210> 795]]>
           <![CDATA[ <211> 59]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 795]]>
          His His Thr Ile Tyr Ile Gly Val His Val Pro Lys Ser Tyr Arg Arg
          1 5 10 15
          Arg Arg Arg His Lys Arg Lys Thr Gly His Lys Glu Lys Lys Glu Lys
                      20 25 30
          Glu Arg Ile Ser Glu Asn Tyr Ser Asp Lys Ser Asp Ile Glu Asn Ala
                  35 40 45
          Asp Glu Ser Ser Ser Ser Ile Leu Lys Pro Leu
              50 55
           <![CDATA[ <210> 796]]>
           <![CDATA[ <211> 44]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 796]]>
          Ser Pro Ala Ala Glu Arg Ile Arg Phe Ile Leu Gly Glu Glu Asp Asp
          1 5 10 15
          Ser Pro Ala Pro Pro Gln Leu Phe Thr Glu Leu Asp Glu Leu Leu Ala
                      20 25 30
          Val Asp Gly Gln Glu Met Glu Trp Lys Glu Thr Ala
                  35 40
           <![CDATA[ <210> 797]]>
           <![CDATA[ <211> 53]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 797]]>
          Trp Ile Lys Phe Glu Glu Lys Val Glu Gln Gly Gly Glu Arg Trp Ser
          1 5 10 15
          Lys Pro His Val Ala Thr Leu Ser Leu His Ser Leu Phe Glu Leu Arg
                      20 25 30
          Thr Cys Met Glu Lys Gly Ser Ile Met Leu Asp Arg Glu Ala Ser Ser
                  35 40 45
          Leu Pro Gln Leu Val
              50
           <![CDATA[ <210> 798]]>
           <![CDATA[ <211> 59]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 798]]>
          Met Ile Val Asp His Gln Ile Glu Thr Gly Leu Leu Lys Pro Glu Leu
          1 5 10 15
          Lys Asp Lys Val Thr Tyr Thr Leu Leu Arg Lys His His Arg His Gln Thr
                      20 25 30
          Lys Lys Ser Asn Leu Arg Ser Leu Ala Asp Ile Gly Lys Thr Val Ser
                  35 40 45
          Ser Ala Ser Arg Met Phe Thr Asn Pro Asp Asn
              50 55
           <![CDATA[ <210> 799]]>
           <![CDATA[ <211> 25]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 799]]>
          Ser Pro Ala Met Thr His Arg Asn Leu Thr Ser Ser Ser Ser Leu Asn Asp
          1 5 10 15
          Ile Ser Asp Lys Pro Glu Lys Asp Gln
                      20 25
           <![CDATA[ <210> 800]]>
           <![CDATA[ <211> 52]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 800]]>
          Leu Lys Asn Lys Phe Met Lys Lys Leu Pro Arg Asp Ala Glu Ala Ser
          1 5 10 15
          Asn Val Leu Val Gly Glu Val Asp Phe Leu Asp Thr Pro Phe Ile Ala
                      20 25 30
          Phe Val Arg Leu Gln Gln Ala Val Met Leu Gly Ala Leu Thr Glu Val
                  35 40 45
          Pro Val Pro Thr
              50
           <![CDATA[ <210> 801]]>
           <![CDATA[ <211> 29]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 801]]>
          Phe Leu Phe Ile Leu Leu Gly Pro Lys Gly Lys Ala Lys Ser Tyr His
          1 5 10 15
          Glu Ile Gly Arg Ala Ile Ala Thr Leu Met Ser Asp Glu
                      20 25
           <![CDATA[ <210> 802]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 802]]>
          Val Phe His Asp Ile Ala Tyr Lys Ala Lys Asp Arg His Asp Leu Ile
          1 5 10 15
          Ala Gly Ile Asp Glu Phe Leu Asp Glu Val Ile Val Leu Pro Pro Gly
                      20 25 30
          Glu Trp Asp Pro Ala Ile Arg Ile Glu Pro Pro Lys Ser Leu Pro Ser
                  35 40 45
          Ser Asp Lys
              50
           <![CDATA[ <210> 803]]>
           <![CDATA[ <211> 37]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 803]]>
          Lys Asn Met Tyr Ser Gly Gly Glu Asn Val Gln Met Asn Gly Asp Thr
          1 5 10 15
          Pro His Asp Gly Gly His Gly Gly Gly Gly Gly His Gly Asp Cys Glu Glu
                      20 25 30
          Leu Gln Arg Thr Gly
                  35
           <![CDATA[ <210> 804]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 804]]>
          Phe Cys Gly Gly Leu Ile Lys Asp Ile Lys Arg Lys Ala Pro Phe Phe
          1 5 10 15
          Ala Ser Asp Phe Tyr Asp Ala Leu Asn Ile Gln Ala Leu Ser Ala Ile
                      20 25 30
          Leu Phe Ile Tyr Leu Ala Thr Val Thr Asn Ala Ile Thr Phe Gly Gly
                  35 40 45
          Leu Leu Gly Asp Ala Thr Asp Asn Met Gln
              50 55
           <![CDATA[ <210> 805]]>
           <![CDATA[ <211> 44]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 805]]>
          Gly Val Leu Glu Ser Phe Leu Gly Thr Ala Val Ser Gly Ala Ile Phe
          1 5 10 15
          Cys Leu Phe Ala Gly Gln Pro Leu Thr Ile Leu Ser Ser Thr Gly Pro
                      20 25 30
          Val Leu Val Phe Glu Arg Leu Leu Phe Asn Phe Ser
                  35 40
           <![CDATA[ <210> 806]]>
           <![CDATA[ <211> 90]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 806]]>
          Asp Asn Asn Phe Asp Tyr Leu Glu Phe Arg Leu Trp Ile Gly Leu Trp
          1 5 10 15
          Ser Ala Phe Leu Cys Leu Ile Leu Val Ala Thr Asp Ala Ser Phe Leu
                      20 25 30
          Val Gln Tyr Phe Thr Arg Phe Thr Glu Glu Gly Phe Ser Ser Leu Ile
                  35 40 45
          Ser Phe Ile Phe Ile Tyr Asp Ala Phe Lys Lys Met Ile Lys Leu Ala
              50 55 60
          Asp Tyr Tyr Pro Ile Asn Ser Asn Phe Lys Val Gly Tyr Asn Thr Leu
          65 70 75 80
          Phe Ser Cys Thr Cys Val Pro Pro Asp Pro
                          85 90
           <![CDATA[ <210> 807]]>
           <![CDATA[ <211> 23]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 807]]>
          Asn Ile Ser Ile Ser Asn Asp Thr Thr Leu Ala Pro Glu Tyr Leu Pro
          1 5 10 15
          Thr Met Ser Ser Thr Asp Met
                      20
           <![CDATA[ <210> 808]]>
           <![CDATA[ <211> 64]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 808]]>
          Tyr His Asn Thr Thr Phe Asp Trp Ala Phe Leu Ser Lys Lys Glu Cys
          1 5 10 15
          Ser Lys Tyr Gly Gly Asn Leu Val Gly Asn Asn Cys Asn Phe Val Pro
                      20 25 30
          Asp Ile Thr Leu Met Ser Phe Ile Leu Phe Leu Gly Thr Tyr Thr Ser
                  35 40 45
          Ser Met Ala Leu Lys Lys Lys Phe Lys Thr Ser Pro Tyr Phe Pro Thr Thr
              50 55 60
           <![CDATA[ <210> 809]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 809]]>
          Ala Arg Lys Leu Ile Ser Asp Phe Ala Ile Ile Leu Ser Ile Leu Ile
          1 5 10 15
          Phe Cys Val Ile Asp Ala Leu Val Gly Val Asp Thr Pro Lys Leu Ile
                      20 25 30
          Val Pro Ser Glu Phe Lys
                  35
           <![CDATA[ <210> 810]]>
           <![CDATA[ <211> 54]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 810]]>
          Pro Thr Ser Pro Asn Arg Gly Trp Phe Val Pro Pro Phe Gly Glu Asn
          1 5 10 15
          Pro Trp Trp Val Cys Leu Ala Ala Ala Ile Pro Ala Leu Leu Val Thr
                      20 25 30
          Ile Leu Ile Phe Met Asp Gln Gln Ile Thr Ala Val Ile Val Asn Arg
                  35 40 45
          Lys Glu His Lys Leu Lys
              50
           <![CDATA[ <210> 811]]>
           <![CDATA[ <211> 59]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 811]]>
          Lys Gly Ala Gly Tyr His Leu Asp Leu Phe Trp Val Ala Ile Leu Met
          1 5 10 15
          Val Ile Cys Ser Leu Met Ala Leu Pro Trp Tyr Val Ala Ala Thr Val
                      20 25 30
          Ile Ser Ile Ala His Ile Asp Ser Leu Lys Met Glu Thr Glu Thr Ser
                  35 40 45
          Ala Pro Gly Glu Gln Pro Lys Phe Leu Gly Val
              50 55
           <![CDATA[ <210> 812]]>
           <![CDATA[ <211> 24]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 812]]>
          Glu Gln Arg Val Thr Gly Thr Leu Val Phe Ile Leu Thr Gly Leu Ser
          1 5 10 15
          Val Phe Met Ala Pro Ile Leu Lys
                      20
           <![CDATA[ <210> 813]]>
           <![CDATA[ <211> 23]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 813]]>
          Phe Ile Pro Met Pro Val Leu Tyr Gly Val Phe Leu Tyr Met Gly Val
          1 5 10 15
          Ala Ser Leu Asn Gly Val Gln
                      20
           <![CDATA[ <210> 814]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 814]]>
          Phe Met Asp Arg Leu Lys Leu Leu Leu Met Pro Leu Lys His Gln Pro
          1 5 10 15
          Asp Phe Ile Tyr Leu Arg His Val Pro Leu Arg Arg Val His Leu Phe
                      20 25 30
          Thr Phe Leu Gln Val Leu Cys Leu Ala Leu Leu Trp Ile Leu Lys Ser
                  35 40 45
          Thr Val Ala Ala Ile Ile Phe Pro Val Met
              50 55
           <![CDATA[ <210> 815]]>
           <![CDATA[ <211> 54]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 815]]>
          Ile Leu Ala Leu Val Ala Val Arg Lys Gly Met Asp Tyr Leu Phe Ser
          1 5 10 15
          Gln His Asp Leu Ser Phe Leu Asp Asp Val Ile Pro Glu Lys Asp Lys
                      20 25 30
          Lys Lys Lys Glu Asp Glu Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Ser Leu
                  35 40 45
          Asp Ser Asp Asn Asp Asp
              50
           <![CDATA[ <210> 816]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 816]]>
          Ser Asp Cys Pro Tyr Ser Glu Lys Val Pro Ser Ile Lys Ile Pro Met
          1 5 10 15
          Asp Ile Met Glu Gln Gln Pro Phe Leu Ser Asp Ser Lys Pro Ser Asp
                      20 25 30
           <![CDATA[ <210> 817]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 817]]>
          Glu Arg Ser Pro Thr Phe Leu Glu Arg His Thr Ser Cys
          1 5 10
           <![CDATA[ <210> 818]]>
           <![CDATA[ <211> 0]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Skip sequence]]>
           <![CDATA[ <400> 818]]>
          000
           <![CDATA[ <210> 819]]>
           <![CDATA[ <211> 1079]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 819]]>
          Met Glu Asp Glu Ala Val Leu Asp Arg Gly Ala Ser Phe Leu Lys His
          1 5 10 15
          Val Cys Asp Glu Glu Glu Val Glu Gly His His Thr Ile Tyr Ile Gly
                      20 25 30
          Val His Val Pro Lys Ser Tyr Arg Arg Arg Arg Arg Arg His Lys Arg Lys
                  35 40 45
          Thr Gly His Lys Glu Lys Lys Glu Lys Glu Arg Ile Ser Glu Asn Tyr
              50 55 60
          Ser Asp Lys Ser Asp Ile Glu Asn Ala Asp Glu Ser Ser Ser Ser Ser Ile
          65 70 75 80
          Leu Lys Pro Leu Ile Ser Pro Ala Ala Glu Arg Ile Arg Phe Ile Leu
                          85 90 95
          Gly Glu Glu Asp Asp Ser Pro Ala Pro Pro Gln Leu Phe Thr Glu Leu
                      100 105 110
          Asp Glu Leu Leu Ala Val Asp Gly Gln Glu Met Glu Trp Lys Glu Thr
                  115 120 125
          Ala Arg Trp Ile Lys Phe Glu Glu Lys Val Glu Gln Gly Gly Glu Arg
              130 135 140
          Trp Ser Lys Pro His Val Ala Thr Leu Ser Leu His Ser Leu Phe Glu
          145 150 155 160
          Leu Arg Thr Cys Met Glu Lys Gly Ser Ile Met Leu Asp Arg Glu Ala
                          165 170 175
          Ser Ser Leu Pro Gln Leu Val Glu Met Ile Val Asp His Gln Ile Glu
                      180 185 190
          Thr Gly Leu Leu Lys Pro Glu Leu Lys Asp Lys Val Thr Tyr Thr Leu
                  195 200 205
          Leu Arg Lys His Arg His Gln Thr Lys Lys Ser Asn Leu Arg Ser Leu
              210 215 220
          Ala Asp Ile Gly Lys Thr Val Ser Ser Ala Ser Arg Met Phe Thr Asn
          225 230 235 240
          Pro Asp Asn Gly Ser Pro Ala Met Thr His Arg Asn Leu Thr Ser Ser
                          245 250 255
          Ser Leu Asn Asp Ile Ser Asp Lys Pro Glu Lys Asp Gln Leu Lys Asn
                      260 265 270
          Lys Phe Met Lys Lys Leu Pro Arg Asp Ala Glu Ala Ser Asn Val Leu
                  275 280 285
          Val Gly Glu Val Asp Phe Leu Asp Thr Pro Phe Ile Ala Phe Val Arg
              290 295 300
          Leu Gln Gln Ala Val Met Leu Gly Ala Leu Thr Glu Val Pro Val Pro
          305 310 315 320
          Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro Lys Gly Lys Ala Lys Ser
                          325 330 335
          Tyr His Glu Ile Gly Arg Ala Ile Ala Thr Leu Met Ser Asp Glu Val
                      340 345 350
          Phe His Asp Ile Ala Tyr Lys Ala Lys Asp Arg His Asp Leu Ile Ala
                  355 360 365
          Gly Ile Asp Glu Phe Leu Asp Glu Val Ile Val Leu Pro Pro Gly Glu
              370 375 380
          Trp Asp Pro Ala Ile Arg Ile Glu Pro Pro Lys Ser Leu Pro Ser Ser
          385 390 395 400
          Asp Lys Arg Lys Asn Met Tyr Ser Gly Gly Glu Asn Val Gln Met Asn
                          405 410 415
          Gly Asp Thr Pro His Asp Gly Gly His Gly Gly Gly Gly His Gly Asp
                      420 425 430
          Cys Glu Glu Leu Gln Arg Thr Gly Arg Phe Cys Gly Gly Leu Ile Lys
                  435 440 445
          Asp Ile Lys Arg Lys Ala Pro Phe Phe Ala Ser Asp Phe Tyr Asp Ala
              450 455 460
          Leu Asn Ile Gln Ala Leu Ser Ala Ile Leu Phe Ile Tyr Leu Ala Thr
          465 470 475 480
          Val Thr Asn Ala Ile Thr Phe Gly Gly Leu Leu Gly Asp Ala Thr Asp
                          485 490 495
          Asn Met Gln Gly Val Leu Glu Ser Phe Leu Gly Thr Ala Val Ser Gly
                      500 505 510
          Ala Ile Phe Cys Leu Phe Ala Gly Gln Pro Leu Thr Ile Leu Ser Ser
                  515 520 525
          Thr Gly Pro Val Leu Val Phe Glu Arg Leu Leu Phe Asn Phe Ser Lys
              530 535 540
          Asp Asn Asn Phe Asp Tyr Leu Glu Phe Arg Leu Trp Ile Gly Leu Trp
          545 550 555 560
          Ser Ala Phe Leu Cys Leu Ile Leu Val Ala Thr Asp Ala Ser Phe Leu
                          565 570 575
          Val Gln Tyr Phe Thr Arg Phe Thr Glu Glu Gly Phe Ser Ser Leu Ile
                      580 585 590
          Ser Phe Ile Phe Ile Tyr Asp Ala Phe Lys Lys Met Ile Lys Leu Ala
                  595 600 605
          Asp Tyr Tyr Pro Ile Asn Ser Asn Phe Lys Val Gly Tyr Asn Thr Leu
              610 615 620
          Phe Ser Cys Thr Cys Val Pro Pro Asp Pro Ala Asn Ile Ser Ile Ser
          625 630 635 640
          Asn Asp Thr Thr Leu Ala Pro Glu Tyr Leu Pro Thr Met Ser Ser Ser Thr
                          645 650 655
          Asp Met Tyr His Asn Thr Thr Phe Asp Trp Ala Phe Leu Ser Lys Lys
                      660 665 670
          Glu Cys Ser Lys Tyr Gly Gly Asn Leu Val Gly Asn Asn Cys Asn Phe
                  675 680 685
          Val Pro Asp Ile Thr Leu Met Ser Phe Ile Leu Phe Leu Gly Thr Tyr
              690 695 700
          Thr Ser Ser Met Ala Leu Lys Lys Phe Lys Thr Ser Pro Tyr Phe Pro
          705 710 715 720
          Thr Thr Ala Arg Lys Leu Ile Ser Asp Phe Ala Ile Ile Leu Ser Ile
                          725 730 735
          Leu Ile Phe Cys Val Ile Asp Ala Leu Val Gly Val Asp Thr Pro Lys
                      740 745 750
          Leu Ile Val Pro Ser Glu Phe Lys Pro Thr Ser Pro Asn Arg Gly Trp
                  755 760 765
          Phe Val Pro Pro Phe Gly Glu Asn Pro Trp Trp Val Cys Leu Ala Ala
              770 775 780
          Ala Ile Pro Ala Leu Leu Val Thr Ile Leu Ile Phe Met Asp Gln Gln
          785 790 795 800
          Ile Thr Ala Val Ile Val Asn Arg Lys Glu His Lys Leu Lys Lys Gly
                          805 810 815
          Ala Gly Tyr His Leu Asp Leu Phe Trp Val Ala Ile Leu Met Val Ile
                      820 825 830
          Cys Ser Leu Met Ala Leu Pro Trp Tyr Val Ala Ala Thr Val Ile Ser
                  835 840 845
          Ile Ala His Ile Asp Ser Leu Lys Met Glu Thr Glu Thr Ser Ala Pro
              850 855 860
          Gly Glu Gln Pro Lys Phe Leu Gly Val Arg Glu Gln Arg Val Thr Gly
          865 870 875 880
          Thr Leu Val Phe Ile Leu Thr Gly Leu Ser Val Phe Met Ala Pro Ile
                          885 890 895
          Leu Lys Phe Ile Pro Met Pro Val Leu Tyr Gly Val Phe Leu Tyr Met
                      900 905 910
          Gly Val Ala Ser Leu Asn Gly Val Gln Phe Met Asp Arg Leu Lys Leu
                  915 920 925
          Leu Leu Met Pro Leu Lys His Gln Pro Asp Phe Ile Tyr Leu Arg His
              930 935 940
          Val Pro Leu Arg Arg Val His Leu Phe Thr Phe Leu Gln Val Leu Cys
          945 950 955 960
          Leu Ala Leu Leu Trp Ile Leu Lys Ser Thr Val Ala Ala Ile Ile Phe
                          965 970 975
          Pro Val Met Ile Leu Ala Leu Val Ala Val Arg Lys Gly Met Asp Tyr
                      980 985 990
          Leu Phe Ser Gln His Asp Leu Ser Phe Leu Asp Asp Val Ile Pro Glu
                  995 1000 1005
          Lys Asp Lys Lys Lys Lys Lys Glu Asp Glu Lys Lys Lys Lys Lys Lys Lys
              1010 1015 1020
          Lys Gly Ser Leu Asp Ser Asp Asn Asp Asp Ser Asp Cys Pro Tyr
              1025 1030 1035
          Ser Glu Lys Val Pro Ser Ile Lys Ile Pro Met Asp Ile Met Glu
              1040 1045 1050
          Gln Gln Pro Phe Leu Ser Asp Ser Lys Pro Ser Asp Arg Glu Arg
              1055 1060 1065
          Ser Pro Thr Phe Leu Glu Arg His Thr Ser Cys
              1070 1075
           <![CDATA[ <210> 820]]>
           <![CDATA[ <211> 2047]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 820]]>
          ggcggcgcgc cgggcagcgc ttcggtggcg gcggcggccg cggtggcagc gaaggcggcg 60
          gcggcggcgg cagtggcagt ggccgctgca gccccaacact ccgccgccaa actggaggag 120
          cgacggaagc cagaccccag gaggatggag gatgaagctg tcctggacag aggggcttcc 180
          ttcctcaagc atgtgtgtga tgaagaagaa gtagaaggcc accataccat ttacatcgga 240
          gtccatgtgc cgaagagtta caggagaagg agacgtcaca agagaaagac agggcacaaa 300
          gaaaagaagg aaaaggagag aatctctgag aactactctg acaaatcaga tattgaaaat 360
          gctgatgaat ccagcagcag catcctaaaa cctctcatct ctcctgctgc agaacgcatc 420
          cgattcatct tgggagagga ggatgacagc ccagctcccc ctcagctctt cacggaactg 480
          gatgagctgc tggccgtgga tgggcaggag atggagtgga aggaaacagc caggtggatc 540
          aagtttgaag aaaaagtgga acagggtggg gaaagatgga gcaagcccca tgtggccaca 600
          ttgtcccttc atagtttatt tgagctgagg acatgtatgg agaaaggatc catcatgctt 660
          gatcgggagg cttcttctct cccacagttg gtggagatga ttgttgacca tcagattgag 720
          acaggcctat tgaaacctga acttaaggat aaggtgacct atactttgct ccggaagcac 780
          cggcatcaaa ccaagaaatc caaccttcgg tccctggctg aattgggaa gacagtctcc 840
          agtgcaagta ggatgtttac caaccctgat aatggtagcc cagccatgac ccataggaat 900
          ctgacttcct ccagtctgaa tgacatttct gataaaccgg agaaggacca gctgaagaat 960
          aagttcatga aaaaattgcc acgtgatgca gaagcttcca acgtgcttgt tggggaggtt 1020
          gactttttgg atactccttt cattgccttt gttaggctac agcaggctgt catgctgggt 1080
          gccctgactg aagttcctgt gcccacaagg ttcttgttca ttctcttagg tcctaagggg 1140
          aaagccaagt cctaccacga gattggcaga gccattgcca ccctgatgtc tgatgaggtg 1200
          ttccatgaca ttgcttataa agcaaaagac aggcacgacc tgattgctgg tattgatgag 1260
          ttcctagatg aagtcatcgt ccttccacct ggggaatggg atccagcaat taggatagag 1320
          cctcctaaga gtcttccatc ctctgacaaa agaaagaata tgtactcagg tggagagaat 1380
          gttcagatga atggggatac gccccatgat ggaggtcacg gaggaggagg acatggggat 1440
          tgtgaagaat tgcagcgaac tggacggttc tgtggtggac taattaaaga cataaagagg 1500
          aaagcgccat tttttgccag tgatttttat gatgctttaa atattcaagc tctttcggca 1560
          attctcttca tttatctggc aactgtaact aatgctatca cttttggagg actgcttggg 1620
          gatgccactg acaacatgca gggcgtgttg gagagtttcc tgggcactgc tgtctctgga 1680
          gccatctttt gcctttttgc tggtcaacca ctcactattc tgagcagcac cggacctgtc 1740
          ctagtttttg agaggcttct atttaatttc agcaaggaca ataattttga ctatttggag 1800
          tttcgccttt ggattggcct gtggtccgcc ttcctatgtc tcattttggt agccactgat 1860
          gccagcttct tggttcaata cttcacacgt ttcacggagg agggcttttc ctctctgatt 1920
          agcttcatct ttatctatga tgctttcaag aagatgatca agcttgcaga ttactaccccc 1980
          atcaactcca acttcaaagt gggctacaac actctctttt cctgtacctg tgtgccacct 2040
          gacccag 2047
           <![CDATA[ <210> 821]]>
           <![CDATA[ <211> 634]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 821]]>
          Met Glu Asp Glu Ala Val Leu Asp Arg Gly Ala Ser Phe Leu Lys His
          1 5 10 15
          Val Cys Asp Glu Glu Glu Val Glu Gly His His Thr Ile Tyr Ile Gly
                      20 25 30
          Val His Val Pro Lys Ser Tyr Arg Arg Arg Arg Arg Arg His Lys Arg Lys
                  35 40 45
          Thr Gly His Lys Glu Lys Lys Glu Lys Glu Arg Ile Ser Glu Asn Tyr
              50 55 60
          Ser Asp Lys Ser Asp Ile Glu Asn Ala Asp Glu Ser Ser Ser Ser Ser Ile
          65 70 75 80
          Leu Lys Pro Leu Ile Ser Pro Ala Ala Glu Arg Ile Arg Phe Ile Leu
                          85 90 95
          Gly Glu Glu Asp Asp Ser Pro Ala Pro Pro Gln Leu Phe Thr Glu Leu
                      100 105 110
          Asp Glu Leu Leu Ala Val Asp Gly Gln Glu Met Glu Trp Lys Glu Thr
                  115 120 125
          Ala Arg Trp Ile Lys Phe Glu Glu Lys Val Glu Gln Gly Gly Glu Arg
              130 135 140
          Trp Ser Lys Pro His Val Ala Thr Leu Ser Leu His Ser Leu Phe Glu
          145 150 155 160
          Leu Arg Thr Cys Met Glu Lys Gly Ser Ile Met Leu Asp Arg Glu Ala
                          165 170 175
          Ser Ser Leu Pro Gln Leu Val Glu Met Ile Val Asp His Gln Ile Glu
                      180 185 190
          Thr Gly Leu Leu Lys Pro Glu Leu Lys Asp Lys Val Thr Tyr Thr Leu
                  195 200 205
          Leu Arg Lys His Arg His Gln Thr Lys Lys Ser Asn Leu Arg Ser Leu
              210 215 220
          Ala Asp Ile Gly Lys Thr Val Ser Ser Ala Ser Arg Met Phe Thr Asn
          225 230 235 240
          Pro Asp Asn Gly Ser Pro Ala Met Thr His Arg Asn Leu Thr Ser Ser
                          245 250 255
          Ser Leu Asn Asp Ile Ser Asp Lys Pro Glu Lys Asp Gln Leu Lys Asn
                      260 265 270
          Lys Phe Met Lys Lys Leu Pro Arg Asp Ala Glu Ala Ser Asn Val Leu
                  275 280 285
          Val Gly Glu Val Asp Phe Leu Asp Thr Pro Phe Ile Ala Phe Val Arg
              290 295 300
          Leu Gln Gln Ala Val Met Leu Gly Ala Leu Thr Glu Val Pro Val Pro
          305 310 315 320
          Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro Lys Gly Lys Ala Lys Ser
                          325 330 335
          Tyr His Glu Ile Gly Arg Ala Ile Ala Thr Leu Met Ser Asp Glu Val
                      340 345 350
          Phe His Asp Ile Ala Tyr Lys Ala Lys Asp Arg His Asp Leu Ile Ala
                  355 360 365
          Gly Ile Asp Glu Phe Leu Asp Glu Val Ile Val Leu Pro Pro Gly Glu
              370 375 380
          Trp Asp Pro Ala Ile Arg Ile Glu Pro Pro Lys Ser Leu Pro Ser Ser
          385 390 395 400
          Asp Lys Arg Lys Asn Met Tyr Ser Gly Gly Glu Asn Val Gln Met Asn
                          405 410 415
          Gly Asp Thr Pro His Asp Gly Gly His Gly Gly Gly Gly His Gly Asp
                      420 425 430
          Cys Glu Glu Leu Gln Arg Thr Gly Arg Phe Cys Gly Gly Leu Ile Lys
                  435 440 445
          Asp Ile Lys Arg Lys Ala Pro Phe Phe Ala Ser Asp Phe Tyr Asp Ala
              450 455 460
          Leu Asn Ile Gln Ala Leu Ser Ala Ile Leu Phe Ile Tyr Leu Ala Thr
          465 470 475 480
          Val Thr Asn Ala Ile Thr Phe Gly Gly Leu Leu Gly Asp Ala Thr Asp
                          485 490 495
          Asn Met Gln Gly Val Leu Glu Ser Phe Leu Gly Thr Ala Val Ser Gly
                      500 505 510
          Ala Ile Phe Cys Leu Phe Ala Gly Gln Pro Leu Thr Ile Leu Ser Ser
                  515 520 525
          Thr Gly Pro Val Leu Val Phe Glu Arg Leu Leu Phe Asn Phe Ser Lys
              530 535 540
          Asp Asn Asn Phe Asp Tyr Leu Glu Phe Arg Leu Trp Ile Gly Leu Trp
          545 550 555 560
          Ser Ala Phe Leu Cys Leu Ile Leu Val Ala Thr Asp Ala Ser Phe Leu
                          565 570 575
          Val Gln Tyr Phe Thr Arg Phe Thr Glu Glu Gly Phe Ser Ser Leu Ile
                      580 585 590
          Ser Phe Ile Phe Ile Tyr Asp Ala Phe Lys Lys Met Ile Lys Leu Ala
                  595 600 605
          Asp Tyr Tyr Pro Ile Asn Ser Asn Phe Lys Val Gly Tyr Asn Thr Leu
              610 615 620
          Phe Ser Cys Thr Cys Val Pro Pro Asp Pro
          625 630
           <![CDATA[ <210> 822]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 822]]>
          atgtgtccaa caaggtgtca atgtccagca ctgtgcaggg cagcaacatc tttgagagaa 60
          cggaggtcct ggcag 75
           <![CDATA[ <210> 823]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 823]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60
          tccttcggtg tgaaa 75
           <![CDATA[ <210> 824]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 824]]>
          atgtgtccaa caaggtgtca atgtccagca ctgtgcaggg cagcaacatc tttgagagaa 60
          cggaggtcct ggcagccttg cctccccgat tgaaagagat gaaaagccag gaatcggctg 120
          caggttccaa actagtcctt cggtgtgaaa 150
           <![CDATA[ <210> 825]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 825]]>
          Val Ser Asn Lys Val Ser Met Ser Ser Thr Val Gln Gly Ser Asn Ile
          1 5 10 15
          Phe Glu Arg Thr Glu Val Leu Ala Ala Leu Pro Pro Arg Leu Lys Glu
                      20 25 30
          Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys
                  35 40 45
          Glu
           <![CDATA[ <210> 826]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 826]]>
          acaggaagca ccctaatgag gagtatgcca acgtgggcac cggggagctg gcagcggagg 60
          tgctcatcca gcaag 75
           <![CDATA[ <210> 827]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 827]]>
          ctacatctac atccaccact gggacaagcc atcttgtaaa atgtgcggag aaggagaaaa 60
          ctttctgtgtgaatg 75
           <![CDATA[ <210> 828]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 828]]>
          acaggaagca ccctaatgag gagtatgcca acgtgggcac cggggagctg gcagcggagg 60
          tgctcatcca gcaagctaca tctacatcca ccactgggac aagccatctt gtaaaatgtg 120
          cggagaagga gaaaactttc tgtgtgaatg 150
           <![CDATA[ <210> 829]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 829]]>
          Arg Lys His Pro Asn Glu Glu Tyr Ala Asn Val Gly Thr Gly Glu Leu
          1 5 10 15
          Ala Ala Glu Val Leu Ile Gln Gln Ala Thr Ser Thr Ser Thr Thr Gly
                      20 25 30
          Thr Ser His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val
                  35 40 45
          Asn
           <![CDATA[ <210> 830]]>
           <![CDATA[ <211> 187]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 830]]>
          atccgccatg ttggatgccg cagattcgcc ataacctcgc cggctctttt cttaaaaaaa 60
          taaaaataaa aagcgaagcg tcagcagggc gccccgcccc ctcggtcggc acgggagggg 120
          gcccggaaga gcccgaggct tttttttcct ccgcggtggg gcgttgccat ggagacgcgg 180
          gcggcag 187
           <![CDATA[ <210> 831]]>
           <![CDATA[ <211> 177]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 831]]>
          aaaacacggc catctttatg tgtaaatgtt gtaacctctt ctcaccaaat cagtcggaac 60
          tcctctccca cgtttcagag aagcacatgg aagaaggggt taatgttgat gagattatta 120
          ttccccttag gccctctgagt acacctgaac cccccaactc aagcaaaacc ggagatg 177
           <![CDATA[ <210> 832]]>
           <![CDATA[ <211> 252]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 832]]>
          agtttttggt catgaagagg aagagaggca ggcctaaggg gtccacgaag aagtccagca 60
          cagaagagga gctggcagaa aacatcgtga gtccgactga ggacagcccg ctggctccgg 120
          aggaagggaa cagcctgcct ccaagcagct tggagtgtag caagtgctgt cggaagttct 180
          ccaacacgcg ccagctgcgg aagcacatct gcatttatcgt gctgaatttg ggtgaggagg 240
          aaggagaagc ag 252
           <![CDATA[ <210> 833]]>
           <![CDATA[ <211> 186]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 833]]>
          gtaacgagtc tgaccttgaa ctagaaaaga agtgtaagga agatgatcgg gaaaaagcct 60
          cgaaaagacc acggtcacag aaaacagaga aagtccagaa gatctcagga aaggaggcca 120
          gacagctttc tggggcgaag aaacccatca taagtgtggt tttaactgca cacgaagcaa 180
          ttccag 186
           <![CDATA[ <210> 834]]>
           <![CDATA[ <211> 151]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 834]]>
          gtgctaccaa gattgtgcca gtggaggctg ggccccctga aacaggagct acaaattctg 60
          agaccacttc agcagacctg gtgcctcgga gaggctacca ggaatacgcc attcagcaga 120
          caccttatga gcaaccaatg aagtcaagca g 151
           <![CDATA[ <210> 835]]>
           <![CDATA[ <211> 1457]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 835]]>
          gctaggtccc actcagctca aaatcttcac ttgtgaatac tgcaacaagg tcttcaagtt 60
          caagcactcg ctgcaggccc acctgaggat ccacaccaat gaaaagccat acaagtgccc 120
          ccagtgcagc tatgccagtg ccatcaaggc caacctcaat gtgcacctgc gcaagcacac 180
          tggagagaag ttcgcctgcg actattgctc gttcacctgc ctgagcaagg gccacctcaa 240
          ggtgcacatc gagcgagtgc acaagaagat caagcagcac tgccgcttct gcaagaagaa 300
          gtactctgac gtcaagaacc tcatcaagca catccgagac gcgcatgacc cacaggaca 360
          gaaggtcaaa gaggccttgg acgagctctg cctgatgacg aggggagggca agcggcagct 420
          gctctatgac tgccacatct gtgagcgcaa gttcaagaac gagctggacc gtgaccgcca 480
          tatgctggtc cacggagaca agtggccttt tgcctgtgag ctctgtggcc atggggccac 540
          caagtaccag gcgctggaac tgcatgtcag gaagcacccc ttcgtgtacg tctgtgccgt 600
          ctgccgcaag aagttcgtca gctccatcag gctgcgcacc cacatcaaag aggtgcacgg 660
          ggctgcccag gaggccttgg tcttcaccag ttccatcaac cagagcttct gcctcctgga 720
          acctggtggg gacatccagc aagaagctct gggggaccag ctacagctgg tggaagagga 780
          gtttgccctc cagggcgtga atgcactcaa ggaagaggcc tgtcctgggg acactcagct 840
          ggagggagggc cggaaggagc cggaggcccc tggggaaatg cctgccccag ctgtgcacct 900
          ggcctccccg caggccgaaa gcacagccct gccaccctgt gagctggaaa ccaccgtggt 960
          ctcctcctca gacctgcatt ctcaagaggt ggtttcagat gattttttgt tgaaaaatga 1020
          tacctcctcc gcagaggctc atgctgctcc tgagaagccc ccagacatgc agcacagaag 1080
          ctcagtccag acgcaaggtg aagtgatcac actactgctg tccaaggccc agagtgctgg 1140
          gtcagatcag gaaagccatg gcgccccagag ccccctaggg gaagggcaga acatggctgt 1200
          gctttcagct ggtgacccag atcccagcag gtgtctcagg tcaaacccag ctgaggcctc 1260
          agacctcctc cctccagtag ctggtggtgg ggacaccatc acacatcagc ctgactcttg 1320
          caaagctgcc cctgagcacc ggtcaggcat caccgctttc atgaaggtcc tgaacagttt 1380
          acagaagaag caaatgaaca ccagcttgtg tgagcggatc cggaaggttt atggagacct 1440
          ggagtgtgaa tactgtg 1457
           <![CDATA[ <210> 836]]>
           <![CDATA[ <211> 233]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 836]]>
          gcaaactttt ttggtaccaa gtgcattttg atatgcatgt ccgcacccac acccgggaac 60
          atctgtatta ttgctctcag tgtcattatt cttccatcac caaaaactgc cttaaacgcc 120
          acgtaattca gaaacacagt aacatcttgc tgaagtgtcc caccgatggc tgtgactact 180
          caactccaga taaatataag ctacaggcac atcttaaagt tcacacagca ctg 233
           <![CDATA[ <210> 837]]>
           <![CDATA[ <211> 88]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 837]]>
          gacaaaagga gttattcttg tcctgtttgt gaaaagtctt tttcagagga tcgattgata 60
          aagtcacata tcaagaccaa ccatcctg 88
           <![CDATA[ <210> 838]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 838]]>
          aggtctccat gagcaccatt tctgaggttc tcgggaggag ggttcagctg aaagggctaa 60
          ttggaaagag agccatgaaa tgcccatatt gtgactttta tttcatgaag aatggctcag 120
          accttcagcg tcatatttgg gctcatgaag 150
           <![CDATA[ <210> 839]]>
           <![CDATA[ <211> 174]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 839]]>
          gtgtgaagcc cttcaagtgt tctttgtgtg agtatgcaac tcgtagcaag agtaacctca 60
          aggctcatat gaatcgtcac agcactgaga aaacccacct atgtgacatg tgtggcaaga 120
          aattcaaatc aaaagggaca ctgaaaagtc acaaactcct tcacactgca gatg 174
           <![CDATA[ <210> 840]]>
           <![CDATA[ <211> 89]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 840]]>
          ggaagcagtt taagtgcacg gtgtgtgact acacagcggc ccagaagcca cagctgctgc 60
          ggcacatgga acagcatgtc tccttcaag 89
           <![CDATA[ <210> 841]]>
           <![CDATA[ <211> 139]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 841]]>
          cctttccgct gtgcccattg ccattactcc tgcaacatat ctggctctct gaagcggcac 60
          tacaacagga agcaccttaa tgaggagtat gccaacgtgg gcaccgggga gctggcagcg 120
          gaggtgctca tccagcaag 139
           <![CDATA[ <210> 842]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 842]]>
          gtggtttgaa gtgtcctgtt tgcagctttg tatatggcac caaatggggag ttcaataggc 60
          acttgaagaa caaacatggc ttgaaggtgg tggaaattga tggagacccc aagtggggag 119
           <![CDATA[ <210> 843]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 843]]>
          acagcaacag aagctcctga ggagccctcc accccagtatc tccacatcac agaggccgaa 60
          gaagacgttc aagggacaca ggcagcggtg gccgcgctcc aggacctgag atacacctct 120
          gagagtg 127
           <![CDATA[ <210> 844]]>
           <![CDATA[ <211> 131]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 844]]>
          gcgaccgact ggaccccacg gccgtgaaca tcctgcagca gatcattgag ctgggcgccg 60
          agacccatga cgccactgcc cttgcctcgg tggttgccat ggcaccaggg acggtgactg 120
          tggttaagca g 131
           <![CDATA[ <210> 845]]>
           <![CDATA[ <211> 934]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 845]]>
          gtcaccgagg aggagcccag ctccaaccac acggtcatga tccaggagac ggtccagcaa 60
          gcgtccgtgg agcttgccga gcagcaccac ctggtggtgt cctccgacga cgtggagggc 120
          attgagacgg tgactgtcta cacgcagggc ggggaggcct cggagttcat cgtctacgtg 180
          caggaggcca tgcagcctgt ggaggagcag gctgtggagc agccggccca ggaactctag 240
          aggacatgtg gcatcggatg gccacagggc ggggctgcca ggctctgcag gcacccaggg 300
          tggggaggcc acccttcctg ccctacccgc agaatggtgc tctcctttgc cctccctgcc 360
          cagcagcctg ataggactct cctagtccaa cttggggtgg gcaaggcagt cagcatcacc 420
          agcaatacca caggacccctc accccagcat agacacacac cccctgaccc ttaccatctg 480
          cttcctgaaa gacttcagtg tcagctcccc tacacacacc ccaacaccttc accccttgct 540
          tcaagattca aacagagact cccagtcccc ctcagcatct tccctgaatc acagccccag 600
          ctccttgacc cccatctagg tgccaaatgt tcatctgcaa ccgctatgca gtctggtgag 660
          aggggagacag ccatcacata gaaagtgacc gtacgggttt ttaatcactg ctgggtgggg 720
          tgggggtagg gggattgtcc tggctttgtc gacaaagtcc cacttccccg agtattaagg 780
          gcccttggta tcaagtgagg taaattcacc catcacagggg tctcgcccta ccatcctgga 840
          attatttcac ttttaagata aatgcactat ttcactgttc gcctcccatt ctaaggaggt 900
          gaggtggttg gaataaaaac agttcctgtc tgaa 934
           <![CDATA[ <210> 846]]>
           <![CDATA[ <211> 4594]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> The complete mRNA polynucleotide sequence of ZFAT]]>
           <![CDATA[ <400> 846]]>
          atccgccatg ttggatgccg cagattcgcc ataacctcgc cggctctttt cttaaaaaaa 60
          taaaaataaa aagcgaagcg tcagcagggc gccccgcccc ctcggtcggc acgggagggg 120
          gcccggaaga gcccgaggct tttttttcct ccgcggtggg gcgttgccat ggagacgcgg 180
          gcggcagaaa acacggccat ctttatgtgt aaatgttgta acctcttctc accaaatcag 240
          tcggaactcc tctcccacgt ttcagagaag cacatggaag aaggggttaa tgttgatgag 300
          attattattc cccttaggcc tctgagtaca cctgaaccccc ccaactcaag caaaaccgga 360
          gatgagtttt tggtcatgaa gaggaagaga ggcaggccta aggggtccac gaagaagtcc 420
          agcacagaag aggagctggc agaaaacatc gtgagtccga ctgaggacag cccgctggct 480
          ccggaggaag ggaacagcct gcctccaagc agcttggagt gtagcaagtg ctgtcggaag 540
          ttctccaaca cgcgccagct gcggaagcac atctgcatta tcgtgctgaa tttgggtgag 600
          gaggaaggag aagcaggtaa cgagtctgac cttgaactag aaaagaagtg taaggaagat 660
          gatcgggaaa aagcctcgaa aagaccacgg tcacagaaaa cagagaaagt ccagaagatc 720
          tcaggaaagg aggccagaca gctttctggg gcgaagaaac ccatcataag tgtggtttta 780
          actgcacacg aagcaattcc aggtgctacc aagattgtgc cagtggaggc tgggccccct 840
          gaaacaggag ctacaaattc tgagaccact tcagcagacc tggtgcctcg gagaggctac 900
          caggaatacg ccattcagca gacaccttat gagcaaccaa tgaagtcaag caggctaggt 960
          cccactcagc tcaaaatctt cacttgtgaa tactgcaaca aggtcttcaa gttcaagcac 1020
          tcgctgcagg cccacctgag gatccacacc aatgaaaagc catacaagtg cccccagtgc 1080
          agctatgcca gtgccatcaa ggccaacctc aatgtgcacc tgcgcaagca cactggagag 1140
          aagttcgcct gcgactattg ctcgttcacc tgcctgagca agggccacct caaggtgcac 1200
          atcgagcgag tgcacaagaa gatcaagcag cactgccgct tctgcaagaa gaagtactct 1260
          gacgtcaaga acctcatcaa gcacatccga gacgcgcatg accccacagga caagaaggtc 1320
          aaagaggcct tggacgagct ctgcctgatg acgagggagg gcaagcggca gctgctctat 1380
          gactgccaca tctgtgagcg caagttcaag aacgagctgg accgtgaccg ccatatgctg 1440
          gtccacggag acaagtggcc ttttgcctgt gagctctgtg gccatggggc caccaagtac 1500
          caggcgctgg aactgcatgt caggaagcac cccttcgtgt acgtctgtgc cgtctgccgc 1560
          aagaagttcg tcagctccat caggctgcgc acccacatca aagaggtgca cggggctgcc 1620
          caggaggcct tggtcttcac cagttccatc aaccagagct tctgcctcct ggaacctggt 1680
          ggggacatcc agcaagaagc tctgggggac cagctacagc tggtggaaga ggagtttgcc 1740
          ctccagggcg tgaatgcact caaggaagag gcctgtcctg gggacactca gctggaggag 1800
          ggccggaagg agccggaggc ccctggggaa atgcctgccc cagctgtgca cctggcctcc 1860
          ccgcaggccg aaagcacagc cctgccaccc tgtgagctgg aaaccaccgt ggtctcctcc 1920
          tcagacctgc attctcaaga ggtggtttca gatgattttttgttgaaaaa tgatacctcc 1980
          tccgcagagg ctcatgctgc tcctgagaag cccccagaca tgcagcacag aagctcagtc 2040
          cagacgcaag gtgaagtgat cacactactg ctgtccaagg cccagagtgc tgggtcagat 2100
          caggaaagcc atggcgccca gagcccccta ggggaagggc agaacatggc tgtgctttca 2160
          gctggtgacc cagatccccag caggtgtctc aggtcaaacc cagctgaggc ctcagacctc 2220
          ctccctccag tagctggtgg tggggacacc atcacacatc agcctgactc ttgcaaagct 2280
          gcccctgagc accggtcagg catcaccgct ttcatgaagg tcctgaacag tttacagaag 2340
          aagcaaatga acaccagctt gtgtgagcgg atccggaagg tttatggaga cctggagtgt 2400
          gaatactgtg gcaaactttt ttggtaccaa gtgcattttg atatgcatgt ccgcacccac 2460
          acccgggaac atctgtatta ttgctctcag tgtcattatt cttccatcac caaaaactgc 2520
          cttaaacgcc acgtaattca gaaacacagt aacatcttgc tgaagtgtcc caccgatggc 2580
          tgtgactact caactccaga taaatataag ctacaggcac atcttaaagt tcacacagca 2640
          ctggacaaaa ggagttattc ttgtcctgtt tgtgaaaagt ctttttcaga ggatcgattg 2700
          ataaagtcac atatcaagac caaccatcct gaggtctcca tgagcaccat ttctgaggtt 2760
          ctcgggagga gggttcagct gaaagggcta attggaaaga gagccatgaa atgcccatat 2820
          tgtgactttt atttcatgaa gaatggctca gaccttcagc gtcatatttg ggctcatgaa 2880
          ggtgtgaagc ccttcaagtg ttctttgtgtgagtatgcaa ctcgtagcaa gagtaacctc 2940
          aaggctcata tgaatcgtca cagcactgag aaaacccacc tatgtgacat gtgtggcaag 3000
          aaattcaaat caaaagggac actgaaaagt cacaaactcc ttcacactgc agatgggaag 3060
          cagtttaagt gcacggtgtg tgactacaca gcggcccaga agccacagct gctgcggcac 3120
          atggaacagc atgtctcctt caagcctttc cgctgtgccc attgccatta ctcctgcaac 3180
          atatctggct ctctgaagcg gcactacaac aggaagcacc ctaatgagga gtatgccaac 3240
          gtgggcaccg gggagctggc agcggaggtg ctcatccagc aaggtggttt gaagtgtcct 3300
          gtttgcagct ttgtatatgg caccaaatgg gagttcaata ggcacttgaa gaacaaacat 3360
          ggcttgaagg tggtggaaat tgatggagac cccaagtggg agacagcaac agaagctcct 3420
          gaggagccct ccaccccagta tctccacatc acagaggccg aagaagacgt tcaagggaca 3480
          caggcagcgg tggccgcgct ccaggacctg agatacacct ctgagagtgg cgaccgactg 3540
          gaccccacgg ccgtgaacat cctgcagcag atcattgagc tgggcgccga gacccatgac 3600
          gccactgccc ttgcctcggt ggttgccatg gcaccaggga cggtgactgt ggttaagcag 3660
          gtcaccgagg aggagcccag ctccaaccac acggtcatga tccaggagac ggtccagcaa 3720
          gcgtccgtgg agcttgccga gcagcaccac ctggtggtgt cctccgacga cgtggagggc 3780
          attgagacgg tgactgtcta cacgcagggc ggggaggcct cggagttcat cgtctacgtg 3840
          caggaggcca tgcagcctgt ggaggagcag gctgtggagc agccggccca ggaactctag 3900
          aggacatgtg gcatcggatg gccacagggc ggggctgcca ggctctgcag gcacccaggg 3960
          tggggaggcc acccttcctg ccctacccgc agaatggtgc tctcctttgc cctccctgcc 4020
          cagcagcctg ataggactct cctagtccaa cttggggtgg gcaaggcagt cagcatcacc 4080
          agcaatacca caggacccctc accccagcat agacacacac cccctgaccc ttaccatctg 4140
          cttcctgaaa gacttcagtg tcagctcccc tacacacacc ccaacaccttc accccttgct 4200
          tcaagattca aacagagact cccagtcccc ctcagcatct tccctgaatc acagccccag 4260
          ctccttgacc cccatctagg tgccaaatgt tcatctgcaa ccgctatgca gtctggtgag 4320
          aggggagacag ccatcacata gaaagtgacc gtacgggttt ttaatcactg ctgggtgggg 4380
          tgggggtagg gggattgtcc tggctttgtc gacaaagtcc cacttccccg agtattaagg 4440
          gcccttggta tcaagtgagg taaattcacc catcacaggg tctcgcccta ccatcctgga 4500
          attatttcac ttttaagata aatgcactat ttcactgttc gcctcccatt ctaaggaggt 4560
          gaggtggttg gaataaaaac agttcctgtc tgaa 4594
           <![CDATA[ <210> 847]]>
           <![CDATA[ <211> 5]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 847]]>
          Met Glu Thr Arg Ala
          1 5
           <![CDATA[ <210> 848]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 848]]>
          Asn Thr Ala Ile Phe Met Cys Lys Cys Cys Asn Leu Phe Ser Pro Asn
          1 5 10 15
          Gln Ser Glu Leu Leu Ser His Val Ser Glu Lys His Met Glu Glu Gly
                      20 25 30
          Val Asn Val Asp Glu Ile Ile Ile Pro Leu Arg Pro Leu Ser Thr Pro
                  35 40 45
          Glu Pro Pro Asn Ser Ser Lys Thr Gly Asp
              50 55
           <![CDATA[ <210> 849]]>
           <![CDATA[ <211> 83]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 849]]>
          Phe Leu Val Met Lys Arg Lys Arg Gly Arg Pro Lys Gly Ser Thr Lys
          1 5 10 15
          Lys Ser Ser Thr Glu Glu Glu Leu Ala Glu Asn Ile Val Ser Pro Thr
                      20 25 30
          Glu Asp Ser Pro Leu Ala Pro Glu Glu Gly Asn Ser Leu Pro Pro Ser
                  35 40 45
          Ser Leu Glu Cys Ser Lys Cys Cys Arg Lys Phe Ser Asn Thr Arg Gln
              50 55 60
          Leu Arg Lys His Ile Cys Ile Ile Val Leu Asn Leu Gly Glu Glu Glu Glu
          65 70 75 80
          Gly Glu Ala
           <![CDATA[ <210> 850]]>
           <![CDATA[ <211> 61]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 850]]>
          Asn Glu Ser Asp Leu Glu Leu Glu Lys Lys Cys Lys Glu Asp Asp Arg
          1 5 10 15
          Glu Lys Ala Ser Lys Arg Pro Arg Ser Gln Lys Thr Glu Lys Val Gln
                      20 25 30
          Lys Ile Ser Gly Lys Glu Ala Arg Gln Leu Ser Gly Ala Lys Lys Pro
                  35 40 45
          Ile Ile Ser Val Val Leu Thr Ala His Glu Ala Ile Pro
              50 55 60
           <![CDATA[ <210> 851]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 851]]>
          Ala Thr Lys Ile Val Pro Val Glu Ala Gly Pro Pro Glu Thr Gly Ala
          1 5 10 15
          Thr Asn Ser Glu Thr Thr Ser Ala Asp Leu Val Pro Arg Arg Gly Tyr
                      20 25 30
          Gln Glu Tyr Ala Ile Gln Gln Thr Pro Tyr Glu Gln Pro Met Lys Ser
                  35 40 45
          Ser
           <![CDATA[ <210> 852]]>
           <![CDATA[ <211> 485]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> ]]> human
           <![CDATA[ <400> 852]]>
          Leu Gly Pro Thr Gln Leu Lys Ile Phe Thr Cys Glu Tyr Cys Asn Lys
          1 5 10 15
          Val Phe Lys Phe Lys His Ser Leu Gln Ala His Leu Arg Ile His Thr
                      20 25 30
          Asn Glu Lys Pro Tyr Lys Cys Pro Gln Cys Ser Tyr Ala Ser Ala Ile
                  35 40 45
          Lys Ala Asn Leu Asn Val His Leu Arg Lys His Thr Gly Glu Lys Phe
              50 55 60
          Ala Cys Asp Tyr Cys Ser Phe Thr Cys Leu Ser Lys Gly His Leu Lys
          65 70 75 80
          Val His Ile Glu Arg Val His Lys Lys Ile Lys Gln His Cys Arg Phe
                          85 90 95
          Cys Lys Lys Lys Tyr Ser Asp Val Lys Asn Leu Ile Lys His Ile Arg
                      100 105 110
          Asp Ala His Asp Pro Gln Asp Lys Lys Val Lys Glu Ala Leu Asp Glu
                  115 120 125
          Leu Cys Leu Met Thr Arg Glu Gly Lys Arg Gln Leu Leu Tyr Asp Cys
              130 135 140
          His Ile Cys Glu Arg Lys Phe Lys Asn Glu Leu Asp Arg Asp Arg His
          145 150 155 160
          Met Leu Val His Gly Asp Lys Trp Pro Phe Ala Cys Glu Leu Cys Gly
                          165 170 175
          His Gly Ala Thr Lys Tyr Gln Ala Leu Glu Leu His Val Arg Lys His
                      180 185 190
          Pro Phe Val Tyr Val Cys Ala Val Cys Arg Lys Lys Phe Val Ser Ser
                  195 200 205
          Ile Arg Leu Arg Thr His Ile Lys Glu Val His Gly Ala Ala Gln Glu
              210 215 220
          Ala Leu Val Phe Thr Ser Ser Ile Asn Gln Ser Phe Cys Leu Leu Glu
          225 230 235 240
          Pro Gly Gly Asp Ile Gln Gln Glu Ala Leu Gly Asp Gln Leu Gln Leu
                          245 250 255
          Val Glu Glu Glu Phe Ala Leu Gln Gly Val Asn Ala Leu Lys Glu Glu
                      260 265 270
          Ala Cys Pro Gly Asp Thr Gln Leu Glu Glu Gly Arg Lys Glu Pro Glu
                  275 280 285
          Ala Pro Gly Glu Met Pro Ala Pro Ala Val His Leu Ala Ser Pro Gln
              290 295 300
          Ala Glu Ser Thr Ala Leu Pro Pro Cys Glu Leu Glu Thr Thr Val Val
          305 310 315 320
          Ser Ser Ser Asp Leu His Ser Gln Glu Val Val Ser Asp Asp Phe Leu
                          325 330 335
          Leu Lys Asn Asp Thr Ser Ser Ala Glu Ala His Ala Ala Pro Glu Lys
                      340 345 350
          Pro Pro Asp Met Gln His Arg Ser Ser Val Gln Thr Gln Gly Glu Val
                  355 360 365
          Ile Thr Leu Leu Leu Ser Lys Ala Gln Ser Ala Gly Ser Asp Gln Glu
              370 375 380
          Ser His Gly Ala Gln Ser Pro Leu Gly Glu Gly Gln Asn Met Ala Val
          385 390 395 400
          Leu Ser Ala Gly Asp Pro Asp Pro Ser Arg Cys Leu Arg Ser Asn Pro
                          405 410 415
          Ala Glu Ala Ser Asp Leu Leu Pro Pro Val Ala Gly Gly Gly Asp Thr
                      420 425 430
          Ile Thr His Gln Pro Asp Ser Cys Lys Ala Ala Pro Glu His Arg Ser
                  435 440 445
          Gly Ile Thr Ala Phe Met Lys Val Leu Asn Ser Leu Gln Lys Lys Gln
              450 455 460
          Met Asn Thr Ser Leu Cys Glu Arg Ile Arg Lys Val Tyr Gly Asp Leu
          465 470 475 480
          Glu Cys Glu Tyr Cys
                          485
           <![CDATA[ <210> 853]]>
           <![CDATA[ <211> 77]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 853]]>
          Lys Leu Phe Trp Tyr Gln Val His Phe Asp Met His Val Arg Thr His
          1 5 10 15
          Thr Arg Glu His Leu Tyr Tyr Cys Ser Gln Cys His Tyr Ser Ser Ile
                      20 25 30
          Thr Lys Asn Cys Leu Lys Arg His Val Ile Gln Lys His Ser Asn Ile
                  35 40 45
          Leu Leu Lys Cys Pro Thr Asp Gly Cys Asp Tyr Ser Thr Pro Asp Lys
              50 55 60
          Tyr Lys Leu Gln Ala His Leu Lys Val His Thr Ala Leu
          65 70 75
           <![CDATA[ <210> 854]]>
           <![CDATA[ <211> 29]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 854]]>
          Asp Lys Arg Ser Tyr Ser Cys Pro Val Cys Glu Lys Ser Phe Ser Glu
          1 5 10 15
          Asp Arg Leu Ile Lys Ser His Ile Lys Thr Asn His Pro
                      20 25
           <![CDATA[ <210> 855]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 855]]>
          Val Ser Met Ser Thr Ile Ser Glu Val Leu Gly Arg Arg Val Gln Leu
          1 5 10 15
          Lys Gly Leu Ile Gly Lys Arg Ala Met Lys Cys Pro Tyr Cys Asp Phe
                      20 25 30
          Tyr Phe Met Lys Asn Gly Ser Asp Leu Gln Arg His Ile Trp Ala His
                  35 40 45
          Glu
           <![CDATA[ <210> 856]]>
           <![CDATA[ <211> 57]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 856]]>
          Val Lys Pro Phe Lys Cys Ser Leu Cys Glu Tyr Ala Thr Arg Ser Lys
          1 5 10 15
          Ser Asn Leu Lys Ala His Met Asn Arg His Ser Thr Glu Lys Thr His
                      20 25 30
          Leu Cys Asp Met Cys Gly Lys Lys Phe Lys Ser Lys Gly Thr Leu Lys
                  35 40 45
          Ser His Lys Leu Leu His Thr Ala Asp
              50 55
           <![CDATA[ <210> 857]]>
           <![CDATA[ <211> 29]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 857]]>
          Lys Gln Phe Lys Cys Thr Val Cys Asp Tyr Thr Ala Ala Gln Lys Pro
          1 5 10 15
          Gln Leu Leu Arg His Met Glu Gln His Val Ser Phe Lys
                      20 25
           <![CDATA[ <210> 858]]>
           <![CDATA[ <211> 46]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 858]]>
          Pro Phe Arg Cys Ala His Cys His Tyr Ser Cys Asn Ile Ser Gly Ser
          1 5 10 15
          Leu Lys Arg His Tyr Asn Arg Lys His Pro Asn Glu Glu Tyr Ala Asn
                      20 25 30
          Val Gly Thr Gly Glu Leu Ala Ala Glu Val Leu Ile Gln Gln
                  35 40 45
           <![CDATA[ <210> 859]]>
           <![CDATA[ <211> 39]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 859]]>
          Gly Leu Lys Cys Pro Val Cys Ser Phe Val Tyr Gly Thr Lys Trp Glu
          1 5 10 15
          Phe Asn Arg His Leu Lys Asn Lys His Gly Leu Lys Val Val Glu Ile
                      20 25 30
          Asp Gly Asp Pro Lys Trp Glu
                  35
           <![CDATA[ <210> 860]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 860]]>
          Thr Ala Thr Glu Ala Pro Glu Glu Pro Ser Thr Gln Tyr Leu His Ile
          1 5 10 15
          Thr Glu Ala Glu Glu Asp Val Gln Gly Thr Gln Ala Ala Val Ala Ala
                      20 25 30
          Leu Gln Asp Leu Arg Tyr Thr Ser Glu Ser
                  35 40
           <![CDATA[ <210> 861]]>
           <![CDATA[ <211> 43]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 861]]>
          Asp Arg Leu Asp Pro Thr Ala Val Asn Ile Leu Gln Gln Ile Ile Glu
          1 5 10 15
          Leu Gly Ala Glu Thr His Asp Ala Thr Ala Leu Ala Ser Val Val Ala
                      20 25 30
          Met Ala Pro Gly Thr Val Thr Val Val Lys Gln
                  35 40
           <![CDATA[ <210> 862]]>
           <![CDATA[ <211> 79]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 862]]>
          Val Thr Glu Glu Glu Pro Ser Ser Asn His Thr Val Met Ile Gln Glu
          1 5 10 15
          Thr Val Gln Gln Ala Ser Val Glu Leu Ala Glu Gln His His Leu Val
                      20 25 30
          Val Ser Ser Asp Asp Val Glu Gly Ile Glu Thr Val Thr Val Tyr Thr
                  35 40 45
          Gln Gly Gly Glu Ala Ser Glu Phe Ile Val Tyr Val Gln Glu Ala Met
              50 55 60
          Gln Pro Val Glu Glu Gln Ala Val Glu Gln Pro Ala Gln Glu Leu
          65 70 75
           <![CDATA[ <210> 863]]>
           <![CDATA[ <211> 1243]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 863]]>
          Met Glu Thr Arg Ala Ala Glu Asn Thr Ala Ile Phe Met Cys Lys Cys
          1 5 10 15
          Cys Asn Leu Phe Ser Pro Asn Gln Ser Glu Leu Leu Ser His Val Ser
                      20 25 30
          Glu Lys His Met Glu Glu Gly Val Asn Val Asp Glu Ile Ile Ile Pro
                  35 40 45
          Leu Arg Pro Leu Ser Thr Pro Glu Pro Pro Asn Ser Ser Lys Thr Gly
              50 55 60
          Asp Glu Phe Leu Val Met Lys Arg Lys Arg Gly Arg Pro Lys Gly Ser
          65 70 75 80
          Thr Lys Lys Ser Ser Thr Glu Glu Glu Leu Ala Glu Asn Ile Val Ser
                          85 90 95
          Pro Thr Glu Asp Ser Pro Leu Ala Pro Glu Glu Gly Asn Ser Leu Pro
                      100 105 110
          Pro Ser Ser Leu Glu Cys Ser Lys Cys Cys Arg Lys Phe Ser Asn Thr
                  115 120 125
          Arg Gln Leu Arg Lys His Ile Cys Ile Ile Val Leu Asn Leu Gly Glu
              130 135 140
          Glu Glu Gly Glu Ala Gly Asn Glu Ser Asp Leu Glu Leu Glu Lys Lys
          145 150 155 160
          Cys Lys Glu Asp Asp Arg Glu Lys Ala Ser Lys Arg Pro Arg Ser Gln
                          165 170 175
          Lys Thr Glu Lys Val Gln Lys Ile Ser Gly Lys Glu Ala Arg Gln Leu
                      180 185 190
          Ser Gly Ala Lys Lys Pro Ile Ile Ser Val Val Leu Thr Ala His Glu
                  195 200 205
          Ala Ile Pro Gly Ala Thr Lys Ile Val Pro Val Glu Ala Gly Pro Pro
              210 215 220
          Glu Thr Gly Ala Thr Asn Ser Glu Thr Thr Ser Ala Asp Leu Val Pro
          225 230 235 240
          Arg Arg Gly Tyr Gln Glu Tyr Ala Ile Gln Gln Thr Pro Tyr Glu Gln
                          245 250 255
          Pro Met Lys Ser Ser Arg Leu Gly Pro Thr Gln Leu Lys Ile Phe Thr
                      260 265 270
          Cys Glu Tyr Cys Asn Lys Val Phe Lys Phe Lys His Ser Leu Gln Ala
                  275 280 285
          His Leu Arg Ile His Thr Asn Glu Lys Pro Tyr Lys Cys Pro Gln Cys
              290 295 300
          Ser Tyr Ala Ser Ala Ile Lys Ala Asn Leu Asn Val His Leu Arg Lys
          305 310 315 320
          His Thr Gly Glu Lys Phe Ala Cys Asp Tyr Cys Ser Phe Thr Cys Leu
                          325 330 335
          Ser Lys Gly His Leu Lys Val His Ile Glu Arg Val His Lys Lys Ile
                      340 345 350
          Lys Gln His Cys Arg Phe Cys Lys Lys Lys Tyr Ser Asp Val Lys Asn
                  355 360 365
          Leu Ile Lys His Ile Arg Asp Ala His Asp Pro Gln Asp Lys Lys Val
              370 375 380
          Lys Glu Ala Leu Asp Glu Leu Cys Leu Met Thr Arg Glu Gly Lys Arg
          385 390 395 400
          Gln Leu Leu Tyr Asp Cys His Ile Cys Glu Arg Lys Phe Lys Asn Glu
                          405 410 415
          Leu Asp Arg Asp Arg His Met Leu Val His Gly Asp Lys Trp Pro Phe
                      420 425 430
          Ala Cys Glu Leu Cys Gly His Gly Ala Thr Lys Tyr Gln Ala Leu Glu
                  435 440 445
          Leu His Val Arg Lys His Pro Phe Val Tyr Val Cys Ala Val Cys Arg
              450 455 460
          Lys Lys Phe Val Ser Ser Ile Arg Leu Arg Thr His Ile Lys Glu Val
          465 470 475 480
          His Gly Ala Ala Gln Glu Ala Leu Val Phe Thr Ser Ser Ile Asn Gln
                          485 490 495
          Ser Phe Cys Leu Leu Glu Pro Gly Gly Asp Ile Gln Gln Glu Ala Leu
                      500 505 510
          Gly Asp Gln Leu Gln Leu Val Glu Glu Glu Phe Ala Leu Gln Gly Val
                  515 520 525
          Asn Ala Leu Lys Glu Glu Ala Cys Pro Gly Asp Thr Gln Leu Glu Glu
              530 535 540
          Gly Arg Lys Glu Pro Glu Ala Pro Gly Glu Met Pro Ala Pro Ala Val
          545 550 555 560
          His Leu Ala Ser Pro Gln Ala Glu Ser Thr Ala Leu Pro Pro Cys Glu
                          565 570 575
          Leu Glu Thr Thr Val Val Ser Ser Ser Asp Leu His Ser Gln Glu Val
                      580 585 590
          Val Ser Asp Asp Phe Leu Leu Lys Asn Asp Thr Ser Ser Ala Glu Ala
                  595 600 605
          His Ala Ala Pro Glu Lys Pro Pro Asp Met Gln His Arg Ser Ser Val
              610 615 620
          Gln Thr Gln Gly Glu Val Ile Thr Leu Leu Leu Ser Lys Ala Gln Ser
          625 630 635 640
          Ala Gly Ser Asp Gln Glu Ser His Gly Ala Gln Ser Pro Leu Gly Glu
                          645 650 655
          Gly Gln Asn Met Ala Val Leu Ser Ala Gly Asp Pro Asp Pro Ser Arg
                      660 665 670
          Cys Leu Arg Ser Asn Pro Ala Glu Ala Ser Asp Leu Leu Pro Pro Val
                  675 680 685
          Ala Gly Gly Gly Asp Thr Ile Thr His Gln Pro Asp Ser Cys Lys Ala
              690 695 700
          Ala Pro Glu His Arg Ser Gly Ile Thr Ala Phe Met Lys Val Leu Asn
          705 710 715 720
          Ser Leu Gln Lys Lys Gln Met Asn Thr Ser Leu Cys Glu Arg Ile Arg
                          725 730 735
          Lys Val Tyr Gly Asp Leu Glu Cys Glu Tyr Cys Gly Lys Leu Phe Trp
                      740 745 750
          Tyr Gln Val His Phe Asp Met His Val Arg Thr His Thr Arg Glu His
                  755 760 765
          Leu Tyr Tyr Cys Ser Gln Cys His Tyr Ser Ser Ile Thr Lys Asn Cys
              770 775 780
          Leu Lys Arg His Val Ile Gln Lys His Ser Asn Ile Leu Leu Lys Cys
          785 790 795 800
          Pro Thr Asp Gly Cys Asp Tyr Ser Thr Pro Asp Lys Tyr Lys Leu Gln
                          805 810 815
          Ala His Leu Lys Val His Thr Ala Leu Asp Lys Arg Ser Tyr Ser Cys
                      820 825 830
          Pro Val Cys Glu Lys Ser Phe Ser Glu Asp Arg Leu Ile Lys Ser His
                  835 840 845
          Ile Lys Thr Asn His Pro Glu Val Ser Met Ser Thr Ile Ser Glu Val
              850 855 860
          Leu Gly Arg Arg Val Gln Leu Lys Gly Leu Ile Gly Lys Arg Ala Met
          865 870 875 880
          Lys Cys Pro Tyr Cys Asp Phe Tyr Phe Met Lys Asn Gly Ser Asp Leu
                          885 890 895
          Gln Arg His Ile Trp Ala His Glu Gly Val Lys Pro Phe Lys Cys Ser
                      900 905 910
          Leu Cys Glu Tyr Ala Thr Arg Ser Lys Ser Asn Leu Lys Ala His Met
                  915 920 925
          Asn Arg His Ser Thr Glu Lys Thr His Leu Cys Asp Met Cys Gly Lys
              930 935 940
          Lys Phe Lys Ser Lys Gly Thr Leu Lys Ser His Lys Leu Leu His Thr
          945 950 955 960
          Ala Asp Gly Lys Gln Phe Lys Cys Thr Val Cys Asp Tyr Thr Ala Ala
                          965 970 975
          Gln Lys Pro Gln Leu Leu Arg His Met Glu Gln His Val Ser Phe Lys
                      980 985 990
          Pro Phe Arg Cys Ala His Cys His Tyr Ser Cys Asn Ile Ser Gly Ser
                  995 1000 1005
          Leu Lys Arg His Tyr Asn Arg Lys His Pro Asn Glu Glu Tyr Ala
              1010 1015 1020
          Asn Val Gly Thr Gly Glu Leu Ala Ala Glu Val Leu Ile Gln Gln
              1025 1030 1035
          Gly Gly Leu Lys Cys Pro Val Cys Ser Phe Val Tyr Gly Thr Lys
              1040 1045 1050
          Trp Glu Phe Asn Arg His Leu Lys Asn Lys His Gly Leu Lys Val
              1055 1060 1065
          Val Glu Ile Asp Gly Asp Pro Lys Trp Glu Thr Ala Thr Glu Ala
              1070 1075 1080
          Pro Glu Glu Pro Ser Thr Gln Tyr Leu His Ile Thr Glu Ala Glu
              1085 1090 1095
          Glu Asp Val Gln Gly Thr Gln Ala Ala Val Ala Ala Leu Gln Asp
              1100 1105 1110
          Leu Arg Tyr Thr Ser Glu Ser Gly Asp Arg Leu Asp Pro Thr Ala
              1115 1120 1125
          Val Asn Ile Leu Gln Gln Ile Ile Glu Leu Gly Ala Glu Thr His
              1130 1135 1140
          Asp Ala Thr Ala Leu Ala Ser Val Val Ala Met Ala Pro Gly Thr
              1145 1150 1155
          Val Thr Val Val Lys Gln Val Thr Glu Glu Glu Pro Ser Ser Asn
              1160 1165 1170
          His Thr Val Met Ile Gln Glu Thr Val Gln Gln Ala Ser Val Glu
              1175 1180 1185
          Leu Ala Glu Gln His His Leu Val Val Ser Ser Asp Asp Val Glu
              1190 1195 1200
          Gly Ile Glu Thr Val Thr Val Tyr Thr Gln Gly Gly Glu Ala Ser
              1205 1210 1215
          Glu Phe Ile Val Tyr Val Gln Glu Ala Met Gln Pro Val Glu Glu
              1220 1225 1230
          Gln Ala Val Glu Gln Pro Ala Gln Glu Leu
              1235 1240
           <![CDATA[ <210> 864]]>
           <![CDATA[ <211> 3283]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 864]]>
          atccgccatg ttggatgccg cagattcgcc ataacctcgc cggctctttt cttaaaaaaa 60
          taaaaataaa aagcgaagcg tcagcagggc gccccgcccc ctcggtcggc acgggagggg 120
          gcccggaaga gcccgaggct tttttttcct ccgcggtggg gcgttgccat ggagacgcgg 180
          gcggcagaaa acacggccat ctttatgtgt aaatgttgta acctcttctc accaaatcag 240
          tcggaactcc tctcccacgt ttcagagaag cacatggaag aaggggttaa tgttgatgag 300
          attattattc cccttaggcc tctgagtaca cctgaaccccc ccaactcaag caaaaccgga 360
          gatgagtttt tggtcatgaa gaggaagaga ggcaggccta aggggtccac gaagaagtcc 420
          agcacagaag aggagctggc agaaaacatc gtgagtccga ctgaggacag cccgctggct 480
          ccggaggaag ggaacagcct gcctccaagc agcttggagt gtagcaagtg ctgtcggaag 540
          ttctccaaca cgcgccagct gcggaagcac atctgcatta tcgtgctgaa tttgggtgag 600
          gaggaaggag aagcaggtaa cgagtctgac cttgaactag aaaagaagtg taaggaagat 660
          gatcgggaaa aagcctcgaa aagaccacgg tcacagaaaa cagagaaagt ccagaagatc 720
          tcaggaaagg aggccagaca gctttctggg gcgaagaaac ccatcataag tgtggtttta 780
          actgcacacg aagcaattcc aggtgctacc aagattgtgc cagtggaggc tgggccccct 840
          gaaacaggag ctacaaattc tgagaccact tcagcagacc tggtgcctcg gagaggctac 900
          caggaatacg ccattcagca gacaccttat gagcaaccaa tgaagtcaag caggctaggt 960
          cccactcagc tcaaaatctt cacttgtgaa tactgcaaca aggtcttcaa gttcaagcac 1020
          tcgctgcagg cccacctgag gatccacacc aatgaaaagc catacaagtg cccccagtgc 1080
          agctatgcca gtgccatcaa ggccaacctc aatgtgcacc tgcgcaagca cactggagag 1140
          aagttcgcct gcgactattg ctcgttcacc tgcctgagca agggccacct caaggtgcac 1200
          atcgagcgag tgcacaagaa gatcaagcag cactgccgct tctgcaagaa gaagtactct 1260
          gacgtcaaga acctcatcaa gcacatccga gacgcgcatg accccacagga caagaaggtc 1320
          aaagaggcct tggacgagct ctgcctgatg acgagggagg gcaagcggca gctgctctat 1380
          gactgccaca tctgtgagcg caagttcaag aacgagctgg accgtgaccg ccatatgctg 1440
          gtccacggag acaagtggcc ttttgcctgt gagctctgtg gccatggggc caccaagtac 1500
          caggcgctgg aactgcatgt caggaagcac cccttcgtgt acgtctgtgc cgtctgccgc 1560
          aagaagttcg tcagctccat caggctgcgc acccacatca aagaggtgca cggggctgcc 1620
          caggaggcct tggtcttcac cagttccatc aaccagagct tctgcctcct ggaacctggt 1680
          ggggacatcc agcaagaagc tctgggggac cagctacagc tggtggaaga ggagtttgcc 1740
          ctccagggcg tgaatgcact caaggaagag gcctgtcctg gggacactca gctggaggag 1800
          ggccggaagg agccggaggc ccctggggaa atgcctgccc cagctgtgca cctggcctcc 1860
          ccgcaggccg aaagcacagc cctgccaccc tgtgagctgg aaaccaccgt ggtctcctcc 1920
          tcagacctgc attctcaaga ggtggtttca gatgattttttgttgaaaaa tgatacctcc 1980
          tccgcagagg ctcatgctgc tcctgagaag cccccagaca tgcagcacag aagctcagtc 2040
          cagacgcaag gtgaagtgat cacactactg ctgtccaagg cccagagtgc tgggtcagat 2100
          caggaaagcc atggcgccca gagcccccta ggggaagggc agaacatggc tgtgctttca 2160
          gctggtgacc cagatccccag caggtgtctc aggtcaaacc cagctgaggc ctcagacctc 2220
          ctccctccag tagctggtgg tggggacacc atcacacatc agcctgactc ttgcaaagct 2280
          gcccctgagc accggtcagg catcaccgct ttcatgaagg tcctgaacag tttacagaag 2340
          aagcaaatga acaccagctt gtgtgagcgg atccggaagg tttatggaga cctggagtgt 2400
          gaatactgtg gcaaactttt ttggtaccaa gtgcattttg atatgcatgt ccgcacccac 2460
          acccgggaac atctgtatta ttgctctcag tgtcattatt cttccatcac caaaaactgc 2520
          cttaaacgcc acgtaattca gaaacacagt aacatcttgc tgaagtgtcc caccgatggc 2580
          tgtgactact caactccaga taaatataag ctacaggcac atcttaaagt tcacacagca 2640
          ctggacaaaa ggagttattc ttgtcctgtt tgtgaaaagt ctttttcaga ggatcgattg 2700
          ataaagtcac atatcaagac caaccatcct gaggtctcca tgagcaccat ttctgaggtt 2760
          ctcgggagga gggttcagct gaaagggcta attggaaaga gagccatgaa atgcccatat 2820
          tgtgactttt atttcatgaa gaatggctca gaccttcagc gtcatatttg ggctcatgaa 2880
          ggtgtgaagc ccttcaagtg ttctttgtgtgagtatgcaa ctcgtagcaa gagtaacctc 2940
          aaggctcata tgaatcgtca cagcactgag aaaacccacc tatgtgacat gtgtggcaag 3000
          aaattcaaat caaaagggac actgaaaagt cacaaactcc ttcacactgc agatgggaag 3060
          cagtttaagt gcacggtgtg tgactacaca gcggcccaga agccacagct gctgcggcac 3120
          atggaacagc atgtctcctt caagcctttc cgctgtgccc attgccatta ctcctgcaac 3180
          atatctggct ctctgaagcg gcactacaac aggaagcacc ctaatgagga gtatgccaac 3240
          gtgggcaccg gggagctggc agcggaggtg ctcatccagc aag 3283
           <![CDATA[ <210> 865]]>
           <![CDATA[ <211> 1038]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 865]]>
          Met Glu Thr Arg Ala Ala Glu Asn Thr Ala Ile Phe Met Cys Lys Cys
          1 5 10 15
          Cys Asn Leu Phe Ser Pro Asn Gln Ser Glu Leu Leu Ser His Val Ser
                      20 25 30
          Glu Lys His Met Glu Glu Gly Val Asn Val Asp Glu Ile Ile Ile Pro
                  35 40 45
          Leu Arg Pro Leu Ser Thr Pro Glu Pro Pro Asn Ser Ser Lys Thr Gly
              50 55 60
          Asp Glu Phe Leu Val Met Lys Arg Lys Arg Gly Arg Pro Lys Gly Ser
          65 70 75 80
          Thr Lys Lys Ser Ser Thr Glu Glu Glu Leu Ala Glu Asn Ile Val Ser
                          85 90 95
          Pro Thr Glu Asp Ser Pro Leu Ala Pro Glu Glu Gly Asn Ser Leu Pro
                      100 105 110
          Pro Ser Ser Leu Glu Cys Ser Lys Cys Cys Arg Lys Phe Ser Asn Thr
                  115 120 125
          Arg Gln Leu Arg Lys His Ile Cys Ile Ile Val Leu Asn Leu Gly Glu
              130 135 140
          Glu Glu Gly Glu Ala Gly Asn Glu Ser Asp Leu Glu Leu Glu Lys Lys
          145 150 155 160
          Cys Lys Glu Asp Asp Arg Glu Lys Ala Ser Lys Arg Pro Arg Ser Gln
                          165 170 175
          Lys Thr Glu Lys Val Gln Lys Ile Ser Gly Lys Glu Ala Arg Gln Leu
                      180 185 190
          Ser Gly Ala Lys Lys Pro Ile Ile Ser Val Val Leu Thr Ala His Glu
                  195 200 205
          Ala Ile Pro Gly Ala Thr Lys Ile Val Pro Val Glu Ala Gly Pro Pro
              210 215 220
          Glu Thr Gly Ala Thr Asn Ser Glu Thr Thr Ser Ala Asp Leu Val Pro
          225 230 235 240
          Arg Arg Gly Tyr Gln Glu Tyr Ala Ile Gln Gln Thr Pro Tyr Glu Gln
                          245 250 255
          Pro Met Lys Ser Ser Arg Leu Gly Pro Thr Gln Leu Lys Ile Phe Thr
                      260 265 270
          Cys Glu Tyr Cys Asn Lys Val Phe Lys Phe Lys His Ser Leu Gln Ala
                  275 280 285
          His Leu Arg Ile His Thr Asn Glu Lys Pro Tyr Lys Cys Pro Gln Cys
              290 295 300
          Ser Tyr Ala Ser Ala Ile Lys Ala Asn Leu Asn Val His Leu Arg Lys
          305 310 315 320
          His Thr Gly Glu Lys Phe Ala Cys Asp Tyr Cys Ser Phe Thr Cys Leu
                          325 330 335
          Ser Lys Gly His Leu Lys Val His Ile Glu Arg Val His Lys Lys Ile
                      340 345 350
          Lys Gln His Cys Arg Phe Cys Lys Lys Lys Tyr Ser Asp Val Lys Asn
                  355 360 365
          Leu Ile Lys His Ile Arg Asp Ala His Asp Pro Gln Asp Lys Lys Val
              370 375 380
          Lys Glu Ala Leu Asp Glu Leu Cys Leu Met Thr Arg Glu Gly Lys Arg
          385 390 395 400
          Gln Leu Leu Tyr Asp Cys His Ile Cys Glu Arg Lys Phe Lys Asn Glu
                          405 410 415
          Leu Asp Arg Asp Arg His Met Leu Val His Gly Asp Lys Trp Pro Phe
                      420 425 430
          Ala Cys Glu Leu Cys Gly His Gly Ala Thr Lys Tyr Gln Ala Leu Glu
                  435 440 445
          Leu His Val Arg Lys His Pro Phe Val Tyr Val Cys Ala Val Cys Arg
              450 455 460
          Lys Lys Phe Val Ser Ser Ile Arg Leu Arg Thr His Ile Lys Glu Val
          465 470 475 480
          His Gly Ala Ala Gln Glu Ala Leu Val Phe Thr Ser Ser Ile Asn Gln
                          485 490 495
          Ser Phe Cys Leu Leu Glu Pro Gly Gly Asp Ile Gln Gln Glu Ala Leu
                      500 505 510
          Gly Asp Gln Leu Gln Leu Val Glu Glu Glu Phe Ala Leu Gln Gly Val
                  515 520 525
          Asn Ala Leu Lys Glu Glu Ala Cys Pro Gly Asp Thr Gln Leu Glu Glu
              530 535 540
          Gly Arg Lys Glu Pro Glu Ala Pro Gly Glu Met Pro Ala Pro Ala Val
          545 550 555 560
          His Leu Ala Ser Pro Gln Ala Glu Ser Thr Ala Leu Pro Pro Cys Glu
                          565 570 575
          Leu Glu Thr Thr Val Val Ser Ser Ser Asp Leu His Ser Gln Glu Val
                      580 585 590
          Val Ser Asp Asp Phe Leu Leu Lys Asn Asp Thr Ser Ser Ala Glu Ala
                  595 600 605
          His Ala Ala Pro Glu Lys Pro Pro Asp Met Gln His Arg Ser Ser Val
              610 615 620
          Gln Thr Gln Gly Glu Val Ile Thr Leu Leu Leu Ser Lys Ala Gln Ser
          625 630 635 640
          Ala Gly Ser Asp Gln Glu Ser His Gly Ala Gln Ser Pro Leu Gly Glu
                          645 650 655
          Gly Gln Asn Met Ala Val Leu Ser Ala Gly Asp Pro Asp Pro Ser Arg
                      660 665 670
          Cys Leu Arg Ser Asn Pro Ala Glu Ala Ser Asp Leu Leu Pro Pro Val
                  675 680 685
          Ala Gly Gly Gly Asp Thr Ile Thr His Gln Pro Asp Ser Cys Lys Ala
              690 695 700
          Ala Pro Glu His Arg Ser Gly Ile Thr Ala Phe Met Lys Val Leu Asn
          705 710 715 720
          Ser Leu Gln Lys Lys Gln Met Asn Thr Ser Leu Cys Glu Arg Ile Arg
                          725 730 735
          Lys Val Tyr Gly Asp Leu Glu Cys Glu Tyr Cys Gly Lys Leu Phe Trp
                      740 745 750
          Tyr Gln Val His Phe Asp Met His Val Arg Thr His Thr Arg Glu His
                  755 760 765
          Leu Tyr Tyr Cys Ser Gln Cys His Tyr Ser Ser Ile Thr Lys Asn Cys
              770 775 780
          Leu Lys Arg His Val Ile Gln Lys His Ser Asn Ile Leu Leu Lys Cys
          785 790 795 800
          Pro Thr Asp Gly Cys Asp Tyr Ser Thr Pro Asp Lys Tyr Lys Leu Gln
                          805 810 815
          Ala His Leu Lys Val His Thr Ala Leu Asp Lys Arg Ser Tyr Ser Cys
                      820 825 830
          Pro Val Cys Glu Lys Ser Phe Ser Glu Asp Arg Leu Ile Lys Ser His
                  835 840 845
          Ile Lys Thr Asn His Pro Glu Val Ser Met Ser Thr Ile Ser Glu Val
              850 855 860
          Leu Gly Arg Arg Val Gln Leu Lys Gly Leu Ile Gly Lys Arg Ala Met
          865 870 875 880
          Lys Cys Pro Tyr Cys Asp Phe Tyr Phe Met Lys Asn Gly Ser Asp Leu
                          885 890 895
          Gln Arg His Ile Trp Ala His Glu Gly Val Lys Pro Phe Lys Cys Ser
                      900 905 910
          Leu Cys Glu Tyr Ala Thr Arg Ser Lys Ser Asn Leu Lys Ala His Met
                  915 920 925
          Asn Arg His Ser Thr Glu Lys Thr His Leu Cys Asp Met Cys Gly Lys
              930 935 940
          Lys Phe Lys Ser Lys Gly Thr Leu Lys Ser His Lys Leu Leu His Thr
          945 950 955 960
          Ala Asp Gly Lys Gln Phe Lys Cys Thr Val Cys Asp Tyr Thr Ala Ala
                          965 970 975
          Gln Lys Pro Gln Leu Leu Arg His Met Glu Gln His Val Ser Phe Lys
                      980 985 990
          Pro Phe Arg Cys Ala His Cys His Tyr Ser Cys Asn Ile Ser Gly Ser
                  995 1000 1005
          Leu Lys Arg His Tyr Asn Arg Lys His Pro Asn Glu Glu Tyr Ala
              1010 1015 1020
          Asn Val Gly Thr Gly Glu Leu Ala Ala Glu Val Leu Ile Gln Gln
              1025 1030 1035
           <![CDATA[ <210> 866]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 866]]>
          gcctcatccc ctcttcagtg caggaatatg ttagcgttgt atcttgggag aaagacacag 60
          tctccatcat cccag 75
           <![CDATA[ <210> 867]]>
           <![CDATA[ <211> 75]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 867]]>
          ccttgcctcc ccgattgaaa gagatgaaaa gccaggaatc ggctgcaggt tccaaactag 60
          tccttcggtg tgaaa 75
           <![CDATA[ <210> 868]]>
           <![CDATA[ <211> 150]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 868]]>
          gcctcatccc ctcttcagtg caggaatatg ttagcgttgt atcttgggag aaagacacag 60
          tctccatcat cccagccttg cctccccgat tgaaagagat gaaaagccag gaatcggctg 120
          caggttccaa actagtcctt cggtgtgaaa 150
           <![CDATA[ <210> 869]]>
           <![CDATA[ <211> 49]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 869]]>
          Leu Ile Pro Ser Ser Val Gln Glu Tyr Val Ser Val Val Ser Trp Glu
          1 5 10 15
          Lys Asp Thr Val Ser Ile Ile Pro Ala Leu Pro Pro Arg Leu Lys Glu
                      20 25 30
          Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys
                  35 40 45
          Glu
           <![CDATA[ <210> 870]]>
           <![CDATA[ <211> 183]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 870]]>
          agccgagcgc tgggctgagg agcagagaga gcggggcgcc gagtgcgggc ggctgggagc 60
          gcgctgagcg ggggagaggc gctgccgcac ggccggccac aggacccacct ccccggagaa 120
          tagggcctct ttatggcatg tggctggtaa ctttcctcct gctcctggac tctttacaca 180
          aag 183
           <![CDATA[ <210> 871]]>
           <![CDATA[ <211> 318]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 871]]>
          cccgccctga agatgttggc accagcctct actttgtaaa tgactccttg cagcaggtga 60
          ccttttccag ctccgtgggg gtggtggtgc cctgcccggc cgcgggctcc cccagcgcgg 120
          cccttcgatg gtacctggcc acaggggacg acatctacga cgtgccgcac atccggcacg 180
          tccacgccaa cgggacgctg cagctctacc ccttctcccc ctccgccttc aatagcttta 240
          tccacgacaa tgactacttc tgcaccgcgg agaacgctgc cggcaagatc cggagcccca 300
          acatccgcgt caaagcag 318
           <![CDATA[ <210> 872]]>
           <![CDATA[ <211> 147]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 872]]>
          ttttcaggga accttacacc gtccgggtgg aggatcaaag gtcaatgcgt ggcaacgtgg 60
          ccgtcttcaa gtgcctcatc ccctcttcag tgcaggaata tgttagcgtt gtatcttggg 120
          agaaagacac agtctccatc atcccag 147
           <![CDATA[ <210> 873]]>
           <![CDATA[ <211> 147]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 873]]>
          aacacaggtt ttttattacc taccacggcg ggctgtacat ctctgacgta cagaaggagg 60
          acgccctctc cacctatcgc tgcatcacca agcacaagta tagcggggag acccggcaga 120
          gcaatggggc acgcctctct gtgacag 147
           <![CDATA[ <210> 874]]>
           <![CDATA[ <211> 279]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 874]]>
          accctgctga gtcgatcccc accatcctgg atggcttcca ctcccaggaa gtgtgggccg 60
          gccacaccgt ggagctgccc tgcaccgcct cgggctaccc tatccccgcc atccgctggc 120
          tcaaggatgg ccggcccctc ccggctgaca gccgctggac caagcgcatc acagggctga 180
          ccatcagcga cttgcggacc gaggacagcg gcacctacat ttgtgaggtc accaacacct 240
          tcggttcggc agaggccaca ggcatcctca tggtcattg 279
           <![CDATA[ <210> 875]]>
           <![CDATA[ <211> 276]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 875]]>
          atccccttca tgtgaccctg acaccaaaga agctgaagac cggcattggc agcacggtca 60
          tcctctcctg tgccctgacg ggctccccag agttcaccat ccgctggtat cgcaacacgg 120
          agctggtgct gcctgacgag gccatctcca tccgcgggct cagcaacgag acgctgctca 180
          tcacctcggc ccagaagagc cattccgggg cctaccagtg cttcgctacc cgcaaggccc 240
          agaccgccca ggactttgcc atcattgcac ttgagg 276
           <![CDATA[ <210> 876]]>
           <![CDATA[ <211> 297]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 876]]>
          atggcacgcc ccgcatcgtc tcgtccttca gcgagaaggt ggtcaaccccc ggggagcagt 60
          tctcactgat gtgtgcggcc aagggcgccc cgccccccac ggtcacctgg gccctcgacg 120
          atgagcccat cgtgcgggat ggcagccacc gcaccaacca gtacaccatg tcggacggca 180
          ccaccatcag ccacatgaac gtcacaggcc cccagatccg cgacgggggc gtgtaccggt 240
          gcacagcgcg gaacttggtg ggcagtgctg aatatcaggc gcgaataaac gtaagag 297
           <![CDATA[ <210> 877]]>
           <![CDATA[ <211> 273]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 877]]>
          gcccacccag catccgggct atgcggaaca tcacagcagt cgccgggcgg gacaccctta 60
          tcaactgcag ggtcatcggc tatccctact actccatcaa gtggtacaag gatgccctgc 120
          tgctgccaga caaccaccgc caggtggtgt ttgagaatgg gaccctcaag ctgactgacg 180
          tgcagaaggg catggatgag ggggagtacc tgtgcagtgt cctcatccag ccccagctct 240
          ccatcagcca gagcgttcac gtagccgtca aag 273
           <![CDATA[ <210> 878]]>
           <![CDATA[ <211> 279]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 878]]>
          tgccccctct gatccagccc ttcgaattcc cacccgcctc catcggccag ctgctctaca 60
          ttccctgtgt ggtgtcctcg ggggacatgc ccatccgtat cacctggagg aaggacggac 120
          aggtgatcat ctcaggctcg ggcgtgacca tcgagagcaa ggaattcatg agctccctgc 180
          agatctctag cgtctccctc aagcacaacg gcaactatac atgcatcgcc agcaacgcag 240
          ccgccaccgt gagccggggag cgccagctca tcgtgcgtg 279
           <![CDATA[ <210> 879]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 879]]>
          tgccccctcg atttgtggtg caacccaaca accaggatgg catctacggc aaagctggtg 60
          tgctcaactg ctcggtggac ggctaccccc cacccaaggt catgtggaag catgccaagg 120
           <![CDATA[ <210> 880]]>
           <![CDATA[ <211> 177]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 880]]>
          ggagcgggaa cccccagcag taccaccctg tgcccctcac tggccgcatc cagatcctgc 60
          ccaacagctc gctgctgatc cgccacgtcc tagaagagga catcggctac tacctctgcc 120
          aggccagcaa cggcgtaggc accgacatca gcaagtccat gttcctcaca gtcaaga 177
           <![CDATA[ <210> 881]]>
           <![CDATA[ <211> 200]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 881]]>
          tcccggccat gatcacttcc caccccaaca ccaccatcgc catcaagggc catgcgaagg 60
          agctaaactg cacggcacgg ggtgagcggc ccatcatcat ccgctggggag aagggggaca 120
          cagtcatcga ccctgaccgc gtcatgcggt atgccatcgc caccaaggac aacggcgacg 180
          aggtcgtctc cacactgaag 200
           <![CDATA[ <210> 882]]>
           <![CDATA[ <211> 97]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 882]]>
          ctcaagcccg ctgaccgtgg ggactctgtg ttcttcagct gccatgccat caactcgtat 60
          ggggaggacc ggggcttgat ccaactcact gtgcaag 97
           <![CDATA[ <210> 883]]>
           <![CDATA[ <211> 129]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 883]]>
          agccccccga ccccccagag ctggagatcc gggaggtgaa ggcccggagc atgaacctgc 60
          gctggaccca gcgattcgac gggaacagca tcatcacggg cttcgacatt gaatacaaga 120
          acaaatcag 129
           <![CDATA[ <210> 884]]>
           <![CDATA[ <211> 168]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 884]]>
          attcctggga cttcaagcag tccaacacgca acatctcccc caccatcaac caggccaaca 60
          ttgtggactt gcacccggca tctgtgtaca gcatccgcat gtactctttc aacaagattg 120
          gccgcagtga accaagcaag gagctcacca tcagcactga ggaggccg 168
           <![CDATA[ <210> 885]]>
           <![CDATA[ <211> 71]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 885]]>
          ctcccgatgg gccccccatg gatgttacct tgcagccagt gacctcacag agcatccagg 60
          tgacctggaa g 71
           <![CDATA[ <210> 886]]>
           <![CDATA[ <211> 241]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 886]]>
          gcacccaaga aggagctgca gaacggtgtc atccggggct accagattgg ctacagagag 60
          aacagccccg gcagcaacgg gcagtacagc atcgtggaga tgaaggccac gggggacagc 120
          gaggtctaca ccctggacaa cctcaagaag ttcgcccagt atggggtggt ggtccaagcc 180
          ttcaatcggg ctggcacggg gccctcttcc agcgagatca atgccaccac tctggaggat 240
          g 241
           <![CDATA[ <210> 887]]>
           <![CDATA[ <211> 147]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 887]]>
          tgcccagcca gccccctgag aacgtccggg ccctgtccat cacttctgac gtggccgtca 60
          tctcctggtc agagcccccg cgcagcaccc tcaatggcgt cctcaaaggc tatcgggtca 120
          tcttctggtc cctctatgtt gatgggg 147
           <![CDATA[ <210> 888]]>
           <![CDATA[ <211> 156]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 888]]>
          agtggggcga gatgcagaac atcaccacca cgcgggagcg ggtggagctg cggggcatgg 60
          agaagttcac caactacagc gtccaggtgc tggcctacac ccaggctggg gacggcgtac 120
          gcagcagtgt gctctacatc cagaccaagg aggacg 156
           <![CDATA[ <210> 889]]>
           <![CDATA[ <211> 140]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 889]]>
          ttccaggtcc ccctgctggc atcaaagctg tcccttcatc agctagcagt gtggttgtgt 60
          cttggctccc ccctaccaag cccaacgggg tgatccgcaa gtacaccatc ttctgttcca 120
          gccccgggtc tggccagccg 140
           <![CDATA[ <210> 890]]>
           <![CDATA[ <211> 154]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 890]]>
          gctcccagcg agtacgagac gagtccagag cagctcttct accggatcgc ccacctaaac 60
          cgcggtcagc agtatctgct gtgggtggcc gccgtcacct ctgccggccg gggcaacagc 120
          agcgagaagg tgaccatcga gcctgctggc aagg 154
           <![CDATA[ <210> 891]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 891]]>
          ccccagcaaa gatcatctcc tttgggggca ccgtgacaac accttggatg aaagatgttc 60
          ggctgccttg caattcagtg ggagatccag cccctgctgt gaagtggacc aaggacag 118
           <![CDATA[ <210> 892]]>
           <![CDATA[ <211> 164]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 892]]>
          tgaagactcg gccattccag tgtccatgga tgggcaccgg ctcatccaca ccaatggcac 60
          actgctgctg cgtgcagtga aggctgagga ctctggctac tacacgtgca cggccaccaa 120
          cactggtggc tttgacacca tcatcgtcaa ccttctggtg caag 164
           <![CDATA[ <210> 893]]>
           <![CDATA[ <211> 99]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 893]]>
          ttcccccgga ccagccccgc ctcactgtct ccaaaacctc agcttcgtcc atcaccctga 60
          cctggattcc aggtgacaat gggggcagct ccatccgag 99
           <![CDATA[ <210> 894]]>
           <![CDATA[ <211> 189]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 894]]>
          gcttcgtgct acagtactcg gtggacaaca gcgaggagtg gaaggatgtg ttcatcagct 60
          ccagcgagcg ctccttcaag ctggacagcc tcaagtgtgg cacgtggtac aaggtgaagc 120
          tggcagccaa gaacagcgtg ggctctgggc gcatcagcga gatcatcgag gccaagaccc 180
          acggggcggg 189
           <![CDATA[ <210> 895]]>
           <![CDATA[ <211> 288]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 895]]>
          agccctcctt cagcaaagac caacacctct tcacccacat caactccacg catgctcggc 60
          ttaacctgca gggctggaac aatgggggct gccctatcac agccatcgtt ctggagtacc 120
          ggcccaaggg gacctgggcc tggcagggcc tccgggccaa cagctccggg gaggtgtttc 180
          tgacggaact gcgagaggcc acgtggtacg agctgcgcat gagggcttgc aacagtgcgg 240
          gctgcggcaa tgaaacagcc cagttcgcca ccctggacta cgatggca 288
           <![CDATA[ <210> 896]]>
           <![CDATA[ <211> 156]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 896]]>
          gcaccattcc acccatcaag tctgctcaag gtgaagggga tgatgtgaag aagctgttca 60
          ccatcggctg ccctgtcatc ctggccaacac tgggggtggc actgctcttc atcgtacgca 120
          agaagaggaa ggagaaacgg ctgaagcgac tccgag 156
           <![CDATA[ <210> 897]]>
           <![CDATA[ <211> 31]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 897]]>
          atgcaaagag tttggcagaa atgttgataa g 31
           <![CDATA[ <210> 898]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 898]]>
          caagaacaat agaagctttg aacccctgt gaaagggcca ccccagggcc cacggctaca 60
          cattgacatc cccagggtcc agctgctcat cgaggacaaa gaaggcatca agcaactgg 119
           <![CDATA[ <210> 899]]>
           <![CDATA[ <211> 153]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 899]]>
          gagatgacaa ggccaccatc cctgtgacag atgctgagtt cagccaagct gtcaacccac 60
          agagcttctg tactggcgtc tccttgcacc acccaaccct catccagagc acaggaccccc 120
          tcatcgacat gtctgacatc cggccaggaa cca 153
           <![CDATA[ <210> 900]]>
           <![CDATA[ <211> 195]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 900]]>
          atccagtgtc caggaagaat gtgaagtcag cccacagcac ccggaaccgg tactcaagcc 60
          agtggaccct gaccaagtgc caggcctcca cacctgcccg caccctcacc tccgactggc 120
          gcaccgtggg ctcccagcat ggtgtcacgg tcactgagag tgacagctac agtgccagcc 180
          tgtcccagga cacag 195
           <![CDATA[ <210> 901]]>
           <![CDATA[ <211> 312]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 901]]>
          acaaaggaag gaacagcatg gtgtccactg agagtgcctc ttccacctac gaggagctgg 60
          cccgggccta tgagcatgcc aagctggagg agcagctgca gcacgccaag tttgagatca 120
          ccgagtgctt catctctgac agttcctctg accagatgac cacaggcacc aacgagaacg 180
          ccgacagcat gacatccatg agcacaccct cagagcctgg catctgccgc tttaccgcct 240
          caccacccaa gccccaggat gcggaccggg gcaaaaacgt ggctgtgccc atccctcacc 300
          gggccaacaa ga 312
           <![CDATA[ <210> 902]]>
           <![CDATA[ <211> 1032]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 902]]>
          gtgactactg caacctgccc ctgtatgcca agtcagaggc cttctttcga aaggcagatg 60
          gacgtgagcc ctgccccgtg gtcccacccc gtgaggcctc catccggaac ctggctcgaa 120
          cctaccacac ccaggctcgc cacctgaccc tggaccctgc cagcaagtcc ttgggccttc 180
          cccacccagg ggcccccgct gccgcctcca cagccacctt acctcagagg actctggcca 240
          tgccagcccc cccagccggc acagcccccc cagcccccgg ccccacccct gctgagccac 300
          ccaccgcccc cagcgctgcc cctccggccc ccagcaccga gcctccacga gccgggggcc 360
          cacacaccaa aatggggggc tccagggact cgcttctcga gatgagcaca tcggggggtag 420
          ggaggtctca gaagcagggg gccggggcct actccaaatc ctacaccctg gtgtagggcc 480
          cgcaggaaga gcagccacgc ctggaccgcg ccgcgccgca gccccacacg ccagctcggc 540
          tgtttttctg catttattat attcaactga cagacaaaaa ccaaccaacg acaaaacaaa 600
          aacccccaat catgaacgcc tgtacataga actcttttgt acaaatgaaa ctattttctt 660
          cttctccatg aagccagggc acaaagaatt tgacagtaca agtcaaatcc cccaccccac 720
          aaaatatgtg tggagatata tatacatata tagacagaca ggaacgcgtc cacgagctat 780
          atatctatat atttctctca ccctattttg agacagaggc acaaagactc agcaattttt 840
          ttccctcctc ctcaccttcc ccccagtcta ggtggttttg acaaagacca aaatcccaac 900
          tcagagacac tgcatgcgat tttactgttc caagaaaacc aggagttgct tcaatttgca 960
          gatgcttatg tgttaatacc tttttctatg aaaaaagacc cagcgccgtg tgcaataaag 1020
          gttatgtttc ta 1032
           <![CDATA[ <210> 903]]>
           <![CDATA[ <211> 6855]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Full mRNA polynucleotide sequence of DSCAML1]]>
           <![CDATA[ <400> 903]]>
          agccgagcgc tgggctgagg agcagagaga gcggggcgcc gagtgcgggc ggctgggagc 60
          gcgctgagcg ggggagaggc gctgccgcac ggccggccac aggacccacct ccccggagaa 120
          tagggcctct ttatggcatg tggctggtaa ctttcctcct gctcctggac tctttacaca 180
          aagcccgccc tgaagatgtt ggcaccagcc tctactttgt aaatgactcc ttgcagcagg 240
          tgaccttttc cagctccgtgggggtggtgg tgccctgccc ggccgcgggc tcccccagcg 300
          cggcccttcg atggtacctg gccacagggg acgacatcta cgacgtgccg cacatccggc 360
          acgtccacgc caacgggacg ctgcagctct accccttctc cccctccgcc ttcaatagct 420
          ttatccacga caatgactac ttctgcaccg cggagaacgc tgccggcaag atccggagcc 480
          ccaacatccg cgtcaaagca gttttcaggg aaccctacac cgtccgggtg gaggatcaaa 540
          ggtcaatgcg tggcaacgtg gccgtcttca agtgcctcat cccctcttca gtgcaggaat 600
          atgttagcgt tgtatcttgg gagaaagaca cagtctccat catcccagaa cacaggtttt 660
          ttattaccta ccacggcggg ctgtacatct ctgacgtaca gaaggaggac gccctctcca 720
          cctatcgctg catcaccaag cacaagtata gcggggagac ccggcagagc aatggggcac 780
          gcctctctgt gacagaccct gctgagtcga tccccaccat cctggatggc ttccactccc 840
          aggaagtgtg ggccggccac accgtggagc tgccctgcac cgcctcgggc taccctatcc 900
          ccgccatccg ctggctcaag gatggccggc ccctcccggc tgacagccgc tggaccaagc 960
          gcatcacagg gctgaccatc agcgacttgc ggaccgagga cagcggcacc tacatttgtg 1020
          aggtcaccaa caccttcggt tcggcagagg ccacaggcat cctcatggtc attgatcccc 1080
          ttcatgtgac cctgacacca aagaagctga agaccggcat tggcagcacg gtcatcctct 1140
          cctgtgccct gacgggctcc ccagagttca ccatccgctg gtatcgcaac acggagctgg 1200
          tgctgcctga cgaggccatc tccatccgcg ggctcagcaa cgagacgctg ctcatcacct 1260
          cggcccagaa gagccattcc ggggcctacc agtgcttcgc tacccgcaag gcccagaccg 1320
          cccaggactt tgccatcatt gcacttgagg atggcacgcc ccgcatcgtc tcgtccttca 1380
          gcgagaaggt ggtcaaccccc ggggagcagt tctcactgat gtgtgcggcc aagggcgccc 1440
          cgccccccac ggtcacctgg gccctcgacg atgagcccat cgtgcgggat ggcagccacc 1500
          gcaccaacca gtacaccatg tcggacggca ccaccatcag ccacatgaac gtcacaggcc 1560
          cccagatccg cgacgggggc gtgtaccggt gcacagcgcg gaacttggtg ggcagtgctg 1620
          aatatcaggc gcgaataaac gtaagaggcc cacccagcat ccgggctatg cggaacatca 1680
          cagcagtcgc cgggcgggac acccttatca actgcagggt catcggctat ccctactact 1740
          ccatcaagtg gtacaaggat gccctgctgc tgccagacaa ccaccgccag gtggtgtttg 1800
          agaatgggac cctcaagctg actgacgtgc agaagggcat ggatgagggg gagtacctgt 1860
          gcagtgtcct catccagccc cagctctcca tcagccagag cgttcacgta gccgtcaaag 1920
          tgccccctct gatccagccc ttcgaattcc cacccgcctc catcggccag ctgctctaca 1980
          ttccctgtgt ggtgtcctcg ggggacatgc ccatccgtat cacctggagg aaggacggac 2040
          aggtgatcat ctcaggctcg ggcgtgacca tcgagagcaa ggaattcatg agctccctgc 2100
          agatctctag cgtctccctc aagcacaacg gcaactatac atgcatcgcc agcaacgcag 2160
          ccgccaccgt gagccggggag cgccagctca tcgtgcgtgt gccccctcga tttgtggtgc 2220
          aacccaacaa ccaggatggc atctacggca aagctggtgt gctcaactgc tcggtggacg 2280
          gctaccccccc acccaaggtc atgtggaagc atgccaaggg gagcgggaac ccccaagcagt 2340
          accacccctgt gcccctcact ggccgcatcc agatcctgcc caacagctcg ctgctgatcc 2400
          gccacgtcct agaagaggac atcggctact acctctgcca ggccagcaac ggcgtaggca 2460
          ccgacatcag caagtccatg ttcctcacag tcaagatccc ggccatgatc acttcccacc 2520
          ccaacacacac catcgccatc aagggccatg cgaaggagct aaactgcacg gcacggggtg 2580
          agcggcccat catcatccgc tgggagaagg gggacacagt catcgaccct gaccgcgtca 2640
          tgcggtatgc catcgccacc aaggacaacg gcgacgaggt cgtctccaca ctgaagctca 2700
          agcccgctga ccgtggggac tctgtgttct tcagctgcca tgccatcaac tcgtatgggg 2760
          aggaccgggg cttgatccaa ctcactgtgc aagagccccc cgacccccca gagctggaga 2820
          tccgggaggt gaaggcccgg agcatgaacc tgcgctggac ccagcgattc gacgggaaca 2880
          gcatcatcac gggcttcgac attgaataca agaacaaatc agattcctgg gacttcaagc 2940
          agtccacacg caacatctcc cccaccatca accaggccaa cattgtggac ttgcacccgg 3000
          catctgtgta cagcatccgc atgtactctt tcaacaagat tggccgcagt gaaccaagca 3060
          aggagctcac catcagcact gaggaggccg ctcccgatgg gccccccatg gatgttacct 3120
          tgcagccagt gacctcacag agcatccagg tgacctggaa ggcacccaag aaggagctgc 3180
          agaacggtgt catccggggc taccagattg gctacagaga gaacagcccc ggcagcaacg 3240
          ggcagtacag catcgtggag atgaaggcca cgggggacag cgaggtctac accctggaca 3300
          acctcaagaa gttcgcccag tatggggtgg tggtccaagc cttcaatcgg gctggcacgg 3360
          ggccctcttc cagcgagatc aatgccacca ctctggagga tgtgcccagc cagccccctg 3420
          agaacgtccg ggccctgtcc atcacttctg acgtggccgt catctcctgg tcagagcccc 3480
          cgcgcagcac cctcaatggc gtcctcaaag gctatcgggt catcttctgg tccctctatg 3540
          ttgatgggga gtggggcgag atgcagaaca tcaccaccac gcgggagcgg gtggagctgc 3600
          ggggcatgga gaagttcacc aactacagcg tccaggtgct ggcctacacc caggctgggg 3660
          acggcgtacg cagcagtgtg ctctacatcc agaccaagga ggacgttcca ggtccccctg 3720
          ctggcatcaa agctgtccct tcatcagcta gcagtgtggt tgtgtcttgg ctccccccta 3780
          ccaagcccaa cggggtgatc cgcaagtaca ccatcttctg ttccagcccc gggtctggcc 3840
          agccggctcc cagcgagtac gagacgagtc cagagcagct cttctaccgg atcgcccacc 3900
          taaaccgcgg tcagcagtat ctgctgtggg tggccgccgt cacctctgcc ggccggggca 3960
          acagcagcga gaaggtgacc atcgagcctg ctggcaaggc cccagcaaag atcatctcct 4020
          ttgggggcac cgtgacaaca ccttggatga aagatgttcg gctgccttgc aattcagtgg 4080
          gagatccagc ccctgctgtg aagtggacca aggacagtga agactcggcc attccagtgt 4140
          ccatggatgg gcaccggctc atccacacca atggcacact gctgctgcgt gcagtgaagg 4200
          ctgaggactc tggctactac acgtgcacgg ccaccaacac tggtggcttt gacaccatca 4260
          tcgtcaacct tctggtgcaa gttcccccgg accagccccg cctcactgtc tccaaaacct 4320
          cagcttcgtc catcaccctg acctggattc caggtgacaa tgggggcagc tccatccgag 4380
          gcttcgtgct acagtactcg gtggacaaca gcgaggagtg gaaggatgtg ttcatcagct 4440
          ccagcgagcg ctccttcaag ctggacagcc tcaagtgtgg cacgtggtac aaggtgaagc 4500
          tggcagccaa gaacagcgtg ggctctgggc gcatcagcga gatcatcgag gccaagaccc 4560
          acgggcggga gccctccttc agcaaagacc aacacctctt cacccacatc aactccacgc 4620
          atgctcggct taacctgcag ggctggaaca atgggggctg ccctatcaca gccatcgttc 4680
          tggagtaccg gcccaagggg acctgggcct ggcagggcct ccgggccaac agctccgggg 4740
          aggtgtttct gacggaactg cgagaggcca cgtggtacga gctgcgcatg agggcttgca 4800
          acagtgcggg ctgcggcaat gaaacagccc agttcgccac cctggactac gatggcagca 4860
          ccattccacc catcaagtct gctcaaggtg aaggggatga tgtgaagaag ctgttcacca 4920
          tcggctgccc tgtcatcctg gccaacactgg gggtggcact gctcttcatc gtacgcaaga 4980
          agaggaagga gaaacggctg aagcgactcc gagatgcaaa gagtttggca gaaatgttga 5040
          taagcaagaa caatagaagc tttgacaccc ctgtgaaagg gccaccccag ggcccacggc 5100
          tacacattga catccccagg gtccagctgc tcatcgagga caaagaaggc atcaagcaac 5160
          tgggagatga caaggccacc atccctgtga cagatgctga gttcagccaa gctgtcaacc 5220
          cacagagctt ctgtactggc gtctccttgc accacccaac cctcatccag agcacaggac 5280
          ccctcatcga catgtctgac atccggccag gaaccaatcc agtgtccagg aagaatgtga 5340
          agtcagccca cagcacccgg aaccggtact caagccagtg gaccctgacc aagtgccagg 5400
          cctccacacc tgcccgcacc ctcacctccg actggcgcac cgtgggctcc cagcatggtg 5460
          tcacggtcac tgagagtgac agctacagtg ccagcctgtc ccaggacaca gacaaaggaa 5520
          ggaacagcat ggtgtccact gagagtgcct cttccaccta cgaggagctg gcccgggcct 5580
          atgagcatgc caagctggag gagcagctgc agcacgccaa gtttgagatc accgagtgct 5640
          tcatctctga cagttcctct gaccagatga ccacaggcac caacgagaac gccgacagca 5700
          tgacatccat gagcacacccc tcagagcctg gcatctgccg ctttaccgcc tcaccacccca 5760
          agccccagga tgcggaccgg ggcaaaaacg tggctgtgcc catccctcac cgggccaaca 5820
          agagtgacta ctgcaacctg cccctgtatg ccaagtcaga ggccttcttt cgaaaggcag 5880
          atggacgtga gccctgcccc gtggtcccac cccgtgaggc ctccatccgg aacctggctc 5940
          gaacctacca cacccaggct cgccacctga ccctggaccc tgccagcaag tccttgggcc 6000
          ttccccaccc aggggccccc gctgccgcct ccacagccac cttacctcag aggactctgg 6060
          ccatgccagc ccccccagcc ggcacagccc ccccagcccc cggccccacc cctgctgagc 6120
          cacccaccgc ccccagcgct gcccctccgg cccccagcac cgagcctcca cgagccgggg 6180
          gcccacacac caaaatgggg ggctccaggg actcgcttct cgagatgagc acatcggggg 6240
          tagggaggtc tcagaagcag ggggccgggg cctactccaa atcctacacc ctggtgtagg 6300
          gcccgcagga agagcagcca cgcctggacc gcgccgcgcc gcagccccac acgccagctc 6360
          ggctgttttt ctgcattatt tatattcaac tgacagacaa aaaccaacca acgacaaaac 6420
          aaaaaccccc aatcatgaac gcctgtacat agaactcttt tgtacaaatg aaactatttt 6480
          cttcttctcc atgaagccag ggcacaaaga atttgacagt acaagtcaaa tcccccaccc 6540
          cacaaaatat gtgtggagat atatatacat atatagacag acaggaacgc gtccacgagc 6600
          tatatatcta tatatttctc tcaccctatt ttgagacaga ggcacaaaga ctcagcaatt 6660
          tttttccctc ctcctcacct tccccccagt ctaggtggtt ttgacaaaga ccaaaatccc 6720
          aactcagaga cactgcatgc gattttactg ttccaagaaa accaggagtt gcttcaattt 6780
          gcagatgctt atgtgttaat acctttttct atgaaaaaag accccagcgcc gtgtgcaata 6840
          aaggttatgtttcta 6855
           <![CDATA[ <210> 904]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 904]]>
          Met Trp Leu Val Thr Phe Leu Leu Leu Leu Asp Ser Leu His Lys
          1 5 10 15
           <![CDATA[ <210> 905]]>
           <![CDATA[ <211> 105]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 905]]>
          Arg Pro Glu Asp Val Gly Thr Ser Leu Tyr Phe Val Asn Asp Ser Leu
          1 5 10 15
          Gln Gln Val Thr Phe Ser Ser Ser Ser Val Gly Val Val Val Pro Cys Pro
                      20 25 30
          Ala Ala Gly Ser Pro Ser Ala Ala Leu Arg Trp Tyr Leu Ala Thr Gly
                  35 40 45
          Asp Asp Ile Tyr Asp Val Pro His Ile Arg His Val His Ala Asn Gly
              50 55 60
          Thr Leu Gln Leu Tyr Pro Phe Ser Pro Ser Ala Phe Asn Ser Phe Ile
          65 70 75 80
          His Asp Asn Asp Tyr Phe Cys Thr Ala Glu Asn Ala Ala Gly Lys Ile
                          85 90 95
          Arg Ser Pro Asn Ile Arg Val Lys Ala
                      100 105
           <![CDATA[ <210> 906]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 906]]>
          Phe Arg Glu Pro Tyr Thr Val Arg Val Glu Asp Gln Arg Ser Met Arg
          1 5 10 15
          Gly Asn Val Ala Val Phe Lys Cys Leu Ile Pro Ser Ser Val Gln Glu
                      20 25 30
          Tyr Val Ser Val Val Ser Trp Glu Lys Asp Thr Val Ser Ile Ile Pro
                  35 40 45
           <![CDATA[ <210> 907]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213]]>> Human]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;907]]&gt;
           <br/>
           <br/> <![CDATA[His Arg Phe Phe Ile Thr Tyr His Gly Gly Leu Tyr Ile Ser Asp Val
          1 5 10 15
          Gln Lys Glu Asp Ala Leu Ser Thr Tyr Arg Cys Ile Thr Lys His Lys
                      20 25 30
          Tyr Ser Gly Glu Thr Arg Gln Ser Asn Gly Ala Arg Leu Ser Val Thr
                  35 40 45
           <![CDATA[ <210> 908]]>
           <![CDATA[ <211> 92]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 908]]>
          Pro Ala Glu Ser Ile Pro Thr Ile Leu Asp Gly Phe His Ser Gln Glu
          1 5 10 15
          Val Trp Ala Gly His Thr Val Glu Leu Pro Cys Thr Ala Ser Gly Tyr
                      20 25 30
          Pro Ile Pro Ala Ile Arg Trp Leu Lys Asp Gly Arg Pro Leu Pro Ala
                  35 40 45
          Asp Ser Arg Trp Thr Lys Arg Ile Thr Gly Leu Thr Ile Ser Asp Leu
              50 55 60
          Arg Thr Glu Asp Ser Gly Thr Tyr Ile Cys Glu Val Thr Asn Thr Phe
          65 70 75 80
          Gly Ser Ala Glu Ala Thr Gly Ile Leu Met Val Ile
                          85 90
           <![CDATA[ <210> 909]]>
           <![CDATA[ <211> 91]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 909]]>
          Pro Leu His Val Thr Leu Thr Pro Lys Lys Leu Lys Thr Gly Ile Gly
          1 5 10 15
          Ser Thr Val Ile Leu Ser Cys Ala Leu Thr Gly Ser Pro Glu Phe Thr
                      20 25 30
          Ile Arg Trp Tyr Arg Asn Thr Glu Leu Val Leu Pro Asp Glu Ala Ile
                  35 40 45
          Ser Ile Arg Gly Leu Ser Asn Glu Thr Leu Leu Ile Thr Ser Ala Gln
              50 55 60
          Lys Ser His Ser Gly Ala Tyr Gln Cys Phe Ala Thr Arg Lys Ala Gln
          65 70 75 80
          Thr Ala Gln Asp Phe Ala Ile Ile Ala Leu Glu
                          85 90
           <![CDATA[ <210> 910]]>
           <![CDATA[ <211> 98]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 910]]>
          Gly Thr Pro Arg Ile Val Ser Ser Phe Ser Glu Lys Val Val Asn Pro
          1 5 10 15
          Gly Glu Gln Phe Ser Leu Met Cys Ala Ala Lys Gly Ala Pro Pro Pro
                      20 25 30
          Thr Val Thr Trp Ala Leu Asp Asp Glu Pro Ile Val Arg Asp Gly Ser
                  35 40 45
          His Arg Thr Asn Gln Tyr Thr Met Ser Asp Gly Thr Thr Ile Ser His
              50 55 60
          Met Asn Val Thr Gly Pro Gln Ile Arg Asp Gly Gly Val Tyr Arg Cys
          65 70 75 80
          Thr Ala Arg Asn Leu Val Gly Ser Ala Glu Tyr Gln Ala Arg Ile Asn
                          85 90 95
          Val Arg
           <![CDATA[ <210> 911]]>
           <![CDATA[ <211> 90]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> ]]> 911
          Pro Pro Ser Ile Arg Ala Met Arg Asn Ile Thr Ala Val Ala Gly Arg
          1 5 10 15
          Asp Thr Leu Ile Asn Cys Arg Val Ile Gly Tyr Pro Tyr Tyr Ser Ile
                      20 25 30
          Lys Trp Tyr Lys Asp Ala Leu Leu Leu Pro Asp Asn His Arg Gln Val
                  35 40 45
          Val Phe Glu Asn Gly Thr Leu Lys Leu Thr Asp Val Gln Lys Gly Met
              50 55 60
          Asp Glu Gly Glu Tyr Leu Cys Ser Val Leu Ile Gln Pro Gln Leu Ser
          65 70 75 80
          Ile Ser Gln Ser Val His Val Ala Val Lys
                          85 90
           <![CDATA[ <210> 912]]>
           <![CDATA[ <211> 92]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 912]]>
          Pro Pro Leu Ile Gln Pro Phe Glu Phe Pro Pro Ala Ser Ile Gly Gln
          1 5 10 15
          Leu Leu Tyr Ile Pro Cys Val Val Ser Ser Gly Asp Met Pro Ile Arg
                      20 25 30
          Ile Thr Trp Arg Lys Asp Gly Gln Val Ile Ile Ser Gly Ser Gly Val
                  35 40 45
          Thr Ile Glu Ser Lys Glu Phe Met Ser Ser Leu Gln Ile Ser Ser Ser Val
              50 55 60
          Ser Leu Lys His Asn Gly Asn Tyr Thr Cys Ile Ala Ser Asn Ala Ala
          65 70 75 80
          Ala Thr Val Ser Arg Glu Arg Gln Leu Ile Val Arg
                          85 90
           <![CDATA[ <210> 913]]>
           <![CDATA[ <211> 39]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 913]]>
          Pro Pro Arg Phe Val Val Gln Pro Asn Asn Gln Asp Gly Ile Tyr Gly
          1 5 10 15
          Lys Ala Gly Val Leu Asn Cys Ser Val Asp Gly Tyr Pro Pro Pro Lys
                      20 25 30
          Val Met Trp Lys His Ala Lys
                  35
           <![CDATA[ <210> 914]]>
           <![CDATA[ <211> 58]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 914]]>
          Ser Gly Asn Pro Gln Gln Tyr His Pro Val Pro Leu Thr Gly Arg Ile
          1 5 10 15
          Gln Ile Leu Pro Asn Ser Ser Leu Leu Ile Arg His Val Leu Glu Glu
                      20 25 30
          Asp Ile Gly Tyr Tyr Tyr Leu Cys Gln Ala Ser Asn Gly Val Gly Thr Asp
                  35 40 45
          Ile Ser Lys Ser Met Phe Leu Thr Val Lys
              50 55
           <![CDATA[ <210> 915]]>
           <![CDATA[ <211> 66]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 915]]>
          Pro Ala Met Ile Thr Ser His Pro Asn Thr Thr Ile Ala Ile Lys Gly
          1 5 10 15
          His Ala Lys Glu Leu Asn Cys Thr Ala Arg Gly Glu Arg Pro Ile Ile
                      20 25 30
          Ile Arg Trp Glu Lys Gly Asp Thr Val Ile Asp Pro Asp Arg Val Met
                  35 40 45
          Arg Tyr Ala Ile Ala Thr Lys Asp Asn Gly Asp Glu Val Val Ser Thr
              50 55 60
          Leu Lys
          65
           <![CDATA[ <210> 916]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 916]]>
          Leu Lys Pro Ala Asp Arg Gly Asp Ser Val Phe Phe Ser Cys His Ala
          1 5 10 15
          Ile Asn Ser Tyr Gly Glu Asp Arg Gly Leu Ile Gln Leu Thr Val Gln
                      20 25 30
           <![CDATA[ <210> 917]]>
           <![CDATA[ <211> 42]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 917]]>
          Pro Pro Asp Pro Pro Glu Leu Glu Ile Arg Glu Val Lys Ala Arg Ser
          1 5 10 15
          Met Asn Leu Arg Trp Thr Gln Arg Phe Asp Gly Asn Ser Ile Ile Thr
                      20 25 30
          Gly Phe Asp Ile Glu Tyr Lys Asn Lys Ser
                  35 40
           <![CDATA[ <210> 918]]>
           <![CDATA[ <211> 55]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 918]]>
          Ser Trp Asp Phe Lys Gln Ser Thr Arg Asn Ile Ser Pro Thr Ile Asn
          1 5 10 15
          Gln Ala Asn Ile Val Asp Leu His Pro Ala Ser Val Tyr Ser Ile Arg
                      20 25 30
          Met Tyr Ser Phe Asn Lys Ile Gly Arg Ser Glu Pro Ser Lys Glu Leu
                  35 40 45
          Thr Ile Ser Thr Glu Glu Ala
              50 55
           <![CDATA[ <210> 919]]>
           <![CDATA[ <211> 23]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 919]]>
          Pro Asp Gly Pro Pro Met Asp Val Thr Leu Gln Pro Val Thr Ser Gln
          1 5 10 15
          Ser Ile Gln Val Thr Trp Lys
                      20
           <![CDATA[ <210> 920]]>
           <![CDATA[ <211> 80]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 920]]>
          Ala Pro Lys Lys Glu Leu Gln Asn Gly Val Ile Arg Gly Tyr Gln Ile
          1 5 10 15
          Gly Tyr Arg Glu Asn Ser Pro Gly Ser Asn Gly Gly Gln Tyr Ser Ile Val
                      20 25 30
          Glu Met Lys Ala Thr Gly Asp Ser Glu Val Tyr Thr Leu Asp Asn Leu
                  35 40 45
          Lys Lys Phe Ala Gln Tyr Gly Val Val Val Gln Ala Phe Asn Arg Ala
              50 55 60
          Gly Thr Gly Pro Ser Ser Ser Glu Ile Asn Ala Thr Thr Leu Glu Asp
          65 70 75 80
           <![CDATA[ <210> 921]]>
           <![CDATA[ <211> 48]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 921]]>
          Pro Ser Gln Pro Pro Glu Asn Val Arg Ala Leu Ser Ile Thr Ser Asp
          1 5 10 15
          Val Ala Val Ile Ser Trp Ser Glu Pro Pro Arg Ser Thr Leu Asn Gly
                      20 25 30
          Val Leu Lys Gly Tyr Arg Val Ile Phe Trp Ser Leu Tyr Val Asp Gly
                  35 40 45
           <![CDATA[ <210> 922]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 922]]>
          Trp Gly Glu Met Gln Asn Ile Thr Thr Thr Arg Glu Arg Val Glu Leu
          1 5 10 15
          Arg Gly Met Glu Lys Phe Thr Asn Tyr Ser Val Gln Val Leu Ala Tyr
                      20 25 30
          Thr Gln Ala Gly Asp Gly Val Arg Ser Ser Val Leu Tyr Ile Gln Thr
                  35 40 45
          Lys Glu Asp
              50
           <![CDATA[ <210> 923]]>
           <![CDATA[ <211> 46]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 923]]>
          Pro Gly Pro Pro Ala Gly Ile Lys Ala Val Pro Ser Ser Ala Ser Ser
          1 5 10 15
          Val Val Val Ser Trp Leu Pro Pro Thr Lys Pro Asn Gly Val Ile Arg
                      20 25 30
          Lys Tyr Thr Ile Phe Cys Ser Ser Pro Gly Ser Gly Gln Pro
                  35 40 45
           <![CDATA[ <210> 924]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 924]]>
          Ala Pro Ser Glu Tyr Glu Thr Ser Pro Glu Gln Leu Phe Tyr Arg Ile
          1 5 10 15
          Ala His Leu Asn Arg Gly Gln Gln Tyr Leu Leu Trp Val Ala Ala Val
                      20 25 30
          Thr Ser Ala Gly Arg Gly Asn Ser Ser Glu Lys Val Thr Ile Glu Pro
                  35 40 45
          Ala Gly Lys
              50
           <![CDATA[ <210> 925]]>
           <![CDATA[ <211> 38]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 925]]>
          Pro Ala Lys Ile Ile Ser Phe Gly Gly Thr Val Thr Thr Pro Trp Met
          1 5 10 15
          Lys Asp Val Arg Leu Pro Cys Asn Ser Val Gly Asp Pro Ala Pro Ala
                      20 25 30
          Val Lys Trp Thr Lys Asp
                  35
           <![CDATA[ <210> 926]]>
           <![CDATA[ <211> 54]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 926]]>
          Glu Asp Ser Ala Ile Pro Val Ser Met Asp Gly His Arg Leu Ile His
          1 5 10 15
          Thr Asn Gly Thr Leu Leu Leu Arg Ala Val Lys Ala Glu Asp Ser Gly
                      20 25 30
          Tyr Tyr Thr Cys Thr Ala Thr Asn Thr Gly Gly Phe Asp Thr Ile Ile
                  35 40 45
          Val Asn Leu Leu Val Gln
              50
           <![CDATA[ <210> 927]]>
           <![CDATA[ <211> 32]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 927]]>
          Pro Pro Asp Gln Pro Arg Leu Thr Val Ser Lys Thr Ser Ala Ser Ser
          1 5 10 15
          Ile Thr Leu Thr Trp Ile Pro Gly Asp Asn Gly Gly Ser Ser Ile Arg
                      20 25 30
           <![CDATA[ <210> 928]]>
           <![CDATA[ <211> 62]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 928]]>
          Phe Val Leu Gln Tyr Ser Val Asp Asn Ser Glu Glu Trp Lys Asp Val
          1 5 10 15
          Phe Ile Ser Ser Ser Glu Arg Ser Phe Lys Leu Asp Ser Leu Lys Cys
                      20 25 30
          Gly Thr Trp Tyr Lys Val Lys Leu Ala Ala Lys Asn Ser Val Gly Ser
                  35 40 45
          Gly Arg Ile Ser Glu Ile Ile Glu Ala Lys Thr His Gly Arg
              50 55 60
           <![CDATA[ <210> 929]]>
           <![CDATA[ <211> 95]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 929]]>
          Pro Ser Phe Ser Lys Asp Gln His Leu Phe Thr His Ile Asn Ser Thr
          1 5 10 15
          His Ala Arg Leu Asn Leu Gln Gly Trp Asn Asn Gly Gly Cys Pro Ile
                      20 25 30
          Thr Ala Ile Val Leu Glu Tyr Arg Pro Lys Gly Thr Trp Ala Trp Gln
                  35 40 45
          Gly Leu Arg Ala Asn Ser Ser Gly Glu Val Phe Leu Thr Glu Leu Arg
              50 55 60
          Glu Ala Thr Trp Tyr Glu Leu Arg Met Arg Ala Cys Asn Ser Ala Gly
          65 70 75 80
          Cys Gly Asn Glu Thr Ala Gln Phe Ala Thr Leu Asp Tyr Asp Gly
                          85 90 95
           <![CDATA[ <210> 930]]>
           <![CDATA[ <211> 51]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 930]]>
          Thr Ile Pro Pro Ile Lys Ser Ala Gln Gly Glu Gly Asp Asp Val Lys
          1 5 10 15
          Lys Leu Phe Thr Ile Gly Cys Pro Val Ile Leu Ala Thr Leu Gly Val
                      20 25 30
          Ala Leu Leu Phe Ile Val Arg Lys Lys Arg Lys Glu Lys Arg Leu Lys
                  35 40 45
          Arg Leu Arg
              50
           <![CDATA[ <210> 931]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 931]]>
          Ala Lys Ser Leu Ala Glu Met Leu Ile
          1 5
           <![CDATA[ <210> 932]]>
           <![CDATA[ <211> 39]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 932]]>
          Lys Asn Asn Arg Ser Phe Asp Thr Pro Val Lys Gly Pro Pro Gln Gly
          1 5 10 15
          Pro Arg Leu His Ile Asp Ile Pro Arg Val Gln Leu Leu Ile Glu Asp
                      20 25 30
          Lys Glu Gly Ile Lys Gln Leu
                  35
           <![CDATA[ <210> 933]]>
           <![CDATA[ <211> 50]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 933]]>
          Asp Asp Lys Ala Thr Ile Pro Val Thr Asp Ala Glu Phe Ser Gln Ala
          1 5 10 15
          Val Asn Pro Gln Ser Phe Cys Thr Gly Val Ser Leu His His Pro Thr
                      20 25 30
          Leu Ile Gln Ser Thr Gly Pro Leu Ile Asp Met Ser Asp Ile Arg Pro
                  35 40 45
          Gly Thr
              50
           <![CDATA[ <210> 934]]>
           <![CDATA[ <211> 64]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 934]]>
          Pro Val Ser Arg Lys Asn Val Lys Ser Ala His Ser Thr Arg Asn Arg
          1 5 10 15
          Tyr Ser Ser Gln Trp Thr Leu Thr Lys Cys Gln Ala Ser Thr Pro Ala
                      20 25 30
          Arg Thr Leu Thr Ser Asp Trp Arg Thr Val Gly Ser Gln His Gly Val
                  35 40 45
          Thr Val Thr Glu Ser Asp Ser Tyr Ser Ala Ser Leu Ser Gln Asp Thr
              50 55 60
           <![CDATA[ <210> 935]]>
           <![CDATA[ <211> 103]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 935]]>
          Lys Gly Arg Asn Ser Met Val Ser Thr Glu Ser Ala Ser Ser Thr Tyr
          1 5 10 15
          Glu Glu Leu Ala Arg Ala Tyr Glu His Ala Lys Leu Glu Glu Gln Leu
                      20 25 30
          Gln His Ala Lys Phe Glu Ile Thr Glu Cys Phe Ile Ser Asp Ser Ser
                  35 40 45
          Ser Asp Gln Met Thr Thr Gly Thr Asn Glu Asn Ala Asp Ser Met Thr
              50 55 60
          Ser Met Ser Thr Pro Ser Glu Pro Gly Ile Cys Arg Phe Thr Ala Ser
          65 70 75 80
          Pro Pro Lys Pro Gln Asp Ala Asp Arg Gly Lys Asn Val Ala Val Pro
                          85 90 95
          Ile Pro His Arg Ala Asn Lys
                      100
           <![CDATA[ <210> 936]]>
           <![CDATA[ <211> 157]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 936]]>
          Asp Tyr Cys Asn Leu Pro Leu Tyr Ala Lys Ser Glu Ala Phe Phe Arg
          1 5 10 15
          Lys Ala Asp Gly Arg Glu Pro Cys Pro Val Val Pro Pro Arg Glu Ala
                      20 25 30
          Ser Ile Arg Asn Leu Ala Arg Thr Tyr His Thr Gln Ala Arg His Leu
                  35 40 45
          Thr Leu Asp Pro Ala Ser Lys Ser Leu Gly Leu Pro His Pro Gly Ala
              50 55 60
          Pro Ala Ala Ala Ser Thr Ala Thr Leu Pro Gln Arg Thr Leu Ala Met
          65 70 75 80
          Pro Ala Pro Pro Ala Gly Thr Ala Pro Pro Ala Pro Gly Pro Thr Pro
                          85 90 95
          Ala Glu Pro Pro Thr Ala Pro Ser Ala Ala Pro Pro Ala Pro Ser Thr
                      100 105 110
          Glu Pro Pro Arg Ala Gly Gly Pro His Thr Lys Met Gly Gly Ser Arg
                  115 120 125
          Asp Ser Leu Leu Glu Met Ser Thr Ser Gly Val Gly Arg Ser Gln Lys
              130 135 140
          Gln Gly Ala Gly Ala Tyr Ser Lys Ser Tyr Thr Leu Val
          145 150 155
           <![CDATA[ <210> 937]]>
           <![CDATA[ <211> 2053]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 937]]> Met Trp Leu Val Thr Phe Leu Leu Leu Leu Asp Ser Leu His Lys Ala 1 5 10 15 Arg Pro Glu Asp Val Gly Thr Ser Leu Tyr Phe Val Asn Asp Ser Leu 20 25 30 Gln Gln Val Thr Phe Ser Ser Ser Val Gly Val Val Pro Cys Pro 35 40 45 Ala Ala Gly Ser Pro Ser Ala Ala Leu Arg Trp Tyr Leu Ala Thr Gly 50 55 60 Asp Asp Ile Tyr Asp Val Pro His Ile Arg His Val His Ala Asn Gly 65 70 75 80 Thr Leu Gln Leu Tyr Pro Phe Ser Pro Ser Ala Phe Asn Ser Phe Ile 85 90 95 His Asp Asn Asp Tyr Phe Cys Thr Ala Glu Asn Ala Ala Gly Lys Ile 100 105 110 Arg Ser Pro Asn Ile Arg Val Lys Ala Val Phe Arg Glu Pro Tyr Thr 115 120 125 Val Arg Val Glu Asp Gln Arg Ser Met Arg Gly Asn Val Ala Val Phe 130 135 140 Lys Cys Leu Ile Pro Ser Ser Val Gln Glu Tyr Val Ser Val Val Ser 145 150 155 16 0 Trp Glu Lys Asp Thr Val Ser Ile Ile Pro Glu His Arg Phe Phe Ile 165 170 175 Thr Tyr His Gly Gly Leu Tyr Ile Ser Asp Val Gln Lys Glu Asp Ala 180 185 190 Leu Ser Thr Tyr Arg Cys Ile Thr Lys His Lys Tyr Serg Glu Thr 195 ARG Gln Sern GLY Ala Ala ARG Leu Ser Val THR ASP Pro Ala Glu Ser 210 215 220 Ile Pro ThR ILEU ASP GLY PHE HIS GLN Glu Val Tra Gly 225 230 23 23 5 240 His Thr Val Glu Leu Pro Cys Thr Ala Ser Gly Tyr Pro Ile Pro Ala 245 250 255 Ile Arg Trp Leu Lys Asp Gly Arg Pro Leu Pro Ala Asp Ser Arg Trp 260 265 270 Thr Lys Arg Ile Thr Gly Leu Thr Ile Ser Asp Leu Arg Thr Glu Asp 275 280 285 Ser Gly Thr Tyr Ile Cys Glu Val Thr Asn Thr Phe Gly Ser Ala Glu 290 295 300 Ala Thr Gly Ile Leu Met Val Ile Asp Pro Leu His Val Thr Leu Thr 305 310 315 320 Pro Lys Lys Leu Lys Thr Gly Ile Gly Ser Thr Val Ile Leu Ser Cys 325 330 335 Ala Leu Thr Gly Ser Pro Glu Phe Thr Ile Arg Trp Tyr Arg Asn Thr 340 345 350 Glu Leu Val Leu Pro Asp Glu Ala Ile Ser Ile Arg Gly Leu Ser Asn 355 360 365 Glu Thr Leu Leu Ile Thr Ser Ala Gln Lys Ser His Ser Gly Ala Tyr 370 375 380 Gln Cys Phe Ala Thr Arg Lys Ala Gln Thr Ala Gln Asp Phe Ala Ile 385 390 395 400 Ile Ala Leu Glu Asp Gly Thr Pro Arg Ile Val Ser Ser Phe Ser Glu 405 410 415 Lys Val Val Asn Pro Gly Glu Gln Phe Ser Leu Met Cys Ala Ala Lys 420 425 430 Gly Ala Pro Pro Pro Thr Val Thr Trp Ala Leu Asp Asp Glu Pro Ile 435 440 445 Val Arg Asp Gly Ser His Arg Thr Asn Gln Tyr Thr Met Ser Asp Gly 450 455 460 Thr Thr Ile Ser His Met Asn Val Thr Gly Pro Gln Ile Arg Asp Gly 465 470 475 480 Gly Val Tyr Arg Cys Thr Ala Arg Asn Leu Val Gly Ser Ala Glu Tyr 485 490 495 Gln ARG Ile Asn Val ARG GLY Pro Pro Serg Ala Met ARG 50055 510 ASN Ile Thr Val Ala Gly ARG ARG ARL Leu Ile Asn CYS ARG Val 515 525 ILE GLY T. YR Pro Tyr Tyr Serle Lys Trp Tyr Lys Asp Ala Leu Leu 530 535 540 Leu Pro Asp Asn His Arg Gln Val Val Phe Glu Asn Gly Thr Leu Lys 545 550 555 560 Leu Thr Asp Val Gln Lys Gly Met Asp Glu Gly Glu Tyr Leu Cys Ser 565 570 5 75 Val Leu Ile Gln Pro Gln Leu Ser Ile Ser Gln Ser Val His Val Ala 580 585 590 Val Lys Val Pro Pro Leu Ile Gln Pro Phe Glu Phe Pro Pro Ala Ser 595 600 605 Ile Gly Gln Leu Leu Tyr Ile Pro Cys Val Val Ser Ser GLY ASP MET 610 620 Pro ILE ARG Ile Trp ARG LYS ASP GLN Val ILE ILE ILE ILE ILE Serite 625 635 640 Serge Val THR Ile Glu Phe Met Serou Gln Ile 645 650 65 65 65 65 65 65 65 65 65 65 65 65 65 65 65 65 65 65 65 5 Ser Ser Val Ser Leu Lys His Asn Gly Asn Tyr Thr Cys Ile Ala Ser 660 665 670 Asn Ala Ala Ala Thr Val Ser Arg Glu Arg Gln Leu Ile Val Arg Val 675 680 685 Pro Pro Arg Phe Val Val Gln Pro Asn Asn Asn Gln Asp Gly Ile Tyr Gly 690 695 700 Lys Ala Gly Val Leu Asn Cys Ser Val Asp Gly Tyr Pro Pro Pro Lys 705 710 715 720 Val Met Trp Lys His Ala Lys Gly Ser Gly Asn Pro Gln Gln Tyr His 725 730 735 Pro Val Pro Leu Thr Gly Arg Ile Gln Ile Leu Pro Asn Serou 740 745 750 Leu Ile ARG His Val Leu Glu GLU ASP ILE GLY Tyr Leu Cys Gln 755 760 760 Ala Sern Gly Val Gly Thr Lyser Met PHE Leu ThR 770 775 780 Val LYS Ile Pro Ala Met Ile Thr Ser His Pro Asn Thr Thr Ile Ala 785 790 795 800 Ile Lys Gly His Ala Lys Glu Leu Asn Cys Thr Ala Arg Gly Glu Arg 805 810 815 Pro Ile Ile Ile Arg Trp Glu Lys Gly Asp Thr Val Ile Asp Pro Asp 820 825 830 Arg Val Met Arg Tyr Ala Ile Ala Thr Lys Asp Asn Gly Asp Glu Val 835 840 845 Val Ser Thr Leu Lys Leu Lys Pro Ala Asp Arg Gly Asp Ser Val Phe 850 855 860 Phe Ser Cys His Ala Ile Asn Ser Tyr Gly Glu Asp Arg Gly Leu Ile 865 870 875 880 Gln Leu Thr Val Gln Glu Pro Pro Asp Pro Pro Glu Leu Glu Ile Arg 885 890 895 Glu Val Lys Ala Arg Ser Met Asn Leu Arg Trp Thr Gln Arg Phe Asp 900 905 910 Gly Asn Ser Ile Ile Thr Gly Phe Asp Ile Glu Tyr Lys Asn Lys Ser 915 920 925 Asp Ser Trp Asp Phe Lys Gln Ser Thr Arg Asn Ile Ser Pro Thr Ile 930 935 940 Asn Gln Ala Asn Ile Val Asp Leu His Pro Ala Ser Val Tyr Ser Ile 945 950 955 960 Arg Met Tyr Ser Phe Asn Lys Ile Gly Arg Ser Glu Pro Ser Lys Glu 965 970 975 Leu Thr Ile Ser Thr Glu Glu Ala Ala Pro Asp Gly Pro Pro Met Asp 980 985 990 Val Thr Leu Gln Pro Val Thr Ser Gln Ser Ile Gln Val Thr Trp Lys 995 1000 1005 Ala Pro Lys Lys Glu Leu Gln Asn Gly Val Ile Arg Gly Tyr Gln 1010 1015 1020 Ile Gly Tyr Arg Glu Asn Ser Pro Gly Ser Asn Gly Gln Tyr Ser 1025 1030 1035 Ile Val Glu Met Lys Ala Thr Gly Asp Ser Glu Val Tyr Thr Leu 1040 1045 1050 Asp Asn Leu Lys Lys Phe Ala Gln Tyr Gly Val Val Val Gln Ala 1055 1060 1065 Phe Asn Arg Ala Gly Th r Gly Pro Ser Ser Ser Ser Glu Ile Asn Ala 1070 1075 1080 Thr Thr Leu Glu Asp Val Pro Ser Gln Pro Pro Glu Asn Val Arg 1085 1090 1095 Ala Leu Ser Ile Thr Ser Asp Val Ala Val Ile Ser Trp Ser Glu 1100 1105 1110 Pro Pro Arg Ser Thr Leu Asn Gly Val Leu Lys Gly Tyr Arg Val 1115 1120 1125 Ile Phe Trp Ser Leu Tyr Val Asp Gly Glu Trp Gly Glu Met Gln 1130 1135 1140 Asn Ile Thr Thr Thr Arg Glu Arg Val Glu Leu Arg Gly Met Glu 1145 1150 1155 Lys Phe Thr Asn Tyr Ser Val Gln Val Leu Ala Tyr Thr Gln Ala 1160 1165 1170 Gly Asp Gly Val Arg Ser Ser Val Leu Tyr Ile Gln Thr Lys Glu 1175 1180 1185 Asp Val Pro Gly Pro Pro Ala Gly Ile Lys Ala Val Pro Ser Ser 1190 1195 1200 Ala Ser Ser Val Val Val Ser Trp Leu Pro Pro Thr Lys Pro Asn 1205 1210 1215 Gly Val Ile Arg Lys Tyr Thr Ile Phe Cys Ser Ser Pro Gly Ser 1220 1225 1230 Gly Gln Pro Ala Pro Ser Glu Tyr Glu Thr Ser Pro Glu Gln Leu 1235 1240 1245 Phe Tyr Arg Ile Ala His Leu Asn Arg Gly Gln Gln Tyr Leu Leu 1250 1255 1260 Trp Val Ala Ala Val Thr Ser Ala Gly Arg Gly Asn Ser Ser Glu 1265 1270 1275 Lys Val Th r Ile Glu Pro Ala Gly Lys Ala Pro Ala Lys Ile Ile 1280 1285 1290 Ser Phe Gly Gly Thr Val Thr Thr Pro Trp Met Lys Asp Val Arg 1295 1300 1305 Leu Pro Cys Asn Ser Val Gly Asp Pro Ala Pro Ala Val Lys Trp 1310 1315 1320 Thr Lys Asp S er Glu Asp Ser Ala Ile Pro Val Ser Met Asp Gly 1325 1330 1335 His Arg Leu Ile His Thr Asn Gly Thr Leu Leu Leu Arg Ala Val 1340 1345 1350 Lys Ala Glu Asp Ser Gly Tyr Tyr Thr Cys Thr Ala Thr Asn Thr 1355 136 0 1365 Gly Gly Phe Asp Thr Ile Ile Val Asn Leu Leu Val Gln Val Pro 1370 1375 1380 Pro Asp Gln Pro Arg Leu Thr Val Ser Lys Thr Ser Ala Ser Ser 1385 1390 1395 Ile Thr Leu Thr Trp Ile Pro Gly Asp Asn Gly Gly Ser Ser Ile 1400 1405 1410 Arg Gly Phe Val Leu Gln Tyr Ser Val Asp Asn Ser Glu Glu Trp 1415 1420 1425 Lys Asp Val Phe Ile Ser Ser Ser Ser Glu Arg Ser Phe Lys Leu Asp 1430 1435 1440 Ser Leu Lys Cys Gly Thr Trp Tyr Lys Val Lys Leu Ala Ala Lys 1445 1450 1455 Asn Ser Val Gly Ser Gly Arg Ile Ser Glu Ile Ile Glu Ala Lys 1460 1465 1470 Thr His Gly Arg Glu Pro Ser Phe Ser Lys Asp Gln His Leu Phe 1475 1480 1485 Thr His Ile As n Ser Thr His Ala Arg Leu Asn Leu Gln Gly Trp 1490 1495 1500 Asn Asn Gly Gly Cys Pro Ile Thr Ala Ile Val Leu Glu Tyr Arg 1505 1510 1515 Pro Lys Gly Thr Trp Ala Trp Gln Gly Leu Arg Ala Asn Ser Ser 1520 15 25 1530 Gly Glu Val Phe Leu Thr Glu Leu Arg Glu Ala Thr Trp Tyr Glu 1535 1540 1545 Leu Arg Met Arg Ala Cys Asn Ser Ala Gly Cys Gly Asn Glu Thr 1550 1555 1560 Ala Gln Phe Ala Thr Leu Asp Tyr Asp Gly Ser Thr Ile Pro 156 5 1570 1575 Ile Lys Ser Ala Gln Gly Glu Gly Asp Val Lys Lys Leu Phe 1580 1585 1590 Thr Ile Gly Cys Pro Val Ile Leu Ala Thr Leu Gly Val Ala Leu 1595 1600 1605 Leu Phe Val Arg Lys Lys Arg Lys Glu Lys Arg Leu Lys Arg 1610 1615 1620 Leu Arg Asp Ala Lys Ser Leu Ala Glu Met Leu Ile Ser Lys Asn 1625 1630 1635 Asn Arg Ser Phe Asp Thr Pro Val Lys Gly Pro Pro Gln Gly Pro 1640 1645 1650 Arg Leu His Ile Asp Ile Pro Ar g Val Gln Leu Leu Ile Glu Asp 1655 1660 1665 Lys Glu Gly Ile Lys Gln Leu Gly Asp Asp Lys Ala Thr Ile Pro 1670 1675 1680 Val Thr Asp Ala Glu Phe Ser Gln Ala Val Asn Pro Gln Ser Phe 1685 1690 1695 Cys Thr Gly Val Ser Leu His His Pro Thr Leu Ile Gln Ser Thr 1700 1705 1710 Gly Pro Leu Ile Asp Met Ser Asp Ile Arg Pro Gly Thr Asn Pro 1715 1720 1725 Val Ser Arg Lys Asn Val Lys Ser Ala His Ser Thr Arg Asn Arg 1730 1735 1 740 Tyr Ser Ser Gln Trp Thr Leu Thr Lys Cys Gln Ala Ser Thr Pro 1745 1750 1755 Ala Arg Thr Leu Thr Ser Asp Trp Arg Thr Val Gly Ser Gln His 1760 1765 1770 Gly Val Thr Val Thr Glu Ser Asp Ser Tyr Ser Ala Ser Leu S er 1775 1780 1785 Gln Asp Thr Asp Lys Gly Arg Asn Ser Met Val Ser Thr Glu Ser 1790 1795 1800 Ala Ser Ser Thr Tyr Glu Glu Leu Ala Arg Ala Tyr Glu His Ala 1805 1810 1815 Lys Leu Glu Glu Gln Leu Gln His Ala Lys Phe Glu Ile Thr Glu 1820 1825 1830 Cys Phe Ile Ser Asp Ser Ser Ser Asp Gln Met Thr Thr Gly Thr 1835 1840 1845 Asn Glu Asn Ala Asp Ser Met Thr Ser Ser Met Thr Pro Ser Glu 1850 1855 1860 Pro Gly Ile Cys Arg Phe Thr Ala Ser Pro Pro Lys Pro Gln Asp 1865 1870 1875 Ala Asp Arg Gly Lys Asn Val Ala Val Pro Ile Pro His Arg Ala 1880 1885 1890 Asn Lys Ser Asp Tyr Cys Asn Leu Pro Leu Tyr Ala Lys Ser Glu 1895 1900 1905 A la Phe Phe ARG LYS ALA ASP GLY ARG GLU Pro Cys Pro Val Val 1910 1920 Pro Pro ARG GLU Ala Serg Asn Leu Ala Ala ARG THR TYR HIS P Pro Ala Ser Lys Seru 1940 1945 1950 Gly Leu Pro His Pro Gly Ala Pro Ala Ala Ala Ser Thr Ala Thr 1955 1960 1965 Leu Pro Gln Arg Thr Leu Ala Met Pro Ala Pro Pro Ala Gly Thr 1970 1975 1980 Ala Pro Pro Ala Pro Gly Pro Thr Pro Ala Glu Pro Pro Thr Ala 1985 1990 1995 Pro Ser Ala Ala Pro Pro Ala Pro Ser Thr Glu Pro Pro Arg Ala 2000 2005 2010 Gly Gly Pro His Thr Lys Met Gly Gly Ser Arg Asp Ser Leu Leu 2015 2020 2025 Glu Met Ser Thr Ser Gly Val Gly Arg Ser Gln Lys Gln Gly Ala 2030 2035 2040 Gly Ala Tyr Ser Lys Ser Tyr Thr Leu Val 2045 2050 <![CDATA[ <210> 938]]>
           <![CDATA[ <211> 648]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 938]]>
          agccgagcgc tgggctgagg agcagagaga gcggggcgcc gagtgcgggc ggctgggagc 60
          gcgctgagcg ggggagaggc gctgccgcac ggccggccac aggacccacct ccccggagaa 120
          tagggcctct ttatggcatg tggctggtaa ctttcctcct gctcctggac tctttacaca 180
          aagcccgccc tgaagatgtt ggcaccagcc tctactttgt aaatgactcc ttgcagcagg 240
          tgaccttttc cagctccgtgggggtggtgg tgccctgccc ggccgcgggc tcccccagcg 300
          cggcccttcg atggtacctg gccacagggg acgacatcta cgacgtgccg cacatccggc 360
          acgtccacgc caacgggacg ctgcagctct accccttctc cccctccgcc ttcaatagct 420
          ttatccacga caatgactac ttctgcaccg cggagaacgc tgccggcaag atccggagcc 480
          ccaacatccg cgtcaaagca gttttcaggg aaccctacac cgtccgggtg gaggatcaaa 540
          ggtcaatgcg tggcaacgtg gccgtcttca agtgcctcat cccctcttca gtgcaggaat 600
          atgttagcgt tgtatcttgg gagaaagaca cagtctccat catcccag 648
           <![CDATA[ <210> 939]]>
           <![CDATA[ <211> 170]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 939]]>
          Met Trp Leu Val Thr Phe Leu Leu Leu Leu Asp Ser Leu His Lys Ala
          1 5 10 15
          Arg Pro Glu Asp Val Gly Thr Ser Leu Tyr Phe Val Asn Asp Ser Leu
                      20 25 30
          Gln Gln Val Thr Phe Ser Ser Ser Ser Val Gly Val Val Val Pro Cys Pro
                  35 40 45
          Ala Ala Gly Ser Pro Ser Ala Ala Leu Arg Trp Tyr Leu Ala Thr Gly
              50 55 60
          Asp Asp Ile Tyr Asp Val Pro His Ile Arg His Val His Ala Asn Gly
          65 70 75 80
          Thr Leu Gln Leu Tyr Pro Phe Ser Pro Ser Ala Phe Asn Ser Phe Ile
                          85 90 95
          His Asp Asn Asp Tyr Phe Cys Thr Ala Glu Asn Ala Ala Gly Lys Ile
                      100 105 110
          Arg Ser Pro Asn Ile Arg Val Lys Ala Val Phe Arg Glu Pro Tyr Thr
                  115 120 125
          Val Arg Val Glu Asp Gln Arg Ser Met Arg Gly Asn Val Ala Val Phe
              130 135 140
          Lys Cys Leu Ile Pro Ser Ser Val Gln Glu Tyr Val Ser Val Val Ser
          145 150 155 160
          Trp Glu Lys Asp Thr Val Ser Ile Ile Pro
                          165 170
           <![CDATA[ <210> 940]]>
           <![CDATA[ <211> 485]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 940]]>
          actcgccgca gcctgcgcgc cttctccagt ccgcggtgcc atggcccccg cccgtctgtt 60
          cgcgctgctg ctgttcttcg taggcggagt cgccgagtcg atccgagaga ctgaggtcat 120
          cgacccccag gacctcctag aaggccgata cttctccgga gccctaccag acgatgagga 180
          tgtagtgggg cccgggcagg aatctgatga ctttgagctg tctggctctg gagatctgga 240
          tgacttggaa gactccatga tcggccctga agttgtccat cccttggtgc ctctagataa 300
          ccatatccct gagagggcag ggtctggggag ccaagtcccc accgaaccca agaaactaga 360
          ggagaatgag gttatcccca agagaatctc acccgttgaa gagagtgagg atgtgtccaa 420
          caaggtgtca atgtccagca ctgtgcaggg cagcaacatc tttgagagaa cggaggtcct 480
          ggcag 485
           <![CDATA[ <210> 941]]>
           <![CDATA[ <211> 148]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Human]]>
           <![CDATA[ <400> 941]]>
          Met Ala Pro Ala Arg Leu Phe Ala Leu Leu Leu Phe Phe Val Gly Gly
          1 5 10 15
          Val Ala Glu Ser Ile Arg Glu Thr Glu Val Ile Asp Pro Gln Asp Leu
                      20 25 30
          Leu Glu Gly Arg Tyr Phe Ser Gly Ala Leu Pro Asp Asp Glu Asp Val
                  35 40 45
          Val Gly Pro Gly Gln Glu Ser Asp Asp Phe Glu Leu Ser Gly Ser Gly
              50 55 60
          Asp Leu Asp Asp Leu Glu Asp Ser Met Ile Gly Pro Glu Val Val His
          65 70 75 80
          Pro Leu Val Pro Leu Asp Asn His Ile Pro Glu Arg Ala Gly Ser Gly
                          85 90 95
          Ser Gln Val Pro Thr Glu Pro Lys Lys Leu Glu Glu Asn Glu Val Ile
                      100 105 110
          Pro Lys Arg Ile Ser Pro Val Glu Glu Ser Glu Asp Val Ser Asn Lys
                  115 120 125
          Val Ser Met Ser Ser Ser Thr Val Gln Gly Ser Asn Ile Phe Glu Arg Thr
              130 135 140
          Glu Val Leu Ala
          145
           <![CDATA[ <210> 942]]>
           <![CDATA[ <211> 33]]>
           <![CDATA[ <212>DNA]]>
           <![CDATA[ <213> Artificial Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> T7 promoter]]>
           <![CDATA[ <400> 942]]>
          cagagatgca taatacgact cactataggg aga 33
          
      

(none)

Claims (61)

A polynucleotide comprising: - a PVALB nucleic acid sequence or an allogenic variant of the PVALB sequence fused to an NRG1 nucleic acid sequence or an allogenic variant of the NRG1 sequence, or - an ASPH nucleic acid sequence or an allogenic variant of the ASPH sequence fused to an NRG1 nucleic acid sequence or an allogenic variant of the NRG1 sequence, or - a DAAM1 nucleic acid sequence or an allogenic variant of the DAAM1 sequence fused to an NRG1 nucleic acid sequence or an allogenic variant of the NRG1 sequence, or - a ZFAT nucleic acid sequence or an allogenic variant of the ZFAT sequence fused to an NRG1 nucleic acid sequence or an allogenic variant of the NRG1 sequence, or - a DACAML1 nucleic acid sequence or an allogenic variant of the DSCAML1 sequence fused to an NRG1 nucleic acid sequence or an allogenic variant of the NRG1 sequence. Such as the polynucleotide of claim 1, wherein - the PVALB nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 439-444, or comprises or consists of any allele variant of any one of SEQ ID NOs: 439-444, and the NRG1 The nucleic acid sequence comprises or consists of any one of SEQ ID NO: 125-138; - the DAAM1 nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 606-631, or comprises or consists of an allele variant of any one of SEQ ID NOs: 606-631, and the NRG1 The nucleic acid sequence comprises or consists of any one of SEQ ID NO: 125-138; - the ZFAT nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 830-846, or comprises any allele variant of any one of SEQ ID NOs: 830-846 or consists of it, and the NRG1 The nucleic acid sequence comprises or consists of any one of SEQ ID NO: 125-138; or - the DSCAML1 nucleic acid sequence comprises or consists of any one of SEQ ID NOs: 870-903, or comprises or consists of an allele variant of any one of SEQ ID NOs: 870-903, and the NRG1 The nucleic acid sequence comprises or consists of any one of SEQ ID NO: 125-138. The polynucleotide of claim 1 or 2, wherein the PVALB, DAAM1, ZFAT or DSCAML1 nucleic acid sequence (or its allele variant) is located at the 5' end of the NRG1 nucleic acid sequence (or its allele variant). The polynucleotide according to any one of claims 1 to 3, wherein - the allele variant of the PVALB nucleic acid sequence has at least 85% identity, preferably at least 90% identity, more preferably at least 95% sequence identity with any one of SEQ ID NO: 439-444 and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, more preferably at least 95% identity sequence identity; - the allele variant of the DAAM1 nucleic acid sequence has at least 85% identity, preferably at least 90% identity, more preferably at least 95% sequence identity to any one of SEQ ID NO: 606-631 and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, more preferably at least 95% identity sequence identity; - the allele variant of the ZFAT nucleic acid sequence has at least 85% identity, preferably at least 90% identity, more preferably at least 95% sequence identity with any one of SEQ ID NO: 830-846 and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, more preferably at least 95% identity sequence identity; or - the allele variant of the DSCAML1 nucleic acid sequence has at least 85% identity, preferably at least 90% identity, more preferably at least 95% sequence identity with any one of SEQ ID NO: 870-903 and the allele variant of the NRG1 nucleic acid sequence has at least 85% identity with any one of SEQ ID NO: 125-138, preferably at least 90% identity, more preferably at least 95% identity sequence identity. The polynucleotide according to any one of claims 1 to 4, wherein - the fusion of the PVALB nucleic acid and the NRG1 nucleic acid comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 437, preferably including the nucleic acids at positions 102 and 103; - the fusion of the DAAM1 nucleic acid and the NRG1 nucleic acid comprises from 2 to about 40 contiguous nucleic acids from SEQ ID NO: 605, preferably including the nucleic acids at positions 75 and 76; - the fusion of the ZFAT nucleic acid and the NRG1 nucleic acid comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 828, preferably including the nucleic acids at positions 75 and 76; or - the fusion of the DSCAML1 nucleic acid and the NRG1 nucleic acid comprises from 2 to about 40 contiguous nucleic acids from SEQ ID NO: 868, preferably including the nucleic acids at positions 75 and 76. The polynucleotide according to any one of claims 1 to 5, wherein the nucleic acid encoding the NRG1 protein sequence (or its allele variant) comprises or encodes the EGF-like domain of NRG1, preferably as SEQ ID NO: 163 EGF-like domains. A polynucleotide comprising: - exon 1 or part of an allogenic variant of exon 1 of VAPB fused to part of an allogenic variant of exon 2 or exon 2 of NRG1; - CADM1 exon 7 or part of an allogenic variant of exon 7, and NRG1 exon 6 or part of an allogenic variant of exon 6; - CD44 exon 5 or part of an allogenic variant of exon 5, and NRG1 exon 2 or part of an allogenic variant of exon 2; - Transcript exon 1 or part of an allogenic variant of exon 1 of SLC3A2, and part of an allogenic variant of exon 5 or exon 5 of NRG1; - VTCN1 exon 2 or part of an allogenic variant of exon 2, and NRG1 exon 2 or part of an allogenic variant of exon 2; - CDH1 exon 11 or part of an allogenic variant of exon 11, and NRG1 exon 2 or part of an allogenic variant of exon 2; - CXADR exon 1 or part of an allogenic variant of exon 1, and NRG1 exon 2 or part of an allogenic variant of exon 2; - part of the allele variant exon 2 or exon 1 of GTF2E2, and part of the allele variant of exon 2 or exon 2 of NRG1; - CSMD1 exon 23 or part of an allogenic variant of exon 23, and NRG1 exon 6 or part of an allogenic variant of exon 6; - PTN exon 4 or part of an allogenic variant of exon 4, and NRG1 exon 2 or part of an allogenic variant of exon 2; - ST14 exon 11 or part of an allogenic variant of exon 11, and NRG1 exon 6 or part of an allogenic variant of exon 6; - THBS1 exon 9 or part of an allogenic variant of exon 9, and NRG1 exon 6 or part of an allogenic variant of exon 6; - AGRN exon 12 or part of an allogenic variant of exon 12, and NRG1 exon 6 or part of an allogenic variant of exon 6; - PVALB exon 4 or part of an allogenic variant of exon 4, and NRG1 exon 6 or part of an allogenic variant of exon 6; - Transcript 3 exon 2 or part of an allogenic variant of exon 2 of SLC3A2 and part of an allogenic variant of exon 6 or exon 6 of NRG1; - APP exon 14 or part of an allogenic variant of exon 14, and NRG1 exon 6 or part of an allogenic variant of exon 6; - WRN exon 33 or part of an allogenic variant of exon 33, and NRG1 exon 6 or part of an allogenic variant of exon 6; - DAAM1 exon 1 or part of an allogenic variant of exon 1, and NRG1 exon 1 or part of an allogenic variant of exon 1; - ASPH exon 22 or part of an allogenic variant of exon 22, and NRG1 exon 2 or part of an allogenic variant of exon 2; - NOTCH2 exon 6 or part of an allogenic variant of exon 6, and NRG1 exon 6 or part of an allogenic variant of exon 6; - CD74 exon 2 or part of an allogenic variant of exon 2, and NRG1 exon 2 or part of an allogenic variant of exon 2; - SDC4 exon 2 or part of an allogenic variant of exon 2, and NRG1 exon 2 or part of an allogenic variant of exon 2; - CD44 exon 5 or part of an allogenic variant of exon 5, and NRG1 exon 6 or part of an allogenic variant of exon 6; - SLC4A4 exon 14 or part of an allogenic variant of exon 14, and NRG1 exon 6 or part of an allogenic variant of exon 6; - SDC4 exon 4 or part of an allogenic variant of exon 4, and NRG1 exon 2 or part of an allogenic variant of exon 2; - ZFAT exon 12 or part of an allogenic variant of exon 12, and NRG1 exon 6 or part of an allogenic variant of exon 6; or - DSCAML1 exon 3 or part of an allogenic variant of exon 3, and NRG1 exon 2 or part of an allogenic variant of exon 2. The polynucleotide as claimed in item 7, wherein exon 1 of VAPB is exon of SEQ ID NO: 17; exon 7 of CADM1 is exon of SEQ ID NO: 39; exon 5 of CD44 Exon of SEQ ID NO: 65; exon 1 of SLC3A2 is exon of SEQ ID NO: 103; exon 2 of VTCN1 is exon of SEQ ID NO: 169; exon of CDH1 11 is the exon of SEQ ID NO: 198; CXADR exon 1 is the exon of SEQ ID NO: 219; GTF2E2 exon 2 is the exon of SEQ ID NO: 236; CSMD1 exon Son 23 is the exon of SEQ ID NO: 279; PTN exon 4 is the exon of SEQ ID NO: 318; ST14 exon 11 is the exon of SEQ ID NO: 342; outside THBS1 Exon 9 is the exon of SEQ ID NO: 386; AGRN exon 12 is the exon of SEQ ID NO: 416; PVALB exon 4 is the exon of SEQ ID NO: 442; the exon of SLC3A2 Exon 2 is the exon of SEQ ID NO: 457; APP exon 14 is the exon of SEQ ID NO: 501; WRN exon 33 is the exon of SEQ ID NO: 562; DAAM1 Exon 1 is the exon of SEQ ID NO: 606; ASPH exon 22 is the exon of SEQ ID NO: 658; NOTCH2 exon 6 is the exon of SEQ ID NO: 700; CD74 exon 2 is the exon of SEQ ID NO: 720; SDC4 exon 2 is the exon of SEQ ID NO: 746; CD44 exon 5 is the exon of SEQ ID NO: 65 ; SLC4A4 exon 14 is the exon of SEQ ID NO: 780; SDC4 exon 4 is the exon of SEQ ID NO: 748; ZFAT exon 12 is the exon of SEQ ID NO: 841 DSCAML1 exon 3 is the exon of SEQ ID NO: 872, and NRG1 exons 1, 2, 5 and 6 are the exons of SEQ ID NO: 125, 126, 129 and 130, respectively. The polynucleotide according to any one of claim 7 or 8, wherein: - The VAPB exon 1 or its allele variant part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - The CADM1 exon 7 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - the CD44 exon 5 or its allele variant part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - the SLC3A2 exon 1 or its allele variant part is located at the 5' end of the NRG1 exon 5 or its allele variant part; - The VTCN1 exon 2 or its allele variant part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - The CDH1 exon 11 or its allele variant part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - The CXADR exon 1 or its allele variant part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - the GTF2E2 exon 2 or its allele variant part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - The CSMD1 exon 23 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - the PTN exon 4 or its allele variant part is located at the 5' end of the NRG1 exon 2 or its allele variant part; - The ST14 exon 11 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - The THBS1 exon 9 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - The AGRN exon 12 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - The PVALB exon 4 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - the SCL3A2 exon 2 or its allele variant part is located at the 5' end of the NRG1 exon 6 or its allele variant part; - the APP exon 14 or its allogenic variant part is located at the 5' end of the NRG1 exon 6 or the allogenic variant part of exon 6; - the WRN exon 33 or its allogenic variant part is located at the 5' end of the NRG1 exon 6 or the allogenic variant part of exon 6; - the DAAM1 exon 1 or its allogenic variant part is located at the 5' end of the NRG1 exon 1 or the allogenic variant part of exon 1; - the ASPH exon 22 or its allogenic variant part is located at the 5' end of the NRG1 exon 2 or the allogenic variant part of exon 2; - the NOTCH2 exon 6 or its allogenic variant part is located at the 5' end of the NRG1 exon 6 or the allogenic variant part of exon 6; - the CD74 exon 2 or allogenic variant part thereof is located at the 5' end of the NRG1 exon 2 or the allogenic variant part of exon 2; - the SDC4 exon 2 or its allogenic variant part is located at the 5' end of the NRG1 exon 2 or the allogenic variant part of exon 2; - the CD44 exon 5 or its allogenic variant part is located at the 5' end of the NRG1 exon 6 or the allogenic variant part of exon 6; - the SLC4A4 exon 14 or its allele variant part is located at the 5' end of the NRG1 exon 6 or the allele variant part of exon 6; - the SDC4 exon 4 or its allogenic variant part is located at the 5' end of the NRG1 exon 2 or the allogenic variant part of exon 2; - the ZFAT exon 12 or its allogenic variant part is located at the 5' end of the NRG1 exon 6 or the allogenic variant part of exon 6; and - The DSCAML1 exon 3 or its allogenic variant part is located at the 5' end of the NRG1 exon 2 or exon 2 allogenic variant part. The polynucleotide according to any one of claims 7 to 9, wherein: - the allele variant of exon 1 of VAPB is at least 85% identical to SEQ ID NO: 17, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 7 of CADM1 is at least 85% identical to SEQ ID NO: 39, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 5 of CD44 is at least 85% identical to SEQ ID NO: 65, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 1 of SLC3A2 is at least 85% identical to SEQ ID NO: 103, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of the exon 2 of VTCN1 is at least 85% identical to SEQ ID NO: 169, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 11 of CDH1 is at least 85% identical to SEQ ID NO: 198, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 2 of NRG1 is at least 85% identical to SEQ ID NO: 126, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 5 of NRG1 is at least 85% identical to SEQ ID NO: 129, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 6 of NRG1 is at least 85% identical to SEQ ID NO: 130, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the CXADR exon 1 allele variant is at least 85% identical to SEQ ID NO: 219, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 2 of GTF2E2 is at least 85% identical to SEQ ID NO: 236, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 23 of CSMD1 is at least 85% identical to SEQ ID NO: 279, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of PTN exon 4 is at least 85% identical to SEQ ID NO: 318, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the ST14 exon 11 allele variant is at least 85% identical to SEQ ID NO: 342, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 9 of THBS1 is at least 85% identical to SEQ ID NO: 386, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 12 of AGRN is at least 85% identical to SEQ ID NO: 416, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 4 of PVALB is at least 85% identical to SEQ ID NO: 442, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 2 of SCL3A2 is at least 85% identical to SEQ ID NO: 457, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the APP exon 14 allele variant is at least 85% identical to SEQ ID NO: 501, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 33 of the WRN is at least 85% identical to SEQ ID NO: 562, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 1 of DAAM1 is at least 85% identical to SEQ ID NO: 606, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 1 of NRG1 is at least 85% identical to SEQ ID NO: 125, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of ASPH exon 22 is at least 85% identical to SEQ ID NO: 658, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 6 of NOTCH2 is at least 85% identical to SEQ ID NO: 700, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the CD74 exon 2 allele variant is at least 85% identical to SEQ ID NO: 720, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 2 of SDC4 is at least 85% identical to SEQ ID NO: 746, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 5 of CD44 is at least 85% identical to SEQ ID NO: 65, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 14 of SLC4A4 is at least 85% identical to SEQ ID NO: 780, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 4 of SDC4 is at least 85% identical to SEQ ID NO: 748, preferably at least 90%, 92%, 94%, 96% or even 98% identical ; - the allele variant of exon 12 of the ZFAT is at least 85% identical to SEQ ID NO: 841, preferably at least 90%, 92%, 94%, 96% or even 98% identical ;and - the allele variant of exon 3 of DSCAML1 is at least 85% identical to SEQ ID NO: 872, preferably at least 90%, 92%, 94%, 96% or even 98% identical . The polynucleotide according to any one of claims 7 to 10, wherein: - the fusion of VAPB and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 3, including the nucleic acids at positions 43 and 44; - the fusion of CADM1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 7, including the nucleic acids at positions 53 and 54; - the fusion of CD44 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 11, including the nucleic acids at positions 52 and 53; - the fusion of SLC3A2 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 15, including the nucleic acids at positions 53 and 54; - the fusion of VTCN1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 166, including the nucleic acids at positions 65 and 66; - the fusion of CDH1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 186, including the nucleic acids at positions 119 and 120; - the fusion of CXADR and NRG1 comprises from 2 to about 40 contiguous nucleic acids from SEQ ID NO: 217, including the nucleic acids at positions 43 and 44; - the fusion of GTF2E2 and NRG1 comprises from 2 to about 40 contiguous nucleic acids from SEQ ID NO: 233, including the nucleic acids at positions 141 and 142; - the fusion of CSMD1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 255, including the nucleic acids at positions 88 and 89; - the fusion of PTN and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 313, including the nucleic acids at positions 102 and 103; - the fusion of ST14 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 330, including the nucleic acids at positions 95 and 96; - the fusion of THBS1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 376, including the nucleic acids at positions 56 and 57; - the fusion of AGRN and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 403, including the nucleic acids at positions 106 and 107; - the fusion of PVALB and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 437, including the nucleic acids at positions 102 and 103; - the fusion of SLC3A2 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 454, including the nucleic acids at positions 93 and 94; - the fusion of APP and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 486, including the nucleic acids at positions 54 and 55; - the fusion of WRN and NRG1 comprises from 2 to about 40 contiguous nucleic acids from SEQ ID NO: 528, including the nucleic acids at positions 96 and 97; - the fusion of DAAM1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 605, including the nucleic acids at positions 75 and 76; - the fusion of ASPH and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 635, including the nucleic acids at positions 75 and 76; - the fusion of NOTCH2 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 693, including the nucleic acids at positions 75 and 76; - the fusion of CD74 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 717, including the nucleic acids at positions 75 and 76; - the fusion of SDC4 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 743, including the nucleic acids at positions 75 and 76; - the fusion of CD44 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 761, including the nucleic acids at positions 75 and 76; - the fusion of SLC4A4 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 765, including the nucleic acids at positions 75 and 76; - the fusion of SDC4 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 824, including the nucleic acids at positions 75 and 76; - the fusion of ZFAT and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 828, including the nucleic acids at positions 75 and 76; and - the fusion of DSCAML1 and NRG1 comprises 2 to about 40 contiguous nucleic acids from SEQ ID NO: 868, including the nucleic acids at positions 75 and 76. The polynucleotide according to any one of claims 7 to 11, wherein: - the fusion of VAPB and NRG1 comprises SEQ ID NO: 3 or an allele variant thereof; - the fusion of CAD1 and NRG1 comprises SEQ ID NO: 7 or an allele variant thereof; - the fusion of CD44 and NRG1 comprises SEQ ID NO: 11 or an allele variant thereof; - the fusion of SLC3A2 and NRG1 comprises SEQ ID NO: 15 or an allele variant thereof; - the fusion of VTCN1 and NRG1 comprises SEQ ID NO: 166 or an allele variant thereof; - the fusion of CDH1 and NRG1 comprises SEQ ID NO: 186 or an allele variant thereof; - the fusion of CXADR and NRG1 comprises SEQ ID NO: 217 or an allele variant thereof; - the fusion of GTF2E2 and NRG1 comprises SEQ ID NO: 233 or an allele variant thereof; - the fusion of CSMD1 and NRG1 comprises SEQ ID NO: 255 or an allele variant thereof; - the fusion of PTN and NRG1 comprises SEQ ID NO: 313 or an allele variant thereof; - the fusion of ST14 and NRG1 comprises SEQ ID NO: 330 or an allele variant thereof; - the fusion of THBS1 and NRG1 comprises SEQ ID NO: 376 or an allele variant thereof; - the fusion of AGRN and NRG1 comprises SEQ ID NO: 403 or an allele variant thereof; - the fusion of PVALB and NRG1 comprises SEQ ID NO: 437 or an allele variant thereof; - the fusion of SLC3A2 and NRG1 comprises SEQ ID NO: 454 or an allele variant thereof; - the fusion of APP and NRG1 comprises SEQ ID NO: 486 or an allele variant thereof; - the fusion of WRN and NRG1 comprises SEQ ID NO: 528 or an allele variant thereof; - the fusion of DAAM1 and NRG1 comprises SEQ ID NO: 605 or an allele variant thereof; - the fusion of ASPH and NRG1 comprises SEQ ID NO: 635 or an allele variant thereof; - the fusion of NOTCH2 and NRG1 comprises SEQ ID NO: 693 or an allele variant thereof; - the fusion of CD74 and NRG1 comprises SEQ ID NO: 717 or an allele variant thereof; - the fusion of SDC4 and NRG1 comprises SEQ ID NO: 743 or an allele variant thereof; - the fusion of CD44 and NRG1 comprises SEQ ID NO: 761 or an allele variant thereof; - the fusion of SLC4A4 and NRG1 comprises SEQ ID NO: 765 or an allele variant thereof; - the fusion of SDC4 and NRG1 comprises SEQ ID NO: 824 or an allele variant thereof; - the fusion of ZFAT and NRG1 comprises SEQ ID NO: 828 or an allele variant thereof; and - the fusion of DSCAML1 and NRG1 comprises SEQ ID NO: 868 or an allegenic variant thereof. The polynucleotide according to any one of claims 7 to 12, wherein: - the VAPB exon 1 part is or comprises SEQ ID NO: 1 or an allele variant of SEQ ID NO: 1; - the exon 7 portion of CADM1 is or comprises SEQ ID NO: 5 or an allele variant of SEQ ID NO: 5; - the portion of exon 5 of CD44 is or comprises SEQ ID NO: 9 or an allele variant of SEQ ID NO: 9; - the SLC3A2 exon 1 portion is or comprises SEQ ID NO: 13 or an allele variant of SEQ ID NO: 13; - the VTCN1 exon 2 part is or comprises SEQ ID NO: 164 or an allele variant of SEQ ID NO: 164; - the exon 11 portion of CDH1 is or comprises SEQ ID NO: 184 or an allele variant of SEQ ID NO: 184; - the CXADR exon 1 portion is or comprises SEQ ID NO: 215 or an allele variant of SEQ ID NO: 215; - the exon 2 portion of GTF2E2 is or comprises SEQ ID NO: 231 or an allele variant of SEQ ID NO: 231; - the exon 23 portion of CSMD1 is or comprises SEQ ID NO: 253 or an allele variant of SEQ ID NO: 253; - the PTN exon 4 part is or comprises SEQ ID NO: 311 or an allele variant of SEQ ID NO: 311; - the portion of exon 11 of ST14 is or comprises SEQ ID NO: 328 or an allele variant of SEQ ID NO: 328; - the part of exon 9 of THBS1 is or comprises SEQ ID NO: 374 or an allele variant of SEQ ID NO: 374; - the AGRN exon 12 portion is or comprises SEQ ID NO: 401 or an allele variant of SEQ ID NO: 401; - the exon 4 portion of PVALB is or comprises SEQ ID NO: 435 or an allele variant of SEQ ID NO: 435; - the SLC3A2 exon 2 portion is or comprises SEQ ID NO: 452 or an allele variant of SEQ ID NO: 452; - the part of exon 2 of NRG1 is or comprises SEQ ID NO: 165 or an allele variant of SEQ ID NO: 165; - the exon 5 portion of NRG1 is or comprises SEQ ID NO: 14 or an allele variant of SEQ ID NO: 14; - the NRG1 exon 6 portion is or comprises SEQ ID NO: 6 or an allele variant thereof; - the APP exon 14 portion is or comprises SEQ ID NO: 484 or an allele variant thereof; - the WRN exon 33 portion is or comprises SEQ ID NO: 526 or an allele variant thereof; - the DAAM1 exon 1 portion is or comprises SEQ ID NO: 603 or an allele variant thereof; - the ASPH exon 22 portion is or comprises SEQ ID NO: 633 or an allele variant thereof; - the NOTCH2 exon 6 portion is or comprises SEQ ID NO: 691 or an allele variant thereof; - the CD74 exon 2 portion is or comprises SEQ ID NO: 715 or an allele variant thereof; - the SDC4 exon 2 portion is or comprises SEQ ID NO: 741 or an allele variant thereof; - the CD44 exon 5 portion is or comprises SEQ ID NO: 759 or an allele variant thereof; - the SLC4A4 exon 14 portion is or comprises SEQ ID NO: 763 or an allele variant thereof; - the SDC4 exon 4 portion is or comprises SEQ ID NO: 822 or an allele variant thereof; - the ZFAT exon 12 portion is or comprises SEQ ID NO: 826 or an allele variant thereof; - the DSCAML1 exon 3 portion is or comprises SEQ ID NO: 866 or an allele variant thereof; and - the exon 1 portion of NRG1 is or comprises SEQ ID NO: 604 or an allele variant thereof. The polynucleotide according to any one of claims 7 to 12, wherein: - the fusion of VAPB and NRG1 comprises a fusion junction between VAPB exon 1 and NRG1 exon 2, preferably between the nucleic acid at position 43 of VAPB of SEQ ID NO: 3 and the nucleic acid at position 44 of NRG1 the junction between - the fusion of CADM1 and NRG1 comprises a fusion junction between CADM1 exon 7 and NRG1 exon 6, preferably between the nucleic acid at position 53 of CADM1 of SEQ ID NO: 7 and the nucleic acid at position 54 of NRG1 the junction between - the fusion of CD44 and NRG1 comprises a fusion junction between CD44 exon 5 and NRG1 exon 2, preferably between the nucleic acid at position 52 of CD44 of SEQ ID NO: 11 and the nucleic acid at position 53 of NRG1 the junction between - the fusion of SLC3A2 and NRG1 comprises a fusion junction between exon 1 of SLC3A2 and exon 5 of NRG1, preferably between the nucleic acid at position 53 of SLC3A2 of SEQ ID NO: 15 and the nucleic acid at position 54 of NRG1 the junction between - the fusion of VTCN1 and NRG1 comprises a fusion junction between VTCN1 exon 2 and NRG1 exon 2, preferably between the nucleic acid at position 65 of VTCN1 of SEQ ID NO: 166 and the nucleic acid at position 66 of NRG1 the junction between - the fusion of CDH1 and NRG1 comprises a fusion junction between exon 11 of CDH1 and exon 2 of NRG1, preferably between the nucleic acid at position 119 of CDH1 of SEQ ID NO: 186 and the nucleic acid at position 120 of NRG1 the junction between - the fusion of CXADR and NRG1 comprises a fusion junction between exon 1 of CXADR and exon 2 of NRG1, preferably between the nucleic acid at position 43 of CXADR of SEQ ID NO: 217 and the nucleic acid at position 44 of NRG1 the junction between - the fusion of GTF2E2 and NRG1 comprises a fusion junction between GTF2E2 exon 2 and NRG1 exon 2, preferably between the nucleic acid at position 141 of GTF2E2 of SEQ ID NO: 233 and the nucleic acid at position 142 of NRG1 the junction between - the fusion of CSMD1 and NRG1 comprises a fusion junction between exon 23 of CSMD1 and exon 6 of NRG1, preferably between the nucleic acid at position 88 of CSMD1 of SEQ ID NO: 255 and the nucleic acid at position 89 of NRG1 the junction between - the fusion of PTN and NRG1 comprises a fusion junction between PTN exon 4 and NRG1 exon 2, preferably between the nucleic acid at position 102 of PTN of SEQ ID NO: 313 and the nucleic acid at position 103 of NRG1 the junction between - the fusion of ST14 and NRG1 comprises a fusion junction between exon 11 of ST14 and exon 6 of NRG1, preferably between the nucleic acid at position 95 of ST14 of SEQ ID NO: 330 and the nucleic acid at position 96 of NRG1 the junction between - The fusion of THBS1 and NRG1 comprises a fusion junction between THBS1 exon 9 and NRG1 exon 6, preferably between the nucleic acid at position 56 of THBS1 of SEQ ID NO: 376 and the nucleic acid at position 57 of NRG1 the junction between - the fusion of AGRN and NRG1 comprises a fusion junction between exon 12 of AGRN and exon 6 of NRG1, preferably between the nucleic acid at position 106 of AGRN of SEQ ID NO: 403 and the nucleic acid at position 107 of NRG1 the junction between - the fusion of PVALB and NRG1 comprises a fusion junction between PVALB exon 4 and NRG1 exon 6, preferably between the nucleic acid at position 102 of PVALB of SEQ ID NO: 437 and the nucleic acid at position 103 of NRG1 the junction between - the fusion of SLC3A2 and NRG1 comprises a fusion junction between exon 2 of SLC3A2 and exon 6 of NRG1, preferably between the nucleic acid at position 93 of SLC3A2 of SEQ ID NO: 454 and the nucleic acid at position 94 of NRG1 the junction between - the fusion of APP and NRG1 comprises a fusion junction between APP exon 14 and NRG1 exon 6, preferably between the nucleic acid at position 54 of APP of SEQ ID NO: 486 and the nucleic acid at position 55 of NRG1 the junction between - the fusion of WRN and NRG1 comprises a fusion junction between WRN exon 33 and NRG1 exon 6, preferably between the nucleic acid at WRN position 96 of SEQ ID NO: 528 and the nucleic acid at position 97 of NRG1 the junction between - the fusion of DAAM1 and NRG1 comprises a fusion junction between exon 1 of DAAM1 and exon 1 of NRG1, preferably between nucleic acid 75 at position DAAM1 of SEQ ID NO: 605 and nucleic acid 76 at position NRG1 the junction between - the fusion of ASPH and NRG1 comprises a fusion junction between ASPH exon 22 and NRG1 exon 2, preferably between the nucleic acid at position 75 of ASPH of SEQ ID NO: 635 and the nucleic acid at position 76 of NRG1 the junction between - the fusion of NOTCH2 and NRG1 comprises a fusion junction between exon 6 of NOTCH2 and exon 6 of NRG1, preferably between the nucleic acid at position 75 of NOTCH2 of SEQ ID NO: 693 and the nucleic acid at position 76 of NRG1 the junction between - the fusion of CD74 and NRG1 comprises a fusion junction between exon 2 of CD74 and exon 2 of NRG1, preferably between the nucleic acid at position 75 of CD74 of SEQ ID NO: 717 and the nucleic acid at position 76 of NRG1 the junction between - the fusion of SDC4 and NRG1 comprises a fusion junction between exon 2 of SDC4 and exon 2 of NRG1, preferably between the nucleic acid at position 75 of SDC4 of SEQ ID NO: 743 and the nucleic acid at position 76 of NRG1 the junction between - the fusion of CD44 and NRG1 comprises a fusion junction between exon 5 of CD44 and exon 6 of NRG1, preferably between the nucleic acid at position 75 of VAPB of SEQ ID NO: 761 and the nucleic acid at position 76 of NRG1 the junction between - the fusion of SLC4A4 and NRG1 comprises a fusion junction between exon 14 of SLC4A4 and exon 6 of NRG1, preferably between the nucleic acid at position 75 of SLC4A4 of SEQ ID NO: 765 and the nucleic acid at position 76 of NRG1 the junction between - the fusion of SDC4 and NRG1 comprises a fusion junction between exon 4 of SDC4 and exon 2 of NRG1, preferably between the nucleic acid at position 75 of SDC4 of SEQ ID NO: 824 and the nucleic acid at position 76 of NRG1 the junction between - the fusion of ZFAT and NRG1 comprises a fusion junction between ZFAT exon 12 and NRG1 exon 6, preferably between the nucleic acid at position 75 of ZFAT of SEQ ID NO: 828 and the nucleic acid at position 76 of NRG1 the junction between; and - the fusion of DSCAML1 and NRG1 comprises a fusion junction between exon 3 of DSCAML1 and exon 2 of NRG1, preferably between the nucleic acid at position 75 of DSCAML1 of SEQ ID NO: 868 and the nucleic acid at position 76 of NRG1 the junction between. The polynucleotide according to any one of the preceding claims, wherein the polynucleotide is isolated or purified. The polynucleotide of any one of the preceding claims, wherein any of the fusions are in-frame fusions. The polynucleotide according to any one of the preceding claims, wherein the polynucleotide is a mammalian polynucleotide, preferably a human polynucleotide. A polypeptide fusion encoded by the polynucleotide of any one of the preceding claims. A vector comprising the polynucleotide according to any one of claims 1-17. A recombinant host cell comprising the polynucleotide according to any one of claims 1 to 17 or the vector according to claim 19. A method for producing a polypeptide fusion as claimed in claim 18, comprising maintaining the host cell as claimed in claim 20 under conditions suitable for the expression of a polynucleotide contained in the host cell, thereby expressing the polynucleotide and producing a polypeptide fusion, followed by isolation or purification of the polypeptide fusion. A method for producing a recombinant host cell, comprising introducing the vector according to claim 19 into a host cell. A detection assay comprising a nucleic acid probe, primer or pair of primers for detecting the presence of the polynucleotide fusion according to any one of claims 1 to 17. A nucleic acid probe, primer or primer pair for detecting the polynucleotide fusion according to any one of claims 1 to 17. The nucleic acid probe, primer or primer pair according to claim 24, which is 10 to 40 nucleotides in length. The nucleic acid probe, primer or primer pair as claimed in item 24 or 25, wherein the detected fusion comprises: - a fusion of VAPB and NRG1 comprising or consisting of SEQ ID NO: 3, and preferably comprising the nucleic acid at position 43 or 44; - a fusion of CADM1 and NRG1 comprising or consisting of SEQ ID NO: 7, and preferably comprising the nucleic acid at position 53 or 54; - a fusion of CD44 and NRG1 comprising or consisting of SEQ ID NO: 11, and preferably comprising the nucleic acid at position 52 or 53; - a fusion of SLC3A2 and NRG1 comprising or consisting of SEQ ID NO: 15, and preferably comprising the nucleic acid at position 53 or 54; - a fusion of VTCN1 and NRG1 comprising or consisting of SEQ ID NO: 166, and preferably comprising the nucleic acid at position 65 or 66; - a fusion of CDH1 and NRG1 comprising or consisting of SEQ ID NO: 186, and preferably comprising the nucleic acid at position 119 or 120; - a fusion of CXADR and NRG1 comprising or consisting of SEQ ID NO: 217, and preferably comprising the nucleic acid at position 43 or 44; - a fusion of GTF2E2 and NRG1 comprising or consisting of SEQ ID NO: 233, and preferably comprising the nucleic acid at position 141 or 142; - a fusion of CSMD1 and NRG1 comprising or consisting of SEQ ID NO: 255, and preferably comprising the nucleic acid at position 88 or 89; - a fusion of PTN and NRG1 comprising or consisting of SEQ ID NO: 313, and preferably comprising the nucleic acid at position 102 or 103; - a fusion of ST14 and NRG1 comprising or consisting of SEQ ID NO: 330, and preferably comprising the nucleic acid at position 95 or 96; - a fusion of THBS1 and NRG1 comprising or consisting of SEQ ID NO: 376, and preferably comprising the nucleic acid at position 56 or 57; - a fusion of AGRN and NRG1 comprising or consisting of SEQ ID NO: 403, and preferably comprising the nucleic acid at position 106 or 107; - a fusion of PVALB and NRG1 comprising or consisting of SEQ ID NO: 437, and preferably comprising the nucleic acid at position 102 or 103; - a fusion of SLC3A2 and NRG1 comprising or consisting of SEQ ID NO: 454, and preferably comprising the nucleic acid at position 93 or 94; -A fusion of APP and NRG1 comprising or consisting of SEQ ID NO: 486, and preferably comprising the nucleic acid at position 54 or 55; - a fusion of WRN and NRG1 comprising or consisting of SEQ ID NO: 528, and preferably comprising the nucleic acid at position 96 or 97; - a fusion of DAAM1 and NRG1 comprising or consisting of SEQ ID NO: 605, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of ASPH and NRG1 comprising or consisting of SEQ ID NO: 635, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of NOTCH2 and NRG1 comprising or consisting of SEQ ID NO: 693, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of CD74 and NRG1 comprising or consisting of SEQ ID NO: 717, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of SDC4 and NRG1 comprising or consisting of SEQ ID NO: 743, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of CD44 and NRG1 comprising or consisting of SEQ ID NO: 761, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of SLC4A4 and NRG1 comprising or consisting of SEQ ID NO: 765, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of SDC4 and NRG1 comprising or consisting of SEQ ID NO: 824, and preferably comprising the nucleic acid at position 75 or 76; - a fusion of ZFAT and NRG1 comprising or consisting of SEQ ID NO: 828, and preferably comprising the nucleic acid at position 75 or 76; and - a fusion of DSCAML1 and NRG1 comprising or consisting of SEQ ID NO: 868, and preferably comprising the nucleic acid at position 75 or 76. The nucleic acid probe, primer or primer pair according to any one of claims 24 to 26, wherein: - the probe, primer or pair of primers for detecting the fusion of VAPB and NRG1 specifically hybridizes to a sequence consisting of exon 1 of VAPB or a sequence located 5' to exon 1, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or pair of primers for detecting the fusion of CADM1 and NRG1 specifically hybridizes to a sequence consisting of exon 7 of CADM1 or a sequence located 5' to exon 7, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or primer pair for detecting the fusion of CD44 and NRG1 specifically hybridizes to a sequence consisting of exon 5 of CD44 or a sequence located 5' to exon 5, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of transcript 6 of SLC3A2 and NRG1 is specific to a sequence consisting of exon 1 of SLC3A2 or a sequence located at the 5' of exon 1 Hybridizes, and/or specifically hybridizes to a sequence consisting of exon 5 of NRG1 or a sequence located 3' to exon 5, or is 95% or higher complementary to these sequences consistency; - the probe, primer or pair of primers for detecting the fusion of VTCN1 and NRG1 specifically hybridizes to a sequence consisting of exon 2 of VTCN1 or a sequence located 5' to exon 2, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or pair of primers for detecting the fusion of CDH1 and NRG1 specifically hybridizes to a sequence consisting of exon 11 of CDH1 or a sequence located 5' to exon 11, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or pair of primers for detecting the fusion of CXADR and NRG1 specifically hybridizes to a sequence consisting of exon 1 of CXADR or a sequence located 5' to exon 1, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or primer pair for detecting the fusion of GTF2E2 and NRG1 specifically hybridizes to a sequence consisting of exon 2 of GTF2E2 or a sequence located 5' to exon 2, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or pair of primers for detecting the fusion of CSMD1 and NRG1 specifically hybridizes to a sequence consisting of exon 23 of CSMD1 or a sequence located 5' to exon 23, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or pair of primers for detecting the fusion of PTN and NRG1 specifically hybridizes to a sequence consisting of exon 4 of PTN or a sequence located 5' to exon 4, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or pair of primers for detecting the fusion of ST14 and NRG1 specifically hybridizes to a sequence consisting of exon 11 of ST14 or a sequence located 5' to exon 11, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or pair of primers for detecting the fusion of THBS1 and NRG1 specifically hybridizes to a sequence consisting of exon 9 of THBS1 or a sequence located 5' to exon 9, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or pair of primers for detecting the fusion of AGRN and NRG1 specifically hybridizes to a sequence consisting of exon 12 of AGRN or a sequence located 5' to exon 12, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or pair of primers for detecting the fusion of PVALB and NRG1 specifically hybridizes to a sequence consisting of exon 4 of PVALB or a sequence located 5' to exon 4, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - The probe, primer or primer pair used to detect the fusion of transcript 3 of SLC3A2 and NRG1 is specifically linked to a sequence consisting of exon 2 of SLC3A2 or a sequence located 5' of exon 2 Hybridizes, and/or specifically hybridizes to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or is 95% or higher complementary to these sequences consistency; - the probe, primer or pair of primers for detecting the fusion of APP and NRG1 specifically hybridizes to a sequence consisting of exon 14 of APP or a sequence located 5' to exon 14, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or pair of primers for detecting the fusion of WRN and NRG1 specifically hybridizes to a sequence consisting of exon 33 of WRN or a sequence located 5' to exon 33, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or pair of primers for detecting the fusion of DAAM1 and NRG1 specifically hybridizes to a sequence consisting of exon 1 of DAAM1 or a sequence located 5' of exon 1, and/or Or specifically hybridize to a sequence consisting of exon 1 of NRG1 or a sequence located 3' of exon 1, or have 95% or higher complementary sequence identity with these sequences; - the probe, primer or pair of primers for detecting the fusion of ASPH and NRG1 specifically hybridizes to a sequence consisting of exon 22 of ASPH or a sequence located 5' to exon 22, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or primer pair for detecting the fusion of NOTCH2 and NRG1 specifically hybridizes to a sequence consisting of exon 6 of NOTCH2 or a sequence located 5' to exon 6, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or primer pair for detecting the fusion of CD74 and NRG1 specifically hybridizes to a sequence consisting of exon 2 of CD74 or a sequence located 5' to exon 2, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or pair of primers for detecting the fusion of SDC4 and NRG1 specifically hybridizes to a sequence consisting of exon 2 of SDC4 or a sequence located 5' to exon 2, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or primer pair for detecting the fusion of CD44 and NRG1 specifically hybridizes to a sequence consisting of exon 5 of CD44 or a sequence located 5' to exon 5, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or pair of primers for detecting the fusion of SLC4A4 and NRG1 specifically hybridizes to a sequence consisting of exon 14 of SLC4A4 or a sequence located 5' to exon 14, and/or or specifically hybridize to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or have 95% or higher complementary sequence identity to these sequences; - the probe, primer or pair of primers for detecting the fusion of SDC4 and NRG1 specifically hybridizes to a sequence consisting of exon 4 of SDC4 or a sequence located 5' to exon 4, and/or or specifically hybridize to a sequence consisting of exon 2 of NRG1 or a sequence located 3' to exon 2, or have 95% or higher complementary sequence identity to such sequences; - the probe, primer or primer pair used to detect the fusion of ZFAT and NRG1 specifically hybridizes to a sequence consisting of exon 12 of ZFAT or a sequence located 5' to exon 12, and/or or specifically hybridizes to a sequence consisting of exon 6 of NRG1 or a sequence located 3' to exon 6, or has 95% or greater complementary sequence identity to such sequences; or - the probe, primer or pair of primers for detecting the fusion of DSCAML1 and NRG1 specifically hybridizes to a sequence consisting of exon 3 of DSCAML1 or a sequence located 5' to exon 3, and/or Or specifically hybridize to a sequence composed of exon 2 of NRG1 or a sequence located 3' of exon 2, or have 95% or higher complementary sequence identity with these sequences. The nucleic acid probe, primer or primer pair as claimed in item 28, wherein: - from VAPB exon 1 comprising or consisting of SEQ ID NO: 17 or an allele variant thereof; - from exon 7 of CADM1 comprising or consisting of SEQ ID NO: 39 or an allele variant thereof; - from exon 5 of CD44 comprising or consisting of SEQ ID NO: 65 or an allele variant thereof; - Exon 1 from SLC3A2 comprises or consists of SEQ ID NO: 103 or an allele variant thereof; - from VTCN1 exon 2 comprising or consisting of SEQ ID NO: 169 or an allele variant thereof; - from CDH1 exon 11 comprising or consisting of SEQ ID NO: 198 or an allele variant thereof; - from exon 1 of CXADR comprising or consisting of SEQ ID NO: 219 or an allele variant thereof; - Exon 2 from GTF2E2 comprises or consists of SEQ ID NO: 236 or an allele variant thereof; - from exon 23 of CSMD1 comprising or consisting of SEQ ID NO: 279 or an allele variant thereof; - from PTN exon 4 comprising or consisting of SEQ ID NO: 318 or an allele variant thereof; - from ST14 exon 11 comprising or consisting of SEQ ID NO: 342 or an allele variant thereof; - from THBS1 exon 9 comprising or consisting of SEQ ID NO: 386 or an allele variant thereof; - from AGRN exon 12 comprising or consisting of SEQ ID NO: 416 or an allele variant thereof; - Exon 4 from PVALB comprises or consists of SEQ ID NO: 442 or an allele variant thereof; - from SLC3A2 exon 2 comprising or consisting of SEQ ID NO: 457 or an allele variant thereof; - from APP exon 14 comprising or consisting of SEQ ID NO: 501 or an allele variant thereof; - from WRN exon 33 comprising or consisting of SEQ ID NO: 562 or an allele variant thereof; - from DAAM1 exon 1 comprising or consisting of SEQ ID NO: 606 or an allele variant thereof; - from ASPH exon 22 comprising or consisting of SEQ ID NO: 658 or an allele variant thereof; - Exon 6 from NOTCH2 comprises or consists of SEQ ID NO: 700 or an allele variant thereof; - from CD74 exon 2 comprising or consisting of SEQ ID NO: 720 or an allele variant thereof; - from SDC4 exon 2 comprising or consisting of SEQ ID NO: 746 or an allele variant thereof; - from exon 5 of CD44 comprising or consisting of SEQ ID NO: 65 or an allele variant thereof; - from SLC4A4 exon 14 comprising or consisting of SEQ ID NO: 780 or an allele variant thereof; - from SDC4 exon 4 comprising or consisting of SEQ ID NO: 748 or an allele variant thereof; - from ZFAT exon 12 comprising or consisting of SEQ ID NO: 841 or an allele variant thereof; - from DSCAML1 exon 3 comprising or consisting of SEQ ID NO: 872 or an allele variant thereof; and - from NRG1 exons 1, 2, 5 and 6 comprising or consisting of SEQ ID NO: 125, 126, 129 and 130 or an allegenic variant thereof, respectively. The nucleic acid probe, primer or primer pair as claimed in item 27, wherein: - The probe, primer or primer pair used to detect the fusion of VAPB and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 17 or its allele variant, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probes, primers or primer pairs used to detect the fusion of CADM1 and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 57 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of CD44 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 99 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probes, primers or primer pairs used to detect the fusion of SLC3A2 and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 103 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 157 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probes, primers or primer pairs used to detect the fusion of VTCN1 and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 181 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of CDH1 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 213 or its allele variant, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of CXADR and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 219 or its allele variant, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of GTF2E2 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 252 or its allele variant, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probes, primers or primer pairs used to detect the fusion of CSMD1 and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 309 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probes, primers or primer pairs used to detect the fusion of PTN and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 326 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of ST14 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 372 or its allele variant, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of THBS1 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 399 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of AGRN and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 433 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of PVALB and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 450 or its allele variant, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of SLC3A2 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 482 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probes, primers or primer pairs used to detect the fusion of APP and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 524 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of WRN and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 601 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of DAAM1 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 606 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 138 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of ASPH and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 689 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of NOTCH2 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 713 or its allele variant, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of CD74 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 739 or its allele variant, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - the probe, primer or primer pair used to detect the fusion of SDC4 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 757 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probe, primer or primer pair used to detect the fusion of CD44 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 99 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probes, primers or primer pairs used to detect the fusion of SLC4A4 and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 820 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - the probe, primer or primer pair used to detect the fusion of SDC4 and NRG1 specifically hybridizes to a sequence consisting of SEQ ID NO: 940 or its allele variants, and/or specifically hybridizes to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences; - The probes, primers or primer pairs used to detect the fusion of ZFAT and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 864 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 155 hybridizes, or has 95% or greater complementary sequence identity to such sequences; and - The probes, primers or primer pairs used to detect the fusion of DSCAML1 and NRG1 specifically hybridize to a sequence consisting of SEQ ID NO: 938 or its allele variants, and/or specifically hybridize to a A sequence consisting of SEQ ID NO: 153 hybridizes, or has 95% or greater complementary sequence identity to such sequences. A first nucleic acid probe and a second nucleic acid probe for use in an in situ hybridization assay to detect the polynucleotide fusion of any one of claims 1 to 17, -wherein the first probe is specifically hybridized to the VAPB sequence at the nucleic acid 5' at position 43 of SEQ ID NO:3, and the second probe is specifically at position 44 of SEQ ID NO:3 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the CADM1 sequence at the nucleic acid 5' at position 53 of SEQ ID NO:7, and the second probe is specifically at position 54 of SEQ ID NO:7 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the CD44 sequence at the nucleic acid 5' at position 52 of SEQ ID NO: 11, and the second probe is specifically at position 53 of SEQ ID NO: 11 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe is specifically hybridized to the SLC3A2 sequence at the nucleic acid 5' at position 53 of SEQ ID NO: 15, and the second probe is specifically at position 54 of SEQ ID NO: 15 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the VTCN1 sequence at the nucleic acid 5' at position 65 of SEQ ID NO: 166, and the second probe is specifically at position 66 of SEQ ID NO: 166 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe is specifically hybridized to the CDH1 sequence at the nucleic acid 5' at position 119 of SEQ ID NO: 186, and the second probe is specifically at position 120 of SEQ ID NO: 186 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the CXADR sequence at the nucleic acid 5' at position 43 of SEQ ID NO: 217, and the second probe is specifically at position 44 of SEQ ID NO: 217 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe specifically hybridizes to the GTF2E2 sequence at the nucleic acid 5' at position 141 of SEQ ID NO: 233, and the second probe is specifically at position 142 of SEQ ID NO: 233 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe is specifically hybridized to the CSMD1 sequence at the nucleic acid 5' at position 88 of SEQ ID NO: 255, and the second probe is specifically at position 89 of SEQ ID NO: 255 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the PTN sequence at the nucleic acid 5' at position 102 of SEQ ID NO:313, and the second probe is specifically at position 103 of SEQ ID NO:313 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the ST14 sequence at the nucleic acid 5' at position 95 of SEQ ID NO:330, and the second probe is specifically at position 96 of SEQ ID NO:330 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe specifically hybridizes to the THBS1 sequence at the nucleic acid 5' at position 56 of SEQ ID NO: 376, and the second probe is specifically at position 57 of SEQ ID NO: 376 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the AGRN sequence at the nucleic acid 5' at position 106 of SEQ ID NO:403, and the second probe is specifically at position 107 of SEQ ID NO:403 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the PVALB sequence at the nucleic acid 5' at position 102 of SEQ ID NO:437, and the second probe is specifically at position 103 of SEQ ID NO:437 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the SLC3A2 sequence at the nucleic acid 5' at position 93 of SEQ ID NO:454, and the second probe is specifically at position 94 of SEQ ID NO:454 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe specifically hybridizes to the APP sequence at the nucleic acid 5' of position 54 of SEQ ID NO: 486, and the second probe specifically hybridizes to the position 55 of SEQ ID NO: 486 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe specifically hybridizes to the WRN sequence at the nucleic acid 5' at position 96 of SEQ ID NO: 528, and the second probe is specifically at position 97 of SEQ ID NO: 528 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe specifically hybridizes to the DAAM1 sequence at the nucleic acid 5' at position 75 of SEQ ID NO:605, and the second probe specifically hybridizes at position 76 of SEQ ID NO:605 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the ASPH sequence at the nucleic acid 5' at position 75 of SEQ ID NO:635, and the second probe is specifically at position 76 of SEQ ID NO:635 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe is specifically hybridized to the NOTCH2 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 693, and the second probe is specifically at position 76 of SEQ ID NO: 693 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe specifically hybridizes to the CD74 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 717, and the second probe is specifically at position 76 of SEQ ID NO: 717 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe is specifically hybridized to the SDC4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 743, and the second probe is specifically at position 76 of SEQ ID NO: 743 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the CD44 sequence at the nucleic acid 5' at position 75 of SEQ ID NO:761, and the second probe is specifically at position 76 of SEQ ID NO:761 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the SLC4A4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO:765, and the second probe is specifically at position 76 of SEQ ID NO:765 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; - wherein the first probe is specifically hybridized to the SDC4 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 824, and the second probe is specifically at position 76 of SEQ ID NO: 824 Hybridization of the NRG1 sequence at the 3' of the nucleic acid; -wherein the first probe is specifically hybridized to the ZFAT sequence at the nucleic acid 5' at position 75 of SEQ ID NO:828, and the second probe is specifically at position 76 of SEQ ID NO:828 hybridization to the NRG1 sequence at the 3' of the nucleic acid; or - wherein the first probe is specifically hybridized to the DSCAML1 sequence at the nucleic acid 5' at position 75 of SEQ ID NO: 868, and the second probe is specifically at position 76 of SEQ ID NO: 868 The NRG1 sequence at the 3' of the nucleic acid hybridizes. A first antibody or a pair of first and second antibodies for detecting the polypeptide encoded by the polynucleotide fusion of any one of claims 1-17. A detection assay comprising a first antibody or a set of first and second antibodies for detecting the presence of a polypeptide encoded by a polynucleotide fusion as claimed in any one of claims 1 to 17, wherein the first antibody or The first and second antibody groups are preferably the first antibody or the first and second antibody groups as claimed in claim 31. The first antibody or the first and second antibody set according to claim 31, or the detection assay according to claim 32, wherein the first antibody binds to a group selected from VAPB-NRG1, CADM1-NRG1, CD44-NRG1, SLC3A2- NRG1, VTCN1-NRG1, CDH1-NRG1, CXADR-NRG1, GTF2E2-NRG1, CSMD1-NRG1, PTN-NRG1, ST14-NRG1, THBS1-NRG1, AGRN-NRG1, PVALB-NRG1, APP-NRG1, WRN-NRG1, The polypeptide fusion of ASPH-NRG1, NOTCH2-NRG1, CD74-NRG1, SDC4-NRG1, SLC4A4-NRG1, ZFAT-NRG1 or DSCAML1-NRG1, and the first and second antibody sets are respectively combined with VAPB and NRG1 or CADM1 and NRG1, or CD44 and NRG1, SLC3A2 and NRG1, VTCN1 and NRG1, CDH1 and NRG1, CXADR and NRG1, GTF2E2 and NRG1, CSMD1 and NRG1, PTN and NRG1, ST14 and NRG1, THBS1 and NRG1, AGRN and NRG1, PVALB and NRG1 , APP and NRG1, WRN and NRG1, ASPH and NRG1, NOTCH2 and NRG1, CD74 and NRG1, SDC4 and NRG1, SLC4A4 and NRG1, ZFAT and NRG1, or DSCAML1 and NRG1. A method for identifying a polynucleotide fusion as claimed in any one of claims 1 to 17, or a polypeptide encoded by it, in a sample, said method comprising testing a sample obtained from an individual to detect whether there is The fusion. A method for detecting the presence of a polynucleotide fusion as in any one of claims 1 to 17, or a polypeptide encoded by it, in a sample, said method comprising testing a sample obtained from an individual to detect in the sample Whether the fusion exists. A method for determining whether an abnormal cell from an individual comprises the polynucleotide fusion according to any one of claims 1 to 17, or a polypeptide encoded by it, said method comprising examining the multinucleated cells of the abnormal cell obtained from the individual Whether the fusion is present in the sample for nucleotide or polypeptide content. A method for identifying an individual with a polynucleotide fusion as in any one of claims 1 to 17, or a polypeptide encoded by it, said method comprising testing a sample obtained from an individual to detect whether there is The fusion. The method according to any one of claims 34 to 37, wherein the test comprises utilizing a nucleic acid probe such as any one of claims 24 to 29, a primer or a primer pair to specifically bind the polynucleotide or by The polypeptide encoded by it is used to detect the fusion, or the fusion is detected using a binding agent that binds a polynucleotide comprising the polynucleotide fusion. The method according to any one of claims 34 to 37, wherein the test comprises amplifying or detecting a sequence for distinguishing the presence or absence of the polynucleotide fusion or the polypeptide encoded by it. The method according to any one of claims 34 to 39, wherein the polynucleotide fusion is obtained from an abnormal cell expressing a polynucleotide fusion comprising the EGF-like domain of NRG1. The method according to any one of claims 34 to 40, wherein the method comprises the step of obtaining a sample from an individual, followed by the step of isolating the polynucleotide or the polypeptide encoded thereby from the sample. The method according to any one of claims 34 to 41, wherein the method comprises the step of purifying or isolating the polynucleotide from the sample. The method according to any one of claims 34 to 42, wherein the binding agent is or comprises a primer, a pair of primers, a probe or an antibody. The method according to any one of claims 34 to 43, wherein the test is an in vitro method, preferably an in vitro method. The method according to any one of claims 34 to 44, wherein the binding agent comprises or is associated with a detectable label. The method according to any one of claims 34 to 45, wherein the sample is a liquid sample or a solid sample, such as a formalin-fixed paraffin-embedded tissue (FFPE) sample. The method according to any one of claims 34 to 46, wherein the sample comprises blood, serum, plasma, pleural fluid, urine, semen, amniotic fluid or ascites. The method according to any one of claims 34 to 47, wherein the sample comprises mutant cells, such as tumor cells or cancer cells, or polynucleotide or polypeptide content thereof. A method of treating an individual suffering from an ErbB-2 and/or ErbB-3 positive cancer or tumor comprising a polynucleotide fusion and/or expressing a fusion polypeptide encoded thereby comprising administering to the individual and an effective amount of ErbB-2 and/or ErbB-3 targeting agent, wherein the fusion is the fusion according to any one of claims 1-17. A method of inhibiting the course of an individual suffering from an ErbB-2 and ErbB-3 positive cancer or tumor comprising a polynucleotide fusion and/or expressing a fusion polypeptide encoded thereby comprising administering to the individual An effective amount of an ErbB-2 and/or ErbB-3 targeting agent, wherein the fusion is the fusion according to any one of claims 1-17. ErbB-2 and/or ErbB for use in the treatment of an individual with an ErbB-2 and ErbB-3 positive cancer or tumor comprising a polynucleotide fusion and/or expressing a fusion polypeptide encoded thereby -3 targeting agents, the treatment comprising administering an effective amount of ErbB-2 and/or ErbB-3 targeting agents to the individual, wherein the fusion is a fusion as claimed in any one of claims 1 to 17 . A method for diagnosing whether an individual has abnormal cells comprising the polynucleotide fusion or the polypeptide encoded by it according to any one of claims 1 to 17, the method comprising testing a sample obtained from an individual to detect Whether the fusion exists. The method of claim 52, wherein the test comprises using a nucleic acid probe such as any one of claims 24 to 29, a primer or a primer pair to specifically bind the polynucleotide or the polypeptide encoded by it to The fusion is detected, or the fusion is detected using a binding agent that binds a polynucleotide comprising the polynucleotide fusion. A method of assessing whether an individual suffers from or is susceptible to cancer or tumor, the method comprising testing a sample obtained from an individual to detect the presence of a polynucleotide fusion according to any one of claims 1 to 17 in the sample or a polypeptide encoded thereby, and by identifying the presence or absence of said polynucleotide or polypeptide fusion to assess said individual suffering from said cancer or tumor or predisposed to developing said cancer or tumor. The method or use according to any one of claims 49 to 51, wherein the ErbB-2 and/or ErbB-3 targeting agent is selected from the group consisting of: an extracellular part that binds ErbB-2 Multispecific antibody with a first antigen-binding site and a second antigen-binding site that binds to the extracellular portion of ErbB-3, a tyrosine kinase inhibitor of ErbB-2, comprising an extracellular portion that binds to ErbB-2 A monospecific diabody comprising an antigen-binding site that binds to the extracellular portion of ErbB-3, or any combination thereof. The method or use according to any one of claims 49 to 51, or 55, wherein the ErbB-2 and/or ErbB-3 targeting agent is zenocutuzumab. The method or use according to any one of claims 35 to 56, wherein the abnormal cell, cancer cell, tumor cell or sample comprises a polynucleotide fusion as claimed in claims 1 to 17 or a polypeptide encoded thereby, and wherein The polynucleotide fusion contained in the cell or sample further comprises in-frame a coding sequence encoding an EGF-like domain of NRG1 fused. The method or use according to any one of claims 35 to 57, wherein the abnormal cell line is from cancer, especially said cancer is adenocarcinoma, more especially mucinous adenocarcinoma, pancreatic cancer, more especially pancreatic adenocarcinoma, More especially pancreatic ductal adenocarcinoma, renal cell carcinoma, sarcoma, bladder cancer, colorectal cancer, rectal cancer, colorectal cancer, gallbladder cancer, head and neck cancer, prostate cancer, uterine cancer, breast cancer, ovarian cancer, liver cancer, endometrial cancer Cancer, lung cancer, preferably non-small cell lung cancer, preferably, more preferably invasive mucinous adenocarcinoma, primary cancer or metastatic cancer. An in vivo animal model comprising the polynucleotide fusion according to any one of claims 1 to 17 and/or expressing the polypeptide fusion encoded by it, wherein the polynucleotide fusion composed of the animal model or The polypeptide fusion preferably consists of the transplanted abnormal cells present in the animal model, or consists of the gene body of the animal model. A method of treating the in vivo animal model of claim 59 with an Erb2 and/or Erb3 targeting agent selected from the group consisting of a first Multispecific antibody with an antigen binding site and a second antigen binding site binding to the extracellular part of ErbB-3, a tyrosine kinase inhibitor of ErbB-2, an antigen comprising an extracellular part that binds ErbB-2 A binding site monospecific diabody, a monospecific diabody comprising an antigen binding site that binds an extracellular portion of ErbB-3, or any combination thereof, the method comprising administering to the animal the Erb2 and/or Erb3 targeting agents. An in situ hybridization assay for use in the detection of VAPB, CADM1, CD44, SLC3A2, VTCN1, CDH1, CXADR, GTF2E2, CSMD1, PTN, ST14, THBS1, AGRN, PVALB, APP, WRN, DAAM1, ASPH, NOTCH2, CD74 , SDC4, SLC4A4, ZFAT or DSCAML1 gene rearrangement first nucleic acid probe and second nucleic acid probe, wherein: - the first probe for detecting the gene rearrangement of VAPB specifically hybridizes with the VAPB sequence at the nucleic acid 5' of position 43 of SEQ ID NO: 1, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : VAPB sequence hybridization at the nucleic acid 3' of position 43 of 1; - the first probe for detecting the gene rearrangement of CADM1 specifically hybridizes with the CADM1 sequence at the nucleic acid 5' of position 53 of SEQ ID NO: 5, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : CADM1 sequence hybridization at the nucleic acid 3' of position 53 of 5; - the first probe for detecting the gene rearrangement of CD44 specifically hybridizes with the CD44 sequence at the nucleic acid 5' of position 52 of SEQ ID NO: 9, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : CD44 sequence hybridization at the nucleic acid 3' of position 52 of 9; - the first probe for detecting the gene rearrangement of SLC3A2 specifically hybridizes with the SLC3A2 sequence at the nucleic acid 5' of position 53 of SEQ ID NO: 13, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : SLC3A2 sequence hybridization at the nucleic acid 3' of position 53 of 13; - the first probe for detecting gene rearrangement of VTCN1 specifically hybridizes with the VTCN1 sequence at the nucleic acid 5' of position 65 of SEQ ID NO: 164, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : VTCN1 sequence hybridization at the nucleic acid 3' of position 65 of 164; - the first probe for detecting the gene rearrangement of CDH1 specifically hybridizes with the CDH1 sequence at the nucleic acid 5' of position 119 of SEQ ID NO: 184, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : CDH1 sequence hybridization at the nucleic acid 3' of position 119 of 184; - the first probe for detecting the gene rearrangement of CXADR specifically hybridizes with the CXADR sequence at the nucleic acid 5' of position 43 of SEQ ID NO: 215, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : CXADR sequence hybridization at the nucleic acid 3' of position 43 of 215; - the first probe for detecting the gene rearrangement of GTF2E2 specifically hybridizes to the GTF2E2 sequence at the nucleic acid 5' of position 141 of SEQ ID NO: 231, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : GTF2E2 sequence hybridization at the nucleic acid 3' of position 141 of 231; - the first probe for detecting gene rearrangement of CSMD1 specifically hybridizes with the CSMD1 sequence at the nucleic acid 5' of position 88 of SEQ ID NO: 253, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : CSMD1 sequence hybridization at the nucleic acid 3' of position 88 of 253; - the first probe for detecting the gene rearrangement of PTN specifically hybridizes with the PTN sequence at the nucleic acid 5' of position 102 of SEQ ID NO: 311, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : PTN sequence hybridization at the nucleic acid 3' of position 102 of 311; - the first probe for detecting the gene rearrangement of ST14 specifically hybridizes with the ST14 sequence at the nucleic acid 5' of position 95 of SEQ ID NO: 328, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : ST14 sequence hybridization at the nucleic acid 3' of position 95 of 328; - the first probe for detecting the gene rearrangement of AGRN specifically hybridizes to the AGRN sequence at the nucleic acid 5' of position 106 of SEQ ID NO: 401, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : AGRN sequence hybridization at the nucleic acid 3' of position 106 of 401; - the first probe for detecting gene rearrangement of THBS1 specifically hybridizes to the THBS1 sequence at the nucleic acid 5' of position 56 of SEQ ID NO: 374, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : THBS1 sequence hybridization at the nucleic acid 3' of position 56 of 374; - the first probe for detecting gene rearrangement of PVALB specifically hybridizes to the PVALB sequence at the nucleic acid 5' of position 102 of SEQ ID NO: 435, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : PVALB sequence hybridization at the nucleic acid 3' of position 102 of 435; - the first probe for detecting gene rearrangement of SLC3A2 specifically hybridizes to the SLC3A2 sequence at the nucleic acid 5' of position 93 of SEQ ID NO: 452, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : SLC3A2 sequence hybridization at the nucleic acid 3' of position 93 of 452; - the first probe for detecting gene rearrangement of APP specifically hybridizes to the APP sequence at the nucleic acid 5' of position 54 of SEQ ID NO: 484, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : APP sequence hybridization at the nucleic acid 3' of position 54 of 484; - the first probe for detecting the gene rearrangement of WRN specifically hybridizes to the WRN sequence at the nucleic acid 5' of position 96 of SEQ ID NO: 526, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : WRN sequence hybridization at the nucleic acid 3' of position 96 of 526; - the first probe for detecting the gene rearrangement of DAAM1 specifically hybridizes to the DAAM1 sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 603, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : DAAM1 sequence hybridization at the nucleic acid 3' of position 75 of 603; - the first probe for detecting the gene rearrangement of ASPH specifically hybridizes to the ASPH sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 633, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : ASPH sequence hybridization at the nucleic acid 3' of position 75 of 633; - the first probe for detecting the gene rearrangement of NOTCH2 specifically hybridizes to the NOTCH2 sequence at the 5' position of the nucleic acid at position 75 of SEQ ID NO: 691, and the second probe specifically hybridizes to the sequence located at SEQ ID NO : the NOTCH2 sequence hybridization at the nucleic acid 3' of position 75 of 691; - the first probe for detecting gene rearrangement of CD74 specifically hybridizes with the CD74 sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 715, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : CD74 sequence hybridization at the nucleic acid 3' of position 75 of 715; - the first probe for detecting the gene rearrangement of SDC4 specifically hybridizes with the SDC4 sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 741, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : SDC4 sequence hybridization at the nucleic acid 3' of position 75 of 741; - the first probe for detecting the gene rearrangement of CD44 specifically hybridizes with the CD44 sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 759, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : CD44 sequence hybridization at the nucleic acid 3' of position 75 of 759; - the first probe for detecting the gene rearrangement of SLC4A4 specifically hybridizes with the SLC4A4 sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 763, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : SLC4A4 sequence hybridization at the nucleic acid 3' of position 75 of 763; - the first probe for detecting the gene rearrangement of SDC4 specifically hybridizes with the SDC4 sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 822, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : SDC4 sequence hybridization at the nucleic acid 3' of position 75 of 822; - the first probe for detecting the gene rearrangement of ZFAT is specifically hybridized with the ZFAT sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 826, and the second probe is specifically hybridized with the sequence located at SEQ ID NO : ZFAT sequence hybridization at the nucleic acid 3' of position 75 of 826; or - the first probe for detecting the gene rearrangement of DSCAML1 specifically hybridizes with the DSCAML1 sequence at the nucleic acid 5' of position 75 of SEQ ID NO: 866, and the second probe specifically hybridizes with the sequence located at SEQ ID NO : DSCAML1 sequence hybridization at position 75 of nucleic acid 3' of 866.